	ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)	CLUSTER	PREPROCESSED_SENTENCE
S18-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S18-BMJ_2010_Apr_29_340_c1640	['this EVIDENCE comes from both case-control and cohort studies and INDICATES that age of operation for such a PROTECTIVE EFFECT MIGHT include both childhood and early Adulthood.67891011\nexposure to ultraviolet radiation in early Life has NOT YET been formally examined but MIGHT be LINKED to excess risk of multiple sclerosis at Birth through seasonal deficiency in maternal Vitamin D concentrations.12A study of half siblings with multiple sclerosis has ALSO SHOWN that risk CAN be maternally MEDIATED.13pregnancy is a vulnerable time for Vitamin d deficiency BECAUSE of increased physiological needs and reduced maternal outdoor activity.14experimental data on Animal Fetal Development INDICATE that Cerebral White Matter is responsive to Vitamin D and that Oligodendrocytes in the Brain and Spinal Cord have Vitamin D Receptors.1516furthermore, maternal Vitamin D depletion alters Neurogenesis in the developing Rat Brain,17with subsequent altered Gene Expression in Adult Life.18a RECENT Genetic STUDY in Humans has FURTHER IMPLICATED Vitamin D as a strong environmental CANDIDATE by SHOWING direct functional INTERACTION with the major locus that determines susceptibility to multiple sclerosis.19ALTHOUGH Human EVIDENCE pertaining to fetal development HAS BEEN DIFFICULT to obtain, the body of RELATED EVIDENCE to date has led SOME to RECOMMEND Antenatal supplementation with Vitamin D to prevent multiple sclerosis.14\nAS an indicator of POSSIBLE Perinatal environmental exposures, such as ultraviolet radiation, individual studies in the northern hemisphere have examined month of Birth and risk of multiple sclerosis with VARIED results.2021222324a large RECENT pooled analysis of Births in the northern hemisphere, HOWEVER, SHOWED an excess of multiple sclerosis among People Born in may and a relative deficit among those Born in november; these results were stronger in familial cases and SUGGESTED INTERACTIONS between Genes and environment that are RELATED to climate and that MIGHT act during Gestation or shortly after Birth.12we EXAMINED month of Birth and risk of multiple sclerosis in australia.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 109), ('SUPERFICIAL_RELATIONSHIP', 120), ('INCOMPLETE_EVIDENCE', 127), ('FULL_UNKNOWN', 237), ('INCOMPLETE_EVIDENCE', 272), ('SUPERFICIAL_RELATIONSHIP', 281), ('INCOMPLETE_EVIDENCE', 399), ('INCOMPLETE_EVIDENCE', 454), ('INCOMPLETE_EVIDENCE', 475), ('SUPERFICIAL_RELATIONSHIP', 493), ('PROBABLE_UNDERSTANDING', 560), ('INCOMPLETE_EVIDENCE', 687), ('INCOMPLETE_EVIDENCE', 984), ('INCOMPLETE_EVIDENCE', 1019), ('SUPERFICIAL_RELATIONSHIP', 1027), ('INCOMPLETE_EVIDENCE', 1074), ('INCOMPLETE_EVIDENCE', 1087), ('SUPERFICIAL_RELATIONSHIP', 1113), ('ANOMALY_CURIOUS_FINDING', 1199), ('ANOMALY_CURIOUS_FINDING', 1199), ('INCOMPLETE_EVIDENCE', 1216), ('INCOMPLETE_EVIDENCE', 1257), ('DIFFICULT_TASK', 1266), ('INCOMPLETE_EVIDENCE', 1299), ('SUPERFICIAL_RELATIONSHIP', 1299), ('INCOMPLETE_EVIDENCE', 1332), ('FUTURE_WORK', 1340), ('PROBABLE_UNDERSTANDING', 1424), ('INCOMPLETE_EVIDENCE', 1443), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1629), ('INCOMPLETE_EVIDENCE', 1662), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1723), ('INCOMPLETE_EVIDENCE', 1732), ('INCOMPLETE_EVIDENCE', 1899), ('SUPERFICIAL_RELATIONSHIP', 1909), ('SUPERFICIAL_RELATIONSHIP', 1961), ('INCOMPLETE_EVIDENCE', 1989), ('QUESTION_ANSWERED_BY_THIS_WORK', 2044)]	40	[('UBERON_0000113', 'post-juvenile adult stage', 166, 'adulthood'), ('UBERON_0000104', 'life cycle', 228, 'life'), ('GO_0007567', 'parturition', 328, 'birth'), ('CHEBI_27300', 'vitamin D', 374, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 539, 'vitamin'), ('NCBITaxon_33208', 'Metazoa', 662, 'animal'), ('GO_0002065', 'columnar/cuboidal epithelial cell differentiation', 669, 'fetal development'), ('UBERON_0002437', 'cerebral hemisphere white matter', 701, 'cerebral white matter'), ('CHEBI_27300', 'vitamin D', 740, 'vitamin D'), ('CL_0000128', 'oligodendrocyte', 759, 'oligodendrocytes'), ('UBERON_0000955', 'brain', 783, 'brain'), ('UBERON_0002240', 'spinal cord', 793, 'spinal cord'), ('CHEBI_27300', 'vitamin D', 810, 'vitamin D'), ('PR_000001708', 'sphingosine 1-phosphate receptor 3', 810, 'vitamin D receptors'), ('CHEBI_27300', 'vitamin D', 856, 'vitamin D'), ('GO_0022008', 'neurogenesis', 883, 'neurogenesis'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 914, 'rat'), ('UBERON_0000955', 'brain', 918, 'brain'), ('GO_0010467', 'gene expression', 950, 'gene expression'), ('SO_0000704', 'gene', 950, 'gene'), ('UBERON_0000113', 'post-juvenile adult stage', 969, 'adult life'), ('SO_0000704', 'gene', 991, 'genetic'), ('NCBITaxon_9606', 'Homo sapiens', 1008, 'humans'), ('CHEBI_27300', 'vitamin D', 1038, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 1210, 'human'), ('GO_0007567', 'parturition', 1350, 'antenatal'), ('CHEBI_27300', 'vitamin D', 1381, 'vitamin D'), ('GO_0036268', 'swimming', 1452, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1452, 'perinatal'), ('GO_0007567', 'parturition', 1587, 'birth'), ('GO_0007567', 'parturition', 1688, 'births'), ('NCBITaxon_10088', 'Mus <genus>', 1777, 'people'), ('GO_0007567', 'parturition', 1784, 'born'), ('GO_0007567', 'parturition', 1831, 'born'), ('SO_0000704', 'gene', 1930, 'genes'), ('GO_0007565', 'female pregnancy', 2006, 'gestation'), ('GO_0007567', 'parturition', 2033, 'birth'), ('GO_0007567', 'parturition', 2062, 'birth')]	0	['comes case-control age operation childhood adulthood.67891011\nexposure ultraviolet radiation life formally excess sclerosis birth seasonal maternal  concentrations.12a half siblings sclerosis maternally mediated.13pregnancy vitamin physiological maternal outdoor activity.14experimental animal fetal cerebral white responsive  oligodendrocytes brain spinal cord  receptors.1516furthermore, maternal  depletion alters neurogenesis rat brain,17with altered gene expression adult life.18a humans  environmental functional locus sclerosis.19although human fetal obtain, antenatal supplementation  sclerosis.14\nas perinatal environmental exposures, ultraviolet radiation, individual northern hemisphere month birth sclerosis results.2021222324a pooled births northern hemisphere, however, excess sclerosis among people born relative among born november; results familial cases genes environment climate  shortly birth.12we month birth sclerosis australia.']
S84-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S84-BMJ_2010_Apr_29_340_c1640	['we could not examine the Vitamin D status of the fetus directly but INSTEAD chose the ambient ultraviolet radiation level experienced by the mother during Gestation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 68)]	1	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'gestation')]	0	[' status fetus ambient ultraviolet radiation experienced mother .']
S87-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S87-BMJ_2010_Apr_29_340_c1640	['RECENT work by sayers et al also INDICATES that ambient erythemal ultraviolet radiation levels during Pregnancy, EVEN in a single location, CAN be used to INDICATE Vitamin D status.29further work COULD CONFIRM the timing of the OBSERVED EFFECT of Prenatal ultraviolet radiation.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 33), ('ANOMALY_CURIOUS_FINDING', 113), ('INCOMPLETE_EVIDENCE', 140), ('INCOMPLETE_EVIDENCE', 155), ('INCOMPLETE_EVIDENCE', 196), ('INCOMPLETE_EVIDENCE', 202), ('INCOMPLETE_EVIDENCE', 228), ('SUPERFICIAL_RELATIONSHIP', 237)]	9	[('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 247, 'prenatal')]	0	['recent sayers et al ambient erythemal ultraviolet radiation levels single location,  status.29further timing  ultraviolet radiation.']
S95-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S95-BMJ_2010_Apr_29_340_c1640	['maternal exposure and health of offspring\nthis report adds to other work SHOWING that maternal exposure to ambient ultraviolet radiation during Pregnancy MIGHT INFLUENCE subsequent health in the offspring.30313233in a new zealand Birth cohort, infants whose mothers were exposed to peak sunshine during the first Trimester were significantly heavier at Birth than infants whose mothers experienced trough levels of sunshine during the same trimester.30in the united kingdom, maternal ambient Ultraviolet B exposure in the third trimester HAS BEEN positively RELATED to bone Mineral density and content at age 9 in offspring.34there is now GROWING INTEREST in the ROLE of maternal Vitamin D deficiency in Pregnancy and the Development of Central Nervous System and Immune disorders, PARTICULARLY schizophrenia,33type 1 diabetes, and other disorders.35ALTHOUGH active Vitamin D3Concentrations in the mother increase substantially during Pregnancy, early fetal supplies are lower36and directly DEPENDENT on the mother.']	[('INCOMPLETE_EVIDENCE', 73), ('INCOMPLETE_EVIDENCE', 154), ('SUPERFICIAL_RELATIONSHIP', 160), ('INCOMPLETE_EVIDENCE', 538), ('SUPERFICIAL_RELATIONSHIP', 558), ('INCOMPLETE_EVIDENCE', 639), ('SUPERFICIAL_RELATIONSHIP', 663), ('IMPORTANT_CONSIDERATION', 782), ('ANOMALY_CURIOUS_FINDING', 848), ('SUPERFICIAL_RELATIONSHIP', 991)]	10	[('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0007567', 'parturition', 230, 'birth'), ('GO_0009294', 'DNA mediated transformation', 313, 'trimester'), ('GO_0007567', 'parturition', 353, 'birth'), ('CHEBI_72754', 'bisphenol AF', 492, 'ultraviolet B'), ('CHEBI_46662', 'mineral', 574, 'mineral'), ('CHEBI_27300', 'vitamin D', 680, 'vitamin D'), ('GO_0007565', 'female pregnancy', 704, 'pregnancy'), ('GO_0008289', 'lipid binding', 722, 'development'), ('GO_0022412', 'cellular process involved in reproduction in multicellular organism', 737, 'central nervous system'), ('UBERON_0001017', 'central nervous system', 737, 'central nervous system'), ('UBERON_0002405', 'immune system', 764, 'immune'), ('PR_000017350', 'serine/threonine-protein kinase VRK2', 866, 'vitamin D3concentrations'), ('GO_0007565', 'female pregnancy', 935, 'pregnancy')]	0	['maternal exposure offspring\nthis maternal exposure ambient ultraviolet radiation  offspring.30313233in zealand birth cohort, infants whose mothers exposed peak sunshine trimester heavier birth infants whose mothers experienced trough levels sunshine trimester.30in united kingdom, maternal ambient ultraviolet b exposure third trimester positively bone mineral density content age 9 offspring.34there maternal   central nervous system immune disorders, schizophrenia,33type diabetes, disorders.35although vitamin d3concentrations mother increase fetal supplies lower36and mother.']
S96-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S96-BMJ_2010_Apr_29_340_c1640	['by the time of Delivery, maternal and infant Cord Serum 25-Hydroxyvitamin d3concentrations are highly CORRELATED.37UNFORTUNATELY, much REMAINS UNKNOWN, leading to large international variations in maternal Vitamin D monitoring and supplementation during Pregnancy.353839\na maternal EFFECT operating Antenatally would also be CONSISTENT with the stronger maternal than paternal “parent of origin” EFFECT in familial multiple sclerosis.1340it HAS BEEN PREVIOUSLY PROPOSED14THAT maternal Vitamin D deficiency, a PROBLEM for SOME dark skinned women migrating to regions with low ambient ultraviolet radiation, such as the uk, MIGHT EXPLAIN the increase in incidence of disease SEEN among second generation migrants in such locations.41our FINDINGS are CONSISTENT with this EXPLANATION.']	[('SUPERFICIAL_RELATIONSHIP', 102), ('ANOMALY_CURIOUS_FINDING', 113), ('ANOMALY_CURIOUS_FINDING', 113), ('FULL_UNKNOWN', 135), ('SUPERFICIAL_RELATIONSHIP', 282), ('INCOMPLETE_EVIDENCE', 325), ('SUPERFICIAL_RELATIONSHIP', 396), ('INCOMPLETE_EVIDENCE', 441), ('INCOMPLETE_EVIDENCE', 450), ('INCOMPLETE_EVIDENCE', 461), ('IMPORTANT_CONSIDERATION', 509), ('INCOMPLETE_EVIDENCE', 521), ('INCOMPLETE_EVIDENCE', 622), ('PROBABLE_UNDERSTANDING', 628), ('INCOMPLETE_EVIDENCE', 673), ('INCOMPLETE_EVIDENCE', 735), ('INCOMPLETE_EVIDENCE', 748), ('PROBABLE_UNDERSTANDING', 769)]	18	[('GO_0007567', 'parturition', 15, 'delivery'), ('UBERON_0002240', 'spinal cord', 45, 'cord'), ('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_67376', 'dihydrooroxylin A', 56, '25-hydroxyvitamin'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy'), ('GO_0007288', 'sperm axoneme assembly', 299, 'antenatally'), ('CHEBI_27300', 'vitamin D', 485, 'vitamin D')]	0	['delivery, maternal infant cord serum 25-hydroxyvitamin d3concentrations correlated.37unfortunately, unknown, international maternal  supplementation .353839\na maternal antenatally maternal paternal “parent origin” familial sclerosis.1340it maternal  deficiency, dark skinned women migrating regions ambient ultraviolet radiation, uk, increase disease among generation migrants locations.41our explanation.']
S99-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S99-BMJ_2010_Apr_29_340_c1640	['ultraviolet radiation exposure during the first trimester would be expected to specifically INFLUENCE Vitamin D concentrations up to early in the second trimester, given that Vitamin D has a half life of one to two months.45in RECENT australian work, higher levels of ambient ultraviolet radiation were ASSOCIATED with higher Vitamin D concentrations at the population level with a lag of one and a half months.46\n\nPOSSIBLE mechanisms\nfirst trimester Vitamin D concentrations MIGHT be particularly IMPORTANT in the development of the Central Nervous System BECAUSE during Early Embryonic Development, Vitamin D receptors are Expressed in the Neuroepithelium and later in the Subventricular Zone.15myelination occurs later; EVEN in mid-Gestation (19-24 weeks) Cortical Axonal tracts are not yet myelinated,47with major myelination of several areas occurring as late as 29-39 weeks.48in addition, the in utero Development Of Immune central Tolerance occurs in the first trimester and Vitamin D has immunomodulating properties.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('INCOMPLETE_EVIDENCE', 227), ('SUPERFICIAL_RELATIONSHIP', 303), ('INCOMPLETE_EVIDENCE', 415), ('INCOMPLETE_EVIDENCE', 476), ('IMPORTANT_CONSIDERATION', 498), ('PROBABLE_UNDERSTANDING', 557), ('ANOMALY_CURIOUS_FINDING', 723)]	8	[('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 326, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 451, 'vitamin D'), ('UBERON_0001017', 'central nervous system', 534, 'central nervous system'), ('UBERON_0019248', 'early embryo', 572, 'early embryonic'), ('GO_0009790', 'embryo development', 578, 'embryonic development'), ('CHEBI_27300', 'vitamin D', 601, 'vitamin D'), ('GO_0010467', 'gene expression', 625, 'expressed'), ('UBERON_0034705', 'developing neuroepithelium', 642, 'neuroepithelium'), ('UBERON_0004922', 'postnatal subventricular zone', 675, 'subventricular zone'), ('GO_0007565', 'female pregnancy', 735, 'gestation'), ('UBERON_0001851', 'cortex', 759, 'cortical'), ('GO_0030424', 'axon', 768, 'axonal'), ('GO_0034102', 'erythrocyte clearance', 908, 'development of ... tolerance'), ('UBERON_0002405', 'immune system', 923, 'immune'), ('CHEBI_27300', 'vitamin D', 982, 'vitamin D')]	0	['ultraviolet radiation exposure trimester  concentrations trimester,  half life months.45in australian work, higher levels ambient ultraviolet radiation higher  concentrations population lag half months.46\n\npossible mechanisms\nfirst trimester  concentrations central nervous system embryonic development,  receptors expressed neuroepithelium subventricular zone.15myelination occurs later; mid- (19-24 weeks) cortical axonal tracts myelinated,47with myelination occurring late 29-39 weeks.48in addition, utero immune central tolerance occurs trimester  immunomodulating properties.']
S100-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S100-BMJ_2010_Apr_29_340_c1640	['the first trimester is also a sensitive period with regard to Prenatal Thymocyte differentiation, with Animal STUDIES SHOWING that chemicals such as Dioxin CAN alter this process, disrupt the development of central tolerance, and LEAD TO increased auto-reactive Peripheral T Cells.49FURTHERMORE, indirect EFFECTS of Vitamin D SHOULD BE CONSIDERED.']	[('INCOMPLETE_EVIDENCE', 110), ('INCOMPLETE_EVIDENCE', 118), ('INCOMPLETE_EVIDENCE', 156), ('SUPERFICIAL_RELATIONSHIP', 230), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 281), ('SUPERFICIAL_RELATIONSHIP', 305), ('FUTURE_WORK', 326), ('FUTURE_WORK', 336)]	8	[('GO_0007565', 'female pregnancy', 62, 'prenatal'), ('CL_0000893', 'thymocyte', 71, 'thymocyte'), ('NCBITaxon_33208', 'Metazoa', 103, 'animal'), ('CHEBI_4553', 'dihydroanhydropodorhizol', 149, 'dioxin'), ('CL_0000111', 'peripheral neuron', 262, 'peripheral T cells'), ('CHEBI_27300', 'vitamin D', 316, 'vitamin D')]	0	['trimester sensitive period regard  thymocyte differentiation, animal chemicals dioxin alter process, central tolerance, auto-reactive peripheral cells.49furthermore,  considered.']
S101-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S101-BMJ_2010_Apr_29_340_c1640	['for example, Vitamin D can down-regulate Interleukin 6, an IMPORTANT mediator of the adverse EFFECT of maternal infection during Pregnancy on neural development in the fetus.505152\n\nPrenatal and Postnatal timing\nour results do not INDICATE that the POSSIBLE beneficial EFFECT of Ultraviolet radiation exposure is confined ONLY to the Prenatal period.']	[('IMPORTANT_CONSIDERATION', 59), ('SUPERFICIAL_RELATIONSHIP', 93), ('INCOMPLETE_EVIDENCE', 231), ('INCOMPLETE_EVIDENCE', 249), ('SUPERFICIAL_RELATIONSHIP', 269), ('INCOMPLETE_EVIDENCE', 322)]	6	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('PR_000008988', 'interleukin-1 family member 5', 41, 'interleukin 6'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy'), ('GO_0007565', 'female pregnancy', 182, 'Prenatal'), ('GO_0007567', 'parturition', 195, 'postnatal'), ('CHEBI_75275', 'tetradecyl sulfonic acid', 279, 'ultraviolet'), ('GO_0007565', 'female pregnancy', 334, 'prenatal')]	0	['example,  down-regulate interleukin 6, maternal infection  neural fetus.505152\n\n postnatal timing\nour results ultraviolet radiation exposure  period.']
S103-BMJ_2010_Apr_29_340_c1640	BMJ_2010_Apr_29_340_c1640	4/2010	S103-BMJ_2010_Apr_29_340_c1640	['overall, epidemiological studies SUPPORT a PROTECTIVE ROLE for Vitamin D in Autoimmune disease, PARTICULARLY in childhood and Adolescence, and Vitamin D supplementation in early Adulthood EFFECTIVELY reduces the risk of multiple sclerosis; THEREFORE, supplementation of adolescents and young Adults COULD BE effectively used for PREVENTION.6the FINDINGS HERE provide the FIRST population BASED evidence beyond month of Birth PATTERNS to INDICATE that Vitamin D supplementation for the PREVENTION of multiple sclerosis MIGHT also NEED to be CONSIDERED during in utero development.14they are CONSISTENT with a multi-hit causal cascade for multiple sclerosis, with PUTATIVE adverse environmental FACTORS, such as low Vitamin D concentrations, acting at more than one stage of Life.53\n\nwhat is already known on this topic\nin the northern hemisphere, there are more cases of multiple sclerosis in People Born in may and fewer in those Born in november\nmaternal exposure to ambient ultraviolet radiation in Pregnancy can be used as an instrumental variable for Vitamin D status during Pregnancy\nlow Vitamin D concentrations HAVE BEEN ASSOCIATED with a higher risk of multiple sclerosis\n\nwhat THIS STUDY adds\nin australia there is a reciprocal PATTERN of month of Birth and risk of multiple sclerosis, with a higher risk for those Born in november-december compared with may-june\nthis PATTERN was accounted FOR by maternal exposure to ambient ultraviolet radiation in the first trimester\nlow maternal exposure to Ultraviolet Radiation in the first trimester was inversely RELATED to risk of multiple sclerosis in the offspring after adjustment for either month of Birth or place of Birth\n\npubmed central:']	[('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 54), ('IMPORTANT_CONSIDERATION', 96), ('IMPORTANT_CONSIDERATION', 188), ('PROBABLE_UNDERSTANDING', 240), ('INCOMPLETE_EVIDENCE', 299), ('SUPERFICIAL_RELATIONSHIP', 329), ('INCOMPLETE_EVIDENCE', 345), ('QUESTION_ANSWERED_BY_THIS_WORK', 354), ('INCOMPLETE_EVIDENCE', 371), ('QUESTION_ANSWERED_BY_THIS_WORK', 388), ('SUPERFICIAL_RELATIONSHIP', 425), ('INCOMPLETE_EVIDENCE', 437), ('SUPERFICIAL_RELATIONSHIP', 485), ('INCOMPLETE_EVIDENCE', 518), ('FUTURE_WORK', 529), ('IMPORTANT_CONSIDERATION', 529), ('FUTURE_WORK', 540), ('IMPORTANT_CONSIDERATION', 540), ('INCOMPLETE_EVIDENCE', 590), ('SUPERFICIAL_RELATIONSHIP', 590), ('PROBABLE_UNDERSTANDING', 662), ('SUPERFICIAL_RELATIONSHIP', 693), ('INCOMPLETE_EVIDENCE', 1118), ('SUPERFICIAL_RELATIONSHIP', 1128), ('QUESTION_ANSWERED_BY_THIS_WORK', 1186), ('SUPERFICIAL_RELATIONSHIP', 1237), ('SUPERFICIAL_RELATIONSHIP', 1378), ('QUESTION_ANSWERED_BY_THIS_WORK', 1400), ('SUPERFICIAL_RELATIONSHIP', 1565)]	31	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 76, 'autoimmune'), ('GO_0048848', 'neurohypophysis morphogenesis', 126, 'adolescence'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('UBERON_0000113', 'post-juvenile adult stage', 178, 'adulthood'), ('UBERON_0007023', 'adult organism', 292, 'adults'), ('GO_0007567', 'parturition', 419, 'birth'), ('CHEBI_27300', 'vitamin D', 451, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 714, 'vitamin D'), ('UBERON_0000104', 'life cycle', 773, 'life'), ('NCBITaxon_10088', 'Mus <genus>', 892, 'people'), ('GO_0007567', 'parturition', 899, 'born'), ('GO_0007567', 'parturition', 930, 'born'), ('GO_0007565', 'female pregnancy', 1001, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1055, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1079, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1093, 'vitamin D'), ('GO_0007567', 'parturition', 1257, 'birth'), ('GO_0007567', 'parturition', 1324, 'born'), ('CHEBI_52927', 'To-Pro-1(2+)', 1506, 'ultraviolet radiation'), ('GO_0007567', 'parturition', 1657, 'birth'), ('GO_0007567', 'parturition', 1675, 'birth')]	0	['overall, epidemiological  autoimmune disease, childhood adolescence,  supplementation adulthood reduces sclerosis; therefore, supplementation adolescents young adults prevention.6the month birth  supplementation sclerosis utero development.14they multi-hit causal cascade sclerosis, environmental factors,  concentrations, life.53\n\nwhat topic\nin northern hemisphere, cases sclerosis people born born november\nmaternal exposure ambient ultraviolet radiation   status \nlow  concentrations higher sclerosis\n\nwhat adds\nin australia reciprocal month birth sclerosis, higher born november-december may-june\nthis maternal exposure ambient ultraviolet radiation trimester\nlow maternal exposure ultraviolet radiation trimester sclerosis offspring adjustment place birth\n\npubmed central:']
S67-PMC1168874	PMC1168874	7/2005	S67-PMC1168874	['it is WORTH MENTIONING that we had three mothers who were treated by 50,000 and one with 100,000 iu doses of Vitamin A daily in the first and second months of Gestation, and later they Delivered newborn infants without any cas25.']	[('IMPORTANT_CONSIDERATION', 6)]	1	[('CHEBI_27300', 'vitamin D', 109, 'vitamin A'), ('GO_0007565', 'female pregnancy', 159, 'gestation'), ('GO_0007567', 'parturition', 185, 'delivered')]	0	['mentioning three mothers treated 50,000 100,000 iu doses  daily months delivered newborn infants cas25.']
S40-PMC1544352	PMC1544352	6/2006	S40-PMC1544352	['(2001), usa [19]survey, self completed questionnaire150 women in 1stto 3rdtrimesters (24% response rate)13% used Dietary Supplement during Pregnancy45 herbs used, most common: echinacea, Pregnancy tea**, ginger, Vitamin B6*, Vitamin C*, multivitamin with herbs, raspberry leaf studies specifically CONCERNED with nausea hollyer et al.']	[('IMPORTANT_CONSIDERATION', 298)]	1	[('CHEBI_23888', 'drug', 113, 'dietary'), ('CHEBI_16158', 'steroid sulfate', 121, 'supplement'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy45'), ('GO_0007565', 'female pregnancy', 187, 'pregnancy'), ('CHEBI_33237', 'vitamin D4', 212, 'vitamin B6'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin C')]	0	['(2001), usa [19]survey, completed questionnaire150 women 1stto 3rdtrimesters (24% response rate)13% dietary supplement  herbs used, common: echinacea,  tea**, ginger, vitamin b6*, *, multivitamin herbs, raspberry leaf nausea hollyer et al.']
S46-PMC1888711	PMC1888711	5/2007	S46-PMC1888711	"['[\'beneficial EFFECTS on Birth weight and the risk of Postpartum endometritis were SEEN for high-risk women"""" [22].moderatedietary Vitamin A deficiencyvitamin a supplementation""""further EVIDENCE on biologically PLAUSIBLE mechanisms of morbidity reduction such as reduced incidence of sepsis and/or reduced MARKERS of inflammation ARE NEEDED"""" [60].lowdietary Micronutrient deficienciesmultiple Micronutrient supplementationone trial in tanzania showed no additional effect on markers of infection (C-Reactive Protein) compared with Iron and Folic Acid [15].lowanemia p. falciparum infectionanti-malarial Drugs""""Drugs given routinely for malaria during Pregnancy reduce SEVERE Antenatal anaemia in the mother, and are ASSOCIATED with higher Birth weight in the baby and PROBABLY fewer Perinatal deaths.\']']"	[('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 80), ('INCOMPLETE_EVIDENCE', 181), ('INCOMPLETE_EVIDENCE', 206), ('SUPERFICIAL_RELATIONSHIP', 301), ('FUTURE_WORK', 325), ('IMPORTANT_CONSIDERATION', 662), ('SUPERFICIAL_RELATIONSHIP', 710), ('PROBABLE_UNDERSTANDING', 762)]	9	[('GO_0007567', 'parturition', 22, 'birth'), ('GO_0007565', 'female pregnancy', 51, 'postpartum'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin A'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 353, 'micronutrient'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 388, 'micronutrient'), ('PR_000005890', 'crooked neck-like protein 1', 492, 'C-reactive protein'), ('CHEBI_24870', 'ion', 526, 'iron'), ('CHEBI_30751', 'formic acid', 535, 'folic acid'), ('CHEBI_23888', 'drug', 598, 'drugs'), ('CHEBI_23888', 'drug', 604, 'Drugs'), ('GO_0007565', 'female pregnancy', 645, 'pregnancy'), ('GO_0007567', 'parturition', 669, 'antenatal'), ('GO_0007567', 'parturition', 733, 'birth'), ('GO_0036268', 'swimming', 777, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 777, 'perinatal')]	0	"['[*beneficial birth oum endometritis women"""" [22].moderatedietan deficiencyvitamin supplementation""""further biologically mechanisms morbidity reduction sepsis and/or inflammation needed"""" [60].lowdietary micronutrient deficienciesmultiple micronutrient supplementationone tanzania infection (c-reactive protein) iron folic acid [15].lowanemia p. falciparum infectionanti-malarial drugs""""drugs routinely malaria dgnancy antenatal anaemia mother, higher birth baby perinatal deaths.*]']"
S48-PMC1888711	PMC1888711	5/2007	S48-PMC1888711	"['[\'routine daily or weekly Antenatal iron or iron plus Folic Acid supplementation MAY BE of benefit, especially where pre-Gestational iron deficiency and anaemia are prevalent"""" [26].moderatedietary Vitamin A deficiencyvitamin A supplementation""""FURTHER EVIDENCE on the effectiveness of adding Vitamin A to Iron and Folic Acid for treatment of anaemia IS NEEDED"""" [60].\']']"	[('INCOMPLETE_EVIDENCE', 79), ('INCOMPLETE_EVIDENCE', 241), ('FUTURE_WORK', 347)]	3	[('GO_0007567', 'parturition', 24, 'antenatal'), ('CHEBI_30751', 'formic acid', 52, 'folic acid'), ('GO_0007565', 'female pregnancy', 119, 'gestational'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 223, 'A'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin A'), ('CHEBI_24870', 'ion', 302, 'iron'), ('CHEBI_30751', 'formic acid', 311, 'folic acid')]	0	"['[*routine daily weekly antenatal iron iron plus folic acid supplementation benefit, pral iron anaemia prevalent"""" [26].moderatedietan deficiencyvitamin supplementation""""further addin iron folic acid treatment anaemia needed"""" [60].*]']"
S123-PMC1888711	PMC1888711	5/2007	S123-PMC1888711	['Albendazole HAS BEEN SHOWN to reduce the decline in haemoglobin during Pregnancy, but there is NO CONCLUSIVE EVIDENCE for an EFFECT of Vitamin A or other Micronutrients on anemia during Pregnancy, PARTICULARLY when compared with Iron and Folate supplementation [60,61].']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 125), ('ANOMALY_CURIOUS_FINDING', 197)]	4	[('CHEBI_16664', 'albendazole', 0, 'Albendazole'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin A'), ('CHEBI_33839', 'macromolecule', 154, 'micronutrients'), ('GO_0007565', 'female pregnancy', 186, 'pregnancy'), ('CHEBI_24870', 'ion', 229, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 238, 'folate')]	0	['albendazole decline haemoglobin  micronutrients anemia iron folate supplementation [60,61].']
S171-PMC2151954	PMC2151954	10/2007	S171-PMC2151954	['with respect to seasonally-fluctuating exposures that MAY UNDERLIE THESE FINDINGS, we SPECULATE that low Prenatal Vitamin D is a CANDIDATE that WARRANTS closer inspection [4].']	[('INCOMPLETE_EVIDENCE', 54), ('SUPERFICIAL_RELATIONSHIP', 58), ('INCOMPLETE_EVIDENCE', 67), ('INCOMPLETE_EVIDENCE', 86), ('INCOMPLETE_EVIDENCE', 129), ('FUTURE_WORK', 144)]	6	[('GO_0007565', 'female pregnancy', 105, 'prenatal'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]	0	['respect seasonally-fluctuating exposures findings,   closer inspection [4].']
S175-PMC2151954	PMC2151954	10/2007	S175-PMC2151954	['for example, low maternal Vitamin D levels HAVE BEEN ASSOCIATED with altered Birth anthropometry, with SOME STUDIES FINDING an ASSOCIATION between Vitamin D deficiency and larger Birth weight and length [29], WHILE others HAVE SHOWN an ASSOCIATION between lower maternal Vitamin D levels and shorter Gestation and smaller Knee-Heel length (a component of Birth length) [22].']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 53), ('INCOMPLETE_EVIDENCE', 103), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 127), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 209), ('INCOMPLETE_EVIDENCE', 222), ('SUPERFICIAL_RELATIONSHIP', 236)]	8	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007567', 'parturition', 77, 'birth'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0007567', 'parturition', 179, 'birth'), ('CHEBI_27300', 'vitamin D', 271, 'vitamin D'), ('GO_0007565', 'female pregnancy', 300, 'gestation'), ('UBERON_0001485', 'knee joint', 322, 'knee-heel'), ('GO_0007567', 'parturition', 355, 'birth')]	0	['example, maternal  levels altered birth anthropometry,  birth length [29], maternal  levels shorter  knee-heel length (a birth length) [22].']
S37-PMC2265059	PMC2265059	3/2008	S37-PMC2265059	['for example, in australia,mcgrath and colleagues (2005b)SUGGESTED that Prenatal Vitamin D ASSOCIATED with maternal exposure to sunlight is ASSOCIATED with the seasonal variation in Birth weight.']	[('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 90), ('SUPERFICIAL_RELATIONSHIP', 139)]	3	[('GO_0007565', 'female pregnancy', 71, 'prenatal'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007567', 'parturition', 181, 'birth')]	0	['example, australia,mcgrath colleagues (2005b)suggested   maternal exposure sunlight seasonal birth weight.']
S102-PMC2290997	PMC2290997	4/2008	S102-PMC2290997	['such groups include Pregnant or breastfeeding women (these states draw upon a mother’s own reserves of Vitamin D), the elderly, and those who MUST avoid the sun.']	[('IMPORTANT_CONSIDERATION', 142)]	1	[('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]	0	[' breastfeeding women (these draw mother’s ), elderly, sun.']
S11-PMC2396486	PMC2396486	6/2008	S11-PMC2396486	['disruptions in pathways RELATED to calcium-binding proteins and Mitochondrial function MAY underlie SOME of the behavioural features ASSOCIATED with Animal MODELS of developmental Vitamin D deficiency\n\nintroduction\nbased on CLUES from epidemiology, we have PROPOSED that low Prenatal Vitamin D MAY BE a risk factor for later development of schizophrenia[1].']	[('SUPERFICIAL_RELATIONSHIP', 24), ('INCOMPLETE_EVIDENCE', 87), ('INCOMPLETE_EVIDENCE', 100), ('SUPERFICIAL_RELATIONSHIP', 133), ('INCOMPLETE_EVIDENCE', 156), ('INCOMPLETE_EVIDENCE', 224), ('INCOMPLETE_EVIDENCE', 257), ('INCOMPLETE_EVIDENCE', 294)]	8	[('GO_0005739', 'mitochondrion', 64, 'mitochondrial'), ('NCBITaxon_33208', 'Metazoa', 149, 'animal'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('GO_0007565', 'female pregnancy', 275, 'prenatal'), ('CHEBI_27300', 'vitamin D', 284, 'vitamin D')]	0	['disruptions calcium-binding proteins mitochondrial behavioural animal developmental  deficiency\n\nintroduction\nbased epidemiology,   schizophrenia[1].']
S13-PMC2396486	PMC2396486	6/2008	S13-PMC2396486	['given that Vitamin D levels in the population fluctuate across the seasons and decrease across higher latitude[4], low Prenatal Vitamin D ‘FITS’ these key environmental features and is THEREFORE a PLAUSIBLE CANDIDATE risk factor for this disease.']	[('SUPERFICIAL_RELATIONSHIP', 139), ('PROBABLE_UNDERSTANDING', 185), ('INCOMPLETE_EVIDENCE', 197), ('INCOMPLETE_EVIDENCE', 207)]	4	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'prenatal'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]	0	['given  levels population fluctuate seasons decrease higher latitude[4],   ‘fits’ environmental disease.']
S15-PMC2396486	PMC2396486	6/2008	S15-PMC2396486	['Rats exposed to low Prenatal Vitamin D have a broad range of neurobiological outcomes that are INFORMATIVE for schizophrenia research.']	[('INCOMPLETE_EVIDENCE', 95)]	1	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Rats'), ('GO_0007565', 'female pregnancy', 20, 'prenatal'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D')]	0	['rats exposed   broad neurobiological outcomes schizophrenia research.']
S13-PMC2405769	PMC2405769	5/2008	S13-PMC2405769	['background\nmultivitamin-Mineral supplementation is RECOMMENDED before and during Pregnancy to ensure adequate intake of several KEY Nutrients including Folate, iron, and more RECENTLY Vitamin D – all of which have IMPORTANCE among Pregnant women, women of Childbearing age, and during Fetal Development [1-6].']	[('FUTURE_WORK', 51), ('IMPORTANT_CONSIDERATION', 128), ('INCOMPLETE_EVIDENCE', 175), ('IMPORTANT_CONSIDERATION', 214)]	4	[('CHEBI_46662', 'mineral', 24, 'mineral'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy'), ('CHEBI_33284', 'nutrient', 132, 'nutrients'), ('CHEBI_30863', '5-azaorotic acid', 152, 'folate'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 231, 'pregnant'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 256, 'childbearing'), ('GO_0002065', 'columnar/cuboidal epithelial cell differentiation', 285, 'fetal development')]	0	['background\nmultivitamin-mineral supplementation  ensure intake nutrients folate, iron,  among  women, women childbearing age, fetal [1-6].']
S0-PMC2581757	PMC2581757	11/2008	S0-PMC2581757	['ROLE of Vitamins C and e in Regulating antioxidant and pro-oxidant markers in Preeclampsia\n\nabstract\nwe compared three groups of Pregnant women: placebo with normotensive women, group a which included preeclamptics, and group b which comprised preeclamptics who were supplemented their diets with Vitamins C and e. Mda increased from 6.22\xa0±\xa02.8 (Placebo) to 8.48\xa0±\xa01.2 (a) and 8.02\xa0±\xa01.8\xa0nmol/ghb (b).']	[('SUPERFICIAL_RELATIONSHIP', 0)]	1	[('CHEBI_27306', 'vitamin B6', 8, 'Vitamins C'), ('PR_000027594', 'histone H3', 8, 'Vitamins C'), ('GO_0065007', 'biological regulation', 28, 'Regulating'), ('GO_0007128', 'meiotic prophase I', 78, 'Preeclampsia'), ('GO_0007565', 'female pregnancy', 129, 'pregnant'), ('CHEBI_27300', 'vitamin D', 297, 'vitamins C'), ('CHEBI_34840', 'methyl methacrylate', 315, 'MDA'), ('CHEBI_26130', 'biological pigment', 346, 'placebo')]	0	['role vitamins c e antioxidant pro-oxidant preeclampsia\n\nabstract\nwe three  women: placebo normotensive women, preeclamptics, b comprised preeclamptics supplemented diets  e. mda 6.22\xa0±\xa02.8 (placebo) 8.48\xa0±\xa01.2 (a) 8.02\xa0±\xa01.8\xa0nmol/ghb (b).']
S13-PMC2581757	PMC2581757	11/2008	S13-PMC2581757	['HOWEVER, in a recent review, antioxidant therapy HAS BEEN SUGGESTED and that the prophylactic supplementation of Vitamins C and E to Pregnant women is ASSOCIATED with reduced incidence of preeclampsia and decreased Placental and Endothelial dysfunction [9].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 151)]	3	[('CHEBI_27300', 'vitamin D', 113, 'vitamins C'), ('PR_000004900', 'complement C3', 122, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 128, 'E'), ('GO_0007565', 'female pregnancy', 133, 'pregnant'), ('UBERON_0001987', 'placenta', 215, 'placental'), ('UBERON_0001986', 'endothelium', 229, 'endothelial')]	0	['however, review, antioxidant therapy prophylactic supplementation  e  women preeclampsia decreased placental endothelial dysfunction [9].']
S16-PMC2581757	PMC2581757	11/2008	S16-PMC2581757	['THUS, decreased Plasma levels of Vitamin E COULD BE a CONTRIBUTORY FACTOR of hypertension in preeclampsia, BUT OTHER STUDIES have not demonstrated significant differences in Plasma Vitamin E levels between normal and Preeclamptic women [13].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 54), ('SUPERFICIAL_RELATIONSHIP', 67), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 107), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 111), ('INCOMPLETE_EVIDENCE', 117)]	7	[('UBERON_0001969', 'blood plasma', 16, 'plasma'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin E'), ('UBERON_0001969', 'blood plasma', 174, 'plasma'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin E'), ('GO_0007565', 'female pregnancy', 217, 'preeclamptic')]	0	['thus, decreased plasma levels  hypertension preeclampsia, plasma  levels normal  women [13].']
S36-PMC2581757	PMC2581757	11/2008	S36-PMC2581757	['in VIEW of the CONTRADICTORY REPORTS and the SERIOUSNESS of preeclampsia, the PRESENT STUDY included the determination of the activities of catalase, sod, Gpx and Grx in the Blood of normal and Preeclamptic women with and without vitamin treatment, along-with the contents of mda, Gsh, gssg, gssg/Gsh, no and Uric Acid, TO collectively EVALUATE the ROLES of Vitamins C and e in the Regulation of these factors.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 15), ('INCOMPLETE_EVIDENCE', 29), ('IMPORTANT_CONSIDERATION', 45), ('QUESTION_ANSWERED_BY_THIS_WORK', 78), ('QUESTION_ANSWERED_BY_THIS_WORK', 320), ('QUESTION_ANSWERED_BY_THIS_WORK', 336), ('SUPERFICIAL_RELATIONSHIP', 349)]	8	[('PR_000008210', 'glutathione peroxidase 1', 155, 'GPx'), ('PR_000008290', 'eukaryotic peptide chain release factor GTP-binding subunit ERF3A', 163, 'GRx'), ('UBERON_0000178', 'blood', 174, 'blood'), ('GO_0007565', 'female pregnancy', 194, 'preeclamptic'), ('CHEBI_16856', 'glutathione', 281, 'GSH'), ('CHEBI_16856', 'glutathione', 297, 'GSH'), ('CHEBI_27226', 'uric acid', 309, 'uric acid'), ('CHEBI_27300', 'vitamin D', 358, 'vitamins C'), ('GO_0065007', 'biological regulation', 382, 'regulation')]	0	['preeclampsia, determination activities catalase, sod, gpx grx blood normal  women vitamin treatment, along-with contents mda, gsh, gssg, gssg/gsh, uric acid, collectively  e factors.']
S45-PMC2581757	PMC2581757	11/2008	S45-PMC2581757	['group b initially consisted of a high number of patients who were viewed as being at an INCREASED RISK of preeclampsia BECAUSE of FACTORS such as preeclampsia in a preceding Pregnancy, hellp syndrome, or eclampsia in any past Pregnancy at any Gestational stage, and who were taking additional Vitamin supplement (1000\xa0mg Vitamin C plus 400\xa0iu Vitamin E per day) from the second Trimester of Pregnancy to Delivery as mentioned for the controls (placebo).']	[('IMPORTANT_CONSIDERATION', 88), ('PROBLEM_COMPLICATION', 119), ('SUPERFICIAL_RELATIONSHIP', 130)]	3	[('GO_0007565', 'female pregnancy', 174, 'pregnancy'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('GO_0007565', 'female pregnancy', 243, 'gestational'), ('CHEBI_33229', 'vitamin (role)', 293, 'vitamin'), ('CHEBI_27300', 'vitamin D', 321, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 343, 'vitamin E'), ('GO_0009294', 'DNA mediated transformation', 378, 'trimester'), ('GO_0007565', 'female pregnancy', 391, 'pregnancy'), ('GO_0007567', 'parturition', 404, 'delivery')]	0	['group b consisted patients preeclampsia preeclampsia preceding hellp syndrome, eclampsia   stage, vitamin supplement (1000\xa0mg  plus 400\xa0iu  day) trimester  delivery (placebo).']
S130-PMC2581757	PMC2581757	11/2008	S130-PMC2581757	['those who consumed Vitamin E and C during the Gestational period from the second Trimester of Pregnancy to Delivery DEMONSTRATED an insignificant ( p \xa0=\xa00.5395) fall in Grx activities.']	[('INCOMPLETE_EVIDENCE', 116)]	1	[('CHEBI_27300', 'vitamin D', 19, 'vitamin E'), ('CHEBI_18245', 'carboxylato group', 33, 'C'), ('GO_0007565', 'female pregnancy', 46, 'gestational'), ('GO_0009294', 'DNA mediated transformation', 81, 'trimester'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('GO_0007567', 'parturition', 107, 'delivery'), ('PR_000008290', 'eukaryotic peptide chain release factor GTP-binding subunit ERF3A', 169, 'GRx')]	0	['consumed  c  period trimester  delivery p \xa0=\xa00.5395) fall grx activities.']
S195-PMC2581757	PMC2581757	11/2008	S195-PMC2581757	['we FOUND that the patients supplemented with Vitamin C 1000\xa0mg plus Vitamin E 400\xa0iu daily from the second Trimester of Pregnancy until Delivery showed improvements in certain biochemical indices during the Development Of Preeclampsia.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin E'), ('GO_0009294', 'DNA mediated transformation', 107, 'trimester'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('GO_0007567', 'parturition', 136, 'delivery'), ('GO_0070483', 'detection of hypoxia', 207, 'development of preeclampsia')]	0	['patients supplemented  1000\xa0mg plus  400\xa0iu daily trimester  delivery biochemical indices preeclampsia.']
S0-PMC2582131	PMC2582131	11/2008	S0-PMC2582131	['Maternal Plasma 25-Hydroxyvitamin D concentrations and the risk for Gestational diabetes mellitus\n\nabstract\n\nbackground\nEVIDENCE is ACCUMULATING for a ROLE of Vitamin D in maintaining normal Glucose Homeostasis.']	[('INCOMPLETE_EVIDENCE', 120), ('INCOMPLETE_EVIDENCE', 132), ('SUPERFICIAL_RELATIONSHIP', 151)]	3	[('UBERON_0000976', 'humerus', 0, 'Maternal'), ('UBERON_0001969', 'blood plasma', 9, 'Plasma'), ('CHEBI_27844', '2*,3*-cyclic AMP', 16, '25-Hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 68, 'Gestational'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('CHEBI_17234', 'glucose', 191, 'glucose'), ('GO_0042593', 'glucose homeostasis', 191, 'glucose homeostasis')]	0	['maternal plasma 25-hydroxyvitamin concentrations  diabetes mellitus\n\nabstract\n\nbackground\nevidence  maintaining normal glucose homeostasis.']
S12-PMC2582131	PMC2582131	11/2008	S12-PMC2582131	['conclusions\nFINDINGS from the PRESENT STUDY SUGGEST that maternal Vitamin D deficiency in early Pregnancy is significantly ASSOCIATED with an elevated RISK for gdm.']	[('INCOMPLETE_EVIDENCE', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 123), ('IMPORTANT_CONSIDERATION', 151)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]	0	['conclusions\nfindings maternal   gdm.']
S19-PMC2582131	PMC2582131	11/2008	S19-PMC2582131	['it HAS long BEEN KNOWN that Vitamin D deficiency is PREVALENT among Pregnant women[20]–[22].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 17), ('IMPORTANT_CONSIDERATION', 52)]	3	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnant')]	0	[' among  women[20]–[22].']
S20-PMC2582131	PMC2582131	11/2008	S20-PMC2582131	['for instance, RECENT DATA among Pregnant women in northern united states INDICATED that Vitamin D deficiency occurred in 29.2% of black women and 5% of white women[23].']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 73)]	2	[('GO_0007565', 'female pregnancy', 32, 'pregnant'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]	0	['instance, among  women northern united  29.2% black women 5% white women[23].']
S21-PMC2582131	PMC2582131	11/2008	S21-PMC2582131	['data on the ROLE of Vitamin D in Glucose Homeostasis during Pregnancy and the development of Gestational Diabetes Mellitus (gdm) are SCANT and findings are INCONSISTENT.']	[('SUPERFICIAL_RELATIONSHIP', 12), ('INCOMPLETE_EVIDENCE', 133), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 156)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_17234', 'glucose', 33, 'glucose'), ('GO_0042593', 'glucose homeostasis', 33, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('GO_0035193', 'larval central nervous system remodeling', 93, 'gestational diabetes mellitus')]	0	['data  glucose homeostasis  gestational diabetes mellitus (gdm) inconsistent.']
S26-PMC2582131	PMC2582131	11/2008	S26-PMC2582131	['in the PRESENT STUDY, we EVALUATED the ASSOCIATION between maternal Plasma Vitamin D concentrations in early Pregnancy and subsequent risk of gdm based ON a prospective cohort study of Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 7), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('SUPERFICIAL_RELATIONSHIP', 39), ('ANOMALY_CURIOUS_FINDING', 152)]	4	[('UBERON_0001969', 'blood plasma', 68, 'plasma'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'pregnancy'), ('GO_0007565', 'female pregnancy', 185, 'pregnant')]	0	['study, maternal plasma  concentrations  gdm  women.']
S79-PMC2582131	PMC2582131	11/2008	S79-PMC2582131	['the risk for gdm was highest for overweight women who were classified as being deficient for Vitamin D (25-[Oh] D<20 ng/ml in Pregnancy); they experienced an APPROXIMATELY 5-fold increased risk as compared with lean women of higher Plasma 25-[Oh] D levels (adjusted or\u200a=\u200a4.93, 95% ci 1.63–14.9) ( table 3 ).10.1371/journal.pone.0003753.t003\n\ncaption (table-wrap): table 3\nodds ratios (or) and 95% confidence intervals (ci) for Gestational diabetes (gdm) according to both maternal Plasma 25-Hydroxyvitamin D deficient status and pre-Pregnancy overweight status.Vitamin D deficiency*overweight**gdm casescontrolsunadjusted or (95% ci)adjusted1or (95% ci)(n\u200a=\u200a57)(n\u200a=\u200a114)nono22751.00 (referent)1.00 (referent)yesno792.65 (0.89–7.93)2.36 (0.75–7.43)noyes16232.37 (1.07–5.25)2.24 (0.99–5.08)yesyes1275.84 (2.05–16.6)4.93 (1.63–14.9) p value for interaction term0.930.93\nVitamin D deficiency is DEFINED as maternal Plasma 25-Hydroxyvitamin D concentrations <20 ng/ml (holick mf,[reference 1]).']	[('INCOMPLETE_EVIDENCE', 158), ('PROBABLE_UNDERSTANDING', 891)]	2	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_34300', '2-naphthoyl-CoA', 104, '25-[OH] D'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 232, 'plasma'), ('CHEBI_34300', '2-naphthoyl-CoA', 239, '25-[OH] D'), ('GO_0007565', 'female pregnancy', 427, 'gestational'), ('UBERON_0001969', 'blood plasma', 481, 'plasma'), ('CHEBI_27844', '2*,3*-cyclic AMP', 488, '25-Hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 533, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 561, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 867, 'Vitamin D'), ('UBERON_0001969', 'blood plasma', 911, 'plasma'), ('CHEBI_27844', '2*,3*-cyclic AMP', 918, '25-Hydroxyvitamin D')]	0	['gdm overweight women  (25-[oh] d<20 ng/ml ); experienced 5-fold lean women higher plasma 25-[oh] levels (adjusted or\u200a=\u200a4.93, 95% ci 1.63–14.9) table 3 ).10.1371/journal.pone.0003753.t003\n\ncaption (table-wrap): table 3\nodds ratios (or) 95% confidence intervals (ci)  diabetes (gdm) maternal plasma 25-hydroxyvitamin status pre- overweight status.vitamin deficiency*overweight**gdm casescontrolsunadjusted (95% ci)adjusted1or (95% ci)(n\u200a=\u200a57)(n\u200a=\u200a114)nono22751.00 (referent)1.00 (referent)yesno792.65 (0.89–7.93)2.36 (0.75–7.43)noyes16232.37 (1.07–5.25)2.24 (0.99–5.08)yesyes1275.84 (2.05–16.6)4.93 (1.63–14.9) p term0.930.93\nvitamin maternal plasma 25-hydroxyvitamin concentrations <20 ng/ml (holick mf,[reference 1]).']
S100-PMC2582131	PMC2582131	11/2008	S100-PMC2582131	['OUR FINDINGS are also GENERALLY CONSISTENT with a relatively large body of LITERATURE documenting a significant and inverse ASSOCIATION of circulating Vitamin D concentrations with measurements of glycemia or presence of type 2 dm among non-Pregnant women, ALTHOUGH the majority of THESE FINDINGS are based ON cross-sectional/RETROSPECTIVE data.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('PROBABLE_UNDERSTANDING', 22), ('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 75), ('SUPERFICIAL_RELATIONSHIP', 124), ('ANOMALY_CURIOUS_FINDING', 257), ('INCOMPLETE_EVIDENCE', 282), ('ANOMALY_CURIOUS_FINDING', 307), ('INCOMPLETE_EVIDENCE', 326)]	9	[('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007565', 'female pregnancy', 241, 'pregnant')]	0	['circulating  concentrations measurements glycemia presence type 2 dm among non- women, cross-sectional/retrospective data.']
S110-PMC2582131	PMC2582131	11/2008	S110-PMC2582131	['first, determination of 25-[Oh] D concentrations using Plasma collected in early Pregnancy served to define the temporal RELATIONSHIP between maternal Vitamin D deficiency and subsequent risk of gdm BECAUSE, in general, Pregnant women develop Gestational diabetes during the late 2ndor 3rdtrimester.']	[('SUPERFICIAL_RELATIONSHIP', 121), ('PROBABLE_UNDERSTANDING', 199)]	2	[('CHEBI_34300', '2-naphthoyl-CoA', 24, '25-[OH] D'), ('UBERON_0001969', 'blood plasma', 55, 'plasma'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007565', 'female pregnancy', 220, 'pregnant'), ('GO_0007565', 'female pregnancy', 243, 'gestational')]	0	['first, determination 25-[oh] concentrations using plasma  served temporal maternal  gdm because, general,  women  diabetes late 2ndor 3rdtrimester.']
S114-PMC2582131	PMC2582131	11/2008	S114-PMC2582131	['first, a single measurement of Plasma 25-[Oh] D concentrations is not LIKELY to provide a time-integrated measure of maternal Vitamin D status during the entire study Pregnancy.']	[('PROBABLE_UNDERSTANDING', 70)]	1	[('UBERON_0001969', 'blood plasma', 31, 'plasma'), ('CHEBI_34300', '2-naphthoyl-CoA', 38, '25-[OH] D'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy')]	0	['first, single plasma 25-[oh] concentrations time-integrated measure maternal  status .']
S115-PMC2582131	PMC2582131	11/2008	S115-PMC2582131	['longitudinal STUDIES with serial measurements of maternal Plasma 25-[Oh] D concentrations, indices of Insulin sensitivity and secretion ARE NEEDED to ELUCIDATE the mechanisms and patho-physiological consequences of maternal Vitamin D deficiency during Pregnancy.']	[('FUTURE_WORK', 13), ('FUTURE_WORK', 136), ('FUTURE_WORK', 150)]	3	[('UBERON_0001969', 'blood plasma', 58, 'plasma'), ('CHEBI_34300', '2-naphthoyl-CoA', 65, '25-[OH] D'), ('PR_000045358', 'insulin family protein', 102, 'insulin'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('GO_0007565', 'female pregnancy', 252, 'pregnancy')]	0	['longitudinal serial measurements maternal plasma 25-[oh] concentrations, indices insulin sensitivity secretion mechanisms patho-physiological maternal  .']
S119-PMC2582131	PMC2582131	11/2008	S119-PMC2582131	['in CONCLUSION, OUR STUDY provides data INDICATING that maternal Vitamin D deficiency in early Pregnancy (i.e.']	[('INCOMPLETE_EVIDENCE', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('INCOMPLETE_EVIDENCE', 39)]	3	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy')]	0	['conclusion, maternal   (i.e.']
S121-PMC2582131	PMC2582131	11/2008	S121-PMC2582131	['such EVIDENCE is valuable in view of the LIMITED prospective DATA on the RELATION of circulating Vitamin D status to impaired Glucose tolerance in either Pregnant or non-Pregnant Individuals.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 73)]	3	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('GO_0007565', 'female pregnancy', 170, 'pregnant'), ('NCBITaxon_1', 'root', 179, 'individuals')]	0	['circulating  status glucose tolerance non- individuals.']
S125-PMC2582131	PMC2582131	11/2008	S125-PMC2582131	['intervention studies[14],[40]–[44]assessing the EFFECT of Vitamin D and Calcium supplements on Glucose Metabolism among non-Pregnant Individuals have yielded MIXED results, which is AT LEAST PARTLY DUE TO VARIATIONS in the dose of supplementation and the duration of follow up.']	[('SUPERFICIAL_RELATIONSHIP', 48), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('PROBABLE_UNDERSTANDING', 182), ('INCOMPLETE_EVIDENCE', 191), ('PROBLEM_COMPLICATION', 198), ('DIFFICULT_TASK', 205)]	6	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 72, 'calcium'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0006006', 'glucose metabolic process', 95, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'pregnant'), ('NCBITaxon_1', 'root', 133, 'individuals')]	0	['intervention studies[14],[40]–[44]assessing  calcium supplements glucose metabolism among non- individuals results, dose supplementation duration up.']
S127-PMC2582131	PMC2582131	11/2008	S127-PMC2582131	['IF CONFIRMED, our data RAISE the POSSIBILITY that treating Vitamin D deficiency in Pregnancy, via supplementation OR lifestyle measures, CAN CONTRIBUTE to the PREVENTION of gdm.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 3), ('EXPLICIT_QUESTION', 23), ('INCOMPLETE_EVIDENCE', 33), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114), ('INCOMPLETE_EVIDENCE', 137), ('SUPERFICIAL_RELATIONSHIP', 141), ('SUPERFICIAL_RELATIONSHIP', 159)]	8	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]	0	['confirmed, treating  via supplementation lifestyle measures, gdm.']
S10-PMC2606998	PMC2606998	6/2007	S10-PMC2606998	['MOST STRIKING were the low levels of Folate and Vitamin D intake both before Pregnancy and at mid-Gestation.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 5)]	2	[('CHEBI_30863', '5-azaorotic acid', 37, 'folate'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0007565', 'female pregnancy', 98, 'gestation')]	0	['levels folate  intake  mid-.']
S12-PMC2606998	PMC2606998	6/2007	S12-PMC2606998	['in the industrialized countries, Intake of Folate, Vitamin\u2009D and iron, all with a SUGGESTED IMPACT on Pregnancy outcome, HAS BEEN REPORTED to be low in Pregnant women3–5.']	[('INCOMPLETE_EVIDENCE', 82), ('SUPERFICIAL_RELATIONSHIP', 92), ('INCOMPLETE_EVIDENCE', 121)]	3	[('GO_0007631', 'feeding behavior', 33, 'intake'), ('CHEBI_30863', '5-azaorotic acid', 43, 'folate'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('GO_0007565', 'female pregnancy', 152, 'pregnant')]	0	['industrialized countries, intake folate,  iron,  outcome,  women3–5.']
S72-PMC2606998	PMC2606998	6/2007	S72-PMC2606998	['relative to the RECOMMENDATIONS for planning a diet (% of ri), the studied women had low intakes of Folate, Vitamin\u2009D, Selenium, Vitamin\u2009E and iron both before and at 18–22 weeks of Pregnancy (table4).']	[('FUTURE_WORK', 16)]	1	[('CHEBI_30863', '5-azaorotic acid', 100, 'folate'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 119, 'selenium'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin E'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy')]	0	['relative diet (% ri), women intakes folate, selenium,  iron 18–22 weeks  (table4).']
S73-PMC2606998	PMC2606998	6/2007	S73-PMC2606998	['when ASSUMING a 20% UNDERREPORTING before Pregnancy, the RECOMMENDATION for Vitamin\u2009E and iron intake was met, but Intake of Folate, Selenium and Vitamin\u2009D remained below ri for non-Pregnant women.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('PROBLEM_COMPLICATION', 20), ('FUTURE_WORK', 57)]	3	[('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin E'), ('GO_0007631', 'feeding behavior', 115, 'intake'), ('CHEBI_30863', '5-azaorotic acid', 125, 'folate'), ('CHEBI_27568', 'selenium atom', 133, 'selenium'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'pregnant')]	0	['20%  iron intake met, intake folate, selenium  ri non- women.']
S74-PMC2606998	PMC2606998	6/2007	S74-PMC2606998	['when recalculating for the ASSUMED 20% underreporting during Pregnancy, mean intakes of Folate, Vitamin\u2009D, Selenium, Vitamin\u2009E and iron were still below ri.']	[('PROBABLE_UNDERSTANDING', 27)]	1	[('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('CHEBI_30863', '5-azaorotic acid', 88, 'folate'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 107, 'selenium'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin E')]	0	['recalculating 20% intakes folate, selenium,  iron ri.']
S84-PMC2606998	PMC2606998	6/2007	S84-PMC2606998	['from this perspective, the most STRIKING result from THIS STUDY was the CONSIDERABLY lower than RECOMMENDED intakes of Folate and Vitamin\u2009D, both before and during Pregnancy, EVEN when PROBABLE UNDERREPORTING was taken INTO ACCOUNT.']	[('ANOMALY_CURIOUS_FINDING', 32), ('QUESTION_ANSWERED_BY_THIS_WORK', 53), ('ANOMALY_CURIOUS_FINDING', 72), ('FUTURE_WORK', 96), ('ANOMALY_CURIOUS_FINDING', 175), ('PROBABLE_UNDERSTANDING', 185), ('PROBLEM_COMPLICATION', 194), ('INCOMPLETE_EVIDENCE', 219)]	8	[('CHEBI_30863', '5-azaorotic acid', 119, 'folate'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 164, 'pregnancy')]	0	['perspective, result intakes folate account.']
S86-PMC2606998	PMC2606998	6/2007	S86-PMC2606998	['both Folate and Vitamin\u2009D are CONSIDERED to have PROFOUND EFFECTS on Pregnancy outcome, as well as on maternal health.6,7.']	[('IMPORTANT_CONSIDERATION', 30), ('INCOMPLETE_EVIDENCE', 30), ('IMPORTANT_CONSIDERATION', 49), ('SUPERFICIAL_RELATIONSHIP', 58)]	4	[('CHEBI_30863', '5-azaorotic acid', 5, 'folate'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy')]	0	['folate   outcome, maternal health.6,7.']
S124-PMC2606998	PMC2606998	6/2007	S124-PMC2606998	['in the PRESENT STUDY Selenium, Calcium and Vitamin\u2009C density were higher, and iron was lower at mid-Gestation compared with the densities of these Nutrients before Gestation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 7)]	1	[('CHEBI_27568', 'selenium atom', 21, 'selenium'), ('CHEBI_22313', 'alkaline earth metal atom', 31, 'calcium'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin C'), ('GO_0007565', 'female pregnancy', 100, 'gestation'), ('CHEBI_33284', 'nutrient', 147, 'nutrients'), ('GO_0007565', 'female pregnancy', 164, 'gestation')]	0	['selenium, calcium  density higher, iron mid- densities nutrients .']
S311-PMC2642759	PMC2642759	1/2009	S311-PMC2642759	"['[""""[87] evaluated WHETHER combined Antenatal Corticosteroid and Vitamin K administration has a BENEFIT, over and above that of Corticosteroid OR Vitamin K used alone, in reducing the frequency and the degree of Periventricular-Intraventricular haemorrhage (pivh) in premature newborns of less than 35 weeks\' Gestation.""""]']"	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 15), ('IMPORTANT_CONSIDERATION', 92)]	2	[('GO_0007567', 'parturition', 32, 'antenatal'), ('CHEBI_36916', 'cation', 42, 'corticosteroid'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin K'), ('CHEBI_36916', 'cation', 124, 'corticosteroid'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin K'), ('UBERON_0002281', 'vestibular membrane of cochlear duct', 208, 'periventricular'), ('UBERON_0006250', 'infundibular recess of 3rd ventricle', 224, 'intraventricular'), ('GO_0007565', 'female pregnancy', 305, 'gestation')]	0	"['[""""[87] combined antenatal corticosteroid k administration benefit, corticosteroid n k alone, reducing frequency degree periventricular-intraventricular haemorrhage (pivh) premature newborns 35 weekion.""""]']"
S185-PMC2646054	PMC2646054	3/2009	S185-PMC2646054	['experiments in hypercholesterolemic Rabbits HAVE SHOWN that administration of the antioxidant Vitamin E during Pregnancy resulted in reduced atherosclerotic lesions in the offspring (16,17), INDICATING that maternal oxidative stress LIKELY plays a ROLE in maternal programming for atherosclerosis.']	[('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 191), ('PROBABLE_UNDERSTANDING', 233), ('SUPERFICIAL_RELATIONSHIP', 248)]	4	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 36, 'rabbits'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin E'), ('GO_0007565', 'female pregnancy', 111, 'pregnancy')]	0	['experiments hypercholesterolemic rabbits administration antioxidant   resulted atherosclerotic lesions offspring (16,17), maternal oxidative plays maternal programming atherosclerosis.']
S483-PMC2679409	PMC2679409	5/2009	S483-PMC2679409	['[96] performed a cochrane review of 5 trials of women who had received Vitamin A in Pregnancy (n = 23,426), but ONLY one study [101], REPORTED Perinatal mortality [loe: 1+] (additional file12).']	[('INCOMPLETE_EVIDENCE', 112), ('INCOMPLETE_EVIDENCE', 134)]	2	[('CHEBI_27300', 'vitamin D', 71, 'vitamin A'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('GO_0036268', 'swimming', 143, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 143, 'perinatal')]	0	['[96] cochrane 5 women received   (n = 23,426), [101], perinatal mortality [loe: 1+] (additional file12).']
S491-PMC2679409	PMC2679409	5/2009	S491-PMC2679409	['3 rcts included.assessed the IMPACT on Pregnancy outcomes of Vitamin A supplementation +/- multivitamins (intervention #1), compared to supplementation with placebo +/- multivitamins (controls).']	[('SUPERFICIAL_RELATIONSHIP', 29)]	1	[('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin A')]	0	['3 rcts included.assessed  outcomes  supplementation +/- multivitamins (intervention #1), supplementation placebo +/- multivitamins (controls).']
S494-PMC2679409	PMC2679409	5/2009	S494-PMC2679409	['1 rct included.assessed the IMPACT on Pregnancy outcomes of Vitamin A (intervention #1) and/or Β-Carotene (intervention #2) supplementation vs. placebo (controls).Fetal death: rr = 1.04 (95% ci: 0.92–1.17) [ns] in women receiving Vitamin A vs. controls, respectively.Fetal death: rr = 1.03 (95% ci: 0.91–1.16) [ns] in women receiving Β-Carotene vs. controls, respectively.wiysonge et al.']	[('SUPERFICIAL_RELATIONSHIP', 28)]	1	[('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 95, 'β-carotene'), ('GO_0008618', '7-methylguanosine metabolic process', 163, 'Fetal'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin A'), ('GO_0008618', '7-methylguanosine metabolic process', 267, 'Fetal'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 334, 'β-carotene')]	0	['1 included.assessed  outcomes  (intervention #1) and/or β-carotene (intervention #2) supplementation vs. placebo (controls).fetal death: rr = 1.04 (95% ci: 0.92–1.17) [ns] women receiving  vs. controls, respectively.fetal death: rr = 1.03 (95% ci: 0.91–1.16) [ns] women receiving β-carotene vs. controls, respectively.wiysonge et al.']
S496-PMC2679409	PMC2679409	5/2009	S496-PMC2679409	['4 rcts included.compared the IMPACT on Pregnancy outcomes of Vitamin A supplementation (intervention) vs. no Vitamin A supplementation (controls).sbr: or = 0.99 (95% ci: 0.67–1.46) [ns] .']	[('SUPERFICIAL_RELATIONSHIP', 29)]	1	[('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin A')]	0	['4 rcts included.compared  outcomes  supplementation (intervention) vs.  supplementation (controls).sbr: = 0.99 (95% ci: 0.67–1.46) [ns] .']
S13-PMC2685863	PMC2685863	5/2009	S13-PMC2685863	['the authors PROPOSE that Vitamin D supplementation at CRITICAL periods during Pregnancy and early childhood MIGHT reduce the RISK for developing ms—a VIEW endorsed by bruce hollis, a nutritional biochemist and professor of pediatrics at the medical university of south carolina.']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 54), ('INCOMPLETE_EVIDENCE', 108), ('IMPORTANT_CONSIDERATION', 125), ('INCOMPLETE_EVIDENCE', 150)]	5	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy')]	0	['authors  supplementation periods  childhood ms—a bruce hollis, nutritional biochemist professor pediatrics medical university south carolina.']
S14-PMC2685863	PMC2685863	5/2009	S14-PMC2685863	['WHEREAS the institute of medicine RECOMMENDS 200 international units of Vitamin D per day (iu/day) for People under age 50, including Pregnant and Lactating women and infants, hollis wrote in the december 2007 issue of the journal of bone and Mineral research that as much as 6,000 iu/day MIGHT be NEEDED to maintain adequate Blood levels of the Vitamin in these populations.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 34), ('INCOMPLETE_EVIDENCE', 289), ('FUTURE_WORK', 298), ('IMPORTANT_CONSIDERATION', 298)]	5	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 103, 'people'), ('GO_0007565', 'female pregnancy', 134, 'pregnant'), ('GO_0007594', 'puparial adhesion', 147, 'lactating'), ('CHEBI_46662', 'mineral', 243, 'Mineral'), ('UBERON_0000178', 'blood', 326, 'blood'), ('CHEBI_33229', 'vitamin (role)', 346, 'vitamin')]	0	['whereas institute medicine 200 international units  day (iu/day) people age 50,  lactating women infants, hollis wrote december 2007 journal bone mineral 6,000 iu/day maintain blood levels vitamin populations.']
S17-PMC2685863	PMC2685863	5/2009	S17-PMC2685863	['“many obstetricians are oblivious to their patients’ Vitamin D status and FALSELY ASSUME that the miniscule amount of Vitamin D contained in Prenatal Vitamins will meet the needs of their patients,” hollis says.']	[('PROBLEM_COMPLICATION', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 82)]	2	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 150, 'vitamins')]	0	['“many obstetricians oblivious patients’  status miniscule amount  contained  vitamins meet patients,” hollis says.']
S169-PMC2716336	PMC2716336	7/2009	S169-PMC2716336	['we FOUND seasonal variations in the Intake of energy, protein, calcium, riboflavin and Vitamin C by Pregnant women.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('GO_0007631', 'feeding behavior', 36, 'intake'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin C'), ('GO_0007565', 'female pregnancy', 100, 'pregnant')]	0	['seasonal intake energy, protein, calcium, riboflavin   women.']
S117-PMC2722583	PMC2722583	1/2009	S117-PMC2722583	['iron deficiency is an IMPORTANT RISK FACTOR for increased maternal mortality, low Birth weight and Preterm Delivery (brabin et al 2001) and the availability of calcium, Iodine, Folate and Vitamins A and D MAY Modulate fetal development (bartley et al 2005).']	[('IMPORTANT_CONSIDERATION', 22), ('SUPERFICIAL_RELATIONSHIP', 32), ('INCOMPLETE_EVIDENCE', 205)]	3	[('GO_0007567', 'parturition', 82, 'birth'), ('GO_0007565', 'female pregnancy', 99, 'preterm'), ('GO_0007567', 'parturition', 107, 'delivery'), ('CHEBI_24859', 'iodine atom', 169, 'iodine'), ('CHEBI_30863', '5-azaorotic acid', 177, 'folate'), ('CHEBI_27300', 'vitamin D', 188, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 203, 'D'), ('GO_0065007', 'biological regulation', 209, 'modulate')]	0	['iron maternal mortality, birth  delivery (brabin et al 2001) availability calcium, iodine, folate  fetal (bartley et al 2005).']
S122-PMC2722583	PMC2722583	1/2009	S122-PMC2722583	['for example, the fact that Prenatal Folate supplementation substantially reduces the risk of Neural Tube defect ONLY IF it is taken Preconceptually is WELL KNOWN BUT improving Vitamin A status before Pregnancy HAS also BEEN SHOWN to have a dramatic and AS YET UNEXPLAINED EFFECT on maternal morbidity and mortality (west et al 1999).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('INCOMPLETE_EVIDENCE', 151), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 162), ('INCOMPLETE_EVIDENCE', 210), ('INCOMPLETE_EVIDENCE', 224), ('INCOMPLETE_EVIDENCE', 253), ('INCOMPLETE_EVIDENCE', 260), ('SUPERFICIAL_RELATIONSHIP', 272)]	8	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_30863', '5-azaorotic acid', 36, 'folate'), ('UBERON_0001049', 'neural tube', 93, 'neural tube'), ('GO_0007608', 'sensory perception of smell', 132, 'preconceptually'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin A'), ('GO_0007565', 'female pregnancy', 200, 'pregnancy')]	0	['example,  folate supplementation reduces neural tube defect preconceptually  status  maternal morbidity mortality (west et al 1999).']
S46-PMC2779500	PMC2779500	11/2009	S46-PMC2779500	['[31] maintain that Prenatal supplementation of Vitamins B, C, and e SHOULD BE continued DUE TO their MANY REPORTED positive EFFECTS on maternal and fetal health.']	[('FUTURE_WORK', 68), ('PROBABLE_UNDERSTANDING', 88), ('PROBLEM_COMPLICATION', 88), ('INCOMPLETE_EVIDENCE', 101), ('INCOMPLETE_EVIDENCE', 106), ('SUPERFICIAL_RELATIONSHIP', 124)]	6	[('GO_0007565', 'female pregnancy', 19, 'prenatal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamins B'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 47, 'vitamins B'), ('CHEBI_18245', 'carboxylato group', 59, 'C'), ('PR_000004900', 'complement C3', 59, 'C')]	0	['[31] maintain  supplementation c, e positive maternal fetal health.']
S23-PMC2821652	PMC2821652	2/2010	S23-PMC2821652	['THUS, in the Human fetus, Vitamin D Metabolism in all LIKELIHOOD begins with 25(Oh)D. as a result, the nutritional Vitamin D status of the Human fetus/neonate is totally DEPENDENT on the Vitamin D stores of the mother [11]; THUS, IF the mother is hypovitaminotic D, her fetus will experience depleted Vitamin D exposure throughout Gestation [14].']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 54), ('SUPERFICIAL_RELATIONSHIP', 170), ('PROBABLE_UNDERSTANDING', 224), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 230)]	5	[('NCBITaxon_9606', 'Homo sapiens', 13, 'human'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 26, 'vitamin D metabolism'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 139, 'human'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 263, 'D'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('GO_0007565', 'female pregnancy', 331, 'gestation')]	0	['thus, human fetus,  metabolism begins 25(oh)d. result, nutritional  status human fetus/neonate totally  stores mother [11]; thus, mother hypovitaminotic d, fetus depleted  exposure throughout  [14].']
S24-PMC2821652	PMC2821652	2/2010	S24-PMC2821652	['WHILE the demands of the fetus on the maternal System for calcium increase throughout Pregnancy, the demands for Vitamin D DO NOT APPEAR TO change.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 123), ('ANOMALY_CURIOUS_FINDING', 130)]	3	[('UBERON_0000467', 'anatomical system', 47, 'system'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]	0	['fetus maternal system calcium increase throughout  change.']
S25-PMC2821652	PMC2821652	2/2010	S25-PMC2821652	['the main determinants of Calcium Homeostasis during Pregnancy are Parathyroid hormone, calcitonin, and the active form of Vitamin D—1,25(Oh)2D (whose synthesis is preferentially maintained EVEN during times of Vitamin D deficiency by upregulation of enzymes for improved utilization of whatever 25(Oh)D is available).']	[('ANOMALY_CURIOUS_FINDING', 189)]	1	[('GO_0055073', 'cadmium ion homeostasis', 25, 'calcium homeostasis'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('UBERON_0001132', 'parathyroid gland', 66, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 134, '25(OH)2D'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 295, '25(OH)D')]	0	['main calcium homeostasis  parathyroid hormone, calcitonin, form —1,25(oh)2d (whose synthesis preferentially times  upregulation enzymes utilization 25(oh)d available).']
S29-PMC2821652	PMC2821652	2/2010	S29-PMC2821652	['DESPITE an expanding Intravascular volume during Pregnancy, maternal Vitamin D status SHOWS seasonal variation but beyond the typical FACTORS that INFLUENCE Vitamin D status in Adults (such as sunlight exposure and bmi), Vitamin D status does not fluctuate during Pregnancy and once supplemented, maternal Blood levels reach steady-state within 2 months [15].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 86), ('SUPERFICIAL_RELATIONSHIP', 134), ('SUPERFICIAL_RELATIONSHIP', 147)]	4	[('GO_0005622', 'intracellular anatomical structure', 21, 'intravascular'), ('GO_0007565', 'female pregnancy', 49, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('UBERON_0007023', 'adult organism', 177, 'adults'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D'), ('GO_0007565', 'female pregnancy', 264, 'pregnancy'), ('UBERON_0000178', 'blood', 306, 'blood')]	0	['despite intravascular volume maternal  status seasonal typical  status adults (such sunlight exposure bmi),  status fluctuate  supplemented, maternal blood levels steady-state 2 months [15].']
S30-PMC2821652	PMC2821652	2/2010	S30-PMC2821652	['these aspects of Calcium and Vitamin D Metabolism are IMPORTANT in the understanding of Vitamin D sufficiency during Pregnancy and the PREMISE that the REQUIREMENTS of Vitamin D are stable throughout Gestation.']	[('IMPORTANT_CONSIDERATION', 54), ('INCOMPLETE_EVIDENCE', 135), ('IMPORTANT_CONSIDERATION', 152)]	3	[('GO_0051216', 'cartilage development', 17, 'calcium ...'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 29, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('GO_0007565', 'female pregnancy', 200, 'gestation')]	0	['aspects calcium  metabolism    throughout .']
S31-PMC2821652	PMC2821652	2/2010	S31-PMC2821652	['EXISTING guidelines RECOMMEND that Pregnant women receive 400\u2009iu of Vitamin D per day via an oral supplement [17,18].']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 20)]	2	[('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]	0	['existing  women receive 400\u2009iu  day via oral supplement [17,18].']
S36-PMC2821652	PMC2821652	2/2010	S36-PMC2821652	['studies are currently UNDERWAY to determine the optimum supplementation dose of Vitamin D among Pregnant women (clinicaltrials.gov: nct00412087 and nct00292591).']	[('INCOMPLETE_EVIDENCE', 22)]	1	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnant')]	0	['studies supplementation dose  among  women (clinicaltrials.gov: nct00412087 nct00292591).']
S74-PMC2821652	PMC2821652	2/2010	S74-PMC2821652	['WHILE there is a MODEL in existence which calculates the predicted change in Serum 25(Oh)D for different doses of Vitamin D supplement, this model was developed using data from men [64], and its applicability to a population of Pregnant females is debatable.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 17)]	2	[('UBERON_0001977', 'blood serum', 77, 'serum'), ('CHEBI_71657', 'versiconol acetate', 83, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 83, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 228, 'pregnant')]	0	['existence calculates serum 25(oh)d doses  supplement, using men [64], applicability population  females debatable.']
S119-PMC2821652	PMC2821652	2/2010	S119-PMC2821652	['in THIS TRIAL, we SOUGHT TO DETERMINE WHETHER there was a significant ASSOCIATION between adherence to Vitamin D supplementation as measured by pill count and assessment of a NOVEL measure of adherence BASED UPON Serum levels of Vitamin D Metabolites in a Pregnant population.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 38), ('SUPERFICIAL_RELATIONSHIP', 70), ('FULL_UNKNOWN', 175), ('QUESTION_ANSWERED_BY_THIS_WORK', 202), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 208)]	8	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('UBERON_0001977', 'blood serum', 213, 'serum'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_25212', 'metabolite', 239, 'metabolites'), ('GO_0007565', 'female pregnancy', 256, 'pregnant')]	0	['trial, adherence  supplementation pill count measure adherence serum levels  metabolites  population.']
S11-PMC2841444	PMC2841444	2/2010	S11-PMC2841444	['the following are SUPPORTED by moderate- to high-quality evidence and STRONGLY RECOMMENDED for lmics:\n• two INTERVENTIONS PREVENT Preterm Births—smoking cessation and Progesterone\n• eight INTERVENTIONS PREVENT stillbirths—balanced protein energy supplementation, screening and treatment of syphilis, intermittant presumptive treatment for malaria during Pregnancy, Insecticide-treated mosquito nets, Birth preparedness, emergency obstetric care, cesarean section for breech presentation, and elective induction for post-term Delivery\n• eleven INTERVENTIONS improve survival of Preterm newborns—prophylactic Steroids in Preterm labor, Antibiotics for prom, Vitamin K supplementation at Delivery, case management of neonatal sepsis and pneumonia, delayed Cord clamping, room air (vs. 100% oxygen) for resuscitation, hospital-based kangaroo mother care, early breastfeeding, thermal care, and Surfactant therapy and application of continued distending pressure to the Lungs for Respiratory Distress syndrome\n\nconclusion\nthe research paradigm for discovery science and intervention development MUST BE BALANCED to address PREVENTION as well as improve morbidity and mortality in all settings.']	[('INCOMPLETE_EVIDENCE', 18), ('PROBABLE_UNDERSTANDING', 70), ('FUTURE_WORK', 79), ('SUPERFICIAL_RELATIONSHIP', 108), ('SUPERFICIAL_RELATIONSHIP', 122), ('SUPERFICIAL_RELATIONSHIP', 188), ('SUPERFICIAL_RELATIONSHIP', 202), ('SUPERFICIAL_RELATIONSHIP', 543), ('IMPORTANT_CONSIDERATION', 1090), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1098), ('SUPERFICIAL_RELATIONSHIP', 1118)]	11	[('GO_0007565', 'female pregnancy', 130, 'preterm births'), ('CHEBI_17026', 'progesterone', 167, 'progesterone'), ('GO_0007565', 'female pregnancy', 354, 'pregnancy'), ('CHEBI_24852', 'insecticide', 365, 'insecticide'), ('GO_0007567', 'parturition', 400, 'birth'), ('GO_0007567', 'parturition', 525, 'delivery'), ('GO_0007565', 'female pregnancy', 577, 'preterm'), ('CHEBI_35341', 'steroid', 607, 'steroids'), ('GO_0007565', 'female pregnancy', 619, 'preterm'), ('CHEBI_33282', 'antibacterial agent', 634, 'antibiotics'), ('CHEBI_27300', 'vitamin D', 656, 'vitamin K'), ('GO_0007567', 'parturition', 685, 'delivery'), ('UBERON_0002240', 'spinal cord', 753, 'cord'), ('CHEBI_35195', 'surfactant', 890, 'surfactant'), ('UBERON_0002048', 'lung', 965, 'lungs'), ('UBERON_0003495', 'respiratory system arteriole', 975, 'respiratory distress')]	0	['following moderate- high-quality lmics:\n• —smoking cessation progesterone\n• eight stillbirths—balanced protein energy supplementation, screening treatment syphilis, intermittant presumptive treatment malaria insecticide-treated mosquito nets, birth preparedness, obstetric care, cesarean section breech presentation, elective induction post-term delivery\n• eleven survival  newborns—prophylactic steroids  labor, antibiotics prom,  supplementation delivery, neonatal sepsis pneumonia, delayed cord clamping, air (vs. 100% oxygen) resuscitation, hospital-based kangaroo mother care, breastfeeding, thermal care, surfactant therapy application distending pressure lungs respiratory distress syndrome\n\nconclusion\nthe science morbidity mortality settings.']
S333-PMC2841444	PMC2841444	2/2010	S333-PMC2841444	['Preterm Birth\na systematic review of four rcts comparing the use of Vitamin A with Placebo in hiv-positive Pregnant women did not show significant EFFECTS on maternal-to-Child hiv Transmission (or 1.06; 95% ci 0.89-1.26) or Preterm Birth (rr 0.88, 95% ci 0.65-1.19).']	[('SUPERFICIAL_RELATIONSHIP', 147)]	1	[('GO_0007565', 'female pregnancy', 0, 'Preterm birth'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin A'), ('CHEBI_26130', 'biological pigment', 83, 'placebo'), ('GO_0007565', 'female pregnancy', 107, 'pregnant'), ('GO_0021863', 'forebrain neuroblast differentiation', 169, '-child ... transmission'), ('GO_0007565', 'female pregnancy', 224, 'preterm birth')]	0	['\na four rcts  placebo hiv-positive  women maternal-to-child hiv transmission (or 1.06; 95% ci 0.89-1.26)  (rr 0.88, 95% ci 0.65-1.19).']
S494-PMC2841444	PMC2841444	2/2010	S494-PMC2841444	['a cochrane review [250] evaluated five randomized or quasi-randomized trials of Vitamin K administered parenterally or orally to women AT RISK of imminent Preterm Birth, none of which were from lmics.']	[('IMPORTANT_CONSIDERATION', 135)]	1	[('CHEBI_27300', 'vitamin D', 80, 'vitamin K'), ('GO_0007565', 'female pregnancy', 155, 'preterm birth')]	0	['cochrane [250] five quasi-randomized  administered parenterally orally women lmics.']
S496-PMC2841444	PMC2841444	2/2010	S496-PMC2841444	['antenatal Vitamin K was ASSOCIATED with a nonsignificant reduction in all grades of pvh (rr 0.82, 95% confidence interval (ci) 0.67-1.00) and in severe pvh (grades 3 and 4) (rr 0.75, 95% ci 0.45-1.25) for babies receiving Prenatal Vitamin K compared with control babies.']	[('SUPERFICIAL_RELATIONSHIP', 24)]	1	[('CHEBI_27300', 'vitamin D', 10, 'vitamin K'), ('GO_0007565', 'female pregnancy', 222, 'prenatal'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin K')]	0	['antenatal  nonsignificant reduction grades pvh (rr 0.82, 95% confidence interval (ci) 0.67-1.00) pvh (grades 3 4) (rr 0.75, 95% ci 0.45-1.25) babies receiving   babies.']
S90-PMC2872349	PMC2872349	4/2010	S90-PMC2872349	['lower concentrations of Serum 25(Oh) Vitamin D in mothers during late Pregnancy were also ASSOCIATED with reduced Whole-body and Lumbar Spine bmc in children at age 9 years [40].']	[('SUPERFICIAL_RELATIONSHIP', 90)]	1	[('UBERON_0001977', 'blood serum', 24, 'serum'), ('CHEBI_30778', 'gallic acid', 30, '25(OH)'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('UBERON_0007688', 'anlage', 114, 'whole'), ('UBERON_0006074', 'lumbar region of vertebral column', 129, 'lumbar spine')]	0	['lower concentrations serum 25(oh)  mothers late  whole-body lumbar spine bmc children age 9 [40].']
S92-PMC2872349	PMC2872349	4/2010	S92-PMC2872349	['estimated exposure to ultraviolet b radiation during late Pregnancy (p < 0.0001) and the maternal use of Vitamin D supplements (p = 0.01) both PREDICTED maternal 25(Oh) Vitamin D concentration, and childhood bone mass (p = 0.03).']	[('SUPERFICIAL_RELATIONSHIP', 143)]	1	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 162, '25(OH)'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]	0	['estimated exposure ultraviolet b radiation late  (p 0.0001) maternal  supplements (p = 0.01) maternal 25(oh)  concentration, childhood bone mass (p = 0.03).']
S94-PMC2872349	PMC2872349	4/2010	S94-PMC2872349	['in developing populations, OFTEN the Nutrient in short supply is Calcium RATHER than Vitamin D: children of mothers, in a mother-offspring cohort study in pune, india [42], who had a higher frequency of Intake of Calcium-rich Foods during Pregnancy had higher total and Lumbar Spine bmc and areal bmd, INDEPENDENT of parental size and bone composition.']	[('PROBABLE_UNDERSTANDING', 27), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 73), ('SUPERFICIAL_RELATIONSHIP', 302)]	3	[('CHEBI_33284', 'nutrient', 37, 'nutrient'), ('CHEBI_22313', 'alkaline earth metal atom', 65, 'calcium'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007631', 'feeding behavior', 203, 'intake'), ('CHEBI_22313', 'alkaline earth metal atom', 213, 'calcium'), ('CHEBI_33290', 'food', 226, 'foods'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy'), ('UBERON_0006074', 'lumbar region of vertebral column', 270, 'lumbar spine')]	0	['populations, nutrient supply calcium : children mothers, mother-offspring pune, india [42], higher frequency intake calcium-rich foods  higher lumbar spine bmc areal bmd, parental bone composition.']
S143-PMC2872349	PMC2872349	4/2010	S143-PMC2872349	['this SUPPORTS the general NEED for a programme of interventional research aimed at improving general dietary quality among women before Conception and during Pregnancy, in addition to studies that EVALUATE the TARGETING of specific Micronutrients such as Vitamin D and Calcium.']	[('INCOMPLETE_EVIDENCE', 5), ('FUTURE_WORK', 26), ('INCOMPLETE_EVIDENCE', 26), ('QUESTION_ANSWERED_BY_THIS_WORK', 197), ('QUESTION_ANSWERED_BY_THIS_WORK', 197), ('FUTURE_WORK', 210)]	6	[('GO_0007620', 'copulation', 136, 'conception'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy'), ('CHEBI_33839', 'macromolecule', 232, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 269, 'calcium')]	0	['programme interventional dietary among women addition micronutrients  calcium.']
S144-PMC2872349	PMC2872349	4/2010	S144-PMC2872349	['the maternal Vitamin D in osteoporosis study (mavidos) is a randomized controlled trial TO INVESTIGATE WHETHER supplementation of Vitamin D during Pregnancy serves to optimize offspring Skeletal Development, and commenced recruitment in 2008.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 88), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103)]	2	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy'), ('GO_0001501', 'skeletal system development', 186, 'skeletal development'), ('UBERON_0004288', 'skeleton', 186, 'skeletal')]	0	['maternal vitamin osteoporosis (mavidos) supplementation   optimize offspring skeletal development, commenced recruitment 2008.']
S145-PMC2872349	PMC2872349	4/2010	S145-PMC2872349	['the STUDY AIMS TO TEST the HYPOTHESIS that Vitamin D supplementation of Pregnant women who have low levels of Vitamin D will result in improved neonatal bone Mineral content.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('INCOMPLETE_EVIDENCE', 27)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_46662', 'mineral', 158, 'mineral')]	0	[' supplementation  women levels  result neonatal bone mineral content.']
S128-PMC2873552	PMC2873552	4/2010	S128-PMC2873552	"['[""""caption (table-wrap): table 2\\n\\nfunctions and diseases related to both ceu and yri Signaturesceuyri diabetes 1.70e-172.70e-20 Coronary Artery disease 3.78e-173.12e-13 Genetic disorder 1.09e-144.53e-14 Cardiovascular disease 1.34e-144.78e-11 non-Insulin-dependent diabetes mellitus 1.03e-128.66e-15 Endocrine System disorder 1.91e-121.25e-18 hypertension 2.13e-122.83e-11 Neurological disorder 2.49e-123.27e-12 crohn\'s disease 7.59e-127.25e-09 bipolar affective disease 3.50e-115.24e-09 Metabolic disorder 5.66e-119.83e-16 inflammatory disorder 2.56e-091.08e-08 Digestive System disorder 2.66e-091.31e-07 Skeletal and muscular disorder 1.49e-081.58e-08 progressive motor neuropathy 2.53e-085.59e-12 Autoimmune disease 7.28e-081.09e-12 immunological disorder 2.46e-073.66e-13 rheumatoid arthritis 3.78e-072.54e-07 shape change of Epithelial Cells 8.86e-07 alzheimer\'s disease 3.60e-062.27e-07 parkinson\'s disease 7.24e-065.29e-06 shape change of Dermal Cells 9.33e-06 Insulin-dependent diabetes mellitus 3.76e-15 neuropathy 5.38e-12 amyotrophic lateral sclerosis 1.36e-09 arthritis 1.44e-07\\n\\nVitamin D HYPOTHESIS\\nan INTERESTING HYPOTHESIS HAS BEEN PROPOSED by mcgrace [28] claiming that low Prenatal Vitamin D increases the risk of a wide range of diseases such as multiple sclerosis, diabetes, schizophrenia, Prostate cancer, Breast cancer and Colorectal cancer because of its versatile function in normal development.""""]']"	[('INCOMPLETE_EVIDENCE', 1099), ('ANOMALY_CURIOUS_FINDING', 1113), ('INCOMPLETE_EVIDENCE', 1125), ('INCOMPLETE_EVIDENCE', 1136), ('INCOMPLETE_EVIDENCE', 1145)]	5	[('GO_0036367', 'light adaption', 82, 'signaturesCEUYRI'), ('UBERON_0001621', 'coronary artery', 125, 'Coronary artery'), ('SO_0000704', 'gene', 166, 'Genetic'), ('UBERON_0004535', 'cardiovascular system', 200, 'Cardiovascular'), ('PR_000045358', 'insulin family protein', 244, 'insulin'), ('UBERON_0000949', 'endocrine system', 297, 'Endocrine system'), ('UBERON_0001016', 'nervous system', 370, 'Neurological'), ('GO_0008152', 'metabolic process', 485, 'Metabolic'), ('UBERON_0004854', 'gastrointestinal system mesentery', 560, 'Digestive system'), ('UBERON_0004288', 'skeleton', 603, 'Skeletal'), ('UBERON_0005445', 'segment of pes', 697, 'Autoimmune'), ('CL_0000066', 'epithelial cell', 827, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 827, 'epithelial'), ('CL_0000346', 'hair follicle dermal papilla cell', 943, 'dermal cells'), ('PR_000045358', 'insulin family protein', 965, 'Insulin'), ('CHEBI_28384', 'vitamin K', 1089, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1188, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1197, 'vitamin D'), ('UBERON_0002367', 'prostate gland', 1307, 'prostate'), ('UBERON_0000310', 'breast', 1324, 'breast'), ('UBERON_0012652', 'colorectum', 1342, 'colorectal')]	0	"['[""""caption (table-wrap): table 2\\n\\nfunctions diseases ceu yri signaturesceuyri diabetes 1.70e-172.70e-20 coronary artery disease 3.78e-173.12e-13 genetic disorder 1.09e-144.53e-14 cardiovascular disease 1.34e-144.78e-11 non-insulin-dependent diabetes mellitus 1.03e-128.66e-15 endocrine system disorder 1.91e-121.25e-18 hypertension 2.13e-122.83e-11 neurological disorder 2.49e-123.27e-12 crohn*s disease 7.59e-127.25e-09 bipolar disease 3.50e-115.24e-09 metabolic disorder 5.66e-119.83e-16 inflammatory disorder 2.56e-091.08e-08 digestive system disorder 2.66e-091.31e-07 skeletal muscular disorder 1.49e-081.58e-08 progressive motor neuropathy 2.53e-085.59e-12 autoimmune disease 7.28e-081.09e-12 immunological disorder 2.46e-073.66e-13 rheumatoid arthritis 3.78e-072.54e-07 epithelial cells 8.86e-07 alzheimer*s disease 3.60e-062.27e-07 parkinson*s disease 7.24e-065.29e-06 dermal cells 9.33e-06 insulin-dependent diabetes mellitus 3.76e-15 neuropathy 5.38e-12 amyotrophic lateral sclerosis 1.36e-09 arthritis 1.44e-07\\n\\nvitamin hypothesis\\nan mcgrace [28] tpitamin diseases sclerosis, diabetes, schizophrenia, prostate cancer, breast cancer colorectal cancer versatile normal development.""""]']"
S111-PMC2874518	PMC2874518	6/2010	S111-PMC2874518	['women in our cohort were receiving adequate amounts of these Micronutrients from their diet alone, as assessed by the 24-hour dietary Recall (table 2), confirming the inverse Supplement HYPOTHESIS, that women who least NEED Supplements are most LIKELY to take them.22\nOTHER STUDIES have SUGGESTED POTENTIAL adverse EFFECTS of SOME Supplements, specifically those containing antioxidant Vitamins such as Vitamins C and E, on Pregnancy outcome when taken by women with adequate dietary Micronutrient intake.']	[('INCOMPLETE_EVIDENCE', 186), ('IMPORTANT_CONSIDERATION', 219), ('PROBABLE_UNDERSTANDING', 245), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 268), ('INCOMPLETE_EVIDENCE', 268), ('INCOMPLETE_EVIDENCE', 287), ('INCOMPLETE_EVIDENCE', 297), ('SUPERFICIAL_RELATIONSHIP', 315), ('INCOMPLETE_EVIDENCE', 326)]	9	[('CHEBI_33839', 'macromolecule', 61, 'micronutrients'), ('GO_0060033', 'anatomical structure regression', 134, 'recall'), ('CHEBI_16158', 'steroid sulfate', 175, 'supplement'), ('CHEBI_33341', 'titanium atom', 224, 'supplements'), ('CHEBI_33341', 'titanium atom', 331, 'supplements'), ('CHEBI_33277', 'gamma-tocotrienol', 386, 'vitamins'), ('CHEBI_27300', 'vitamin D', 403, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 418, 'E'), ('GO_0007565', 'female pregnancy', 424, 'pregnancy'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 484, 'micronutrient')]	0	['women receiving amounts micronutrients diet alone, 24-hour dietary recall (table 2), supplement hypothesis, women supplements them.22\nother supplements, containing antioxidant vitamins  e,  outcome women dietary micronutrient intake.']
S115-PMC2874518	PMC2874518	6/2010	S115-PMC2874518	['in a randomised controlled trial TO ASSESS the EFFECT of Vitamin E and C supplementation during Pregnancy on the incidence of pre-eclampsia, poston et al.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 47)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin E'), ('CHEBI_18245', 'carboxylato group', 71, 'C'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]	0	['randomised  c supplementation  pre-eclampsia, poston et al.']
S121-PMC2874518	PMC2874518	6/2010	S121-PMC2874518	['the PATTERN of dietary supplement use in our cohort, with most women taking Supplements (mainly Folic Acid) in the first Trimester, is expected because there is no national RECOMMENDATION in england for routine Supplement-taking during Pregnancy apart from Folic Acid in the first trimester and Vitamin D for Pregnant women in ‘high-RISK’ groups.30there is no national RECOMMENDATION to take multivitamin and Mineral supplements at any stage during Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('FUTURE_WORK', 173), ('IMPORTANT_CONSIDERATION', 333), ('FUTURE_WORK', 369)]	4	[('CHEBI_33341', 'titanium atom', 76, 'supplements'), ('CHEBI_30751', 'formic acid', 96, 'folic acid'), ('GO_0009294', 'DNA mediated transformation', 121, 'trimester'), ('CHEBI_16158', 'steroid sulfate', 211, 'supplement'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy'), ('CHEBI_30751', 'formic acid', 257, 'folic acid'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D'), ('GO_0007565', 'female pregnancy', 309, 'pregnant'), ('CHEBI_46662', 'mineral', 409, 'mineral'), ('GO_0007565', 'female pregnancy', 449, 'pregnancy')]	0	['dietary supplement cohort, women supplements (mainly folic acid) trimester, national england routine supplement-taking  folic acid trimester   women ‘high-risk’ groups.30there national multivitamin mineral supplements .']
S35-PMC2889879	PMC2889879	5/2010	S35-PMC2889879	['furthermore, it HAS BEEN HYPOTHESIZED that Prenatal Vitamin D deficiency is a risk factor for schizophrenia, SUPPORTED by the ROLE of this Vitamin in Cell Growth and differentiation, the excess of winter births in schizophrenia (a period when Vitamin D levels are low), and increased Births of pre-schizophrenic subjects in urban areas, where Vitamin D deficiency is higher [12,18].']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 109), ('SUPERFICIAL_RELATIONSHIP', 126)]	4	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 139, 'vitamin'), ('GO_0016049', 'cell growth', 150, 'cell growth'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('GO_0007567', 'parturition', 284, 'births'), ('CHEBI_27300', 'vitamin D', 343, 'vitamin D')]	0	['furthermore,   schizophrenia, vitamin cell differentiation, excess winter births schizophrenia (a period  levels low), births pre-schizophrenic subjects urban areas,  higher [12,18].']
S136-PMC2889879	PMC2889879	5/2010	S136-PMC2889879	['Prenatal Vitamin D deficiency has been PROPOSED to be a risk factor for the development of schizophrenia [12].']	[('INCOMPLETE_EVIDENCE', 39)]	1	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D')]	0	['  schizophrenia [12].']
S138-PMC2889879	PMC2889879	5/2010	S138-PMC2889879	['HOWEVER, a SMALL pilot STUDY of maternal Vitamin D levels in archived Prenatal Sera, SHOWED no decrease in Prenatal Vitamin D in subjects who later developed schizophrenia [33].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 85)]	3	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'prenatal'), ('UBERON_0001977', 'blood serum', 79, 'sera'), ('GO_0007565', 'female pregnancy', 107, 'prenatal'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]	0	['however, maternal  levels archived  sera, decrease   subjects schizophrenia [33].']
S146-PMC2889879	PMC2889879	5/2010	S146-PMC2889879	['our results of the PROTECTIVE EFFECT of fatty fish COULD IN PART be due to the content of Vitamin D. WHILE the epidemiological EVIDENCE LINKING low Prenatal Vitamin D and schizophrenia REMAINS INCONCLUSIVE, Rodent MODELS have provided COMPELLING EVIDENCE about the ROLE of Vitamin D deficiency for Brain Development like larger lateral volumes [36], subtle Memory dysfunction and altered attention processing [37] which have IMPLICATIONS for neuropsychiatric disorders.']	[('SUPERFICIAL_RELATIONSHIP', 19), ('SUPERFICIAL_RELATIONSHIP', 30), ('INCOMPLETE_EVIDENCE', 51), ('INCOMPLETE_EVIDENCE', 57), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 101), ('INCOMPLETE_EVIDENCE', 127), ('SUPERFICIAL_RELATIONSHIP', 136), ('INCOMPLETE_EVIDENCE', 185), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 193), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 214), ('INCOMPLETE_EVIDENCE', 235), ('SUPERFICIAL_RELATIONSHIP', 265), ('IMPORTANT_CONSIDERATION', 425)]	13	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'prenatal'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 207, 'rodent'), ('CHEBI_27300', 'vitamin D', 273, 'vitamin D'), ('GO_0007420', 'brain development', 298, 'brain development'), ('UBERON_0000955', 'brain', 298, 'brain'), ('GO_0007613', 'memory', 357, 'memory')]	0	['results fatty fish content .   schizophrenia inconclusive, rodent  brain lateral volumes [36], subtle memory dysfunction altered processing [37] neuropsychiatric disorders.']
S0-PMC2913107	PMC2913107	8/2010	S0-PMC2913107	['on the aetiology of autism\ni have SUGGESTED that the primary environmental TRIGGER for autism is not vaccinations, Toxins or infections, BUT Gestational and early childhood Vitamin D deficiency (1,2).']	[('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 75), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 137)]	3	[('CHEBI_27026', 'toxin', 115, 'toxins'), ('GO_0007565', 'female pregnancy', 141, 'gestational'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D')]	0	['aetiology autism\ni environmental autism vaccinations, toxins infections,  childhood  (1,2).']
S1-PMC2913107	PMC2913107	8/2010	S1-PMC2913107	['subsequently, the title of an article in scientific american RECENTLY ASKED, ‘WHAT IF Vitamin D deficiency is a cause of autism?’ (3) since then, an ARTICLE on Vitamin D and autism in acta paediatrica (4) and the accompanying COMMENTARY (5) have added to the ACCELERATING SUSPICION that Vitamin D deficiency – EITHER during Pregnancy OR early childhood – MAY BE an environmental TRIGGER for the Genetic disease of autism.']	[('INCOMPLETE_EVIDENCE', 61), ('EXPLICIT_QUESTION', 70), ('EXPLICIT_QUESTION', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 83), ('EXPLICIT_QUESTION', 127), ('INCOMPLETE_EVIDENCE', 149), ('INCOMPLETE_EVIDENCE', 226), ('IMPORTANT_CONSIDERATION', 259), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 272), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 310), ('INCOMPLETE_EVIDENCE', 355), ('SUPERFICIAL_RELATIONSHIP', 379)]	12	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 287, 'vitamin D'), ('GO_0007565', 'female pregnancy', 324, 'pregnancy'), ('SO_0000704', 'gene', 395, 'genetic')]	0	['subsequently, title scientific american asked, ‘what  autism?’ (3) then,  autism acta paediatrica (4) (5) added  childhood environmental genetic disease autism.']
S8-PMC2913107	PMC2913107	8/2010	S8-PMC2913107	['a 2008 REVIEW DETAILED the DEVASTATING EFFECT Gestational Vitamin D deficiency has on developing Mammalian Brains (7).']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 27), ('SUPERFICIAL_RELATIONSHIP', 39)]	4	[('GO_0007565', 'female pregnancy', 46, 'gestational'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('NCBITaxon_40674', 'Mammalia', 97, 'mammalian'), ('UBERON_0000955', 'brain', 107, 'brains')]	0	['2008   mammalian brains (7).']
S9-PMC2913107	PMC2913107	8/2010	S9-PMC2913107	['UNFORTUNATELY, the tiny 10 μg (400 iu) dose in Prenatal Vitamins is VIRTUALLY IRRELEVANT in PREVENTING the current EPIDEMIC of Gestational Vitamin D deficiency (8).']	[('IMPORTANT_CONSIDERATION', 0), ('PROBABLE_UNDERSTANDING', 68), ('IMPORTANT_CONSIDERATION', 78), ('SUPERFICIAL_RELATIONSHIP', 92), ('IMPORTANT_CONSIDERATION', 115)]	5	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 56, 'vitamins'), ('GO_0007565', 'female pregnancy', 127, 'gestational'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]	0	['unfortunately, tiny 10 μg (400 iu) dose  vitamins   (8).']
S10-PMC2913107	PMC2913107	8/2010	S10-PMC2913107	['FOR THIS REASON, in 2007, the canadian paediatric society CAUTIONED Pregnant women they MAY REQUIRE NOT 400 iu/day BUT 2000 iu/day, or more, to PREVENT Gestational Vitamin D deficiency (9).']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 58), ('INCOMPLETE_EVIDENCE', 88), ('IMPORTANT_CONSIDERATION', 92), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100), ('SUPERFICIAL_RELATIONSHIP', 144)]	6	[('GO_0007565', 'female pregnancy', 68, 'pregnant'), ('GO_0007565', 'female pregnancy', 152, 'gestational'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]	0	['reason, 2007, canadian paediatric society  women 400 iu/day 2000 iu/day, more,   (9).']
S106-PMC2963768	PMC2963768	10/2010	S106-PMC2963768	['HOWEVER, these age-DEPENDENT DIFFERENCES MAY HAVE BEEN CONFOUNDED by seasonal timing of Gestation—a younger age IMPLIED that the third trimester COINCIDED with the expected seasonal nadir of Vitamin D Synthesis, when maternal Vitamin D stores MIGHT be relatively depleted and, THUS, when transfer of Vitamin D Metabolites to the foetus MAY have been minimized.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 19), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 29), ('INCOMPLETE_EVIDENCE', 41), ('INCOMPLETE_EVIDENCE', 45), ('DIFFICULT_TASK', 55), ('SUPERFICIAL_RELATIONSHIP', 112), ('SUPERFICIAL_RELATIONSHIP', 145), ('INCOMPLETE_EVIDENCE', 243), ('PROBABLE_UNDERSTANDING', 277), ('INCOMPLETE_EVIDENCE', 336)]	11	[('GO_0007565', 'female pregnancy', 88, 'gestation'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 191, 'vitamin D synthesis'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 300, 'vitamin D'), ('CHEBI_25212', 'metabolite', 310, 'metabolites')]	0	['however, age-dependent seasonal timing —a younger age third trimester seasonal nadir  synthesis, maternal  stores depleted and, thus, transfer  metabolites foetus minimized.']
S160-PMC2996405	PMC2996405	11/2010	S160-PMC2996405	['in Mice, it HAS BEEN SUGGESTED that changes in Brain Development induced by Prenatal Vitamin D deficiency LEAD TO specific functional alterations in hippocampal Synaptic plasticity [53].']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 106)]	2	[('NCBITaxon_10088', 'Mus <genus>', 3, 'mice'), ('GO_0007420', 'brain development', 47, 'brain development'), ('UBERON_0000955', 'brain', 47, 'brain'), ('GO_0007565', 'female pregnancy', 76, 'prenatal'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0045202', 'synapse', 161, 'synaptic')]	0	['mice, changes brain induced   functional alterations hippocampal synaptic plasticity [53].']
S235-PMC2999828	PMC2999828	3/2009	S235-PMC2999828	['numerous individual Nutrients consumed by the mother during Pregnancy HAVE BEEN SUGGESTED as being preventive for development of atopic diseases in the child; these include apples or fish,[80] Vitamin D,[107] Vitamin E,[108] and various Probiotics, the latter HAVING BEEN SHOWN to be effective in Mouse MODELS [109] and Human studies [110].']	[('INCOMPLETE_EVIDENCE', 70), ('INCOMPLETE_EVIDENCE', 80), ('INCOMPLETE_EVIDENCE', 260), ('INCOMPLETE_EVIDENCE', 303)]	4	[('CHEBI_33284', 'nutrient', 20, 'nutrients'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin E'), ('CHEBI_26346', 'prostaglandins J', 237, 'probiotics'), ('NCBITaxon_10088', 'Mus <genus>', 297, 'mouse'), ('NCBITaxon_9606', 'Homo sapiens', 320, 'human')]	0	['numerous individual nutrients consumed mother  atopic diseases child; apples fish,[80] ,[107] ,[108] probiotics, latter mouse [109] human [110].']
S12-PMC3004407	PMC3004407	12/2010	S12-PMC3004407	['THESE FINDINGS RAISE the ISSUE of adequacy of current Vitamin D RECOMMENDATIONS for Pregnant women.']	[('INCOMPLETE_EVIDENCE', 0), ('EXPLICIT_QUESTION', 15), ('PROBLEM_COMPLICATION', 25), ('FUTURE_WORK', 64)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnant')]	0	['  women.']
S16-PMC3004407	PMC3004407	12/2010	S16-PMC3004407	['RATHER, Vitamin D is now seen as a preprohormone whose active Metabolites act not only to ensure Calcium Homeostasis and bone health [5] but also act as mediators of Immune function in general [6,7], and specific to Pregnancy, play a ROLE in Immune tolerance, Insulin resistance, and Preeclampsia [8–12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 234)]	2	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('CHEBI_25212', 'metabolite', 62, 'metabolites'), ('GO_0055073', 'cadmium ion homeostasis', 97, 'calcium homeostasis'), ('UBERON_0002405', 'immune system', 166, 'immune'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy'), ('UBERON_0002405', 'immune system', 242, 'immune'), ('PR_000045358', 'insulin family protein', 260, 'insulin'), ('GO_0007128', 'meiotic prophase I', 284, 'preeclampsia')]	0	['rather,  preprohormone whose metabolites ensure calcium homeostasis bone [5] immune [6,7], play immune tolerance, insulin resistance, preeclampsia [8–12].']
S20-PMC3004407	PMC3004407	12/2010	S20-PMC3004407	['EARLIER REPORTS of Vitamin D deficiency during Pregnancy have focused on women living in northern europe (latitude 50–55°n), which DID NOT include women of diverse racial/ethnic backgrounds living in a sun-rich environment [5,31,32].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 131)]	3	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy')]	0	['earlier   women living northern europe (latitude 50–55°n), women racial/ethnic backgrounds living sun-rich environment [5,31,32].']
S22-PMC3004407	PMC3004407	12/2010	S22-PMC3004407	['AS a result of the CONCERN regarding the prevalence of Vitamin D deficiency among Pregnant women receiving care at community health centers, and TO CLARIFY earlier scientific STUDIES which REPORTED that a majority of african-american and hispanic women are Vitamin D deficient [34–40], a cross-sectional study of Pregnant women presenting at a community health center network in south carolina at latitude 32°n was designed and implemented.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 19), ('PROBLEM_COMPLICATION', 19), ('QUESTION_ANSWERED_BY_THIS_WORK', 145), ('FUTURE_WORK', 148), ('INCOMPLETE_EVIDENCE', 175), ('INCOMPLETE_EVIDENCE', 189)]	7	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnant'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin D'), ('GO_0007565', 'female pregnancy', 313, 'pregnant')]	0	['result regarding  among  women receiving community centers, scientific african-american hispanic women  women presenting community south carolina latitude 32°n implemented.']
S23-PMC3004407	PMC3004407	12/2010	S23-PMC3004407	['the AIM of THIS STUDY was to define the prevalence of Vitamin D deficiency in a large and ethnically diverse cross-sectional sample of Pregnant women living in a sun-rich environment with ample access to sunlight during most of the year.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11)]	2	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 135, 'pregnant')]	0	[' ethnically cross-sectional sample  women living sun-rich environment access sunlight year.']
S95-PMC3004407	PMC3004407	12/2010	S95-PMC3004407	['the odds of Vitamin D deficiency (AS measured by 25(Oh)D concentration) did NOT APPEAR TO change as a function of Gestational age; women in their later stages of Pregnancy had a SIMILAR odds of Vitamin D deficiency and insufficiency for a given race/ethnicity than women who had their 25(Oh)D concentrations measured earlier in Pregnancy ( p = .43).']	[('PROBABLE_UNDERSTANDING', 34), ('ANOMALY_CURIOUS_FINDING', 76), ('ANOMALY_CURIOUS_FINDING', 80), ('SUPERFICIAL_RELATIONSHIP', 178)]	4	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('GO_0007565', 'female pregnancy', 162, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 285, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 291, 'D'), ('GO_0007565', 'female pregnancy', 328, 'pregnancy')]	0	[' (as 25(oh)d concentration)  age; women stages   race/ethnicity women 25(oh)d concentrations  p = .43).']
S130-PMC3004407	PMC3004407	12/2010	S130-PMC3004407	['women who reported taking a Prenatal Vitamin containing 400\u2009iu Vitamin D did not differ from those who did not in Vitamin D status as measured by 25(Oh)d.\nWHILE present in caucasian women, the greatest prevalence of deficiency was NOTED in those women of darker pigmentation, specifically, african-american and hispanic women.']	[('ANOMALY_CURIOUS_FINDING', 155), ('ANOMALY_CURIOUS_FINDING', 231)]	2	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 37, 'vitamin'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 146, '25(OH')]	0	['women  vitamin containing 400\u2009iu   status 25(oh)d.\nwhile caucasian women, women darker pigmentation, specifically, african-american hispanic women.']
S131-PMC3004407	PMC3004407	12/2010	S131-PMC3004407	['WHILE there was a significant variation in 25(Oh)D concentrations between racial/ethnic categories, the deficiency did not APPEAR to change as a function of Gestational age; women in their later stages of Pregnancy had a SIMILAR risk of Vitamin D deficiency and insufficiency for a given race/ethnicity compared with women who had their 25(Oh)D concentrations measured earlier in Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 123), ('SUPERFICIAL_RELATIONSHIP', 221)]	3	[('CHEBI_71657', 'versiconol acetate', 43, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 43, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 49, 'D'), ('GO_0007565', 'female pregnancy', 157, 'gestational'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 337, '25(OH)D'), ('GO_0007565', 'female pregnancy', 380, 'pregnancy')]	0	['25(oh)d concentrations racial/ethnic categories,  age; women stages   race/ethnicity women 25(oh)d concentrations .']
S143-PMC3004407	PMC3004407	12/2010	S143-PMC3004407	['after accounting for the EFFECT of Gestational age through multivariable regression, 25(Oh)D status retained a significant negative ASSOCIATION with pth, CONFIRMING that EVEN during Pregnancy, pth is a PREDICTOR of Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 25), ('SUPERFICIAL_RELATIONSHIP', 132), ('PROBABLE_UNDERSTANDING', 154), ('ANOMALY_CURIOUS_FINDING', 170), ('SUPERFICIAL_RELATIONSHIP', 202)]	5	[('GO_0007565', 'female pregnancy', 35, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 87, '(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 91, 'D'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D')]	0	[' age multivariable regression, 25(oh)d status retained pth, pth  deficiency.']
S146-PMC3004407	PMC3004407	12/2010	S146-PMC3004407	['using both circulating 25(Oh)D and pth as MARKERS of Vitamin D deficiency, THESE FINDINGS UNDERSCORE RECENT REPORTS of widespread Vitamin D deficiency among Pregnant women, EVEN in areas of the world with ample sunlight.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 90), ('INCOMPLETE_EVIDENCE', 101), ('INCOMPLETE_EVIDENCE', 108), ('ANOMALY_CURIOUS_FINDING', 173)]	6	[('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'pregnant')]	0	['using circulating 25(oh)d pth  deficiency,  among  women, world sunlight.']
S147-PMC3004407	PMC3004407	12/2010	S147-PMC3004407	['this is concerning in that the EFFECTS of Vitamin D deficiency among Pregnancy women are not limited to the women: IF a mother has Vitamin D insufficiency, or worse, deficiency, her fetus is developing in a hypovitaminotic state.']	[('SUPERFICIAL_RELATIONSHIP', 31), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]	0	[' among  women women: mother  insufficiency, worse, deficiency, fetus hypovitaminotic state.']
S150-PMC3004407	PMC3004407	12/2010	S150-PMC3004407	['what is MOST CONCERNING is that use of Prenatal Vitamins containing 400\u2009iu/tablet was IRRELEVANT in AFFECTING Vitamin D status: those who took their prescribed Prenatal vitamin containing Vitamin D did not differ from those who did not.']	[('PROBABLE_UNDERSTANDING', 8), ('IMPORTANT_CONSIDERATION', 13), ('IMPORTANT_CONSIDERATION', 86), ('SUPERFICIAL_RELATIONSHIP', 100)]	4	[('GO_0007565', 'female pregnancy', 39, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 48, 'vitamins'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'prenatal'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D')]	0	[' vitamins containing 400\u2009iu/tablet  status: took prescribed  vitamin containing  not.']
S151-PMC3004407	PMC3004407	12/2010	S151-PMC3004407	['women taking their Prenatal Vitamins SHOULD BE counseled that the amount of Vitamin D contained in their Prenatal Vitamin will not affect their Vitamin D status [33,56,57].']	[('FUTURE_WORK', 37)]	1	[('GO_0007565', 'female pregnancy', 19, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 28, 'vitamins'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 114, 'vitamin'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]	0	['women  vitamins counseled amount  contained  vitamin  status [33,56,57].']
S152-PMC3004407	PMC3004407	12/2010	S152-PMC3004407	['the STRENGTHS of the study are that a large and diverse group of women at various stages of Pregnancy were studied to: (1) ascertain their Vitamin D status at the time of presentation to a community health center and (2) find WHAT FACTORS were most PREDICTIVE of that status in a sun-rich environment where THEORETICALLY there are no LIMITATIONS to achieving an adequate Vitamin D status.']	[('IMPORTANT_CONSIDERATION', 4), ('EXPLICIT_QUESTION', 226), ('SUPERFICIAL_RELATIONSHIP', 231), ('SUPERFICIAL_RELATIONSHIP', 249), ('INCOMPLETE_EVIDENCE', 307), ('INCOMPLETE_EVIDENCE', 334)]	6	[('GO_0007565', 'female pregnancy', 92, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 371, 'vitamin D')]	0	['women stages  to: (1) ascertain  status presentation community (2) status sun-rich environment achieving  status.']
S158-PMC3004407	PMC3004407	12/2010	S158-PMC3004407	['studies TO EXAMINE the BENEFIT of higher doses of Vitamin D during Pregnancy SUGGEST that the dose of Vitamin D FOUND in MOST Prenatal Vitamins—400\u2009iu—is INADEQUATE to meet the NEEDS of the Pregnant woman and her growing fetus [11,32,34,39,60–67].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('IMPORTANT_CONSIDERATION', 23), ('INCOMPLETE_EVIDENCE', 77), ('INCOMPLETE_EVIDENCE', 112), ('PROBABLE_UNDERSTANDING', 121), ('IMPORTANT_CONSIDERATION', 154), ('IMPORTANT_CONSIDERATION', 177)]	7	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 135, 'vitamins'), ('GO_0007565', 'female pregnancy', 190, 'pregnant')]	0	['studies higher doses   dose   vitamins—400\u2009iu—is meet  woman fetus [11,32,34,39,60–67].']
S3-PMC3032617	PMC3032617	5/2010	S3-PMC3032617	['the AIM of the study was TO INVESTIGATE, in a ugandan rural Pregnant women cohort, the preventive EFFECTS of Vitamin C supplementation on hospital admission.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('SUPERFICIAL_RELATIONSHIP', 98)]	3	[('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin C')]	0	['investigate, ugandan rural  women cohort,  supplementation hospital admission.']
S5-PMC3032617	PMC3032617	5/2010	S5-PMC3032617	['the primary outcome measure of this study was TO ASSESS the PREVENTION of hospitalization during Pregnancy in the group of women supplemented with Vitamin C compared to the controls.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('SUPERFICIAL_RELATIONSHIP', 60)]	2	[('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin C')]	0	['outcome measure hospitalization  women supplemented  controls.']
S8-PMC3032617	PMC3032617	5/2010	S8-PMC3032617	['conclusion\nthe results of THIS STUDY SUGGEST including Vitamin C in the GUIDELINES of multivitamin PREVENTION for Pregnant women, ESPECIALLY in developing countries where seasonal availability of fruits and Vegetables COULD result in adverse clinical outcomes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('INCOMPLETE_EVIDENCE', 37), ('IMPORTANT_CONSIDERATION', 72), ('PROBABLE_UNDERSTANDING', 72), ('SUPERFICIAL_RELATIONSHIP', 99), ('IMPORTANT_CONSIDERATION', 130), ('INCOMPLETE_EVIDENCE', 218)]	7	[('CHEBI_27300', 'vitamin D', 55, 'vitamin C'), ('GO_0007565', 'female pregnancy', 114, 'pregnant'), ('CHEBI_33267', 'elemental nitrogen', 207, 'vegetables')]	0	['conclusion\nthe results  multivitamin  women, countries seasonal availability fruits vegetables result outcomes.']
S37-PMC3032617	PMC3032617	5/2010	S37-PMC3032617	['all this considerations led us TO INVESTIGATE, in an open-label cohort randomized study, the preventive EFFECTS of regular Vitamin C supplementation on overall hospitalization rate in the Pregnant women population attending a ugandan rural health centre for Antenatal assessment.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('SUPERFICIAL_RELATIONSHIP', 104)]	2	[('CHEBI_27300', 'vitamin D', 123, 'vitamin C'), ('GO_0007565', 'female pregnancy', 188, 'pregnant'), ('GO_0007567', 'parturition', 258, 'antenatal')]	0	['us investigate, open-label study,  supplementation hospitalization rate  women population attending ugandan rural centre antenatal assessment.']
S38-PMC3032617	PMC3032617	5/2010	S38-PMC3032617	['the primary outcome measure of this study was TO ASSESS the PREVENTION of hospitalization during Pregnancy in the group of women supplemented with Vitamin C compared to the controls, and the secondary outcome measures were to compare the overall mother-to-child health benefits in the two groups, such as: overall hospitalization rate, weight gain during Pregnancy (normal <16kg), term Pregnancy (≥37 Gestational weeks), Preterm Delivery, Miscarriage (<24 Gestational weeks) and child low Birth weight (<2500g) and Gestational systolic Blood pressure.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('SUPERFICIAL_RELATIONSHIP', 60)]	2	[('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin C'), ('GO_0007565', 'female pregnancy', 355, 'pregnancy'), ('GO_0007565', 'female pregnancy', 386, 'pregnancy'), ('GO_0007565', 'female pregnancy', 401, 'gestational'), ('GO_0007565', 'female pregnancy', 421, 'preterm'), ('GO_0007567', 'parturition', 429, 'delivery'), ('GO_0046660', 'female sex differentiation', 439, 'miscarriage'), ('GO_0007565', 'female pregnancy', 456, 'gestational'), ('GO_0007567', 'parturition', 489, 'birth'), ('GO_0007565', 'female pregnancy', 515, 'gestational'), ('UBERON_0000178', 'blood', 536, 'blood')]	0	['outcome measure hospitalization  women supplemented  controls, secondary outcome mother-to-child groups, as: hospitalization rate, gain  (normal <16kg), term  (≥37  weeks),  delivery, miscarriage (<24  weeks) child birth (<2500g)  systolic blood pressure.']
S60-PMC3032617	PMC3032617	5/2010	S60-PMC3032617	['we HYPOTHESIZED to record at least 30% of women not hospitalized during Pregnancy in the control group in consideration of the fact they were supplemented regularly throughout their Pregnancy with Ferrous, Folic Acid and b-Complex for anemia prevention, also followed-up every month, ON THE OTHER SIDE at least a 50% of women not hospitalized in the group of women supplemented with Vitamin C in a 1:1 randomized ratio.']	[('INCOMPLETE_EVIDENCE', 3), ('DIFFICULT_TASK', 223), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 284)]	3	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('CHEBI_15378', 'hydron', 197, 'ferrous'), ('CHEBI_30751', 'formic acid', 206, 'folic acid'), ('CHEBI_34652', 'compactin diol lactone', 223, 'complex'), ('GO_0032991', 'protein-containing complex', 223, 'complex'), ('CHEBI_27300', 'vitamin D', 383, 'vitamin C')]	0	['30% women hospitalized  supplemented regularly throughout  ferrous, folic acid b-complex anemia prevention, followed-up month, 50% women hospitalized women supplemented  1:1 ratio.']
S92-PMC3032617	PMC3032617	5/2010	S92-PMC3032617	['chi squared value=9.971 with 4 degrees of freedom\n\ncaption (table-wrap): table 4:\nsystolic Blood pressure (bp) variation from baseline to Delivery in the two groups of womenbaseline (median, range)Delivery*(median, range)average increase (mmhg)p Vitamin C97 (86-134)104 (92-132)8.040.0001controls98 (83-133)103 (79-129)4.50.0001\nin cases of Miscarriage or Preterm Delivery, the last Antenatal bp value was considered in the analysis\n\ncaption (fig): figure 1:\n\nstudy flow diagram\n\ncaption (fig): figure 2:\n\npatients’ distribution in the two treatment groups according to the number of times hospitalized\n\ndiscussion\nin this randomized, open label, cohort study, the daily Vitamin C supplementation provided IMPORTANT clinical signs in the group of women treated.']	[('IMPORTANT_CONSIDERATION', 706)]	1	[('UBERON_0000178', 'blood', 91, 'blood'), ('GO_0007567', 'parturition', 138, 'delivery'), ('GO_0007586', 'digestion', 197, 'Delivery'), ('CHEBI_80326', 'Neuropeptide FF', 246, 'Vitamin C97'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 246, 'Vitamin C97'), ('GO_0046660', 'female sex differentiation', 341, 'miscarriage'), ('GO_0007565', 'female pregnancy', 356, 'preterm'), ('GO_0007567', 'parturition', 364, 'delivery'), ('GO_0007567', 'parturition', 383, 'antenatal'), ('CHEBI_27300', 'vitamin D', 671, 'vitamin C')]	0	['chi squared value=9.971 4 degrees freedom\n\ncaption (table-wrap): table 4:\nsystolic blood pressure (bp) baseline delivery womenbaseline (median, range)delivery*(median, range)average increase (mmhg)p vitamin c97 (86-134)104 (92-132)8.040.0001controls98 (83-133)103 (79-129)4.50.0001\nin cases miscarriage  delivery, last antenatal bp analysis\n\ncaption (fig): figure 1:\n\nstudy flow diagram\n\ncaption (fig): figure 2:\n\npatients’ distribution treatment times hospitalized\n\ndiscussion\nin randomized, label, study, daily  supplementation women treated.']
S99-PMC3032617	PMC3032617	5/2010	S99-PMC3032617	['in the case of children Born with a body weight lower than 2500g, the significant difference FOUND among groups in favor of the Vitamin C women is INTRIGUING as it CAN be INTERPRETED as more and better energy supply to child during Gestation.']	[('INCOMPLETE_EVIDENCE', 93), ('ANOMALY_CURIOUS_FINDING', 147), ('INCOMPLETE_EVIDENCE', 164), ('PROBABLE_UNDERSTANDING', 171)]	4	[('GO_0007567', 'parturition', 24, 'born'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin C'), ('GO_0007565', 'female pregnancy', 232, 'gestation')]	0	['children born 2500g, among  women energy supply child .']
S102-PMC3032617	PMC3032617	5/2010	S102-PMC3032617	['INTERESTINGLY, ALTHOUGH the average weight gain was normal in the two groups during Pregnancy without any significant statistical difference, this was FOUND lower in the Vitamin C group COMPARED TO controls, and this COULD SUGGEST the POSSIBILITY of a better Fatty Acid Catabolism provided by high dose Vitamin C intake which IS KNOWN to enhance Carnitine synthesis, a fundamental long chain Fatty Acid transporter to the Mitochondrial site for energy production in form of atp, also, Ascorbic Acid is INVOLVED in the biosynthetic pathway of Thyroid hormones which are known regulators of the basal Metabolism.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 15), ('INCOMPLETE_EVIDENCE', 151), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 186), ('INCOMPLETE_EVIDENCE', 217), ('INCOMPLETE_EVIDENCE', 223), ('INCOMPLETE_EVIDENCE', 235), ('INCOMPLETE_EVIDENCE', 326), ('SUPERFICIAL_RELATIONSHIP', 502)]	9	[('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin C'), ('CHEBI_35366', 'fatty acid', 259, 'fatty acid'), ('GO_0009062', 'fatty acid catabolic process', 259, 'fatty acid catabolism'), ('CHEBI_27300', 'vitamin D', 303, 'vitamin C'), ('CHEBI_17126', 'carnitine', 346, 'carnitine'), ('GO_0015915', 'fatty-acyl group transport', 392, 'fatty acid'), ('GO_0005739', 'mitochondrion', 422, 'mitochondrial'), ('CHEBI_22652', 'ascorbic acid', 485, 'ascorbic acid'), ('CHEBI_9437', 'temoporfin', 542, 'thyroid'), ('UBERON_0002046', 'thyroid gland', 542, 'thyroid'), ('GO_0008152', 'metabolic process', 599, 'metabolism')]	0	['interestingly, average gain normal  statistical difference,  controls, fatty acid catabolism dose  intake carnitine synthesis, chain fatty acid transporter mitochondrial site energy production form atp, also, ascorbic acid biosynthetic thyroid hormones basal metabolism.']
S107-PMC3032617	PMC3032617	5/2010	S107-PMC3032617	['considering the IMPORTANCE of systolic Blood pressure during Pregnancy which is a direct reflex of mother’s Blood output and THEREFORE child Nutrient provision, we compared in each group the difference from baseline to end of Pregnancy and a significant average increase was FOUND in both groups from baseline, with a higher increase in the Vitamin C group.']	[('IMPORTANT_CONSIDERATION', 16), ('PROBABLE_UNDERSTANDING', 125), ('INCOMPLETE_EVIDENCE', 275)]	3	[('UBERON_0000178', 'blood', 39, 'blood'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('UBERON_0000178', 'blood', 108, 'blood'), ('CHEBI_33284', 'nutrient', 141, 'nutrient'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 341, 'vitamin C')]	0	['considering systolic blood pressure  reflex mother’s blood output child nutrient provision, baseline  average increase baseline, higher increase  group.']
S116-PMC3032617	PMC3032617	5/2010	S116-PMC3032617	['moreover, the supplementation of a relatively cheap, clinically SAFE and health-bearing integrator as Vitamin C, PROVED to add overall BENEFITS in terms of hospitalization and several other mother-to-child outcomes RELEVANT during Pregnancy.']	[('IMPORTANT_CONSIDERATION', 64), ('PROBABLE_UNDERSTANDING', 113), ('IMPORTANT_CONSIDERATION', 135), ('IMPORTANT_CONSIDERATION', 215)]	4	[('CHEBI_27300', 'vitamin D', 102, 'vitamin C'), ('GO_0007565', 'female pregnancy', 231, 'pregnancy')]	0	['moreover, supplementation cheap, clinically health-bearing integrator terms hospitalization mother-to-child outcomes .']
S128-PMC3032617	PMC3032617	5/2010	S128-PMC3032617	['our results INDICATE the benefit of adding Vitamin C in the guidelines of multivitamin supplementation to Pregnant women.']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('CHEBI_27300', 'vitamin D', 43, 'vitamin C'), ('GO_0007565', 'female pregnancy', 106, 'pregnant')]	0	['results adding  multivitamin supplementation  women.']
S0-PMC3034879	PMC3034879	12/2010	S0-PMC3034879	['maternal Vitamin D status AFFECTS bone growth in early childhood—a prospective cohort study\n\nabstract\n\nsummary\nin this prospective study, 87 children were followed up from Birth to 14\xa0months with data on maternal Vitamin D status during the Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 26)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 172, 'birth'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('GO_0007565', 'female pregnancy', 241, 'pregnancy')]	0	['maternal  status bone childhood—a study\n\nabstract\n\nsummary\nin study, 87 children followed birth 14\xa0months maternal  status .']
S3-PMC3034879	PMC3034879	12/2010	S3-PMC3034879	['we EVALUATED the ROLE of Prenatal and Postnatal Vitamin D status on bone parameters in early infancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 17)]	2	[('GO_0007565', 'female pregnancy', 25, 'prenatal'), ('GO_0007567', 'parturition', 38, 'postnatal'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D')]	0	[' postnatal  status bone parameters infancy.']
S8-PMC3034879	PMC3034879	12/2010	S8-PMC3034879	['FINDINGS were compared with maternal Vitamin D status during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy')]	0	['findings maternal  status .']
S15-PMC3034879	PMC3034879	12/2010	S15-PMC3034879	['FURTHER ATTENTION SHOULD BE PAID to improving Vitamin D status during Pregnancy.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 8), ('FUTURE_WORK', 18), ('IMPORTANT_CONSIDERATION', 28)]	4	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy')]	0	[' status .']
S19-PMC3034879	PMC3034879	12/2010	S19-PMC3034879	['low maternal Vitamin D status or inadequate dietary Vitamin D intake during Pregnancy PREDISPOSES children to asthma and allergic rhinitis [6], diabetes [7], acute lower respiratory infection [8], and impaired bone mass accrual.']	[('SUPERFICIAL_RELATIONSHIP', 86)]	1	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy')]	0	['low maternal  status dietary  intake  children asthma allergic rhinitis [6], diabetes [7], acute respiratory infection [8], bone mass accrual.']
S26-PMC3034879	PMC3034879	12/2010	S26-PMC3034879	['PREVIOUSLY the authors of the current study have REPORTED that during the Pregnancy, 69% of the women and 37% of the newborns at Birth were Vitamin D deficient (defined in women AS S-25-Ohd <50\xa0nmol/l [18,19] and in the newborn AS <37.5\xa0nmol/l [20]).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 49), ('PROBABLE_UNDERSTANDING', 178), ('PROBABLE_UNDERSTANDING', 228)]	4	[('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 129, 'birth'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('CHEBI_16786', 'vestitone', 181, 'S-'), ('CHEBI_72765', 'verruculogen', 183, '25-OHD'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 183, '25')]	0	['previously authors 69% women 37% newborns birth  (defined women s-25-ohd <50\xa0nmol/l [18,19] newborn <37.5\xa0nmol/l [20]).']
S98-PMC3034879	PMC3034879	12/2010	S98-PMC3034879	['caption (table-wrap): table\xa01\n\nbackground characteristics and changes in them from baseline value given as mean (sd)low dhigh dindependent samples t -test n 4443age, months14.9 (0.5)14.8 (0.5)0.336males, %58550.842aanthropometric and growth variables \xa0weight, kg10.8 (1.3)10.8 (1.3)0.997\xa0relative weight−1.2 (8.1)0.2 (6.7)0.382\xa0∆weight, kg7.1 (1.1)7.2 (1.0)0.624\xa0weight velocity, g/month475 (72)488 (67)0.446\xa0height, cm79.0 (2.8)78.4 (3.5)0.386\xa0height z-score0.25 (1.0)0.03 (1.2)0.378\xa0∆height, cm27.9 (2.0)27.7 (2.9)0.732\xa0height velocity, cm/month1.88 (0.12)1.87 (0.19)0.951 history of Breast feeding and dietary intakes \xa0duration of exclusive breastfeeding, months4.2 (1.9)4.3 (2.0)0.755\xa0currently Breastfed, n (%)11 (26.8)7 (16.6)0.196a\xa0energy intake, kcal/day920 (220)930 (180)0.770\xa0fat intake, g/day28.6 (7.9)28.0 (6.9)0.698\xa0protein Intake, g/day43 (13)42 (10)0.481\xa0Calcium intake, mg/day820 (320)840 (260)0.863\xa0total intake of Vitamin D, μg/day12.4 (3.1)12.2 (2.9)0.782 motor and language skills \xa0age when learnt to crawl, months8.0 (1.8)8.2 (1.8)0.690\xa0age when Learnt to stand, months8.4 (1.7)8.5 (1.6)0.668\xa0age when learnt to walk with support, months8.8 (1.6)10.1 (1.5)0.001\xa0age when Learnt to walk without support, months11.9 (1.6)12.1 (1.5)0.458\xa0number of words in use5.7 (6.2)6.8 (7.7)0.490\napearson chi square\nDESPITE lower Vitamin D concentration during Pregnancy and at Birth in low d than in high d (means 35.7 vs. 54.2\xa0nmol/l, and in the Cord 40.5 and 59.3\xa0nmol/l, independent samples t -test; p \u2009<\u20090.001, respectively), the 25-Ohd concentrations in the two groups at 14\xa0months were SIMILAR (63 vs. 66\xa0nmol/l, p \u2009=\u20090.58).']	[('ANOMALY_CURIOUS_FINDING', 1322), ('SUPERFICIAL_RELATIONSHIP', 1599)]	2	[('UBERON_0000310', 'breast', 586, 'breast'), ('GO_0007567', 'parturition', 699, 'breastfed'), ('GO_0007631', 'feeding behavior', 837, 'intake'), ('CHEBI_31341', 'calcium dihydroxide', 870, 'Calcium'), ('CHEBI_27300', 'vitamin D', 932, 'vitamin D'), ('GO_0007612', 'learning', 1067, 'learnt'), ('GO_0007612', 'learning', 1192, 'learnt'), ('CHEBI_27300', 'vitamin D', 1336, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1367, 'pregnancy'), ('GO_0007567', 'parturition', 1384, 'birth'), ('UBERON_0002240', 'spinal cord', 1454, 'cord'), ('CHEBI_72765', 'verruculogen', 1541, '25-OHD')]	0	['caption (table-wrap): table\xa01\n\nbackground characteristics changes baseline (sd)low dhigh dindependent samples -test n 4443age, months14.9 (0.5)14.8 (0.5)0.336males, %58550.842aanthropometric \xa0weight, kg10.8 (1.3)10.8 (1.3)0.997\xa0relative weight−1.2 (8.1)0.2 (6.7)0.382\xa0∆weight, kg7.1 (1.1)7.2 (1.0)0.624\xa0weight velocity, g/month475 (72)488 (67)0.446\xa0height, cm79.0 (2.8)78.4 (3.5)0.386\xa0height z-score0.25 (1.0)0.03 (1.2)0.378\xa0∆height, cm27.9 (2.0)27.7 (2.9)0.732\xa0height velocity, cm/month1.88 (0.12)1.87 (0.19)0.951 breast feeding dietary intakes \xa0duration breastfeeding, months4.2 (1.9)4.3 (2.0)0.755\xa0currently breastfed, n (%)11 (26.8)7 (16.6)0.196a\xa0energy intake, kcal/day920 (220)930 (180)0.770\xa0fat intake, g/day28.6 (7.9)28.0 (6.9)0.698\xa0protein intake, g/day43 (13)42 (10)0.481\xa0calcium intake, mg/day820 (320)840 (260)0.863\xa0total intake μg/day12.4 (3.1)12.2 (2.9)0.782 motor language skills \xa0age learnt crawl, months8.0 (1.8)8.2 (1.8)0.690\xa0age learnt stand, months8.4 (1.7)8.5 (1.6)0.668\xa0age learnt walk support, months8.8 (1.6)10.1 (1.5)0.001\xa0age learnt walk support, months11.9 (1.6)12.1 (1.5)0.458\xa0number words use5.7 (6.2)6.8 (7.7)0.490\napearson chi square\ndespite  concentration  birth (means 35.7 vs. 54.2\xa0nmol/l, cord 40.5 59.3\xa0nmol/l, samples -test; p \u2009<\u20090.001, respectively), 25-ohd concentrations 14\xa0months (63 vs. 66\xa0nmol/l, p \u2009=\u20090.58).']
S153-PMC3034879	PMC3034879	12/2010	S153-PMC3034879	['Tibia csa REMAINED SOMEWHAT larger in infants whose mothers had better Vitamin D status during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 19)]	2	[('UBERON_0000979', 'tibia', 0, 'Tibia'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 95, 'pregnancy')]	0	['tibia csa infants whose mothers  status .']
S167-PMC3034879	PMC3034879	12/2010	S167-PMC3034879	['SOME STUDIES have witnessed that insufficient Vitamin D status during Pregnancy is RELATED to lower bone Mineral status in the newborn [9,10,28].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 83)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('CHEBI_46662', 'mineral', 105, 'mineral')]	0	[' status  bone mineral status newborn [9,10,28].']
S168-PMC3034879	PMC3034879	12/2010	S168-PMC3034879	['initially, 70% of the mothers were Vitamin D deficient during the Pregnancy AS their mean Serum 25-Ohd for first trimester and 2\xa0days Postpartum was less than 50\xa0nmol/l.']	[('PROBABLE_UNDERSTANDING', 76)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy'), ('UBERON_0001977', 'blood serum', 90, 'serum'), ('CHEBI_72765', 'verruculogen', 96, '25-OHD'), ('GO_0007565', 'female pregnancy', 134, 'postpartum')]	0	['initially, 70% mothers   serum 25-ohd trimester 2\xa0days  50\xa0nmol/l.']
S189-PMC3034879	PMC3034879	12/2010	S189-PMC3034879	['there was a positive ASSOCIATION between total intake of Vitamin D and 25-Ohd in the entire group and in high d, but NOT among those infants in low D whose Vitamin D status during Pregnancy was worse.']	[('SUPERFICIAL_RELATIONSHIP', 21), ('ANOMALY_CURIOUS_FINDING', 117)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_72765', 'verruculogen', 71, '25-OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 148, 'D'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('GO_0007565', 'female pregnancy', 180, 'pregnancy')]	0	['positive intake  25-ohd entire d, among infants whose  status  worse.']
S202-PMC3034879	PMC3034879	12/2010	S202-PMC3034879	['based ON these OBSERVATIONS, ADDITIONAL EFFORTS SHOULD BE MADE to improve Vitamin D status during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 6), ('ANOMALY_CURIOUS_FINDING', 6), ('INCOMPLETE_EVIDENCE', 15), ('FUTURE_WORK', 29), ('FUTURE_WORK', 40), ('FUTURE_WORK', 48)]	6	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy')]	0	['based observations,  status .']
S75-PMC3039633	PMC3039633	2/2011	S75-PMC3039633	['[30]302 children (australia)1,3(at 4 yrs)stanford-binet intelligence scale strengths and difficulties questionnaireiron vs. placebo20 weeks Gestation to Birth∅ 1,317/21\n1 = Cognitive Development\n2 = Motor Development\n3 = Behavioral Development\n4 = Visual Development\n5 = auditory development\n∅ = no effect of Nutrient(s) on development\n+ = positive EFFECT of Nutrient(s) on development\n- = negative EFFECT of Nutrient(s) on development\nmvm = multivitamin-Mineral\nHchp = high calorie, high protein\nlclp = low calorie, low protein\nmvm-a = multivitamin-Mineral without Vitamin a\nmvm+a = multivitamin-Mineral with Vitamin A\nld = lower dosage\ngiven the heterogeneity of methods and outcome measures in the studies reviewed, it was NOT FEASIBLE to compare effect sizes or to perform a meta-analysis.']	[('SUPERFICIAL_RELATIONSHIP', 349), ('SUPERFICIAL_RELATIONSHIP', 399), ('DIFFICULT_TASK', 726)]	3	[('GO_0007565', 'female pregnancy', 140, 'gestation'), ('GO_0007567', 'parturition', 153, 'birth'), ('GO_0007567', 'parturition', 158, '∅'), ('GO_0050787', 'detoxification of mercury ion', 173, 'cognitive development'), ('GO_0009653', 'anatomical structure morphogenesis', 199, 'motor development'), ('GO_0007420', 'brain development', 221, 'behavioral development'), ('GO_0007506', 'gonadal mesoderm development', 248, 'visual development'), ('CHEBI_33284', 'nutrient', 309, 'nutrient'), ('CHEBI_33284', 'nutrient', 359, 'nutrient'), ('CHEBI_33284', 'nutrient', 409, 'nutrient'), ('CHEBI_46662', 'mineral', 455, 'mineral'), ('CHEBI_17883', 'hydrogen chloride', 463, 'HCHP'), ('CHEBI_46662', 'mineral', 550, 'mineral'), ('CHEBI_33229', 'vitamin (role)', 566, 'vitamin'), ('CHEBI_46662', 'mineral', 597, 'mineral'), ('CHEBI_27300', 'vitamin D', 610, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 618, 'A')]	0	['[30]302 children (australia)1,3(at 4 yrs)stanford-binet intelligence questionnaireiron vs. placebo20 weeks  birth∅ 1,317/21\n1 = cognitive development\n2 = motor development\n3 = behavioral development\n4 = visual development\n5 = auditory development\n∅ = nutrient(s) development\n+ = positive nutrient(s) development\n- = nutrient(s) development\nmvm = multivitamin-mineral\nhchp = calorie, protein\nlclp = calorie, protein\nmvm-a = multivitamin-mineral vitamin a\nmvm+a = multivitamin-mineral \nld = dosage\ngiven outcome reviewed, sizes perform meta-analysis.']
S2-PMC3061267	PMC3061267	2/2011	S2-PMC3061267	['adequate Vitamin D and Calcium nutrition throughout Life MAY reduce the RISK of osteoporosis, and Calcium supplementation during Pregnancy MAY reduce Preeclampsia and low Birth weight.']	[('INCOMPLETE_EVIDENCE', 57), ('IMPORTANT_CONSIDERATION', 72), ('INCOMPLETE_EVIDENCE', 139)]	3	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 23, 'calcium'), ('UBERON_0000104', 'life cycle', 52, 'life'), ('CHEBI_22313', 'alkaline earth metal atom', 98, 'calcium'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 150, 'preeclampsia'), ('GO_0007567', 'parturition', 171, 'birth')]	0	['adequate  calcium nutrition throughout life osteoporosis, calcium supplementation  preeclampsia birth weight.']
S29-PMC3061267	PMC3061267	2/2011	S29-PMC3061267	['nutrient deficiencies LINKED to PUBLIC HEALTH PROBLEMS in women\n\nCalcium and Vitamin D\nCalcium (1,200 mg elemental Ca/d) was found to reduce all four Premenstrual syndrome symptoms examined in an older clinical trial [7].']	[('SUPERFICIAL_RELATIONSHIP', 22), ('IMPORTANT_CONSIDERATION', 32), ('IMPORTANT_CONSIDERATION', 46)]	3	[('CHEBI_31341', 'calcium dihydroxide', 65, 'Calcium'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_31341', 'calcium dihydroxide', 87, 'Calcium'), ('CHEBI_32588', 'potassium chloride', 115, 'Ca'), ('GO_0007565', 'female pregnancy', 150, 'premenstrual')]	0	['nutrient women\n\ncalcium \ncalcium (1,200 mg elemental ca/d) four  syndrome symptoms older [7].']
S49-PMC3061267	PMC3061267	2/2011	S49-PMC3061267	['one TRIAL in nepal FOUND that giving Pregnant women frequent small doses of Vitamin A reduced maternal mortality by 44% [22].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 19)]	2	[('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin A')]	0	['one nepal  women doses  maternal mortality 44% [22].']
S10-PMC3075531	PMC3075531	7/2010	S10-PMC3075531	['introduction\nmultiple sclerosis (ms) is a chronic PROBABLY with Autoimmune basis and UNCERTAIN etiology characterized by Demyelinative and inflammatory physiopathology causing Axonal damages.12this disease AFFECTS females more than males with ordinary 10 years Relapsing-remitting course and secondary progressive phase.2on histological basis, T Helper Cells type 1 (th1) is the MOST RESPONSIBLE cause for pathologies SEEN in ms.1–3there are multiple RISK FACTORS for ms in a COMPLEX RELATIONSHIP with each other from Genetic ones to environmental FACTORS BUT exact mechanism leading to ms has REMAINED UNCLEAR yet.45from GUESSED environmental RISK FACTORS for ms, past infection with Ebv, smoking and low Serum level of Vitamin D are more favorable.67the MOST IMPORTANT Vitamin in calcium and Phosphor Homeostasis is Vitamin D. this Vitamin has PROPOSED POTENTIAL power for Modulating Immune System.48this is achieved via enhancing the Phagocytic function of Monocytes9And decreasing the secretion of Il-6, Il-12, Tnf-Α and Pge2 by Monocytes.10also, immature or semi mature Apc’S cannot mature in presence of 1,25 (Oh)2D.8MANY STUDIES SHOWED a ROLE of paracrine function and Nerve Growth Factor Synthesis Of Vitamin D in Cns and also, SHOWED that deficiency of this Vitamin in Pregnancy Period CAN cause Neural System disorder in Animal cases.811–14then, Vitamin D has a near RELATION with ms and the results of DIFFERENT studies can be summarized as follows: first, the EFFECT of latitude via exposure to sun light and Serum level of Vitamin D on ms prevalence, that increases with distance from equator, with ONLY one EXCEPTION in norway.23815second, vander et al.']	[('PROBABLE_UNDERSTANDING', 50), ('FULL_UNKNOWN', 85), ('SUPERFICIAL_RELATIONSHIP', 206), ('PROBABLE_UNDERSTANDING', 379), ('PROBABLE_UNDERSTANDING', 384), ('INCOMPLETE_EVIDENCE', 418), ('SUPERFICIAL_RELATIONSHIP', 451), ('DIFFICULT_TASK', 476), ('SUPERFICIAL_RELATIONSHIP', 484), ('SUPERFICIAL_RELATIONSHIP', 548), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 556), ('INCOMPLETE_EVIDENCE', 594), ('FULL_UNKNOWN', 603), ('INCOMPLETE_EVIDENCE', 622), ('SUPERFICIAL_RELATIONSHIP', 644), ('PROBABLE_UNDERSTANDING', 756), ('IMPORTANT_CONSIDERATION', 761), ('INCOMPLETE_EVIDENCE', 846), ('INCOMPLETE_EVIDENCE', 855), ('INCOMPLETE_EVIDENCE', 1123), ('INCOMPLETE_EVIDENCE', 1136), ('SUPERFICIAL_RELATIONSHIP', 1145), ('INCOMPLETE_EVIDENCE', 1236), ('INCOMPLETE_EVIDENCE', 1295), ('SUPERFICIAL_RELATIONSHIP', 1377), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1413), ('SUPERFICIAL_RELATIONSHIP', 1472), ('ANOMALY_CURIOUS_FINDING', 1612), ('ANOMALY_CURIOUS_FINDING', 1621)]	29	[('UBERON_0001442', 'skeleton of manus', 64, 'autoimmune'), ('GO_0006188', 'IMP biosynthetic process', 121, 'demyelinative'), ('GO_0030424', 'axon', 176, 'axonal'), ('GO_0065007', 'biological regulation', 261, 'relapsing'), ('CL_0000545', 'T-helper 1 cell', 344, 'T helper cells'), ('SO_0000704', 'gene', 518, 'genetic'), ('NCBITaxon_10088', 'Mus <genus>', 685, 'EBV'), ('UBERON_0001977', 'blood serum', 706, 'serum'), ('CHEBI_27300', 'vitamin D', 721, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 771, 'vitamin'), ('CHEBI_30215', 'muonide', 794, 'phosphor'), ('GO_0042592', 'homeostatic process', 803, 'homeostasis'), ('CHEBI_27300', 'vitamin D', 818, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 834, 'vitamin'), ('GO_0065007', 'biological regulation', 875, 'modulating'), ('UBERON_0002405', 'immune system', 886, 'immune system'), ('GO_0006909', 'phagocytosis', 937, 'phagocytic'), ('CL_0002198', 'oncocyte', 960, 'monocytes9and'), ('PR_000001470', 'interleukin-28B', 1002, 'IL-6'), ('PR_000001470', 'interleukin-28B', 1008, 'IL-12'), ('PR_000000134', 'tumor necrosis factor alpha', 1015, 'TNF-α'), ('PR_000012560', 'peroxisomal membrane protein PEX14', 1025, 'PGE2'), ('CL_0000576', 'monocyte', 1033, 'monocytes'), ('PR_000004122', 'adenomatous polyposis coli protein', 1075, 'APC'), ('PR_000011000', 'N-alpha-acetyltransferase 60', 1079, 's'), ('CHEBI_82784', 'PVP38-Ag NP', 1110, '1,25 (OH)2D'), ('UBERON_0001021', 'nerve', 1176, 'nerve'), ('GO_0040007', 'growth', 1182, 'growth factor'), ('GO_0030474', 'spindle pole body duplication', 1196, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 1209, 'vitamin D'), ('UBERON_0001017', 'central nervous system', 1222, 'CNS'), ('CHEBI_33229', 'vitamin (role)', 1267, 'vitamin'), ('GO_0007565', 'female pregnancy', 1278, 'pregnancy'), ('UBERON_0018298', 'stylocone', 1278, 'pregnancy period'), ('UBERON_0023879', 'neural system', 1305, 'neural system'), ('NCBITaxon_33208', 'Metazoa', 1331, 'animal'), ('CHEBI_27300', 'vitamin D', 1356, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1521, 'serum'), ('CHEBI_27300', 'vitamin D', 1536, 'vitamin D')]	0	['introduction\nmultiple sclerosis (ms) chronic autoimmune etiology demyelinative inflammatory physiopathology axonal damages.12this disease females males ordinary 10 relapsing-remitting course secondary progressive phase.2on histological basis, helper cells type (th1) pathologies ms.1–3there ms genetic ones environmental exact ms yet.45from environmental ms, infection ebv, smoking serum  favorable.67the vitamin calcium phosphor homeostasis . vitamin immune system.48this achieved via phagocytic monocytes9and decreasing secretion il-6, il-12, tnf-α pge2 monocytes.10also, immature semi mature apc’s mature presence 1,25 (oh)2d.8many paracrine nerve synthesis  cns also, vitamin  period neural system disorder animal cases.811–14then,  ms results follows: first, latitude via exposure sun serum  ms prevalence, distance equator, norway.23815second, vander et al.']
S55-PMC3075531	PMC3075531	7/2010	S55-PMC3075531	['in a pooled analysis of data from canada, uk, denmark, and sweden including more than 40,000 Individuals with ms, significantly fewer (8.5%) People with ms were Born in november and significantly more (9.1%) were Born in may.39THIS FINDING SUGGESTS that Prenatal exposures or exposures in the first months of Life COULD BE IMPORTANT in ms etiology, BUT the LINK to Vitamin D is UNCLEAR.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 227), ('INCOMPLETE_EVIDENCE', 232), ('INCOMPLETE_EVIDENCE', 240), ('INCOMPLETE_EVIDENCE', 314), ('IMPORTANT_CONSIDERATION', 323), ('ANOMALY_CURIOUS_FINDING', 349), ('SUPERFICIAL_RELATIONSHIP', 357), ('FULL_UNKNOWN', 378)]	8	[('NCBITaxon_1', 'root', 93, 'individuals'), ('NCBITaxon_10088', 'Mus <genus>', 141, 'people'), ('GO_0007567', 'parturition', 161, 'born'), ('GO_0007567', 'parturition', 213, 'born'), ('GO_0007565', 'female pregnancy', 254, 'prenatal'), ('UBERON_0000104', 'life cycle', 309, 'life'), ('CHEBI_27300', 'vitamin D', 365, 'vitamin D')]	0	['pooled canada, uk, denmark, sweden 40,000 individuals ms, (8.5%) people ms born november (9.1%) born may.39this  exposures exposures months life ms etiology,  unclear.']
S4-PMC3099599	PMC3099599	5/2011	S4-PMC3099599	['subdural hematoma MAY also be the result of common Birth trauma, COMPLICATED by Prenatal Vitamin D deficiency, which also CONTRIBUTES to the appearance of Long Bone fractures commonly ASSOCIATED with child abuse.']	[('INCOMPLETE_EVIDENCE', 18), ('DIFFICULT_TASK', 65), ('SUPERFICIAL_RELATIONSHIP', 122), ('SUPERFICIAL_RELATIONSHIP', 184)]	4	[('GO_0007567', 'parturition', 51, 'birth'), ('GO_0007565', 'female pregnancy', 80, 'prenatal'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0002495', 'long bone', 155, 'long bone')]	0	['subdural hematoma result birth trauma,   deficiency, bone fractures child abuse.']
S19-PMC3103150	PMC3103150	3/2011	S19-PMC3103150	['there are a FEW REPORTS of Vitamin D deficiency among Pregnant women and Cord Blood of their newborns910and Breastfed young infants from india1112.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 16)]	2	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnant'), ('UBERON_0002240', 'spinal cord', 73, 'cord'), ('UBERON_0000178', 'blood', 78, 'blood'), ('GO_0007567', 'parturition', 108, 'breastfed')]	0	[' among  women cord blood newborns910and breastfed young infants india1112.']
S102-PMC3103150	PMC3103150	3/2011	S102-PMC3103150	['discussion\nwe FOUND a high prevalence of Vitamin D deficiency in term, appropriate for Gestational age breastfed infants and their mothers.']	[('INCOMPLETE_EVIDENCE', 14)]	1	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'gestational')]	0	['discussion\nwe  term,  age breastfed infants mothers.']
S115-PMC3103150	PMC3103150	3/2011	S115-PMC3103150	['ALTERNATIVE EXPLANATION can be that these infants accrued lower stores of Vitamin D in utero as the latter half of Pregnancy was in winter season.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 12)]	2	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy')]	0	['alternative infants accrued stores  utero latter half  winter season.']
S126-PMC3103150	PMC3103150	3/2011	S126-PMC3103150	['in the united states, the CURRENTLY RECOMMENDED adequate intake for Vitamin D during Pregnancy as well as Lactation is 200 iu/day34.']	[('INCOMPLETE_EVIDENCE', 26), ('FUTURE_WORK', 36)]	2	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('GO_0007595', 'lactation', 106, 'lactation')]	0	['united states, intake   lactation 200 iu/day34.']
S131-PMC3103150	PMC3103150	3/2011	S131-PMC3103150	['LARGER STUDIES and meta-analysis SHOULD BE conducted to CONFIRM the FINDINGS of the PRESENT study and develop RECOMMENDATIONS for Vitamin D supplementation for Pregnant and Lactating women and young infants.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 33), ('INCOMPLETE_EVIDENCE', 56), ('INCOMPLETE_EVIDENCE', 68), ('QUESTION_ANSWERED_BY_THIS_WORK', 84), ('FUTURE_WORK', 110)]	6	[('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnant'), ('GO_0007594', 'puparial adhesion', 173, 'lactating')]	0	['larger meta-analysis  supplementation  lactating women young infants.']
S37-PMC3107676	PMC3107676	4/2011	S37-PMC3107676	['PREVIOUS STUDIES have NOT REPORTED prevalence of Vitamin C supplementation among women who took Drugs classified as Nitrosatable or INDICATED the EFFECTS of Vitamin C intake on any ASSOCIATIONS between Nitrosatable Drug use and adverse Pregnancy outcomes.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 132), ('SUPERFICIAL_RELATIONSHIP', 146), ('SUPERFICIAL_RELATIONSHIP', 181)]	5	[('CHEBI_27300', 'vitamin D', 49, 'vitamin C'), ('CHEBI_23888', 'drug', 96, 'drugs'), ('CHEBI_7587', 'nitroalkane', 116, 'nitrosatable'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin C'), ('CHEBI_75872', '(R)-sarin', 202, 'nitrosatable drug'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy')]	0	['previous  supplementation among women took drugs nitrosatable  intake nitrosatable drug  outcomes.']
S38-PMC3107676	PMC3107676	4/2011	S38-PMC3107676	['accounting for Vitamin C use when assessing the EFFECTS of Nitrosatable Drugs on Pregnancy outcomes MAY prove to be CRITICALLY IMPORTANT.']	[('SUPERFICIAL_RELATIONSHIP', 48), ('INCOMPLETE_EVIDENCE', 100), ('IMPORTANT_CONSIDERATION', 116), ('IMPORTANT_CONSIDERATION', 127)]	4	[('CHEBI_27300', 'vitamin D', 15, 'vitamin C'), ('CHEBI_7496', 'nelfinavir', 59, 'nitrosatable drugs'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy')]	0	['accounting  nitrosatable drugs  outcomes important.']
S39-PMC3107676	PMC3107676	4/2011	S39-PMC3107676	['the PURPOSE of OUR STUDY was (1) TO describe the prevalence and PATTERNS of Nitrosatable Drug use among u.s. women during the first Trimester of Pregnancy, including type of Drug (secondary or tertiary Amine, amide) and indication of use; (2) TO EXAMINE maternal factors ASSOCIATED with Nitrosatable Drug use; and (3) TO INVESTIGATE the prevalence of supplemental Vitamin C use among women who took Nitrosatable Drugs in early Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 64), ('QUESTION_ANSWERED_BY_THIS_WORK', 243), ('SUPERFICIAL_RELATIONSHIP', 271), ('QUESTION_ANSWERED_BY_THIS_WORK', 318)]	7	[('CHEBI_75872', '(R)-sarin', 76, 'nitrosatable drug'), ('GO_0009294', 'DNA mediated transformation', 132, 'trimester'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('CHEBI_23888', 'drug', 174, 'drug'), ('CHEBI_32952', 'amine', 202, 'amine'), ('CHEBI_7587', 'nitroalkane', 287, 'nitrosatable'), ('CHEBI_23888', 'drug', 300, 'drug'), ('CHEBI_27300', 'vitamin D', 364, 'vitamin C'), ('CHEBI_7496', 'nelfinavir', 399, 'nitrosatable drugs'), ('GO_0007565', 'female pregnancy', 427, 'pregnancy')]	0	['(1) nitrosatable drug among u.s. women trimester type drug (secondary tertiary amine, amide) use; (2) maternal nitrosatable drug use; (3) supplemental  among women took nitrosatable drugs .']
S71-PMC3107676	PMC3107676	4/2011	S71-PMC3107676	['because Vitamin C supplement use varied CONSIDERABLY by month during the first trimester, we EXAMINED prevalence of supplement use (none, less than daily, daily) separately during the first, second, and third months of Pregnancy by Nitrosatable Drug use during the first trimester.']	[('ANOMALY_CURIOUS_FINDING', 40), ('QUESTION_ANSWERED_BY_THIS_WORK', 93)]	2	[('CHEBI_27300', 'vitamin D', 8, 'vitamin C'), ('GO_0007565', 'female pregnancy', 219, 'pregnancy'), ('CHEBI_75872', '(R)-sarin', 232, 'nitrosatable drug')]	0	[' supplement month trimester, supplement (none, daily, daily) separately first, second, third months  nitrosatable drug trimester.']
S105-PMC3107676	PMC3107676	4/2011	S105-PMC3107676	['among women who took Nitrosatable Drugs, <40% reported daily use of a supplement with Vitamin C during the first month of Pregnancy (table 3), ALTHOUGH APPROXIMATELY 80% took such a Supplement daily by the third month.']	[('ANOMALY_CURIOUS_FINDING', 143), ('INCOMPLETE_EVIDENCE', 152)]	2	[('CHEBI_7496', 'nelfinavir', 21, 'nitrosatable drugs'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin C'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('CHEBI_16158', 'steroid sulfate', 182, 'supplement')]	0	['among women took nitrosatable drugs, <40% daily supplement  month  (table 3), 80% took supplement daily third month.']
S106-PMC3107676	PMC3107676	4/2011	S106-PMC3107676	['in the first month of Pregnancy, between 40 and 41% (DEPENDING ON the type of Nitrosatable Drug taken) of participants who took Nitrosatable Drugs did not take any Supplements with Vitamin C; the proportion of nonusers dropped to 12.3% by the third month of Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 53)]	1	[('GO_0007565', 'female pregnancy', 22, 'pregnancy'), ('CHEBI_7587', 'nitroalkane', 78, 'nitrosatable'), ('CHEBI_23888', 'drug', 91, 'drug'), ('CHEBI_7587', 'nitroalkane', 128, 'nitrosatable'), ('CHEBI_23888', 'drug', 141, 'drugs'), ('CHEBI_33341', 'titanium atom', 164, 'supplements'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin C'), ('GO_0007565', 'female pregnancy', 258, 'pregnancy')]	0	['month 40 41% (depending type nitrosatable drug taken) participants took nitrosatable drugs supplements proportion nonusers dropped 12.3% third month .']
S114-PMC3107676	PMC3107676	4/2011	S114-PMC3107676	['during the first and second months of Pregnancy, a sizable proportion of women who took Nitrosatable Drugs denied taking vitamin supplements with Vitamin C (41.6% and 19.3%, respectively), a WELL-DOCUMENTED Inhibitor Of Nitrosation.']	[('PROBABLE_UNDERSTANDING', 191)]	1	[('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('CHEBI_7496', 'nelfinavir', 88, 'nitrosatable drugs'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin C'), ('CHEBI_50854', 'hydrocortamate hydrochloride', 207, 'inhibitor of'), ('CHEBI_52846', 'cycloalkane ring', 220, 'nitrosation')]	0	['months sizable proportion women took nitrosatable drugs denied vitamin supplements  (41.6% 19.3%, respectively), inhibitor nitrosation.']
S115-PMC3107676	PMC3107676	4/2011	S115-PMC3107676	['by the third month of Pregnancy, APPROXIMATELY 80% reported taking Supplements that MOST LIKELY contained Vitamin C.\ncompared with prevalence ESTIMATES in PREVIOUSLY PUBLISHED STUDIES, the PRESENT STUDY has the highest REPORTED prevalence of Nitrosatable Drug use during early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 33), ('PROBABLE_UNDERSTANDING', 84), ('PROBABLE_UNDERSTANDING', 89), ('INCOMPLETE_EVIDENCE', 142), ('INCOMPLETE_EVIDENCE', 155), ('QUESTION_ANSWERED_BY_THIS_WORK', 189), ('INCOMPLETE_EVIDENCE', 219)]	7	[('GO_0007565', 'female pregnancy', 22, 'pregnancy'), ('CHEBI_33341', 'titanium atom', 67, 'supplements'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin C'), ('CHEBI_75872', '(R)-sarin', 242, 'nitrosatable drug'), ('GO_0007565', 'female pregnancy', 277, 'pregnancy')]	0	['third month 80% supplements contained .\ncompared studies, nitrosatable drug .']
S78-PMC3120197	PMC3120197	7/2011	S78-PMC3120197	['AS EXPECTED, higher nonheme iron intake was ASSOCIATED with higher intake of fruits, vegetables, fiber, and Vitamin C.\n\ncaption (table-wrap): table 1\n\nparticipants’ characteristics according to quartiles of dietary Heme and nonheme iron intake, seattle and tacoma, wa, omega cohort studycharacteristicdietary Heme iron (mg per day)dietary nonheme iron (mg per day)cohortquintile 1quintile 2quintile 3quintile 4 p for trendquintile 1quintile 2quintile 3quintile 4 p for trend n 3,158806765793794787790791790interval—<0.480.48–0.750.76–1.11≥1.12<9.109.10–12.1612.17–15.97≥12.98median—0.300.610.931.43<0.0017.1610.6513.8119.60<0.001maternal age (years)32.732.632.732.633.00.1032.432.932.932.70.11prepregnancy bmi (kg/m2)23.522.623.223.524.6<0.00123.623.623.423.20.04non-hispanic white (%)87.787.689.588.884.80.0880.987.689.992.2<0.001<12 years of education (%)3.13.72.23.43.00.723.63.03.22.70.35not married (%)10.011.08.19.311.50.6211.49.98.410.30.30nullipara (%)62.267.063.562.256.1<0.00160.261.863.663.20.17smoked during Pregnancy (%)5.45.14.45.46.70.117.14.74.85.10.10prenatal Vitamin use (%)97.697.897.398.197.40.8797.598.497.197.60.72iron deficiency anemia (%)2.33.12.41.81.80.0512.32.01.63.00.43physically inactive in Pregnancy (%)12.111.811.113.112.50.4411.913.911.511.10.35history of hypertension (%)4.23.53.73.56.20.024.35.14.33.20.19family history of hypertension (%)49.245.949.248.952.80.0152.548.248.347.70.08family history of diabetes (%)13.512.313.713.614.40.2614.613.812.812.80.23total energy intake (kcal)1,7171,4201,5631,7862,096<0.0011,1851,6061,8572,216<0.001calories from Carbohydrate (%)53.057.154.452.048.4<0.00151.352.253.555.0<0.001calories from protein (%)17.415.917.117.818.8<0.00117.517.317.517.20.28calories from total fat (%)31.529.330.532.034.1<0.00132.732.331.029.9<0.001calories from Saturated fat (%)11.210.610.911.412.0<0.00111.711.511.110.6<0.001calories from trans fat (%)1.110.971.051.151.25<0.0011.161.141.081.05<0.001calories from polyunsaturated fat (%)6.56.26.36.56.9<0.0016.76.66.46.3<0.001calories from N-3 Fatty Acids (%)0.760.710.750.770.82<0.0010.820.780.730.71<0.001dietary Cholesterol (mg)*271222247269315<0.001298287274249<0.001dietary Vitamin C (mg)*136148142138123<0.001118129129151<0.001dietary Vitamin E (mg)*15.716.416.215.615.00.0019.311.413.722.2<0.001total dietary fiber (g)*20.922.721.820.919.2<0.00116.719.220.923.4<0.001dietary calcium (g)*1.411.541.491.421.27<0.0011.321.321.381.51<0.001dietary total iron (mg)*16.216.716.616.116.00.0029.312.415.222.0<0.001fruits and vegetables (servings per day)4.44.14.24.64.9<0.0013.24.34.75.5<0.001whole grains (servings per day)0.630.580.590.670.68<0.0010.400.530.710.88<0.001red and processed meats (servings per day)0.660.190.470.731.24<0.0010.500.650.720.76<0.001poultry meats (servings per day)0.230.090.190.260.37<0.0010.180.220.240.27<0.001fish meats (servings per day)0.200.110.180.220.28<0.0010.150.180.200.25<0.001\ndata are means or percentages.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 44)]	2	[('CHEBI_27300', 'vitamin D', 108, 'vitamin C'), ('CHEBI_30413', 'heme', 215, 'heme'), ('CHEBI_30413', 'heme', 309, 'heme'), ('GO_0007565', 'female pregnancy', 1020, 'pregnancy'), ('CHEBI_33229', 'vitamin (role)', 1077, 'vitamin'), ('GO_0007565', 'female pregnancy', 1221, 'pregnancy'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 1589, 'carbohydrate'), ('CHEBI_51247', 'texas red', 1813, 'saturated'), ('CHEBI_30256', 'thiocarbonyl group', 2043, 'n-3'), ('CHEBI_35366', 'fatty acid', 2047, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 2118, 'cholesterol'), ('CHEBI_27300', 'vitamin D', 2182, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 2244, 'vitamin E')]	0	['expected, higher nonheme iron intake higher intake fruits, vegetables, fiber, .\n\ncaption (table-wrap): table 1\n\nparticipants’ characteristics quartiles dietary heme nonheme iron intake, seattle tacoma, wa, omega studycharacteristicdietary heme iron (mg day)dietary nonheme iron (mg day)cohortquintile 1quintile 2quintile 3quintile 4 p trendquintile 1quintile 2quintile 3quintile 4 p n 3,158806765793794787790791790interval—<0.480.48–0.750.76–1.11≥1.12<9.109.10–12.1612.17–15.97≥12.98median—0.300.610.931.43<0.0017.1610.6513.8119.60<0.001maternal age (years)32.732.632.732.633.00.1032.432.932.932.70.11prepregnancy bmi (kg/m2)23.522.623.223.524.6<0.00123.623.623.423.20.04non-hispanic white (%)87.787.689.588.884.80.0880.987.689.992.2<0.001<12 (%)3.13.72.23.43.00.723.63.03.22.70.35not married (%)10.011.08.19.311.50.6211.49.98.410.30.30nullipara (%)62.267.063.562.256.1<0.00160.261.863.663.20.17smoked  (%)5.45.14.45.46.70.117.14.74.85.10.10prenatal vitamin (%)97.697.897.398.197.40.8797.598.497.197.60.72iron anemia (%)2.33.12.41.81.80.0512.32.01.63.00.43physically inactive  (%)12.111.811.113.112.50.4411.913.911.511.10.35history hypertension (%)4.23.53.73.56.20.024.35.14.33.20.19family hypertension (%)49.245.949.248.952.80.0152.548.248.347.70.08family diabetes (%)13.512.313.713.614.40.2614.613.812.812.80.23total energy intake (kcal)1,7171,4201,5631,7862,096<0.0011,1851,6061,8572,216<0.001calories carbohydrate (%)53.057.154.452.048.4<0.00151.352.253.555.0<0.001calories protein (%)17.415.917.117.818.8<0.00117.517.317.517.20.28calories fat (%)31.529.330.532.034.1<0.00132.732.331.029.9<0.001calories saturated fat (%)11.210.610.911.412.0<0.00111.711.511.110.6<0.001calories trans fat (%)1.110.971.051.151.25<0.0011.161.141.081.05<0.001calories polyunsaturated fat (%)6.56.26.36.56.9<0.0016.76.66.46.3<0.001calories n-3 fatty acids (%)0.760.710.750.770.82<0.0010.820.780.730.71<0.001dietary cholesterol (mg)*271222247269315<0.001298287274249<0.001dietary  (mg)*136148142138123<0.001118129129151<0.001dietary  (mg)*15.716.416.215.615.00.0019.311.413.722.2<0.001total dietary fiber (g)*20.922.721.820.919.2<0.00116.719.220.923.4<0.001dietary calcium (g)*1.411.541.491.421.27<0.0011.321.321.381.51<0.001dietary iron (mg)*16.216.716.616.116.00.0029.312.415.222.0<0.001fruits vegetables (servings day)4.44.14.24.64.9<0.0013.24.34.75.5<0.001whole grains (servings day)0.630.580.590.670.68<0.0010.400.530.710.88<0.001red processed meats (servings day)0.660.190.470.731.24<0.0010.500.650.720.76<0.001poultry meats (servings day)0.230.090.190.260.37<0.0010.180.220.240.27<0.001fish meats (servings day)0.200.110.180.220.28<0.0010.150.180.200.25<0.001\ndata percentages.']
S3-PMC3171895	PMC3171895	9/2011	S3-PMC3171895	['the PRESENT PAPER summarises the CURRENT understanding of selected Micronutrient antioxidants Selenium, copper, zinc, manganese, and Vitamins C and e in Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('INCOMPLETE_EVIDENCE', 33)]	2	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 67, 'micronutrient'), ('CHEBI_27568', 'selenium atom', 94, 'selenium'), ('CHEBI_27300', 'vitamin D', 133, 'vitamins C'), ('PR_000004900', 'complement C3', 142, 'C'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy')]	0	['summarises selected micronutrient antioxidants selenium, copper, zinc, manganese,  e .']
S36-PMC3171895	PMC3171895	9/2011	S36-PMC3171895	['methods\na number of Micronutrients and Vitamins are KNOWN to serve as antioxidants or be essential Cofactors for antioxidant enzymes; these include Selenium, copper, zinc, manganese, and Vitamins C and e. THE PRESENT PAPER summarises CURRENT UNDERSTANDING of the IMPORTANCE of these Micronutrient antioxidants in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 52), ('QUESTION_ANSWERED_BY_THIS_WORK', 205), ('QUESTION_ANSWERED_BY_THIS_WORK', 209), ('INCOMPLETE_EVIDENCE', 234), ('IMPORTANT_CONSIDERATION', 263)]	5	[('CHEBI_33839', 'macromolecule', 20, 'micronutrients'), ('CHEBI_33277', 'gamma-tocotrienol', 39, 'vitamins'), ('CHEBI_23357', 'cofactor', 99, 'cofactors'), ('CHEBI_27568', 'selenium atom', 148, 'selenium'), ('CHEBI_27300', 'vitamin D', 187, 'vitamins C'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 283, 'micronutrient'), ('GO_0007565', 'female pregnancy', 313, 'pregnancy')]	0	['methods\na micronutrients vitamins antioxidants antioxidant enzymes; selenium, copper, zinc, manganese,  e. summarises micronutrient antioxidants .']
S141-PMC3171895	PMC3171895	9/2011	S141-PMC3171895	['vitamin c is commonly included in low doses (<200\u2009mg/day) within multivitamin preparations for Pregnancy but HAS also BEEN given in higher doses (up to 1000\u2009mg/day) as a supplement, alone or in combination with Vitamin E [127].']	[('INCOMPLETE_EVIDENCE', 109)]	1	[('GO_0007565', 'female pregnancy', 95, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin E')]	0	['vitamin c doses (<200\u2009mg/day) multivitamin preparations  higher doses (up 1000\u2009mg/day) supplement, combination  [127].']
S145-PMC3171895	PMC3171895	9/2011	S145-PMC3171895	['a CONSIDERABLE INTEREST exists regarding PREVENTION of Maternal and Perinatal Morbidity with Vitamins C and E. HOWEVER, the most RECENT meta-analysis of ten trials (6533 women) published in 2008 of antioxidant supplementation (including Vitamin C and e but also OTHER supplements such as Lycopene) SHOWED no difference in the relative risk (rr) of Preeclampsia (rr 0.73, 95% ci 0.51 to 1.06), Preterm Birth (before 37 weeks) (rr 1.10, 95% ci 0.99 to 1.22), sga infants (rr 0.83, 95% ci 0.62 to 1.11), or any baby death (rr 1.12, 95% ci 0.81 to 1.53) [7].']	[('ANOMALY_CURIOUS_FINDING', 2), ('ANOMALY_CURIOUS_FINDING', 15), ('IMPORTANT_CONSIDERATION', 15), ('SUPERFICIAL_RELATIONSHIP', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 111), ('INCOMPLETE_EVIDENCE', 129), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 262), ('INCOMPLETE_EVIDENCE', 298)]	8	[('GO_0007618', 'mating', 55, 'maternal ...'), ('GO_0019230', 'proprioception', 68, 'perinatal morbidity'), ('UBERON_0012101', 'perinatal stage', 68, 'perinatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamins C'), ('PR_000004900', 'complement C3', 102, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 108, 'E'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin C'), ('CHEBI_15948', 'lycopene', 288, 'lycopene'), ('GO_0007128', 'meiotic prophase I', 348, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 393, 'preterm'), ('GO_0007567', 'parturition', 401, 'birth')]	0	['regarding maternal perinatal morbidity  e. however, meta-analysis ten (6533 women) 2008 antioxidant supplementation (including  e supplements lycopene) relative (rr) preeclampsia (rr 0.73, 95% ci 0.51 1.06),  birth (before 37 weeks) (rr 1.10, 95% ci 0.99 1.22), sga infants (rr 0.83, 95% ci 0.62 1.11), baby death (rr 1.12, 95% ci 0.81 1.53) [7].']
S147-PMC3171895	PMC3171895	9/2011	S147-PMC3171895	['a couple of subsequent RECENT multicentre double-blinded randomised trials of a combination of Vitamin C and E [130,131] also FOUND that supplementation did not reduce the rate of Preeclampsia or Gestational hypertension and, like the Vitamins in Preeclampsia trial in 2006 [132], increased the risk of fetal loss or Perinatal death and preterm prelabour rupture of Membranes.']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 126)]	2	[('CHEBI_27300', 'vitamin D', 95, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 109, 'E'), ('GO_0007128', 'meiotic prophase I', 180, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 196, 'gestational'), ('CHEBI_28371', 'vitamin K epoxide', 235, 'Vitamins'), ('GO_0007128', 'meiotic prophase I', 247, 'Preeclampsia'), ('GO_0036268', 'swimming', 317, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 317, 'perinatal'), ('UBERON_0000922', 'embryo', 366, 'membranes')]	0	['couple multicentre double-blinded randomised combination  e [130,131] supplementation rate preeclampsia  hypertension and, vitamins preeclampsia 2006 [132], fetal loss perinatal death preterm prelabour rupture membranes.']
S148-PMC3171895	PMC3171895	9/2011	S148-PMC3171895	['ANOTHER RECENT multicentre placebo-controlled TRIAL of Vitamin C and E in women with type-1 diabetes in Pregnancy (Dapit) also REPORTED no differences in the rates of Preeclampsia between supplemented or placebo groups [133].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 127)]	4	[('CHEBI_27300', 'vitamin D', 55, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 69, 'E'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy'), ('CHEBI_73285', '3-iodo-4-aminobenzyl-5*-N-methylcarboxamidoadenosine', 115, 'DAPIT'), ('GO_0007128', 'meiotic prophase I', 167, 'preeclampsia')]	0	['another multicentre placebo-controlled  e women type-1 diabetes  (dapit) rates preeclampsia supplemented placebo [133].']
S21-PMC3231892	PMC3231892	4/2011	S21-PMC3231892	['women of Reproductive age, ESPECIALLY Pregnant women, in developing countries are recognized to be AT RISK of multiple Micronutrient deficiencies, such as Iron, Folic Acid, Iodine, zinc, Vitamins A and d, riboflavin, b6 and b12, with the LIKELIHOOD of adverse EFFECTS on the mother and Pregnancy outcomes [1,6].']	[('IMPORTANT_CONSIDERATION', 27), ('IMPORTANT_CONSIDERATION', 99), ('PROBABLE_UNDERSTANDING', 238), ('SUPERFICIAL_RELATIONSHIP', 260)]	4	[('GO_0000003', 'reproduction', 9, 'reproductive'), ('GO_0007565', 'female pregnancy', 38, 'pregnant'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 119, 'micronutrient'), ('CHEBI_24870', 'ion', 155, 'iron'), ('CHEBI_30751', 'formic acid', 161, 'folic acid'), ('CHEBI_24859', 'iodine atom', 173, 'iodine'), ('CHEBI_27300', 'vitamin D', 187, 'vitamins A'), ('GO_0007565', 'female pregnancy', 286, 'pregnancy')]	0	['women reproductive age,  women, countries micronutrient deficiencies, iron, folic acid, iodine, zinc,  d, riboflavin, b6 b12, mother  outcomes [1,6].']
S1-PMC3235789	PMC3235789	12/2011	S1-PMC3235789	['TO INVESTIGATE ASSOCIATIONS among Serum 25-Hydroxy-Vitamin D (25-Oh-D), Folate, Omega-6/Omega-3 Fatty Acid ratio and bacterial vaginosis (bv) during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 15)]	2	[('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_70487', '(-)-sanguinolignan C', 40, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 62, '25-OH-D'), ('CHEBI_30863', '5-azaorotic acid', 72, 'folate'), ('CHEBI_79370', 'ibho#10', 80, 'omega-6'), ('CHEBI_79370', 'ibho#10', 88, 'omega-3'), ('CHEBI_35366', 'fatty acid', 96, 'fatty acid'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy')]	0	['among serum 25-hydroxy- (25-oh-d), folate, omega-6/omega-3 fatty acid ratio bacterial vaginosis (bv) .']
S22-PMC3235789	PMC3235789	12/2011	S22-PMC3235789	['ONE us cohort STUDY has EXAMINED the ASSOCIATION between maternal Vitamin D status and bv in Pregnancy, FINDING a dose-response RELATIONSHIP between the mean unadjusted Serum 25-Oh-D concentration and the prevalence of Bv per gram stain of Vaginal smears obtained in early Pregnancy [29].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 104), ('SUPERFICIAL_RELATIONSHIP', 128)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('UBERON_0001977', 'blood serum', 169, 'serum'), ('CHEBI_65350', 'lorcaserin hydrochloride', 177, '-OH-D'), ('PR_000004696', 'apoptosis facilitator Bcl-2-like protein 14', 219, 'BV'), ('UBERON_0001987', 'placenta', 240, 'vaginal'), ('GO_0007565', 'female pregnancy', 273, 'pregnancy')]	0	['one us maternal  status bv dose-response unadjusted serum 25-oh-d concentration bv gram stain vaginal smears  [29].']
S23-PMC3235789	PMC3235789	12/2011	S23-PMC3235789	['national health and nutrition examination survey (nhanes) data from 2001–2004 REVEAL that Vitamin D deficiency is ASSOCIATED with bv in Pregnant, but not nonpregnant, women (aor 2.87, 95% ci: 1.13–7.28) [30].']	[('INCOMPLETE_EVIDENCE', 78), ('SUPERFICIAL_RELATIONSHIP', 114)]	2	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 136, 'pregnant')]	0	['national survey (nhanes) 2001–2004  bv nonpregnant, women (aor 2.87, 95% ci: 1.13–7.28) [30].']
S25-PMC3235789	PMC3235789	12/2011	S25-PMC3235789	['a cohort study of low-income, Pregnant african-american women FOUND no association between bv and dietary Intake of protein and Vitamins A and C [32].']	[('INCOMPLETE_EVIDENCE', 62)]	1	[('GO_0007565', 'female pregnancy', 30, 'pregnant'), ('GO_0007631', 'feeding behavior', 106, 'intake'), ('CHEBI_27300', 'vitamin D', 128, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 137, 'A'), ('CHEBI_18245', 'carboxylato group', 143, 'C'), ('PR_000004900', 'complement C3', 143, 'C')]	0	['low-income,  african-american women bv dietary intake protein  c [32].']
S32-PMC3235789	PMC3235789	12/2011	S32-PMC3235789	['THIS STUDY involved the biochemical assessment of Vitamin D, Folate, and polyunsaturated Fatty Acid status from stored edta Plasma samples collected during the Delivery admission and comparison of Vitamin D, Folate, and polyunsaturated Fatty Acid nutriture for women with and without a diagnosis of bv during the Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0)]	1	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 61, 'folate'), ('CHEBI_35366', 'fatty acid', 89, 'fatty acid'), ('UBERON_0001969', 'blood plasma', 124, 'plasma'), ('GO_0007567', 'parturition', 160, 'delivery'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 208, 'folate'), ('CHEBI_35366', 'fatty acid', 236, 'fatty acid'), ('GO_0007565', 'female pregnancy', 313, 'pregnancy')]	0	['biochemical folate, polyunsaturated fatty acid status stored edta plasma samples delivery admission folate, polyunsaturated fatty acid nutriture women diagnosis bv .']
S99-PMC3235789	PMC3235789	12/2011	S99-PMC3235789	['in the case of Vitamin D deficiency, OUR FINDINGS are CONSISTENT with a RECENT cohort of Pregnant women, which FOUND a dose-response RELATIONSHIP between 25-Oh-D and the PREVALENCE of Bv during Pregnancy [29], and a nationally representative cross-sectional study of women in the united states, which found that 25-Oh-D <30\u2009ng/ml significantly increased the odds of bv during Pregnancy (aor 2.87, 95% ci: 1.13–7.28) [30].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 37), ('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 72), ('INCOMPLETE_EVIDENCE', 111), ('SUPERFICIAL_RELATIONSHIP', 133), ('IMPORTANT_CONSIDERATION', 170)]	6	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnant'), ('CHEBI_17808', 'IDP', 157, 'OH-D'), ('PR_000004696', 'apoptosis facilitator Bcl-2-like protein 14', 184, 'BV'), ('GO_0007565', 'female pregnancy', 194, 'pregnancy'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 312, '25-OH-D'), ('GO_0007565', 'female pregnancy', 376, 'pregnancy')]	0	[' deficiency,  women, dose-response 25-oh-d bv  [29], nationally representative cross-sectional women united states, 25-oh-d <30\u2009ng/ml bv  (aor 2.87, 95% ci: 1.13–7.28) [30].']
S129-PMC3235789	PMC3235789	12/2011	S129-PMC3235789	['conclusions\nthis case-control study FOUND a significant ASSOCIATION between maternal Plasma 25-Hydroxy-Vitamin D <12\u2009ng/ml and Folate <5\u2009ug/ml and bv during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 56)]	2	[('UBERON_0001969', 'blood plasma', 85, 'plasma'), ('CHEBI_70487', '(-)-sanguinolignan C', 92, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 127, 'folate'), ('GO_0007565', 'female pregnancy', 157, 'pregnancy')]	0	['conclusions\nthis case-control maternal plasma 25-hydroxy- <12\u2009ng/ml folate <5\u2009ug/ml bv .']
S0-PMC3257641	PMC3257641	3/2010	S0-PMC3257641	['Vitamin D status during Pregnancy and aspects of offspring health\n\nabstract\nlow maternal Vitamin D levels during Pregnancy HAVE BEEN LINKED to various health outcomes in the offspring, ranging from periconceptional EFFECTS to diseases of Adult onset.']	[('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 133), ('SUPERFICIAL_RELATIONSHIP', 215)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 24, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('UBERON_0007023', 'adult organism', 238, 'adult')]	0	['vitamin status  aspects offspring health\n\nabstract\nlow maternal  levels  outcomes offspring, periconceptional diseases adult onset.']
S4-PMC3257641	PMC3257641	3/2010	S4-PMC3257641	['the EVIDENCE to date SUPPORTS that women SHOULD BE monitored and treated for Vitamin D deficiency during Pregnancy BUT OPTIMAL and upper limit Serum 25(Oh)D levels during Pregnancy are NOT KNOWN.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 21), ('FUTURE_WORK', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 115), ('IMPORTANT_CONSIDERATION', 119), ('FULL_UNKNOWN', 185)]	6	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'pregnancy'), ('UBERON_0001977', 'blood serum', 143, 'serum'), ('CHEBI_71657', 'versiconol acetate', 149, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 149, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy')]	0	['women monitored treated   upper serum 25(oh)d levels  known.']
S5-PMC3257641	PMC3257641	3/2010	S5-PMC3257641	['1. review\nthe high PREVALENCE of Vitamin D insufficiency during Pregnancy is increasingly RECOGNIZED, amid GROWING EVIDENCE that the Intrauterine environment CAN have both immediate and long-lasting EFFECTS on health of the offspring.']	[('IMPORTANT_CONSIDERATION', 19), ('PROBABLE_UNDERSTANDING', 90), ('INCOMPLETE_EVIDENCE', 107), ('INCOMPLETE_EVIDENCE', 158), ('SUPERFICIAL_RELATIONSHIP', 199)]	5	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('UBERON_0022293', 'reproductive gland secretion', 133, 'intrauterine')]	0	['1. review\nthe   recognized, amid intrauterine environment long-lasting offspring.']
S6-PMC3257641	PMC3257641	3/2010	S6-PMC3257641	['in THIS REVIEW, we OUTLINE the RESEARCH EVIDENCE TO DATE RELATING to Vitamin D status and Pregnancy, including a range of POSSIBLE health outcomes from pre-Conception to later Life (figure 1).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 40), ('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 57), ('INCOMPLETE_EVIDENCE', 122)]	7	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('GO_0007620', 'copulation', 156, 'conception'), ('UBERON_0000104', 'life cycle', 176, 'life')]	0	['review,  status outcomes pre-conception life (figure 1).']
S39-PMC3257641	PMC3257641	3/2010	S39-PMC3257641	['the prevalence of low Vitamin D status during Pregnancy\nas noted above, Vitamin D adequacy DEPENDS on both endogenous, uv-induced synthesis, and exogenous sources, i.e., diet and Supplements.']	[('SUPERFICIAL_RELATIONSHIP', 91)]	1	[('CHEBI_28384', 'vitamin K', 22, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 179, 'supplements')]	0	['vitamin status \nas above,  endogenous, uv-induced synthesis, exogenous sources, i.e., diet supplements.']
S42-PMC3257641	PMC3257641	3/2010	S42-PMC3257641	['as for OTHER population groups, Pregnant women living at high latitude and low altitude, with dark skin pigmentation or skin USUALLY covered by clothing will be at increased risk of Vitamin D deficiency [31,32], UNLESS dietary intake is high (table 1).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 7), ('INCOMPLETE_EVIDENCE', 125), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 212)]	3	[('GO_0007565', 'female pregnancy', 32, 'pregnant'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D')]	0	['population groups,  women living latitude altitude, dark skin pigmentation skin covered clothing  [31,32], dietary intake (table 1).']
S43-PMC3257641	PMC3257641	3/2010	S43-PMC3257641	['furthermore, SINCE 25(Oh)D is stored in Adipose Tissue, there is SOME EVIDENCE that obesity is a FURTHER RISK FACTOR for Vitamin D insufficiency.nutrients-02-00389-t001_table 1\n\ncaption (table-wrap): table 1\n\nrisk factors for Vitamin D deficiency.low ambient uvr level high latitude locationwinter season inadequate sun exposure built or indoor environmentextensive clothing cover (e.g., veiled)excess sun avoidance – (shade, sunscreen) host factors dark skin pigmentationold ageobesitymalabsorptive syndromes (e.g., inflammatory Bowel disease)\nMANY STUDIES HAVE REPORTED on the Vitamin D status of Pregnant women, in a range of environments (summarized intable 2, including studies from 1997–2006).']	[('PROBLEM_COMPLICATION', 13), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 97), ('SUPERFICIAL_RELATIONSHIP', 105), ('INCOMPLETE_EVIDENCE', 545), ('INCOMPLETE_EVIDENCE', 558)]	6	[('CHEBI_71657', 'versiconol acetate', 19, '25(OH)D'), ('UBERON_0001013', 'adipose tissue', 40, 'adipose tissue'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('UBERON_0000160', 'intestine', 530, 'bowel'), ('CHEBI_27300', 'vitamin D', 579, 'vitamin D'), ('GO_0007565', 'female pregnancy', 599, 'pregnant')]	0	['furthermore, 25(oh)d stored adipose tissue, obesity  insufficiency.nutrients-02-00389-t001_table 1\n\ncaption (table-wrap): table 1\n\nrisk  deficiency.low ambient uvr latitude locationwinter season sun exposure built indoor environmentextensive clothing cover (e.g., veiled)excess sun avoidance (shade, sunscreen) host dark skin pigmentationold ageobesitymalabsorptive syndromes (e.g., inflammatory bowel disease)\nmany  status  women, environments (summarized intable 2, 1997–2006).']
S45-PMC3257641	PMC3257641	3/2010	S45-PMC3257641	['NEVERTHELESS, low Vitamin D status is also PREVALENT in Pregnant caucasian populations, PARTICULARLY those not receiving supplementation (table 2).nutrients-02-00389-t002_table 2\n\ncaption (table-wrap): table 2\n\nthe prevalence of a low Vitamin D status in Pregnancy.referenceyearcountrypopulationstage Of Pregnancydefinition% n/n[127]1997iraniran women attending largest tehran hospitaldelivery<25 nmol/l80% (40/50)[128]1997-2001usaafrican american–90% receiving Prenatal Vitamins4-21 week Gestation<37.5 nmol/l44.9% (89/194)[128]1997-2001usawhite–90% receiving Prenatal Vitamins4-21 week Gestation<37.5 nmol/l2% (4/199)[128]1997-2001usaafrican–american37-42 weeks<37.5 nmol/l29.2% (54/185)[128]1997-2001usawhite37-42 weeks<37.5 nmol/l5% (10/199)[128]1997-2001usaturkish12 week Gestation<25 nmol/l83.5% (66/79)[128]1997-2001usamoroccan12 week Gestation<25 nmol/l81.2% (56/69)[128]1997-2001usaother non-western12 week Gestation<25 nmol/l59% (62/105)[129]1999irelandcaucasians in ulster–on supplements (54–55on)12 weeks<25 nmol/l4.5% (1/22)[129]1999irelandno supplements12 weeks<25 nmol/l44.2% (34/77)[129]1999irelandsupplements20 weeks<25 nmol/l22.7% (5/22)[129]1999irelandno supplements20 weeks<25 nmol/l50.6% (39/77)[129]1999irelandsupplements35 weeks<25 nmol/l0% (0/22)[129]1999irelandno supplements35 weeks<25 nmol/l20.8% (16/77)[32]1999-2000australiaveiled &/or dark skinned women attending Antenatal clinicduring Antenatal care, when a routine Blood test was ordered<22.5 nmol/l80.5% (66/82)[130]1999-2000united arab emirateskuwaitdelivery<25 nmol/l40% (86/214)[131]2002indiaattendees of queen mary’s hosptal, lucknow (26.8on) northern india – urbandelivery–full term, live<22.5 nmol/l84.3% (118/140)[131]2002indiaattendees of queen mary’s hosptal, lucknow (26.8on) northern india–urbanrural<56.3 nmol/l84%(56/67)[132]2005-2006indiaresidents of barabanki district, 26.8onsecond trimester<50 nmol/l74.1% (103/139)\n\n4.1.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 43), ('ANOMALY_CURIOUS_FINDING', 88), ('IMPORTANT_CONSIDERATION', 88)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnant'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy'), ('GO_0007308', 'oocyte construction', 301, 'of PregnancyDefinition'), ('GO_0007565', 'female pregnancy', 462, 'prenatal'), ('CHEBI_38749', 'dihydroxyflavanone', 471, 'vitamins4'), ('GO_0007565', 'female pregnancy', 489, 'gestation'), ('GO_0007565', 'female pregnancy', 561, 'prenatal'), ('CHEBI_38749', 'dihydroxyflavanone', 570, 'vitamins4'), ('GO_0007565', 'female pregnancy', 588, 'gestation'), ('GO_0007565', 'female pregnancy', 777, 'gestation'), ('GO_0007565', 'female pregnancy', 842, 'gestation'), ('GO_0007565', 'female pregnancy', 916, 'gestation'), ('GO_0007567', 'parturition', 1394, 'antenatal'), ('GO_0007567', 'parturition', 1417, 'antenatal'), ('UBERON_0000178', 'blood', 1448, 'blood')]	0	['nevertheless,  status  caucasian populations, receiving supplementation (table 2).nutrients-02-00389-t002_table 2\n\ncaption (table-wrap): table 2\n\nthe  status .referenceyearcountrypopulationstage pregnancydefinition% n/n[127]1997iraniran women attending largest tehran hospitaldelivery<25 nmol/l80% (40/50)[128]1997-2001usaafrican american–90% receiving  vitamins4-21 week <37.5 nmol/l44.9% (89/194)[128]1997-2001usawhite–90% receiving  vitamins4-21 week <37.5 nmol/l2% (4/199)[128]1997-2001usaafrican–american37-42 weeks<37.5 nmol/l29.2% (54/185)[128]1997-2001usawhite37-42 weeks<37.5 nmol/l5% (10/199)[128]1997-2001usaturkish12 week <25 nmol/l83.5% (66/79)[128]1997-2001usamoroccan12 week <25 nmol/l81.2% (56/69)[128]1997-2001usaother non-western12 week <25 nmol/l59% (62/105)[129]1999irelandcaucasians ulster–on supplements (54–55on)12 weeks<25 nmol/l4.5% (1/22)[129]1999irelandno supplements12 weeks<25 nmol/l44.2% (34/77)[129]1999irelandsupplements20 weeks<25 nmol/l22.7% (5/22)[129]1999irelandno supplements20 weeks<25 nmol/l50.6% (39/77)[129]1999irelandsupplements35 weeks<25 nmol/l0% (0/22)[129]1999irelandno supplements35 weeks<25 nmol/l20.8% (16/77)[32]1999-2000australiaveiled &/or dark skinned women attending antenatal clinicduring antenatal care, routine blood ordered<22.5 nmol/l80.5% (66/82)[130]1999-2000united arab emirateskuwaitdelivery<25 nmol/l40% (86/214)[131]2002indiaattendees queen mary’s hosptal, lucknow (26.8on) northern india urbandelivery–full term, live<22.5 nmol/l84.3% (118/140)[131]2002indiaattendees queen mary’s hosptal, lucknow (26.8on) northern india–urbanrural<56.3 nmol/l84%(56/67)[132]2005-2006indiaresidents barabanki district, 26.8onsecond trimester<50 nmol/l74.1% (103/139)\n\n4.1.']
S48-PMC3257641	PMC3257641	3/2010	S48-PMC3257641	['a NUMBER OF STUDIES within non-Pregnant Adult populations have examined 25(Oh)D levels in RELATION to DIFFERENT dosages, preparations or dosing intervals of oral Vitamin D (reviewed in[33]).']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 90), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 102)]	3	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('UBERON_0007023', 'adult organism', 40, 'adult'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 72, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]	0	['non- adult populations 25(oh)d levels dosages, preparations dosing intervals oral  (reviewed in[33]).']
S51-PMC3257641	PMC3257641	3/2010	S51-PMC3257641	['FEW STUDIES to date have examined Vitamin D supplementation during Pregnancy, and optimal 25(Oh)D levels have not yet been defined [35,36].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D')]	0	[' supplementation 25(oh)d levels [35,36].']
S52-PMC3257641	PMC3257641	3/2010	S52-PMC3257641	['a daily dose of 1000 iu/day DOES NOT APPEAR TO BE sufficient to achieve and maintain Vitamin D adequacy in women who are Vitamin D deficient at the start of Pregnancy [37,38].']	[('ANOMALY_CURIOUS_FINDING', 28), ('ANOMALY_CURIOUS_FINDING', 37)]	2	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'pregnancy')]	0	['daily dose 1000 iu/day achieve maintain  women   [37,38].']
S75-PMC3257641	PMC3257641	3/2010	S75-PMC3257641	['ONGOING RESEARCH is examining the ROLE of 1,25(Oh)2D in decreasing the risk of infections during Pregnancy and WHETHER Vitamin D status alters the risk of developing adverse outcomes following such infections.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 111)]	3	[('CHEBI_82784', 'PVP38-Ag NP', 42, '1,25(OH)2D'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]	0	['ongoing 1,25(oh)2d decreasing infections   status alters outcomes following infections.']
S80-PMC3257641	PMC3257641	3/2010	S80-PMC3257641	['among Vitamin D deficient Pregnant women, fetal ultrasound revealed splaying of the Distal Metaphysis Of the fetal Femur as early as 19 weeks, with the APPEARANCE being very SIMILAR TO that SEEN in childhood (Vitamin D-deficient) rickets [56].']	[('ANOMALY_CURIOUS_FINDING', 152), ('INCOMPLETE_EVIDENCE', 174), ('INCOMPLETE_EVIDENCE', 190)]	3	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('UBERON_0001389', 'soleus muscle', 84, 'distal'), ('UBERON_0006865', 'metaphysis of femur', 91, 'metaphysis of ... femur'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]	0	['among   women, fetal ultrasound splaying distal metaphysis fetal femur 19 weeks, childhood (-deficient) rickets [56].']
S92-PMC3257641	PMC3257641	3/2010	S92-PMC3257641	['Birth weight\nOBSERVATIONAL STUDIES of Vitamin D status during Pregnancy and physical characteristics of the offspring are FEW and provide CONFLICTING results.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 138)]	3	[('GO_0007567', 'parturition', 0, 'Birth'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy')]	0	['birth weight\nobservational  status  physical characteristics offspring results.']
S93-PMC3257641	PMC3257641	3/2010	S93-PMC3257641	['ONE STUDY FOUND Pregnancies of mothers with low Vitamin D status were shorter (by 0.7 week; 95% ci −1.3, −0.1) [60], and the babies had poorer Intrauterine long bone growth [60], WHILE in OTHER studies, offspring had lower Birth weight [61,62,63].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 188)]	4	[('GO_0007565', 'female pregnancy', 16, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0022293', 'reproductive gland secretion', 143, 'intrauterine'), ('GO_0007567', 'parturition', 223, 'birth')]	0	['one  mothers  status shorter (by 0.7 week; 95% ci −1.3, −0.1) [60], babies intrauterine bone [60], studies, offspring birth [61,62,63].']
S98-PMC3257641	PMC3257641	3/2010	S98-PMC3257641	['the media REPORTED on a reduction in both Preterm Birth and small-for-dates babies, with Vitamin D supplementation [41], BUT formal publication of the FINDINGS had not occurred at the time of writing this review, THUS these reports cannot BE formally evaluated.']	[('INCOMPLETE_EVIDENCE', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121), ('INCOMPLETE_EVIDENCE', 151), ('PROBABLE_UNDERSTANDING', 213), ('ANOMALY_CURIOUS_FINDING', 239)]	5	[('GO_0007565', 'female pregnancy', 42, 'preterm'), ('GO_0007567', 'parturition', 50, 'birth'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]	0	['media reduction  birth small-for-dates babies,  supplementation [41], writing review, formally evaluated.']
S104-PMC3257641	PMC3257641	3/2010	S104-PMC3257641	['excess Vitamin D administration during Pregnancy COULD also POTENTIALLY be of CONCERN.']	[('INCOMPLETE_EVIDENCE', 49), ('INCOMPLETE_EVIDENCE', 60), ('PROBLEM_COMPLICATION', 78)]	3	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('GO_0007565', 'female pregnancy', 39, 'pregnancy')]	0	['excess  administration  concern.']
S105-PMC3257641	PMC3257641	3/2010	S105-PMC3257641	['Rats receiving very high-dose Vitamin D during Gestation and early development (CONSIDERABLY higher than would be administered to Humans) had adverse changes in elastin content and organization in the Aorta CONSISTENT with increased later risk of hypertension or aneurysm [73].']	[('ANOMALY_CURIOUS_FINDING', 80), ('INCOMPLETE_EVIDENCE', 207)]	2	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Rats'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'gestation'), ('NCBITaxon_9606', 'Homo sapiens', 130, 'humans'), ('UBERON_0000947', 'aorta', 201, 'aorta')]	0	['rats receiving high-dose   (considerably higher administered humans) changes elastin content organization aorta hypertension aneurysm [73].']
S119-PMC3257641	PMC3257641	3/2010	S119-PMC3257641	['a norwegian case control study FOUND cod Liver oil use during Pregnancy was ASSOCIATED with lower risk of type 1 diabetes in the offspring, INDICATING Vitamin D or the N-3 Fatty Acids Eicosapentaenoic Acid and Docosahexaenoic Acid in the cod Liver oil, or both, MAY have a PROTECTIVE EFFECT against type i diabetes [89].']	[('INCOMPLETE_EVIDENCE', 31), ('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 140), ('INCOMPLETE_EVIDENCE', 262), ('SUPERFICIAL_RELATIONSHIP', 273), ('SUPERFICIAL_RELATIONSHIP', 284)]	6	[('UBERON_0002107', 'liver', 41, 'liver'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('CHEBI_35418', 'N-acetylneuraminate', 168, 'n-3 fatty acids'), ('CHEBI_36003', 'decenoic acid', 184, 'eicosapentaenoic acid'), ('CHEBI_36003', 'decenoic acid', 210, 'docosahexaenoic acid'), ('UBERON_0002107', 'liver', 242, 'liver')]	0	['norwegian cod liver oil  type diabetes offspring,  n-3 fatty acids eicosapentaenoic acid docosahexaenoic acid cod liver oil, both, type diabetes [89].']
S121-PMC3257641	PMC3257641	3/2010	S121-PMC3257641	['low Vitamin D intake during Pregnancy HAS BEEN ASSOCIATED with an increased risk of asthma, eczema or hay fever [92,93], WHILE winter Birth was ASSOCIATED with higher Ige levels and lower Il-10 than summer Birth [57].']	[('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 47), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121), ('ANOMALY_CURIOUS_FINDING', 121), ('SUPERFICIAL_RELATIONSHIP', 144)]	5	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 28, 'pregnancy'), ('GO_0007567', 'parturition', 134, 'birth'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 167, 'IgE'), ('PR_000001470', 'interleukin-28B', 188, 'IL-10'), ('GO_0007567', 'parturition', 206, 'birth')]	0	['low  intake  asthma, eczema hay fever [92,93], winter birth higher ige levels il-10 summer birth [57].']
S132-PMC3257641	PMC3257641	3/2010	S132-PMC3257641	['this is a DIFFICULT BUT IMPORTANT AREA to research [101,102,103,104], with Animal work indicting transient Prenatal Vitamin D deficiency is ASSOCIATED with subtle alterations in Learning and Memory functions in Adult Rats [105].']	[('DIFFICULT_TASK', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('IMPORTANT_CONSIDERATION', 24), ('FUTURE_WORK', 34), ('SUPERFICIAL_RELATIONSHIP', 140)]	5	[('NCBITaxon_33208', 'Metazoa', 75, 'animal'), ('GO_0007565', 'female pregnancy', 107, 'prenatal'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007612', 'learning', 178, 'learning'), ('GO_0007613', 'memory', 191, 'memory'), ('UBERON_0007023', 'adult organism', 211, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 217, 'rats')]	0	['[101,102,103,104], animal indicting transient   subtle alterations learning memory functions adult rats [105].']
S136-PMC3257641	PMC3257641	3/2010	S136-PMC3257641	['using Prenatal ambient uvr levels as an instrumental variable for Vitamin D levels in Pregnancy [113], an inverse ASSOCIATION between maternal ambient uvr exposure during the late first trimester and ms risk was OBSERVED [110].']	[('SUPERFICIAL_RELATIONSHIP', 114), ('INCOMPLETE_EVIDENCE', 212)]	2	[('GO_0007565', 'female pregnancy', 6, 'prenatal'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy')]	0	['using  ambient uvr levels  levels  [113], maternal ambient uvr exposure late trimester ms [110].']
S139-PMC3257641	PMC3257641	3/2010	S139-PMC3257641	['OTHER CANDIDATE diseases that REQUIRE FURTHER RESEARCH with regard to the POTENTIAL ROLE of Prenatal Vitamin D status.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6), ('FUTURE_WORK', 30), ('IMPORTANT_CONSIDERATION', 30), ('FUTURE_WORK', 38), ('INCOMPLETE_EVIDENCE', 74), ('SUPERFICIAL_RELATIONSHIP', 84)]	7	[('GO_0007565', 'female pregnancy', 92, 'prenatal'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]	0	['diseases regard   status.']
S147-PMC3257641	PMC3257641	3/2010	S147-PMC3257641	['overview\nIN SUMMARY, we have reviewed the EXISTING EVIDENCE for a range of POSSIBLE adverse offspring health outcomes resulting from low maternal Vitamin D status in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 42), ('INCOMPLETE_EVIDENCE', 75)]	3	[('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy')]	0	['overview\nin summary, offspring outcomes resulting maternal  status .']
S150-PMC3257641	PMC3257641	3/2010	S150-PMC3257641	['EVEN with these trials (mostly of high risk women, many years ago) being systematically reviewed, it APPEARS that there is NOT ENOUGH EVIDENCE to evaluate the EFFECTS of Vitamin D supplementation in Pregnancy [124].']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 101), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 159)]	4	[('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy')]	0	['even (mostly women, ago) systematically reviewed,  supplementation  [124].']
S153-PMC3257641	PMC3257641	3/2010	S153-PMC3257641	['HOWEVER, the MAJORITY of POTENTIAL adverse offspring health outcomes pertain to low Prenatal Vitamin D status and the EVOLVING EVIDENCE has provided greater IMPETUS for PUBLIC HEALTH EFFORTS to ensure mothers are not frankly Vitamin D deficient (<25 nmol/l) in Pregnancy, ALTHOUGH the value of treating relative Vitamin D insufficiency in Pregnancy is NOT clearly ESTABLISHED.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 13), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 118), ('IMPORTANT_CONSIDERATION', 157), ('IMPORTANT_CONSIDERATION', 169), ('FUTURE_WORK', 183), ('ANOMALY_CURIOUS_FINDING', 272), ('FULL_UNKNOWN', 352)]	9	[('GO_0007565', 'female pregnancy', 84, 'prenatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D'), ('GO_0007565', 'female pregnancy', 261, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 312, 'vitamin D'), ('GO_0007565', 'female pregnancy', 339, 'pregnancy')]	0	['however, offspring outcomes   status ensure mothers frankly  (<25 nmol/l) treating relative   established.']
S154-PMC3257641	PMC3257641	3/2010	S154-PMC3257641	['women AT RISK of Vitamin D deficiency SHOULD BE monitored and treated during Pregnancy for Vitamin D deficiency [22].']	[('IMPORTANT_CONSIDERATION', 6), ('FUTURE_WORK', 38)]	2	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]	0	['women  monitored treated   [22].']
S161-PMC3257641	PMC3257641	3/2010	S161-PMC3257641	['for these studies, observational studies will NEED to include seasonal variation in Vitamin D status, POTENTIALLY CONFOUNDING by other seasonal factors such as infection, and also deseasonalized interpersonal variation in Ingested Vitamin D or uvr-derived Vitamin D. with regard to these deaseasonalized MARKERS of Vitamin D status, it is highly LIKELY that Vitamin d status in Pregnancy will be CORRELATED with Ingested or uvr-derived Vitamin D exposure for mothers preceding Pregnancy and offspring after Pregnancy.']	[('FUTURE_WORK', 46), ('INCOMPLETE_EVIDENCE', 102), ('PROBLEM_COMPLICATION', 114), ('SUPERFICIAL_RELATIONSHIP', 304), ('PROBABLE_UNDERSTANDING', 346), ('SUPERFICIAL_RELATIONSHIP', 396)]	6	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007631', 'feeding behavior', 222, 'ingested'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 315, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 358, 'vitamin'), ('GO_0007565', 'female pregnancy', 378, 'pregnancy'), ('GO_0007631', 'feeding behavior', 412, 'ingested'), ('CHEBI_27300', 'vitamin D', 436, 'vitamin D'), ('GO_0007565', 'female pregnancy', 477, 'pregnancy'), ('GO_0007565', 'female pregnancy', 507, 'pregnancy')]	0	['studies, seasonal  status, seasonal infection, deseasonalized interpersonal ingested  uvr-derived . regard deaseasonalized  status, vitamin status  ingested uvr-derived  exposure mothers preceding  offspring .']
S162-PMC3257641	PMC3257641	3/2010	S162-PMC3257641	['in this situation, the timing of low Vitamin D’s EFFECT over the Life Course will HAVE TO BE carefully determined, using specific Life Course analytic techniques [125], TO ASSESS WHETHER any low Prenatal Vitamin D status is INDEPENDENTLY ASSOCIATED with health outcomes INDEPENDENTLY of the mother’s Vitamin D status before Pregnancy and the offspring’s Vitamin D status during Postnatal Life.']	[('SUPERFICIAL_RELATIONSHIP', 49), ('IMPORTANT_CONSIDERATION', 82), ('QUESTION_ANSWERED_BY_THIS_WORK', 169), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179), ('SUPERFICIAL_RELATIONSHIP', 224), ('SUPERFICIAL_RELATIONSHIP', 238), ('SUPERFICIAL_RELATIONSHIP', 270)]	7	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0001281', 'hepatic sinusoid', 65, 'life course'), ('UBERON_0001281', 'hepatic sinusoid', 130, 'life course'), ('GO_0007565', 'female pregnancy', 195, 'prenatal'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 300, 'vitamin D'), ('GO_0007565', 'female pregnancy', 324, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 354, 'vitamin D'), ('GO_0007567', 'parturition', 378, 'postnatal'), ('UBERON_0000104', 'life cycle', 388, 'life')]	0	['situation, timing ’s life course determined, using life course analytic techniques [125],   status outcomes mother’s  status  offspring’s  status postnatal life.']
S79-PMC3271033	PMC3271033	1/2012	S79-PMC3271033	['Prenatal Vitamin Supplement composition VARIED by brand; however, most brands included 200 iu Vitamin D per pill.']	[('DIFFICULT_TASK', 40)]	1	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_63635', 'valganciclovir', 9, 'vitamin supplement'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]	0	[' vitamin supplement composition brand; however, brands 200 iu  pill.']
S159-PMC3271033	PMC3271033	1/2012	S159-PMC3271033	['OUR FINDINGS SUPPORT current GUIDELINES to begin Vitamin D supplementation of 400 iu/day to all Breast-Fed infants in the first week of Life and to FURTHER ENCOURAGE the provision of adequate Vitamin D to Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('PROBABLE_UNDERSTANDING', 29), ('FUTURE_WORK', 148), ('FUTURE_WORK', 156)]	5	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007567', 'parturition', 96, 'breast'), ('UBERON_0000310', 'breast', 96, 'breast'), ('GO_0007631', 'feeding behavior', 103, 'fed'), ('UBERON_0000104', 'life cycle', 136, 'life'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('GO_0007565', 'female pregnancy', 205, 'pregnant')]	0	[' supplementation 400 iu/day breast-fed infants week life provision   women.']
S42-PMC3272870	PMC3272870	12/2011	S42-PMC3272870	['during Pregnancy Vitamin D and Calcium Metabolism undergo significant changes to provide the calcium NEEDED for maternal Skeletal preservation and foetal Skeletal Formation.']	[('IMPORTANT_CONSIDERATION', 101)]	1	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0070583', 'spore membrane bending pathway', 17, 'vitamin D ...'), ('CHEBI_22313', 'alkaline earth metal atom', 31, 'calcium'), ('GO_0018884', 'carbazole metabolic process', 31, 'calcium metabolism'), ('UBERON_0004288', 'skeleton', 121, 'skeletal'), ('GO_0001501', 'skeletal system development', 154, 'skeletal formation'), ('UBERON_0004288', 'skeleton', 154, 'skeletal')]	0	['  calcium metabolism undergo changes calcium maternal skeletal preservation foetal skeletal formation.']
S51-PMC3272870	PMC3272870	12/2011	S51-PMC3272870	['Vitamin D is LIKELY SAFE during Pregnancy and Breast feeding when taken by mouth in RECOMMENDED amounts, that is 10 mcg (400 usp units) of Vitamin D daily in normal Pregnancy.']	[('PROBABLE_UNDERSTANDING', 13), ('IMPORTANT_CONSIDERATION', 20), ('FUTURE_WORK', 84)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 32, 'pregnancy'), ('UBERON_0000310', 'breast', 46, 'breast'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 165, 'pregnancy')]	0	['vitamin  breast feeding mouth amounts, 10 mcg (400 usp units)  daily normal .']
S92-PMC3276988	PMC3276988	9/2011	S92-PMC3276988	['[24] cleft palate HAS been experimentally produced in new Born Rats by Feeding diets either deficient or excessive in Vitamin A to maternal Rats during Pregnancy.']	[('IMPORTANT_CONSIDERATION', 18)]	1	[('GO_0007567', 'parturition', 58, 'born'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 63, 'rats'), ('GO_0007631', 'feeding behavior', 71, 'feeding'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin A'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 140, 'rats'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy')]	0	['[24] cleft palate experimentally born rats feeding diets excessive  maternal rats .']
S11-PMC3277098	PMC3277098	12/2011	S11-PMC3277098	['we AIM to review the CURRENT EVIDENCE on Vitamin D in RELATION to Immune mechanisms and FOCUS on the EFFECT of Pregnancy and Early Life exposure on Allergy Development.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 54), ('QUESTION_ANSWERED_BY_THIS_WORK', 88), ('SUPERFICIAL_RELATIONSHIP', 101)]	5	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('UBERON_0002405', 'immune system', 66, 'immune'), ('GO_0007565', 'female pregnancy', 111, 'pregnancy'), ('UBERON_0001847', 'lobule of pinna', 125, 'early life'), ('GO_0060021', 'roof of mouth development', 148, 'allergy development')]	0	[' immune mechanisms  life exposure allergy development.']
S107-PMC3277098	PMC3277098	12/2011	S107-PMC3277098	['maternal Vitamin D intake during Pregnancy (assessed by Food frequency questionnaires), is reported to be inversely ASSOCIATED with wheeze [49,50,51], allergic rhinitis and asthma [6].']	[('SUPERFICIAL_RELATIONSHIP', 116)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_33290', 'food', 56, 'food')]	0	['maternal  intake  (assessed food frequency questionnaires), wheeze [49,50,51], allergic rhinitis asthma [6].']
S122-PMC3277098	PMC3277098	12/2011	S122-PMC3277098	['[6] who FOUND lower rates of both allergic rhinitis (or 0.85; 95% ci 0.75–0.96, p< 0.01) and asthma (or 0.80; 95% ci 0.65–0.98, p< 0.05) in 5 year old children with higher maternal Vitamin D intake in Pregnancy, with no relationship to eczema (or 0.95; 95% ci 0.86–1.05, p> 0.05).']	[('INCOMPLETE_EVIDENCE', 8)]	1	[('CHEBI_27300', 'vitamin D', 181, 'vitamin D'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy')]	0	['[6] rates allergic rhinitis (or 0.85; 95% ci 0.75–0.96, p< 0.01) asthma (or 0.80; 95% ci 0.65–0.98, p< 0.05) 5 year old children higher maternal  intake eczema (or 0.95; 95% ci 0.86–1.05, p> 0.05).']
S132-PMC3277098	PMC3277098	12/2011	S132-PMC3277098	['RECORDED Serum 25(Oh)D in addition to dietary and supplemental Vitamin D intake and ESTIMATED uv exposure in 466 Pregnant women in the uk [55].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 84)]	2	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]	0	['recorded serum 25(oh)d addition dietary supplemental  intake uv exposure 466  women uk [55].']
S0-PMC3296991	PMC3296991	2/2012	S0-PMC3296991	['EVIDENCE of ASSOCIATIONS between feto-maternal Vitamin D status, Cord Parathyroid Hormone and bone-specific alkaline phosphatase, and newborn Whole body bone Mineral content\n\nabstract\nin SPITE of a high prevalence of Vitamin D inadequacy in Pregnant women and neonates, RELATIONSHIPS among Vitamin D status (25(Oh)D), Parathyroid hormone (pth), bone specific alkaline phosphatase (balp), and Whole body bone Mineral content (wbbmc) in the newborn are POORLY characterized.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 12), ('ANOMALY_CURIOUS_FINDING', 187), ('SUPERFICIAL_RELATIONSHIP', 270), ('PROBLEM_COMPLICATION', 451)]	5	[('CHEBI_28384', 'vitamin K', 47, 'Vitamin D'), ('UBERON_0000948', 'heart', 65, 'Cord'), ('UBERON_0001132', 'parathyroid gland', 70, 'Parathyroid'), ('CHEBI_5762', 'hordatine A', 82, 'Hormone'), ('UBERON_0004043', 'semicircular canal ampulla', 142, 'Whole'), ('CHEBI_46662', 'mineral', 158, 'Mineral'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('GO_0007565', 'female pregnancy', 241, 'pregnant'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 308, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 318, 'parathyroid'), ('UBERON_0007688', 'anlage', 392, 'whole'), ('CHEBI_46662', 'mineral', 408, 'mineral')]	0	['evidence feto-maternal vitamin status, cord parathyroid hormone bone-specific alkaline phosphatase, newborn whole bone mineral content\n\nabstract\nin  inadequacy  women neonates, among  status (25(oh)d), parathyroid hormone (pth), bone alkaline phosphatase (balp), whole bone mineral content (wbbmc) newborn characterized.']
S17-PMC3296991	PMC3296991	2/2012	S17-PMC3296991	['bone BIOMARKERS including balp increase during Pregnancy REGARDLESS OF Vitamin D status and attain higher values in Umbilical Cord Blood than maternal Blood [14], POSSIBLY reflecting higher rates of bone turnover.']	[('SUPERFICIAL_RELATIONSHIP', 5), ('INCOMPLETE_EVIDENCE', 57), ('INCOMPLETE_EVIDENCE', 163)]	3	[('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0002331', 'umbilical cord', 116, 'umbilical cord'), ('UBERON_0000178', 'blood', 131, 'blood'), ('UBERON_0000178', 'blood', 151, 'blood')]	0	['bone balp increase   status attain higher values umbilical cord blood maternal blood [14], higher rates bone turnover.']
S19-PMC3296991	PMC3296991	2/2012	S19-PMC3296991	['DEMONSTRATED that maternal Vitamin D status CAN INFLUENCE Fetal Femoral Development as early as 19 weeks Gestation [15].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 48)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007631', 'feeding behavior', 58, 'fetal'), ('GO_0009556', 'microsporogenesis', 64, 'femoral development'), ('UBERON_0000981', 'femur', 64, 'femoral'), ('GO_0007565', 'female pregnancy', 105, 'gestation')]	0	['demonstrated maternal  status fetal femoral 19 weeks  [15].']
S48-PMC3296991	PMC3296991	2/2012	S48-PMC3296991	['statistical analysis\nmeasurement of infant wbbmc by dxa in the present study was conducted as a secondary outcome in a comprehensive study estimating prevalence, PREDICTORS, and consequences of Vitamin D status during Pregnancy [18].']	[('SUPERFICIAL_RELATIONSHIP', 162)]	1	[('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('GO_0007565', 'female pregnancy', 218, 'pregnancy')]	0	['statistical analysis\nmeasurement infant wbbmc dxa secondary outcome prevalence, predictors,  status  [18].']
S76-PMC3296991	PMC3296991	2/2012	S76-PMC3296991	['season, maternal age, race, pre-Gestational bmi, Vitamin D intake, and Vitamin D status and infant age at the time of the scan, Gestational age at Birth, Feeding pattern (Breast Fed, Formula Fed, or mixed) and Vitamin D status did NOT remain in the final predictive models.']	[('ANOMALY_CURIOUS_FINDING', 231)]	1	[('GO_0007565', 'female pregnancy', 32, 'gestational'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 128, 'gestational'), ('GO_0007567', 'parturition', 147, 'birth'), ('GO_0007631', 'feeding behavior', 154, 'feeding'), ('GO_0007567', 'parturition', 171, 'breast fed'), ('UBERON_0000310', 'breast', 171, 'breast'), ('GO_0009407', 'toxin catabolic process', 183, 'formula fed'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D')]	0	['season, maternal age, race, pre- bmi,  intake,  status infant age scan,  age birth, feeding (breast fed, formula fed, mixed)  status final models.']
S102-PMC3296991	PMC3296991	2/2012	S102-PMC3296991	['because Vitamin D inadequacy during Gestation and its IMPACTS on offspring bone integrity are of PUBLIC HEALTH CONCERN, FURTHER STUDIES ARE WARRANTED to investigate the COMPLEX mechanisms LINKING in utero Vitamin D status to fetal Bone Development.']	[('SUPERFICIAL_RELATIONSHIP', 54), ('IMPORTANT_CONSIDERATION', 97), ('FUTURE_WORK', 120), ('FUTURE_WORK', 128), ('DIFFICULT_TASK', 169), ('SUPERFICIAL_RELATIONSHIP', 188)]	6	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 36, 'gestation'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D'), ('GO_0048539', 'bone marrow development', 231, 'bone development')]	0	[' inadequacy  offspring bone integrity concern, mechanisms utero  status fetal bone development.']
S43-PMC3309463	PMC3309463	6/2011	S43-PMC3309463	['it HAS BEEN PROPOSED that developmental Vitamin D deficiency MAY CONTRIBUTE to the increased risk of schizophrenia in dark-skinned migrants and those living in crowded urban settings.28both dark skin and urban residence are ASSOCIATED with an INCREASED risk of hypovitaminosis D.29developmental Vitamin D deficiency MAY also UNDERLIE the well-replicated season of birth EFFECT FOUND in schizophrenia (those Born in winter and spring have a small but significant increased risk of schizophrenia).30vitamin D is a potent pro-differentiation agent and CAN INFLUENCE Brain functioning via many DIFFERENT pathways.31the Vitamin D receptor and the enzyme required for the manufacture of the hormonally active form of Vitamin D have BEEN IDENTIFIED in the Human Brain,32AND THERE IS EVIDENCE from Rodent MODELS DEMONSTRATING that transient Prenatal Vitamin D deficiency results in persistent changes in Adult Brain structure, neurochemistry and behavior.33our species has evolved in settings where Vitamin D is abundant, and migration to colder climates and urban-related lifestyle factors have left modern Humans at increased risk of hypovitaminosis D.\ninspired by the conceptual framework described above, we PROPOSE that the absence of adequate Vitamin D levels during development deprives the Organism of expected instructions from the environment.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 61), ('SUPERFICIAL_RELATIONSHIP', 65), ('SUPERFICIAL_RELATIONSHIP', 224), ('IMPORTANT_CONSIDERATION', 243), ('INCOMPLETE_EVIDENCE', 316), ('SUPERFICIAL_RELATIONSHIP', 325), ('SUPERFICIAL_RELATIONSHIP', 370), ('INCOMPLETE_EVIDENCE', 377), ('INCOMPLETE_EVIDENCE', 549), ('SUPERFICIAL_RELATIONSHIP', 553), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 590), ('ANOMALY_CURIOUS_FINDING', 726), ('INCOMPLETE_EVIDENCE', 731), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 761), ('INCOMPLETE_EVIDENCE', 767), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 797), ('INCOMPLETE_EVIDENCE', 797), ('INCOMPLETE_EVIDENCE', 804), ('INCOMPLETE_EVIDENCE', 1204)]	21	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 277, 'D'), ('CHEBI_27300', 'vitamin D', 295, 'vitamin D'), ('GO_0007567', 'parturition', 407, 'born'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 505, 'D'), ('UBERON_0000955', 'brain', 563, 'brain'), ('CHEBI_27300', 'vitamin D', 615, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 711, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 749, 'human'), ('UBERON_0000955', 'brain', 755, 'brain'), ('NCBITaxon_33208', 'Metazoa', 790, 'rodent'), ('GO_0007565', 'female pregnancy', 833, 'prenatal'), ('CHEBI_27300', 'vitamin D', 842, 'vitamin D'), ('UBERON_0007023', 'adult organism', 896, 'adult'), ('UBERON_0000955', 'brain', 902, 'brain'), ('CHEBI_27300', 'vitamin D', 991, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 1100, 'humans'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1144, 'D'), ('CHEBI_27300', 'vitamin D', 1241, 'vitamin D'), ('NCBITaxon_1', 'root', 1290, 'organism')]	0	['developmental  schizophrenia dark-skinned migrants living crowded urban settings.28both dark skin urban residence hypovitaminosis d.29developmental  well-replicated season birth schizophrenia (those born winter spring schizophrenia).30vitamin potent pro-differentiation agent brain functioning via pathways.31the  receptor enzyme manufacture hormonally form  human brain,32and rodent transient   results changes adult brain structure, neurochemistry behavior.33our species settings  abundant, migration colder climates urban-related lifestyle left modern humans hypovitaminosis d.\ninspired above, absence  levels deprives organism instructions environment.']
S45-PMC3309463	PMC3309463	6/2011	S45-PMC3309463	['we SPECULATE that Prenatal Vitamin D deficiency would be one of many DIFFERENT exposures that COULD decanalize Brain Development and lead TO an increased susceptibility to schizophrenia.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 69), ('INCOMPLETE_EVIDENCE', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 138)]	4	[('GO_0007565', 'female pregnancy', 18, 'prenatal'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007420', 'brain development', 111, 'brain development'), ('UBERON_0000955', 'brain', 111, 'brain')]	0	['  exposures decanalize brain schizophrenia.']
S89-PMC3309463	PMC3309463	6/2011	S89-PMC3309463	['with respect to the epidemiology of schizophrenia, we OUTLINE HOW one CANDIDATE environmental RISK FACTOR, low Prenatal Vitamin D, CAN result in environmental editing of Brain Development.']	[('INCOMPLETE_EVIDENCE', 54), ('EXPLICIT_QUESTION', 62), ('INCOMPLETE_EVIDENCE', 70), ('SUPERFICIAL_RELATIONSHIP', 94), ('INCOMPLETE_EVIDENCE', 131)]	5	[('GO_0007565', 'female pregnancy', 111, 'prenatal'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 128, 'D'), ('GO_0007420', 'brain development', 170, 'brain development'), ('UBERON_0000955', 'brain', 170, 'brain')]	0	['respect epidemiology schizophrenia, environmental factor,  result environmental editing brain development.']
S23-PMC3313761	PMC3313761	3/2012	S23-PMC3313761	['higher Prenatal Vitamin D levels are shown to have a protective ROLE against wheezing in young children in epidemiological studies.']	[('SUPERFICIAL_RELATIONSHIP', 64)]	1	[('GO_0007565', 'female pregnancy', 7, 'prenatal'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]	0	['higher   levels wheezing young children epidemiological studies.']
S60-PMC3319623	PMC3319623	4/2012	S60-PMC3319623	['Animal MODELS of Gestational Vitamin D deficiency HIGHLIGHT the IMPORTANT ROLE of Vitamin D for correct Neurodevelopment[25].']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 50), ('IMPORTANT_CONSIDERATION', 64), ('SUPERFICIAL_RELATIONSHIP', 74)]	4	[('NCBITaxon_33208', 'Metazoa', 0, 'Animal'), ('GO_0007565', 'female pregnancy', 17, 'gestational'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007399', 'nervous system development', 104, 'neurodevelopment')]	0	['animal    neurodevelopment[25].']
S171-PMC3338544	PMC3338544	4/2012	S171-PMC3338544	['taken together these findings INDICATE that attentional processing is largely intact in a c57bl/6 Mouse MODEL of Prenatal Vitamin D deficiency, SUGGESTING that Dvd deficiency has LITTLE TO NO effect on the systems Governing attention in the Mouse.']	[('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 144), ('FULL_UNKNOWN', 179)]	4	[('NCBITaxon_10088', 'Mus <genus>', 98, 'mouse'), ('GO_0007565', 'female pregnancy', 113, 'prenatal'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('PR_000006770', 'cytoplasmic dynein 1 heavy chain 1', 160, 'DVD'), ('GO_0065007', 'biological regulation', 214, 'governing'), ('NCBITaxon_10088', 'Mus <genus>', 241, 'mouse')]	0	['taken attentional processing intact c57bl/6 mouse   deficiency, dvd systems mouse.']
S1-PMC3347007	PMC3347007	4/2012	S1-PMC3347007	['the AIMS of the PRESENT STUDY were to ESTIMATE the intake and sources of Vitamin D in danish Pregnant women and TO EXAMINE POTENTIAL DETERMINANTS of Vitamin D intake of the recommended level (10 µg per day).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 38), ('QUESTION_ANSWERED_BY_THIS_WORK', 112), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 133)]	6	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 93, 'pregnant'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D')]	0	['intake sources  danish  women  intake (10 µg day).']
S6-PMC3347007	PMC3347007	4/2012	S6-PMC3347007	['we PROPOSE that clinicians ENCOURAGE Vitamin D supplementation among Pregnant women, with SPECIAL FOCUS on vulnerable groups such as the young, smokers and multiparous women, in order to improve maternal and fetal health both during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 27), ('IMPORTANT_CONSIDERATION', 90), ('IMPORTANT_CONSIDERATION', 98)]	4	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('GO_0007565', 'female pregnancy', 243, 'pregnancy')]	0	['clinicians  supplementation among  women, young, smokers multiparous women, maternal fetal .']
S12-PMC3347007	PMC3347007	4/2012	S12-PMC3347007	['during Pregnancy, Vitamin D is transported from mother to fetus through the Placenta in the form of 25(Oh)D which is also the established MARKER of Vitamin D status [1,3,4].']	[('SUPERFICIAL_RELATIONSHIP', 138)]	1	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('UBERON_0001987', 'placenta', 76, 'placenta'), ('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]	0	[' transported mother fetus placenta form 25(oh)d  status [1,3,4].']
S14-PMC3347007	PMC3347007	4/2012	S14-PMC3347007	['this SUGGESTS that Vitamin D deficiency in Pregnancy will LEAD TO more children being Born deficient [5].']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 58)]	2	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('GO_0007567', 'parturition', 86, 'born')]	0	['  children born [5].']
S18-PMC3347007	PMC3347007	4/2012	S18-PMC3347007	['studies have also SUGGESTED that Vitamin D sufficiency has a PROTECTIVE EFFECT against pre-term Delivery and Gestational diabetes mellitus through its immunomodulatory and anti-inflammatory properties [9].']	[('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 61), ('SUPERFICIAL_RELATIONSHIP', 72)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007567', 'parturition', 96, 'delivery'), ('GO_0007565', 'female pregnancy', 109, 'gestational')]	0	['studies  pre-term delivery  diabetes mellitus immunomodulatory anti-inflammatory properties [9].']
S20-PMC3347007	PMC3347007	4/2012	S20-PMC3347007	['OTHER SUGGESTED CONSEQUENCES of Vitamin D deficiency during Pregnancy are increased risks of: schizophrenia, type 1 diabetes, multiple sclerosis, Heart disease, cancer, and small for Gestational age diagnosis [10,11,12,13].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6), ('PROBLEM_COMPLICATION', 16)]	3	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('UBERON_0000948', 'heart', 146, 'heart'), ('GO_0007565', 'female pregnancy', 183, 'gestational')]	0	['  of: schizophrenia, type diabetes, sclerosis, disease, cancer,  age diagnosis [10,11,12,13].']
S22-PMC3347007	PMC3347007	4/2012	S22-PMC3347007	['in scandinavia, all Pregnant women are RECOMMENDED 10 µg of Vitamin D per day to ensure sufficient Vitamin D status [14].']	[('FUTURE_WORK', 39)]	1	[('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]	0	['scandinavia,  women 10 µg  day ensure  status [14].']
S25-PMC3347007	PMC3347007	4/2012	S25-PMC3347007	['SEVERAL STUDIES have REPORTED that Vitamin D intake among Pregnant women is lower than recommended.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 21)]	2	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnant')]	0	['several  intake among  women recommended.']
S27-PMC3347007	PMC3347007	4/2012	S27-PMC3347007	['the danish national Birth cohort (dnbc) offers information on Vitamin D intake in danish Pregnant women as well as information on socio-demographic and lifestyle factors, and is THEREBY an excellent OPPORTUNITY TO investigate POTENTIAL DETERMINANTS of Vitamin D intake.']	[('PROBABLE_UNDERSTANDING', 178), ('FUTURE_WORK', 199), ('QUESTION_ANSWERED_BY_THIS_WORK', 211), ('INCOMPLETE_EVIDENCE', 226), ('SUPERFICIAL_RELATIONSHIP', 236)]	5	[('GO_0007567', 'parturition', 20, 'Birth'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnant'), ('CHEBI_27300', 'vitamin D', 252, 'vitamin D')]	0	['danish national birth (dnbc) offers  intake danish  women socio-demographic lifestyle factors,  intake.']
S30-PMC3347007	PMC3347007	4/2012	S30-PMC3347007	['the AIMS of the PRESENT STUDY, conducted within the danish national Birth cohort, were: (1) to ESTIMATE the Vitamin D intake among danish Pregnant women; (2) TO INVESTIGATE the sources of Vitamin D; and (3) TO EXAMINE POTENTIAL DETERMINANTS of sufficient total Vitamin D intake among danish Pregnant women, including Gestational, lifestyle, and dietary factors.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 95), ('QUESTION_ANSWERED_BY_THIS_WORK', 158), ('QUESTION_ANSWERED_BY_THIS_WORK', 207), ('INCOMPLETE_EVIDENCE', 218), ('SUPERFICIAL_RELATIONSHIP', 228)]	7	[('GO_0007567', 'parturition', 68, 'Birth'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnant'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('GO_0007565', 'female pregnancy', 317, 'gestational')]	0	['study, danish national birth cohort, were: (1)  intake among danish  women; (2) sources (3)  intake among danish  women, lifestyle, dietary factors.']
S40-PMC3347007	PMC3347007	4/2012	S40-PMC3347007	['after exclusion of participants with MISSING information on dietary Vitamin D intake, our study population consisted of 68,447 Pregnancies from all over denmark.']	[('PROBLEM_COMPLICATION', 37)]	1	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancies')]	0	['exclusion participants dietary  intake, population consisted 68,447  denmark.']
S63-PMC3347007	PMC3347007	4/2012	S63-PMC3347007	['the following FACTORS were regarded as POTENTIAL DETERMINANTS of Vitamin D intake and included in the analyses: maternal age (<20, 20–25, 25–30, 30–35, 35–40, ≥40), pre-Pregnancy bmi (≤18.5, 18.5–25, 25–30, 30–35, 35–40, >40), energy intake, parity (0, 1, 2, 3+), civil status (single, coupled/married), socio-occupational status (high, medium, skilled, student, unskilled, unemployed), physical activity level (inactive, light, moderate, high), smoking during Pregnancy (non-smoker, occasional smoker, <15 cigarettes per day, ≥15 cigarettes per day), Alcohol Consumption during Pregnancy (yes, no), season of filling out the ffq, and planned Pregnancy (planned, partly planned, not planned).']	[('SUPERFICIAL_RELATIONSHIP', 14), ('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 49)]	3	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'pregnancy'), ('GO_0007565', 'female pregnancy', 461, 'pregnancy'), ('CHEBI_30879', 'alcohol', 552, 'alcohol'), ('GO_0007631', 'feeding behavior', 560, 'consumption'), ('GO_0007565', 'female pregnancy', 579, 'pregnancy'), ('GO_0007565', 'female pregnancy', 643, 'pregnancy')]	0	['following  intake analyses: maternal age (<20, 20–25, 25–30, 30–35, 35–40, ≥40), pre- bmi (≤18.5, 18.5–25, 25–30, 30–35, 35–40, >40), energy intake, parity (0, 1, 2, 3+), civil status (single, coupled/married), socio-occupational status (high, medium, skilled, student, unskilled, unemployed), physical activity (inactive, light, moderate, high), smoking  (non-smoker, smoker, <15 cigarettes day, ≥15 cigarettes day), alcohol consumption  (yes, no), season filling ffq,  (planned, planned, planned).']
S79-PMC3347007	PMC3347007	4/2012	S79-PMC3347007	['67.6% of participants reported use of Vitamin D supplements in any dose (table 1) and 36.9% reported use of Vitamin D supplements of AT LEAST 10 µg, which is the dose now RECOMMENDED during Pregnancy by the danish national board of health .']	[('PROBABLE_UNDERSTANDING', 133), ('FUTURE_WORK', 171)]	2	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 190, 'pregnancy')]	0	['67.6% participants  supplements dose (table 1) 36.9%  supplements 10 µg, dose  danish national board .']
S82-PMC3347007	PMC3347007	4/2012	S82-PMC3347007	['in Gestational week 20 to 25 (the period also covered by the ffq), the proportion of women reporting use of Vitamin D supplements ≥10 µg per day was APPROXIMATELY 30%.']	[('INCOMPLETE_EVIDENCE', 149)]	1	[('GO_0007565', 'female pregnancy', 3, 'gestational'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]	0	[' week 20 25 (the period covered ffq), proportion women  supplements ≥10 µg day 30%.']
S87-PMC3347007	PMC3347007	4/2012	S87-PMC3347007	['caption (fig): figure 2\n\nproportion of women (%) reporting intake of Vitamin D supplements ≥10 µg per day per Gestational week in Gestational week 1 to 39 BASED ON information from dnbc interviews 2 and 3 ( n = 68,447).nutrients-04-00259-t002_table 2\n\ncaption (table-wrap): table 2\n\nmean intake of Vitamin D from diet, supplements and total intake, along with ranking of sources according to quartiles of total Vitamin D intake ( n = 68,447) *.quartiles of total Vitamin D intake (µg/day)1234mean Vitamin D intakeµg/day (%)orderµg/day (%)orderµg/day (%)orderµg/day (%)ordertotal2.62 (100)6.82 (100)11.20 (100)16.29 (100)supplements0.03 (1.15)23.31 (48.53)27.88 (70.36)111.46 (70.35)1diet2.59 (98.85)13.51 (51.47)13.33 (29.73)24.83 (29.65)2\n* based on information from the Food frequency questionnaire covering Intake in Gestational weeks 21–25.nutrients-04-00259-t003_table 3\n\ncaption (table-wrap): table 3\n\nmean intake of Vitamin D from Food groups according to quartiles of dietary Vitamin D intake in Gestational weeks 21–25 ( n = 68,447) *.quartiles of dietary Vitamin D intake (µg/day)1234mean Vitamin D intakeµg/day (%)orderµg/day (%)orderµg/day (%)orderµg/day (%)orderall Food groups1.7 (100)2.6 (100)3.7 (100)6.3 (100)Pork0.2 (11.8)30.2 (7.7)40.2 (5.4)40.2 (3.2)3beef/veal0.2 (11.8)30.2 (7.7)40.2 (5.4)40.2 (3.2)3processed meat0.1 (5.9)40.1 (3.8)50.1 (2.7)50.1 (1.6)4fish and seafood0.4 (23.5)10.9 (34.6)11.8 (48.6)14.3 (68.3)1egg0.2 (11.8)30.4 (15.4)30.4 (10.8)30.5 (7.9)2low fat dairy0.3 (17.6)20.5 (19.2)20.5 (13.5)20.5 (7.9)2\n* based on information from the Food frequency questionnaire.']	[('PROBABLE_UNDERSTANDING', 155)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'gestational'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 463, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 497, 'vitamin D'), ('CHEBI_33290', 'food', 772, 'food'), ('GO_0007631', 'feeding behavior', 810, 'intake'), ('GO_0007565', 'female pregnancy', 820, 'gestational'), ('CHEBI_27300', 'vitamin D', 923, 'vitamin D'), ('CHEBI_33290', 'food', 938, 'food'), ('CHEBI_27300', 'vitamin D', 984, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1004, 'gestational'), ('CHEBI_27300', 'vitamin D', 1065, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1099, 'vitamin D'), ('CHEBI_33290', 'food', 1179, 'food'), ('PR_000013039', 'POU domain, class 3, transcription factor 2', 1226, 'Pork0'), ('CHEBI_33290', 'food', 1570, 'food')]	0	['caption (fig): figure 2\n\nproportion women (%) intake  supplements ≥10 µg day  week  week 39 dnbc interviews 2 3 n = 68,447).nutrients-04-00259-t002_table 2\n\ncaption (table-wrap): table 2\n\nmean intake  diet, supplements intake, along ranking sources quartiles  intake n = 68,447) *.quartiles  intake (µg/day)1234mean  intakeµg/day (%)orderµg/day (%)orderµg/day (%)orderµg/day (%)ordertotal2.62 (100)6.82 (100)11.20 (100)16.29 (100)supplements0.03 (1.15)23.31 (48.53)27.88 (70.36)111.46 (70.35)1diet2.59 (98.85)13.51 (51.47)13.33 (29.73)24.83 (29.65)2\n* food frequency questionnaire covering intake  weeks 21–25.nutrients-04-00259-t003_table 3\n\ncaption (table-wrap): table 3\n\nmean intake  food quartiles dietary  intake  weeks 21–25 n = 68,447) *.quartiles dietary  intake (µg/day)1234mean  intakeµg/day (%)orderµg/day (%)orderµg/day (%)orderµg/day (%)orderall food groups1.7 (100)2.6 (100)3.7 (100)6.3 (100)pork0.2 (11.8)30.2 (7.7)40.2 (5.4)40.2 (3.2)3beef/veal0.2 (11.8)30.2 (7.7)40.2 (5.4)40.2 (3.2)3processed meat0.1 (5.9)40.1 (3.8)50.1 (2.7)50.1 (1.6)4fish seafood0.4 (23.5)10.9 (34.6)11.8 (48.6)14.3 (68.3)1egg0.2 (11.8)30.4 (15.4)30.4 (10.8)30.5 (7.9)2low fat dairy0.3 (17.6)20.5 (19.2)20.5 (13.5)20.5 (7.9)2\n* food frequency questionnaire.']
S97-PMC3347007	PMC3347007	4/2012	S97-PMC3347007	['adjustment for pre-Pregnancy bmi, parity, civil status, socio-occupational status, physical activity level, season of filling out the ffq, smoking and alcohol use during Pregnancy, total energy intake, and Planning Of Pregnancy made the direct ASSOCIATION between maternal age and sufficient total Vitamin D intake stronger.']	[('SUPERFICIAL_RELATIONSHIP', 244)]	1	[('GO_0007565', 'female pregnancy', 19, 'pregnancy'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy'), ('GO_0006915', 'apoptotic process', 206, 'planning of pregnancy'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D')]	0	['adjustment pre- bmi, parity, civil status, socio-occupational status, physical activity level, season filling ffq, smoking alcohol energy intake, pregnancy maternal age  intake stronger.']
S99-PMC3347007	PMC3347007	4/2012	S99-PMC3347007	['inclusion of the above-mentioned covariates in the analyses made the ASSOCIATION between sufficient total Vitamin D intake and number of children stronger, but had no effect on the ASSOCIATION between sufficient total Vitamin D intake and number of smoked cigarettes during Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 69), ('SUPERFICIAL_RELATIONSHIP', 181)]	2	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D'), ('GO_0007565', 'female pregnancy', 274, 'pregnancy')]	0	['inclusion above-mentioned covariates  intake children stronger,  intake smoked cigarettes .']
S131-PMC3347007	PMC3347007	4/2012	S131-PMC3347007	['none of the participants reported dietary intakes that match the RECOMMENDED intake level in Pregnancy of 10 µg per day, which underlines the NECESSITY of Vitamin D supplementation.']	[('FUTURE_WORK', 65), ('IMPORTANT_CONSIDERATION', 142)]	2	[('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]	0	['none participants dietary intakes match intake  10 µg day,  supplementation.']
S132-PMC3347007	PMC3347007	4/2012	S132-PMC3347007	['the RECOMMENDATIONS for Pregnant women in most northern countries include a Vitamin D supplement of 10 µg per day.']	[('FUTURE_WORK', 4), ('IMPORTANT_CONSIDERATION', 4)]	2	[('GO_0007565', 'female pregnancy', 24, 'pregnant'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]	0	[' women northern countries  supplement 10 µg day.']
S134-PMC3347007	PMC3347007	4/2012	S134-PMC3347007	['when the study was conducted there were no formal RECOMMENDATIONS from the danish national board of health on use of Vitamin D supplements during Pregnancy, and both the number of users and the supplement dose MAY THEREFORE be higher today.']	[('FUTURE_WORK', 50), ('INCOMPLETE_EVIDENCE', 210), ('PROBABLE_UNDERSTANDING', 214)]	3	[('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy')]	0	['danish national board  supplements users supplement dose higher today.']
S137-PMC3347007	PMC3347007	4/2012	S137-PMC3347007	['the most common doses of Vitamin D in supplements were 10 µg and 5 µg, INDICATING that the available supplements in denmark all have doses of 5 and 10 µg Vitamin D. low dose supplements make it DIFFICULT for the women to obtain the RECOMMENDED dose of Vitamin D. all Vitamin D supplements aimed at Pregnant women SHOULD THEREFORE contain 10 µg.']	[('INCOMPLETE_EVIDENCE', 71), ('DIFFICULT_TASK', 194), ('FUTURE_WORK', 232), ('FUTURE_WORK', 313), ('PROBABLE_UNDERSTANDING', 320)]	5	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 252, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D'), ('GO_0007565', 'female pregnancy', 298, 'pregnant')]	0	['doses  supplements 10 µg 5 µg, supplements denmark doses 5 10 µg . dose supplements women obtain dose .  supplements  women contain 10 µg.']
S141-PMC3347007	PMC3347007	4/2012	S141-PMC3347007	['in a finnish Pregnancy study 74% of Vitamin D among Supplement users came from Supplements, BUT ONLY 15% reached the recommended intake level of 10 µg per day [27].']	[('ANOMALY_CURIOUS_FINDING', 92), ('ANOMALY_CURIOUS_FINDING', 96)]	2	[('GO_0007565', 'female pregnancy', 13, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 52, 'supplement'), ('CHEBI_33341', 'titanium atom', 79, 'supplements')]	0	['finnish  74%  among supplement users came supplements, 15% intake 10 µg day [27].']
S156-PMC3347007	PMC3347007	4/2012	S156-PMC3347007	['smokers MIGHT be overall less health conscious and THEREFORE not aware of the IMPORTANCE of using Vitamin D supplements in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 8), ('PROBABLE_UNDERSTANDING', 51), ('IMPORTANT_CONSIDERATION', 78)]	3	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy')]	0	['smokers using  supplements .']
S161-PMC3347007	PMC3347007	4/2012	S161-PMC3347007	['AS EXPECTED, Pregnancy-planners were more LIKELY to have sufficient total Vitamin D intake, PROBABLY BECAUSE they were more conscious about their Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 42), ('PROBABLE_UNDERSTANDING', 92), ('PROBABLE_UNDERSTANDING', 101)]	4	[('GO_0007565', 'female pregnancy', 13, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy')]	0	['expected, -planners  intake, .']
S184-PMC3347007	PMC3347007	4/2012	S184-PMC3347007	['determinants of Vitamin D insufficiency MUST BE TAKEN INTO CONSIDERATION in making RECOMMENDATIONS on Vitamin D intake in Pregnancy, to include more vulnerable groups that MAY BE at higher risk of deficiency.']	[('IMPORTANT_CONSIDERATION', 40), ('IMPORTANT_CONSIDERATION', 48), ('FUTURE_WORK', 83), ('INCOMPLETE_EVIDENCE', 172)]	4	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy')]	0	['determinants   intake higher deficiency.']
S190-PMC3347007	PMC3347007	4/2012	S190-PMC3347007	['we PROPOSE that clinicians SHOULD ENCOURAGE Vitamin D supplementation among Pregnant women, with a SPECIAL FOCUS on vulnerable groups, such as younger, smoking and multiparous women, IN ORDER to improve maternal and fetal health both during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 27), ('FUTURE_WORK', 34), ('IMPORTANT_CONSIDERATION', 99), ('IMPORTANT_CONSIDERATION', 107), ('QUESTION_ANSWERED_BY_THIS_WORK', 183)]	6	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnant'), ('GO_0007565', 'female pregnancy', 251, 'pregnancy')]	0	['clinicians  supplementation among  women, groups, younger, smoking multiparous women, maternal fetal .']
S0-PMC3347028	PMC3347028	3/2012	S0-PMC3347028	['Vitamin D and its ROLE during Pregnancy in attaining optimal health of mother and fetus\n\nabstract\nDESPITE its discovery a hundred years ago, Vitamin D has emerged as one of the most CONTROVERSIAL Nutrients and prohormones of the 21st century.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('ANOMALY_CURIOUS_FINDING', 98), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 182)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 30, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('CHEBI_33284', 'nutrient', 196, 'nutrients')]	0	['vitamin  attaining mother fetus\n\nabstract\ndespite hundred ago,  nutrients prohormones 21st century.']
S2-PMC3347028	PMC3347028	3/2012	S2-PMC3347028	['there are clear indicators from in vitro and Animal in vivo studies that POINT to Vitamin D’s INDISPUTABLE ROLE in both Innate and Adaptive Immunity; HOWEVER, the translation of THESE FINDINGS to clinical practice, including the Care of the Pregnant woman, has not occurred.']	[('INCOMPLETE_EVIDENCE', 73), ('IMPORTANT_CONSIDERATION', 94), ('SUPERFICIAL_RELATIONSHIP', 107), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 150), ('INCOMPLETE_EVIDENCE', 178)]	5	[('NCBITaxon_33208', 'Metazoa', 45, 'animal'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007631', 'feeding behavior', 120, 'innate ...'), ('GO_0051866', 'general adaptation syndrome', 131, 'adaptive immunity'), ('GO_0007567', 'parturition', 229, 'care'), ('GO_0007565', 'female pregnancy', 241, 'pregnant')]	0	['animal vivo ’s innate adaptive immunity; however, translation practice,  woman, occurred.']
S3-PMC3347028	PMC3347028	3/2012	S3-PMC3347028	['until RECENTLY, there HAS BEEN a PAUCITY of data from randomized controlled trials to establish clear cut beneficial EFFECTS of Vitamin D supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 117)]	4	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy')]	0	['recently, cut  supplementation .']
S16-PMC3347028	PMC3347028	3/2012	S16-PMC3347028	['it is with these CAUTIONS and confessions that we approach THIS review about Vitamin D’s ROLE during Pregnancy.']	[('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 17), ('QUESTION_ANSWERED_BY_THIS_WORK', 59), ('SUPERFICIAL_RELATIONSHIP', 89)]	4	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy')]	0	['confessions ’s .']
S17-PMC3347028	PMC3347028	3/2012	S17-PMC3347028	['in the sections ahead, we will FOCUS on one Micronutrient—Vitamin D—and will discuss WHAT we KNOW and what we surely do NOT KNOW in the context of the Pregnant woman and her developing fetus.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('EXPLICIT_QUESTION', 85), ('INCOMPLETE_EVIDENCE', 93), ('FULL_UNKNOWN', 120)]	4	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 44, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnant')]	0	['sections ahead, micronutrient——and context  woman fetus.']
S32-PMC3347028	PMC3347028	3/2012	S32-PMC3347028	['a western diet, HOWEVER, provides less than 200 iu (5 μg) Vitamin D/day, a point that was reestablished in our two recently completed Vitamin D clinical trial during Pregnancy [6].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 16)]	1	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy')]	0	['western diet, however, 200 iu (5 μg) /day, reestablished completed   [6].']
S36-PMC3347028	PMC3347028	3/2012	S36-PMC3347028	['general Vitamin D Metabolism\nIN ORDER TO understand the DIFFERENCES between the nonpregnant and Pregnant states and their EFFECTS on Vitamin D Metabolism, it is ESSENTIAL to understand the nonpregnant state first.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 122), ('IMPORTANT_CONSIDERATION', 161)]	4	[('CHEBI_28384', 'vitamin K', 8, 'Vitamin D'), ('GO_0046443', 'FAD metabolic process', 8, 'Vitamin D Metabolism'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 8, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnant'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 133, 'vitamin D metabolism'), ('PR_000006444', 'diacylglycerol kinase delta', 141, 'D')]	0	['general vitamin metabolism\nin nonpregnant   metabolism, nonpregnant first.']
S53-PMC3347028	PMC3347028	3/2012	S53-PMC3347028	['during Pregnancy, the Placenta is PROBABLY the most prominent site for Extra-Renal activation of Vitamin D [13].']	[('PROBABLE_UNDERSTANDING', 34)]	1	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('UBERON_0001987', 'placenta', 22, 'placenta'), ('UBERON_0000478', 'extraembryonic structure', 71, 'extra-renal'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]	0	['placenta site extra-renal activation  [13].']
S70-PMC3347028	PMC3347028	3/2012	S70-PMC3347028	['[23], SHOWED that Ifn-Γ-mediated Antimicrobial activity of Human Macrophages, especially IMPORTANT in hiv and tuberculosis patients, is DEPENDENT on Vitamin D. BOTH STUDY findings have IMPLICATIONS for the Pregnant woman and her developing fetus, BUT our understanding of such processes following maternal exposure to a pathogen or maternal infection REMAINS SCANT.']	[('INCOMPLETE_EVIDENCE', 6), ('IMPORTANT_CONSIDERATION', 89), ('SUPERFICIAL_RELATIONSHIP', 136), ('INCOMPLETE_EVIDENCE', 160), ('IMPORTANT_CONSIDERATION', 185), ('ANOMALY_CURIOUS_FINDING', 247), ('INCOMPLETE_EVIDENCE', 351), ('INCOMPLETE_EVIDENCE', 359)]	8	[('PR_000008920', 'interferon alpha-7', 18, 'IFN-γ'), ('CHEBI_65381', 'albizoside C', 33, 'antimicrobial'), ('NCBITaxon_9606', 'Homo sapiens', 59, 'human'), ('CL_0000235', 'macrophage', 65, 'macrophages'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0007565', 'female pregnancy', 206, 'pregnant')]	0	['[23], ifn-γ-mediated antimicrobial activity human macrophages, hiv tuberculosis patients, .  woman fetus, processes following maternal exposure pathogen maternal infection scant.']
S79-PMC3347028	PMC3347028	3/2012	S79-PMC3347028	['additionally, the ROLE of Vitamin D in Immune function intensifies the NEED to establish Vitamin D sufficiency during Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('INCOMPLETE_EVIDENCE', 71)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0002405', 'immune system', 39, 'immune'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy')]	0	['additionally,  immune intensifies  .']
S86-PMC3347028	PMC3347028	3/2012	S86-PMC3347028	['it is INTERESTING that during Pregnancy alone and at no other time during the Lifecycle there is an uncoupling of Vitamin D Metabolism from calcium such that by the end of the first trimester, 1,25(Oh)2D levels are more than double what they are during the nonpregnant state without concurrent changes in Serum calcium concentrations [6].']	[('ANOMALY_CURIOUS_FINDING', 6)]	1	[('GO_0007565', 'female pregnancy', 30, 'pregnancy'), ('UBERON_0000104', 'life cycle', 78, 'lifecycle'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 114, 'vitamin D metabolism'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 195, '25(OH)2D'), ('UBERON_0001977', 'blood serum', 305, 'serum')]	0	[' lifecycle uncoupling  metabolism calcium trimester, 1,25(oh)2d levels nonpregnant changes serum calcium concentrations [6].']
S87-PMC3347028	PMC3347028	3/2012	S87-PMC3347028	['it IS NOT SURPRISING, then that during Pregnancy pth as a MARKER of Vitamin D status is a LESS RELIABLE PREDICTOR than in nonpregnant Adults [60,61,62].']	[('PROBABLE_UNDERSTANDING', 3), ('PROBABLE_UNDERSTANDING', 6), ('ANOMALY_CURIOUS_FINDING', 10), ('SUPERFICIAL_RELATIONSHIP', 58), ('INCOMPLETE_EVIDENCE', 90), ('IMPORTANT_CONSIDERATION', 95), ('SUPERFICIAL_RELATIONSHIP', 104)]	7	[('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('UBERON_0007023', 'adult organism', 134, 'adults')]	0	['surprising,  pth  status nonpregnant adults [60,61,62].']
S97-PMC3347028	PMC3347028	3/2012	S97-PMC3347028	['WHILE okonofua, et al, SUGGEST that normalization of maternal calcium and pth would be useful endpoints in determining the success of Vitamin D supplementation during Pregnancy, more RECENT STUDIES SUGGEST that BECAUSE pth threshold ESTIMATES cannot be precisely defined, total circulating 25(Oh)D ALONE is a BETTER measure of maternal Vitamin D status [60,64,65].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 198), ('PROBLEM_COMPLICATION', 211), ('INCOMPLETE_EVIDENCE', 233), ('ANOMALY_CURIOUS_FINDING', 298), ('INCOMPLETE_EVIDENCE', 298), ('INCOMPLETE_EVIDENCE', 309)]	9	[('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 290, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]	0	['okonofua, et al, normalization maternal calcium pth endpoints  supplementation pth defined, circulating 25(oh)d measure maternal  status [60,64,65].']
S107-PMC3347028	PMC3347028	3/2012	S107-PMC3347028	['beyond childhood, SEVERE Vitamin D deficiency CAN occur in young women, including those who are Pregnant, with higher RISK with advancing age in a woman’s Lifecycle.']	[('IMPORTANT_CONSIDERATION', 18), ('INCOMPLETE_EVIDENCE', 46), ('IMPORTANT_CONSIDERATION', 118)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnant'), ('GO_0006266', 'DNA ligation', 155, 'lifecycle')]	0	['beyond childhood,  occur young women, higher age woman’s lifecycle.']
S109-PMC3347028	PMC3347028	3/2012	S109-PMC3347028	['throughout Gestation, IF a woman is Vitamin D deficient, it APPEARS to IMPACT fetal bone health more than maternal [66,67,68].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('ANOMALY_CURIOUS_FINDING', 60), ('SUPERFICIAL_RELATIONSHIP', 71)]	3	[('GO_0007565', 'female pregnancy', 11, 'gestation'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]	0	['throughout woman  deficient, fetal bone maternal [66,67,68].']
S123-PMC3347028	PMC3347028	3/2012	S123-PMC3347028	['a GLOBAL PERSPECTIVE on Vitamin D status of women during Pregnancy\nwith improved laboratory techniques for the measurement of Vitamin D developed in the early 1980’s [73], investigators began to measure the Vitamin D status of Pregnant women.']	[('IMPORTANT_CONSIDERATION', 2), ('INCOMPLETE_EVIDENCE', 9)]	2	[('CHEBI_28384', 'vitamin K', 24, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D'), ('GO_0007565', 'female pregnancy', 227, 'pregnant')]	0	['vitamin status women \nwith laboratory techniques  1980’s [73], measure  status  women.']
S133-PMC3347028	PMC3347028	3/2012	S133-PMC3347028	['women—including Pregnant women, with a bmi greater than 30 are at INCREASED RISK of Vitamin D deficiency [70].']	[('IMPORTANT_CONSIDERATION', 66)]	1	[('GO_0007565', 'female pregnancy', 16, 'pregnant'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]	0	['women—including  women, bmi 30  [70].']
S143-PMC3347028	PMC3347028	3/2012	S143-PMC3347028	['from the prior sections, IT IS CLEAR that Vitamin D deficiency during Pregnancy is common throughout the world YET WHAT EFFECT does deficiency have on the mother and her developing fetus?']	[('PROBABLE_UNDERSTANDING', 25), ('ANOMALY_CURIOUS_FINDING', 111), ('EXPLICIT_QUESTION', 115), ('SUPERFICIAL_RELATIONSHIP', 120), ('EXPLICIT_QUESTION', 186)]	5	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy')]	0	['sections,   throughout world mother fetus?']
S149-PMC3347028	PMC3347028	3/2012	S149-PMC3347028	['[100], comparing growth parameters in newborn infants with the maternal Intakes of milk and Vitamin D during Pregnancy, FOUND an ASSOCIATION between Vitamin D intake during Pregnancy and Birth weight.']	[('INCOMPLETE_EVIDENCE', 120), ('SUPERFICIAL_RELATIONSHIP', 129)]	2	[('GO_0007631', 'feeding behavior', 72, 'intakes'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy'), ('GO_0007567', 'parturition', 187, 'birth')]	0	['[100], parameters newborn infants maternal intakes milk   intake  birth weight.']
S156-PMC3347028	PMC3347028	3/2012	S156-PMC3347028	['BECAUSE Vitamin D status has not been a consistent CONCERN during Pregnancy, long-term DATA are SPARSE.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 51), ('INCOMPLETE_EVIDENCE', 87)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy')]	0	[' status long-term sparse.']
S157-PMC3347028	PMC3347028	3/2012	S157-PMC3347028	['the FEW STUDIES that HAVE BEEN conducted have FOCUSED more on discernible neonatal EFFECTS of Vitamin D during Pregnancy, RATHER than the long-latency and later health EFFECTS.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 21), ('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('SUPERFICIAL_RELATIONSHIP', 83), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 122), ('SUPERFICIAL_RELATIONSHIP', 168)]	6	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'pregnancy')]	0	['discernible neonatal  long-latency effects.']
S180-PMC3347028	PMC3347028	3/2012	S180-PMC3347028	['SINCE the modern diet supplies less than 10% of one’s total Vitamin D REQUIREMENTS, IF judicious sunlight exposure is not an option, then the only alternative for the Pregnant woman is Vitamin D supplementation.']	[('PROBLEM_COMPLICATION', 0), ('IMPORTANT_CONSIDERATION', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 84)]	3	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnant'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]	0	['since modern diet supplies 10% one’s  requirements,  woman  supplementation.']
S182-PMC3347028	PMC3347028	3/2012	S182-PMC3347028	['effectiveness of Vitamin D supplementation during Pregnancy\nthere HAS BEEN a PAUCITY OF studies evaluating the REQUIREMENTS and EFFECTS of Vitamin D supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 66), ('INCOMPLETE_EVIDENCE', 77), ('IMPORTANT_CONSIDERATION', 111), ('SUPERFICIAL_RELATIONSHIP', 128)]	4	[('CHEBI_28384', 'vitamin K', 17, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 172, 'pregnancy')]	0	['effectiveness vitamin supplementation \nthere  supplementation .']
S183-PMC3347028	PMC3347028	3/2012	S183-PMC3347028	['the studies that were available in a cochrane review more than a decade ago INDICATED that the adequate intake (Ai) for Vitamin D during Pregnancy of 400 iu/day is grossly INADEQUATE, especially with ethnic minorities [147].']	[('INCOMPLETE_EVIDENCE', 76), ('PROBLEM_COMPLICATION', 172)]	2	[('CHEBI_28741', 'sodium fluoride', 112, 'AI'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy')]	0	['cochrane decade ago intake (ai)   400 iu/day inadequate, ethnic minorities [147].']
S184-PMC3347028	PMC3347028	3/2012	S184-PMC3347028	['AS PREDICTED by Vitamin D pharmacokinetics, supplements of 1000 iu/day of Vitamin D to Pregnant women result in a 12.5 to 15.0 nmol/l increase in circulating 25(Oh)D concentrations in both maternal and Cord Serum compared with nonsupplemented controls [75,76,77].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 3)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 158, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 158, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 202, 'cord'), ('UBERON_0001977', 'blood serum', 207, 'serum')]	0	[' pharmacokinetics, supplements 1000 iu/day   women result 12.5 15.0 nmol/l increase circulating 25(oh)d concentrations maternal cord serum nonsupplemented [75,76,77].']
S185-PMC3347028	PMC3347028	3/2012	S185-PMC3347028	['this PREMISE is SUPPORTED by our two randomized clinical trials involving Vitamin D supplementation of Pregnant women [6,148].']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 16)]	2	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnant')]	0	[' supplementation  women [6,148].']
S187-PMC3347028	PMC3347028	3/2012	S187-PMC3347028	['results of two RECENT randomized controlled trials during Pregnancy\nin our RECENTLY completed nichd Vitamin D supplementation trial involving a diverse group of Pregnant women less than 16 weeks of Gestation, 4000 iu (100 μg) Vitamin D3/day was SUPERIOR to 400 (control)- or 2000 iu/day in achieving circulating 25(Oh)d of at least 40 ng/ml (100 nmol/l), the point at which 1,25(Oh)2D begins to be optimized (seefigure 2) [6].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 245)]	3	[('GO_0007565', 'female pregnancy', 58, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnant'), ('GO_0007565', 'female pregnancy', 198, 'gestation'), ('CHEBI_33279', 'vitamin D5', 226, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 226, 'vitamin D3'), ('CHEBI_63056', 'zinc cation', 312, '25(OH'), ('CHEBI_82784', 'PVP38-Ag NP', 374, '1,25(OH)2D')]	0	['results \nin completed nichd  supplementation  women 16 weeks 4000 iu (100 μg) vitamin d3/day 400 (control)- 2000 iu/day achieving circulating 25(oh)d 40 ng/ml (100 nmol/l), 1,25(oh)2d begins (seefigure 2) [6].']
S191-PMC3347028	PMC3347028	3/2012	S191-PMC3347028	['EVEN in the latter trial where women were randomized to either 2000 iu (50 μg) or 4000 iu (100 μg) Vitamin D3/day, there were no safety ISSUES surrounding Vitamin D supplementation and there was a TREND where specific health COMPLICATIONS of Pregnancy such as Preterm Birth, Preterm Labor, hypertensive orders of Pregnancy, Gestational diabetes, and infection were higher in the 400 iu-compared with the 4000 iu-group, but did not reach statistical significance [149].']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 136), ('PROBLEM_COMPLICATION', 136), ('INCOMPLETE_EVIDENCE', 197), ('IMPORTANT_CONSIDERATION', 225), ('PROBLEM_COMPLICATION', 225)]	6	[('CHEBI_33279', 'vitamin D5', 99, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 99, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy'), ('GO_0007565', 'female pregnancy', 260, 'preterm birth'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 275, 'preterm labor'), ('GO_0007565', 'female pregnancy', 313, 'pregnancy'), ('GO_0007565', 'female pregnancy', 324, 'gestational')]	0	['even latter women 4000 iu (100 μg) vitamin d3/day, surrounding  supplementation  preterm labor, hypertensive orders  diabetes, infection higher 400 iu-compared 4000 iu-group, statistical [149].']
S196-PMC3347028	PMC3347028	3/2012	S196-PMC3347028	['secondary analysis INDICATED that Preterm Birth and labor were inversely RELATED to pre-Delivery Vitamin D status (Preterm Birth or = 0.50 per 10 ng/ml, p = 0.002; Preterm Labor or Birth or = 0.72 per 10 ng/ml, p = 0.012), an EFFECT that PERSISTED EVEN after controlling for race.']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 73), ('SUPERFICIAL_RELATIONSHIP', 226), ('INCOMPLETE_EVIDENCE', 238), ('ANOMALY_CURIOUS_FINDING', 248)]	5	[('GO_0007565', 'female pregnancy', 34, 'preterm'), ('GO_0007567', 'parturition', 42, 'birth'), ('GO_0007567', 'parturition', 88, 'delivery'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'preterm'), ('GO_0007567', 'parturition', 123, 'birth'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 164, 'preterm labor'), ('GO_0007567', 'parturition', 181, 'birth')]	0	['secondary  birth labor pre-delivery  status birth = 0.50 10 ng/ml, p = 0.002; preterm labor birth = 0.72 10 ng/ml, p = 0.012), controlling race.']
S217-PMC3347028	PMC3347028	3/2012	S217-PMC3347028	['studies specifically designed and powered to answer the QUESTION of WHETHER OR NOT Vitamin D supplementation LEADS TO improved health outcomes—lower RISK of Preterm Birth, preeclampsia, and infection REMAIN to be done.']	[('EXPLICIT_QUESTION', 56), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('SUPERFICIAL_RELATIONSHIP', 109), ('IMPORTANT_CONSIDERATION', 149), ('INCOMPLETE_EVIDENCE', 200)]	5	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'preterm birth')]	0	['studies powered  supplementation outcomes—lower preeclampsia, infection done.']
S218-PMC3347028	PMC3347028	3/2012	S218-PMC3347028	['we can conservatively say that WHILE we do not understand completely the ROLE of 1,25(Oh)2D during Pregnancy, achieving OPTIMAL production can be done SAFELY with 4000 iu Vitamin D3/day, which APPEARS TO BE the amount of Vitamin D that would be conservatively generated by the body with adequate sunlight exposure over the duration of Gestation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 31), ('SUPERFICIAL_RELATIONSHIP', 73), ('IMPORTANT_CONSIDERATION', 120), ('IMPORTANT_CONSIDERATION', 151), ('ANOMALY_CURIOUS_FINDING', 193)]	5	[('CHEBI_37958', 'dye', 81, '1,'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 83, '25(OH)2D'), ('GO_0007565', 'female pregnancy', 99, 'pregnancy'), ('CHEBI_33279', 'vitamin D5', 171, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 171, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D'), ('GO_0007565', 'female pregnancy', 335, 'gestation')]	0	['1,25(oh)2d achieving production done 4000 iu vitamin d3/day, amount  generated sunlight exposure duration .']
S220-PMC3347028	PMC3347028	3/2012	S220-PMC3347028	['unanswered questions and direction of FUTURE RESEARCH endeavors\nthere are many UNANSWERED QUESTIONS about Vitamin D’s “true” ROLE during Pregnancy: at no other time during the Lifecycle is 25(Oh)D so closely LINKED with 1,25(Oh)2D [6].']	[('FUTURE_WORK', 38), ('ANOMALY_CURIOUS_FINDING', 79), ('EXPLICIT_QUESTION', 90), ('SUPERFICIAL_RELATIONSHIP', 125), ('SUPERFICIAL_RELATIONSHIP', 208)]	5	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0000104', 'life cycle', 176, 'lifecycle'), ('CHEBI_71657', 'versiconol acetate', 189, '25(OH)D'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 222, '25(OH)2D')]	0	['unanswered endeavors\nthere ’s “true” : lifecycle 25(oh)d 1,25(oh)2d [6].']
S224-PMC3347028	PMC3347028	3/2012	S224-PMC3347028	['it is INTERESTING that epidemiological studies involving Pregnant women with Preeclampsia—a clinical picture of inflammation and vasculitis—Vitamin D deficiency HAS BEEN IMPLICATED [152,153,154].']	[('ANOMALY_CURIOUS_FINDING', 6), ('INCOMPLETE_EVIDENCE', 161), ('SUPERFICIAL_RELATIONSHIP', 170)]	3	[('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 77, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D')]	0	['epidemiological  women preeclampsia—a picture inflammation vasculitis— [152,153,154].']
S226-PMC3347028	PMC3347028	3/2012	S226-PMC3347028	['the health effects data from Vitamin D supplementation trials THUS FAR, WHILE TANTALIZING, are NOT CONCLUSIVE in SHOWING definitive “proof” for Vitamin D AS a POTENTIAL CANDIDATE in the reduction of comorbidities of Pregnancy, YET one CANNOT DISMISS the strong CORRELATION between reduced RISK with increased Serum 25(Oh)D concentrations.']	[('INCOMPLETE_EVIDENCE', 62), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 72), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('INCOMPLETE_EVIDENCE', 113), ('PROBABLE_UNDERSTANDING', 154), ('INCOMPLETE_EVIDENCE', 159), ('INCOMPLETE_EVIDENCE', 169), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 227), ('ANOMALY_CURIOUS_FINDING', 227), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 235), ('SUPERFICIAL_RELATIONSHIP', 261), ('IMPORTANT_CONSIDERATION', 289)]	13	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy'), ('UBERON_0001977', 'blood serum', 309, 'serum'), ('CHEBI_71657', 'versiconol acetate', 315, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 315, '25(OH)D')]	0	[' supplementation far, tantalizing, “proof”  reduction comorbidities dismiss serum 25(oh)d concentrations.']
S232-PMC3347028	PMC3347028	3/2012	S232-PMC3347028	['WHAT about Vitamin D’s ROLE in maintaining Immune Homeostasis during Pregnancy?']	[('EXPLICIT_QUESTION', 0), ('SUPERFICIAL_RELATIONSHIP', 23), ('EXPLICIT_QUESTION', 78)]	3	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0055090', 'acylglycerol homeostasis', 43, 'immune homeostasis'), ('UBERON_0002405', 'immune system', 43, 'immune'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy')]	0	['’s maintaining immune homeostasis ?']
S237-PMC3347028	PMC3347028	3/2012	S237-PMC3347028	['conclusions\nthe ROLE of Vitamin D during Pregnancy and its EFFECT on maternal and fetal health is just BEGINNING TO BE understood.']	[('SUPERFICIAL_RELATIONSHIP', 16), ('SUPERFICIAL_RELATIONSHIP', 59), ('INCOMPLETE_EVIDENCE', 103)]	3	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy')]	0	['conclusions\nthe   maternal fetal understood.']
S238-PMC3347028	PMC3347028	3/2012	S238-PMC3347028	['in the last five years, there has been an explosion of published data concerning the Immune EFFECTS of Vitamin D, YET LITTLE IS KNOWN in this regard about the specific Immune EFFECTS of Vitamin D during Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('ANOMALY_CURIOUS_FINDING', 114), ('FULL_UNKNOWN', 118), ('SUPERFICIAL_RELATIONSHIP', 175)]	4	[('UBERON_0002405', 'immune system', 85, 'immune'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('UBERON_0002405', 'immune system', 168, 'immune'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]	0	['last five years, explosion immune regard immune  .']
S239-PMC3347028	PMC3347028	3/2012	S239-PMC3347028	['what is clear, HOWEVER, is that Vitamin D deficiency during Pregnancy is RAMPANT throughout the world, including countries such as the united states and great britain.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 15), ('IMPORTANT_CONSIDERATION', 73)]	2	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy')]	0	['clear, however,   throughout world, countries united britain.']
S242-PMC3347028	PMC3347028	3/2012	S242-PMC3347028	['a RECENT randomized controlled TRIAL with 350 women of diverse racial and ethnic backgrounds SHOWED that 4000 iu Vitamin D/day is MOST EFFECTIVE in improving the Vitamin D status of Pregnant women, attaining circulating levels of at least 40 ng/ml (100 nmol/l) for 25(Oh)D, and was NECESSARY to achieve OPTIMAL 1,25(Oh)2D production.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 93), ('PROBABLE_UNDERSTANDING', 130), ('SUPERFICIAL_RELATIONSHIP', 135), ('IMPORTANT_CONSIDERATION', 282), ('IMPORTANT_CONSIDERATION', 303)]	6	[('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 267, '(OH ... D'), ('CHEBI_37983', 'sulfur-35 atom', 311, '1'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 313, '25(OH)2D')]	0	['350 women racial ethnic backgrounds 4000 iu /day  status  women, attaining circulating levels 40 ng/ml (100 nmol/l) 25(oh)d, achieve 1,25(oh)2d production.']
S4-PMC3355895	PMC3355895	1/2011	S4-PMC3355895	['THUS factors such as maternal lifestyle, diet, body build, physical activity, and Vitamin D status in Pregnancy all APPEAR to INFLUENCE offspring bone Mineral accrual.']	[('PROBABLE_UNDERSTANDING', 0), ('ANOMALY_CURIOUS_FINDING', 116), ('SUPERFICIAL_RELATIONSHIP', 126)]	3	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('CHEBI_46662', 'mineral', 151, 'mineral')]	0	['thus maternal lifestyle, diet, build, physical activity,  status  offspring bone mineral accrual.']
S52-PMC3355895	PMC3355895	1/2011	S52-PMC3355895	['these OBSERVATIONS MAY SUGGEST a POSSIBLE mechanism for the INFLUENCE of maternal Vitamin D status on Placental Calcium Transport and Intrauterine bone Mineral accrual.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 60)]	5	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'placental'), ('UBERON_0001987', 'placenta', 102, 'placental'), ('GO_0006816', 'calcium ion transport', 112, 'calcium transport'), ('UBERON_0022293', 'reproductive gland secretion', 134, 'intrauterine'), ('CHEBI_46662', 'mineral', 152, 'mineral')]	0	['maternal  status  calcium transport intrauterine bone mineral accrual.']
S84-PMC3355895	PMC3355895	1/2011	S84-PMC3355895	['lower concentrations of Serum 25(oh)-Vitamin D in mothers during late Pregnancy were ASSOCIATED with reduced Whole body bmc and bmd in children at age 9 years (javaid et al.,2006a).']	[('SUPERFICIAL_RELATIONSHIP', 85)]	1	[('UBERON_0001977', 'blood serum', 24, 'serum'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('UBERON_0007688', 'anlage', 109, 'whole')]	0	['lower concentrations serum 25(oh)- mothers late  whole bmc bmd children age 9 (javaid et al.,2006a).']
S85-PMC3355895	PMC3355895	1/2011	S85-PMC3355895	['estimated exposure to ultraviolet b radiation during late Pregnancy ( p \u2009<\u20090.0001) and the maternal use of Vitamin D supplements ( p \u2009=\u20090.01) both PREDICTED maternal 25(oh)-Vitamin D concentration, and childhood bmc ( p \u2009=\u20090.03).']	[('SUPERFICIAL_RELATIONSHIP', 147)]	1	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D')]	0	['estimated exposure ultraviolet b radiation late  p \u2009<\u20090.0001) maternal  supplements p \u2009=\u20090.01) maternal 25(oh)- concentration, childhood bmc p \u2009=\u20090.03).']
S87-PMC3355895	PMC3355895	1/2011	S87-PMC3355895	['FINDINGS from the avon longitudinal study of parents and children (sayers and tobias,2009) FURTHER REINFORCED the IMPORTANCE of maternal 25(Oh)-Vitamin D levels, DEMONSTRATING a positive ASSOCIATION between ambient ultraviolet b radiation in Pregnancy and offspring bmc at 9 years old.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 91), ('INCOMPLETE_EVIDENCE', 99), ('IMPORTANT_CONSIDERATION', 114), ('INCOMPLETE_EVIDENCE', 162), ('SUPERFICIAL_RELATIONSHIP', 187)]	6	[('CHEBI_63056', 'zinc cation', 137, '25(OH'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy')]	0	['findings parents children (sayers tobias,2009) maternal 25(oh)- levels, positive ambient ultraviolet b radiation  offspring bmc 9 old.']
S36-PMC3356951	PMC3356951	4/2012	S36-PMC3356951	['[12425] Pregnant and Lactating women who take a Prenatal Vitamin and a Calcium supplement with Vitamin D remain at high RISK for vdd.']	[('IMPORTANT_CONSIDERATION', 120)]	1	[('GO_0007565', 'female pregnancy', 8, 'Pregnant'), ('GO_0007594', 'puparial adhesion', 21, 'lactating'), ('GO_0007565', 'female pregnancy', 48, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 57, 'vitamin'), ('CHEBI_22313', 'alkaline earth metal atom', 71, 'calcium'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]	0	['[12425]  lactating women  vitamin calcium supplement  vdd.']
S17-PMC3366289	PMC3366289	7/2011	S17-PMC3366289	['DEFICIENCY of Thiamine and Vitamin A as well as a high prevalence of anemia HAS BEEN DOCUMENTED in Pregnant and Postpartum women in this population [8–10].']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 76), ('INCOMPLETE_EVIDENCE', 85)]	3	[('CHEBI_26948', 'vitamin B1', 14, 'thiamine'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin A'), ('GO_0007565', 'female pregnancy', 99, 'pregnant'), ('GO_0007565', 'female pregnancy', 112, 'postpartum')]	0	['deficiency thiamine  anemia   women population [8–10].']
S1-PMC3395583	PMC3395583	7/2012	S1-PMC3395583	"['[""""we AIMED TO INVESTIGATE WHETHER season of Birth INFLUENCES the risk of rheumatoid arthritis, crohn\'s disease, ulcerative colitis and systemic lupus erythematosus in addition to multiple sclerosis, and TO EXPLORE the CORRELATION between the risk of id and predicted ultraviolet b (uvb) light exposure and Vitamin D status during Gestation.""""]']"	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('SUPERFICIAL_RELATIONSHIP', 48), ('QUESTION_ANSWERED_BY_THIS_WORK', 201), ('SUPERFICIAL_RELATIONSHIP', 216)]	6	[('GO_0007567', 'parturition', 42, 'birth'), ('CHEBI_27300', 'vitamin D', 304, 'vitamin D'), ('GO_0007565', 'female pregnancy', 328, 'gestation')]	0	"['[""""we season birth rheumatoid arthritis, crohn*s disease, ulcerative colitis systemic lupus erythematosus addition sclerosis, id ultraviolet b (uvb) exposure status duriion.""""]']"
S3-PMC3395583	PMC3395583	7/2012	S3-PMC3395583	"['[""""predicted uvb radiation and Vitamin D status in different time windows during Pregnancy were calculated for each month of Birth and CORRELATED with risk of id using the spearman\'s correlation coefficient.""""]']"	[('SUPERFICIAL_RELATIONSHIP', 132)]	1	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('GO_0007567', 'parturition', 122, 'birth')]	0	"['[""""predicted uvb radiation status durincy month birth id using spearman*s coefficient.""""]']"
S8-PMC3395583	PMC3395583	7/2012	S8-PMC3395583	['Gestational uvb and Vitamin D exposure MAY BE IMPLICATED in the aetiology of id.']	[('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 46)]	2	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]	0	[' uvb  exposure aetiology id.']
S24-PMC3395583	PMC3395583	7/2012	S24-PMC3395583	['since all these conditions HAVE BEEN LINKED to Vitamin D deficiency [23,24], we also TESTED WHETHER the risk of disease by month of Birth follows the same seasonal distribution of predicted ultraviolet b (uvb) light radiation and 25-Hydroxyvitamin D (25-Oh-D) levels during Gestation.']	[('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 37), ('QUESTION_ANSWERED_BY_THIS_WORK', 85), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 92)]	4	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007567', 'parturition', 132, 'birth'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 230, '25-hydroxyvitamin D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 251, '25-OH-D'), ('GO_0007565', 'female pregnancy', 274, 'gestation')]	0	['since conditions  [23,24], disease month birth follows seasonal distribution ultraviolet b (uvb) radiation 25-hydroxyvitamin (25-oh-d) levels .']
S36-PMC3395583	PMC3395583	7/2012	S36-PMC3395583	['average monthly 25-Oh-D levels were collected from a large cohort of Adult scottish and english women (n = 3,787) as previously described [28] and used as a PROXY for the seasonal variation in Gestational Vitamin D status.']	[('SUPERFICIAL_RELATIONSHIP', 157)]	1	[('CHEBI_46744', 'DDT-2,3-dihydrodiol', 16, '25-OH-D'), ('UBERON_0007023', 'adult organism', 69, 'adult'), ('GO_0007565', 'female pregnancy', 193, 'gestational'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]	0	['average monthly 25-oh-d levels adult scottish english women (n = 3,787) [28] seasonal   status.']
S56-PMC3395583	PMC3395583	7/2012	S56-PMC3395583	['we next INVESTIGATED WHETHER the monthly risk of id inversely CORRELATED with PREDICTED Gestational Uvb exposure and Vitamin D status during different Trimesters of Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 21), ('SUPERFICIAL_RELATIONSHIP', 62), ('SUPERFICIAL_RELATIONSHIP', 78)]	4	[('GO_0007565', 'female pregnancy', 88, 'gestational'), ('CHEBI_37043', 'pyrimidine 2*-deoxyribonucleoside 5*-triphosphate', 100, 'UVB'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0043033', 'isoamylase complex', 151, 'trimesters'), ('GO_0007565', 'female pregnancy', 165, 'pregnancy')]	0	['monthly id  uvb exposure  status trimesters .']
S88-PMC3395583	PMC3395583	7/2012	S88-PMC3395583	['this is also the case among Pregnant women, whose Vitamin D status largely DEPENDS on season and follows the same distribution as the levels of the general population [28,42,43].']	[('SUPERFICIAL_RELATIONSHIP', 75)]	1	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]	0	['among  women, whose  status season follows distribution levels population [28,42,43].']
S105-PMC3395583	PMC3395583	7/2012	S105-PMC3395583	['Gestational Vitamin D deficiency APPEARS TO BE a PLAUSIBLE causative agent.']	[('ANOMALY_CURIOUS_FINDING', 33), ('INCOMPLETE_EVIDENCE', 49)]	2	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D')]	0	['  causative agent.']
S33-PMC3403156	PMC3403156	7/2012	S33-PMC3403156	['antioxidant administration of Melatonin or Vitamin C to Pregnant Sheep increased Umbilical vascular [5] and fetal Femoral Artery conductance [4], respectively, by mechanisms ASSOCIATED with increased Nitric Oxide (No) bioavailability following decreased Superoxide Anion levels.']	[('SUPERFICIAL_RELATIONSHIP', 174)]	1	[('CHEBI_25179', 'melanins', 30, 'melatonin'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin C'), ('GO_0007565', 'female pregnancy', 56, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 65, 'sheep'), ('UBERON_0007118', 'umbilicus', 81, 'umbilical'), ('UBERON_0002060', 'femoral artery', 114, 'femoral artery'), ('CHEBI_16480', 'nitric oxide', 200, 'nitric oxide'), ('CHEBI_16382', 'iodide', 214, 'NO'), ('CHEBI_62945', 'thromboxane anion', 254, 'superoxide anion')]	0	['antioxidant administration melatonin   sheep umbilical vascular [5] fetal femoral artery conductance [4], respectively, mechanisms nitric oxide (no) bioavailability following decreased superoxide anion levels.']
S97-PMC3403156	PMC3403156	7/2012	S97-PMC3403156	['Prenatal Vitamin C inhibited the hypoxia-induced increase in fetal Cardiac Hsp70 Expression and Adult Myocardial contractility ASSOCIATED with Β 1 Adrenoceptor stimulation in Rat offspring [36].']	[('SUPERFICIAL_RELATIONSHIP', 127)]	1	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin C'), ('UBERON_0000948', 'heart', 67, 'cardiac'), ('PR_000008794', 'heat shock factor protein 5', 75, 'HSP70'), ('GO_0010467', 'gene expression', 81, 'expression'), ('UBERON_0007023', 'adult organism', 96, 'adult'), ('UBERON_0002349', 'myocardium', 102, 'myocardial'), ('PR_000001595', 'leukotriene B4 receptor 2', 143, 'β 1 adrenoceptor'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 175, 'rat')]	0	['  inhibited hypoxia-induced increase fetal cardiac hsp70 expression adult myocardial contractility β adrenoceptor stimulation rat offspring [36].']
S1-PMC3407995	PMC3407995	7/2012	S1-PMC3407995	['purpose: to highlight the POTENTIAL BENEFITS of maternal supplementation with Docosahexaenoic Acid (Dha) and other IMPORTANT complimentary Nutrients, including Vitamin D, Folic Acid and Iodine during Pregnancy and/or Breast feeding for Foetal and/or infant Brain Development and/or function.']	[('INCOMPLETE_EVIDENCE', 26), ('IMPORTANT_CONSIDERATION', 36), ('IMPORTANT_CONSIDERATION', 115)]	3	[('CHEBI_36003', 'decenoic acid', 78, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 100, 'DHA'), ('CHEBI_33284', 'nutrient', 139, 'nutrients'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('CHEBI_30751', 'formic acid', 171, 'folic acid'), ('CHEBI_24859', 'iodine atom', 186, 'iodine'), ('GO_0007565', 'female pregnancy', 200, 'pregnancy'), ('UBERON_0000310', 'breast', 217, 'breast'), ('GO_0000009', 'alpha-1,6-mannosyltransferase activity', 236, 'foetal ...'), ('GO_0007420', 'brain development', 257, 'brain development'), ('UBERON_0000955', 'brain', 257, 'brain')]	0	['purpose: maternal supplementation docosahexaenoic acid (dha) complimentary nutrients, folic acid iodine  and/or breast feeding foetal and/or infant brain and/or function.']
S13-PMC3407995	PMC3407995	7/2012	S13-PMC3407995	['a review of current literature was UNDERTAKEN to summarize the POTENTIAL benefits of maternal supplementation with Dha, Vitamin D, Folic Acid and Iodine during Pregnancy and/or Breast feeding for Foetal and/or infant Brain Development and/or function.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 35), ('INCOMPLETE_EVIDENCE', 63)]	2	[('CHEBI_17874', 'dihydrozeatin', 115, 'DHA'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_30751', 'formic acid', 131, 'folic acid'), ('CHEBI_24859', 'iodine atom', 146, 'iodine'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy'), ('UBERON_0000310', 'breast', 177, 'breast'), ('GO_0000009', 'alpha-1,6-mannosyltransferase activity', 196, 'foetal ...'), ('GO_0007420', 'brain development', 217, 'brain development'), ('UBERON_0000955', 'brain', 217, 'brain')]	0	['maternal supplementation dha, folic acid iodine  and/or breast feeding foetal and/or infant brain and/or function.']
S16-PMC3407995	PMC3407995	7/2012	S16-PMC3407995	['titles and abstracts were reviewed and reports were selected for inclusion in the review if they were systematic reviews, meta-analyses, randomised controlled trials, cohort studies, cross-sectional or case-control studies and IF they reported BENEFITS and/or harms ASSOCIATED with maternal supplementation with Dha, Vitamin D, Folic Acid or Iodine during Pregnancy and/or Lactation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 227), ('IMPORTANT_CONSIDERATION', 244), ('SUPERFICIAL_RELATIONSHIP', 266)]	3	[('CHEBI_17874', 'dihydrozeatin', 312, 'DHA'), ('CHEBI_27300', 'vitamin D', 317, 'vitamin D'), ('CHEBI_30751', 'formic acid', 328, 'folic acid'), ('CHEBI_24859', 'iodine atom', 342, 'iodine'), ('GO_0007565', 'female pregnancy', 356, 'pregnancy'), ('GO_0007595', 'lactation', 373, 'lactation')]	0	['titles abstracts selected inclusion reviews, meta-analyses, randomised trials, studies, cross-sectional case-control harms maternal supplementation dha, folic acid iodine  and/or lactation.']
S18-PMC3407995	PMC3407995	7/2012	S18-PMC3407995	['data was reviewed and summarized to discuss the RELEVANCE of dietary Dha, Vitamin D, Folic Acid and Iodine to Foetal and infant Brain Development and function, to PRESENT EVIDENCE DEMONSTRATING dietary deficiency of these Nutrients in many populations, to highlight the POTENTIAL benefits of maternal supplementation during Pregnancy and/or Lactation on foetal and/or infant outcomes and to include SAFE Intake RECOMMENDATIONS.']	[('IMPORTANT_CONSIDERATION', 48), ('INCOMPLETE_EVIDENCE', 163), ('INCOMPLETE_EVIDENCE', 180), ('INCOMPLETE_EVIDENCE', 270), ('IMPORTANT_CONSIDERATION', 399), ('FUTURE_WORK', 411)]	6	[('CHEBI_17874', 'dihydrozeatin', 69, 'DHA'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_30751', 'formic acid', 85, 'folic acid'), ('CHEBI_24859', 'iodine atom', 100, 'iodine'), ('GO_0000009', 'alpha-1,6-mannosyltransferase activity', 110, 'foetal ...'), ('GO_0007420', 'brain development', 128, 'brain development'), ('UBERON_0000955', 'brain', 128, 'brain'), ('CHEBI_33284', 'nutrient', 222, 'nutrients'), ('GO_0007565', 'female pregnancy', 324, 'pregnancy'), ('GO_0007595', 'lactation', 341, 'lactation'), ('GO_0007631', 'feeding behavior', 404, 'intake')]	0	['data dietary dha, folic acid iodine foetal infant brain function, dietary nutrients populations, maternal supplementation  and/or lactation foetal and/or infant outcomes intake recommendations.']
S91-PMC3407995	PMC3407995	7/2012	S91-PMC3407995	['in addition, Pregnant women with darker skin pigmentation are at EVEN greater RISK of low Vitamin D status as COMPARED to Pregnant women with lighter skin pigmentation [49].']	[('ANOMALY_CURIOUS_FINDING', 65), ('IMPORTANT_CONSIDERATION', 78), ('ANOMALY_CURIOUS_FINDING', 110)]	3	[('GO_0007565', 'female pregnancy', 13, 'pregnant'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnant')]	0	['addition,  women darker skin pigmentation  status  women lighter skin pigmentation [49].']
S92-PMC3407995	PMC3407995	7/2012	S92-PMC3407995	['Vitamin D is IMPORTANT during Pregnancy to:\nbuild strong Bones—Vitamin D ensures foetal supply of Calcium for strong Bones [45] including those of the Skull.']	[('IMPORTANT_CONSIDERATION', 13)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 30, 'pregnancy'), ('UBERON_0001474', 'bone element', 57, 'bones'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 98, 'calcium'), ('UBERON_0001474', 'bone element', 117, 'bones'), ('UBERON_0003129', 'skull', 151, 'skull')]	0	['vitamin  to:\nbuild bones— foetal supply calcium bones [45] skull.']
S98-PMC3407995	PMC3407995	7/2012	S98-PMC3407995	['promote normal Brain Development—PRELIMINARY RESEARCH SUGGESTS that Gestational Vitamin D insufficiency HAS BEEN LINKED to altered Brain Development and Adult mental health [49], in particular schizophrenia [54].']	[('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 104), ('SUPERFICIAL_RELATIONSHIP', 113)]	4	[('GO_0007420', 'brain development', 15, 'brain development'), ('UBERON_0000955', 'brain', 15, 'brain'), ('GO_0007565', 'female pregnancy', 68, 'gestational'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007420', 'brain development', 131, 'brain development'), ('UBERON_0000955', 'brain', 131, 'brain'), ('UBERON_0007023', 'adult organism', 153, 'adult')]	0	['promote normal brain development—preliminary   altered brain adult mental [49], schizophrenia [54].']
S253-PMC3407995	PMC3407995	7/2012	S253-PMC3407995	['a STUDY in black and white Pregnant women residing in the northern united states FOUND that approximately 29% of black Pregnant women and 5% of white Pregnant women had Vitamin D deficiency (Serum 25(Oh)D less than 37.5 nmol/l); WHEREAS 54% of black women and 47% of white women had Vitamin D insufficiency (defined as Serum 25(Oh)D levels 37.5 to 80 nmol/l) [122].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 81), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 229)]	3	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('GO_0007565', 'female pregnancy', 119, 'pregnant'), ('GO_0007565', 'female pregnancy', 150, 'pregnant'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('UBERON_0001977', 'blood serum', 191, 'serum'), ('CHEBI_71657', 'versiconol acetate', 197, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 197, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D'), ('UBERON_0001977', 'blood serum', 319, 'serum'), ('CHEBI_71657', 'versiconol acetate', 325, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 325, '25 ... OH ... D')]	0	['black white  women residing northern united 29% black  women 5% white  women  (serum 25(oh)d 37.5 nmol/l); 54% black women 47% white women  (defined serum 25(oh)d levels 37.5 80 nmol/l) [122].']
S254-PMC3407995	PMC3407995	7/2012	S254-PMC3407995	['RECENT STUDIES in white Pregnant women also SHOW high prevalence of Vitamin D deficiency in the uk [123] and ireland [124].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 44)]	2	[('GO_0007565', 'female pregnancy', 24, 'pregnant'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]	0	['recent white  women  uk [123] ireland [124].']
S256-PMC3407995	PMC3407995	7/2012	S256-PMC3407995	['seasonal variation increases the risk of Vitamin D deficiency in Pregnancy, with greater prevalence of Vitamin D deficiency during the winter months COMPARED TO the summer months [139].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 149)]	1	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]	0	['seasonal   winter months summer months [139].']
S257-PMC3407995	PMC3407995	7/2012	S257-PMC3407995	['differences in latitude HAVE also BEEN SHOWN to INFLUENCE the concentration of Vitamin D in a majority of Pregnant women [140].']	[('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 48)]	2	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'pregnant')]	0	['differences latitude concentration   women [140].']
S258-PMC3407995	PMC3407995	7/2012	S258-PMC3407995	['a recent review of studies LINKING maternal Vitamin D status during Pregnancy with maternal, foetal and Postnatal outcomes SUPPORTS a ROLE of maternal Vitamin D status, PARTICULARLY early in Pregnancy, in Modulating the risk of Pregnancy complications and in sustaining foetal growth, body composition, Skeletal Development, Immune Maturation and Respiratory health [141].']	[('SUPERFICIAL_RELATIONSHIP', 27), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 134), ('IMPORTANT_CONSIDERATION', 169)]	4	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy'), ('GO_0007567', 'parturition', 104, 'postnatal'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007565', 'female pregnancy', 191, 'pregnancy'), ('GO_0065007', 'biological regulation', 205, 'modulating'), ('GO_0007565', 'female pregnancy', 228, 'pregnancy'), ('GO_0001501', 'skeletal system development', 303, 'skeletal development'), ('UBERON_0004288', 'skeleton', 303, 'skeletal'), ('GO_0050900', 'leukocyte migration', 325, 'immune maturation'), ('UBERON_0002405', 'immune system', 325, 'immune'), ('UBERON_0001004', 'respiratory system', 347, 'respiratory')]	0	['maternal  status  maternal, foetal postnatal outcomes maternal  status,  sustaining foetal growth, composition, skeletal development, immune maturation respiratory [141].']
S260-PMC3407995	PMC3407995	7/2012	S260-PMC3407995	['Miscarriages CAN also result from an increased rate of bacterial vaginosis in the 1st Trimester of Pregnancy that is ASSOCIATED with low Vitamin D status [49].']	[('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 117)]	2	[('GO_0042700', 'luteinizing hormone signaling pathway', 0, 'Miscarriages'), ('GO_0009294', 'DNA mediated transformation', 86, 'trimester'), ('GO_0007565', 'female pregnancy', 99, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]	0	['miscarriages result rate bacterial vaginosis 1st trimester   status [49].']
S261-PMC3407995	PMC3407995	7/2012	S261-PMC3407995	['maternal Vitamin D status early in Pregnancy was ASSOCIATED with risk of low Birth weight and small-for-Gestational age infants in ONE STUDY, WHEREAS another study FOUND this RELATION ONLY among white women [141].']	[('SUPERFICIAL_RELATIONSHIP', 49), ('INCOMPLETE_EVIDENCE', 131), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 142), ('INCOMPLETE_EVIDENCE', 164), ('SUPERFICIAL_RELATIONSHIP', 175), ('ANOMALY_CURIOUS_FINDING', 184), ('INCOMPLETE_EVIDENCE', 184)]	7	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('GO_0007567', 'parturition', 77, 'birth'), ('GO_0007565', 'female pregnancy', 104, 'gestational')]	0	['maternal  status  birth small-for- age infants study, among white women [141].']
S263-PMC3407995	PMC3407995	7/2012	S263-PMC3407995	['evidence from RECENT STUDIES SUGGESTS an early Prenatal INFLUENCE of maternal Vitamin D status on foetal Skeletal Development, with lasting Postnatal EFFECTS [141].']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 56), ('SUPERFICIAL_RELATIONSHIP', 150)]	4	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0001501', 'skeletal system development', 105, 'skeletal development'), ('UBERON_0004288', 'skeleton', 105, 'skeletal'), ('GO_0007567', 'parturition', 140, 'postnatal')]	0	['evidence  maternal  status foetal skeletal development, lasting postnatal [141].']
S264-PMC3407995	PMC3407995	7/2012	S264-PMC3407995	['in addition, one STUDY has SUGGESTED that supplementation during Pregnancy MAY BE NECESSARY to assure adequate concentration of Vitamin D in Breast Milk during Lactation [142].']	[('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 82)]	4	[('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('UBERON_0001348', 'brown adipose tissue', 141, 'breast milk'), ('GO_0007595', 'lactation', 160, 'lactation')]	0	['addition, supplementation  assure concentration  breast milk lactation [142].']
S283-PMC3407995	PMC3407995	7/2012	S283-PMC3407995	['the authors CONCLUDED that Vitamin D deficiency is high among Pregnant urban pakistani women and their newborns and is a PUBLIC HEALTH PROBLEM that NEEDS URGENT ATTENTION [137].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 121), ('IMPORTANT_CONSIDERATION', 135), ('FUTURE_WORK', 148), ('IMPORTANT_CONSIDERATION', 148), ('IMPORTANT_CONSIDERATION', 154), ('FUTURE_WORK', 161)]	7	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnant')]	0	['authors  among  urban pakistani women newborns [137].']
S289-PMC3407995	PMC3407995	7/2012	S289-PMC3407995	['Pregnancy maintenance\na cohort study of 23,423 nulliparous Pregnant women taking part in the norwegian mother and child cohort study FOUND a 27% reduction in risk of Preeclampsia in women taking Vitamin D supplements relative to those who did not take Supplements [145].']	[('INCOMPLETE_EVIDENCE', 133)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 59, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 166, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 252, 'supplements')]	0	[' maintenance\na 23,423 nulliparous  women norwegian mother child 27% reduction preeclampsia women  supplements relative supplements [145].']
S293-PMC3407995	PMC3407995	7/2012	S293-PMC3407995	['THERE IS EVIDENCE that Vitamin D during Pregnancy is INVOLVED in foetal Brain Development and that maternal Vitamin D deficiency during Pregnancy CAN alter the structure and function of the Brain resulting in Life long behavioural changes in the offspring [146,147,148].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 53), ('INCOMPLETE_EVIDENCE', 146)]	3	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 40, 'pregnancy'), ('GO_0007420', 'brain development', 72, 'brain development'), ('UBERON_0000955', 'brain', 72, 'brain'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 136, 'pregnancy'), ('UBERON_0000955', 'brain', 190, 'brain'), ('UBERON_0000104', 'life cycle', 209, 'life')]	0	['  foetal brain maternal   alter structure brain resulting life behavioural changes offspring [146,147,148].']
S302-PMC3407995	PMC3407995	7/2012	S302-PMC3407995	['the authors CONCLUDED that Prenatal Vitamin D supplements in women AT RISK of deficiency COULD reduce the risk of schizophrenia in their offspring [149].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 67), ('INCOMPLETE_EVIDENCE', 89)]	3	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]	0	['authors   supplements women schizophrenia offspring [149].']
S306-PMC3407995	PMC3407995	7/2012	S306-PMC3407995	['studies SHOWING CORRELATION between maternal and foetal Vitamin D status\nfive hundred and six Pregnant women were given 400 iu (10μg) of Vitamin D per day from about the 12th week of Pregnancy until Delivery [150].']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 16)]	2	[('CHEBI_28384', 'vitamin K', 56, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnant'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0007565', 'female pregnancy', 183, 'pregnancy'), ('GO_0007567', 'parturition', 199, 'delivery')]	0	['studies maternal foetal vitamin status\nfive hundred six  women 400 iu (10μg)  day 12th week  delivery [150].']
S312-PMC3407995	PMC3407995	7/2012	S312-PMC3407995	['these results SUGGEST that Vitamin D supplementation during Pregnancy would be beneficial for mothers, whose intake from diet and skin Synthesis is APPRECIABLY less than 500 iu of vitamin d daily.']	[('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 148)]	2	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('GO_0009057', 'macromolecule catabolic process', 135, 'synthesis')]	0	['results  supplementation  mothers, whose intake diet skin synthesis 500 iu vitamin daily.']
S432-PMC3407995	PMC3407995	7/2012	S432-PMC3407995	['Vitamin D\ncurrently there are NO CONSISTENT RECOMMENDATIONS amongst or EVEN within countries for Vitamin D intake during Pregnancy and Lactation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 30), ('FUTURE_WORK', 44), ('ANOMALY_CURIOUS_FINDING', 71)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 121, 'pregnancy'), ('GO_0007595', 'lactation', 135, 'lactation')]	0	['vitamin d\ncurrently amongst countries  intake  lactation.']
S434-PMC3407995	PMC3407995	7/2012	S434-PMC3407995	['in 2011, the us Endocrine task force on Vitamin D STATED that 15 μg (600 iu) daily MAY not be enough to correct Vitamin D deficiency in Pregnant and Lactating women.']	[('INCOMPLETE_EVIDENCE', 50), ('INCOMPLETE_EVIDENCE', 83)]	2	[('UBERON_0005063', 'left ventricular compact myocardium', 16, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007565', 'female pregnancy', 136, 'pregnant'), ('GO_0007594', 'puparial adhesion', 149, 'lactating')]	0	['2011, us endocrine task force  15 μg (600 iu) daily   lactating women.']
S435-PMC3407995	PMC3407995	7/2012	S435-PMC3407995	['their RECOMMENDATION was 37.5–50 μg 1500–2000 iu) per day in Pregnant and Lactating women with Vitamin D deficiency [172].table 1includes RECOMMENDATIONS from various health agencies and governments around the world.Nutrients-04-00799-t001_table 1\n\ncaption (table-wrap): table 1\n\nVitamin D intake RECOMMENDATIONS during Pregnancy and Lactation.agency/governmentrecommendationuk—for the elderly, Pregnant & Lactating women [173]dietary reference values 10 µg/day (400 iu/day)uk department of health 2007—for Pregnant and Lactating women [45]10 µg/day (400 iu/day)uk national institute of health and clinical excellence guideline review panel 2007 [45]all women SHOULD BE informed about the IMPORTANCE for their own and their baby’s health of maintaining adequate Vitamin D stores during Pregnancy and whilst Breast feeding and may choose to take 400 iu/day.canadian paediatric society [45]50 μg/day (2000 iu/day) throughout Pregnancyfederal department of health canada [45]5 μg/day (200 iu/day) for Pregnant and Breast-feeding womeneuropean commission [45]10 μg/day (400 iu/day) during Pregnancyworld health organisation 2004 [45]5 μg/day (200 iu/day) during Pregnancythe institute of medicine us 2010 [172,174]15 μg/day (600 iu/day) in Pregnant and Lactating womenus Endocrine task force on Vitamin D 2011 [174]37.5–50 μg/day (1500–2000 iu) in Pregnant and Lactating women with Vitamin D deficiency.']	[('FUTURE_WORK', 6), ('FUTURE_WORK', 138), ('FUTURE_WORK', 297), ('FUTURE_WORK', 660), ('IMPORTANT_CONSIDERATION', 689)]	5	[('GO_0007565', 'female pregnancy', 61, 'pregnant'), ('GO_0007594', 'puparial adhesion', 74, 'lactating'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_33284', 'nutrient', 216, 'nutrients'), ('CHEBI_28384', 'vitamin K', 280, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 320, 'pregnancy'), ('GO_0007595', 'lactation', 334, 'lactation'), ('GO_0007565', 'female pregnancy', 395, 'pregnant'), ('GO_0007594', 'puparial adhesion', 406, 'lactating'), ('GO_0007565', 'female pregnancy', 507, 'pregnant'), ('GO_0007594', 'puparial adhesion', 520, 'lactating'), ('CHEBI_27300', 'vitamin D', 762, 'vitamin D'), ('GO_0007565', 'female pregnancy', 786, 'pregnancy'), ('UBERON_0000310', 'breast', 807, 'breast'), ('GO_0007565', 'female pregnancy', 923, 'pregnancyFederal'), ('GO_0007565', 'female pregnancy', 998, 'pregnant'), ('UBERON_0000310', 'breast', 1011, 'breast'), ('GO_0014065', 'phosphatidylinositol 3-kinase signaling', 1085, 'pregnancyWorld'), ('GO_0036240', 'septal periplasm', 1158, 'pregnancyThe'), ('GO_0007565', 'female pregnancy', 1236, 'pregnant'), ('GO_0007594', 'puparial adhesion', 1249, 'lactating'), ('GO_0009790', 'embryo development', 1267, 'Endocrine'), ('UBERON_0005063', 'left ventricular compact myocardium', 1267, 'Endocrine'), ('CHEBI_28384', 'vitamin K', 1291, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1291, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1344, 'pregnant'), ('GO_0007594', 'puparial adhesion', 1357, 'lactating'), ('CHEBI_27300', 'vitamin D', 1378, 'vitamin D')]	0	['37.5–50 μg 1500–2000 iu) day  lactating women  [172].table 1includes agencies governments world.nutrients-04-00799-t001_table 1\n\ncaption (table-wrap): table 1\n\nvitamin intake  lactation.agency/governmentrecommendationuk—for elderly,  & lactating women [173]dietary values 10 µg/day (400 iu/day)uk department 2007—for  lactating women [45]10 µg/day (400 iu/day)uk national institute excellence panel 2007 [45]all women baby’s maintaining  stores  breast feeding 400 iu/day.canadian paediatric society [45]50 μg/day (2000 iu/day) throughout  department canada [45]5 μg/day (200 iu/day)  breast-feeding womeneuropean commission [45]10 μg/day (400 iu/day) pregnancyworld organisation 2004 [45]5 μg/day (200 iu/day) pregnancythe institute medicine us 2010 [172,174]15 μg/day (600 iu/day)  lactating womenus endocrine task force vitamin 2011 [174]37.5–50 μg/day (1500–2000 iu)  lactating women  deficiency.']
S436-PMC3407995	PMC3407995	7/2012	S436-PMC3407995	['a RECENT cochrane review ASSESSED the EFFECTS and SAFETY of Vitamin D supplementation in Pregnancy and EXAMINED WHETHER supplementation with Vitamin D alone OR in combination with Calcium and other Vitamins and Minerals given to women during Pregnancy COULD SAFELY improve Pregnancy outcomes [175].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 25), ('SUPERFICIAL_RELATIONSHIP', 38), ('IMPORTANT_CONSIDERATION', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 103), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('INCOMPLETE_EVIDENCE', 252), ('IMPORTANT_CONSIDERATION', 258)]	8	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 180, 'calcium'), ('CHEBI_33277', 'gamma-tocotrienol', 198, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 211, 'minerals'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy'), ('GO_0007565', 'female pregnancy', 273, 'pregnancy')]	0	[' supplementation  supplementation  combination calcium vitamins minerals women   outcomes [175].']
S438-PMC3407995	PMC3407995	7/2012	S438-PMC3407995	['data from four trials involving 414 women CONSISTENTLY SHOWED that women who received Vitamin D supplements during Pregnancy had higher concentrations of Vitamin D in Serum at term than those women who received no intervention or a placebo; HOWEVER the magnitude of the response was highly heterogenous.']	[('PROBABLE_UNDERSTANDING', 42), ('INCOMPLETE_EVIDENCE', 55), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 241)]	3	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('UBERON_0001977', 'blood serum', 167, 'serum')]	0	['data four 414 women women received  supplements  higher concentrations  serum term women received placebo; magnitude response heterogenous.']
S442-PMC3407995	PMC3407995	7/2012	S442-PMC3407995	['the authors CONCLUDED that Vitamin D supplementation in a single or continued dose during Pregnancy increases Serum Vitamin D concentrations.']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('UBERON_0001977', 'blood serum', 110, 'serum'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]	0	['authors  supplementation single dose  serum  concentrations.']
S445-PMC3407995	PMC3407995	7/2012	S445-PMC3407995	['RECENTLY, a randomized, controlled trial, including 350 women with a singleton Pregnancy at 12 to 16 weeks’ Gestation supplemented with 400 (10 μg), 2000 (50 μg), or 4000 iu (100 μg) of Vitamin D per day until Delivery.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('GO_0007565', 'female pregnancy', 108, 'gestation'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('GO_0007567', 'parturition', 210, 'delivery')]	0	['recently, randomized, trial, 350 women singleton  12 16 weeks’  supplemented 400 (10 μg), 2000 (50 μg), 4000 iu (100 μg)  day delivery.']
S449-PMC3407995	PMC3407995	7/2012	S449-PMC3407995	['the authors CONCLUDED that Vitamin D supplementation of 4000 iu/day for Pregnant women is SAFE and MOST EFFECTIVE in achieving sufficiency in all women and their neonates regardless of race, WHEREAS the current ESTIMATED average REQUIREMENT is comparatively ineffective at achieving adequate circulating 25(Oh)D concentrations, especially in african americans [179].']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 90), ('PROBABLE_UNDERSTANDING', 99), ('SUPERFICIAL_RELATIONSHIP', 104), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 191), ('INCOMPLETE_EVIDENCE', 211), ('IMPORTANT_CONSIDERATION', 229)]	7	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 304, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 304, '25(OH)D')]	0	['authors  supplementation 4000 iu/day  women achieving women neonates race, average comparatively ineffective achieving circulating 25(oh)d concentrations, african americans [179].']
S486-PMC3407995	PMC3407995	7/2012	S486-PMC3407995	['epidemiological studies have LINKED low maternal Vitamin D status to SEVERE Preeclampsia resulting in Miscarriage, risk of low Birth weight and small-for-Gestational age infants, neonatal hypocalcaemia with seizures and POSSIBLE INVOLVEMENT in the development of schizophrenia.']	[('SUPERFICIAL_RELATIONSHIP', 29), ('IMPORTANT_CONSIDERATION', 69), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 229)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 76, 'preeclampsia'), ('GO_0046660', 'female sex differentiation', 102, 'miscarriage'), ('GO_0007567', 'parturition', 127, 'birth'), ('GO_0007565', 'female pregnancy', 154, 'gestational')]	0	['epidemiological maternal  status preeclampsia resulting miscarriage, birth small-for- age infants, neonatal hypocalcaemia seizures schizophrenia.']
S42-PMC3409554	PMC3409554	7/2012	S42-PMC3409554	['calf and pork Liver have a high content of Iron with a good bioavailability, but the danish health authorities ADVISE Pregnant women not to consume pork Liver and pork Liver paté due to the high content of Vitamin A, which POSSIBLY MAY cause malformations in the fetus [18].']	[('FUTURE_WORK', 111), ('INCOMPLETE_EVIDENCE', 223), ('INCOMPLETE_EVIDENCE', 232)]	3	[('UBERON_0002107', 'liver', 14, 'liver'), ('CHEBI_24870', 'ion', 43, 'iron'), ('GO_0007565', 'female pregnancy', 118, 'pregnant'), ('UBERON_0002107', 'liver', 153, 'liver'), ('UBERON_0002107', 'liver', 168, 'liver'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin A')]	0	['calf pork liver content iron bioavailability, danish authorities  women consume pork liver pork liver paté content malformations fetus [18].']
S13-PMC3411795	PMC3411795	8/2012	S13-PMC3411795	['in particular those Animal MODELS that HAVE BEEN developed specifically to address KNOWN epidemiological risk factors for schizophrenia, such as Prenatal Vitamin D deficiency or Prenatal infection, reveal very early changes in Da Development[9],[10],[11],[12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 27), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 39), ('INCOMPLETE_EVIDENCE', 83)]	4	[('NCBITaxon_33208', 'Metazoa', 20, 'animal'), ('GO_0007565', 'female pregnancy', 145, 'prenatal'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'prenatal'), ('GO_0060539', 'diaphragm development', 227, 'DA development')]	0	['animal epidemiological schizophrenia,    infection, changes da development[9],[10],[11],[12].']
S66-PMC3417531	PMC3417531	7/2012	S66-PMC3417531	"['[""""(91)childreninfectious diseasehigh rate of simkania negevensis among canadian inuit infants hospitalized with Lower Respiratory Tract infections (92)childrennutritioniron deficiency and anaemia prevalence and ASSOCIATED etiologic RISK FACTORS in first nations and inuit communities in northern ontario and nunavut (93)childrennutritionfood insecurity among inuit preschoolers: nunavut inuit child health survey, 2007–2008 (59)childrennutritionvitamin D status of inuit preschoolers reflects season and Vitamin D intake (56)childrenenvironment/environmental exposures; infectious diseaseeffect of Prenatal exposure to Polychlorinated Biphenyls on incidence of acute Respiratory infections in preschool inuit children (25)childrenchronic disease; interventions/programmingthe benefits of sound field amplification in classrooms of inuit students of nunavik: a pilot project (73)childrensocial DETERMINANTS of health; tobaccocultural, socioeconomic, and health indicators among inuit preschoolers: nunavut inuit child health survey, 2007–2008 (9)childreninfectious disease; tobaccoindoor air quality and the risk of Lower Respiratory Tract infections in young canadian inuit children (41)childreninfectious disease; interventions/programmingheat recovery ventilators prevent Respiratory disorders in inuit children (40)childrengenetics; nutritionadaptation of inuit children to a low-calcium diet (83)childreninfectious disease; health care, policy, Human resourcesbronchiolitis in inuit children from a canadian central arctic community, 1995–1996 (69)youthchronic diseasecauses and CONTRIBUTIONS to differences in Life expectancy for inuit nunangat and canada, 1994–2003 (82)youthinfectious diseaseotitis media and Hearing loss among 12–16 year-old inuit of inukjuak, quebec, canada (35)youthinjuryinjury mortality risk assessment and targeting the subpopulations for prevention in the northwest territories, canada (86)youthnutritionage differences in Vitamin A intake among canadian inuit (55)youthmental health and wellbeingcompleted suicides among the inuit of northern quebec, 1982–1996: a case-control study (77)youthmental health and wellbeing; social determinants of healthsuicidality in a sample of arctic households (76)youthinfectious disease; interventions/programminghiv testing experiences of aboriginal youth in canada: service IMPLICATIONS (74)youthinfections disease; social determinants of healthdeterminants of Sexually Transmitted infections among canadian inuit adolescent populations (30)youthinfections disease; mental health and wellbeingyouth sexual health in nunavut: a needs-based survey of knowledge, attitudes and behaviour (31)maternalbirth outcomesreclaiming Birth, health, and community: midwifery in the inuit villages of nunavik, canada (68)maternalenvironment/environmental exposuresorganochlorine levels in maternal and Umbilical Cord Blood Plasma in arctic canada (49)maternalenvironment/environmental exposuresexposure of the inuit population of nunavik (arctic quebec) to lead and mercury (48)maternalnutritiondietary assessment of indigenous canadian arctic women with a focus on Pregnancy and Lactation (54)maternalnutritioncontribution of selected traditional and market Foods to the diet of nunavik inuit women (57)maternalbirth outcomes; tobaccomaternal smoking at first Prenatal visit as a MARKER of risk for adverse Pregnancy outcomes in the qikiqtaaluk (baffin) region (8)maternalnutrition; environment/environmental exposuresfish Consumption and Blood Lipids in 3 ethnic groups of quebec (canada) (51)maternalhealth care, policy, Human resources; Birth outcomesconverging epistemologies: CRITICAL ISSUES in canadian inuit Childbirth and Pregnancy (65)maternalenvironment/environmental exposures; nutritiondeterminants of Polychlorinated Biphenyls and Methylmercury exposure in inuit women of Childbearing age (50)maternalhealth care, policy, Human resources; interventions/programmingthe outcome of Perinatal Care in inukjuak, nunavik, canada 1998–2002 (70)maternalhealth care, policy, Human resources; Birth outcomesthe inuulitsivik maternities: culturally appropriate midwifery and epistemological accommodation (66)maternalinfectious disease; interventions/programmingoncogenic human papillomavirus infection and Cervical lesions in aboriginal women in nunavut, canada (94)maternalchronic disease; social determinants of health; tobacco; mental health and Wellbeingthe health of cree, inuit and southern quebec women: similarities and differences (79)maternalnutrition; social DETERMINANTS of health; environment/environmental exposuresfood insecurity among inuit women exacerbated by socioeconomic stresses and climate change (60)children; youthchronic diseasethe RELATIONSHIP between socio-economic and geographic factors and asthma among canada\'s aboriginal populations (81)children; youthinfectious diseasehospitalization due to pneumonia among innu, inuit and non-aboriginal communities, newfoundland and labrador, canada (24)children; maternalbirth outcomesheart defects and other malformations in the inuit in canada: a baseline study (62)children; maternalbirth outcomesbirth outcomes in the inuit-inhabited areas of canada (95)children; maternalbirth outcomesdegree of rural isolation and Birth outcomes (63)children; maternalbirth outcomesrisks of adverse Pregnancy outcomes among inuit and north american indian women in quebec, 1985–97 (64)children; maternalenvironment/environmental exposuresprenatal exposure to Methylmercury and Pcbs AFFECTS distinct stages of information processing: an event-related POTENTIAL study with inuit children (44)children; maternalenvironment/environmental exposuresthe RELATION of lead neurotoxicity to the event-related potential p3b component in inuit children from arctic quebec (47)children; maternalenvironment/environmental exposuresthyroid hormone levels of Pregnant inuit women and their infants exposed to environmental contaminants (96)children; maternalenvironment/environmental exposuresneuromotor functions in inuit preschool children exposed to Pb, Pcbs, and hg (43)children; maternalenvironment/environmental exposuresbeneficial EFFECTS of a polyunsaturated Fatty Acid on infant development: EVIDENCE from the inuit of arctic quebec (52)children; maternalenvironment/environmental exposuresthe RELATION of environmental contaminants exposure to behavioural indicators in inuit preschoolers in arctic quebec (46)children; maternalinfectious diseaseneonatal Vitamin A deficiency and its IMPACT on acute Respiratory infections among preschool inuit children (33)children; maternalnutritionanaemia and iron status in inuit infants from northern quebec (97)children; maternalbirth outcomes; nutritioncongenital Heart defects in canadian inuit: is more Folic Acid making a difference?""""]']"	[('SUPERFICIAL_RELATIONSHIP', 209), ('SUPERFICIAL_RELATIONSHIP', 230), ('SUPERFICIAL_RELATIONSHIP', 891), ('SUPERFICIAL_RELATIONSHIP', 1581), ('IMPORTANT_CONSIDERATION', 2342), ('SUPERFICIAL_RELATIONSHIP', 3334), ('IMPORTANT_CONSIDERATION', 3635), ('IMPORTANT_CONSIDERATION', 3644), ('SUPERFICIAL_RELATIONSHIP', 4527), ('SUPERFICIAL_RELATIONSHIP', 4715), ('SUPERFICIAL_RELATIONSHIP', 5499), ('INCOMPLETE_EVIDENCE', 5567), ('SUPERFICIAL_RELATIONSHIP', 5664), ('SUPERFICIAL_RELATIONSHIP', 6139), ('INCOMPLETE_EVIDENCE', 6202), ('SUPERFICIAL_RELATIONSHIP', 6304), ('SUPERFICIAL_RELATIONSHIP', 6495), ('EXPLICIT_QUESTION', 6787)]	18	[('UBERON_0004905', 'articulation', 110, 'lower respiratory tract'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 451, 'D'), ('CHEBI_27300', 'vitamin D', 502, 'vitamin D'), ('GO_0007565', 'female pregnancy', 596, 'prenatal'), ('CHEBI_53421', 'poly(oxymethylene) macromolecule', 617, 'polychlorinated biphenyls'), ('UBERON_0001004', 'respiratory system', 665, 'respiratory'), ('UBERON_0004905', 'articulation', 1113, 'lower respiratory tract'), ('UBERON_0001004', 'respiratory system', 1272, 'respiratory'), ('NCBITaxon_9606', 'Homo sapiens', 1447, 'human'), ('UBERON_0000104', 'life cycle', 1613, 'life'), ('GO_0007605', 'sensory perception of sound', 1714, 'hearing'), ('CHEBI_27300', 'vitamin D', 1952, 'vitamin A'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 2429, 'sexually transmitted'), ('GO_0007567', 'parturition', 2689, 'birth'), ('UBERON_0002331', 'umbilical cord', 2855, 'umbilical cord'), ('UBERON_0000178', 'blood', 2870, 'blood'), ('UBERON_0001969', 'blood plasma', 2876, 'plasma'), ('GO_0007565', 'female pregnancy', 3119, 'pregnancy'), ('GO_0007595', 'lactation', 3133, 'lactation'), ('CHEBI_33290', 'food', 3212, 'foods'), ('GO_0007565', 'female pregnancy', 3314, 'prenatal'), ('GO_0007565', 'female pregnancy', 3361, 'pregnancy'), ('GO_0007631', 'feeding behavior', 3477, 'consumption'), ('UBERON_0000178', 'blood', 3493, 'blood'), ('CHEBI_18059', 'lipid', 3499, 'lipids'), ('NCBITaxon_9606', 'Homo sapiens', 3577, 'human'), ('GO_0007567', 'parturition', 3594, 'birth'), ('GO_0007623', 'circadian rhythm', 3669, 'childbirth'), ('GO_0007565', 'female pregnancy', 3684, 'pregnancy'), ('CHEBI_53421', 'poly(oxymethylene) macromolecule', 3768, 'polychlorinated biphenyls'), ('CHEBI_33963', 'metallocene', 3798, 'methylmercury'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 3839, 'childbearing'), ('NCBITaxon_9606', 'Homo sapiens', 3889, 'human'), ('GO_0036356', 'cyclic 2,3-diphosphoglycerate synthetase activity', 3946, 'perinatal care'), ('UBERON_0012101', 'perinatal stage', 3946, 'perinatal'), ('NCBITaxon_9606', 'Homo sapiens', 4033, 'human'), ('GO_0007567', 'parturition', 4050, 'birth'), ('UBERON_0005434', 'cervical region', 4263, 'cervical'), ('GO_0035706', 'T-helper 1 cell chemotaxis', 4406, 'wellbeingThe'), ('GO_0007567', 'parturition', 5248, 'birth'), ('GO_0007565', 'female pregnancy', 5316, 'pregnancy'), ('CHEBI_33963', 'metallocene', 5476, 'methylmercury'), ('CHEBI_26199', 'polyprenol', 5494, 'PCBs'), ('GO_0007565', 'female pregnancy', 5860, 'pregnant'), ('CHEBI_37983', 'sulfur-35 atom', 6054, 'Pb'), ('CHEBI_26199', 'polyprenol', 6058, 'PCBs'), ('CHEBI_35366', 'fatty acid', 6168, 'fatty acid'), ('CHEBI_27300', 'vitamin D', 6466, 'vitamin A'), ('UBERON_0001004', 'respiratory system', 6511, 'respiratory'), ('UBERON_0000948', 'heart', 6716, 'heart'), ('CHEBI_30751', 'formic acid', 6757, 'folic acid')]	0	"['[""""(91)childreninfectious diseasehigh rate simkania negevensis among canadian inuit infants hospitalized respiratory tract infections (92)childrennutritioniron anaemia etiologic nations inuit communities northern ontario nunavut (93)childrennutritionfood among inuit preschoolers: nunavut inuit child survey, 2007–2008 (59)childrennutritionvitamin status inuit preschoolers season intake (56)childrenenvironment/environmental exposures; infectious diseaseeffect tal exposure polychlorinated biphenyls acute respiratory infections preschool inuit children (25)childrenchronic disease; interventions/programmingthe amplification classrooms inuit students nunavik: (73)childrensocial health; tobaccocultural, socioeconomic, among inuit preschoolers: nunavut inuit child survey, 2007–2008 (9)childreninfectious disease; tobaccoindoor air respiratory tract infections young canadian inuit children (41)childreninfectious disease; interventions/programmingheat recovery ventilators respiratory disorders inuit children (40)childrengenetics; nutritionadaptation inuit children low-calcium diet (83)childreninfectious disease; care, policy, human resourcesbronchiolitis inuit children canadian central arctic community, 1995–1996 (69)youthchronic diseasecauses life expectancy inuit nunangat canada, 1994–2003 (82)youthinfectious diseaseotitis media hearing loss among 12–16 year-old inuit inukjuak, quebec, canada (35)youthinjuryinjury mortality subpopulations northwest territories, canada (86)youthnutritionage n intake among canadian inuit (55)youthmental wellbeingcompleted suicides among inuit northern quebec, 1982–1996: case-control (77)youthmental wellbeing; social healthsuicidality sample arctic households (76)youthinfectious disease; interventions/programminghiv testing experiences aboriginal youth canada: service (74)youthinfections disease; social healthdeterminants sexually transmitted infections among canadian inuit adolescent populations (30)youthinfections disease; mental wellbeingyouth sexual nunavut: needs-based survey knowledge, attitudes behaviour (31)maternalbirth outcomesreclaiming birth, health, community: midwifery inuit villages nunavik, canada (68)maternalenvironment/environmental exposuresorganochlorine levels maternal umbilical cord blood plasma arctic canada (49)maternalenvironment/environmental exposuresexposure inuit population nunavik (arctic quebec) mercury (48)maternalnutritiondietary indigenous canadian arctic women ncy lactation (54)maternalnutritioncontribution selected market foods diet nunavik inuit women (57)maternalbirth outcomes; tobaccomaternal smoking firtal visit adverncy outcomes qikiqtaaluk (baffin) region (8)maternalnutrition; environment/environmental exposuresfish consumption blood lipids 3 ethnic quebec (canada) (51)maternalhealth care, policy, human resources; birth outcomesconverging epistemologies: canadian inuit childbirth ancy (65)maternalenvironment/environmental exposures; nutritiondeterminants polychlorinated biphenyls methylmercury exposure inuit women childbearing age (50)maternalhealth care, policy, human resources; interventions/programmingthe outcome perinatal inukjuak, nunavik, canada 1998–2002 (70)maternalhealth care, policy, human resources; birth outcomesthe inuulitsivik maternities: culturally midwifery epistemological accommodation (66)maternalinfectious disease; interventions/programmingoncogenic human papillomavirus infection cervical lesions aboriginal women nunavut, canada (94)maternalchronic disease; social health; tobacco; mental wellbeingthe cree, inuit southern quebec women: (79)maternalnutrition; social health; environment/environmental exposuresfood among inuit women exacerbated socioeconomic climate (60)children; youthchronic diseasethe socio-economic geographic asthma among canada*s aboriginal populations (81)children; youthinfectious diseasehospitalization pneumonia among innu, inuit non-aboriginal communities, newfoundland labrador, canada (24)children; maternalbirth outcomesheart defects malformations inuit canada: baseline (62)children; maternalbirth outcomesbirth outcomes inuit-inhabited canada (95)children; maternalbirth outcomesdegree rural isolation birth outcomes (63)children; maternalbirth outcomesrisks adverncy outcomes among inuit north american indian women quebec, 1985–97 (64)children; maternalenvironment/environmental exposuresprenatal exposure methylmercury pcbs stages processing: event-related inuit children (44)children; maternalenvironment/environmental exposuresthe neurotoxicity event-related p3b inuit children arctic quebec (47)children; maternalenvironment/environmental exposuresthyroid hormone levels ant inuit women infants exposed environmental (96)children; maternalenvironment/environmental exposuresneuromotor functions inuit preschool children exposed pb, pcbs, hg (43)children; maternalenvironment/environmental exposuresbeneficial polyunsaturated fatty acid infant development: inuit arctic quebec (52)children; maternalenvironment/environmental exposuresthe environmental exposure behavioural inuit preschoolers arctic quebec (46)children; maternalinfectious diseaseneonatn acute respiratory infections among preschool inuit children (33)children; maternalnutritionanaemia iron status inuit infants northern quebec (97)children; maternalbirth outcomes; nutritioncongenital defects canadian inuit: folic acid difference?""""]']"
S164-PMC3424155	PMC3424155	8/2012	S164-PMC3424155	['discussion\nmicronutrient deficiency during development, such as maternal Vitamin D deficiency, is a subject of increasing IMPORTANCE BECAUSE of the nutritional deficiencies caused by excessive consumption of junk Food during Pregnancy.']	[('IMPORTANT_CONSIDERATION', 122), ('PROBABLE_UNDERSTANDING', 133)]	2	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_33290', 'food', 213, 'food'), ('GO_0007565', 'female pregnancy', 225, 'pregnancy')]	0	['discussion\nmicronutrient development, maternal  deficiency, subject nutritional excessive consumption junk food .']
S166-PMC3424155	PMC3424155	8/2012	S166-PMC3424155	['a RECENT STUDY of Pregnant women in europe REPORTED that ONLY 12% had an OPTIMAL level of Vitamin D[20].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 43), ('ANOMALY_CURIOUS_FINDING', 57), ('IMPORTANT_CONSIDERATION', 73)]	4	[('GO_0007565', 'female pregnancy', 18, 'pregnant'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]	0	[' women europe 12% [20].']
S169-PMC3424155	PMC3424155	8/2012	S169-PMC3424155	['furthermore, NOT ONLY the f1 generation BUT ALSO the f2 generation was AFFECTED by the Gestational Vitamin D deficiency of the f0 generation Mice.']	[('ANOMALY_CURIOUS_FINDING', 13), ('SUPERFICIAL_RELATIONSHIP', 71)]	2	[('GO_0007565', 'female pregnancy', 87, 'gestational'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 141, 'mice')]	0	['furthermore, f1 generation f2 generation   f0 generation mice.']
S171-PMC3424155	PMC3424155	8/2012	S171-PMC3424155	['PREVIOUS STUDIES in rodents HAVE SHOWN that the restriction of Vitamin D for a period of six weeks prior to Mating assures Vitamin D deficiency during Pregnancy[13],[22].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 28)]	2	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007618', 'mating', 108, 'mating'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy')]	0	['previous rodents  period six weeks mating assures  [13],[22].']
S172-PMC3424155	PMC3424155	8/2012	S172-PMC3424155	['Vitamin D deficiency during the third Trimester of Pregnancy in Humans HAS BEEN ASSOCIATED with Cardiovascular disease, diabetes and obesity in offspring[23], which COULD BE LINKED to the POTENTIAL ROLE of Vitamin D in the Regulation Of Adiposity[24],[25].']	[('INCOMPLETE_EVIDENCE', 71), ('SUPERFICIAL_RELATIONSHIP', 80), ('INCOMPLETE_EVIDENCE', 165), ('SUPERFICIAL_RELATIONSHIP', 174), ('INCOMPLETE_EVIDENCE', 188), ('SUPERFICIAL_RELATIONSHIP', 198), ('SUPERFICIAL_RELATIONSHIP', 223)]	7	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0009294', 'DNA mediated transformation', 38, 'trimester'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy'), ('NCBITaxon_9606', 'Homo sapiens', 64, 'humans'), ('UBERON_0004535', 'cardiovascular system', 96, 'cardiovascular'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0045752', 'positive regulation of Toll signaling pathway', 223, 'regulation of adiposity')]	0	['vitamin third trimester  humans cardiovascular disease, diabetes obesity offspring[23],  adiposity[24],[25].']
S22-PMC3427192	PMC3427192	4/2012	S22-PMC3427192	['WHILE SOME STUDIES quantified maternal dietary Intake of Vitamin D during the final Trimester of Pregnancy, others measured Vitamin D levels within the Plasma and whole Blood of Pregnant women (table 1).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6)]	2	[('GO_0007631', 'feeding behavior', 47, 'intake'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 84, 'trimester'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 152, 'plasma'), ('UBERON_0000178', 'blood', 169, 'blood'), ('GO_0007565', 'female pregnancy', 178, 'pregnant')]	0	['quantified maternal dietary intake  final trimester  levels plasma whole blood  women (table 1).']
S24-PMC3427192	PMC3427192	4/2012	S24-PMC3427192	['it is also IMPORTANT TO NOTE that ASSOCIATIONS between Prenatal Vitamin D exposure, wheezing and subsequent asthma have NOT BEEN CONSISTENT across studies.']	[('IMPORTANT_CONSIDERATION', 11), ('SUPERFICIAL_RELATIONSHIP', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 120)]	3	[('GO_0007565', 'female pregnancy', 55, 'prenatal'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]	0	['  exposure, wheezing asthma studies.']
S28-PMC3427192	PMC3427192	4/2012	S28-PMC3427192	['studies of Vitamin D exposure in early Life and Respiratory outcomesauthoryearcountrystudy designsample sizeage of children at assessmentdetermination of Vitamin D statusassociation between Vitamin D and Respiratory outcomesbelderbos572011netherlandsprospective cohort156 neonatesbirth to 1 ymaternal Food-frequency questionnaire and Cord Blood 25(Oh)Dlower 25(Oh)D concentrations ASSOCIATED with an increased risk of Respiratory syncytial Virus infectioncamargo582007united statesprospective cohort1194 mother-child dyads3 ymaternal Food-frequency questionnairehighest quartile of Vitamin D intake during Pregnancy ASSOCIATED with a lower risk of recurrent wheezingcamargo592011new zealandprospective cohort922 newbornsbirth to 5 ycord Blood 25(Oh)Dhigher 25(Oh)D ASSOCIATED with a decreased risk of Respiratory infection and wheezing BUT NO associations with childhood asthma NOTEDCARROLL602011CANADACROSS-sectional340 mother-infant dyads5–29 weeksmaternal whole Blood 25(Oh)Dincreasing maternal 25(Oh)D ASSOCIATED with decreased odds of asthma in mothers BUT no associations with infantile wheezing noteddevereux612007scotlandprospective cohort2000 Pregnant women, 1212 children5 ymaternal Food-frequency questionnairehighest and lowest maternal Vitamin D intakes ASSOCIATED with lower risk of wheezingerkkola622009finlandprospective cohort1669 mother-child dyads5 ymaternal Food-frequency questionnairehigher maternal Vitamin D intake ASSOCIATED with lower risk of asthma and allergic rhinitisgale632008ukprospective cohort466 mothers and 178 children9 mo and 9 ymaternal Serum 25(Oh)Dmaternal Vitamin D levels > 75 nmol/l ASSOCIATED with increased risk of atopic dermatitis and asthmamiyake642010japanprospective cohort763 mother-child dyads16–24 momaternal Food-frequency questionnairehigher maternal Vitamin D intake ASSOCIATED with a decreased risk of wheeze and atopic dermatitismorales652012spainprospective cohort1724 children12 mo, 4–6 ymaternal plasma 25(Oh)Dincreased maternal 25(Oh)D ASSOCIATED with a decreased risk of lower Respiratory infections BUT NOT wheezing or asthmarothers662011united statesprospective cohort219 childrenbirth to 5 ycord Blood 25(Oh)Dboth low and high Cord Blood 25(Oh)D ASSOCIATED with increased Aeroallergen sensitization BUT NOT with allergic rhinitis or asthma\nin other Birth cohort studies where 25(Oh)D concentrations were measured in the Plasma and whole Blood of Pregnant women, median 25(Oh)D concentrations ranged from APPROXIMATELY 20 to 29.5 ng/ml.60,63,65a 50% decrease in the odds of maternal asthma was FURTHER OBSERVED with every 35 nmol/l increase in 25(Oh)D levels, SUGGESTING a POSSIBLE LINK between Vitamin D status and asthma during Pregnancy.60HOWEVER, similar to the studies of maternal Vitamin D intake, NO CONSISTENT RELATIONSHIPS between 25(Oh)D concentrations and Respiratory symptoms during childhood HAVE BEEN observed.']	[('SUPERFICIAL_RELATIONSHIP', 381), ('SUPERFICIAL_RELATIONSHIP', 616), ('SUPERFICIAL_RELATIONSHIP', 765), ('ANOMALY_CURIOUS_FINDING', 836), ('ANOMALY_CURIOUS_FINDING', 878), ('SUPERFICIAL_RELATIONSHIP', 1006), ('ANOMALY_CURIOUS_FINDING', 1058), ('SUPERFICIAL_RELATIONSHIP', 1267), ('SUPERFICIAL_RELATIONSHIP', 1439), ('SUPERFICIAL_RELATIONSHIP', 1627), ('SUPERFICIAL_RELATIONSHIP', 1824), ('SUPERFICIAL_RELATIONSHIP', 1999), ('ANOMALY_CURIOUS_FINDING', 2064), ('SUPERFICIAL_RELATIONSHIP', 2213), ('ANOMALY_CURIOUS_FINDING', 2266), ('INCOMPLETE_EVIDENCE', 2471), ('INCOMPLETE_EVIDENCE', 2560), ('INCOMPLETE_EVIDENCE', 2568), ('INCOMPLETE_EVIDENCE', 2626), ('INCOMPLETE_EVIDENCE', 2639), ('SUPERFICIAL_RELATIONSHIP', 2648), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2706), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2770), ('SUPERFICIAL_RELATIONSHIP', 2784), ('INCOMPLETE_EVIDENCE', 2871)]	25	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0000104', 'life cycle', 39, 'life'), ('UBERON_0001004', 'respiratory system', 48, 'respiratory'), ('CHEBI_28384', 'vitamin K', 154, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 204, 'respiratory'), ('CHEBI_33290', 'food', 301, 'food'), ('UBERON_0002240', 'spinal cord', 334, 'cord'), ('UBERON_0000178', 'blood', 339, 'blood'), ('CHEBI_78858', '(R)-2-methylpyrrolidine', 345, '25(OH)DLower'), ('CHEBI_71657', 'versiconol acetate', 358, '25(OH)D'), ('UBERON_0001004', 'respiratory system', 418, 'respiratory'), ('NCBITaxon_1', 'root', 440, 'virus'), ('CHEBI_33290', 'food', 534, 'food'), ('CHEBI_27300', 'vitamin D', 582, 'vitamin D'), ('GO_0007565', 'female pregnancy', 606, 'pregnancy'), ('UBERON_0000178', 'blood', 737, 'blood'), ('CHEBI_72842', '9-oxo-ODE', 743, '25(OH)DHigher'), ('CHEBI_71657', 'versiconol acetate', 757, '25(OH)D'), ('UBERON_0001004', 'respiratory system', 801, 'respiratory'), ('UBERON_0000178', 'blood', 965, 'blood'), ('CHEBI_74350', 'N-diazoacetylnorleucine methyl ester', 971, '25(OH)DIncreasing'), ('PR_000011614', 'opioid growth factor receptor', 974, 'OH'), ('PR_000006449', 'diacylglycerol kinase kappa', 977, 'DIncreasing'), ('CHEBI_71657', 'versiconol acetate', 998, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 998, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 1152, 'pregnant'), ('CHEBI_33290', 'food', 1193, 'food'), ('CHEBI_27300', 'vitamin D', 1249, 'vitamin D'), ('CHEBI_33290', 'food', 1378, 'food'), ('CHEBI_27300', 'vitamin D', 1422, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1576, 'serum'), ('CHEBI_51469', 'butyllithium', 1582, '25(OH)DMaternal'), ('CHEBI_27300', 'vitamin D', 1598, 'vitamin D'), ('CHEBI_33290', 'food', 1763, 'food'), ('CHEBI_27300', 'vitamin D', 1807, 'vitamin D'), ('CHEBI_86378', '(25R)-3beta-hydroxycholest-5-en-26-oic acid', 1965, '25(OH)DIncreased'), ('PR_000011040', 'nuclear receptor coactivator 1', 1967, '(OH'), ('CHEBI_71657', 'versiconol acetate', 1991, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1991, '25(OH ... D'), ('UBERON_0001004', 'respiratory system', 2041, 'respiratory'), ('UBERON_0000178', 'blood', 2163, 'blood'), ('CHEBI_73803', 'Ala-Asp', 2169, '25(OH)DBoth'), ('UBERON_0002240', 'spinal cord', 2194, 'cord'), ('UBERON_0000178', 'blood', 2199, 'blood'), ('CHEBI_71657', 'versiconol acetate', 2205, '25(OH)D'), ('CHEBI_2500', 'Aescin', 2239, 'aeroallergen'), ('GO_0007567', 'parturition', 2316, 'birth'), ('CHEBI_71657', 'versiconol acetate', 2343, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 2387, 'plasma'), ('UBERON_0000178', 'blood', 2404, 'blood'), ('GO_0007565', 'female pregnancy', 2413, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 2436, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 2610, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 2616, 'D'), ('CHEBI_27300', 'vitamin D', 2661, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2696, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 2752, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 2806, '25(OH)D'), ('UBERON_0001004', 'respiratory system', 2833, 'respiratory')]	0	['studies  exposure life respiratory outcomesauthoryearcountrystudy designsample sizeage children assessmentdetermination vitamin statusassociation  respiratory outcomesbelderbos572011netherlandsprospective cohort156 neonatesbirth ymaternal food-frequency questionnaire cord blood 25(oh)dlower 25(oh)d concentrations respiratory syncytial virus infectioncamargo582007united statesprospective cohort1194 mother-child dyads3 ymaternal food-frequency questionnairehighest quartile  intake  recurrent wheezingcamargo592011new zealandprospective cohort922 newbornsbirth 5 ycord blood 25(oh)dhigher 25(oh)d decreased respiratory infection wheezing childhood asthma notedcarroll602011canadacross-sectional340 mother-infant dyads5–29 weeksmaternal whole blood 25(oh)dincreasing maternal 25(oh)d decreased asthma mothers infantile wheezing noteddevereux612007scotlandprospective cohort2000  women, 1212 children5 ymaternal food-frequency questionnairehighest lowest maternal  intakes wheezingerkkola622009finlandprospective cohort1669 mother-child dyads5 ymaternal food-frequency questionnairehigher maternal  intake asthma allergic rhinitisgale632008ukprospective cohort466 mothers 178 children9 mo 9 ymaternal serum 25(oh)dmaternal  levels > 75 nmol/l atopic dermatitis asthmamiyake642010japanprospective cohort763 mother-child dyads16–24 momaternal food-frequency questionnairehigher maternal  intake decreased wheeze atopic dermatitismorales652012spainprospective cohort1724 children12 mo, 4–6 ymaternal plasma 25(oh)dincreased maternal 25(oh)d decreased respiratory infections wheezing asthmarothers662011united statesprospective cohort219 childrenbirth 5 ycord blood 25(oh)dboth cord blood 25(oh)d aeroallergen sensitization allergic rhinitis asthma\nin birth 25(oh)d concentrations plasma whole blood  women, median 25(oh)d concentrations ranged 20 29.5 ng/ml.60,63,65a 50% decrease maternal asthma 35 nmol/l increase 25(oh)d levels,  status asthma .60however, maternal  intake, 25(oh)d concentrations respiratory symptoms childhood observed.']
S35-PMC3427192	PMC3427192	4/2012	S35-PMC3427192	['HOWEVER, it is IMPORTANT TO NOTE that a large percentage of children were lost to follow-up, and THUS the resulting sample of mothers had higher concentrations of 25(Oh)D and were older, less LIKELY to smoke during Pregnancy, and more educated.63therefore WHILE there MAY BE therapeutic window for vitamin D supplementation in early Life, FURTHER STUDIES ARE NEEDED to more clearly understand the RISKS of high Vitamin D intake and bioavailability during the early childhood years.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 15), ('PROBABLE_UNDERSTANDING', 97), ('PROBABLE_UNDERSTANDING', 192), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 256), ('INCOMPLETE_EVIDENCE', 268), ('FUTURE_WORK', 339), ('FUTURE_WORK', 347), ('IMPORTANT_CONSIDERATION', 397)]	9	[('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 306, 'D'), ('UBERON_0000104', 'life cycle', 333, 'life'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D')]	0	['however, percentage children follow-up, resulting sample mothers higher concentrations 25(oh)d older, smoke educated.63therefore window vitamin supplementation life,  intake bioavailability childhood years.']
S0-PMC3427250	PMC3427250	8/2012	S0-PMC3427250	['high prevalence of Vitamin D deficiency in Pregnant women: a national cross-sectional survey\n\nabstract\nan increasing NUMBER OF STUDIES SUGGEST that Vitamin D deficiency during Pregnancy is ASSOCIATED with multiple adverse health outcomes in mothers, neonates and children.']	[('INCOMPLETE_EVIDENCE', 117), ('INCOMPLETE_EVIDENCE', 135), ('SUPERFICIAL_RELATIONSHIP', 189)]	3	[('CHEBI_28384', 'vitamin K', 19, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 19, 'Vitamin'), ('GO_0007565', 'female pregnancy', 43, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('GO_0007565', 'female pregnancy', 176, 'pregnancy')]	0	['high vitamin  women: national cross-sectional survey\n\nabstract\nan   outcomes mothers, neonates children.']
S1-PMC3427250	PMC3427250	8/2012	S1-PMC3427250	['there are NO representative country data AVAILABLE on Vitamin D status of Pregnant women in europe.']	[('FULL_UNKNOWN', 10)]	1	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnant')]	0	[' status  women europe.']
S2-PMC3427250	PMC3427250	8/2012	S2-PMC3427250	['the AIM of THIS STUDY was to estimate the prevalence of Vitamin D deficiency among belgian Pregnant women and TO ASSESS the determinants of Vitamin D status in the first and third Trimester of Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 110)]	3	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnant'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 180, 'trimester'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy')]	0	[' among belgian  women  status third trimester .']
S8-PMC3427250	PMC3427250	8/2012	S8-PMC3427250	['of all women included, 62.0% reported taking Vitamin D-containing multivitamins, of which ONLY 24.2% started taking those before Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 90)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]	0	['women included, 62.0% -containing multivitamins, 24.2% .']
S11-PMC3427250	PMC3427250	8/2012	S11-PMC3427250	['in conclusion, Vitamin D deficiency is highly prevalent among Pregnant women in belgium and this RAISES CONCERNS about the health consequences for the mother and the offspring.']	[('IMPORTANT_CONSIDERATION', 97)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnant')]	0	['conclusion,  among  women belgium mother offspring.']
S17-PMC3427250	PMC3427250	8/2012	S17-PMC3427250	['in addition, an increasing NUMBER OF STUDIES SUGGEST that Vitamin D deficiency during Pregnancy is ASSOCIATED with multiple adverse health outcomes in mothers (Gestational diabetes and pre-eclampsia), in neonates (wheezing) and children (low bone Mineral density, type-1 diabetes, eczema)[16]–[22].']	[('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 45), ('SUPERFICIAL_RELATIONSHIP', 99)]	3	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy'), ('GO_0007565', 'female pregnancy', 160, 'gestational'), ('CHEBI_46662', 'mineral', 247, 'mineral')]	0	['addition,   outcomes mothers diabetes pre-eclampsia), neonates (wheezing) children (low bone mineral density, type-1 diabetes, eczema)[16]–[22].']
S31-PMC3427250	PMC3427250	8/2012	S31-PMC3427250	['there is a GROWING CONCERN about the health CONSEQUENCES of the high prevalence of Vitamin D deficiency worldwide among the general population, including Pregnant women.']	[('INCOMPLETE_EVIDENCE', 11), ('IMPORTANT_CONSIDERATION', 19), ('PROBLEM_COMPLICATION', 44)]	3	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnant')]	0	[' among population,  women.']
S32-PMC3427250	PMC3427250	8/2012	S32-PMC3427250	['the adequacy of the current Vitamin D dietary RECOMMENDATIONS to reach an optimal Vitamin D status during Pregnancy HAS BEEN QUESTIONED[24].']	[('FUTURE_WORK', 46), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy')]	0	[' dietary  status  questioned[24].']
S33-PMC3427250	PMC3427250	8/2012	S33-PMC3427250	['ALTHOUGH previous small surveys SUGGEST that Vitamin D deficiency among Pregnant women is common in europe[29],[30], there are NO RELIABLE country-wide estimates of Vitamin D status of Pregnant women in european countries.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 127)]	3	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 185, 'pregnant')]	0	['although  among  women europe[29],[30], country-wide  status  women european countries.']
S34-PMC3427250	PMC3427250	8/2012	S34-PMC3427250	['THEREFORE the AIM of THIS STUDY was to carry out the FIRST national representative random sample survey on Vitamin D status in Pregnant women in a european country and TO ASSESS the determinants of Vitamin D status in the first and third Trimester of Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('INCOMPLETE_EVIDENCE', 53), ('QUESTION_ANSWERED_BY_THIS_WORK', 168)]	5	[('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'pregnant'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 238, 'trimester'), ('GO_0007565', 'female pregnancy', 251, 'pregnancy')]	0	['therefore carry national representative random sample survey  status  women european country  status third trimester .']
S66-PMC3427250	PMC3427250	8/2012	S66-PMC3427250	['of all women included, 15% Smoked during Pregnancy and 12% reported having drunk Alcohol during Pregnancy (table 2).10.1371/journal.pone.0043868.t002\n\ncaption (table-wrap): table 2\ncharacteristics of the Pregnant women included in the study (n\u200a=\u200a1311) (belgian national survey on Vitamin D status in Pregnant women, 2010–2011).characteristicnmean age28.5±5.11305mean bmi*(kg/m2)24.4±5.11290% underweight5.6673% healthy weight59.20763% overweight22.09285% obese13.10169 ethnicity % white/caucasian73.61965% asiatic2.5233% african (black)4.8864% north african13.42176% hispanic0.9212% not known4.6561 education level % secondary education or lower54.54715% higher education27.23357% university or higher14.87195% other education0.233% no diploma0.699% not known2.4432 smoking % yes16.78220% of which during past 4 wks15.41202% no82.911087% not known0.314 Drinking Alcohol % yes20.37267% of which during past 4 wks11.51151% no78.491029% not known1.1415\nfirst trimester bmi used as a PROXY for Prepregnancy bmi.']	[('SUPERFICIAL_RELATIONSHIP', 980)]	1	[('GO_0007601', 'visual perception', 27, 'smoked'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('CHEBI_30879', 'alcohol', 81, 'alcohol'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy'), ('GO_0007565', 'female pregnancy', 204, 'pregnant'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('GO_0007565', 'female pregnancy', 300, 'pregnant'), ('GO_0006307', 'DNA dealkylation involved in DNA repair', 853, 'Drinking'), ('CHEBI_30879', 'alcohol', 862, 'alcohol'), ('GO_0007565', 'female pregnancy', 990, 'prepregnancy')]	0	['women included, 15% smoked  12% drunk alcohol  (table 2).10.1371/journal.pone.0043868.t002\n\ncaption (table-wrap): table 2\ncharacteristics  women (n\u200a=\u200a1311) (belgian national survey  status  women, 2010–2011).characteristicnmean age28.5±5.11305mean bmi*(kg/m2)24.4±5.11290% underweight5.6673% healthy weight59.20763% overweight22.09285% obese13.10169 ethnicity % white/caucasian73.61965% asiatic2.5233% african (black)4.8864% north african13.42176% hispanic0.9212% known4.6561 % secondary lower54.54715% higher education27.23357% university higher14.87195% education0.233% diploma0.699% known2.4432 smoking % yes16.78220% 4 wks15.41202% no82.911087% known0.314 drinking alcohol % yes20.37267% 4 wks11.51151% no78.491029% known1.1415\nfirst trimester bmi  bmi.']
S85-PMC3427250	PMC3427250	8/2012	S85-PMC3427250	['in addition the risk of Vitamin D deficiency was significantly lower in summer, spring and autumn compared to winter (table 4).10.1371/journal.pone.0043868.t004\n\ncaption (table-wrap): table 4\nrisk of Vitamin D deficiency during Pregnancy in belgium (25-(Oh)D <20 ng/ml) (n\u200a=\u200a1100), results of multiple logistic regressions.n of subjectsn of deficient casesor[95% conf interval]p season winter4702781.000spring3841270.2340.1650.332<0.001summer93120.1000.0490.203<0.001autumn3511660.5500.3910.7750.001bmi*1.0511.0221.080<0.001 smoking yes2191181.000no10784650.7010.4801.0250.067 use of multivitamins containing Vitamin D no4893171.000yes8092660.2240.1680.300<0.001 ethnicity caucasian, white9553691.000asiatic33192.8231.2356.4540.014african (black)64341.3090.6942.4680.406north african1741306.0483.8139.595<0.001hispanic1275.3051.54918.1670.008 education level secondary education or less7194131.000high school3531080.4880.3490.681<0.001university195520.5090.3310.7830.002 frequency of fish Consumption (non-fatty fish) never2261171.000less than once a month225900.5640.3540.8970.0161–3 days a month5052160.8390.5641.2480.3861 day per week2701240.7940.5061.2480.3182–4 days a week or more frequent69350.5620.2891.0950.090 sometimes going on holidays to sunny climates yes8823661.000no4082151.7031.2482.3240.001\nfirst Trimester bmi used as a PROXY for Prepregnancy bmi.']	[('SUPERFICIAL_RELATIONSHIP', 1339)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('GO_0007565', 'female pregnancy', 228, 'pregnancy'), ('CHEBI_72657', '19,20-DiHDPA', 250, '25-(OH)D'), ('CHEBI_27300', 'vitamin D', 609, 'vitamin D'), ('GO_0007631', 'feeding behavior', 989, 'consumption'), ('GO_0009294', 'DNA mediated transformation', 1315, 'trimester'), ('UBERON_0002371', 'bone marrow', 1315, 'trimester'), ('GO_0007565', 'female pregnancy', 1349, 'prepregnancy')]	0	['addition  summer, spring autumn winter (table 4).10.1371/journal.pone.0043868.t004\n\ncaption (table-wrap): table 4\nrisk   belgium (25-(oh)d <20 ng/ml) (n\u200a=\u200a1100), results logistic regressions.n subjectsn casesor[95% conf interval]p season winter4702781.000spring3841270.2340.1650.332<0.001summer93120.1000.0490.203<0.001autumn3511660.5500.3910.7750.001bmi*1.0511.0221.080<0.001 smoking yes2191181.000no10784650.7010.4801.0250.067 multivitamins containing  no4893171.000yes8092660.2240.1680.300<0.001 ethnicity caucasian, white9553691.000asiatic33192.8231.2356.4540.014african (black)64341.3090.6942.4680.406north african1741306.0483.8139.595<0.001hispanic1275.3051.54918.1670.008 secondary less7194131.000high school3531080.4880.3490.681<0.001university195520.5090.3310.7830.002 frequency fish consumption (non-fatty fish) never2261171.000less month225900.5640.3540.8970.0161–3 days month5052160.8390.5641.2480.3861 day week2701240.7940.5061.2480.3182–4 days week frequent69350.5620.2891.0950.090 going holidays sunny climates yes8823661.000no4082151.7031.2482.3240.001\nfirst trimester bmi  bmi.']
S90-PMC3427250	PMC3427250	8/2012	S90-PMC3427250	['ON THE OTHER HAND risk of severe Vitamin D deficiency decreased for women who reported Alcohol Consumption during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0)]	2	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_30879', 'alcohol', 87, 'alcohol'), ('GO_0007631', 'feeding behavior', 95, 'consumption'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy')]	0	[' decreased women alcohol consumption .']
S93-PMC3427250	PMC3427250	8/2012	S93-PMC3427250	['discussion\nDESPITE the fact that more than 60% of the Pregnant women reported taking multivitamins containing Vitamin D during Pregnancy, nearly 45% of the women were vitamin d deficient (25-(Oh)D <20 ng/ml).']	[('ANOMALY_CURIOUS_FINDING', 11)]	1	[('GO_0007565', 'female pregnancy', 54, 'pregnant'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('CHEBI_72657', '19,20-DiHDPA', 188, '25-(OH)D')]	0	['discussion\ndespite 60%  women multivitamins containing  45% women vitamin (25-(oh)d <20 ng/ml).']
S97-PMC3427250	PMC3427250	8/2012	S97-PMC3427250	['however, the PRESENT STUDY is the FIRST national survey on Vitamin D status among Pregnant women in belgium.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('INCOMPLETE_EVIDENCE', 34)]	2	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnant')]	0	['however, national survey  status among  women belgium.']
S99-PMC3427250	PMC3427250	8/2012	S99-PMC3427250	['the prevalence of vitamin deficiency (25-(Oh)D <20 ng/ml) is high in many european countries[36]–[43]and SOME STUDIES SUGGEST that Pregnant women in europe are also at high risk of Vitamin D deficiency[29],[30].']	[('INCOMPLETE_EVIDENCE', 105), ('INCOMPLETE_EVIDENCE', 118)]	2	[('CHEBI_72657', '19,20-DiHDPA', 38, '25-(OH)D'), ('GO_0007565', 'female pregnancy', 131, 'pregnant'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]	0	['vitamin (25-(oh)d <20 ng/ml) european countries[36]–[43]and  women europe  deficiency[29],[30].']
S103-PMC3427250	PMC3427250	8/2012	S103-PMC3427250	['ethnicity was also a major DETERMINANT of Vitamin D status in the PRESENT STUDY, as PREVIOUSLY reported in the Adult population[32]and in Pregnant women[29],[48],[49].']	[('SUPERFICIAL_RELATIONSHIP', 27), ('QUESTION_ANSWERED_BY_THIS_WORK', 66), ('INCOMPLETE_EVIDENCE', 84)]	3	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('UBERON_0007023', 'adult organism', 111, 'adult'), ('GO_0007565', 'female pregnancy', 138, 'pregnant')]	0	['ethnicity  status study, adult population[32]and  women[29],[48],[49].']
S105-PMC3427250	PMC3427250	8/2012	S105-PMC3427250	['in addition education level was ASSOCIATED with Vitamin D status in our Pregnant women population.']	[('SUPERFICIAL_RELATIONSHIP', 32)]	1	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant')]	0	['addition  status  women population.']
S107-PMC3427250	PMC3427250	8/2012	S107-PMC3427250	['INTERESTINGLY the risk for severe Vitamin D deficiency was lower among women who reported Alcohol consumption during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_30879', 'alcohol', 90, 'alcohol'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy')]	0	['interestingly  among women alcohol consumption .']
S116-PMC3427250	PMC3427250	8/2012	S116-PMC3427250	['the adequate intake of Vitamin D during Pregnancy and Lactation is UNKNOWN, ALTHOUGH it APPEARS TO BE greater than the current dietary RECOMMENDATIONS of 400 iu/d or 10 µg/d[58].']	[('FULL_UNKNOWN', 67), ('ANOMALY_CURIOUS_FINDING', 76), ('ANOMALY_CURIOUS_FINDING', 88), ('FUTURE_WORK', 135)]	4	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 40, 'pregnancy'), ('GO_0007595', 'lactation', 54, 'lactation')]	0	['intake   lactation unknown, dietary 400 iu/d 10 µg/d[58].']
S117-PMC3427250	PMC3427250	8/2012	S117-PMC3427250	['SOME studies SUGGEST that the dietary requirement during Pregnancy and Lactation MAY BE as high as 6000 iu/d[59]and recognize that AT LEAST 1500–2000 iu/d of Vitamin D MAY BE NEEDED in order to maintain a Blood level of 25(Oh)D above 30 ng/ml[24].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 81), ('PROBABLE_UNDERSTANDING', 131), ('INCOMPLETE_EVIDENCE', 168), ('FUTURE_WORK', 175)]	6	[('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('GO_0007595', 'lactation', 71, 'lactation'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('UBERON_0000178', 'blood', 205, 'blood'), ('CHEBI_71657', 'versiconol acetate', 220, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 220, '25(OH)D')]	0	['dietary  lactation 6000 iu/d[59]and 1500–2000 iu/d  maintain blood 25(oh)d 30 ng/ml[24].']
S118-PMC3427250	PMC3427250	8/2012	S118-PMC3427250	['as those authors recognize that the EVIDENCE to propose such Intakes IS SCARCE and as long as the health benefits of having Serum 25(Oh)D levels higher than 30 ng/ml are NOT clearly ESTABLISHED particularly in Pregnant women, the belgian superior health council STILL RECOMMENDS a Vitamin D supplement of 20 µg/day or 800 iu during Pregnancy[58].']	[('INCOMPLETE_EVIDENCE', 36), ('FULL_UNKNOWN', 170), ('IMPORTANT_CONSIDERATION', 262), ('FUTURE_WORK', 268)]	4	[('GO_0007631', 'feeding behavior', 61, 'intakes'), ('UBERON_0001977', 'blood serum', 124, 'serum'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 132, '(OH ... D'), ('GO_0007565', 'female pregnancy', 210, 'pregnant'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D'), ('GO_0007565', 'female pregnancy', 332, 'pregnancy')]	0	['authors intakes serum 25(oh)d levels higher 30 ng/ml  women, belgian council  supplement 20 µg/day 800 iu [58].']
S119-PMC3427250	PMC3427250	8/2012	S119-PMC3427250	['HOWEVER, the Vitamin D content of multivitamins for Pregnant women in belgium is ONLY 400 iu INDICATING EVEN this RECOMMENDATION is not followed as Pregnant women only take one Multivitamin pill a day.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 81), ('INCOMPLETE_EVIDENCE', 93), ('ANOMALY_CURIOUS_FINDING', 104), ('FUTURE_WORK', 114)]	5	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnant'), ('GO_0007565', 'female pregnancy', 148, 'pregnant'), ('CHEBI_7025', 'mupirocin', 177, 'multivitamin')]	0	['however,  content multivitamins  women belgium 400 iu followed  women multivitamin pill day.']
S122-PMC3427250	PMC3427250	8/2012	S122-PMC3427250	['in addition to the UNCERTAINTY CONCERNING the optimal Vitamin D intakes preventing Vitamin D deficiency, there exists also a LACK OF RECOMMENDATIONS to treat Vitamin D deficient Pregnant women.']	[('FULL_UNKNOWN', 19), ('PROBLEM_COMPLICATION', 31), ('INCOMPLETE_EVIDENCE', 125), ('FUTURE_WORK', 133)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnant')]	0	['addition  intakes  deficiency, treat   women.']
S124-PMC3427250	PMC3427250	8/2012	S124-PMC3427250	['the UNCOVERING of the magnitude of Vitamin D deficiency in Pregnant women in belgium (and western europe) SHOULD BE translated into NEW RESEARCH in order to fill the huge KNOWLEDGE GAP CONCERNING the adequate amount of Vitamin D to prevent and treat Vitamin D deficient Pregnant women.']	[('INCOMPLETE_EVIDENCE', 4), ('FUTURE_WORK', 106), ('INCOMPLETE_EVIDENCE', 132), ('FULL_UNKNOWN', 171), ('PROBLEM_COMPLICATION', 185)]	5	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 59, 'pregnant'), ('CHEBI_27300', 'vitamin D', 219, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 250, 'vitamin D'), ('GO_0007565', 'female pregnancy', 270, 'pregnant')]	0	['magnitude   women belgium (and western europe) fill huge amount  treat   women.']
S125-PMC3427250	PMC3427250	8/2012	S125-PMC3427250	['in addition, an increasing NUMBER OF STUDIES SUGGEST that Gestational Vitamin D deficiency is ASSOCIATED with multiple adverse health outcomes in mothers and children[16]–[22].']	[('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 45), ('SUPERFICIAL_RELATIONSHIP', 94)]	3	[('GO_0007565', 'female pregnancy', 58, 'gestational'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]	0	['addition,   outcomes mothers children[16]–[22].']
S126-PMC3427250	PMC3427250	8/2012	S126-PMC3427250	['THEREFORE, there is an URGENT NEED of randomised controlled trials of Vitamin D supplementation to investigate the maternal and neonatal health benefits of correcting Vitamin D deficiency during Pregnancy[24].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 23), ('FUTURE_WORK', 30)]	3	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 195, 'pregnancy')]	0	['therefore, randomised  supplementation maternal neonatal correcting  [24].']
S127-PMC3427250	PMC3427250	8/2012	S127-PMC3427250	['given the high prevalence of Vitamin D deficiency in Pregnant women in belgium and PROBABLY in many european countries, a Vitamin D nutrition policy IS NEEDED at the country and european level.']	[('PROBABLE_UNDERSTANDING', 83), ('FUTURE_WORK', 149)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 53, 'pregnant'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D')]	0	['given   women belgium european countries,  nutrition policy country european level.']
S128-PMC3427250	PMC3427250	8/2012	S128-PMC3427250	['the current Vitamin D RECOMMENDATIONS for Pregnant women are clearly INSUFFICIENT to prevent and EVEN more to treat Vitamin D deficient Pregnant women.']	[('FUTURE_WORK', 22), ('PROBLEM_COMPLICATION', 69), ('ANOMALY_CURIOUS_FINDING', 97)]	3	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 136, 'pregnant')]	0	['  women treat   women.']
S129-PMC3427250	PMC3427250	8/2012	S129-PMC3427250	['UNTIL the adequate treatment of Vitamin D deficient Pregnant women is established, a safe approach MAY BE to correct Vitamin D deficiency by TARGETING Pregnant women at high risk of severe Vitamin D deficiency.']	[('FUTURE_WORK', 0), ('INCOMPLETE_EVIDENCE', 99), ('FUTURE_WORK', 141)]	3	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnant'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnant'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D')]	0	['treatment   women established,   women  deficiency.']
S130-PMC3427250	PMC3427250	8/2012	S130-PMC3427250	['in addition the current Vitamin D content of multivitamins for Pregnancy, 400 iu, do not EVEN comply with the current belgian RECOMMENDATIONS of 800 iu per day, THEREFORE a PRUDENT step SHOULD AT LEAST be to increase the Vitamin D content in multivitamins for Pregnant women to 800 iu.']	[('ANOMALY_CURIOUS_FINDING', 89), ('FUTURE_WORK', 126), ('PROBABLE_UNDERSTANDING', 161), ('FUTURE_WORK', 173), ('FUTURE_WORK', 186), ('PROBABLE_UNDERSTANDING', 193)]	6	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D'), ('GO_0007565', 'female pregnancy', 260, 'pregnant')]	0	['addition  content multivitamins 400 iu, comply belgian 800 iu day, step increase  content multivitamins  women 800 iu.']
S131-PMC3427250	PMC3427250	8/2012	S131-PMC3427250	['in conclusion, DESPITE that more than 60% of the Pregnant women reported taking multivitamins containing Vitamin D, Vitamin D deficiency is highly prevalent among Pregnant women in belgium and up to 12% of Pregnant women are severely Vitamin D deficient.']	[('ANOMALY_CURIOUS_FINDING', 15)]	1	[('GO_0007565', 'female pregnancy', 49, 'pregnant'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnant'), ('GO_0007565', 'female pregnancy', 206, 'pregnant'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D')]	0	['conclusion, 60%  women multivitamins containing  among  women belgium 12%  women  deficient.']
S22-PMC3437304	PMC3437304	8/2012	S22-PMC3437304	['Prenatal exposure to Pets, Vitamin D supplement, or antioxidants such as mediterranean diet is shown to be PROTECTIVE from the development of asthma.']	[('SUPERFICIAL_RELATIONSHIP', 107)]	1	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('NCBITaxon_10088', 'Mus <genus>', 21, 'pets'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]	0	[' exposure pets,  supplement, antioxidants mediterranean diet asthma.']
S20-PMC3458940	PMC3458940	9/2012	S20-PMC3458940	['EVEN mild Gestational Vitamin A deficiency LEADS to a deficit in Nephron number, which MAY predispose the Kidney to abnormal development or function when ASSOCIATED with other morbidities[8].']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 43), ('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 154)]	4	[('GO_0007565', 'female pregnancy', 10, 'gestational'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('UBERON_0001285', 'nephron', 65, 'nephron'), ('UBERON_0002113', 'kidney', 106, 'kidney')]	0	['even   nephron number, kidney abnormal morbidities[8].']
S32-PMC3465343	PMC3465343	10/2012	S32-PMC3465343	['epidemiologic evidence has SUGGESTED that Vitamin A deficiency (vad) is not uncommon among Pregnant women and children in developing countries[20].']	[('INCOMPLETE_EVIDENCE', 27)]	1	[('CHEBI_27300', 'vitamin D', 42, 'vitamin A'), ('GO_0007565', 'female pregnancy', 91, 'pregnant')]	0	['epidemiologic  (vad) among  women children countries[20].']
S40-PMC3465343	PMC3465343	10/2012	S40-PMC3465343	['ra is a derivative of Vitamin A and is REQUIRED for synchronous left-right Development Of Somites, either maternal vad during Pregnancy or an Embryonic defect in Metabolism from Vitamin A to ra MIGHT be ASSOCIATED with increased risk of Human vertebral defects.']	[('IMPORTANT_CONSIDERATION', 39), ('INCOMPLETE_EVIDENCE', 194), ('SUPERFICIAL_RELATIONSHIP', 203)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('GO_0042461', 'photoreceptor cell development', 75, 'development of somites'), ('UBERON_0002329', 'somite', 90, 'somites'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('UBERON_0000922', 'embryo', 142, 'embryonic'), ('GO_0008152', 'metabolic process', 162, 'metabolism'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin A'), ('NCBITaxon_9606', 'Homo sapiens', 237, 'human')]	0	['ra derivative  synchronous left-right somites, maternal vad  embryonic defect metabolism  ra human vertebral defects.']
S126-PMC3465343	PMC3465343	10/2012	S126-PMC3465343	['the phenomenon that Gestational Vitamin A deficiency disrupts Embryonic Development HAS BEEN KNOWN for over 80 years.']	[('INCOMPLETE_EVIDENCE', 84), ('INCOMPLETE_EVIDENCE', 93)]	2	[('GO_0007565', 'female pregnancy', 20, 'gestational'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin A'), ('GO_0009790', 'embryo development', 62, 'embryonic development'), ('UBERON_0000922', 'embryo', 62, 'embryonic')]	0	['  disrupts embryonic 80 years.']
S143-PMC3465343	PMC3465343	10/2012	S143-PMC3465343	['TO verify the reduction of Vitamin A in Mice receiving vad diet, we measured the Vitamin A level of mothers before Mating and their offspring at Postnatal day 1, and confirmed the vad status during Pregnancy in the vad group as previously described[33].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin A'), ('NCBITaxon_10088', 'Mus <genus>', 40, 'mice'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin A'), ('GO_0007618', 'mating', 115, 'mating'), ('GO_0007567', 'parturition', 145, 'postnatal'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy')]	0	['reduction  mice receiving vad diet,  mothers mating offspring postnatal day 1, vad status  vad described[33].']
S177-PMC3465343	PMC3465343	10/2012	S177-PMC3465343	['GIVEN that vad is STILL a SERIOUS and PREVALENT PUBLIC HEALTH PROBLEM in the world especially among Pregnant women and children and dietary Vitamin A is ONLY available from limited sources, including vegetables in the form of Β-Carotene or meat as Retinyl Esters, vad MAY BE an IMPORTANT cause of Human congenital Spinal deformities[43].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 18), ('IMPORTANT_CONSIDERATION', 26), ('IMPORTANT_CONSIDERATION', 38), ('IMPORTANT_CONSIDERATION', 48), ('PROBLEM_COMPLICATION', 62), ('INCOMPLETE_EVIDENCE', 153), ('INCOMPLETE_EVIDENCE', 268), ('IMPORTANT_CONSIDERATION', 278)]	9	[('GO_0007565', 'female pregnancy', 100, 'pregnant'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 226, 'β-carotene'), ('CHEBI_26523', 'reactive oxygen species', 248, 'retinyl esters'), ('NCBITaxon_9606', 'Homo sapiens', 297, 'human'), ('UBERON_0001130', 'vertebral column', 314, 'spinal')]	0	['given vad world among  women children dietary  sources, vegetables form β-carotene meat retinyl esters, vad human congenital spinal deformities[43].']
S0-PMC3470091	PMC3470091	9/2012	S0-PMC3470091	['the EFFICACY and SAFETY of a high dose of Vitamin D in mothers with Gestational diabetes mellitus: a randomized controlled clinical TRIAL\n\nabstract\nbackground: during Pregnancy and Lactation outstanding changes occur in mother’s Vitamin D Metabolism.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('IMPORTANT_CONSIDERATION', 17), ('QUESTION_ANSWERED_BY_THIS_WORK', 132)]	3	[('CHEBI_28384', 'vitamin K', 42, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 42, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'Gestational'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy'), ('GO_0007595', 'lactation', 181, 'lactation'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 229, 'vitamin D metabolism')]	0	['dose vitamin mothers  diabetes mellitus: trial\n\nabstract\nbackground:  lactation changes occur mother’s  metabolism.']
S1-PMC3470091	PMC3470091	9/2012	S1-PMC3470091	['THIS STUDY was carried out TO EVALUATE the efficacy of 300,000 iu Vitamin D given intramuscularly on body status in new cases of Gestational diabetes mellitus (gdm).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 27)]	2	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'gestational')]	0	['carried 300,000 iu  intramuscularly status cases  diabetes mellitus (gdm).']
S15-PMC3470091	PMC3470091	9/2012	S15-PMC3470091	['these changes occur ACCORDING TO the needs for the mineralization of the fetus Bones as well as adequate secretion of Vitamin D in mother’s Milk.1\nDUE TO rapid fetal development, PARTICULARLY bone Calcification at the terminal stages of Pregnancy, there is a POSSIBILITY of Vitamin D deficiency to occur in mothers.']	[('SUPERFICIAL_RELATIONSHIP', 20), ('PROBABLE_UNDERSTANDING', 147), ('IMPORTANT_CONSIDERATION', 179), ('INCOMPLETE_EVIDENCE', 259)]	4	[('UBERON_0001474', 'bone element', 79, 'bones'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('UBERON_0001913', 'milk', 140, 'milk'), ('GO_0051301', 'cell division', 197, 'calcification'), ('GO_0007565', 'female pregnancy', 237, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]	0	['changes occur mineralization fetus bones secretion  mother’s milk.1\ndue rapid fetal development, bone calcification terminal stages  occur mothers.']
S17-PMC3470091	PMC3470091	9/2012	S17-PMC3470091	['studies have INDICATED that during Pregnancy Vitamin D deficiency varies from 18% to 84%, which varies with the region under the study and type of clothing.2,3vitamin d deficiency among Breast-Fed children in the regions with heavy sunshine such as the middle east is high.3-5this hypovitaminosis which is DUE TO limited exposure to sun of mothers’ and their babies as well as low Vitamin D intake by mothers.']	[('INCOMPLETE_EVIDENCE', 13), ('PROBABLE_UNDERSTANDING', 306)]	2	[('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007567', 'parturition', 186, 'breast'), ('UBERON_0000310', 'breast', 186, 'breast'), ('GO_0007631', 'feeding behavior', 193, 'fed'), ('CHEBI_27300', 'vitamin D', 381, 'vitamin D')]	0	['studies   18% 84%, region type clothing.2,3vitamin among breast-fed children regions sunshine middle east high.3-5this hypovitaminosis exposure sun mothers’ babies  intake mothers.']
S19-PMC3470091	PMC3470091	9/2012	S19-PMC3470091	['such a RELATION HAS BEEN ATTRIBUTED to special receptors for Vitamin D in Pancreatic Betacells.9moreover, Vitamin D WAS SHOWN to have positive EFFECTS on Insulin sensitivity, and its deficiency to have negative EFFECTS on the function of Betacells.11IN AGREEMENT with this, cohort studies REVEALED that Vitamin D had a PROTECTIVE EFFECT against diabetes type Ii.8,11also, Serum concentration of Vitamin D during 24-29thweek of Pregnancy in women suffering from Gestational diabetes mellitus (gdm) was lower than that in women without the disease.12\nthe study of Vitamin D status and improving it in the Lactating mothers with previous gdm is of CONSPICUOUS VALUE.4,13\ndue to the limited exposure to sunshine and inadequate Intake, the level of Vitamin D is reduced in the milk of Lactating mothers.']	[('SUPERFICIAL_RELATIONSHIP', 7), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 143), ('SUPERFICIAL_RELATIONSHIP', 211), ('INCOMPLETE_EVIDENCE', 250), ('INCOMPLETE_EVIDENCE', 289), ('SUPERFICIAL_RELATIONSHIP', 319), ('SUPERFICIAL_RELATIONSHIP', 330), ('IMPORTANT_CONSIDERATION', 645)]	11	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CL_0000169', 'type B pancreatic cell', 74, 'pancreatic betacells'), ('UBERON_0001264', 'pancreas', 74, 'pancreatic'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('PR_000045358', 'insulin family protein', 154, 'insulin'), ('CL_0000365', 'animal zygote', 238, 'betacells'), ('CHEBI_27300', 'vitamin D', 303, 'vitamin D'), ('CL_0002212', 'type II muscle cell', 359, 'II'), ('UBERON_0001977', 'blood serum', 372, 'serum'), ('CHEBI_27300', 'vitamin D', 395, 'vitamin D'), ('GO_0007565', 'female pregnancy', 427, 'pregnancy'), ('GO_0007565', 'female pregnancy', 461, 'gestational'), ('CHEBI_27300', 'vitamin D', 562, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 603, 'lactating'), ('GO_0007631', 'feeding behavior', 723, 'intake'), ('CHEBI_27300', 'vitamin D', 744, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 780, 'lactating')]	0	['receptors  pancreatic betacells.9moreover,  positive insulin sensitivity, betacells.11in this,  diabetes type ii.8,11also, serum concentration  24-29thweek  women  diabetes mellitus (gdm) women disease.12\nthe  status lactating mothers gdm value.4,13\ndue exposure sunshine intake,  milk lactating mothers.']
S84-PMC3470091	PMC3470091	9/2012	S84-PMC3470091	['OUR STUDY REVEALED that a single high dose injection of Vitamin D is more economic and effective PARTICULARLY in Lactating mothers who refrain from Consuming oral daily doses due to Postpartum care, unwillingness or depression.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10), ('ANOMALY_CURIOUS_FINDING', 97)]	3	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 113, 'lactating'), ('GO_0007631', 'feeding behavior', 148, 'consuming'), ('GO_0007565', 'female pregnancy', 182, 'postpartum')]	0	['single dose injection  economic lactating mothers oral daily doses  care, unwillingness depression.']
S92-PMC3470091	PMC3470091	9/2012	S92-PMC3470091	['further STUDIES ARE NEEDED to evaluate the EFFECT of Postpartum supplementation of Vitamin D on antirachitic FACTOR of the mother’s Milk, and infant’s health indexes.']	[('FUTURE_WORK', 8), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 109)]	3	[('GO_0007565', 'female pregnancy', 53, 'postpartum'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('UBERON_0001913', 'milk', 132, 'milk')]	0	[' supplementation  antirachitic mother’s milk, infant’s indexes.']
S2-PMC3471827	PMC3471827	10/2012	S2-PMC3471827	['ttp and Vitamin E are ESSENTIAL for Productive Pregnancy in rodents, but their precise physiological ROLE in Embryogenesis is UNKNOWN.']	[('IMPORTANT_CONSIDERATION', 22), ('SUPERFICIAL_RELATIONSHIP', 101), ('FULL_UNKNOWN', 126)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin E'), ('GO_0007128', 'meiotic prophase I', 36, 'productive'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('GO_0009790', 'embryo development', 109, 'embryogenesis')]	0	['ttp  productive  rodents, precise physiological embryogenesis unknown.']
S111-PMC3471827	PMC3471827	10/2012	S111-PMC3471827	['in SUPPORT of this NOTION, PREVIOUS STUDIES HAVE SHOWN a clear ASSOCIATION between maternal Vitamin E status during Gestation and Cognitive function of the offspring[21]–[23].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 63)]	5	[('CHEBI_27300', 'vitamin D', 92, 'vitamin E'), ('GO_0007565', 'female pregnancy', 116, 'gestation'), ('GO_0050890', 'cognition', 130, 'cognitive')]	0	['notion, maternal  status  cognitive offspring[21]–[23].']
S0-PMC3472720	PMC3472720	8/2012	S0-PMC3472720	['Prenatal Vitamin D deficiency INDUCES an early and more SEVERE experimental Autoimmune encephalomyelitis in the second generation\n\nabstract\nin a PREVIOUS STUDY, we DEMONSTRATED that Mouse Adult f1offspring, exposed to a Vitamin D deficiency during Pregnancy, developed a less SEVERE and delayed experimental Autoimmune encephalomyelitis (eae), when compared with control offspring.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('IMPORTANT_CONSIDERATION', 56), ('INCOMPLETE_EVIDENCE', 145), ('INCOMPLETE_EVIDENCE', 164), ('IMPORTANT_CONSIDERATION', 276)]	5	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('UBERON_0005445', 'segment of pes', 76, 'Autoimmune'), ('NCBITaxon_10088', 'Mus <genus>', 182, 'mouse'), ('UBERON_0007023', 'adult organism', 188, 'adult'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy'), ('UBERON_0005445', 'segment of pes', 308, 'Autoimmune')]	0	[' vitamin autoimmune encephalomyelitis generation\n\nabstract\nin study, mouse adult f1offspring, exposed  delayed autoimmune encephalomyelitis (eae), offspring.']
S5-PMC3472720	PMC3472720	8/2012	S5-PMC3472720	['using the refgensep database for ms trios (the patient and his/her parents), we collected the parents’ dates of Birth and assessed a potential season of Birth EFFECT that COULD POTENTIALLY be indicative of the Vitamin D status of the Pregnant grandmothers.']	[('SUPERFICIAL_RELATIONSHIP', 159), ('INCOMPLETE_EVIDENCE', 171), ('INCOMPLETE_EVIDENCE', 177)]	3	[('GO_0007567', 'parturition', 112, 'birth'), ('GO_0007567', 'parturition', 153, 'birth'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('GO_0007565', 'female pregnancy', 234, 'pregnant')]	0	['using refgensep database ms trios (the patient his/her parents), parents’ dates birth season birth  status  grandmothers.']
S12-PMC3472720	PMC3472720	8/2012	S12-PMC3472720	['IN ORDER TO TEST the HYPOTHESIS that low Vitamin D status during Gestation is a RISK FACTOR for ms, we explored a well-DESCRIBED developmental Vitamin D (dvd) deficiency Rodent MODEL, [11,12].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 80), ('INCOMPLETE_EVIDENCE', 119), ('INCOMPLETE_EVIDENCE', 177)]	6	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'gestation'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 170, 'rodent')]	0	[' status  ms, well-described developmental  (dvd) rodent model, [11,12].']
S14-PMC3472720	PMC3472720	8/2012	S14-PMC3472720	['BASED ON findings from epidemiology, we predicted that offspring exposed to low Prenatal Vitamin D would be at INCREASED RISK of ms.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 0), ('IMPORTANT_CONSIDERATION', 111)]	3	[('GO_0007565', 'female pregnancy', 80, 'prenatal'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]	0	['based epidemiology, offspring exposed   ms.']
S22-PMC3472720	PMC3472720	8/2012	S22-PMC3472720	['we wondered IF the second generation (f2) had any persisting alterations in Immune function RELATED to the Vitamin D status of the Pregnant f0female Mice.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('SUPERFICIAL_RELATIONSHIP', 92)]	2	[('UBERON_0002405', 'immune system', 76, 'immune'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 149, 'mice')]	0	['generation (f2) persisting alterations immune  status  f0female mice.']
S24-PMC3472720	PMC3472720	8/2012	S24-PMC3472720	['in this series of experiments, ONLY the Pregnant f0female Mice and their Growing Fetuses were Vitamin D deficient.']	[('ANOMALY_CURIOUS_FINDING', 31)]	1	[('GO_0007565', 'female pregnancy', 40, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 58, 'mice'), ('GO_0040007', 'growth', 73, 'growing'), ('UBERON_0000309', 'body wall', 81, 'fetuses'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]	0	['experiments,  f0female mice fetuses  deficient.']
S32-PMC3472720	PMC3472720	8/2012	S32-PMC3472720	['using the refgensep database for ms trios (the patient and his/her parents), we collected the parents’ dates of Birth and assessed a potential season of Birth EFFECT that COULD POTENTIALLY be indicative of the Vitamin D status of the Pregnant grandmothers.']	[('SUPERFICIAL_RELATIONSHIP', 159), ('INCOMPLETE_EVIDENCE', 171), ('INCOMPLETE_EVIDENCE', 177)]	3	[('GO_0007567', 'parturition', 112, 'birth'), ('GO_0007567', 'parturition', 153, 'birth'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('GO_0007565', 'female pregnancy', 234, 'pregnant')]	0	['using refgensep database ms trios (the patient his/her parents), parents’ dates birth season birth  status  grandmothers.']
S41-PMC3472720	PMC3472720	8/2012	S41-PMC3472720	['in a PREVIOUS experiment, we DEMONSTRATED that a Prenatal Vitamin D deficiency induces a milder and delayed eae in the f1generation [14].']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 29)]	2	[('GO_0007565', 'female pregnancy', 49, 'prenatal'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]	0	['experiment,   milder delayed eae f1generation [14].']
S110-PMC3472720	PMC3472720	8/2012	S110-PMC3472720	['IN LINE WITH our Animal study, we predicted that parents developing in a Vitamin D poor environment during the third Trimester of Pregnancy, in other words those born in spring, will be at higher risk of Giving Birth to ms Individuals.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('NCBITaxon_33208', 'Metazoa', 17, 'animal'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 117, 'trimester'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('GO_0040007', 'growth', 204, 'giving'), ('GO_0007567', 'parturition', 211, 'birth'), ('NCBITaxon_1', 'root', 223, 'individuals')]	0	['animal study, parents  environment third trimester words born spring, higher birth ms individuals.']
S108-PMC3475131	PMC3475131	6/2012	S108-PMC3475131	['use of different Supplements (n\u2009=\u20097 reviews)\n\nlaboratory outcomes\nseven systematic reviews (four of high quality) investigated the EFFECTS of Micronutrients other than iron and Folic Acid [16,18-23] and FOUND NO EVIDENCE TO SUPPORT the use of Vitamin B12, Vitamin C, calcium or zinc to prevent anaemia during Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 131), ('INCOMPLETE_EVIDENCE', 203), ('INCOMPLETE_EVIDENCE', 209)]	3	[('CHEBI_33341', 'titanium atom', 17, 'supplements'), ('CHEBI_33839', 'macromolecule', 142, 'micronutrients'), ('CHEBI_30751', 'formic acid', 177, 'folic acid'), ('CHEBI_33279', 'vitamin D5', 243, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin C'), ('GO_0007565', 'female pregnancy', 309, 'pregnancy')]	0	['use supplements (n\u2009=\u20097 reviews)\n\nlaboratory outcomes\nseven (four quality) micronutrients iron folic acid [16,18-23] vitamin b12, calcium zinc anaemia .']
S108-PMC3476426	PMC3476426	8/2012	S108-PMC3476426	['maternal Vitamin D deficiency MAY BE a risk factor for autism, POSSIBLY by AFFECTING fetal Brain Development as well as by AFFECTING maternal Immune System status during Pregnancy [37,38].']	[('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 63), ('SUPERFICIAL_RELATIONSHIP', 75), ('SUPERFICIAL_RELATIONSHIP', 123)]	4	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007420', 'brain development', 91, 'brain development'), ('UBERON_0000955', 'brain', 91, 'brain'), ('UBERON_0002405', 'immune system', 142, 'immune system'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy')]	0	['maternal  autism, fetal brain maternal immune system status  [37,38].']
S110-PMC3476426	PMC3476426	8/2012	S110-PMC3476426	['UNFORTUNATELY, the tiny 10 μg (400 iu) dose in Prenatal Vitamins is VIRTUALLY IRRELEVANT in PREVENTING Gestational Vitamin D deficiency [40].']	[('IMPORTANT_CONSIDERATION', 0), ('PROBABLE_UNDERSTANDING', 68), ('IMPORTANT_CONSIDERATION', 78), ('SUPERFICIAL_RELATIONSHIP', 92)]	4	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 56, 'vitamins'), ('GO_0007565', 'female pregnancy', 103, 'gestational'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]	0	['unfortunately, tiny 10 μg (400 iu) dose  vitamins   [40].']
S111-PMC3476426	PMC3476426	8/2012	S111-PMC3476426	['FOR THIS REASON, in 2007, the canadian paediatric society RECOMMENDED 2000 iu/day, or more, to prevent Gestational Vitamin D deficiency [25].']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 58)]	2	[('GO_0007565', 'female pregnancy', 103, 'gestational'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]	0	['reason, 2007, canadian paediatric society 2000 iu/day, more,   [25].']
S0-PMC3485340	PMC3485340	10/2012	S0-PMC3485340	['maternal vitamin c deficiency during Pregnancy persistently impairs hippocampal Neurogenesis in offspring of guinea pigs\n\nabstract\nwhile having the highest Vitamin C (vitc) concentrations in the body, specific functions of Vitc in the Brain HAVE ONLY RECENTLY BEEN acknowledged.']	[('IMPORTANT_CONSIDERATION', 241), ('INCOMPLETE_EVIDENCE', 246), ('INCOMPLETE_EVIDENCE', 251)]	3	[('GO_0007565', 'female pregnancy', 37, 'Pregnancy'), ('GO_0001822', 'kidney development', 80, 'Neurogenesis'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin C'), ('PR_000017299', 'VIP peptides', 223, 'VitC'), ('UBERON_0000955', 'brain', 235, 'brain')]	0	['maternal vitamin c  hippocampal neurogenesis offspring guinea pigs\n\nabstract\nwhile  (vitc) concentrations body, functions vitc brain acknowledged.']
S147-PMC3485340	PMC3485340	10/2012	S147-PMC3485340	['these results INDICATE that Prenatal vitc deficiency negatively AFFECTS the Migration Of newborn Cells into the Gl.10.1371/journal.pone.0048488.g004\n\ncaption (fig): figure 4\nPrenatal Vitamin C deficiency causes sustained reduction in Postnatal Migration Of newborn Cells into the granule layer.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 64)]	2	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('GO_0016477', 'cell migration', 76, 'migration of ... cells'), ('UBERON_0001792', 'ganglionic layer of retina', 112, 'GL'), ('GO_0007565', 'female pregnancy', 174, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin C'), ('GO_0007567', 'parturition', 234, 'postnatal'), ('GO_0016477', 'cell migration', 244, 'migration of ... cells')]	0	['results  vitc migration newborn cells gl.10.1371/journal.pone.0048488.g004\n\ncaption (fig): figure 4\n  causes sustained reduction postnatal migration newborn cells granule layer.']
S114-PMC3488410	PMC3488410	10/2012	S114-PMC3488410	['INTERESTINGLY, SOME of the Vitamin D deficiency EFFECTS COULD BE RELATED to later Gestational periods THUS POSSIBLY expanding the HAZARDOUS time window for the neurobiological development of schizophrenia [129].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 15), ('SUPERFICIAL_RELATIONSHIP', 48), ('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 65), ('PROBABLE_UNDERSTANDING', 102), ('INCOMPLETE_EVIDENCE', 107), ('IMPORTANT_CONSIDERATION', 130)]	8	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'gestational')]	0	['interestingly,   periods window neurobiological schizophrenia [129].']
S222-PMC3501517	PMC3501517	11/2012	S222-PMC3501517	['additionally, in the prior study, the breeders were Vitamin D deficient; WHEREAS, ours were only placed in a Vitamin deficient environment once they were already visibly Pregnant.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 73)]	1	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 109, 'vitamin'), ('GO_0007565', 'female pregnancy', 170, 'pregnant')]	0	['additionally, study, breeders  deficient; whereas, vitamin environment .']
S223-PMC3501517	PMC3501517	11/2012	S223-PMC3501517	['the DIFFERENCES that the OTHER group saw MAY BE more the result of maternal and early Gestational Vitamin D deficiency and its EFFECTS on Fetal Lung Development.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 25), ('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 127)]	4	[('GO_0007565', 'female pregnancy', 86, 'gestational'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007631', 'feeding behavior', 138, 'fetal'), ('GO_0030324', 'lung development', 144, 'lung development'), ('UBERON_0002048', 'lung', 144, 'lung')]	0	['result maternal   fetal lung development.']
S23-PMC3504157	PMC3504157	11/2012	S23-PMC3504157	['MANY health providers NOW RECOMMEND nhps including Prenatal Vitamins, iron supplementation, calcium, and Vitamin D for a range of RECOGNIZED indications including deficiency states such as rickets and anemia, as well as illnesses such as multiple sclerosis.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 22), ('FUTURE_WORK', 26), ('PROBABLE_UNDERSTANDING', 130)]	4	[('GO_0007565', 'female pregnancy', 51, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 60, 'vitamins'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]	0	['many providers nhps  vitamins, iron supplementation, calcium,  rickets anemia, illnesses sclerosis.']
S24-PMC3509518	PMC3509518	11/2012	S24-PMC3509518	['THEREFORE, the AIM of THIS STUDY was TO PROSPECTIVELY ASSESS the EFFECTS of Maternal intakes of selected Antioxidants (Β-Carotene, Vitamin C, Vitamin E, copper and zinc) in Pregnancy on early infant allergic outcomes, namely eczema, Immunoglobulin e (Ige)-mediated Food allergy, allergic sensitisation and wheeze in a population at high risk of developing allergic disease BASED ON familial ASSOCIATION.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('QUESTION_ANSWERED_BY_THIS_WORK', 37), ('SUPERFICIAL_RELATIONSHIP', 65), ('SUPERFICIAL_RELATIONSHIP', 373), ('SUPERFICIAL_RELATIONSHIP', 391)]	7	[('GO_0007618', 'mating', 76, 'maternal'), ('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 105, 'antioxidants'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 119, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin E'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy'), ('GO_0019815', 'B cell receptor complex', 233, 'Immunoglobulin'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 251, 'IgE'), ('CHEBI_33290', 'food', 265, 'food')]	0	['therefore, maternal intakes selected antioxidants (β-carotene, , copper zinc)  infant allergic outcomes, namely eczema, immunoglobulin e (ige)-mediated food allergy, allergic sensitisation wheeze population allergic disease familial association.']
S76-PMC3509518	PMC3509518	11/2012	S76-PMC3509518	['in the majority of Pregnant women dietary intakes of antioxidants well met the RECOMMENDED daily intake (rdi) except for Vitamin E and zinc (table 2) [18].']	[('FUTURE_WORK', 79)]	1	[('GO_0007565', 'female pregnancy', 19, 'pregnant'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin E')]	0	[' women dietary intakes antioxidants met daily intake (rdi)  zinc (table 2) [18].']
S100-PMC3509518	PMC3509518	11/2012	S100-PMC3509518	['IN SUMMARY, there were no statistically significant associations OBSERVED between total intake of specific antioxidants (Β-Carotene, Vitamin C, e, zinc and copper) in Pregnancy and the risk of developing eczema, Food allergy, wheeze, sensitisation or any allergic disease neither in the crude nor adjusted analyses (data not shown).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 65)]	2	[('CHEBI_28064', 'cyanidin 3-O-rutinoside', 121, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin C'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy'), ('CHEBI_33290', 'food', 212, 'food')]	0	['summary, statistically intake antioxidants (β-carotene, e, zinc copper)  eczema, food allergy, wheeze, sensitisation allergic disease adjusted (data shown).']
S103-PMC3509518	PMC3509518	11/2012	S103-PMC3509518	['discussion\nin this study, there were SOME inverse (“PROTECTIVE”) RELATIONSHIPS between antioxidant intakes in Pregnancy and infant allergic outcomes, but this was ONLY evident for selected antioxidant factors (Vitamin C and copper) and ONLY SEEN in RELATION to dietary Nutrients and not for dietary supplements per se .']	[('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 52), ('SUPERFICIAL_RELATIONSHIP', 65), ('INCOMPLETE_EVIDENCE', 163), ('INCOMPLETE_EVIDENCE', 236), ('INCOMPLETE_EVIDENCE', 241), ('SUPERFICIAL_RELATIONSHIP', 249)]	7	[('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin C'), ('CHEBI_33284', 'nutrient', 269, 'nutrients')]	0	['discussion\nin study, (“protective”) antioxidant intakes  infant allergic outcomes, selected antioxidant copper) dietary nutrients dietary supplements se .']
S105-PMC3509518	PMC3509518	11/2012	S105-PMC3509518	['furthermore, maternal dietary Vitamin C intake in Pregnancy APPEARED PROTECTIVE against Development Of Wheeze in the first year of Life.']	[('ANOMALY_CURIOUS_FINDING', 60), ('SUPERFICIAL_RELATIONSHIP', 69)]	2	[('CHEBI_27300', 'vitamin D', 30, 'vitamin C'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('GO_0060041', 'retina development in camera-type eye', 88, 'development of wheeze'), ('UBERON_0000104', 'life cycle', 131, 'life')]	0	['furthermore, maternal dietary  intake  wheeze year life.']
S127-PMC3509518	PMC3509518	11/2012	S127-PMC3509518	['with a more LIMITED DATASET available, a meta-analysis on two published Birth cohort studies [9,10] OBSERVED no association between maternal Vitamin C intake in Pregnancy and wheeze at 2 years of age [23].']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 100)]	2	[('GO_0007567', 'parturition', 72, 'birth'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin C'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy')]	0	['available, meta-analysis birth [9,10] maternal  intake  wheeze 2 age [23].']
S128-PMC3509518	PMC3509518	11/2012	S128-PMC3509518	['there is a PAUCITY of intervention studies with Vitamin C in Pregnancy for PREVENTION of allergic disease.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 75)]	2	[('CHEBI_27300', 'vitamin D', 48, 'vitamin C'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy')]	0	['  allergic disease.']
S131-PMC3509518	PMC3509518	11/2012	S131-PMC3509518	['we could not confirm PREVIOUS FINDINGS that reduced maternal Vitamin E intakes were ASSOCIATED with increased risk of developing childhood wheeze [9,10,11,12] DESPITE the fact that almost 50% of Pregnant mothers did not meet the rdi when intakes from diet alone were TAKEN INTO ACCOUNT, and 20% of the mothers did not meet the rdi when total Vitamin E intakes were analysed [18].']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 84), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 159), ('ANOMALY_CURIOUS_FINDING', 159), ('IMPORTANT_CONSIDERATION', 267)]	6	[('CHEBI_27300', 'vitamin D', 61, 'vitamin E'), ('GO_0007565', 'female pregnancy', 195, 'pregnant'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin E')]	0	['maternal  intakes childhood wheeze [9,10,11,12] 50%  mothers meet rdi intakes diet account, 20% mothers meet rdi  intakes [18].']
S3-PMC3513049	PMC3513049	2/2012	S3-PMC3513049	['Prenatal Vitamin D inadequacy HAS BEEN HYPOTHESIZED as a risk factor for pediatric atopy and asthma.']	[('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 39)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D')]	0	['  inadequacy pediatric atopy asthma.']
S8-PMC3513049	PMC3513049	2/2012	S8-PMC3513049	['for whites, but not african americans, having no pet compared to 1 or >1 pet during Pregnancy was ASSOCIATED with lower Cord Blood Vitamin D concentrations (37.7, 45.2, 47.0 nmol/l, respectively, p = 0.001).']	[('SUPERFICIAL_RELATIONSHIP', 98)]	1	[('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('UBERON_0009472', 'axilla', 120, 'cord blood'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]	0	['whites, african americans, pet >1 pet  cord blood  concentrations (37.7, 45.2, 47.0 nmol/l, respectively, p = 0.001).']
S1-PMC3515553	PMC3515553	12/2012	S1-PMC3515553	['Brain Development occurs primarily in utero and early infancy, BUT the ROLE of maternal Vitamin B-12 status during Pregnancy on offspring Cognitive function is UNCLEAR.']	[('ANOMALY_CURIOUS_FINDING', 63), ('SUPERFICIAL_RELATIONSHIP', 71), ('FULL_UNKNOWN', 160)]	3	[('GO_0060132', 'prolactin secreting cell development', 0, 'Brain development'), ('UBERON_0000955', 'brain', 0, 'Brain'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 88, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('GO_0050890', 'cognition', 138, 'cognitive')]	0	['brain occurs utero infancy, maternal -12 status  offspring cognitive unclear.']
S2-PMC3515553	PMC3515553	12/2012	S2-PMC3515553	['in THIS STUDY we ASSESSED the EFFECT of Vitamin B-12 status in well-nourished Pregnant women on the Cognitive ability of their offspring in a uk birth cohort (alspac).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 17), ('SUPERFICIAL_RELATIONSHIP', 30)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 40, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 78, 'pregnant'), ('GO_0050890', 'cognition', 100, 'cognitive')]	0	['-12 status well-nourished  women cognitive ability offspring uk birth (alspac).']
S14-PMC3515553	PMC3515553	12/2012	S14-PMC3515553	['BECAUSE of the transfer from mother to offspring of Vitamin B-12 during Pregnancy and Lactation, maternal REQUIREMENTS during these periods are increased and deficiency CAN occur[5].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 106), ('INCOMPLETE_EVIDENCE', 169)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 52, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0007595', 'lactation', 86, 'lactation')]	0	['transfer mother offspring -12  lactation, maternal periods occur[5].']
S15-PMC3515553	PMC3515553	12/2012	S15-PMC3515553	['DESPITE the IMPORTANCE of Vitamin B-12 to Neuronal Development and the dependency of the developing foetus and infant on maternal Vitamin B-12 status, it is UNKNOWN WHETHER variation in maternal Pregnancy Vitamin B-12, across the normal range, INFLUENCES offspring Neurodevelopment.']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 12), ('FULL_UNKNOWN', 157), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 165), ('SUPERFICIAL_RELATIONSHIP', 244)]	5	[('CHEBI_27300', 'vitamin D', 26, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 26, 'vitamin B-12'), ('CL_0000540', 'neuron', 42, 'neuronal'), ('GO_0007399', 'nervous system development', 42, 'neuronal development'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 130, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 195, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 205, 'vitamin B-12'), ('GO_0007399', 'nervous system development', 265, 'neurodevelopment')]	0	['despite -12 neuronal foetus infant maternal -12 status, maternal  -12, normal range, offspring neurodevelopment.']
S21-PMC3515553	PMC3515553	12/2012	S21-PMC3515553	['the AIM of THIS STUDY was TO EXAMINE the ASSOCIATION of maternal dietary Intake of Vitamin B-12 and also of Snps in Fut2 and tcn2 with offspring iq assessed at age 8 in a population of european origin.figure 1shows the framework for the HYPOTHESIS that we have EXAMINED HERE concerning the LINKS between maternal Vitamin B-12 during Pregnancy with offspring iq.10.1371/journal.pone.0051084.g001\n\ncaption (fig): figure 1\ndiagram showing the framework of the mendelian randomization approach used in this study.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('SUPERFICIAL_RELATIONSHIP', 41), ('INCOMPLETE_EVIDENCE', 237), ('QUESTION_ANSWERED_BY_THIS_WORK', 261), ('QUESTION_ANSWERED_BY_THIS_WORK', 270), ('SUPERFICIAL_RELATIONSHIP', 290)]	8	[('GO_0007631', 'feeding behavior', 73, 'intake'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 83, 'vitamin B-12'), ('SO_0000694', 'SNP', 108, 'SNPs'), ('PR_000007719', 'frizzled-2', 116, 'FUT2'), ('CHEBI_27300', 'vitamin D', 313, 'vitamin B'), ('GO_0007565', 'female pregnancy', 333, 'pregnancy')]	0	['maternal dietary intake -12 snps fut2 tcn2 offspring iq age 8 population european origin.figure maternal -12  offspring iq.10.1371/journal.pone.0051084.g001\n\ncaption (fig): figure 1\ndiagram mendelian randomization study.']
S53-PMC3515553	PMC3515553	12/2012	S53-PMC3515553	['in the observational analyses of maternal dietary Vitamin B-12 in Pregnancy, we also EXAMINED POSSIBLE MEDIATION by Gestational age, Birth-weight and breastfeeding (obtained from repeat Postnatal maternal completed questionnaires and derived as no breastfeeding, breastfeeding for <3 months, for 3 to 5 months, for ≥6 months).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 85), ('INCOMPLETE_EVIDENCE', 94), ('SUPERFICIAL_RELATIONSHIP', 103)]	3	[('CHEBI_27300', 'vitamin D', 50, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 50, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy'), ('GO_0007565', 'female pregnancy', 116, 'gestational'), ('GO_0007567', 'parturition', 133, 'birth'), ('GO_0007567', 'parturition', 186, 'postnatal')]	0	['maternal dietary -12  age, birth-weight breastfeeding (obtained repeat postnatal maternal completed questionnaires breastfeeding, breastfeeding <3 months, 3 5 months, ≥6 months).']
S69-PMC3515553	PMC3515553	12/2012	S69-PMC3515553	['in these analyses, we log transformed Vitamin B-12 to base 2 so that results are INTERPRETED as a mean difference in iq per doubling of Vitamin B-12 intake or status.10.1371/journal.pone.0051084.t002\n\ncaption (table-wrap): table 2\nASSOCIATION of maternal dietary vitamin b-12 Intake during Pregnancy with offspring iq at age 8.']	[('PROBABLE_UNDERSTANDING', 81), ('SUPERFICIAL_RELATIONSHIP', 231)]	2	[('CHEBI_27300', 'vitamin D', 38, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 38, 'vitamin B-12'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin B'), ('GO_0007631', 'feeding behavior', 276, 'intake'), ('GO_0007565', 'female pregnancy', 290, 'pregnancy')]	0	['analyses, log transformed -12 2 results iq doubling status.10.1371/journal.pone.0051084.t002\n\ncaption (table-wrap): table 2\nassociation maternal dietary vitamin b-12 intake  offspring iq age 8.']
S75-PMC3515553	PMC3515553	12/2012	S75-PMC3515553	['AS offspring genotype MAY INFLUENCE Cognitive ability per se , we adjusted for offspring genotype to estimate the EFFECT of maternal Vitamin B-12 status during Pregnancy on offspring iq.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 22), ('SUPERFICIAL_RELATIONSHIP', 26), ('SUPERFICIAL_RELATIONSHIP', 114)]	4	[('GO_0050890', 'cognition', 36, 'cognitive'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 133, 'vitamin B-12'), ('CHEBI_37983', 'sulfur-35 atom', 143, '12'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy')]	0	['offspring genotype cognitive ability se adjusted offspring genotype maternal -12 status  offspring iq.']
S86-PMC3515553	PMC3515553	12/2012	S86-PMC3515553	['dietary maternal Vitamin B-12 intake, Cord Blood Vitamin B-12 and offspring iq\nmother’s dietary intake of Vitamin B-12 during Pregnancy was ASSOCIATED with offspring iq in simple age, sex and energy Intake adjusted analyses (model 1), with offspring iq being on average 2.0 (95%ci 1.3, 2.8; p<0.001) points greater per doubling of maternal dietary Vitamin B-12 intake (table 2).']	[('SUPERFICIAL_RELATIONSHIP', 140)]	1	[('PR_000027594', 'histone H3', 17, 'Vitamin B'), ('UBERON_0000948', 'heart', 38, 'Cord'), ('UBERON_0000178', 'blood', 43, 'Blood'), ('PR_000027594', 'histone H3', 49, 'Vitamin B'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 114, 'B'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('GO_0007631', 'feeding behavior', 199, 'intake'), ('CHEBI_85855', 'diacylglycerol 46:7', 348, 'vitamin B-12'), ('PR_000017269', 'ventral anterior homeobox 2', 348, 'vitamin B-12')]	0	['dietary maternal vitamin b-12 intake, cord blood vitamin b-12 offspring iq\nmother’s dietary intake -12  offspring iq age, sex energy intake adjusted (model 1), offspring iq average 2.0 (95%ci 1.3, 2.8; p<0.001) doubling maternal dietary vitamin b-12 intake (table 2).']
S93-PMC3515553	PMC3515553	12/2012	S93-PMC3515553	['Vitamin B-12 status RELATED Snps, maternal dietary intake of Vitamin B-12 and Cord Blood Vitamin B-12\nneither of the maternal Snps was associated with maternal dietary Intake of Vitamin B-12 during Pregnancy in a linear model, ALTHOUGH tcn2 rs1801198 heterozygotes showed higher Vitamin B-12 intake than either homozygote group (p\u200a=\u200a0.02).']	[('SUPERFICIAL_RELATIONSHIP', 20), ('ANOMALY_CURIOUS_FINDING', 227)]	2	[('PR_000017269', 'ventral anterior homeobox 2', 0, 'Vitamin B-12'), ('SO_0000694', 'SNP', 28, 'SNPs'), ('PR_000017269', 'ventral anterior homeobox 2', 61, 'Vitamin B-12'), ('UBERON_0000948', 'heart', 78, 'Cord'), ('UBERON_0000178', 'blood', 83, 'Blood'), ('PR_000017269', 'ventral anterior homeobox 2', 89, 'Vitamin B-12'), ('SO_0000694', 'SNP', 126, 'SNPs'), ('GO_0007631', 'feeding behavior', 168, 'intake'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 178, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 279, 'vitamin B-12')]	0	['vitamin b-12 status snps, maternal dietary intake vitamin b-12 cord blood vitamin b-12\nneither maternal snps maternal dietary intake -12  linear model, tcn2 rs1801198 heterozygotes higher -12 intake homozygote (p\u200a=\u200a0.02).']
S99-PMC3515553	PMC3515553	12/2012	S99-PMC3515553	['offspring Haplotypes were not associated with Cord Blood Vitamin B-12 (data not shown).10.1371/journal.pone.0051084.t003\n\ncaption (table-wrap): table 3\nASSOCIATION of maternal genotype at Snps RELATED to Vitamin B-12 Metabolism with maternal dietary intake at 32 weeks Pregnant and Vitamin B-12 Cord Blood concentration.Snpgenotypenamedian (iqr) of maternal Vitaminb-12 dietary intake (µg/day)nmedian (iqr) of Vitamin B-12 Cord Blood (pmol/l) Fut2 rs492602tt16424.2 (3.0, 6.1)62291 (183, 397)tc31874.2 (3.0, 6.1)128300 (196, 424)cc16484.3 (3.0, 6.2)50294 (214, 534)ratio of geometric means perc Allele (95% ci)64771.00 (0.98, 1.02)2401.08 (0.97, 1.19)p-valuea0.82/0.960.15/0.31 tcn2 rs1801198gg12764.1 (3.0, 5.9)41276 (173, 369)cg32214.3 (3.2, 6.2)125279 (196, 417)cc20024.1 (3.0, 6.1)68318 (226, 436)ratio of geometric meansper c Allele (95% ci)64991.01 (0.99, 1.03)2341.13 (1.02–1.25)p-valuea0.44/0.020.02/0.07 tcn2 rs9606756aa54834.3 (3.1, 6.2)193288 (205, 397)ag16504.3 (3.0, 6.1)58298 (206, 484)gg1204.0 (2.9, 6.1)2238 (82, 394)ratio of geometric meansper G Allele (95% ci)72530.99 (0.96, 1.01)2531.03 (0.89, 1.18)p-valuea0.23/0.460.73/0.31\nn reflects the number of mothers with genotype and dietary Intake or offspring Cord Blood Vitamin B-12 data, regardless of whether there was offspring iq data available for them as well.']	[('SUPERFICIAL_RELATIONSHIP', 152), ('SUPERFICIAL_RELATIONSHIP', 193)]	2	[('SO_0001024', 'haplotype', 10, 'haplotypes'), ('UBERON_0002240', 'spinal cord', 46, 'cord'), ('UBERON_0000178', 'blood', 51, 'blood'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 57, 'vitamin B-12'), ('SO_0000694', 'SNP', 188, 'SNPs'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin B'), ('GO_0009235', 'cobalamin metabolic process', 204, 'vitamin B-12 metabolism'), ('PR_000017269', 'ventral anterior homeobox 2', 204, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 269, 'pregnant'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin B'), ('UBERON_0002240', 'spinal cord', 295, 'cord'), ('UBERON_0000178', 'blood', 300, 'blood'), ('SO_0001744', 'UPD', 320, 'SNPgenotypeNamedian'), ('CHEBI_27300', 'vitamin D', 358, 'vitaminB'), ('PR_000017269', 'ventral anterior homeobox 2', 358, 'vitaminB-12'), ('CHEBI_27300', 'vitamin D', 410, 'vitamin B'), ('UBERON_0002240', 'spinal cord', 423, 'cord'), ('UBERON_0000178', 'blood', 428, 'blood'), ('PR_000007719', 'frizzled-2', 443, 'FUT2'), ('SO_0001023', 'allele', 595, 'allele'), ('SO_0001023', 'allele', 831, 'allele'), ('SO_0001434', 'cassette_pseudogene', 1061, 'G'), ('SO_0001023', 'allele', 1063, 'allele'), ('GO_0007631', 'feeding behavior', 1205, 'intake'), ('UBERON_0002240', 'spinal cord', 1225, 'cord'), ('UBERON_0000178', 'blood', 1230, 'blood'), ('CHEBI_27300', 'vitamin D', 1236, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 1236, 'vitamin B-12')]	0	['offspring haplotypes cord blood -12 (data shown).10.1371/journal.pone.0051084.t003\n\ncaption (table-wrap): table 3\nassociation maternal genotype snps -12 metabolism maternal dietary intake 32 weeks  -12 cord blood concentration.snpgenotypenamedian (iqr) maternal -12 dietary intake (µg/day)nmedian (iqr) -12 cord blood (pmol/l) fut2 rs492602tt16424.2 (3.0, 6.1)62291 (183, 397)tc31874.2 (3.0, 6.1)128300 (196, 424)cc16484.3 (3.0, 6.2)50294 (214, 534)ratio geometric perc allele (95% ci)64771.00 (0.98, 1.02)2401.08 (0.97, 1.19)p-valuea0.82/0.960.15/0.31 tcn2 rs1801198gg12764.1 (3.0, 5.9)41276 (173, 369)cg32214.3 (3.2, 6.2)125279 (196, 417)cc20024.1 (3.0, 6.1)68318 (226, 436)ratio geometric meansper c allele (95% ci)64991.01 (0.99, 1.03)2341.13 (1.02–1.25)p-valuea0.44/0.020.02/0.07 tcn2 rs9606756aa54834.3 (3.1, 6.2)193288 (205, 397)ag16504.3 (3.0, 6.1)58298 (206, 484)gg1204.0 (2.9, 6.1)2238 (82, 394)ratio geometric meansper g allele (95% ci)72530.99 (0.96, 1.01)2531.03 (0.89, 1.18)p-valuea0.23/0.460.73/0.31\nn mothers genotype dietary intake offspring cord blood -12 data, offspring iq well.']
S127-PMC3515553	PMC3515553	12/2012	S127-PMC3515553	['discussion\n\nmain findings\nTO THE BEST OF OUR KNOWLEDGE THIS is the FIRST STUDY to EXAMINE the IMPACT of differential concentrations of circulating Vitamin B-12 on offspring iq through the use of records of Maternal Pregnancy Vitamin B-12 intake, as well as Vitamin B-12 RELATED Genetic variants.']	[('PROBABLE_UNDERSTANDING', 26), ('QUESTION_ANSWERED_BY_THIS_WORK', 55), ('INCOMPLETE_EVIDENCE', 67), ('QUESTION_ANSWERED_BY_THIS_WORK', 73), ('QUESTION_ANSWERED_BY_THIS_WORK', 82), ('SUPERFICIAL_RELATIONSHIP', 94), ('SUPERFICIAL_RELATIONSHIP', 270)]	7	[('CHEBI_27300', 'vitamin D', 147, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 147, 'vitamin B-12'), ('GO_0007618', 'mating', 206, 'maternal'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 225, 'vitamin B-12'), ('CHEBI_37983', 'sulfur-35 atom', 235, '12'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 257, 'vitamin B-12'), ('SO_0000704', 'gene', 278, 'genetic')]	0	['discussion\n\nmain findings\nto concentrations circulating -12 offspring iq records maternal  -12 intake, -12 genetic variants.']
S154-PMC3515553	PMC3515553	12/2012	S154-PMC3515553	['YET, LITTLE IS KNOWN about the INFLUENCE that low Plasma Vitamin B-12 during Pregnancy MAY have on the Cognitive ability of children later in Life.']	[('ANOMALY_CURIOUS_FINDING', 0), ('FULL_UNKNOWN', 5), ('SUPERFICIAL_RELATIONSHIP', 31), ('INCOMPLETE_EVIDENCE', 87)]	4	[('UBERON_0001969', 'blood plasma', 50, 'plasma'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 57, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0050890', 'cognition', 103, 'cognitive'), ('UBERON_0000104', 'life cycle', 142, 'life')]	0	['yet, plasma -12  cognitive ability children life.']
S155-PMC3515553	PMC3515553	12/2012	S155-PMC3515553	['in mexico, a study that assessed maternal diet during the first Trimester of Pregnancy and offspring Neurodevelopment REPORTED a decrease in Cognition test scores among children of mothers with a deficient intake of Vitamin B-12 (<2 µg/day)[7].']	[('INCOMPLETE_EVIDENCE', 118)]	1	[('GO_0009294', 'DNA mediated transformation', 64, 'trimester'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0007399', 'nervous system development', 101, 'neurodevelopment'), ('GO_0050890', 'cognition', 141, 'cognition'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 216, 'vitamin B-12')]	0	['mexico, maternal diet trimester  offspring neurodevelopment decrease cognition scores among children mothers intake -12 (<2 µg/day)[7].']
S181-PMC3515553	PMC3515553	12/2012	S181-PMC3515553	['caption (supplementary-material): table s5\n\nASSOCIATION of maternal genotype at Snps RELATED to Vitamin B-12 Metabolism with offspring iq at age 8, stratified by Maternal Pregnancy RECOMMENDED daily amount (rda) of Vitamin B-12.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 85), ('FUTURE_WORK', 181)]	3	[('SO_0000694', 'SNP', 80, 'SNPs'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin B'), ('GO_0009235', 'cobalamin metabolic process', 96, 'vitamin B-12 metabolism'), ('PR_000017269', 'ventral anterior homeobox 2', 96, 'vitamin B-12'), ('GO_0007618', 'mating', 162, 'maternal'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 215, 'vitamin B-12')]	0	['caption (supplementary-material): table s5\n\nassociation maternal genotype snps -12 metabolism offspring iq age 8, stratified maternal  daily amount (rda) -12.']
S1-PMC3521768	PMC3521768	12/2012	S1-PMC3521768	['objective\nTO ASSESS the INDEPENDENT and INTERACTION EFFECTS of Prenatal zinc and Vitamin A deficiencies on Birthweight in rural sidama, southern ethiopia.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('SUPERFICIAL_RELATIONSHIP', 24), ('SUPERFICIAL_RELATIONSHIP', 40), ('SUPERFICIAL_RELATIONSHIP', 52)]	4	[('GO_0007565', 'female pregnancy', 63, 'prenatal'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin A'), ('GO_0007596', 'blood coagulation', 107, 'birthweight')]	0	['objective\nto  zinc  birthweight rural sidama, southern ethiopia.']
S27-PMC3521768	PMC3521768	12/2012	S27-PMC3521768	['pertaining Vitamin A, a meta-analysis CONCLUDED that Prenatal Vitamin A supplementation does not significantly reduce RISK of lbw[16].']	[('INCOMPLETE_EVIDENCE', 38), ('IMPORTANT_CONSIDERATION', 118)]	2	[('CHEBI_27300', 'vitamin D', 11, 'vitamin A'), ('GO_0007565', 'female pregnancy', 53, 'prenatal'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin A')]	0	['pertaining meta-analysis   supplementation lbw[16].']
S30-PMC3521768	PMC3521768	12/2012	S30-PMC3521768	['the PURPOSE of THE CURRENT STUDY is TO INVESTIGATE the INDEPENDENT and INTERACTION EFFECTS of Prenatal zinc and Vitamin A deficiencies on Birthweight in rural sidama, southern ethiopia.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 36), ('SUPERFICIAL_RELATIONSHIP', 55), ('SUPERFICIAL_RELATIONSHIP', 71), ('SUPERFICIAL_RELATIONSHIP', 83)]	6	[('GO_0007565', 'female pregnancy', 94, 'prenatal'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin A'), ('GO_0007596', 'blood coagulation', 138, 'birthweight')]	0	[' zinc  birthweight rural sidama, southern ethiopia.']
S32-PMC3521768	PMC3521768	12/2012	S32-PMC3521768	['DESPITE the existence of MANY rcts and OBSERVATIONAL studies which evaluated the EFFECT of Prenatal zinc and Vitamin A status on Birthweight, THE CURRENT STUDY is WORTH documentable as it HAS BEEN conducted in area with high prevalence of zinc and Vitamin A deficiencies.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 81), ('QUESTION_ANSWERED_BY_THIS_WORK', 142), ('ANOMALY_CURIOUS_FINDING', 163), ('INCOMPLETE_EVIDENCE', 188)]	8	[('GO_0007565', 'female pregnancy', 91, 'prenatal'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin A'), ('GO_0007596', 'blood coagulation', 129, 'birthweight'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin A')]	0	['despite existence rcts  zinc  status birthweight, documentable zinc  deficiencies.']
S66-PMC3521768	PMC3521768	12/2012	S66-PMC3521768	['apart from the main independent variables (Prenatal Vitamin A and zinc statuses), OTHER independent variables of interest were maternal Literacy (ability to Read and write), maternal employment, household wealth index, agro-ecological zone, antenatal care (anc) follow up, Blood pressure during Pregnancy, type of staple diet, distance from the nearby health facility, maternal thinness (maternal mid-upper Arm circumference (muac) less than 220 mm), maternal stunting (maternal height less than 145 cm), elevated crp (crp greater or equal to 5 mg/dl), newborn sex, maternal age and primiparity.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 82)]	1	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin A'), ('GO_0007612', 'learning', 136, 'literacy'), ('GO_0006281', 'DNA repair', 157, 'read'), ('UBERON_0000178', 'blood', 273, 'blood'), ('GO_0007565', 'female pregnancy', 295, 'pregnancy'), ('UBERON_0002362', 'arachnoid mater', 407, 'Arm')]	0	['apart main  zinc statuses), maternal literacy (ability read write), maternal employment, household wealth index, agro-ecological zone, antenatal (anc) up, blood pressure type diet, distance nearby facility, maternal thinness (maternal mid-upper arm circumference (muac) 220 mm), maternal stunting (maternal height 145 cm), elevated crp (crp equal 5 mg/dl), newborn sex, maternal age primiparity.']
S169-PMC3534399	PMC3534399	10/2012	S169-PMC3534399	['a single trial (in hiv-infected mothers) has investigated a LIMITED range of T-Cell subsets in Pregnancy, but not in the offspring, and FOUND that limited mmn supplementation (Vitamins B, c and e), BUT NOT Vitamin A alone, increased cd4+ and cd8+ counts [25].']	[('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 136), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 198), ('ANOMALY_CURIOUS_FINDING', 202)]	4	[('CL_0000084', 'T cell', 77, 'T-cell'), ('GO_0007565', 'female pregnancy', 95, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 176, 'vitamins B'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin A')]	0	['single (in hiv-infected mothers) t-cell subsets offspring, mmn supplementation (, c e),  alone, cd4+ cd8+ counts [25].']
S76-PMC3544621	PMC3544621	11/2012	S76-PMC3544621	['[21]5 (1999-2006)provision of advice regarding Vitamin A supplementation in hiv infected womenrisk of Mother-To-Child Transmission (mtct) of hiv,Birth weight, stillbirth rate and ptdno evidence of an EFFECT on the risk of Prenatal or Postnatal mtct of hiv (rr 1.06, 95% ci 0.89-1.26).']	[('SUPERFICIAL_RELATIONSHIP', 200)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin A'), ('GO_0060126', 'somatotropin secreting cell differentiation', 102, 'Mother-to-Child Transmission'), ('GO_0007567', 'parturition', 145, 'birth'), ('GO_0007565', 'female pregnancy', 222, 'prenatal'), ('GO_0007567', 'parturition', 234, 'postnatal')]	0	['[21]5 (1999-2006)provision regarding  supplementation hiv infected womenrisk mother-to-child transmission (mtct) hiv,birth weight, stillbirth rate ptdno  postnatal mtct hiv (rr 1.06, 95% ci 0.89-1.26).']
S0-PMC3552819	PMC3552819	12/2012	S0-PMC3552819	['pharmacokinetics of a single oral dose of Vitamin D3 (70,000 iu) in Pregnant and non-Pregnant women\n\nabstract\n\nbackground\nimprovements in Antenatal Vitamin D status MAY have maternal-infant health benefits.']	[('INCOMPLETE_EVIDENCE', 165)]	1	[('CHEBI_33279', 'vitamin D5', 42, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 42, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 68, 'pregnant'), ('GO_0007565', 'female pregnancy', 85, 'pregnant'), ('GO_0007567', 'parturition', 138, 'antenatal'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]	0	['pharmacokinetics single oral dose vitamin d3 (70,000 iu)  non- women\n\nabstract\n\nbackground\nimprovements antenatal  status maternal-infant benefits.']
S14-PMC3552819	PMC3552819	12/2012	S14-PMC3552819	['HOWEVER, VERY FEW STUDIES have rigorously addressed Vitamin D supplementation during Pregnancy, and the single-dose Vitamin D3 Pregnancy trials published to date have provided LITTLE insight into pharmacokinetics or SAFETY [5,6].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 9), ('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 176), ('IMPORTANT_CONSIDERATION', 216)]	5	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('CHEBI_33279', 'vitamin D5', 116, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 116, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy')]	0	['however, rigorously  supplementation single-dose vitamin d3  pharmacokinetics [5,6].']
S15-PMC3552819	PMC3552819	12/2012	S15-PMC3552819	['moreover, there is a near complete absence of Pharmacological data in south asia, where the Vitamin D status of Pregnant women [7] and young infants [8] is poor IN SPITE of the tropical climate.']	[('ANOMALY_CURIOUS_FINDING', 161)]	1	[('CHEBI_52217', 'pharmaceutical', 46, 'pharmacological'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnant')]	0	['moreover, absence pharmacological south asia,  status  women [7] young infants [8] tropical climate.']
S134-PMC3552819	PMC3552819	12/2012	S134-PMC3552819	['caption (table-wrap): table 4\n\nPregnancy and newborn outcomes for Pregnant participants who received only a single dose of 70,000 iu Vitamin D at enrollment and were followed up to Deliveryn13Gestational age at Birth , weeks (by lmp)amean (±sd)38.8 (±1.8)range35.7 – 42.0 Preterm, n (%)2 (15%) Birth weightb(g)\xa0mean (±sd)c2441 (±354)range (g)1890 – 3005n/n (%) low Birth weight6/12 (50%) Delivery mode , n/n (%) cesarean sectiond8/13 (62%) sex , n (%) female5 (38%) live Birthse12/13 alive at 1 month of agef11/13\na.in a sample of 113 Deliveries at the study site (october 2009 to january 2010) for which there was a recalled first day of last Menstrual period, the mean Gestational age at Birth was ESTIMATED to be 39.7 weeks (±2.2).']	[('INCOMPLETE_EVIDENCE', 700)]	1	[('GO_0007565', 'female pregnancy', 31, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 66, 'pregnant'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0042742', 'defense response to bacterium', 181, 'deliveryN13Gestational'), ('GO_0007567', 'parturition', 211, 'birth'), ('GO_0007128', 'meiotic prophase I', 272, 'Preterm'), ('GO_0007567', 'parturition', 294, 'Birth'), ('GO_0007567', 'parturition', 365, 'Birth'), ('GO_0007586', 'digestion', 388, 'Delivery'), ('GO_0007596', 'blood coagulation', 471, 'birthse12'), ('GO_0007567', 'parturition', 535, 'deliveries'), ('GO_0007613', 'memory', 644, 'menstrual'), ('UBERON_0001347', 'white adipose tissue', 644, 'menstrual'), ('GO_0007565', 'female pregnancy', 671, 'gestational'), ('GO_0007567', 'parturition', 690, 'birth')]	0	['caption (table-wrap): table 4\n\n newborn outcomes  participants received single dose 70,000 iu  enrollment followed deliveryn13gestational age birth weeks (by lmp)amean (±sd)38.8 (±1.8)range35.7 42.0 preterm, n (%)2 (15%) birth weightb(g)\xa0mean (±sd)c2441 (±354)range (g)1890 3005n/n (%) birth weight6/12 (50%) delivery mode n/n (%) cesarean sectiond8/13 (62%) sex n (%) female5 (38%) live birthse12/13 alive month agef11/13\na.in sample 113 deliveries site (october 2009 january 2010) recalled day last menstrual period,  age birth 39.7 weeks (±2.2).']
S192-PMC3552819	PMC3552819	12/2012	S192-PMC3552819	['higher concentrations of Vitamin D-binding protein during Pregnancy [[26] MAY have efficiently buffered the absorbed Vitamin D3 and slowed its Transport To the Liver where it undergoes 25-hydroxylation [27]].']	[('INCOMPLETE_EVIDENCE', 74)]	1	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_33279', 'vitamin D5', 117, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 117, 'vitamin D3'), ('GO_0006301', 'postreplication repair', 143, 'transport to ... liver'), ('UBERON_0002107', 'liver', 160, 'liver')]	0	['higher concentrations -binding protein  [[26] efficiently absorbed vitamin d3 transport liver undergoes 25-hydroxylation [27]].']
S202-PMC3552819	PMC3552819	12/2012	S202-PMC3552819	['the single Vitamin D3 dose of 70,000 iu did not provoke hypercalcemia or hypercalciuria in non-Pregnant or Pregnant participants, and available data INDICATED that adverse Perinatal events were neither temporally nor mechanistically linked to Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 149)]	1	[('CHEBI_33279', 'vitamin D5', 11, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 11, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('GO_0007565', 'female pregnancy', 107, 'pregnant'), ('GO_0036268', 'swimming', 172, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 172, 'perinatal'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D')]	0	['single vitamin d3 dose 70,000 iu hypercalcemia hypercalciuria perinatal events temporally mechanistically  supplementation.']
S221-PMC3552819	PMC3552819	12/2012	S221-PMC3552819	['LIKEWISE, we DID NOT document any NOTABLE Pregnancy-related hypersensitivity to a Vitamin D dose of 70,000 iu in terms of its EFFECTS on calcium Homeostasis.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 13), ('ANOMALY_CURIOUS_FINDING', 34), ('SUPERFICIAL_RELATIONSHIP', 126)]	4	[('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0042592', 'homeostatic process', 145, 'homeostasis')]	0	['likewise, -related hypersensitivity  dose 70,000 iu terms calcium homeostasis.']
S10-PMC3582478	PMC3582478	2/2013	S10-PMC3582478	['changes in Fatty Acid composition during Pregnancy quickly return to the normal range following Parturition HOWEVER, an increase in the Omega-6/3 ratio increases the risk of Ppd11,12low maternal Omega-3 Polyunsaturated Fatty Acid Intake is SUGGESTED to CONTRIBUTE to decreased maternal and fetal health, INTERACTING with the Serotonin transporter Alleles to CONTRIBUTE TO ppd.13\ndecreased Pregnancy Vitamin D ASSOCIATES with many RISK FACTORS for ppd, including Preeclampsia,14SUGGESTING that it will indirectly Modulate ppd susceptibility.']	[('ANOMALY_CURIOUS_FINDING', 108), ('INCOMPLETE_EVIDENCE', 240), ('SUPERFICIAL_RELATIONSHIP', 253), ('SUPERFICIAL_RELATIONSHIP', 304), ('SUPERFICIAL_RELATIONSHIP', 358), ('SUPERFICIAL_RELATIONSHIP', 409), ('SUPERFICIAL_RELATIONSHIP', 430), ('INCOMPLETE_EVIDENCE', 475)]	8	[('CHEBI_35366', 'fatty acid', 11, 'fatty acid'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('GO_0019230', 'proprioception', 96, 'parturition'), ('CHEBI_30823', 'oleate', 136, 'omega'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 174, 'PPD11'), ('CHEBI_79370', 'ibho#10', 195, 'omega-3'), ('GO_0033576', 'protein glycosylation in cytosol', 203, 'polyunsaturated fatty acid intake'), ('CHEBI_35366', 'fatty acid', 219, 'fatty acid'), ('CHEBI_28790', 'serotonin', 325, 'serotonin'), ('SO_0001023', 'allele', 347, 'alleles'), ('GO_0007565', 'female pregnancy', 389, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 399, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 462, 'preeclampsia'), ('GO_0065007', 'biological regulation', 512, 'modulate')]	0	['changes fatty acid composition  quickly return normal following parturition however, increase omega-6/3 ratio ppd11,12low maternal omega-3 polyunsaturated fatty acid intake decreased maternal fetal health, serotonin transporter alleles ppd.13\ndecreased   ppd, preeclampsia,14suggesting ppd susceptibility.']
S179-PMC3586494	PMC3586494	2/2013	S179-PMC3586494	['female a/a Mice Fed a methyl-supplemented diet with extra Folate, Vitamin B-12,Choline, and betaine 2 weeks prior to Mating with male Avy/ a agouti Mice and throughout Pregnancy and Lactation passed along the agouti Gene to their offspring intact, YET DEMONSTRATED a shift in distribution towards having more offspring with the pseudoagouti phenotype [76].']	[('ANOMALY_CURIOUS_FINDING', 248), ('INCOMPLETE_EVIDENCE', 252)]	2	[('NCBITaxon_10088', 'Mus <genus>', 11, 'mice'), ('GO_0007631', 'feeding behavior', 16, 'fed'), ('CHEBI_30863', '5-azaorotic acid', 58, 'folate'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 66, 'vitamin B-12'), ('CHEBI_15354', 'choline', 79, 'choline'), ('GO_0007618', 'mating', 117, 'mating'), ('PR_000004155', 'apolipoprotein E', 134, 'Avy'), ('NCBITaxon_10088', 'Mus <genus>', 148, 'mice'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('GO_0007595', 'lactation', 182, 'lactation'), ('SO_0000704', 'gene', 216, 'gene')]	0	['female a/a mice fed methyl-supplemented diet extra folate, -12,choline, betaine 2 weeks mating male avy/ agouti mice throughout  lactation passed along agouti gene offspring intact, distribution offspring pseudoagouti phenotype [76].']
S199-PMC3599191	PMC3599191	1/2013	S199-PMC3599191	['Intake Of Vitamin D during Pregnancy, EITHER through the diet OR through supplements, has a protective ROLE against asthma and atopic dermatitis.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 62), ('SUPERFICIAL_RELATIONSHIP', 103)]	3	[('GO_0060384', 'innervation', 0, 'Intake of'), ('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 27, 'pregnancy')]	0	['intake  supplements, asthma atopic dermatitis.']
S201-PMC3599191	PMC3599191	1/2013	S201-PMC3599191	['the average dose of Vitamin D to be taken is ABOUT 600 ui/day [110], but MANY STUDIES INDICATE that a higher dose of Vitamin D during Pregnancy and Lactation, up to 1000 ui/day, is NECESSARY to achieve a good level of Vitamin D assets [111].']	[('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 73), ('INCOMPLETE_EVIDENCE', 86), ('IMPORTANT_CONSIDERATION', 181)]	4	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('GO_0007595', 'lactation', 148, 'lactation'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D')]	0	['average dose  600 ui/day [110], higher dose   lactation, 1000 ui/day, achieve  assets [111].']
S221-PMC3613945	PMC3613945	2/2013	S221-PMC3613945	['Prostate cancer\nstudies HAVE SHOWN that Vitamin D CAN inhibit Proliferation and Differentiation Of Human Prostatic Cells in vitro 162and 1,25(Oh)2D3Has marked anti-tumor EFFECTS in Animal MODELS163.']	[('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 50), ('SUPERFICIAL_RELATIONSHIP', 170), ('INCOMPLETE_EVIDENCE', 188)]	4	[('UBERON_0002367', 'prostate gland', 0, 'Prostate'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'proliferation ...'), ('GO_0030154', 'cell differentiation', 80, 'differentiation of ... cells'), ('NCBITaxon_9606', 'Homo sapiens', 99, 'human'), ('CL_0002492', 'strial marginal cell', 105, 'prostatic cells'), ('UBERON_0000054', 'macula', 105, 'prostatic'), ('CHEBI_17996', 'chloride', 138, ','), ('CHEBI_73376', 'Ala-Met-Ser-Arg', 139, '25(OH)2D3has'), ('NCBITaxon_33208', 'Metazoa', 181, 'animal')]	0	['prostate cancer\nstudies  inhibit  human prostatic cells 162and 1,25(oh)2d3has marked anti-tumor animal models163.']
S250-PMC3613945	PMC3613945	2/2013	S250-PMC3613945	['the UNDERLYING molecular mechanism governing this ASSOCIATION is NOT KNOWN, but Prenatal Vitamin D deficiency is ASSOCIATED with structural and functional deficits common to schizophrenic patients.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('SUPERFICIAL_RELATIONSHIP', 50), ('FULL_UNKNOWN', 65), ('SUPERFICIAL_RELATIONSHIP', 113)]	4	[('GO_0007565', 'female pregnancy', 80, 'prenatal'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]	0	['molecular known,   structural functional schizophrenic patients.']
S139-PMC3616124	PMC3616124	4/2013	S139-PMC3616124	['hp phenotype, Prenatal/multivitamin use at randomization, and Plasma Ascorbate\nhp phenotype INFLUENCES Plasma Ascorbate concentration[35], PROVIDING a POTENTIAL mechanism by which hp phenotype MIGHT INFLUENCE treatment response to Vitamin C and E. we EXAMINED the RELATIONSHIP between hp phenotype and Plasma Ascorbate in a pre-planned analysis.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('PROBABLE_UNDERSTANDING', 139), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 193), ('SUPERFICIAL_RELATIONSHIP', 199), ('QUESTION_ANSWERED_BY_THIS_WORK', 251), ('SUPERFICIAL_RELATIONSHIP', 264)]	7	[('GO_0007565', 'female pregnancy', 14, 'Prenatal'), ('UBERON_0001969', 'blood plasma', 62, 'Plasma'), ('CHEBI_2874', 'Asimicin', 69, 'Ascorbate'), ('UBERON_0001969', 'blood plasma', 103, 'plasma'), ('CHEBI_22651', 'ascorbate', 110, 'ascorbate'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 245, 'E'), ('UBERON_0001969', 'blood plasma', 302, 'plasma'), ('CHEBI_22651', 'ascorbate', 309, 'ascorbate')]	0	['hp phenotype, /multivitamin randomization, plasma ascorbate\nhp phenotype plasma ascorbate concentration[35], hp phenotype treatment response  e. hp phenotype plasma ascorbate pre-planned analysis.']
S92-PMC3629265	PMC3629265	4/2013	S92-PMC3629265	['conclusion\nwe SUGGEST that the amount of Vitamin D supplementation NEEDED to prevent deficiency in infants residing in communities in the temperate region SHOULD BE REVISITED, PARTICULARLY for those at high risk for Prenatal deficiency.']	[('INCOMPLETE_EVIDENCE', 14), ('FUTURE_WORK', 67), ('IMPORTANT_CONSIDERATION', 67), ('FUTURE_WORK', 155), ('FUTURE_WORK', 165), ('IMPORTANT_CONSIDERATION', 176)]	6	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'prenatal')]	0	['conclusion\nwe amount  supplementation infants residing communities temperate region revisited,  deficiency.']
S40-PMC3635901	PMC3635901	4/2013	S40-PMC3635901	['moreover, the cost–benefit ratio of providing Vitamin D as a preventative medicine to the general population SHOULD BE evaluated, together with the routine monitoring of Gestational Vitamin D levels [20].']	[('FUTURE_WORK', 109)]	1	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'gestational'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D')]	0	['moreover, cost–benefit ratio  preventative medicine population evaluated, routine   levels [20].']
S0-PMC3641012	PMC3641012	4/2013	S0-PMC3641012	['randomized placebo-controlled trial of high-dose Prenatal third-Trimester Vitamin D3 supplementation in bangladesh: the avidd trial\n\nabstract\n\nbackground\nantenatal Vitamin D status MAY be ASSOCIATED with the RISK of adverse Pregnancy and neonatal outcomes; HOWEVER, the benefits of Vitamin D supplementation during Pregnancy remain UNKNOWN.']	[('INCOMPLETE_EVIDENCE', 181), ('SUPERFICIAL_RELATIONSHIP', 188), ('IMPORTANT_CONSIDERATION', 208), ('ANOMALY_CURIOUS_FINDING', 257), ('FULL_UNKNOWN', 332)]	5	[('GO_0007565', 'female pregnancy', 49, 'prenatal'), ('GO_0009294', 'DNA mediated transformation', 64, 'trimester'), ('CHEBI_33279', 'vitamin D5', 74, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 74, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 224, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D'), ('GO_0007565', 'female pregnancy', 315, 'pregnancy')]	0	['randomized placebo-controlled high-dose  third-trimester vitamin d3 supplementation bangladesh: avidd trial\n\nabstract\n\nbackground\nantenatal  status  neonatal outcomes; however,  supplementation  unknown.']
S14-PMC3641012	PMC3641012	4/2013	S14-PMC3641012	['CURRENTLY, there is INSUFFICIENT EVIDENCE to EITHER SUPPORT OR REFUTE the benefits of any given supplemental Vitamin D dose during Pregnancy [8,9].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 45), ('INCOMPLETE_EVIDENCE', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 63)]	5	[('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy')]	0	['currently, supplemental  dose  [8,9].']
S15-PMC3641012	PMC3641012	4/2013	S15-PMC3641012	['moreover, the SAFETY of high-dose Prenatal Vitamin D regimens (i.e., doses that substantially exceed the conventional Prenatal intake of 400 to 600\xa0iu/day) has yet to be established [6].']	[('IMPORTANT_CONSIDERATION', 14)]	1	[('GO_0007565', 'female pregnancy', 34, 'prenatal'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 118, 'prenatal')]	0	['moreover, high-dose   regimens (i.e., doses exceed  intake 400 600\xa0iu/day) [6].']
S18-PMC3641012	PMC3641012	4/2013	S18-PMC3641012	['uncertainty surrounding Vitamin D REQUIREMENTS in Pregnancy has LED TO DIVERGENT dose RECOMMENDATIONS; for example, the unicef Antenatal Micronutrient formulation contains 200\xa0iu/day [11], the canadian paediatric society has SUGGESTED 2000\xa0iu/day [12], and hollis et al.']	[('IMPORTANT_CONSIDERATION', 34), ('SUPERFICIAL_RELATIONSHIP', 64), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 71), ('FUTURE_WORK', 86), ('INCOMPLETE_EVIDENCE', 225)]	5	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('GO_0007567', 'parturition', 127, 'antenatal'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 137, 'micronutrient')]	0	['uncertainty surrounding   dose recommendations; example, unicef antenatal micronutrient formulation contains 200\xa0iu/day [11], canadian paediatric society 2000\xa0iu/day [12], hollis et al.']
S20-PMC3641012	PMC3641012	4/2013	S20-PMC3641012	['SIMILARLY, the 25(Oh)D THRESHOLD to define Vitamin D sufficiency is DEBATED; the iom set 50\xa0nmol/l as a lower limit of sufficiency [7], YET OTHER expert bodies such as the american academy of pediatrics have SUGGESTED that Pregnant women attain Serum 25(Oh)D >80\xa0nmol/l [14].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 136), ('ANOMALY_CURIOUS_FINDING', 136), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 140), ('INCOMPLETE_EVIDENCE', 208)]	7	[('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 223, 'pregnant'), ('UBERON_0001977', 'blood serum', 245, 'serum'), ('CHEBI_71657', 'versiconol acetate', 251, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 251, '25(OH)D')]	0	['similarly, 25(oh)d  debated; iom set 50\xa0nmol/l [7], bodies american academy pediatrics  women attain serum 25(oh)d >80\xa0nmol/l [14].']
S21-PMC3641012	PMC3641012	4/2013	S21-PMC3641012	['determination of the Vitamin D intake level (and corresponding Serum 25(Oh)D concentration) that SAFELY optimizes Vitamin D-responsive maternal-infant health outcomes would have GLOBAL IMPLICATIONS, but MAY be particularly RELEVANT to resource-poor communities in south asia, where a relatively low Prenatal Vitamin D status OVERLAPS with a HIGH BURDEN of morbidity and mortality ASSOCIATED with adverse Birth and early infant health outcomes [15].']	[('IMPORTANT_CONSIDERATION', 97), ('IMPORTANT_CONSIDERATION', 178), ('IMPORTANT_CONSIDERATION', 185), ('INCOMPLETE_EVIDENCE', 203), ('SUPERFICIAL_RELATIONSHIP', 223), ('SUPERFICIAL_RELATIONSHIP', 325), ('IMPORTANT_CONSIDERATION', 341), ('SUPERFICIAL_RELATIONSHIP', 380)]	8	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001977', 'blood serum', 63, 'serum'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 69, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 299, 'prenatal'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin D'), ('GO_0007567', 'parturition', 404, 'birth')]	0	['determination  intake (and serum 25(oh)d concentration) optimizes -responsive maternal-infant outcomes implications, resource-poor communities south asia,   status morbidity mortality birth infant outcomes [15].']
S161-PMC3641012	PMC3641012	4/2013	S161-PMC3641012	['given the substantial inter-Individual VARIABILITY in the response to Vitamin D supplementation (figure\xa03), we EXPLORED the ROLE of the following POTENTIAL MODIFIERS of the magnitude of the change in 25(Oh)D (δ25(Oh)D) from baseline to Delivery (selected a priori ): maternal weight at baseline, maternal age, Gestational age, maternal body mass index at baseline (bmi), gravidity, parity, baseline Pth status, season and baseline Vitamin D status.']	[('DIFFICULT_TASK', 39), ('QUESTION_ANSWERED_BY_THIS_WORK', 111), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 146), ('SUPERFICIAL_RELATIONSHIP', 156)]	5	[('NCBITaxon_1', 'root', 28, 'individual'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 206, 'D'), ('CHEBI_33010', 'chromide(1-)', 212, '(OH)D'), ('GO_0007567', 'parturition', 236, 'delivery'), ('GO_0007565', 'female pregnancy', 310, 'gestational'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 399, 'PTH'), ('CHEBI_27300', 'vitamin D', 431, 'vitamin D')]	0	['given inter-individual response  supplementation (figure\xa03), following magnitude 25(oh)d (δ25(oh)d) baseline delivery (selected ): maternal baseline, maternal age,  age, maternal mass baseline (bmi), gravidity, parity, baseline pth status, season baseline  status.']
S226-PMC3641012	PMC3641012	4/2013	S226-PMC3641012	['in comparison to the lc-ms/ms method used HERE, the immunoassay used in the pilot study (diasorin liaison total) MAY have UNDER-estimated 25(Oh)D because of raised dbp concentrations in Pregnancy [29] OR relative imprecision at the higher 25(Oh)D range attained in the Vitamin D group [30,31].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 42), ('INCOMPLETE_EVIDENCE', 113), ('IMPORTANT_CONSIDERATION', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 201)]	4	[('CHEBI_71657', 'versiconol acetate', 138, '25(OH)D'), ('GO_0007565', 'female pregnancy', 186, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 239, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]	0	['lc-ms/ms here, immunoassay (diasorin liaison total) under-estimated 25(oh)d dbp concentrations  [29] relative higher 25(oh)d attained  [30,31].']
S234-PMC3641012	PMC3641012	4/2013	S234-PMC3641012	['CONCLUDED from their trial findings “that the current Vitamin D ear and rda for Pregnant women issued in 2010 by the iom SHOULD BE raised to 4000\xa0iu of Vitamin D per day” [13].']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 121)]	2	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 160, 'D')]	0	['concluded “that  ear rda  women issued 2010 iom 4000\xa0iu  day” [13].']
S249-PMC3641012	PMC3641012	4/2013	S249-PMC3641012	['because of the high dose of Vitamin D not previously studied in Pregnancy, enrolment was LIMITED to healthy women at low risk of Pregnancy complications, and who were most LIKELY to adhere to the protocol; as such, generalizability of the findings MAY BE LIMITED.']	[('INCOMPLETE_EVIDENCE', 89), ('PROBABLE_UNDERSTANDING', 172), ('INCOMPLETE_EVIDENCE', 248), ('INCOMPLETE_EVIDENCE', 255)]	4	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]	0	['dose  enrolment healthy women  complications, adhere protocol; such, generalizability limited.']
S0-PMC3651971	PMC3651971	5/2013	S0-PMC3651971	['cognitive and motor skills in school-aged children following maternal Vitamin A supplementation during Pregnancy in rural nepal: a follow-up of a placebo-controlled, randomised cohort\n\nabstract\n\nobjective\nTO DETERMINE the EFFECTS of maternal Vitamin A supplementation from Preconception through Postpartum on Cognitive and Motor Development of children at 10–13\u2005years of age in rural nepal.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 205), ('SUPERFICIAL_RELATIONSHIP', 222)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin A'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin A'), ('GO_0007565', 'female pregnancy', 273, 'preconception'), ('GO_0007565', 'female pregnancy', 295, 'postpartum'), ('GO_0050890', 'cognition', 309, 'cognitive ...'), ('GO_0009653', 'anatomical structure morphogenesis', 323, 'motor development')]	0	['cognitive motor skills school-aged children following maternal  supplementation  rural nepal: follow-up placebo-controlled, randomised cohort\n\nabstract\n\nobjective\nto maternal  supplementation   cognitive motor children 10–13\u2005years age rural nepal.']
S24-PMC3651971	PMC3651971	5/2013	S24-PMC3651971	['introduction\nrisk for Cognitive and motor impairment begins in the Womb, where nutritional restrictions on Embryofetal Tissue growth, differentiation, development and Maturation MAY disturb growth, maturation and function of the Central Nervous System.1neural myelination and Synaptogenesis are underway before 24\u2005weeks’ Gestational age, Neural Tube Formation and Cell Migration are complete before the third Trimester of Pregnancy, and basic structures of the Brain formed before Birth.2as complex structures and functions extend as a cascade, disruptions to nascent systems by nutritional and OTHER insults CAN be amplified with age.3\nEmbryofetal Development is sensitive to Gestational deficiency in Vitamin A,4most EVIDENT in Animals by gross anomalies in Organ and Tissue Morphogenesis, development, structure and function.5–7Retinoic Acid, the oxidised Metabolite and transcriptional ligand of Vitamin A, Regulates the Expression of hox Genes that are essential in Neural Tube Formation,8the Development Of Neurons, and in Synaptic Signalling that UNDERLIES Learning and Memory.9–13developing neural Tissue in the Mouse is ESPECIALLY sensitive to variation in Retinoic Acid exposure near Parturition, a time analogous to the second Trimester of Human Gestation, when deficiency can induce behavioural problems and mild structural damage within the Limbic Cortex.14\nchronic dietary Vitamin A deficiency is common among Pregnant women in poor countries,1516leading TO concern that it MAY have adverse consequences for Cognitive and Motor Development Of the Fetus.']	[('INCOMPLETE_EVIDENCE', 178), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 595), ('INCOMPLETE_EVIDENCE', 609), ('PROBABLE_UNDERSTANDING', 719), ('SUPERFICIAL_RELATIONSHIP', 1054), ('ANOMALY_CURIOUS_FINDING', 1129), ('QUESTION_ANSWERED_BY_THIS_WORK', 1469), ('INCOMPLETE_EVIDENCE', 1488)]	8	[('GO_0050890', 'cognition', 22, 'cognitive'), ('UBERON_0002396', 'vomer', 67, 'womb'), ('UBERON_0000922', 'embryo', 107, 'embryofetal'), ('UBERON_0000479', 'tissue', 119, 'tissue'), ('GO_0007618', 'mating', 167, 'maturation'), ('UBERON_0001017', 'central nervous system', 229, 'central nervous system'), ('GO_0007416', 'synapse assembly', 276, 'synaptogenesis'), ('GO_0007565', 'female pregnancy', 321, 'gestational'), ('GO_0042136', 'neurotransmitter biosynthetic process', 338, 'neural tube formation'), ('UBERON_0001049', 'neural tube', 338, 'neural tube'), ('GO_0016477', 'cell migration', 364, 'cell migration'), ('GO_0009294', 'DNA mediated transformation', 409, 'trimester'), ('GO_0007565', 'female pregnancy', 422, 'pregnancy'), ('UBERON_0000955', 'brain', 461, 'brain'), ('GO_0007567', 'parturition', 481, 'birth'), ('GO_0009790', 'embryo development', 637, 'Embryofetal development'), ('UBERON_0000922', 'embryo', 637, 'Embryofetal'), ('GO_0007565', 'female pregnancy', 677, 'gestational'), ('CHEBI_27300', 'vitamin D', 703, 'vitamin A'), ('NCBITaxon_33208', 'Metazoa', 730, 'animals'), ('UBERON_0000062', 'organ', 760, 'organ'), ('GO_0048729', 'tissue morphogenesis', 770, 'tissue morphogenesis'), ('UBERON_0000479', 'tissue', 770, 'tissue'), ('CHEBI_52071', 'dextran', 828, '5'), ('CHEBI_24115', 'fuconate', 830, '7Retinoic acid'), ('CHEBI_39382', 'flufenoxuron', 859, 'metabolite'), ('CHEBI_27300', 'vitamin D', 900, 'vitamin A'), ('GO_0065007', 'biological regulation', 911, 'regulates'), ('GO_0010467', 'gene expression', 925, 'expression'), ('SO_0000704', 'gene', 943, 'genes'), ('GO_0042136', 'neurotransmitter biosynthetic process', 971, 'neural tube formation'), ('UBERON_0001049', 'neural tube', 971, 'neural tube'), ('GO_0046697', 'decidualization', 998, 'development of neurons'), ('CL_0000540', 'neuron', 1013, 'neurons'), ('GO_0045202', 'synapse', 1029, 'synaptic'), ('GO_0099536', 'synaptic signaling', 1029, 'synaptic signalling'), ('GO_0007612', 'learning', 1064, 'learning'), ('GO_0007613', 'memory', 1077, 'memory'), ('UBERON_0000479', 'tissue', 1106, 'tissue'), ('NCBITaxon_10088', 'Mus <genus>', 1120, 'mouse'), ('CHEBI_26536', 'retinoic acid', 1166, 'retinoic acid'), ('GO_0019230', 'proprioception', 1194, 'parturition'), ('GO_0009294', 'DNA mediated transformation', 1238, 'trimester'), ('NCBITaxon_9606', 'Homo sapiens', 1251, 'human'), ('GO_0007565', 'female pregnancy', 1257, 'gestation'), ('UBERON_0016542', 'limbic cortex', 1354, 'limbic cortex'), ('CHEBI_27300', 'vitamin D', 1387, 'vitamin A'), ('GO_0007565', 'female pregnancy', 1424, 'pregnant'), ('GO_0050890', 'cognition', 1522, 'cognitive ...'), ('GO_0048870', 'cell motility', 1536, 'motor development of ... fetus')]	0	['introduction\nrisk cognitive motor impairment begins womb, nutritional embryofetal tissue growth, differentiation, maturation disturb growth, maturation central nervous system.1neural myelination synaptogenesis 24\u2005weeks’  age, neural tube formation cell migration third trimester structures brain formed birth.2as structures functions cascade, nascent systems nutritional insults amplified age.3\nembryofetal sensitive  ,4most animals anomalies organ tissue morphogenesis, development, structure function.5–7retinoic acid, oxidised metabolite transcriptional ligand expression hox genes neural tube formation,8the neurons, synaptic signalling learning memory.9–13developing neural tissue mouse sensitive retinoic acid exposure parturition, trimester human behavioural structural limbic cortex.14\nchronic dietary  among  women countries,1516leading cognitive motor fetus.']
S27-PMC3651971	PMC3651971	5/2013	S27-PMC3651971	['THIS STUDY is the FIRST TO EXAMINE EFFECTS of routine, maternal Vitamin A supplementation before, during and following Pregnancy, provided via a randomised, placebo-controlled trial, on child Cognitive and motor ability.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('SUPERFICIAL_RELATIONSHIP', 35)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin A'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('GO_0050890', 'cognition', 192, 'cognitive')]	0	['routine, maternal  supplementation before, following via randomised, placebo-controlled trial, child cognitive motor ability.']
S28-PMC3651971	PMC3651971	5/2013	S28-PMC3651971	['the trial was conducted in a chronically undernourished population where supplementation with Vitamin A or Β-Carotene reduced maternal mortality,20biochemical Vitamin A deficiency,21night blindness22and morbidity,23but had no overall effect on infant mortality.24in the long term, at 9–13\u2005years of age, the intervention HAS BEEN SHOWN to have improved Lung size25and innate aspects of Immunity,26but has not affected biomarker risk factors for Cardiovascular diseases.27\n\nmethods\n\nselection and description of sample\nthis study followed a sample of Children Born to women who participated in a cluster-randomised, placebo-controlled trial of Vitamin A or Β-Carotene supplementation before, during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 320)]	1	[('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 107, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin A'), ('UBERON_0002048', 'lung', 352, 'lung'), ('GO_0007566', 'embryo implantation', 385, 'immunity'), ('UBERON_0004535', 'cardiovascular system', 444, 'cardiovascular'), ('GO_0050890', 'cognition', 549, 'children'), ('GO_0007567', 'parturition', 558, 'born'), ('CHEBI_27300', 'vitamin D', 642, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 655, 'β-carotene'), ('GO_0007565', 'female pregnancy', 707, 'pregnancy')]	0	['chronically undernourished population supplementation  β-carotene maternal mortality,20biochemical  deficiency,21night blindness22and morbidity,23but infant mortality.24in term, 9–13\u2005years age, lung size25and innate aspects immunity,26but cardiovascular diseases.27\n\nmethods\n\nselection sample\nthis followed sample children born women participated cluster-randomised, placebo-controlled  β-carotene supplementation before, .']
S80-PMC3651971	PMC3651971	5/2013	S80-PMC3651971	"['[""""further, children whose mother\'s histories of Gestational night blindness during the trial were missing (n=31) were excluded from the sampling frame because night blindness is an INDICATOR of Vitamin A deficiency and was CONSIDERED an ESSENTIAL exposure of interest for other research questions in this study.""""]']"	[('SUPERFICIAL_RELATIONSHIP', 179), ('INCOMPLETE_EVIDENCE', 221), ('IMPORTANT_CONSIDERATION', 235)]	3	[('GO_0007565', 'female pregnancy', 46, 'gestational'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin A')]	0	"['[""""further, children whose mother*s histories nal night blindness (n=31) sampling night blindness n exposure study.""""]']"
S89-PMC3651971	PMC3651971	5/2013	S89-PMC3651971	['comparisons between participants of the randomised Supplement group\nthe Vitamin A and placebo groups of tested children were similar on measures of socioeconomic and nutritional status assessed during the original nnips-2 trial, the one IMPORTANT and expected difference being that a higher proportion of children whose mothers had been night blind during Pregnancy were in the placebo vs Vitamin A group (15.5% vs 8.2%, p=0.02).']	[('IMPORTANT_CONSIDERATION', 237)]	1	[('CHEBI_16158', 'steroid sulfate', 51, 'supplement'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin A'), ('GO_0007565', 'female pregnancy', 356, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 389, 'vitamin A')]	0	['comparisons participants randomised supplement group\nthe  placebo children socioeconomic nutritional status nnips-2 trial, higher proportion children whose mothers night blind  placebo  (15.5% 8.2%, p=0.02).']
S139-PMC3651971	PMC3651971	5/2013	S139-PMC3651971	['the lack of EFFECT is UNLIKELY to be DUE TO a lack of Vitamin A deficiency among Pregnant women; ∼20% of mothers were NOTED to have a Serum Retinol concentration below 0.70\u2005µmol/l, a prevalence that fell to ∼3% with supplementation.20gestational night blindness of ∼10% also responded to Vitamin A supplementation,37and the risk of Maternal death was reduced by ∼40% through supplementation.20there was no lack of Cognitive or motor effect, which is LIKELY to be OWING TO the POOR response to supplementation among the offspring; infants Born to supplemented women had a higher Serum Retinol than infants Born to Placebo mothers by 3\u2005months of age.24the children Born to supplemented women also had better Lung function (as measured by the forced Expiratory volume at 1\u2005s and forced vital capacity)25and raised natural Antibody levels26in childhood, FURTHER EVIDENCE of a physiological EFFECT.']	[('SUPERFICIAL_RELATIONSHIP', 12), ('PROBABLE_UNDERSTANDING', 22), ('PROBLEM_COMPLICATION', 37), ('ANOMALY_CURIOUS_FINDING', 118), ('PROBABLE_UNDERSTANDING', 450), ('PROBLEM_COMPLICATION', 463), ('PROBLEM_COMPLICATION', 476), ('INCOMPLETE_EVIDENCE', 850), ('SUPERFICIAL_RELATIONSHIP', 886)]	9	[('CHEBI_27300', 'vitamin D', 54, 'vitamin A'), ('GO_0007565', 'female pregnancy', 81, 'pregnant'), ('UBERON_0001977', 'blood serum', 134, 'serum'), ('CHEBI_26536', 'retinoic acid', 140, 'retinol'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin A'), ('GO_0007618', 'mating', 332, 'maternal'), ('GO_0050890', 'cognition', 414, 'cognitive'), ('GO_0007567', 'parturition', 538, 'born'), ('UBERON_0001977', 'blood serum', 578, 'serum'), ('CHEBI_26536', 'retinoic acid', 584, 'retinol'), ('GO_0007567', 'parturition', 605, 'born'), ('CHEBI_26130', 'biological pigment', 613, 'placebo'), ('GO_0007567', 'parturition', 663, 'born'), ('UBERON_0002048', 'lung', 706, 'lung'), ('GO_0010467', 'gene expression', 747, 'expiratory'), ('GO_0042571', 'immunoglobulin complex, circulating', 819, 'antibody')]	0	[' among  women; ∼20% mothers serum retinol concentration 0.70\u2005µmol/l, fell ∼3% supplementation.20gestational night blindness ∼10% responded  supplementation,37and maternal death ∼40% supplementation.20there cognitive motor effect, response supplementation among offspring; infants born supplemented women higher serum retinol infants born placebo mothers 3\u2005months age.24the children born supplemented women lung (as forced expiratory volume 1\u2005s forced capacity)25and natural antibody levels26in childhood, physiological effect.']
S140-PMC3651971	PMC3651971	5/2013	S140-PMC3651971	['the HYPOTHESISED EFFECT of Gestational Vitamin A supplementation on Cognition and Motor Development is BASED ON sound THEORY.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 17), ('PROBABLE_UNDERSTANDING', 103), ('SUPERFICIAL_RELATIONSHIP', 103), ('INCOMPLETE_EVIDENCE', 118)]	5	[('GO_0007565', 'female pregnancy', 27, 'gestational'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin A'), ('GO_0050890', 'cognition', 68, 'cognition'), ('GO_0009653', 'anatomical structure morphogenesis', 82, 'motor development')]	0	['  supplementation cognition motor theory.']
S2-PMC3659910	PMC3659910	1/2013	S2-PMC3659910	['RESEARCH INDICATES that adequate Vitamin D intake in Pregnancy is OPTIMAL for maternal, fetal and child health.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 9), ('IMPORTANT_CONSIDERATION', 66)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy')]	0	['research  intake  maternal, fetal child health.']
S7-PMC3659910	PMC3659910	1/2013	S7-PMC3659910	['THEREFORE, PREVENTION of Vitamin D deficiency among Pregnant women is ESSENTIAL.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 11), ('IMPORTANT_CONSIDERATION', 70)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnant')]	0	['therefore,  among  women essential.']
S8-PMC3659910	PMC3659910	1/2013	S8-PMC3659910	['the CURRENTLY RECOMMENDED supplementation amount of Vitamin D is NOT SUFFICIENT to maintain a value of 25 Hydroxy Vitamin D above 30 ng/ml, during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 4), ('FUTURE_WORK', 14), ('IMPORTANT_CONSIDERATION', 65)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_45557', 'sec-butyl group', 103, '25 hydroxy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 122, 'D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy')]	0	['supplementation amount  maintain 25 hydroxy  30 ng/ml, .']
S9-PMC3659910	PMC3659910	1/2013	S9-PMC3659910	['STUDIES ARE UNDERWAY to establish the RECOMMENDED daily doses of Vitamin D in Pregnant women.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 38)]	2	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnant')]	0	['studies daily doses   women.']
S11-PMC3659910	PMC3659910	1/2013	S11-PMC3659910	['THIS REVIEW discusses Vitamin D Metabolism, dietary REQUIREMENTS and RECOMMENDATIONS and IMPLICATIONS of Vitamin D deficiency during Pregnancy and Lactation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('IMPORTANT_CONSIDERATION', 52), ('FUTURE_WORK', 69), ('IMPORTANT_CONSIDERATION', 89)]	4	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 22, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('GO_0007595', 'lactation', 147, 'lactation')]	0	['discusses  metabolism, dietary   lactation.']
S16-PMC3659910	PMC3659910	1/2013	S16-PMC3659910	['[1] the QUESTION scientists HAVE BEEN working on for almost a decade is WHY and HOW Vitamin D is AFFECTING Conception, Pregnancy and the health of the newborn.']	[('EXPLICIT_QUESTION', 8), ('INCOMPLETE_EVIDENCE', 28), ('EXPLICIT_QUESTION', 72), ('EXPLICIT_QUESTION', 80), ('SUPERFICIAL_RELATIONSHIP', 97)]	5	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007620', 'copulation', 107, 'conception'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy')]	0	['[1] scientists working decade  conception,  newborn.']
S17-PMC3659910	PMC3659910	1/2013	S17-PMC3659910	['[2] also the media has been taking increasing INTEREST, and public EXPECTATIONS have been RAISED regarding the enhanced ROLES for Vitamin D in Pregnancy.']	[('IMPORTANT_CONSIDERATION', 46), ('FUTURE_PREDICTION', 67), ('EXPLICIT_QUESTION', 90), ('SUPERFICIAL_RELATIONSHIP', 120)]	4	[('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]	0	['[2] media interest, regarding  .']
S44-PMC3659910	PMC3659910	1/2013	S44-PMC3659910	['the REQUIREMENT for Vitamin D in maintaining normal Calcium Metabolism throughout Pregnancy and Lactation in mothers, fetuses and newborn infants is STILL CONTROVERSIAL.']	[('IMPORTANT_CONSIDERATION', 4), ('IMPORTANT_CONSIDERATION', 149), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 155)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0018884', 'carbazole metabolic process', 52, 'calcium metabolism'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('GO_0007595', 'lactation', 96, 'lactation')]	0	[' maintaining normal calcium metabolism throughout  lactation mothers, fetuses newborn infants controversial.']
S45-PMC3659910	PMC3659910	1/2013	S45-PMC3659910	['IT IS CLEAR, HOWEVER, that Vitamin D REQUIREMENTS are increased in mothers during Pregnancy and Lactation.']	[('PROBABLE_UNDERSTANDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 13), ('IMPORTANT_CONSIDERATION', 37)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('GO_0007595', 'lactation', 96, 'lactation')]	0	['clear, however,  mothers  lactation.']
S64-PMC3659910	PMC3659910	1/2013	S64-PMC3659910	"['[""""although Liver and cod Liver oil contain Vitamin D, they are not recommended in Pregnancy as they also contain too much Vitamin A.\\nVitamin D is a unique Nutrient BECAUSE its REQUIREMENT can be met by both endogenous production from sunlight as well as exogenous dietary sources, which COMPLICATES determining the body\'s daily nutritional REQUIREMENTS.""""]']"	[('PROBABLE_UNDERSTANDING', 162), ('IMPORTANT_CONSIDERATION', 174), ('DIFFICULT_TASK', 285), ('IMPORTANT_CONSIDERATION', 338)]	4	[('UBERON_0002107', 'liver', 9, 'liver'), ('UBERON_0002107', 'liver', 23, 'liver'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A'), ('CHEBI_28384', 'vitamin K', 131, 'Vitamin D'), ('CHEBI_33284', 'nutrient', 153, 'nutrient')]	0	"['[""""although liver cod liver oil contan d, ncy contain mun a.\\nvitamin nutrient met endogenous production sunlight exogenous dietary sources, body*s daily nutritional requirements.""""]']"
S70-PMC3659910	PMC3659910	1/2013	S70-PMC3659910	['pre-Pregnancy obesity is also ASSOCIATED with significant increases in the odds of maternal and neonatal Vitamin D deficiency, INDEPENDENT of other FACTORS such as ethnicity.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('SUPERFICIAL_RELATIONSHIP', 127), ('SUPERFICIAL_RELATIONSHIP', 148)]	3	[('GO_0007565', 'female pregnancy', 4, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]	0	['pre- obesity maternal neonatal  deficiency, ethnicity.']
S78-PMC3659910	PMC3659910	1/2013	S78-PMC3659910	['[17] NEW RESEARCH SUGGESTS that women who take high doses of Vitamin D during Pregnancy have a greatly reduced RISK of COMPLICATIONS, including Gestational diabetes, preterm Birth, and infection.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 18), ('IMPORTANT_CONSIDERATION', 111), ('IMPORTANT_CONSIDERATION', 119)]	4	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('GO_0007565', 'female pregnancy', 144, 'gestational'), ('GO_0007567', 'parturition', 174, 'birth')]	0	['[17] women doses   complications,  diabetes, preterm birth, infection.']
S80-PMC3659910	PMC3659910	1/2013	S80-PMC3659910	['w\nepidemiological analyses IMPLICATED high dietary Vitamin D intake during Pregnancy results in Birth of syndromic babies.']	[('SUPERFICIAL_RELATIONSHIP', 27)]	1	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('GO_0007567', 'parturition', 96, 'birth')]	0	['w\nepidemiological dietary  intake  results birth syndromic babies.']
S85-PMC3659910	PMC3659910	1/2013	S85-PMC3659910	['VARIOUS Human STUDIES are done SO FAR involving Pharmacological doses of Vitamin D during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 31)]	2	[('NCBITaxon_9606', 'Homo sapiens', 8, 'human'), ('CHEBI_52217', 'pharmaceutical', 48, 'pharmacological'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy')]	0	['various human done pharmacological doses  .']
S88-PMC3659910	PMC3659910	1/2013	S88-PMC3659910	['REPORTED that as hypoparathyroid patients have completed many Pregnancies while receiving Ergocalciferol,[21] it is UNLIKELY that material Vitamin D, 25(Oh) D, or 24,25(Oh) 2D per se are Teratogens.']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 116)]	2	[('GO_0007565', 'female pregnancy', 62, 'pregnancies'), ('CHEBI_4910', 'etomidate', 90, 'ergocalciferol'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 150, '25(OH) D'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 166, '25(OH) 2D'), ('CHEBI_50114', 'estrogen', 187, 'teratogens')]	0	['reported hypoparathyroid patients completed  receiving ergocalciferol,[21] material 25(oh) d, 24,25(oh) 2d se teratogens.']
S89-PMC3659910	PMC3659910	1/2013	S89-PMC3659910	['MOST Prenatal Vitamins have around 400 iu of Vitamin D, and MOST health groups RECOMMEND taking no more than 2,000 iu of the Vitamin in supplement form daily.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 60), ('FUTURE_WORK', 79)]	3	[('GO_0007565', 'female pregnancy', 5, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 14, 'vitamins'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 125, 'vitamin')]	0	[' vitamins 400 iu 2,000 iu vitamin supplement form daily.']
S96-PMC3659910	PMC3659910	1/2013	S96-PMC3659910	['ROLE of Vitamin D in Pregnant women\nadequate Vitamin D intake is ESSENTIAL for maternal and fetal health during Pregnancy, and PREVENTION of adverse outcomes.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('IMPORTANT_CONSIDERATION', 65), ('SUPERFICIAL_RELATIONSHIP', 127)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 21, 'pregnant'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy')]	0	['role   women\nadequate  intake maternal fetal outcomes.']
S97-PMC3659910	PMC3659910	1/2013	S97-PMC3659910	['RECENT work EMPHASIZES the IMPORTANCE of NON-CLASSICAL ROLES of Vitamin D in Pregnancy and the Placenta.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 12), ('IMPORTANT_CONSIDERATION', 27), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 41), ('SUPERFICIAL_RELATIONSHIP', 55)]	5	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('UBERON_0001987', 'placenta', 95, 'placenta')]	0	['recent   placenta.']
S101-PMC3659910	PMC3659910	1/2013	S101-PMC3659910	['a NEW STUDY FINDS that women who develop SEVERE Preeclampsia TEND to have lower Blood levels of Vitamin D than healthy Pregnant women raising the POSSIBILITY that the vitamin plays a ROLE in the COMPLICATION.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 41), ('PROBABLE_UNDERSTANDING', 61), ('INCOMPLETE_EVIDENCE', 146), ('SUPERFICIAL_RELATIONSHIP', 183), ('IMPORTANT_CONSIDERATION', 195)]	7	[('GO_0007128', 'meiotic prophase I', 48, 'preeclampsia'), ('UBERON_0000178', 'blood', 80, 'blood'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnant')]	0	['women preeclampsia blood levels  healthy  women vitamin plays complication.']
S105-PMC3659910	PMC3659910	1/2013	S105-PMC3659910	['STUDIES by other groups HAVE REPORTED abnormal Expression of 1α-hydroxylase, a Vitamin D—activating enzyme in Preeclamptic Pregnancies, REVEALING a POTENTIAL ROLE for 1,25(Oh) 2D3 as a REGULATOR of Placentation.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 136), ('INCOMPLETE_EVIDENCE', 148), ('SUPERFICIAL_RELATIONSHIP', 158), ('SUPERFICIAL_RELATIONSHIP', 185)]	6	[('GO_0010467', 'gene expression', 47, 'expression'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'preeclamptic'), ('GO_0007565', 'female pregnancy', 123, 'pregnancies'), ('CHEBI_73394', 'Ala-Ser', 169, '25(OH) 2D3'), ('PR_000010977', 'nucleosome assembly protein 1-like 3', 169, '25(OH) 2D3'), ('GO_0001890', 'placenta development', 198, 'placentation')]	0	['studies abnormal expression 1α-hydroxylase, —activating enzyme  1,25(oh) 2d3 placentation.']
S106-PMC3659910	PMC3659910	1/2013	S106-PMC3659910	['induction of the 1α-hydroxylase in early Gestation MIGHT provide a mechanism by which environmental or dietary Vitamin D CAN INFLUENCE fetal-Placental Development.']	[('INCOMPLETE_EVIDENCE', 51), ('INCOMPLETE_EVIDENCE', 121), ('SUPERFICIAL_RELATIONSHIP', 125)]	3	[('GO_0007565', 'female pregnancy', 41, 'gestation'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0001890', 'placenta development', 141, 'placental development'), ('UBERON_0001987', 'placenta', 141, 'placental')]	0	['induction 1α-hydroxylase  environmental dietary  fetal-placental development.']
S124-PMC3659910	PMC3659910	1/2013	S124-PMC3659910	['the cochrane review CONCLUDED that there is NOT ENOUGH EVIDENCE TO EVALUATE the REQUIREMENTS and EFFECTS of Vitamin D supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 55), ('FUTURE_WORK', 64), ('IMPORTANT_CONSIDERATION', 80), ('SUPERFICIAL_RELATIONSHIP', 97)]	6	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'pregnancy')]	0	['cochrane  supplementation .']
S125-PMC3659910	PMC3659910	1/2013	S125-PMC3659910	['data from three trials involving 463 women SHOW a TREND for women who receive Vitamin D supplementation during Pregnancy to more frequently have a baby with a Birth weight below 2500 grams than those women receiving no treatment or placebo, ALTHOUGH the statistical significance was borderline.']	[('INCOMPLETE_EVIDENCE', 43), ('INCOMPLETE_EVIDENCE', 50), ('PROBLEM_COMPLICATION', 241)]	3	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'pregnancy'), ('GO_0007567', 'parturition', 159, 'birth')]	0	['data three 463 women women receive  supplementation  baby birth 2500 grams women receiving treatment placebo, statistical borderline.']
S128-PMC3659910	PMC3659910	1/2013	S128-PMC3659910	['a RECENT STUDY provides EVIDENCE with reference to the CONSEQUENCES of Vitamin D deficiency on the Neurodevelopment Of the Fetus during Pregnancy in a Rat MODEL.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 24), ('IMPORTANT_CONSIDERATION', 55), ('INCOMPLETE_EVIDENCE', 155)]	4	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0001503', 'ossification', 99, 'neurodevelopment of ... fetus'), ('GO_0007565', 'female pregnancy', 136, 'pregnancy'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 151, 'rat')]	0	[' neurodevelopment fetus  rat model.']
S131-PMC3659910	PMC3659910	1/2013	S131-PMC3659910	['RESEARCH has FOUND direct CONNECTIONS between Vitamin D and the Genes KNOWN to be INVOLVED in ms, BUT exact pathology and WHETHER Vitamin D supplements during Pregnancy OR childhood can lessen the likelihood of the child developing ms later in Life is NOT KNOWN.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 70), ('SUPERFICIAL_RELATIONSHIP', 82), ('ANOMALY_CURIOUS_FINDING', 98), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 122), ('FULL_UNKNOWN', 252)]	8	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('SO_0000704', 'gene', 64, 'genes'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 159, 'pregnancy'), ('UBERON_0000104', 'life cycle', 244, 'life')]	0	['research  genes ms, exact pathology  supplements  childhood child ms life known.']
S132-PMC3659910	PMC3659910	1/2013	S132-PMC3659910	['while there is INTEREST in the ROLE of Vitamin D in the PREVENTION of multiple sclerosis, following epidemiological STUDIES DEMONSTRATING an ASSOCIATION between Vitamin D supplementation and reduced PREVALENCE of the disease, FUTURE RESEARCH, including randomized controlled trials in Pregnant or nonpregnant Individuals, is AWAITED TO CONFIRM OR REFUTE such BENEFIT.']	[('IMPORTANT_CONSIDERATION', 15), ('SUPERFICIAL_RELATIONSHIP', 31), ('SUPERFICIAL_RELATIONSHIP', 56), ('INCOMPLETE_EVIDENCE', 116), ('INCOMPLETE_EVIDENCE', 124), ('SUPERFICIAL_RELATIONSHIP', 141), ('IMPORTANT_CONSIDERATION', 199), ('FUTURE_WORK', 226), ('FUTURE_WORK', 325), ('FUTURE_WORK', 333), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 344), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 347), ('IMPORTANT_CONSIDERATION', 359)]	13	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('GO_0007565', 'female pregnancy', 285, 'pregnant'), ('NCBITaxon_1', 'root', 309, 'individuals')]	0	[' sclerosis, following epidemiological  supplementation disease, research,  nonpregnant individuals, benefit.']
S142-PMC3659910	PMC3659910	1/2013	S142-PMC3659910	['while Vitamin D supplementation in Pregnancy has PREVIOUSLY been ASSOCIATED with reduced RISK of wheezing and type 1 diabetes.']	[('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 65), ('IMPORTANT_CONSIDERATION', 89)]	3	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'pregnancy')]	0	[' supplementation  wheezing type diabetes.']
S146-PMC3659910	PMC3659910	1/2013	S146-PMC3659910	['[34] INTERESTINGLY, Vitamin D deficiency during Pregnancy is also ASSOCIATED with RISKS of health PROBLEMS later in childhood, including improper Bone Development at 9 yrs of age, asthma,[36] Dental Cavities, schizophrenia, and type i diabetes.']	[('ANOMALY_CURIOUS_FINDING', 5), ('SUPERFICIAL_RELATIONSHIP', 66), ('IMPORTANT_CONSIDERATION', 82), ('IMPORTANT_CONSIDERATION', 98)]	4	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('GO_0048539', 'bone marrow development', 146, 'bone development'), ('UBERON_0001076', 'neural spine', 192, 'dental cavities')]	0	['[34] interestingly,   childhood, bone 9 yrs age, asthma,[36] dental cavities, schizophrenia, type diabetes.']
S149-PMC3659910	PMC3659910	1/2013	S149-PMC3659910	['women of indian origin, ESPECIALLY Pregnant women, are KNOWN to have a high PREVALENCE of Vitamin D deficiency.']	[('IMPORTANT_CONSIDERATION', 24), ('INCOMPLETE_EVIDENCE', 55), ('IMPORTANT_CONSIDERATION', 76)]	3	[('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]	0	['women indian origin,  women,  deficiency.']
S155-PMC3659910	PMC3659910	1/2013	S155-PMC3659910	['testing and treatment for Vitamin D deficiency\nwomen of Reproductive age are ASSUMED TO BE able to obtain the RECOMMENDED intake for ALMOST ALL Vitamins without the use of supplements, and no national organization RECOMMENDS routine Vitamin D supplementation during Pregnancy unless a woman is at nutritional RISK.']	[('PROBABLE_UNDERSTANDING', 77), ('FUTURE_PREDICTION', 85), ('FUTURE_WORK', 110), ('PROBABLE_UNDERSTANDING', 133), ('FUTURE_WORK', 214), ('IMPORTANT_CONSIDERATION', 309)]	6	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0000003', 'reproduction', 56, 'reproductive'), ('CHEBI_33277', 'gamma-tocotrienol', 144, 'vitamins'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('GO_0007565', 'female pregnancy', 266, 'pregnancy')]	0	['testing treatment  deficiency\nwomen reproductive age able obtain intake vitamins supplements, national organization routine  supplementation  woman nutritional risk.']
S159-PMC3659910	PMC3659910	1/2013	S159-PMC3659910	['[4142] endocrine society issues practice guideline on Vitamin D and the GUIDELINE RECOMMEND that clinicians screen for Vitamin D deficiency in People AT RISK for deficiency, including obese Individuals, blacks, Pregnant and Lactating women, and patients with malabsorption syndromes.']	[('PROBABLE_UNDERSTANDING', 72), ('FUTURE_WORK', 82), ('IMPORTANT_CONSIDERATION', 150)]	3	[('CHEBI_28384', 'vitamin K', 54, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 143, 'people'), ('NCBITaxon_1', 'root', 190, 'individuals'), ('GO_0007565', 'female pregnancy', 211, 'pregnant'), ('GO_0007594', 'puparial adhesion', 224, 'lactating')]	0	['[4142] endocrine society vitamin clinicians screen  people deficiency, obese individuals, blacks,  lactating women, patients malabsorption syndromes.']
S160-PMC3659910	PMC3659910	1/2013	S160-PMC3659910	['[43] IF electing to test Vitamin D status, Serum 25-Hydroxyvitamin D is the ACCEPTED BIOMARKER to be offered early in Pregnancy.']	[('IMPORTANT_CONSIDERATION', 5), ('INCOMPLETE_EVIDENCE', 76), ('SUPERFICIAL_RELATIONSHIP', 85)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 49, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy')]	0	['[43] electing  status, serum 25-hydroxyvitamin offered .']
S166-PMC3659910	PMC3659910	1/2013	S166-PMC3659910	['[44] CONTROVERSY exists regarding the optimum concentration of Serum 25-Hydroxyvitamin D for DEFINING Vitamin D deficiency, ESPECIALLY in Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('INCOMPLETE_EVIDENCE', 93), ('IMPORTANT_CONSIDERATION', 124)]	3	[('UBERON_0001977', 'blood serum', 63, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 69, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy')]	0	['[44] regarding concentration serum 25-hydroxyvitamin  deficiency, .']
S169-PMC3659910	PMC3659910	1/2013	S169-PMC3659910	['as was RECENTLY POINTED out in a cochrane review, the topic of maternal Vitamin D REQUIREMENTS during Pregnancy HAS BEEN POORLY studied.']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 16), ('IMPORTANT_CONSIDERATION', 82), ('INCOMPLETE_EVIDENCE', 112), ('PROBLEM_COMPLICATION', 121)]	5	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'pregnancy')]	0	['cochrane review, maternal   studied.']
S170-PMC3659910	PMC3659910	1/2013	S170-PMC3659910	['the reality is that the actual Vitamin D REQUIREMENT during Pregnancy is NOT KNOWN.']	[('IMPORTANT_CONSIDERATION', 41), ('FULL_UNKNOWN', 73)]	2	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy')]	0	['actual   known.']
S172-PMC3659910	PMC3659910	1/2013	S172-PMC3659910	['there is NO dietary RECOMMENDED intake (dri) for Vitamin D. what IS KNOWN today is that for a Pregnant woman, the adequate intake for Vitamin D is 200 iu per day.']	[('FULL_UNKNOWN', 9), ('FUTURE_WORK', 20), ('INCOMPLETE_EVIDENCE', 65)]	3	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnant'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]	0	['dietary intake (dri) . today  woman, intake  200 iu day.']
S173-PMC3659910	PMC3659910	1/2013	S173-PMC3659910	['HOWEVER this RECOMMENDED level, which was LARGELY ARBITRARILY set, SEEMS TO BE LESS HELPFUL to improve the nutritional Vitamin D status of Pregnant women.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 13), ('INCOMPLETE_EVIDENCE', 42), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 50), ('ANOMALY_CURIOUS_FINDING', 67), ('FUTURE_PREDICTION', 73), ('IMPORTANT_CONSIDERATION', 79)]	7	[('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'pregnant')]	0	['however level, set, nutritional  status  women.']
S174-PMC3659910	PMC3659910	1/2013	S174-PMC3659910	"['[""""national osteoporosis foundation\'s (nof) RECOMMENDS 400-800iu Vitamin D for Pregnant women.""""]']"	[('FUTURE_WORK', 41)]	1	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnant')]	0	"['[""""national osteoporosis foundation*s (nof) 400-800n fant women.""""]']"
S177-PMC3659910	PMC3659910	1/2013	S177-PMC3659910	"['[""""current nice GUIDANCE STATES clearly that Pregnant women are informed, at their first Antenatal booking, of the IMPORTANCE of adequate Vitamin D during Pregnancy and after, to maintain their own and their baby\'s health.""""]']"	[('FUTURE_WORK', 13), ('INCOMPLETE_EVIDENCE', 22), ('IMPORTANT_CONSIDERATION', 112)]	3	[('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('GO_0007567', 'parturition', 86, 'antenatal'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy')]	0	"['[""""current nice thant women informed, antenatal booking, adequan durincy after, maintain baby*s health.""""]']"
S186-PMC3659910	PMC3659910	1/2013	S186-PMC3659910	['also women are ENCOURAGED to continue to take Vitamin D supplements after Pregnancy to HELP PROTECT against health PROBLEMS such as osteoporosis.']	[('IMPORTANT_CONSIDERATION', 15), ('FUTURE_WORK', 87), ('SUPERFICIAL_RELATIONSHIP', 92), ('IMPORTANT_CONSIDERATION', 115)]	4	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy')]	0	['also women  supplements  osteoporosis.']
S189-PMC3659910	PMC3659910	1/2013	S189-PMC3659910	['the current LACK OF EVIDENCE of benefit for women at lower RISK of Vitamin D deficiency points to the NEED FOR FURTHER RESEARCH into Vitamin D supplementation in Pregnant women with clinical neonatal and infant end-points under SCRUTINY.']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 59), ('FUTURE_WORK', 102), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 228)]	4	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0007565', 'female pregnancy', 162, 'pregnant')]	0	['women   supplementation  women neonatal infant end-points scrutiny.']
S191-PMC3659910	PMC3659910	1/2013	S191-PMC3659910	['FURTHER RESEARCH is REQUIRED, PARTICULARLY to establish the dose NEEDED to supplement Pregnant women with pre-existing deficiency and the OPTIMAL Gestation at which Vitamin D supplementation SHOULD BE started.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 20), ('IMPORTANT_CONSIDERATION', 30), ('IMPORTANT_CONSIDERATION', 65), ('IMPORTANT_CONSIDERATION', 138), ('IMPORTANT_CONSIDERATION', 191)]	6	[('GO_0007565', 'female pregnancy', 86, 'pregnant'), ('GO_0007565', 'female pregnancy', 146, 'gestation'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]	0	['required, dose supplement  women pre-existing   supplementation started.']
S192-PMC3659910	PMC3659910	1/2013	S192-PMC3659910	['RECOMMENDATIONS SHOULD BE made on informing women of the IMPORTANCE of maintaining adequate Vitamin D stores in Pregnancy, PARTICULARLY for those at greatest RISK of Vitamin D deficiency.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 16), ('IMPORTANT_CONSIDERATION', 57), ('IMPORTANT_CONSIDERATION', 123), ('IMPORTANT_CONSIDERATION', 158)]	5	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D')]	0	['recommendations women maintaining  stores  deficiency.']
S194-PMC3659910	PMC3659910	1/2013	S194-PMC3659910	"['[\'FUTURE STUDIES are ESSENTIAL to determine the true Vitamin D REQUIREMENT during Pregnancy NOT ONLY for maternal Skeletal preservation and fetal Skeletal Formation, BUT ALSO for fetal “Imprinting"""" that MAY AFFECT Neurodevelopment, Immune function and chronic disease SUSCEPTIBILITY soon after Birth as well as later in Life.\']']"	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 19), ('IMPORTANT_CONSIDERATION', 61), ('ANOMALY_CURIOUS_FINDING', 90), ('FUTURE_PREDICTION', 201), ('SUPERFICIAL_RELATIONSHIP', 205), ('IMPORTANT_CONSIDERATION', 266)]	7	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('UBERON_0004288', 'skeleton', 112, 'skeletal'), ('GO_0001501', 'skeletal system development', 144, 'skeletal formation'), ('UBERON_0004288', 'skeleton', 144, 'skeletal'), ('GO_0071514', 'genetic imprinting', 184, 'imprinting'), ('GO_0007399', 'nervous system development', 212, 'neurodevelopment'), ('UBERON_0002405', 'immune system', 230, 'immune'), ('GO_0007567', 'parturition', 292, 'birth'), ('UBERON_0000104', 'life cycle', 318, 'life')]	0	"['[*future tru durincy maternal skeletal preservation fetal skeletal formation, fetal “imprinting"""" neurodevelopment, immune chronic disease soon birth life.*]']"
S54-PMC3662163	PMC3662163	3/2013	S54-PMC3662163	['Folic Acid and Vitamin D are Vitamins which are ADVISED in the netherlands during Pregnancy [10].']	[('FUTURE_WORK', 48)]	1	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_33277', 'gamma-tocotrienol', 29, 'vitamins'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]	0	['folic acid  vitamins netherlands  [10].']
S56-PMC3662163	PMC3662163	3/2013	S56-PMC3662163	['when Prenatal Vitamins were REPORTED, we considered them as multivitamins designed for Pregnant women containing more and/or other Vitamins than Folic Acid and Vitamin D. because Prenatal Vitamins are not actively advised by midwifes in the netherlands during Pregnancy, we considered them as Otc-medication.']	[('INCOMPLETE_EVIDENCE', 28)]	1	[('GO_0007565', 'female pregnancy', 5, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 14, 'vitamins'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('CHEBI_33277', 'gamma-tocotrienol', 131, 'vitamins'), ('CHEBI_30751', 'formic acid', 145, 'folic acid'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('GO_0007565', 'female pregnancy', 179, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 188, 'vitamins'), ('GO_0007565', 'female pregnancy', 260, 'pregnancy'), ('CHEBI_74959', 'O(4)-phospho-D-tyrosine', 293, 'OTC')]	0	[' vitamins reported, multivitamins  women containing and/or vitamins folic acid .  vitamins actively midwifes netherlands otc-medication.']
S12-PMC3668200	PMC3668200	5/2013	S12-PMC3668200	['a study performed among Pregnant women DEMONSTRATED that fetal growth, expressed as Femur length, was reduced when the mother had low Vitamin D levels during the winter in a high-latitude area5).']	[('INCOMPLETE_EVIDENCE', 39)]	1	[('GO_0007565', 'female pregnancy', 24, 'pregnant'), ('UBERON_0000981', 'femur', 84, 'femur'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]	0	['among  women fetal growth, expressed femur length, mother  levels winter high-latitude area5).']
S15-PMC3668200	PMC3668200	5/2013	S15-PMC3668200	['a light skin color MAY BE REQUIRED in women to produce relatively high amounts of Vitamin D NECESSARY for Pregnancy and Lactation8).']	[('INCOMPLETE_EVIDENCE', 19), ('IMPORTANT_CONSIDERATION', 26), ('IMPORTANT_CONSIDERATION', 92)]	3	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('GO_0007595', 'lactation', 120, 'lactation8')]	0	['skin color women produce amounts   lactation8).']
S37-PMC3668200	PMC3668200	5/2013	S37-PMC3668200	['in addition, women with increased skin pigmentation or those with little sunlight exposure are AT RISK of Vitamin D deficiency and MAY NEED additional Vitamin D supplementation, especially during Pregnancy and Lactation.']	[('IMPORTANT_CONSIDERATION', 95), ('INCOMPLETE_EVIDENCE', 131), ('IMPORTANT_CONSIDERATION', 135)]	3	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007565', 'female pregnancy', 196, 'pregnancy'), ('GO_0007595', 'lactation', 210, 'lactation')]	0	['addition, women skin pigmentation sunlight exposure   supplementation,  lactation.']
S41-PMC3668200	PMC3668200	5/2013	S41-PMC3668200	['THEREFORE, daily supplementation with 400 iu of Vitamin D during the last Trimester of Pregnancy HAS BEEN practiced, ALBEIT with MINIMAL EFFECT on circulating 25(Oh)D concentrations in the mother and infant at term.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 97), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 117), ('ANOMALY_CURIOUS_FINDING', 117), ('INCOMPLETE_EVIDENCE', 129), ('SUPERFICIAL_RELATIONSHIP', 137)]	6	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 74, 'trimester'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 159, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 165, 'D')]	0	['therefore, daily supplementation 400 iu  last trimester  practiced, circulating 25(oh)d concentrations mother infant term.']
S42-PMC3668200	PMC3668200	5/2013	S42-PMC3668200	['NEVERTHELESS, it is NOTEWORTHY that infants Born to unsupplemented Vitamin D-deficient mothers were LIKELY to have early Vitamin D deficiency compared with those whose mothers were supplemented with Vitamin D during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 20), ('PROBABLE_UNDERSTANDING', 100)]	3	[('GO_0007567', 'parturition', 44, 'born'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy')]	0	['nevertheless, infants born unsupplemented -deficient mothers  whose mothers supplemented  .']
S43-PMC3668200	PMC3668200	5/2013	S43-PMC3668200	['a canadian study that evaluated Serum Vitamin D and Mineral levels among infants REPORTED that newborns whose mothers had adequate intakes of milk and Vitamin D during Pregnancy showed increased Birth weight BUT NOT Head circumference or length at Birth17).']	[('INCOMPLETE_EVIDENCE', 81), ('ANOMALY_CURIOUS_FINDING', 208)]	2	[('UBERON_0001977', 'blood serum', 32, 'serum'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_46662', 'mineral', 52, 'mineral'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('GO_0007567', 'parturition', 195, 'birth'), ('UBERON_0000033', 'head', 216, 'head'), ('GO_0007567', 'parturition', 248, 'birth17')]	0	['canadian serum  mineral levels among infants newborns whose mothers intakes milk   birth head circumference length birth17).']
S50-PMC3668200	PMC3668200	5/2013	S50-PMC3668200	['with respect to Prenatal supplementation, the GENERALLY prescribed daily intake of 400 iu of Vitamin D is NOT sufficient to achieve the OPTIMAL Vitamin D status in newborns18).']	[('PROBABLE_UNDERSTANDING', 46), ('ANOMALY_CURIOUS_FINDING', 106), ('IMPORTANT_CONSIDERATION', 136)]	3	[('GO_0007565', 'female pregnancy', 16, 'prenatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]	0	['respect  supplementation, prescribed daily intake 400 iu  achieve  status newborns18).']
S0-PMC3672018	PMC3672018	5/2013	S0-PMC3672018	['the INFLUENCE of early exposure to Vitamin D for development of Diseases later in Life\n\nabstract\n\nbackground\nVitamin D deficiency is common among otherwise healthy Pregnant women and MAY have CONSEQUENCES for them as well as the early Development and long-term health Of their Children.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 183), ('IMPORTANT_CONSIDERATION', 192)]	3	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007586', 'digestion', 64, 'diseases'), ('UBERON_0000104', 'life cycle', 82, 'life'), ('CHEBI_28384', 'vitamin K', 109, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 164, 'pregnant'), ('GO_0001709', 'cell fate determination', 235, 'development ... - ... of ... children')]	0	['exposure  diseases life\n\nabstract\n\nbackground\nvitamin among healthy  women long-term children.']
S4-PMC3672018	PMC3672018	5/2013	S4-PMC3672018	['apart from determining the INFLUENCES of exposure prior to Conception and during Prenatal Life, we will EXAMINE the IMPORTANCE of Vitamin D exposure during specific seasons and trimesters, by comparing disease incidence among Individuals Born before and after fortification.']	[('SUPERFICIAL_RELATIONSHIP', 27), ('QUESTION_ANSWERED_BY_THIS_WORK', 104), ('IMPORTANT_CONSIDERATION', 116)]	3	[('GO_0007620', 'copulation', 59, 'conception'), ('GO_0007565', 'female pregnancy', 81, 'prenatal'), ('UBERON_0000104', 'life cycle', 90, 'life'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('NCBITaxon_1', 'root', 226, 'individuals'), ('GO_0007567', 'parturition', 238, 'born')]	0	['apart exposure  life,  exposure seasons trimesters, disease among individuals born fortification.']
S5-PMC3672018	PMC3672018	5/2013	S5-PMC3672018	['the danish national databases assure that there are a sufficient number of Individuals to verify any Vitamin D EFFECTS during different Gestation phases.']	[('SUPERFICIAL_RELATIONSHIP', 111)]	1	[('NCBITaxon_1', 'root', 75, 'individuals'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 136, 'gestation')]	0	['danish national databases assure individuals   phases.']
S7-PMC3672018	PMC3672018	5/2013	S7-PMC3672018	['discussion\nthe results of the study will contribute to our CURRENT understanding of the SIGNIFICANCE of supplementation with Vitamin D. more specifically, they will enable new RESEARCH in related fields, including interventional research designed to assess supplementation NEEDS for different subgroups of Pregnant women.']	[('INCOMPLETE_EVIDENCE', 59), ('IMPORTANT_CONSIDERATION', 88), ('FUTURE_WORK', 176), ('IMPORTANT_CONSIDERATION', 273)]	4	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007565', 'female pregnancy', 306, 'pregnant')]	0	['discussion\nthe results supplementation . specifically, fields, interventional supplementation subgroups  women.']
S20-PMC3672018	PMC3672018	5/2013	S20-PMC3672018	['low Vitamin D during Gestation and in early Life MAY THEREFORE play an IMPORTANT ROLE for susceptibility to bone fragility, obesity and Autoimmune diseases later in Life [6].']	[('INCOMPLETE_EVIDENCE', 49), ('PROBABLE_UNDERSTANDING', 53), ('IMPORTANT_CONSIDERATION', 71), ('SUPERFICIAL_RELATIONSHIP', 81)]	4	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 21, 'gestation'), ('UBERON_0000104', 'life cycle', 44, 'life'), ('UBERON_0001442', 'skeleton of manus', 136, 'autoimmune'), ('UBERON_0000104', 'life cycle', 165, 'life')]	0	['low   life play bone fragility, obesity autoimmune diseases life [6].']
S29-PMC3672018	PMC3672018	5/2013	S29-PMC3672018	['with the high general prevalence of Vitamin D deficiency, the status of Pregnant and Lactating women is of particular CONCERN.']	[('PROBLEM_COMPLICATION', 118)]	1	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('GO_0007594', 'puparial adhesion', 85, 'lactating')]	0	[' deficiency, status  lactating women concern.']
S31-PMC3672018	PMC3672018	5/2013	S31-PMC3672018	['Pregnancy is a time of particular SUSCEPTIBILITY to Vitamin D deficiency, AS both maternal and fetal demands for the Vitamin NEED to be met [11,12].']	[('IMPORTANT_CONSIDERATION', 34), ('PROBABLE_UNDERSTANDING', 74), ('IMPORTANT_CONSIDERATION', 125)]	3	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 117, 'vitamin')]	0	['  deficiency, maternal fetal vitamin met [11,12].']
S39-PMC3672018	PMC3672018	5/2013	S39-PMC3672018	['SOME STUDIES have FOUND that Adult obesity varies as a function of month of Birth and that subjects Born from winter to spring become more obese, POSSIBLY due to low Vitamin D levels from restricted maternal sun exposure during the third Trimester of Pregnancy [16].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 146)]	3	[('UBERON_0007023', 'adult organism', 29, 'adult'), ('GO_0007567', 'parturition', 76, 'birth'), ('GO_0007567', 'parturition', 100, 'born'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 238, 'trimester'), ('GO_0007565', 'female pregnancy', 251, 'pregnancy')]	0	['adult obesity month birth subjects born winter spring obese,  levels maternal sun exposure third trimester  [16].']
S40-PMC3672018	PMC3672018	5/2013	S40-PMC3672018	['furthermore, a RECENT STUDY REPORTED that a low level of maternal Vitamin D during Pregnancy was RELATED to high fat and low muscle in offspring at ages 5–9 [15].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 97)]	3	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]	0	['furthermore, maternal   fat muscle offspring ages 5–9 [15].']
S44-PMC3672018	PMC3672018	5/2013	S44-PMC3672018	['BOTH STUDIES SUGGEST that Prenatal malnutrition strongly IMPACTS Adult health, ALTHOUGH neither INDICATES specific EFFECTS from the lack of Vitamin D. the EFFECT of Vitamin D levels during Gestation, THUS, has never previously been followed in large populations.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 57), ('ANOMALY_CURIOUS_FINDING', 79), ('INCOMPLETE_EVIDENCE', 96), ('SUPERFICIAL_RELATIONSHIP', 115), ('SUPERFICIAL_RELATIONSHIP', 155), ('PROBABLE_UNDERSTANDING', 200)]	8	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('UBERON_0007023', 'adult organism', 65, 'adult'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 189, 'gestation')]	0	[' malnutrition adult health, .  levels thus, followed populations.']
S45-PMC3672018	PMC3672018	5/2013	S45-PMC3672018	['furthermore, large-scale interventional STUDIES ARE NEEDED to examine HOW Vitamin D exposure during Pregnancy AFFECTS long-term health outcomes of offspring.']	[('FUTURE_WORK', 40), ('EXPLICIT_QUESTION', 70), ('SUPERFICIAL_RELATIONSHIP', 110)]	3	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy')]	0	['furthermore, interventional  exposure  long-term outcomes offspring.']
S51-PMC3672018	PMC3672018	5/2013	S51-PMC3672018	['initially the PRESENT STUDY will include an in-depth examination of the INFLUENCE of exposure to Vitamin D during Pregnancy for development of fractures of the Wrist, forearm, upper Arm and Shoulder, as well as fractures of Ankle; development of obesity; and development of t1d during child- and Adulthood.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 72)]	2	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('UBERON_0004452', 'carpal region', 160, 'wrist'), ('UBERON_0001460', 'arm', 182, 'arm'), ('UBERON_0001467', 'shoulder', 190, 'shoulder'), ('UBERON_0004454', 'tarsal region', 224, 'ankle'), ('UBERON_0000113', 'post-juvenile adult stage', 296, 'adulthood')]	0	['initially exposure   fractures wrist, forearm, upper arm shoulder, fractures ankle; obesity; t1d child- adulthood.']
S52-PMC3672018	PMC3672018	5/2013	S52-PMC3672018	['furthermore, the large number of subjects that will be followed will ensure that the EFFECTS of Vitamin D exposure in RELATION to the timing of the seasons of Gestational development also can be examined.']	[('SUPERFICIAL_RELATIONSHIP', 85), ('SUPERFICIAL_RELATIONSHIP', 118)]	2	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007565', 'female pregnancy', 159, 'gestational')]	0	['furthermore, subjects followed ensure  exposure timing seasons  examined.']
S92-PMC3672018	PMC3672018	5/2013	S92-PMC3672018	['exposure assessment\nfour main analyses of exposure related to initiation and termination of Vitamin D fortification will be considered for each of the disease outcomes:\n1. Perinatal exposure to Vitamin D for offspring;\n2. seasonal variation in Vitamin D exposure in different Pregnancy trimesters;\n3. exposure to Vitamin D adjusted for Genetic and common environmental INFLUENCES;\n4. levels of Vitamin D (25(Oh)D3) measured in infant Blood from dbs cards.']	[('SUPERFICIAL_RELATIONSHIP', 369)]	1	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0036268', 'swimming', 172, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 172, 'perinatal'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 244, 'vitamin D'), ('GO_0007565', 'female pregnancy', 276, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 313, 'vitamin D'), ('SO_0000704', 'gene', 336, 'genetic'), ('CHEBI_27300', 'vitamin D', 394, 'vitamin D'), ('CHEBI_62946', 'ammonium sulfate', 405, '25(OH)D3'), ('UBERON_0000178', 'blood', 434, 'blood')]	0	['exposure assessment\nfour main exposure initiation termination  fortification disease outcomes:\n1. perinatal exposure  offspring;\n2. seasonal  exposure  trimesters;\n3. exposure  adjusted genetic environmental influences;\n4. levels  (25(oh)d3) infant blood dbs cards.']
S100-PMC3672018	PMC3672018	5/2013	S100-PMC3672018	['WHETHER OR NOT exposure to Vitamin D fortification in different Gestational trimesters is IMPORTANT will be examined.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 90)]	2	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'gestational')]	0	['whether exposure  fortification  trimesters examined.']
S101-PMC3672018	PMC3672018	5/2013	S101-PMC3672018	['for instance, INFLUENCE of low Vitamin D on obesity and Adipose Tissues MAY BE particularly IMPORTANT for children whose third Gestation periods occur during winter, WHILE INFLUENCE of low Vitamin D on Autoimmune diseases MAY BE particularly IMPORTANT for children whose first Gestational trimester occurs during winter.']	[('SUPERFICIAL_RELATIONSHIP', 14), ('INCOMPLETE_EVIDENCE', 72), ('IMPORTANT_CONSIDERATION', 92), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 166), ('SUPERFICIAL_RELATIONSHIP', 172), ('INCOMPLETE_EVIDENCE', 222), ('IMPORTANT_CONSIDERATION', 242)]	7	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('UBERON_0001013', 'adipose tissue', 56, 'adipose tissues'), ('GO_0007565', 'female pregnancy', 127, 'gestation'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 202, 'autoimmune'), ('GO_0007565', 'female pregnancy', 277, 'gestational')]	0	['instance,  obesity adipose tissues children whose third  periods occur winter,  autoimmune diseases children whose  trimester occurs winter.']
S107-PMC3672018	PMC3672018	5/2013	S107-PMC3672018	['25(Oh)D3 level from dbs cards\nBECAUSE the 25(Oh)D3 levels in the newborn Blood REFLECTS the Vitamin D status of the newborn as well as the mother at the end of Pregnancy [29], measurement of 25(Oh)D3 levels in dbs will serve as VALIDATION for the EFFECT of fortification for incident cases.']	[('PROBABLE_UNDERSTANDING', 30), ('SUPERFICIAL_RELATIONSHIP', 79), ('INCOMPLETE_EVIDENCE', 228), ('SUPERFICIAL_RELATIONSHIP', 247)]	4	[('CHEBI_62946', 'ammonium sulfate', 0, '25(OH)D3'), ('PR_000029655', '28S rRNA (cytosine-C(5))-methyltransferase', 0, '25(OH)D3'), ('CHEBI_62946', 'ammonium sulfate', 42, '25(OH)D3'), ('PR_000029655', '28S rRNA (cytosine-C(5))-methyltransferase', 42, '25(OH)D3'), ('UBERON_0000178', 'blood', 73, 'blood'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy'), ('CHEBI_62946', 'ammonium sulfate', 191, '25(OH)D3'), ('PR_000029655', '28S rRNA (cytosine-C(5))-methyltransferase', 191, '25(OH)D3')]	0	['25(oh)d3 dbs cards\nbecause 25(oh)d3 levels newborn blood  status newborn mother  [29], 25(oh)d3 levels dbs fortification incident cases.']
S7-PMC3679329	PMC3679329	6/2013	S7-PMC3679329	['among Pregnant women, the proportion of women with an Intake of Vitamin C (from diet alone) below the ESTIMATED average REQUIREMENTS (ear) was lower among supplement users [users (44%) vs. non-users (68%)], and the proportion of Lactating women with intakes of iron (from diet alone) below the ear was lower among Supplement users [usesr (17%) vs. non-users (38%)].']	[('INCOMPLETE_EVIDENCE', 102), ('IMPORTANT_CONSIDERATION', 120)]	2	[('GO_0007565', 'female pregnancy', 6, 'pregnant'), ('GO_0007631', 'feeding behavior', 54, 'intake'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin C'), ('GO_0007594', 'puparial adhesion', 229, 'lactating'), ('CHEBI_16158', 'steroid sulfate', 314, 'supplement')]	0	['among  women, proportion women intake  (from diet alone) average (ear) among supplement users [users (44%) vs. non-users (68%)], proportion lactating women intakes iron (from diet alone) ear among supplement users [usesr (17%) vs. non-users (38%)].']
S8-PMC3679329	PMC3679329	6/2013	S8-PMC3679329	['these results SUGGEST that among Pregnant and Lactating women, those who do not use dietary supplements TEND to have a lower intake of healthy Foods, such as beans and vegetables, as well as a lower intake of dietary fiber and Β-Carotene, which are abundant in these Foods, and non-users are more LIKELY than users to have INADEQUATE Intake of micro-Nutrient such as Vitamin C and iron.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 104), ('PROBABLE_UNDERSTANDING', 297), ('IMPORTANT_CONSIDERATION', 323), ('PROBLEM_COMPLICATION', 323)]	5	[('GO_0007565', 'female pregnancy', 33, 'pregnant'), ('GO_0007594', 'puparial adhesion', 46, 'lactating'), ('CHEBI_33290', 'food', 143, 'foods'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 227, 'β-carotene'), ('CHEBI_33290', 'food', 267, 'foods'), ('GO_0007631', 'feeding behavior', 334, 'intake'), ('CHEBI_33284', 'nutrient', 350, 'nutrient'), ('CHEBI_27300', 'vitamin D', 367, 'vitamin C')]	0	['results among  lactating women, dietary supplements intake healthy foods, beans vegetables, intake dietary fiber β-carotene, abundant foods, non-users users intake micro-nutrient  iron.']
S81-PMC3679329	PMC3679329	6/2013	S81-PMC3679329	['also SHOWED that non-Pregnant, non-Lactating Adults who were regular users of any type of Supplement consumed more vegetables and fruits, especially those high in Vitamin C [20].']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('GO_0007565', 'female pregnancy', 21, 'pregnant'), ('GO_0007594', 'puparial adhesion', 35, 'lactating'), ('UBERON_0007023', 'adult organism', 45, 'adults'), ('CHEBI_16158', 'steroid sulfate', 90, 'supplement'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin C')]	0	['also non-, non-lactating adults users type supplement consumed vegetables fruits,  [20].']
S82-PMC3679329	PMC3679329	6/2013	S82-PMC3679329	['in the PRESENT STUDY, among Pregnant women, the proportion of women with an Intake of Vitamin C (from diet alone) below the ear was significantly higher among Supplement non-users (68%) than among users (44%).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 7)]	1	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('GO_0007631', 'feeding behavior', 76, 'intake'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 159, 'supplement')]	0	['study, among  women, proportion women intake  (from diet alone) ear higher among supplement non-users (68%) among users (44%).']
S10-PMC3685533	PMC3685533	6/2013	S10-PMC3685533	['conclusions\nthe PRESENT STUDY SHOWS a high prevalence of Vitamin D insufficiency and deficiency in newborns with significant differences observed to be DUE TO ethnicity, skin colour and maternal supplementation during the Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 30), ('PROBLEM_COMPLICATION', 152)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 222, 'pregnancy')]	0	['conclusions\nthe  newborns ethnicity, skin colour maternal supplementation .']
S18-PMC3685533	PMC3685533	6/2013	S18-PMC3685533	['current data within the literature DEMONSTRATES a high prevalence of Vitamin D insufficiency not ONLY in Adult and in children, BUT ALSO in Pregnant women and in their neonates [3-5].']	[('INCOMPLETE_EVIDENCE', 35), ('ANOMALY_CURIOUS_FINDING', 97), ('ANOMALY_CURIOUS_FINDING', 128)]	3	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('UBERON_0007023', 'adult organism', 105, 'adult'), ('GO_0007565', 'female pregnancy', 140, 'pregnant')]	0	['current  adult children,  women neonates [3-5].']
S23-PMC3685533	PMC3685533	6/2013	S23-PMC3685533	['HOWEVER, most Pregnant women are Vitamin D deficient or insufficient with a consequential deficiency or insufficiency in their neonates [5-8].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('GO_0007565', 'female pregnancy', 14, 'pregnant'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]	0	['however,  women  consequential neonates [5-8].']
S31-PMC3685533	PMC3685533	6/2013	S31-PMC3685533	['data SUGGESTS that doses exceeding 1000 iu of Vitamin D per day are NECESSARY to achieve sufficienct 25Ohd concentrations in Pregnant women [18].']	[('INCOMPLETE_EVIDENCE', 5), ('IMPORTANT_CONSIDERATION', 68)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 101, '25OHD'), ('GO_0007565', 'female pregnancy', 125, 'pregnant')]	0	['data doses exceeding 1000 iu  day achieve sufficienct 25ohd concentrations  women [18].']
S32-PMC3685533	PMC3685533	6/2013	S32-PMC3685533	['DISCORDANT data are present with respect to the ROLE of Vitamin D supplementation during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 48)]	2	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy')]	0	['discordant respect  supplementation .']
S34-PMC3685533	PMC3685533	6/2013	S34-PMC3685533	['further, multivitamin use during Pregnancy HAS BEEN DEMONSTRATED to not be sufficient to correct pre-existing maternal Vitamin D deficiency [19-22].']	[('INCOMPLETE_EVIDENCE', 43)]	1	[('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]	0	['further, multivitamin  pre-existing maternal  [19-22].']
S78-PMC3685533	PMC3685533	6/2013	S78-PMC3685533	['when CONSIDERING the maternal multivitamin Intake during Pregnancy, all mothers supplemented with Vitamin D DEMONSTRATED higher 25Ohd values in both Cord Blood (24.5\u2009±\u200911.9 vs 17.2\u2009±\u20099.2 ng/ml; p\u2009<\u20090.01) and in neonatal Serum (17.7\u2009±\u20099.3 vs 11.1\u2009±\u20096 ng/ml; p\u2009<\u20090.001).']	[('IMPORTANT_CONSIDERATION', 5), ('INCOMPLETE_EVIDENCE', 108)]	2	[('GO_0007631', 'feeding behavior', 43, 'intake'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 128, '25OHD'), ('UBERON_0002240', 'spinal cord', 149, 'cord'), ('UBERON_0000178', 'blood', 154, 'blood'), ('UBERON_0001977', 'blood serum', 220, 'serum')]	0	['maternal multivitamin intake mothers supplemented  higher 25ohd values cord blood (24.5\u2009±\u200911.9 17.2\u2009±\u20099.2 ng/ml; p\u2009<\u20090.01) neonatal serum (17.7\u2009±\u20099.3 11.1\u2009±\u20096 ng/ml; p\u2009<\u20090.001).']
S87-PMC3685533	PMC3685533	6/2013	S87-PMC3685533	['neonates fs with no supplementation during Pregnancy, SHOWED Vitamin D levels higher than unsupplemented lob and mbb neonates (p\u2009<\u20090.05).']	[('INCOMPLETE_EVIDENCE', 54)]	1	[('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]	0	['neonates fs supplementation  levels higher unsupplemented lob mbb neonates (p\u2009<\u20090.05).']
S98-PMC3685533	PMC3685533	6/2013	S98-PMC3685533	['multiple regression analysis REVEALED that Vitamin D levels in Cord Blood were PREDICTED (r2: 0.670; p\u2009<\u20090.0001) by neonatal Vitamin D values (standardized β: 0.818), when corrected for Vitamin D supplementation and Gestational age.']	[('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 79)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 63, 'cord'), ('UBERON_0000178', 'blood', 68, 'blood'), ('CHEBI_28384', 'vitamin K', 125, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'gestational')]	0	['multiple regression  levels cord blood (r2: 0.670; p\u2009<\u20090.0001) neonatal vitamin values (standardized β: 0.818), corrected  supplementation  age.']
S99-PMC3685533	PMC3685533	6/2013	S99-PMC3685533	['likewise neonatal Vitamin D levels were PREDICTED (r2: 0.670; p\u2009<\u20090.0001) by Vitamin D values on Cord Blood (standardized β: 0.818), when corrected for Vitamin D supplementation and Gestational age.']	[('SUPERFICIAL_RELATIONSHIP', 40)]	1	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 77, 'Vitamin D'), ('UBERON_0002240', 'spinal cord', 97, 'cord'), ('UBERON_0000178', 'blood', 102, 'blood'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'gestational')]	0	['likewise neonatal  levels (r2: 0.670; p\u2009<\u20090.0001) vitamin values cord blood (standardized β: 0.818), corrected  supplementation  age.']
S119-PMC3685533	PMC3685533	6/2013	S119-PMC3685533	['we have also INVESTIGATED the ROLE of supplementation in Pregnancy on Vitamin D Cord Blood and Serum levels.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('SUPERFICIAL_RELATIONSHIP', 30)]	2	[('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 80, 'cord'), ('UBERON_0000178', 'blood', 85, 'blood'), ('UBERON_0001977', 'blood serum', 95, 'serum')]	0	['supplementation   cord blood serum levels.']
S124-PMC3685533	PMC3685533	6/2013	S124-PMC3685533	['after Birth ONLY fs newborns unsupplemented SHOWED Vitamin D levels higher than lob and mbb; no differences were found in case of maternal supplementation in Pregnancy, MOST LIKELY DUE TO a specific ROLE of supplementation in neonates.']	[('ANOMALY_CURIOUS_FINDING', 12), ('INCOMPLETE_EVIDENCE', 44), ('PROBABLE_UNDERSTANDING', 169), ('PROBABLE_UNDERSTANDING', 181), ('PROBLEM_COMPLICATION', 181), ('SUPERFICIAL_RELATIONSHIP', 199)]	6	[('GO_0007567', 'parturition', 6, 'birth'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]	0	['birth fs newborns unsupplemented  levels higher lob mbb; maternal supplementation supplementation neonates.']
S126-PMC3685533	PMC3685533	6/2013	S126-PMC3685533	['ALTHOUGH SEVERAL STUDIES are AVAILABLE on Vitamin D supplementation during Pregnancy, its APPROPRIATE dose is NOT CLEAR [19-21].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 29), ('IMPORTANT_CONSIDERATION', 90), ('FULL_UNKNOWN', 110)]	5	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy')]	0	['although  supplementation dose [19-21].']
S128-PMC3685533	PMC3685533	6/2013	S128-PMC3685533	['a RECENT cochrane on Vitamin D supplementation during Pregnancy SHOWED that with supplementation, there is an increase Serum 25Ohd levels in neonates [22].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 64)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('UBERON_0001977', 'blood serum', 119, 'serum'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 125, '25OHD')]	0	['cochrane  supplementation  supplementation, increase serum 25ohd levels neonates [22].']
S0-PMC3691177	PMC3691177	6/2013	S0-PMC3691177	['Prenatal Vitamin D supplementation and child Respiratory health: a randomised controlled trial\n\nabstract\n\nbackground\nOBSERVATIONAL studies SUGGEST high Prenatal Vitamin D intake MAY BE ASSOCIATED with reduced childhood wheezing.']	[('INCOMPLETE_EVIDENCE', 117), ('INCOMPLETE_EVIDENCE', 139), ('INCOMPLETE_EVIDENCE', 178), ('SUPERFICIAL_RELATIONSHIP', 185)]	4	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('UBERON_0001004', 'respiratory system', 45, 'Respiratory'), ('GO_0007565', 'female pregnancy', 152, 'prenatal'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]	0	[' vitamin supplementation child respiratory health: randomised trial\n\nabstract\n\nbackground\nobservational   intake childhood wheezing.']
S1-PMC3691177	PMC3691177	6/2013	S1-PMC3691177	['we EXAMINED the EFFECT of Prenatal Vitamin D on childhood wheezing in an interventional study.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 16)]	2	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D')]	0	['  childhood wheezing interventional study.']
S12-PMC3691177	PMC3691177	6/2013	S12-PMC3691177	['conclusion\nPrenatal Vitamin D supplementation in late Pregnancy that had a modest EFFECT on Cord Blood Vitamin D level, was not associated with decreased wheezing in offspring at age three years.']	[('SUPERFICIAL_RELATIONSHIP', 82)]	1	[('GO_0007565', 'female pregnancy', 11, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 92, 'cord'), ('UBERON_0000178', 'blood', 97, 'blood'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]	0	['conclusion\n  supplementation late  cord blood  level, decreased wheezing offspring age three years.']
S13-PMC3691177	PMC3691177	6/2013	S13-PMC3691177	['trial registration\ncontrolled-trials.comisrctn68645785\n\nintroduction\nseveral observational studies have SUGGESTED a PROTECTIVE EFFECT of higher maternal Vitamin D intake during Pregnancy on RISK of wheezing[1]–[3], asthma and allergic rhinitis[4], and eczema[3]in offspring.']	[('INCOMPLETE_EVIDENCE', 104), ('SUPERFICIAL_RELATIONSHIP', 116), ('SUPERFICIAL_RELATIONSHIP', 127), ('IMPORTANT_CONSIDERATION', 190)]	4	[('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('GO_0007565', 'female pregnancy', 177, 'pregnancy')]	0	['trial registration\ncontrolled-trials.comisrctn68645785\n\nintroduction\nseveral higher maternal  intake  wheezing[1]–[3], asthma allergic rhinitis[4], eczema[3]in offspring.']
S21-PMC3691177	PMC3691177	6/2013	S21-PMC3691177	['Vitamin D insufficiency is NEVERTHELESS very common during Pregnancy[15]–[17], and it HAS BEEN PROPOSED that Prenatal Vitamin D supplementation MAY PREVENT childhood wheezing and asthma[18].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 27), ('INCOMPLETE_EVIDENCE', 86), ('INCOMPLETE_EVIDENCE', 95), ('INCOMPLETE_EVIDENCE', 144), ('SUPERFICIAL_RELATIONSHIP', 148)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('GO_0007565', 'female pregnancy', 109, 'prenatal'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]	0	['vitamin [15]–[17],   supplementation childhood wheezing asthma[18].']
S22-PMC3691177	PMC3691177	6/2013	S22-PMC3691177	['we assessed children whose mothers had taken part in a randomised controlled trial of Prenatal Vitamin D supplementation, TO DETERMINE WHETHER supplementation PREVENTED wheezing or allergic disease in the first 3 years of Life[19].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 122), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('SUPERFICIAL_RELATIONSHIP', 159)]	3	[('GO_0007565', 'female pregnancy', 86, 'prenatal'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('UBERON_0000104', 'life cycle', 222, 'life')]	0	['children whose mothers randomised   supplementation, supplementation wheezing allergic disease 3 life[19].']
S35-PMC3691177	PMC3691177	6/2013	S35-PMC3691177	['women were given instructions to swallow the tablets whole and to avoid other multivitamin supplements containing Vitamin D. this trial was CONDUCTED before national guidance on routinely providing advice on Vitamin D intake during Pregnancy was introduced in march 2008[14].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 140)]	1	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('GO_0007565', 'female pregnancy', 232, 'pregnancy')]	0	['women instructions swallow tablets whole multivitamin supplements containing . national routinely  intake  march 2008[14].']
S74-PMC3691177	PMC3691177	6/2013	S74-PMC3691177	['as PREVIOUSLY reported[19], median Cord 25(Oh)D levels at Delivery were significantly higher in supplemented children COMPARED TO the control group [control 17 nmol/l (interquartile range (iqr) 14–22); daily dose 26 nmol/l (iqr 17–45); p<0.001; bolus dose 25 nmol/l (iqr 18–34); p<0.001)].10.1371/journal.pone.0066627.g001\n\ncaption (fig): figure 1\nrecruitment and follow up of study participants.10.1371/journal.pone.0066627.t001\n\ncaption (table-wrap): table 1\ncharacteristics of study participants followed up at age three years.controldaily Vitamin dbolus vitamin dcombined Vitamin D(n\u200a=\u200a50)(n\u200a=\u200a56)(n\u200a=\u200a52)(n\u200a=\u200a108)baseline maternal 25(Oh)D <25 nmol/l, n/n (%)24/50 (48)25/56 (45)22/52 (42)47/108 (44)male sex, n/n (%)27/50 (54)32/56 (57)26/52 (50)58/108 (55)Birth weight (g), mean (sd)3268 (585)3321 (525)3290 (467)3307 (497)ethnicity, n (%)asian12 (24)15 (27)13 (25)28 (26)middle eastern13 (26)14 (25)14 (26)28 (26)black12 (24)14 (25)13 (25)27 (25)white13 (26)13 (23)12 (24)25 (23)ga at Delivery (weeks), mean (sd)40 (1)39 (2)40 (1)39 (2)nulliparous mother, n/n (%)23/50 (46)20/56 (36)21/52 (40)41/108 (38)Vaginal Delivery, n/n (%)29/50 (58)35/56 (63)28/52 (54)63/108 (58)maternal smoking during Pregnancy, n/n (%)2/48 (4)3/55 (5)0/46 (0)3/101 (3)presence of household smokers, n/n (%)16/48 (33)15/55 (27)17/46 (37)32/101 (32)number of children in household, mean (sd)2 (1)2 (1)2 (1)2 (1)age mother left full time education, mean (sd)20 (3)20 (4)21 (4)21 (4)child in nursery, n/n (%)27/48 (56)36/55 (65)20/45 (44)57/101 (56)Cat or Dog in household, n/n (%)4/48 (8)5/54 (9)4/46 (9)9/100 (9)maternal fitzpatrick skin score grade 3–6, n/n (%)28/44 (64)33/49 (67)28/43 (65)61/92 (66)maternal regular vitamin intake at three years, n/n (%)9/46 (20)16/53 (30)16/45 (36)32/98 (33)at least one parent with allergic disease, n/n (%)23/45 (51)35/53 (66)21/45 (47)56/98 (57)exclusively Breast-Fed for 4 months, n/n (%)22/48 (46)20/54 (37)23/44 (52)43/98 (44)any child vitamin supplementation, n/n (%)30/48 (63)34/55 (62)30/46 (65)64/101 (63)completed immunizations to date, n/n (%)48/49 (98)54/55 (98)43/47 (91)97/102 (95)age at time of assessment (months), median (iqr)37.9 (36.9, 39.9)37.1 (36.5, 38.8)37.4 (36.5, 39.5)37.3 (36.5, 39.0)child fitzpatrick skin score grade 3–6, n (%)29/42 (69)34/48 (71)29/43 (67)63/91 (69)child bmi z score age 3, mean (sd)0.51 (1.48)0.35 (1.15)0.62 (1.15)0.47 (1.15)child outdoors >1 hour/day, n/n (%)32/48 (67)34/53 (64)33/45 (73)67/98 (68)child tv/computer >2 hours/day, n/n (%)24/48 (50)18/53 (34)17/45 (38)35/98 (36)child 25(Oh)D (nmol/l) age 3, median (iqr)42 (27, 68)35 (21, 66)42 (30, 93)41 (26, 72)\ndata shown are for all participants analysed.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118)]	2	[('UBERON_0002240', 'spinal cord', 35, 'cord'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 40, '25(OH ... D'), ('GO_0007567', 'parturition', 58, 'delivery'), ('CHEBI_33229', 'vitamin (role)', 543, 'vitamin'), ('CHEBI_27300', 'vitamin D', 576, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 636, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 636, '25(OH ... D'), ('GO_0007567', 'parturition', 762, 'Birth'), ('GO_0007567', 'parturition', 992, 'delivery'), ('GO_0007567', 'parturition', 1111, 'Vaginal'), ('UBERON_0000970', 'eye', 1111, 'Vaginal'), ('GO_0007567', 'parturition', 1119, 'delivery'), ('GO_0007565', 'female pregnancy', 1201, 'pregnancy'), ('NCBITaxon_10088', 'Mus <genus>', 1529, 'Cat'), ('NCBITaxon_33208', 'Metazoa', 1536, 'dog'), ('GO_0007567', 'parturition', 1880, 'breast'), ('UBERON_0000310', 'breast', 1880, 'breast'), ('GO_0007631', 'feeding behavior', 1887, 'fed'), ('CHEBI_71657', 'versiconol acetate', 2555, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 2558, 'OH)D')]	0	['reported[19], median cord 25(oh)d levels delivery higher supplemented children [control 17 nmol/l (interquartile (iqr) 14–22); daily dose 26 nmol/l (iqr 17–45); p<0.001; bolus dose 25 nmol/l (iqr 18–34); p<0.001)].10.1371/journal.pone.0066627.g001\n\ncaption (fig): figure 1\nrecruitment participants.10.1371/journal.pone.0066627.t001\n\ncaption (table-wrap): table 1\ncharacteristics participants followed age three years.controldaily vitamin dbolus vitamin dcombined (n\u200a=\u200a50)(n\u200a=\u200a56)(n\u200a=\u200a52)(n\u200a=\u200a108)baseline maternal 25(oh)d <25 nmol/l, n/n (%)24/50 (48)25/56 (45)22/52 (42)47/108 (44)male sex, n/n (%)27/50 (54)32/56 (57)26/52 (50)58/108 (55)birth (g), (sd)3268 (585)3321 (525)3290 (467)3307 (497)ethnicity, n (%)asian12 (24)15 (27)13 (25)28 (26)middle eastern13 (26)14 (25)14 (26)28 (26)black12 (24)14 (25)13 (25)27 (25)white13 (26)13 (23)12 (24)25 (23)ga delivery (weeks), (sd)40 (1)39 (2)40 (1)39 (2)nulliparous mother, n/n (%)23/50 (46)20/56 (36)21/52 (40)41/108 (38)vaginal delivery, n/n (%)29/50 (58)35/56 (63)28/52 (54)63/108 (58)maternal smoking n/n (%)2/48 (4)3/55 (5)0/46 (0)3/101 (3)presence household smokers, n/n (%)16/48 (33)15/55 (27)17/46 (37)32/101 (32)number children household, (sd)2 (1)2 (1)2 (1)2 (1)age mother left education, (sd)20 (3)20 (4)21 (4)21 (4)child nursery, n/n (%)27/48 (56)36/55 (65)20/45 (44)57/101 (56)cat dog household, n/n (%)4/48 (8)5/54 (9)4/46 (9)9/100 (9)maternal fitzpatrick skin score grade 3–6, n/n (%)28/44 (64)33/49 (67)28/43 (65)61/92 (66)maternal vitamin intake three years, n/n (%)9/46 (20)16/53 (30)16/45 (36)32/98 (33)at parent allergic disease, n/n (%)23/45 (51)35/53 (66)21/45 (47)56/98 (57)exclusively breast-fed 4 months, n/n (%)22/48 (46)20/54 (37)23/44 (52)43/98 (44)any child vitamin supplementation, n/n (%)30/48 (63)34/55 (62)30/46 (65)64/101 (63)completed immunizations date, n/n (%)48/49 (98)54/55 (98)43/47 (91)97/102 (95)age (months), median (iqr)37.9 (36.9, 39.9)37.1 (36.5, 38.8)37.4 (36.5, 39.5)37.3 (36.5, 39.0)child fitzpatrick skin score grade 3–6, n (%)29/42 (69)34/48 (71)29/43 (67)63/91 (69)child bmi z score age 3, (sd)0.51 (1.48)0.35 (1.15)0.62 (1.15)0.47 (1.15)child outdoors >1 hour/day, n/n (%)32/48 (67)34/53 (64)33/45 (73)67/98 (68)child tv/computer >2 hours/day, n/n (%)24/48 (50)18/53 (34)17/45 (38)35/98 (36)child 25(oh)d (nmol/l) age 3, median (iqr)42 (27, 68)35 (21, 66)42 (30, 93)41 (26, 72)\ndata participants analysed.']
S107-PMC3691177	PMC3691177	6/2013	S107-PMC3691177	['discussion\nin THIS randomised CONTROLLED TRIAL of Vitamin D supplementation in late Pregnancy in a relatively deficient mixed race population, daily supplementation with 800 iu Ergocalciferol or a single bolus dose of 200,000 iu Cholecalciferol from 27 weeks Gestation did not prevent wheezing, allergic disease or influence measures of Lung function or allergic inflammation in offspring in the first three years of Life.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('QUESTION_ANSWERED_BY_THIS_WORK', 30)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_4910', 'etomidate', 177, 'ergocalciferol'), ('CHEBI_52550', 'theopalauamide', 229, 'cholecalciferol'), ('GO_0007565', 'female pregnancy', 259, 'gestation'), ('UBERON_0002048', 'lung', 337, 'lung'), ('UBERON_0000104', 'life cycle', 417, 'life')]	0	['discussion\nin randomised  supplementation late  race population, daily supplementation 800 iu ergocalciferol single bolus dose 200,000 iu cholecalciferol 27 weeks  wheezing, allergic disease lung allergic inflammation offspring three life.']
S109-PMC3691177	PMC3691177	6/2013	S109-PMC3691177	['our results SUGGEST that the MOST LIKELY EXPLANATION for the FINDING of decreased wheezing risk in offspring of mothers with a higher Vitamin D intake during Pregnancy in observational studies[1]–[4], is CONFOUNDING by OTHER dietary or lifestyle factors ASSOCIATED with Vitamin D intake.']	[('INCOMPLETE_EVIDENCE', 12), ('PROBABLE_UNDERSTANDING', 29), ('PROBABLE_UNDERSTANDING', 34), ('PROBABLE_UNDERSTANDING', 41), ('INCOMPLETE_EVIDENCE', 61), ('PROBLEM_COMPLICATION', 204), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 219), ('SUPERFICIAL_RELATIONSHIP', 254)]	8	[('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D')]	0	['results decreased wheezing offspring mothers higher  intake  studies[1]–[4], dietary lifestyle  intake.']
S117-PMC3691177	PMC3691177	6/2013	S117-PMC3691177	['the 95% confidence interval for our primary outcome measure was 0.49 to 1.50, so we are UNABLE TO confidently exclude EFFECTS of Prenatal vitamin D supplementation on RISK of wheezing, or on the development of atopy especially in mothers treated with daily Vitamin D. third, we DID NOT assess Vitamin D receptor polymorphisms or OTHER POTENTIALLY IMPORTANT genotypic variations.']	[('DIFFICULT_TASK', 88), ('SUPERFICIAL_RELATIONSHIP', 118), ('IMPORTANT_CONSIDERATION', 167), ('INCOMPLETE_EVIDENCE', 278), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 329), ('INCOMPLETE_EVIDENCE', 335), ('IMPORTANT_CONSIDERATION', 347)]	7	[('GO_0007565', 'female pregnancy', 129, 'prenatal'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 146, 'D'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D')]	0	['95% confidence interval outcome measure 0.49 1.50,  vitamin supplementation wheezing, atopy mothers treated daily . third,  receptor polymorphisms genotypic variations.']
S126-PMC3691177	PMC3691177	6/2013	S126-PMC3691177	['ALTHOUGH the Vitamin D doses used in this trial were greater than the current RECOMMENDED intake for Pregnant women of 400 iu/day during Pregnancy in the united kingdom[14],[17], and 600 iu in the united states[25], ONLY a small percentage of offspring had Cord 25(Oh)D levels in the sufficient range (13% daily group, 3% bolus group).']	[('ANOMALY_CURIOUS_FINDING', 0), ('FUTURE_WORK', 78), ('INCOMPLETE_EVIDENCE', 216)]	3	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnant'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 257, 'cord'), ('CHEBI_71657', 'versiconol acetate', 262, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 262, '25(OH)D')]	0	['although  doses intake  women 400 iu/day  united kingdom[14],[17], 600 iu united states[25], percentage offspring cord 25(oh)d levels (13% daily group, 3% bolus group).']
S127-PMC3691177	PMC3691177	6/2013	S127-PMC3691177	['it HAS RECENTLY BEEN SHOWN that doses of 4000 iu of Vitamin D daily are SAFE and effective for short term treatment of Vitamin D deficiency during Pregnancy[30], ALTHOUGH the long term EFFECTS on child health have NOT BEEN STUDIED.']	[('INCOMPLETE_EVIDENCE', 3), ('IMPORTANT_CONSIDERATION', 72), ('ANOMALY_CURIOUS_FINDING', 162), ('SUPERFICIAL_RELATIONSHIP', 185), ('FULL_UNKNOWN', 214)]	5	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy')]	0	['doses 4000 iu  daily term treatment  [30], term child studied.']
S128-PMC3691177	PMC3691177	6/2013	S128-PMC3691177	['two on-going trials, the Vitamin D Prenatal asthma reduction trial (nct00920621), and abcvitamind (nct00856947) are specifically exploring the EFFECTS of earlier and higher dose Prenatal Vitamin D supplementation on child health.']	[('SUPERFICIAL_RELATIONSHIP', 143)]	1	[('CHEBI_28384', 'vitamin K', 25, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'Prenatal'), ('GO_0007565', 'female pregnancy', 178, 'prenatal'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]	0	['two on-going trials, vitamin  asthma reduction (nct00920621), abcvitamind (nct00856947) higher dose   supplementation child health.']
S129-PMC3691177	PMC3691177	6/2013	S129-PMC3691177	['two RECENT OBSERVATIONAL STUDIES that DOCUMENTED Prenatal Vitamin D status by measuring Cord Blood 25(Oh)D concentration, FOUND RELATIONSHIPS with allergic sensitisation and/or wheezing in early childhood[8],[31].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 38), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 128)]	5	[('GO_0007565', 'female pregnancy', 49, 'prenatal'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 88, 'cord'), ('UBERON_0000178', 'blood', 93, 'blood'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 99, '25(OH ... D')]	0	['two   status measuring cord blood 25(oh)d concentration, allergic sensitisation and/or wheezing childhood[8],[31].']
S132-PMC3691177	PMC3691177	6/2013	S132-PMC3691177	['the results of our randomised controlled trial do not SUPPORT a strong causal RELATIONSHIP between low Prenatal Vitamin D status within the deficient/insufficient range and INCREASED RISK of Allergic sensitization or wheezing in early childhood.']	[('INCOMPLETE_EVIDENCE', 54), ('SUPERFICIAL_RELATIONSHIP', 78), ('IMPORTANT_CONSIDERATION', 173)]	3	[('GO_0007565', 'female pregnancy', 103, 'prenatal'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0040011', 'locomotion', 191, 'allergic')]	0	['results randomised causal   status deficient/insufficient allergic sensitization wheezing childhood.']
S134-PMC3691177	PMC3691177	6/2013	S134-PMC3691177	['the FINDINGS of OUR STUDY are specific to a population of Vitamin D deficient women (half had baseline 25(Oh)D levels below 25 nmol/l) and two specific forms of Prenatal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16)]	2	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 103, '25(OH)D'), ('GO_0007565', 'female pregnancy', 161, 'prenatal'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]	0	['population  women (half baseline 25(oh)d levels 25 nmol/l) forms   supplementation.']
S137-PMC3691177	PMC3691177	6/2013	S137-PMC3691177	['ALTHOUGH THESE FINDINGS cannot automatically be generalised to OTHER populations of Pregnant women, one MIGHT expect Prenatal Vitamin D supplementation to SHOW its clearest clinical EFFECTS in a deficient population such as this.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 63), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 155), ('SUPERFICIAL_RELATIONSHIP', 182)]	7	[('GO_0007565', 'female pregnancy', 84, 'pregnant'), ('GO_0007565', 'female pregnancy', 117, 'prenatal'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]	0	['although automatically generalised populations  women,   supplementation population this.']
S138-PMC3691177	PMC3691177	6/2013	S138-PMC3691177	['IN SUMMARY we FOUND NO EVIDENCE for a protective effect of Prenatal Vitamin D supplementation from 27 weeks Gestation on childhood wheezing, allergic disease, Lung function or markers of Airway inflammation in the first 3 years of Life.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 20)]	3	[('GO_0007565', 'female pregnancy', 59, 'prenatal'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'gestation'), ('UBERON_0002048', 'lung', 159, 'lung'), ('UBERON_0001005', 'respiratory airway', 187, 'airway'), ('UBERON_0000104', 'life cycle', 231, 'life')]	0	['  supplementation 27 weeks  childhood wheezing, allergic disease, lung airway inflammation 3 life.']
S139-PMC3691177	PMC3691177	6/2013	S139-PMC3691177	['given the modest EFFECTS on Cord Blood Vitamin D achieved by these INTERVENTIONS, the SAFETY and efficacy of higher dose Prenatal Vitamin D supplementation STRATEGIES NEED TO BE explored.']	[('SUPERFICIAL_RELATIONSHIP', 17), ('SUPERFICIAL_RELATIONSHIP', 67), ('IMPORTANT_CONSIDERATION', 86), ('FUTURE_WORK', 156), ('FUTURE_WORK', 167)]	5	[('UBERON_0002240', 'spinal cord', 28, 'cord'), ('UBERON_0000178', 'blood', 33, 'blood'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 121, 'prenatal'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]	0	['given cord blood  achieved interventions, higher dose   supplementation explored.']
S64-PMC3695234	PMC3695234	7/2013	S64-PMC3695234	['chi et al.16ASSESSED the INFLUENCE of Prenatal Vitamin D status on Immune function at Birth.']	[('INCOMPLETE_EVIDENCE', 10), ('SUPERFICIAL_RELATIONSHIP', 25)]	2	[('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('UBERON_0002405', 'immune system', 67, 'immune'), ('GO_0007567', 'parturition', 86, 'birth')]	0	['chi et al.16assessed   status immune birth.']
S0-PMC3702245	PMC3702245	6/2013	S0-PMC3702245	['Vitamin D nutrition in Pregnancy: current opinion\n\nabstract\nthere is INCREASING INTEREST in Vitamin D nutrition during Pregnancy because of widespread REPORTS of a high prevalence of low vitamin d status in Pregnant women.']	[('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 151)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('GO_0007565', 'female pregnancy', 207, 'pregnant')]	0	['vitamin nutrition : opinion\n\nabstract\nthere  nutrition  vitamin status  women.']
S2-PMC3702245	PMC3702245	6/2013	S2-PMC3702245	['CONSISTENT with the expanded ROLE of Vitamin D, RECENT OBSERVATIONAL STUDIES have DEMONSTRATED that low Vitamin D status in Pregnancy is ASSOCIATED with multiple POTENTIAL adverse maternal, fetal, and infant outcomes and CONTRIBUTES to low Vitamin D status in infants at Birth.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 29), ('INCOMPLETE_EVIDENCE', 48), ('INCOMPLETE_EVIDENCE', 55), ('INCOMPLETE_EVIDENCE', 82), ('SUPERFICIAL_RELATIONSHIP', 137), ('INCOMPLETE_EVIDENCE', 162), ('SUPERFICIAL_RELATIONSHIP', 221)]	8	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D'), ('GO_0007567', 'parturition', 271, 'birth')]	0	['consistent  status  maternal, fetal, infant outcomes  status infants birth.']
S3-PMC3702245	PMC3702245	6/2013	S3-PMC3702245	['THEREFORE, an overview of the CURRENT understanding of Vitamin D nutrition in Pregnancy and a review of the results of studies to optimize Vitamin D status during Pregnancy and in the offspring is of PUBLIC HEALTH IMPORTANCE and timely.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 30), ('IMPORTANT_CONSIDERATION', 200), ('IMPORTANT_CONSIDERATION', 214)]	4	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy')]	0	['therefore,  nutrition  results optimize  status  offspring timely.']
S4-PMC3702245	PMC3702245	6/2013	S4-PMC3702245	['introduction\nVitamin D deficiency in Pregnancy is widespread in many parts of the world,1and there is an ASSOCIATION between low Vitamin D status and multiple POTENTIAL adverse outcomes of Pregnancy.2–5therefore, Vitamin D nutrition in Pregnancy SHOULD BE of GLOBAL HEALTH INTEREST.']	[('SUPERFICIAL_RELATIONSHIP', 105), ('INCOMPLETE_EVIDENCE', 159), ('FUTURE_WORK', 246), ('IMPORTANT_CONSIDERATION', 259)]	4	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 37, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007565', 'female pregnancy', 189, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy')]	0	['introduction\nvitamin  parts world,1and  status outcomes .2–5therefore,  nutrition  interest.']
S5-PMC3702245	PMC3702245	6/2013	S5-PMC3702245	['ALTHOUGH the Synthesis and Metabolism Of Vitamin D in the nonpregnant state is WELL KNOWN, its Metabolism during Pregnancy is LESS WELL UNDERSTOOD.3the classical action of vitamin d is to maintain Calcium Homeostasis and bone health.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 79), ('INCOMPLETE_EVIDENCE', 126)]	3	[('GO_0007416', 'synapse assembly', 13, 'synthesis ...'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 27, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0008152', 'metabolic process', 95, 'metabolism'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('GO_0055073', 'cadmium ion homeostasis', 197, 'calcium homeostasis')]	0	['although synthesis metabolism  nonpregnant known, metabolism  understood.3the vitamin maintain calcium homeostasis bone health.']
S6-PMC3702245	PMC3702245	6/2013	S6-PMC3702245	['in addition, it is now known to be INVOLVED in Immunomodulation, Cell Proliferation, and Cell Differentiation, and in other physiologic functions in diverse Tissues and Organs, including the Brain, Pancreas, and Heart.6despite the REPORTED high prevalence of Vitamin D deficiency and its POSSIBLE consequences, the criteria for defining an optimal level in the body, and HENCE the amount of Vitamin D intake REQUIRED to maintain adequate levels, is CONTROVERSIAL.3,7,8this overview addresses the CURRENT INFORMATION about Vitamin D function, the GLOBAL BURDEN and POTENTIAL consequences of low Vitamin D status in Pregnancy, and current STRATEGIES to optimize Vitamin D status in Pregnant mothers and their offspring.']	[('SUPERFICIAL_RELATIONSHIP', 35), ('INCOMPLETE_EVIDENCE', 231), ('INCOMPLETE_EVIDENCE', 288), ('PROBABLE_UNDERSTANDING', 371), ('IMPORTANT_CONSIDERATION', 408), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 449), ('INCOMPLETE_EVIDENCE', 496), ('IMPORTANT_CONSIDERATION', 546), ('INCOMPLETE_EVIDENCE', 564), ('FUTURE_WORK', 637)]	10	[('GO_0050900', 'leukocyte migration', 47, 'immunomodulation'), ('GO_0008283', 'cell proliferation', 65, 'cell proliferation'), ('GO_0030154', 'cell differentiation', 89, 'cell differentiation'), ('UBERON_0000479', 'tissue', 157, 'tissues'), ('UBERON_0000062', 'organ', 169, 'organs'), ('UBERON_0000955', 'brain', 191, 'brain'), ('UBERON_0001264', 'pancreas', 198, 'pancreas'), ('UBERON_0000948', 'heart', 212, 'heart'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 391, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 522, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 594, 'vitamin D'), ('GO_0007565', 'female pregnancy', 614, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 660, 'vitamin D'), ('GO_0007565', 'female pregnancy', 680, 'pregnant')]	0	['addition, immunomodulation, cell proliferation, cell differentiation, physiologic functions tissues organs, brain, pancreas, heart.6despite  consequences, criteria body, amount  intake maintain levels, controversial.3,7,8this  function,  status optimize  status  mothers offspring.']
S10-PMC3702245	PMC3702245	6/2013	S10-PMC3702245	['a second hydroxylation takes place in the Kidney, which converts 25(Oh)D to the most biologically active Metabolite, 1,25-Dihydroxyvitamin D, the major classical physiologic function of which is to increase calcium and Phosphorus absorption from the Gut in order to maintain Calcium Homeostasis and promote mineralization of Osteoid bone.9\nalthough the Renal 1-alpha hydroxylase (Cytochrome P450 [Cyp]27B1) enzyme is a MAJOR DETERMINANT of Synthesis of 1,25-Dihydroxyvitamin D, IT IS KNOWN that Cyp27B1 is Expressed in Nonrenal Tissues to produce 1,25 Dihydroxyvitamin D.6,19in addition, Vitamin D receptors are also Expressed in a variety of Organs, Tissues, and cells (seefigure 1).20the 1,25-Dihydroxyvitamin D locally produced in Extrarenal Tissues, such as immune cells, Pancreatic Beta Cells, the Intestine, Prostate, Breast, and other Organs, Controls multiple Vitamin D-responsive Genes, and THUS plays an important physiologic ROLE in Cardiovascular health,21,22the Adaptive and Innate Immune Responses,23,24insulin secretion,25,26regulation of Cell Proliferation, Differentiation, and Apoptosis, and inhibition of Angiogenesis.27\n\nVitamin D Homeostasis and functions during Pregnancy\nthe classical function of Vitamin D is to maintain calcium Homeostasis.']	[('IMPORTANT_CONSIDERATION', 419), ('SUPERFICIAL_RELATIONSHIP', 425), ('INCOMPLETE_EVIDENCE', 478), ('PROBABLE_UNDERSTANDING', 900), ('SUPERFICIAL_RELATIONSHIP', 936)]	5	[('UBERON_0002113', 'kidney', 42, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('CHEBI_39382', 'flufenoxuron', 105, 'metabolite'), ('CHEBI_67472', '15-epi-lupulin B', 117, '1,25-dihydroxyvitamin D'), ('CHEBI_35885', 'secondary phosphine', 219, 'phosphorus'), ('UBERON_0001555', 'digestive tract', 250, 'gut'), ('GO_0055073', 'cadmium ion homeostasis', 275, 'calcium homeostasis'), ('UBERON_0008883', 'osteoid', 325, 'osteoid'), ('UBERON_0002113', 'kidney', 353, 'renal'), ('CHEBI_4056', 'cytochrome', 380, 'cytochrome'), ('PR_000006100', 'aromatase', 380, 'cytochrome P450'), ('PR_000006138', 'cytochrome P450 4F11', 397, 'CYP ... 27B1'), ('GO_0009057', 'macromolecule catabolic process', 440, 'synthesis'), ('CHEBI_67472', '15-epi-lupulin B', 453, '1,25-dihydroxyvitamin D'), ('PR_000006101', 'cytochrome P450 1A1', 495, 'CYP27B1'), ('GO_0010467', 'gene expression', 506, 'expressed'), ('UBERON_0002481', 'bone tissue', 519, 'nonrenal tissues'), ('CHEBI_67469', '15-hydroxyajubractin C', 547, '1,25 dihydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 588, 'vitamin D'), ('GO_0010467', 'gene expression', 617, 'expressed'), ('UBERON_0000062', 'organ', 643, 'organs'), ('UBERON_0000479', 'tissue', 651, 'tissues'), ('CHEBI_67472', '15-epi-lupulin B', 690, '1,25-dihydroxyvitamin D'), ('UBERON_0005292', 'extraembryonic tissue', 734, 'extrarenal tissues'), ('CL_0000169', 'type B pancreatic cell', 776, 'pancreatic beta cells'), ('UBERON_0001264', 'pancreas', 776, 'pancreatic'), ('UBERON_0000160', 'intestine', 803, 'intestine'), ('UBERON_0002367', 'prostate gland', 814, 'prostate'), ('UBERON_0000310', 'breast', 824, 'breast'), ('UBERON_0000062', 'organ', 842, 'organs'), ('GO_0065007', 'biological regulation', 850, 'controls'), ('CHEBI_27300', 'vitamin D', 868, 'vitamin D'), ('SO_0000704', 'gene', 889, 'genes'), ('UBERON_0004535', 'cardiovascular system', 944, 'cardiovascular'), ('GO_0051886', 'negative regulation of timing of anagen', 975, 'adaptive ...'), ('GO_0044419', 'biological process involved in interspecies interaction between organisms', 988, 'innate immune responses'), ('UBERON_0002405', 'immune system', 995, 'immune'), ('GO_0030154', 'cell differentiation', 1054, 'cell proliferation ... differentiation'), ('GO_0006915', 'apoptotic process', 1095, 'apoptosis'), ('GO_0001525', 'angiogenesis', 1124, 'angiogenesis'), ('CHEBI_28384', 'vitamin K', 1141, 'Vitamin D'), ('GO_0042592', 'homeostatic process', 1151, 'homeostasis'), ('GO_0007565', 'female pregnancy', 1184, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1220, 'vitamin D'), ('GO_0042592', 'homeostatic process', 1253, 'homeostasis')]	0	['hydroxylation takes place kidney, converts 25(oh)d biologically metabolite, 1,25-dihydroxyvitamin d, physiologic increase calcium phosphorus absorption gut maintain calcium homeostasis mineralization osteoid bone.9\nalthough renal 1-alpha hydroxylase (cytochrome p450 [cyp]27b1) enzyme synthesis 1,25-dihydroxyvitamin d, cyp27b1 expressed nonrenal tissues produce 1,25 dihydroxyvitamin d.6,19in addition,  receptors expressed organs, tissues, cells (seefigure 1).20the 1,25-dihydroxyvitamin locally extrarenal tissues, immune cells, pancreatic beta cells, intestine, prostate, breast, organs, -responsive genes, plays physiologic cardiovascular health,21,22the adaptive innate immune responses,23,24insulin secretion,25,26regulation cell proliferation, differentiation, apoptosis, inhibition angiogenesis.27\n\nvitamin homeostasis functions \nthe  maintain calcium homeostasis.']
S13-PMC3702245	PMC3702245	6/2013	S13-PMC3702245	['HOWEVER, sustained Vitamin D deficiency results in rickets in children and osteomalacia in Adults.28the COMMONLY evaluated BIOMARKERS of Vitamin D nutrition include Serum 25(Oh)D concentrations, the inverse RELATIONSHIP between 25(Oh)D and Parathyroid hormone, Intestinal calcium absorption, and assessment of Skeletal integrity.29WHILE there is an inverse RELATIONSHIP between Serum Parathyroid hormone and 25(Oh)D in nonpregnant states, this RELATIONSHIP HAS BEEN SHOWN in RECENT STUDIES to be weak during Pregnancy,6,18,30,31INDICATING that Serum Parathyroid hormone MAY BE a LESS RELIABLE BIOMARKER of maternal Vitamin D status during Pregnancy than Serum 25(Oh)d.32the maternal 25(Oh)D level does not vary significantly during Pregnancy unless there is a change in Vitamin D intake or Endogenous Synthesis.2,33,34HOWEVER, Serum 1,25(Oh)2D levels increase by 100%–200% starting in the first trimester in both the mother and the fetus.35–37the increase in maternal 1,25(Oh)2D, which originates mostly from the Kidneys, accounts for increased Intestinal calcium absorption during Pregnancy.38,39the increase in fetal 1,25(Oh)2D level SEEMS to BE RELATED to synthesis in Placental and Fetal Tissues.39,40\nan IMPORTANT aspect of Vitamin D nutrition in Pregnancy is that the Vitamin D status of the infant at Birth and in early infancy DEPENDS ON the vitamin d status of the mother during Pregnancy.41vitamin D stores in the infant start with transplacental Transfer of 25(Oh)D in early Pregnancy from mother to fetus.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 104), ('SUPERFICIAL_RELATIONSHIP', 123), ('SUPERFICIAL_RELATIONSHIP', 207), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 329), ('SUPERFICIAL_RELATIONSHIP', 357), ('SUPERFICIAL_RELATIONSHIP', 444), ('INCOMPLETE_EVIDENCE', 457), ('INCOMPLETE_EVIDENCE', 475), ('INCOMPLETE_EVIDENCE', 526), ('INCOMPLETE_EVIDENCE', 570), ('INCOMPLETE_EVIDENCE', 579), ('IMPORTANT_CONSIDERATION', 584), ('SUPERFICIAL_RELATIONSHIP', 593), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 816), ('ANOMALY_CURIOUS_FINDING', 1136), ('ANOMALY_CURIOUS_FINDING', 1145), ('SUPERFICIAL_RELATIONSHIP', 1148), ('IMPORTANT_CONSIDERATION', 1209), ('SUPERFICIAL_RELATIONSHIP', 1335)]	20	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('UBERON_0007023', 'adult organism', 91, 'adults'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('UBERON_0001977', 'blood serum', 165, 'serum'), ('CHEBI_30778', 'gallic acid', 171, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 177, 'D'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 240, 'parathyroid'), ('UBERON_0000160', 'intestine', 261, 'intestinal'), ('UBERON_0004288', 'skeleton', 310, 'skeletal'), ('UBERON_0001977', 'blood serum', 378, 'serum'), ('UBERON_0001132', 'parathyroid gland', 384, 'parathyroid'), ('CHEBI_71657', 'versiconol acetate', 408, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 411, 'OH ... D'), ('GO_0007565', 'female pregnancy', 508, 'pregnancy'), ('UBERON_0001977', 'blood serum', 544, 'serum'), ('UBERON_0001132', 'parathyroid gland', 550, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 615, 'vitamin D'), ('GO_0007565', 'female pregnancy', 639, 'pregnancy'), ('UBERON_0001977', 'blood serum', 654, 'serum'), ('CHEBI_30778', 'gallic acid', 660, '25(OH)'), ('CHEBI_71657', 'versiconol acetate', 683, '25(OH)D'), ('GO_0007565', 'female pregnancy', 732, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 770, 'vitamin D'), ('GO_0042400', 'ectoine catabolic process', 790, 'endogenous synthesis'), ('UBERON_0001977', 'blood serum', 827, 'serum'), ('CHEBI_37958', 'dye', 833, '1,'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 835, '25(OH)2D'), ('CHEBI_37958', 'dye', 968, '1,'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 970, '25(OH)2D'), ('UBERON_0002113', 'kidney', 1013, 'kidneys'), ('UBERON_0000160', 'intestine', 1045, 'intestinal'), ('GO_0007565', 'female pregnancy', 1082, 'pregnancy'), ('CHEBI_37958', 'dye', 1119, '1,'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 1121, '25(OH)2D'), ('UBERON_0001987', 'placenta', 1172, 'placental'), ('UBERON_0005291', 'embryonic tissue', 1186, 'fetal tissues'), ('CHEBI_27300', 'vitamin D', 1229, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1252, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1274, 'vitamin D'), ('GO_0007567', 'parturition', 1308, 'birth'), ('GO_0007565', 'female pregnancy', 1388, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1408, 'D'), ('GO_0006412', 'translation', 1457, 'transfer'), ('CHEBI_71657', 'versiconol acetate', 1469, '25(OH)D'), ('GO_0007565', 'female pregnancy', 1486, 'pregnancy')]	0	['however, sustained  results rickets children osteomalacia adults.28the  nutrition serum 25(oh)d concentrations, 25(oh)d parathyroid hormone, intestinal calcium absorption, skeletal integrity.29while serum parathyroid hormone 25(oh)d nonpregnant states, ,6,18,30,31indicating serum parathyroid hormone maternal  status  serum 25(oh)d.32the maternal 25(oh)d   intake endogenous synthesis.2,33,34however, serum 1,25(oh)2d levels increase 100%–200% trimester mother fetus.35–37the increase maternal 1,25(oh)2d, originates kidneys, intestinal calcium absorption .38,39the increase fetal 1,25(oh)2d synthesis placental fetal tissues.39,40\nan aspect  nutrition   status infant birth infancy vitamin status mother .41vitamin stores infant transplacental transfer 25(oh)d  mother fetus.']
S15-PMC3702245	PMC3702245	6/2013	S15-PMC3702245	['IN GENERAL, Cord Blood 25(Oh)D concentrations are APPROXIMATELY 60%–89% of the maternal value.11,17,35,41–47THEREFORE, maintaining optimum Vitamin D nutrition during Pregnancy is ESSENTIAL for PREVENTION of hypovitaminosis D in the fetus and Vitamin D deficiency at Birth and in early infancy.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 50), ('ANOMALY_CURIOUS_FINDING', 106), ('IMPORTANT_CONSIDERATION', 179), ('SUPERFICIAL_RELATIONSHIP', 193)]	5	[('UBERON_0002240', 'spinal cord', 12, 'cord'), ('UBERON_0000178', 'blood', 17, 'blood'), ('CHEBI_71657', 'versiconol acetate', 23, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 23, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 223, 'D'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D'), ('GO_0007567', 'parturition', 266, 'birth')]	0	['general, cord blood 25(oh)d concentrations 60%–89% maternal value.11,17,35,41–47therefore, maintaining  nutrition  hypovitaminosis fetus  birth infancy.']
S16-PMC3702245	PMC3702245	6/2013	S16-PMC3702245	['high prevalence of low Vitamin D intake in Pregnancy\nthe Vitamin D status in Adults, including Pregnant women, is based currently on measurement of Serum 25(Oh)D concentrations, BUT WHAT constitutes the “normal” OR “optimal” level is CONTROVERSIAL.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 178), ('EXPLICIT_QUESTION', 182), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 212), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 234)]	4	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0007023', 'adult organism', 77, 'adults'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('UBERON_0001977', 'blood serum', 148, 'serum'), ('CHEBI_63056', 'zinc cation', 154, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 160, 'D')]	0	['high  intake \nthe  status adults,  women, serum 25(oh)d concentrations, “normal” “optimal” controversial.']
S17-PMC3702245	PMC3702245	6/2013	S17-PMC3702245	['the institute of medicine in the us in its RECENT report RECOMMENDS that a Serum 25(Oh)D concentration of 50 nmol/l (20 ng/ml) is adequate for calcium absorption and bone health in Adults, including Pregnant women, in the us and canada.7HOWEVER, new clinical guidelines from the endocrine society RECOMMEND maintaining a Serum 25(Oh)D concentration >75 nmol/l (30 ng/ml) in order to maximize calcium absorption and bone health, and for POTENTIAL Extraskeletal benefits noted in observational studies.8many RECENT STUDIES13,15–17,48–57that evaluated Vitamin D nutrition during Pregnancy in different geographic locations REPORTED wide VARIATION in Vitamin D status depending on latitude, season, sunlight exposure behavior, and Vitamin D intake (table 1).']	[('INCOMPLETE_EVIDENCE', 43), ('FUTURE_WORK', 57), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('FUTURE_WORK', 297), ('INCOMPLETE_EVIDENCE', 436), ('INCOMPLETE_EVIDENCE', 506), ('INCOMPLETE_EVIDENCE', 620), ('DIFFICULT_TASK', 634)]	8	[('UBERON_0001977', 'blood serum', 75, 'serum'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 81, '25(OH)D'), ('UBERON_0007023', 'adult organism', 181, 'adults'), ('GO_0007565', 'female pregnancy', 199, 'pregnant'), ('UBERON_0001977', 'blood serum', 321, 'serum'), ('CHEBI_71657', 'versiconol acetate', 327, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 327, '25(OH)D'), ('UBERON_0001431', 'distal carpal bone 2', 446, 'extraskeletal'), ('CHEBI_27300', 'vitamin D', 549, 'vitamin D'), ('GO_0007565', 'female pregnancy', 576, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 647, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 727, 'vitamin D')]	0	['institute medicine us serum 25(oh)d concentration 50 nmol/l (20 ng/ml) calcium absorption bone adults,  women, us canada.7however, endocrine society maintaining serum 25(oh)d concentration >75 nmol/l (30 ng/ml) maximize calcium absorption bone health, extraskeletal studies.8many studies13,15–17,48–57that  nutrition  geographic locations  status latitude, season, sunlight exposure behavior,  intake (table 1).']
S20-PMC3702245	PMC3702245	6/2013	S20-PMC3702245	['implications of low Vitamin D status during Pregnancy\n\nSkeletal and calcemic COMPLICATIONS\nit is GENERALLY ACCEPTED that maternal Vitamin D deficiency CAN result in osteomalacia.']	[('PROBLEM_COMPLICATION', 77), ('PROBABLE_UNDERSTANDING', 97), ('INCOMPLETE_EVIDENCE', 107), ('INCOMPLETE_EVIDENCE', 151)]	4	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('UBERON_0004288', 'skeleton', 55, 'Skeletal'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]	0	['implications  status \n\nskeletal calcemic complications\nit maternal  result osteomalacia.']
S21-PMC3702245	PMC3702245	6/2013	S21-PMC3702245	['a Serum 25(Oh)D concentration <25 nmol/l (10 ng/ml), which is ASSOCIATED with INCREASED RISK of osteomalacia in Adults,7is common during Pregnancy, AS INDICATED by RECENT REPORTS from many parts of the world.1for example, Serum 25(Oh)D < 25 nmol/l during Pregnancy HAS BEEN REPORTED in 17%–18% of the caucasian population in the uk,48,4961% of a mixed population in new zealand,5432%–42% in the indian population,15,4559%–84% of a nonwestern population in the netherlands,1441% of the kuwaiti population,1680% of the iranian population,17and 75% of the arab population in the united arab emirates.1HOWEVER, there are LIMITED STUDIES on the ASSOCIATION between such low levels of Vitamin D status and Skeletal integrity in Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 62), ('IMPORTANT_CONSIDERATION', 78), ('PROBABLE_UNDERSTANDING', 148), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 164), ('INCOMPLETE_EVIDENCE', 171), ('INCOMPLETE_EVIDENCE', 265), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 597), ('INCOMPLETE_EVIDENCE', 617), ('SUPERFICIAL_RELATIONSHIP', 640)]	10	[('UBERON_0001977', 'blood serum', 2, 'serum'), ('CHEBI_71657', 'versiconol acetate', 8, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 8, '25(OH)D'), ('UBERON_0007023', 'adult organism', 112, 'adults'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 228, '25(OH)D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 679, 'vitamin D'), ('UBERON_0004288', 'skeleton', 700, 'skeletal'), ('GO_0007565', 'female pregnancy', 722, 'pregnant')]	0	['serum 25(oh)d concentration <25 nmol/l (10 ng/ml), osteomalacia adults,7is parts world.1for example, serum 25(oh)d 25 nmol/l  17%–18% caucasian population uk,48,4961% population zealand,5432%–42% indian population,15,4559%–84% nonwestern population netherlands,1441% kuwaiti population,1680% iranian population,17and 75% arab population united arab emirates.1however, levels  status skeletal integrity  women.']
S24-PMC3702245	PMC3702245	6/2013	S24-PMC3702245	['further, a RECENT STUDY of the RELATIONSHIP between Serum 25(Oh)D and bone turnover in Pregnant women in istanbul, turkey, FOUND a negative CORRELATION between the second and third trimester and Postpartum 25(Oh)D concentrations and Serum cross-linked c-terminal telopeptide of Type 1 Collagen, which is a MARKER of Bone Resorption.58THESE studies SEEM to INDICATE a LINK between very low Vitamin D status and subclinical osteomalacia in the mothers.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 31), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 140), ('SUPERFICIAL_RELATIONSHIP', 306), ('INCOMPLETE_EVIDENCE', 332), ('ANOMALY_CURIOUS_FINDING', 348), ('INCOMPLETE_EVIDENCE', 356), ('SUPERFICIAL_RELATIONSHIP', 367)]	9	[('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 58, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('GO_0007565', 'female pregnancy', 195, 'postpartum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('UBERON_0001977', 'blood serum', 233, 'serum'), ('PR_000002123', 'C-C motif chemokine 3', 278, 'type 1 collagen'), ('GO_0045453', 'bone resorption', 316, 'bone resorption'), ('CHEBI_27300', 'vitamin D', 389, 'vitamin D')]	0	['further, serum 25(oh)d bone turnover  women istanbul, turkey, third trimester  25(oh)d concentrations serum cross-linked c-terminal telopeptide type collagen, bone resorption.58these  status subclinical osteomalacia mothers.']
S26-PMC3702245	PMC3702245	6/2013	S26-PMC3702245	['from Animal studies and SOME Human data, it is SUGGESTED that mineralization of the Fetal Skeleton is independent of Vitamin D and, THEREFORE, maternal Vitamin D deficiency has little EFFECT on fetal Skeletal Development.59IN CONTRAST, SOME recent OBSERVATIONAL STUDIES SUGGEST that Vitamin D nutrition during Pregnancy MAY AFFECT fetal Bone Development.']	[('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 47), ('PROBABLE_UNDERSTANDING', 132), ('SUPERFICIAL_RELATIONSHIP', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 221), ('INCOMPLETE_EVIDENCE', 236), ('INCOMPLETE_EVIDENCE', 248), ('INCOMPLETE_EVIDENCE', 270), ('INCOMPLETE_EVIDENCE', 320), ('SUPERFICIAL_RELATIONSHIP', 324)]	10	[('NCBITaxon_33208', 'Metazoa', 5, 'animal'), ('NCBITaxon_9606', 'Homo sapiens', 29, 'human'), ('UBERON_0000922', 'embryo', 84, 'fetal'), ('UBERON_0004288', 'skeleton', 90, 'skeleton'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('GO_0001501', 'skeletal system development', 200, 'skeletal development'), ('UBERON_0004288', 'skeleton', 200, 'skeletal'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D'), ('GO_0007565', 'female pregnancy', 310, 'pregnancy'), ('GO_0048539', 'bone marrow development', 337, 'bone development')]	0	['animal human data, mineralization fetal skeleton  and, therefore, maternal  fetal skeletal development.59in contrast,  nutrition  fetal bone development.']
S30-PMC3702245	PMC3702245	6/2013	S30-PMC3702245	['maternal 25(Oh)D concentrations during Pregnancy was SHOWN in ONE uk STUDY48TO AFFECT childhood bone mass at nine years of age, but this WAS NOT confirmed in a larger more RECENT STUDY from the uk.61in populations where Vitamin D deficiency is very SEVERE, maternal Vitamin D deficiency during Pregnancy HAS BEEN ASSOCIATED with neonatal craniotabes62and congenital rickets.63–65taken TOGETHER, the results from OBSERVATIONAL studies SUGGEST a POSSIBLE EFFECT of low maternal 25(Oh)D during Pregnancy on Fetal Bone Development, BUT the ASSOCIATION with lower childhood bone mass is UNPROVEN.']	[('INCOMPLETE_EVIDENCE', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 62), ('INCOMPLETE_EVIDENCE', 69), ('SUPERFICIAL_RELATIONSHIP', 79), ('INCOMPLETE_EVIDENCE', 137), ('INCOMPLETE_EVIDENCE', 172), ('IMPORTANT_CONSIDERATION', 249), ('INCOMPLETE_EVIDENCE', 304), ('SUPERFICIAL_RELATIONSHIP', 313), ('INCOMPLETE_EVIDENCE', 385), ('INCOMPLETE_EVIDENCE', 412), ('INCOMPLETE_EVIDENCE', 434), ('INCOMPLETE_EVIDENCE', 444), ('SUPERFICIAL_RELATIONSHIP', 453), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 528), ('ANOMALY_CURIOUS_FINDING', 528), ('SUPERFICIAL_RELATIONSHIP', 536), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 582), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 582)]	19	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 9, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('GO_0007565', 'female pregnancy', 294, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 476, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 479, 'OH ... D'), ('GO_0007565', 'female pregnancy', 491, 'pregnancy'), ('GO_0007631', 'feeding behavior', 504, 'fetal'), ('GO_0048539', 'bone marrow development', 510, 'bone development')]	0	['maternal 25(oh)d concentrations  uk childhood bone mass nine age, uk.61in populations  severe, maternal   neonatal craniotabes62and congenital rickets.63–65taken together, results maternal 25(oh)d  fetal bone development, childhood bone mass unproven.']
S32-PMC3702245	PMC3702245	6/2013	S32-PMC3702245	['SEVERE hypocalcemia occasionally presenting as neonatal seizures is a known COMPLICATION of maternal Vitamin D deficiency during Pregnancy.66,67\n\nextraskeletal and noncalcemic COMPLICATIONS of Vitamin D deficiency during Pregnancy\nseveral Extraskeletal COMPLICATIONS of Vitamin D deficiency during Pregnancy HAVE BEEN REPORTED in the mother, fetus, and infant.']	[('IMPORTANT_CONSIDERATION', 0), ('PROBLEM_COMPLICATION', 76), ('PROBLEM_COMPLICATION', 176), ('PROBLEM_COMPLICATION', 253), ('INCOMPLETE_EVIDENCE', 308)]	5	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('GO_0007565', 'female pregnancy', 221, 'pregnancy'), ('UBERON_0001431', 'distal carpal bone 2', 239, 'extraskeletal'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D'), ('GO_0007565', 'female pregnancy', 298, 'pregnancy')]	0	['severe hypocalcemia presenting neonatal seizures maternal  .66,67\n\nextraskeletal noncalcemic  \nseveral extraskeletal   mother, fetus, infant.']
S36-PMC3702245	PMC3702245	6/2013	S36-PMC3702245	['intervention trials and observational studies have also FOUND an ASSOCIATION between risk of small-for-Gestational age infants and maternal Vitamin D nutrition during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 65)]	2	[('GO_0007565', 'female pregnancy', 103, 'gestational'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnancy')]	0	['intervention small-for- age infants maternal  nutrition .']
S38-PMC3702245	PMC3702245	6/2013	S38-PMC3702245	['the RELATIONSHIP between maternal Vitamin D status and small-for-Gestational age infants was found to be u-shaped in a study from pittsburgh in the us,81BUT this WAS NOT CONFIRMED in the above studies.68,80the REASONS for this DIFFERENCE are UNCLEAR.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 151), ('INCOMPLETE_EVIDENCE', 162), ('PROBABLE_UNDERSTANDING', 210), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 227), ('FULL_UNKNOWN', 242)]	6	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'gestational')]	0	['maternal  status small-for- pittsburgh us,81but studies.68,80the unclear.']
S40-PMC3702245	PMC3702245	6/2013	S40-PMC3702245	['randomized controlled STUDIES including larger sample sizes and repeated Vitamin D measurements during Pregnancy WILL BE NEEDED to CONFIRM the RELATIONSHIP between Vitamin D supplementation and fetal growth.82\n\nmaternal COMPLICATIONS\nOBSERVATIONAL studies REPORTED an ASSOCIATION between maternal Vitamin D status during Pregnancy and development of pre-eclampsia, which has both a Genetic and an immunologic pathogenesis.']	[('FUTURE_WORK', 22), ('FUTURE_WORK', 113), ('INCOMPLETE_EVIDENCE', 131), ('SUPERFICIAL_RELATIONSHIP', 143), ('PROBLEM_COMPLICATION', 220), ('INCOMPLETE_EVIDENCE', 234), ('INCOMPLETE_EVIDENCE', 256), ('SUPERFICIAL_RELATIONSHIP', 268)]	8	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin D'), ('GO_0007565', 'female pregnancy', 321, 'pregnancy'), ('SO_0000704', 'gene', 382, 'genetic')]	0	['randomized sample sizes  measurements   supplementation fetal growth.82\n\nmaternal complications\nobservational maternal  status  pre-eclampsia, genetic immunologic pathogenesis.']
S44-PMC3702245	PMC3702245	6/2013	S44-PMC3702245	['with INCREASING INTEREST in the ROLE of Vitamin D in Glucose Homeostasis, the ASSOCIATION between maternal Serum 25(Oh)D concentration in early Pregnancy and the risk of Gestational diabetes mellitus was investigated in a study from the national institutes of health, bethesda, md.85the authors FOUND that maternal Vitamin D deficiency [serum 25(Oh)D < 50 nmol/l] was ASSOCIATED with a higher risk of Gestational diabetes mellitus (adjusted odds ratio 2.66; ci 1.01–7.02).']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 78), ('INCOMPLETE_EVIDENCE', 295), ('SUPERFICIAL_RELATIONSHIP', 368)]	5	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_17234', 'glucose', 53, 'glucose'), ('GO_0042593', 'glucose homeostasis', 53, 'glucose homeostasis'), ('UBERON_0001977', 'blood serum', 107, 'serum'), ('CHEBI_71657', 'versiconol acetate', 113, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 113, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0007565', 'female pregnancy', 170, 'gestational'), ('CHEBI_27300', 'vitamin D', 315, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 343, '25(OH)D'), ('GO_0007565', 'female pregnancy', 401, 'gestational')]	0	[' glucose homeostasis, maternal serum 25(oh)d concentration   diabetes mellitus national institutes health, bethesda, md.85the authors maternal  [serum 25(oh)d 50 nmol/l] higher  diabetes mellitus (adjusted ratio 2.66; ci 1.01–7.02).']
S45-PMC3702245	PMC3702245	6/2013	S45-PMC3702245	['CONSISTENT with THIS report, a systematic review and meta-analysis of seven observational studies performed between 2008 and 2011 FOUND Serum 25(Oh)D < 50 nmol/l to be ASSOCIATED with Gestational diabetes BUT with an overall lower odds ratio of 1.61 (ci 1.19–2.17).86another meta-analysis of maternal Vitamin D status and Pregnancy outcomes,87which included 24 studies up to 2012, FOUND an overall INCREASED RISK of Preeclampsia (odds ratio 2.09; ci 1.50–2.90) and Gestational diabetes (odds ratio 1.38; ci 1.12–1.70).']	[('INCOMPLETE_EVIDENCE', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 168), ('ANOMALY_CURIOUS_FINDING', 205), ('INCOMPLETE_EVIDENCE', 381), ('IMPORTANT_CONSIDERATION', 398)]	7	[('UBERON_0001977', 'blood serum', 136, 'serum'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 142, '25(OH)D'), ('GO_0007565', 'female pregnancy', 184, 'gestational'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('GO_0007565', 'female pregnancy', 322, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 416, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 465, 'gestational')]	0	['consistent report, meta-analysis seven 2008 2011 serum 25(oh)d 50 nmol/l  diabetes ratio 1.61 (ci 1.19–2.17).86another meta-analysis maternal  status  outcomes,87which 24 2012, preeclampsia (odds ratio 2.09; ci 1.50–2.90)  diabetes (odds ratio 1.38; ci 1.12–1.70).']
S49-PMC3702245	PMC3702245	6/2013	S49-PMC3702245	['in SUPPORT of this premise is the FINDING that Vitamin D deficiency is an INDEPENDENT RISK FACTOR for bacterial vaginosis in Pregnant women.88a study from pittsburgh SHOWED an inverse dose-response RELATIONSHIP between Serum 25(Oh)D concentrations and the prevalence of bacterial vaginosis.88compared with a Serum concentration of 75 nmol/l, the prevalence of bacterial vaginosis increased 1.65-fold (ci 1.01–2.69) and 1.26-fold (ci 1.01–1.57) at Serum concentrations of 20 nmol/l and 50 nmol/l, respectively.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 74), ('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 166), ('SUPERFICIAL_RELATIONSHIP', 198)]	6	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnant'), ('UBERON_0001977', 'blood serum', 219, 'serum'), ('CHEBI_71657', 'versiconol acetate', 225, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 225, '25(OH ... D'), ('UBERON_0001977', 'blood serum', 308, 'serum'), ('UBERON_0001977', 'blood serum', 447, 'serum')]	0	[' bacterial vaginosis  women.88a pittsburgh dose-response serum 25(oh)d concentrations bacterial vaginosis.88compared serum concentration 75 nmol/l, bacterial vaginosis 1.65-fold (ci 1.01–2.69) 1.26-fold (ci 1.01–1.57) serum concentrations 20 nmol/l 50 nmol/l, respectively.']
S50-PMC3702245	PMC3702245	6/2013	S50-PMC3702245	['in another large study from new york in the us,89bacterial vaginosis was ONLY ASSOCIATED with Vitamin D deficiency (Serum 25(Oh)D < 75 nmol/l) in Pregnant women (adjusted odds ratio 2.87; ci 1.13–7.28).']	[('INCOMPLETE_EVIDENCE', 73), ('SUPERFICIAL_RELATIONSHIP', 78)]	2	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0001977', 'blood serum', 116, 'serum'), ('CHEBI_71657', 'versiconol acetate', 122, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 122, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 146, 'pregnant')]	0	['york us,89bacterial vaginosis  (serum 25(oh)d 75 nmol/l)  women (adjusted ratio 2.87; ci 1.13–7.28).']
S51-PMC3702245	PMC3702245	6/2013	S51-PMC3702245	['further, there is a SUGGESTION of an ASSOCIATION between Vitamin D and Periodontal disease,90and maternal Serum 25(Oh)D < 75 nmol/l during Early Pregnancy HAS BEEN ASSOCIATED with a two-fold INCREASED risk of Periodontal disease.91in a RECENT randomized controlled TRIAL of Vitamin D supplementation from south carolina, Vitamin D supplementation of 4000 iu/day during Pregnancy was ASSOCIATED with a reduction in the risk of combined morbidities, such as Maternal infection, Preterm labor, and Preterm Birth.92\nIN VIEW of the POSSIBLE ASSOCIATION between maternal Vitamin D status and the pattern of fetal growth, pre-eclampsia, Gestational diabetes mellitus, and maternal infection, and the significant POTENTIAL for Perinatal morbidities ASSOCIATED with these conditions, evaluation of Vitamin D nutrition in early Pregnancy and the EFFECT of appropriate supplementation SEEMS WARRANTED.']	[('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 155), ('SUPERFICIAL_RELATIONSHIP', 164), ('IMPORTANT_CONSIDERATION', 191), ('INCOMPLETE_EVIDENCE', 236), ('SUPERFICIAL_RELATIONSHIP', 383), ('QUESTION_ANSWERED_BY_THIS_WORK', 512), ('INCOMPLETE_EVIDENCE', 515), ('INCOMPLETE_EVIDENCE', 527), ('SUPERFICIAL_RELATIONSHIP', 536), ('INCOMPLETE_EVIDENCE', 705), ('SUPERFICIAL_RELATIONSHIP', 741), ('SUPERFICIAL_RELATIONSHIP', 836), ('ANOMALY_CURIOUS_FINDING', 874), ('FUTURE_WORK', 874)]	16	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0001758', 'periodontium', 71, 'periodontal'), ('UBERON_0001977', 'blood serum', 106, 'serum'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 112, '25(OH ... D'), ('GO_0051318', 'G1 phase', 139, 'early'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('UBERON_0001758', 'periodontium', 209, 'periodontal'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 321, 'vitamin D'), ('GO_0007565', 'female pregnancy', 369, 'pregnancy'), ('GO_0007618', 'mating', 456, 'maternal'), ('GO_0007565', 'female pregnancy', 476, 'preterm'), ('GO_0007565', 'female pregnancy', 495, 'preterm'), ('GO_0007567', 'parturition', 503, 'birth'), ('CHEBI_27300', 'vitamin D', 565, 'vitamin D'), ('GO_0007565', 'female pregnancy', 630, 'gestational'), ('GO_0036268', 'swimming', 719, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 719, 'perinatal'), ('CHEBI_27300', 'vitamin D', 789, 'vitamin D'), ('GO_0007565', 'female pregnancy', 818, 'pregnancy')]	0	['further,  periodontal disease,90and maternal serum 25(oh)d 75 nmol/l  two-fold periodontal disease.91in  supplementation south carolina,  supplementation 4000 iu/day  reduction combined morbidities, maternal infection,  labor,  birth.92\nin maternal  status fetal growth, pre-eclampsia,  diabetes mellitus, maternal infection, perinatal morbidities conditions,  nutrition  supplementation warranted.']
S52-PMC3702245	PMC3702245	6/2013	S52-PMC3702245	['IMPACT on neonate and infant\nboth in vitro and observational studies have DEMONSTRATED that Vitamin D status during Pregnancy IMPACTS the Immune Response of the offspring.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 74), ('SUPERFICIAL_RELATIONSHIP', 126)]	3	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('GO_0006955', 'immune response', 138, 'immune response'), ('UBERON_0002405', 'immune system', 138, 'immune')]	0	['impact neonate infant\nboth  status  immune response offspring.']
S56-PMC3702245	PMC3702245	6/2013	S56-PMC3702245	['IN CONTRAST, an OBSERVATIONAL study REPORTED an increased RISK of infantile eczema and pneumonia in ASSOCIATION with maternal Serum 25(Oh)D > 75 nmol/l in the last trimester.76HOWEVER, another RECENT STUDY with a larger sample size from the same institution DID NOT FIND an ASSOCIATION between maternal 25(Oh)d > 75 nmol/l in late Pregnancy and eczema or asthma at 12 months and three and six years of age.97there was no report on the ASSOCIATION between maternal Vitamin D status and Respiratory infections in the latter study.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 36), ('IMPORTANT_CONSIDERATION', 58), ('SUPERFICIAL_RELATIONSHIP', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('INCOMPLETE_EVIDENCE', 193), ('INCOMPLETE_EVIDENCE', 258), ('SUPERFICIAL_RELATIONSHIP', 274), ('SUPERFICIAL_RELATIONSHIP', 435)]	10	[('UBERON_0001977', 'blood serum', 126, 'serum'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 132, '25(OH)D'), ('CHEBI_30778', 'gallic acid', 303, '25(OH)'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 303, '25(OH'), ('GO_0007565', 'female pregnancy', 331, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 464, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 485, 'respiratory')]	0	['contrast, infantile eczema pneumonia maternal serum 25(oh)d > 75 nmol/l last trimester.76however, sample institution maternal 25(oh)d > 75 nmol/l late  eczema asthma 12 months three six age.97there maternal  status respiratory infections latter study.']
S57-PMC3702245	PMC3702245	6/2013	S57-PMC3702245	['regarding Neurocognitive Development, WHILE ONE STUDY FOUND no association between maternal Vitamin D status during Pregnancy and Neurocognitive function,76a RECENT larger-sized STUDY LINKED maternal Serum 25(Oh)D levels during Pregnancy with Language Development in the offspring.98the results of the above studies SUGGEST that childhood infections, atopy, and Neurocognitive development NEED TO BE included as outcomes of interest following Vitamin D supplementation in Pregnancy, and that clinical trials SHOULD include a RELEVANT group of subjects CONSIDERED to be replete for Vitamin D.\ntaken TOGETHER, the high prevalence of Vitamin D deficiency in Pregnancy and the POSSIBLE multiple POTENTIAL adverse EFFECTS on mother and offspring IDENTIFIED in SEVERAL epidemiologic STUDIES UNDERSCORE the URGENT NEED FOR large randomized controlled TRIALS to identify the amount of Vitamin D supplementation that optimizes Vitamin D status during Pregnancy, and to DETERMINE the EFFECT of supplementation on POTENTIAL adverse conditions ASSOCIATED with Vitamin D deficiency and any POSSIBLE Vitamin D excess.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 38), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 158), ('SUPERFICIAL_RELATIONSHIP', 184), ('INCOMPLETE_EVIDENCE', 316), ('FUTURE_WORK', 389), ('FUTURE_WORK', 508), ('IMPORTANT_CONSIDERATION', 525), ('IMPORTANT_CONSIDERATION', 552), ('INCOMPLETE_EVIDENCE', 598), ('INCOMPLETE_EVIDENCE', 673), ('INCOMPLETE_EVIDENCE', 691), ('SUPERFICIAL_RELATIONSHIP', 709), ('INCOMPLETE_EVIDENCE', 741), ('INCOMPLETE_EVIDENCE', 755), ('IMPORTANT_CONSIDERATION', 785), ('IMPORTANT_CONSIDERATION', 800), ('FUTURE_WORK', 807), ('INCOMPLETE_EVIDENCE', 807), ('FUTURE_WORK', 844), ('QUESTION_ANSWERED_BY_THIS_WORK', 960), ('SUPERFICIAL_RELATIONSHIP', 974), ('INCOMPLETE_EVIDENCE', 1003), ('SUPERFICIAL_RELATIONSHIP', 1032), ('INCOMPLETE_EVIDENCE', 1077)]	26	[('GO_0007399', 'nervous system development', 10, 'neurocognitive development'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('GO_0050905', 'neuromuscular process', 130, 'neurocognitive'), ('UBERON_0001977', 'blood serum', 200, 'serum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 206, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 228, 'pregnancy'), ('GO_0060132', 'prolactin secreting cell development', 243, 'language development'), ('GO_0050905', 'neuromuscular process', 362, 'neurocognitive'), ('CHEBI_27300', 'vitamin D', 443, 'vitamin D'), ('GO_0007565', 'female pregnancy', 472, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 581, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 631, 'vitamin D'), ('GO_0007565', 'female pregnancy', 655, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 877, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 918, 'vitamin D'), ('GO_0007565', 'female pregnancy', 942, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1048, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1086, 'vitamin D')]	0	['regarding neurocognitive development, maternal  status  neurocognitive function,76a maternal serum 25(oh)d levels  language offspring.98the results childhood infections, atopy, neurocognitive outcomes following  supplementation subjects replete .\ntaken together,   mother offspring epidemiologic amount  supplementation optimizes  status supplementation conditions   excess.']
S58-PMC3702245	PMC3702245	6/2013	S58-PMC3702245	['Vitamin D REQUIREMENT during Pregnancy\nin ORDER TO DETERMINE the Vitamin D REQUIREMENT during Pregnancy, one NEEDS to define the target Serum 25(Oh)D concentration considered as “normal” or “optimal”.']	[('IMPORTANT_CONSIDERATION', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 42), ('IMPORTANT_CONSIDERATION', 75), ('FUTURE_WORK', 109), ('IMPORTANT_CONSIDERATION', 109)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 29, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('UBERON_0001977', 'blood serum', 136, 'serum'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 148, 'D')]	0	['vitamin \nin  serum 25(oh)d concentration “normal” “optimal”.']
S63-PMC3702245	PMC3702245	6/2013	S63-PMC3702245	['a review of the FEW previous randomized controlled TRIALS of Vitamin D supplementation during Pregnancy INDICATES that doses of 400–1600 iu/day were INSUFFICIENT in achieving a mean Serum 25(Oh)D concentration ≥50 nmol/l in most of the studies.41in a RECENT Vitamin D supplementation TRIAL from the uk, a multiethnic group of 180 Pregnant women were randomized at 27 weeks’ Gestation to receive a single Oral dose of 200,000 iu of Vitamin D, daily supplementation of 800 iu, or no treatment.33the median Serum 25(Oh)D concentration in the 800 iu/day group at study entry was 26 nmol/l (interquartile range 22–37), and the median 25(Oh)D concentration at delivery following supplementation was 42 nmol/l (interquartile range 31–76).']	[('INCOMPLETE_EVIDENCE', 16), ('FUTURE_WORK', 51), ('INCOMPLETE_EVIDENCE', 104), ('IMPORTANT_CONSIDERATION', 149), ('PROBLEM_COMPLICATION', 149), ('INCOMPLETE_EVIDENCE', 251), ('INCOMPLETE_EVIDENCE', 284)]	7	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('UBERON_0001977', 'blood serum', 182, 'serum'), ('CHEBI_71657', 'versiconol acetate', 188, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 188, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('GO_0007565', 'female pregnancy', 330, 'pregnant'), ('GO_0007565', 'female pregnancy', 374, 'gestation'), ('UBERON_0000165', 'mouth', 404, 'oral'), ('CHEBI_27300', 'vitamin D', 431, 'vitamin D'), ('UBERON_0001977', 'blood serum', 504, 'serum'), ('CHEBI_71657', 'versiconol acetate', 510, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 510, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 629, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 629, '25(OH)D')]	0	[' supplementation  doses 400–1600 iu/day achieving serum 25(oh)d concentration ≥50 nmol/l studies.41in uk, multiethnic 180  women 27 weeks’  receive single oral dose 200,000 iu daily supplementation 800 iu, treatment.33the median serum 25(oh)d concentration 800 iu/day 26 nmol/l (interquartile 22–37), median 25(oh)d concentration delivery following supplementation 42 nmol/l (interquartile 31–76).']
S68-PMC3702245	PMC3702245	6/2013	S68-PMC3702245	['these two studies and older RESEARCH41INDICATE that, in populations with a high prevalence of SEVERE Vitamin D sufficiency, supplementation up to 1600 iu/day MAY BE inadequate to achieve the RECOMMENDED target Serum 25(Oh)D concentration of 50 nmol/l.7in two RECENT STUDIES from india, which used large single-dose supplementation of 120,000 iu at the fifth and seventh month of Gestation15Or at the second and third trimester,69only 25% and 62%, respectively, achieved a Serum 25(Oh)D concentration >50 nmol/l.']	[('INCOMPLETE_EVIDENCE', 28), ('IMPORTANT_CONSIDERATION', 94), ('INCOMPLETE_EVIDENCE', 158), ('FUTURE_WORK', 191), ('INCOMPLETE_EVIDENCE', 259)]	5	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 216, '25(OH)D'), ('GO_0007565', 'female pregnancy', 379, 'gestation15or'), ('UBERON_0001977', 'blood serum', 472, 'serum'), ('CHEBI_71657', 'versiconol acetate', 478, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 478, '25(OH)D')]	0	['older that, populations  sufficiency, supplementation 1600 iu/day achieve serum 25(oh)d concentration 50 nmol/l.7in india, single-dose supplementation 120,000 iu fifth seventh month  third trimester,69only 25% 62%, respectively, achieved serum 25(oh)d concentration >50 nmol/l.']
S69-PMC3702245	PMC3702245	6/2013	S69-PMC3702245	['the RECENT cochrane review of Vitamin D supplementation alone during Pregnancy79Considered five trials that compared the EFFECTS of supplementation with placebo or no supplementation.33,73,77,78,102the review CONCLUDED that Vitamin D supplementation increases Serum 25(Oh)D concentrations during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 121), ('INCOMPLETE_EVIDENCE', 209)]	3	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0016441', 'posttranscriptional gene silencing', 69, 'pregnancy79considered'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('UBERON_0001977', 'blood serum', 260, 'serum'), ('CHEBI_71657', 'versiconol acetate', 266, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 266, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 296, 'pregnancy')]	0	[' supplementation pregnancy79considered five supplementation placebo supplementation.33,73,77,78,102the  supplementation serum 25(oh)d concentrations .']
S70-PMC3702245	PMC3702245	6/2013	S70-PMC3702245	['OF NOTE, in two of the five studies, the mean concentration of 25(Oh)D after supplementation was <50 nmol/l,33,78and Serum 25(Oh)D WAS NOT MEASURED in ONE STUDY.73all these STUDIES underscore the uncertainty about the amount of Vitamin D supplementation REQUIRED to optimize Vitamin D status in Pregnancy and which would be generalizable worldwide.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 131), ('INCOMPLETE_EVIDENCE', 151), ('INCOMPLETE_EVIDENCE', 173), ('IMPORTANT_CONSIDERATION', 254)]	5	[('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_71657', 'versiconol acetate', 123, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 123, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 275, 'vitamin D'), ('GO_0007565', 'female pregnancy', 295, 'pregnancy')]	0	['note, five studies, concentration 25(oh)d supplementation <50 nmol/l,33,78and serum 25(oh)d study.73all amount  supplementation optimize  status  worldwide.']
S72-PMC3702245	PMC3702245	6/2013	S72-PMC3702245	['the institute of MEDICINE7CONSIDERS a Serum 25(Oh)D concentration >50 nmol/l AS acceptable, WHILE the Endocrine society and Vitamin D EXPERTS RECOMMEND >75 nmol/l.8,99a RECENT STUDY among traditional populations in tanzania with type vi (dark) skin color living in a sun-abundant environment RECOMMENDED a mean Serum 25(Oh)D concentration of 115 nmol/l in nonpregnant Adults and 139 nmol/l in Pregnant women.57the question then is: WHAT Serum concentration of 25(Oh)D is “normal” in Adults, including during Pregnancy?']	[('INCOMPLETE_EVIDENCE', 17), ('PROBABLE_UNDERSTANDING', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 92), ('PROBABLE_UNDERSTANDING', 134), ('FUTURE_WORK', 142), ('INCOMPLETE_EVIDENCE', 169), ('FUTURE_WORK', 292), ('EXPLICIT_QUESTION', 432), ('EXPLICIT_QUESTION', 517)]	9	[('UBERON_0001977', 'blood serum', 38, 'serum'), ('CHEBI_71657', 'versiconol acetate', 44, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 44, '25(OH)D'), ('UBERON_0005063', 'left ventricular compact myocardium', 102, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('UBERON_0001977', 'blood serum', 311, 'serum'), ('CHEBI_71657', 'versiconol acetate', 317, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 317, '25(OH)D'), ('UBERON_0007023', 'adult organism', 368, 'adults'), ('GO_0007565', 'female pregnancy', 393, 'pregnant'), ('UBERON_0001977', 'blood serum', 437, 'serum'), ('CHEBI_71657', 'versiconol acetate', 460, '25(OH)D'), ('UBERON_0007023', 'adult organism', 483, 'adults'), ('GO_0007565', 'female pregnancy', 508, 'pregnancy')]	0	['institute serum 25(oh)d concentration >50 nmol/l acceptable, endocrine society  >75 nmol/l.8,99a among populations tanzania type vi (dark) skin color living sun-abundant environment serum 25(oh)d concentration 115 nmol/l nonpregnant adults 139 nmol/l  women.57the is: serum concentration 25(oh)d “normal” adults, ?']
S73-PMC3702245	PMC3702245	6/2013	S73-PMC3702245	['WHILE the DEBATE and studies to identify OPTIMAL Serum 25(Oh)D concentration CONTINUE, it is PRUDENT to monitor Vitamin D status and develop STRATEGIES to ensure AT LEAST a minimum Serum 25(Oh)D concentration of 50 nmol/l in Pregnant women, especially in an environment where Vitamin D deficiency is endemic.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 10), ('IMPORTANT_CONSIDERATION', 41), ('FUTURE_WORK', 77), ('FUTURE_WORK', 93), ('IMPORTANT_CONSIDERATION', 93), ('FUTURE_WORK', 141), ('PROBABLE_UNDERSTANDING', 162)]	8	[('UBERON_0001977', 'blood serum', 49, 'serum'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 55, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('UBERON_0001977', 'blood serum', 181, 'serum'), ('CHEBI_71657', 'versiconol acetate', 187, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 187, '25(OH)D'), ('GO_0007565', 'female pregnancy', 225, 'pregnant'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D')]	0	['serum 25(oh)d concentration continue,  status ensure minimum serum 25(oh)d concentration 50 nmol/l  women, environment  endemic.']
S75-PMC3702245	PMC3702245	6/2013	S75-PMC3702245	['because of CONTROVERSY surrounding Vitamin D REQUIREMENTS during Pregnancy, investigators from south carolina performed a comprehensive, large, randomized controlled study of Vitamin D supplementation in Pregnancy to achieve optimal Vitamin D status, DEFINED as a Serum 25(Oh)D concentration ≥80 nmol/l at Delivery.18BASED on the pharmacokinetics of Vitamin d, the authors INVESTIGATED the SAFETY and EFFECTIVENESS of high-dose Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 11), ('IMPORTANT_CONSIDERATION', 45), ('PROBABLE_UNDERSTANDING', 251), ('PROBABLE_UNDERSTANDING', 315), ('QUESTION_ANSWERED_BY_THIS_WORK', 373), ('IMPORTANT_CONSIDERATION', 390), ('SUPERFICIAL_RELATIONSHIP', 401)]	7	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('UBERON_0001977', 'blood serum', 264, 'serum'), ('CHEBI_71657', 'versiconol acetate', 270, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 270, '25(OH)D'), ('GO_0007567', 'parturition', 306, 'delivery'), ('CHEBI_33229', 'vitamin (role)', 350, 'vitamin'), ('CHEBI_27300', 'vitamin D', 428, 'vitamin D')]	0	['surrounding  south carolina comprehensive, large,  supplementation  achieve  status, serum 25(oh)d concentration ≥80 nmol/l delivery.18based pharmacokinetics vitamin d, authors high-dose  supplementation.']
S79-PMC3702245	PMC3702245	6/2013	S79-PMC3702245	['Vitamin D status was monitored in the mother during Pregnancy and in Cord Blood AS a SURROGATE marker of infant Vitamin D status at Birth.']	[('PROBABLE_UNDERSTANDING', 80), ('SUPERFICIAL_RELATIONSHIP', 85)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 69, 'cord'), ('UBERON_0000178', 'blood', 74, 'blood'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007567', 'parturition', 132, 'birth')]	0	['vitamin status monitored mother  cord blood infant  status birth.']
S92-PMC3702245	PMC3702245	6/2013	S92-PMC3702245	['the authors also FOUND that maternal Vitamin D supplementation with 4000 iu/day decreased the risk of combined comorbidities, including infection, Preterm Birth, Gestational diabetes, and pre-eclampsia,82and SUGGESTED that ADDITIONAL STUDIES with adequate power for assessment of OTHER endpoints WERE NEEDED.']	[('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 208), ('FUTURE_WORK', 223), ('FUTURE_WORK', 234), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 280), ('FUTURE_WORK', 296)]	6	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'preterm birth'), ('GO_0007565', 'female pregnancy', 162, 'gestational')]	0	['authors maternal  supplementation 4000 iu/day decreased combined comorbidities, infection,  diabetes, pre-eclampsia,82and endpoints needed.']
S93-PMC3702245	PMC3702245	6/2013	S93-PMC3702245	['another RECENT STUDY from the united arab emirates among Pregnant arab women with a high prevalence of Vitamin D deficiency also CONFIRMED that 4000 iu/day of Vitamin D supplementation was SAFE and more EFFECTIVE than 2000 iu/day and 400 iu/day in optimizing Vitamin D status during Pregnancy and in achieving Vitamin D sufficiency at Birth in mothers and offspring.106in the united arab emirates study, the increment from baseline to Delivery was about four-fold higher than expected BASED ON previous pharmacokinetic STUDIES, POSSIBLY RELATED to low baseline Vitamin D status.100this INDICATES that baseline Vitamin D status SHOULD BE taken INTO CONSIDERATION when evaluating Vitamin D supplementation.100,107\nthe FINDINGS of these RECENT intervention STUDIES INDICATE an URGENT NEED for more randomized controlled trials in diverse geographic locations with large sample sizes to identify the Vitamin D intake REQUIRED to optimize Vitamin D status, and TO ASSESS the EFFECT on Pregnancy-related and infant-related COMPLICATIONS.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 129), ('IMPORTANT_CONSIDERATION', 189), ('SUPERFICIAL_RELATIONSHIP', 203), ('PROBABLE_UNDERSTANDING', 485), ('INCOMPLETE_EVIDENCE', 519), ('INCOMPLETE_EVIDENCE', 528), ('SUPERFICIAL_RELATIONSHIP', 537), ('INCOMPLETE_EVIDENCE', 586), ('FUTURE_WORK', 627), ('IMPORTANT_CONSIDERATION', 643), ('FUTURE_WORK', 648), ('INCOMPLETE_EVIDENCE', 716), ('INCOMPLETE_EVIDENCE', 734), ('INCOMPLETE_EVIDENCE', 762), ('IMPORTANT_CONSIDERATION', 774), ('FUTURE_WORK', 781), ('IMPORTANT_CONSIDERATION', 913), ('QUESTION_ANSWERED_BY_THIS_WORK', 956), ('SUPERFICIAL_RELATIONSHIP', 970), ('PROBLEM_COMPLICATION', 1017)]	21	[('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin D'), ('GO_0007565', 'female pregnancy', 283, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin D'), ('GO_0007567', 'parturition', 335, 'birth'), ('GO_0007567', 'parturition', 435, 'delivery'), ('CHEBI_27300', 'vitamin D', 561, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 610, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 678, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 896, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 934, 'vitamin D'), ('GO_0007565', 'female pregnancy', 980, 'pregnancy')]	0	['another united arab emirates among  arab women  4000 iu/day  supplementation 2000 iu/day 400 iu/day optimizing  status  achieving  birth mothers offspring.106in united arab emirates study, increment baseline delivery four-fold higher pharmacokinetic studies, baseline  status.100this baseline  status  supplementation.100,107\nthe geographic locations sample sizes  intake optimize  status, -related infant-related complications.']
S95-PMC3702245	PMC3702245	6/2013	S95-PMC3702245	['conclusion\nthe criteria for defining optimal Vitamin D intake during Pregnancy REMAIN CONTROVERSIAL.']	[('INCOMPLETE_EVIDENCE', 79), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 86)]	2	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy')]	0	['conclusion\nthe criteria  intake  controversial.']
S96-PMC3702245	PMC3702245	6/2013	S96-PMC3702245	['in VIEW of the high prevalence of low Vitamin D status in Pregnancy worldwide, INTERVENTION trials to identify optimal Vitamin D status and the REQUIRED SAFE Vitamin D intake COULD BE an IMPORTANT part of PUBLIC HEALTH STRATEGY to improve the health of mothers, and the short-term and long-term outcomes for their offspring.']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 79), ('IMPORTANT_CONSIDERATION', 144), ('IMPORTANT_CONSIDERATION', 153), ('INCOMPLETE_EVIDENCE', 175), ('IMPORTANT_CONSIDERATION', 187), ('IMPORTANT_CONSIDERATION', 205), ('FUTURE_WORK', 219)]	8	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]	0	[' status  worldwide,  status  intake mothers, short-term long-term outcomes offspring.']
S0-PMC3702339	PMC3702339	6/2013	S0-PMC3702339	['prevalence and CORRELATES of Prenatal Vitamin A deficiency in rural sidama, southern ethiopia\n\nabstract\na cross-sectional study was CONDUCTED TO ASSESS the prevalence and CORRELATES of Prenatal Vitamin A deficiency (vad) in rural sidama, southern ethiopia.']	[('SUPERFICIAL_RELATIONSHIP', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 132), ('QUESTION_ANSWERED_BY_THIS_WORK', 142), ('SUPERFICIAL_RELATIONSHIP', 171)]	4	[('GO_0007565', 'female pregnancy', 29, 'Prenatal'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 38, 'Vitamin A'), ('GO_0007565', 'female pregnancy', 185, 'prenatal'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin A')]	0	['prevalence  vitamin rural sidama, southern ethiopia\n\nabstract\na cross-sectional   (vad) rural sidama, southern ethiopia.']
S152-PMC3702339	PMC3702339	6/2013	S152-PMC3702339	['association between Vitamin A status and various POTENTIAL risk factors among Pregnant women in rural sidama, southern ethiopia, february 2011variableserum Retinol µmol/l (mean ±sd)vad+vad-crude or (95% ci)adjusted or (95% ci)**staple diet\xa0\xa0enset-based0.81±0.411802711.28 (0.93-1.77)-\xa0\xa0Cereal-based0.88±0.42851641r-dietary diversity in the previous day\xa0\xa0low (dds ≤3)0.75±0.411191242.55 (1.63-4.00)*1.94 (1.17-3.19)*\xa0\xa0optimal (dds of 4 or 5)0.87±0.411082101.37 (0.88-2.12)1.10 (0.70-1.72)\xa0\xa0high (dds ≥6)0.91±0.43381011r1rconsumed Foods from Animal source in the previous day\xa0\xa0no0.81±0.422163031.92 (1.33-2.78)*1.51 (1.04-2.13)*\xa0\xa0yes0.91±0.39491321r1rsevere acute malnutrition\xa0\xa0no (muac ≥220 mm)0.87±0.421783301r1r\xa0\xa0yes (muac <220 mm)0.75±0.39871051.54 (1.10-2.15)*1.26 (0.88-1.81)zinc deficiency status\xa0\xa0non-deficient0.92±0.41912381r1r\xa0\xa0deficient0.76±0.401741972.31 (1.68-3.17)*1.80 (1.28-2.53)*parity\xa0\xa000.89±0.4034821r1r\xa0\xa01-20.85±0.411021741.41 (0.86-2.26)1.14 (0.69-1.87)\xa0\xa03-40.84±0.42911401.57 (0.97-2.53)1.35 (0.81-2.26)\xa0\xa0≥50.72±0.4038392.35 (1.29-4.28)*1.92 (1.02-3.64)*walking distance from nearby Health facility\xa0\xa00-30 minutes0.83±0.412293691r-\xa0\xa0longer than 30 minutes0.89±0.4436660.88 (0.57-1.36)-number of anc follow-ups\xa0\xa000.87±0.411212431r1r\xa0\xa01-20.80±0.431341731.56 (1.14-2.13)*1.42 (0.97-2.02)\xa0\xa0≥30.86±0.4110191.06 (0.48-2.34)0.70 (0.30-1.64)received Nutrition education during Pregnancy\xa0\xa0yes0.80±0.41701051r-\xa0\xa0no0.85±0.421953300.89 (0.62-1.26)-\n*statistically significant association at 0.05 level of significance;\n**adjusted for all significant variables in the table plus Gestational age and crp level; ci=confidence interval; r=reference value; sd=standard deviation\n\nlinear regression modelling\nin the linear regression model, ABOUT 26.2% of the VARIABILITY in Serum Retinol level (μmol/l) was explained by 8 independent variables (table 2).']	[('INCOMPLETE_EVIDENCE', 49), ('INCOMPLETE_EVIDENCE', 1742), ('DIFFICULT_TASK', 1761)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin A'), ('GO_0007565', 'female pregnancy', 78, 'pregnant'), ('CHEBI_26536', 'retinoic acid', 156, 'retinol'), ('CHEBI_27989', 'cis-dodec-3-enoyl-CoA', 286, 'Cereal'), ('CHEBI_33290', 'food', 529, 'foods'), ('NCBITaxon_33208', 'Metazoa', 540, 'animal'), ('UBERON_0000025', 'tube', 1103, 'health'), ('CHEBI_35222', 'inhibitor', 1361, 'nutrition'), ('GO_0007565', 'female pregnancy', 1388, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1585, 'gestational'), ('UBERON_0001977', 'blood serum', 1776, 'serum'), ('CHEBI_26536', 'retinoic acid', 1782, 'retinol')]	0	['association  status among  women rural sidama, southern ethiopia, february 2011variableserum retinol µmol/l (mean ±sd)vad+vad-crude (95% ci)adjusted (95% ci)**staple diet\xa0\xa0enset-based0.81±0.411802711.28 (0.93-1.77)-\xa0\xa0cereal-based0.88±0.42851641r-dietary diversity day\xa0\xa0low (dds ≤3)0.75±0.411191242.55 (1.63-4.00)*1.94 (1.17-3.19)*\xa0\xa0optimal (dds 4 5)0.87±0.411082101.37 (0.88-2.12)1.10 (0.70-1.72)\xa0\xa0high (dds ≥6)0.91±0.43381011r1rconsumed foods animal day\xa0\xa0no0.81±0.422163031.92 (1.33-2.78)*1.51 (1.04-2.13)*\xa0\xa0yes0.91±0.39491321r1rsevere acute malnutrition\xa0\xa0no (muac ≥220 mm)0.87±0.421783301r1r\xa0\xa0yes (muac <220 mm)0.75±0.39871051.54 (1.10-2.15)*1.26 (0.88-1.81)zinc status\xa0\xa0non-deficient0.92±0.41912381r1r\xa0\xa0deficient0.76±0.401741972.31 (1.68-3.17)*1.80 (1.28-2.53)*parity\xa0\xa000.89±0.4034821r1r\xa0\xa01-20.85±0.411021741.41 (0.86-2.26)1.14 (0.69-1.87)\xa0\xa03-40.84±0.42911401.57 (0.97-2.53)1.35 (0.81-2.26)\xa0\xa0≥50.72±0.4038392.35 (1.29-4.28)*1.92 (1.02-3.64)*walking distance nearby facility\xa0\xa00-30 minutes0.83±0.412293691r-\xa0\xa0longer 30 minutes0.89±0.4436660.88 (0.57-1.36)-number anc follow-ups\xa0\xa000.87±0.411212431r1r\xa0\xa01-20.80±0.431341731.56 (1.14-2.13)*1.42 (0.97-2.02)\xa0\xa0≥30.86±0.4110191.06 (0.48-2.34)0.70 (0.30-1.64)received nutrition \xa0\xa0yes0.80±0.41701051r-\xa0\xa0no0.85±0.421953300.89 (0.62-1.26)-\n*statistically 0.05 significance;\n**adjusted table plus  age crp level; ci=confidence interval; r=reference value; sd=standard deviation\n\nlinear regression modelling\nin linear regression model, 26.2% serum retinol (μmol/l) 8 (table 2).']
S198-PMC3702339	PMC3702339	6/2013	S198-PMC3702339	['a study in Pregnant rhesus monkeys CONCLUDED that, in the zinc-deficient groups, zinc AFFECTS Vitamin A Metabolism by altering the formation or release of holo-Retinol-Binding Protein (43).']	[('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 86)]	2	[('GO_0007565', 'female pregnancy', 11, 'pregnant'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('GO_0070639', 'vitamin D2 metabolic process', 94, 'vitamin A metabolism'), ('CHEBI_26536', 'retinoic acid', 160, 'retinol'), ('PR_000013779', 'histone-binding protein RBBP7', 160, 'retinol-binding protein')]	0	[' rhesus monkeys that, zinc-deficient groups, zinc  metabolism altering formation release holo-retinol-binding protein (43).']
S199-PMC3702339	PMC3702339	6/2013	S199-PMC3702339	['Zinc supplementation trial in Pregnant nepalese women also SUGGESTED that Zinc potentiates the EFFECT of Vitamin A in restoring night-Vision among night-blind Pregnant women with low initial Serum zinc concentrations (44).']	[('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 95)]	2	[('CHEBI_27377', 'Unsym-bis(4*-chlorophenyl)ethylene', 0, 'Zinc'), ('GO_0007565', 'female pregnancy', 30, 'pregnant'), ('CHEBI_33340', 'zinc group element atom', 74, 'zinc'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin A'), ('GO_0007601', 'visual perception', 134, 'vision'), ('GO_0007565', 'female pregnancy', 159, 'pregnant'), ('UBERON_0001977', 'blood serum', 191, 'serum')]	0	['zinc supplementation  nepalese women zinc potentiates  restoring night-vision among night-blind  women serum zinc concentrations (44).']
S24-PMC3704911	PMC3704911	7/2013	S24-PMC3704911	['additionally, Prenatal DEFICIENCIES in Vitamins D and E HAVE BEEN ASSOCIATED with increased incidences of Respiratory difficulties, including wheezing and asthma, in the offspring [7], and maternal Vitamin D deficiencies HAVE BEEN RELATED to observed hyper-Locomotion in the Adult Rat [8].']	[('IMPORTANT_CONSIDERATION', 23), ('INCOMPLETE_EVIDENCE', 56), ('SUPERFICIAL_RELATIONSHIP', 66), ('INCOMPLETE_EVIDENCE', 221), ('SUPERFICIAL_RELATIONSHIP', 231)]	5	[('GO_0007565', 'female pregnancy', 14, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamins D'), ('PR_000006444', 'diacylglycerol kinase delta', 48, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 54, 'E'), ('UBERON_0001004', 'respiratory system', 106, 'respiratory'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('GO_0040011', 'locomotion', 257, 'locomotion'), ('UBERON_0007023', 'adult organism', 275, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 281, 'rat')]	0	['additionally,   e incidences respiratory difficulties, wheezing asthma, offspring [7], maternal  hyper-locomotion adult rat [8].']
S160-PMC3705146	PMC3705146	5/2013	S160-PMC3705146	['furthermore, a RECENT report DEMONSTRATES an equivalently strong season-of-Birth EFFECT in multiple sclerosis with peaks in april and may and in PARALLEL with schizophrenia (torrey et al.,1997; davies et al.,2003), deficits in births of future multiple sclerosis patients during october and november (dobson et al.,2013), a FINDING the authors ATTRIBUTE to VARIATIONS in sunlight during Gestation and to the resulting variations in Vitamin D availability.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 81), ('SUPERFICIAL_RELATIONSHIP', 145), ('INCOMPLETE_EVIDENCE', 324), ('SUPERFICIAL_RELATIONSHIP', 344), ('DIFFICULT_TASK', 357)]	7	[('GO_0007567', 'parturition', 75, 'birth'), ('GO_0007565', 'female pregnancy', 387, 'gestation'), ('CHEBI_27300', 'vitamin D', 432, 'vitamin D')]	0	['furthermore, equivalently season-of-birth sclerosis peaks april schizophrenia (torrey et al.,1997; davies et al.,2003), births sclerosis patients october november (dobson et al.,2013), authors sunlight  resulting  availability.']
S195-PMC3705146	PMC3705146	5/2013	S195-PMC3705146	['ALTHOUGH sunlight-induced Vitamin D is not an IMPORTANT source of Vitamin D for lower Animals, it HAS BEEN SHOWN that Prenatal dietary Vitamin D in sprague-dawley Rats has significant EFFECTS on Postnatal anxiety and social behaviors (pan et al.,2013).']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 46), ('INCOMPLETE_EVIDENCE', 98), ('SUPERFICIAL_RELATIONSHIP', 184)]	4	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 86, 'animals'), ('GO_0007565', 'female pregnancy', 118, 'prenatal'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 163, 'rats'), ('GO_0007567', 'parturition', 195, 'postnatal')]	0	['although sunlight-induced   animals,  dietary  sprague-dawley rats postnatal anxiety social behaviors (pan et al.,2013).']
S208-PMC3705146	PMC3705146	5/2013	S208-PMC3705146	['with respect to the POSSIBLE ROLE of sunlight intensity in behavioral phenotypes, it HAS BEEN PROPOSED that cutaneous Vitamin D generation MAY BE INVOLVED in Gestational EFFECTS that Modulate the eventual development of schizophrenia (mcgrath and welham,1999).']	[('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 29), ('INCOMPLETE_EVIDENCE', 85), ('INCOMPLETE_EVIDENCE', 94), ('INCOMPLETE_EVIDENCE', 139), ('SUPERFICIAL_RELATIONSHIP', 146), ('SUPERFICIAL_RELATIONSHIP', 170)]	7	[('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007565', 'female pregnancy', 158, 'gestational'), ('GO_0065007', 'biological regulation', 183, 'modulate')]	0	['respect sunlight intensity behavioral phenotypes, cutaneous  generation  eventual schizophrenia (mcgrath welham,1999).']
S225-PMC3705146	PMC3705146	5/2013	S225-PMC3705146	['(2007) who FOUND that Prenatal Vitamin D deficiency in rodents LEADS to elevations in the functional antagonist of alpha-msh , the melanotropic peptide mch .']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 63)]	2	[('GO_0007565', 'female pregnancy', 22, 'prenatal'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]	0	['(2007)   rodents elevations functional antagonist alpha-msh melanotropic peptide mch .']
S226-PMC3705146	PMC3705146	5/2013	S226-PMC3705146	['HOWEVER, mcgrath and colleagues have ALSO SHOWN that the RELATIONSHIP between Vitamin D in Gestation and subsequent schizophrenia MAY BE COMPLEX, in that those with low maternal vitamin d are at INCREASED RISK of bearing offspring who become schizophrenic as are those with overly high Vitamin D (mcgrath et al.,2010a).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 57), ('INCOMPLETE_EVIDENCE', 130), ('DIFFICULT_TASK', 137), ('IMPORTANT_CONSIDERATION', 195)]	6	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'gestation'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D')]	0	['however, mcgrath colleagues   schizophrenia complex, maternal vitamin offspring schizophrenic  (mcgrath et al.,2010a).']
S13-PMC3705320	PMC3705320	3/2013	S13-PMC3705320	['introduction\nthe maternal-infant health benefits of Vitamin D supplementation during Pregnancy remain UNCERTAIN [1,2].']	[('FULL_UNKNOWN', 102)]	1	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy')]	0	['introduction\nthe maternal-infant  supplementation  [1,2].']
S14-PMC3705320	PMC3705320	3/2013	S14-PMC3705320	['HOWEVER, observational studies have SUGGESTED ASSOCIATIONS between Vitamin D status during Pregnancy and Postnatal infant health outcomes [3,4,5].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 46)]	3	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('GO_0007567', 'parturition', 105, 'postnatal')]	0	['however,  status  postnatal infant outcomes [3,4,5].']
S18-PMC3705320	PMC3705320	3/2013	S18-PMC3705320	['THEREFORE, to guide the design of clinical trials of Antenatal Vitamin D supplementation in bangladesh, we CONDUCTED a randomized open-label pilot trial of two Antenatal Vitamin d3 supplementation doses that were several fold higher than those in typical Prenatal supplements.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 107)]	2	[('GO_0007567', 'parturition', 53, 'antenatal'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007567', 'parturition', 160, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 170, 'vitamin'), ('GO_0007565', 'female pregnancy', 255, 'prenatal')]	0	['therefore, antenatal  supplementation bangladesh, open-label antenatal vitamin d3 supplementation doses fold higher typical  supplements.']
S25-PMC3705320	PMC3705320	3/2013	S25-PMC3705320	['reasons for exclusion were: preexisting medical condition; current Vitamin D supplement use; Anti-convulsant or anti-Mycobacterial medications; severe anemia (hemoglobin concentration <70 g/l); hypertension at enrollment (systolic Blood pressure ≥140 mmhg or diastolic Blood pressure ≥90 mmhg on at least two measurements); major risk FACTORS for Preterm Delivery or Pregnancy complications; or previous delivery of an infant with a congenital anomaly or Perinatal death.']	[('SUPERFICIAL_RELATIONSHIP', 335)]	1	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_59132', 'antigen', 93, 'anti'), ('CHEBI_52217', 'pharmaceutical', 117, 'mycobacterial'), ('UBERON_0000178', 'blood', 231, 'blood'), ('UBERON_0000178', 'blood', 269, 'blood'), ('GO_0007565', 'female pregnancy', 347, 'preterm'), ('GO_0007567', 'parturition', 355, 'delivery'), ('GO_0007565', 'female pregnancy', 367, 'pregnancy'), ('GO_0036268', 'swimming', 455, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 455, 'perinatal')]	0	['reasons exclusion were: preexisting medical condition;  supplement use; anti-convulsant anti-mycobacterial medications; anemia (hemoglobin concentration <70 g/l); hypertension enrollment (systolic blood pressure ≥140 mmhg diastolic blood pressure ≥90 mmhg measurements);  delivery  complications; delivery infant congenital anomaly perinatal death.']
S178-PMC3705320	PMC3705320	3/2013	S178-PMC3705320	['in Pregnant participants, the higher-dose Vitamin D regimen had a significant suppressive EFFECT on maternal pth secretion, relative to the lower dose, as INDICATED by the change in average Pth concentrations from baseline to delivery, SIMILAR TO PREVIOUS OBSERVATIONS by wagner et al.']	[('SUPERFICIAL_RELATIONSHIP', 90), ('INCOMPLETE_EVIDENCE', 155), ('INCOMPLETE_EVIDENCE', 236), ('INCOMPLETE_EVIDENCE', 247), ('INCOMPLETE_EVIDENCE', 256)]	5	[('GO_0007565', 'female pregnancy', 3, 'pregnant'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 190, 'PTH')]	0	[' participants, higher-dose  regimen suppressive maternal pth secretion, relative dose, average pth concentrations baseline delivery, wagner et al.']
S180-PMC3705320	PMC3705320	3/2013	S180-PMC3705320	['HOWEVER, SINCE the ROLE of pth as a Vitamin D status BIOMARKER during Pregnancy is UNCLEAR [26], the clinical significance of the APPARENT dose-response EFFECT of Vitamin D on pth REQUIRES FURTHER STUDY.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBLEM_COMPLICATION', 9), ('SUPERFICIAL_RELATIONSHIP', 19), ('SUPERFICIAL_RELATIONSHIP', 53), ('FULL_UNKNOWN', 83), ('ANOMALY_CURIOUS_FINDING', 130), ('SUPERFICIAL_RELATIONSHIP', 153), ('IMPORTANT_CONSIDERATION', 180), ('FUTURE_WORK', 189)]	9	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]	0	['however, pth  status  [26], dose-response  pth study.']
S193-PMC3705320	PMC3705320	3/2013	S193-PMC3705320	['first, precision of ESTIMATES of Pharmacokinetic parameters and between-group comparisons, as well as the generalizability of inferences regarding maternal-fetal SAFETY of high-dose Vitamin D supplementation, were LIMITED by the SMALL number of participants, stringent inclusion/exclusion criteria, and enrolment of Pregnant and non-Pregnant participants at one clinic site.']	[('INCOMPLETE_EVIDENCE', 20), ('IMPORTANT_CONSIDERATION', 162), ('INCOMPLETE_EVIDENCE', 214), ('INCOMPLETE_EVIDENCE', 229)]	4	[('CHEBI_87163', 'dihydroisopentenyldehydrorhodopin', 33, 'pharmacokinetic'), ('GO_0006909', 'phagocytosis', 33, 'pharmacokinetic'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('GO_0007565', 'female pregnancy', 316, 'pregnant'), ('GO_0007565', 'female pregnancy', 333, 'pregnant')]	0	['first, precision pharmacokinetic parameters between-group comparisons, generalizability regarding maternal-fetal high-dose  supplementation, participants, stringent inclusion/exclusion criteria, enrolment  non- participants clinic site.']
S201-PMC3705320	PMC3705320	3/2013	S201-PMC3705320	['NONETHELESS, increases in the mean calcium concentration (within the normal range) and suppression of pth secretion among Pregnant women receiving the higher-dose regimen (70,000 iu initial dose followed by weekly doses of 35,000 iu) HIGHLIGHTED the physiological IMPACT of the intervention and the NEED to cautiously address POTENTIAL Pregnancy-specific sensitivities to Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 234), ('SUPERFICIAL_RELATIONSHIP', 264), ('FUTURE_WORK', 299), ('INCOMPLETE_EVIDENCE', 299), ('INCOMPLETE_EVIDENCE', 326)]	7	[('GO_0007565', 'female pregnancy', 122, 'pregnant'), ('GO_0007565', 'female pregnancy', 336, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 372, 'vitamin D')]	0	['nonetheless, calcium concentration (within normal range) suppression pth secretion among  women receiving higher-dose regimen (70,000 iu dose followed weekly doses 35,000 iu) physiological -specific sensitivities  supplementation.']
S206-PMC3705320	PMC3705320	3/2013	S206-PMC3705320	['FUTURE TRIALS in dhaka will address the dose-dependency of the EFFECTS of Prenatal Vitamin D supplementation on infant growth and morbidity.']	[('FUTURE_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 63)]	2	[('GO_0007565', 'female pregnancy', 74, 'prenatal'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]	0	['future dhaka dose-dependency   supplementation infant morbidity.']
S243-PMC3708703	PMC3708703	6/2013	S243-PMC3708703	['in our trial we FOUND a high prevalence of Iodine (93%) and Vitamin D deficiency (18%) among women in late Pregnancy.']	[('INCOMPLETE_EVIDENCE', 16)]	1	[('CHEBI_24859', 'iodine atom', 43, 'iodine'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy')]	0	['iodine (93%)  (18%) among women late .']
S34-PMC3713405	PMC3713405	7/2013	S34-PMC3713405	['we begin with a concise summary of the epidemiological CLUES that SUGGEST altered Prenatal/Perinatal Vitamin D levels increase the risk of developing schizophrenia.']	[('INCOMPLETE_EVIDENCE', 55), ('INCOMPLETE_EVIDENCE', 66)]	2	[('GO_0007565', 'female pregnancy', 82, 'prenatal'), ('GO_0036268', 'swimming', 91, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 91, 'perinatal'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]	0	['concise epidemiological altered /perinatal  levels increase schizophrenia.']
S49-PMC3713405	PMC3713405	7/2013	S49-PMC3713405	['most RECENTLY, and most IMPORTANTLY, a danish population-based case-control study (423 cases and 423 control) that directly assessed Vitamin D levels in Blood Spots from NEW born infants provided SOLID EVIDENCE SHOWING that low Prenatal Vitamin D levels are ASSOCIATED with an INCREASED RISK of schizophrenia (mcgrath et al., 2010).']	[('INCOMPLETE_EVIDENCE', 5), ('IMPORTANT_CONSIDERATION', 24), ('FULL_UNKNOWN', 170), ('INCOMPLETE_EVIDENCE', 196), ('INCOMPLETE_EVIDENCE', 211), ('SUPERFICIAL_RELATIONSHIP', 258), ('IMPORTANT_CONSIDERATION', 277)]	7	[('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 153, 'blood spots'), ('GO_0007565', 'female pregnancy', 228, 'prenatal'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]	0	['recently, importantly, danish population-based case-control (423 cases 423 control)  levels blood spots born infants   levels schizophrenia (mcgrath et al., 2010).']
S51-PMC3713405	PMC3713405	7/2013	S51-PMC3713405	['to establish the biological PLAUSIBILITY of WHETHER Dvd deficiency COULD BE RELATED to schizophrenia, our group ESTABLISHED a Dvd-deficient Rat MODEL which HAS SHOWN that low Prenatal Vitamin D adversely AFFECTS Brain Development and Adult behavior, ESPECIALLY da development and da-RELATED behaviors.']	[('INCOMPLETE_EVIDENCE', 28), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 44), ('INCOMPLETE_EVIDENCE', 67), ('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 112), ('INCOMPLETE_EVIDENCE', 144), ('INCOMPLETE_EVIDENCE', 156), ('SUPERFICIAL_RELATIONSHIP', 204), ('IMPORTANT_CONSIDERATION', 250), ('SUPERFICIAL_RELATIONSHIP', 283)]	10	[('PR_000006770', 'cytoplasmic dynein 1 heavy chain 1', 52, 'DVD'), ('PR_000006770', 'cytoplasmic dynein 1 heavy chain 1', 126, 'DVD'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 140, 'rat'), ('GO_0007565', 'female pregnancy', 175, 'prenatal'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007420', 'brain development', 212, 'brain development'), ('UBERON_0000955', 'brain', 212, 'brain'), ('UBERON_0007023', 'adult organism', 234, 'adult')]	0	['biological dvd schizophrenia, dvd-deficient rat   adversely brain adult behavior, da da-related behaviors.']
S126-PMC3713405	PMC3713405	7/2013	S126-PMC3713405	['Vitamin D deficiency in the later portion of Gestation is REQUIRED to elicit this behavioral sensitivity WHEREAS Vitamin D deficiency during the early portion of Gestation has no IMPACT (o’loan et al., 2007).']	[('IMPORTANT_CONSIDERATION', 58), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 105), ('SUPERFICIAL_RELATIONSHIP', 179)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 45, 'gestation'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007565', 'female pregnancy', 162, 'gestation')]	0	['vitamin portion  elicit behavioral sensitivity  portion  (o’loan et al., 2007).']
S3-PMC3717170	PMC3717170	5/2013	S3-PMC3717170	['THIS REPORT summarizes RECENT RESEARCH on the ROLES for Vitamin D in cancer, Immunity and Autoimmune diseases, Cardiovascular and Respiratory health, Pregnancy, obesity, Erythropoiesis, diabetes, muscle function, and Aging.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 46)]	3	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007566', 'embryo implantation', 77, 'immunity'), ('UBERON_0001442', 'skeleton of manus', 90, 'autoimmune'), ('UBERON_0004535', 'cardiovascular system', 111, 'cardiovascular'), ('UBERON_0001004', 'respiratory system', 130, 'respiratory'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('GO_0030218', 'erythrocyte differentiation', 170, 'erythropoiesis'), ('GO_0007568', 'aging', 217, 'aging')]	0	['summarizes  cancer, immunity autoimmune diseases, cardiovascular respiratory health, obesity, erythropoiesis, diabetes, muscle function, aging.']
S68-PMC3717170	PMC3717170	5/2013	S68-PMC3717170	['Vitamin D during Pregnancy and Lactation\nVitamin D as a preprohormone has EFFECTS that extend beyond Calcium Metabolism and Homeostasis throughout Life but which are most vivid during Pregnancy when Vitamin D Metabolism is disengaged from its usual constraints.12at no other time during the Lifecycle is 25(Oh)D3Linked directly to 1,25(Oh)2d3production, the latter rising more than 2.5 times above nonpregnant levels.12this elevation of 1,25(oh)2d3likely serves the purpose of Immune Regulation, THOUGH there HAVE BEEN ONLY a FEW STUDIES that have evaluated the EFFECT of Vitamin D status on Immune function during Pregnancy to SUPPORT THIS HYPOTHESIS.']	[('SUPERFICIAL_RELATIONSHIP', 74), ('SUPERFICIAL_RELATIONSHIP', 484), ('ANOMALY_CURIOUS_FINDING', 496), ('INCOMPLETE_EVIDENCE', 509), ('INCOMPLETE_EVIDENCE', 519), ('INCOMPLETE_EVIDENCE', 526), ('SUPERFICIAL_RELATIONSHIP', 562), ('INCOMPLETE_EVIDENCE', 628), ('QUESTION_ANSWERED_BY_THIS_WORK', 636), ('INCOMPLETE_EVIDENCE', 641)]	10	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 17, 'pregnancy'), ('GO_0007595', 'lactation', 31, 'lactation'), ('CHEBI_28384', 'vitamin K', 41, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 41, 'Vitamin D'), ('GO_0018884', 'carbazole metabolic process', 101, 'calcium metabolism'), ('GO_0042592', 'homeostatic process', 124, 'homeostasis'), ('UBERON_0000104', 'life cycle', 147, 'life'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 199, 'vitamin D metabolism'), ('UBERON_0000104', 'life cycle', 291, 'lifecycle'), ('CHEBI_77914', '3-methylbut-1-ene', 304, '25(OH)D3linked'), ('CHEBI_63056', 'zinc cation', 333, '25(OH'), ('CHEBI_17996', 'chloride', 438, ','), ('GO_0002521', 'leukocyte differentiation', 477, 'immune regulation'), ('UBERON_0002405', 'immune system', 477, 'immune'), ('CHEBI_27300', 'vitamin D', 572, 'vitamin D'), ('UBERON_0002405', 'immune system', 592, 'immune'), ('GO_0007565', 'female pregnancy', 615, 'pregnancy')]	0	['vitamin  lactation\nvitamin preprohormone calcium metabolism homeostasis throughout life vivid   metabolism disengaged usual constraints.12at lifecycle 25(oh)d3linked 1,25(oh)2d3production, latter 2.5 times nonpregnant levels.12this elevation 1,25(oh)2d3likely immune regulation,  status immune  hypothesis.']
S69-PMC3717170	PMC3717170	5/2013	S69-PMC3717170	"['[""""in addition, FEW randomized controlled trials HAVE BEEN conducted in Pregnant women to determine optimal Vitamin D status.13–15\\ncarol l. wagner (medical university of south carolina) DISCUSSED two RECENT STUDIES performed by her group in collaboration with bruce hollis\'s group—the national institute of child health and Human development (nichd) Vitamin D Pregnancy trial12and the thrasher research fund Vitamin D community-based supplementation trial16—that INDICATE that 400 iu Vitamin D, the amount found in MOST Prenatal Vitamins, is INADEQUATE and that 4000 iu/day is NECESSARY to optimize 1,25(Oh)2D3Production, achieved when total circulating 25(Oh)d3is at least 40 ng/ml (fig.""""]']"	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 197), ('INCOMPLETE_EVIDENCE', 460), ('PROBABLE_UNDERSTANDING', 512), ('IMPORTANT_CONSIDERATION', 539), ('PROBLEM_COMPLICATION', 539), ('IMPORTANT_CONSIDERATION', 574)]	9	[('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 321, 'Human'), ('CHEBI_28384', 'vitamin K', 347, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 357, 'Pregnancy'), ('CHEBI_28384', 'vitamin K', 405, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 405, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 481, 'vitamin D'), ('GO_0007565', 'female pregnancy', 517, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 526, 'vitamins'), ('CHEBI_37983', 'sulfur-35 atom', 596, '1'), ('CHEBI_74151', 'S-palmitoyl-L-cysteine residue', 597, ',25(OH)2D3production'), ('PR_000029121', 'leucine-rich repeat and guanylate kinase domain-containing protein', 604, '2D3production'), ('CHEBI_33310', 'neon atom', 653, '(OH)')]	0	"['[""""in addition, ant women optimn status.13–15\\ncarol l. wagner (medical university south carolina) collaboration bruce hollis*s group—the national institute child human (nichd) vitamiancy trial12and thrasher fund vitamin community-based supplementation trial16—that 400in d, amount matal vitamins, 4000 iu/day optimize 1,25(oh)2d3production, achieved circulating 25(oh)d3is 40 ng/ml (fig.""""]']"
S73-PMC3717170	PMC3717170	5/2013	S73-PMC3717170	['YET, before such FINDINGS are fully EMBRACED, the mechanism(s) of action of Vitamin D and its PROTECTIVE EFFECT during Pregnancy MUST BE BETTER delineated.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 94), ('SUPERFICIAL_RELATIONSHIP', 105), ('IMPORTANT_CONSIDERATION', 129), ('INCOMPLETE_EVIDENCE', 137)]	8	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy')]	0	['yet, embraced, mechanism(s)   delineated.']
S74-PMC3717170	PMC3717170	5/2013	S74-PMC3717170	['ADDITIONAL RESEARCH that addresses the IMPACT of Vitamin D on Immune Homeostasis during Pregnancy and its EFFECTS during early infancy and later childhood becomes ESSENTIAL.']	[('FUTURE_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 39), ('SUPERFICIAL_RELATIONSHIP', 106), ('IMPORTANT_CONSIDERATION', 163)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0055090', 'acylglycerol homeostasis', 62, 'immune homeostasis'), ('UBERON_0002405', 'immune system', 62, 'immune'), ('GO_0007565', 'female pregnancy', 88, 'pregnancy')]	0	['additional  immune homeostasis  infancy childhood becomes essential.']
S162-PMC3717170	PMC3717170	5/2013	S162-PMC3717170	['Vitamin D and physical and Cognitive function in older persons\nluigi ferrucci (national institute on Aging) DISCUSSED RECENT EVIDENCE LINKING Vitamin D deficiency to the pathogenesis and clinical Progression Of chronic Diseases highly prevalent in older Persons.']	[('INCOMPLETE_EVIDENCE', 108), ('INCOMPLETE_EVIDENCE', 118), ('SUPERFICIAL_RELATIONSHIP', 134)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0050890', 'cognition', 27, 'cognitive'), ('GO_0007568', 'aging', 101, 'Aging'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('GO_0007565', 'female pregnancy', 196, 'progression of ... diseases'), ('NCBITaxon_10088', 'Mus <genus>', 254, 'persons')]	0	['vitamin physical cognitive older persons\nluigi ferrucci (national institute aging)  pathogenesis  chronic  older persons.']
S9-PMC3717763	PMC3717763	8/2013	S9-PMC3717763	['this scheme provides low-income families in the uk with fixed-value Food vouchers and vitamin coupons for eligible women and young children.1vitamin coupons can be exchanged for branded hs vitamin tablets for women (70\u2005mg Vitamin C, 10\u2005µg Vitamin D and 400\u2005µg Folic Acid daily during Pregnancy, and one year Postpartum) and drops for children (233\u2005µg Vitamin A, 20\u2005µg Vitamin C, and 7.5\u2005µg Vitamin D3 daily between\n\ncaption (boxed-text)\nwhat is already known on THIS topic\ncurrent uk GUIDANCE is that vulnerable groups of Pregnant and breastfeeding women and young children SHOULD take Vitamin Supplements (including Vitamins A, c and d) to protect against the greater RISK of Birth defects and poor health outcomes in later Life.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 462), ('FUTURE_WORK', 484), ('FUTURE_WORK', 574), ('IMPORTANT_CONSIDERATION', 669)]	4	[('CHEBI_33290', 'food', 68, 'food'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 239, 'vitamin D'), ('CHEBI_30751', 'formic acid', 260, 'folic acid'), ('GO_0007565', 'female pregnancy', 284, 'pregnancy'), ('GO_0007565', 'female pregnancy', 308, 'postpartum'), ('CHEBI_27300', 'vitamin D', 351, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin C'), ('CHEBI_33279', 'vitamin D5', 390, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 390, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 522, 'pregnant'), ('CHEBI_33229', 'vitamin (role)', 586, 'vitamin'), ('CHEBI_33341', 'titanium atom', 594, 'supplements'), ('CHEBI_27300', 'vitamin D', 617, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 626, 'A'), ('GO_0007567', 'parturition', 677, 'birth'), ('UBERON_0000104', 'life cycle', 725, 'life')]	0	['scheme low-income families uk fixed-value food vouchers vitamin coupons eligible women young children.1vitamin coupons exchanged branded hs vitamin tablets women (70\u2005mg 10\u2005µg  400\u2005µg folic acid daily year drops children (233\u2005µg 20\u2005µg 7.5\u2005µg vitamin d3 daily between\n\ncaption (boxed-text)\nwhat topic\ncurrent uk  breastfeeding women young children vitamin supplements (including c d) birth defects outcomes life.']
S18-PMC3717763	PMC3717763	8/2013	S18-PMC3717763	"['[""""in RECENT YEARS, there HAS BEEN particular CONCERN about Vitamin D levels among children in the uk, and the rise in Vitamin D deficiency disease, presenting as rickets, symptomatic hypocalcaemia and motor delay.5–12vitamin d is hard to source through diet alone; 90% comes from exposure to sunlight.13if the mother\'s Vitamin D status is low during Pregnancy, the infant will also have low levels.14estimates CONSISTENTLY SHOW that the MAJORITY of uk children aged between 1.5 and 3\\u2005years do not get their daily reference Nutrient intake of Vitamin D.15–18one RECENT STUDY REPORTS that supplying hs Vitamins to all Pregnant women and young children resulted in a substantial reduction in symptomatic Vitamin D deficiency in children in one primary care trust (pct), where 75% of the population were from ethnic minority groups PARTICULARLY AT RISK of Vitamin D deficiency.19\\nTHIS PAPER reports on research with parents and professionals with the AIM of understanding WHY the provision of free hs Vitamins has not resulted in higher levels of use among low income families in england.""""]']"	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 23), ('IMPORTANT_CONSIDERATION', 43), ('PROBABLE_UNDERSTANDING', 408), ('INCOMPLETE_EVIDENCE', 421), ('PROBABLE_UNDERSTANDING', 435), ('INCOMPLETE_EVIDENCE', 559), ('INCOMPLETE_EVIDENCE', 572), ('IMPORTANT_CONSIDERATION', 826), ('IMPORTANT_CONSIDERATION', 839), ('QUESTION_ANSWERED_BY_THIS_WORK', 874), ('QUESTION_ANSWERED_BY_THIS_WORK', 945), ('EXPLICIT_QUESTION', 966)]	13	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 317, 'vitamin D'), ('GO_0007565', 'female pregnancy', 348, 'pregnancy'), ('CHEBI_33284', 'nutrient', 521, 'nutrient'), ('CHEBI_27300', 'vitamin D', 540, 'vitamin D'), ('CHEBI_33277', 'gamma-tocotrienol', 598, 'vitamins'), ('GO_0007565', 'female pregnancy', 614, 'pregnant'), ('CHEBI_27300', 'vitamin D', 699, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 850, 'vitamin D'), ('CHEBI_33277', 'gamma-tocotrienol', 995, 'vitamins')]	0	"['[""""in years, abon levels among children uk, rise n disease, presenting rickets, symptomatic hypocalcaemia motor delay.5–12vitamin diet alone; 90% comes exposure sunlight.13if mothern status durincy, infant levels.14estimates uk children aged 1.5 3\\u2005years get daily nutrient initamin d.15–18one supplying hs vitaminspregnant women young children resulted reduction sympitamin children trust (pct), 75% population ethnic itamin deficiency.19\\nthis parents professionals provision hs vitamins resulted higher levels among income families england.""""]']"
S169-PMC3728489	PMC3728489	7/2013	S169-PMC3728489	['it HAS also BEEN SUGGESTED that maternal Intake of Vitamin E and polyunsaturated Fatty Acids during Pregnancy MAY INFLUENCE Development Of the Immune System and be IMPLICATED in childhood asthma and allergy.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 110), ('SUPERFICIAL_RELATIONSHIP', 114), ('SUPERFICIAL_RELATIONSHIP', 164)]	5	[('GO_0007631', 'feeding behavior', 41, 'intake'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin E'), ('CHEBI_35366', 'fatty acid', 81, 'fatty acids'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('GO_0002020', 'protease binding', 124, 'development of ... immune system'), ('UBERON_0002405', 'immune system', 143, 'immune system')]	0	['maternal intake  polyunsaturated fatty acids  immune system childhood asthma allergy.']
S312-PMC3728489	PMC3728489	7/2013	S312-PMC3728489	['it HAS BEEN PROPOSED, THOUGH NOT PROVEN, that low levels of Vitamin D during Pregnancy and infancy COULD increase the RISK of Neurodevelopmental disorders, and that supplementation COULD play a ROLE in prevention.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 99), ('IMPORTANT_CONSIDERATION', 118), ('INCOMPLETE_EVIDENCE', 181), ('SUPERFICIAL_RELATIONSHIP', 194)]	8	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0007399', 'nervous system development', 126, 'neurodevelopmental')]	0	['proposed, proven, levels   infancy increase neurodevelopmental disorders, supplementation play prevention.']
S17-PMC3739737	PMC3739737	8/2013	S17-PMC3739737	['the HYPOTHESIS that low Vitamin D levels AFFECT the developing Brain is SUPPORTED by data from Prenatal Vitamin D deficiency in rodents, in which the foetus develops in utero in a Vitamin D-deficient but normocalcaemic dam[7],[8].']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 41), ('INCOMPLETE_EVIDENCE', 72)]	3	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0000955', 'brain', 63, 'brain'), ('GO_0007565', 'female pregnancy', 95, 'prenatal'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D')]	0	[' levels brain   rodents, foetus develops utero -deficient normocalcaemic dam[7],[8].']
S27-PMC3742894	PMC3742894	7/2013	S27-PMC3742894	['to improve the nutritional status (the MAJOR cause of anemia in Pregnancy) of ethiopian women, there HAVE BEEN several interventions by the ministry of health through its essential nutrition action plan (ena), consisting of supplementation of three major Nutrients (Vitamin A, Iron, and Iodine) and other promotive activities to improve maternal and child nutrition (18).']	[('IMPORTANT_CONSIDERATION', 39), ('INCOMPLETE_EVIDENCE', 101)]	2	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('CHEBI_33284', 'nutrient', 255, 'nutrients'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin A'), ('CHEBI_24870', 'ion', 277, 'iron'), ('CHEBI_24859', 'iodine atom', 287, 'iodine')]	0	['nutritional status (the anemia ethiopian women, ministry nutrition (ena), consisting supplementation three nutrients (, iron, iodine) promotive activities maternal child nutrition (18).']
S21-PMC3760821	PMC3760821	9/2013	S21-PMC3760821	['hypovitaminosis D is commonly SEEN in both Pregnant and non-Pregnant women worldwide[5]; with many FACTORS IMPACTING on Vitamin D status, including; exposure to sunlight, skin colour, season, latitude and obesity, among others[6].']	[('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 99), ('SUPERFICIAL_RELATIONSHIP', 107)]	3	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 16, 'D'), ('GO_0007565', 'female pregnancy', 43, 'pregnant'), ('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]	0	['hypovitaminosis  non- women worldwide[5];  status, including; exposure sunlight, skin colour, season, latitude obesity, among others[6].']
S25-PMC3760821	PMC3760821	9/2013	S25-PMC3760821	['DESPITE the LACK OF change/decline in 25Ohd levels, levels of the biologically active Vitamin D Metabolite, 1,25 Dihydroxy Vitamin D [1,25(Oh)2D], are KNOWN to increase by 100% or more during Pregnancy[7],[10].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 151)]	3	[('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 38, '25OHD'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 96, 'metabolite'), ('CHEBI_50341', '1-hydroxyethyl group', 108, '1,25 dihydroxy'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_72698', '(2R)-trihomocitric acid', 138, '(OH)2D'), ('GO_0007565', 'female pregnancy', 192, 'pregnancy')]	0	['despite change/decline 25ohd levels, levels biologically  metabolite, 1,25 dihydroxy  [1,25(oh)2d], increase 100% [7],[10].']
S28-PMC3760821	PMC3760821	9/2013	S28-PMC3760821	['this APPARENT rise in 1,25(Oh)2D has LED TO the SUGGESTION that Pregnant women MAY REQUIRE higher cellular exposure to active Vitamin D during the second and third trimesters, and HAS BEEN interpreted by SOME as PROVIDING EVIDENCE for its POTENTIAL ROLE in obstetric well-Being[8].']	[('ANOMALY_CURIOUS_FINDING', 5), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 48), ('INCOMPLETE_EVIDENCE', 79), ('IMPORTANT_CONSIDERATION', 83), ('INCOMPLETE_EVIDENCE', 180), ('INCOMPLETE_EVIDENCE', 204), ('PROBABLE_UNDERSTANDING', 212), ('INCOMPLETE_EVIDENCE', 222), ('INCOMPLETE_EVIDENCE', 239), ('SUPERFICIAL_RELATIONSHIP', 249)]	11	[('CHEBI_17996', 'chloride', 23, ','), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 24, '25(OH)2D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0016441', 'posttranscriptional gene silencing', 271, '-being')]	0	['rise 1,25(oh)2d  women higher cellular exposure  third trimesters, obstetric well-being[8].']
S34-PMC3760821	PMC3760821	9/2013	S34-PMC3760821	['the results of a large RECENTLY published prospective study has, HOWEVER, FOUND NO EVIDENCE of an association between the maternal Vitamin D status in Pregnancy and late childhood bone Mineral content (average age 10 yrs)[14].']	[('INCOMPLETE_EVIDENCE', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 65), ('INCOMPLETE_EVIDENCE', 74), ('INCOMPLETE_EVIDENCE', 80)]	4	[('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy'), ('CHEBI_46662', 'mineral', 185, 'mineral')]	0	['results has, however, maternal  status  late childhood bone mineral content (average age 10 yrs)[14].']
S42-PMC3760821	PMC3760821	9/2013	S42-PMC3760821	['women with t1dm have an INCREASED RISK of Pregnancy complications including; Miscarriage, congenital malformations, macrosomia, still Birth, pre-term Birth and pre-eclampsia[22], SOME of which HAVE BEEN REPORTED to be ASSOCIATED with Vitamin D deficiency in Pregnancy.']	[('IMPORTANT_CONSIDERATION', 24), ('INCOMPLETE_EVIDENCE', 179), ('INCOMPLETE_EVIDENCE', 193), ('SUPERFICIAL_RELATIONSHIP', 218)]	4	[('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('GO_0046660', 'female sex differentiation', 77, 'miscarriage'), ('GO_0007567', 'parturition', 134, 'birth'), ('GO_0007567', 'parturition', 150, 'birth'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D'), ('GO_0007565', 'female pregnancy', 258, 'pregnancy')]	0	['women t1dm  including; miscarriage, congenital malformations, macrosomia, birth, pre-term birth pre-eclampsia[22],  .']
S108-PMC3760821	PMC3760821	9/2013	S108-PMC3760821	['the results in this table have not been analysed with respect to season and observed differences in t1dm and control women are, THEREFORE, DUE TO differences in season of sampling.10.1371/journal.pone.0074068.t002\n\ncaption (table-wrap): table 2\nVitamin D deficiency and insufficiency of Pregnant women and neonates, split by maternal diabetes, using various cut-off levels.Pregnant womengestation and level of Vitamin D deficiencycontrol groupt1dm groupn%n%≤14 weeks<12.5 nmol/l14.511.8<25 nmol/l1045.5916.4<50 nmol/l1672.74174.5<75 nmol/l2090.95090.9<100 nmol/l22100.05498.2>14<28 weeks<12.5 nmol/l25.011.5<25 nmol/l2152.51929.2<50 nmol/l3485.04670.8<75 nmol/l3997.56193.8<100 nmol/l40100.065100.0≥28 weeks<12.5 nmol/l611.534.8<25 nmol/l2650.02845.2<50 nmol/l4586.55182.3<75 nmol/l5198.162100.0<100 nmol/l52100.062100.0 Pregnant womenneonatal level of Vitamin D deficiencycontrol groupt1dm groupn%n% Cord Blood<12.5 nmol/l832.01628.6<25 nmol/l2392.04478.6<50 nmol/l25100.056100.0\ndata are cumulative n and cumulative %.']	[('PROBABLE_UNDERSTANDING', 128), ('PROBLEM_COMPLICATION', 139)]	2	[('CHEBI_28384', 'vitamin K', 245, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 245, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 287, 'pregnant'), ('GO_0007565', 'female pregnancy', 373, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 410, 'vitamin D'), ('GO_0007565', 'female pregnancy', 821, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 853, 'vitamin D'), ('UBERON_0000948', 'heart', 901, 'Cord'), ('UBERON_0000178', 'blood', 906, 'blood')]	0	['results table respect season t1dm women are, therefore, season sampling.10.1371/journal.pone.0074068.t002\n\ncaption (table-wrap): table 2\nvitamin  women neonates, maternal diabetes, using cut-off levels. womengestation  deficiencycontrol groupt1dm groupn%n%≤14 weeks<12.5 nmol/l14.511.8<25 nmol/l1045.5916.4<50 nmol/l1672.74174.5<75 nmol/l2090.95090.9<100 nmol/l22100.05498.2>14<28 weeks<12.5 nmol/l25.011.5<25 nmol/l2152.51929.2<50 nmol/l3485.04670.8<75 nmol/l3997.56193.8<100 nmol/l40100.065100.0≥28 weeks<12.5 nmol/l611.534.8<25 nmol/l2650.02845.2<50 nmol/l4586.55182.3<75 nmol/l5198.162100.0<100 nmol/l52100.062100.0  womenneonatal  deficiencycontrol groupt1dm groupn%n% cord blood<12.5 nmol/l832.01628.6<25 nmol/l2392.04478.6<50 nmol/l25100.056100.0\ndata cumulative n cumulative %.']
S109-PMC3760821	PMC3760821	9/2013	S109-PMC3760821	['table 2 SHOWS that Vitamin D deficiency, defined as 25Ohd levels <25 nmol/l, was apparent in both the control and the t1dm groups across the entire Pregnancy.']	[('INCOMPLETE_EVIDENCE', 8)]	1	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 52, '25OHD'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy')]	0	['table 2  deficiency, 25ohd levels <25 nmol/l, t1dm entire .']
S155-PMC3760821	PMC3760821	9/2013	S155-PMC3760821	['the FINDINGS of THE CURRENT STUDY that, in women with t1dm, low Vitamin D levels are EVIDENCED throughout Gestation are IN AGREEMENT with PREVIOUS GROUPS who HAVE reported compromised Vitamin D status in Pregnancy[5].']	[('INCOMPLETE_EVIDENCE', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 85), ('INCOMPLETE_EVIDENCE', 120), ('INCOMPLETE_EVIDENCE', 138), ('IMPORTANT_CONSIDERATION', 158)]	6	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'gestation'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy')]	0	['that, women t1dm,  levels throughout   status [5].']
S159-PMC3760821	PMC3760821	9/2013	S159-PMC3760821	['THESE FINDINGS SUPPORT the CONTENTION that measurement of Vitamin D levels prior to, and during Pregnancy, SHOULD BE RECOMMENDED, and that Vitamin D supplementation be initiated when deficiency is CONFIRMED.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 27), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 27), ('FUTURE_WORK', 107), ('FUTURE_WORK', 117), ('INCOMPLETE_EVIDENCE', 197)]	7	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]	0	[' levels to, recommended,  supplementation confirmed.']
S163-PMC3760821	PMC3760821	9/2013	S163-PMC3760821	['department of health GUIDELINES in the uk CURRENTLY RECOMMEND Pregnant women to supplement with 10 µg/day to protect against Vitamin D deficiency[29], but this is DISPUTED by SOME[30].']	[('PROBABLE_UNDERSTANDING', 21), ('INCOMPLETE_EVIDENCE', 42), ('FUTURE_WORK', 52), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 163), ('INCOMPLETE_EVIDENCE', 175)]	5	[('GO_0007565', 'female pregnancy', 62, 'pregnant'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]	0	['department uk  women supplement 10 µg/day  deficiency[29], some[30].']
S164-PMC3760821	PMC3760821	9/2013	S164-PMC3760821	['hollis et al .,[30]ARGUE that supplementation of up to 100 µg/day is more effective at maintaining Vitamin D sufficiency throughout Pregnancy, when compared with 10 and 50 µg/day.']	[('INCOMPLETE_EVIDENCE', 19)]	1	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007565', 'female pregnancy', 132, 'pregnancy')]	0	['hollis et al .,[30]argue supplementation 100 µg/day maintaining  throughout 10 50 µg/day.']
S173-PMC3760821	PMC3760821	9/2013	S173-PMC3760821	['a KEY FINDING of THE CURRENT STUDY is that in t1dm Pregnancy, maternal Vitamin D levels EXHIBIT an INDEPENDENT inverse RELATIONSHIP with hba1clevels.']	[('IMPORTANT_CONSIDERATION', 2), ('INCOMPLETE_EVIDENCE', 6), ('QUESTION_ANSWERED_BY_THIS_WORK', 17), ('ANOMALY_CURIOUS_FINDING', 88), ('SUPERFICIAL_RELATIONSHIP', 99), ('SUPERFICIAL_RELATIONSHIP', 119)]	6	[('GO_0007565', 'female pregnancy', 51, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]	0	['t1dm maternal  levels hba1clevels.']
S181-PMC3760821	PMC3760821	9/2013	S181-PMC3760821	['clearly, prospective clinical randomised controlled trials of Vitamin D supplementation ARE REQUIRED TO evaluate and CLARIFY the ASSOCIATION between Vitamin D status and Glycaemic Control in t1dm Pregnancy.']	[('FUTURE_WORK', 88), ('IMPORTANT_CONSIDERATION', 92), ('QUESTION_ANSWERED_BY_THIS_WORK', 101), ('FUTURE_WORK', 117), ('SUPERFICIAL_RELATIONSHIP', 129)]	5	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0051162', 'L-arabitol metabolic process', 170, 'glycaemic control'), ('GO_0007565', 'female pregnancy', 196, 'pregnancy')]	0	['clearly, randomised  supplementation  status glycaemic t1dm .']
S184-PMC3760821	PMC3760821	9/2013	S184-PMC3760821	['in conclusion, the FINDING that Vitamin D DEPENDENT processes MAY BE negatively IMPACTED by maternal nutritional status and obesity in a t1dm cohort is a significant one and provides FURTHER EVIDENCE that population-based INTERVENTIONS aimed at reducing obesity and improving pre-Pregnancy and Gestational Vitamin D status ARE NEEDED.']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 42), ('INCOMPLETE_EVIDENCE', 62), ('SUPERFICIAL_RELATIONSHIP', 80), ('FUTURE_WORK', 183), ('INCOMPLETE_EVIDENCE', 183), ('FUTURE_WORK', 222), ('FUTURE_WORK', 323)]	8	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 280, 'pregnancy'), ('GO_0007565', 'female pregnancy', 294, 'gestational'), ('CHEBI_27300', 'vitamin D', 306, 'vitamin D')]	0	['conclusion,  processes maternal nutritional status obesity t1dm population-based reducing obesity pre-   status needed.']
S1-PMC3773018	PMC3773018	4/2013	S1-PMC3773018	['the combined ROLE of Prenatal and Postnatal Vitamin D status in the development of Food Sensitization (fs) and Food Allergy REMAINS under-STUDIED.']	[('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 124), ('INCOMPLETE_EVIDENCE', 137)]	3	[('GO_0007565', 'female pregnancy', 21, 'prenatal'), ('GO_0007567', 'parturition', 34, 'postnatal'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_33290', 'food', 83, 'food'), ('GO_0031318', 'detection of folic acid', 83, 'food sensitization'), ('CHEBI_33290', 'food', 111, 'food'), ('GO_0007631', 'feeding behavior', 111, 'food allergy')]	0	['combined  postnatal  status food sensitization (fs) food allergy under-studied.']
S7-PMC3773018	PMC3773018	4/2013	S7-PMC3773018	['conclusions\nPrenatal and early Postnatal Vitamin D levels, along with individual Genetic susceptibility, SHOULD BE CONSIDERED in assessing the ROLE of Vitamin D in the development of fs and Food allergy.']	[('FUTURE_WORK', 105), ('FUTURE_WORK', 115), ('SUPERFICIAL_RELATIONSHIP', 143)]	3	[('GO_0007565', 'female pregnancy', 12, 'Prenatal'), ('GO_0007567', 'parturition', 31, 'postnatal'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('SO_0000704', 'gene', 81, 'genetic'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('CHEBI_33290', 'food', 190, 'food')]	0	['conclusions\n postnatal  levels, along individual genetic susceptibility,  fs food allergy.']
S13-PMC3773018	PMC3773018	4/2013	S13-PMC3773018	['to date, ONLY three birth cohort studies have examined the EFFECT of Prenatal Vitamin D exposure on allergic phenotypes using Cord Blood 25(Oh)D concentrations, an objective measure of Vitamin D status reflecting both dietary intake and sun exposure.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 59)]	2	[('GO_0007565', 'female pregnancy', 69, 'prenatal'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 126, 'cord'), ('UBERON_0000178', 'blood', 131, 'blood'), ('CHEBI_71657', 'versiconol acetate', 137, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 137, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]	0	['date, three birth   exposure allergic phenotypes using cord blood 25(oh)d concentrations, measure  status dietary intake sun exposure.']
S19-PMC3773018	PMC3773018	4/2013	S19-PMC3773018	['HOWEVER, FINDINGS regarding the combined EFFECTS of Prenatal and Postnatal Vitamin D status on fs, two of the most CRITICAL periods for Immune System Development (19,20), are UNCLEAR.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 41), ('IMPORTANT_CONSIDERATION', 115), ('FULL_UNKNOWN', 175)]	5	[('GO_0007565', 'female pregnancy', 52, 'prenatal'), ('GO_0007567', 'parturition', 65, 'postnatal'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0002520', 'immune system development', 136, 'immune system development'), ('UBERON_0002405', 'immune system', 136, 'immune system')]	0	['however, regarding combined  postnatal  status fs, periods immune system (19,20), unclear.']
S54-PMC3773018	PMC3773018	4/2013	S54-PMC3773018	['SIMILAR ASSOCIATION PATTERNS between persistently low Vitamin D and high risk of fs were SEEN among children with 25(Oh)D measurements within 1 year of age and 1–3 years of age; among children Born in winter and non-winter; among children Born Preterm (< 37 weeks of Gestation) and children born term (>= 37 weeks) (data not shown).']	[('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 8), ('SUPERFICIAL_RELATIONSHIP', 20), ('INCOMPLETE_EVIDENCE', 89)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 114, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 114, '25(OH ... D'), ('GO_0007567', 'parturition', 193, 'born'), ('GO_0007567', 'parturition', 239, 'born'), ('GO_0007565', 'female pregnancy', 244, 'preterm'), ('GO_0007565', 'female pregnancy', 267, 'gestation')]	0	['similar  fs among children 25(oh)d measurements year age 1–3 age; among children born winter non-winter; among children born  (< 37 weeks children born term (>= 37 weeks) (data shown).']
S63-PMC3773018	PMC3773018	4/2013	S63-PMC3773018	['OUR FINDINGS SUGGEST that both Prenatal and early Postnatal Vitamin D levels APPEAR TO play an IMPORTANT ROLE in the development of fs, ESPECIALLY among those with specific genotypes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('ANOMALY_CURIOUS_FINDING', 77), ('IMPORTANT_CONSIDERATION', 95), ('SUPERFICIAL_RELATIONSHIP', 105), ('ANOMALY_CURIOUS_FINDING', 136)]	6	[('GO_0007565', 'female pregnancy', 31, 'prenatal'), ('GO_0007567', 'parturition', 50, 'postnatal'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]	0	[' postnatal  levels play fs, among genotypes.']
S82-PMC3773018	PMC3773018	4/2013	S82-PMC3773018	['OF NOTE, OUR FINDINGS from the stratified analyses SUGGESTED stronger ASSOCIATIONS between low Vitamin D status and high RISK of fs among children Born Preterm, which NEEDS to be FURTHER explored in a larger sample.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('INCOMPLETE_EVIDENCE', 51), ('SUPERFICIAL_RELATIONSHIP', 70), ('IMPORTANT_CONSIDERATION', 121), ('IMPORTANT_CONSIDERATION', 167), ('FUTURE_WORK', 179), ('INCOMPLETE_EVIDENCE', 179)]	8	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('GO_0007567', 'parturition', 147, 'born'), ('GO_0007565', 'female pregnancy', 152, 'preterm')]	0	['note, stratified  status fs among children born sample.']
S0-PMC3798907	PMC3798907	8/2013	S0-PMC3798907	['COMPLEX EFFECTS of Vitamin E and vitamin c supplementation on in vitro neonatal Mononuclear Cell responses to allergens\n\nabstract\nlow maternal dietary Vitamin E (but not Vitamin C) Intake during Pregnancy HAS BEEN ASSOCIATED with increased in vitro Cord Blood Mononuclear Cell (Cbmc) proliferative responses, childhood wheezing and asthma.']	[('DIFFICULT_TASK', 0), ('SUPERFICIAL_RELATIONSHIP', 8), ('INCOMPLETE_EVIDENCE', 205), ('SUPERFICIAL_RELATIONSHIP', 214)]	4	[('CHEBI_28384', 'vitamin K', 19, 'Vitamin E'), ('CL_0000842', 'mononuclear cell', 80, 'Mononuclear Cell'), ('GO_0030061', 'mitochondrial crista', 80, 'Mononuclear'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin C'), ('GO_0007631', 'feeding behavior', 181, 'intake'), ('GO_0007565', 'female pregnancy', 195, 'pregnancy'), ('CL_0002153', 'corneocyte', 249, 'cord'), ('UBERON_0002240', 'spinal cord', 249, 'cord'), ('CL_0000081', 'blood cell', 254, 'blood'), ('UBERON_0000178', 'blood', 254, 'blood'), ('CL_0000842', 'mononuclear cell', 260, 'mononuclear cell'), ('GO_0031097', 'medial cortex', 260, 'mononuclear'), ('CL_0002062', 'type I pneumocyte', 278, 'CBMC')]	0	['complex vitamin e vitamin c supplementation neonatal mononuclear cell responses allergens\n\nabstract\nlow maternal dietary  (but intake  cord blood mononuclear cell (cbmc) proliferative responses, childhood wheezing asthma.']
S14-PMC3798907	PMC3798907	8/2013	S14-PMC3798907	['three Birth cohort studies HAVE REPORTED reduced maternal dietary Vitamin E intake during Pregnancy to be ASSOCIATED with an increased LIKELIHOOD of childhood wheezing [9,10] and asthma [11].']	[('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 106), ('PROBABLE_UNDERSTANDING', 135)]	3	[('GO_0007567', 'parturition', 6, 'birth'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin E'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy')]	0	['three birth maternal dietary  intake  childhood wheezing [9,10] asthma [11].']
S15-PMC3798907	PMC3798907	8/2013	S15-PMC3798907	['moreover, two of these cohorts have DEMONSTRATED that low maternal Vitamin E intake during Pregnancy is ASSOCIATED with increased in vitro proliferative responses by Cord Blood Mononuclear Cells (cbmc) and that this ASSOCIATION is independent of the POTENTIALLY CONFOUNDING EFFECTS of Birth order, sex, maternal atopy and maternal smoking [12,13].']	[('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 216), ('INCOMPLETE_EVIDENCE', 250), ('PROBLEM_COMPLICATION', 262), ('SUPERFICIAL_RELATIONSHIP', 274)]	6	[('CHEBI_27300', 'vitamin D', 67, 'vitamin E'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('CL_0000752', 'cone retinal bipolar cell', 166, 'cord blood mononuclear cells'), ('UBERON_0002240', 'spinal cord', 166, 'cord'), ('UBERON_0000178', 'blood', 171, 'blood'), ('GO_0031097', 'medial cortex', 177, 'mononuclear'), ('GO_0007567', 'parturition', 285, 'birth')]	0	['moreover, cohorts maternal  intake  proliferative responses cord blood mononuclear cells (cbmc) birth order, sex, maternal atopy maternal smoking [12,13].']
S16-PMC3798907	PMC3798907	8/2013	S16-PMC3798907	['BASED ON these FINDINGS, there HAVE BEEN CALLS FOR trials of Vitamin E based intervention during Pregnancy [14].']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 0), ('ANOMALY_CURIOUS_FINDING', 6), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 31), ('IMPORTANT_CONSIDERATION', 41), ('IMPORTANT_CONSIDERATION', 41), ('IMPORTANT_CONSIDERATION', 41)]	8	[('CHEBI_27300', 'vitamin D', 61, 'vitamin E'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy')]	0	['based findings,   [14].']
S20-PMC3798907	PMC3798907	8/2013	S20-PMC3798907	['secondly, ALTHOUGH cbmc responses are ASSOCIATED with maternal dietary Vitamin E intake during Pregnancy, there is no association with maternal or Cord Blood Α-Tocopherol [12].']	[('ANOMALY_CURIOUS_FINDING', 10), ('SUPERFICIAL_RELATIONSHIP', 38)]	2	[('CHEBI_27300', 'vitamin D', 71, 'vitamin E'), ('GO_0007565', 'female pregnancy', 95, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 147, 'cord'), ('UBERON_0000178', 'blood', 152, 'blood'), ('CHEBI_27725', 'butin', 158, 'α-tocopherol')]	0	['secondly, cbmc responses maternal dietary  intake maternal cord blood α-tocopherol [12].']
S21-PMC3798907	PMC3798907	8/2013	S21-PMC3798907	['these considerations RAISE the POSSIBILITY that the OBSERVED epidemiological ASSOCIATION between maternal Vitamin E intake during Pregnancy and cbmc responses MAY NOT be a direct ASSOCIATION BUT MERELY a consequence of CONFOUNDING by other Nutrients ASSOCIATED with Vitamin E.\nTO INVESTIGATE these ISSUES further, and to inform any intervention trial, we CONDUCTED an ex vivo study to test WHETHER the OBSERVED epidemiological ASSOCIATION between reduced maternal Vitamin E intake during Pregnancy and increased cbmc responses COULD BE EXPLAINED by a direct causal EFFECT.']	[('EXPLICIT_QUESTION', 21), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 52), ('SUPERFICIAL_RELATIONSHIP', 77), ('INCOMPLETE_EVIDENCE', 159), ('ANOMALY_CURIOUS_FINDING', 163), ('SUPERFICIAL_RELATIONSHIP', 179), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 191), ('ANOMALY_CURIOUS_FINDING', 195), ('ANOMALY_CURIOUS_FINDING', 195), ('PROBLEM_COMPLICATION', 219), ('SUPERFICIAL_RELATIONSHIP', 250), ('QUESTION_ANSWERED_BY_THIS_WORK', 277), ('PROBLEM_COMPLICATION', 298), ('QUESTION_ANSWERED_BY_THIS_WORK', 355), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 390), ('INCOMPLETE_EVIDENCE', 402), ('SUPERFICIAL_RELATIONSHIP', 427), ('INCOMPLETE_EVIDENCE', 527), ('PROBABLE_UNDERSTANDING', 536), ('SUPERFICIAL_RELATIONSHIP', 565)]	21	[('CHEBI_27300', 'vitamin D', 106, 'vitamin E'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_33284', 'nutrient', 240, 'nutrients'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 464, 'vitamin E'), ('GO_0007565', 'female pregnancy', 488, 'pregnancy')]	0	['epidemiological maternal  intake  cbmc responses nutrients .\nto further, trial, ex vivo epidemiological maternal  intake  cbmc responses causal effect.']
S100-PMC3798907	PMC3798907	8/2013	S100-PMC3798907	['discussion\nTHIS STUDY was BASED ON our novel OBSERVATION in a general population study, that low maternal Vitamin E intake during Pregnancy is INDEPENDENTLY ASSOCIATED with increased in vitro Proliferative Responses by cbmc and an increased LIKELIHOOD of asthma in children aged 5 years.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('SUPERFICIAL_RELATIONSHIP', 26), ('ANOMALY_CURIOUS_FINDING', 45), ('SUPERFICIAL_RELATIONSHIP', 143), ('SUPERFICIAL_RELATIONSHIP', 157), ('PROBABLE_UNDERSTANDING', 241)]	6	[('CHEBI_27300', 'vitamin D', 106, 'vitamin E'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('GO_0001780', 'neutrophil homeostasis', 192, 'proliferative responses')]	0	['discussion\nthis population study, maternal  intake  proliferative responses cbmc asthma children aged 5 years.']
S102-PMC3798907	PMC3798907	8/2013	S102-PMC3798907	['before embarking on a Vitamin E intervention study during Pregnancy we wanted TO TEST WHETHER in vitro Vitamin E supplementation COULD Modulate Neonatal Immune Responses, REASONING that the demonstration of a direct EFFECT would justify Vitamin E supplementation, WHEREAS FAILURE to demonstrate a direct EFFECT would justify ALTERNATIVE dietary STRATEGIES to increase Vitamin E intake.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 86), ('INCOMPLETE_EVIDENCE', 129), ('PROBABLE_UNDERSTANDING', 171), ('PROBABLE_UNDERSTANDING', 171), ('SUPERFICIAL_RELATIONSHIP', 216), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 264), ('PROBLEM_COMPLICATION', 272), ('SUPERFICIAL_RELATIONSHIP', 304), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 325), ('FUTURE_WORK', 345)]	11	[('CHEBI_27300', 'vitamin D', 22, 'vitamin E'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin E'), ('GO_0065007', 'biological regulation', 135, 'modulate'), ('GO_0007567', 'parturition', 144, 'neonatal'), ('GO_0006955', 'immune response', 153, 'immune responses'), ('UBERON_0002405', 'immune system', 153, 'immune'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin E')]	0	['embarking    supplementation neonatal immune responses,  supplementation, dietary increase  intake.']
S103-PMC3798907	PMC3798907	8/2013	S103-PMC3798907	['vitamin c was included as a control comparator GIVEN the absence of epidemiological evidence of an ASSOCIATION between Maternal Vitamin C intake during Pregnancy and cbmc responses and childhood asthma [9,10,11].']	[('PROBABLE_UNDERSTANDING', 47), ('SUPERFICIAL_RELATIONSHIP', 99)]	2	[('GO_0007618', 'mating', 119, 'maternal'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin C'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy')]	0	['vitamin c comparator absence epidemiological maternal  intake  cbmc responses childhood asthma [9,10,11].']
S107-PMC3798907	PMC3798907	8/2013	S107-PMC3798907	['this is an IMPORTANT differential result because, together with the between-subject variation and the COMPLEX EFFECTS on Cytokine Production, it INDICATES that the observed in vivo epidemiological ASSOCIATION between maternal Vitamin E intake during Pregnancy and cbmc responses and childhood asthma/wheeze cannot be EXPLAINED by a direct and CONSISTENT EFFECT on overall th-cell responsiveness, as originally HYPOTHESISED [22].']	[('IMPORTANT_CONSIDERATION', 11), ('DIFFICULT_TASK', 102), ('SUPERFICIAL_RELATIONSHIP', 110), ('INCOMPLETE_EVIDENCE', 145), ('SUPERFICIAL_RELATIONSHIP', 197), ('PROBABLE_UNDERSTANDING', 317), ('INCOMPLETE_EVIDENCE', 343), ('SUPERFICIAL_RELATIONSHIP', 354), ('INCOMPLETE_EVIDENCE', 410)]	9	[('GO_0001814', 'negative regulation of antibody-dependent cellular cytotoxicity', 121, 'cytokine production'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin E'), ('GO_0007565', 'female pregnancy', 250, 'pregnancy')]	0	['result because, between-subject cytokine production, vivo epidemiological maternal  intake  cbmc responses childhood asthma/wheeze th-cell responsiveness, [22].']
S109-PMC3798907	PMC3798907	8/2013	S109-PMC3798907	['a further POSSIBILITY raised by THE CURRENT STUDY is that isolated maternal Vitamin E supplementation during Pregnancy MAY have MIXED or EVEN adverse CONSEQUENCES for atopic sensitisation to different Allergens.']	[('INCOMPLETE_EVIDENCE', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 32), ('INCOMPLETE_EVIDENCE', 119), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 128), ('ANOMALY_CURIOUS_FINDING', 137), ('PROBLEM_COMPLICATION', 150)]	6	[('CHEBI_27300', 'vitamin D', 76, 'vitamin E'), ('GO_0007565', 'female pregnancy', 109, 'pregnancy'), ('CHEBI_33663', 'cyclic hydrocarbon', 201, 'allergens')]	0	['maternal  supplementation  atopic sensitisation allergens.']
S121-PMC3798907	PMC3798907	8/2013	S121-PMC3798907	['this study followed on from our observation of an ASSOCIATION between maternal Vitamin E intake during Pregnancy and cbmc proliferative Responses [12].']	[('SUPERFICIAL_RELATIONSHIP', 50)]	1	[('CHEBI_27300', 'vitamin D', 79, 'vitamin E'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0060033', 'anatomical structure regression', 136, 'responses')]	0	['followed maternal  intake  cbmc proliferative responses [12].']
S138-PMC3798907	PMC3798907	8/2013	S138-PMC3798907	['HOWEVER, our original OBSERVATION was between maternal Vitamin E intake and cbmc responses, we FOUND no associations between cbmc responses and maternal (and Cord) Blood Ascorbate Tocopherol at 10 weeks Gestation or at Delivery [12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 22), ('INCOMPLETE_EVIDENCE', 95)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin E'), ('UBERON_0002240', 'spinal cord', 158, 'cord'), ('UBERON_0000178', 'blood', 164, 'blood'), ('CHEBI_22651', 'ascorbate', 170, 'ascorbate'), ('CHEBI_27013', 'tocopherol', 180, 'tocopherol'), ('GO_0007565', 'female pregnancy', 203, 'gestation'), ('GO_0007567', 'parturition', 219, 'delivery')]	0	['however, maternal  intake cbmc responses, cbmc responses maternal (and cord) blood ascorbate tocopherol 10 weeks  delivery [12].']
S0-PMC3809191	PMC3809191	1/2013	S0-PMC3809191	['frequency of Vitamin D deficiency in Pregnant diabetics at baskent university hospital, istanbul\n\nabstract\nobjective: TO FIND out the frequency of Vitamin D deficiency and its RELATION with Glucose parameters and the incidence of Gestational diabetes (gdm).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 118), ('SUPERFICIAL_RELATIONSHIP', 176)]	2	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_17234', 'glucose', 190, 'glucose'), ('GO_0007565', 'female pregnancy', 230, 'gestational')]	0	['frequency vitamin  diabetics baskent university hospital, istanbul\n\nabstract\nobjective: frequency  glucose parameters  diabetes (gdm).']
S18-PMC3809191	PMC3809191	1/2013	S18-PMC3809191	['Pregnant women with history of Pregestational diabetes, multiple Pregnancies, fetal abnormality, chronic Renal or Liver failure and history of Consumption of Calcium supplements or Vitamin D were EXCLUDED from the study.']	[('INCOMPLETE_EVIDENCE', 196)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 31, 'pregestational'), ('GO_0007565', 'female pregnancy', 65, 'pregnancies'), ('UBERON_0002113', 'kidney', 105, 'renal'), ('UBERON_0002107', 'liver', 114, 'liver'), ('GO_0007631', 'feeding behavior', 143, 'consumption'), ('CHEBI_22313', 'alkaline earth metal atom', 158, 'calcium'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]	0	[' women  diabetes, fetal abnormality, chronic renal liver consumption calcium supplements  study.']
S49-PMC3809191	PMC3809191	1/2013	S49-PMC3809191	['Dental problems and muscle cramps were SEEN more frequent in Vitamin D deficient Pregnant women COMPARED TO non-Vitamin D deficient Pregnant women (fig.']	[('INCOMPLETE_EVIDENCE', 39), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 96)]	2	[('UBERON_0001091', 'calcareous tooth', 0, 'Dental'), ('CHEBI_28384', 'vitamin K', 61, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnant'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007565', 'female pregnancy', 132, 'pregnant')]	0	['dental muscle cramps vitamin  women non-  women (fig.']
S53-PMC3809191	PMC3809191	1/2013	S53-PMC3809191	['THIS EVIDENCE is CONSISTENT with low Vitamin D levels in either Pregnant or non-Pregnant Individuals in our country as in the rest of the world.11,12HOWEVER we did not FIND significant association of low levels of Serum 25 (Oh) D with elevated RISK for gdm EVEN after adjustment for conventional risk FACTORS for diabetes.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 17), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 147), ('INCOMPLETE_EVIDENCE', 168), ('IMPORTANT_CONSIDERATION', 244), ('ANOMALY_CURIOUS_FINDING', 257), ('SUPERFICIAL_RELATIONSHIP', 301)]	8	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('NCBITaxon_1', 'root', 89, 'individuals'), ('UBERON_0001977', 'blood serum', 214, 'serum'), ('CHEBI_71657', 'versiconol acetate', 220, '25 (OH) D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 220, '25 (OH) D')]	0	[' levels levels serum 25 (oh) gdm adjustment diabetes.']
S55-PMC3809191	PMC3809191	1/2013	S55-PMC3809191	['in ONE cross-sectional STUDY, Serum 25(Oh) D levels during 24-28 weeks of Gestation were lower in gdm women than in nondiabetic Pregnant women.9in ANOTHER STUDY, maternal Serum 25 (Oh) D concentrations measured at the time of gdm screening test were significantly and inversely ASSOCIATED with fasting glucose, ALTHOUGH the ASSOCIATION of Vitamin D with gdm risk was not statistically significant.8our FINDINGS are also CONSISTENT with a study in an indian population, SHOWING no significant ASSOCIATION between 25 (Oh) D concentrations (at 30 weeks of Gestation) and gdm risk.6\ndeficiency of Vitamin D was shown to be ASSOCIATED with fetal and Brain growth deficiency and type 1 diabetes in children.13significantly reduced risk of type 1 Diabetes Mellitus Development was FOUND when high doses of Vitamin D supplementation (up to 2000 iu/d) were given during infancy in a Birth-cohort study.14\nVitamin D deficiency was also ASSOCIATED with INCREASED risk for Pregnancy complications and SERIOUS health PROBLEMS in the offspring.5,15-17higher risks of Preeclampsia and cesarean section ratios were shown in Pregnants with low levels of Vitamin D.16,17moreover supplementation of Vitamin D HAS BEEN DEMONSTRATED to decrease the RISK of Preeclampsia by 27% in a STUDY.18\n\ncaption (fig): fig.1\n\nthe correlation between Serum Vitamin D and pth levels\n\ncaption (fig): fig.2\n\nSerum Vitamin D levels in veiled and nonveiled Pregnant\n\ncaption (fig): fig.3\n\nVitamin D levels and the frequency of muscle cramps (x²=3.57, p=0.05).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 147), ('SUPERFICIAL_RELATIONSHIP', 278), ('ANOMALY_CURIOUS_FINDING', 311), ('SUPERFICIAL_RELATIONSHIP', 324), ('INCOMPLETE_EVIDENCE', 402), ('INCOMPLETE_EVIDENCE', 420), ('INCOMPLETE_EVIDENCE', 469), ('SUPERFICIAL_RELATIONSHIP', 492), ('SUPERFICIAL_RELATIONSHIP', 619), ('INCOMPLETE_EVIDENCE', 774), ('SUPERFICIAL_RELATIONSHIP', 926), ('IMPORTANT_CONSIDERATION', 942), ('IMPORTANT_CONSIDERATION', 989), ('IMPORTANT_CONSIDERATION', 1004), ('INCOMPLETE_EVIDENCE', 1190), ('IMPORTANT_CONSIDERATION', 1228), ('INCOMPLETE_EVIDENCE', 1261)]	19	[('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_71657', 'versiconol acetate', 36, '25(OH) D'), ('PR_000008838', 'serine protease HTRA1', 36, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 74, 'gestation'), ('GO_0007565', 'female pregnancy', 128, 'pregnant'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_71657', 'versiconol acetate', 177, '25 (OH) D'), ('PR_000009880', 'Lon protease, mitochondrial', 177, '25 ... OH ... D'), ('CHEBI_28384', 'vitamin K', 339, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 339, 'Vitamin'), ('CHEBI_71657', 'versiconol acetate', 512, '25 (OH) D'), ('GO_0007565', 'female pregnancy', 553, 'gestation'), ('CHEBI_27300', 'vitamin D', 593, 'vitamin D'), ('UBERON_0000955', 'brain', 645, 'brain'), ('GO_1903709', 'uterine gland development', 740, 'diabetes mellitus development'), ('CHEBI_27300', 'vitamin D', 799, 'vitamin D'), ('GO_0007567', 'parturition', 874, 'birth'), ('CHEBI_28384', 'vitamin K', 896, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 961, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 1053, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 1108, 'pregnants'), ('CHEBI_28384', 'vitamin K', 1137, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 1180, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 1236, 'preeclampsia'), ('UBERON_0001977', 'blood serum', 1317, 'serum'), ('CHEBI_28384', 'vitamin K', 1323, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1323, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 1371, 'Serum'), ('CHEBI_28384', 'vitamin K', 1377, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1377, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1418, 'pregnant'), ('CHEBI_28384', 'vitamin K', 1450, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1450, 'Vitamin D')]	0	['cross-sectional study, serum 25(oh) levels 24-28 weeks  gdm women nondiabetic  women.9in study, maternal serum 25 (oh) concentrations gdm screening fasting glucose, vitamin gdm statistically significant.8our indian population, 25 (oh) concentrations (at 30 weeks gdm risk.6\ndeficiency  fetal brain type diabetes children.13significantly type diabetes mellitus doses  supplementation (up 2000 iu/d) infancy birth-cohort study.14\nvitamin  offspring.5,15-17higher preeclampsia cesarean section ratios  levels vitamin d.16,17moreover supplementation  decrease preeclampsia 27% study.18\n\ncaption (fig): fig.1\n\nthe serum vitamin pth levels\n\ncaption (fig): fig.2\n\nserum vitamin levels nonveiled \n\ncaption (fig): fig.3\n\nvitamin levels frequency muscle cramps (x²=3.57, p=0.05).']
S60-PMC3809191	PMC3809191	1/2013	S60-PMC3809191	['first, Serum 25 (Oh) D concentrations determined in late trimester MAY not show the status of maternal Vitamin D during the whole Pregnancy Period and HENCE to IDENTIFY the ASSOCIATION of Gdm Development and Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 67), ('PROBABLE_UNDERSTANDING', 151), ('QUESTION_ANSWERED_BY_THIS_WORK', 160), ('SUPERFICIAL_RELATIONSHIP', 173)]	4	[('UBERON_0001977', 'blood serum', 7, 'serum'), ('CHEBI_71657', 'versiconol acetate', 13, '25 (OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 21, 'D'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('UBERON_0018298', 'stylocone', 130, 'pregnancy period'), ('GO_0072147', 'glomerular parietal epithelial cell fate commitment', 188, 'GDM development'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D')]	0	['first, serum 25 (oh) concentrations late trimester status maternal  whole  period gdm  status.']
S64-PMC3809191	PMC3809191	1/2013	S64-PMC3809191	['ALTHOUGH there is NO CONSENSUS for routine Vitamin D screening in Pregnancy, being ALERT about the vitamin\xa0d deficiency and its symptoms and optimising when NECESSARY by replacement and/or through taking lifestyle measures MAY BE RECOMMENDED to prevent the Birth of Vitamin D-deficient infants from Vitamin D-deficient mothers.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 18), ('IMPORTANT_CONSIDERATION', 83), ('IMPORTANT_CONSIDERATION', 157), ('INCOMPLETE_EVIDENCE', 223), ('FUTURE_WORK', 230)]	7	[('CHEBI_28384', 'vitamin K', 43, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy'), ('GO_0007567', 'parturition', 257, 'birth'), ('CHEBI_28384', 'vitamin K', 266, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 266, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D')]	0	['although routine vitamin screening vitamin\xa0d symptoms optimising replacement and/or lifestyle birth vitamin d-deficient infants -deficient mothers.']
S0-PMC3814422	PMC3814422	10/2013	S0-PMC3814422	['maternal 25-Hydroxyvitamin D and its ASSOCIATION with childhood atopic outcomes and Lung function\n\nabstract\n\nbackground\nit HAS BEEN SUGGESTED that maternal Vitamin D status in Pregnancy INFLUENCES the risk of asthma and atopy in the offspring.']	[('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 186)]	3	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 9, '25-hydroxyvitamin D'), ('UBERON_0002048', 'lung', 84, 'lung'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('GO_0007565', 'female pregnancy', 176, 'pregnancy')]	0	['maternal 25-hydroxyvitamin childhood atopic outcomes lung function\n\nabstract\n\nbackground\nit maternal  status  asthma atopy offspring.']
S10-PMC3814422	PMC3814422	10/2013	S10-PMC3814422	['introduction\nVitamin D MAY play an IMPORTANT ROLE in normal fetal Lung and Immune System Development1And there is increasing SPECULATION that maternal Vitamin D status in Pregnancy MIGHT be causally LINKED to the development of asthma and atopy in the offspring.']	[('INCOMPLETE_EVIDENCE', 23), ('IMPORTANT_CONSIDERATION', 35), ('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 125), ('INCOMPLETE_EVIDENCE', 181), ('SUPERFICIAL_RELATIONSHIP', 199)]	6	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('GO_0006266', 'DNA ligation', 66, 'lung ...'), ('UBERON_0002048', 'lung', 66, 'lung'), ('GO_0002415', 'immunoglobulin transcytosis in epithelial cells mediated by polymeric immunoglobulin receptor', 75, 'immune system development1and'), ('UBERON_0002405', 'immune system', 75, 'immune system'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy')]	0	['introduction\nvitamin play normal fetal lung immune system development1and maternal  status  causally asthma atopy offspring.']
S13-PMC3814422	PMC3814422	10/2013	S13-PMC3814422	['studies of maternal dietary Intake have MOSTLY REPORTED inverse RELATIONSHIPS between maternal Vitamin D intake in Pregnancy and early childhood wheeze, asthma, allergic rhinitis and eczema8–10.']	[('INCOMPLETE_EVIDENCE', 40), ('PROBABLE_UNDERSTANDING', 40), ('SUPERFICIAL_RELATIONSHIP', 64)]	3	[('GO_0007631', 'feeding behavior', 28, 'intake'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy')]	0	['studies maternal dietary intake maternal  intake  childhood wheeze, asthma, allergic rhinitis eczema8–10.']
S47-PMC3814422	PMC3814422	10/2013	S47-PMC3814422	['potential confounders and mediators\nwe considered the following as POTENTIAL CONFOUNDERS BECAUSE of their KNOWN or POTENTIAL PLAUSIBLE ASSOCIATION with both maternal concentrations of Vitamin D and with childhood atopic and Lung function outcomes21,22: maternal FACTORS during Pregnancy [smoking, infections, anxiety score, Antibiotic use, Paracetamol use, body mass index (bmi) and Alcohol intake], OTHER maternal factors (educational level, housing tenure, financial difficulties, ethnicity, age, parity, history of asthma, eczema, rhinoconjunctivitis, migraine) and Postnatal FACTORS that MAY reflect a background socio-economic CONFOUNDING pathway originating prior to Birth (breastfeeding, day care, pets, exposure to damp/mould in home, environmental tobacco smoke exposure and number of younger siblings).']	[('INCOMPLETE_EVIDENCE', 67), ('PROBLEM_COMPLICATION', 77), ('PROBLEM_COMPLICATION', 89), ('INCOMPLETE_EVIDENCE', 106), ('INCOMPLETE_EVIDENCE', 115), ('INCOMPLETE_EVIDENCE', 125), ('SUPERFICIAL_RELATIONSHIP', 135), ('SUPERFICIAL_RELATIONSHIP', 262), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 400), ('SUPERFICIAL_RELATIONSHIP', 579), ('INCOMPLETE_EVIDENCE', 592), ('PROBLEM_COMPLICATION', 632)]	12	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0002048', 'lung', 224, 'lung'), ('GO_0007565', 'female pregnancy', 277, 'pregnancy'), ('CHEBI_33282', 'antibacterial agent', 324, 'antibiotic'), ('CHEBI_46195', 'paracetamol', 340, 'paracetamol'), ('CHEBI_30879', 'alcohol', 383, 'alcohol'), ('GO_0007567', 'parturition', 569, 'postnatal'), ('GO_0007567', 'parturition', 673, 'birth')]	0	['potential mediators\nwe following maternal concentrations  childhood atopic lung outcomes21,22: maternal  [smoking, infections, anxiety score, antibiotic use, paracetamol use, mass (bmi) alcohol intake], maternal (educational level, housing tenure, financial difficulties, ethnicity, age, parity, asthma, eczema, rhinoconjunctivitis, migraine) postnatal background socio-economic originating birth (breastfeeding, day care, pets, exposure damp/mould home, environmental tobacco smoke exposure younger siblings).']
S119-PMC3814422	PMC3814422	10/2013	S119-PMC3814422	['furthermore, from a PUBLIC HEALTH perspective Maternal Pregnancy Vitamin D as a risk FACTOR for future offspring atopy or Respiratory health would only be of MAJOR IMPORTANCE IF it was relevant to most of the population and not ONLY those members at the extremes.']	[('IMPORTANT_CONSIDERATION', 20), ('SUPERFICIAL_RELATIONSHIP', 85), ('IMPORTANT_CONSIDERATION', 158), ('IMPORTANT_CONSIDERATION', 164), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 175), ('ANOMALY_CURIOUS_FINDING', 228)]	6	[('GO_0007618', 'mating', 46, 'maternal'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 122, 'respiratory')]	0	['furthermore, maternal   offspring atopy respiratory population members extremes.']
S121-PMC3814422	PMC3814422	10/2013	S121-PMC3814422	['IT IS POSSIBLE that this is a POOR MARKER of Vitamin D levels over Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 30), ('SUPERFICIAL_RELATIONSHIP', 35)]	3	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy')]	0	[' levels .']
S130-PMC3814422	PMC3814422	10/2013	S130-PMC3814422	['ALTHOUGH we COULD NOT directly investigate the ASSOCIATION of maternal 25(Oh)D with Early Life Respiratory infections, the LACK OF ASSOCIATION with transient early wheezing phenotype ARGUES AGAINST a PROTECTIVE EFFECT of Prenatal Vitamin D on Respiratory Viral infections in early childhood.']	[('ANOMALY_CURIOUS_FINDING', 0), ('DIFFICULT_TASK', 12), ('ANOMALY_CURIOUS_FINDING', 18), ('SUPERFICIAL_RELATIONSHIP', 47), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 131), ('INCOMPLETE_EVIDENCE', 183), ('SUPERFICIAL_RELATIONSHIP', 200), ('SUPERFICIAL_RELATIONSHIP', 211)]	9	[('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 71, '25(OH ... D'), ('UBERON_0001847', 'lobule of pinna', 84, 'early life'), ('UBERON_0001004', 'respiratory system', 95, 'respiratory'), ('GO_0007565', 'female pregnancy', 221, 'prenatal'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 243, 'respiratory'), ('NCBITaxon_1', 'root', 255, 'viral')]	0	['although maternal 25(oh)d life respiratory infections, transient wheezing phenotype   respiratory viral infections childhood.']
S132-PMC3814422	PMC3814422	10/2013	S132-PMC3814422	['the MAJORITY of positive findings come from studies of maternal dietary intake of Vitamin D in Pregnancy8–10,28.']	[('PROBABLE_UNDERSTANDING', 4)]	1	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 95, 'pregnancy8')]	0	['positive come maternal dietary intake  –10,28.']
S139-PMC3814422	PMC3814422	10/2013	S139-PMC3814422	['in particular, we have not FOUND EVIDENCE to SUGGEST that higher Prenatal Vitamin D status in Pregnancy PROTECTS against the development of early childhood wheezing or later asthma.']	[('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 45), ('SUPERFICIAL_RELATIONSHIP', 104)]	3	[('GO_0007565', 'female pregnancy', 65, 'prenatal'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy')]	0	['particular, higher   status  childhood wheezing asthma.']
S140-PMC3814422	PMC3814422	10/2013	S140-PMC3814422	['WHILST definitive evidence will ONLY come from randomized trials of Vitamin D supplementation during Pregnancy, which are currently underway (e.g.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 32)]	2	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy')]	0	['whilst come  supplementation (e.g.']
S142-PMC3814422	PMC3814422	10/2013	S142-PMC3814422	['reassuringly, our data also SUGGEST that higher maternal Vitamin D status in Pregnancy is UNLIKELY to increase the risk of atopy in the offspring.']	[('INCOMPLETE_EVIDENCE', 28), ('PROBABLE_UNDERSTANDING', 90)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy')]	0	['reassuringly, higher maternal  status  increase atopy offspring.']
S5-PMC3827489	PMC3827489	10/2013	S5-PMC3827489	['it is RECOMMENDED that all infants, children, and adolescents have a minimum daily intake of 400 iu (10 µg) of Vitamin D. SINCE the vitamin d status of the newborn is highly RELATED to maternal Vitamin D levels, optimal Vitamin D levels in the mother during Pregnancy SHOULD BE maintained.']	[('FUTURE_WORK', 6), ('PROBABLE_UNDERSTANDING', 122), ('SUPERFICIAL_RELATIONSHIP', 174), ('FUTURE_WORK', 268)]	4	[('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('GO_0007565', 'female pregnancy', 258, 'pregnancy')]	0	['infants, children, adolescents minimum daily intake 400 iu (10 µg) . vitamin status newborn maternal  levels,  levels mother  maintained.']
S90-PMC3827489	PMC3827489	10/2013	S90-PMC3827489	['THEREFORE, adequate Vitamin D levels in the mother during Pregnancy promote BETTER bone health in the offspring65).']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 76)]	2	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy')]	0	['therefore,  levels mother  bone offspring65).']
S92-PMC3827489	PMC3827489	10/2013	S92-PMC3827489	['this FINDING MAY BE EXPLAINED BY PREVIOUS STUDIES SUGGESTING that higher Vitamin D levels or appropriate Vitamin D intake in Pregnant women is ASSOCIATED with increased infant Birth weight66,67).']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 13), ('ANOMALY_CURIOUS_FINDING', 17), ('PROBABLE_UNDERSTANDING', 20), ('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 50), ('SUPERFICIAL_RELATIONSHIP', 143)]	7	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnant'), ('GO_0007567', 'parturition', 176, 'birth')]	0	['higher  levels  intake  women infant birth weight66,67).']
S94-PMC3827489	PMC3827489	10/2013	S94-PMC3827489	['there are prospective studies SUGGESTING that higher maternal Vitamin D status during Pregnancy MAY lower the development of wheezing episodes in infancy70,71)or Lower Respiratory Tract infections72).']	[('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 96)]	2	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy'), ('UBERON_0009567', 'nail of pedal digit', 162, 'lower'), ('UBERON_0000065', 'respiratory tract', 168, 'respiratory tract')]	0	['higher maternal  status  wheezing episodes infancy70,71)or respiratory tract infections72).']
S95-PMC3827489	PMC3827489	10/2013	S95-PMC3827489	['ONE STUDY FOUND that higher maternal Vitamin D status during Pregnancy increased the development of atopic dermatitis or asthma in the offspring69), and another FOUND no significant associations between maternal late-Pregnancy Vitamin D status and either asthma or wheezing at the age of 6 years73).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 161)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('GO_0007565', 'female pregnancy', 217, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D')]	0	['one higher maternal  status  atopic dermatitis asthma offspring69), maternal late-  status wheezing age 6 years73).']
S96-PMC3827489	PMC3827489	10/2013	S96-PMC3827489	['IN GENERAL, the OBSERVATIONAL EVIDENCE LINKING low maternal Vitamin D status during Pregnancy to an increase in the risk of allergic diseases in the offspring SEEMS more convincing.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 39), ('ANOMALY_CURIOUS_FINDING', 159)]	5	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy')]	0	['general, maternal  status  increase allergic diseases offspring convincing.']
S98-PMC3827489	PMC3827489	10/2013	S98-PMC3827489	['the daily Vitamin D RECOMMENDATION for women during Pregnancy and Lactation is 600 iu (15 µg) ACCORDING TO the u.s. Food and Drug administration.']	[('FUTURE_WORK', 20), ('INCOMPLETE_EVIDENCE', 94)]	2	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('GO_0007595', 'lactation', 66, 'lactation'), ('CHEBI_33290', 'food', 116, 'Food'), ('CHEBI_23888', 'drug', 125, 'Drug')]	0	['daily  women  lactation 600 iu (15 µg) u.s. food drug administration.']
S99-PMC3827489	PMC3827489	10/2013	S99-PMC3827489	['in 2011, the u.s. Endocrine task force on Vitamin D REPORTED that 600 iu/day MAY not be sufficient to correct Vitamin D deficiency in Pregnant and Lactating women, and THEREFORE SUGGESTED 1,500-2,000 iu/day for Pregnant and Lactating women with Vitamin D deficiency75).']	[('INCOMPLETE_EVIDENCE', 52), ('INCOMPLETE_EVIDENCE', 77), ('PROBABLE_UNDERSTANDING', 168), ('INCOMPLETE_EVIDENCE', 178)]	4	[('GO_0009790', 'embryo development', 18, 'Endocrine'), ('CHEBI_28384', 'vitamin K', 42, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnant'), ('GO_0007594', 'puparial adhesion', 147, 'lactating'), ('GO_0007565', 'female pregnancy', 211, 'pregnant'), ('GO_0007594', 'puparial adhesion', 224, 'lactating'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D')]	0	['2011, u.s. endocrine task force vitamin 600 iu/day   lactating women, 1,500-2,000 iu/day  lactating women  deficiency75).']
S100-PMC3827489	PMC3827489	10/2013	S100-PMC3827489	['it is NOT KNOWN, however, HOW much amount of Vitamin D supplementation is NEEDED for korean children and Pregnant women in order to maintain adequate concentrations of vitamin D. CONSIDERING the high prevalence of Vitamin D insufficiency or deficiency in koreans, ESPECIALLY children and adolscents6,22-24), this ISSUE NEEDS TO BE addressed URGENTLY by FUTURE STUDIES.']	[('FULL_UNKNOWN', 6), ('EXPLICIT_QUESTION', 26), ('IMPORTANT_CONSIDERATION', 74), ('INCOMPLETE_EVIDENCE', 179), ('IMPORTANT_CONSIDERATION', 264), ('PROBLEM_COMPLICATION', 313), ('IMPORTANT_CONSIDERATION', 319), ('IMPORTANT_CONSIDERATION', 341), ('FUTURE_WORK', 353)]	9	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin D')]	0	['known, however, amount  supplementation korean children  women maintain concentrations vitamin d.  koreans, children adolscents6,22-24), studies.']
S115-PMC3855580	PMC3855580	10/2013	S115-PMC3855580	['in the ONLY data from a randomised controlled trial, children of women in nepal who were supplemented with Vitamin A plus Folic Acid from early Gestation had less microalbuminuria and a lower prevalence of Metabolic syndrome at 6–8\xa0years than children of mothers supplemented with Vitamin A alone [29].']	[('INCOMPLETE_EVIDENCE', 7)]	1	[('CHEBI_27300', 'vitamin D', 107, 'vitamin A'), ('CHEBI_30751', 'formic acid', 122, 'folic acid'), ('GO_0007565', 'female pregnancy', 144, 'gestation'), ('GO_0008152', 'metabolic process', 206, 'metabolic'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin A')]	0	['randomised trial, children women nepal supplemented  plus folic acid  microalbuminuria metabolic syndrome 6–8\xa0years children mothers supplemented  [29].']
S0-PMC3873449	PMC3873449	12/2013	S0-PMC3873449	['the high prevalence of Vitamin D deficiency and its RELATED maternal FACTORS in Pregnant women in beijing\n\nabstract\nmaternal Vitamin D deficiency HAS BEEN SUGGESTED to INFLUENCE fetal and neonatal health.']	[('SUPERFICIAL_RELATIONSHIP', 52), ('SUPERFICIAL_RELATIONSHIP', 69), ('INCOMPLETE_EVIDENCE', 146), ('SUPERFICIAL_RELATIONSHIP', 168)]	4	[('CHEBI_28384', 'vitamin K', 23, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]	0	['vitamin maternal  women beijing\n\nabstract\nmaternal  fetal neonatal health.']
S1-PMC3873449	PMC3873449	12/2013	S1-PMC3873449	['LITTLE IS KNOWN about Vitamin D status in chinese Pregnant women.']	[('FULL_UNKNOWN', 0)]	1	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnant')]	0	['little  status chinese  women.']
S2-PMC3873449	PMC3873449	12/2013	S2-PMC3873449	['the PURPOSE of THIS STUDY was TO ASSESS the Vitamin D status of Pregnant women residing in beijing in winter AND EVALUATE the IMPACT of maternal factors on Serum 25-hydroxyvitamin d [25(Oh)D] levels.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('QUESTION_ANSWERED_BY_THIS_WORK', 109), ('SUPERFICIAL_RELATIONSHIP', 126)]	5	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant'), ('UBERON_0001977', 'blood serum', 156, 'serum'), ('CHEBI_71657', 'versiconol acetate', 183, '25(OH)D')]	0	[' status  women residing beijing winter maternal serum 25-hydroxyvitamin [25(oh)d] levels.']
S11-PMC3873449	PMC3873449	12/2013	S11-PMC3873449	['Pregnant women in beijing are at very high RISK of Vitamin D deficiency in winter.']	[('IMPORTANT_CONSIDERATION', 43)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D')]	0	[' women beijing  winter.']
S13-PMC3873449	PMC3873449	12/2013	S13-PMC3873449	['HOWEVER, neither prolonging the time of sunlight exposure nor Multivitamin supplements CAN effectively prevent Pregnant women from Vitamin D deficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 87)]	2	[('CHEBI_7025', 'mupirocin', 62, 'multivitamin'), ('GO_0007565', 'female pregnancy', 111, 'pregnant'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]	0	['however, prolonging sunlight exposure multivitamin supplements  women  deficiency.']
S14-PMC3873449	PMC3873449	12/2013	S14-PMC3873449	['OTHER measures MIGHT have to be taken for Pregnant women to improve their Vitamin D status in winter.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 15)]	2	[('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]	0	[' women  status winter.']
S17-PMC3873449	PMC3873449	12/2013	S17-PMC3873449	['adequate 25(Oh)D levels are particularly IMPORTANT for women who Become Pregnant, BECAUSE mothers HAVE to sustain their own Vitamin D stores as well as those of their fetuses [2,3].']	[('IMPORTANT_CONSIDERATION', 41), ('PROBABLE_UNDERSTANDING', 82), ('IMPORTANT_CONSIDERATION', 98)]	3	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('GO_0007567', 'parturition', 65, 'become'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]	0	['adequate 25(oh)d levels women mothers sustain  stores fetuses [2,3].']
S22-PMC3873449	PMC3873449	12/2013	S22-PMC3873449	['a RECENT STUDY systematically reviews randomized controlled trials and observational studies of maternal Vitamin D status in Pregnancy on the Extraskeletal health of the offspring [7].']	[('INCOMPLETE_EVIDENCE', 2)]	1	[('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy'), ('UBERON_0001431', 'distal carpal bone 2', 142, 'extraskeletal')]	0	['systematically maternal  status  extraskeletal offspring [7].']
S25-PMC3873449	PMC3873449	12/2013	S25-PMC3873449	['there is LITTLE EVIDENCE concerning the ROLE of maternal Vitamin D in Pregnancy in their child Autoimmune diseases.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 40)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('UBERON_0001442', 'skeleton of manus', 95, 'autoimmune')]	0	['maternal   child autoimmune diseases.']
S26-PMC3873449	PMC3873449	12/2013	S26-PMC3873449	['FURTHER INVESTIGATION IS NEEDED in order to confirm the EFFECT of Vitamin D deficiency during Pregnancy on various diseases in childhood.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 8), ('SUPERFICIAL_RELATIONSHIP', 56)]	3	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy')]	0	['  diseases childhood.']
S27-PMC3873449	PMC3873449	12/2013	S27-PMC3873449	['during the past several decades, NUMEROUS STUDIES HAVE REPORTED a high prevalence of Vitamin D deficiency among Pregnant women in countries where women wear concealing clothing such as india [8], saudi arabia [9] and iran [10] and countries in northern latitudes such as the united kingdom [6] and norway [11].']	[('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 50)]	2	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnant')]	0	['decades,  among  women countries women wear concealing clothing india [8], saudi arabia [9] iran [10] countries northern latitudes united kingdom [6] norway [11].']
S29-PMC3873449	PMC3873449	12/2013	S29-PMC3873449	['FEW STUDIES have examined Vitamin D status in chinese Pregnant women.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnant')]	0	[' status chinese  women.']
S34-PMC3873449	PMC3873449	12/2013	S34-PMC3873449	['indeed, in a RECENT small sample size STUDY[12], we FOUND an extremely high prevalence of Vitamin D deficiency (90%) in Pregnant women in beijing in spring.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 52)]	2	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 120, 'pregnant')]	0	['indeed, study[12],  (90%)  women beijing spring.']
S36-PMC3873449	PMC3873449	12/2013	S36-PMC3873449	['also, LITTLE IS KNOWN about maternal FACTORS INFLUENCING Vitamin D status in chinese Pregnant women.']	[('FULL_UNKNOWN', 6), ('SUPERFICIAL_RELATIONSHIP', 37), ('SUPERFICIAL_RELATIONSHIP', 45)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnant')]	0	['also, maternal  status chinese  women.']
S39-PMC3873449	PMC3873449	12/2013	S39-PMC3873449	['there is considerable INTEREST in FACTORS that MAY INFLUENCE Vitamin D status in chinese Pregnant women.']	[('ANOMALY_CURIOUS_FINDING', 22), ('SUPERFICIAL_RELATIONSHIP', 34), ('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 51)]	4	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnant')]	0	[' status chinese  women.']
S41-PMC3873449	PMC3873449	12/2013	S41-PMC3873449	['maternal pre-Pregnant weight and pre-Pregnant body mass index (bmi) are also included SINCE Adipose Tissue HAS BEEN SHOWN to Sequester Vitamin D [14].']	[('PROBABLE_UNDERSTANDING', 86), ('INCOMPLETE_EVIDENCE', 107)]	2	[('GO_0007565', 'female pregnancy', 13, 'pregnant'), ('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('UBERON_0001013', 'adipose tissue', 92, 'adipose tissue'), ('GO_0051235', 'maintenance of location', 125, 'sequester'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D')]	0	['maternal pre- pre- mass (bmi) adipose tissue sequester  [14].']
S42-PMC3873449	PMC3873449	12/2013	S42-PMC3873449	['the PURPOSE of THIS STUDY was TO ASSESS the Vitamin D status in Pregnant women residing in beijing in winter.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 30)]	3	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant')]	0	[' status  women residing beijing winter.']
S44-PMC3873449	PMC3873449	12/2013	S44-PMC3873449	['the results SHOULD provide a BETTER UNDERSTANDING of the maternal FACTORS that INFLUENCE Vitamin D status during Pregnancy and help in raising AWARENESS as well as SUGGESTING STRATEGIES to prevent Vitamin D deficiency in china.']	[('FUTURE_WORK', 12), ('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 66), ('SUPERFICIAL_RELATIONSHIP', 79), ('IMPORTANT_CONSIDERATION', 143), ('FUTURE_WORK', 164), ('INCOMPLETE_EVIDENCE', 164), ('FUTURE_WORK', 175)]	8	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D')]	0	['results maternal  status   china.']
S92-PMC3873449	PMC3873449	12/2013	S92-PMC3873449	['the prevalence of Vitamin D deficiency (25(Oh)D < 50 nmol/l ) was 96.8% and no women had Serum 25(Oh)D concentrations ≥ 75 nmol/l which is CONSIDERED AS an OPTIMAL level.10.1371/journal.pone.0085081.t001\n\ncaption (table-wrap): table 1\nprevalence of Vitamin D deficiency and insufficiency in Pregnant women.25(Oh)D levelsnumber%severe deficiency5644.8(< 25 nmol/l )mild deficiency6552.0(25- < 50 nmol/l)insufficiency43.2(50 - < 75 nmol/l)sufficiency00.0(≥75 nmol/l)total125100.0\n\nmaternal characteristics and Vitamin D status\nmaternal characteristics, stratified by Vitamin D status, are shown intable 2.']	[('IMPORTANT_CONSIDERATION', 139), ('PROBABLE_UNDERSTANDING', 150), ('IMPORTANT_CONSIDERATION', 156)]	3	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 40, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 46, 'D'), ('UBERON_0001977', 'blood serum', 89, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 98, 'OH)D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 306, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 508, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 565, 'vitamin D')]	0	[' (25(oh)d 50 nmol/l 96.8% women serum 25(oh)d concentrations ≥ 75 nmol/l level.10.1371/journal.pone.0085081.t001\n\ncaption (table-wrap): table 1\nprevalence   women.25(oh)d levelsnumber%severe deficiency5644.8(< 25 nmol/l )mild deficiency6552.0(25- 50 nmol/l)insufficiency43.2(50 75 nmol/l)sufficiency00.0(≥75 nmol/l)total125100.0\n\nmaternal characteristics  status\nmaternal characteristics, stratified  status, intable 2.']
S115-PMC3873449	PMC3873449	12/2013	S115-PMC3873449	['discussion\nthe PRESENT STUDY SHOWED a high prevalence of Vitamin D deficiency among Pregnant women in the beijing urban area (39.9 °n), northern china in winter.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('INCOMPLETE_EVIDENCE', 29)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnant')]	0	['discussion\nthe  among  women beijing urban (39.9 °n), northern china winter.']
S118-PMC3873449	PMC3873449	12/2013	S118-PMC3873449	['these STUDIES SUGGEST that Pregnant women in beijing are at very high RISK of Vitamin D deficiency in either winter or spring.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 70)]	3	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]	0	[' women beijing  spring.']
S119-PMC3873449	PMC3873449	12/2013	S119-PMC3873449	['OTHER STUDIES have DEMONSTRATED that Vitamin D deficiency is common in Pregnant women in DIFFERENT countries, such as 31% in southern india [8], 19.5% in greece [20] and 5.7 % in iran [10].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 19), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 89)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnant')]	0	['  women countries, 31% southern india [8], 19.5% greece [20] 5.7 % iran [10].']
S120-PMC3873449	PMC3873449	12/2013	S120-PMC3873449	['ONE STUDY OBSERVED the Vitamin D status in Pregnant women of several ethnic backgrounds who reside in the hague in the netherlands (52° n).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 10)]	2	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'pregnant')]	0	['one  status  women ethnic backgrounds reside hague netherlands (52° n).']
S122-PMC3873449	PMC3873449	12/2013	S122-PMC3873449	['a study from chengdu urban area (30.7°n; southwest china) SHOWED that the prevalence of Vitamin D deficiency was 57.1% in Pregnant women in spring [22].']	[('INCOMPLETE_EVIDENCE', 58)]	1	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnant')]	0	['chengdu urban (30.7°n; southwest china)  57.1%  women spring [22].']
S124-PMC3873449	PMC3873449	12/2013	S124-PMC3873449	['it SEEMS, HOWEVER, that all Pregnant women are at a high RISK of Vitamin D deficiency.']	[('ANOMALY_CURIOUS_FINDING', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 10), ('IMPORTANT_CONSIDERATION', 57)]	3	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]	0	['seems, however,  women  deficiency.']
S130-PMC3873449	PMC3873449	12/2013	S130-PMC3873449	['this SUGGESTS that sun exposure plays a ROLE in maintaining Vitamin D levels in chinese Pregnant women in winter.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 40)]	2	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'pregnant')]	0	['sun exposure plays maintaining  levels chinese  women winter.']
S135-PMC3873449	PMC3873449	12/2013	S135-PMC3873449	['THEREFORE it is NECESSARY to educate People about the knowledge of Vitamin D, ESPECIALLY for Pregnant women.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 16), ('IMPORTANT_CONSIDERATION', 78)]	3	[('NCBITaxon_10088', 'Mus <genus>', 37, 'people'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 93, 'pregnant')]	0	['therefore educate people  women.']
S144-PMC3873449	PMC3873449	12/2013	S144-PMC3873449	['this MAY SUGGEST that the ROLE of sun exposure is LIMITED in elevating Vitamin D concentration in Pregnant women residing in beijing in winter.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 50)]	4	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnant')]	0	['sun exposure elevating  concentration  women residing beijing winter.']
S161-PMC3873449	PMC3873449	12/2013	S161-PMC3873449	['it is NOT SURPRISING that there is a high prevalence of Vitamin D deficiency in Pregnant women residing in beijing in winter.']	[('PROBABLE_UNDERSTANDING', 6)]	1	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant')]	0	['  women residing beijing winter.']
S168-PMC3873449	PMC3873449	12/2013	S168-PMC3873449	['THEREFORE OTHER EFFECTIVE measures MAY NEED to be taken to improve Vitamin D status in chinese Pregnant women.']	[('PROBABLE_UNDERSTANDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 10), ('SUPERFICIAL_RELATIONSHIP', 16), ('INCOMPLETE_EVIDENCE', 35), ('FUTURE_WORK', 39)]	5	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 95, 'pregnant')]	0	['therefore  status chinese  women.']
S172-PMC3873449	PMC3873449	12/2013	S172-PMC3873449	['the Supplements in our study used were most commonly Pregnancy-specific multivitamins, containing relatively low doses of Vitamin D (between 5 and 12·5 μg/d), OBVIOUSLY, which does not effectively alter the outcome of high prevalence of Vitamin D deficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 159)]	1	[('CHEBI_33341', 'titanium atom', 4, 'supplements'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]	0	['supplements -specific multivitamins, containing doses  (between 5 12·5 μg/d), obviously, alter outcome  deficiency.']
S182-PMC3873449	PMC3873449	12/2013	S182-PMC3873449	['HOWEVER, in Pregnant women, a study evaluating Plasma Vitamin D status HAS SHOWN that Vitamin D supplementation of <2000 iu/day is not EFFECTIVE in achieving sufficiency [42].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 71), ('SUPERFICIAL_RELATIONSHIP', 135)]	3	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('UBERON_0001969', 'blood plasma', 47, 'plasma'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D')]	0	['however,  women, plasma  status  supplementation <2000 iu/day achieving [42].']
S183-PMC3873449	PMC3873449	12/2013	S183-PMC3873449	['ANOTHER STUDY SHOWED that Vitamin D supplementation of 4000 iu/day for Pregnant women is MOST EFFECTIVE in achieving sufficiency in all women REGARDLESS OF race [43].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('PROBABLE_UNDERSTANDING', 89), ('SUPERFICIAL_RELATIONSHIP', 94), ('INCOMPLETE_EVIDENCE', 142)]	5	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnant')]	0	['another  supplementation 4000 iu/day  women achieving women race [43].']
S184-PMC3873449	PMC3873449	12/2013	S184-PMC3873449	['in 2011, the us endocrine society endorsed the need for at LEAST 600 iu(15 ug)/ day of Vitamin D supplementation for women during Pregnancy and up to 1500–2000 iu/day to maintain 25(Oh)D Blood levels above 30 ng/ml [16].']	[('PROBABLE_UNDERSTANDING', 59)]	1	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 179, '25(OH)D'), ('UBERON_0000178', 'blood', 187, 'blood')]	0	['2011, us endocrine society 600 iu(15 ug)/ day  supplementation women  1500–2000 iu/day maintain 25(oh)d blood levels 30 ng/ml [16].']
S186-PMC3873449	PMC3873449	12/2013	S186-PMC3873449	['a hundred percent of Pregnant women had Vitamin D insufficiency in OUR STUDY.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 67)]	1	[('GO_0007565', 'female pregnancy', 21, 'pregnant'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]	0	['hundred percent  women  study.']
S187-PMC3873449	PMC3873449	12/2013	S187-PMC3873449	['ON THE BASIS of THESE FINDINGS, it SEEMS logical that Pregnant women SHOULD routinely be supplemented with Vitamin D in china.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('ANOMALY_CURIOUS_FINDING', 35), ('FUTURE_WORK', 69)]	4	[('GO_0007565', 'female pregnancy', 54, 'pregnant'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]	0	['findings,  women routinely supplemented  china.']
S188-PMC3873449	PMC3873449	12/2013	S188-PMC3873449	['HOWEVER, SINCE there is INSUFFICIENT DATA to evaluate the EFFECTIVENESS of Vitamin D supplementation during Pregnancy Vitamin D supplementation as routine Antenatal care is YET TO BE DETERMINED.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBLEM_COMPLICATION', 9), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 58), ('FULL_UNKNOWN', 173)]	5	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007567', 'parturition', 155, 'antenatal')]	0	['however,  supplementation   supplementation routine antenatal determined.']
S189-PMC3873449	PMC3873449	12/2013	S189-PMC3873449	['FURTHER high quality randomized TRIALS ARE REQUIRED to evaluate the SAFETY and effectiveness of Vitamin D supplementation in Pregnancy.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 68)]	2	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy')]	0	[' supplementation .']
S199-PMC3873449	PMC3873449	12/2013	S199-PMC3873449	['it HAS BEEN REPORTED that pre-gravid obese women had significantly lower Serum 25(Oh)D concentrations and dose-DEPENDENT RELATIONS between pre-Pregnancy bmi and maternal Vitamin D status [48].']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 111), ('SUPERFICIAL_RELATIONSHIP', 121)]	3	[('UBERON_0001977', 'blood serum', 73, 'serum'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 79, '25(OH)D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]	0	['pre-gravid obese women serum 25(oh)d concentrations dose-dependent pre- bmi maternal  status [48].']
S210-PMC3873449	PMC3873449	12/2013	S210-PMC3873449	['TO OUR KNOWLEDGE, THIS STUDY is the FIRST to report the INFLUENCE of maternal FACTORS on Vitamin D status in chinese Pregnant women.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 56), ('SUPERFICIAL_RELATIONSHIP', 78)]	5	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnant')]	0	['knowledge, maternal  status chinese  women.']
S211-PMC3873449	PMC3873449	12/2013	S211-PMC3873449	['this design allowed us TO ASSESS the IMPACT of these factors on Vitamin D status in chinese Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('SUPERFICIAL_RELATIONSHIP', 37)]	2	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 92, 'pregnant')]	0	['allowed us  status chinese  women.']
S212-PMC3873449	PMC3873449	12/2013	S212-PMC3873449	['the EFFECT of prolonging the duration of sun exposure on maintaining appropriate Vitamin D levels is LIMITED in Pregnant women residing in beijing in winter.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 101)]	2	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnant')]	0	['prolonging duration sun exposure maintaining  levels  women residing beijing winter.']
S213-PMC3873449	PMC3873449	12/2013	S213-PMC3873449	['IMPORTANTLY, we did have the INFORMATION on multivitamin supplement usage, which allowed us to SHOW that WHILE Pregnancy-specific multivitamin supplements improve the status in women at low risk of severe Vitamin D deficiency, it does not prevent women from Vitamin D deficiency in winter.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 105)]	4	[('GO_0007565', 'female pregnancy', 111, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]	0	['importantly, multivitamin supplement usage, allowed us -specific multivitamin supplements status women  deficiency, women  winter.']
S214-PMC3873449	PMC3873449	12/2013	S214-PMC3873449	['measures MAY HAVE TO BE taken to improve Vitamin D status in Pregnant women in china.']	[('INCOMPLETE_EVIDENCE', 9), ('IMPORTANT_CONSIDERATION', 13)]	2	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 61, 'pregnant')]	0	['measures  status  women china.']
S2-PMC3882256	PMC3882256	1/2014	S2-PMC3882256	['objective\nTO EXAMINE the RELATIONSHIP between Maternal Pregnancy dietary and supplement iron Intake and hemoglobin, with offspring’s Arterial stiffness (measured by Carotid-radial pulse wave velocity), Endothelial function (measured by Brachial Artery flow mediated dilatation), Blood pressure, and adiposity (measured by body mass index), test for mediation by cord ferritin, Birth weight, Gestational age, and child dietary iron intake, and for EFFECT modification by maternal Vitamin C intake and offspring sex.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('SUPERFICIAL_RELATIONSHIP', 25), ('SUPERFICIAL_RELATIONSHIP', 447)]	3	[('GO_0007618', 'mating', 46, 'maternal'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('GO_0007631', 'feeding behavior', 93, 'intake'), ('UBERON_0001637', 'artery', 133, 'arterial'), ('UBERON_0005396', 'carotid artery segment', 165, 'carotid'), ('UBERON_0001986', 'endothelium', 202, 'endothelial'), ('UBERON_0001398', 'brachial artery', 236, 'brachial artery'), ('UBERON_0000178', 'blood', 279, 'blood'), ('GO_0007567', 'parturition', 377, 'birth'), ('GO_0007565', 'female pregnancy', 391, 'gestational'), ('CHEBI_27300', 'vitamin D', 479, 'vitamin C')]	0	['objective\nto maternal  dietary supplement iron intake hemoglobin, offspring’s arterial stiffness (measured carotid-radial pulse wave velocity), endothelial (measured brachial artery flow dilatation), blood pressure, adiposity (measured mass index), cord ferritin, birth weight,  age, child dietary iron intake, maternal  intake offspring sex.']
S25-PMC3882256	PMC3882256	1/2014	S25-PMC3882256	['we EXAMINED WHETHER any observed ASSOCIATIONS were MEDIATED by Cord Blood ferritin levels, Gestational age, offspring’s birthweight, and dietary iron intake and explored WHETHER offspring sex and maternal Vitamin C intake moderate any ASSOCIATIONS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('SUPERFICIAL_RELATIONSHIP', 33), ('SUPERFICIAL_RELATIONSHIP', 51), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('SUPERFICIAL_RELATIONSHIP', 235)]	6	[('UBERON_0002240', 'spinal cord', 63, 'cord'), ('UBERON_0000178', 'blood', 68, 'blood'), ('GO_0007565', 'female pregnancy', 91, 'gestational'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin C')]	0	['cord blood ferritin levels,  age, offspring’s birthweight, dietary iron intake offspring sex maternal  intake associations.']
S86-PMC3882256	PMC3882256	1/2014	S86-PMC3882256	['women with dietary iron intake equal to or more than the uk reference Nutrient intake for iron were more LIKELY to be older, vegetarian, with higher educational qualification, report higher total energy and Vitamin C intake, have lower pre-Pregnancy body mass index, and were less LIKELY to smoke during Pregnancy.10.1371/journal.pone.0084684.t001\n\ncaption (table-wrap): table 1\nstudy sample characteristics (complete cases for exposures, outcomes, confounders and Mediators n\u200a=\u200a2958) and alspac sample characteristics (with dietary iron intake data n\u200a=\u200a12116).complete case samplealspac sample (with dietary data) dietary iron Intake # (mg/day) (m, sd * ) 10.7 (3.2)10.4 (3.4) dietary iron intake <uk rni ## (%, 95% ci ** ) 89.2 (88.0, 90.3)90.3 (89.7, 90.8) dietary iron intake <uk lrni ### (%, 95% ci) 18.0 (16.7, 19.5)25.0 (24.2, 25.8) dietary Vitamin C intake ## (mg/day) (m, sd) 85.9 (34.5)80.1 (35.3) age of mother (yrs) (m, sd) 29.5 (4.2)28.5 (4.8) pre-Pregnancy bmi (kg/m2) (m, sd) 22.8 (3.5)22.9 (3.6) total energy Intake (kj) (m, sd) 7,483 (1,908)7,415 (2,081) smoking in Pregnancy (%, 95% ci ** ) 15.4 (14.1, 16.7)25.2 (24.4, 26.0) caucasian (%, 95% ci) 98.8 (98.4, 99.2)97.5 (97.2, 97.8) university degree (%, 95% ci) 18.6 (17.2, 20.0)13.8 (13.1, 14.4) vegetarian (%, 95% ci) 6.1 (5.3, 7.0)5.2 (4.8, 5.6) primigravida (%, 95% ci) 48.8 (47.0, 50.6)44.8 (43.9, 45.7) early Pregnancy maternal anemia (<11 g/dl) (%, 95% ci) 4.4 (3.7, 5.1)5.1 (4.6, 5.5) report taking Iron supplements before 32 wks Gestation (%, 95% ci) 44.9 (43.1, 46.7)47.5 (46.6, 48.4) child gender (male) (%, 95% ci) 50.8 (49.0, 52.6)51.5 (50.6, 52.4) Birthweight (g) (m, sd) 3,448 (499)3,411 (544) Gestational age (wks) (m, sd) 39.6 (1.6)39.5 (1.8)\n#Food frequency questionnaire at 32 weeks Gestation.']	[('PROBABLE_UNDERSTANDING', 105), ('PROBABLE_UNDERSTANDING', 281)]	2	[('CHEBI_33284', 'nutrient', 70, 'Nutrient'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin C'), ('GO_0007565', 'female pregnancy', 240, 'pregnancy'), ('GO_0007565', 'female pregnancy', 304, 'pregnancy'), ('CHEBI_35222', 'inhibitor', 465, 'mediators'), ('GO_0007631', 'feeding behavior', 628, 'intake'), ('CHEBI_27300', 'vitamin D', 848, 'vitamin C'), ('GO_0007565', 'female pregnancy', 961, 'pregnancy'), ('GO_0007631', 'feeding behavior', 1025, 'intake'), ('GO_0007565', 'female pregnancy', 1083, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1384, 'pregnancy'), ('CHEBI_24870', 'ion', 1476, 'iron'), ('GO_0007565', 'female pregnancy', 1507, 'gestation'), ('GO_0007608', 'sensory perception of smell', 1631, 'Birthweight'), ('GO_0007565', 'female pregnancy', 1678, 'Gestational'), ('CHEBI_33290', 'food', 1730, 'Food'), ('GO_0007565', 'female pregnancy', 1771, 'gestation')]	0	['women dietary iron intake equal uk nutrient intake iron older, vegetarian, higher educational qualification, higher energy  intake, pre- mass index, smoke .10.1371/journal.pone.0084684.t001\n\ncaption (table-wrap): table 1\nstudy sample characteristics (complete cases exposures, outcomes, n\u200a=\u200a2958) alspac sample characteristics (with dietary iron intake n\u200a=\u200a12116).complete samplealspac sample (with dietary data) dietary iron intake # (mg/day) (m, sd * 10.7 (3.2)10.4 (3.4) dietary iron intake <uk rni ## (%, 95% ci ** 89.2 (88.0, 90.3)90.3 (89.7, 90.8) dietary iron intake <uk lrni ### (%, 95% ci) 18.0 (16.7, 19.5)25.0 (24.2, 25.8) dietary  intake ## (mg/day) (m, sd) 85.9 (34.5)80.1 (35.3) age mother (yrs) (m, sd) 29.5 (4.2)28.5 (4.8) pre- bmi (kg/m2) (m, sd) 22.8 (3.5)22.9 (3.6) energy intake (kj) (m, sd) 7,483 (1,908)7,415 (2,081) smoking  (%, 95% ci ** 15.4 (14.1, 16.7)25.2 (24.4, 26.0) caucasian (%, 95% ci) 98.8 (98.4, 99.2)97.5 (97.2, 97.8) university degree (%, 95% ci) 18.6 (17.2, 20.0)13.8 (13.1, 14.4) vegetarian (%, 95% ci) 6.1 (5.3, 7.0)5.2 (4.8, 5.6) primigravida (%, 95% ci) 48.8 (47.0, 50.6)44.8 (43.9, 45.7)  maternal anemia (<11 g/dl) (%, 95% ci) 4.4 (3.7, 5.1)5.1 (4.6, 5.5) iron supplements 32 wks  (%, 95% ci) 44.9 (43.1, 46.7)47.5 (46.6, 48.4) child gender (male) (%, 95% ci) 50.8 (49.0, 52.6)51.5 (50.6, 52.4) birthweight (g) (m, sd) 3,448 (499)3,411 (544)  age (wks) (m, sd) 39.6 (1.6)39.5 (1.8)\n#food frequency questionnaire 32 weeks .']
S108-PMC3882256	PMC3882256	1/2014	S108-PMC3882256	['there was also no association between cord ferritin and either maternal dietary iron intake or hemoglobin.10.1371/journal.pone.0084684.t005\n\ncaption (table-wrap): table 5\nmultivariable linear regression estimates from stratified analyses for associations between Maternal Iron intake and hemoglobin in Pregnancy with offspring vascular indicators and body mass index with testing for EFFECT modification by maternal Vitamin C intake during Pregnancy and child sex (n\u200a=\u200a2958).offspring pulse wavevelocity (m/s)offspring Flow mediateddilatation (%)offspring systolic bloodpressure (mmhg)offspring diastolic bloodpressure (mmhg)offspring body massindex (kg/m2)b#99% ci®p*b#99% ci®p*b#99% ci®p*b#99% ci®p*b#99% ci®p* Maternal Pregnancy dietary iron intake (continuous) (per 10 mg/d) in participants with Vitamin Cintake >50 mg/day0−0.3, 0.30.50.6−0.2, 1.50.5−0.3−2.4, 1.90.70.8−1.1, 2.70.80−.0.7, 0.60.3in participants with Vitamin Cintake ≤50 mg/day0.2−0.7, 1.1−0.3−2.7, 2.1−1.8−7.3, 3.71.2−4.0, 6.41.2−1.1, 3.5males0.2−0.2, 0.60.40.6−0.4, 1.60.20.4−2.3, 3.10.90.9−1.5, 3.20.70.2−0.7, 1.00.4females0−0.4, 0.40.5−0.7, 1.6−0.9−3.8, 2.00.7−1.9, 3.30.1−0.9, 1.0 maternal Pregnancy Iron supplement use in participants with Vitamin cintake >50 mg/day0−0.1, 0.20.20.30, 0.70.1−0.8−1.7, 0.10.9−0.4−1.2, 0.50.90.1−0.2, 0.30.9in participants with Vitamin Cintake ≤50 mg/day0.2−0.1, 0.5−0.3−1.1, 0.6−0.8−2.7, 1.2−0.1−2.0, 1.80−0.8, 0.8males0.1−0.1, 0.20.80.2−0.2, 0.60.9−0.9−2.1, 0.30.7−0.9−1.9, 0.10.06−0.1−0.4, 0.30.5females0.1−0.1, 0.20.3−0.3, 0.7−0.7−1.9, 0.50.2−0.8, 1.30.1−0.3, 0.5 maternal early Pregnancy anemia (<11 g/dl) males0−0.4, 0.40.90.2−0.9, 1.20.3−1.3−4.1, 1.40.80.3−2.1, 2.60.40.4−0.5, 1.20.2females−0.1−0.5, 0.4−0.5−1.7, 0.7−1.0−4.1, 2.1−0.9−3.7, 1.8−0.2−1.2, 0.8\n#adjusting for potential CONFOUNDING characteristics: maternal age, pre-Pregnancy bmi, smoking in Pregnancy, educational qualification (AS a PROXY for socioeconomic status), parity, and maternal total energy intake in the models with dietary iron intake as exposure).']	[('SUPERFICIAL_RELATIONSHIP', 384), ('PROBLEM_COMPLICATION', 1794), ('PROBABLE_UNDERSTANDING', 1905), ('SUPERFICIAL_RELATIONSHIP', 1910)]	4	[('GO_0007618', 'mating', 263, 'maternal'), ('CHEBI_24870', 'ion', 272, 'iron'), ('GO_0007565', 'female pregnancy', 302, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 416, 'vitamin C'), ('GO_0007565', 'female pregnancy', 440, 'pregnancy'), ('GO_0007601', 'visual perception', 519, 'flow'), ('GO_0007618', 'mating', 713, 'Maternal'), ('GO_0007565', 'female pregnancy', 722, 'pregnancy'), ('CHEBI_64167', 'alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp', 800, 'vitamin Cintake'), ('CHEBI_64167', 'alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp', 920, 'vitamin Cintake'), ('GO_0007565', 'female pregnancy', 1164, 'pregnancy'), ('CHEBI_24870', 'ion', 1174, 'iron'), ('CHEBI_33229', 'vitamin (role)', 1215, 'vitamin'), ('CHEBI_64167', 'alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp', 1334, 'vitamin Cintake'), ('GO_0007565', 'female pregnancy', 1589, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1841, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1867, 'pregnancy')]	0	['cord ferritin maternal dietary iron intake hemoglobin.10.1371/journal.pone.0084684.t005\n\ncaption (table-wrap): table 5\nmultivariable linear regression stratified maternal iron intake hemoglobin  offspring vascular mass testing maternal  intake  child sex (n\u200a=\u200a2958).offspring pulse wavevelocity (m/s)offspring flow mediateddilatation (%)offspring systolic bloodpressure (mmhg)offspring diastolic bloodpressure (mmhg)offspring massindex (kg/m2)b#99% ci®p*b#99% ci®p*b#99% ci®p*b#99% ci®p*b#99% ci®p* maternal  dietary iron intake (continuous) (per 10 mg/d) participants vitamin cintake >50 mg/day0−0.3, 0.30.50.6−0.2, 1.50.5−0.3−2.4, 1.90.70.8−1.1, 2.70.80−.0.7, 0.60.3in participants vitamin cintake ≤50 mg/day0.2−0.7, 1.1−0.3−2.7, 2.1−1.8−7.3, 3.71.2−4.0, 6.41.2−1.1, 3.5males0.2−0.2, 0.60.40.6−0.4, 1.60.20.4−2.3, 3.10.90.9−1.5, 3.20.70.2−0.7, 1.00.4females0−0.4, 0.40.5−0.7, 1.6−0.9−3.8, 2.00.7−1.9, 3.30.1−0.9, 1.0 maternal  iron supplement participants vitamin cintake >50 mg/day0−0.1, 0.20.20.30, 0.70.1−0.8−1.7, 0.10.9−0.4−1.2, 0.50.90.1−0.2, 0.30.9in participants vitamin cintake ≤50 mg/day0.2−0.1, 0.5−0.3−1.1, 0.6−0.8−2.7, 1.2−0.1−2.0, 1.80−0.8, 0.8males0.1−0.1, 0.20.80.2−0.2, 0.60.9−0.9−2.1, 0.30.7−0.9−1.9, 0.10.06−0.1−0.4, 0.30.5females0.1−0.1, 0.20.3−0.3, 0.7−0.7−1.9, 0.50.2−0.8, 1.30.1−0.3, 0.5 maternal  anemia (<11 g/dl) males0−0.4, 0.40.90.2−0.9, 1.20.3−1.3−4.1, 1.40.80.3−2.1, 2.60.40.4−0.5, 1.20.2females−0.1−0.5, 0.4−0.5−1.7, 0.7−1.0−4.1, 2.1−0.9−3.7, 1.8−0.2−1.2, 0.8\n#adjusting characteristics: maternal age, pre- bmi, smoking educational qualification (as socioeconomic status), parity, maternal energy intake dietary iron intake exposure).']
S1-PMC3888066	PMC3888066	12/2012	S1-PMC3888066	['in 1995, rothman et al DEMONSTRATED an ASSOCIATION between excessive Vitamin A, >10,000 iu/day, during the first Trimester of Pregnancy and Teratogenic EFFECTS, particularly in the Central Nervous System.']	[('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 39), ('SUPERFICIAL_RELATIONSHIP', 152)]	3	[('CHEBI_27300', 'vitamin D', 69, 'vitamin A'), ('GO_0009294', 'DNA mediated transformation', 113, 'trimester'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('CHEBI_50905', 'teratogenic agent', 140, 'teratogenic'), ('UBERON_0001017', 'central nervous system', 181, 'central nervous system')]	0	['1995, rothman et al excessive >10,000 iu/day, trimester  teratogenic effects, central nervous system.']
S3-PMC3888066	PMC3888066	12/2012	S3-PMC3888066	['THEREFORE, there MAY BE a narrow therapeutic ratio for Vitamin A during Pregnancy that has not PREVIOUSLY been fully appreciated.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 95)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin A'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy')]	0	['therefore, narrow ratio   appreciated.']
S12-PMC3888066	PMC3888066	12/2012	S12-PMC3888066	['this NOTION is BASED ON the KNOWN Teratogenic EFFECTS of Retinoic Acids on the Central Nervous System,1–3the CALCULATED dose of Retinol and Beta Carotene Ingested by the mother during early Pregnancy, and STRONG EVIDENCE that the fetus Metabolizes Beta Carotene to Retinoids and has LIMITED ability to store Beta Carotene in Fat Cells.4–7\nin 1995, rothman et al DEMONSTRATED that high maternal dietary intake of Vitamin A in the form of Retinol, ie, >10,000 iu/day, particularly in the first Trimester, MAY BE ASSOCIATED with Cranial-Neural-Crest Birth defects.8using a smooth regression curve, THIS study of 22,748 Pregnant women and their offspring IDENTIFIED 1 infant in 57 with malformations that COULD BE ATTRIBUTED to the intake of supplements of Preformed Vitamin A at a dose >10,000 iu/day.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 15), ('ANOMALY_CURIOUS_FINDING', 21), ('ANOMALY_CURIOUS_FINDING', 21), ('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 205), ('INCOMPLETE_EVIDENCE', 283), ('INCOMPLETE_EVIDENCE', 362), ('INCOMPLETE_EVIDENCE', 503), ('SUPERFICIAL_RELATIONSHIP', 510), ('QUESTION_ANSWERED_BY_THIS_WORK', 595), ('INCOMPLETE_EVIDENCE', 651), ('INCOMPLETE_EVIDENCE', 701), ('SUPERFICIAL_RELATIONSHIP', 710)]	16	[('CHEBI_50905', 'teratogenic agent', 34, 'teratogenic'), ('CHEBI_26536', 'retinoic acid', 57, 'retinoic acids'), ('UBERON_0001017', 'central nervous system', 79, 'central nervous system'), ('CHEBI_26536', 'retinoic acid', 128, 'retinol'), ('CHEBI_51438', 'D-isoascorbic acid', 140, 'beta carotene'), ('GO_0007631', 'feeding behavior', 154, 'ingested'), ('GO_0007565', 'female pregnancy', 190, 'pregnancy'), ('GO_0008152', 'metabolic process', 236, 'metabolizes'), ('CHEBI_51438', 'D-isoascorbic acid', 248, 'beta carotene'), ('CHEBI_26537', 'retinoid', 265, 'retinoids'), ('CHEBI_51438', 'D-isoascorbic acid', 308, 'beta carotene'), ('CL_0000136', 'fat cell', 325, 'fat cells'), ('CHEBI_27300', 'vitamin D', 412, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 437, 'retinol'), ('GO_0009294', 'DNA mediated transformation', 492, 'trimester'), ('UBERON_0001456', 'face', 526, 'cranial'), ('UBERON_0002342', 'neural crest', 534, 'neural-crest'), ('GO_0007567', 'parturition', 547, 'birth'), ('GO_0007565', 'female pregnancy', 616, 'pregnant'), ('GO_0007565', 'female pregnancy', 753, 'preformed'), ('CHEBI_27300', 'vitamin D', 763, 'vitamin A')]	0	['teratogenic retinoic acids central nervous system,1–3the dose retinol beta carotene ingested mother fetus metabolizes beta carotene retinoids ability store beta carotene fat cells.4–7\nin 1995, rothman et al maternal dietary intake  form retinol, ie, >10,000 iu/day, trimester, cranial-neural-crest birth defects.8using smooth regression curve, 22,748  women offspring infant 57 malformations intake supplements   dose >10,000 iu/day.']
S28-PMC3888066	PMC3888066	12/2012	S28-PMC3888066	['in addition, studying fetal Mice with knock out lesions for Comi and Retinol Binding Protein, kim et al “demonstrate UNEQUIVOCALLY that Beta Carotene CAN serve as an alternative Vitamin A source for the in situ Synthesis Of Retinoids in developing Tissues by the action of cmoi.”4\nthe equation for isomerization with 13-Trans Retinoic Acid as the energy-favored conformation is:isomerase13-cis\u2009Retinoic\u2009Acid↔13-Trans\u2009Retinoic\u2009Acid\nclearly, an increase in the concentration of 13-Trans Retinoic Acid will shift the equilibrium to the left, increasing Production Of Teratogenic 13-Cis Retinoic Acid.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 117), ('INCOMPLETE_EVIDENCE', 150)]	2	[('NCBITaxon_10088', 'Mus <genus>', 28, 'mice'), ('PR_000003266', 'collagen type II alpha chain', 60, 'COMI'), ('CHEBI_26536', 'retinoic acid', 69, 'retinol'), ('PR_000014009', 'regulating synaptic membrane exocytosis protein 1', 69, 'retinol binding protein'), ('CHEBI_51438', 'D-isoascorbic acid', 136, 'beta carotene'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin A'), ('GO_0010198', 'synergid death', 211, 'synthesis of retinoids'), ('CHEBI_26537', 'retinoid', 224, 'retinoids'), ('UBERON_0000479', 'tissue', 248, 'tissues'), ('CHEBI_38356', 'trans-hex-4-enoic acid', 317, '13-trans retinoic acid'), ('CHEBI_26536', 'retinoic acid', 394, 'retinoic acid'), ('CHEBI_38356', 'trans-hex-4-enoic acid', 408, '13-trans retinoic acid'), ('CHEBI_37983', 'sulfur-35 atom', 476, '13-'), ('CHEBI_64330', 'wybutoxosine', 479, 'trans retinoic acid'), ('GO_0007565', 'female pregnancy', 550, 'production of'), ('CHEBI_50905', 'teratogenic agent', 564, 'teratogenic'), ('GO_0006572', 'tyrosine catabolic process', 564, 'teratogenic ... retinoic acid'), ('CHEBI_61206', '2-hexenoic acid', 576, '13-cis retinoic acid')]	0	['addition, fetal mice knock lesions comi retinol binding protein, kim et al “demonstrate beta carotene  situ synthesis retinoids tissues cmoi.”4\nthe equation isomerization 13-trans retinoic acid energy-favored conformation is:isomerase13-cis\u2009retinoic\u2009acid↔13-trans\u2009retinoic\u2009acid\nclearly, increase concentration 13-trans retinoic acid equilibrium left,  teratogenic 13-cis retinoic acid.']
S45-PMC3888066	PMC3888066	12/2012	S45-PMC3888066	['examples of non-fortified Foods that are high in Vitamin A or beta Carotene are listed intable 5.37\n\ncalculation of Vitamin A and beta Carotene intake during Pregnancy\nthe absorption, Metabolism, storage, and Excretion Of Beta Carotene and Retinol in the mother are NOT COMPLETELY UNDERSTOOD; HOWEVER, most investigators agree that consumption of these forms of Vitamin A is RELATED to maternal Serum levels.38–40in ONE STUDY, maternal diet INFLUENCED Cord levels of Beta Carotene, but not Vitamin A.41absorption Of Beta Carotene from raw carrots and a low fat diet is very low compared to carrot juice.42according to current literature, 6 μg of Ingested Beta Carotene convert to 1 Retinol equivalent, or 1 μg Retinol, but ratios have ranged from 3.3:1 to 26:1.43,44\nbased on the discussion above, it MAY BE apparent that Maternal Ingestion of non-Beta Carotene sources of Vitamin A in foods + fortified foods + nutritional supplements would not LIKELY elevate Retinoic Acid levels in the fetus to Teratogenic levels.']	[('INCOMPLETE_EVIDENCE', 266), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 293), ('SUPERFICIAL_RELATIONSHIP', 375), ('INCOMPLETE_EVIDENCE', 416), ('SUPERFICIAL_RELATIONSHIP', 441), ('INCOMPLETE_EVIDENCE', 801), ('PROBABLE_UNDERSTANDING', 946)]	7	[('CHEBI_33290', 'food', 26, 'foods'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin A'), ('CHEBI_23042', 'carotene', 67, 'carotene'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin A'), ('CHEBI_23042', 'carotene', 135, 'carotene'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy'), ('GO_0008152', 'metabolic process', 184, 'metabolism'), ('GO_0007530', 'sex determination', 209, 'excretion of ... carotene'), ('CHEBI_51438', 'D-isoascorbic acid', 222, 'beta carotene'), ('CHEBI_26536', 'retinoic acid', 240, 'retinol'), ('GO_0060033', 'anatomical structure regression', 240, 'retinol'), ('CHEBI_27300', 'vitamin D', 362, 'vitamin A'), ('UBERON_0001977', 'blood serum', 395, 'serum'), ('UBERON_0002240', 'spinal cord', 452, 'cord'), ('CHEBI_51438', 'D-isoascorbic acid', 467, 'beta carotene'), ('CHEBI_27300', 'vitamin D', 490, 'vitamin A'), ('GO_0046311', 'prenylcysteine biosynthetic process', 513, 'of ... carotene'), ('CHEBI_51438', 'D-isoascorbic acid', 516, 'beta carotene'), ('GO_0007631', 'feeding behavior', 646, 'ingested'), ('CHEBI_51438', 'D-isoascorbic acid', 655, 'beta carotene'), ('CHEBI_26536', 'retinoic acid', 682, 'retinol'), ('CHEBI_26536', 'retinoic acid', 710, 'retinol'), ('GO_0007618', 'mating', 822, 'maternal'), ('GO_0007631', 'feeding behavior', 831, 'ingestion'), ('CHEBI_51438', 'D-isoascorbic acid', 848, 'beta carotene'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 961, 'retinoic acid'), ('CHEBI_50905', 'teratogenic agent', 998, 'teratogenic'), ('GO_0031649', 'heat generation', 998, 'teratogenic')]	0	['examples non-fortified foods  beta carotene listed intable 5.37\n\ncalculation  beta carotene intake \nthe absorption, metabolism, storage, excretion beta carotene retinol mother understood; however, consumption forms  maternal serum levels.38–40in study, maternal diet cord levels beta carotene, .41absorption beta carotene raw carrots fat diet carrot juice.42according literature, 6 μg ingested beta carotene convert retinol equivalent, μg retinol, ratios ranged 3.3:1 26:1.43,44\nbased discussion above, maternal ingestion non-beta carotene sources  foods + fortified foods + nutritional supplements elevate retinoic acid levels fetus teratogenic levels.']
S58-PMC3888066	PMC3888066	12/2012	S58-PMC3888066	['this author BELIEVES that AWARENESS and simple monitoring of all POTENTIAL sources of Retinoic Acid during the first Trimester of Pregnancy, including nutritional supplements, dietary Vitamin A from Animal sources, and Beta Carotene, MAY decrease the incidence of Neurodevelopmental disorders.']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 26), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 234)]	4	[('CHEBI_26536', 'retinoic acid', 86, 'retinoic acid'), ('GO_0009294', 'DNA mediated transformation', 117, 'trimester'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin A'), ('NCBITaxon_33208', 'Metazoa', 199, 'animal'), ('CHEBI_86157', 'cadmium sulfate hydrate', 219, 'beta'), ('CHEBI_23042', 'carotene', 224, 'carotene'), ('GO_0007399', 'nervous system development', 264, 'neurodevelopmental')]	0	['author sources retinoic acid trimester nutritional supplements, dietary  animal sources, beta carotene, decrease neurodevelopmental disorders.']
S94-PMC3901983	PMC3901983	1/2013	S94-PMC3901983	['the adequate level of the Vitamin A is NECESSARY especially in the second and third Pregnancy trimesters for normal Fetal Lung Development and Maturation.']	[('IMPORTANT_CONSIDERATION', 39)]	1	[('CHEBI_27300', 'vitamin D', 26, 'vitamin A'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('GO_0007631', 'feeding behavior', 116, 'fetal'), ('GO_0030324', 'lung development', 122, 'lung development'), ('UBERON_0002048', 'lung', 122, 'lung'), ('GO_0007618', 'mating', 143, 'maturation')]	0	[' third  trimesters normal fetal lung maturation.']
S97-PMC3901983	PMC3901983	1/2013	S97-PMC3901983	['it HAS BEEN SUGGESTED that the Vitamin A status of Pregnant women CAN INFLUENCE Vitamin A stores in the fetus Liver [20].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 70)]	3	[('CHEBI_27300', 'vitamin D', 31, 'vitamin A'), ('GO_0007565', 'female pregnancy', 51, 'pregnant'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin A'), ('UBERON_0002107', 'liver', 110, 'liver')]	0	[' status  women  stores fetus liver [20].']
S103-PMC3901983	PMC3901983	1/2013	S103-PMC3901983	['there are no reports now on the NUMBER of Pregnant women presenting this disturbance, BUT it is NOTABLE that Vitamin K has already limited Placental Transfer during normal Pregnancy.']	[('INCOMPLETE_EVIDENCE', 32), ('ANOMALY_CURIOUS_FINDING', 86), ('ANOMALY_CURIOUS_FINDING', 96)]	3	[('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin K'), ('GO_0001966', 'thigmotaxis', 139, 'placental transfer'), ('UBERON_0001987', 'placenta', 139, 'placental'), ('GO_0007565', 'female pregnancy', 172, 'pregnancy')]	0	[' women presenting disturbance,  placental transfer normal .']
S104-PMC3901983	PMC3901983	1/2013	S104-PMC3901983	['the excessive vomiting or fat malabsorbtion, AFFECTING Pregnant women after bariatric surgery, MAY lead to a higher risk of Vitamin K-deficient bleeding disorders of the neonates of these mothers.']	[('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 95)]	2	[('GO_0007565', 'female pregnancy', 55, 'pregnant'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin K')]	0	['excessive vomiting fat malabsorbtion,  women bariatric surgery, higher -deficient bleeding disorders neonates mothers.']
S0-PMC3926113	PMC3926113	1/2014	S0-PMC3926113	['Prenatal Vitamin C deficiency results in DIFFERENTIAL levels of oxidative stress during late Gestation in foetal guinea pig Brains\n\nabstract\nantioxidant defences are comparatively low during Foetal Development making the Brain PARTICULARLY susceptible to oxidative stress during antioxidant deficiencies.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 41), ('ANOMALY_CURIOUS_FINDING', 227)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin C'), ('GO_0007565', 'female pregnancy', 93, 'gestation'), ('UBERON_0000955', 'brain', 124, 'brains'), ('GO_0060324', 'face development', 191, 'foetal development'), ('UBERON_0000955', 'brain', 221, 'brain')]	0	['  results levels oxidative late  foetal guinea pig brains\n\nabstract\nantioxidant defences comparatively foetal brain oxidative antioxidant deficiencies.']
S2-PMC3926113	PMC3926113	1/2014	S2-PMC3926113	['in the PRESENT STUDY, we INVESTIGATED the developmental pattern and EFFECT of vitc deficiency on antioxidants, Vitamin E and Superoxide dismutase (sod), assessed oxidative damage by measuring Malondialdehyde (Mda), Hydroxynonenal (Hne) and Nitrotyrosine (Nt) and analysed Gene and protein Expression of Apoptosis marker Caspase-3 in the guinea pig foetal Brain at two Gestational (gd) time points, gd 45/pre-term and gd 56/near term following either a vitc sufficient (ctrl) or deficient (def) maternal dietary regime.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 7), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('SUPERFICIAL_RELATIONSHIP', 68)]	3	[('CHEBI_27300', 'vitamin D', 111, 'vitamin E'), ('CHEBI_18421', 'superoxide', 125, 'superoxide'), ('CHEBI_16480', 'nitric oxide', 192, 'malondialdehyde'), ('CHEBI_34840', 'methyl methacrylate', 209, 'MDA'), ('CHEBI_5445', 'glyceraldehyde', 215, 'hydroxynonenal'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 231, 'HNE'), ('CHEBI_50654', 'but-2-enoate ester', 240, 'nitrotyrosine'), ('CHEBI_13389', 'NAD', 255, 'NT'), ('SO_0000704', 'gene', 272, 'gene'), ('GO_0010467', 'gene expression', 289, 'expression'), ('GO_0006915', 'apoptotic process', 303, 'apoptosis'), ('PR_000002319', 'catenin beta-1 isoform 1', 320, 'caspase-3'), ('UBERON_0000955', 'brain', 355, 'brain'), ('GO_0007565', 'female pregnancy', 368, 'gestational')]	0	['study, developmental vitc antioxidants,  superoxide dismutase (sod), oxidative measuring malondialdehyde (mda), hydroxynonenal (hne) nitrotyrosine (nt) gene protein expression apoptosis caspase-3 guinea pig foetal brain  (gd) points, gd 45/pre-term gd 56/near term following (def) maternal dietary regime.']
S148-PMC3926113	PMC3926113	1/2014	S148-PMC3926113	['Prenatal vitc deficiency in the guinea pig foetal Brain does not Modulate levels of Vitamin E, nt or Hne Protein modifications or Caspase-3 HOWEVER, increases sod activity as compensation ALTHOUGH this is not adequate to prevent increased Lipid peroxidation at the investigated time points.']	[('ANOMALY_CURIOUS_FINDING', 140), ('ANOMALY_CURIOUS_FINDING', 188)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('UBERON_0000955', 'brain', 50, 'brain'), ('GO_0065007', 'biological regulation', 65, 'modulate'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin E'), ('PR_000008653', 'hepatocyte nuclear factor 1-beta', 101, 'HNE'), ('GO_0000239', 'pachytene', 105, 'protein'), ('PR_000002319', 'catenin beta-1 isoform 1', 130, 'caspase-3'), ('CHEBI_18059', 'lipid', 239, 'lipid')]	0	[' vitc guinea pig foetal brain levels nt hne protein modifications caspase-3 however, sod activity compensation lipid peroxidation points.']
S20-PMC3930526	PMC3930526	2/2014	S20-PMC3930526	['in belgian, it was REPORTED that 74.1% of Pregnant women were Vitamin D deficiency[3].']	[('INCOMPLETE_EVIDENCE', 19)]	1	[('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D')]	0	['belgian, 74.1%  women  deficiency[3].']
S27-PMC3930526	PMC3930526	2/2014	S27-PMC3930526	['it was REPORTED that children of mothers with higher levels of Vitamin C during Pregnancy MAY BE taller and heavier at the age of 6 and 12 months[10].']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 90)]	2	[('CHEBI_27300', 'vitamin D', 63, 'vitamin C'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy')]	0	['children mothers higher levels   taller heavier age 6 12 months[10].']
S28-PMC3930526	PMC3930526	2/2014	S28-PMC3930526	['in another STUDY carried out in indonesia, Vitamin A supplementation among Pregnant women improves child growth at certain periods in the first two years compared with the combined supplementation of zinc and Vitamin A[11].']	[('INCOMPLETE_EVIDENCE', 11)]	1	[('CHEBI_27300', 'vitamin D', 43, 'vitamin A'), ('GO_0007565', 'female pregnancy', 75, 'pregnant'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin A')]	0	['carried indonesia,  supplementation among  women child periods combined supplementation zinc [11].']
S150-PMC3930526	PMC3930526	2/2014	S150-PMC3930526	['Prenatal Selenium[62]and Vitamin A[63]COULD also play a ROLE in Postnatal growth.']	[('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 56)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27568', 'selenium atom', 9, 'selenium'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin A'), ('GO_0007567', 'parturition', 64, 'postnatal')]	0	[' selenium[62]and [63]could play postnatal growth.']
S23-PMC3970319	PMC3970319	5/2013	S23-PMC3970319	['multiple-Micronutrient supplements (mmss) provided in Pregnancy compared with Iron and Folate supplements were marginally ASSOCIATED with lower offspring systolic, BUT NOT diastolic, Blood pressure at 2 y of age in one nepalese study (10) but were unrelated to offspring Blood pressure at 6–8 y in a separate nepalese trial where mmss were compared with Vitamin A supplementation (11).']	[('SUPERFICIAL_RELATIONSHIP', 122), ('ANOMALY_CURIOUS_FINDING', 164)]	2	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 9, 'micronutrient'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('CHEBI_24870', 'ion', 78, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 87, 'folate'), ('UBERON_0000178', 'blood', 183, 'blood'), ('UBERON_0000178', 'blood', 271, 'blood'), ('CHEBI_27300', 'vitamin D', 354, 'vitamin A')]	0	['multiple-micronutrient supplements (mmss)  iron folate supplements marginally offspring systolic, diastolic, blood pressure 2 age (10) offspring blood pressure 6–8 separate nepalese mmss  supplementation (11).']
S36-PMC3973641	PMC3973641	4/2014	S36-PMC3973641	['considering that exposure to suboptimal nutrition during early development LEADS TO a long-term, age-DEPENDENT Metabolic response[26], we INVESTIGATED the EFFECTS of a Vitamin B-deficient diet during Pregnancy or Pregnancy/Lactation in Mice offspring.']	[('SUPERFICIAL_RELATIONSHIP', 75), ('SUPERFICIAL_RELATIONSHIP', 101), ('QUESTION_ANSWERED_BY_THIS_WORK', 138), ('SUPERFICIAL_RELATIONSHIP', 155)]	4	[('GO_0008152', 'metabolic process', 111, 'metabolic'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin B'), ('GO_0007565', 'female pregnancy', 200, 'pregnancy'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy'), ('GO_0007595', 'lactation', 223, 'lactation'), ('NCBITaxon_10088', 'Mus <genus>', 236, 'mice')]	0	['considering exposure nutrition long-term, age-dependent metabolic response[26], -deficient diet  /lactation mice offspring.']
S180-PMC3973641	PMC3973641	4/2014	S180-PMC3973641	['the analysis on these time points allows us to infer the consequences of Vitamin B and Choline deficiency during Pregnancy and Pregnancy/Lactation in the short term (pnd 0, 5 and 28), and POSSIBLE changes that arise or remain even after the introduction of the standard diet (post-weaning) can be observed in the medium and long term, pnd 90 and 210, respectively.']	[('INCOMPLETE_EVIDENCE', 188)]	1	[('CHEBI_27300', 'vitamin D', 73, 'vitamin B'), ('CHEBI_15354', 'choline', 87, 'choline'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('GO_0007595', 'lactation', 137, 'lactation')]	0	['us  choline  /lactation term (pnd 0, 5 28), changes arise introduction diet (post-weaning) medium term, pnd 90 210, respectively.']
S2-PMC3991049	PMC3991049	11/2013	S2-PMC3991049	['the current GUIDELINES for Vitamin D intake during Pregnancy of 200–400 iu has LITTLE scientific SUPPORT and HAS BEEN RECENTLY CHALLENGED.']	[('IMPORTANT_CONSIDERATION', 12), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 79), ('INCOMPLETE_EVIDENCE', 97), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 118), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127)]	7	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy')]	0	[' intake  200–400 iu challenged.']
S3-PMC3991049	PMC3991049	11/2013	S3-PMC3991049	['we CONDUCTED THIS STUDY TO DETERMINE the prevalence of Vitamin D deficiency among Pregnant women and TO EVALUATE the EFFECTIVENESS and level of weekly Oral 50,000 iu of Vitamin D supplementation for the mother and the newborn.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 101), ('SUPERFICIAL_RELATIONSHIP', 117)]	5	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnant'), ('UBERON_0000165', 'mouth', 151, 'oral'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]	0	[' among  women weekly oral 50,000 iu  supplementation mother newborn.']
S15-PMC3991049	PMC3991049	11/2013	S15-PMC3991049	"['[""""conclusion: weekly doses of 50,000 Vitamin D during Pregnancy maintains acceptable Vitamin D level during Pregnancy and the newborn\'s Vitamin D level CORRELATES with the mother\'s levels.""""]']"	[('SUPERFICIAL_RELATIONSHIP', 150)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]	0	"['[""""conclusion: weekly doses 50,0n durincy acceptabn durincy newbornn mother*s levels.""""]']"
S21-PMC3991049	PMC3991049	11/2013	S21-PMC3991049	['a high prevalence of Vitamin D insufficiency was FOUND in Pregnant women in different studies with DIFFERENT ethnic and geographical backgrounds.4–8the average Prenatal Vitamins contain 400 iu of Vitamin D, which PARTIALLY EXPLAINS this high prevalence of Vitamin D insufficiency in Pregnant women.']	[('INCOMPLETE_EVIDENCE', 49), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 99), ('INCOMPLETE_EVIDENCE', 213), ('PROBABLE_UNDERSTANDING', 223)]	4	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnant'), ('GO_0007565', 'female pregnancy', 160, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 169, 'vitamins'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D'), ('GO_0007565', 'female pregnancy', 283, 'pregnant')]	0	['  women different ethnic geographical backgrounds.4–8the average  vitamins contain 400 iu   women.']
S22-PMC3991049	PMC3991049	11/2013	S22-PMC3991049	['Vitamin D supplementation during Pregnancy REMAINS CONTROVERSIAL and the current RECOMMENDED REQUIREMENT for Vitamin D during Pregnancy (200–400 iu/d) has LITTLE scientific SUPPORT.']	[('INCOMPLETE_EVIDENCE', 43), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 51), ('FUTURE_WORK', 81), ('IMPORTANT_CONSIDERATION', 93), ('INCOMPLETE_EVIDENCE', 155), ('INCOMPLETE_EVIDENCE', 173)]	6	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy')]	0	['vitamin supplementation    (200–400 iu/d) scientific support.']
S24-PMC3991049	PMC3991049	11/2013	S24-PMC3991049	"['[""""a RECENT STUDY SHOWED that a daily supplement of 4000 iu of Vitamin D was REQUIRED to sustain normal Metabolism in Pregnancy and this dose was EFFECTIVE and SAFE.9\\nin THIS STUDY we EVALUATED the prevalence of Vitamin D deficiency in Pregnant women and EVALUATED the EFFECT of weekly Oral 50,000 iu of Vitamin D on mothers\' and newborn\'s level of Vitamin D.\\n\\nmethods\\nTHIS is a prospective observational study conducted at a single center at hamad medical corporation in doha, qatar.""""]']"	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 74), ('SUPERFICIAL_RELATIONSHIP', 143), ('IMPORTANT_CONSIDERATION', 157), ('QUESTION_ANSWERED_BY_THIS_WORK', 167), ('QUESTION_ANSWERED_BY_THIS_WORK', 181), ('QUESTION_ANSWERED_BY_THIS_WORK', 252), ('SUPERFICIAL_RELATIONSHIP', 266), ('QUESTION_ANSWERED_BY_THIS_WORK', 366)]	10	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0008152', 'metabolic process', 101, 'metabolism'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('GO_0007565', 'female pregnancy', 233, 'pregnant'), ('UBERON_0000165', 'mouth', 283, 'oral'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 346, 'vitamin D')]	0	"['[""""a daily supplement 4000 iu n sustain normal metabolism ncy dose safe.9\\nin prevalencein deficiencynant women weekly oral 50,000 iuin mothers* newborn*s levelin d.\\n\\nmethods\\nthis single hamad medical corporation doha, qatar.""""]']"
S60-PMC3991049	PMC3991049	11/2013	S60-PMC3991049	['we observed no toxic levels of Vitamin D during the study and non reached levels above (>80\xa0ng/ml) during Pregnancy AS the highest Vitamin D level was 70\xa0ng/ml in Pregnant mothers, and no toxic level reached in their new Born with a highest level of 59\xa0ng/dl.']	[('PROBABLE_UNDERSTANDING', 116)]	1	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnant'), ('GO_0007567', 'parturition', 221, 'born')]	0	['toxic levels  levels (>80\xa0ng/ml)   70\xa0ng/ml  mothers, toxic born 59\xa0ng/dl.']
S63-PMC3991049	PMC3991049	11/2013	S63-PMC3991049	"['[""""newborns\' Vitamin D levels CORRELATED positively with maternal 25-Hydroxyvitamin D (p\\xa0<\\xa00.001).10in a study from china, jing wang et al., reported 57.1% of Pregnant women and 44.2% showed deficiency, and 97.4% of women and 96.1% of neonates SHOWED Vitamin D insufficiency.11\\nbodnar et al.,12REPORTED the prevalence of Vitamin D deficiency and insufficiency in 200 caucasian and 200 african-american Pregnant women and in the Cord Blood samples of their neonates.""""]']"	[('SUPERFICIAL_RELATIONSHIP', 27), ('INCOMPLETE_EVIDENCE', 241), ('INCOMPLETE_EVIDENCE', 289)]	3	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 63, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 156, 'pregnant'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 318, 'vitamin D'), ('GO_0007565', 'female pregnancy', 399, 'pregnant'), ('UBERON_0002240', 'spinal cord', 425, 'cord'), ('UBERON_0000178', 'blood', 430, 'blood')]	0	"['[""""newbornn levels positively maternal 25-hydroxyvitamin (p\\xa0<\\xa00.001).10in china, jing wang et al.,  pregnant women 44.2% deficiency, 97.4% women 96.1% neonatevitamin insufficiency.11\\nbodnar et al.,12reported prev vitamin 200 caucasian 200 africann pregnant women cord blood samples neonates.""""]']"
S68-PMC3991049	PMC3991049	11/2013	S68-PMC3991049	['SEVERAL STUDIES have REPORTED ASSOCIATION between infant size and Vitamin D status.13,14reduced concentration of 25-Hydroxyvitamin D in mothers during late Pregnancy is ASSOCIATED with reduced Whole Body and Lumbar-Spine bone Mineral content in their children at the age of 9 years.15several studies HYPOTHESIZED that low Prenatal and Perinatal Vitamin D concentrations AFFECT the functional characteristics of various Tissues of the body, which leads to greater risk in later Life of multiple sclerosis, cancer, Insulin-dependent diabetes mellitus and schizophrenia.16,17\nthe current RECOMMENDED dose of Vitamin D during Pregnancy DIFFERS in DIFFERENT parts of the world.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 30), ('SUPERFICIAL_RELATIONSHIP', 169), ('INCOMPLETE_EVIDENCE', 300), ('SUPERFICIAL_RELATIONSHIP', 370), ('FUTURE_WORK', 585), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 632), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 643)]	9	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 113, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 156, 'pregnancy'), ('UBERON_0000468', 'multicellular organism', 193, 'whole body'), ('UBERON_0006074', 'lumbar region of vertebral column', 208, 'lumbar-spine'), ('CHEBI_46662', 'mineral', 226, 'mineral'), ('GO_0007565', 'female pregnancy', 322, 'prenatal'), ('GO_0036268', 'swimming', 335, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 335, 'perinatal'), ('CHEBI_27300', 'vitamin D', 345, 'vitamin D'), ('UBERON_0000479', 'tissue', 419, 'tissues'), ('UBERON_0000104', 'life cycle', 477, 'life'), ('PR_000045358', 'insulin family protein', 513, 'insulin'), ('CHEBI_27300', 'vitamin D', 605, 'vitamin D'), ('GO_0007565', 'female pregnancy', 622, 'pregnancy')]	0	['several infant  status.13,14reduced concentration 25-hydroxyvitamin mothers late  whole lumbar-spine bone mineral content children age 9 years.15several  perinatal  concentrations functional characteristics tissues body, life sclerosis, cancer, insulin-dependent diabetes mellitus schizophrenia.16,17\nthe dose   parts world.']
S69-PMC3991049	PMC3991049	11/2013	S69-PMC3991049	['the RECOMMENDED daily intake of Vitamin D is 200 iu/day in the united states, australia, new zealand and canada.18–20in the uk, the daily recommended dose is 400 iu/day.21HISTORICALLY, Vitamin D supplementation during Pregnancy WAS THOUGHT TO be a risk factor for Supravalvular stenosis in infants, which was BASED ON a 1964 case report.22\nDIFFERENT STUDIES SUGGESTED that the daily use 1000 iu,23–272000 iu,284000 iu,29and 6400 iu30would HELP to eliminate Vitamin D insufficiency without apparent toxicity in Pregnant women and their infants.']	[('FUTURE_WORK', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 169), ('INCOMPLETE_EVIDENCE', 228), ('INCOMPLETE_EVIDENCE', 232), ('INCOMPLETE_EVIDENCE', 309), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 340), ('INCOMPLETE_EVIDENCE', 350), ('INCOMPLETE_EVIDENCE', 358), ('FUTURE_WORK', 439)]	9	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D'), ('GO_0007565', 'female pregnancy', 218, 'pregnancy'), ('UBERON_2000442', 'supraneural bone', 264, 'supravalvular'), ('CHEBI_27300', 'vitamin D', 457, 'vitamin D'), ('GO_0007565', 'female pregnancy', 510, 'pregnant')]	0	['daily intake  200 iu/day united states, australia, zealand canada.18–20in uk, daily dose 400 iu/day.21historically,  supplementation  supravalvular stenosis infants, 1964 report.22\ndifferent daily 1000 iu,23–272000 iu,284000 iu,29and 6400 iu30would eliminate  toxicity  women infants.']
S72-PMC3991049	PMC3991049	11/2013	S72-PMC3991049	['hypercalcemia, which is the most WORRYING toxicity, occurs with Vitamin D levels of more than 80 or 100\xa0ng/ml; and in OUR STUDY no one reached this level through out Pregnancy and in newborns with normal levels of calcium IN SPITE of supplementation.']	[('IMPORTANT_CONSIDERATION', 33), ('QUESTION_ANSWERED_BY_THIS_WORK', 118), ('ANOMALY_CURIOUS_FINDING', 222)]	3	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy')]	0	['hypercalcemia, toxicity, occurs  levels 80 100\xa0ng/ml;  newborns normal levels calcium supplementation.']
S74-PMC3991049	PMC3991049	11/2013	S74-PMC3991049	['no adverse effects were observed in these mothers or their infants.33\nOUR STUDY DEMONSTRATED that low Vitamin D level is common in Pregnant mothers in qatar.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 70), ('INCOMPLETE_EVIDENCE', 80), ('QUESTION_ANSWERED_BY_THIS_WORK', 80)]	3	[('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnant')]	0	['mothers infants.33\nour   mothers qatar.']
S80-PMC3991049	PMC3991049	11/2013	S80-PMC3991049	['we NEED rct of Vitamin D supplementation with measurement of 25-Hydroxyvitamin D to determine the baseline status, the level achieved on supplementation with appropriate design to avoid any CONFOUNDER, and TO ASSESS WHAT is the appropriate level of Vitamin D during Pregnancy and in newborns with no complications or toxicity through out.']	[('FUTURE_WORK', 3), ('PROBLEM_COMPLICATION', 190), ('QUESTION_ANSWERED_BY_THIS_WORK', 206), ('EXPLICIT_QUESTION', 216)]	4	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 61, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('GO_0007565', 'female pregnancy', 266, 'pregnancy')]	0	[' supplementation 25-hydroxyvitamin baseline status, achieved supplementation confounder,   newborns toxicity out.']
S81-PMC3991049	PMC3991049	11/2013	S81-PMC3991049	['studies are UNDERWAY in the us to establish Vitamin D REQUIREMENTS during Pregnancy (http://clinicaltrials.gov#r01hd043921).']	[('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 54)]	2	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy')]	0	['studies us   (http://clinicaltrials.gov#r01hd043921).']
S128-PMC3994635	PMC3994635	8/2010	S128-PMC3994635	['the EFFECTS of the Pregnancy Supplement were superimposed on the changes in biochemistry from 20 wk of Pregnancy to 13 wk Postpartum as experienced by both groups of women (ie, significant reductions in Urinary Calcium Excretion and Plasma concentrations of Vitamin D Metabolites plus increases in Plasma concentrations of pth and bone turnover markers) (table 5).']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('GO_0007565', 'female pregnancy', 19, 'pregnancy'), ('CHEBI_16158', 'steroid sulfate', 29, 'supplement'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0007565', 'female pregnancy', 122, 'postpartum'), ('GO_0060073', 'micturition', 203, 'urinary'), ('UBERON_0001088', 'urine', 203, 'urinary'), ('GO_0036161', 'calcitonin secretion', 211, 'calcium excretion'), ('UBERON_0001969', 'blood plasma', 233, 'plasma'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_25212', 'metabolite', 268, 'metabolites'), ('UBERON_0001969', 'blood plasma', 298, 'plasma')]	0	[' supplement superimposed changes biochemistry 20 wk  13 wk  experienced women (ie, reductions urinary calcium excretion plasma concentrations  metabolites plus plasma concentrations pth bone turnover markers) (table 5).']
S22-PMC4018592	PMC4018592	4/2014	S22-PMC4018592	['[17] in a study in nepal, multiple Micronutrient supplementations during Pregnancy did NOT reduce early infant mortality;[18] HOWEVER, it led TO improved folate status and reduced the prevalence of riboflavin, Vitamin B6, Vitamin B12, Folate and Vitamin D deficiencies.']	[('ANOMALY_CURIOUS_FINDING', 87), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 126), ('QUESTION_ANSWERED_BY_THIS_WORK', 142)]	3	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 35, 'micronutrient'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_33237', 'vitamin D4', 210, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 222, 'vitamin B12'), ('CHEBI_30863', '5-azaorotic acid', 235, 'folate'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D')]	0	['[17] nepal, micronutrient supplementations  infant mortality;[18] however, folate status riboflavin, vitamin b6, vitamin b12, folate  deficiencies.']
S6-PMC4034700	PMC4034700	5/2014	S6-PMC4034700	['ALTHOUGH clinical trials on the use of antioxidant Vitamins in Pregnancy proved largely UNSUCCESSFUL, the scope for their use STILL exists GIVEN the beneficial cardioprotective EFFECTS of antioxidant-rich mediterranean diet, periconceptual Vitamin use and the synergistic EFFECT of Vitamin C andl-Arginine.']	[('ANOMALY_CURIOUS_FINDING', 0), ('DIFFICULT_TASK', 88), ('IMPORTANT_CONSIDERATION', 126), ('PROBABLE_UNDERSTANDING', 139), ('SUPERFICIAL_RELATIONSHIP', 177), ('SUPERFICIAL_RELATIONSHIP', 272)]	6	[('CHEBI_33277', 'gamma-tocotrienol', 51, 'vitamins'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy'), ('CHEBI_33229', 'vitamin (role)', 240, 'vitamin'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin C'), ('CHEBI_15511', 'trans-feruloyl-CoA', 296, '-arginine')]	0	['although antioxidant vitamins  unsuccessful, cardioprotective antioxidant-rich mediterranean diet, periconceptual vitamin synergistic  andl-arginine.']
S258-PMC4034700	PMC4034700	5/2014	S258-PMC4034700	['ALTHOUGH clinical trials on the use of antioxidant Vitamins in Pregnancy proved largely UNSUCCESSFUL, the scope for their use STILL exists GIVEN the beneficial cardioprotective EFFECTS of antioxidant-rich mediterranean diet, periconceptual Vitamin use and the synergistic EFFECT of Vitamin C andl-Arginine.']	[('ANOMALY_CURIOUS_FINDING', 0), ('DIFFICULT_TASK', 88), ('IMPORTANT_CONSIDERATION', 126), ('PROBABLE_UNDERSTANDING', 139), ('SUPERFICIAL_RELATIONSHIP', 177), ('SUPERFICIAL_RELATIONSHIP', 272)]	6	[('CHEBI_33277', 'gamma-tocotrienol', 51, 'vitamins'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy'), ('CHEBI_33229', 'vitamin (role)', 240, 'vitamin'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin C'), ('CHEBI_15511', 'trans-feruloyl-CoA', 296, '-arginine')]	0	['although antioxidant vitamins  unsuccessful, cardioprotective antioxidant-rich mediterranean diet, periconceptual vitamin synergistic  andl-arginine.']
S227-PMC4045304	PMC4045304	2/2014	S227-PMC4045304	['the ROLE or ROLES Vitamin D MAY play in development of asd MAY BE resolved by randomized clinical trials of Prenatal Vitamin D supplementation or Vitamin D supplementation of newborns or in early childhood.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('SUPERFICIAL_RELATIONSHIP', 12), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 59)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'prenatal'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D')]	0	[' play asd resolved   supplementation  supplementation newborns childhood.']
S44-PMC4051754	PMC4051754	6/2014	S44-PMC4051754	['the numerical difference between the two groups in Prepartum concentrations of Vitamin A, and partly, Vitamin E, are LIKELY RELATED with the dry matter intake which was higher in of vs. re Prepartum (see[10]for Feed Intake).']	[('PROBABLE_UNDERSTANDING', 117), ('SUPERFICIAL_RELATIONSHIP', 124)]	2	[('GO_0007565', 'female pregnancy', 51, 'prepartum'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin E'), ('GO_0007565', 'female pregnancy', 189, 'prepartum'), ('GO_0007631', 'feeding behavior', 211, 'feed intake')]	0	['numerical  concentrations partly, dry intake higher vs.  (see[10]for feed intake).']
S45-PMC4051754	PMC4051754	6/2014	S45-PMC4051754	['the concentration of Vitamin E TENDED to be lower after +14 days relative to Parturition ( d ) in of vs. re DESPITE the lack of difference in Feed Intake Postpartum[10](figure 1).']	[('SUPERFICIAL_RELATIONSHIP', 31), ('ANOMALY_CURIOUS_FINDING', 108)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin E'), ('GO_0019230', 'proprioception', 77, 'parturition'), ('GO_0007631', 'feeding behavior', 142, 'feed intake'), ('GO_0007565', 'female pregnancy', 154, 'postpartum')]	0	['concentration  +14 days relative parturition vs. feed intake [10](figure 1).']
S10-PMC4072587	PMC4072587	6/2014	S10-PMC4072587	['OUR FINDINGS STRENGTHEN the EVIDENCE for giving Vitamin D supplementation during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 28)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy')]	0	[' supplementation .']
S12-PMC4072587	PMC4072587	6/2014	S12-PMC4072587	['IMPORTANT biological functions involving growth and developmental outcomes HAVE BEEN ATTRIBUTED to Vitamin D, and deficiency during Pregnancy MAY result in IMPORTANT health CONSEQUENCES for both mother and child[3],[4],[5].']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 75), ('SUPERFICIAL_RELATIONSHIP', 85), ('INCOMPLETE_EVIDENCE', 142), ('IMPORTANT_CONSIDERATION', 156), ('IMPORTANT_CONSIDERATION', 173)]	6	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007565', 'female pregnancy', 132, 'pregnancy')]	0	['important biological functions developmental outcomes  result mother child[3],[4],[5].']
S16-PMC4072587	PMC4072587	6/2014	S16-PMC4072587	['ALTHOUGH the current RECOMMENDED dietary intake of Vitamin D during Pregnancy ranges from 600 to 2000 international units (iu) per day[8], a standardised definition of Vitamin D deficiency during Pregnancy REMAINS CONTROVERSIAL[4],[9],[10],[11].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('FUTURE_WORK', 21), ('INCOMPLETE_EVIDENCE', 206), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 214)]	5	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('GO_0007565', 'female pregnancy', 196, 'pregnancy')]	0	['although dietary intake   ranges 600 2000 international units (iu) day[8], standardised definition   controversial[4],[9],[10],[11].']
S18-PMC4072587	PMC4072587	6/2014	S18-PMC4072587	['[12]categorised Vitamin D insufficiency for Pregnancy outcomes AS Serum 25-Ohd concentration less than 75 nmol/l, and for Vitamin D insufficiency for Birth outcomes, AS Serum 25-Ohd concentration less than 37.5 nmol/l[12].']	[('PROBABLE_UNDERSTANDING', 63), ('PROBABLE_UNDERSTANDING', 166)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_72765', 'verruculogen', 72, '25-OHD'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('GO_0007567', 'parturition', 150, 'birth'), ('UBERON_0001977', 'blood serum', 169, 'serum'), ('CHEBI_72765', 'verruculogen', 175, '25-OHD')]	0	['[12]categorised   outcomes serum 25-ohd concentration 75 nmol/l,  birth outcomes, serum 25-ohd concentration 37.5 nmol/l[12].']
S20-PMC4072587	PMC4072587	6/2014	S20-PMC4072587	['adverse maternal and neonatal outcomes HAVE previously BEEN DESCRIBED in ASSOCIATION with Antenatal Vitamin D deficiency, including INCREASED risk of pre-eclampsia, Gestational diabetes, caesarean section, as well as low Birth weight and small for Gestational age infants[15],[16],[17],[18],[19].']	[('INCOMPLETE_EVIDENCE', 39), ('INCOMPLETE_EVIDENCE', 60), ('SUPERFICIAL_RELATIONSHIP', 73), ('IMPORTANT_CONSIDERATION', 132)]	4	[('GO_0007567', 'parturition', 90, 'antenatal'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 165, 'gestational'), ('GO_0007567', 'parturition', 221, 'birth'), ('GO_0007565', 'female pregnancy', 248, 'gestational')]	0	['adverse maternal neonatal outcomes antenatal  deficiency, pre-eclampsia,  diabetes, caesarean section, birth  age infants[15],[16],[17],[18],[19].']
S23-PMC4072587	PMC4072587	6/2014	S23-PMC4072587	['Vitamin D insufficiency in vietnam HAS PREVIOUSLY been REPORTED to be as high as 46%[27],[28],[29], HOWEVER, there is LIMITED DATA on the BURDEN and CONSEQUENCES of Vitamin D deficiency during Pregnancy in this setting[17]and FEW STUDIES have followed Infants past the Neonatal Period.']	[('IMPORTANT_CONSIDERATION', 35), ('INCOMPLETE_EVIDENCE', 39), ('INCOMPLETE_EVIDENCE', 55), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100), ('INCOMPLETE_EVIDENCE', 118), ('IMPORTANT_CONSIDERATION', 138), ('IMPORTANT_CONSIDERATION', 149), ('INCOMPLETE_EVIDENCE', 226)]	8	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy'), ('UBERON_0002397', 'maxilla', 252, 'infants'), ('UBERON_0007221', 'neonate stage', 269, 'neonatal period')]	0	['vitamin vietnam 46%[27],[28],[29], however,   setting[17]and followed infants neonatal period.']
S24-PMC4072587	PMC4072587	6/2014	S24-PMC4072587	['the ROLE of Vitamin D deficiency during Pregnancy on longer term infant outcomes, PARTICULARLY with regard to early Childhood development is UNCLEAR.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('IMPORTANT_CONSIDERATION', 82), ('FULL_UNKNOWN', 141)]	3	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007565', 'female pregnancy', 40, 'pregnancy'), ('UBERON_0013628', 'pollical pad', 116, 'childhood')]	0	['  longer term infant outcomes, regard childhood unclear.']
S77-PMC4072587	PMC4072587	6/2014	S77-PMC4072587	['multivariable linear regression was performed to derive estimates of mean differences (95% confidence intervals (ci)) of the continuous outcome data (developmental composite scores of the infant at 6 months, Gestational age and anthropometric measurements) ASSOCIATED with maternal Vitamin D concentrations at 32 weeks, and multivariable logistic regression was used to assess the ASSOCIATIONS between maternal Vitamin D concentrations and the binary outcomes (Preterm Delivery, low Birth weight, small for Gestational age and infant stunting).']	[('SUPERFICIAL_RELATIONSHIP', 257), ('SUPERFICIAL_RELATIONSHIP', 381)]	2	[('GO_0007565', 'female pregnancy', 208, 'gestational'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('GO_0007565', 'female pregnancy', 461, 'preterm'), ('GO_0007567', 'parturition', 469, 'delivery'), ('GO_0007567', 'parturition', 483, 'birth'), ('GO_0007565', 'female pregnancy', 507, 'gestational')]	0	['multivariable linear regression derive (95% confidence intervals (ci)) continuous outcome (developmental composite scores infant 6 months,  age anthropometric measurements) maternal  concentrations 32 weeks, multivariable logistic regression maternal  concentrations binary outcomes delivery, birth weight,  age infant stunting).']
S89-PMC4072587	PMC4072587	6/2014	S89-PMC4072587	['maternal Vitamin D and Birth outcomes\ntable 3summarizes Birth outcomes RELATED to maternal Vitamin D in late Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 23, 'birth'), ('GO_0007567', 'parturition', 56, 'birth'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'pregnancy')]	0	['maternal  birth outcomes\ntable birth outcomes maternal  late .']
S90-PMC4072587	PMC4072587	6/2014	S90-PMC4072587	['a TREND towards an ASSOCIATION with Preterm Delivery (odds ratio (or) 0.77 per 25 nmol/l increase in Vitamin D concentration, 95% ci 0.57 to 1.05) and small for Gestational age (odds ratio (or) 1.37 per 25 nmol/l increase in Vitamin D concentration, 95% ci 0.98 to 1.91) was observed.']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 19)]	2	[('GO_0007565', 'female pregnancy', 36, 'preterm'), ('GO_0007567', 'parturition', 44, 'delivery'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D')]	0	[' delivery (odds ratio (or) 0.77 25 nmol/l increase  concentration, 95% ci 0.57 1.05)  age (odds ratio (or) 1.37 25 nmol/l increase  concentration, 95% ci 0.98 1.91) observed.']
S91-PMC4072587	PMC4072587	6/2014	S91-PMC4072587	['for the 49.5% of infants with a measurement of Head circumference, there was an inverse RELATIONSHIP between infant Head circumference at Birth and maternal 25-ohd (md of −0.35 cm per 25 nmol/l increase in Vitamin D concentration, 95% ci −0.62 to −0.09).10.1371/journal.pone.0099005.t003\n\ncaption (table-wrap): table 3\nBirth outcomes associated with maternal Serum 25-ohd concentration (nmol/l) at 32 weeks Gestation (unadjusted and adjusted models).unadjusted modeladjusted model 1adjusted model 2birth outcomesmean [sd] or no.']	[('SUPERFICIAL_RELATIONSHIP', 88)]	1	[('UBERON_0000033', 'head', 47, 'head'), ('UBERON_0000033', 'head', 116, 'head'), ('GO_0007567', 'parturition', 138, 'birth'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0007567', 'parturition', 319, 'Birth'), ('UBERON_0001977', 'blood serum', 359, 'serum'), ('GO_0007565', 'female pregnancy', 407, 'gestation')]	0	['49.5% infants head circumference, infant head circumference birth maternal 25-ohd (md −0.35 cm 25 nmol/l increase  concentration, 95% ci −0.62 −0.09).10.1371/journal.pone.0099005.t003\n\ncaption (table-wrap): table 3\nbirth outcomes maternal serum 25-ohd concentration (nmol/l) 32 weeks  (unadjusted adjusted models).unadjusted modeladjusted 1adjusted 2birth outcomesmean [sd] no.']
S99-PMC4072587	PMC4072587	6/2014	S99-PMC4072587	['HOWEVER, lower language composite scores were SEEN in infants Born to women with Vitamin D deficiency (<37.5 nmol/l) compared to those Born to women who were Vitamin D replete (≥75 nmol/l) (md −3.48, 95% ci −5.52 to −1.44) (table 5).10.1371/journal.pone.0099005.t004\n\ncaption (table-wrap): table 4\ndevelopmental composite scores at 6 months of age ASSOCIATED with maternal Serum 25-Ohd concentration (nmol/l) at 32 weeks Gestation.unadjusted modeladjusted model 1adjusted model 2domainmean developmental composite score [sd]mean difference1,2(95% ci)p valuemean difference1,3(95% ci)p valuemean difference1,4(95% ci)p valuecognitive104.5 [10.1]−0.47 (−1.22 to 0.27)0.21−0.39 (−1.19 to 0.40)0.30−0.43 (−1.23 to 0.370.29language97.8 [7.6]−0.02 (−0.58 to 0.55)0.960.04 (−0.51 to 0.59)0.890.08 (−0.47 to 0.63)0.77motor110.9 [13.4]0.03 (−0.97 to 1.03)0.950.25 (−0.71 to 1.21)0.610.05 (−0.92 to 0.64)0.92socio-emotional79.6 [9.8]−0.12 (−0.85 to 0.61)0.75−0.06 (−0.81 to 0.70)0.88−0.14 (−0.92 to 0.64)0.71\nvalues are ESTIMATED mean difference for each outcome associated with a 25 nmol/l increase in Vitamin.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 46), ('SUPERFICIAL_RELATIONSHIP', 348), ('INCOMPLETE_EVIDENCE', 1010)]	5	[('GO_0007567', 'parturition', 62, 'born'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007567', 'parturition', 135, 'born'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('UBERON_0001977', 'blood serum', 373, 'serum'), ('CHEBI_72765', 'verruculogen', 379, '25-OHD'), ('GO_0007565', 'female pregnancy', 421, 'gestation'), ('CHEBI_33229', 'vitamin (role)', 1093, 'vitamin')]	0	['however, language composite scores infants born women  (<37.5 nmol/l) born women  replete (≥75 nmol/l) (md −3.48, 95% ci −5.52 −1.44) (table 5).10.1371/journal.pone.0099005.t004\n\ncaption (table-wrap): table 4\ndevelopmental composite scores 6 months age maternal serum 25-ohd concentration (nmol/l) 32 weeks .unadjusted modeladjusted 1adjusted 2domainmean developmental composite score [sd]mean difference1,2(95% ci)p valuemean difference1,3(95% ci)p valuemean difference1,4(95% ci)p valuecognitive104.5 [10.1]−0.47 (−1.22 0.27)0.21−0.39 (−1.19 0.40)0.30−0.43 (−1.23 0.370.29language97.8 [7.6]−0.02 (−0.58 0.55)0.960.04 (−0.51 0.59)0.890.08 (−0.47 0.63)0.77motor110.9 [13.4]0.03 (−0.97 1.03)0.950.25 (−0.71 1.21)0.610.05 (−0.92 0.64)0.92socio-emotional79.6 [9.8]−0.12 (−0.85 0.61)0.75−0.06 (−0.81 0.70)0.88−0.14 (−0.92 0.64)0.71\nvalues outcome 25 nmol/l increase vitamin.']
S108-PMC4072587	PMC4072587	6/2014	S108-PMC4072587	['maternal Vitamin D and anthropometric measurements at six months of age\nan inverse ASSOCIATION between maternal 25-Ohd and infant length-for-age z scores at 6 months of age was DEMONSTRATED (md −0.09 per 25 nmol/l increase in Vitamin D concentration, 95% ci −0.12 to −0.02) (table 6).10.1371/journal.pone.0099005.t006\n\ncaption (table-wrap): table 6\ninfant anthropometric outcomes at 6 months of age ASSOCIATED with maternal Serum 25-Ohd concentration (nmol/l) at 32 weeks Gestation.unadjusted modeladjusted modelinfant anthropometric outcomesmean [sd] ornumber(%)mean difference1,3or odds ratio2,3(95% ci)p valuemean difference1,4or odds ratio2,4(95% ci)p valuelength (cm)66.0 [2.28]−0.10 (−0.27 to 0.06)10.23−0.11 (−0.26 to 0.05)10.19weight (kg)7.71 [0.98]−0.02 (−0.09 to 0.05)10.61−0.03 (−0.10 to 0.04)10.45head circumference (cm)42.6 [1.43]0.003 (−0.10 to 0.11)10.95−0.01 (−0.10 to 0.11)10.95haz−0.57 [0.91]−0.09 (−0.15 to −0.02)1 0.02 −0.09 (−0.12 to −0.02)1 0.02 stunted55/891 (6.2)0.92 (0.68 to 1.26)20.620.89 (0.59 to 1.32)20.52\nvalues are estimated mean difference for each outcome associated with a 25 nmol/l increase in Vitamin D.\nconcentration (95% confidence interval).']	[('SUPERFICIAL_RELATIONSHIP', 83), ('INCOMPLETE_EVIDENCE', 177), ('SUPERFICIAL_RELATIONSHIP', 399)]	3	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_72765', 'verruculogen', 112, '25-OHD'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('UBERON_0001977', 'blood serum', 424, 'serum'), ('CHEBI_72765', 'verruculogen', 430, '25-OHD'), ('GO_0007565', 'female pregnancy', 472, 'gestation'), ('CHEBI_27300', 'vitamin D', 1130, 'vitamin D')]	0	['maternal  anthropometric measurements six months age\nan maternal 25-ohd infant length-for-age z scores 6 months age (md −0.09 25 nmol/l increase  concentration, 95% ci −0.12 −0.02) (table 6).10.1371/journal.pone.0099005.t006\n\ncaption (table-wrap): table 6\ninfant anthropometric outcomes 6 months age maternal serum 25-ohd concentration (nmol/l) 32 weeks .unadjusted modeladjusted modelinfant anthropometric outcomesmean [sd] ornumber(%)mean difference1,3or ratio2,3(95% ci)p valuemean difference1,4or ratio2,4(95% ci)p valuelength (cm)66.0 [2.28]−0.10 (−0.27 0.06)10.23−0.11 (−0.26 0.05)10.19weight (kg)7.71 [0.98]−0.02 (−0.09 0.05)10.61−0.03 (−0.10 0.04)10.45head circumference (cm)42.6 [1.43]0.003 (−0.10 0.11)10.95−0.01 (−0.10 0.11)10.95haz−0.57 [0.91]−0.09 (−0.15 −0.02)1 0.02 −0.09 (−0.12 −0.02)1 0.02 stunted55/891 (6.2)0.92 (0.68 1.26)20.620.89 (0.59 1.32)20.52\nvalues outcome 25 nmol/l increase .\nconcentration (95% confidence interval).']
S112-PMC4072587	PMC4072587	6/2014	S112-PMC4072587	['discussion\nthese results INDICATE that there is a high prevalence of Vitamin D insufficiency in Pregnant women residing in rural ha nam province, vietnam.']	[('INCOMPLETE_EVIDENCE', 25)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnant')]	0	['discussion\nthese results   women residing rural ha nam province, vietnam.']
S113-PMC4072587	PMC4072587	6/2014	S113-PMC4072587	['OUR FINDINGS SHOW that low Vitamin D levels in late Pregnancy (<37.5 nmol/l) are ASSOCIATED with reduced infant Language Development at six months of age.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 81)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('GO_0060132', 'prolactin secreting cell development', 112, 'language development')]	0	[' levels late  (<37.5 nmol/l) infant language six months age.']
S121-PMC4072587	PMC4072587	6/2014	S121-PMC4072587	['our finding of an ASSOCIATION between maternal Vitamin D and infant Language composite scores, that was ONLY observed when maternal Vitamin D levels fell below 37.5 nmol/l in late Pregnancy, RAISES the POSSIBILITY that there is a threshold EFFECT, and that Language impairment is a feature of more marked Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('ANOMALY_CURIOUS_FINDING', 104), ('INCOMPLETE_EVIDENCE', 104), ('EXPLICIT_QUESTION', 191), ('INCOMPLETE_EVIDENCE', 202), ('SUPERFICIAL_RELATIONSHIP', 240)]	6	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0006266', 'DNA ligation', 68, 'language'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('GO_0007565', 'female pregnancy', 180, 'pregnancy'), ('GO_0006266', 'DNA ligation', 257, 'language'), ('CHEBI_27300', 'vitamin D', 305, 'vitamin D')]	0	['maternal  infant language composite scores, maternal  levels fell 37.5 nmol/l late effect, language impairment marked  deficiency.']
S124-PMC4072587	PMC4072587	6/2014	S124-PMC4072587	['RECENT RESEARCH SUGGESTS that Vitamin D deficiency during Pregnancy or early childhood MAY BE an environmental TRIGGER for autism spectrum disorder in infants Genetically predisposed to autism, EITHER through its EFFECT on Neuronal function and Brain Development, or through Gene interaction and Regulation.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 111), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 194), ('SUPERFICIAL_RELATIONSHIP', 213)]	6	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('SO_0000704', 'gene', 159, 'genetically'), ('CL_0000540', 'neuron', 223, 'neuronal'), ('GO_0007420', 'brain development', 245, 'brain development'), ('UBERON_0000955', 'brain', 245, 'brain'), ('SO_0000704', 'gene', 275, 'gene'), ('GO_0065007', 'biological regulation', 296, 'regulation')]	0	['recent   childhood environmental autism spectrum disorder infants genetically autism, neuronal brain development, gene regulation.']
S128-PMC4072587	PMC4072587	6/2014	S128-PMC4072587	['PREVIOUS authors have SUGGESTED that accelerated growth in length MAY occur during an infant’s first year of Life in infants Born to mothers with Vitamin D <30 nmol/l, as infant Vitamin D levels increase Postnatally, through post-Natal Vitamin D supplementation[5].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 66)]	3	[('UBERON_0000104', 'life cycle', 109, 'life'), ('GO_0007567', 'parturition', 125, 'born'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'postnatally'), ('GO_0007567', 'parturition', 230, 'natal'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D')]	0	['previous authors accelerated length occur infant’s year life infants born mothers  <30 nmol/l, infant  levels increase post-natal  supplementation[5].']
S130-PMC4072587	PMC4072587	6/2014	S130-PMC4072587	['we FOUND increasing maternal Vitamin D concentration SHOWED a TREND towards a reduced RISK of Preterm Delivery.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 62), ('IMPORTANT_CONSIDERATION', 86)]	4	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'preterm'), ('GO_0007567', 'parturition', 102, 'delivery')]	0	['maternal  concentration  delivery.']
S131-PMC4072587	PMC4072587	6/2014	S131-PMC4072587	['a positive ASSOCIATION between maternal Vitamin D concentration and Gestational duration has PREVIOUSLY been DESCRIBED[41],[42], and morley et al.']	[('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 93), ('INCOMPLETE_EVIDENCE', 109)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'gestational')]	0	['positive maternal  concentration  duration described[41],[42], morley et al.']
S133-PMC4072587	PMC4072587	6/2014	S133-PMC4072587	['a pooled analyses of two PREVIOUS STUDIES[17]SHOWED no significant link between Vitamin D supplementation and Preterm Delivery, however the two studies had SMALL sample sizes (350 and 180 participants)[4],[44], with relatively large loss to follow up (30%).']	[('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 156)]	3	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'preterm'), ('GO_0007567', 'parturition', 118, 'delivery')]	0	['pooled studies[17]showed  supplementation  delivery, sizes (350 180 participants)[4],[44], loss (30%).']
S137-PMC4072587	PMC4072587	6/2014	S137-PMC4072587	['this is IN KEEPING WITH a cochrane review of data from three trials SHOWING that Vitamin D supplementation during Pregnancy did not affect Birth weight or Birth length[13].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 68)]	2	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('GO_0007567', 'parturition', 139, 'birth'), ('GO_0007567', 'parturition', 155, 'birth')]	0	['keeping cochrane three  supplementation  birth birth length[13].']
S144-PMC4072587	PMC4072587	6/2014	S144-PMC4072587	['there are no standardised definitions for Vitamin D thresholds in Pregnancy (deficiency, insufficiency and sufficiency), HOWEVER a RECENT meta-analysis defined insufficiency for Pregnancy outcomes as less than 75 vnmol/l, and insufficiency for Birth variables as less than 37.5 nmol/l[12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 121), ('INCOMPLETE_EVIDENCE', 131)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('GO_0007567', 'parturition', 244, 'birth')]	0	['standardised definitions   (deficiency, sufficiency), meta-analysis  outcomes 75 vnmol/l, birth 37.5 nmol/l[12].']
S148-PMC4072587	PMC4072587	6/2014	S148-PMC4072587	['SOME authors have also SUGGESTED that the cut off for sufficient Vitamin D levels during Pregnancy SHOULD BE as high as 100–150 nmo/l[10],[11], and THEREFORE the PROBLEM of Vitamin D deficiency in vietnam and OTHER south east asian countries MAY BE EVEN more widespread than PREVIOUSLY THOUGHT.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 23), ('FUTURE_WORK', 99), ('PROBABLE_UNDERSTANDING', 148), ('IMPORTANT_CONSIDERATION', 162), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 209), ('INCOMPLETE_EVIDENCE', 242), ('ANOMALY_CURIOUS_FINDING', 249), ('INCOMPLETE_EVIDENCE', 275), ('INCOMPLETE_EVIDENCE', 286)]	10	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D')]	0	['authors cut  levels  100–150 nmo/l[10],[11],  vietnam south east asian countries thought.']
S155-PMC4072587	PMC4072587	6/2014	S155-PMC4072587	['conclusions\nOUR STUDY INDICATES that low levels of Vitamin D during Pregnancy are of CONCERN in rural vietnam, and are ASSOCIATED with impaired Language Development at 6 months of age.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('INCOMPLETE_EVIDENCE', 22), ('PROBLEM_COMPLICATION', 85), ('SUPERFICIAL_RELATIONSHIP', 119)]	4	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy'), ('GO_0060132', 'prolactin secreting cell development', 144, 'language development')]	0	['conclusions\nour levels   rural vietnam, language 6 months age.']
S156-PMC4072587	PMC4072587	6/2014	S156-PMC4072587	['our results STRENGTHEN the EVIDENCE for giving Vitamin D supplementation during Pregnancy and HIGHLIGHT the NEED FOR FURTHER RESEARCH to explore the IMPACT of supplementation on longer term child growth and developmental outcomes, PARTICULARLY with regard to language.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 94), ('FUTURE_WORK', 108), ('INCOMPLETE_EVIDENCE', 108), ('SUPERFICIAL_RELATIONSHIP', 149), ('IMPORTANT_CONSIDERATION', 231)]	7	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy')]	0	['results  supplementation  supplementation longer term child developmental outcomes, regard language.']
S246-PMC4113768	PMC4113768	7/2014	S246-PMC4113768	['strategies aimed at improving maternal Vitamin D status during Pregnancy, especially in the winter months, ARE NEEDED and MIGHT decrease the RISK of lrti in early childhood.']	[('FUTURE_WORK', 107), ('INCOMPLETE_EVIDENCE', 122), ('IMPORTANT_CONSIDERATION', 141)]	3	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy')]	0	['strategies maternal  status winter months, decrease lrti childhood.']
S355-PMC4113768	PMC4113768	7/2014	S355-PMC4113768	['this resulted in a research project within our practice, where we identified and treated Vitamin D deficiency in Pregnancy to try and PREVENT rickets in our community.']	[('SUPERFICIAL_RELATIONSHIP', 134)]	1	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy')]	0	['resulted practice, treated   rickets community.']
S579-PMC4113768	PMC4113768	7/2014	S579-PMC4113768	['background: SEVERAL STUDIES have investigated the ASSOCIATION between Vitamin D in Pregnancy and Birth weight, but the conclusion of the studies are NOT CLEAR.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 50), ('FULL_UNKNOWN', 149)]	3	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007567', 'parturition', 97, 'birth')]	0	['background:   birth weight, clear.']
S580-PMC4113768	PMC4113768	7/2014	S580-PMC4113768	['AIM: the PRESENT STUDY EXAMINED IF exposure to Vitamin D from fortified Margarine and milk during Prenatal Life INFLUENCED Birth weight.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 32), ('SUPERFICIAL_RELATIONSHIP', 112)]	5	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_6784', 'mestranol', 72, 'margarine'), ('GO_0007565', 'female pregnancy', 98, 'prenatal'), ('UBERON_0000104', 'life cycle', 107, 'life'), ('GO_0007567', 'parturition', 123, 'birth')]	0	['aim: exposure  fortified margarine milk  life birth weight.']
S582-PMC4113768	PMC4113768	7/2014	S582-PMC4113768	['the INFLUENCE of Vitamin D exposure during Prenatal Life on Birth weight was INVESTIGATED among 59,411 danish children by comparing Birth weight among Individuals Born before, during, and after fortification.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 77)]	2	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('UBERON_0000104', 'life cycle', 52, 'life'), ('GO_0007567', 'parturition', 60, 'birth'), ('GO_0007567', 'parturition', 132, 'birth'), ('NCBITaxon_1', 'root', 151, 'individuals'), ('GO_0007567', 'parturition', 163, 'born')]	0	[' exposure  life birth among 59,411 danish children birth among individuals born before, during, fortification.']
S587-PMC4113768	PMC4113768	7/2014	S587-PMC4113768	['conclusion: exposure to Vitamin D from fortified Margarine and milk during Prenatal Life altered Birth weight, but the ASSOCIATIONS were INCONSISTENT.']	[('SUPERFICIAL_RELATIONSHIP', 119), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 137)]	2	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_6784', 'mestranol', 49, 'margarine'), ('GO_0007565', 'female pregnancy', 75, 'prenatal'), ('UBERON_0000104', 'life cycle', 84, 'life'), ('GO_0007567', 'parturition', 97, 'birth')]	0	['conclusion: exposure  fortified margarine milk  life altered birth weight, inconsistent.']
S588-PMC4113768	PMC4113768	7/2014	S588-PMC4113768	['we SPECULATE that the EFFECT of Vitamin D exposure in Pregnancy is modified by the exposure prior to Conception.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 22)]	2	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('GO_0007620', 'copulation', 101, 'conception')]	0	[' exposure  exposure conception.']
S602-PMC4113768	PMC4113768	7/2014	S602-PMC4113768	['the current analysis, based on two large cohort studies, EXAMINED the ASSOCIATION between peri-Pregnancy Vitamin D status in mothers, season of Birth of their offspring, and the risk of incident Peanut/Tree Nut (p/tn) allergy during childhood.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 57), ('SUPERFICIAL_RELATIONSHIP', 70)]	2	[('GO_0007565', 'female pregnancy', 95, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007567', 'parturition', 144, 'birth'), ('NCBITaxon_10088', 'Mus <genus>', 195, 'peanut'), ('NCBITaxon_33208', 'Metazoa', 202, 'tree nut')]	0	['analysis, studies, peri-  status mothers, season birth offspring, incident peanut/tree nut (p/tn) allergy childhood.']
S622-PMC4113768	PMC4113768	7/2014	S622-PMC4113768	['conclusions: peri-Pregnancy Vitamin D status of mothers had a u-shaped ASSOCIATION with risk of p/tn allergy in offspring, with lowest risk for mothers with predicted 25Ohd between 80–85 nmol/l.']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('GO_0007565', 'female pregnancy', 18, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 167, '25OHD')]	0	['conclusions: peri-  status mothers u-shaped p/tn allergy offspring, lowest mothers 25ohd 80–85 nmol/l.']
S633-PMC4113768	PMC4113768	7/2014	S633-PMC4113768	"['[""""maternal Vitamin D status in Pregnancy is ASSOCIATED with adiposity in the offspring: findings from the southampton women\'s survey.""""]']"	[('SUPERFICIAL_RELATIONSHIP', 42)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 29, 'pregnancy')]	0	"['[""""maternn status ncy adiposity offspring: southampton women*s survey.""""]']"
S826-PMC4113768	PMC4113768	7/2014	S826-PMC4113768	['methods: we CONDUCTED an audit TO DETERMINE the level of information given to Pregnant and breastfeeding women regarding Vitamin D and to gauge the knowledge of midwifery and medical staff on Postnatal wards.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 31)]	2	[('GO_0007565', 'female pregnancy', 78, 'pregnant'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('GO_0007567', 'parturition', 192, 'postnatal')]	0	['methods: audit  breastfeeding women regarding  gauge midwifery medical staff postnatal wards.']
S827-PMC4113768	PMC4113768	7/2014	S827-PMC4113768	['the audit was based on two standards: (1) antenatal standard nice 62- at booking women SHOULD BE given information and advice on the IMPORTANCE of taking a 10 microgram Vitamin D supplement per day during Pregnancy and whilst breastfeeding.']	[('FUTURE_WORK', 87), ('IMPORTANT_CONSIDERATION', 133)]	2	[('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy')]	0	['audit standards: (1) antenatal nice 62- booking women 10 microgram  supplement day  breastfeeding.']
S995-PMC4113768	PMC4113768	7/2014	S995-PMC4113768	['our AIM was to EXPLORE ASSOCIATIONS between maternal and Cord 25(Oh)D concentrations and Vitamin D supplementation during Pregnancy and infancy and Gross Motor Development in infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('SUPERFICIAL_RELATIONSHIP', 23)]	3	[('UBERON_0002240', 'spinal cord', 57, 'cord'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 65, 'OH ... D'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('GO_0008406', 'gonad development', 148, 'gross motor development')]	0	['maternal cord 25(oh)d concentrations  supplementation  infancy motor infants.']
S1026-PMC4113768	PMC4113768	7/2014	S1026-PMC4113768	['maternal Vitamin D supplementation reduces the risk of infection and pre-term Birth: a population study on 36,181 Pregnancies\n\nhyppönen, e.; cavadino, a.; williams, d.; czeizel, e.\nbackground: adequate Vitamin D nutrition HAS BEEN SUGGESTED to be ESSENTIAL for the successful maintenance of Pregnancy, with increasing interest on its EFFECTS on Placental function, infection risk and inflammatory responses.']	[('INCOMPLETE_EVIDENCE', 222), ('IMPORTANT_CONSIDERATION', 247), ('SUPERFICIAL_RELATIONSHIP', 334)]	3	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 9, 'Vitamin D'), ('GO_0007567', 'parturition', 78, 'Birth'), ('GO_0007565', 'female pregnancy', 114, 'Pregnancies'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('GO_0007565', 'female pregnancy', 291, 'pregnancy'), ('UBERON_0001987', 'placenta', 345, 'placental')]	0	['maternal vitamin supplementation reduces infection pre-term birth: population 36,181 \n\nhyppönen, e.; cavadino, a.; williams, d.; czeizel, e.\nbackground:  nutrition maintenance placental function, infection inflammatory responses.']
S1027-PMC4113768	PMC4113768	7/2014	S1027-PMC4113768	['THIS STUDY was done TO EVALUATE the ASSOCIATION between maternal Vitamin D supplementation during Pregnancy, the risk of bacterial and Viral infections, and their POSSIBLE CONTRIBUTION to the risk of pre-term Birth.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 20), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 163), ('SUPERFICIAL_RELATIONSHIP', 172)]	5	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('NCBITaxon_1', 'root', 135, 'viral'), ('GO_0007567', 'parturition', 209, 'birth')]	0	['done maternal  supplementation bacterial viral infections, pre-term birth.']
S1035-PMC4113768	PMC4113768	7/2014	S1035-PMC4113768	['risk of premature Birth was NOTABLY lower for mothers who took Vitamin D supplementation during Pregnancy (0.53, 0.43–0.66 for multivitamin; 0.44, 0.40–0.49 for single preparation), with the ASSOCIATION remaining unaffected by adjustment for infections.']	[('ANOMALY_CURIOUS_FINDING', 28), ('SUPERFICIAL_RELATIONSHIP', 191)]	2	[('GO_0007567', 'parturition', 18, 'birth'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]	0	['risk premature birth mothers took  supplementation  (0.53, 0.43–0.66 multivitamin; 0.44, 0.40–0.49 single preparation), unaffected adjustment infections.']
S1036-PMC4113768	PMC4113768	7/2014	S1036-PMC4113768	['HOWEVER, a stronger reduction in the risk of pre-term Birth by single preparation Vitamin D was seen in Pregnancies complicated with maternal infection (0.39, 0.29–0.52, p = 6.8e−12), compared to Prematurity following an infection-free Pregnancy (0.46, 0.41–0.52, p = 7.6e−39).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('GO_0007567', 'parturition', 54, 'birth'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 104, 'pregnancies'), ('GO_0007565', 'female pregnancy', 196, 'prematurity'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy')]	0	['however, reduction pre-term birth single preparation   maternal infection (0.39, 0.29–0.52, p = 6.8e−12),  following infection-free  (0.46, 0.41–0.52, p = 7.6e−39).']
S1037-PMC4113768	PMC4113768	7/2014	S1037-PMC4113768	['conclusions: maternal Vitamin D supplementation during Pregnancy was ASSOCIATED with NOTABLE reductions in the risk of infections and pre-term Birth.']	[('SUPERFICIAL_RELATIONSHIP', 69), ('ANOMALY_CURIOUS_FINDING', 85), ('IMPORTANT_CONSIDERATION', 85)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('GO_0007567', 'parturition', 143, 'birth')]	0	['conclusions: maternal  supplementation  reductions infections pre-term birth.']
S1038-PMC4113768	PMC4113768	7/2014	S1038-PMC4113768	['these data SUGGEST that the RELATED EFFECTS are strong and CONSISTENT across DIFFERENT types of infections, HIGHLIGHTING THE NEED to PREVENT Vitamin D deficiency in Pregnant mothers.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 28), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 59), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 77), ('IMPORTANT_CONSIDERATION', 108), ('INCOMPLETE_EVIDENCE', 108), ('INCOMPLETE_EVIDENCE', 121), ('FUTURE_WORK', 125), ('SUPERFICIAL_RELATIONSHIP', 133)]	11	[('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 165, 'pregnant')]	0	['infections,   mothers.']
S1077-PMC4113768	PMC4113768	7/2014	S1077-PMC4113768	['higher Serum 25(Oh) Vitamin D levels were CONSISTENTLY FOUND among subjects with no prevalent Cardiovascular risk factors ( p> 0.05) except for those subjects with serum crp level ≥3 mg/l, tc/Hdl-C ratio ≥5, and those with 4 or more Pregnancies.']	[('PROBABLE_UNDERSTANDING', 42), ('INCOMPLETE_EVIDENCE', 55)]	2	[('UBERON_0001977', 'blood serum', 7, 'serum'), ('CHEBI_30778', 'gallic acid', 13, '25(OH)'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 94, 'cardiovascular'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 192, 'HDL-C'), ('GO_0007565', 'female pregnancy', 233, 'pregnancies')]	0	['higher serum 25(oh)  levels among subjects cardiovascular p> 0.05) subjects serum crp ≥3 mg/l, tc/hdl-c ratio ≥5, 4 .']
S1331-PMC4113768	PMC4113768	7/2014	S1331-PMC4113768	"['[""""Vitamin D supplementation in an edinburgh general practice population and ANECDOTAL evidence\\n\\nrhein, h.m.; johnson, g.\\nbackground: after we became aware of the widespread Vitamin D deficiency in our scottish general practice population in edinburgh at a latitude of 56\', our patients have received for the past few years the offer of prescriptions for Vitamin D supplements: 20,000 iu weekly for MOST Adults, 2000 iu daily for Pregnant women, 1000 iu daily for children aged 5–12, 400 iu daily for babies and children aged 0–5.""""]']"	[('INCOMPLETE_EVIDENCE', 74), ('PROBABLE_UNDERSTANDING', 396)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 352, 'vitamin D'), ('UBERON_0007023', 'adult organism', 401, 'adults'), ('GO_0007565', 'female pregnancy', 427, 'pregnant')]	0	"['[""""vitamin supplementation edinburgh population evidence\\n\\nrhein, h.m.; johnson, g.\\nbackground: became widesamin scottish population edinburgh latitude 56*, patients received prescriptionamin supplements: 20,000 iu weekly adults, 2000 iu dailegnant women, 1000 iu daily children aged 5–12, 400 iu daily babies children aged 0–5.""""]']"
S1793-PMC4113768	PMC4113768	7/2014	S1793-PMC4113768	['the AIM of the PRESENT STUDY was to follow up the study participants INVESTIGATING WHETHER the EFFECT of Vitamin D is restricted to the Prenatal period OR can also be SEEN in one or two year old infants INDEPENDENTLY from the maternal status during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 69), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 83), ('SUPERFICIAL_RELATIONSHIP', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 152), ('INCOMPLETE_EVIDENCE', 167), ('SUPERFICIAL_RELATIONSHIP', 203)]	8	[('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 136, 'prenatal'), ('GO_0007565', 'female pregnancy', 249, 'pregnancy')]	0	['participants   period year old infants maternal status .']
S1805-PMC4113768	PMC4113768	7/2014	S1805-PMC4113768	['conclusions: OUR STUDY DEMONSTRATES that in east germany region (latitude: 51.3667) the Vitamin D status of one year old children is sufficient DUE to a general rickets prophylaxis, WHEREAS levels of two years old infants drop back to levels similar SEEN for Pregnant mothers.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('INCOMPLETE_EVIDENCE', 23), ('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('IMPORTANT_CONSIDERATION', 144), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 182), ('INCOMPLETE_EVIDENCE', 250)]	6	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 259, 'pregnant')]	0	['conclusions: east germany region (latitude: 51.3667)  status year old children rickets prophylaxis, levels old infants drop back levels  mothers.']
S1834-PMC4113768	PMC4113768	7/2014	S1834-PMC4113768	['during this period, the danish government mandated the fortification of Margarine with Vitamin D, 1.25 mg/100 g. in this talk we will analyze and discuss the benefits ASSOCIATED with Prenatal Consumption of Vitamin D fortified Foods in terms of the development of schizophrenia amongst the progeny later in Life.']	[('SUPERFICIAL_RELATIONSHIP', 167)]	1	[('CHEBI_6784', 'mestranol', 72, 'margarine'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 183, 'prenatal'), ('GO_0007631', 'feeding behavior', 192, 'consumption'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D'), ('CHEBI_33290', 'food', 227, 'foods'), ('UBERON_0000104', 'life cycle', 307, 'life')]	0	['period, danish government mandated fortification margarine 1.25 mg/100 g. talk  consumption  fortified foods terms schizophrenia amongst progeny life.']
S1841-PMC4113768	PMC4113768	7/2014	S1841-PMC4113768	['TO TEST the HYPOTHESIS of an ASSOCIATION between the Prenatal exposure to Vitamin D fortified Foods and the risk of the progeny developing schizophrenia later in Life, cox regression models were fit.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 29)]	3	[('GO_0007565', 'female pregnancy', 53, 'prenatal'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_33290', 'food', 94, 'foods'), ('UBERON_0000104', 'life cycle', 162, 'life')]	0	[' exposure  fortified foods progeny schizophrenia life, cox regression fit.']
S2043-PMC4113768	PMC4113768	7/2014	S2043-PMC4113768	['the RECENT iom 2011 report on dietary reference intakes for Calcium and Vitamin D for north america is apt for the irish population by providing the most COMPREHENSIVE EVIDENCE-BASED REPORT on Vitamin D.\nmethods: since 2007, we have conducted studies of Vitamin D status by measuring Serum 25-Hydroxy Vitamin D (25Ohd) in: preterm infants shortly after Birth ( n = 274) and after 15 weeks ( n = 148); paired term infants and mothers at Birth ( n = 39); children and adolescents from age 1 to 18 years ( n = 252); mothers during Pregnancy and infants at Birth divided according to winter Birth ( n = 30) and summer Birth ( n = 30); Pregnant mothers and ethnicity ( n = 116); patients attending an osteoporosis clinic ( n = 100); patients with cystic fibrosis ( n = 114); patients with multiple sclerosis ( n = 331) compared with healthy relatives ( n = 229) during winter months in 3 different regions in ireland; and patients with psoriasis undergoing phototherapy during the winter months ( n = 29) compared with controls ( n = 29).']	[('INCOMPLETE_EVIDENCE', 4), ('PROBABLE_UNDERSTANDING', 154), ('INCOMPLETE_EVIDENCE', 168), ('QUESTION_ANSWERED_BY_THIS_WORK', 177), ('QUESTION_ANSWERED_BY_THIS_WORK', 177), ('INCOMPLETE_EVIDENCE', 183)]	6	[('CHEBI_31341', 'calcium dihydroxide', 60, 'Calcium'), ('CHEBI_28384', 'vitamin K', 72, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 201, 'D'), ('CHEBI_27300', 'vitamin D', 254, 'vitamin D'), ('UBERON_0001977', 'blood serum', 284, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 290, '25-hydroxy vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 312, '25OHD'), ('GO_0007567', 'parturition', 353, 'birth'), ('GO_0007567', 'parturition', 436, 'birth'), ('GO_0007565', 'female pregnancy', 528, 'pregnancy'), ('GO_0007567', 'parturition', 553, 'birth'), ('GO_0007567', 'parturition', 587, 'birth'), ('GO_0007567', 'parturition', 614, 'birth'), ('GO_0007565', 'female pregnancy', 631, 'pregnant')]	0	['iom 2011 dietary intakes calcium vitamin north america apt irish population .\nmethods: 2007,  status measuring serum 25-hydroxy vitamin (25ohd) in: preterm infants shortly birth n = 274) 15 weeks n = 148); paired term infants mothers birth n = 39); children adolescents age 18 n = 252); mothers  infants birth winter birth n = 30) summer birth n = 30);  mothers ethnicity n = 116); patients attending osteoporosis clinic n = 100); patients cystic fibrosis n = 114); patients sclerosis n = 331) healthy relatives n = 229) winter months 3 regions ireland; patients psoriasis undergoing phototherapy winter months n = 29) n = 29).']
S2045-PMC4113768	PMC4113768	7/2014	S2045-PMC4113768	['results: prevalence for Vitamin D status (25Ohd nmol/l < 30, 30–50, > 50–125, > 125) was NOTED for the following groups: preterm at 3 weeks (14%, 65%, 21%, 0%); preterm at 15 weeks on 400 iu/day (3%, 11%, 86%, 8%); Pregnant women at term (21%, 34%, 45%, 0%) with Cord Blood at term (59%, 28%, 13%, 0%); children ranging from 1–18 years (22%, 33%, 45%, 0%); osteoporosis on 400–800 iu/day (1%, 8%, 91%, 2%); and cystic fibrosis on 400–1600 iu/d (23%, 28%, 49%, 3%); healthy Adults in winter (21%, 46%, 33%, 0%); and multiple sclerosis in winter (40%, 32%, 28%, 1%).']	[('ANOMALY_CURIOUS_FINDING', 89)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 42, '25OHD'), ('GO_0007565', 'female pregnancy', 215, 'pregnant'), ('UBERON_0002240', 'spinal cord', 263, 'cord'), ('UBERON_0000178', 'blood', 268, 'blood'), ('UBERON_0007023', 'adult organism', 473, 'adults')]	0	['results:  status (25ohd nmol/l 30, 30–50, > 50–125, > 125) following groups: preterm 3 weeks (14%, 65%, 21%, 0%); preterm 15 weeks 400 iu/day (3%, 11%, 86%, 8%);  women term (21%, 34%, 45%, 0%) cord blood term (59%, 28%, 13%, 0%); children 1–18 (22%, 33%, 45%, 0%); osteoporosis 400–800 iu/day (1%, 8%, 91%, 2%); cystic fibrosis 400–1600 iu/d (23%, 28%, 49%, 3%); healthy adults winter (21%, 46%, 33%, 0%); sclerosis winter (40%, 32%, 28%, 1%).']
S2046-PMC4113768	PMC4113768	7/2014	S2046-PMC4113768	['season had a distinct EFFECT on Vitamin D status during Pregnancy but not on Cord Blood.']	[('SUPERFICIAL_RELATIONSHIP', 22)]	1	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnancy'), ('UBERON_0009472', 'axilla', 77, 'cord blood')]	0	['season  status  cord blood.']
S2393-PMC4113768	PMC4113768	7/2014	S2393-PMC4113768	['background: we performed a systematic review TO EXPLORE WHETHER (1) low maternal circulating 25(Oh)-Vitamin D (25(Oh)D) during Pregnancy is ASSOCIATED with impairment of offspring health; and (2) maternal supplementation with Vitamin D in Pregnancy MIGHT ameliorate these EFFECTS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 140), ('INCOMPLETE_EVIDENCE', 249), ('SUPERFICIAL_RELATIONSHIP', 272)]	5	[('CHEBI_63056', 'zinc cation', 93, '25(OH'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 111, '25(OH)D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy')]	0	['background: (1) maternal circulating 25(oh)- (25(oh)d)  impairment offspring health; (2) maternal supplementation   ameliorate effects.']
S2398-PMC4113768	PMC4113768	7/2014	S2398-PMC4113768	['eligible studies included Pregnant women and their offspring, and one or more RELEVANT exposures (either assessment of Vitamin D status (dietary intake, sunlight exposure, circulating 25(Oh)D) or supplementation of participants with Vitamin D or Vitamin D containing Food e.g., oily fish) and outcomes (offspring birth weight, Birth length, Head circumference, bone mass, anthropometry and body composition, risk of asthma and atopy, small for Gestational dates, Preterm Birth, type 1 diabetes, low Birth weight, Serum calcium concentration, Blood pressure and rickets).']	[('IMPORTANT_CONSIDERATION', 78)]	1	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 184, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 190, 'D'), ('CHEBI_27300', 'vitamin D', 233, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D'), ('CHEBI_33290', 'food', 267, 'food'), ('GO_0007567', 'parturition', 327, 'birth'), ('UBERON_0000033', 'head', 341, 'head'), ('GO_0007565', 'female pregnancy', 444, 'gestational'), ('GO_0007565', 'female pregnancy', 463, 'preterm birth'), ('GO_0007567', 'parturition', 499, 'birth'), ('UBERON_0001977', 'blood serum', 513, 'serum'), ('UBERON_0000178', 'blood', 542, 'blood')]	0	['eligible  women offspring, exposures (either  status (dietary intake, sunlight exposure, circulating 25(oh)d) supplementation participants   containing food e.g., oily fish) outcomes (offspring birth weight, birth length, head circumference, bone mass, anthropometry composition, asthma atopy,  dates, type diabetes, birth weight, serum calcium concentration, blood pressure rickets).']
S2414-PMC4113768	PMC4113768	7/2014	S2414-PMC4113768	['we have PREVIOUSLY DEMONSTRATED that maternal lifestyle, body build, physical activity and Vitamin D status during Pregnancy are ASSOCIATED with offspring bone mass.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 129)]	3	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy')]	0	['maternal lifestyle, build, physical activity  status  offspring bone mass.']
S2584-PMC4113768	PMC4113768	7/2014	S2584-PMC4113768	['to date, the INFLUENCE of Vitamin D status during Gestation on long-term risk of t1d has not been widely studied.']	[('SUPERFICIAL_RELATIONSHIP', 13)]	1	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'gestation')]	0	['date,  status  long-term t1d studied.']
S2593-PMC4113768	PMC4113768	7/2014	S2593-PMC4113768	['THUS, OUR STUDY AIMED TO ASSESS IF Intake of Foods fortified with Vitamin D during Gestation had an EFFECT on the RISK of t1d later in Life.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 6), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 32), ('SUPERFICIAL_RELATIONSHIP', 100), ('IMPORTANT_CONSIDERATION', 114)]	7	[('GO_0007631', 'feeding behavior', 35, 'intake'), ('CHEBI_33290', 'food', 45, 'foods'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'gestation'), ('UBERON_0000104', 'life cycle', 135, 'life')]	0	['thus, intake foods fortified   t1d life.']
S2594-PMC4113768	PMC4113768	7/2014	S2594-PMC4113768	['THIS sub-study TESTED the HYPOTHESIS that seasonality of month of Birth in t1d is more pronounced among Individuals who were not exposed to Vitamin D fortification during Gestation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('INCOMPLETE_EVIDENCE', 26)]	3	[('GO_0007567', 'parturition', 66, 'birth'), ('NCBITaxon_1', 'root', 104, 'individuals'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007565', 'female pregnancy', 171, 'gestation')]	0	['sub-study seasonality month birth t1d among individuals exposed  fortification .']
S2602-PMC4113768	PMC4113768	7/2014	S2602-PMC4113768	['conclusions: TO ASSESS the IMPACT of exposure to Vitamin D during Gestation for later t1d risk we studied seasonality of month of Birth in a specific context of Food fortification practices in denmark.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('SUPERFICIAL_RELATIONSHIP', 27)]	2	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'gestation'), ('GO_0007567', 'parturition', 130, 'birth'), ('CHEBI_33290', 'food', 161, 'food')]	0	['conclusions: exposure   t1d seasonality month birth context food fortification practices denmark.']
S2603-PMC4113768	PMC4113768	7/2014	S2603-PMC4113768	['we HYPOTHESIZED that Gestational exposure to milk fortified with Vitamin D would attenuate seasonality of month of Birth.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('GO_0007565', 'female pregnancy', 21, 'gestational'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007567', 'parturition', 115, 'birth')]	0	[' exposure milk fortified  seasonality month birth.']
S2637-PMC4113768	PMC4113768	7/2014	S2637-PMC4113768	['; inskip, h.m.; cooper, c.; harvey, n.c.\nbackground: maternal 25-Hydroxy-Vitamin D (25(Oh)d) status in Pregnancy HAS BEEN ASSOCIATED with offspring Bone Development and adiposity.']	[('INCOMPLETE_EVIDENCE', 113), ('SUPERFICIAL_RELATIONSHIP', 122)]	2	[('CHEBI_70487', '(-)-sanguinolignan C', 62, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 84, '25(OH'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0048539', 'bone marrow development', 148, 'bone development')]	0	['; inskip, h.m.; cooper, c.; harvey, n.c.\nbackground: maternal 25-hydroxy- (25(oh)d) status  offspring bone adiposity.']
S2646-PMC4113768	PMC4113768	7/2014	S2646-PMC4113768	['median maternal 25(Oh)D was 61 nmol/l (iqr 43–88 nmol/l), and ONLY 9.2% of mothers were using Vitamin D supplementation (at LEAST 400 iu/day) in late Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 62), ('PROBABLE_UNDERSTANDING', 124)]	2	[('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 16, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy')]	0	['median maternal 25(oh)d 61 nmol/l (iqr 43–88 nmol/l), 9.2% mothers using  supplementation (at 400 iu/day) late .']
S3079-PMC4113768	PMC4113768	7/2014	S3079-PMC4113768	['; boyle, r.j.\nbackground: OBSERVATIONAL STUDIES SUGGEST high Prenatal Vitamin D intake MAY BE ASSOCIATED with reduced childhood wheezing.']	[('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 40), ('INCOMPLETE_EVIDENCE', 48), ('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 94)]	5	[('GO_0007565', 'female pregnancy', 61, 'prenatal'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]	0	['; boyle, r.j.\nbackground:   intake childhood wheezing.']
S3080-PMC4113768	PMC4113768	7/2014	S3080-PMC4113768	['we EXAMINED the EFFECT of Prenatal Vitamin D on childhood wheezing in an interventional study.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 16)]	2	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D')]	0	['  childhood wheezing interventional study.']
S3091-PMC4113768	PMC4113768	7/2014	S3091-PMC4113768	['conclusion: Prenatal Vitamin D supplementation in late Pregnancy that had a modest EFFECT on Cord Blood Vitamin D level, was not associated with decreased wheezing in offspring at age three years.']	[('SUPERFICIAL_RELATIONSHIP', 83)]	1	[('GO_0007565', 'female pregnancy', 12, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 93, 'cord'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]	0	['conclusion:   supplementation late  cord blood  level, decreased wheezing offspring age three years.']
S3248-PMC4113768	PMC4113768	7/2014	S3248-PMC4113768	['Prenatal Vitamin D deficiency in a Rat pup MODEL HAS BEEN ASSOCIATED with Ventriculomegaly and Brain overgrowth and abnormal behaviour WHILE a FEW STUDIES have DEMONSTRATED an ASSOCIATION between Prenatal Vitamin D deficiency and lower Birthweight.']	[('INCOMPLETE_EVIDENCE', 43), ('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 58), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('INCOMPLETE_EVIDENCE', 143), ('INCOMPLETE_EVIDENCE', 160), ('SUPERFICIAL_RELATIONSHIP', 176)]	7	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 35, 'rat'), ('UBERON_0001137', 'dorsum', 74, 'ventriculomegaly'), ('UBERON_0000955', 'brain', 95, 'brain'), ('GO_0007565', 'female pregnancy', 196, 'prenatal'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D'), ('GO_0007596', 'blood coagulation', 236, 'birthweight')]	0	['  rat pup ventriculomegaly brain overgrowth abnormal behaviour   birthweight.']
S3336-PMC4113768	PMC4113768	7/2014	S3336-PMC4113768	['; xiao, j.p.; zang, j.; fei, x.; zhu, y.; pei, j.j.\nbackground: thereare LITTLE DATA about the status of Vitamin D in Pregnant women and their newborns in china, and we EVALUATED the Vitamin D status in Pregnant women and their newborns all the year around in wuxi city (north latitude 32°), jiangsu province, china.']	[('FULL_UNKNOWN', 73), ('INCOMPLETE_EVIDENCE', 73), ('QUESTION_ANSWERED_BY_THIS_WORK', 169)]	3	[('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 118, 'pregnant'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D'), ('GO_0007565', 'female pregnancy', 203, 'pregnant')]	0	['; xiao, j.p.; zang, j.; fei, x.; zhu, y.; pei, j.j.\nbackground: thereare status   women newborns china,  status  women newborns year wuxi city (north latitude 32°), jiangsu province, china.']
S3345-PMC4113768	PMC4113768	7/2014	S3345-PMC4113768	['(4) the Vitamin D status of Pregnant women SHOWED the same TREND as the air temperature fluctuations, BUT its phase lagged behind about two months, reaching its highest value in september.']	[('INCOMPLETE_EVIDENCE', 43), ('INCOMPLETE_EVIDENCE', 59), ('ANOMALY_CURIOUS_FINDING', 102)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 28, 'pregnant')]	0	['(4)  status  women air temperature fluctuations, phase lagged behind months, reaching september.']
S3349-PMC4113768	PMC4113768	7/2014	S3349-PMC4113768	['and the Vitamin D status in Pregnant women is significantly INFLUENCED by air temperature which is RELATED to the exposure of ultraviolet rays.']	[('SUPERFICIAL_RELATIONSHIP', 60), ('SUPERFICIAL_RELATIONSHIP', 99)]	2	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 28, 'pregnant')]	0	[' status  women air temperature exposure ultraviolet rays.']
S217-PMC4161853	PMC4161853	8/2014	S217-PMC4161853	['moreover, Gestational Vitamin A deficiency in Animal models HAS BEEN SHOWN to reduce the Intestinal Immune Response by decreasing the number of Immune Cells in Rat offspring [119] and Controlling the size of Secondary Lymph Organ and the efficiency of Immune Responses in the Adult Mouse offspring [120].']	[('INCOMPLETE_EVIDENCE', 60)]	1	[('GO_0007565', 'female pregnancy', 10, 'gestational'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('NCBITaxon_33208', 'Metazoa', 46, 'animal'), ('UBERON_0000160', 'intestine', 89, 'intestinal'), ('GO_0006955', 'immune response', 100, 'immune response'), ('UBERON_0002405', 'immune system', 100, 'immune'), ('CL_0000738', 'leukocyte', 144, 'immune cells'), ('UBERON_0002405', 'immune system', 144, 'immune'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 160, 'rat'), ('GO_0065007', 'biological regulation', 184, 'controlling'), ('UBERON_0005174', 'dorsal region element', 208, 'secondary lymph organ'), ('GO_0006955', 'immune response', 252, 'immune responses'), ('UBERON_0002405', 'immune system', 252, 'immune'), ('UBERON_0007023', 'adult organism', 276, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 282, 'mouse')]	0	['moreover,   animal intestinal immune response decreasing immune cells rat offspring [119] controlling secondary lymph organ efficiency immune responses adult mouse offspring [120].']
S231-PMC4161944	PMC4161944	9/2014	S231-PMC4161944	['independent of nutrition or pathogen exposure, seasonality CAN also change diurnal exposure to sunlight and levels of circulating Vitamin D. in the united kingdom, Vitamin D status during Gestation and Birth month HAS BEEN ASSOCIATED with diseases with Immune involvement, including rheumatoid arthritis, irritable Bowel diseases, and multiple sclerosis (174).']	[('INCOMPLETE_EVIDENCE', 59), ('INCOMPLETE_EVIDENCE', 214), ('SUPERFICIAL_RELATIONSHIP', 223)]	3	[('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 188, 'gestation'), ('GO_0007567', 'parturition', 202, 'birth'), ('UBERON_0002405', 'immune system', 253, 'immune'), ('UBERON_0000160', 'intestine', 315, 'bowel')]	0	['independent nutrition pathogen exposure, seasonality diurnal exposure sunlight levels circulating . united kingdom,  status  birth month diseases immune involvement, rheumatoid arthritis, irritable bowel diseases, sclerosis (174).']
S15-PMC4169453	PMC4169453	9/2014	S15-PMC4169453	['Postpartum deterioration of Vitamin D status MIGHT be EXPLAINED, AT LEAST IN PART, by less frequent multivitamin intake during Lactation compared to Pregnancy[5],[6]and decreasing multivitamin Intake in the course of Lactation[2].']	[('INCOMPLETE_EVIDENCE', 45), ('PROBABLE_UNDERSTANDING', 54), ('PROBABLE_UNDERSTANDING', 65), ('INCOMPLETE_EVIDENCE', 74)]	4	[('GO_0007567', 'parturition', 0, 'Postpartum'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007595', 'lactation', 127, 'lactation'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy'), ('GO_0007631', 'feeding behavior', 193, 'intake'), ('GO_0007595', 'lactation', 217, 'lactation')]	0	['postpartum deterioration  status explained, part, multivitamin intake lactation [5],[6]and decreasing multivitamin intake course lactation[2].']
S142-PMC4169453	PMC4169453	9/2014	S142-PMC4169453	['a CORRELATION between maternal and breastfed infants’ 25(Oh)D levels was STILL significant after 3 and 6 months of Vitamin D supplementation BUT APPEARED weaker than the Postpartum CORRELATION: in the 400 iu/d group at v3 r\u200a=\u200a0.35 ( p \u200a=\u200a0.003) and at v6 r\u200a=\u200a0.4 ( p \u200a=\u200a0.0009), and in the 1200 iu/d group at v3 r\u200a=\u200a0.3 ( p \u200a=\u200a0.01) and at v6 r\u200a=\u200a0.39 ( p \u200a=\u200a0.0007), respectively.']	[('SUPERFICIAL_RELATIONSHIP', 2), ('ANOMALY_CURIOUS_FINDING', 73), ('IMPORTANT_CONSIDERATION', 73), ('ANOMALY_CURIOUS_FINDING', 141), ('ANOMALY_CURIOUS_FINDING', 145), ('SUPERFICIAL_RELATIONSHIP', 181)]	6	[('CHEBI_71657', 'versiconol acetate', 54, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 60, 'D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'postpartum')]	0	['maternal breastfed infants’ 25(oh)d levels 3 6 months  supplementation  correlation: 400 iu/d v3 r\u200a=\u200a0.35 p \u200a=\u200a0.003) v6 r\u200a=\u200a0.4 p \u200a=\u200a0.0009), 1200 iu/d v3 r\u200a=\u200a0.3 p \u200a=\u200a0.01) v6 r\u200a=\u200a0.39 p \u200a=\u200a0.0007), respectively.']
S229-PMC4169453	PMC4169453	9/2014	S229-PMC4169453	['Animal data demonstrate that, INSTEAD of Vitamin D, Calcitriol, or the Vitamin D receptor, the increase in Intestinal calcium absorption is LIKELY due to the Pregnancy-RELATED increase in Duodenal Expression of the calcium transporter Gene Trpv6 [53].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 30), ('PROBABLE_UNDERSTANDING', 140), ('SUPERFICIAL_RELATIONSHIP', 168)]	3	[('NCBITaxon_33208', 'Metazoa', 0, 'Animal'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 52, 'calcitriol'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0000160', 'intestine', 107, 'intestinal'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy'), ('UBERON_0001245', 'anus', 188, 'duodenal'), ('GO_0010467', 'gene expression', 197, 'expression'), ('SO_0000704', 'gene', 235, 'gene'), ('PR_000016580', 'tropomyosin beta chain', 240, 'Trpv6')]	0	['animal that, calcitriol,  receptor, increase intestinal calcium absorption -related increase duodenal expression calcium transporter gene trpv6 [53].']
S239-PMC4169453	PMC4169453	9/2014	S239-PMC4169453	['conclusions\nIN SUMMARY, OUR STUDY SHOWED a very high prevalence (∼65%) of Postpartum Vitamin D deficiency among caucasian mothers and their newborn offspring living at latitude 52°n.']	[('INCOMPLETE_EVIDENCE', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('INCOMPLETE_EVIDENCE', 34)]	3	[('GO_0007565', 'female pregnancy', 74, 'postpartum'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]	0	['conclusions\nin summary, (∼65%)   among caucasian mothers newborn offspring living latitude 52°n.']
S135-PMC4171568	PMC4171568	9/2014	S135-PMC4171568	['Vitamin D as a risk factor for the development of schizophrenia\nit HAS BEEN HYPOTHESIZED that low Prenatal Vitamin D is a risk factor for the incidence of Adult-onset schizophrenia AS the lack of this fat-soluble Vitamin and Steroid Hormone MAY DETRIMENTALLY IMPACT on the developing foetal Brain [102].']	[('INCOMPLETE_EVIDENCE', 67), ('INCOMPLETE_EVIDENCE', 76), ('PROBABLE_UNDERSTANDING', 181), ('INCOMPLETE_EVIDENCE', 241), ('IMPORTANT_CONSIDERATION', 245), ('SUPERFICIAL_RELATIONSHIP', 259)]	6	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'prenatal'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0007023', 'adult organism', 155, 'adult'), ('CHEBI_33229', 'vitamin (role)', 213, 'vitamin'), ('CHEBI_26764', 'steroid hormone', 225, 'steroid hormone'), ('UBERON_0000955', 'brain', 291, 'brain')]	0	['vitamin schizophrenia\nit   adult-onset schizophrenia fat-soluble vitamin steroid hormone foetal brain [102].']
S136-PMC4171568	PMC4171568	9/2014	S136-PMC4171568	['research using Animal MODELS HAS SHOWN that low Prenatal Vitamin D alters Brain Development [103].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('INCOMPLETE_EVIDENCE', 29)]	2	[('NCBITaxon_33208', 'Metazoa', 15, 'animal'), ('GO_0007565', 'female pregnancy', 48, 'prenatal'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007420', 'brain development', 74, 'brain development'), ('UBERON_0000955', 'brain', 74, 'brain')]	0	['research using animal   alters brain [103].']
S134-PMC4172095	PMC4172095	8/2014	S134-PMC4172095	['nutritional guidelines for Pregnancy tend to HIGHLIGHT the IMPORTANCE of ensuring sufficient Intake of a range of Micronutrients, including Iron, Folic Acid, b vitamins, zinc, magnesium, Iodine, Vitamin A, and Calcium (kaiser et al., 2002).']	[('INCOMPLETE_EVIDENCE', 45), ('IMPORTANT_CONSIDERATION', 59)]	2	[('GO_0007565', 'female pregnancy', 27, 'pregnancy'), ('GO_0007631', 'feeding behavior', 93, 'intake'), ('CHEBI_33839', 'macromolecule', 114, 'micronutrients'), ('CHEBI_24870', 'ion', 140, 'iron'), ('CHEBI_30751', 'formic acid', 146, 'folic acid'), ('CHEBI_24859', 'iodine atom', 187, 'iodine'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin A'), ('CHEBI_22313', 'alkaline earth metal atom', 210, 'calcium')]	0	['nutritional  ensuring intake micronutrients, iron, folic acid, b vitamins, zinc, magnesium, iodine, calcium (kaiser et al., 2002).']
S1-PMC4188019	PMC4188019	1/2010	S1-PMC4188019	['LITTLE IS KNOWN on Vitamin D deficiency in Pregnant women in belgium, non on the IMPACT of wearing Head and/or body cover.']	[('FULL_UNKNOWN', 0), ('SUPERFICIAL_RELATIONSHIP', 81)]	2	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'pregnant'), ('UBERON_0000033', 'head', 99, 'head')]	0	['little   women belgium, wearing head and/or cover.']
S2-PMC4188019	PMC4188019	1/2010	S2-PMC4188019	['OBJECTIVES : THIS was a PRELIMINARY EXPLORATION of the Vitamin D status in Pregnant women visiting the Antenatal clinic in the antwerp university hospital.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('INCOMPLETE_EVIDENCE', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 36)]	4	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnant'), ('GO_0007567', 'parturition', 103, 'antenatal'), ('UBERON_0001760', 'frontal sinus', 103, 'antenatal')]	0	['objectives :  status  women visiting antenatal clinic antwerp university hospital.']
S39-PMC4188019	PMC4188019	1/2010	S39-PMC4188019	['linear regression was used to analyse wether Vitamin D level is INFLUENCED by Gestational age, maternal age, parity, gravidity, sun exposure, intake of Supplements and/or date of Blood sample .']	[('SUPERFICIAL_RELATIONSHIP', 64)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'gestational'), ('CHEBI_33341', 'titanium atom', 152, 'supplements'), ('UBERON_0000178', 'blood', 179, 'blood')]	0	['linear regression analyse wether   age, maternal age, parity, gravidity, sun exposure, intake supplements and/or blood sample .']
S69-PMC4188019	PMC4188019	1/2010	S69-PMC4188019	['NO CONSENSUS exists on the RECOMMENDED intake and supplementation of 25-Oh Vitamin D during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 27)]	2	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 69, '25-OH'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007565', 'female pregnancy', 92, 'pregnancy')]	0	['intake supplementation 25-oh  .']
S81-PMC4188019	PMC4188019	1/2010	S81-PMC4188019	['conclusion\nlow Vitamin D levels are frequently FOUND in Pregnancy but the optimal Serum concentration REMAINS UNKNOWN.']	[('INCOMPLETE_EVIDENCE', 47), ('FULL_UNKNOWN', 102)]	2	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnancy'), ('UBERON_0001977', 'blood serum', 82, 'serum')]	0	['conclusion\nlow  levels  serum concentration unknown.']
S201-PMC4192458	PMC4192458	9/2014	S201-PMC4192458	['fruit and vegetables are low in fat and calories, and are IMPORTANT sources of Nutrients RELATED to hypertension in non-Pregnant populations including dietary fiber, calcium, Magnesium, Potassium, and Vitamins C [67].']	[('IMPORTANT_CONSIDERATION', 58), ('SUPERFICIAL_RELATIONSHIP', 89)]	2	[('CHEBI_33284', 'nutrient', 79, 'nutrients'), ('GO_0007565', 'female pregnancy', 120, 'pregnant'), ('CHEBI_22313', 'alkaline earth metal atom', 175, 'magnesium'), ('CHEBI_22314', 'alkali metal atom', 186, 'potassium'), ('CHEBI_27300', 'vitamin D', 201, 'vitamins C')]	0	['fruit vegetables fat calories, sources nutrients hypertension non- populations dietary fiber, calcium, magnesium, potassium,  [67].']
S178-PMC4193194	PMC4193194	10/2014	S178-PMC4193194	['as with OTHER oxidative stress Metabolites, levels of antioxidant enzymes and Compounds, such as catalase, Superoxide dismutase (sod) and Vitamin E HAVE BEEN found to be variable in pe studies compared to normal Pregnancies (bilodeau,2014).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 8), ('INCOMPLETE_EVIDENCE', 148)]	2	[('CHEBI_25212', 'metabolite', 31, 'metabolites'), ('CHEBI_36357', 'polyatomic entity', 78, 'compounds'), ('CHEBI_18421', 'superoxide', 107, 'superoxide'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin E'), ('GO_0007565', 'female pregnancy', 212, 'pregnancies')]	0	['oxidative metabolites, levels antioxidant enzymes compounds, catalase, superoxide dismutase (sod)  pe normal  (bilodeau,2014).']
S187-PMC4193194	PMC4193194	10/2014	S187-PMC4193194	['the study, called combined antioxidants and Preeclampsia prediction studies (capps), had the OBJECTIVE of determining WHETHER Vitamin C and E COULD reduce the frequency of Pregnancy related hypertension.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 93), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 118), ('INCOMPLETE_EVIDENCE', 142)]	3	[('GO_0007128', 'meiotic prophase I', 44, 'Preeclampsia'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 140, 'E'), ('GO_0007565', 'female pregnancy', 172, 'pregnancy')]	0	['study, combined antioxidants preeclampsia (capps),  e frequency  hypertension.']
S188-PMC4193194	PMC4193194	10/2014	S188-PMC4193194	['results from this STUDY SHOWED that the supplementation with Vitamin C and E in a low-risk cohort of women DEMONSTRATED no significant differences in maternal or newborn complications RELATED to hypertension during Pregnancy (roberts et al.,2010; weissgerber et al.,2013).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 107), ('SUPERFICIAL_RELATIONSHIP', 184)]	4	[('CHEBI_27300', 'vitamin D', 61, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 75, 'E'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy')]	0	['results supplementation  e low-risk women maternal newborn hypertension  (roberts et al.,2010; weissgerber et al.,2013).']
S190-PMC4193194	PMC4193194	10/2014	S190-PMC4193194	['ALIGNED with this FINDINGS, the cochrane collaboration initiative have CONCLUDED on its latest review on Antioxidants for preventing pe that evidence from trials reviewed does NOT SUPPORT the use of Vitamin C and E during Pregnancy for the PREVENTION of Preeclampsia and other outcomes (rumbold et al.,2008; salles et al.,2012).']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 176), ('SUPERFICIAL_RELATIONSHIP', 240)]	5	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 105, 'antioxidants'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 213, 'E'), ('GO_0007565', 'female pregnancy', 222, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 254, 'preeclampsia')]	0	['aligned findings, cochrane collaboration antioxidants pe  e  preeclampsia outcomes (rumbold et al.,2008; salles et al.,2012).']
S14-PMC4210927	PMC4210927	10/2014	S14-PMC4210927	['in Preconception nutrition care, besides Folic Acid supplementation [3], it is IMPORTANT to have an adequate intake of Iron, Iodine, Calcium, Vitamins A and d, essential Fatty-Acids and dietary supplements, when NECESSARY [4,5].']	[('IMPORTANT_CONSIDERATION', 79), ('IMPORTANT_CONSIDERATION', 212)]	2	[('GO_0007565', 'female pregnancy', 3, 'preconception'), ('CHEBI_30751', 'formic acid', 41, 'folic acid'), ('CHEBI_24870', 'ion', 119, 'iron'), ('CHEBI_24859', 'iodine atom', 125, 'iodine'), ('CHEBI_22313', 'alkaline earth metal atom', 133, 'calcium'), ('CHEBI_27300', 'vitamin D', 142, 'vitamins A'), ('CHEBI_35366', 'fatty acid', 170, 'fatty-acids')]	0	[' nutrition care, folic acid supplementation [3], intake iron, iodine, calcium,  d, fatty-acids dietary supplements, [4,5].']
S20-PMC4210927	PMC4210927	10/2014	S20-PMC4210927	['IN GENERAL, Pregnant women in developed countries are AT RISK of SUBOPTIMAL intakes of Folate, Iron and Vitamin D [20].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 54), ('IMPORTANT_CONSIDERATION', 65)]	3	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('CHEBI_30863', '5-azaorotic acid', 87, 'folate'), ('CHEBI_24870', 'ion', 95, 'iron'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]	0	['general,  women countries intakes folate, iron  [20].']
S72-PMC4216020	PMC4216020	10/2014	S72-PMC4216020	['a larger prospective study, HOWEVER, DID NOT demonstrate an ASSOCIATED RISK between maternal smoking and jia.92\nOTHER Perinatal exposures and Pregnancy-related FACTORS HAVE BEEN investigated.47,92an australian study that reviewed 262 cases and matched controls IDENTIFIED a TREND towards a PROTECTIVE EFFECT with Prenatal Nutritional Supplements.47the mothers of children that eventually developed jia were less LIKELY to receive supplementation with Prenatal multivitamins (24.9% versus 30.8%), Vitamin D (3.3% versus 7.8%), Fish Oil (2.9% versus 6.4%), Calcium (10.2% versus 14.9%), Iron (35.4% versus 40.3%), and Folate (61.4% versus 64.8%) while Pregnant compared to controls.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 28), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 60), ('IMPORTANT_CONSIDERATION', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('SUPERFICIAL_RELATIONSHIP', 160), ('INCOMPLETE_EVIDENCE', 168), ('INCOMPLETE_EVIDENCE', 261), ('INCOMPLETE_EVIDENCE', 274), ('SUPERFICIAL_RELATIONSHIP', 290), ('SUPERFICIAL_RELATIONSHIP', 301), ('PROBABLE_UNDERSTANDING', 412)]	12	[('GO_0036268', 'swimming', 118, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 118, 'perinatal'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy'), ('GO_0007565', 'female pregnancy', 313, 'prenatal'), ('CHEBI_7495', 'nefazodone hydrochloride', 322, 'nutritional'), ('CHEBI_33341', 'titanium atom', 334, 'supplements'), ('GO_0007565', 'female pregnancy', 451, 'prenatal'), ('CHEBI_27300', 'vitamin D', 496, 'vitamin D'), ('CHEBI_34766', 'Furamizole', 526, 'fish oil'), ('CHEBI_22313', 'alkaline earth metal atom', 555, 'calcium'), ('CHEBI_24870', 'ion', 585, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 616, 'folate'), ('GO_0007565', 'female pregnancy', 650, 'pregnant')]	0	['study, however, maternal smoking jia.92\nother perinatal exposures -related investigated.47,92an 262 cases  nutritional supplements.47the mothers children eventually jia receive supplementation  multivitamins (24.9% 30.8%),  (3.3% 7.8%), fish oil (2.9% 6.4%), calcium (10.2% 14.9%), iron (35.4% 40.3%), folate (61.4% 64.8%)  controls.']
S7-PMC4221707	PMC4221707	11/2014	S7-PMC4221707	['intake of Folate and Vitamin D supplements was GENERALLY high in the Pregnant group and LED TO significantly higher total estimated Intake of Vitamin D and Folate in the pregnant group.']	[('PROBABLE_UNDERSTANDING', 47), ('SUPERFICIAL_RELATIONSHIP', 88)]	2	[('CHEBI_30863', '5-azaorotic acid', 10, 'folate'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('GO_0007631', 'feeding behavior', 132, 'intake'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 156, 'folate')]	0	['intake folate  supplements  higher intake  folate pregnant group.']
S11-PMC4221707	PMC4221707	11/2014	S11-PMC4221707	['AS they also had a low intake (below the nordic nutritional recommendations) of Folate, Vitamin D, and Iron from foods, some of these women and their unborn children are POSSIBLY AT RISK for adverse EFFECTS on the Pregnancy and Birth outcome.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 170), ('IMPORTANT_CONSIDERATION', 179), ('SUPERFICIAL_RELATIONSHIP', 199)]	4	[('CHEBI_30863', '5-azaorotic acid', 80, 'folate'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_24870', 'ion', 103, 'iron'), ('GO_0007565', 'female pregnancy', 214, 'pregnancy'), ('GO_0007567', 'parturition', 228, 'birth')]	0	['intake (below nordic nutritional recommendations) folate, iron foods, women unborn children  birth outcome.']
S17-PMC4221707	PMC4221707	11/2014	S17-PMC4221707	['the nnr RECOMMENDS that Pregnant women increase their Folate intake by 65%, Selenium by 40%, iron, zinc, and Vitamin D by 25 - 30%, and Calcium, Phosphorus, and most other Minerals and Vitamins by 20% [3].']	[('FUTURE_WORK', 8)]	1	[('GO_0007565', 'female pregnancy', 24, 'pregnant'), ('CHEBI_30863', '5-azaorotic acid', 54, 'folate'), ('CHEBI_27568', 'selenium atom', 76, 'selenium'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 136, 'calcium'), ('CHEBI_35885', 'secondary phosphine', 145, 'phosphorus'), ('CHEBI_46751', 'quinolizidine', 172, 'minerals'), ('CHEBI_33277', 'gamma-tocotrienol', 185, 'vitamins')]	0	['nnr  women increase folate intake 65%, selenium 40%, iron, zinc,  25 30%, calcium, phosphorus, minerals vitamins 20% [3].']
S20-PMC4221707	PMC4221707	11/2014	S20-PMC4221707	['SIMILAR STUDIES focusing on early Pregnant caucasian women in great britain HAVE SHOWN INADEQUATE intakes of Vitamin C, Folate, Calcium, and iron [8–10].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 76), ('PROBLEM_COMPLICATION', 87)]	3	[('GO_0007565', 'female pregnancy', 34, 'pregnant'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin C'), ('CHEBI_30863', '5-azaorotic acid', 120, 'folate'), ('CHEBI_22313', 'alkaline earth metal atom', 128, 'calcium')]	0	['similar  caucasian women britain intakes folate, calcium, iron [8–10].']
S23-PMC4221707	PMC4221707	11/2014	S23-PMC4221707	['low Folate levels are also SUGGESTED to be ASSOCIATED with other Birth defects, such as cleft lip and palate, Heart defects, and autism [11,12], and low levels of Vitamin D are ASSOCIATED with various adverse Pregnancy and Birth outcomes [13,14].']	[('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 43), ('SUPERFICIAL_RELATIONSHIP', 177)]	3	[('CHEBI_30863', '5-azaorotic acid', 4, 'folate'), ('GO_0007567', 'parturition', 65, 'birth'), ('UBERON_0000948', 'heart', 110, 'heart'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy'), ('GO_0007567', 'parturition', 223, 'birth')]	0	['low folate levels birth defects, cleft lip palate, defects, autism [11,12], levels   birth outcomes [13,14].']
S24-PMC4221707	PMC4221707	11/2014	S24-PMC4221707	['THUS, the low intake of Folate, Vitamin D, and iron FOUND in swedish women who are of Childbearing age is of SPECIAL CONCERN, as women do not SEEM to improve the quality of their overall diet during Pregnancy [7,15].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 52), ('ANOMALY_CURIOUS_FINDING', 109), ('PROBLEM_COMPLICATION', 117), ('ANOMALY_CURIOUS_FINDING', 142)]	5	[('CHEBI_30863', '5-azaorotic acid', 24, 'folate'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 86, 'childbearing'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy')]	0	['thus, intake folate, iron swedish women childbearing age concern, women diet  [7,15].']
S134-PMC4221707	PMC4221707	11/2014	S134-PMC4221707	['mean daily Intake (amounts/day) of whole grain, Sucrose, total fat, saturated fat, monounsaturated fat, polyunsaturated fat, Iodine, calcium, Vitamin D, Folate, and Vitamin B12 from Foods did not differ between the Pregnant and referent women REGARDLESS OF standardization by the residual method or not, WHEREAS iron Intake from Foods TENDED to be lower in the Pregnant women (table\xa02).']	[('INCOMPLETE_EVIDENCE', 243), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 304), ('SUPERFICIAL_RELATIONSHIP', 335)]	3	[('GO_0007631', 'feeding behavior', 11, 'intake'), ('CHEBI_17992', 'sucrose', 48, 'sucrose'), ('CHEBI_24859', 'iodine atom', 125, 'iodine'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 153, 'folate'), ('CHEBI_33279', 'vitamin D5', 165, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 165, 'vitamin B12'), ('CHEBI_33290', 'food', 182, 'foods'), ('GO_0007565', 'female pregnancy', 215, 'pregnant'), ('GO_0007631', 'feeding behavior', 317, 'intake'), ('CHEBI_33290', 'food', 329, 'foods'), ('GO_0007565', 'female pregnancy', 361, 'pregnant')]	0	['mean daily intake (amounts/day) whole grain, sucrose, fat, saturated fat, monounsaturated fat, polyunsaturated fat, iodine, calcium, folate, vitamin b12 foods  referent women standardization residual not, iron intake foods  women (table\xa02).']
S137-PMC4221707	PMC4221707	11/2014	S137-PMC4221707	['addition from Supplements LED TO significantly higher estimated intake of Vitamin D and Folate and borderline significantly higher intake of Calcium and Vitamin B12 in the Pregnant than referent women, WHEREAS ESTIMATED Intake of iron supplement EVENED out the difference in Intakes from Foods only (table\xa02).']	[('SUPERFICIAL_RELATIONSHIP', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 202), ('INCOMPLETE_EVIDENCE', 210), ('ANOMALY_CURIOUS_FINDING', 246)]	4	[('CHEBI_33341', 'titanium atom', 14, 'supplements'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 88, 'folate'), ('CHEBI_22313', 'alkaline earth metal atom', 141, 'calcium'), ('CHEBI_33279', 'vitamin D5', 153, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 153, 'vitamin B12'), ('GO_0007565', 'female pregnancy', 172, 'pregnant'), ('GO_0007631', 'feeding behavior', 220, 'intake'), ('GO_0007631', 'feeding behavior', 275, 'intakes'), ('CHEBI_33290', 'food', 288, 'foods')]	0	['addition supplements higher intake  folate borderline higher intake calcium vitamin b12  referent women, intake iron supplement intakes foods (table\xa02).']
S178-PMC4221707	PMC4221707	11/2014	S178-PMC4221707	['IN GENERAL, this 2009 report FOUND that the intake of Folate and Vitamin D from foods was not sufficient to cover the nutritional demands during Pregnancy, and supplements were USUALLY REQUIRED before and during Pregnancy [37,38].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 177), ('IMPORTANT_CONSIDERATION', 185)]	4	[('CHEBI_30863', '5-azaorotic acid', 54, 'folate'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('GO_0007565', 'female pregnancy', 212, 'pregnancy')]	0	['general, 2009 intake folate  foods cover nutritional supplements  [37,38].']
S183-PMC4221707	PMC4221707	11/2014	S183-PMC4221707	['AS IN PREVIOUS STUDIES from sweden in women in Childbearing age [7], THIS STUDY FOUND that early Pregnant women had a low intake of Vitamin D and Folate from Foods.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 6), ('QUESTION_ANSWERED_BY_THIS_WORK', 69), ('INCOMPLETE_EVIDENCE', 80)]	4	[('GO_0007129', 'homologous chromosome pairing at meiosis', 47, 'childbearing'), ('GO_0007565', 'female pregnancy', 97, 'pregnant'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 146, 'folate'), ('CHEBI_33290', 'food', 158, 'foods')]	0	['sweden women childbearing age [7],  women intake  folate foods.']
S14-PMC4256222	PMC4256222	12/2014	S14-PMC4256222	['introduction\nAdult bone mass MAY BE INFLUENCED by FACTORS operating as early as in fetal Life[1], and there has in particular been interest on the ROLE of maternal Vitamin D status in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 36), ('SUPERFICIAL_RELATIONSHIP', 50), ('SUPERFICIAL_RELATIONSHIP', 147)]	4	[('UBERON_0007023', 'adult organism', 13, 'Adult'), ('UBERON_0000104', 'life cycle', 89, 'life'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]	0	['introduction\nadult bone mass fetal life[1], maternal  status .']
S21-PMC4256222	PMC4256222	12/2014	S21-PMC4256222	['TO OUR KNOWLEDGE, NO earlier STUDIES have focused on the INFLUENCE of Vitamin D status during Pregnancy on incident occurrences of offspring bone fractures during childhood.']	[('PROBABLE_UNDERSTANDING', 0), ('FULL_UNKNOWN', 18), ('SUPERFICIAL_RELATIONSHIP', 57)]	3	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy')]	0	['knowledge,  status  incident offspring bone fractures childhood.']
S25-PMC4256222	PMC4256222	12/2014	S25-PMC4256222	['in a prospective cohort with follow up over two decades, we therefore EXAMINED WHETHER the risk of bone fractures during the first 18 years of Life was ASSOCIATED with the maternal status of Vitamin D in Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 79), ('SUPERFICIAL_RELATIONSHIP', 152)]	3	[('UBERON_0000104', 'life cycle', 143, 'life'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy')]	0	['decades, bone fractures 18 life maternal status  .']
S74-PMC4256222	PMC4256222	12/2014	S74-PMC4256222	['women without a measured Vitamin D status were more OFTEN in the 30thweek of Gestation during the winter months (dec/jan/feb).']	[('PROBABLE_UNDERSTANDING', 52)]	1	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'gestation')]	0	['women  status 30thweek  winter months (dec/jan/feb).']
S79-PMC4256222	PMC4256222	12/2014	S79-PMC4256222	['season for Blood sampling was highly RELATED to the status of Vitamin D (p<0.001).10.1371/journal.pone.0114334.t001\n\ncaption (table-wrap): table 1\nbackground characteristics of participants in the dafo88 cohort according to offspring bone fracture (yes/no) and maternal vitamin d status (nmol/l) around Gestational week 30 (n\u200a=\u200a850) in aarhus city, denmark.fracturevitamin d status (%)missing %yes n\u200a=\u200a294no n\u200a=\u200a556 p value<50 n\u200a=\u200a21750–74.9 n\u200a=\u200a19975–125 n\u200a=\u200a321>125 n\u200a=\u200a113 p valuematernalage (mean)29.129.00.72a28.829.329.128.90.62abmi (mean)3.621.321.50.26a21.921.221.421.10.10aeducationstatus (%)unskilled14.012.70.85b17.110.712.313.00.59bskilled25.426.424.627.324.929.6university39.036.435.835.337.941.7higheracademic14.316.914.419.816.710.2other7.37.58.06.98.25.6smokingnever (%)5.357.461.20.30b55.856.062.567.00.12bparity (%)nulliparous58.857.00.26b46.157.864.261.10.004b1 child28.933.440.533.225.930.12+children12.29.513.49.010.08.8sex, boy (%)57.149.80.04b48.455.851.755.70.41bseason of blood draw (%)mar/apr/may14.011.90.26b12.414.616.24.4<0.001bjun/jul/aug30.825.88.818.134.372.6sep/oct/nov34.237.452.135.729.917.7dec/jan/feb21.024.826.731.719.65.3\ntwo-sided anova for measure of association.']	[('SUPERFICIAL_RELATIONSHIP', 37)]	1	[('UBERON_0000178', 'blood', 11, 'blood'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 303, 'gestational')]	0	['season blood sampling status  (p<0.001).10.1371/journal.pone.0114334.t001\n\ncaption (table-wrap): table 1\nbackground characteristics participants dafo88 offspring bone fracture (yes/no) maternal vitamin status (nmol/l)  week 30 (n\u200a=\u200a850) aarhus city, denmark.fracturevitamin status (%)missing %yes n\u200a=\u200a294no n\u200a=\u200a556 p value<50 n\u200a=\u200a21750–74.9 n\u200a=\u200a19975–125 n\u200a=\u200a321>125 n\u200a=\u200a113 p valuematernalage (mean)29.129.00.72a28.829.329.128.90.62abmi (mean)3.621.321.50.26a21.921.221.421.10.10aeducationstatus (%)unskilled14.012.70.85b17.110.712.313.00.59bskilled25.426.424.627.324.929.6university39.036.435.835.337.941.7higheracademic14.316.914.419.816.710.2other7.37.58.06.98.25.6smokingnever (%)5.357.461.20.30b55.856.062.567.00.12bparity (%)nulliparous58.857.00.26b46.157.864.261.10.004b1 child28.933.440.533.225.930.12+children12.29.513.49.010.08.8sex, boy (%)57.149.80.04b48.455.851.755.70.41bseason blood draw (%)mar/apr/may14.011.90.26b12.414.616.24.4<0.001bjun/jul/aug30.825.88.818.134.372.6sep/oct/nov34.237.452.135.729.917.7dec/jan/feb21.024.826.731.719.65.3\ntwo-sided anova measure association.']
S97-PMC4256222	PMC4256222	12/2014	S97-PMC4256222	['HOWEVER, in sensitivity analyses we FOUND a borderline significant inverse ASSOCIATION (p\u200a=\u200a0.054) between Vitamin D status in Pregnancy and offspring Forearm fractures.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 75)]	3	[('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('UBERON_0002386', 'forelimb zeugopod', 151, 'forearm')]	0	['however, sensitivity borderline (p\u200a=\u200a0.054)  status  offspring forearm fractures.']
S102-PMC4256222	PMC4256222	12/2014	S102-PMC4256222	['in that study, the authors SUGGESTED their findings to be caused by seasonal variation in Vitamin D status during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 27)]	1	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy')]	0	['study, authors seasonal  status .']
S103-PMC4256222	PMC4256222	12/2014	S103-PMC4256222	['HOWEVER, IF our results are reliable, there MIGHT be OTHER aspects UNDERLYING a seasonal variation during Pregnancy on bone fracture risk later in Life INDEPENDENTLY of Vitamin D status.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('INCOMPLETE_EVIDENCE', 44), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 53), ('SUPERFICIAL_RELATIONSHIP', 67), ('SUPERFICIAL_RELATIONSHIP', 152)]	6	[('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('UBERON_0000104', 'life cycle', 147, 'life'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]	0	['however, results reliable, aspects seasonal  bone fracture life  status.']
S108-PMC4256222	PMC4256222	12/2014	S108-PMC4256222	['[5]SHOWED a direct ASSOCIATION between maternal Vitamin D status during Pregnancy and bmc and bmd in 160 offspring at 9 years of age.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 19)]	2	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy')]	0	['[5]showed maternal  status  bmc bmd 160 offspring 9 age.']
S113-PMC4256222	PMC4256222	12/2014	S113-PMC4256222	['[8]in the same cohort FOUND no RELEVANT association between maternal Vitamin D status in Pregnancy and bmc in 3960 offspring at 9–10 years of age.']	[('INCOMPLETE_EVIDENCE', 22), ('IMPORTANT_CONSIDERATION', 31)]	2	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy')]	0	['[8]in maternal  status  bmc 3960 offspring 9–10 age.']
S126-PMC4256222	PMC4256222	12/2014	S126-PMC4256222	['we FOUND a borderline significant inverse ASSOCIATION between Vitamin D status in Pregnancy and offspring Forearm fractures.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 42)]	2	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('UBERON_0002386', 'forelimb zeugopod', 106, 'forearm')]	0	['borderline  status  offspring forearm fractures.']
S137-PMC4256222	PMC4256222	12/2014	S137-PMC4256222	['furthermore, OBSERVATIONS HAVE SHOWN that infant Vitamin D deficiency CAN be eliminated as early as 9 months Postpartum, IF Vitamin D drops with 10 µg of Vitamin D per day are given as RECOMMENDED[34].']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 70), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121), ('FUTURE_WORK', 185)]	5	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'postpartum'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]	0	['furthermore, infant  eliminated 9 months  drops 10 µg  day recommended[34].']
S144-PMC4256222	PMC4256222	12/2014	S144-PMC4256222	['in conclusion, our data INDICATED no overall association between maternal Vitamin D status during Pregnancy and offspring bone fractures in a prospective cohort with 18 years of follow-up through high-quality registries.']	[('INCOMPLETE_EVIDENCE', 24)]	1	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy')]	0	['conclusion, maternal  status  offspring bone fractures 18 follow-up high-quality registries.']
S296-PMC4258799	PMC4258799	11/2014	S296-PMC4258799	['rcts and prospective studies CONCUR that oral supplementation of Vitamin E reduces Lipid Peroxidation damage [102,150], improves Sperm Motility [102,103] and function [101] as well as improve Fertilization [150] and Pregnancy rates [102,103].']	[('INCOMPLETE_EVIDENCE', 29)]	1	[('CHEBI_27300', 'vitamin D', 65, 'vitamin E'), ('CHEBI_18059', 'lipid', 83, 'lipid'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 89, 'peroxidation'), ('CL_0000019', 'sperm', 129, 'sperm'), ('GO_0065007', 'biological regulation', 135, 'motility'), ('GO_0009566', 'fertilization', 192, 'fertilization'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy')]	0	['rcts oral supplementation  reduces lipid peroxidation [102,150], sperm motility [102,103] [101] fertilization [150]  rates [102,103].']
S310-PMC4258799	PMC4258799	11/2014	S310-PMC4258799	['HOWEVER, subsequent observational studies in men with POOR Sperm dna integrity showed that supplementation with both Vitamins E and C resulted in fewer Spermatozoa with fragmented dna [107,108], as well as higher Implantation and clinical Pregnancy rates [108].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 54)]	2	[('CL_0000019', 'sperm', 59, 'sperm'), ('CHEBI_27300', 'vitamin D', 117, 'vitamins E'), ('CHEBI_18245', 'carboxylato group', 132, 'C'), ('CL_0000019', 'sperm', 152, 'spermatozoa'), ('GO_0007566', 'embryo implantation', 213, 'implantation'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy')]	0	['however, men sperm dna integrity supplementation  c resulted spermatozoa fragmented dna [107,108], higher implantation  rates [108].']
S315-PMC4258799	PMC4258799	11/2014	S315-PMC4258799	['HOWEVER, smaller prospective studies SHOWED that oral Vitamin C supplementation in women, EITHER undergoing ivf-et treatment [123] or with Luteal phase defects [124], LEAD TO increased Pregnancy rates.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 37), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 90), ('SUPERFICIAL_RELATIONSHIP', 167)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin C'), ('GO_0007565', 'female pregnancy', 139, 'luteal'), ('GO_0007565', 'female pregnancy', 185, 'pregnancy')]	0	['however, oral  supplementation women, undergoing ivf-et treatment [123]  phase defects [124],  rates.']
S1-PMC4263713	PMC4263713	12/2014	S1-PMC4263713	['our PREVIOUS STUDY DEMONSTRATED that Gestational or early-Life Vitamin A deficiency decreases the number of Immune Cells in offspring.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 19)]	2	[('GO_0007565', 'female pregnancy', 37, 'gestational'), ('UBERON_0000104', 'life cycle', 58, 'life'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin A'), ('CL_0000738', 'leukocyte', 108, 'immune cells'), ('UBERON_0002405', 'immune system', 108, 'immune')]	0	[' early-life  decreases immune cells offspring.']
S9-PMC4263713	PMC4263713	12/2014	S9-PMC4263713	['in conclusion, the BEST recovery of a subset of Lymphocytes in the offspring of Gestational Vitamin A-deficient Rats and the greatest improvement in the Intestinal Mucosal immune response are achieved when Vitamin A supplementation occurs during the early Postnatal period.']	[('IMPORTANT_CONSIDERATION', 19)]	1	[('CL_0000542', 'lymphocyte', 48, 'lymphocytes'), ('GO_0007565', 'female pregnancy', 80, 'gestational'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin A'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 112, 'rats'), ('UBERON_0001262', 'wall of intestine', 153, 'intestinal mucosal'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin A'), ('GO_0007567', 'parturition', 256, 'postnatal')]	0	['conclusion, recovery subset lymphocytes offspring  -deficient rats intestinal mucosal immune response achieved  supplementation occurs postnatal period.']
S29-PMC4268639	PMC4268639	11/2014	S29-PMC4268639	['caption (table-wrap): table 1\n\nEMPHASIS of nutrition education classesnutrientspreconception1st trimester2nd trimester3rd trimesterpostnatal protein adequatecomplete, Carnitine, methionine, cysteine, 0.8 g/kgcomplete, adequate 1.1 g/kgcomplete, adequate 1.1 g/kgcomplete, adequate fat essential Fatty Acidsomega 3omega 3omega 3omega 3 Carbohydrate complexcomplexcomplex,fiber complexcomplex Minerals Iodine, iron, magnesium, zinc, calcium, Seleniumiodine, Seleniumiron, magnesium, calciumiron, zinc, magnesiumiron, calcium Vitamins methylation factorsvitamins d, b6, b12, folatevitamins e, D, cvitamins C, ab Vitamins, Vitamin D Phytonutrients full range of colors of fruits and vegetablescolors: oxidative reservecolors: Organ growthcolors: newborn preferencecolors: oxidant balance Probiotics immune balanceimmune balanceimmune balance\n\ncaption (table-wrap): table 2\n\nPrenatal supplements adjusted to levels of Hemoglobin, hematocrit, mean corpuscular volume, Vitamin D, Zinc, Carnitine, and mthfr statusvitamin a Mixed Carotenoids5000 iumethylcobalamin800 µgchromium (Chromium Niacinate)200 µgvitamin c250 mgbiotin100 µgmolybdenum (Molybdenum Glycinate)25 µgvitamin d32000 iupantothenic Acid (D-Calcium Pantothenate)25 mgomega-3 Fatty Acids620 mgvitamin E (Mixed)110 iuiron (iron Bisglycinate)25 mgepa400 mgthiamine (Mononitrate)5 mgiodine (Potassium Iodide)150 µgdha200 mgriboflavin (5 phosphate)5 mgzinc (Zinc Citrate)25 mgother omega-320 mgniacinamide25 mgselenium (l Selenomethionine)100 µgl-Carnitine as 1492 mg l-Carnitine tartrate1000 mgb6(Pyridoxal 5 Phosphate)15 mgcopper (Copper Gluconate)1.5 mgprobiotic blend: lactobacillus acidophilus 60 b cful-5-Methylfolate1000 µgmanganese (manganese gluconate)5 mg bifidobacterium lectis, lactobacillus plantarum, lactobacillus salivarius, streptococcus thermophilus\nabbreviations: cfu, colony-forming unit; Dha, Docosahexaenoic Acid; Epa, Eicosapentaenoic Acid; mthfr, Methylenetetrahydrofolate reductase.']	[('IMPORTANT_CONSIDERATION', 31)]	1	[('CHEBI_17126', 'carnitine', 167, 'carnitine'), ('CHEBI_39327', '(1S)-cis-(alphaR)-cyhalothrin', 295, 'fatty acidsOmega'), ('CHEBI_16646', 'carbohydrate', 335, 'Carbohydrate'), ('CHEBI_25468', 'naphthaldehydes', 391, 'Minerals'), ('CHEBI_31719', 'ipriflavone', 400, 'Iodine'), ('CHEBI_9107', 'senecionine', 440, 'seleniumIodine'), ('CHEBI_30483', 'trihydridotellurate(1-)', 456, 'seleniumIron'), ('CHEBI_28371', 'vitamin K epoxide', 523, 'Vitamins'), ('PR_000006444', 'diacylglycerol kinase delta', 590, 'D'), ('PR_000004900', 'complement C3', 603, 'C'), ('CHEBI_33277', 'gamma-tocotrienol', 609, 'vitamins'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin D'), ('CHEBI_36961', 'chalcocarbonic acid', 629, 'Phytonutrients'), ('UBERON_0000062', 'organ', 722, 'organ'), ('CHEBI_8474', 'propane-2-thiol', 784, 'Probiotics'), ('GO_0007565', 'female pregnancy', 870, 'Prenatal'), ('CHEBI_5679', 'herniarin', 913, 'Hemoglobin'), ('CHEBI_28384', 'vitamin K', 962, 'Vitamin D'), ('CHEBI_27377', 'Unsym-bis(4*-chlorophenyl)ethylene', 973, 'Zinc'), ('CHEBI_17126', 'carnitine', 979, 'Carnitine'), ('CHEBI_60004', 'mixture', 1016, 'mixed'), ('CHEBI_77957', 'm-fluoro-L-phenylalanine', 1022, 'carotenoids5000'), ('CHEBI_53471', 'chromium(III) sulfate', 1071, 'chromium niacinate'), ('UBERON_0002365', 'exocrine gland', 1135, 'molybdenum'), ('CHEBI_32508', 'glycinate', 1146, 'glycinate'), ('CHEBI_37527', 'acid', 1190, 'acid'), ('CHEBI_38294', 'dicarba-nido-undecaborane(11)', 1196, 'd-calcium pantothenate'), ('CHEBI_78128', 'fatty acid anion 24:0', 1232, 'fatty acids620'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1257, 'E'), ('CHEBI_60004', 'mixture', 1260, 'mixed'), ('CHEBI_32499', 'amineptine', 1283, 'bisglycinate'), ('CHEBI_29440', 'methanuidyl', 1320, 'mononitrate'), ('CHEBI_8346', 'potassium iodide', 1344, 'potassium iodide'), ('CHEBI_46916', 'vinyl acetate', 1410, 'zinc citrate'), ('CHEBI_26630', 'selenocystathionine', 1474, 'selenomethionine'), ('CHEBI_17126', 'carnitine', 1499, 'carnitine'), ('CHEBI_17126', 'carnitine', 1522, 'carnitine'), ('CHEBI_16462', 'glycylpeptide', 1550, 'Pyridoxal 5 phosphate'), ('CHEBI_23401', 'coumaric acid', 1585, 'copper gluconate'), ('CHEBI_82350', '5-Nitroacenaphthene', 1661, '5-Methylfolate1000'), ('CHEBI_17874', 'dihydrozeatin', 1861, 'DHA'), ('CHEBI_36003', 'decenoic acid', 1866, 'docosahexaenoic acid'), ('CHEBI_34733', 'EPN', 1888, 'EPA'), ('CHEBI_36003', 'decenoic acid', 1893, 'eicosapentaenoic acid'), ('CHEBI_38725', 'mevinphos', 1923, 'methylenetetrahydrofolate')]	0	['caption (table-wrap): table 1\n\nemphasis nutrition classesnutrientspreconception1st trimester2nd trimester3rd trimesterpostnatal protein adequatecomplete, carnitine, methionine, cysteine, 0.8 g/kgcomplete, 1.1 g/kgcomplete, 1.1 g/kgcomplete, fat fatty acidsomega 3omega 3omega 3omega 3 carbohydrate complexcomplexcomplex,fiber complexcomplex minerals iodine, iron, magnesium, zinc, calcium, seleniumiodine, seleniumiron, magnesium, calciumiron, zinc, magnesiumiron, calcium vitamins methylation factorsvitamins d, b6, b12, folatevitamins e, d, cvitamins c, ab vitamins,  phytonutrients colors fruits vegetablescolors: oxidative reservecolors: organ growthcolors: newborn preferencecolors: oxidant balance probiotics immune balanceimmune balanceimmune balance\n\ncaption (table-wrap): table 2\n\n supplements adjusted levels hemoglobin, hematocrit, corpuscular volume, vitamin d, zinc, carnitine, mthfr statusvitamin carotenoids5000 iumethylcobalamin800 µgchromium (chromium niacinate)200 µgvitamin c250 mgbiotin100 µgmolybdenum (molybdenum glycinate)25 µgvitamin d32000 iupantothenic acid (d-calcium pantothenate)25 mgomega-3 fatty acids620 mgvitamin e (mixed)110 iuiron (iron bisglycinate)25 mgepa400 mgthiamine (mononitrate)5 mgiodine (potassium iodide)150 µgdha200 mgriboflavin (5 phosphate)5 mgzinc (zinc citrate)25 mgother omega-320 mgniacinamide25 mgselenium (l selenomethionine)100 µgl-carnitine 1492 mg l-carnitine tartrate1000 mgb6(pyridoxal 5 phosphate)15 mgcopper (copper gluconate)1.5 mgprobiotic blend: lactobacillus acidophilus 60 b cful-5-methylfolate1000 µgmanganese (manganese gluconate)5 mg bifidobacterium lectis, lactobacillus plantarum, lactobacillus salivarius, streptococcus thermophilus\nabbreviations: cfu, colony-forming unit; dha, docosahexaenoic acid; epa, eicosapentaenoic acid; mthfr, methylenetetrahydrofolate reductase.']
S45-PMC4275593	PMC4275593	9/2014	S45-PMC4275593	['the supply of free or cheap Vitamin A and D tablets, milk, orange juice and cod Liver oil to expectant mothers and children through the wartime vitamin welfare scheme, with their perceived ROLE in the decline of maternal mortality, consolidated the IMPORTANCE of dietary supplements in Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 189), ('IMPORTANT_CONSIDERATION', 249)]	2	[('CHEBI_27300', 'vitamin D', 28, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 42, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 42, 'D'), ('UBERON_0002107', 'liver', 80, 'liver'), ('GO_0007565', 'female pregnancy', 286, 'pregnancy')]	0	['supply cheap  tablets, milk, orange juice cod liver oil expectant mothers children wartime vitamin welfare scheme, decline maternal mortality, consolidated dietary supplements .']
S127-PMC4275595	PMC4275595	9/2014	S127-PMC4275595	['a green ration book issued to Pregnant women on the production of a medical certificate entitled them to receive orange juice, cod Liver oil, Vitamin A and d tablets, an extra pint of Milk a day, an extra half ration of meat a week, and an extra Egg per allocation.64women were urged by a ministry of Food advertisement ‘welcome little stranger’, that ‘the very best welcome you can give your baby is a beautiful body, a contented disposition—and a healthy, happy mother.’ another advertisement WARNED them against giving these extra Foods to other family members, telling them, ‘don’t let dad get all the meat.’65\nthe interviewees had differing stories to tell about their Antenatal care.']	[('IMPORTANT_CONSIDERATION', 495)]	1	[('GO_0007565', 'female pregnancy', 30, 'pregnant'), ('UBERON_0002107', 'liver', 131, 'liver'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin A'), ('UBERON_0001913', 'milk', 184, 'milk'), ('CL_0000025', 'egg cell', 246, 'egg'), ('CHEBI_33290', 'food', 301, 'Food'), ('CHEBI_33290', 'food', 534, 'foods'), ('GO_0007567', 'parturition', 674, 'antenatal')]	0	['green ration book issued  women production medical certificate entitled receive orange juice, cod liver oil,  tablets, extra pint milk day, extra half ration meat week, extra egg allocation.64women ministry food advertisement ‘welcome stranger’, ‘the baby beautiful body, contented disposition—and healthy, happy mother.’ advertisement extra foods family members, telling them, ‘don’t let dad get meat.’65\nthe interviewees stories antenatal care.']
S186-PMC4277121	PMC4277121	12/2015	S186-PMC4277121	['in an ATTEMPT to prevent the developmental consequences of elevated oxidative stress, Pregnant ts65dn female Mice and their offspring were treated with a Vitamin E-enriched diet (0.002%, or tenfold lower than the amounts used in lockrow et al94).94offspring were continued on the enriched diet and tested on the mwm at 10 weeks of age.']	[('DIFFICULT_TASK', 6)]	1	[('GO_0007565', 'female pregnancy', 86, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 109, 'mice'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin E')]	0	['developmental elevated oxidative stress,  ts65dn female mice offspring treated -enriched diet (0.002%, tenfold amounts lockrow et al94).94offspring enriched diet mwm 10 weeks age.']
S257-PMC4277121	PMC4277121	12/2015	S257-PMC4277121	['for two Drugs, Fluoxetine and sag 1.1, treatment solely in the early Postnatal time periods resulted in successful l/m at young Adult ages of 6 weeks and 16 weeks, respectively.53,77indeed, for rescue on the mwm (but not on the spontaneous alternation y-maze), sag 1.1 treatment involved only a single p0 injection.77three Drugs were tested by the treatment of only Pregnant dams: Fluoxetine and Nap/sal were injected during Gestation;59,98and Choline was provided in Food to dams during Gestation and through weaning.105in another treatment, Vitamin E was provided in Food both to dams during Gestation and to the offspring through to the age of l/m testing.94in each case, the Prenatal Drug exposure resulted in AT LEAST the partial rescue of l/m in Adult offspring.']	[('PROBABLE_UNDERSTANDING', 714)]	1	[('CHEBI_23888', 'drug', 8, 'drugs'), ('CHEBI_5131', 'flurochloridone', 15, 'fluoxetine'), ('GO_0007567', 'parturition', 69, 'postnatal'), ('UBERON_0007023', 'adult organism', 128, 'adult'), ('CHEBI_23888', 'drug', 323, 'drugs'), ('GO_0007565', 'female pregnancy', 366, 'pregnant'), ('CHEBI_5131', 'flurochloridone', 381, 'fluoxetine'), ('CHEBI_13389', 'NAD', 396, 'NAP'), ('GO_0007565', 'female pregnancy', 425, 'gestation'), ('CHEBI_15354', 'choline', 444, 'choline'), ('CHEBI_33290', 'food', 468, 'food'), ('GO_0007565', 'female pregnancy', 488, 'gestation'), ('CHEBI_27300', 'vitamin D', 543, 'vitamin E'), ('CHEBI_33290', 'food', 569, 'food'), ('GO_0007565', 'female pregnancy', 594, 'gestation'), ('GO_0007565', 'female pregnancy', 679, 'prenatal'), ('CHEBI_23888', 'drug', 688, 'drug'), ('UBERON_0007023', 'adult organism', 752, 'adult')]	0	['drugs, fluoxetine sag 1.1, treatment postnatal periods resulted l/m young adult ages 6 weeks 16 weeks, respectively.53,77indeed, rescue mwm (but spontaneous alternation y-maze), sag 1.1 treatment single p0 injection.77three drugs treatment  dams: fluoxetine nap/sal injected ;59,98and choline food dams  weaning.105in treatment,  food dams  offspring age l/m testing.94in case,  drug exposure resulted rescue l/m adult offspring.']
S0-PMC4303849	PMC4303849	1/2015	S0-PMC4303849	['Regulation Of Calcitriol Biosynthesis and activity: focus on Gestational Vitamin D deficiency and adverse Pregnancy outcomes\n\nabstract\nVitamin D has garnered a great deal of ATTENTION in RECENT years DUE TO a GLOBAL prevalence of Vitamin D deficiency ASSOCIATED with an INCREASED RISK of a variety of Human diseases.']	[('INCOMPLETE_EVIDENCE', 174), ('INCOMPLETE_EVIDENCE', 187), ('PROBABLE_UNDERSTANDING', 200), ('IMPORTANT_CONSIDERATION', 209), ('SUPERFICIAL_RELATIONSHIP', 251), ('IMPORTANT_CONSIDERATION', 270)]	6	[('GO_1900952', 'positive regulation of 18-methylnonadec-1-ene biosynthetic process', 0, 'Regulation of Calcitriol Biosynthesis'), ('CHEBI_17823', 'calcitriol', 14, 'Calcitriol'), ('PR_000004909', 'complement component C8 beta chain', 14, 'Calcitriol'), ('GO_0007565', 'female pregnancy', 61, 'Gestational'), ('CHEBI_28384', 'vitamin K', 73, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 73, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'Pregnancy'), ('CHEBI_28384', 'vitamin K', 135, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 135, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 301, 'human')]	0	['regulation calcitriol biosynthesis activity:  vitamin  outcomes\n\nabstract\nvitamin garnered deal  human diseases.']
S2-PMC4303849	PMC4303849	1/2015	S2-PMC4303849	['THEREFORE, factors that Regulate Vitamin D Metabolism are of main IMPORTANCE, especially during Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 66)]	2	[('GO_0065007', 'biological regulation', 24, 'regulate'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 33, 'vitamin D metabolism'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]	0	['therefore, regulate  metabolism main importance, .']
S7-PMC4303849	PMC4303849	1/2015	S7-PMC4303849	['THIS REVIEW provides a current overview on the Regulation Of Vitamin D Metabolism, FOCUSING on Vitamin D deficiency during Gestation and its IMPACT on Pregnancy outcomes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 47), ('QUESTION_ANSWERED_BY_THIS_WORK', 83), ('SUPERFICIAL_RELATIONSHIP', 141)]	4	[('GO_0019216', 'regulation of lipid metabolic process', 47, 'regulation of vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'gestation'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy')]	0	[' metabolism,    outcomes.']
S246-PMC4303849	PMC4303849	1/2015	S246-PMC4303849	['in this regard, a study performed with Pregnant women in germany SHOWED that during the winter months, 98% of the maternal Blood samples and 94% of the Cord Blood samples had 25Ohd levels < 50 nmol/l, WHILE in the summer months, ONLY 49% of the women and 35% of the Cord Blood samples were Vitamin D deficient [220].']	[('INCOMPLETE_EVIDENCE', 65), ('ANOMALY_CURIOUS_FINDING', 201), ('ANOMALY_CURIOUS_FINDING', 229)]	3	[('GO_0007565', 'female pregnancy', 39, 'pregnant'), ('UBERON_0000178', 'blood', 123, 'blood'), ('UBERON_0002240', 'spinal cord', 152, 'cord'), ('UBERON_0000178', 'blood', 157, 'blood'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 175, '25OHD'), ('UBERON_0002240', 'spinal cord', 266, 'cord'), ('UBERON_0000178', 'blood', 271, 'blood'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin D')]	0	[' women germany winter months, 98% maternal blood samples 94% cord blood samples 25ohd levels 50 nmol/l, summer months, 49% women 35% cord blood samples  [220].']
S21-PMC4329404	PMC4329404	10/2014	S21-PMC4329404	"['[""""maternal Vitamin D status during Pregnancy MAY also determine risk of asthma Development RATHER than the child\'s own Vitamin D levels.""""]']"	[('INCOMPLETE_EVIDENCE', 43), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 89)]	2	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('GO_0008289', 'lipid binding', 77, 'development'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]	0	"['[""""maternn status durincy asthma child*s levels.""""]']"
S22-PMC4329404	PMC4329404	10/2014	S22-PMC4329404	['reduced maternal Vitamin D during Pregnancy HAS BEEN ASSOCIATED with an increase in early wheeze, but this ASSOCIATION does not extend to asthma at school age (14–16).']	[('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 53), ('SUPERFICIAL_RELATIONSHIP', 107)]	3	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 34, 'pregnancy')]	0	['reduced maternal   increase wheeze, asthma school age (14–16).']
S30-PMC4329404	PMC4329404	10/2014	S30-PMC4329404	['Pregnant females were Fed a Vitamin D-deficient diet starting from day-16 Gestation (last trimester) to FOCUS on Immune-mediated mechanisms of disease development in offspring and to limit any EFFECTS of in utero Vitamin D deficiency on foetal Lung growth and Development (27).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 104), ('SUPERFICIAL_RELATIONSHIP', 193)]	2	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007631', 'feeding behavior', 22, 'fed'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'gestation'), ('UBERON_0002405', 'immune system', 113, 'immune'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('GO_0030324', 'lung development', 244, 'lung ... development'), ('UBERON_0002048', 'lung', 244, 'lung')]	0	[' females fed -deficient diet day-16  (last trimester) immune-mediated mechanisms disease offspring utero  foetal lung (27).']
S133-PMC4329404	PMC4329404	10/2014	S133-PMC4329404	['discussion\nwe HAVE SHOWN that Adult female Mice given a Vitamin D-deficient diet for 4\xa0weeks (from day-16 Gestation until 3\xa0weeks Postpartum) developed a th2-skewed Pulmonary Immune phenotype, concomitant with reduced Cd4+Il-10+Regulatory Cells.']	[('INCOMPLETE_EVIDENCE', 14)]	1	[('UBERON_0007023', 'adult organism', 30, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 43, 'mice'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'gestation'), ('GO_0007565', 'female pregnancy', 130, 'postpartum'), ('UBERON_0002048', 'lung', 165, 'pulmonary'), ('UBERON_0002405', 'immune system', 175, 'immune'), ('PR_000001204', 'C-C chemokine receptor type 8', 218, 'CD4'), ('PR_000001470', 'interleukin-28B', 222, 'IL-10'), ('CL_0000232', 'erythrocyte', 228, 'regulatory cells'), ('GO_0065007', 'biological regulation', 228, 'regulatory')]	0	['discussion\nwe adult female mice 4\xa0weeks (from day-16  3\xa0weeks th2-skewed pulmonary immune phenotype, cd4+il-10+regulatory cells.']
S145-PMC4329404	PMC4329404	10/2014	S145-PMC4329404	['isolated Vitamin D deficiency throughout Gestation HAS BEEN SHOWN to cause deficits in Lung function in 2-week-old Mouse offspring (27).']	[('INCOMPLETE_EVIDENCE', 51)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'gestation'), ('UBERON_0002048', 'lung', 87, 'lung'), ('NCBITaxon_10088', 'Mus <genus>', 115, 'mouse')]	0	['isolated  throughout  lung 2-week-old mouse offspring (27).']
S13-PMC4329745	PMC4329745	10/2014	S13-PMC4329745	['FEW STUDIES HAVE BEEN performed on Vitamin D status in this country, focused mainly on Pregnant or elderly women (5,6).']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 12)]	2	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'pregnant')]	0	[' status country,  elderly women (5,6).']
S69-PMC4329745	PMC4329745	10/2014	S69-PMC4329745	['DEMONSTRATED that low early-Pregnancy Vitamin D status was ASSOCIATED with more depressive symptoms in Pregnancy (11).']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 59)]	2	[('GO_0007565', 'female pregnancy', 28, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]	0	['demonstrated early-  status depressive symptoms  (11).']
S93-PMC4340999	PMC4340999	3/2015	S93-PMC4340999	['INCONSISTENT findings and MIXED explanations of underlying mechanism HAVE BEEN REPORTED, including SPECULATION that early temperature exposure is ASSOCIATED with physiological Regulation Of Birth Weight or that extremely low ambient temperature INFLUENCES the Conceived Embryo or the selection of the Sperm that fuses with the Ovum.19–21HOWEVER, the findings from the current study APPEARED to more strongly SUGGEST the POSSIBLE etiological ROLE of Prenatal maternal exposure to ultraviolet b radiation (uvb) and Vitamin D status in Adult chronic diseases.29–31\nsun exposure provides one of the MAJOR ways to meet Vitamin D REQUIREMENTS during Pregnancy, ESPECIALLY for those of older generations.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 26), ('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 99), ('SUPERFICIAL_RELATIONSHIP', 146), ('SUPERFICIAL_RELATIONSHIP', 176), ('SUPERFICIAL_RELATIONSHIP', 245), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 334), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 335), ('ANOMALY_CURIOUS_FINDING', 382), ('INCOMPLETE_EVIDENCE', 408), ('INCOMPLETE_EVIDENCE', 420), ('SUPERFICIAL_RELATIONSHIP', 441), ('IMPORTANT_CONSIDERATION', 595), ('IMPORTANT_CONSIDERATION', 624), ('IMPORTANT_CONSIDERATION', 655)]	16	[('GO_0009937', 'regulation of gibberellic acid mediated signaling pathway', 176, 'regulation of birth weight'), ('GO_0070268', 'cornification', 260, 'conceived'), ('UBERON_0000922', 'embryo', 270, 'embryo'), ('CL_0000019', 'sperm', 301, 'sperm'), ('UBERON_0000978', 'leg', 327, 'ovum'), ('GO_0007565', 'female pregnancy', 449, 'prenatal'), ('CHEBI_27300', 'vitamin D', 513, 'vitamin D'), ('UBERON_0007023', 'adult organism', 533, 'adult'), ('CHEBI_27300', 'vitamin D', 614, 'vitamin D'), ('GO_0007565', 'female pregnancy', 644, 'pregnancy')]	0	['inconsistent reported, temperature exposure physiological birth ambient temperature conceived embryo selection sperm fuses ovum.19–21however, etiological  maternal exposure ultraviolet b radiation (uvb)  status adult chronic diseases.29–31\nsun exposure meet  older generations.']
S94-PMC4340999	PMC4340999	3/2015	S94-PMC4340999	['for latitudes with distinct seasonal changes in availability of uvb, there is a WELL-DOCUMENTED seasonal cycle in Vitamin D status, with a maximum in late summer and a minimum in late winter.32low Vitamin D during Gestation MAY STRONGLY INFLUENCE susceptibility to obesity later in Life.33\nhowever, relatively LITTLE IS KNOWN about the critical period of fetal growth at which low Vitamin D is of particular IMPORTANCE.']	[('PROBABLE_UNDERSTANDING', 80), ('INCOMPLETE_EVIDENCE', 85), ('INCOMPLETE_EVIDENCE', 224), ('PROBABLE_UNDERSTANDING', 228), ('SUPERFICIAL_RELATIONSHIP', 237), ('FULL_UNKNOWN', 310), ('IMPORTANT_CONSIDERATION', 408)]	7	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('GO_0007565', 'female pregnancy', 214, 'gestation'), ('UBERON_0000104', 'life cycle', 282, 'life'), ('CHEBI_27300', 'vitamin D', 381, 'vitamin D')]	0	['latitudes seasonal changes availability uvb, seasonal cycle  status, maximum late summer minimum late winter.32low   obesity life.33\nhowever, period fetal  importance.']
S95-PMC4340999	PMC4340999	3/2015	S95-PMC4340999	['low Vitamin D during the second or third Trimester of Pregnancy HAS BEEN SUGGESTED to be ASSOCIATED with Adult obesity.31,33in THE CURRENT STUDY, spring and early summer peaks and winter troughs for bmi and wc were evident.']	[('INCOMPLETE_EVIDENCE', 64), ('SUPERFICIAL_RELATIONSHIP', 89), ('QUESTION_ANSWERED_BY_THIS_WORK', 127)]	3	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 41, 'trimester'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('UBERON_0007023', 'adult organism', 105, 'adult')]	0	['low  third trimester  adult obesity.31,33in study, spring summer peaks winter troughs bmi wc evident.']
S98-PMC4340999	PMC4340999	3/2015	S98-PMC4340999	['up to now, a FEW STUDIES have EXAMINED the ASSOCIATION between lower maternal Vitamin D levels in later Pregnancy and offspring adiposity at age 6 years34; at birth, age 9 months and age 9 years35; at ages 5 and 9.5 years36; and at age 35 years,37and shown INCONSISTENT results.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 30), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('SUPERFICIAL_RELATIONSHIP', 43), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 257)]	5	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy')]	0	['now, maternal  levels  offspring adiposity age 6 years34; birth, age 9 months age 9 years35; ages 5 9.5 years36; age 35 years,37and results.']
S99-PMC4340999	PMC4340999	3/2015	S99-PMC4340999	['FURTHER STUDIES ARE WARRANTED to test the ASSOCIATION between Prenatal Vitamin D status and Adult adiposity in an Adult population older than 35 years.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 8), ('SUPERFICIAL_RELATIONSHIP', 42)]	3	[('GO_0007565', 'female pregnancy', 62, 'prenatal'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0007023', 'adult organism', 92, 'adult'), ('UBERON_0007023', 'adult organism', 114, 'adult')]	0	['  status adult adiposity adult population older 35 years.']
S101-PMC4340999	PMC4340999	3/2015	S101-PMC4340999	['month of Birth and three trimesters in relation to the calendar month of year, season, and the level of uvb radiation\nto OUR KNOWLEDGE, NO PREVIOUS STUDY has examined the RELATIONSHIP between Prenatal Vitamin D status and ll.']	[('PROBABLE_UNDERSTANDING', 121), ('FULL_UNKNOWN', 136), ('SUPERFICIAL_RELATIONSHIP', 171)]	3	[('GO_0007567', 'parturition', 9, 'birth'), ('GO_0007565', 'female pregnancy', 192, 'prenatal'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D')]	0	['month birth three trimesters calendar month year, season, uvb radiation\nto knowledge,   status ll.']
S109-PMC4340999	PMC4340999	3/2015	S109-PMC4340999	['results in the PRESENT STUDY IMPLY that Prenatal Vitamin D status MIGHT be a POTENTIAL pathway LINKING ll with Adult risks of obesity39,40and a range of chronic diseases.8–10HOWEVER, seasonal variation in ll DEPENDING ON region SUGGESTS that ll CAN ONLY be used as anthropometric BIOMARKER of Prenatal Vitamin D status in SOME geographic regions.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('PROBABLE_UNDERSTANDING', 29), ('INCOMPLETE_EVIDENCE', 66), ('INCOMPLETE_EVIDENCE', 77), ('SUPERFICIAL_RELATIONSHIP', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 172), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 208), ('INCOMPLETE_EVIDENCE', 228), ('INCOMPLETE_EVIDENCE', 245), ('INCOMPLETE_EVIDENCE', 249), ('SUPERFICIAL_RELATIONSHIP', 280), ('INCOMPLETE_EVIDENCE', 322)]	12	[('GO_0007565', 'female pregnancy', 40, 'prenatal'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('UBERON_0007023', 'adult organism', 111, 'adult'), ('GO_0007565', 'female pregnancy', 293, 'prenatal'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D')]	0	['results   status adult obesity39,40and chronic diseases.8–10however, seasonal region anthropometric   status geographic regions.']
S112-PMC4340999	PMC4340999	3/2015	S112-PMC4340999	['ALTHOUGH THE CURRENT STUDY is UNABLE TO precisely determine the REASON for mob variation in Adult measures of ll, general adiposity, and central adiposity, the study improves our current understanding of a POTENTIAL ASSOCIATION of Prenatal low exposure to Vitamin D during late second and early third trimesters with short ll and adiposity in later Life.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('DIFFICULT_TASK', 30), ('PROBABLE_UNDERSTANDING', 64), ('INCOMPLETE_EVIDENCE', 206), ('SUPERFICIAL_RELATIONSHIP', 216)]	6	[('UBERON_0007023', 'adult organism', 92, 'adult'), ('GO_0007565', 'female pregnancy', 231, 'prenatal'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D'), ('UBERON_0000104', 'life cycle', 349, 'life')]	0	['although mob adult ll, adiposity, central adiposity,  exposure  late third trimesters adiposity life.']
S113-PMC4340999	PMC4340999	3/2015	S113-PMC4340999	['Vitamin D insufficiency during Pregnancy is highly PREVALENT in a diverse range of populations living at various latitudes and in both developed and developing societies.29,33the adverse EFFECTS of Vitamin D insufficiency on offspring during development and later in Life HAVE also BEEN extended greatly.29–31from a PUBLIC HEALTH perspective, the POTENTIAL to PREVENT common chronic diseases via low-cost, simple, and SAFE Food fortification is an attractive option.33\nsome POTENTIAL limitations of this study WARRANT CONSIDERATION.']	[('IMPORTANT_CONSIDERATION', 51), ('SUPERFICIAL_RELATIONSHIP', 187), ('INCOMPLETE_EVIDENCE', 272), ('IMPORTANT_CONSIDERATION', 316), ('INCOMPLETE_EVIDENCE', 347), ('SUPERFICIAL_RELATIONSHIP', 360), ('IMPORTANT_CONSIDERATION', 418), ('INCOMPLETE_EVIDENCE', 474), ('FUTURE_WORK', 510), ('FUTURE_WORK', 518)]	10	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 31, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('UBERON_0000104', 'life cycle', 267, 'life'), ('CHEBI_33290', 'food', 423, 'food')]	0	['vitamin  populations living latitudes societies.29,33the  offspring life greatly.29–31from perspective, chronic diseases via low-cost, simple, food fortification option.33\nsome consideration.']
S125-PMC4340999	PMC4340999	3/2015	S125-PMC4340999	['this is also the FIRST-ever population-BASED EVIDENCE LINKING low Prenatal sun-RELATED uvb exposure (and lower Vitamin D by PROXY) to ll and the susceptibility to obesity later in Life and also SUGGESTING that late second and early third trimesters MIGHT be a CRITICAL period for the above-mentioned EFFECTS ALTHOUGH such EVIDENCE is non-specific, it WARRANTS FURTHER STUDIES in this AREA.']	[('INCOMPLETE_EVIDENCE', 17), ('QUESTION_ANSWERED_BY_THIS_WORK', 39), ('INCOMPLETE_EVIDENCE', 45), ('SUPERFICIAL_RELATIONSHIP', 54), ('SUPERFICIAL_RELATIONSHIP', 79), ('SUPERFICIAL_RELATIONSHIP', 124), ('INCOMPLETE_EVIDENCE', 194), ('INCOMPLETE_EVIDENCE', 249), ('IMPORTANT_CONSIDERATION', 260), ('SUPERFICIAL_RELATIONSHIP', 300), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 308), ('INCOMPLETE_EVIDENCE', 322), ('FUTURE_WORK', 351), ('FUTURE_WORK', 360), ('FUTURE_WORK', 384)]	15	[('GO_0007565', 'female pregnancy', 66, 'prenatal'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('UBERON_0000104', 'life cycle', 180, 'life')]	0	['population-based  sun-related uvb exposure (and  proxy) obesity life late third trimesters period above-mentioned non-specific, area.']
S13-PMC4368185	PMC4368185	3/2015	S13-PMC4368185	['Folic Acid (Fa), a Water-soluble Vitamin B, is an ESSENTIAL Nutrient during Gestation for Dna Methylation, Synthesis and Repair, and it is well KNOWN to reduce the RISK of Neural Tube defect (ntd) in the new-born [1,2].']	[('IMPORTANT_CONSIDERATION', 50), ('INCOMPLETE_EVIDENCE', 144), ('IMPORTANT_CONSIDERATION', 164)]	3	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('CHEBI_30751', 'formic acid', 12, 'FA'), ('CHEBI_15377', 'water', 19, 'water'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin B'), ('CHEBI_33284', 'nutrient', 60, 'nutrient'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('GO_0019277', 'UDP-N-acetylgalactosamine biosynthetic process', 90, 'DNA methylation ... synthesis'), ('GO_0006281', 'DNA repair', 121, 'repair'), ('UBERON_0001049', 'neural tube', 172, 'neural tube')]	0	['folic acid (fa), water-soluble nutrient  dna methylation, synthesis repair, neural tube defect (ntd) new-born [1,2].']
S75-PMC4377870	PMC4377870	3/2015	S75-PMC4377870	['maternal intake of Vitamin E, Vitamin D, milk, cheese and calcium during Pregnancy are negatively ASSOCIATED, WHILE Vitamin C is positively ASSOCIATED, with wheezing in early childhood [57,58].']	[('SUPERFICIAL_RELATIONSHIP', 98), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 110), ('ANOMALY_CURIOUS_FINDING', 110), ('SUPERFICIAL_RELATIONSHIP', 140)]	4	[('CHEBI_27300', 'vitamin D', 19, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin C')]	0	['maternal intake , milk, cheese calcium  associated,  positively associated, wheezing childhood [57,58].']
S108-PMC4377870	PMC4377870	3/2015	S108-PMC4377870	['dietary intake of Vitamin E lower than RECOMMENDED dietary intakes HAS BEEN REPORTED in Pregnant women with a family history of allergic disease [88] and RECENT work in Animal MODELS has HIGHLIGHTED Α-Tocopherol MAY BE IMPORTANT for allergic mothers in Pregnancy.']	[('FUTURE_WORK', 39), ('INCOMPLETE_EVIDENCE', 67), ('INCOMPLETE_EVIDENCE', 154), ('INCOMPLETE_EVIDENCE', 176), ('INCOMPLETE_EVIDENCE', 187), ('INCOMPLETE_EVIDENCE', 212), ('IMPORTANT_CONSIDERATION', 219)]	7	[('CHEBI_27300', 'vitamin D', 18, 'vitamin E'), ('GO_0007565', 'female pregnancy', 88, 'pregnant'), ('NCBITaxon_33208', 'Metazoa', 169, 'animal'), ('CHEBI_27725', 'butin', 199, 'α-tocopherol'), ('GO_0007565', 'female pregnancy', 253, 'pregnancy')]	0	['dietary intake  dietary intakes  women family allergic disease [88] animal α-tocopherol allergic mothers .']
S152-PMC4377870	PMC4377870	3/2015	S152-PMC4377870	['[119] FOUND that Vitamin D deficiency at 18 weeks Gestation was ASSOCIATED with lower Lung function and current wheeze in children 6 years of age and an increased risk of asthma in boys.']	[('INCOMPLETE_EVIDENCE', 6), ('SUPERFICIAL_RELATIONSHIP', 64)]	2	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'gestation'), ('UBERON_0002048', 'lung', 86, 'lung')]	0	['[119]  18 weeks  lung wheeze children 6 age asthma boys.']
S92-PMC4377879	PMC4377879	3/2015	S92-PMC4377879	['AS Pregnancy does not require additional Vitamin E and it is common in MOST diets, additional Vitamin E is UNLIKELY to be REQUIRED [21].']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 71), ('PROBABLE_UNDERSTANDING', 107), ('IMPORTANT_CONSIDERATION', 122)]	4	[('GO_0007565', 'female pregnancy', 3, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin E')]	0	['  diets,  [21].']
S95-PMC4377879	PMC4377879	3/2015	S95-PMC4377879	['POSSIBLE side-effects of overdosage of Vitamin E and Vitamin C in Pregnancy are discussed below (section 7.2).']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 39, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin C'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy')]	0	['possible side-effects overdosage    (section 7.2).']
S179-PMC4377879	PMC4377879	3/2015	S179-PMC4377879	['indicators of low Vitamin B-12 are ASSOCIATED with adverse Pregnancy outcomes, anaemia, low birthweight, and Intrauterine retardation [9].']	[('SUPERFICIAL_RELATIONSHIP', 35)]	1	[('CHEBI_27300', 'vitamin D', 18, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 18, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('UBERON_0022293', 'reproductive gland secretion', 109, 'intrauterine')]	0	['indicators -12  outcomes, anaemia, birthweight, intrauterine retardation [9].']
S181-PMC4377879	PMC4377879	3/2015	S181-PMC4377879	['oral supplementation of urban indian women with Vitamin B-12 throughout Pregnancy and early Lactation significantly increased Vitamin B-12 status of both mothers and infants [9] and so WORTH CONSIDERING where Vitamin B12 intakes are marginal.']	[('IMPORTANT_CONSIDERATION', 185), ('FUTURE_WORK', 191)]	2	[('CHEBI_27300', 'vitamin D', 48, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 48, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0007595', 'lactation', 92, 'lactation'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 126, 'vitamin B-12'), ('CHEBI_33279', 'vitamin D5', 209, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 217, 'B12')]	0	['oral supplementation urban indian women -12 throughout  lactation -12 status mothers infants [9] vitamin b12 intakes marginal.']
S262-PMC4377879	PMC4377879	3/2015	S262-PMC4377879	['the provision of balanced energy protein supplementary Foods to underweight Pregnant women was also considered to have enough EVIDENCE of reduction in sga and stillbirths and improved Birthweights for widespread implementation, WHEREAS maternal Vitamin D and zinc supplementation, WHILE promising, were CONSIDERED to have INSUFFICIENT evidence [18].']	[('INCOMPLETE_EVIDENCE', 126), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 281), ('ANOMALY_CURIOUS_FINDING', 281), ('INCOMPLETE_EVIDENCE', 303), ('INCOMPLETE_EVIDENCE', 322)]	6	[('CHEBI_33290', 'food', 55, 'foods'), ('GO_0007565', 'female pregnancy', 76, 'pregnant'), ('GO_0007596', 'blood coagulation', 184, 'birthweights'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D')]	0	['provision energy protein supplementary foods underweight  women reduction sga stillbirths birthweights implementation, maternal  zinc supplementation, promising, [18].']
S12-PMC4377896	PMC4377896	3/2015	S12-PMC4377896	['introduction\nfish is a source of several Nutrients that are IMPORTANT during Pregnancy for healthy Foetal Development including Iodine, Long Chain Omega-3 polyunsaturated Fatty Acids (lc n- 3pufas), and Vitamins A, D and B12 [1].']	[('IMPORTANT_CONSIDERATION', 60)]	1	[('CHEBI_33284', 'nutrient', 41, 'nutrients'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0060324', 'face development', 99, 'foetal development'), ('CHEBI_24859', 'iodine atom', 128, 'iodine'), ('CHEBI_77190', 'CDP-dipalmitoyl-sn-glycerol(2-)', 136, 'long chain omega-3'), ('CHEBI_35366', 'fatty acid', 171, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 203, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 203, 'vitamins A'), ('PR_000006444', 'diacylglycerol kinase delta', 215, 'D'), ('CHEBI_27778', 'abequose', 221, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 221, 'B12')]	0	['introduction\nfish nutrients  healthy foetal iodine, chain omega-3 polyunsaturated fatty acids (lc n- 3pufas), b12 [1].']
S148-PMC4377896	PMC4377896	3/2015	S148-PMC4377896	['this MAY BE attributable to the synergistic EFFECTS of Food [34] and ASSOCIATED with fish being a source of OTHER Nutrients which are IMPORTANT for infant development such as Iodine and Vitamin D. presently, there HAVE BEEN NO randomised control TRIALS examining Neurocognitive outcomes ASSOCIATED with Prenatal multivitamin use and infant Neurodevelopment, and these are UNLIKELY to occur given ethical IMPLICATIONS of such [35].']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 69), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 108), ('IMPORTANT_CONSIDERATION', 134), ('INCOMPLETE_EVIDENCE', 214), ('FULL_UNKNOWN', 224), ('SUPERFICIAL_RELATIONSHIP', 287), ('PROBABLE_UNDERSTANDING', 372), ('IMPORTANT_CONSIDERATION', 404)]	10	[('CHEBI_33290', 'food', 55, 'food'), ('CHEBI_33284', 'nutrient', 114, 'nutrients'), ('CHEBI_24859', 'iodine atom', 175, 'iodine'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('GO_0050905', 'neuromuscular process', 263, 'neurocognitive'), ('GO_0007565', 'female pregnancy', 303, 'prenatal'), ('GO_0007399', 'nervous system development', 340, 'neurodevelopment')]	0	['synergistic food [34] fish nutrients infant iodine . presently, randomised neurocognitive outcomes  multivitamin infant neurodevelopment, occur ethical [35].']
S91-PMC4380381	PMC4380381	3/2015	S91-PMC4380381	['a thorough review of the patient’s medications MAY reveal one of a NUMBER OF agents KNOWN to cause Intracranial hypertension including Vitamin A and Nitrofurantoin.35\nfirst-line therapy for iih in Pregnancy is diet and weight control.35second-line therapies include serial Lps and/or Acetazolamide (category c).']	[('INCOMPLETE_EVIDENCE', 47), ('INCOMPLETE_EVIDENCE', 67), ('INCOMPLETE_EVIDENCE', 84)]	3	[('UBERON_2000442', 'supraneural bone', 99, 'intracranial'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin A'), ('CHEBI_85122', 'paraben', 149, 'nitrofurantoin'), ('GO_0007565', 'female pregnancy', 197, 'pregnancy'), ('CHEBI_16412', 'lipopolysaccharide', 273, 'LPs'), ('CHEBI_27690', 'acetazolamide', 284, 'acetazolamide')]	0	['thorough patient’s medications agents intracranial hypertension  nitrofurantoin.35\nfirst-line therapy iih  diet control.35second-line therapies serial lps and/or acetazolamide (category c).']
S0-PMC4380518	PMC4380518	9/2014	S0-PMC4380518	['Prenatal Vitamin use and Vitamin D status during Pregnancy, differences by race and overweight status\n\nabstract\n\nobjective\nwe AIMED TO STUDY WHETHER Prenatal Vitamin (pnv) use PROTECTS against low 25(Oh)D levels in all women and PARTICULARLY in obese and black women who are both AT RISK of Vitamin D deficiency and poor pregnancy outcomes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 126), ('QUESTION_ANSWERED_BY_THIS_WORK', 132), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('SUPERFICIAL_RELATIONSHIP', 176), ('IMPORTANT_CONSIDERATION', 229), ('IMPORTANT_CONSIDERATION', 280)]	6	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_33229', 'vitamin (role)', 9, 'Vitamin'), ('CHEBI_28384', 'vitamin K', 25, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 49, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 149, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 158, 'vitamin'), ('CHEBI_71657', 'versiconol acetate', 197, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 203, 'D'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin D')]	0	[' vitamin vitamin status race overweight status\n\nabstract\n\nobjective\nwe  vitamin (pnv) 25(oh)d levels women obese black women  pregnancy outcomes.']
S6-PMC4380518	PMC4380518	9/2014	S6-PMC4380518	['conclusions\nongoing trials of Vitamin D supplementation during Pregnancy SHOULD CONSIDER POTENTIAL EFFECT MODIFICATION by race/ethnicity.']	[('FUTURE_WORK', 73), ('FUTURE_WORK', 80), ('INCOMPLETE_EVIDENCE', 89), ('PROBLEM_COMPLICATION', 99)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy')]	0	['conclusions\nongoing  supplementation  race/ethnicity.']
S7-PMC4380518	PMC4380518	9/2014	S7-PMC4380518	['introduction\nPerinatal health outcomes VARY dramatically by race in the united states.1african american women develop Preeclampsia more OFTEN than their white counterparts2and are more LIKELY to develop preterm labor.3the result is that black infants are 60% more LIKELY BE preterm and four times more LIKELY to die due to prematurity than white infants.1BECAUSE of less efficient Vitamin D Synthesis in the skin of darker Pigmented Individuals, african americans are at higher RISK than white americans of Vitamin D deficiency.4,5black women are also more LIKELY than white women to be overweight or obese6which is of CONCERN BECAUSE obesity is another RISK FACTOR for Vitamin D deficiency5,7and poor Perinatal outcomes.8in OBSERVATIONAL studies, 25-Hydroxyvitamin D (25[Oh]D) levels HAVE BEEN SHOWN to be ASSOCIATED with higher risk of several adverse Perinatal outcomes including Gestational diabetes9,10, preeclampsia,11preterm Birth12And small-for-Gestational age status.13,14,15,16,17BECAUSE of the PAUCITY of Vitamin D trial data with respect to Perinatal outcomes, WHETHER DIFFERENCES in Vitamin D status during Pregnancy explains or partially explains Perinatal DISPARITIES is PLAUSIBLE18but REMAINS UNKNOWN.']	[('DIFFICULT_TASK', 39), ('PROBABLE_UNDERSTANDING', 136), ('PROBABLE_UNDERSTANDING', 185), ('PROBABLE_UNDERSTANDING', 264), ('PROBABLE_UNDERSTANDING', 302), ('PROBABLE_UNDERSTANDING', 355), ('IMPORTANT_CONSIDERATION', 478), ('PROBABLE_UNDERSTANDING', 557), ('PROBLEM_COMPLICATION', 619), ('PROBABLE_UNDERSTANDING', 627), ('SUPERFICIAL_RELATIONSHIP', 654), ('INCOMPLETE_EVIDENCE', 725), ('INCOMPLETE_EVIDENCE', 785), ('SUPERFICIAL_RELATIONSHIP', 807), ('PROBABLE_UNDERSTANDING', 990), ('INCOMPLETE_EVIDENCE', 1005), ('EXPLICIT_QUESTION', 1073), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1081), ('IMPORTANT_CONSIDERATION', 1171), ('INCOMPLETE_EVIDENCE', 1186), ('FULL_UNKNOWN', 1201)]	21	[('GO_0036268', 'swimming', 13, 'Perinatal'), ('UBERON_0012101', 'perinatal stage', 13, 'Perinatal'), ('GO_0007128', 'meiotic prophase I', 118, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 381, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 381, 'vitamin D synthesis'), ('CHEBI_26130', 'biological pigment', 423, 'pigmented'), ('NCBITaxon_1', 'root', 433, 'individuals'), ('CHEBI_27300', 'vitamin D', 507, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 670, 'vitamin D'), ('GO_0036268', 'swimming', 702, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 702, 'perinatal'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 748, '25-hydroxyvitamin D'), ('CHEBI_15643', '(6R)-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-6H-pterin', 769, '25[OH]D'), ('GO_0036268', 'swimming', 854, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 854, 'perinatal'), ('GO_0007565', 'female pregnancy', 883, 'gestational'), ('GO_0007594', 'puparial adhesion', 932, 'birth12and'), ('GO_0007565', 'female pregnancy', 953, 'gestational'), ('CHEBI_27300', 'vitamin D', 1016, 'vitamin D'), ('GO_0036268', 'swimming', 1053, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1053, 'perinatal'), ('CHEBI_27300', 'vitamin D', 1096, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1120, 'pregnancy'), ('GO_0036268', 'swimming', 1161, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1161, 'perinatal')]	0	['introduction\nperinatal outcomes race united states.1african american women preeclampsia white counterparts2and preterm labor.3the result black infants 60% preterm four times die prematurity white infants.1because efficient  synthesis skin darker pigmented individuals, african americans higher white americans  deficiency.4,5black women white women overweight obese6which obesity  deficiency5,7and perinatal outcomes.8in studies, 25-hydroxyvitamin (25[oh]d) levels higher perinatal outcomes  diabetes9,10, preeclampsia,11preterm birth12and small-for- age status.13,14,15,16,17because  respect perinatal outcomes, perinatal plausible18but unknown.']
S8-PMC4380518	PMC4380518	9/2014	S8-PMC4380518	['furthermore, WHILE multivitamin intake HAS BEEN SHOWN to VARY by race,19it REMAINS UNKNOWN WHETHER multivitamin intake improves Vitamin D status among the HIGHEST RISK groups (african americans and overweight/obese) during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 13), ('INCOMPLETE_EVIDENCE', 39), ('DIFFICULT_TASK', 57), ('FULL_UNKNOWN', 75), ('EXPLICIT_QUESTION', 91), ('IMPORTANT_CONSIDERATION', 155)]	6	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('GO_0007565', 'female pregnancy', 223, 'pregnancy')]	0	['furthermore, multivitamin intake race,19it multivitamin intake  status among (african americans overweight/obese) .']
S10-PMC4380518	PMC4380518	9/2014	S10-PMC4380518	['our HYPOTHESIS was that lack of Prenatal vitamin (pnv) use WOULD BE ASSOCIATED with Vitamin D deficiency (DEFINED as <50 nmol/).']	[('INCOMPLETE_EVIDENCE', 4), ('FUTURE_PREDICTION', 59), ('SUPERFICIAL_RELATIONSHIP', 68), ('PROBABLE_UNDERSTANDING', 106)]	4	[('GO_0007565', 'female pregnancy', 32, 'prenatal'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]	0	[' vitamin (pnv)  (defined <50 nmol/).']
S36-PMC4380518	PMC4380518	9/2014	S36-PMC4380518	['in other words, early pnv use was ASSOCIATED with Vitamin D sufficiency earlier in Pregnancy BUT NOT later in Pregnancy (table 4).']	[('SUPERFICIAL_RELATIONSHIP', 34), ('ANOMALY_CURIOUS_FINDING', 93)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy')]	0	['words, pnv    (table 4).']
S47-PMC4380518	PMC4380518	9/2014	S47-PMC4380518	['discussion\nour data SUGGEST that WHILE Prenatal pnv use is ASSOCIATED with lower odds of Vitamin D deficiency, the ASSOCIATION is NOT UNIFORM.']	[('INCOMPLETE_EVIDENCE', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 33), ('SUPERFICIAL_RELATIONSHIP', 59), ('SUPERFICIAL_RELATIONSHIP', 115), ('DIFFICULT_TASK', 130)]	5	[('GO_0007565', 'female pregnancy', 39, 'prenatal'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]	0	['discussion\nour  pnv  deficiency, uniform.']
S52-PMC4380518	PMC4380518	9/2014	S52-PMC4380518	['shea et al studied 2500 elderly Adults and FOUND that lack of pnv use was ASSOCIATED with higher odds of Vitamin D insufficiency (<75 nmol/l) in both black (5.2 (95% ci: 3.5, 7.7)) and white participants (or 2.6, 95% ci: 2.0, 3.2), HOWEVER these subjects were much older and not Pregnant.26a SMALL turkish STUDY of 79 Pregnant women SHOWED significantly higher 25(Oh)D levels among women reporting pnv use in the third trimester,27BUT this study DID NOT include women of african descent and DID NOT have the power to address POTENTIAL INTERACTION by bmi.']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 232), ('INCOMPLETE_EVIDENCE', 292), ('INCOMPLETE_EVIDENCE', 333), ('PROBLEM_COMPLICATION', 431), ('INCOMPLETE_EVIDENCE', 446), ('INCOMPLETE_EVIDENCE', 491), ('INCOMPLETE_EVIDENCE', 525), ('SUPERFICIAL_RELATIONSHIP', 535)]	10	[('UBERON_0007023', 'adult organism', 32, 'adults'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 279, 'pregnant'), ('GO_0007565', 'female pregnancy', 318, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 361, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 361, '25(OH)D')]	0	['shea et al 2500 elderly adults pnv higher  (<75 nmol/l) black (5.2 (95% ci: 3.5, 7.7)) white participants (or 2.6, 95% ci: 2.0, 3.2), subjects older .26a turkish 79  women higher 25(oh)d levels among women pnv third trimester,27but women african descent bmi.']
S65-PMC4380518	PMC4380518	9/2014	S65-PMC4380518	['IN CONTRAST, our data SUPPORT INVESTIGATION into higher doses of Vitamin D in subgroups at high RISK IF BENEFITS are demonstrated by ONGOING TRIALS in Pregnancy of achieving higher 25(Oh)D levels.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 22), ('FUTURE_WORK', 30), ('IMPORTANT_CONSIDERATION', 96), ('FUTURE_PREDICTION', 101), ('IMPORTANT_CONSIDERATION', 104), ('INCOMPLETE_EVIDENCE', 133)]	7	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 181, '25(OH)D')]	0	['contrast, higher doses  subgroups  achieving higher 25(oh)d levels.']
S67-PMC4380518	PMC4380518	9/2014	S67-PMC4380518	['in conclusion, we FOUND that lack of pnv use during Pregnancy was ASSOCIATED with Vitamin D deficiency early in Pregnancy, BUT NOT among black women.']	[('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 66), ('ANOMALY_CURIOUS_FINDING', 123)]	3	[('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy')]	0	['conclusion, pnv   among black women.']
S68-PMC4380518	PMC4380518	9/2014	S68-PMC4380518	['IN LIGHT OF two RECENT meta-analyses/systematic reviews CONCLUDING that low 25(Oh)D levels during Pregnancy are ASSOCIATED with SEVERAL morbidities in Pregnancy15,16, optimizing Vitamin D status during Pregnancy MAY BE IMPORTANT.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 16), ('PROBABLE_UNDERSTANDING', 56), ('SUPERFICIAL_RELATIONSHIP', 112), ('INCOMPLETE_EVIDENCE', 128), ('INCOMPLETE_EVIDENCE', 212), ('IMPORTANT_CONSIDERATION', 219)]	7	[('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 76, '25 ... OH ... D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy15'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy')]	0	['meta-analyses/systematic 25(oh)d levels  morbidities ,16, optimizing  status  important.']
S69-PMC4380518	PMC4380518	9/2014	S69-PMC4380518	['ONGOING TRIALS of Vitamin D supplementation during Pregnancy SHOULD CONSIDER EFFECT MODIFICATION by race/ethnicity.']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 61), ('FUTURE_WORK', 68), ('PROBLEM_COMPLICATION', 77)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy')]	0	['ongoing  supplementation  race/ethnicity.']
S80-PMC4383226	PMC4383226	2/2015	S80-PMC4383226	['HOWEVER, for antigenemia, Vitamin A was moderately more PROTECTIVE in older children (ptrend<0.001), the more time passed since supplementation (ptrend<0.001) or if supplementation was given during the wet season (ptrend=0.04).table 3reveals that ASSOCIATIONS between Vitamin A and parasitemia were stronger among children 36–59 months of age or if their mother took an Antimalarial during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 56), ('SUPERFICIAL_RELATIONSHIP', 247)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin A'), ('CHEBI_67261', '(Z)-2,3-dehydroadipyl-CoA(5-)', 370, 'antimalarial'), ('GO_0007565', 'female pregnancy', 390, 'pregnancy')]	0	['however, antigenemia,  moderately older children (ptrend<0.001), passed supplementation (ptrend<0.001) supplementation wet season (ptrend=0.04).table 3reveals  parasitemia among children 36–59 months age mother took antimalarial .']
S108-PMC4383226	PMC4383226	2/2015	S108-PMC4383226	"['[""""Placental malaria and Vitamin A\\ndifferences in the IMPACT of Vitamin A on malaria infection by Birth weight, and having a mother who used Antimalarials during the child\'s Gestational period SUGGESTS exposure to Placental malaria MAY play a CRITICAL ROLE in Vitamin A\'s PROTECTIVE EFFECT mechanisms later on in childhood.""""]']"	[('SUPERFICIAL_RELATIONSHIP', 51), ('INCOMPLETE_EVIDENCE', 190), ('INCOMPLETE_EVIDENCE', 229), ('IMPORTANT_CONSIDERATION', 240), ('SUPERFICIAL_RELATIONSHIP', 249), ('SUPERFICIAL_RELATIONSHIP', 269), ('SUPERFICIAL_RELATIONSHIP', 280)]	7	[('UBERON_0001987', 'placenta', 0, 'Placental'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin A'), ('GO_0007567', 'parturition', 95, 'birth'), ('CHEBI_22580', 'anthraquinone', 138, 'antimalarials'), ('GO_0007565', 'female pregnancy', 171, 'gestational'), ('UBERON_0001987', 'placenta', 211, 'placental'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin A')]	0	"['[""""placental malaria a\\ndifferences impactin malaria infection birth weight, mother antimalarials chilonal period exposure placental malaria play rolein a*s mechanisms childhood.""""]']"
S112-PMC4383226	PMC4383226	2/2015	S112-PMC4383226	['ADDITIONAL RESEARCH MAY BE WARRANTED on the IMPACT of Vitamin A supplementation in young children with known Prenatal exposure to malaria.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 11), ('FUTURE_WORK', 20), ('SUPERFICIAL_RELATIONSHIP', 44)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin A'), ('GO_0007565', 'female pregnancy', 109, 'prenatal')]	0	['additional  supplementation young children  exposure malaria.']
S254-PMC4383575	PMC4383575	1/2015	S254-PMC4383575	['several POTENTIAL modifiable FACTORS (e.g., higher maternal pre-Pregnancy bmi, low maternal Intake of healthy Foods, and low Intake of fruits rich in Vitamin C) were IDENTIFIED as POTENTIAL RISK FACTORS.']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 29), ('INCOMPLETE_EVIDENCE', 166), ('INCOMPLETE_EVIDENCE', 180), ('SUPERFICIAL_RELATIONSHIP', 190)]	5	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007631', 'feeding behavior', 92, 'intake'), ('CHEBI_33290', 'food', 110, 'foods'), ('GO_0007631', 'feeding behavior', 125, 'intake'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin C')]	0	['several (e.g., higher maternal pre- bmi, maternal intake healthy foods, intake fruits rich factors.']
S72-PMC4392531	PMC4392531	3/2015	S72-PMC4392531	['they DEMONSTRATED that in those women who Consumed less than 10% of Foods containing Vitamin C and less than 21 mg per day of this Vitamin before Pregnancy, the risk of premature rupture Of the Fetal Membranes and Preterm Delivery were two times higher than in other women.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('GO_0007631', 'feeding behavior', 42, 'consumed'), ('CHEBI_33290', 'food', 68, 'foods'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin C'), ('CHEBI_33229', 'vitamin (role)', 131, 'vitamin'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy'), ('GO_0007608', 'sensory perception of smell', 187, 'of ...'), ('UBERON_0000922', 'embryo', 194, 'fetal'), ('UBERON_0000922', 'embryo', 200, 'membranes'), ('GO_0007565', 'female pregnancy', 214, 'preterm'), ('GO_0007567', 'parturition', 222, 'delivery')]	0	['women consumed 10% foods containing  21 mg day vitamin premature rupture fetal membranes  delivery times higher women.']
S77-PMC4392531	PMC4392531	3/2015	S77-PMC4392531	['[15] with reviewing a large NUMBER of controlled clinical trials, villar and colleagues CONCLUDED that lack of antioxidants including Vitamins A, e, and C in Pregnant women CAN increase the incidence of pre-eclampsia.']	[('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 88), ('INCOMPLETE_EVIDENCE', 173)]	3	[('CHEBI_27300', 'vitamin D', 134, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 143, 'A'), ('PR_000004900', 'complement C3', 153, 'C'), ('GO_0007565', 'female pregnancy', 158, 'pregnant')]	0	['[15] trials, villar colleagues antioxidants e, c  women increase pre-eclampsia.']
S97-PMC4392531	PMC4392531	3/2015	S97-PMC4392531	"['[""""it is DOCUMENTED that limiting Milk Intake during Pregnancy COULD reduce the absorption of protein, calcium, and Vitamin D, which COULD THREATEN the infant\'s health through reducing the Birth weight.""""]']"	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 130), ('IMPORTANT_CONSIDERATION', 136)]	4	[('GO_0007614', 'short-term memory', 31, 'milk'), ('GO_0007631', 'feeding behavior', 36, 'intake'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007567', 'parturition', 186, 'birth')]	0	"['[""""it milk intake durincy absorption protein, calcium, d, infant*s reducing birth weight.""""]']"
S425-PMC4392553	PMC4392553	3/2015	S425-PMC4392553	['[34] FOUND deficient levels of Vitamin D in 83% of black women and 92% of their newborns, as well as in 47% of white women and 66% of their newborns, DESPITE the fact that over 90% of the women were on Prenatal Vitamins.']	[('INCOMPLETE_EVIDENCE', 5), ('ANOMALY_CURIOUS_FINDING', 150)]	2	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 202, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 211, 'vitamins')]	0	['[34] levels  83% black women 92% newborns, 47% white women 66% newborns, 90% women  vitamins.']
S7-PMC4396835	PMC4396835	1/2015	S7-PMC4396835	['conclusions\nthe FINDINGS SUGGEST that low Prenatal Vitamin D MAY act as a risk factor for asd, HOWEVER, there is a NEED FOR replication with larger samples.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 61), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('FUTURE_WORK', 115)]	5	[('GO_0007565', 'female pregnancy', 42, 'prenatal'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D')]	0	['conclusions\nthe   asd, however, replication samples.']
S8-PMC4396835	PMC4396835	1/2015	S8-PMC4396835	['FUTURE RESEARCH SHOULD study WHETHER OR NOT adequate supplementation of Vitamin D to Pregnant women MIGHT lower the RISK for asd in the offspring.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 29), ('INCOMPLETE_EVIDENCE', 100), ('IMPORTANT_CONSIDERATION', 116)]	5	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnant')]	0	['future supplementation   women asd offspring.']
S21-PMC4396835	PMC4396835	1/2015	S21-PMC4396835	['later, the negative IMPACT of Prenatal Vitamin D deficiency on Brain Development was POSTULATED by mcgrath [17], MAINLY BASED on epidemiological data.']	[('SUPERFICIAL_RELATIONSHIP', 20), ('INCOMPLETE_EVIDENCE', 85), ('PROBABLE_UNDERSTANDING', 113), ('QUESTION_ANSWERED_BY_THIS_WORK', 120)]	4	[('GO_0007565', 'female pregnancy', 30, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007420', 'brain development', 63, 'brain development'), ('UBERON_0000955', 'brain', 63, 'brain')]	0	['later,   brain mcgrath [17], epidemiological data.']
S23-PMC4396835	PMC4396835	1/2015	S23-PMC4396835	['Prenatal Vitamin D deficiency HAS now been PROPOSED as a risk factor for Neurodevelopmental disorders such as schizophrenia [22] and autism [23–27].']	[('IMPORTANT_CONSIDERATION', 30), ('INCOMPLETE_EVIDENCE', 43)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007399', 'nervous system development', 73, 'neurodevelopmental')]	0	['  neurodevelopmental disorders schizophrenia [22] autism [23–27].']
S24-PMC4396835	PMC4396835	1/2015	S24-PMC4396835	['several epidemiological FINDINGS indirectly SUPPORT a POSSIBLE ROLE for Prenatal Vitamin D deficiency in autism.']	[('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 54), ('SUPERFICIAL_RELATIONSHIP', 63)]	4	[('GO_0007565', 'female pregnancy', 72, 'prenatal'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]	0	['several epidemiological   autism.']
S31-PMC4396835	PMC4396835	1/2015	S31-PMC4396835	['a NUMBER OF STUDIES in sweden, denmark, uk and north-east usa on season of Birth HAVE SHOWN that more children with asd are Born in winter and spring [42,43], with highest relative rates in march [44,45] SUGGESTING that lower Vitamin D status in the mother during Pregnancy may constitute a risk FACTOR [46].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 81), ('INCOMPLETE_EVIDENCE', 204), ('SUPERFICIAL_RELATIONSHIP', 296)]	4	[('GO_0007567', 'parturition', 75, 'birth'), ('GO_0007567', 'parturition', 124, 'born'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('GO_0007565', 'female pregnancy', 264, 'pregnancy')]	0	['sweden, denmark, uk north-east usa season birth children asd born winter spring [42,43], relative rates march [44,45]  status mother  [46].']
S168-PMC4396835	PMC4396835	1/2015	S168-PMC4396835	['conclusion\nOUR FINDINGS of a low Vitamin D level in a group of newborn children, who later developed asd, provide SUPPORT for the HYPOTHESIS that developmental Vitamin D deficiency during late Pregnancy MAY carry an INCREASED risk of asd in the child, along with several other RISK FACTORS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('INCOMPLETE_EVIDENCE', 114), ('INCOMPLETE_EVIDENCE', 130), ('INCOMPLETE_EVIDENCE', 203), ('IMPORTANT_CONSIDERATION', 216), ('SUPERFICIAL_RELATIONSHIP', 277)]	6	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy')]	0	['conclusion\nour  newborn children, asd, developmental  late  carry asd child, along factors.']
S171-PMC4396835	PMC4396835	1/2015	S171-PMC4396835	['FUTURE RESEARCH SHOULD include a larger cohort followed prospectively and also study WHETHER OR NOT adequate supplementation of Vitamin D to Pregnant women MIGHT lower the RISK for asd in the offspring.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 85), ('INCOMPLETE_EVIDENCE', 156), ('IMPORTANT_CONSIDERATION', 172)]	5	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'pregnant')]	0	['future followed supplementation   women asd offspring.']
S28-PMC4396888	PMC4396888	3/2015	S28-PMC4396888	['studies HAVE SHOWN that Pregnant women in urban poor settlements in delhi had a poor dietary intake with majority of women Consuming less than 50% of recommended dietary allowances for protein, Iron and Vitamin A with their Intake not being significantly different from their non-Pregnant counterparts [15,16].']	[('INCOMPLETE_EVIDENCE', 8)]	1	[('GO_0007565', 'female pregnancy', 24, 'pregnant'), ('GO_0007631', 'feeding behavior', 123, 'consuming'), ('CHEBI_24870', 'ion', 194, 'iron'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin A'), ('GO_0007631', 'feeding behavior', 224, 'intake'), ('GO_0007565', 'female pregnancy', 280, 'pregnant')]	0	['studies  women urban settlements delhi dietary intake women 50% dietary allowances protein, iron  intake non- counterparts [15,16].']
S1-PMC4405493	PMC4405493	4/2015	S1-PMC4405493	['the EFFECT of Vitamin D deficiency in Pregnancy is UNKNOWN, but HAS BEEN ASSOCIATED with adverse Pregnancy outcomes.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('FULL_UNKNOWN', 51), ('INCOMPLETE_EVIDENCE', 64), ('SUPERFICIAL_RELATIONSHIP', 73)]	4	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy')]	0	['  unknown,  outcomes.']
S16-PMC4405493	PMC4405493	4/2015	S16-PMC4405493	['certain HIGH risk groups for Vitamin D deficiency in Pregnancy HAVE BEEN IDENTIFIED, including vegetarians, women with limited sun exposure (e.g., those who live in cold climates, northern latitudes, or wear sun and winter protective clothing), and ethnic minorities, especially those with darker skin [2].']	[('IMPORTANT_CONSIDERATION', 8), ('INCOMPLETE_EVIDENCE', 63), ('INCOMPLETE_EVIDENCE', 73)]	3	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy')]	0	['certain   identified, vegetarians, women sun exposure (e.g., live cold climates, northern latitudes, wear sun winter clothing), ethnic minorities, darker skin [2].']
S18-PMC4405493	PMC4405493	4/2015	S18-PMC4405493	['during Pregnancy, severe maternal Vitamin D deficiency, AS defined as Serum 25-Hydroxyvitamin D (25-Oh Vitamin D) concentrations less than 5 ng/ml, HAS BEEN ASSOCIATED with disordered Skeletal Homeostasis, congenital rickets, and fractures of the newborn [4].']	[('PROBABLE_UNDERSTANDING', 56), ('INCOMPLETE_EVIDENCE', 148), ('SUPERFICIAL_RELATIONSHIP', 157)]	3	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('UBERON_0001977', 'blood serum', 70, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 76, '25-hydroxyvitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 97, '25-OH'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0043276', 'anoikis', 184, 'skeletal homeostasis'), ('UBERON_0004288', 'skeleton', 184, 'skeletal')]	0	['maternal  deficiency, serum 25-hydroxyvitamin (25-oh concentrations 5 ng/ml, disordered skeletal homeostasis, congenital rickets, fractures newborn [4].']
S19-PMC4405493	PMC4405493	4/2015	S19-PMC4405493	['HOWEVER, the EFFECT of less SEVERE Vitamin D deficiency and insufficiency on maternal and fetal outcomes during Pregnancy is LESS CLEAR.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 13), ('IMPORTANT_CONSIDERATION', 28), ('FULL_UNKNOWN', 125)]	4	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy')]	0	['however,  maternal fetal outcomes  clear.']
S20-PMC4405493	PMC4405493	4/2015	S20-PMC4405493	['RECENT observational and randomized control trials have ATTEMPTED TO investigate THIS ISSUE, but there REMAINS LIMITED GUIDANCE on the management of Vitamin D deficiency during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0), ('DIFFICULT_TASK', 56), ('INCOMPLETE_EVIDENCE', 56), ('QUESTION_ANSWERED_BY_THIS_WORK', 66), ('QUESTION_ANSWERED_BY_THIS_WORK', 81), ('PROBLEM_COMPLICATION', 86), ('INCOMPLETE_EVIDENCE', 103), ('INCOMPLETE_EVIDENCE', 111), ('FUTURE_WORK', 119)]	9	[('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0007565', 'female pregnancy', 177, 'pregnancy')]	0	['recent issue,  .']
S22-PMC4405493	PMC4405493	4/2015	S22-PMC4405493	['HOWEVER, OTHER STUDIES have DEMONSTRATED no association between Vitamin D status and adverse Pregnancy outcomes [11–12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 28)]	3	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 93, 'pregnancy')]	0	['however,  status  outcomes [11–12].']
S23-PMC4405493	PMC4405493	4/2015	S23-PMC4405493	['the MAJORITY of randomized control trials and observational studies measure Vitamin D late in the Pregnancy, when Prenatal Vitamins containing 400 iu of Vitamin D have been prescribed [13].']	[('PROBABLE_UNDERSTANDING', 4)]	1	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('GO_0007565', 'female pregnancy', 114, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 123, 'vitamins'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]	0	['measure  late  vitamins containing 400 iu  prescribed [13].']
S24-PMC4405493	PMC4405493	4/2015	S24-PMC4405493	['THUS, we SOUGHT TO DETERMINE IF Vitamin D deficiency in the first trimester of nulliparous patients is ASSOCIATED with clinical outcomes MOST ASSOCIATED with SIGNIFICANT maternal and fetal morbidity and mortality: Preeclampsia, Gestational diabetes, Preterm Delivery, spontaneous abortion, and growth restriction.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 29), ('SUPERFICIAL_RELATIONSHIP', 103), ('PROBABLE_UNDERSTANDING', 137), ('SUPERFICIAL_RELATIONSHIP', 142), ('IMPORTANT_CONSIDERATION', 158)]	8	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 214, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 228, 'gestational'), ('GO_0007565', 'female pregnancy', 250, 'preterm'), ('GO_0007567', 'parturition', 258, 'delivery')]	0	['thus,  trimester nulliparous patients outcomes maternal fetal morbidity mortality: preeclampsia,  diabetes,  delivery, spontaneous abortion, restriction.']
S77-PMC4405493	PMC4405493	4/2015	S77-PMC4405493	['mean Gestational age of recruitment and Vitamin D Plasma measurement was 62.2 ± 29.7 days (8.9 ± 4.2 weeks).a Pregnancy was considered COMPLICATED if the patient was diagnosed with any of the following adverse Pregnancy outcomes: Preeclampsia, Gestational diabetes, spontaneous Preterm Delivery, Intrauterine growth restriction, or spontaneous Abortion (table 1).']	[('DIFFICULT_TASK', 135)]	1	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 50, 'plasma'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007565', 'female pregnancy', 210, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 230, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 244, 'gestational'), ('GO_0007565', 'female pregnancy', 278, 'preterm'), ('GO_0007567', 'parturition', 286, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 296, 'intrauterine'), ('GO_0007569', 'cell aging', 344, 'abortion')]	0	['mean  age recruitment  plasma 62.2 ± 29.7 days (8.9 ± 4.2 weeks).a  patient diagnosed following  outcomes: preeclampsia,  diabetes, spontaneous  delivery, intrauterine restriction, spontaneous abortion (table 1).']
S86-PMC4405493	PMC4405493	4/2015	S86-PMC4405493	['information on patient time in the area prior to Pregnancy, dietary intake of Vitamin D, and sun exposure was NOT AVAILABLE.']	[('INCOMPLETE_EVIDENCE', 110)]	1	[('GO_0007565', 'female pregnancy', 49, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]	0	['information patient dietary intake sun exposure available.']
S105-PMC4405493	PMC4405493	4/2015	S105-PMC4405493	['BECAUSE there were TOO few patient in the category of Vitamin D deficient (<20ng/ml [50nmol/l]) for meaningful statistical analysis, patients categorized as either Vitamin D insufficient or deficient were combined into one category (insufficient/deficient, <30ng/ml [75nmol/l]) for subsequent statistical analysis (table 5).10.1371/journal.pone.0123763.t004\n\ncaption (table-wrap): table 4\ndistribution of clinical outcomes in women categorized as Vitamin D deficient, insufficient, or sufficient.Vitamin D categoryno complications n (% of 176)all complications n (% of 59)Preeclampsia n (% of 19)spontaneous Preterm Delivery n (% of 10)iugr n (% of 9)gdm n (% of 5)spontaneous fetal loss n (% of 16) deficient (<20 ng/ml) 18 (10)6 (10)2 (11)1 (10)1 (11)0 (0)2 (13) (n = 24)insufficient (21–29 ng/ml) 105 (60)36 (61)10 (53)6 (60)7 (78)3 (60)10 (63) (n = 141)sufficient (>30 ng/ml) 53 (30)17 (29)7 (37)3 (30)1 (11)2 (40)4 (25) (n = 70)\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.10.1371/journal.pone.0123763.t005\n\ncaption (table-wrap): table 5\nlogistic regression analysis of clinical outcomes in women categorized as Vitamin D sufficient compared to Vitamin D insufficient or deficient women.Vitamin D sufficient (≥30 ng/ml)Vitamin D insufficient or deficient (<30 ng/ml)n (% of 70)n (% of 165)adjusted**or (95% ci)* no complications 53 (75.7)123 (74.5)- all complications 17 (24.2)42 (25.5)1.01 (0.947–1.164) Preeclampsia 7 (10)12 (7.2)1.36 (0.48–3.88) spontaneous Preterm Delivery 3 (4.3)7 (4.2)0.78 (0.17–3.55) iugr 1 (1.4)8 (4.8)0.33 (0.38–2.83) gdm 2 (2.9)3 (1.8)2.60 (0.28–27.24) spontaneous abortion 4 (5.7)12 (7.2)0.65 (0.18–2.28)\n*, note: none of the differences were p<0.05 by logistic regression (chi-square analysis)\n**, adjusted for bmi, season, ethnicity, and tobacco use\nor, odds ratio\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.']	[('PROBLEM_COMPLICATION', 0), ('PROBLEM_COMPLICATION', 19)]	2	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 447, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 447, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 496, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 496, 'Vitamin D'), ('GO_0007128', 'meiotic prophase I', 572, 'Preeclampsia'), ('GO_0007128', 'meiotic prophase I', 608, 'Preterm'), ('GO_0007567', 'parturition', 616, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 940, 'intrauterine'), ('GO_0007565', 'female pregnancy', 978, 'gestational'), ('CHEBI_27300', 'vitamin D', 1147, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1180, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 1222, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 1254, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1254, 'Vitamin D'), ('GO_0007128', 'meiotic prophase I', 1440, 'Preeclampsia'), ('GO_0007128', 'meiotic prophase I', 1496, 'Preterm'), ('GO_0007567', 'parturition', 1504, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 1837, 'intrauterine'), ('GO_0007565', 'female pregnancy', 1875, 'gestational')]	0	['patient category  (<20ng/ml [50nmol/l]) statistical analysis, patients categorized combined category (insufficient/deficient, <30ng/ml [75nmol/l]) statistical (table 5).10.1371/journal.pone.0123763.t004\n\ncaption (table-wrap): table 4\ndistribution outcomes women categorized vitamin deficient, insufficient, sufficient.vitamin categoryno n (% 176)all n (% 59)preeclampsia n (% 19)spontaneous preterm delivery n (% 10)iugr n (% 9)gdm n (% 5)spontaneous fetal loss n (% 16) (<20 ng/ml) 18 (10)6 (10)2 (11)1 (10)1 (11)0 (0)2 (13) (n = 24)insufficient (21–29 ng/ml) 105 (60)36 (61)10 (53)6 (60)7 (78)3 (60)10 (63) (n = 141)sufficient (>30 ng/ml) 53 (30)17 (29)7 (37)3 (30)1 (11)2 (40)4 (25) (n = 70)\niugr, intrauterine restriction; gdm,  diabetes mellitus.10.1371/journal.pone.0123763.t005\n\ncaption (table-wrap): table 5\nlogistic regression outcomes women categorized   women.vitamin (≥30 ng/ml)vitamin (<30 ng/ml)n (% 70)n (% 165)adjusted**or (95% ci)* 53 (75.7)123 (74.5)- 17 (24.2)42 (25.5)1.01 (0.947–1.164) preeclampsia 7 (10)12 (7.2)1.36 (0.48–3.88) spontaneous preterm delivery 3 (4.3)7 (4.2)0.78 (0.17–3.55) iugr (1.4)8 (4.8)0.33 (0.38–2.83) gdm 2 (2.9)3 (1.8)2.60 (0.28–27.24) spontaneous abortion 4 (5.7)12 (7.2)0.65 (0.18–2.28)\n*, p<0.05 logistic regression (chi-square analysis)\n**, adjusted bmi, season, ethnicity, tobacco use\nor, ratio\niugr, intrauterine restriction; gdm,  diabetes mellitus.']
S113-PMC4405493	PMC4405493	4/2015	S113-PMC4405493	['these women did not have preexisting hypertension, diabetes, or other medical problems that would increase their RISK for Pregnancy complications or Vitamin D deficiency.']	[('IMPORTANT_CONSIDERATION', 113)]	1	[('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D')]	0	['women preexisting hypertension, diabetes, medical increase   deficiency.']
S114-PMC4405493	PMC4405493	4/2015	S114-PMC4405493	['ALTHOUGH we recruited ONLY young, nulliparous, previously healthy women, the majority of our patients were either Vitamin D deficient (10%, <20 ng/ml) or Vitamin D insufficient (60%, 20–29 ng/ml) according TO the criteria published by the institute for medicine.18of the 235 patients included in the study, 41 of them had a prior Pregnancy which had resulted in a spontaneous First Trimester Miscarriage or elective termination.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 22), ('QUESTION_ANSWERED_BY_THIS_WORK', 206)]	3	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('GO_0007565', 'female pregnancy', 330, 'pregnancy'), ('GO_0042733', 'embryonic digit morphogenesis', 376, 'first trimester'), ('GO_0046660', 'female sex differentiation', 392, 'miscarriage')]	0	['although recruited young, nulliparous, healthy women, patients  (60%, 20–29 ng/ml) criteria institute medicine.18of 235 patients study, 41  resulted spontaneous trimester miscarriage elective termination.']
S117-PMC4405493	PMC4405493	4/2015	S117-PMC4405493	['this study was NOT POWERED to detect ASSOCIATIONS between Vitamin D status and these individual Pregnancy complications.fig 1compares our study population with RECENTLY PUBLISHED cohort studies and randomized controlled trials (reviewed in christesen [2012] and wei [2013]) [13,39].10.1371/journal.pone.0123763.g001\n\ncaption (fig): fig 1\ncomparison of study parameters in recent Vitamin D OBSERVATIONAL and intervention studies.']	[('DIFFICULT_TASK', 15), ('SUPERFICIAL_RELATIONSHIP', 37), ('INCOMPLETE_EVIDENCE', 160), ('INCOMPLETE_EVIDENCE', 389)]	4	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 379, 'vitamin D')]	0	['powered  status individual  complications.fig population (reviewed christesen [2012] wei [2013]) [13,39].10.1371/journal.pone.0123763.g001\n\ncaption (fig): fig 1\ncomparison parameters  studies.']
S118-PMC4405493	PMC4405493	4/2015	S118-PMC4405493	['RISK FACTORS for Vitamin D deficiency include INADEQUATE sun or uv light exposure, physiologic factors (such as dark skin pigmentation, obesity, Pregnancy, certain medical problems), and low Vitamin D intake [2–3].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('IMPORTANT_CONSIDERATION', 46)]	2	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]	0	['risk  sun uv exposure, physiologic (such dark skin pigmentation, obesity, medical problems),  intake [2–3].']
S126-PMC4405493	PMC4405493	4/2015	S126-PMC4405493	['BECAUSE Vitamin D deficiency is so widespread, determining WHETHER Vitamin D deficiency is ASSOCIATED with adverse Pregnancy outcomes is an area of MAJOR PUBLIC HEALTH CONCERN.']	[('PROBABLE_UNDERSTANDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 59), ('SUPERFICIAL_RELATIONSHIP', 91), ('IMPORTANT_CONSIDERATION', 148), ('IMPORTANT_CONSIDERATION', 154)]	5	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy')]	0	[' widespread,   outcomes concern.']
S127-PMC4405493	PMC4405493	4/2015	S127-PMC4405493	['it is UNCLEAR WHETHER Vitamin D deficiency is causal in the DISPARITIES in adverse Pregnancy outcomes between caucasians and african americans.']	[('FULL_UNKNOWN', 6), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('IMPORTANT_CONSIDERATION', 60)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]	0	[' causal  outcomes caucasians african americans.']
S147-PMC4405493	PMC4405493	4/2015	S147-PMC4405493	['the ROLE Vitamin D plays in adverse clinical outcomes such as Preeclampsia, Gestational diabetes, Preterm Labor, growth restriction, and spontaneous Abortion is SPECULATIVE, but MAY INVOLVE Vitamin D’s Regulation Of Placental Trophoblast Invasion and Angiogenesis, in addition to its anti-inflammatory properties [5].']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 161), ('INCOMPLETE_EVIDENCE', 178), ('SUPERFICIAL_RELATIONSHIP', 182), ('SUPERFICIAL_RELATIONSHIP', 202)]	5	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 62, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 76, 'gestational'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 98, 'preterm labor'), ('GO_0007569', 'cell aging', 149, 'abortion'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('GO_1900101', 'regulation of endoplasmic reticulum unfolded protein response', 202, 'regulation of ... invasion ...'), ('UBERON_0001987', 'placenta', 216, 'placental'), ('UBERON_0000088', 'trophoblast', 226, 'trophoblast'), ('GO_0001525', 'angiogenesis', 251, 'angiogenesis')]	0	[' plays outcomes preeclampsia,  diabetes, preterm labor, restriction, spontaneous abortion speculative, ’s placental trophoblast invasion angiogenesis, addition anti-inflammatory properties [5].']
S154-PMC4405493	PMC4405493	4/2015	S154-PMC4405493	['during Pregnancy, 25-Oh Vitamin D diffuses across the Placenta and the fetus relies entirely on the Vitamin D stores of the mother: IF the mother is deficient, so is the fetus [5].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 132)]	1	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 18, '25-OH'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0001987', 'placenta', 54, 'placenta'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]	0	['25-oh  diffuses placenta fetus relies  stores mother: mother deficient, fetus [5].']
S155-PMC4405493	PMC4405493	4/2015	S155-PMC4405493	['THUS, in combination with its immunomodulatory and anti-inflammatory properties, Vitamin D MAY play a POTENTIAL ROLE in the PREVENTION of Preterm Birth and small-for-Gestational-age neonates.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 91), ('INCOMPLETE_EVIDENCE', 102), ('SUPERFICIAL_RELATIONSHIP', 112), ('SUPERFICIAL_RELATIONSHIP', 124)]	5	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'preterm birth'), ('GO_0007565', 'female pregnancy', 166, 'gestational')]	0	['thus, combination immunomodulatory anti-inflammatory properties,  play  small-for--age neonates.']
S157-PMC4405493	PMC4405493	4/2015	S157-PMC4405493	['HOWEVER, WHETHER Vitamin D deficiency is a RISK FACTOR for Gestational diabetes in itself OR IF Vitamin D supplementation CAN PREVENT gdm is YET UNKNOWN [72].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('SUPERFICIAL_RELATIONSHIP', 43), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 93), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 126), ('FULL_UNKNOWN', 141)]	7	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 59, 'gestational'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]	0	['however,   diabetes  supplementation gdm [72].']
S158-PMC4405493	PMC4405493	4/2015	S158-PMC4405493	['although Vitamin D has a biologically POSSIBLE ROLE in all the aforementioned disorders, this WAS NOT DEMONSTRATED in our population AS Vitamin D deficiency did not increase the odds for adverse Pregnancy outcome in OUR STUDY.']	[('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 47), ('INCOMPLETE_EVIDENCE', 94), ('INCOMPLETE_EVIDENCE', 102), ('PROBABLE_UNDERSTANDING', 133), ('QUESTION_ANSWERED_BY_THIS_WORK', 216)]	6	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('GO_0007565', 'female pregnancy', 195, 'pregnancy')]	0	['although  biologically disorders, population  increase  outcome study.']
S175-PMC4405493	PMC4405493	4/2015	S175-PMC4405493	['this study was NOT POWERED to detect ASSOCIATIONS between Vitamin D status and these individual complications of Pregnancy.']	[('DIFFICULT_TASK', 15), ('SUPERFICIAL_RELATIONSHIP', 37)]	2	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy')]	0	['powered  status individual .']
S178-PMC4405493	PMC4405493	4/2015	S178-PMC4405493	['ALTHOUGH OUR STUDY DID NOT DEMONSTRATE an association of Vitamin D Plasma concentration with select clinical outcomes, the prevalence of sub-optimal Vitamin D concentrations in patient plasma EMPHASIZES THE NEED for CONTINUED RESEARCH on hypovitaminosis d in Pregnancy and Reproductive health.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('INCOMPLETE_EVIDENCE', 19), ('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('IMPORTANT_CONSIDERATION', 192), ('INCOMPLETE_EVIDENCE', 192), ('INCOMPLETE_EVIDENCE', 203), ('FUTURE_WORK', 207), ('FUTURE_WORK', 216)]	10	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 67, 'plasma'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0007565', 'female pregnancy', 259, 'pregnancy'), ('GO_0000003', 'reproduction', 273, 'reproductive')]	0	['although  plasma concentration select outcomes, sub-optimal  concentrations patient plasma hypovitaminosis  reproductive health.']
S28-PMC4417995	PMC4417995	4/2015	S28-PMC4417995	['both children and Pregnant/Lactating women are identified as groups PARTICULARLY vulnerable to Vitamin D deficiency [15].']	[('IMPORTANT_CONSIDERATION', 68)]	1	[('GO_0007565', 'female pregnancy', 18, 'pregnant'), ('GO_0007594', 'puparial adhesion', 27, 'lactating'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]	0	['children /lactating women  [15].']
S93-PMC4417995	PMC4417995	4/2015	S93-PMC4417995	['Pregnancy Vitamin D levels\nthe maternal Vitamin D profile during Pregnancy HAS also BEEN long DEBATED.']	[('INCOMPLETE_EVIDENCE', 75), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 94)]	2	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('CHEBI_28384', 'vitamin K', 10, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnancy')]	0	[' vitamin levels\nthe maternal  profile  debated.']
S96-PMC4417995	PMC4417995	4/2015	S96-PMC4417995	['[44] reported that high Vitamin D values during Pregnancy MIGHT also be harmful with respect to Allergic disease development: children whose mothers had a 25(Oh)D concentration during Pregnancy of greater than 30\u2009ng/ml had an increased risk of atopic eczema on examination at 9 months compared with children whose mothers had a concentration of less than 12\u2009ng/ml.']	[('INCOMPLETE_EVIDENCE', 58)]	1	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('GO_0040011', 'locomotion', 96, 'allergic'), ('CHEBI_63056', 'zinc cation', 155, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 161, 'D'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]	0	['[44]  values  respect allergic disease development: children whose mothers 25(oh)d concentration  30\u2009ng/ml 9 months children whose mothers concentration 12\u2009ng/ml.']
S97-PMC4417995	PMC4417995	4/2015	S97-PMC4417995	['CONVERSELY, OTHER STUDIES DEMONSTRATED that children Born from mothers with low Fish or Vitamin D intake during Pregnancy had an increased prevalence of ad [45,46].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 26)]	4	[('GO_0007567', 'parturition', 53, 'born'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 80, 'fish'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy')]	0	['conversely, children born mothers fish  intake  ad [45,46].']
S0-PMC4427001	PMC4427001	4/2015	S0-PMC4427001	['Vitamin D status in women with Gestational diabetes mellitus during Pregnancy and Postpartum\n\nabstract\nof many Vitamin D Extraskeletal functions, its modulatory ROLE in Insulin secretion and action is ESPECIALLY RELEVANT for Gestational diabetes mellitus (gdm).']	[('SUPERFICIAL_RELATIONSHIP', 161), ('IMPORTANT_CONSIDERATION', 201), ('SUPERFICIAL_RELATIONSHIP', 212)]	3	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 31, 'Gestational'), ('GO_0007565', 'female pregnancy', 68, 'Pregnancy'), ('GO_0007567', 'parturition', 82, 'Postpartum'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 121, 'extraskeletal'), ('PR_000045358', 'insulin family protein', 169, 'insulin'), ('GO_0007565', 'female pregnancy', 225, 'gestational')]	0	['vitamin status women  diabetes mellitus  postpartum\n\nabstract\nof  extraskeletal functions, modulatory insulin secretion  diabetes mellitus (gdm).']
S1-PMC4427001	PMC4427001	4/2015	S1-PMC4427001	['the AIMS of the PRESENT STUDY were TO DETERMINE Midgestational and early Postpartum Vitamin D status in Pregnant women with and without gdm and to describe the RELATIONSHIP between Midgestational and Postpartum Vitamin D status and parallel changes of Glucose tolerance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 35), ('SUPERFICIAL_RELATIONSHIP', 160)]	4	[('GO_0007507', 'heart development', 48, 'midgestational'), ('GO_0007565', 'female pregnancy', 73, 'postpartum'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007565', 'female pregnancy', 104, 'pregnant'), ('GO_0007507', 'heart development', 181, 'midgestational'), ('GO_0007565', 'female pregnancy', 200, 'postpartum'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D'), ('CHEBI_17234', 'glucose', 252, 'glucose')]	0	['midgestational   status  women gdm midgestational   status changes glucose tolerance.']
S4-PMC4427001	PMC4427001	4/2015	S4-PMC4427001	['Vitamin D was not significantly decreased in gdm compared to controls during Pregnancy; HOWEVER, both groups of Pregnant women exhibited high prevalence of Vitamin D deficiency.']	[('ANOMALY_CURIOUS_FINDING', 88)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0007565', 'female pregnancy', 112, 'pregnant'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D')]	0	['vitamin decreased gdm however,  women  deficiency.']
S33-PMC4427001	PMC4427001	4/2015	S33-PMC4427001	['a NUMBER OF STUDIES focused on PUTATIVE ROLE of Vitamin D deficiency in various Pregnancy pathologies including gdm [21–23].']	[('INCOMPLETE_EVIDENCE', 2), ('PROBABLE_UNDERSTANDING', 31), ('SUPERFICIAL_RELATIONSHIP', 40)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy')]	0	['  pathologies gdm [21–23].']
S38-PMC4427001	PMC4427001	4/2015	S38-PMC4427001	['currently, LITTLE IS KNOWN about Postpartum Vitamin D status in women with history of gdm and POSSIBLE RELATIONSHIP between 25(Oh)D Plasma levels measured at the time of gdm diagnosis and the degree of Glucose (in)tolerance Postpartum.']	[('FULL_UNKNOWN', 11), ('INCOMPLETE_EVIDENCE', 94), ('SUPERFICIAL_RELATIONSHIP', 103)]	3	[('GO_0007565', 'female pregnancy', 33, 'postpartum'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 124, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 132, 'plasma'), ('CHEBI_17234', 'glucose', 202, 'glucose'), ('GO_0007565', 'female pregnancy', 224, 'postpartum')]	0	['currently,   status women gdm 25(oh)d plasma levels gdm diagnosis degree glucose (in)tolerance .']
S40-PMC4427001	PMC4427001	4/2015	S40-PMC4427001	['THEREFORE, the AIMS of the PRESENT STUDY were (1) TO DETERMINE Midgestational and early Postpartum Vitamin D status by measuring 25(Oh)D Plasma levels in Pregnant women with and without gdm to CONFIRM the hypothetical deficiency in gdm in central european population and (2) to describe the RELATIONSHIP between Midgestational and Postpartum Vitamin D status and parallel changes of parameters characterising Glucose tolerance.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 27), ('QUESTION_ANSWERED_BY_THIS_WORK', 50), ('INCOMPLETE_EVIDENCE', 193), ('SUPERFICIAL_RELATIONSHIP', 291)]	6	[('GO_0007507', 'heart development', 63, 'midgestational'), ('GO_0007565', 'female pregnancy', 88, 'postpartum'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 132, 'OH ... D'), ('UBERON_0001969', 'blood plasma', 137, 'plasma'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('GO_0007507', 'heart development', 312, 'midgestational'), ('GO_0007565', 'female pregnancy', 331, 'postpartum'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin D'), ('CHEBI_17234', 'glucose', 409, 'glucose')]	0	['therefore, (1) midgestational   status measuring 25(oh)d plasma levels  women gdm gdm central european population (2) midgestational   status changes parameters characterising glucose tolerance.']
S43-PMC4427001	PMC4427001	4/2015	S43-PMC4427001	['subjects\nto avoid the CONFOUNDING FACTOR of seasonal variation of Vitamin D levels, the recruitment of study subjects was confined to women whose 24–30th weeks of Gestation (i.e., the first, Midgestational Blood sampling) spanned winter months (i.e., january, february, and march).']	[('PROBLEM_COMPLICATION', 22)]	1	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'gestation'), ('GO_0007507', 'heart development', 191, 'midgestational'), ('UBERON_0000178', 'blood', 206, 'blood')]	0	['subjects\nto seasonal  levels, subjects women whose 24–30th weeks  (i.e., first, midgestational blood sampling) spanned winter months (i.e., january, february, march).']
S83-PMC4427001	PMC4427001	4/2015	S83-PMC4427001	"['[""""in OUR STUDY, we have FOUND that Midgestational Vitamin D deficiency (i.e., 25(Oh)D levels < 50\\u2009nmol/l) was present in majority of the study sample, that is, 45 of 47 (95.7%) women with gdm and 27 of 29 (93.1%) healthy Pregnant women ( p = ns, fisher\'s exact test).""""]']"	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 22)]	2	[('GO_0007507', 'heart development', 33, 'midgestational'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('GO_0007565', 'female pregnancy', 219, 'pregnant')]	0	"['[""""in study, midgestationn (i.e., 25(oh)d levels 50\\u2009nmol/l) sample, is, 45 47 (95.7%) women gdm 27 29 (93.1%) pregnant women p = ns, fisher*s exact test).""""]']"
S97-PMC4427001	PMC4427001	4/2015	S97-PMC4427001	['ALTHOUGH there is NO GENERAL CONSENSUS on the criteria for Vitamin D deficiency in Pregnant women, in OUR STUDY we have FOUND high prevalence of deficiency (when using cut-off < 50\u2009nmol/l) in overall study sample: 95.7% of women with gdm and 93.1% of controls were Vitamin D deficient during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 102), ('INCOMPLETE_EVIDENCE', 120)]	5	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnant'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D'), ('GO_0007565', 'female pregnancy', 292, 'pregnancy')]	0	['although criteria   women, (when using cut-off 50\u2009nmol/l) sample: 95.7% women gdm 93.1%  .']
S105-PMC4427001	PMC4427001	4/2015	S105-PMC4427001	['[23] HAVE SHOWN that Vitamin D deficiency (≤50\u2009nmol/l) in caucasian population (irish women) CAN occur in 95% of Pregnant women in 12th week of Pregnancy, in 90% in 20th week, in 66% in 35th week, and in 15% 3 days Postpartum.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 93)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0007565', 'female pregnancy', 215, 'postpartum')]	0	['[23]  (≤50\u2009nmol/l) caucasian population (irish women) occur 95%  women 12th week 90% 20th week, 66% 35th week, 15% 3 days .']
S123-PMC4427001	PMC4427001	4/2015	S123-PMC4427001	['our results are IN AGREEMENT with OTHER published STUDIES reporting LACK OF association between Vitamin D levels in Pregnancy and gdm.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 34), ('INCOMPLETE_EVIDENCE', 68)]	3	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy')]	0	['results  levels  gdm.']
S126-PMC4427001	PMC4427001	4/2015	S126-PMC4427001	['[43] DID NOT FIND association between maternal Vitamin D status in 559 nondiabetic Pregnant women from south india and the RISK of gdm.']	[('INCOMPLETE_EVIDENCE', 5), ('IMPORTANT_CONSIDERATION', 123)]	2	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnant')]	0	['[43] maternal  status 559 nondiabetic  women south india gdm.']
S140-PMC4427001	PMC4427001	4/2015	S140-PMC4427001	['DESPITE the fact that 147 australian women with gdm were advised to take daily Prenatal multivitamins containing 400\u2009iu or 500\u2009iu Vitamin D, 41% of the participants had Vitamin D deficiency.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('GO_0007565', 'female pregnancy', 79, 'prenatal'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]	0	['despite 147 australian women gdm daily  multivitamins containing 400\u2009iu 500\u2009iu 41% participants  deficiency.']
S150-PMC4427001	PMC4427001	4/2015	S150-PMC4427001	['conclusions\nour study in Pregnant women of central european population DID NOT REPLICATE sporadic PREVIOUS FINDINGS of significantly decreased levels of Vitamin D in Gdm Pregnancy; HOWEVER, results SEEM TO BE criteria-sensitive (who versus iadpsg) and the topic WARRANTS FURTHER STUDY.']	[('INCOMPLETE_EVIDENCE', 71), ('ANOMALY_CURIOUS_FINDING', 75), ('INCOMPLETE_EVIDENCE', 79), ('INCOMPLETE_EVIDENCE', 98), ('INCOMPLETE_EVIDENCE', 107), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 181), ('ANOMALY_CURIOUS_FINDING', 198), ('FUTURE_WORK', 262), ('FUTURE_WORK', 271)]	9	[('GO_0007565', 'female pregnancy', 25, 'pregnant'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('GO_0070477', 'endospore core', 166, 'GDM'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy')]	0	['conclusions\nour  women central european population sporadic decreased levels  gdm however, results criteria-sensitive (who iadpsg) study.']
S151-PMC4427001	PMC4427001	4/2015	S151-PMC4427001	['we CONFIRMED overall high prevalence of Vitamin D deficiency in Pregnant women IN SPITE of the gdm presence.']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 79)]	2	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant')]	0	['  women gdm presence.']
S25-PMC4438573	PMC4438573	5/2015	S25-PMC4438573	['the ONLY STUDY to date that has assessed the EFFECTS of maternal Nutrient supplementation on malaria Antibody levels REPORTED that Vitamin A Prenatal supplements were ASSOCIATED with a reduction in Antibody responses to a Placental-binding isolate ej-24, but no significant changes in Antibody responses to non-Pregnancy related parasite Isolates were observed [22].']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 117), ('SUPERFICIAL_RELATIONSHIP', 167)]	4	[('CHEBI_33284', 'nutrient', 65, 'nutrient'), ('GO_0042571', 'immunoglobulin complex, circulating', 101, 'antibody'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin A'), ('GO_0007565', 'female pregnancy', 141, 'prenatal'), ('GO_0042571', 'immunoglobulin complex, circulating', 198, 'antibody'), ('UBERON_0001987', 'placenta', 222, 'placental'), ('GO_0042571', 'immunoglobulin complex, circulating', 285, 'antibody'), ('GO_0007565', 'female pregnancy', 311, 'pregnancy'), ('SO_0001040', 'integrated_plasmid', 338, 'isolates')]	0	['maternal nutrient supplementation malaria antibody levels   supplements reduction antibody responses placental-binding isolate ej-24, changes antibody responses non- parasite isolates [22].']
S184-PMC4438628	PMC4438628	5/2015	S184-PMC4438628	['Human and/or experimental research SHOWS that acute and cumulative psychological stress (and ASSOCIATED MARKERS of Allostatic load) [273-276], environmental Pollutants [277-282], crowding [283], acoustic stress [284], heat stress [285], westernized dietary patterns [286], high Fructose and Sodium [287], dietary Age and Food Additives via processed foods [288,289], lack of colorful dietary Phytochemicals [290,291], magnesium deficiency [292], inadequate omega-3 [293], Antibiotic administration [294], excess Alcohol consumption [295,296], the Oral periodontopathogen p. gingivalis (when Swallowed) [297], tobacco exposure [298,299], sedentary behavior [300], Circadian disruptions [301], Sleep problems with functional constipation [302], and low levels of Vitamin D [303,304] are each individually ASSOCIATED with marked shifts in the Intestinal microbiota.']	[('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 93), ('SUPERFICIAL_RELATIONSHIP', 104), ('SUPERFICIAL_RELATIONSHIP', 803)]	4	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('GO_0007565', 'female pregnancy', 115, 'allostatic'), ('CHEBI_26199', 'polyprenol', 157, 'pollutants'), ('CHEBI_28757', 'fructose', 278, 'fructose'), ('CHEBI_52632', 'potassium-39 atom', 291, 'sodium'), ('CHEBI_80551', 'APC', 313, 'AGE'), ('CHEBI_77968', 'humectant', 321, 'food additives'), ('CHEBI_26254', 'prenylnaphthoquinone', 392, 'phytochemicals'), ('CHEBI_33282', 'antibacterial agent', 472, 'antibiotic'), ('CHEBI_30879', 'alcohol', 512, 'alcohol'), ('UBERON_0000165', 'mouth', 547, 'oral'), ('GO_0035196', 'production of miRNAs involved in gene silencing by miRNA', 591, 'swallowed'), ('GO_0051216', 'cartilage development', 663, 'circadian'), ('GO_0030431', 'sleep', 692, 'sleep'), ('CHEBI_27300', 'vitamin D', 761, 'vitamin D'), ('UBERON_0000160', 'intestine', 840, 'intestinal')]	0	['human and/or acute cumulative psychological (and  load) [273-276], environmental pollutants [277-282], crowding [283], acoustic [284], heat [285], westernized dietary [286], fructose sodium [287], dietary age food additives via processed foods [288,289], colorful dietary phytochemicals [290,291], magnesium [292], omega-3 [293], antibiotic administration [294], excess alcohol consumption [295,296], oral periodontopathogen p. gingivalis (when swallowed) [297], tobacco exposure [298,299], sedentary behavior [300], circadian [301], sleep functional constipation [302], levels  [303,304] individually marked intestinal microbiota.']
S537-PMC4448820	PMC4448820	5/2015	S537-PMC4448820	['caption (table-wrap): table 6\n\neffects of Micronutrient supplementation on Immune function and vaccine responses (Human studies)1type of malnutrition and type of Immune functioneffects of supplementation on Immune System (reference)vitamin a\u2003Epithelial barrier function● high-dose vas above 6 mo of age decreases risk of death from infections such as measles and diarrheal diseases (290)● vas in the context of hiv infection or Lower Respiratory Tract infections HAS BEEN ASSOCIATED with adverse outcomes (105,263,290–292)● improved barrier function (105)● abnormal dual-Sugar (Lactulose, Mannitol) Intestinal permeability inversely CORRELATED with Serum Retinol (293) and PARTIALLY normalized by supplementation in va-deficient Individuals in SOME STUDIES (294) BUT NOT OTHERS (295,296)● increased symptomatology after high-dose vas during acute Lower Respiratory Tract infections REPORTED in SOME STUDIES (105) MAY INDICATE restored Mucus Production\u2003innate physiologic barriers● vas did not affect crp, saa, and/or agp concentrations among children with subclinical or clinical vad (297–299)● crp and agp did not change in men with low va stores given va (300)\u2003Macrophage function● increased Monocyte numbers (301)● decreased Tnf-Α concentrations in children (301) BUT the OPPOSITE in men (106)● decreased Ifn-Γ concentrations in children (302) but not in Pregnant women (303)● increased Il-10 concentrations in children (105,301) BUT no or an opposite effect in Adults (106,303,304)\u2003Neutrophil function● Neutrophil Phagocytosis of latex beads increased in va-deficient children given a single dose of Va (305)● Neutrophil Phagocytosis of E. Coli did not change in men with low Va stores given Va (300)\u2003Nk Cell function● an increase in Nk Cells in hiv-infected children supplemented with Va (105)● Nk Cell numbers did not change in men with low Va given supplemental Va; HOWEVER, there was a positive CORRELATION between Va stores and Peripheral Blood Nk Cells (300)\u2003T Cell function● increased Lymphocyte counts, particularly cd4 counts (105)● Cd4:Cd8 ratios were increased or unchanged by supplementation (306)● increase in Naive cd4 T Cells after supplementation; higher Memory Cd8, Cd45Ro (307)● higher Mitogen-induced Il-2, Il-4, and Tnf in response to supplementation (106)\u2003B Cell function● supplementation had no overall effect on Measles vaccine response (308) and a negative response in Individuals with baseline high titers (103)● no overall effect on oral polio vaccination● supplemented children increased Igg1 responses to dtp, minor igg3 response, no change in igg2 and igg4 (309)● no overall effect on bcg vaccine in Va-supplemented children, lower response in va-supplemented boys at 2 mo (310)● increased Antibody responses to some vaccines (Measles vaccine by 9 mo of age, oral polio vaccine, type 1, hepatitis b vaccine, rabies vaccine) (103)● short-term diminished cellular response to ppd in boys (103) and hospitalized children (105)Zinc\u2003Epithelial barrier function● zn supplementation in children LED TO an improvement in the lactulose:Mannitol Excretion ratio in SOME (311) BUT NOT OTHER (312,313) STUDIES; ratio MAY improve in infected children without zn deficiency given supplemental zn (314)\u2003innate physiologic barriers ● zn-supplemented children had higher Serum Complement C3 (315)\u2003Nk Cell function● children with diarrhea supplemented with zn supplementation do not exhibit an increase in Nk Cells (316)● increased Nk Cell activity in the elderly (317)\u2003T Cell function● increased cd4+ cell count in aids patients (318)● increased Thymocyte count in Thymus (319)● increased thymulin activity (320)● no CONSISTENT effect of zn supplementation on dth to tb Antigen [reviewed in (103)]\u2003B Cell function● no effect of zn supplementation of mothers on Bcg response in children (321)\nagp, α1-acid Glycoprotein; bcg, bacille calmette-guérin; cd, cluster of differentiation; Cd45Ro , Cluster Of Differentiation Antigen 45 Ro; Crp, c-reactive protein; dth, delayed-type hypersensitivity; dtp, diphtheria tetanus-pertussis; ppd, purified protein derivative; saa, Serum Amyloid a; tb, tuberculosis; va, Vitamin A; vad, Vitamin A deficiency; vas, Vitamin A supplementation.']	[('INCOMPLETE_EVIDENCE', 463), ('SUPERFICIAL_RELATIONSHIP', 472), ('SUPERFICIAL_RELATIONSHIP', 633), ('INCOMPLETE_EVIDENCE', 673), ('INCOMPLETE_EVIDENCE', 744), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 763), ('INCOMPLETE_EVIDENCE', 882), ('INCOMPLETE_EVIDENCE', 894), ('INCOMPLETE_EVIDENCE', 913), ('INCOMPLETE_EVIDENCE', 917), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1267), ('ANOMALY_CURIOUS_FINDING', 1267), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1275), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1433), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1873), ('SUPERFICIAL_RELATIONSHIP', 1903), ('SUPERFICIAL_RELATIONSHIP', 3021), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 3088), ('INCOMPLETE_EVIDENCE', 3088), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 3099), ('INCOMPLETE_EVIDENCE', 3123), ('INCOMPLETE_EVIDENCE', 3138), ('INCOMPLETE_EVIDENCE', 3633)]	23	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 42, 'micronutrient'), ('UBERON_0002405', 'immune system', 75, 'immune'), ('NCBITaxon_9606', 'Homo sapiens', 114, 'human'), ('UBERON_0002405', 'immune system', 162, 'immune'), ('UBERON_0002405', 'immune system', 207, 'immune system'), ('UBERON_0000483', 'epithelium', 242, 'Epithelial'), ('UBERON_0004905', 'articulation', 428, 'lower respiratory tract'), ('CHEBI_24870', 'ion', 571, 'sugar'), ('CHEBI_25098', 'lyxoside', 578, 'lactulose'), ('CHEBI_25169', 'mannoside', 589, 'mannitol'), ('UBERON_0000160', 'intestine', 599, 'intestinal'), ('UBERON_0001977', 'blood serum', 649, 'serum'), ('CHEBI_26536', 'retinoic acid', 655, 'retinol'), ('NCBITaxon_1', 'root', 729, 'individuals'), ('UBERON_0004905', 'articulation', 847, 'lower respiratory tract'), ('GO_0007498', 'mesoderm development', 935, 'mucus production'), ('UBERON_0000912', 'mucus', 935, 'mucus'), ('CL_0000235', 'macrophage', 1163, 'Macrophage'), ('CL_0000576', 'monocyte', 1194, 'monocyte'), ('PR_000000134', 'tumor necrosis factor alpha', 1228, 'TNF-α'), ('PR_000008920', 'interferon alpha-7', 1308, 'IFN-γ'), ('GO_0007565', 'female pregnancy', 1358, 'pregnant'), ('PR_000001470', 'interleukin-28B', 1390, 'IL-10'), ('UBERON_0007023', 'adult organism', 1465, 'adults'), ('CL_0000775', 'neutrophil', 1486, 'Neutrophil'), ('CL_0000775', 'neutrophil', 1507, 'Neutrophil'), ('GO_0007608', 'sensory perception of smell', 1507, 'Neutrophil'), ('GO_0006909', 'phagocytosis', 1518, 'phagocytosis'), ('CHEBI_37958', 'dye', 1604, 'VA'), ('CL_0000775', 'neutrophil', 1614, 'Neutrophil'), ('GO_0070231', 'T cell apoptotic process', 1614, 'Neutrophil phagocytosis'), ('NCBITaxon_10088', 'Mus <genus>', 1641, 'E. coli'), ('CHEBI_37958', 'dye', 1680, 'VA'), ('CHEBI_37958', 'dye', 1696, 'VA'), ('CL_0000623', 'natural killer cell', 1705, 'NK cell'), ('GO_0005634', 'nucleus', 1705, 'NK'), ('CL_0000623', 'natural killer cell', 1738, 'NK cells'), ('GO_0005634', 'nucleus', 1738, 'NK'), ('CHEBI_37958', 'dye', 1790, 'VA'), ('CL_0000623', 'natural killer cell', 1800, 'NK cell'), ('GO_0005634', 'nucleus', 1800, 'NK'), ('CHEBI_37958', 'dye', 1847, 'VA'), ('CHEBI_37958', 'dye', 1869, 'VA'), ('CHEBI_37958', 'dye', 1923, 'VA'), ('UBERON_0012101', 'perinatal stage', 1937, 'peripheral blood'), ('CL_0000623', 'natural killer cell', 1954, 'NK cells'), ('GO_0005634', 'nucleus', 1954, 'NK'), ('CL_0000084', 'T cell', 1969, 'T cell'), ('CL_0000542', 'lymphocyte', 1996, 'lymphocyte'), ('PR_000001204', 'C-C chemokine receptor type 8', 2046, 'CD4'), ('PR_000005170', 'CD37 molecule', 2050, 'CD8'), ('CL_0000898', 'naive T cell', 2127, 'naive ... T cells'), ('GO_0007613', 'memory', 2175, 'memory'), ('PR_000005170', 'CD37 molecule', 2182, 'CD8'), ('PR_000005170', 'CD37 molecule', 2187, 'CD45RO'), ('CHEBI_52290', 'mitogen', 2208, 'mitogen'), ('PR_000001470', 'interleukin-28B', 2224, 'IL-2'), ('PR_000001470', 'interleukin-28B', 2230, 'IL-4'), ('PR_000016482', 'tumor necrosis factor receptor superfamily member 18', 2240, 'TNF'), ('CL_0000236', 'B cell', 2281, 'B cell'), ('NCBITaxon_33208', 'Metazoa', 2339, 'measles'), ('NCBITaxon_1', 'root', 2397, 'individuals'), ('GO_0071735', 'IgG immunoglobulin complex', 2519, 'IgG1'), ('CHEBI_37958', 'dye', 2633, 'VA'), ('GO_0042571', 'immunoglobulin complex, circulating', 2723, 'antibody'), ('NCBITaxon_33208', 'Metazoa', 2760, 'measles'), ('CHEBI_27377', 'Unsym-bis(4*-chlorophenyl)ethylene', 2956, 'Zinc'), ('UBERON_0000483', 'epithelium', 2961, 'Epithelial'), ('CHEBI_25169', 'mannoside', 3060, 'mannitol'), ('GO_0007588', 'excretion', 3069, 'excretion'), ('UBERON_0001977', 'blood serum', 3287, 'serum'), ('PR_000004908', 'complement component C8 alpha chain', 3293, 'complement C3'), ('CL_0000623', 'natural killer cell', 3313, 'NK cell'), ('GO_0005634', 'nucleus', 3313, 'NK'), ('CL_0000623', 'natural killer cell', 3421, 'NK cells'), ('CL_0000623', 'natural killer cell', 3447, 'NK cell'), ('CL_0000084', 'T cell', 3485, 'T cell'), ('CL_0000893', 'thymocyte', 3562, 'thymocyte'), ('UBERON_0002370', 'thymus', 3581, 'thymus'), ('CHEBI_59132', 'antigen', 3686, 'antigen'), ('CL_0000236', 'B cell', 3714, 'B cell'), ('CHEBI_33250', 'atom', 3777, 'BCG'), ('CHEBI_17089', 'glycoprotein', 3821, 'glycoprotein'), ('PR_000005170', 'CD37 molecule', 3897, 'CD45RO'), ('PR_000011040', 'nuclear receptor coactivator 1', 3906, 'cluster of differentiation antigen 45 RO'), ('CHEBI_59132', 'antigen', 3933, 'antigen'), ('PR_000005890', 'crooked neck-like protein 1', 3948, 'CRP'), ('UBERON_0001977', 'blood serum', 4083, 'serum'), ('CHEBI_60425', 'amyloid fibril', 4089, 'amyloid'), ('CHEBI_27300', 'vitamin D', 4122, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 4138, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 4165, 'vitamin A')]	0	['caption (table-wrap): table 6\n\neffects micronutrient supplementation immune vaccine responses (human studies)1type malnutrition type immune functioneffects supplementation immune system (reference)vitamin a\u2003epithelial function● high-dose vas 6 mo age decreases death infections measles diarrheal diseases (290)● vas context hiv infection respiratory tract infections outcomes (105,263,290–292)● (105)● abnormal dual-sugar (lactulose, mannitol) intestinal permeability serum retinol (293) normalized supplementation va-deficient individuals (294) (295,296)● symptomatology high-dose vas acute respiratory tract infections (105) restored mucus production\u2003innate physiologic barriers● vas crp, saa, and/or agp concentrations among children subclinical vad (297–299)● crp agp men va stores va (300)\u2003macrophage function● monocyte (301)● decreased tnf-α concentrations children (301) men (106)● decreased ifn-γ concentrations children (302)  women (303)● il-10 concentrations children (105,301) adults (106,303,304)\u2003neutrophil function● neutrophil phagocytosis latex beads va-deficient children single dose va (305)● neutrophil phagocytosis e. coli men va stores va (300)\u2003nk cell function● increase nk cells hiv-infected children supplemented va (105)● nk cell men va supplemental va; however, positive va stores peripheral blood nk cells (300)\u2003t cell function● lymphocyte counts, cd4 counts (105)● cd4:cd8 ratios supplementation (306)● increase naive cd4 cells supplementation; higher memory cd8, cd45ro (307)● higher mitogen-induced il-2, il-4, tnf response supplementation (106)\u2003b cell function● supplementation measles vaccine response (308) response individuals baseline titers (103)● oral polio vaccination● supplemented children igg1 responses dtp, minor igg3 response, igg2 igg4 (309)● bcg vaccine va-supplemented children, response va-supplemented boys 2 mo (310)● antibody responses vaccines (measles vaccine 9 mo age, oral polio vaccine, type 1, hepatitis b vaccine, rabies vaccine) (103)● short-term diminished cellular response ppd boys (103) hospitalized children (105)zinc\u2003epithelial function● zn supplementation children lactulose:mannitol excretion ratio (311) (312,313) studies; ratio infected children zn supplemental zn (314)\u2003innate physiologic ● zn-supplemented children higher serum c3 (315)\u2003nk cell function● children diarrhea supplemented zn supplementation increase nk cells (316)● nk cell activity elderly (317)\u2003t cell function● cd4+ cell count patients (318)● thymocyte count thymus (319)● thymulin activity (320)● zn supplementation dth tb antigen [reviewed (103)]\u2003b cell function● zn supplementation mothers bcg response children (321)\nagp, α1-acid glycoprotein; bcg, bacille calmette-guérin; cd, cluster differentiation; cd45ro cluster antigen 45 ro; crp, c-reactive protein; dth, delayed-type hypersensitivity; dtp, diphtheria tetanus-pertussis; ppd, purified protein derivative; saa, serum amyloid a; tb, tuberculosis; va, vad,  deficiency; vas,  supplementation.']
S867-PMC4448820	PMC4448820	5/2015	S867-PMC4448820	['ANOTHER example is the observation that Vitamin A supplementation, which GENERALLY lowers mortality in children, increased the RISK of Mother-To-Child Hiv Transmission in pregnant and Postpartum hiv-infected women in tanzania (469), ALTHOUGH not in south africa (470) or malawi (471).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 73), ('IMPORTANT_CONSIDERATION', 127), ('ANOMALY_CURIOUS_FINDING', 233)]	4	[('CHEBI_27300', 'vitamin D', 40, 'vitamin A'), ('GO_0007063', 'regulation of sister chromatid cohesion', 135, 'mother-to-child HIV transmission'), ('GO_0007565', 'female pregnancy', 184, 'postpartum')]	0	['another example  supplementation, lowers mortality children, mother-to-child hiv transmission pregnant  hiv-infected women tanzania (469), south africa (470) malawi (471).']
S868-PMC4448820	PMC4448820	5/2015	S868-PMC4448820	['in infants of hiv-positive mothers, Postpartum maternal and neonatal Vitamin A supplementation MAY hasten progression to death in breastfed children who are pcr negative at 6 wk (291).']	[('INCOMPLETE_EVIDENCE', 95)]	1	[('GO_0007565', 'female pregnancy', 36, 'postpartum'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin A')]	0	['infants hiv-positive mothers,  maternal neonatal  supplementation hasten progression death breastfed children pcr 6 wk (291).']
S1039-PMC4448820	PMC4448820	5/2015	S1039-PMC4448820	['Vitamin D\n\n● POOR Prenatal Vitamin D status HAS BEEN IMPLICATED in increased asthma risk and severity in the offspring, ALTHOUGH EVIDENCE TO SUPPORT an IMPORTANT RELATION remains CONTROVERSIAL (577).']	[('IMPORTANT_CONSIDERATION', 13), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 53), ('ANOMALY_CURIOUS_FINDING', 120), ('INCOMPLETE_EVIDENCE', 129), ('IMPORTANT_CONSIDERATION', 152), ('SUPERFICIAL_RELATIONSHIP', 162), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179)]	8	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 18, 'prenatal'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]	0	['vitamin d\n\n●   status asthma offspring, (577).']
S1473-PMC4448820	PMC4448820	5/2015	S1473-PMC4448820	['HOWEVER, recent data from a subset of women recruited as part of a national survey in cameroon INDICATE that Human-milk Vitamin A concentrations (casual samples at ≥1 mo Postpartum) were ASSOCIATED with crp, and this ASSOCIATION SEEMED TO BE EXPLAINED by a decrease in Plasma rbp (776).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 95), ('SUPERFICIAL_RELATIONSHIP', 187), ('SUPERFICIAL_RELATIONSHIP', 217), ('ANOMALY_CURIOUS_FINDING', 229), ('PROBABLE_UNDERSTANDING', 242)]	6	[('NCBITaxon_9606', 'Homo sapiens', 109, 'human'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A'), ('GO_0007565', 'female pregnancy', 170, 'postpartum'), ('UBERON_0001969', 'blood plasma', 269, 'plasma')]	0	['however, subset women recruited national survey cameroon human-milk  concentrations (casual samples ≥1 mo crp, decrease plasma rbp (776).']
S0-PMC4452099	PMC4452099	6/2015	S0-PMC4452099	['Gestational and early infancy exposure to margarine fortified with Vitamin D through a national danish programme and the risk of type 1 diabetes: the d-tect study\n\nabstract\nthe OBJECTIVE of the study was TO ASSESS WHETHER Gestational and early Infancy exposure to low dose Vitamin D from a mandatory Margarine fortification programme in denmark INFLUENCED the risk of developing type 1 diabetes (t1d) before age of 15 years.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 177), ('QUESTION_ANSWERED_BY_THIS_WORK', 204), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 214), ('SUPERFICIAL_RELATIONSHIP', 345)]	4	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_28384', 'vitamin K', 67, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 67, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 222, 'gestational'), ('UBERON_0000023', 'wing', 244, 'infancy'), ('CHEBI_27300', 'vitamin D', 273, 'vitamin D'), ('CHEBI_6784', 'mestranol', 300, 'margarine')]	0	[' infancy exposure margarine fortified vitamin national danish programme type diabetes: d-tect study\n\nabstract\nthe  infancy exposure dose  margarine fortification programme denmark type diabetes (t1d) age 15 years.']
S3-PMC4452099	PMC4452099	6/2015	S3-PMC4452099	['we further MODELLED birth cohort EFFECTS in children developing t1d as a linear spline, and compared the slopes between the birth cohorts with various Prenatal and infancy exposures to Vitamin D fortification.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 33)]	2	[('GO_0007565', 'female pregnancy', 151, 'prenatal'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin D')]	0	['birth children t1d linear spline, slopes birth cohorts  infancy exposures  fortification.']
S7-PMC4452099	PMC4452099	6/2015	S7-PMC4452099	['in conclusion, we FOUND NO EVIDENCE TO SUPPORT that exposure to low dose Vitamin D from the danish mandatory Margarine fortification regimen during Gestational and first Postnatal year of Life changed the risk of developing t1d before the age of 15 years.']	[('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 24)]	2	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_6784', 'mestranol', 109, 'margarine'), ('GO_0007565', 'female pregnancy', 148, 'gestational'), ('GO_0007567', 'parturition', 170, 'postnatal'), ('UBERON_0000104', 'life cycle', 188, 'life')]	0	['conclusion, exposure dose  danish margarine fortification regimen  postnatal year life t1d age 15 years.']
S13-PMC4452099	PMC4452099	6/2015	S13-PMC4452099	['a variety of environmental t1d risk and PROTECTIVE FACTORS, including Vitamin D supplementation during Gestation and in early infancy, HAVE BEEN investigated [5–9].']	[('SUPERFICIAL_RELATIONSHIP', 40), ('INCOMPLETE_EVIDENCE', 135)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'gestation')]	0	['environmental t1d factors,  supplementation  infancy, [5–9].']
S15-PMC4452099	PMC4452099	6/2015	S15-PMC4452099	['one HYPOTHESIS is that Vitamin D in Pregnant women is INVOLVED in the processes of Immunological Adaptation down-regulating the T Helper type 1 (th1) pro-inflammatory cytokine Responses, that POSSIBLY CONTRIBUTE to the Destruction Of Beta-Cells[10].']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 54), ('INCOMPLETE_EVIDENCE', 192), ('SUPERFICIAL_RELATIONSHIP', 201)]	4	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 36, 'pregnant'), ('GO_0002455', 'humoral immune response mediated by circulating immunoglobulin', 83, 'immunological adaptation'), ('CL_0002061', 'T-helper 9 cell', 128, 'T helper'), ('GO_0060033', 'anatomical structure regression', 176, 'responses'), ('GO_0048468', 'cell development', 219, 'destruction of ... cells'), ('CL_0000349', 'extraembryonic cell', 234, 'beta-cells')]	0	['one   women processes immunological adaptation down-regulating helper type (th1) pro-inflammatory cytokine responses, destruction beta-cells[10].']
S17-PMC4452099	PMC4452099	6/2015	S17-PMC4452099	['Animal studies DEMONSTRATED that in Mice, Prenatal Vitamin D supplementation PREVENTED the development of t1d [13,14].']	[('INCOMPLETE_EVIDENCE', 15), ('SUPERFICIAL_RELATIONSHIP', 77)]	2	[('NCBITaxon_33208', 'Metazoa', 0, 'Animal'), ('NCBITaxon_10088', 'Mus <genus>', 36, 'mice'), ('GO_0007565', 'female pregnancy', 42, 'prenatal'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D')]	0	['animal mice,   supplementation t1d [13,14].']
S18-PMC4452099	PMC4452099	6/2015	S18-PMC4452099	['SEVERAL epidemiological STUDIES also FOUND that the risk of t1d was decreased in Individuals supplemented with Vitamin D during Gestation or infancy, and that the PROTECTIVE EFFECT was directly DEPENDENT ON the supplementation dose: the larger the dose, the smaller t1d risk [15].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 163), ('SUPERFICIAL_RELATIONSHIP', 174), ('SUPERFICIAL_RELATIONSHIP', 194)]	6	[('NCBITaxon_1', 'root', 81, 'individuals'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0007565', 'female pregnancy', 128, 'gestation')]	0	['several epidemiological t1d decreased individuals supplemented   infancy, supplementation dose: dose, t1d [15].']
S28-PMC4452099	PMC4452099	6/2015	S28-PMC4452099	['the AIM of THIS STUDY was TO ASSESS WHETHER Gestational and early Infancy exposure to small extra doses of Vitamin D coming from fortified Margarine INFLUENCED the risk of developing t1d later in Life.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 36), ('SUPERFICIAL_RELATIONSHIP', 149)]	5	[('GO_0007565', 'female pregnancy', 44, 'gestational'), ('UBERON_0000023', 'wing', 66, 'infancy'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_6784', 'mestranol', 139, 'margarine'), ('UBERON_0000104', 'life cycle', 196, 'life')]	0	[' infancy exposure extra doses  coming fortified margarine t1d life.']
S29-PMC4452099	PMC4452099	6/2015	S29-PMC4452099	['we HYPOTHESISED that t1d risk will be lower among Individuals Born in denmark during the period of obligatory Margarine fortification—and THEREFORE exposed to Vitamin D fortified Food during Gestation or Infancy—compared to Individuals Born in years when Margarine was not fortified—and CONSEQUENTLY unexposed to extra Vitamin D coming from fortified Margarine at any period of early Life.']	[('INCOMPLETE_EVIDENCE', 3), ('PROBABLE_UNDERSTANDING', 138), ('PROBABLE_UNDERSTANDING', 287)]	3	[('NCBITaxon_1', 'root', 50, 'individuals'), ('GO_0007567', 'parturition', 62, 'born'), ('CHEBI_6784', 'mestranol', 110, 'margarine'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('CHEBI_33290', 'food', 179, 'food'), ('GO_0007565', 'female pregnancy', 191, 'gestation'), ('UBERON_0000023', 'wing', 204, 'infancy'), ('NCBITaxon_1', 'root', 224, 'individuals'), ('GO_0007567', 'parturition', 236, 'born'), ('CHEBI_6784', 'mestranol', 255, 'margarine'), ('CHEBI_27300', 'vitamin D', 319, 'vitamin D'), ('CHEBI_6784', 'mestranol', 351, 'margarine'), ('UBERON_0000104', 'life cycle', 384, 'life')]	0	['t1d among individuals born denmark period obligatory margarine fortification—and exposed  fortified food  infancy—compared individuals born margarine fortified—and unexposed extra  coming fortified margarine period life.']
S68-PMC4452099	PMC4452099	6/2015	S68-PMC4452099	['the size of the study population in various Gestational period groups is presented in tables1and2.10.1371/journal.pone.0128631.t001\n\ncaption (table-wrap): table 1\nstudied population by periods of various Gestational exposures to Vitamin D fortification, t1d onset age, and sex.n (%)Birth period in RELATION to exposure to Vitamin D fortification during Gestationexposure: jan 1983-may 1985*washout: jun 1985-aug 1986*non-exposure: sep 1986-dec 1988*total127,20769,667134,749\xa0\xa0\xa0\xa0males (% from total)65,266 (51.3)35,729 (51.3)69,436 (51.5)t1d until 15 (% from total)298 (0.23)184 (0.26)404 (0.30)\xa0\xa0\xa0\xa0in males (% from above)157 (52.7)99 (53.8)224 (55.4)t1d at 0–4 (% from total)32 (0.02)28 (0.04)54 (0.04)\xa0\xa0\xa0\xa0in males (% from above)21 (65.6)11 (39.3)35 (64.8)t1d at 5–9 (% from total)83 (0.07)55 (0.08)131 (0.10)\xa0\xa0\xa0\xa0in males (% from above)38 (45.8)29 (52.7)75 (57.3)t1d at 10–15 (% from total)183 (0.14)101 (0.14)219 (0.16)\xa0\xa0\xa0\xa0in males (% from above)98 (53.6)59 (58.4)114 (52.1)\n* including the starting and ending months.10.1371/journal.pone.0128631.t002\n\ncaption (table-wrap): table 2\nstudied population by periods of various first Postnatal year exposures to Vitamin D fortification, t1d onset age, and sex.n (%)Birth period in relation to exposure to Vitamin D fortification during first year of Postnatal Lifeexposure: jan 1983-may 1984*washout: jun 1984-aug 1986*non-exposure: sep 1986-dec 1988*total73,986122,888134,749males (% from total)37,977 (51.3)63,018 (51.3)69,436 (51.5)t1d until 15 (% from total)156 (0.23)326 (0.26)404 (0.30)in males (% from above)82 (52.6)174 (53.4)224 (55.4)t1d at 0–4 (% from total)15 (0.02)45 (0.04)54 (0.04)in males (% from above)7 (46.7)25 (55.6)35 (64.8)t1d at 5–9 (% from total)49 (0.07)89 (0.08)131 (0.10)in males (% from above)19 (38.8)48 (53.9)75 (57.3)t1d at 10–15 (% from total)92 (0.14)192 (0.14)219 (0.16)in males (% from above)56 (60.9)101 (52.6)114 (52.1)\n* including the starting and ending months.']	[('SUPERFICIAL_RELATIONSHIP', 298)]	1	[('GO_0007565', 'female pregnancy', 44, 'gestational'), ('GO_0007565', 'female pregnancy', 204, 'gestational'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('GO_0007567', 'parturition', 282, 'Birth'), ('CHEBI_27300', 'vitamin D', 322, 'vitamin D'), ('GO_0007530', 'sex determination', 353, 'gestationExposure'), ('GO_0007567', 'parturition', 1131, 'postnatal'), ('CHEBI_27300', 'vitamin D', 1159, 'vitamin D'), ('GO_0007567', 'parturition', 1212, 'Birth'), ('CHEBI_27300', 'vitamin D', 1252, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 1260, 'D'), ('GO_0007567', 'parturition', 1297, 'postnatal'), ('UBERON_0002004', 'trunk of sciatic nerve', 1307, 'lifeExposure')]	0	['population  period tables1and2.10.1371/journal.pone.0128631.t001\n\ncaption (table-wrap): table 1\nstudied population periods  exposures  fortification, t1d onset age, sex.n (%)birth period exposure  fortification gestationexposure: jan 1983-may 1985*washout: jun 1985-aug 1986*non-exposure: sep 1986-dec 1988*total127,20769,667134,749\xa0\xa0\xa0\xa0males (% total)65,266 (51.3)35,729 (51.3)69,436 (51.5)t1d 15 (% total)298 (0.23)184 (0.26)404 (0.30)\xa0\xa0\xa0\xa0in males (% above)157 (52.7)99 (53.8)224 (55.4)t1d 0–4 (% total)32 (0.02)28 (0.04)54 (0.04)\xa0\xa0\xa0\xa0in males (% above)21 (65.6)11 (39.3)35 (64.8)t1d 5–9 (% total)83 (0.07)55 (0.08)131 (0.10)\xa0\xa0\xa0\xa0in males (% above)38 (45.8)29 (52.7)75 (57.3)t1d 10–15 (% total)183 (0.14)101 (0.14)219 (0.16)\xa0\xa0\xa0\xa0in males (% above)98 (53.6)59 (58.4)114 (52.1)\n* ending months.10.1371/journal.pone.0128631.t002\n\ncaption (table-wrap): table 2\nstudied population periods postnatal year exposures  fortification, t1d onset age, sex.n (%)birth period exposure  fortification year postnatal lifeexposure: jan 1983-may 1984*washout: jun 1984-aug 1986*non-exposure: sep 1986-dec 1988*total73,986122,888134,749males (% total)37,977 (51.3)63,018 (51.3)69,436 (51.5)t1d 15 (% total)156 (0.23)326 (0.26)404 (0.30)in males (% above)82 (52.6)174 (53.4)224 (55.4)t1d 0–4 (% total)15 (0.02)45 (0.04)54 (0.04)in males (% above)7 (46.7)25 (55.6)35 (64.8)t1d 5–9 (% total)49 (0.07)89 (0.08)131 (0.10)in males (% above)19 (38.8)48 (53.9)75 (57.3)t1d 10–15 (% total)92 (0.14)192 (0.14)219 (0.16)in males (% above)56 (60.9)101 (52.6)114 (52.1)\n* ending months.']
S84-PMC4452099	PMC4452099	6/2015	S84-PMC4452099	['one REASON for the absence of a detectable RELATIONSHIP between td risk and Early Life exposure to fortified Margarine COULD BE the actual dose of Vitamin D added to Margarine, and therefore the dose which Individuals were exposed to during Gestation and/or during the first year of Life.']	[('PROBABLE_UNDERSTANDING', 4), ('SUPERFICIAL_RELATIONSHIP', 43), ('INCOMPLETE_EVIDENCE', 119)]	3	[('UBERON_0001847', 'lobule of pinna', 76, 'early life'), ('CHEBI_6784', 'mestranol', 109, 'margarine'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_6784', 'mestranol', 166, 'margarine'), ('NCBITaxon_1', 'root', 206, 'individuals'), ('GO_0007565', 'female pregnancy', 241, 'gestation'), ('UBERON_0000104', 'life cycle', 283, 'life')]	0	['one absence td life exposure fortified margarine actual dose  added margarine, dose individuals exposed  and/or year life.']
S86-PMC4452099	PMC4452099	6/2015	S86-PMC4452099	['ACCORDING TO results from PREVIOUS STUDIES, Pregnant danish women are getting APPROXIMATELY 3 μg of Vitamin D per day from the diet [26], which in turn SUGGESTS that the amount of Vitamin D coming from the fortified Margarine (i.e.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 78), ('INCOMPLETE_EVIDENCE', 152)]	4	[('GO_0007565', 'female pregnancy', 44, 'pregnant'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('CHEBI_6784', 'mestranol', 216, 'margarine')]	0	['according results studies,  danish women getting 3 μg  day diet [26], turn amount  coming fortified margarine (i.e.']
S89-PMC4452099	PMC4452099	6/2015	S89-PMC4452099	['the Intake of Vitamin D among Pregnant and Lactating women CORRELATES well with the Vitamin D Serum levels [28].']	[('SUPERFICIAL_RELATIONSHIP', 59)]	1	[('GO_0007631', 'feeding behavior', 4, 'intake'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 30, 'pregnant'), ('GO_0007594', 'puparial adhesion', 43, 'lactating'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('UBERON_0001977', 'blood serum', 94, 'serum')]	0	['intake  among  lactating women  serum levels [28].']
S90-PMC4452099	PMC4452099	6/2015	S90-PMC4452099	['BECAUSE Vitamin D travels freely through the Placenta, the doses of foetal Vitamin D will be similar with the doses that the Pregnant women were getting [29].']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('UBERON_0001987', 'placenta', 45, 'placenta'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnant')]	0	[' travels freely placenta, doses foetal  doses  women getting [29].']
S109-PMC4452099	PMC4452099	6/2015	S109-PMC4452099	['conclusions\nwe did not find that Gestational or early Infancy exposure to small extra doses of Vitamin D coming from the danish mandatory Margarine fortification programme INFLUENCED the risk of developing t1d later in Life.']	[('SUPERFICIAL_RELATIONSHIP', 172)]	1	[('GO_0007565', 'female pregnancy', 33, 'gestational'), ('UBERON_0000023', 'wing', 54, 'infancy'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_6784', 'mestranol', 138, 'margarine'), ('UBERON_0000104', 'life cycle', 219, 'life')]	0	['conclusions\nwe  infancy exposure extra doses  coming danish margarine fortification programme t1d life.']
S0-PMC4466139	PMC4466139	6/2015	S0-PMC4466139	['high prevalence of Vitamin D deficiency in native versus migrant mothers and newborns in the north of italy: a CALL TO act with a stronger prevention program\n\nabstract\n\nbackground\nVitamin D status during Pregnancy is RELATED to neonatal Vitamin D status.']	[('IMPORTANT_CONSIDERATION', 111), ('SUPERFICIAL_RELATIONSHIP', 217)]	2	[('CHEBI_28384', 'vitamin K', 19, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 19, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 180, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]	0	['high vitamin native migrant mothers newborns north italy: program\n\nabstract\n\nbackground\nvitamin status  neonatal  status.']
S16-PMC4466139	PMC4466139	6/2015	S16-PMC4466139	['Vitamin D levels during fetal Life and the Neonatal Period MAY play a ROLE in the development of these conditions through epigenetic changes [11], THEREFORE, Vitamin D status during Pregnancy and in the newborn COULD provide IMPORTANT information.']	[('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 70), ('PROBABLE_UNDERSTANDING', 147), ('INCOMPLETE_EVIDENCE', 211), ('IMPORTANT_CONSIDERATION', 225)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0000104', 'life cycle', 30, 'life'), ('UBERON_0007221', 'neonate stage', 43, 'neonatal period'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy')]	0	['vitamin levels fetal life neonatal period play conditions epigenetic changes [11], therefore,  status  newborn information.']
S83-PMC4466139	PMC4466139	6/2015	S83-PMC4466139	['a daily supplementation of 400 iu of Vitamin D LED TO 105 (37%) mothers (93 italian and 12 migrants) and 56 (20%) newborns (53 italian and 3 migrants) to have Blood 25Ohd values above the cut-off of sufficiency (fixed at 50 nmol/l) (table 5).10.1371/journal.pone.0129586.t005\n\ncaption (table-wrap): table 5\nnumber and percentage of subjects under Vitamin D supplementation (400 iu per day) SHOWING sufficient levels of Vitamin D (25Ohd≥50 nmol/l).subjectsall (283)italian (213)migrant (70)p value newborns 56 (20%)53 (24.9%)3 (4.3%)<0.001 mothers 105 (37%)93 (43.7%)12 (17.1%)<0.001\nno significant associations between maternal and neonatal 25Ohd levels and maternal weight gain in Pregnancy or Birth weight were FOUND.']	[('SUPERFICIAL_RELATIONSHIP', 47), ('INCOMPLETE_EVIDENCE', 390), ('INCOMPLETE_EVIDENCE', 713)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0000178', 'blood', 159, 'blood'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 165, '25OHD'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 419, 'vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 430, '25OHD'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 641, '25OHD'), ('GO_0007565', 'female pregnancy', 682, 'pregnancy'), ('GO_0007567', 'parturition', 695, 'birth')]	0	['daily supplementation 400 iu  105 (37%) mothers (93 italian 12 migrants) 56 (20%) newborns (53 italian 3 migrants) blood 25ohd values cut-off (fixed 50 nmol/l) (table 5).10.1371/journal.pone.0129586.t005\n\ncaption (table-wrap): table 5\nnumber percentage subjects  supplementation (400 iu day) levels  (25ohd≥50 nmol/l).subjectsall (283)italian (213)migrant (70)p newborns 56 (20%)53 (24.9%)3 (4.3%)<0.001 mothers 105 (37%)93 (43.7%)12 (17.1%)<0.001\nno maternal neonatal 25ohd levels maternal gain  birth found.']
S84-PMC4466139	PMC4466139	6/2015	S84-PMC4466139	['multivariate adjusted regression model analysis (r-square: 0.302), adjusted for maternal age and education SHOWED a LINK between maternal 25Ohd level and season (p<0.0001), country of origin (north africa, p<0.0001; africa, p = 0.0052; asia, p = 0.0003; south america, p = 0.0002) and Vitamin D supplementation in Pregnancy (p<0.0001), while Vitamin D Intake from diet was non-significant (p = 0.944).']	[('INCOMPLETE_EVIDENCE', 107), ('SUPERFICIAL_RELATIONSHIP', 116)]	2	[('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 138, '25OHD'), ('CHEBI_27300', 'vitamin D', 285, 'vitamin D'), ('GO_0007565', 'female pregnancy', 314, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin D'), ('GO_0007631', 'feeding behavior', 352, 'intake')]	0	['multivariate adjusted regression (r-square: 0.302), adjusted maternal age maternal 25ohd season (p<0.0001), country origin (north africa, p<0.0001; africa, p = 0.0052; asia, p = 0.0003; south america, p = 0.0002)  supplementation  (p<0.0001),  intake diet non-significant (p = 0.944).']
S95-PMC4466139	PMC4466139	6/2015	S95-PMC4466139	['AS ALREADY KNOWN, Placental Transfer provides Vitamin D from mother to fetus, especially in the last trimester of Gestation [31] THUS neonatal and maternal 25Ohd levels are closely LINKED.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 3), ('PROBABLE_UNDERSTANDING', 129), ('SUPERFICIAL_RELATIONSHIP', 181)]	4	[('UBERON_0001987', 'placenta', 18, 'placental'), ('GO_0006412', 'translation', 28, 'transfer'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'gestation'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 156, '25OHD')]	0	['known, placental transfer  mother fetus, last trimester  [31] neonatal maternal 25ohd levels linked.']
S102-PMC4466139	PMC4466139	6/2015	S102-PMC4466139	['our results SHOW that few migrant mothers are supplemented with Vitamin D during Pregnancy, especially in the last month, SUGGESTING that more extensive PREVENTION and education programs SHOULD be adopted.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 153), ('FUTURE_WORK', 187)]	4	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy')]	0	['results migrant mothers supplemented  last month, adopted.']
S103-PMC4466139	PMC4466139	6/2015	S103-PMC4466139	['furthermore, when we analyzed the ROLE of diet and supplementation in Pregnancy and their EFFECTS on mothers and newborns, Vitamin D intake through diet was (136 iu on average) under 400 iu (recommended minimum), with an Intake slightly higher in migrants than italian mothers.']	[('SUPERFICIAL_RELATIONSHIP', 34), ('SUPERFICIAL_RELATIONSHIP', 90)]	2	[('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007631', 'feeding behavior', 221, 'intake')]	0	['furthermore, diet supplementation  mothers newborns,  intake diet (136 iu average) 400 iu (recommended minimum), intake higher migrants italian mothers.']
S106-PMC4466139	PMC4466139	6/2015	S106-PMC4466139	['these results SHOW a strong ROLE for supplementation in increasing 25Ohd levels and also that supplementation at 400 iu/die is INSUFFICIENT to provide an appropriate Vitamin D status in Pregnant women and their offsprings.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 28), ('PROBLEM_COMPLICATION', 127)]	3	[('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 67, '25OHD'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('GO_0007565', 'female pregnancy', 186, 'pregnant')]	0	['results supplementation 25ohd levels supplementation 400 iu/die  status  women offsprings.']
S108-PMC4466139	PMC4466139	6/2015	S108-PMC4466139	['Vitamin D deficiency in Pregnancy in spite of taking supplementation MAY BE AS a result of an INSUFFICIENT dose of Vitamin D contained in multivitamins in Prenatal supplements many of which contain only 400 iu or 500 iu, as PREVIOUSLY SHOWN in OTHER studies [33,34].']	[('INCOMPLETE_EVIDENCE', 69), ('PROBABLE_UNDERSTANDING', 76), ('IMPORTANT_CONSIDERATION', 94), ('INCOMPLETE_EVIDENCE', 224), ('INCOMPLETE_EVIDENCE', 244)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 24, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'prenatal')]	0	['vitamin  supplementation result dose  contained multivitamins  supplements contain 400 iu 500 iu, [33,34].']
S112-PMC4466139	PMC4466139	6/2015	S112-PMC4466139	['RECENTLY, an increasing NUMBER OF STUDIES HAVE SHOWN that higher doses of Vitamin D supplementation are SAFE and EFFECTIVE in Pregnant women.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 42), ('IMPORTANT_CONSIDERATION', 104), ('SUPERFICIAL_RELATIONSHIP', 113)]	5	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'pregnant')]	0	['recently, higher doses  supplementation  women.']
S116-PMC4466139	PMC4466139	6/2015	S116-PMC4466139	['the RELATIONSHIP between 25Ohd levels, ethnicity and supplementation in Pregnancy SUGGESTS a ROLE for Genetic DETERMINANTS for Vitamin D status and STRESSES the IMPORTANCE of Vitamin D integration in preventative STRATEGIES.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 82), ('SUPERFICIAL_RELATIONSHIP', 93), ('SUPERFICIAL_RELATIONSHIP', 110), ('IMPORTANT_CONSIDERATION', 148), ('IMPORTANT_CONSIDERATION', 161), ('FUTURE_WORK', 213)]	7	[('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 25, '25OHD'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('SO_0000704', 'gene', 102, 'genetic'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D')]	0	['25ohd levels, ethnicity supplementation  genetic  status  integration preventative strategies.']
S117-PMC4466139	PMC4466139	6/2015	S117-PMC4466139	['OUR FINDINGS also underline the IMPORTANCE of certain RISK FACTORS in causing Vitamin D deficiency such as immigration, dark skin, and lack of Vitamin D supplementation during the Third Trimester of Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('IMPORTANT_CONSIDERATION', 32), ('SUPERFICIAL_RELATIONSHIP', 54)]	3	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('GO_0042793', 'plastid transcription', 180, 'third trimester'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy')]	0	[' immigration, dark skin,  supplementation third trimester .']
S121-PMC4466139	PMC4466139	6/2015	S121-PMC4466139	['in conclusion, Vitamin D insufficiency in Pregnancy is widely present in piedmont and it is RELATED to Vitamin D status in newborns.']	[('SUPERFICIAL_RELATIONSHIP', 92)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]	0	['conclusion,   piedmont  status newborns.']
S147-PMC4476607	PMC4476607	1/2015	S147-PMC4476607	['ALTHOUGH antioxidant treatments in Animal MODELS are encouraging, researchers PREMATURELY terminated a clinical trial utilizing high doses of Vitamins C and E in women with Alcohol-exposed Pregnancies BECAUSE of SAFETY CONCERNS (goh et al.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 42), ('INCOMPLETE_EVIDENCE', 42), ('PROBLEM_COMPLICATION', 78), ('PROBLEM_COMPLICATION', 201), ('IMPORTANT_CONSIDERATION', 212), ('IMPORTANT_CONSIDERATION', 219), ('PROBLEM_COMPLICATION', 219)]	9	[('NCBITaxon_33208', 'Metazoa', 35, 'animal'), ('CHEBI_27300', 'vitamin D', 142, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 157, 'E'), ('CHEBI_30879', 'alcohol', 173, 'alcohol'), ('GO_0007565', 'female pregnancy', 189, 'pregnancies')]	0	['although antioxidant treatments animal encouraging, terminated utilizing doses  e women alcohol-exposed  (goh et al.']
S179-PMC4488777	PMC4488777	5/2015	S179-PMC4488777	['this is why even during the most physiological Pregnancy Vitamin D supplementation in the amount of 800–1000 iu daily is HIGHLY RECOMMENDED [65].']	[('IMPORTANT_CONSIDERATION', 121)]	1	[('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]	0	['physiological   supplementation amount 800–1000 iu daily [65].']
S182-PMC4488777	PMC4488777	5/2015	S182-PMC4488777	['during the preparation for Pregnancy in vd-deficient females (with Serum vd 50–125nmol/l), it is ADVISED to supplement Vitamin D prior to the first visit in a Fertility clinic.']	[('FUTURE_WORK', 97)]	1	[('GO_0007565', 'female pregnancy', 27, 'pregnancy'), ('UBERON_0001977', 'blood serum', 67, 'serum'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('GO_0009566', 'fertilization', 159, 'fertility')]	0	['preparation  vd-deficient females (with serum vd 50–125nmol/l), supplement  visit fertility clinic.']
S187-PMC4488777	PMC4488777	5/2015	S187-PMC4488777	['conclusions\nCURRENT RESEARCH on the ROLE of Vitamin D in Fertility impairments, such as polycystic Ovary syndrome, Uterine fibroids, improper Semen parameters and in the case of in vitro treatments and Pregnancy failure, SUGGESTS it plays an IMPORTANT ROLE in Human Reproduction processes.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 221), ('IMPORTANT_CONSIDERATION', 242), ('SUPERFICIAL_RELATIONSHIP', 252)]	5	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0009566', 'fertilization', 57, 'fertility'), ('UBERON_0000992', 'ovary', 99, 'ovary'), ('UBERON_0000995', 'uterus', 115, 'uterine'), ('UBERON_0001968', 'semen', 142, 'semen'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy'), ('NCBITaxon_9606', 'Homo sapiens', 260, 'human'), ('GO_0000003', 'reproduction', 266, 'reproduction')]	0	['conclusions\ncurrent  fertility impairments, polycystic ovary syndrome, uterine fibroids, semen parameters treatments  failure, plays human reproduction processes.']
S137-PMC4490503	PMC4490503	6/2015	S137-PMC4490503	['gdm develops when beta cell dysfunction coexists, and MAY BE characterised by further abnormalities in adipokine and cytokine profiles, increased Free Fatty Acids (ffa), Triglycerides (tg), low Vitamin D and Endothelial dysfunction.ijms-16-13442-t001_table 1\n\ncaption (table-wrap): table 1\n\nlongitudinal studies of inflammatory markers in prediction of gdm.inflammatory markerfirst author (year)study designgdm statusgdm diagnostic criteriagestational age at testing (weeks)EFFECT in gdmmatching or adjustment for confounderstnf-αkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter and coustan criteria [64]pre-gravid 12–14 weeks 34–36 weekstnf-Α ↑ 34–36 weeks in gdm inversely CORRELATED with Insulin sensitivityfat massgao (2008) [65]nested case-control22 gdm 10 igt 20 ngtunknown12–20 weeks 24–32 weekstnf-Α ↑ in gdm positively CORRELATED with bmi 14–20 weeksn/ageorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmisaucedo (2011) [67]prospective60 gdm 60 ngt24–28 weeks ada criteria 2010 [68]30 weeks 6 weeks 6 months Postpartumtnf-Α ↑ in both groups at 6 weeks Tnf-Α ↑ 6months Postpartum in gdmage weightlopez-tinoco (2012) [69]case-control63 gdm 63 ngt24–28 weeks nddg criteria [70]mean ~29 weekstnf-Α ↑ in gdmbmiguillemette (2014) [71]prospective61 gdm 695 ngt24–28 weeks iadpsg criteria [44]5–16 weeks 24–28 weekstnf-Α ↑ in both groups and ASSOCIATED with Insulin resistanceage bmi tg adiponectin.il-6morrisett (2011) [72]case-control20 gdm 27 ngt26.1 ± 3.7 weeks cda criteria [73]26.1 ± 3.7 weeks 8 weeks post-partumil-6 ↑ in gdm and post-Partum, CORRELATED with Insulin sensitivity and bmibmihassiakos (2015) [74]case-control40 gdm 94 ngt24–28 weeks iadpsg criteria [44]11–14 weekil-6 ↑ in gdm and inversely RELATED to Birth weightmaternal weightleptinkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter and coustan criteria [64]pre-gravid 12–14 weeks 34–36 weeksleptin ↑ across Pregnancy inverse CORRELATION with Insulin sensitivity, BUT non-significant when adjusted for fat massfat massgeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmiqiu (2004) [75]prospective47 gdm 776 ngt26–28 weeks carpenter and coustan criteria [64]13 weeks10-ng/ml ↑ in leptin ASSOCIATED with 20% ↑ gdmparity bmi family history of non-Insulin dependent diabetesadiponectingeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksage ethnicity gravidity parity bmimcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weekadiponectin ↓ gdm and offspringage maternal weightwilliams (2004) [77]nested case-control41 gdm 70 ngt26–28 weeks carpenter and coustan criteria [64]13 week4.6-fold ↑ risk of gdm if adiponectin < 6.4 mcg/ml, overweight women 11-fold ↑ risk of gdmbmilain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter and coustan criteria [64]9.3 ± 2.6 weeksadiponectin < 25th 11-fold ↑ risk gdmbmilowe (2010) [57]prospective1481 Pregnant women24–32 weeks 2 h 75 g ogtt unblinded if fpg > 5.8 mmol/l 2 h > 11.1 mmol/l or random Glucose ≥ 8.9 mmol/l24–32 weeks↓ adiponectin ASSOCIATED with ↑ Glucose and bmibmi c-peptide Gestation genderlacroix (2013) [79]prospective38 gdm 407 ngt24–28 weeks iadpsg criteria [44]6–13 week↓ adiponectin ASSOCIATED with ↑ risk gdm (or1.12 per 1 µg/ml ↓ of adiponectin) and ASSOCIATED with Insulin sensitivitybmi hba1cianniello (2013) [39]prospective16 gdm 32 ngt24–28 weeks carpenter and coustan criteria [64]all trimesters↓ adiponectin PREDICTIVE of gdm in overweight/obesen/aweerakiet (2006) [80]prospective60 gdm 299 ngt24–28 weeks carpenter and coustan criteria [64]21–27 weekadiponectin 10 µg/ml has sensitivity of 91% and specificity of 31% for gdmbmirbp-4krzyzanovska (2008) [81]nested case-control20 gdm 22 ngt24–28 weeks carpenter and coustan criteria [64]30 weekrbp-4 ↓ in gdmn/ananda (2013) [82]nested case-control60 gdm 240 ngt24–28 weeks who criteria 2006 [83]11–13 weeksno differencen/aabetew (2013) [84]nested case-control173 gdm 187 ngt24–28 weeks carpenter and coustan criteria [64]16 weeksrbp-4 ↑ in gdm BUT NOT significant after adjustmentmaternal age ethnicityresistinlain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter and coustan criteria [64]9.3 ± 2.6 weeksno differencebmigeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmilowe (2010) [57]prospective1481 Pregnant women24–32 weeks 2 h 75 g ogtt unblinded if fpg > 5.8 mmol/l 2 h > 11.1 mmol/l or Random Glucose ≥ 8.9 mmol/l24–32 weeksnot ASSOCIATED with Glucose or Birth weightbmi c-peptide Gestation gendernanda (2012) [85]nested case-control60 gdm 240 ngt24–28 weeks who criteria 2006 [83]11–13 weeksno differencen/amcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weeksresistin ↓ in gdm and offspringage maternal weightvisfatinkrzyzanovska (2006) [86]nested case-control64 gdm 30 ngt24–28 weeks carpenter and coustan criteria [64]28–30 weeks 38–40 weeks 2 weeks post-Partumvisfatin ↑ in gdmbmiferreira (2011) [87]case-control100 gdm 300 ngt24–28 weeks who criteria 2006 [83]11–13 weekvisfatin ↑ in gdmn/a\nngt = normal Glucose tolerance; igt = impaired Glucose tolerance; fpg = fasting plasma Glucose; homa-ir = homeostasis model assessment for Insulin resistance; matsuda index = measure of Insulin sensitivity; bmi = body mass index; tg = Triglycerides; n/a = not available; ↓ = decreased levels; ↑ = increased levels; adips = australasian diabetes in Pregnancy society; ada = american diabetes association; nddg = national diabetes data group; iadpsg = international association of diabetes and Pregnancy study group; cda = canadian diabetes association; who = world health organisation.']	[('INCOMPLETE_EVIDENCE', 54), ('SUPERFICIAL_RELATIONSHIP', 474), ('SUPERFICIAL_RELATIONSHIP', 689), ('SUPERFICIAL_RELATIONSHIP', 842), ('SUPERFICIAL_RELATIONSHIP', 1457), ('SUPERFICIAL_RELATIONSHIP', 1665), ('SUPERFICIAL_RELATIONSHIP', 1827), ('SUPERFICIAL_RELATIONSHIP', 2027), ('ANOMALY_CURIOUS_FINDING', 2065), ('SUPERFICIAL_RELATIONSHIP', 2387), ('SUPERFICIAL_RELATIONSHIP', 3275), ('SUPERFICIAL_RELATIONSHIP', 3437), ('SUPERFICIAL_RELATIONSHIP', 3506), ('SUPERFICIAL_RELATIONSHIP', 3670), ('ANOMALY_CURIOUS_FINDING', 4255), ('SUPERFICIAL_RELATIONSHIP', 4764)]	16	[('CHEBI_37958', 'dye', 146, 'free'), ('CHEBI_35366', 'fatty acid', 151, 'fatty acids'), ('CHEBI_17855', 'triglyceride', 170, 'triglycerides'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('UBERON_0001986', 'endothelium', 208, 'endothelial'), ('PR_000000034', 'BMP', 655, '-α'), ('PR_000045358', 'insulin family protein', 705, 'insulin'), ('PR_000000034', 'BMP', 819, '-α'), ('GO_0030254', 'protein secretion by the type III secretion system', 1131, 'postpartumTNF'), ('PR_000000034', 'BMP', 1144, '-α'), ('PR_000000134', 'tumor necrosis factor alpha', 1175, 'TNF-α'), ('GO_0007565', 'female pregnancy', 1191, 'postpartum'), ('PR_000000034', 'BMP', 1314, '-α'), ('PR_000000034', 'BMP', 1433, '-α'), ('PR_000045358', 'insulin family protein', 1473, 'insulin'), ('PR_000000035', 'BMP receptor type-1A', 1636, '-6'), ('GO_0007567', 'parturition', 1657, 'partum'), ('PR_000045358', 'insulin family protein', 1681, 'insulin'), ('PR_000000035', 'BMP receptor type-1A', 1801, '-6'), ('GO_0007567', 'parturition', 1838, 'birth'), ('GO_0007565', 'female pregnancy', 2009, 'pregnancy'), ('PR_000045358', 'insulin family protein', 2044, 'insulin'), ('PR_000045358', 'insulin family protein', 2445, 'insulin'), ('GO_0007565', 'female pregnancy', 3132, 'pregnant'), ('CHEBI_17234', 'glucose', 3230, 'glucose'), ('CHEBI_17234', 'glucose', 3293, 'glucose'), ('GO_0007565', 'female pregnancy', 3322, 'gestation'), ('PR_000045358', 'insulin family protein', 3522, 'insulin'), ('GO_0007565', 'female pregnancy', 4631, 'pregnant'), ('CHEBI_45267', 'praziquantel', 4722, 'random'), ('CHEBI_17234', 'glucose', 4729, 'glucose'), ('CHEBI_17234', 'glucose', 4780, 'glucose'), ('GO_0007567', 'parturition', 4791, 'birth'), ('GO_0007565', 'female pregnancy', 4817, 'gestation'), ('GO_0030164', 'protein denaturation', 5223, 'partumVisfatin'), ('CHEBI_17234', 'glucose', 5374, 'glucose'), ('CHEBI_17234', 'glucose', 5408, 'glucose'), ('CHEBI_17234', 'glucose', 5448, 'glucose'), ('PR_000045358', 'insulin family protein', 5500, 'insulin'), ('PR_000045358', 'insulin family protein', 5547, 'insulin'), ('CHEBI_17855', 'triglyceride', 5596, 'triglycerides'), ('GO_0007565', 'female pregnancy', 5709, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 5853, 'Pregnancy')]	0	['gdm develops beta cell dysfunction coexists, abnormalities adipokine cytokine profiles, fatty acids (ffa), triglycerides (tg),  endothelial dysfunction.ijms-16-13442-t001_table 1\n\ncaption (table-wrap): table 1\n\nlongitudinal inflammatory gdm.inflammatory markerfirst designgdm statusgdm diagnostic criteriagestational age testing (weeks)effect gdmmatching adjustment confounderstnf-αkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter coustan criteria [64]pre-gravid 12–14 weeks 34–36 weekstnf-α ↑ 34–36 weeks gdm insulin sensitivityfat massgao (2008) [65]nested case-control22 gdm 10 igt 20 ngtunknown12–20 weeks 24–32 weekstnf-α ↑ gdm positively bmi 14–20 weeksn/ageorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmisaucedo (2011) [67]prospective60 gdm 60 ngt24–28 weeks ada criteria 2010 [68]30 weeks 6 weeks 6 months postpartumtnf-α ↑ 6 weeks tnf-α ↑ 6months  gdmage weightlopez-tinoco (2012) [69]case-control63 gdm 63 ngt24–28 weeks nddg criteria [70]mean ~29 weekstnf-α ↑ gdmbmiguillemette (2014) [71]prospective61 gdm 695 ngt24–28 weeks iadpsg criteria [44]5–16 weeks 24–28 weekstnf-α ↑ insulin resistanceage bmi tg adiponectin.il-6morrisett (2011) [72]case-control20 gdm 27 ngt26.1 ± 3.7 weeks cda criteria [73]26.1 ± 3.7 weeks 8 weeks post-partumil-6 ↑ gdm post-partum, insulin sensitivity bmibmihassiakos (2015) [74]case-control40 gdm 94 ngt24–28 weeks iadpsg criteria [44]11–14 weekil-6 ↑ gdm birth weightmaternal weightleptinkirwan (2002) [63]prospective5 gdm 10 ngt24–28 weeks carpenter coustan criteria [64]pre-gravid 12–14 weeks 34–36 weeksleptin ↑  insulin sensitivity, non-significant adjusted fat massfat massgeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmiqiu (2004) [75]prospective47 gdm 776 ngt26–28 weeks carpenter coustan criteria [64]13 weeks10-ng/ml ↑ leptin 20% ↑ gdmparity bmi family non-insulin diabetesadiponectingeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksage ethnicity gravidity parity bmimcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weekadiponectin gdm offspringage maternal weightwilliams (2004) [77]nested case-control41 gdm 70 ngt26–28 weeks carpenter coustan criteria [64]13 week4.6-fold ↑ gdm adiponectin 6.4 mcg/ml, overweight women 11-fold ↑ gdmbmilain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter coustan criteria [64]9.3 ± 2.6 weeksadiponectin 25th 11-fold ↑ gdmbmilowe (2010) [57]prospective1481  women24–32 weeks 2 h 75 g ogtt unblinded fpg > 5.8 mmol/l 2 h > 11.1 mmol/l random glucose ≥ 8.9 mmol/l24–32 weeks↓ adiponectin ↑ glucose bmibmi c-peptide  genderlacroix (2013) [79]prospective38 gdm 407 ngt24–28 weeks iadpsg criteria [44]6–13 week↓ adiponectin ↑ gdm (or1.12 µg/ml adiponectin) insulin sensitivitybmi hba1cianniello (2013) [39]prospective16 gdm 32 ngt24–28 weeks carpenter coustan criteria [64]all trimesters↓ adiponectin gdm overweight/obesen/aweerakiet (2006) [80]prospective60 gdm 299 ngt24–28 weeks carpenter coustan criteria [64]21–27 weekadiponectin 10 µg/ml sensitivity 91% specificity 31% gdmbmirbp-4krzyzanovska (2008) [81]nested case-control20 gdm 22 ngt24–28 weeks carpenter coustan criteria [64]30 weekrbp-4 gdmn/ananda (2013) [82]nested case-control60 gdm 240 ngt24–28 weeks criteria 2006 [83]11–13 weeksno differencen/aabetew (2013) [84]nested case-control173 gdm 187 ngt24–28 weeks carpenter coustan criteria [64]16 weeksrbp-4 ↑ gdm adjustmentmaternal age ethnicityresistinlain (2008) [78]nested case-control30 gdm 29 ngt24–28 weeks carpenter coustan criteria [64]9.3 ± 2.6 weeksno differencebmigeorgiou (2008) [56]nested case-control14 gdm 14 ngt28 weeks adips criteria 1998 [66]11 weeks 24–28 weeksno differenceage ethnicity gravidity parity bmilowe (2010) [57]prospective1481  women24–32 weeks 2 h 75 g ogtt unblinded fpg > 5.8 mmol/l 2 h > 11.1 mmol/l random glucose ≥ 8.9 mmol/l24–32 weeksnot glucose birth weightbmi c-peptide  gendernanda (2012) [85]nested case-control60 gdm 240 ngt24–28 weeks criteria 2006 [83]11–13 weeksno differencen/amcmanus (2014) [76]case-control36 gdm 37 ngt24–28 weeks cda criteria [73]31 weeksresistin gdm offspringage maternal weightvisfatinkrzyzanovska (2006) [86]nested case-control64 gdm 30 ngt24–28 weeks carpenter coustan criteria [64]28–30 weeks 38–40 weeks 2 weeks post-partumvisfatin ↑ gdmbmiferreira (2011) [87]case-control100 gdm 300 ngt24–28 weeks criteria 2006 [83]11–13 weekvisfatin ↑ gdmn/a\nngt = normal glucose tolerance; igt = glucose tolerance; fpg = fasting plasma glucose; homa-ir = homeostasis insulin resistance; matsuda = measure insulin sensitivity; bmi = mass index; tg = triglycerides; n/a = available; = decreased levels; ↑ = levels; adips = australasian diabetes  society; ada = american diabetes association; nddg = national diabetes group; iadpsg = international diabetes  group; cda = canadian diabetes association; = world organisation.']
S296-PMC4490503	PMC4490503	6/2015	S296-PMC4490503	['early Pregnancy Vitamin D status HAS BEEN inversely ASSOCIATED with gdm risk [123].']	[('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 52)]	2	[('GO_0007565', 'female pregnancy', 6, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]	0	['early   status gdm [123].']
S298-PMC4490503	PMC4490503	6/2015	S298-PMC4490503	['FOUND that increased Parathyroid hormone, RATHER than Vitamin D deficiency was INDEPENDENTLY ASSOCIATED with dysglycaemia in Pregnancy in 524 women when tested in conjunction with the ogtt [124].']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 42), ('SUPERFICIAL_RELATIONSHIP', 79), ('SUPERFICIAL_RELATIONSHIP', 93)]	4	[('UBERON_0001132', 'parathyroid gland', 21, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy')]	0	['found parathyroid hormone,  dysglycaemia  524 women ogtt [124].']
S43-PMC4499266	PMC4499266	4/2015	S43-PMC4499266	['the lack of Gestational Vitamin A HAS BEEN SUGGESTED to CONTRIBUTE to Hearing loss development in developing countries [7].']	[('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 56)]	2	[('GO_0007565', 'female pregnancy', 12, 'gestational'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin A'), ('GO_0007605', 'sensory perception of sound', 70, 'hearing')]	0	['  hearing loss countries [7].']
S1-PMC4499946	PMC4499946	7/2015	S1-PMC4499946	['SOME observational STUDIES have SUGGESTED that Prenatal Vitamin D deficiency increases the RISK of adverse Pregnancy and/or Birth outcomes; HOWEVER, there is SCANT EVIDENCE from controlled trials, leading the world health organization to advise against routine Vitamin D supplementation in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 32), ('IMPORTANT_CONSIDERATION', 91), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 140), ('INCOMPLETE_EVIDENCE', 158)]	5	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 107, 'pregnancy ...'), ('GO_0007567', 'parturition', 124, 'birth'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D'), ('GO_0007565', 'female pregnancy', 290, 'pregnancy')]	0	['  pregnancy and/or birth outcomes; however, trials, world organization routine  supplementation .']
S24-PMC4499946	PMC4499946	7/2015	S24-PMC4499946	['in south asia, there is a high prevalence of biochemical Vitamin D deficiency among women and young infants [15]; in dhaka, we FOUND that 34 % of Pregnant women at 26–29 weeks Gestation ( n = 160) had Serum 25-Hydroxyvitamin D (25(Oh)D) concentrations less than 30 nmol/l, and that 64 % had 25(Oh)D levels less than 50 nmol/l [16], a threshold for sufficiency adopted by the institute of medicine (iom) [17].']	[('INCOMPLETE_EVIDENCE', 127)]	1	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnant'), ('GO_0007565', 'female pregnancy', 176, 'gestation'), ('UBERON_0001977', 'blood serum', 201, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 207, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 228, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 291, '25(OH)D')]	0	['south asia, biochemical  among women young infants [15]; dhaka, 34 %  women 26–29 weeks  n = 160) serum 25-hydroxyvitamin (25(oh)d) concentrations 30 nmol/l, 64 % 25(oh)d levels 50 nmol/l [16], institute medicine (iom) [17].']
S27-PMC4499946	PMC4499946	7/2015	S27-PMC4499946	['because maternal Vitamin D status is the PREDOMINANT DETERMINANT of fetal and neonatal Vitamin D stores [18], Prenatal Vitamin D supplementation represents the OPTIMAL approach to testing the EFFECT of improving maternal-infant Vitamin D status on fetal-infant growth and other health outcomes.']	[('PROBABLE_UNDERSTANDING', 41), ('SUPERFICIAL_RELATIONSHIP', 53), ('IMPORTANT_CONSIDERATION', 160), ('SUPERFICIAL_RELATIONSHIP', 192)]	4	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'prenatal'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D')]	0	['maternal  status fetal neonatal  stores [18],   supplementation testing maternal-infant  status fetal-infant outcomes.']
S28-PMC4499946	PMC4499946	7/2015	S28-PMC4499946	['OBSERVATIONAL studies of the ASSOCIATION between maternal Prenatal Vitamin D status and infant anthropometry have yielded CONFLICTING findings [19–23].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 122)]	3	[('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]	0	['observational maternal   status infant anthropometry [19–23].']
S29-PMC4499946	PMC4499946	7/2015	S29-PMC4499946	['the EFFECTS of Prenatal Vitamin D supplementation on infant length have not been widely studied in controlled trials.']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('GO_0007565', 'female pregnancy', 15, 'prenatal'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]	0	['  supplementation infant length trials.']
S30-PMC4499946	PMC4499946	7/2015	S30-PMC4499946	['in a study conducted in the 1970s in london, england, Prenatal Vitamin D supplementation reduced the RISK of small for Gestational age (sga) versus control, BUT there was no significant effect on Birth length [24]; however, the infants in the Vitamin D group had significantly greater mean length at 1 year of age [25].']	[('IMPORTANT_CONSIDERATION', 101), ('ANOMALY_CURIOUS_FINDING', 157)]	2	[('GO_0007565', 'female pregnancy', 54, 'prenatal'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'gestational'), ('GO_0007567', 'parturition', 196, 'birth'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D')]	0	['1970s london, england,   supplementation  age (sga) control, birth length [24]; however, infants  length year age [25].']
S34-PMC4499946	PMC4499946	7/2015	S34-PMC4499946	['analyses of the EFFECT of Prenatal Vitamin D supplementation on infant length among 134 infants followed up to 1 year of age REVEALED that infants Born to women in the Vitamin D group had mean length for age z-scores (lazs) at 1 year that were significantly greater than infants in the placebo group (mean = 0.44 z-score units higher; 95% confidence interval [ci], 0.06–0.82) [26].']	[('SUPERFICIAL_RELATIONSHIP', 16), ('INCOMPLETE_EVIDENCE', 125)]	2	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007567', 'parturition', 147, 'born'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D')]	0	['analyses   supplementation infant length among 134 infants followed year age infants born women  length age z-scores (lazs) year infants placebo (mean = 0.44 z-score units higher; 95% confidence interval [ci], 0.06–0.82) [26].']
S37-PMC4499946	PMC4499946	7/2015	S37-PMC4499946	['HOWEVER, SOME Animal [27] and observational [21,28] studies have SUGGESTED an EFFECT of maternal Prenatal Vitamin D status on growth of the fetus.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 65), ('SUPERFICIAL_RELATIONSHIP', 78)]	4	[('NCBITaxon_33208', 'Metazoa', 14, 'animal'), ('GO_0007565', 'female pregnancy', 97, 'prenatal'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]	0	['however, animal [27] [21,28] maternal   status fetus.']
S39-PMC4499946	PMC4499946	7/2015	S39-PMC4499946	['some observational studies have SUGGESTED that Antenatal Vitamin D deficiency increases the RISK of adverse Pregnancy and Birth outcomes, including sga [30,31].']	[('INCOMPLETE_EVIDENCE', 32), ('IMPORTANT_CONSIDERATION', 92)]	2	[('GO_0007567', 'parturition', 47, 'antenatal'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'pregnancy'), ('GO_0007567', 'parturition', 122, 'birth')]	0	['antenatal   birth outcomes, sga [30,31].']
S40-PMC4499946	PMC4499946	7/2015	S40-PMC4499946	['HOWEVER, there is SCANT EVIDENCE from controlled clinical trials [31,32], and the world health organization (who) RECENTLY advised against routine Vitamin D supplementation in Pregnancy until further data become available [33].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 114)]	3	[('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0007565', 'female pregnancy', 176, 'pregnancy')]	0	['however, [31,32], world organization (who) routine  supplementation  [33].']
S41-PMC4499946	PMC4499946	7/2015	S41-PMC4499946	['BUILDING ON our EARLIER FINDINGS of a beneficial EFFECT of Prenatal Vitamin D supplementation on infant length in a PRELIMINARY TRIAL [26], we are conducting a larger dose-ranging trial of maternal Vitamin D3Supplementation in dhaka, bangladesh.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 49), ('INCOMPLETE_EVIDENCE', 116)]	5	[('GO_0007565', 'female pregnancy', 59, 'prenatal'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_52915', 'phosphatediyl group', 198, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 198, 'vitamin D3supplementation')]	0	['building   supplementation infant length [26], dose-ranging maternal vitamin d3supplementation dhaka, bangladesh.']
S46-PMC4499946	PMC4499946	7/2015	S46-PMC4499946	['objectives\nthe primary AIMS of the trial are to estimate (1) the effect of maternal Prenatal oral Vitamind3Supplementation (4200 iu/wk, 16,800 iu/wk, or 28,000 iu/wk administered as weekly doses) versus placebo on infant length at 1 year of age in dhaka, bangladesh; and (2) the EFFECT of maternal Postpartum oral Vitamin D3Supplementation (28,000 iu/wk) versus placebo on length at 1 year of age among infants Born to women who received Vitamin D 28,000 iu/wk during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 23), ('SUPERFICIAL_RELATIONSHIP', 279)]	2	[('GO_0007565', 'female pregnancy', 84, 'prenatal'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 98, 'vitaminD3supplementation'), ('GO_0007565', 'female pregnancy', 298, 'postpartum'), ('CHEBI_52915', 'phosphatediyl group', 314, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 314, 'vitamin D3supplementation'), ('GO_0007567', 'parturition', 411, 'born'), ('CHEBI_27300', 'vitamin D', 438, 'vitamin D'), ('GO_0007565', 'female pregnancy', 468, 'pregnancy')]	0	['objectives\nthe (1) maternal  oral vitamind3supplementation (4200 iu/wk, 16,800 iu/wk, 28,000 iu/wk administered weekly doses) placebo infant length year age dhaka, bangladesh; (2) maternal  oral vitamin d3supplementation (28,000 iu/wk) placebo length year age among infants born women received  28,000 iu/wk .']
S65-PMC4499946	PMC4499946	7/2015	S65-PMC4499946	['Pregnant women are not enrolled if any of the following exclusion criteria apply: self-reported history of any medical condition or Medications that MAY predispose to Vitamin D sensitivity, altered Vitamin D Metabolism, and/or hypercalcemia (e.g., active tuberculosis or current therapy for tuberculosis, sarcoidosis, history of Renal and/or Ureteral stones, Parathyroid disease, Renal or Liver failure, or current use of antiseizure Medications); high-risk Pregnancy based on point-of-care (poc) testing (hemoglobin [hb]<70 g/l; proteinuria, defined as ≥300 mg/dl based on Urine dipstick; hypertension, defined as systolic Blood pressure ≥140 mmhg and/or diastolic Blood pressure ≥90 mmhg); high-risk Pregnancy based on maternal report and/or past ultrasound findings (multiple Gestation, major congenital anomaly, severe oligohydramnios); unwillingness to stop taking non-study Vitamin D or Calcium supplements or a multivitamins containing Calcium and/or Vitamin D; currently prescribed Vitamin D supplements as part of a physician’s treatment plan for Vitamin D deficiency; and/or previous enrollment in the mdig trial during a prior Pregnancy.']	[('INCOMPLETE_EVIDENCE', 149)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_25441', 'mycothiols', 132, 'medications'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 198, 'vitamin D metabolism'), ('UBERON_0002113', 'kidney', 329, 'renal'), ('UBERON_0000056', 'ureter', 342, 'ureteral'), ('UBERON_0001132', 'parathyroid gland', 359, 'parathyroid'), ('UBERON_0002113', 'kidney', 380, 'renal'), ('UBERON_0002107', 'liver', 389, 'liver'), ('CHEBI_25441', 'mycothiols', 434, 'medications'), ('GO_0007565', 'female pregnancy', 458, 'pregnancy'), ('UBERON_0001088', 'urine', 574, 'urine'), ('UBERON_0000178', 'blood', 624, 'blood'), ('UBERON_0000178', 'blood', 666, 'blood'), ('GO_0007565', 'female pregnancy', 702, 'pregnancy'), ('GO_0007565', 'female pregnancy', 779, 'gestation'), ('CHEBI_27300', 'vitamin D', 880, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 893, 'calcium'), ('CHEBI_22313', 'alkaline earth metal atom', 943, 'calcium'), ('CHEBI_27300', 'vitamin D', 958, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 990, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1056, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1138, 'pregnancy')]	0	[' women enrolled following exclusion criteria apply: medical condition medications  sensitivity, altered  metabolism, and/or hypercalcemia (e.g., tuberculosis therapy tuberculosis, sarcoidosis, renal and/or ureteral stones, parathyroid disease, renal liver failure, antiseizure medications);  point-of-care (poc) testing (hemoglobin [hb]<70 g/l; proteinuria, ≥300 mg/dl urine dipstick; hypertension, systolic blood pressure ≥140 mmhg and/or diastolic blood pressure ≥90 mmhg);  maternal and/or ultrasound (multiple congenital anomaly, oligohydramnios); unwillingness stop  calcium supplements multivitamins containing calcium and/or prescribed  supplements physician’s treatment  deficiency; and/or enrollment mdig .']
S77-PMC4499946	PMC4499946	7/2015	S77-PMC4499946	['TO ASSESS the EFFECT of Prenatal Vitamin D, we PLAN TO perform five primary between-group analyses, comprising each Vitamin D dose versus placebo (three comparisons) and comparisons between adjacent doses (two comparisons).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 14), ('FUTURE_WORK', 47)]	3	[('GO_0007565', 'female pregnancy', 24, 'prenatal'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]	0	[' perform five between-group analyses, comprising  dose placebo (three comparisons) comparisons adjacent doses (two comparisons).']
S80-PMC4499946	PMC4499946	7/2015	S80-PMC4499946	['in our PRELIMINARY trial, we OBSERVED an increase in Laz of 0.44 at 1 year attributable to Prenatal Vitamin D supplementation, which CORRESPONDED to an increase of 1.1 cm (95 % ci, 0.06–2.0), adjusted for sex [26].']	[('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 133)]	3	[('PR_000009655', 'laminin subunit beta-2', 53, 'LAZ'), ('GO_0007565', 'female pregnancy', 91, 'prenatal'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]	0	['trial, increase laz 0.44 year   supplementation, increase 1.1 cm (95 % ci, 0.06–2.0), adjusted sex [26].']
S98-PMC4499946	PMC4499946	7/2015	S98-PMC4499946	['our PREVIOUS pharmacokinetic FINDINGS among Pregnant women in dhaka [16,40] HAVE GENERALLY BEEN CONSISTENT with published ESTIMATES of the Vitamin D-to-25(Oh)D dose–response RELATIONSHIP in non-Pregnant Adults (i.e., an APPROXIMATELY 0.7 nmol/l increase in 25(Oh)D at steady state for each 1 μg/day of Vitamin D3[41,42]).']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 29), ('INCOMPLETE_EVIDENCE', 76), ('PROBABLE_UNDERSTANDING', 81), ('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 174), ('INCOMPLETE_EVIDENCE', 220)]	8	[('GO_0007565', 'female pregnancy', 44, 'pregnant'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 155, 'OH)D'), ('GO_0007565', 'female pregnancy', 194, 'pregnant'), ('UBERON_0007023', 'adult organism', 203, 'adults'), ('CHEBI_63056', 'zinc cation', 257, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 263, 'D'), ('CHEBI_33279', 'vitamin D5', 302, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 302, 'vitamin D3')]	0	['pharmacokinetic among  women dhaka [16,40] -to-25(oh)d dose–response non- adults (i.e., 0.7 nmol/l increase 25(oh)d steady μg/day vitamin d3[41,42]).']
S218-PMC4499946	PMC4499946	7/2015	S218-PMC4499946	['our PRELIMINARY trial data REVEALED a discernible EFFECT of Prenatal Vitamin D supplementation on infant Laz at 1 year [26].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 27), ('SUPERFICIAL_RELATIONSHIP', 50)]	3	[('GO_0007565', 'female pregnancy', 60, 'prenatal'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('PR_000009655', 'laminin subunit beta-2', 105, 'LAZ')]	0	['discernible   supplementation infant laz year [26].']
S229-PMC4499946	PMC4499946	7/2015	S229-PMC4499946	['TO ASSESS the EFFECT of Prenatal Vitamin D on mean Laz at 1 year of age, we PLAN TO perform five primary between-group analyses: each Prenatal Vitamin D dose versus placebo (three pairwise comparisons), as well as comparisons between all adjacent Vitamin D doses (two pairwise comparisons).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 14), ('FUTURE_WORK', 76)]	3	[('GO_0007565', 'female pregnancy', 24, 'prenatal'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('PR_000009655', 'laminin subunit beta-2', 51, 'LAZ'), ('GO_0007565', 'female pregnancy', 134, 'prenatal'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin D')]	0	['  laz year age, perform five between-group analyses:   dose placebo (three pairwise comparisons), comparisons adjacent  doses (two pairwise comparisons).']
S255-PMC4499946	PMC4499946	7/2015	S255-PMC4499946	['participant safety monitoring\nparticipant safety during the intervention phase is monitored by study personnel based on (1) a checklist of maternal symptoms that MAY INDICATE Vitamin D toxicity or other medical concerns during weekly follow-up visits, (2) passive and active monitoring for maternal and infant clinical events, and (3) maternal Serum calcium measurement at scheduled intervals during the intervention phase (baseline, 30 weeks of Gestation, Delivery, 3 months Postpartum, and 6 months Postpartum).']	[('INCOMPLETE_EVIDENCE', 162), ('INCOMPLETE_EVIDENCE', 166)]	2	[('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('UBERON_0001977', 'blood serum', 344, 'serum'), ('GO_0007565', 'female pregnancy', 446, 'gestation'), ('GO_0007567', 'parturition', 457, 'delivery'), ('GO_0007565', 'female pregnancy', 476, 'postpartum'), ('GO_0007565', 'female pregnancy', 501, 'postpartum')]	0	['participant monitoring\nparticipant phase monitored personnel (1) checklist maternal symptoms  toxicity medical weekly follow-up visits, (2) passive maternal infant events, (3) maternal serum calcium scheduled intervals phase (baseline, 30 weeks delivery, 3 months 6 months ).']
S290-PMC4499946	PMC4499946	7/2015	S290-PMC4499946	['discussion\nsince the publication of the 2010 iom report on Vitamin D and the design of the mdig trial and dosing regimens in 2012, there have been several new REPORTS of biochemical and clinical findings of Prenatal Vitamin D supplementation trials conducted in iran [67–69], the united arab emirates [70], pakistan [71], new zealand [72], and australia [73].']	[('INCOMPLETE_EVIDENCE', 159)]	1	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 207, 'prenatal'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D')]	0	['discussion\nsince 2010 iom  mdig dosing regimens 2012, biochemical   supplementation iran [67–69], united arab emirates [70], pakistan [71], zealand [72], australia [73].']
S294-PMC4499946	PMC4499946	7/2015	S294-PMC4499946	['HOWEVER, these and OTHER registered Prenatal Vitamin D trials are being conducted in high-income countries.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 19)]	2	[('GO_0007565', 'female pregnancy', 36, 'prenatal'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]	0	['however, registered   high-income countries.']
S34-PMC4514967	PMC4514967	12/2014	S34-PMC4514967	['for example, subclinical Vitamin A deficiency is PREVALENT, AFFECTING an ESTIMATED one-third of children and 15% of Pregnant women,19and increases the risk of death from diarrhea (and measles).']	[('IMPORTANT_CONSIDERATION', 49), ('SUPERFICIAL_RELATIONSHIP', 60), ('INCOMPLETE_EVIDENCE', 73)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin A'), ('GO_0007565', 'female pregnancy', 116, 'pregnant')]	0	['example, subclinical  prevalent, one-third children 15%  women,19and death diarrhea (and measles).']
S87-PMC4514967	PMC4514967	12/2014	S87-PMC4514967	['low Cord Blood Vitamin D levels are a PREDICTOR of subsequent infant Respiratory infections.70,71HOWEVER, data from clinical trials are too LIMITED to draw conclusions about the efficacy and SAFETY of Vitamin D supplementation in Pregnancy.72meta-analyses have HIGHLIGHTED THE NEED to extend endpoints in intervention trials of multiple Micronutrients in Pregnancy.30the timing of Nutrient interventions during Pregnancy or before Conception is an IMPORTANT clinical study parameter to CONSIDER in any meta-analysis designed to evaluate the EFFECTS of an intervention or interventions and the OBSERVED effect size.']	[('SUPERFICIAL_RELATIONSHIP', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('INCOMPLETE_EVIDENCE', 140), ('IMPORTANT_CONSIDERATION', 191), ('INCOMPLETE_EVIDENCE', 261), ('INCOMPLETE_EVIDENCE', 273), ('FUTURE_WORK', 277), ('IMPORTANT_CONSIDERATION', 448), ('FUTURE_WORK', 486), ('SUPERFICIAL_RELATIONSHIP', 541), ('INCOMPLETE_EVIDENCE', 593)]	11	[('UBERON_0002240', 'spinal cord', 4, 'cord'), ('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 69, 'respiratory'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D'), ('GO_0007565', 'female pregnancy', 230, 'pregnancy'), ('CHEBI_33839', 'macromolecule', 337, 'micronutrients'), ('GO_0007565', 'female pregnancy', 355, 'pregnancy'), ('CHEBI_33284', 'nutrient', 381, 'nutrient'), ('GO_0007565', 'female pregnancy', 411, 'pregnancy'), ('GO_0007620', 'copulation', 431, 'conception')]	0	['low cord blood  levels infant respiratory infections.70,71however, draw  supplementation .72meta-analyses endpoints micronutrients .30the timing nutrient  parameter meta-analysis size.']
S17-PMC4586451	PMC4586451	10/2015	S17-PMC4586451	['for example, it HAS BEEN FOUND that excessive intakes of Vitamin A or low intakes of Folate CAN be Teratogenic at this critical period during the early weeks of Pregnancy when the first Embryonic Processes occur, resulting in an assortment of Birth defects.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 92)]	2	[('CHEBI_27300', 'vitamin D', 57, 'vitamin A'), ('CHEBI_30863', '5-azaorotic acid', 85, 'folate'), ('CHEBI_50905', 'teratogenic agent', 99, 'teratogenic'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy'), ('UBERON_0004023', 'ganglionic eminence', 186, 'embryonic processes'), ('GO_0007567', 'parturition', 243, 'birth')]	0	['example, excessive intakes  intakes folate teratogenic period weeks  embryonic processes occur, resulting assortment birth defects.']
S18-PMC4586451	PMC4586451	10/2015	S18-PMC4586451	['this has LED to dietary RECOMMENDATIONS for Pregnancy that limit concentrated sources of Vitamin A and stress the IMPORTANCE of periconceptional Folic Acid supplementation, which HAS BEEN SHOWN to be PROTECTIVE against Neural Tube defects.4\nTHERE IS EVIDENCE that optimal fetal Neurodevelopment is DEPENDENT on specific Nutrients supplied by the mother mainly from dietary sources; these MAY include Long-Chain polyunsaturated Fatty Acids (lc-pufas) such as Docosahexaenoic Acid (Dha), an N-3 Fatty Acid, and arachidonic acid, an N-6 Fatty Acid.']	[('SUPERFICIAL_RELATIONSHIP', 9), ('FUTURE_WORK', 24), ('IMPORTANT_CONSIDERATION', 114), ('INCOMPLETE_EVIDENCE', 179), ('SUPERFICIAL_RELATIONSHIP', 200), ('INCOMPLETE_EVIDENCE', 241), ('SUPERFICIAL_RELATIONSHIP', 298), ('INCOMPLETE_EVIDENCE', 388)]	8	[('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('CHEBI_30751', 'formic acid', 145, 'folic acid'), ('UBERON_0001049', 'neural tube', 219, 'neural tube'), ('GO_0007399', 'nervous system development', 278, 'neurodevelopment'), ('CHEBI_33284', 'nutrient', 320, 'nutrients'), ('CHEBI_28911', 'cob(III)alamin', 400, 'long-chain'), ('CHEBI_35366', 'fatty acid', 427, 'fatty acids'), ('CHEBI_36003', 'decenoic acid', 458, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 480, 'DHA'), ('CHEBI_35245', 'GDP-galactose', 489, 'n-3 fatty acid'), ('CHEBI_18320', '1,4-dithiothreitol', 530, 'n-6'), ('CHEBI_35366', 'fatty acid', 534, 'fatty acid')]	0	['dietary  sources  periconceptional folic acid supplementation, neural tube defects.4\nthere fetal neurodevelopment nutrients supplied mother dietary sources; long-chain polyunsaturated fatty acids (lc-pufas) docosahexaenoic acid (dha), n-3 fatty acid, arachidonic acid, n-6 fatty acid.']
S21-PMC4586451	PMC4586451	10/2015	S21-PMC4586451	['it is also POSSIBLE that fish Intake during Pregnancy INFLUENCES Neurodevelopment via a mechanism not related to its Fatty Acid content; OTHER active substances include its Vitamin D and Iodine content or its POSSIBLE contamination with mercury.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 54), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 137), ('INCOMPLETE_EVIDENCE', 209)]	4	[('GO_0007631', 'feeding behavior', 30, 'intake'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('GO_0007399', 'nervous system development', 65, 'neurodevelopment'), ('CHEBI_35366', 'fatty acid', 117, 'fatty acid'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 187, 'iodine')]	0	['fish intake  neurodevelopment via fatty acid content; substances  iodine content mercury.']
S190-PMC4586451	PMC4586451	10/2015	S190-PMC4586451	['a weak ASSOCIATION was FOUND between maternal dietary iron and magnesium Intake and height, particularly sitting height; it was greatly attenuated on full adjustment.19\n\ncaption (table-wrap): table 3\n\nassociations of maternal dietary intakes, iron supplement use, anemia, and Vitamin D status during Pregnancy with measures of offspring growth, Blood pressure, and Bone developmentmeasure in childdietary factoradjustments appliedminimally adjusted resultsfully adjusted resultscommentsheight at 7.5 y, n = 6663 singletons19\niron\nmagnesium\nvitamin c\nminimal: child sex, age at measurement, Pregnancy energy Intake\nfull: plus maternal age, bmi, height, smoking, seb, parity, breastfeeding\nβ = 0.08 (95% ci, 0.05–0.12), p< 0.001\nβ = 0.10 (95% ci, 0.07–0.14), p< 0.001\nβ = 0.05 (95% ci, 0.03–0.08), p< 0.001\nβ = 0.04 (95% ci, 0.01–0.08), p = 0.02\nβ = 0.05 (95% ci, 0.01–0.08), p = 0.04\nβ = 0.02 (95% ci, −0.01 to 0.04), p = 0.2\nregression analysis using standard deviation scores.']	[('SUPERFICIAL_RELATIONSHIP', 7), ('INCOMPLETE_EVIDENCE', 23)]	2	[('GO_0007631', 'feeding behavior', 73, 'intake'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D'), ('GO_0007565', 'female pregnancy', 300, 'pregnancy'), ('UBERON_0000178', 'blood', 345, 'blood'), ('GO_0007567', 'parturition', 365, 'bone'), ('GO_0007565', 'female pregnancy', 590, 'pregnancy'), ('GO_0007631', 'feeding behavior', 607, 'intake')]	0	['maternal dietary iron magnesium intake height, sitting height; attenuated adjustment.19\n\ncaption (table-wrap): table 3\n\nassociations maternal dietary intakes, iron supplement use, anemia,  status  offspring growth, blood pressure, bone developmentmeasure childdietary factoradjustments appliedminimally adjusted resultsfully adjusted resultscommentsheight 7.5 y, n = 6663 singletons19\niron\nmagnesium\nvitamin c\nminimal: child sex, age measurement,  energy intake\nfull: plus maternal age, bmi, height, smoking, seb, parity, breastfeeding\nβ = 0.08 (95% ci, 0.05–0.12), p< 0.001\nβ = 0.10 (95% ci, 0.07–0.14), p< 0.001\nβ = 0.05 (95% ci, 0.03–0.08), p< 0.001\nβ = 0.04 (95% ci, 0.01–0.08), p = 0.02\nβ = 0.05 (95% ci, 0.01–0.08), p = 0.04\nβ = 0.02 (95% ci, −0.01 0.04), p = 0.2\nregression using deviation scores.']
S212-PMC4586451	PMC4586451	10/2015	S212-PMC4586451	['there was also no evidence of an association between maternal Vitamin D status during Pregnancy and offspring bone Mineral content (table 3).24the SUGGESTION that maternal body fat stores are IMPORTANT for fetal bone Mineral deposition was investigated in a further study.25there was NO evidence of an independent association between maternal Prepregnancy bmi and offspring bone mass at age 9 years once adjustments were made for Birth weight and the current height and weight of the child.25\nthese data SUGGEST it is UNLIKELY that Pregnancy diet has an IMPORTANT EFFECT on any of the outcomes investigated in this section, ALTHOUGH the ASSOCIATIONS that were FOUND were with Nutrients that are most LIKELY to be inadequate in the diet of this population.8\n\nNeurocognitive and behavioral development Of the offspring\nBrain Cell Membranes have a high content of n-3 lc-pufas, and the predominant sources of these Nutrients in the diets of uk residents are fish and seafood.']	[('INCOMPLETE_EVIDENCE', 147), ('IMPORTANT_CONSIDERATION', 192), ('INCOMPLETE_EVIDENCE', 284), ('INCOMPLETE_EVIDENCE', 504), ('PROBABLE_UNDERSTANDING', 518), ('IMPORTANT_CONSIDERATION', 554), ('SUPERFICIAL_RELATIONSHIP', 564), ('ANOMALY_CURIOUS_FINDING', 624), ('SUPERFICIAL_RELATIONSHIP', 637), ('INCOMPLETE_EVIDENCE', 660), ('PROBABLE_UNDERSTANDING', 700)]	11	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy'), ('CHEBI_46662', 'mineral', 115, 'mineral'), ('CHEBI_46662', 'mineral', 217, 'mineral'), ('GO_0007565', 'female pregnancy', 343, 'prepregnancy'), ('GO_0007567', 'parturition', 430, 'birth'), ('GO_0007565', 'female pregnancy', 532, 'pregnancy'), ('CHEBI_33284', 'nutrient', 676, 'nutrients'), ('GO_0043102', 'amino acid salvage', 758, 'Neurocognitive ... of ...'), ('UBERON_0000955', 'brain', 817, 'Brain'), ('GO_0005886', 'plasma membrane', 823, 'cell membranes'), ('CHEBI_33284', 'nutrient', 912, 'nutrients')]	0	['maternal  status  offspring bone mineral content (table 3).24the maternal fat stores fetal bone mineral deposition study.25there maternal  bmi offspring bone mass age 9 birth height child.25\nthese  diet outcomes section, nutrients diet population.8\n\nneurocognitive behavioral offspring\nbrain cell membranes content n-3 lc-pufas, sources nutrients diets uk residents fish seafood.']
S47-PMC4592566	PMC4592566	10/2015	S47-PMC4592566	['the topic guide contained a list of LIKELY pre-Pregnancy actions which interviewers could use as a prompt if needed (the list included: supplements – Folic Acid, multivitamins for Pregnancy, ordinary multivitamins, Vitamin D, iron, omega 3, Vitamin C, zinc; lifestyle actions – Eating a healthy diet, weight, Caffeine, Alcohol, smoking, Drugs, including street Drugs, prescription Drugs, over-the-counter Drugs; and health care advice – seeing a health professional for advice about getting Pregnant, immunizations, Dental checks, Sexually Transmitted infections, and stopping contraception).']	[('PROBABLE_UNDERSTANDING', 36)]	1	[('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_30751', 'formic acid', 150, 'folic acid'), ('GO_0007565', 'female pregnancy', 180, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin C'), ('GO_0051318', 'G1 phase', 278, 'eating'), ('CHEBI_27732', 'caffeine', 309, 'caffeine'), ('CHEBI_30879', 'alcohol', 319, 'alcohol'), ('CHEBI_23888', 'drug', 337, 'drugs'), ('CHEBI_23888', 'drug', 361, 'drugs'), ('CHEBI_23888', 'drug', 381, 'drugs'), ('CHEBI_23888', 'drug', 405, 'drugs'), ('GO_0007565', 'female pregnancy', 491, 'pregnant'), ('UBERON_0001091', 'calcareous tooth', 516, 'dental'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 531, 'sexually transmitted')]	0	['contained list pre- interviewers (the list included: supplements folic acid, multivitamins ordinary multivitamins, iron, omega 3, zinc; lifestyle eating healthy diet, weight, caffeine, alcohol, smoking, drugs, street drugs, prescription drugs, over-the-counter drugs; health professional getting immunizations, dental checks, sexually transmitted infections, stopping contraception).']
S14-PMC4595656	PMC4595656	10/2015	S14-PMC4595656	['among the general population, Pregnant women are CONSIDERED to be AT RISK of Vitamin D deficiency (vd).']	[('IMPORTANT_CONSIDERATION', 49), ('IMPORTANT_CONSIDERATION', 66)]	2	[('GO_0007565', 'female pregnancy', 30, 'pregnant'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D')]	0	['among population,  women  (vd).']
S56-PMC4595656	PMC4595656	10/2015	S56-PMC4595656	['the authors CONCLUDED that exposure to low Prenatal Vitamin D has a selective IMPACT on certain aspects of Memory ONLY, with disruption of latent inhibition, but no effect on Memory acquisition and Memory Retrieval.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 78), ('INCOMPLETE_EVIDENCE', 114)]	3	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007613', 'memory', 107, 'memory'), ('GO_0007613', 'memory', 175, 'memory'), ('GO_0030317', 'flagellated sperm motility', 198, 'memory retrieval')]	0	['authors exposure   aspects memory only, latent inhibition, memory acquisition memory retrieval.']
S71-PMC4595656	PMC4595656	10/2015	S71-PMC4595656	['several groups of Rats were treated and compared e.g., no depletion, replete at Birth, replete at weaning, depleted until 10 weeks of age, or depleted between 5 and 10 weeks of age, and they FOUND that ONLY the combined Prenatal and chronic Postnatal Vitamin D deprivation, BUT NOT early Life hypovitaminosis on its own, resulted in an impaired response.']	[('INCOMPLETE_EVIDENCE', 191), ('ANOMALY_CURIOUS_FINDING', 202), ('ANOMALY_CURIOUS_FINDING', 274)]	3	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 18, 'rats'), ('GO_0007567', 'parturition', 80, 'birth'), ('GO_0007565', 'female pregnancy', 220, 'prenatal'), ('GO_0007567', 'parturition', 241, 'postnatal'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D'), ('UBERON_0000104', 'life cycle', 288, 'life')]	0	['several rats treated e.g., depletion, replete birth, replete weaning, depleted 10 weeks age, depleted 5 10 weeks age, combined  chronic postnatal  deprivation, life hypovitaminosis own, resulted response.']
S107-PMC4595656	PMC4595656	10/2015	S107-PMC4595656	['ALTHOUGH the concentration of hormone used to supplement in vitro is higher than that DETECTED in standard Rat Chow, Vitamin D levels in Humans HAVE BEEN FOUND in more than ONE STUDY to be elevated in Pregnancy (seki et al.,1991; ardawi et al.,1997).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 86), ('INCOMPLETE_EVIDENCE', 144), ('INCOMPLETE_EVIDENCE', 154), ('INCOMPLETE_EVIDENCE', 173)]	5	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 107, 'rat'), ('CHEBI_33290', 'food', 111, 'chow'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 137, 'humans'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy')]	0	['although concentration hormone supplement higher rat chow,  levels humans elevated  (seki et al.,1991; ardawi et al.,1997).']
S130-PMC4595656	PMC4595656	10/2015	S130-PMC4595656	['low Prenatal Vitamin D HAS BEEN POSTULATED AS an epigenetic risk factor for same (mcgrath,1999), and transient vd IS CONSIDERED a developmental MODEL in schizophrenia research.']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 32), ('PROBABLE_UNDERSTANDING', 43), ('INCOMPLETE_EVIDENCE', 114), ('INCOMPLETE_EVIDENCE', 144)]	5	[('GO_0007565', 'female pregnancy', 4, 'prenatal'), ('CHEBI_27300', 'vitamin D', 13, 'vitamin D')]	0	['low   epigenetic (mcgrath,1999), transient vd developmental schizophrenia research.']
S9-PMC4598849	PMC4598849	10/2015	S9-PMC4598849	['WHETHER the common Vitamin D deficiency during Pregnancy CONTRIBUTES to any of the GLOBAL adverse fetal growth epidemic REMAINS UNKNOWN.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('EXPLICIT_QUESTION', 0), ('SUPERFICIAL_RELATIONSHIP', 57), ('IMPORTANT_CONSIDERATION', 83), ('FULL_UNKNOWN', 120)]	5	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy')]	0	['whether   fetal unknown.']
S10-PMC4598849	PMC4598849	10/2015	S10-PMC4598849	['maternal Vitamin D deficiency during Pregnancy is a SIGNIFICANT PUBLIC HEALTH PROBLEM GLOBALLY78DUE to the combined EFFECTS of limited sunlight exposure, INADEQUATE intake, and additional growth NEEDS of the fetus.']	[('IMPORTANT_CONSIDERATION', 52), ('PROBLEM_COMPLICATION', 78), ('IMPORTANT_CONSIDERATION', 86), ('SUPERFICIAL_RELATIONSHIP', 116), ('IMPORTANT_CONSIDERATION', 154), ('IMPORTANT_CONSIDERATION', 195)]	6	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 37, 'pregnancy')]	0	['maternal   combined sunlight exposure, intake, fetus.']
S11-PMC4598849	PMC4598849	10/2015	S11-PMC4598849	['the LINK between maternal Vitamin D status and fetal growth, AS measured most frequently by infant Birth weight and small for Gestational age (sga), HAS BEEN explored by a NUMBER OF observational STUDIES9101112131415AND randomized supplementation trials1617181920worldwide with MIXED results.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('PROBABLE_UNDERSTANDING', 61), ('INCOMPLETE_EVIDENCE', 149), ('INCOMPLETE_EVIDENCE', 172), ('INCOMPLETE_EVIDENCE', 196), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 278)]	6	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007567', 'parturition', 99, 'birth'), ('GO_0007565', 'female pregnancy', 126, 'gestational')]	0	['maternal  status fetal growth, infant birth  age (sga), supplementation trials1617181920worldwide results.']
S15-PMC4598849	PMC4598849	10/2015	S15-PMC4598849	['the CONFLICTING findings MAY BE DUE TO VARIATIONS of study designs including the Gestational weeks of Vitamin D testing, the cut-point of Vitamin D, ethnicity of the study population, Genetic variation and outcome variables.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('INCOMPLETE_EVIDENCE', 25), ('PROBLEM_COMPLICATION', 32), ('DIFFICULT_TASK', 39)]	4	[('GO_0007565', 'female pregnancy', 81, 'gestational'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('SO_0000704', 'gene', 184, 'genetic')]	0	[' weeks  testing, cut-point ethnicity population, genetic outcome variables.']
S48-PMC4598849	PMC4598849	10/2015	S48-PMC4598849	['compared with north american and european countries (the mean 25(Oh)D levels of Pregnant women in us and uk is APPROXIMATELY 50\u2009nmol/l), asian countries MAYBE have more Pregnant women with Vitamin D deficiency1326272829.']	[('INCOMPLETE_EVIDENCE', 111), ('INCOMPLETE_EVIDENCE', 153)]	2	[('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 62, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('GO_0007565', 'female pregnancy', 169, 'pregnant'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D')]	0	['compared north american european countries (the 25(oh)d levels  women us uk 50\u2009nmol/l), asian countries  women  deficiency1326272829.']
S54-PMC4598849	PMC4598849	10/2015	S54-PMC4598849	['another case-control study SUGGESTED that infants Born before 32 wks’ Gestation had an increased RISK of Vitamin D deficiency compared with mature infant, HOWEVER, there was no statistically significant difference in mean Cord Blood 25(Oh)D levels between sga and non-sga infants29.']	[('INCOMPLETE_EVIDENCE', 27), ('IMPORTANT_CONSIDERATION', 97), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 155), ('ANOMALY_CURIOUS_FINDING', 155)]	4	[('GO_0007567', 'parturition', 50, 'born'), ('GO_0007565', 'female pregnancy', 70, 'gestation'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 222, 'cord'), ('UBERON_0000178', 'blood', 227, 'blood'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 233, '25(OH ... D')]	0	['another case-control infants born 32 wks’   mature infant, however, statistically cord blood 25(oh)d levels sga non-sga infants29.']
S60-PMC4598849	PMC4598849	10/2015	S60-PMC4598849	['ALTHOUGH the neonatal 25(Oh)D levels at Birth cannot fully represent the Vitamin D status during CRITICAL times of Gestation DUE TO a half-life of several weeks of 25(Oh)D34, IT was quite POSSIBLE that the neonates with lower or higher Cord Blood 25(Oh)D levels MAY also have lower or higher average levels of 25(Oh)D during the whole Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 97), ('PROBLEM_COMPLICATION', 125), ('ANOMALY_CURIOUS_FINDING', 175), ('INCOMPLETE_EVIDENCE', 188), ('INCOMPLETE_EVIDENCE', 262)]	7	[('CHEBI_71657', 'versiconol acetate', 22, '25(OH)D'), ('GO_0007567', 'parturition', 40, 'birth'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'gestation'), ('CHEBI_79189', 'D-ribofuranose-2,5-bisphosphate', 164, '25(OH)D34'), ('PR_000001177', 'D(2) dopamine receptor', 170, 'D34'), ('UBERON_0002240', 'spinal cord', 236, 'cord'), ('UBERON_0000178', 'blood', 241, 'blood'), ('CHEBI_71657', 'versiconol acetate', 247, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 253, 'D'), ('CHEBI_71657', 'versiconol acetate', 310, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 316, 'D'), ('GO_0007565', 'female pregnancy', 335, 'pregnancy')]	0	['although neonatal 25(oh)d levels birth  status times  half-life weeks 25(oh)d34, neonates higher cord blood 25(oh)d levels higher average levels 25(oh)d whole .']
S61-PMC4598849	PMC4598849	10/2015	S61-PMC4598849	['THEREFORE, the inverted u shaped RELATIONSHIP in THIS STUDY MAYBE SUGGESTED that Gestational Vitamin D MAY have dual biological EFFECTS on the fetal growth.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 33), ('QUESTION_ANSWERED_BY_THIS_WORK', 49), ('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 66), ('INCOMPLETE_EVIDENCE', 103), ('SUPERFICIAL_RELATIONSHIP', 128)]	7	[('GO_0007565', 'female pregnancy', 81, 'gestational'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]	0	['therefore, inverted u   biological fetal growth.']
S76-PMC4598849	PMC4598849	10/2015	S76-PMC4598849	['HOWEVER, we were UNABLE TO assess the EFFECT of Vitamin D levels during early Pregnancy on fetal growth as these data are unavailable.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('DIFFICULT_TASK', 17), ('SUPERFICIAL_RELATIONSHIP', 38)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy')]	0	['however,  levels  fetal unavailable.']
S80-PMC4598849	PMC4598849	10/2015	S80-PMC4598849	['the FINDINGS SUGGESTED that Vitamin D supplements during Pregnancy SHOULD BE ENCOURAGED, BUT with CAUTION.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 13), ('FUTURE_WORK', 67), ('FUTURE_WORK', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 89), ('INCOMPLETE_EVIDENCE', 98)]	6	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy')]	0	[' supplements  encouraged, caution.']
S50-PMC4600246	PMC4600246	10/2015	S50-PMC4600246	['it HAS BEEN PRESUMED that Prenatal Vitamin K deficiency induced by warfarin MAY BE the UNDERLYING cause of these calcifications.4344indeed, SEVERAL STUDIES INDICATE a CONNECTION between warfarin and Arterial calcifications.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 76), ('SUPERFICIAL_RELATIONSHIP', 87), ('INCOMPLETE_EVIDENCE', 140), ('INCOMPLETE_EVIDENCE', 156), ('SUPERFICIAL_RELATIONSHIP', 167)]	8	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin K'), ('UBERON_0001637', 'artery', 199, 'arterial')]	0	['  induced warfarin calcifications.4344indeed, warfarin arterial calcifications.']
S2-PMC4605923	PMC4605923	11/2015	S2-PMC4605923	['Food intake is a WELL-known environmental FACTOR that INFLUENCES Allergy Development and three specific Nutrients-Vitamin D, Omega 3 polyunsaturated Fatty Acids and Folate-have RECENTLY attracted ATTENTION.1\nthe methyl donor Folate is a WELL-KNOWN Nutrient supplement given during early Pregnancy to prevent neutral Tube defects in the developing fetus.']	[('PROBABLE_UNDERSTANDING', 17), ('SUPERFICIAL_RELATIONSHIP', 42), ('SUPERFICIAL_RELATIONSHIP', 54), ('INCOMPLETE_EVIDENCE', 177), ('INCOMPLETE_EVIDENCE', 196), ('PROBABLE_UNDERSTANDING', 237)]	6	[('CHEBI_33290', 'food', 0, 'Food'), ('GO_0060021', 'roof of mouth development', 65, 'allergy development'), ('CHEBI_33284', 'nutrient', 104, 'nutrients'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_82673', '2-amino-6,7-dimethyl-4-oxo-8-(1*-D-ribityl)-4,8-dihydropteridine', 125, 'omega 3'), ('CHEBI_35366', 'fatty acid', 149, 'fatty acids'), ('CHEBI_30863', '5-azaorotic acid', 165, 'folate'), ('CHEBI_30863', '5-azaorotic acid', 225, 'folate'), ('CHEBI_33284', 'nutrient', 248, 'nutrient'), ('GO_0007565', 'female pregnancy', 287, 'pregnancy'), ('UBERON_0000025', 'tube', 316, 'tube')]	0	['food intake environmental allergy three nutrients-, omega 3 polyunsaturated fatty acids folate-have attracted attention.1\nthe methyl donor folate nutrient supplement  neutral tube defects fetus.']
S85-PMC4613350	PMC4613350	9/2015	S85-PMC4613350	['matched for body mass index (bmi);6exclusion: Vitamin C and/or Vitamin E supplements, history of major medical complications, major fetal defects, repeated spontaneous abortion, use of an Illicit Drug or Warfarin treatment during the current Pregnancy;7inclusion: nulliparous women with singleton Pregnancies without major fetal chromosomal or structural anomaly;8exclusion: women who had a previous fetus with a chromosomal abnormality and women with Insulin-dependent diabetes mellitus;9exclusion: aids or hepatitis, cases of major fetal anomaly, fetal death and women with Placenta previa, Placenta accrete, or Placental abruption;10general population, singleton Pregnancies;11a priori high risk Pregnancies;12general population;13inclusion: singleton Pregnancy, exclusion: diabetes and chromosomal abnormalities;14exclusion: chronic Hepatic or Renal diseases, Pregnancies with major fetal abnormalities and those ending in termination, Miscarriage or fetal death <24 weeks;15exclusion : known aneuploidy and major congenital malformations;16exclusion: Miscarriages;17exclusion: congenital abnormalities or Medication use;18randomly selected controls;19exclusion: multifetal Gestation, diabetes, chromosomal or structural abnormalities;20exclusion: increased risk factors of pe, sga or ptb, known major fetal anomaly or abnormal karyotype, intervention that MAY modify Pregnancy outcome such as treatment with Aspirin or Progesterone;21inclusion: history of pe in a previous Pregnancy, chronic hypertension, chronic Renal disease, Antiphospholipid syndrome, systemic lupus erythematosus, Pregestational diabetes mellitus, obesity (bmi ≥ 30 kg/m2).']	[('INCOMPLETE_EVIDENCE', 1361)]	1	[('CHEBI_27300', 'vitamin D', 46, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin E'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 188, 'illicit drug'), ('CHEBI_10033', 'warfarin', 204, 'warfarin'), ('GO_0007565', 'female pregnancy', 242, 'pregnancy'), ('GO_0007565', 'female pregnancy', 297, 'pregnancies'), ('PR_000045358', 'insulin family protein', 452, 'insulin'), ('UBERON_0001987', 'placenta', 576, 'placenta'), ('UBERON_0001987', 'placenta', 593, 'placenta'), ('UBERON_0001987', 'placenta', 614, 'placental'), ('GO_0007565', 'female pregnancy', 666, 'pregnancies'), ('GO_0007565', 'female pregnancy', 699, 'pregnancies'), ('GO_0007565', 'female pregnancy', 755, 'pregnancy'), ('UBERON_0002107', 'liver', 837, 'hepatic'), ('UBERON_0002113', 'kidney', 848, 'renal'), ('GO_0007565', 'female pregnancy', 864, 'pregnancies'), ('GO_0046660', 'female sex differentiation', 940, 'miscarriage'), ('GO_0042706', 'eye photoreceptor cell fate commitment', 1056, 'miscarriages'), ('CHEBI_60211', 'compound Z', 1110, 'medication'), ('GO_0007565', 'female pregnancy', 1178, 'gestation'), ('GO_0007565', 'female pregnancy', 1372, 'pregnancy'), ('CHEBI_2904', 'atenolol', 1413, 'aspirin'), ('CHEBI_17026', 'progesterone', 1424, 'progesterone'), ('GO_0007565', 'female pregnancy', 1478, 'pregnancy'), ('UBERON_0002113', 'kidney', 1519, 'renal'), ('CHEBI_16240', 'hydrogen peroxide', 1534, 'antiphospholipid'), ('GO_0007565', 'female pregnancy', 1591, 'pregestational')]	0	['matched mass (bmi);6exclusion:  and/or  supplements, medical complications, fetal defects, spontaneous abortion, illicit drug warfarin treatment ;7inclusion: nulliparous women singleton  fetal chromosomal structural anomaly;8exclusion: women fetus chromosomal abnormality women insulin-dependent diabetes mellitus;9exclusion: hepatitis, cases fetal anomaly, fetal death women placenta previa, placenta accrete, placental abruption;10general population, singleton ;11a ;12general population;13inclusion: singleton exclusion: diabetes chromosomal abnormalities;14exclusion: chronic hepatic renal diseases,  fetal abnormalities ending termination, miscarriage fetal death <24 weeks;15exclusion : aneuploidy congenital malformations;16exclusion: miscarriages;17exclusion: congenital abnormalities medication use;18randomly selected controls;19exclusion: multifetal diabetes, chromosomal structural abnormalities;20exclusion: pe, sga ptb, fetal anomaly abnormal karyotype,  outcome treatment aspirin progesterone;21inclusion: pe chronic hypertension, chronic renal disease, antiphospholipid syndrome, systemic lupus erythematosus,  diabetes mellitus, obesity (bmi ≥ 30 kg/m2).']
S18-PMC4624803	PMC4624803	10/2015	S18-PMC4624803	['the levels of Vitamin D at Birth SHOULD BE a good ESTIMATE of the child’s Vitamin D levels, AT LEAST in the later part of the Gestation.']	[('FUTURE_WORK', 33), ('INCOMPLETE_EVIDENCE', 50), ('PROBABLE_UNDERSTANDING', 92)]	3	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007567', 'parturition', 27, 'birth'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'gestation')]	0	['levels  birth child’s  levels, .']
S19-PMC4624803	PMC4624803	10/2015	S19-PMC4624803	['AIM\nthe AIM of the STUDY was TO TEST the HYPOTHESIS that low levels of Vitamin D in the child during Pregnancy are a risk FACTOR for adhd in the offspring.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 19), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 122)]	6	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy')]	0	['aim\nthe levels  child  adhd offspring.']
S85-PMC4624803	PMC4624803	10/2015	S85-PMC4624803	['adjustment was made for the covariates age of mother, smoking of mother, season of Birth january to march and season of Birth july to september.all childrenchildren with mothers Born in swedenestimate95% confidence limitsp-valueestimate95% confidence limitsp-valuemodel 1-0.77-2.32, 0.770.32-1.11-2.76, 0.530.18model 2-0.77-2.25, 0.700.30-1.08-2.77, 0.620.21model 3-1.00-2.40, 0.390.16-1.00-2.47, 0.460.18model 4-0.99-2.34, 0.360.15-1.11-2.66, 0.440.16\n\ndiscussion\nOUR STUDY FAILS to SUPPORT the HYPOTHESIS that low levels of Vitamin D during Pregnancy are a risk FACTOR for adhd in the offspring.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 465), ('PROBLEM_COMPLICATION', 475), ('INCOMPLETE_EVIDENCE', 484), ('INCOMPLETE_EVIDENCE', 496), ('SUPERFICIAL_RELATIONSHIP', 564)]	5	[('GO_0007567', 'parturition', 83, 'birth'), ('GO_0007567', 'parturition', 120, 'birth'), ('GO_0007567', 'parturition', 178, 'born'), ('CHEBI_27300', 'vitamin D', 526, 'vitamin D'), ('GO_0007565', 'female pregnancy', 543, 'pregnancy')]	0	['adjustment covariates age mother, smoking mother, season birth january march season birth july september.all childrenchildren mothers born swedenestimate95% confidence limitsp-valueestimate95% confidence limitsp-valuemodel 1-0.77-2.32, 0.770.32-1.11-2.76, 0.530.18model 2-0.77-2.25, 0.700.30-1.08-2.77, 0.620.21model 3-1.00-2.40, 0.390.16-1.00-2.47, 0.460.18model 4-0.99-2.34, 0.360.15-1.11-2.66, 0.440.16\n\ndiscussion\nour levels   adhd offspring.']
S99-PMC4624803	PMC4624803	10/2015	S99-PMC4624803	['[11] SHOWED that the mother’s Vitamin D status during Pregnancy had no association with behavioural problems in the offspring, including symptoms of adhd, several years later.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy')]	0	['[11] mother’s  status  behavioural offspring, symptoms adhd, later.']
S101-PMC4624803	PMC4624803	10/2015	S101-PMC4624803	['WHILE strøm et al have analysed the levels of D Vitamin in the Serum from the mothers at Pregnancy, we have analysed D Vitamin levels in the Serum collected from the child at Birth, which should REFLECT the Prenatal Vitamin D status of the child.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 195)]	2	[('CHEBI_28748', 'doxorubicin', 46, 'D vitamin'), ('UBERON_0001977', 'blood serum', 63, 'serum'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_28748', 'doxorubicin', 117, 'D vitamin'), ('UBERON_0001977', 'blood serum', 141, 'serum'), ('GO_0007567', 'parturition', 175, 'birth'), ('GO_0007565', 'female pregnancy', 207, 'prenatal'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D')]	0	['strøm et al levels vitamin serum mothers vitamin levels serum child birth,   status child.']
S115-PMC4624803	PMC4624803	10/2015	S115-PMC4624803	['conclusion\nwe FOUND NO SUPPORT for the HYPOTHESIS that low levels of Vitamin D during Pregnancy are a risk factor for adhd in the offspring.']	[('INCOMPLETE_EVIDENCE', 14), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('INCOMPLETE_EVIDENCE', 39)]	3	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy')]	0	['conclusion\nwe levels   adhd offspring.']
S61-PMC4627942	PMC4627942	10/2015	S61-PMC4627942	['a study in west kiang hdss, gambia, SHOWED that nutritional rickets, a disease caused largely by Vitamin D deficiency, the EFFECTS of which CAN include Cardiac failure and hypoglycaemic seizures, was more PREVALENT in infants whose mothers had poor Vitamin D status during Pregnancy (21).']	[('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 123), ('INCOMPLETE_EVIDENCE', 140), ('IMPORTANT_CONSIDERATION', 205)]	4	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('UBERON_0000948', 'heart', 152, 'cardiac'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D'), ('GO_0007565', 'female pregnancy', 273, 'pregnancy')]	0	['west kiang hdss, gambia, nutritional rickets, disease  deficiency, cardiac hypoglycaemic seizures, infants whose mothers  status  (21).']
S93-PMC4627942	PMC4627942	10/2015	S93-PMC4627942	['(31) FOUND that providing Pregnant women who are hiv-positive with Vitamin A supplementation MAY improve the Gut function of their hiv-infected infants.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 93)]	2	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin A'), ('UBERON_0001555', 'digestive tract', 109, 'gut')]	0	['(31)  women hiv-positive  supplementation gut hiv-infected infants.']
S103-PMC4627942	PMC4627942	10/2015	S103-PMC4627942	['caption (table-wrap): table 2\n\nbiological causes of malnutrition: findings from indepth studieshdss siteyearauthorsmain findingsagincourt hdss, south africa2011kimani-murage et al.children infected with hiv had significantly worse nutritional outcomes than their uninfected peers.west kiang hdss, gambia2008nwenekahiv-positive children had significantly worse scores in terms of weight-for-age, height-for-age, and bmi than hiv-negative children.africa centre, south africa2007papathakis et al.breastfeeding mothers in south africa who were hiv-positive had poorer protein and Micronutrient status than hiv-negative women.africa centre, south africa2001filteau et al.providing Pregnant women who are hiv-positive with Vitamin A supplementation MAY improve Gut function of their hiv-infected infants.']	[('INCOMPLETE_EVIDENCE', 744)]	1	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 577, 'micronutrient'), ('GO_0007565', 'female pregnancy', 677, 'pregnant'), ('CHEBI_27300', 'vitamin D', 718, 'vitamin A'), ('UBERON_0001555', 'digestive tract', 756, 'gut')]	0	['caption (table-wrap): table 2\n\nbiological causes malnutrition: indepth studieshdss siteyearauthorsmain findingsagincourt hdss, south africa2011kimani-murage et al.children infected hiv nutritional outcomes uninfected peers.west kiang hdss, gambia2008nwenekahiv-positive children scores terms weight-for-age, height-for-age, bmi hiv-negative children.africa centre, south africa2007papathakis et al.breastfeeding mothers south africa hiv-positive protein micronutrient status hiv-negative women.africa centre, south africa2001filteau et al.providing  women hiv-positive  supplementation gut hiv-infected infants.']
S197-PMC4627942	PMC4627942	10/2015	S197-PMC4627942	['in ghana, Vitamin A supplementation was found to increase Liver reserves of mothers during the Postpartum period, with the EFFECTS persisting for at least five months (72).']	[('SUPERFICIAL_RELATIONSHIP', 123)]	1	[('CHEBI_27300', 'vitamin D', 10, 'vitamin A'), ('UBERON_0002107', 'liver', 58, 'liver'), ('GO_0007565', 'female pregnancy', 95, 'postpartum')]	0	['ghana,  supplementation increase liver mothers  period, persisting five months (72).']
S221-PMC4627942	PMC4627942	10/2015	S221-PMC4627942	"['[""""caption (table-wrap): table 5\\n\\ntackling malnutrition – prevention EFFORTS: findings from indepth studieshdss siteyearauthorsmain findingsbandim hdss, guinea-bissau2004nielsen et al.during civil war, Vitamin A supplementation for children helped reduce mortality.bandim hdss, guinea-bissau2005nielsen et al.during civil war, supplementary Feeding programme helped reduce mortality in children.filabavi hdss, vietnam2009nga et al.fortification with multiple Micronutrients of biscuits provided in schools reduced risk of anaemia and of iron and zinc deficiencies by 40%.nouna hdss, burkina faso2003müller et al.no significant impact of Zinc supplementation for children on height-for-age, weight-for-age, and weight-for-height scores.kintampo hdss, ghana2007newton et al.no positive EFFECT of Vitamin A supplements in combination with vaccines during the first few months of Life.farafenni hdss, gambia2013van der merwe et al.fish oil supplementation had no effect on growth, Intestinal integrity, morbidity, or cognitive development.kilifi hdss, kenya2010akech et al.use of low-dose hypotonic Fluid resuscitation for children who develop shock AS a result of SEVERE malnutrition has poor outcomes in terms of persistent shock, oliguria, and high case fatality.agincourt hdss, south africa2003deen et al.introduction of who guidelines in two hospitals strengthened the management of malnutrition.kintampo hdss, ghana2006tchum et al.vitamin a supplementation increased Liver reserves of mothers during the Postpartum period, with EFFECTS persisting for at least five months.niakhar hdss, senegal2006ly et al.provision of high energy, Nutrient-dense Food supplements to infants aged between four and seven months contributed to decreased Postpartum weight loss in their mothers.west kiang hdss, gambia2011hawkesworth et al.Nutrient supplementation during Pregnancy had little effect on infants’ risk of cardiovascular disease.west kiang hdss, gambia2009hawkesworth et al.protein-energy supplementation of mothers during Pregnancy had no effect on the Blood pressure of their children in adolescence.west kiang hdss, gambia2009prentice et al.Calcium supplementation for Pregnant mothers had no effect on foetal and infant growth.west kiang hdss, gambia2010jarjou et al.women given Calcium Supplements while Pregnant had lower bone Mineral content, bone area and bone Mineral density at the Hip during the 12-month Lactation period than other women.dikgale hdss, south africa2002nthangeni et al.the majority of People with type 2 diabetes had poor Glycaemic Control and were obese or had high blood pressure and were given poor advice by health educators.africa centre hdss, south africa2002o\'donnell et al.agencies working to tackle a flood disaster in bangladesh in 1998 achieved MIXED results in terms of meeting international disaster response standards.""""]']"	[('FUTURE_WORK', 66), ('SUPERFICIAL_RELATIONSHIP', 781), ('PROBABLE_UNDERSTANDING', 1143), ('IMPORTANT_CONSIDERATION', 1158), ('SUPERFICIAL_RELATIONSHIP', 1527), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2776)]	6	[('CHEBI_27300', 'vitamin D', 199, 'vitamin A'), ('GO_0007631', 'feeding behavior', 338, 'feeding'), ('CHEBI_33839', 'macromolecule', 456, 'micronutrients'), ('CHEBI_33340', 'zinc group element atom', 634, 'zinc'), ('CHEBI_27300', 'vitamin D', 791, 'vitamin A'), ('UBERON_0000104', 'life cycle', 873, 'life'), ('UBERON_0000160', 'intestine', 974, 'intestinal'), ('UBERON_0006314', 'bodily fluid', 1092, 'fluid'), ('UBERON_0002107', 'liver', 1466, 'liver'), ('GO_0007565', 'female pregnancy', 1503, 'postpartum'), ('CHEBI_33284', 'nutrient', 1631, 'nutrient'), ('CHEBI_33290', 'food', 1646, 'food'), ('GO_0007565', 'female pregnancy', 1734, 'postpartum'), ('CHEBI_33284', 'nutrient', 1819, 'Nutrient'), ('GO_0007565', 'female pregnancy', 1851, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2016, 'pregnancy'), ('UBERON_0000178', 'blood', 2047, 'blood'), ('CHEBI_31341', 'calcium dihydroxide', 2137, 'Calcium'), ('GO_0007565', 'female pregnancy', 2165, 'pregnant'), ('CHEBI_22313', 'alkaline earth metal atom', 2276, 'calcium'), ('CHEBI_33341', 'titanium atom', 2284, 'supplements'), ('GO_0007565', 'female pregnancy', 2302, 'pregnant'), ('CHEBI_46662', 'mineral', 2326, 'mineral'), ('CHEBI_46662', 'mineral', 2362, 'mineral'), ('UBERON_0001464', 'hip', 2385, 'hip'), ('GO_0007595', 'lactation', 2409, 'lactation'), ('NCBITaxon_10088', 'Mus <genus>', 2505, 'people'), ('GO_0051162', 'L-arabitol metabolic process', 2542, 'glycaemic control')]	0	"['[""""caption (table-wrap): table 5\\n\\ntackling malnutrition efforts: indepth studieshdss siteyearauthorsmain findingsbandim hdss, guinea-bissau2004nielsen et al.during civil min supplementation children mortality.bandim hdss, guinea-bissau2005nielsen et al.during civil war, supplementary feeding programme mortality children.filabavi hdss, vietnam2009nga et al.fortification micronutrients biscuits schools anaemia iron zinc 40%.nouna hdss, burkina faso2003müller et al.no zinc supplementation children height-for-age, weight-for-age, weight-for-height scores.kintampo hdss, ghana2007newton et al.no positive effecmin supplements combination vaccines months life.farafenni hdss, gambia2013van der merwe et al.fish oil supplementation growth, intestinal integrity, morbidity, cognitive development.kilifi hdss, kenya2010akech et al.use low-dose hypotonic fluid resuscitation children shock result malnutrition outcomes terms shock, oliguria, fatality.agincourt hdss, south africa2003deen et al.introduction hospitals malnutrition.kintampo hdss, ghana2006tchum et al.vitamin supplementation liver mothers duringartum period, persisting five months.niakhar hdss, senegal2006ly et al.provision energy, nutrient-dense food supplements infants aged four seven months decreartum loss mothers.west kiang hdss, gambia2011hawkesworth et al.nutrient supplementation dunancy infants’ cardiovascular disease.west kiang hdss, gambia2009hawkesworth et al.protein-energy supplementation mothers dunancy blood pressure children adolescence.west kiang hdss, gambia2009prentice et al.calcium supplementationgnant mothers foetal infant growth.west kiang hdss, gambia2010jarjou et al.women calcium supplements wgnant bone mineral content, bone bone mineral density hip 12-month lactation period women.dikgale hdss, south africa2002nthangeni et al.the people type 2 diabetes glycaemic obese blood pressure educators.africa centre hdss, south africa2002o*donnell et al.agencies working tackle flood disaster bangladesh 1998 achieved terms meeting international disaster response standards.""""]']"
S0-PMC4632418	PMC4632418	10/2015	S0-PMC4632418	['Vitamin D deficiency increases the risk of Gestational diabetes mellitus: a meta-analysis of observational studies\n\nabstract\nthe results investigating the RELATIONSHIP between Vitamin D levels and Gestational diabetes mellitus (gdm) are INCONSISTENT.']	[('SUPERFICIAL_RELATIONSHIP', 155), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 237)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'Gestational'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('GO_0007565', 'female pregnancy', 197, 'gestational')]	0	['vitamin  diabetes mellitus: meta-analysis studies\n\nabstract\nthe results  levels  diabetes mellitus (gdm) inconsistent.']
S19-PMC4632418	PMC4632418	10/2015	S19-PMC4632418	['furthermore, Pregnant and Lactating women who take a Prenatal Vitamin and a Calcium supplement with Vitamin D remain at HIGH RISK for Vitamin D deficiency.']	[('IMPORTANT_CONSIDERATION', 120)]	1	[('GO_0007565', 'female pregnancy', 13, 'pregnant'), ('GO_0007594', 'puparial adhesion', 26, 'lactating'), ('GO_0007565', 'female pregnancy', 53, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 62, 'vitamin'), ('CHEBI_22313', 'alkaline earth metal atom', 76, 'calcium'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]	0	['furthermore,  lactating women  vitamin calcium supplement   deficiency.']
S20-PMC4632418	PMC4632418	10/2015	S20-PMC4632418	['it HAS BEEN REPORTED that 40%–100% of Vitamin D deficiency during Pregnancy are FOUND in sweden, oman, uk, usa, australia, pakista, urban india, japan and china [7,8,9,10,11].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 80)]	3	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy')]	0	['40%–100%   sweden, oman, uk, usa, australia, pakista, urban india, japan china [7,8,9,10,11].']
S22-PMC4632418	PMC4632418	10/2015	S22-PMC4632418	['the ROLE of Vitamin D on Gdm Development HAS been studied, and Vitamin D deficiency APPEARS TO BE ASSOCIATED with altered Glucose Homeostasis during Pregnancy [12,13].']	[('SUPERFICIAL_RELATIONSHIP', 4), ('IMPORTANT_CONSIDERATION', 41), ('ANOMALY_CURIOUS_FINDING', 84), ('SUPERFICIAL_RELATIONSHIP', 98)]	4	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0072147', 'glomerular parietal epithelial cell fate commitment', 25, 'GDM development'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_17234', 'glucose', 122, 'glucose'), ('GO_0042593', 'glucose homeostasis', 122, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy')]	0	[' gdm studied,  altered glucose homeostasis  [12,13].']
S34-PMC4632418	PMC4632418	10/2015	S34-PMC4632418	['study selection\noriginal research evaluating the ASSOCIATIONS between Vitamin D status and Pregnancy outcomes were scrutinized and subsequently selected if they fulfilled the following inclusion criteria: a. study population was Pregnant women without pre-existing chronic disease; b. gdm as outcome and the control were women with normal Glucose tolerance (ngt); c. contained RELEVANT data to calculate the effect size and corresponding 95% confidence intervals (ci); d. met the predefined methodological quality assessment criteria for observational studies (supplementary data box 1) [18]; e. only studies published in english were considered.']	[('SUPERFICIAL_RELATIONSHIP', 49), ('IMPORTANT_CONSIDERATION', 377)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('GO_0007565', 'female pregnancy', 229, 'pregnant'), ('CHEBI_17234', 'glucose', 339, 'glucose')]	0	['study selection\noriginal  status  outcomes scrutinized selected fulfilled following inclusion criteria: population  women pre-existing chronic disease; b. gdm outcome women normal glucose tolerance (ngt); c. contained calculate 95% confidence intervals (ci); d. met predefined methodological criteria (supplementary box 1) [18]; e. english considered.']
S88-PMC4632418	PMC4632418	10/2015	S88-PMC4632418	['exclusion of two studies [15,36] in which Pregnant women were Vitamin D sufficient (with 25(Oh)D level greater than 75 nmol/l) yielded SIMILAR results (wmd = −5.04; 95% ci, −6.43 to −3.64), and LITTLE evidence of heterogeneity was OBSERVED among the remaining studies ( i2= 37.50%, p = 0.077).']	[('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 194), ('INCOMPLETE_EVIDENCE', 231)]	3	[('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D')]	0	['exclusion [15,36]  women  (with 25(oh)d 75 nmol/l) results (wmd = −5.04; 95% ci, −6.43 −3.64), among i2= 37.50%, p = 0.077).']
S96-PMC4632418	PMC4632418	10/2015	S96-PMC4632418	['discussion\nthere HAS BEEN a rapidly GROWING INTEREST in the ASSOCIATION between Vitamin D and risk of Gestational diabetes mellitus.']	[('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 60)]	3	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'gestational')]	0	['discussion\nthere rapidly   diabetes mellitus.']
S98-PMC4632418	PMC4632418	10/2015	S98-PMC4632418	['SIMILARLY, our meta-analysis of 20 independent observational studies provided STRONG EVIDENCE that Vitamin D deficiency was ASSOCIATED with an INCREASED RISK of Gestational diabetes.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 78), ('PROBABLE_UNDERSTANDING', 78), ('SUPERFICIAL_RELATIONSHIP', 124), ('IMPORTANT_CONSIDERATION', 143)]	6	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'gestational')]	0	['similarly, meta-analysis 20   diabetes.']
S107-PMC4632418	PMC4632418	10/2015	S107-PMC4632418	['for ONE STUDY, the majority of study participants were reported Consuming Prenatal multivitamins or taking Nutritional supplements, as well as living in a geographical location which MAY AFFECT the Vitamin D status [15].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 183), ('SUPERFICIAL_RELATIONSHIP', 187)]	3	[('GO_0007631', 'feeding behavior', 64, 'consuming'), ('GO_0007565', 'female pregnancy', 74, 'prenatal'), ('CHEBI_7495', 'nefazodone hydrochloride', 107, 'nutritional'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D')]	0	['study, participants  multivitamins nutritional supplements, living geographical location  status [15].']
S111-PMC4632418	PMC4632418	10/2015	S111-PMC4632418	['OUR FINDINGS for increased risk of Gestational diabetes with Vitamin D deficiency are biologically PLAUSIBLE.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 99)]	2	[('GO_0007565', 'female pregnancy', 35, 'gestational'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]	0	[' diabetes  biologically plausible.']
S116-PMC4632418	PMC4632418	10/2015	S116-PMC4632418	['there are MAJOR causes behind Vitamin D deficiency during Pregnancy, such as INADEQUATE exposure to sunlight, low Vitamin D intake and more REQUIREMENTS for Vitamin D. Vitamin D supplementation during Pregnancy has beneficial EFFECTS on glycaemia, Insulin sensitivity [45], Insulin resistance [46] and Metabolic profiles [47].']	[('IMPORTANT_CONSIDERATION', 10), ('IMPORTANT_CONSIDERATION', 77), ('IMPORTANT_CONSIDERATION', 140), ('SUPERFICIAL_RELATIONSHIP', 226)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 168, 'Vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 176, 'D'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy'), ('PR_000045358', 'insulin family protein', 248, 'insulin'), ('PR_000045358', 'insulin family protein', 274, 'insulin'), ('GO_0008152', 'metabolic process', 302, 'metabolic')]	0	['behind  exposure sunlight,  intake . vitamin supplementation  glycaemia, insulin sensitivity [45], insulin resistance [46] metabolic [47].']
S117-PMC4632418	PMC4632418	10/2015	S117-PMC4632418	['HOWEVER, there is an active DEBATE on the appropriate intake of Vitamin D in Pregnancy [12].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 28)]	2	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy')]	0	['however, intake   [12].']
S125-PMC4632418	PMC4632418	10/2015	S125-PMC4632418	['INTERESTINGLY, we just FOUND that two researches [23,34] of Pregnant women with Vitamin D sufficiency are nested case-control and case-control studies, respectively, which tests the HYPOTHESIS mentioned above BETTER.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 182), ('INCOMPLETE_EVIDENCE', 209)]	4	[('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]	0	['interestingly, [23,34]  women  case-control case-control studies, respectively, better.']
S126-PMC4632418	PMC4632418	10/2015	S126-PMC4632418	['thirdly, there is one more POINT that the OBSERVED ASSOCIATIONS between maternal Vitamin D status and the risk of adverse Pregnancy outcomes COULD BE AFFECTED by CONFOUNDING FACTORS, such as bmi and skin tone.']	[('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 42), ('SUPERFICIAL_RELATIONSHIP', 51), ('INCOMPLETE_EVIDENCE', 141), ('SUPERFICIAL_RELATIONSHIP', 150), ('PROBLEM_COMPLICATION', 162)]	6	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy')]	0	['thirdly, maternal  status  outcomes factors, bmi skin tone.']
S127-PMC4632418	PMC4632418	10/2015	S127-PMC4632418	['taking bmi for example, increased bmi in Pregnancy is ASSOCIATED with higher risk of gdm [49], as well as increased risk of Vitamin D deficiency [5].']	[('SUPERFICIAL_RELATIONSHIP', 54)]	1	[('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]	0	['taking bmi example, bmi  higher gdm [49],  [5].']
S132-PMC4632418	PMC4632418	10/2015	S132-PMC4632418	['conclusions\nin CONCLUSION, the EVIDENCE from THIS ARTICLE INDICATES a CONSISTENT ASSOCIATION between Vitamin D deficiency and an INCREASED RISK of Gestational diabetes mellitus.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 31), ('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('INCOMPLETE_EVIDENCE', 58), ('INCOMPLETE_EVIDENCE', 70), ('SUPERFICIAL_RELATIONSHIP', 81), ('IMPORTANT_CONSIDERATION', 129)]	7	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'gestational')]	0	['conclusions\nin conclusion,   diabetes mellitus.']
S72-PMC4632423	PMC4632423	10/2015	S72-PMC4632423	['analysis of Serum levels of Micronutrients in the random subset of 25 very severely obese compared with 25 lean women CONFIRMED the significantly lower circulating levels of iron, vitamin b12, Folate, Vitamin A, copper, zinc and selenium with TRENDS for lower Vitamin E/Cholesterol and 25(Oh)D in very severely obese in early Pregnancy (table 3).']	[('INCOMPLETE_EVIDENCE', 118), ('INCOMPLETE_EVIDENCE', 243), ('SUPERFICIAL_RELATIONSHIP', 243)]	3	[('UBERON_0001977', 'blood serum', 12, 'serum'), ('CHEBI_33839', 'macromolecule', 28, 'micronutrients'), ('CHEBI_30863', '5-azaorotic acid', 193, 'folate'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin A'), ('CHEBI_28384', 'vitamin K', 260, 'Vitamin E'), ('CHEBI_16113', 'cholesterol', 270, 'cholesterol'), ('CHEBI_71657', 'versiconol acetate', 286, '25(OH)D'), ('GO_0007565', 'female pregnancy', 326, 'pregnancy')]	0	['analysis serum levels micronutrients random subset 25 obese 25 lean women circulating levels iron, vitamin b12, folate, copper, zinc selenium vitamin e/cholesterol 25(oh)d obese  (table 3).']
S74-PMC4632423	PMC4632423	10/2015	S74-PMC4632423	['there were SIMILAR PATTERNS in late Pregnancy other than for iron, Vitamin A, zinc and Selenium which were no longer significantly different between groups.nutrients-07-05403-t002_table 2\n\ncaption (table-wrap): table 2\n\nreported daily Nutrient intakes in lean and very severely obese women in early and late Pregnancy.Nutrientearly Pregnancylate Pregnancylean n = 93obese n = 148lean n = 87obese n = 146medianc25–c75medianc25–c75ppadjmedianc25–c75medianc25–c75ppadjenergy (kcal)2349(1995–2846)2435(1975–3040)*2354(1957–2876)2173(1747–2672)*protein (g)94.1(75–114)98.6(73–125)*90.5(76–117)87.7(69–113)*fat (g)91.6(75–118)95.6(73–122)*91.8(73–124)87.9(65–108)Carbohydrate (g)302.1(252–355)309.8(249–387)*304.1(258–361)278.8(227–346)*sfa (g)34.6(28–28)38.5(28–51)*36.2(29–50)35.1(25–44)mufa (g)32.1(26–42)33.2(25–43)*31.9(25–42)30.1(22–37)*Pufa (mg)15.9(13–20)16(12–22)**15.2(13–20)14.1(11–19)*Cholesterol (g)277(191–353)290.5(202–390)255(189–365)271.5(197–376)Sugars (g)134.9(109–176)150.3(113–195)*142(110–179)132.7(99–174)**Starch (g)150(130–196)156(121–191)*158(121–183)136(107–175)*fibre (g)22.8(20–29)20.6(16–26)***23.3(18–27)19(14–24)***Sodium (mg)3200(2375–3969)3389(2551–4065)*3239(2638–3896)2926(2298–3595)potassium (mg)3876(3262–4679)39533036–5017)*3813(3265–4769)34762845–4648*Calcium (mg)1233(1006–1496)1195.5(945–1603)**1268(1015–1579)1077(837–1415)*magnesium (mg)426(375–519)399.5(327–487)***417(355–527)359(289–452)***Phosphorus (mg)1791(1483–2106)1779.5(1423–2311)*1753(1476–2215)1652(1276–2097)**Iron (mg)16.5(14–20)14.5(11–19)***16.1(13–20)13(10–17)***copper (mg)3.2(2–4)2.9(2–4)*3.1(2.7–4)2.6(2.1–3.4)**Zinc (mg)12.1(9–15)12.1(9–15)**11.8(9–15)10.9(8–14)*Chloride (mg)4786(3899–6097)4998(3873–6273)*4871(3992–5900)4428.5(3552–5523)Manganese (mg)4.6(4–6)3.6(3–5)***4.5(3–6)3.2(2.6–4.3)***Selenium (µg)64(51–80)61(44–84)***63(51–80)58(41–77)**Iodine (µg)233(186–307)246.5(173–313)249(189–331)221.5(157–290)**Retinol (µg)320(228–436)319(220–466)316(221–504)290.5(200–423)Β–Carotene (µg)4362(3081–6848)4109(2361–6127)*4082(2594–6533)3340(2245–5023)Vitamin D (µg)3.8(2.8–5.7)3.1(2–4.6)*4(2.7–5.7)2.8(1.9–4.4)*Vitamin E (mg)12(9.8–15)11.4(8.3–13.4)**12(9–15.6)10.2(7–13)***Thiamine (mg)2(1.7–2.3)2(1.6–2.5)*2(1.6–2.4)1.8(1.5–2.3)*riboflavin (mg)2.1(1.8–2.7)2.2(1.5–2.8)***2.2(1.8–2.9)1.9(1.4–2.6)***niacin (mg)23.2(19–28)24.5(18–31)**22.5(18–28)22.6(16–29)*potential niacin (mg)20.9(16–25)20.5(15–27)*19.4(16–26)18.4(14–24)**Vitamin B6 (mg)2.5(2–3)2.7(2–3.3)*2.5(2.1–3.2)2.5(1.8–3.1)*Vitamin B12 (mg)6.2(4.6–8.8)6.2(4.2–8.6)6(4.9–9)5.7(3.9–7.7)Folate (µg)350(282–439)310.5(225–387)***362(268–436)276(202–353)***pa (mg)6.2(5.1–7.7)6.5(4.8–8.1)*6.2(5.1–7.9)5.7(4.5–7.7)*Biotin (µg)45.4(37–56)41.8(31–52)***44.1(37–59)37.2(27–50)****vitamin c (mg)160(120–204)160(110–227)**151(111–102)147(86–199)**Vitamin K (mg)69.9(43–137)34(22–68)**57.3(39–132)32.6(17–67)**\nc25: 25th percentile, c75: 75th percentile; p : ln-transformed crude intakes; padj: ln-transformed crude intakes adjusted for total energy intake, age, parity, ethnicity & depcat; * p< 0.05; ** p< 0.001.nutrients-07-05403-t003_table 3\n\ncaption (table-Wrap): table 3\n\nSerum levels of essential Micronutrients in early and late Pregnancy.early Pregnancy (16 weeks)late Pregnancy (28 weeks)obese n = 25lean n = 25 p *obese n = 25lean n = 25 p *iron (μmol/l)15.7 (4.7)23.4 (5.9)<0.000112.5 (5.3)14.7 (7.1)0.24vitamin B12 (ng/l)239.6 (87.7)389.1 (138.4)<0.0001202.1 (56.2)262.4 (96.4)0.02folate (μg/l)7.9 (4.2)15.0 (2.7)<0.00013.9 (2.8)10.6 (5.7)<0.0001vitamin A (μmol/l)1.2 (0.26)1.36 (0.28)0.0461.0 (0.24)1.1 (0.31)0.38vitamin e (μmol/l)29.6 (6.74)28.9 (5.78)0.69231.9 (8.46)38.1 (7.21)0.009cholesterol (mmol/l)5.67 (0.82)5.00 (0.85)0.0075.8 (0.79)6.6 (0.94)0.011vite/Chol5.26 (1.04)5.82 (0.91)0.0545.5 (1.06)5.9 (0.86)0.135copper (μmol/l)32.9 (4.5)26.1 (4.9)<0.000134.4 (4.1)28.2 (3.9)<0.0001copper+(μmol/l)33.1 (4.4)33.1 (5.3)<0.000134.5 (4.3)28.0 (3.7)<0.0001zinc (umol/l)9.7 (1.17)10.7 (1.30)0.0089.1 (0.92)9.3 (0.94)0.413zinc/albumin0.32 (0.04)0.31 (0.03)0.1720.32 (0.02)0.32 (0.03)0.958selenium (μmol/l)0.85 (0.13)1.02 (0.16)<0.00010.79 (0.11)0.89 (0.14)0.009selenium+(μmol/l)0.89 (0.14)1.00 (0.16)0.0500.85 (0.11)0.87 (0.14)0.437total 25Ohd (nmol/l)++51.1 (16.89)68.1 (29.91)0.07045.5 (32.54)68.7 (27.34)0.093crp (mg/l)12.0 (8.48)3.7 (3.35)<0.000113.4 (8.1)4.7 (5.6)0.001albumin (g/l)30.1 (1.98)34.5 (2.97)<0.000128.1 (1.2)29.3 (2.0)0.034\ndata are means (sd).']	[('SUPERFICIAL_RELATIONSHIP', 11), ('SUPERFICIAL_RELATIONSHIP', 19)]	2	[('GO_0007565', 'female pregnancy', 36, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin A'), ('CHEBI_27568', 'selenium atom', 87, 'selenium'), ('CHEBI_33284', 'nutrient', 235, 'nutrient'), ('GO_0007565', 'female pregnancy', 308, 'pregnancy'), ('CHEBI_36823', 'pseudohalo group', 318, 'NutrientEarly'), ('GO_0006412', 'translation', 332, 'pregnancyLate'), ('GO_0006562', 'proline catabolic process', 346, 'pregnancyLean'), ('CHEBI_16646', 'carbohydrate', 657, 'Carbohydrate'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 837, 'PUFA'), ('CHEBI_16113', 'cholesterol', 891, 'Cholesterol'), ('CHEBI_86939', 's perillic acid', 958, 'Sugars'), ('CHEBI_28017', 'starch', 1024, 'Starch'), ('CHEBI_33314', 'radon atom', 1141, 'Sodium'), ('CHEBI_31341', 'calcium dihydroxide', 1286, 'Calcium'), ('CHEBI_30207', 'phosphorus(.)', 1431, 'Phosphorus'), ('CHEBI_24870', 'ion', 1511, 'Iron'), ('CHEBI_27377', 'Unsym-bis(4*-chlorophenyl)ethylene', 1620, 'Zinc'), ('CHEBI_17996', 'chloride', 1672, 'Chloride'), ('CHEBI_33309', 'noble gas atom', 1748, 'Manganese'), ('CHEBI_27568', 'selenium atom', 1804, 'Selenium'), ('CHEBI_31719', 'ipriflavone', 1858, 'Iodine'), ('CHEBI_27810', 'resorcinol', 1923, 'Retinol'), ('CHEBI_35193', 'tetraterpene', 1985, 'β–carotene'), ('CHEBI_28384', 'vitamin K', 2061, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 2061, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 2121, 'Vitamin E'), ('CHEBI_32215', 'thiamphenicol', 2184, 'Thiamine'), ('CHEBI_27306', 'vitamin B6', 2436, 'Vitamin B6'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 2444, 'B6'), ('CHEBI_28334', 'malonamoyl-CoA', 2495, 'Vitamin B12'), ('PR_000017279', 'testis-specific basic protein Y 1', 2495, 'Vitamin B12'), ('CHEBI_81245', 'Vulpecholate', 2555, 'Folate'), ('CHEBI_15956', 'biotin', 2679, 'Biotin'), ('CHEBI_28384', 'vitamin K', 2806, 'Vitamin K'), ('PR_000017453', 'protein Wnt-9b', 3120, 'WRAP'), ('UBERON_0001977', 'blood serum', 3136, 'Serum'), ('CHEBI_33839', 'macromolecule', 3162, 'micronutrients'), ('GO_0007565', 'female pregnancy', 3195, 'pregnancy'), ('GO_0007565', 'female pregnancy', 3211, 'pregnancy'), ('GO_0007565', 'female pregnancy', 3236, 'pregnancy'), ('CHEBI_27778', 'abequose', 3382, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 3382, 'B12'), ('PR_000004370', 'asialoglycoprotein receptor 2', 3525, 'A'), ('CHEBI_30799', 'dioxosuccinic acid', 3734, 'Chol5'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 4208, '25OHD')]	0	['late  iron, zinc selenium groups.nutrients-07-05403-t002_table 2\n\ncaption (table-wrap): table 2\n\nreported daily nutrient intakes lean obese women late .nutrientearly pregnancylate pregnancylean n = 93obese n = 148lean n = 87obese n = 146medianc25–c75medianc25–c75ppadjmedianc25–c75medianc25–c75ppadjenergy (kcal)2349(1995–2846)2435(1975–3040)*2354(1957–2876)2173(1747–2672)*protein (g)94.1(75–114)98.6(73–125)*90.5(76–117)87.7(69–113)*fat (g)91.6(75–118)95.6(73–122)*91.8(73–124)87.9(65–108)carbohydrate (g)302.1(252–355)309.8(249–387)*304.1(258–361)278.8(227–346)*sfa (g)34.6(28–28)38.5(28–51)*36.2(29–50)35.1(25–44)mufa (g)32.1(26–42)33.2(25–43)*31.9(25–42)30.1(22–37)*pufa (mg)15.9(13–20)16(12–22)**15.2(13–20)14.1(11–19)*cholesterol (g)277(191–353)290.5(202–390)255(189–365)271.5(197–376)sugars (g)134.9(109–176)150.3(113–195)*142(110–179)132.7(99–174)**starch (g)150(130–196)156(121–191)*158(121–183)136(107–175)*fibre (g)22.8(20–29)20.6(16–26)***23.3(18–27)19(14–24)***sodium (mg)3200(2375–3969)3389(2551–4065)*3239(2638–3896)2926(2298–3595)potassium (mg)3876(3262–4679)39533036–5017)*3813(3265–4769)34762845–4648*calcium (mg)1233(1006–1496)1195.5(945–1603)**1268(1015–1579)1077(837–1415)*magnesium (mg)426(375–519)399.5(327–487)***417(355–527)359(289–452)***phosphorus (mg)1791(1483–2106)1779.5(1423–2311)*1753(1476–2215)1652(1276–2097)**iron (mg)16.5(14–20)14.5(11–19)***16.1(13–20)13(10–17)***copper (mg)3.2(2–4)2.9(2–4)*3.1(2.7–4)2.6(2.1–3.4)**zinc (mg)12.1(9–15)12.1(9–15)**11.8(9–15)10.9(8–14)*chloride (mg)4786(3899–6097)4998(3873–6273)*4871(3992–5900)4428.5(3552–5523)manganese (mg)4.6(4–6)3.6(3–5)***4.5(3–6)3.2(2.6–4.3)***selenium (µg)64(51–80)61(44–84)***63(51–80)58(41–77)**iodine (µg)233(186–307)246.5(173–313)249(189–331)221.5(157–290)**retinol (µg)320(228–436)319(220–466)316(221–504)290.5(200–423)β–carotene (µg)4362(3081–6848)4109(2361–6127)*4082(2594–6533)3340(2245–5023)vitamin (µg)3.8(2.8–5.7)3.1(2–4.6)*4(2.7–5.7)2.8(1.9–4.4)*vitamin e (mg)12(9.8–15)11.4(8.3–13.4)**12(9–15.6)10.2(7–13)***thiamine (mg)2(1.7–2.3)2(1.6–2.5)*2(1.6–2.4)1.8(1.5–2.3)*riboflavin (mg)2.1(1.8–2.7)2.2(1.5–2.8)***2.2(1.8–2.9)1.9(1.4–2.6)***niacin (mg)23.2(19–28)24.5(18–31)**22.5(18–28)22.6(16–29)*potential niacin (mg)20.9(16–25)20.5(15–27)*19.4(16–26)18.4(14–24)**vitamin b6 (mg)2.5(2–3)2.7(2–3.3)*2.5(2.1–3.2)2.5(1.8–3.1)*vitamin b12 (mg)6.2(4.6–8.8)6.2(4.2–8.6)6(4.9–9)5.7(3.9–7.7)folate (µg)350(282–439)310.5(225–387)***362(268–436)276(202–353)***pa (mg)6.2(5.1–7.7)6.5(4.8–8.1)*6.2(5.1–7.9)5.7(4.5–7.7)*biotin (µg)45.4(37–56)41.8(31–52)***44.1(37–59)37.2(27–50)****vitamin c (mg)160(120–204)160(110–227)**151(111–102)147(86–199)**vitamin k (mg)69.9(43–137)34(22–68)**57.3(39–132)32.6(17–67)**\nc25: 25th percentile, c75: 75th percentile; p : ln-transformed intakes; padj: ln-transformed intakes adjusted energy intake, age, parity, ethnicity & depcat; * p< 0.05; ** p< 0.001.nutrients-07-05403-t003_table 3\n\ncaption (table-wrap): table 3\n\nserum levels micronutrients late .early  (16 weeks)late  (28 weeks)obese n = 25lean n = 25 p *obese n = 25lean n = 25 p *iron (μmol/l)15.7 (4.7)23.4 (5.9)<0.000112.5 (5.3)14.7 (7.1)0.24vitamin b12 (ng/l)239.6 (87.7)389.1 (138.4)<0.0001202.1 (56.2)262.4 (96.4)0.02folate (μg/l)7.9 (4.2)15.0 (2.7)<0.00013.9 (2.8)10.6 (5.7)<0.0001vitamin (μmol/l)1.2 (0.26)1.36 (0.28)0.0461.0 (0.24)1.1 (0.31)0.38vitamin e (μmol/l)29.6 (6.74)28.9 (5.78)0.69231.9 (8.46)38.1 (7.21)0.009cholesterol (mmol/l)5.67 (0.82)5.00 (0.85)0.0075.8 (0.79)6.6 (0.94)0.011vite/chol5.26 (1.04)5.82 (0.91)0.0545.5 (1.06)5.9 (0.86)0.135copper (μmol/l)32.9 (4.5)26.1 (4.9)<0.000134.4 (4.1)28.2 (3.9)<0.0001copper+(μmol/l)33.1 (4.4)33.1 (5.3)<0.000134.5 (4.3)28.0 (3.7)<0.0001zinc (umol/l)9.7 (1.17)10.7 (1.30)0.0089.1 (0.92)9.3 (0.94)0.413zinc/albumin0.32 (0.04)0.31 (0.03)0.1720.32 (0.02)0.32 (0.03)0.958selenium (μmol/l)0.85 (0.13)1.02 (0.16)<0.00010.79 (0.11)0.89 (0.14)0.009selenium+(μmol/l)0.89 (0.14)1.00 (0.16)0.0500.85 (0.11)0.87 (0.14)0.437total 25ohd (nmol/l)++51.1 (16.89)68.1 (29.91)0.07045.5 (32.54)68.7 (27.34)0.093crp (mg/l)12.0 (8.48)3.7 (3.35)<0.000113.4 (8.1)4.7 (5.6)0.001albumin (g/l)30.1 (1.98)34.5 (2.97)<0.000128.1 (1.2)29.3 (2.0)0.034\ndata (sd).']
S100-PMC4632423	PMC4632423	10/2015	S100-PMC4632423	['both Folate and Vitamin D deficiencies HAVE BEEN ASSOCIATED with INCREASED RISKS of pre-eclampsia, Preterm Delivery, low Birth weight and fetal growth restriction [26,27].']	[('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 49), ('IMPORTANT_CONSIDERATION', 65)]	3	[('CHEBI_30863', '5-azaorotic acid', 5, 'folate'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 99, 'preterm'), ('GO_0007567', 'parturition', 107, 'delivery'), ('GO_0007567', 'parturition', 121, 'birth')]	0	['folate  pre-eclampsia,  delivery, birth fetal [26,27].']
S106-PMC4632423	PMC4632423	10/2015	S106-PMC4632423	['increased adiposity itself is ASSOCIATED with lower Serum levels of some fat-soluble Nutrients, such as Vitamin D, and this PREDICTS poor status of this Nutrient during Pregnancy [27].']	[('SUPERFICIAL_RELATIONSHIP', 30), ('SUPERFICIAL_RELATIONSHIP', 124)]	2	[('UBERON_0001977', 'blood serum', 52, 'serum'), ('CHEBI_33284', 'nutrient', 85, 'nutrients'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('CHEBI_33284', 'nutrient', 153, 'nutrient'), ('GO_0007565', 'female pregnancy', 169, 'pregnancy')]	0	['increased adiposity serum levels fat-soluble nutrients, status nutrient  [27].']
S18-PMC4645901	PMC4645901	8/2014	S18-PMC4645901	['[1] currently, the department of health RECOMMENDS 10 micrograms (400 units) of Vitamin D daily for Pregnant and breastfeeding mothers, and 8.5 micrograms (340 units) daily for breastfed babies under the age of 6 months.']	[('FUTURE_WORK', 40)]	1	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnant')]	0	['[1] currently, department 10 micrograms (400 units)  daily  breastfeeding mothers, 8.5 micrograms (340 units) daily breastfed babies age 6 months.']
S36-PMC4645901	PMC4645901	8/2014	S36-PMC4645901	['[4]\nthose AT RISK of Vitamin D deficiency include: Pregnant mothers, babies who are exclusively Breastfed, those who have darker skin, those who cover up most of their body when outside, and patients with certain medical conditions AFFECTING Gut absorption or who suffer from long term Liver and Kidney disease.']	[('IMPORTANT_CONSIDERATION', 10), ('SUPERFICIAL_RELATIONSHIP', 232)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnant'), ('GO_0007567', 'parturition', 96, 'breastfed'), ('UBERON_0001555', 'digestive tract', 242, 'gut'), ('UBERON_0002107', 'liver', 286, 'liver'), ('UBERON_0002113', 'kidney', 296, 'kidney')]	0	['[4]\nthose  include:  mothers, babies exclusively breastfed, darker skin, cover outside, patients medical conditions gut absorption term liver kidney disease.']
S73-PMC4645901	PMC4645901	8/2014	S73-PMC4645901	['this MAY BE due to the increased AWARENESS of Vitamin D deficiency by the general public, and THEREFORE an increased uptake of Vitamin supplements during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 5), ('IMPORTANT_CONSIDERATION', 33), ('PROBABLE_UNDERSTANDING', 94)]	3	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 127, 'vitamin'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy')]	0	[' public, uptake vitamin supplements .']
S83-PMC4645901	PMC4645901	8/2014	S83-PMC4645901	['a relatively SMALL data set MEANT it was NOT POSSIBLE to draw convincing CONCLUSIONS between dose of vitamin supplementation during Pregnancy and Vitamin D levels in babies.']	[('INCOMPLETE_EVIDENCE', 13), ('PROBABLE_UNDERSTANDING', 28), ('DIFFICULT_TASK', 41), ('PROBABLE_UNDERSTANDING', 73)]	4	[('GO_0007565', 'female pregnancy', 132, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D')]	0	['set draw dose vitamin supplementation   levels babies.']
S175-PMC4663595	PMC4663595	11/2015	S175-PMC4663595	['our group also REPORTED that Dha supplementation with 400 mg/day during Pregnancy induced Dna Methylation changes in inflammatory Genes and Line-1 , especially in infants born to mothers who smoked during Pregnancy [99].nutrients-07-05467-t002_table 2\n\ncaption (table-wrap): table 2\n\nintervention studies for maternal nutritional status and epigenetic profile in offspring.Nutrientsmechanismoutcomesamplemethodref.Folate and Multivitamins(1)Dna Methylation↓ methylation of Igf2 2r in girls, ↓ methylation of Gtl2-2 in boyscord Blood27K illumina[93]folatedna methylation↓ methylation of Line1 Cord Bloodpyrosequencing[94]Dna Methylation↑ methylation of Igf2 dmrcord Bloodepi-typer[95]Dna Methylation↓ methylation of h19 dmr (4 cpgs)Cord Bloodpyrosequencing[96]Dna Methylation↓ methylation of peg3 and Line1 ; ↑ methylation of Igf2 Cord Bloodpyrosequencing[97]cholinedna methylationhistone modification↑ methylation of crh , Nr3C1 in Placenta; ↓ methylation of crh , Nr3C1 in Cord Blood Leukocyte; ↑ H3K9Me2Placenta, Cord Bloodlc-ms/ms[98]Dhadna Methylation↑ Line1 methylation ↑ Infγ/Il13 methylation ratiocord Bloodpyrosequencing[99]\n(1)Zinc and Vitamins A, b, c and d; Peg3, Paternally-Expressed Gene 3; Crh, Corticotropin-Releasing Hormone; Nr3C1, Nuclear receptor subfamily 3, Group C, Member 1.']	[('INCOMPLETE_EVIDENCE', 15)]	1	[('CHEBI_17874', 'dihydrozeatin', 29, 'DHA'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0006306', 'DNA methylation', 90, 'DNA methylation'), ('SO_0000704', 'gene', 130, 'genes'), ('PR_000009877', 'loss of heterozygosity 11 chromosomal region 2 gene A protein', 140, 'LINE-1'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy'), ('CHEBI_8329', 'Pomiferin', 373, 'NutrientsMechanismOutcomeSampleMethodRef'), ('CHEBI_81245', 'Vulpecholate', 414, 'Folate'), ('CHEBI_7036', 'Musennin', 425, 'Multivitamins'), ('GO_0006323', 'DNA packaging', 441, 'DNA methylation↓'), ('PR_000008989', 'interleukin-1 family member 7', 473, 'IGF2'), ('PR_000008305', 'glutathione S-transferase theta-1', 508, 'GTL2'), ('UBERON_0001977', 'blood serum', 527, 'blood27k'), ('PR_000009877', 'loss of heterozygosity 11 chromosomal region 2 gene A protein', 586, 'LINE1'), ('UBERON_0000948', 'heart', 592, 'Cord'), ('UBERON_0011919', 'yolk sac blood island', 597, 'bloodPyrosequencing'), ('GO_0006306', 'DNA methylation', 620, 'DNA methylation'), ('PR_000008989', 'interleukin-1 family member 7', 652, 'IGF2'), ('UBERON_0001970', 'bile', 665, 'bloodEpi'), ('GO_0006323', 'DNA packaging', 683, 'DNA methylation↓'), ('UBERON_0000948', 'heart', 731, 'Cord'), ('UBERON_0011919', 'yolk sac blood island', 736, 'bloodPyrosequencing'), ('GO_0006323', 'DNA packaging', 759, 'DNA methylation↓'), ('PR_000009877', 'loss of heterozygosity 11 chromosomal region 2 gene A protein', 800, 'LINE1'), ('PR_000008989', 'interleukin-1 family member 7', 825, 'IGF2'), ('UBERON_0000948', 'heart', 830, 'Cord'), ('UBERON_0011919', 'yolk sac blood island', 835, 'bloodPyrosequencing'), ('PR_000011403', 'photoreceptor-specific nuclear receptor', 923, 'NR3C1'), ('UBERON_0001987', 'placenta', 932, 'placenta'), ('PR_000011403', 'photoreceptor-specific nuclear receptor', 965, 'NR3C1'), ('CL_0000107', 'autonomic neuron', 974, 'cord blood'), ('UBERON_0002240', 'spinal cord', 974, 'cord'), ('UBERON_0000178', 'blood', 979, 'blood'), ('CL_0000738', 'leukocyte', 985, 'leukocyte'), ('SO_0001736', 'H3K9_methylation_site', 998, 'H3K9me2Placenta'), ('UBERON_0002240', 'spinal cord', 1015, 'cord'), ('UBERON_0000178', 'blood', 1020, 'bloodLC'), ('GO_0010424', 'DNA methylation on cytosine within a CG sequence', 1037, 'DHADNA methylation'), ('PR_000009877', 'loss of heterozygosity 11 chromosomal region 2 gene A protein', 1057, 'LINE1'), ('PR_000009020', 'Golgi-resident adenosine 3*,5*-bisphosphate 3*-phosphatase', 1077, 'INFγ'), ('PR_000001470', 'interleukin-28B', 1082, 'IL13'), ('UBERON_0011919', 'yolk sac blood island', 1109, 'bloodPyrosequencing'), ('CHEBI_27377', 'Unsym-bis(4*-chlorophenyl)ethylene', 1136, 'Zinc'), ('CHEBI_27300', 'vitamin D', 1145, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 1154, 'A'), ('PR_000012529', 'PDZK1-interacting protein 1', 1169, 'PEG3'), ('PR_000012270', 'pappalysin-1', 1175, 'paternally-expressed gene 3'), ('GO_0010467', 'gene expression', 1186, 'expressed'), ('SO_0000704', 'gene', 1196, 'gene'), ('PR_000005864', 'protein CREG2', 1204, 'CRH'), ('CHEBI_3918', 'crocetin', 1209, 'corticotropin'), ('PR_000005968', 'cystatin-M', 1209, 'corticotropin-releasing hormone'), ('CHEBI_33280', 'molecular messenger', 1233, 'hormone'), ('PR_000011403', 'photoreceptor-specific nuclear receptor', 1242, 'NR3C1'), ('GO_0005634', 'nucleus', 1249, 'nuclear'), ('PR_000008294', 'glutathione S-transferase A1', 1279, 'group C, member 1')]	0	['dha supplementation 400 mg/day  induced dna methylation changes inflammatory genes line-1 infants born mothers smoked  [99].nutrients-07-05467-t002_table 2\n\ncaption (table-wrap): table 2\n\nintervention maternal nutritional status epigenetic profile offspring.nutrientsmechanismoutcomesamplemethodref.folate multivitamins(1)dna methylation↓ methylation igf2 2r girls, methylation gtl2-2 boyscord blood27k illumina[93]folatedna methylation↓ methylation line1 cord bloodpyrosequencing[94]dna methylation↑ methylation igf2 dmrcord bloodepi-typer[95]dna methylation↓ methylation h19 dmr (4 cpgs)cord bloodpyrosequencing[96]dna methylation↓ methylation peg3 line1 ↑ methylation igf2 cord bloodpyrosequencing[97]cholinedna methylationhistone modification↑ methylation crh nr3c1 placenta; methylation crh nr3c1 cord blood leukocyte; ↑ h3k9me2placenta, cord bloodlc-ms/ms[98]dhadna methylation↑ line1 methylation ↑ infγ/il13 methylation ratiocord bloodpyrosequencing[99]\n(1)zinc b, c d; peg3, paternally-expressed gene 3; crh, corticotropin-releasing hormone; nr3c1, nuclear receptor subfamily 3, c, member 1.']
S1-PMC4673623	PMC4673623	11/2015	S1-PMC4673623	['Folate, Choline, betaine and Vitamin B-12) during Pregnancy is ESSENTIAL for normal maternal and fetal Methionine Metabolism, and is CRITICAL for IMPORTANT Metabolic processes including those INVOLVED in developmental programming.']	[('IMPORTANT_CONSIDERATION', 63), ('IMPORTANT_CONSIDERATION', 133), ('IMPORTANT_CONSIDERATION', 146), ('SUPERFICIAL_RELATIONSHIP', 192)]	4	[('CHEBI_30863', '5-azaorotic acid', 0, 'folate'), ('CHEBI_15354', 'choline', 8, 'choline'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 29, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('GO_0006555', 'methionine metabolic process', 103, 'methionine metabolism'), ('GO_0008152', 'metabolic process', 156, 'metabolic')]	0	['folate, choline, betaine -12)  normal maternal fetal methionine metabolism, metabolic processes developmental programming.']
S2-PMC4684854	PMC4684854	12/2015	S2-PMC4684854	['THIS PAPER provides a brief review of POTENTIAL health outcomes RECENTLY LINKED to Gestational Vitamin D deficiency, including Preterm Birth, cesarean Delivery, and Gestational diabetes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 38), ('INCOMPLETE_EVIDENCE', 64), ('SUPERFICIAL_RELATIONSHIP', 73)]	4	[('GO_0007565', 'female pregnancy', 83, 'gestational'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'preterm birth'), ('GO_0007567', 'parturition', 151, 'delivery'), ('GO_0007565', 'female pregnancy', 165, 'gestational')]	0	['outcomes   deficiency, cesarean delivery,  diabetes.']
S3-PMC4684854	PMC4684854	12/2015	S3-PMC4684854	['ALTHOUGH immediate costs for obstetric COMPLICATIONS RELATED to Gestational Vitamin D insufficiency MAY BE modest, the short- and long-term costs for pediatric healthcare resulting from such Gestational COMPLICATIONS MAY BE enormous and present an enduring BURDEN on Healthcare systems.']	[('ANOMALY_CURIOUS_FINDING', 0), ('PROBLEM_COMPLICATION', 39), ('SUPERFICIAL_RELATIONSHIP', 53), ('INCOMPLETE_EVIDENCE', 100), ('IMPORTANT_CONSIDERATION', 203), ('INCOMPLETE_EVIDENCE', 217), ('IMPORTANT_CONSIDERATION', 257)]	7	[('GO_0007565', 'female pregnancy', 64, 'gestational'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 191, 'gestational'), ('UBERON_0004151', 'cardiac chamber', 267, 'healthcare')]	0	['although costs obstetric   modest, short- long-term costs pediatric healthcare resulting  enduring healthcare systems.']
S4-PMC4684854	PMC4684854	12/2015	S4-PMC4684854	['with INCREASING EVIDENCE POINTING TO fetal origins of SOME later Life disease, securing Vitamin D sufficiency in Pregnancy APPEARS TO BE a simple, SAFE, and cost-EFFECTIVE measure that CAN be incorporated into routine Preconception and Prenatal Care in the offices of primary care clinicians.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 54), ('ANOMALY_CURIOUS_FINDING', 123), ('IMPORTANT_CONSIDERATION', 147), ('SUPERFICIAL_RELATIONSHIP', 162), ('INCOMPLETE_EVIDENCE', 185)]	7	[('UBERON_0000104', 'life cycle', 65, 'life'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('GO_0007565', 'female pregnancy', 218, 'preconception'), ('GO_0008283', 'cell proliferation', 236, 'prenatal care')]	0	['fetal origins life disease,   simple, safe, cost-effective measure incorporated routine  prenatal offices clinicians.']
S38-PMC4684854	PMC4684854	12/2015	S38-PMC4684854	['with the EMERGING EVIDENCE that Vitamin D acts epigenetically in the Regulation of over 2700 different Genes [36], there HAS BEEN much RECENT RESEARCH exploring the widespread prevalence of Vitamin D deficiency through the continuum of Life, including the Gestational and Neonatal Period.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 69), ('INCOMPLETE_EVIDENCE', 121), ('INCOMPLETE_EVIDENCE', 135)]	4	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0065007', 'biological regulation', 69, 'regulation'), ('SO_0000704', 'gene', 103, 'genes'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('UBERON_0000104', 'life cycle', 236, 'life'), ('GO_0007565', 'female pregnancy', 256, 'gestational'), ('UBERON_0007221', 'neonate stage', 272, 'neonatal period')]	0	[' epigenetically 2700 genes [36],  continuum life,  neonatal period.']
S39-PMC4684854	PMC4684854	12/2015	S39-PMC4684854	['THIS PAPER is DESIGNED to review the literature FINDINGS about the enduring IMPACT of Gestational Vitamin D sufficiency on Maternal and pediatric health and Well-Being.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 76)]	4	[('GO_0007565', 'female pregnancy', 86, 'gestational'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007618', 'mating', 123, 'maternal'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 157, 'well-being')]	0	['enduring   maternal pediatric well-being.']
S43-PMC4684854	PMC4684854	12/2015	S43-PMC4684854	['a primary OBSERVATION, HOWEVER, was that LIMITED scientific LITERATURE is available on the issue of Gestational Vitamin D insufficiency as it RELATES to long-term health outcomes.']	[('ANOMALY_CURIOUS_FINDING', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 23), ('INCOMPLETE_EVIDENCE', 41), ('SUPERFICIAL_RELATIONSHIP', 142)]	4	[('GO_0007565', 'female pregnancy', 100, 'gestational'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]	0	['observation, however,   long-term outcomes.']
S51-PMC4684854	PMC4684854	12/2015	S51-PMC4684854	['with such widespread deficiency, it is VITAL to determine WHETHER OR NOT low Gestational levels of Vitamin D are a SIGNIFICANT DETERMINANT of Reproductive and pediatric health outcomes.']	[('IMPORTANT_CONSIDERATION', 39), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 58), ('IMPORTANT_CONSIDERATION', 115), ('SUPERFICIAL_RELATIONSHIP', 127)]	4	[('GO_0007565', 'female pregnancy', 77, 'gestational'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0000003', 'reproduction', 142, 'reproductive')]	0	['deficiency,  levels  reproductive pediatric outcomes.']
S57-PMC4684854	PMC4684854	12/2015	S57-PMC4684854	['LIMITATIONS of Vitamin D research as RELATED to Gestational outcomes\nALTHOUGH maternal-fetal outcomes in the presence of adequate Gestational Vitamin D are GENERALLY favorable as REPORTED in the medical literature, SOME reports HAVE BEEN INCONSISTENT and CAST DOUBT on the LINK between Gestational Vitamin D sufficiency and health.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 37), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 69), ('ANOMALY_CURIOUS_FINDING', 69), ('PROBABLE_UNDERSTANDING', 156), ('INCOMPLETE_EVIDENCE', 179), ('INCOMPLETE_EVIDENCE', 215), ('INCOMPLETE_EVIDENCE', 228), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 238), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 255), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 260), ('INCOMPLETE_EVIDENCE', 260), ('SUPERFICIAL_RELATIONSHIP', 273)]	13	[('CHEBI_28384', 'vitamin K', 15, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'Gestational'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('GO_0007565', 'female pregnancy', 286, 'gestational'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D')]	0	['limitations vitamin  outcomes\nalthough maternal-fetal outcomes presence   medical literature,   health.']
S58-PMC4684854	PMC4684854	12/2015	S58-PMC4684854	['specifically, supplementation of Vitamin D in Pregnancy in SOME studies APPEARS TO SUGGEST marked BENEFIT WHILE research in OTHER publications does NOT APPEAR TO confer significant improvement in maternal-fetal outcomes [44].']	[('INCOMPLETE_EVIDENCE', 59), ('ANOMALY_CURIOUS_FINDING', 72), ('INCOMPLETE_EVIDENCE', 83), ('IMPORTANT_CONSIDERATION', 98), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 106), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('ANOMALY_CURIOUS_FINDING', 148), ('ANOMALY_CURIOUS_FINDING', 152)]	8	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'pregnancy')]	0	['specifically, supplementation   marked publications maternal-fetal outcomes [44].']
S60-PMC4684854	PMC4684854	12/2015	S60-PMC4684854	['FOUND that Gestational Vitamin D supplementation was ASSOCIATED with increased Birth weight and Birth length BUT, UNLIKE SOME OTHER RESEARCH, was not associated with other beneficial maternal and neonatal outcomes such as reductions in preeclampsia, Gestational diabetes, small for Gestational age infants, Preterm Birth, or rates of cesarean Delivery [44].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 109), ('ANOMALY_CURIOUS_FINDING', 109), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114), ('INCOMPLETE_EVIDENCE', 121), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 126)]	7	[('GO_0007565', 'female pregnancy', 11, 'gestational'), ('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007567', 'parturition', 79, 'birth'), ('GO_0007567', 'parturition', 96, 'birth'), ('GO_0007565', 'female pregnancy', 250, 'gestational'), ('GO_0007565', 'female pregnancy', 282, 'gestational'), ('GO_0007565', 'female pregnancy', 307, 'preterm birth'), ('GO_0007567', 'parturition', 343, 'delivery')]	0	['found   supplementation birth birth length but, research, maternal neonatal outcomes reductions preeclampsia,  diabetes,  age infants, rates cesarean delivery [44].']
S61-PMC4684854	PMC4684854	12/2015	S61-PMC4684854	['the APPARENT DISPARITY between findings in VARIOUS STUDIES has caused SOME to reflexively CONCLUDE that Vitamin D status in Pregnancy is IRRELEVANT to maternal-fetal outcomes.']	[('ANOMALY_CURIOUS_FINDING', 4), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 13), ('ANOMALY_CURIOUS_FINDING', 13), ('IMPORTANT_CONSIDERATION', 13), ('INCOMPLETE_EVIDENCE', 43), ('INCOMPLETE_EVIDENCE', 70), ('PROBABLE_UNDERSTANDING', 90), ('IMPORTANT_CONSIDERATION', 137)]	8	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy')]	0	['reflexively  status  maternal-fetal outcomes.']
S66-PMC4684854	PMC4684854	12/2015	S66-PMC4684854	['many of the RECENT publications CHALLENGING the efficacy of Gestational Vitamin D sufficiency HAVE BEEN meta-analyses which ATTEMPT to synthesize diverse data from numerous observational and supplementation studies which do NOT NECESSARILY incorporate individual differences in these central DETERMINANTS.']	[('INCOMPLETE_EVIDENCE', 12), ('DIFFICULT_TASK', 32), ('INCOMPLETE_EVIDENCE', 94), ('DIFFICULT_TASK', 124), ('INCOMPLETE_EVIDENCE', 224), ('SUPERFICIAL_RELATIONSHIP', 292)]	6	[('GO_0007565', 'female pregnancy', 60, 'gestational'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]	0	['many publications   meta-analyses synthesize supplementation incorporate individual central determinants.']
S70-PMC4684854	PMC4684854	12/2015	S70-PMC4684854	['(ii) commencement of supplementation at differing times during the Gestation MAY miss CRITICAL periods when Vitamin D MAY play a PIVOTAL ROLE.']	[('INCOMPLETE_EVIDENCE', 77), ('IMPORTANT_CONSIDERATION', 86), ('INCOMPLETE_EVIDENCE', 118), ('IMPORTANT_CONSIDERATION', 129), ('SUPERFICIAL_RELATIONSHIP', 137)]	5	[('GO_0007565', 'female pregnancy', 67, 'gestation'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]	0	['(ii) commencement supplementation times  periods  play role.']
S74-PMC4684854	PMC4684854	12/2015	S74-PMC4684854	['accordingly, a CRITICAL appraisal of such meta-analyses is in order to achieve an accurate perspective on the efficacy of Gestational Vitamin D supplementation.']	[('IMPORTANT_CONSIDERATION', 15)]	1	[('GO_0007565', 'female pregnancy', 122, 'gestational'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]	0	['accordingly, appraisal meta-analyses achieve   supplementation.']
S76-PMC4684854	PMC4684854	12/2015	S76-PMC4684854	['Gestational Vitamin D status and obstetrical outcomes\nthe list of adverse Gestational outcomes in Pregnancy ASSOCIATED with Vitamin D insufficiency continues to mount.']	[('SUPERFICIAL_RELATIONSHIP', 108)]	1	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_28384', 'vitamin K', 12, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'gestational'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]	0	[' vitamin status obstetrical outcomes\nthe list  outcomes   mount.']
S77-PMC4684854	PMC4684854	12/2015	S77-PMC4684854	['early in Pregnancy, for example, an increased risk of First Trimester Miscarriage HAS BEEN LINKED to INADEQUATE maternal Vitamin D levels [49].']	[('INCOMPLETE_EVIDENCE', 82), ('SUPERFICIAL_RELATIONSHIP', 91), ('IMPORTANT_CONSIDERATION', 101)]	3	[('GO_0007565', 'female pregnancy', 9, 'pregnancy'), ('GO_0042733', 'embryonic digit morphogenesis', 54, 'first trimester'), ('GO_0046660', 'female sex differentiation', 70, 'miscarriage'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]	0	['early example, trimester miscarriage maternal  levels [49].']
S81-PMC4684854	PMC4684854	12/2015	S81-PMC4684854	['a NUMBER OF papers have CONFIRMED an INCREASED RISK of developing Gestational diabetes in those with INADEQUATE Vitamin D levels [52,53].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 24), ('IMPORTANT_CONSIDERATION', 37), ('IMPORTANT_CONSIDERATION', 101)]	4	[('GO_0007565', 'female pregnancy', 66, 'gestational'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]	0	[' diabetes  levels [52,53].']
S84-PMC4684854	PMC4684854	12/2015	S84-PMC4684854	['obesity presents a CONFOUNDING INFLUENCE in THIS discussion, however, AS a greater bmi is ASSOCIATED with lower Vitamin D levels as well as greater Insulin resistance and risk for Gestational diabetes.']	[('PROBLEM_COMPLICATION', 19), ('SUPERFICIAL_RELATIONSHIP', 31), ('QUESTION_ANSWERED_BY_THIS_WORK', 44), ('PROBABLE_UNDERSTANDING', 70), ('SUPERFICIAL_RELATIONSHIP', 90)]	5	[('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('PR_000045358', 'insulin family protein', 148, 'insulin'), ('GO_0007565', 'female pregnancy', 180, 'gestational')]	0	['obesity presents discussion, however, bmi  levels insulin resistance  diabetes.']
S87-PMC4684854	PMC4684854	12/2015	S87-PMC4684854	['escalating EVIDENCE in the literature CONFIRMS a PROTECTIVE ASSOCIATION between maternal Vitamin D sufficiency and the incidence of Preterm Birth [58–60].']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 49), ('SUPERFICIAL_RELATIONSHIP', 60)]	4	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 132, 'preterm birth')]	0	['escalating maternal   [58–60].']
S90-PMC4684854	PMC4684854	12/2015	S90-PMC4684854	['ANOTHER STUDY FOUND that infants Born before 32 weeks of Gestation were 2.4 times more LIKELY to have Vitamin D levels below 50\u2009nmol/l when compared with those Born after 32 weeks of Gestation [61].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 14), ('PROBABLE_UNDERSTANDING', 87)]	3	[('GO_0007567', 'parturition', 33, 'born'), ('GO_0007565', 'female pregnancy', 57, 'gestation'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007567', 'parturition', 160, 'born'), ('GO_0007565', 'female pregnancy', 183, 'gestation')]	0	['another infants born 32 weeks  2.4 times  levels 50\u2009nmol/l born 32 weeks  [61].']
S91-PMC4684854	PMC4684854	12/2015	S91-PMC4684854	['other Gestational ISSUES also APPEAR TO BE INFLUENCED by maternal Vitamin D levels.']	[('IMPORTANT_CONSIDERATION', 18), ('ANOMALY_CURIOUS_FINDING', 30), ('SUPERFICIAL_RELATIONSHIP', 43)]	3	[('GO_0007565', 'female pregnancy', 6, 'gestational'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]	0	[' maternal  levels.']
S94-PMC4684854	PMC4684854	12/2015	S94-PMC4684854	['a systematic review and meta-analysis of 24 studies SUGGESTED that low maternal Vitamin D levels in Pregnancy MAY BE ASSOCIATED with an INCREASED RISK of small for Gestational age infants, as well as being LINKED to preeclampsia, Gestational diabetes, and Preterm Birth [66].']	[('INCOMPLETE_EVIDENCE', 52), ('INCOMPLETE_EVIDENCE', 110), ('SUPERFICIAL_RELATIONSHIP', 117), ('IMPORTANT_CONSIDERATION', 136), ('SUPERFICIAL_RELATIONSHIP', 206)]	5	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('GO_0007565', 'female pregnancy', 164, 'gestational'), ('GO_0007565', 'female pregnancy', 230, 'gestational'), ('GO_0007565', 'female pregnancy', 256, 'preterm birth')]	0	['meta-analysis 24 maternal  levels   age infants, preeclampsia,  diabetes,  [66].']
S95-PMC4684854	PMC4684854	12/2015	S95-PMC4684854	['another systematic review and meta-analysis published in the british medical journal also LINKED Vitamin D insufficiency with an INCREASED RISK of Gestational diabetes, Preeclampsia, and small for Gestational age infants [65].']	[('SUPERFICIAL_RELATIONSHIP', 90), ('IMPORTANT_CONSIDERATION', 129)]	2	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'gestational'), ('GO_0007128', 'meiotic prophase I', 169, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 197, 'gestational')]	0	['another meta-analysis british medical journal   diabetes, preeclampsia,  age infants [65].']
S101-PMC4684854	PMC4684854	12/2015	S101-PMC4684854	['Gestational Vitamin D status also APPEARS to INFLUENCE outcomes beyond the Pregnancy and Delivery.']	[('ANOMALY_CURIOUS_FINDING', 34), ('SUPERFICIAL_RELATIONSHIP', 45)]	2	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('GO_0007567', 'parturition', 89, 'delivery')]	0	['  status outcomes  delivery.']
S108-PMC4684854	PMC4684854	12/2015	S108-PMC4684854	['for example, PRELIMINARY EVIDENCE SUGGESTS that insufficient levels of Prenatal Vitamin D MAY BE a factor in the development of autism [74] and lower Respiratory infections [75].']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 34), ('INCOMPLETE_EVIDENCE', 90)]	3	[('GO_0007565', 'female pregnancy', 71, 'prenatal'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 150, 'respiratory')]	0	['example, levels   autism [74] respiratory infections [75].']
S109-PMC4684854	PMC4684854	12/2015	S109-PMC4684854	['a spanish study to this end FOUND that mothers who had Gestational Vitamin D levels above 75\u2009nmol/l had offspring with a one-third lower rate of acute Respiratory Tract infections during the first year of Life [76].']	[('INCOMPLETE_EVIDENCE', 28)]	1	[('GO_0007565', 'female pregnancy', 55, 'gestational'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('UBERON_0000065', 'respiratory tract', 151, 'respiratory tract'), ('UBERON_0000104', 'life cycle', 205, 'life')]	0	['spanish mothers   levels 75\u2009nmol/l offspring one-third rate acute respiratory tract infections year life [76].']
S110-PMC4684854	PMC4684854	12/2015	S110-PMC4684854	['a RECENT body of work has begun TO SUGGEST that lower Gestational Vitamin D levels MAY also be ASSOCIATED with higher rates of pediatric atopic disease [77], food sensitivities [78], atopic dermatitis [79], eczema [80], asthma [81], impaired Lung function [82], allergic disease [83], and other conditions frequently characterized by a hypersensitive Immune state.']	[('INCOMPLETE_EVIDENCE', 2), ('QUESTION_ANSWERED_BY_THIS_WORK', 32), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 83), ('SUPERFICIAL_RELATIONSHIP', 95)]	5	[('GO_0007565', 'female pregnancy', 54, 'gestational'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('UBERON_0002048', 'lung', 242, 'lung'), ('UBERON_0002405', 'immune system', 351, 'immune')]	0	['  levels higher rates pediatric atopic disease [77], food sensitivities [78], atopic dermatitis [79], eczema [80], asthma [81], lung [82], allergic disease [83], conditions hypersensitive immune state.']
S112-PMC4684854	PMC4684854	12/2015	S112-PMC4684854	['AS hypersensitivity outcomes MAY also be seen in those children Born to mothers contaminated with assorted Xenobiotics in Pregnancy [84–89], HOWEVER, it is NOT KNOWN WHETHER the Immune Dysregulation and hypersensitivity MAY BE the consequence of a primary Gestational insufficiency of Vitamin D, OR WHETHER various chemical Toxicants MIGHT play a ROLE by impairing Vitamin D Uptake, Renal synthesis, and assimilation [25,90] WHILE at the same time inducing Immune compromise and hypersensitivity through OTHER mechanisms [91].']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 141), ('FULL_UNKNOWN', 156), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 166), ('INCOMPLETE_EVIDENCE', 220), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 296), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 299), ('INCOMPLETE_EVIDENCE', 334), ('SUPERFICIAL_RELATIONSHIP', 347), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 425), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 504)]	12	[('GO_0007567', 'parturition', 64, 'born'), ('CHEBI_35703', 'xenobiotic', 107, 'xenobiotics'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('GO_0001774', 'microglial cell activation', 178, 'immune dysregulation'), ('UBERON_0002405', 'immune system', 178, 'immune'), ('GO_0007565', 'female pregnancy', 256, 'gestational'), ('CHEBI_27300', 'vitamin D', 285, 'vitamin D'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 324, 'toxicants'), ('CHEBI_27300', 'vitamin D', 365, 'vitamin D'), ('GO_0071939', 'vitamin A import', 365, 'vitamin D uptake'), ('UBERON_0002113', 'kidney', 383, 'renal'), ('UBERON_0002405', 'immune system', 457, 'immune')]	0	['hypersensitivity outcomes children born mothers assorted xenobiotics  [84–89], however, immune dysregulation hypersensitivity  chemical toxicants play impairing  uptake, renal synthesis, assimilation [25,90] inducing immune hypersensitivity mechanisms [91].']
S113-PMC4684854	PMC4684854	12/2015	S113-PMC4684854	['maternal Vitamin D status during Gestation also APPEARS TO have INFLUENCE on many OTHER health indices in the future of the offspring.']	[('ANOMALY_CURIOUS_FINDING', 48), ('SUPERFICIAL_RELATIONSHIP', 64), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 82)]	3	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'gestation')]	0	['maternal  status  indices offspring.']
S114-PMC4684854	PMC4684854	12/2015	S114-PMC4684854	['for example, Gestational Vitamin D status DIRECTLY CORRELATES with subsequent Whole-Body and Lumbar Spine bone Mineral content in progeny at 9 years of age [92].']	[('SUPERFICIAL_RELATIONSHIP', 42), ('SUPERFICIAL_RELATIONSHIP', 51)]	2	[('GO_0007565', 'female pregnancy', 13, 'gestational'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('UBERON_0000468', 'multicellular organism', 78, 'whole-body'), ('UBERON_0006074', 'lumbar region of vertebral column', 93, 'lumbar spine'), ('CHEBI_46662', 'mineral', 111, 'mineral')]	0	['example,   status whole-body lumbar spine bone mineral content progeny 9 age [92].']
S115-PMC4684854	PMC4684854	12/2015	S115-PMC4684854	['furthermore, an INTERESTING cohort study CORRELATING maternal Vitamin D deficiency at 18 weeks of Pregnancy and health outcomes of progeny FOUND that Gestational Vitamin D deficiency was ASSOCIATED with impaired Lung Development in 6-year-old offspring, Neurocognitive difficulties at age 10, increased risk of Eating disorders in Adolescence, and lower peak bone mass at 20 years [93].']	[('ANOMALY_CURIOUS_FINDING', 16), ('SUPERFICIAL_RELATIONSHIP', 41), ('INCOMPLETE_EVIDENCE', 139), ('SUPERFICIAL_RELATIONSHIP', 187)]	4	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('GO_0007565', 'female pregnancy', 150, 'gestational'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('GO_0030324', 'lung development', 212, 'lung development'), ('UBERON_0002048', 'lung', 212, 'lung'), ('GO_0050905', 'neuromuscular process', 254, 'neurocognitive'), ('GO_0051318', 'G1 phase', 311, 'eating'), ('GO_0048848', 'neurohypophysis morphogenesis', 331, 'adolescence')]	0	['furthermore, maternal  18 weeks  outcomes progeny   lung 6-year-old offspring, neurocognitive age 10, eating disorders adolescence, peak bone mass 20 [93].']
S117-PMC4684854	PMC4684854	12/2015	S117-PMC4684854	['finally, Gestational Vitamin D levels MAY IMPACT Adult health AS there is EARLY EVIDENCE that Vitamin D sufficiency in Pregnancy MAY have a PROTECTIVE ROLE in the development of Adult onset multiple sclerosis [94].']	[('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 42), ('PROBABLE_UNDERSTANDING', 62), ('INCOMPLETE_EVIDENCE', 74), ('INCOMPLETE_EVIDENCE', 129), ('SUPERFICIAL_RELATIONSHIP', 140), ('SUPERFICIAL_RELATIONSHIP', 151)]	7	[('GO_0007565', 'female pregnancy', 9, 'gestational'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0007023', 'adult organism', 49, 'adult'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('UBERON_0007023', 'adult organism', 178, 'adult')]	0	['finally,   levels adult   adult onset sclerosis [94].']
S119-PMC4684854	PMC4684854	12/2015	S119-PMC4684854	['economic burden of Gestational Vitamin D deficiency\nthe economic IMPACT of Vitamin D deficiency as it RELATES to maternal-fetal health is DIFFICULT to objectively quantify AS INSUFFICIENT evidence has ACCUMULATED THUS FAR on the totality of short- and long-term sequelae of Vitamin D insufficiency.']	[('SUPERFICIAL_RELATIONSHIP', 65), ('SUPERFICIAL_RELATIONSHIP', 102), ('DIFFICULT_TASK', 138), ('PROBABLE_UNDERSTANDING', 172), ('INCOMPLETE_EVIDENCE', 175), ('PROBLEM_COMPLICATION', 175), ('INCOMPLETE_EVIDENCE', 201), ('INCOMPLETE_EVIDENCE', 213)]	8	[('GO_0007565', 'female pregnancy', 19, 'Gestational'), ('CHEBI_28384', 'vitamin K', 31, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]	0	['economic  vitamin deficiency\nthe economic  maternal-fetal objectively quantify short- long-term sequelae  insufficiency.']
S127-PMC4684854	PMC4684854	12/2015	S127-PMC4684854	['with regard to economic challenges ASSOCIATED with Vitamin D insufficiency, SUFFICE it to say that there are CONSIDERABLE costs POTENTIALLY ASSOCIATED with Gestational Vitamin D insufficiency [99] as well as corresponding BENEFITS and cost savings resulting from inexpensive supplementation with this ESSENTIAL Nutrient [99].']	[('SUPERFICIAL_RELATIONSHIP', 35), ('IMPORTANT_CONSIDERATION', 76), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 140), ('IMPORTANT_CONSIDERATION', 222), ('IMPORTANT_CONSIDERATION', 301)]	7	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 156, 'gestational'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('CHEBI_33284', 'nutrient', 311, 'nutrient')]	0	['regard economic  insufficiency, costs   [99] cost savings resulting supplementation nutrient [99].']
S132-PMC4684854	PMC4684854	12/2015	S132-PMC4684854	['it is APPARENT that training is REQUIRED to establish clinical competency in (i) understanding of the ROLE of various Nutrients in Human health, (ii) HOW TO ASSESS nutritional biochemistry in patients, and (iii) and HOW to intervene to secure Nutrient sufficiency for Individuals and population groups\nwith the MOUNTING EVIDENCE of several health sequelae ASSOCIATED with Gestational Vitamin D deficiency, the VALUE of Preconception education and care by health providers and PUBLIC HEALTH bodies to secure Vitamin D sufficiency throughout Gestation is EVIDENT.']	[('ANOMALY_CURIOUS_FINDING', 6), ('PROBABLE_UNDERSTANDING', 6), ('IMPORTANT_CONSIDERATION', 32), ('SUPERFICIAL_RELATIONSHIP', 102), ('EXPLICIT_QUESTION', 150), ('QUESTION_ANSWERED_BY_THIS_WORK', 154), ('EXPLICIT_QUESTION', 216), ('INCOMPLETE_EVIDENCE', 311), ('SUPERFICIAL_RELATIONSHIP', 356), ('IMPORTANT_CONSIDERATION', 410), ('IMPORTANT_CONSIDERATION', 476), ('PROBABLE_UNDERSTANDING', 553)]	12	[('CHEBI_33284', 'nutrient', 118, 'nutrients'), ('NCBITaxon_9606', 'Homo sapiens', 131, 'human'), ('CHEBI_33284', 'nutrient', 243, 'nutrient'), ('NCBITaxon_1', 'root', 268, 'individuals'), ('GO_0007565', 'female pregnancy', 372, 'gestational'), ('CHEBI_27300', 'vitamin D', 384, 'vitamin D'), ('GO_0007565', 'female pregnancy', 419, 'preconception'), ('CHEBI_27300', 'vitamin D', 507, 'vitamin D'), ('GO_0007565', 'female pregnancy', 540, 'gestation')]	0	['competency (i) nutrients human health, (ii) nutritional biochemistry patients, (iii) intervene secure nutrient individuals population groups\nwith sequelae   deficiency,  providers bodies secure  throughout  evident.']
S133-PMC4684854	PMC4684854	12/2015	S133-PMC4684854	['as Pregnant women [105], particularly those with dark skin [106], are at CONSIDERABLE RISK for experiencing Vitamin D insufficiency [39], it is IMPORTANT to have a HIGH INDEX OF SUSPICION and to EFFECTIVELY preclude, assess for, and manage Vitamin D inadequacy, as would be done with OTHER biochemical irregularities.']	[('IMPORTANT_CONSIDERATION', 73), ('IMPORTANT_CONSIDERATION', 144), ('INCOMPLETE_EVIDENCE', 164), ('IMPORTANT_CONSIDERATION', 195), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 284)]	5	[('GO_0007565', 'female pregnancy', 3, 'pregnant'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D')]	0	[' women [105], dark skin [106], experiencing  [39], preclude, for, manage  inadequacy, done biochemical irregularities.']
S136-PMC4684854	PMC4684854	12/2015	S136-PMC4684854	['one researcher has SUGGESTED that the dietary REQUIREMENT during Pregnancy and Lactation MAY actually be as high as 6000\u2009iu/day [108], BUT most researchers have concluded, with OUR CURRENT KNOWLEDGE, that a supplemental Vitamin D intake of 4000\u2009iu/day is OPTIMAL [30].']	[('INCOMPLETE_EVIDENCE', 19), ('IMPORTANT_CONSIDERATION', 46), ('INCOMPLETE_EVIDENCE', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('QUESTION_ANSWERED_BY_THIS_WORK', 177), ('INCOMPLETE_EVIDENCE', 181), ('FUTURE_WORK', 189), ('IMPORTANT_CONSIDERATION', 255)]	8	[('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('GO_0007595', 'lactation', 79, 'lactation'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D')]	0	['one researcher dietary  lactation 6000\u2009iu/day [108], concluded, knowledge, supplemental  intake 4000\u2009iu/day [30].']
S137-PMC4684854	PMC4684854	12/2015	S137-PMC4684854	"['[""""as discussed, individual Vitamin D indices CAN be INFLUENCED by various DETERMINANTS DESPITE specific levels of supplementation; it is THUS the author\'s RECOMMENDATION that a personalized medical approach be taken via individual screening for 25(Oh)D as a routine part of Preconception and Prenatal care.""""]']"	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 50), ('SUPERFICIAL_RELATIONSHIP', 72), ('ANOMALY_CURIOUS_FINDING', 85), ('PROBABLE_UNDERSTANDING', 135), ('FUTURE_WORK', 153)]	6	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 243, '25(OH)D'), ('GO_0007565', 'female pregnancy', 272, 'preconception'), ('GO_0007565', 'female pregnancy', 290, 'prenatal')]	0	"['[""""as discussed, individun indices levels supplementation; author*s personalized medical via individual screening 25(oh)d routine ion atal care.""""]']"
S139-PMC4684854	PMC4684854	12/2015	S139-PMC4684854	['with the recognition that Vitamin D plays an ESSENTIAL ROLE in myriad Genes that encode for health and Well-Being in the offspring, it behooves the medical and PUBLIC HEALTH community to endeavor to secure Vitamin D adequacy in the Gestational period.']	[('IMPORTANT_CONSIDERATION', 45), ('SUPERFICIAL_RELATIONSHIP', 55), ('IMPORTANT_CONSIDERATION', 160)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('SO_0000704', 'gene', 70, 'genes'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 103, 'well-being'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0007565', 'female pregnancy', 232, 'gestational')]	0	[' plays genes encode well-being offspring, behooves medical community endeavor secure   period.']
S140-PMC4684854	PMC4684854	12/2015	S140-PMC4684854	['the ONGOING personal health BURDEN ASSOCIATED with Gestational Vitamin D insufficiency throughout many parts of the world has the POTENTIAL to be ameliorated CONSIDERABLY by straightforward educational and healthcare measures in the Preconception and Prenatal period to secure Vitamin D sufficiency throughout Pregnancy.']	[('IMPORTANT_CONSIDERATION', 4), ('IMPORTANT_CONSIDERATION', 28), ('PROBLEM_COMPLICATION', 28), ('SUPERFICIAL_RELATIONSHIP', 35), ('INCOMPLETE_EVIDENCE', 130), ('ANOMALY_CURIOUS_FINDING', 158)]	6	[('GO_0007565', 'female pregnancy', 51, 'gestational'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 233, 'preconception'), ('GO_0007565', 'female pregnancy', 251, 'prenatal'), ('CHEBI_27300', 'vitamin D', 277, 'vitamin D'), ('GO_0007565', 'female pregnancy', 310, 'pregnancy')]	0	['personal   throughout parts world ameliorated educational healthcare   period secure  throughout .']
S141-PMC4684854	PMC4684854	12/2015	S141-PMC4684854	['it is time for maternity health providers to be apprised of the POTENTIAL for improved and enduring health and well-Being ASSOCIATED with inexpensive measures to secure Vitamin D nutritional adequacy during Gestation, the most vulnerable time in the Life Cycle of the developing child.']	[('INCOMPLETE_EVIDENCE', 64), ('SUPERFICIAL_RELATIONSHIP', 122)]	2	[('GO_0016441', 'posttranscriptional gene silencing', 115, '-being'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 207, 'gestation'), ('UBERON_0000104', 'life cycle', 250, 'life cycle')]	0	['maternity providers apprised enduring well-being secure  nutritional life cycle child.']
S13-PMC4689556	PMC4689556	12/2015	S13-PMC4689556	['conclusions\nwe FOUND NO EVIDENCE that Prenatal Vitamin D supplementation from 27 weeks Gestation to Delivery, at doses which FAILED to completely correct maternal Vitamin D deficiency, INFLUENCE overall healthcare utilisation in children in the first 3 years.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 21), ('DIFFICULT_TASK', 125), ('SUPERFICIAL_RELATIONSHIP', 185)]	4	[('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('GO_0007567', 'parturition', 100, 'delivery'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]	0	['conclusions\nwe   supplementation 27 weeks  delivery, doses maternal  deficiency, healthcare utilisation children 3 years.']
S20-PMC4689556	PMC4689556	12/2015	S20-PMC4689556	['thus FAR there HAS BEEN a LACK OF randomised controlled trial evidence to definitively confirm OR REFUTE the RELATIONSHIP between Prenatal Vitamin D and childhood health outcomes FOUND in OBSERVATIONAL studies.']	[('ANOMALY_CURIOUS_FINDING', 5), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 26), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 98), ('SUPERFICIAL_RELATIONSHIP', 109), ('INCOMPLETE_EVIDENCE', 179), ('INCOMPLETE_EVIDENCE', 188)]	8	[('GO_0007565', 'female pregnancy', 130, 'prenatal'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]	0	['thus randomised   childhood outcomes studies.']
S26-PMC4689556	PMC4689556	12/2015	S26-PMC4689556	['we HYPOTHESIZED that Prenatal Vitamin D supplementation during Pregnancy would reduce a child’s healthcare utilisation during the first three years of Life through improved health status, by using the e-hr to quantify our outcome total healthcare utilisation.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('GO_0007565', 'female pregnancy', 21, 'prenatal'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy'), ('UBERON_0000104', 'life cycle', 151, 'life')]	0	['  supplementation  child’s healthcare utilisation three life status, using e-hr quantify outcome healthcare utilisation.']
S39-PMC4689556	PMC4689556	12/2015	S39-PMC4689556	['women were given instructions to swallow the tablets whole and to avoid other multivitamin supplements containing Vitamin D. this trial was CONDUCTED before national guidance on routinely providing advice on Vitamin D intake during Pregnancy was introduced in march 2008 [26].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 140)]	1	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('GO_0007565', 'female pregnancy', 232, 'pregnancy')]	0	['women instructions swallow tablets whole multivitamin supplements containing . national routinely  intake  march 2008 [26].']
S141-PMC4689556	PMC4689556	12/2015	S141-PMC4689556	['discussion\nwe EVALUATED WHETHER two specific dosing regimens of Prenatal Vitamin D supplementation COULD reduce health care utilisation in the first three years of Life.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('INCOMPLETE_EVIDENCE', 99)]	3	[('GO_0007565', 'female pregnancy', 64, 'prenatal'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0000104', 'life cycle', 164, 'life')]	0	['discussion\nwe dosing regimens   supplementation utilisation three life.']
S143-PMC4689556	PMC4689556	12/2015	S143-PMC4689556	['we FOUND NO EVIDENCE that Prenatal Vitamin D status is RELATED to healthcare utilisation, HOWEVER one MIGHT argue that the very SMALL number of subjects with adequate Vitamin D status LIMITED the power of this analysis.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 55), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 90), ('INCOMPLETE_EVIDENCE', 102), ('INCOMPLETE_EVIDENCE', 128), ('INCOMPLETE_EVIDENCE', 184)]	7	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]	0	['  status healthcare utilisation, subjects  status analysis.']
S144-PMC4689556	PMC4689556	12/2015	S144-PMC4689556	['these data CONTRAST WITH RECENT FINDINGS that higher dose Vitamin D during Pregnancy and infancy CAN reduce Upper Respiratory Tract infections in infancy [38].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 11), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 97)]	3	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('UBERON_0001557', 'upper respiratory tract', 108, 'upper respiratory tract')]	0	['higher dose   infancy upper respiratory tract infections infancy [38].']
S145-PMC4689556	PMC4689556	12/2015	S145-PMC4689556	['our NEW FINDINGS SUGGEST that Prenatal maternal Vitamin D levels MAY BE less IMPORTANT than Postnatal infant Vitamin D levels for determining infant health outcomes, AT LEAST within the insufficient/deficient range.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 65), ('IMPORTANT_CONSIDERATION', 77), ('PROBABLE_UNDERSTANDING', 166)]	5	[('GO_0007565', 'female pregnancy', 30, 'prenatal'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007567', 'parturition', 92, 'postnatal'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D')]	0	[' maternal  levels postnatal infant  levels infant outcomes, insufficient/deficient range.']
S149-PMC4689556	PMC4689556	12/2015	S149-PMC4689556	['[39]\nstudies in OTHER populations, USUALLY with higher Prenatal Vitamin D status THAN ours, have FOUND an inverse RELATIONSHIP between Cord Blood 25(Oh) Vitamin D level and child health outcomes [4].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 16), ('INCOMPLETE_EVIDENCE', 35), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 81), ('INCOMPLETE_EVIDENCE', 97), ('SUPERFICIAL_RELATIONSHIP', 114)]	5	[('GO_0007565', 'female pregnancy', 55, 'prenatal'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 135, 'cord'), ('UBERON_0000178', 'blood', 140, 'blood'), ('CHEBI_30778', 'gallic acid', 146, '25(OH)'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]	0	['[39]\nstudies populations, higher   status ours, cord blood 25(oh)  child outcomes [4].']
S151-PMC4689556	PMC4689556	12/2015	S151-PMC4689556	['the FINDINGS from our trial, the FIRST Prenatal Vitamin D intervention trial to report child health outcomes, SUGGEST that either the dosing regimen used in this study was INADEQUATE, OR that the RELATIONSHIP between Cord Blood 25(Oh) Vitamin D and child health SEEN in OBSERVATIONAL studies MAY BE RELATED to hidden CONFOUNDERS.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 110), ('IMPORTANT_CONSIDERATION', 172), ('PROBLEM_COMPLICATION', 172), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 184), ('SUPERFICIAL_RELATIONSHIP', 196), ('INCOMPLETE_EVIDENCE', 262), ('INCOMPLETE_EVIDENCE', 270), ('INCOMPLETE_EVIDENCE', 292), ('SUPERFICIAL_RELATIONSHIP', 299), ('PROBLEM_COMPLICATION', 317)]	12	[('GO_0007565', 'female pregnancy', 39, 'prenatal'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0009472', 'axilla', 217, 'cord blood'), ('CHEBI_30778', 'gallic acid', 228, '25(OH)'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D')]	0	['trial,   child outcomes, dosing regimen inadequate, cord blood 25(oh)  child hidden confounders.']
S159-PMC4689556	PMC4689556	12/2015	S159-PMC4689556	['HOWEVER, guidance from the national institute for clinical excellence and royal college of obstetricians and gynaecologists in the uk now acknowledge this as a minimum dose for all Pregnant or breastfeeding women and that higher dosing SHOULD BE CONSIDERED in those at high RISK of Vitamin D deficiency [41,42].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 236), ('FUTURE_WORK', 246), ('IMPORTANT_CONSIDERATION', 246), ('IMPORTANT_CONSIDERATION', 274)]	5	[('GO_0007565', 'female pregnancy', 181, 'pregnant'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D')]	0	['however, national institute excellence royal college obstetricians gynaecologists uk minimum dose  breastfeeding women higher dosing  [41,42].']
S165-PMC4689556	PMC4689556	12/2015	S165-PMC4689556	['), there REMAINS an IMPORTANT QUESTION WHETHER Prenatal Vitamin D supplementation at doses which reliably achieve sufficiency in the target population, CAN improve healthcare outcomes for young children.']	[('INCOMPLETE_EVIDENCE', 9), ('IMPORTANT_CONSIDERATION', 20), ('EXPLICIT_QUESTION', 30), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 39), ('EXPLICIT_QUESTION', 39), ('INCOMPLETE_EVIDENCE', 152)]	6	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D')]	0	['),   supplementation doses reliably achieve population, healthcare outcomes young children.']
S166-PMC4689556	PMC4689556	12/2015	S166-PMC4689556	['the RELATIONSHIP between Prenatal Vitamin D status and child health outcomes MAY not be linear.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 77)]	2	[('GO_0007565', 'female pregnancy', 25, 'prenatal'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]	0	['  status child outcomes linear.']
S167-PMC4689556	PMC4689556	12/2015	S167-PMC4689556	['given that SOME observational studies SUGGEST adverse child Respiratory health outcomes are ASSOCIATED with very high maternal Vitamin D level during Pregnancy, empiric data ARE NEEDED before high dose Prenatal Vitamin D supplementation CAN be routinely RECOMMENDED [44].']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 38), ('SUPERFICIAL_RELATIONSHIP', 92), ('FUTURE_WORK', 174), ('INCOMPLETE_EVIDENCE', 237), ('FUTURE_WORK', 254)]	6	[('UBERON_0001004', 'respiratory system', 60, 'respiratory'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('GO_0007565', 'female pregnancy', 202, 'prenatal'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]	0	['given child respiratory outcomes maternal  empiric dose   supplementation routinely [44].']
S171-PMC4689556	PMC4689556	12/2015	S171-PMC4689556	['a further LIMITATION of the study is its SMALL size and wide confidence intervals, SO that a small EFFECT of Prenatal Vitamin D on child healthcare utilization in the first 3 years CANNOT BE confidently EXCLUDED.']	[('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 41), ('PROBABLE_UNDERSTANDING', 83), ('SUPERFICIAL_RELATIONSHIP', 99), ('DIFFICULT_TASK', 181), ('INCOMPLETE_EVIDENCE', 203)]	6	[('GO_0007565', 'female pregnancy', 109, 'prenatal'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]	0	['confidence intervals,   child healthcare utilization 3 excluded.']
S173-PMC4689556	PMC4689556	12/2015	S173-PMC4689556	['overall the data SUGGEST that a clinically meaningful RELATIONSHIP between this regime of Vitamin D supplementation in Pregnancy in a deficient population, or these levels of Vitamin D in Cord-Blood or at three years of age, and healthcare utilization is UNLIKELY.']	[('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 54), ('PROBABLE_UNDERSTANDING', 255)]	3	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 188, 'cord'), ('UBERON_0000178', 'blood', 193, 'blood')]	0	['overall clinically regime  supplementation  population, levels  cord-blood three age, healthcare utilization unlikely.']
S183-PMC4689556	PMC4689556	12/2015	S183-PMC4689556	['ALTHOUGH our confidence in the findings is LIMITED by the SMALL SAMPLE size, these data SUGGEST that IF Prenatal Vitamin D is used to promote improved child health outcome, then a Postnatal component to treatment, and/or or higher doses MAY BE NEEDED.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 43), ('INCOMPLETE_EVIDENCE', 58), ('INCOMPLETE_EVIDENCE', 88), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 101), ('INCOMPLETE_EVIDENCE', 237), ('FUTURE_WORK', 244)]	7	[('GO_0007565', 'female pregnancy', 104, 'prenatal'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007567', 'parturition', 180, 'postnatal')]	0	['although confidence size, postnatal treatment, and/or higher doses needed.']
S184-PMC4689556	PMC4689556	12/2015	S184-PMC4689556	['a RECENT systematic REVIEW of Prenatal Vitamin D supplementation FOUND HETEROGENEOUS study designs and INCONSISTENT findings [52].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 71), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103)]	5	[('GO_0007565', 'female pregnancy', 30, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]	0	['  supplementation [52].']
S186-PMC4689556	PMC4689556	12/2015	S186-PMC4689556	['in that context FURTHER DATA are AWAITED from two larger randomised controlled trials, vdarrt [53] and abcvitamind [54], to establish WHETHER higher dose daily Prenatal Vitamin D supplementation will IMPACT on child health outcomes.']	[('FUTURE_WORK', 16), ('FUTURE_WORK', 33), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 134), ('SUPERFICIAL_RELATIONSHIP', 200)]	4	[('GO_0007565', 'female pregnancy', 160, 'prenatal'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]	0	['context randomised trials, vdarrt [53] abcvitamind [54], higher dose daily   supplementation child outcomes.']
S0-PMC4690051	PMC4690051	12/2015	S0-PMC4690051	['Gestational vitamin 25(oh)d status as a risk factor for Receptive Language Development: a 24-month, longitudinal, observational study\n\nabstract\nemerging data suggest that Vitamin D status during childhood and Adolescence CAN AFFECT Neurocognitive Development.']	[('INCOMPLETE_EVIDENCE', 221), ('SUPERFICIAL_RELATIONSHIP', 225)]	2	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('GO_0000003', 'reproduction', 56, 'Receptive'), ('GO_0008584', 'male gonad development', 66, 'Language Development'), ('UBERON_0003215', 'alveolus', 66, 'Language'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('GO_0048848', 'neurohypophysis morphogenesis', 209, 'adolescence'), ('GO_0007399', 'nervous system development', 232, 'neurocognitive development')]	0	[' vitamin 25(oh)d status receptive language development: 24-month, longitudinal, study\n\nabstract\nemerging  status childhood adolescence neurocognitive development.']
S74-PMC4690051	PMC4690051	12/2015	S74-PMC4690051	['BASED ON supplemental studies of Vitamin D during Pregnancy, a 10 ng/ml increase in 25(Oh)D has resulted in a PROTECTIVE odds ratio for healthy Pregnancy outcomes [37]; THUS, we ASSESSED such EFFECTS on Cognitive and language scaled scores.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 110), ('PROBABLE_UNDERSTANDING', 169), ('QUESTION_ANSWERED_BY_THIS_WORK', 178), ('SUPERFICIAL_RELATIONSHIP', 192)]	5	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 84, '25(OH)D'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy'), ('GO_0050890', 'cognition', 203, 'cognitive')]	0	['based supplemental  10 ng/ml increase 25(oh)d resulted ratio healthy  outcomes [37]; thus, cognitive language scaled scores.']
S76-PMC4690051	PMC4690051	12/2015	S76-PMC4690051	['using stepwise selection (0.20 for entry, 0.05 to stay) to remove the insignificant variables, we retained 25(Oh)D status in the model while assessing the following POSSIBLE CONFOUNDERS: race (aa or ea), maternal iq, use of tobacco products or Alcohol during Pregnancy, maternal dietary Intake of Vitamin D, age, pre-Pregnancy bmi, total number of completed Pregnancies, Gestational hypertension or Gestational diabetes, insurance status, level of maternal education, marital status, child’s age at cv2, and Gestational age at Birth.']	[('INCOMPLETE_EVIDENCE', 165), ('PROBLEM_COMPLICATION', 174)]	2	[('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 107, '25(OH)D'), ('CHEBI_30879', 'alcohol', 244, 'alcohol'), ('GO_0007565', 'female pregnancy', 259, 'pregnancy'), ('GO_0007631', 'feeding behavior', 287, 'intake'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin D'), ('GO_0007565', 'female pregnancy', 317, 'pregnancy'), ('GO_0007565', 'female pregnancy', 358, 'pregnancies'), ('GO_0007565', 'female pregnancy', 371, 'gestational'), ('GO_0007565', 'female pregnancy', 399, 'gestational'), ('GO_0007565', 'female pregnancy', 508, 'gestational'), ('GO_0007567', 'parturition', 527, 'birth')]	0	['using stepwise selection (0.20 entry, 0.05 stay) remove variables, retained 25(oh)d status following confounders: race (aa ea), maternal iq, tobacco products alcohol maternal dietary intake age, pre- bmi, completed  hypertension  diabetes, insurance status, maternal education, marital status, child’s age cv2,  age birth.']
S117-PMC4690051	PMC4690051	12/2015	S117-PMC4690051	['Murine dams maintained on Vitamin D deficient diets before and during Pregnancy display alterations in Murine Brain morphology that COULD CONTRIBUTE to deficits in Memory, Learning, and attention processing [39].']	[('INCOMPLETE_EVIDENCE', 132), ('SUPERFICIAL_RELATIONSHIP', 138)]	2	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Murine'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('NCBITaxon_39107', 'Murinae', 103, 'murine'), ('UBERON_0000955', 'brain', 110, 'brain'), ('GO_0007613', 'memory', 164, 'memory'), ('GO_0007612', 'learning', 172, 'learning')]	0	['murine dams  diets  display alterations brain morphology memory, learning, processing [39].']
S167-PMC4690051	PMC4690051	12/2015	S167-PMC4690051	['we RECENTLY REPORTED [57] that Dna Methylation is jointly Modulated by ancestry and Gestational Vitamin D levels, observations which SUPPORT multidimensional FACTORS.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 133), ('SUPERFICIAL_RELATIONSHIP', 158)]	4	[('GO_0006306', 'DNA methylation', 31, 'DNA methylation'), ('GO_0065007', 'biological regulation', 58, 'modulated'), ('GO_0007565', 'female pregnancy', 84, 'gestational'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]	0	['[57] dna methylation ancestry   levels, multidimensional factors.']
S18-PMC4691762	PMC4691762	12/2015	S18-PMC4691762	['Vitamin D deficiency (currently defined as 25Ohd3<50\u2005nmol/l) has become MORE COMMON in modern communities over time, PRESUMABLY DUE TO INADEQUATE sun exposure resulting from indoor activities and skin cancer CONCERNS.13vitamin d deficiency is common in victoria, australia and also APPEARS TO BE increasing among Pregnant women14and infants.6in addition, the prevalence of infant Vitamin D deficiency was fourfold higher among fully Breastfed infants than fully formula Fed (p<0.001) EVEN at 12\u2005months after solid Food had been introduced.15\nUNLIKE OTHER countries in the northern hemisphere, australia does not RECOMMEND universal Vitamin D supplementation.']	[('PROBABLE_UNDERSTANDING', 72), ('PROBABLE_UNDERSTANDING', 117), ('PROBABLE_UNDERSTANDING', 128), ('IMPORTANT_CONSIDERATION', 135), ('IMPORTANT_CONSIDERATION', 208), ('ANOMALY_CURIOUS_FINDING', 282), ('ANOMALY_CURIOUS_FINDING', 484), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 542), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 549), ('FUTURE_WORK', 612)]	10	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_63058', '(2R,3S)-EHNA', 43, '25OHD3'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 43, '25OHD3'), ('GO_0007565', 'female pregnancy', 313, 'pregnant'), ('CHEBI_27300', 'vitamin D', 380, 'vitamin D'), ('GO_0007567', 'parturition', 433, 'breastfed'), ('GO_0007631', 'feeding behavior', 470, 'fed'), ('CHEBI_33290', 'food', 514, 'food'), ('CHEBI_27300', 'vitamin D', 632, 'vitamin D')]	0	['vitamin (currently 25ohd3<50\u2005nmol/l) modern communities time, sun exposure resulting indoor activities skin cancer concerns.13vitamin victoria, australia among  women14and infants.6in addition, infant  fourfold higher among breastfed infants formula fed (p<0.001) 12\u2005months food introduced.15\nunlike countries northern hemisphere, australia  supplementation.']
S0-PMC4719746	PMC4719746	1/2016	S0-PMC4719746	['Vitamin D deficiency and supplementation in Pregnancy in a multiethnic population-based cohort\n\nabstract\n\nbackground\nTO INVESTIGATE ethnic DIFFERENCES in Vitamin D levels during Pregnancy, assess RISK factors for Vitamin D deficiency and explore the EFFECT of Vitamin D supplementation in women with deficiency in early Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 117), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 139), ('SUPERFICIAL_RELATIONSHIP', 196), ('SUPERFICIAL_RELATIONSHIP', 250)]	4	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 260, 'vitamin D'), ('GO_0007565', 'female pregnancy', 320, 'pregnancy')]	0	['vitamin supplementation  multiethnic population-based cohort\n\nabstract\n\nbackground\nto ethnic  levels   supplementation women .']
S13-PMC4719746	PMC4719746	1/2016	S13-PMC4719746	['in europe, Vitamin D deficiency is REPORTED to be PREVALENT among Pregnant ethnic minority women in the netherlands [2] and uk [3], but is also OBSERVED in the majority population [3–5].']	[('INCOMPLETE_EVIDENCE', 35), ('IMPORTANT_CONSIDERATION', 50), ('INCOMPLETE_EVIDENCE', 144)]	3	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnant')]	0	['europe,  among  ethnic women netherlands [2] uk [3], population [3–5].']
S14-PMC4719746	PMC4719746	1/2016	S14-PMC4719746	['LITTLE IS KNOWN about the prevalence of Vitamin D deficiency among asian and african Pregnant women living in northern europe, although a FEW SMALL STUDIES from sweden [6,7] and norway [8] report a high prevalence of Vitamin D deficiency among somali and pakistani women.']	[('FULL_UNKNOWN', 0), ('INCOMPLETE_EVIDENCE', 138), ('INCOMPLETE_EVIDENCE', 142)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnant'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D')]	0	['little  among asian african  women living northern europe, sweden [6,7] norway [8]  among somali pakistani women.']
S15-PMC4719746	PMC4719746	1/2016	S15-PMC4719746	['there are FEW population-based STUDIES exploring Vitamin D deficiency in Pregnancy in today’s multiethnic europe, and LITTLE IS KNOWN about the IMPACT of socioeconomic status or the EFFECT of Vitamin D supplements [9,10].']	[('INCOMPLETE_EVIDENCE', 10), ('FULL_UNKNOWN', 118), ('SUPERFICIAL_RELATIONSHIP', 144), ('SUPERFICIAL_RELATIONSHIP', 182)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D')]	0	['population-based   today’s multiethnic europe, socioeconomic status  supplements [9,10].']
S16-PMC4719746	PMC4719746	1/2016	S16-PMC4719746	['also studies of multiethnic populations in australia have uncovered maternal country of Birth in asia and africa AS RISK FACTOR of Vitamin D deficiency in Pregnancy [11].']	[('PROBABLE_UNDERSTANDING', 113), ('SUPERFICIAL_RELATIONSHIP', 116)]	2	[('GO_0007567', 'parturition', 88, 'birth'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'pregnancy')]	0	['also multiethnic populations australia maternal country birth asia africa   [11].']
S20-PMC4719746	PMC4719746	1/2016	S20-PMC4719746	['DESPITE the CONTROVERSIES RELATED to adverse outcomes, and LACK OF EVIDENCE of clear benefits of routine supplementation, most western countries RECOMMEND Vitamin D supplementation during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 59), ('FUTURE_WORK', 145)]	5	[('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('GO_0007565', 'female pregnancy', 188, 'pregnancy')]	0	['despite outcomes, routine supplementation, western countries  supplementation .']
S21-PMC4719746	PMC4719746	1/2016	S21-PMC4719746	['the AIMS of THIS PAPER were TO INVESTIGATE ethnic DIFFERENCES in Vitamin D levels during Pregnancy, ASSESS RISK FACTORS for Vitamin D deficiency and explore the EFFECT of Vitamin D supplementation in women identified with low values during early Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 28), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 100), ('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 161)]	7	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 171, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 179, 'D'), ('GO_0007565', 'female pregnancy', 246, 'pregnancy')]	0	['ethnic  levels  vitamin supplementation women values .']
S46-PMC4719746	PMC4719746	1/2016	S46-PMC4719746	['according to national clinical guidelines for antenatal care, the RECOMMENDATION of Vitamin D intake during a normal Pregnancy is 10\xa0μg/day [21].']	[('FUTURE_WORK', 66)]	1	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy')]	0	['according national antenatal care,  intake normal  10\xa0μg/day [21].']
S47-PMC4719746	PMC4719746	1/2016	S47-PMC4719746	['all participants were asked about their Intake of Vitamin D supplements including Prenatal Vitamins during the past two weeks at both visits, and self-reported intake was categorized AS “ Vitamin D ≥10\xa0μg/day” and “no or Vitamin D <10\xa0μg/day”.']	[('PROBABLE_UNDERSTANDING', 183)]	1	[('GO_0007631', 'feeding behavior', 40, 'intake'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 91, 'vitamins'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D')]	0	['participants intake  supplements  vitamins weeks visits, intake categorized “  ≥10\xa0μg/day” “no  <10\xa0μg/day”.']
S50-PMC4719746	PMC4719746	1/2016	S50-PMC4719746	['the RECOMMENDATION of Vitamin D supplementation\npre-planned, and ACCORDING TO the protocol, women with 25(Oh)D less than the laboratory’s lower reference range (<37\xa0nmol/l) at Gestational week 15 were provided with written information describing their 25(Oh)D D concentration, and they were RECOMMENDED to consult their general practitioner (gp) for treatment.']	[('FUTURE_WORK', 4), ('INCOMPLETE_EVIDENCE', 65), ('FUTURE_WORK', 291)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('GO_0007565', 'female pregnancy', 176, 'gestational'), ('CHEBI_29156', 'Gly-tRNA(Gly)', 252, '25(OH)D D'), ('PR_000007367', 'fibrosin-1-like protein', 252, '25(OH)D D')]	0	[' supplementation\npre-planned, protocol, women 25(oh)d laboratory’s (<37\xa0nmol/l)  week 15 written 25(oh)d concentration, consult practitioner (gp) treatment.']
S63-PMC4719746	PMC4719746	1/2016	S63-PMC4719746	['explanatory linear regression models were performed TO ASSESS the relationship between ethnicity and the concentration of 25(Oh)D, both at inclusion and in Gestational week 28, accounting for the following POTENTIAL CONFOUNDING FACTORS: Gestational week, age, parity, season, education, Vitamin D supplements and pre-Pregnancy bmi.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 52), ('INCOMPLETE_EVIDENCE', 206), ('PROBLEM_COMPLICATION', 216)]	3	[('CHEBI_71657', 'versiconol acetate', 122, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 128, 'D'), ('GO_0007565', 'female pregnancy', 156, 'gestational'), ('GO_0007565', 'female pregnancy', 237, 'gestational'), ('CHEBI_27300', 'vitamin D', 287, 'vitamin D'), ('GO_0007565', 'female pregnancy', 317, 'pregnancy')]	0	['explanatory linear regression ethnicity concentration 25(oh)d, inclusion  week 28, following factors:  week, age, parity, season, education,  supplements pre- bmi.']
S78-PMC4719746	PMC4719746	1/2016	S78-PMC4719746	['aincluding 3 women from usa and canada\nbincomplete data on the variables BECAUSE of MISSING values for 6–12 women\nat Gestational week 28, the proportion of south asian and middle eastern women who had used Vitamin D supplements ≥10\xa0μg/day over the past two weeks was higher than at Gestational week 15 ( p \u2009<\u20090.01 and p \u2009<\u20090.05, respectively).']	[('PROBLEM_COMPLICATION', 73), ('PROBLEM_COMPLICATION', 84)]	2	[('GO_0007565', 'female pregnancy', 117, 'gestational'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0007565', 'female pregnancy', 282, 'gestational')]	0	['aincluding 3 women usa canada\nbincomplete values 6–12 women\nat  week 28, proportion south asian middle eastern women  supplements ≥10\xa0μg/day weeks higher  week 15 p \u2009<\u20090.01 p \u2009<\u20090.05, respectively).']
S87-PMC4719746	PMC4719746	1/2016	S87-PMC4719746	['crude mean (sd) Vitamin D [25(Oh)D in nmol/l] levels according to POTENTIAL explanatory factorsat inclusionat Gestational week 28 n \u2009=\u2009748 n \u2009=\u2009748mean(sd)mean(sd)overall mean 25(Oh)d50(27)59(29)age at inclusion\u2009\u2009\u2009≤30\xa0years47(25)55(27)\u2009\u2009\u2009>30\xa0years54(28)62(30)parity (para 0 ref)53(26)61(29)\u2009\u2009\u2009para 152(28)59(27)\u2009\u2009\u2009para ≥242(25)52(30)western europe (ref)69(24)72(28)\u2009\u2009\u2009south asia32(19)46(23)\u2009\u2009\u2009middle east34(20)51(29)\u2009\u2009\u2009sub-saharan africa38(18)45(25)\u2009\u2009\u2009east asia51(17)53(19)\u2009\u2009\u2009other56(21)63(26)season of Blood sample\u2009\u2009\u2009summer56(29)60(29)\u2009\u2009\u2009winter46(24)57(27)education level (>12\xa0years ref)60(27)67(27)\u2009\u2009\u200910-12 years46(25)56(29)\u2009\u2009\u2009<10\xa0years37(20)44(23)Vitamin D supplements\u2009\u2009\u2009≥10\xa0μga57(26)61(28)\u2009\u2009\u2009no or <10\xa0μg42(26)53(29)pre-Pregnancy bmi; kg/m2(normal weight (<25) ref)51(27)59(29)\u2009\u2009\u2009overweight (≥25/<30)51(27)61(31)\u2009\u2009\u2009obesity (≥30)48(24)54(24)\naintake of ≥10\xa0μg Vitamin D daily past two weeks\n\ncaption (fig): fig.']	[('INCOMPLETE_EVIDENCE', 66)]	1	[('CHEBI_28384', 'vitamin K', 16, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 16, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 27, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 27, '25 ... OH ... D'), ('GO_0007565', 'female pregnancy', 110, 'gestational'), ('CHEBI_30778', 'gallic acid', 176, '25(OH)'), ('UBERON_0000178', 'blood', 503, 'blood'), ('CHEBI_28384', 'vitamin K', 650, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 724, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 863, 'vitamin D')]	0	['crude (sd) vitamin [25(oh)d nmol/l] levels factorsat inclusionat  week 28 n \u2009=\u2009748 n \u2009=\u2009748mean(sd)mean(sd)overall 25(oh)d50(27)59(29)age inclusion\u2009\u2009\u2009≤30\xa0years47(25)55(27)\u2009\u2009\u2009>30\xa0years54(28)62(30)parity (para 0 ref)53(26)61(29)\u2009\u2009\u2009para 152(28)59(27)\u2009\u2009\u2009para ≥242(25)52(30)western europe (ref)69(24)72(28)\u2009\u2009\u2009south asia32(19)46(23)\u2009\u2009\u2009middle east34(20)51(29)\u2009\u2009\u2009sub-saharan africa38(18)45(25)\u2009\u2009\u2009east asia51(17)53(19)\u2009\u2009\u2009other56(21)63(26)season blood sample\u2009\u2009\u2009summer56(29)60(29)\u2009\u2009\u2009winter46(24)57(27)education (>12\xa0years ref)60(27)67(27)\u2009\u2009\u200910-12 years46(25)56(29)\u2009\u2009\u2009<10\xa0years37(20)44(23)vitamin supplements\u2009\u2009\u2009≥10\xa0μga57(26)61(28)\u2009\u2009\u2009no <10\xa0μg42(26)53(29)pre- bmi; kg/m2(normal (<25) ref)51(27)59(29)\u2009\u2009\u2009overweight (≥25/<30)51(27)61(31)\u2009\u2009\u2009obesity (≥30)48(24)54(24)\naintake ≥10\xa0μg  daily weeks\n\ncaption (fig): fig.']
S95-PMC4719746	PMC4719746	1/2016	S95-PMC4719746	"['[\'=\\u20090.24independent variabler2adj.b95\\xa0% cib95\\xa0% cir2adj.b95\\xa0% cib95\\xa0% cilowerupperlowerupperlowerupperloweruppergestational week at inclusion (<15 ref)−0.0010.01ᅟ≥15−0.56−4.43.3 −6.4−10−2.3**−4.6−8.3−0.92* age at inclusion0.03 0.940.551.3** 0.14−0.210.490.03 1.10.641.5**0.700.261.1** parity (para 0 ref)0.020.01ᅟpara1−1.2−5.43.10.24−3.13.6−2.8−7.41.8 −4.4−8.7−0.22* ᅟpara ≥2 −11−17−6.3** −3.2−7.61.3 −9.3−15−3.8** −5.4−110.25geographic region (western europe ref)0.380.16ᅟsouth asia −37−40−33**−28−33−23**−26−31−21**−17−23−11** ᅟmiddle east −34−39−30**−24−29−18**−21−26−15**−9.5−16−2.9** ᅟsub-saharan africa −31−37−25**−20−27−13**−26−34−19**−12−20−3.1** ᅟeast asia −17−24−10**−11−18−3.9**−19−28−11**−11−20−1.6* ᅟother −13−19−6.4**−7.6−14−0.90*−9.0−17−1.3* −1.4−9.66.9season (summer ref)0.030.01ᅟwinter −9.9−14−6.1**−5.2−8.9−1.4**−5.7−9.8−1.6** −1.3−6.13.4geographic region*seasona−11−16−4.8**−15−22−7.4** education level (>12 y ref)0.110.08ᅟ10-12 year −14−18−10**−3.7−7.1−0.30*−11−15−6.8** −1.8−6.12.5ᅟ<10\\xa0year −23−28−17**−5.2−10−0.31*−23−29−17**−8.6−15−2.5** Vitamin D supplements (≥10μgbref)0.080.02ᅟno or <10\\xa0μg −15−19−11**−11−14−7.7**−8.2−13−3.8**−9.8−14−5.8** pre-Pregnancy bmi (<25\\xa0kg/m2ref)−0.001−0.001ᅟ≥25\\xa0kg/m2−0.76−4.73.2−0.11−4.44.2\\nathe EFFECT of season on 25(Oh)d differed by ethnicity: the interaction term is """"1"""" for records with both non-western and winter and """"0"""" for western and summer (ref)\\nbintake of ≥10\\xa0μg Vitamin D daily past two weeks\\nbold numbers indicate p \\u2009<\\u20090.05 (* p \\u2009<\\u20090.05, ** p \\u2009<\\u20090.01)\\n\\nVitamin D status at Gestational week 28\\nat the beginning of the third trimester, the prevalence of 25(Oh)D <50\\xa0nmol/l among the largest ethnic minority groups was lower than at study inclusion: south asia: 62\\xa0%, the middle east: 58\\xa0% and sub-saharan africa: 63\\xa0%.\']']"	[('SUPERFICIAL_RELATIONSHIP', 1248)]	1	[('CHEBI_28384', 'vitamin K', 1059, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1168, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 1268, '25(OH)'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1268, '25(OH'), ('CHEBI_27300', 'vitamin D', 1427, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 1435, 'D'), ('CHEBI_28384', 'vitamin K', 1519, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1539, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1618, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 1618, '25 ... OH ... D')]	0	"['[*=\\u20090.24independent variabler2adj.b95\\xa0% cib95\\xa0% cir2adj.b95\\xa0% cib95\\xa0% cilowerupperlowerupperlowerupperloweruppergestational week inclusion (<15 ref)−0.0010.01ᅟ≥15−0.56−4.43.3 −6.4−10−2.3**−4.6−8.3−0.92* age inclusion0.03 0.940.551.3** 0.14−0.210.490.03 1.10.641.5**0.700.261.1** parity (para 0 ref)0.020.01ᅟpara1−1.2−5.43.10.24−3.13.6−2.8−7.41.8 −4.4−8.7−0.22* ᅟpara ≥2 −11−17−6.3** −3.2−7.61.3 −9.3−15−3.8** −5.4−110.25geographic region (western europe ref)0.380.16ᅟsouth asia −37−40−33**−28−33−23**−26−31−21**−17−23−11** ᅟmiddle east −34−39−30**−24−29−18**−21−26−15**−9.5−16−2.9** ᅟsub-saharan africa −31−37−25**−20−27−13**−26−34−19**−12−20−3.1** ᅟeast asia −17−24−10**−11−18−3.9**−19−28−11**−11−20−1.6* ᅟother −13−19−6.4**−7.6−14−0.90*−9.0−17−1.3* −1.4−9.66.9season (summer ref)0.030.01ᅟwinter −9.9−14−6.1**−5.2−8.9−1.4**−5.7−9.8−1.6** −1.3−6.13.4geographic region*seasona−11−16−4.8**−15−22−7.4** (>12 ref)0.110.08ᅟ10-12 year −14−18−10**−3.7−7.1−0.30*−11−15−6.8** −1.8−6.12.5ᅟ<10\\xa0year −23−28−17**−5.2−10−0.31*−23−29−17**−8.6−15−2.5** vitamin supplements (≥10μgbref)0.080.02ᅟno <10\\xa0μg −15−19−11**−11−14−7.7**−8.2−1.8−14−5.8** pre-pregnancy bmi (<25\\xa0kg/m2ref)−0.001−0.001ᅟ≥25\\xa0kg/m2−0.76−4.73.2−0.11−4.44.2\\nathe season 25(oh)d ethnicity: term """"1"""" records non-western winter """"0"""" westerner (ref)\\nbintake ≥10\\xa0μg vitamin daily weeks\\nbold p \\u2009<\\u20090.009<\\u20090.05, ** p \\u2009<\\u20090.01)\\n\\nvitamin status gestational week 28\\nat third trimester, 25(oh)d <50\\xa0nmol/l among largest ethnic inclusion: south asia: 62\\xa0%, middle east: 58\\xa0% sub-saharan africa: 63\\xa0%.*]']"
S99-PMC4719746	PMC4719746	1/2016	S99-PMC4719746	['in addition, age, parity, education, intake of Vitamin D supplementation and Gestational week at inclusion were independently ASSOCIATED with 25(Oh)D concentrations.']	[('SUPERFICIAL_RELATIONSHIP', 126)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 142, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 148, 'D')]	0	['addition, age, parity, education, intake  supplementation  week inclusion 25(oh)d concentrations.']
S104-PMC4719746	PMC4719746	1/2016	S104-PMC4719746	['ONLY 37\xa0% of these women reported an intake of ≥10\xa0μg/day of Vitamin D supplements, BUT at Gestational week 28, this proportion had increased to 73\xa0% ( p \u2009<\u20090.01).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 0), ('ANOMALY_CURIOUS_FINDING', 84)]	3	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'gestational')]	0	['37\xa0% women intake ≥10\xa0μg/day  supplements,  week 28, proportion 73\xa0% p \u2009<\u20090.01).']
S118-PMC4719746	PMC4719746	1/2016	S118-PMC4719746	['women with <37\xa0nmol/l at baseline were RECOMMENDED 20\xa0μg or 30\xa0μg Vitamin D daily\n\ndiscussion\n\nmain findings\nin THIS cohort study we FOUND a high prevalence of Vitamin D deficiency (<50\xa0nmol/l) in early Pregnancy among women from south asia, middle east and sub-saharan africa, and severe deficiency (<25\xa0nmol/l) was prevalent among women from these regions.']	[('FUTURE_WORK', 39), ('QUESTION_ANSWERED_BY_THIS_WORK', 112), ('INCOMPLETE_EVIDENCE', 133)]	3	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]	0	['women <37\xa0nmol/l baseline 20\xa0μg 30\xa0μg  daily\n\ndiscussion\n\nmain findings\nin  (<50\xa0nmol/l)  among women south asia, middle east sub-saharan africa, (<25\xa0nmol/l) among women regions.']
S131-PMC4719746	PMC4719746	1/2016	S131-PMC4719746	['INTERPRETATION\nOUR FINDINGS are IN LINE WITH others CONFIRMING widespread Vitamin D deficiency during Pregnancy among ethnic minorities [2,3,11,23,24], although SOME STUDIES from northern europe have FOUND a comparatively higher prevalence and more SEVERE deficiency THAN observed in OUR STUDY [6,25].']	[('INCOMPLETE_EVIDENCE', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('INCOMPLETE_EVIDENCE', 32), ('PROBABLE_UNDERSTANDING', 52), ('INCOMPLETE_EVIDENCE', 161), ('INCOMPLETE_EVIDENCE', 200), ('IMPORTANT_CONSIDERATION', 249), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 267), ('QUESTION_ANSWERED_BY_THIS_WORK', 284)]	9	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'pregnancy')]	0	['interpretation\nour   among ethnic minorities [2,3,11,23,24], northern europe comparatively higher [6,25].']
S141-PMC4719746	PMC4719746	1/2016	S141-PMC4719746	['the DEBATE about the OPTIMAL dose of Vitamin D supplementation during Pregnancy is ONGOING.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('IMPORTANT_CONSIDERATION', 21), ('IMPORTANT_CONSIDERATION', 83)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy')]	0	['dose  supplementation  ongoing.']
S142-PMC4719746	PMC4719746	1/2016	S142-PMC4719746	['GUIDELINES from scandinavia and uk RECOMMEND all Pregnant women supplement intake with 10\xa0μg (400\xa0iu) Vitamin D daily to prevent Vitamin D deficiency [21,34,35].']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 35)]	2	[('GO_0007565', 'female pregnancy', 49, 'pregnant'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]	0	['guidelines scandinavia uk  women supplement intake 10\xa0μg (400\xa0iu)  daily  [21,34,35].']
S147-PMC4719746	PMC4719746	1/2016	S147-PMC4719746	['SEVERAL STUDIES among Pregnant women have SHOWED a marked increase in 25(Oh)D with daily supplements of Vitamin D [11,24,43,44].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 42)]	2	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]	0	['several among  women marked increase 25(oh)d daily supplements  [11,24,43,44].']
S150-PMC4719746	PMC4719746	1/2016	S150-PMC4719746	['in women who were RECOMMENDED daily Vitamin D supplements of 20\xa0μg or 30\xa0μg due to low values in early Pregnancy, we OBSERVED an increase in self-reported use of supplements at the follow-up visit.']	[('FUTURE_WORK', 18), ('INCOMPLETE_EVIDENCE', 117)]	2	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]	0	['women daily  supplements 20\xa0μg 30\xa0μg values increase supplements follow-up visit.']
S157-PMC4719746	PMC4719746	1/2016	S157-PMC4719746	['supplementation with a higher dose of Vitamin D than 20\xa0μg or 30\xa0μg would LIKELY be sufficient to achieve acceptable 25(Oh)D concentration in Pregnancy.']	[('PROBABLE_UNDERSTANDING', 74)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 117, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 117, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy')]	0	['supplementation higher dose  20\xa0μg 30\xa0μg achieve 25(oh)d concentration .']
S158-PMC4719746	PMC4719746	1/2016	S158-PMC4719746	['conclusion\nwe FOUND that Vitamin D deficiency was PREVALENT among south asian, middle eastern and african women in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 50)]	2	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 121, 'pregnancy')]	0	['conclusion\nwe  among south asian, middle eastern african women .']
S161-PMC4719746	PMC4719746	1/2016	S161-PMC4719746	['this cost-effective, and easy-to-administer RECOMMENDATION LIKELY CONTRIBUTED the most to the improved Vitamin D status later in Pregnancy for these women.']	[('FUTURE_WORK', 44), ('PROBABLE_UNDERSTANDING', 59), ('SUPERFICIAL_RELATIONSHIP', 66)]	3	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]	0	['cost-effective, easy-to-administer  status  women.']
S126-PMC4728621	PMC4728621	1/2016	S126-PMC4728621	['no association between change in maternal weight from late Pregnancy to 6 months Postpartum and any measure of offspring anthropometry was observed.nutrients-08-00007-t003_table 3\n\ncaption (table-wrap): table 3\n\nmaternal and paternal characteristics and maternal Nutrient intakes associated with 6 months old offspring adiposity-adjusted analysis *.model variabletotal model bseb p -value r2adjp -value weight for length z-score 0.0790.001trimester 1 sodium0.00030.00010.003 weight for age z-score 0.141<0.001trimester 2 Saturated Fatty (%Te)0.0750.0270.005 length for age z-score 0.186<0.001trimester 1 Carotene9.63e−050.000040.013trimester 1 Pufa (%te)0.1590.0490.002 bmi for age z-score 0.0710.002trimester 1 sodium0.00030.00010.003 muac-for-age z-score 0.1820.001trimester 3 sodium0.00030.00010.009gestational weight gain (kg)0.0590.0180.002 Triceps skinfold-for-age z-score 0.0880.003trimester 3 Vitamin C−0.0050.0030.035trimester 3 glycaemic index0.0530.0230.023 Subscapular Skinfold-for-age z-score 0.0710.045moderate pa baseline (number of 20 min intervals/day)0.1150.0450.013 thigh circumference 0.0990.001trimester 1 sodium0.0010.00030.013trimester 1 Carotene0.00020.000080.038trimester 3 Carbohydrate (%te)−0.0810.0340.019 Biceps Skinfold 0.1090.003trimester 1 Thiamine0.6030.2070.004baseline minutes sitting/weekday0.0020.0010.064trimester 3 glycaemic index0.1210.040.003 sum of Triceps and Subscapular Skinfolds 0.0670.015trimester 2 Vitamin C−0.0150.0050.007 waist:hip circumference ratio 0.163<0.001trimester 1 Vitamin B6−0.0280.0120.019trimester 3 potassium3.01e−058.39e−06<0.001trimester 1 Glycaemic index−0.0040.0010.004trimester 2 Saturated Fat (%te)0.0060.002<0.001\nbackwards stepwise multiple linear regression was used for this analysis * adjusted for well-established INFLUENCES on neonatal size.']	[('SUPERFICIAL_RELATIONSHIP', 1791)]	1	[('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('GO_0007565', 'female pregnancy', 81, 'postpartum'), ('CHEBI_33284', 'nutrient', 263, 'nutrient'), ('CHEBI_26710', 'sodium chloride', 521, 'saturated fatty'), ('CHEBI_87158', 'SU1498', 539, 'TE'), ('CHEBI_23042', 'carotene', 604, 'carotene9'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 644, 'PUFA'), ('UBERON_0001509', 'triceps brachii', 846, 'Triceps'), ('CHEBI_27300', 'vitamin D', 901, 'vitamin C'), ('UBERON_0012295', 'Guérin*s valve', 969, 'Subscapular skinfold'), ('CHEBI_87207', 'pyrimidine fungicide', 1161, 'carotene0'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 1199, 'carbohydrate'), ('UBERON_0001530', 'common carotid artery plus branches', 1234, 'Biceps'), ('UBERON_0009007', 'superficial inguinal lymph node', 1241, 'skinfold'), ('CHEBI_48466', 'glutaredoxin disulfide', 1272, 'thiamine0'), ('UBERON_0001509', 'triceps brachii', 1391, 'triceps'), ('UBERON_3010813', 'vent glands', 1403, 'subscapular skinfolds'), ('CHEBI_27300', 'vitamin D', 1447, 'vitamin C'), ('CHEBI_33237', 'vitamin D4', 1526, 'vitamin B6'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 1534, 'B6'), ('CHEBI_24400', 'glycoside', 1607, 'glycaemic'), ('CHEBI_26710', 'sodium chloride', 1650, 'saturated fat')]	0	['maternal late  6 months  measure offspring anthropometry observed.nutrients-08-00007-t003_table 3\n\ncaption (table-wrap): table 3\n\nmaternal paternal characteristics maternal nutrient intakes 6 months old offspring adiposity-adjusted *.model variabletotal bseb p -value r2adjp length z-score 0.0790.001trimester sodium0.00030.00010.003 age z-score 0.141<0.001trimester 2 saturated fatty (%te)0.0750.0270.005 length age z-score 0.186<0.001trimester carotene9.63e−050.000040.013trimester pufa (%te)0.1590.0490.002 bmi age z-score 0.0710.002trimester sodium0.00030.00010.003 muac-for-age z-score 0.1820.001trimester 3 sodium0.00030.00010.009gestational gain (kg)0.0590.0180.002 triceps skinfold-for-age z-score 0.0880.003trimester 3 −0.0050.0030.035trimester 3 glycaemic index0.0530.0230.023 subscapular skinfold-for-age z-score 0.0710.045moderate pa baseline (number 20 min intervals/day)0.1150.0450.013 thigh circumference 0.0990.001trimester sodium0.0010.00030.013trimester carotene0.00020.000080.038trimester 3 carbohydrate (%te)−0.0810.0340.019 biceps skinfold 0.1090.003trimester thiamine0.6030.2070.004baseline minutes sitting/weekday0.0020.0010.064trimester 3 glycaemic index0.1210.040.003 sum triceps subscapular skinfolds 0.0670.015trimester 2 −0.0150.0050.007 waist:hip circumference ratio 0.163<0.001trimester vitamin b6−0.0280.0120.019trimester 3 potassium3.01e−058.39e−06<0.001trimester glycaemic index−0.0040.0010.004trimester 2 saturated fat (%te)0.0060.002<0.001\nbackwards stepwise linear regression * adjusted neonatal size.']
S0-PMC4729160	PMC4729160	1/2016	S0-PMC4729160	['prevalence and INFLUENCE FACTORS of Vitamin A deficiency of chinese Pregnant women\n\nabstract\n\nbackground\nvitamin a plays an IMPORTANT ROLE in the periods of rapid Cellular Growth and Differentiation, especially during Pregnancy, which is supplied by the mother to the fetus.']	[('SUPERFICIAL_RELATIONSHIP', 15), ('SUPERFICIAL_RELATIONSHIP', 25), ('IMPORTANT_CONSIDERATION', 124), ('SUPERFICIAL_RELATIONSHIP', 134)]	4	[('CHEBI_27300', 'vitamin D', 36, 'vitamin A'), ('GO_0007565', 'female pregnancy', 68, 'pregnant'), ('GO_0001775', 'cell activation', 163, 'cellular growth ... differentiation'), ('GO_0007565', 'female pregnancy', 218, 'pregnancy')]	0	['prevalence  chinese  women\n\nabstract\n\nbackground\nvitamin plays periods rapid cellular differentiation, supplied mother fetus.']
S22-PMC4729160	PMC4729160	1/2016	S22-PMC4729160	['the MAJORITY of studies focus on vad of Pregnant women, it FOUND Vitamin A deficiency was strongly ASSOCIATED with Pregnancy and Birth outcomes.']	[('PROBABLE_UNDERSTANDING', 4), ('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 99)]	3	[('GO_0007565', 'female pregnancy', 40, 'pregnant'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin A'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('GO_0007567', 'parturition', 129, 'birth')]	0	['vad  women,   birth outcomes.']
S23-PMC4729160	PMC4729160	1/2016	S23-PMC4729160	['they FOUND Antenatal Vitamin A supplementation decreased anemia [4,5], Preterm Delivery [5,6], Intrauterine growth retardation [6], low Birth weight [4], deformity [7], preeclampsia/eclampsia [8,9], poor infant growth [4], neonatal and infant mortality [4,10], and maternal mortality [10,11].']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('GO_0007567', 'parturition', 11, 'antenatal'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('GO_0007565', 'female pregnancy', 71, 'preterm'), ('GO_0007567', 'parturition', 79, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 95, 'intrauterine'), ('GO_0007567', 'parturition', 136, 'birth')]	0	['antenatal  supplementation decreased anemia [4,5],  delivery [5,6], intrauterine retardation [6], birth [4], deformity [7], preeclampsia/eclampsia [8,9], infant [4], neonatal infant mortality [4,10], maternal mortality [10,11].']
S24-PMC4729160	PMC4729160	1/2016	S24-PMC4729160	['vitamin a status is assessed by the Serum concentration of Retinol, but there was little about its value as a MARKER of Vitamin A status during Pregnancy in china.']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('UBERON_0001977', 'blood serum', 36, 'serum'), ('CHEBI_26536', 'retinoic acid', 59, 'retinol'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A'), ('GO_0007565', 'female pregnancy', 144, 'pregnancy')]	0	['vitamin status serum concentration retinol,  status  china.']
S25-PMC4729160	PMC4729160	1/2016	S25-PMC4729160	['a PREVIOUS STUDY [12] which BASED ON SMALL sample size FOUND that chinese Pregnant women’s Vitamin A concentration was 1.13\u2009±\u20090.37\xa0μmol/l, and 24 of 143 Pregnant women (16.80\xa0%) was Vitamin A deficiency, while another 52 Pregnant women (36.4\xa0%) was marginal Vitamin A deficiency.']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 28), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 55)]	4	[('GO_0007565', 'female pregnancy', 74, 'pregnant'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin A'), ('GO_0007565', 'female pregnancy', 153, 'pregnant'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin A'), ('GO_0007565', 'female pregnancy', 221, 'pregnant'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin A')]	0	['[12] chinese  women’s  concentration 1.13\u2009±\u20090.37\xa0μmol/l, 24 143  women (16.80\xa0%)  deficiency, 52  women (36.4\xa0%)  deficiency.']
S87-PMC4729160	PMC4729160	1/2016	S87-PMC4729160	['62(0.24–1.62)–\u2003general rural areas72840.94(0.42–2.13)–\u2003poor rural areas332383.48(1.72–7.03)a4.73(2.67–8.41)acollege or university\u2003no527802.03(1.07–3.85)a3.17 (1.51–6.67)a\u2003yes1236511income\u2003\u2009<\u200910,000141854.60(1.30–16.24)a4.91 (1.31–18.46)a\u200310,000–20,000223174.21(1.24–14.26)a4.33 (1.18–15.90)a\u200320,000–30,000254613.29(0.98–11.03)a3.64 (1.01–13.16)a\u2003\u2009>\u2009=30,000318211drinking\u2003yes201184.00(2.26–6.94)a3.10 (1.65–5.81)a\u2003no44102711smoking\u2003non-smoker without passive smoking2452911\u2003non-smoker with passive smoking315941.15(0.67–1.99)–\u2003smokers9229.02(3.75–21.67)a5.68 (2.23–14.49)agestational age\u2003first trimester1046111\u2003second trimester182743.03(1.38–6.66)a2.40(1.05–5.46)a\u2003third trimester364104.05(1.98–8.26)a2.82(1.34–5.93)a\nastatistically significant at 0.05 level of significance\n\ndiscussion\nOUR STUDY FIRST REPORTED about the Vitamin A nutritional status in a large group of chinese Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 786), ('INCOMPLETE_EVIDENCE', 796), ('INCOMPLETE_EVIDENCE', 802)]	3	[('CHEBI_27300', 'vitamin D', 821, 'vitamin A'), ('GO_0007565', 'female pregnancy', 878, 'pregnant')]	0	['62(0.24–1.62)–\u2003general rural areas72840.94(0.42–2.13)–\u2003poor rural areas332383.48(1.72–7.03)a4.73(2.67–8.41)acollege university\u2003no527802.03(1.07–3.85)a3.17 (1.51–6.67)a\u2003yes1236511income\u2003\u2009<\u200910,000141854.60(1.30–16.24)a4.91 (1.31–18.46)a\u200310,000–20,000223174.21(1.24–14.26)a4.33 (1.18–15.90)a\u200320,000–30,000254613.29(0.98–11.03)a3.64 (1.01–13.16)a\u2003\u2009>\u2009=30,000318211drinking\u2003yes201184.00(2.26–6.94)a3.10 (1.65–5.81)a\u2003no44102711smoking\u2003non-smoker passive smoking2452911\u2003non-smoker passive smoking315941.15(0.67–1.99)–\u2003smokers9229.02(3.75–21.67)a5.68 (2.23–14.49)agestational age\u2003first trimester1046111\u2003second trimester182743.03(1.38–6.66)a2.40(1.05–5.46)a\u2003third trimester364104.05(1.98–8.26)a2.82(1.34–5.93)a\nastatistically 0.05 significance\n\ndiscussion\nour  nutritional status chinese  women.']
S94-PMC4729160	PMC4729160	1/2016	S94-PMC4729160	['in THE CURRENT STUDY, Pregnant women age and va status were negatively ASSOCIATED and the level of Vitamin A decreased with age.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 71)]	2	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin A')]	0	['study,  women age va status  decreased age.']
S100-PMC4729160	PMC4729160	1/2016	S100-PMC4729160	['the PRESENT STUDY SHOWED that Retinol concentrations of anemia and Pregnant women with Vitamin A supplements were higher than no anemia and Pregnant women without Vitamin A supplements.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('INCOMPLETE_EVIDENCE', 18)]	2	[('CHEBI_26536', 'retinoic acid', 30, 'retinol'), ('GO_0007565', 'female pregnancy', 67, 'pregnant'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin A'), ('GO_0007565', 'female pregnancy', 140, 'pregnant'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin A')]	0	['retinol concentrations anemia  women  supplements higher anemia  women  supplements.']
S108-PMC4729160	PMC4729160	1/2016	S108-PMC4729160	['this MAY REFLECT a TRUE reduction in Vitamin A stores with increasing Gestation, as PROPOSED by a large trial of weekly Vitamin A supplementation in bangladesh [24].']	[('INCOMPLETE_EVIDENCE', 5), ('PROBABLE_UNDERSTANDING', 9), ('PROBABLE_UNDERSTANDING', 19), ('INCOMPLETE_EVIDENCE', 84)]	4	[('CHEBI_27300', 'vitamin D', 37, 'vitamin A'), ('GO_0007565', 'female pregnancy', 70, 'gestation'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A')]	0	['reduction  stores weekly  supplementation bangladesh [24].']
S127-PMC4729160	PMC4729160	1/2016	S127-PMC4729160	['it is also LACK OF assessment of the participants’ physical behavior condition which INFLUENCES Vitamin A status of chinese Pregnant women.']	[('FULL_UNKNOWN', 11), ('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 85)]	3	[('CHEBI_27300', 'vitamin D', 96, 'vitamin A'), ('GO_0007565', 'female pregnancy', 124, 'pregnant')]	0	['participants’ physical behavior condition  status chinese  women.']
S128-PMC4729160	PMC4729160	1/2016	S128-PMC4729160	['MORE STUDIES ARE NEEDED to understand the INFLUENCE FACTORS of Vitamin A status of chinese Pregnant women.']	[('ANOMALY_CURIOUS_FINDING', 0), ('FUTURE_WORK', 5), ('SUPERFICIAL_RELATIONSHIP', 42)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin A'), ('GO_0007565', 'female pregnancy', 91, 'pregnant')]	0	[' status chinese  women.']
S129-PMC4729160	PMC4729160	1/2016	S129-PMC4729160	['conclusions\nIN SUMMARY, THE CURRENT STUDY REPORTED the prevalence of Vitamin A among chinese Pregnant women and the prevalence of vad was 5.3\xa0%, which was a MILD PUBLIC-HEALTH ISSUE in china.']	[('INCOMPLETE_EVIDENCE', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('INCOMPLETE_EVIDENCE', 42), ('IMPORTANT_CONSIDERATION', 157), ('IMPORTANT_CONSIDERATION', 162), ('IMPORTANT_CONSIDERATION', 176)]	6	[('CHEBI_27300', 'vitamin D', 69, 'vitamin A'), ('GO_0007565', 'female pregnancy', 93, 'pregnant')]	0	['conclusions\nin summary,  among chinese  women vad 5.3\xa0%, public-health china.']
S132-PMC4729160	PMC4729160	1/2016	S132-PMC4729160	['so in the FUTURE health public policy on Vitamin A SHOULD BE paid more ATTENTION on Pregnant women with pertinent INFLUENCE FACTORS of vad, accordingly, eliminate vad improve the nutritional status of chinese Pregnant women.']	[('FUTURE_WORK', 10), ('FUTURE_WORK', 51), ('IMPORTANT_CONSIDERATION', 71), ('SUPERFICIAL_RELATIONSHIP', 114), ('SUPERFICIAL_RELATIONSHIP', 124)]	5	[('CHEBI_27300', 'vitamin D', 41, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 49, 'A'), ('GO_0007565', 'female pregnancy', 84, 'pregnant'), ('GO_0007565', 'female pregnancy', 209, 'pregnant')]	0	['policy   women vad, accordingly, eliminate vad nutritional status chinese  women.']
S30-PMC4730270	PMC4730270	12/2015	S30-PMC4730270	['risks AFFECTING early-Life bp of offspring examined in these cohorts include smoking, low Vitamin D intake, Gestational hypertension, maternal obesity, short-term breastfeeding, excessive Postnatal weight gain, and undernutrition [10,11,12,13,14,15,16,17,18,19,20].']	[('SUPERFICIAL_RELATIONSHIP', 6)]	1	[('UBERON_0000104', 'life cycle', 22, 'life'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'gestational'), ('GO_0007567', 'parturition', 188, 'postnatal')]	0	['risks early-life bp offspring cohorts smoking,  intake,  hypertension, maternal obesity, short-term breastfeeding, excessive postnatal gain, undernutrition [10,11,12,13,14,15,16,17,18,19,20].']
S31-PMC4764019	PMC4764019	1/2016	S31-PMC4764019	['once again, may Births would have followed a winter-long, Vitamin D–deprived Pregnancy, WHEREAS november Births would have followed a summer-long pregnancy with PRESUMABLY higher Vitamin D status values.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 88), ('PROBABLE_UNDERSTANDING', 161)]	2	[('GO_0007567', 'parturition', 16, 'births'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('GO_0007567', 'parturition', 105, 'births'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D')]	0	['again, births followed winter-long, –deprived november births followed summer-long pregnancy higher  status values.']
S36-PMC4764019	PMC4764019	1/2016	S36-PMC4764019	['pregnancy complications\none of the most STRIKING and SURPRISING findings to emerge from the finnish Birth cohort study DESCRIBED PREVIOUSLY was the fact that 20+ years after their infancy exposure to Vitamin D, women in the cohort who, as Adults, became Pregnant exhibited an APPROXIMATE 50% reduction in risk of Preeclampsia in their own first Pregnancies,8once again, relative to women who had not received the then RECOMMENDED 2000 iu/d of Vitamin D in infancy.']	[('ANOMALY_CURIOUS_FINDING', 40), ('ANOMALY_CURIOUS_FINDING', 53), ('INCOMPLETE_EVIDENCE', 119), ('INCOMPLETE_EVIDENCE', 129), ('INCOMPLETE_EVIDENCE', 276), ('FUTURE_WORK', 418)]	6	[('GO_0007567', 'parturition', 100, 'birth'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D'), ('UBERON_0007023', 'adult organism', 239, 'adults'), ('GO_0007565', 'female pregnancy', 254, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 313, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 345, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 443, 'vitamin D')]	0	['pregnancy complications\none 20+ infancy exposure women who, adults, became  50% reduction preeclampsia ,8once again, relative women received 2000 iu/d  infancy.']
S49-PMC4764019	PMC4764019	1/2016	S49-PMC4764019	['this is BECAUSE, EVEN IF there were no connection between the Vitamin D status and the observed Learning difficulty, the group of Pregnant women to be studied would HAVE TO BE placed and maintained on a Vitamin D status, which is recognized to be INADEQUATE on OTHER grounds (ie, <18 ng/ml) and THEREFORE productive of harmful outcomes.']	[('PROBLEM_COMPLICATION', 8), ('ANOMALY_CURIOUS_FINDING', 17), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('IMPORTANT_CONSIDERATION', 165), ('IMPORTANT_CONSIDERATION', 247), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 261), ('PROBABLE_UNDERSTANDING', 295)]	7	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007612', 'learning', 96, 'learning'), ('GO_0007565', 'female pregnancy', 130, 'pregnant'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D')]	0	['because,  status learning difficulty,  women  status, (ie, <18 ng/ml) productive outcomes.']
S125-PMC4765528	PMC4765528	12/2015	S125-PMC4765528	['further work from that group also SUGGESTS that maternal Vitamin D stores CAN INFLUENCE Fetal Femoral Development at as early as 19 weeks Gestation [59].']	[('INCOMPLETE_EVIDENCE', 34), ('INCOMPLETE_EVIDENCE', 74), ('SUPERFICIAL_RELATIONSHIP', 78)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007631', 'feeding behavior', 88, 'fetal'), ('GO_0009556', 'microsporogenesis', 94, 'femoral development'), ('UBERON_0000981', 'femur', 94, 'femoral'), ('GO_0007565', 'female pregnancy', 138, 'gestation')]	0	['maternal  stores fetal femoral 19 weeks  [59].']
S1-PMC4770602	PMC4770602	1/2016	S1-PMC4770602	['the AIM of the PRESENT STUDY was TO INVESTIGATE the ASSOCIATION between Vitamin D supplement and Preeclampsia in Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('SUPERFICIAL_RELATIONSHIP', 52)]	4	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 97, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]	0	[' supplement preeclampsia  women.']
S9-PMC4770602	PMC4770602	1/2016	S9-PMC4770602	['conclusion:\nIN SUMMARY, our results DEMONSTRATED that Vitamin D supplementation during the third Trimester of Pregnancy; DESPITE the non-significant ASSOCIATION between Vitamin D supplementation and preeclampsia, reduce the risk of preeclampsia.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 36), ('ANOMALY_CURIOUS_FINDING', 121), ('SUPERFICIAL_RELATIONSHIP', 149)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 97, 'trimester'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]	0	['conclusion:\nin summary, results  supplementation third trimester non-significant  supplementation preeclampsia, preeclampsia.']
S14-PMC4770602	PMC4770602	1/2016	S14-PMC4770602	['[123] data from SOME STUDIES SUPPORTS ASSOCIATIONS of Vitamin D deficiency and Preterm Birth, decreased Birth weight, and hypertensive disease in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 38)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'preterm'), ('GO_0007567', 'parturition', 87, 'birth'), ('GO_0007567', 'parturition', 104, 'birth'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy')]	0	['[123]   birth, decreased birth weight, hypertensive disease .']
S21-PMC4770602	PMC4770602	1/2016	S21-PMC4770602	['[5] deficiency of Vitamin D is diagnosed at level of <32 ng/ml and using the secriteria,[10] Vitamin D deficiency is very common in Pregnancy with up to 50% of Individuals,[111213] THOUGH, DEPENDING ON the country of residence and local clothing customs, a prevalence ranges from 18-84% is REPORTED by PREVIOUS STUDIES.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 181), ('ANOMALY_CURIOUS_FINDING', 181), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 189), ('INCOMPLETE_EVIDENCE', 290), ('INCOMPLETE_EVIDENCE', 302)]	5	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('GO_0007565', 'female pregnancy', 132, 'pregnancy'), ('NCBITaxon_1', 'root', 160, 'individuals')]	0	['[5]  diagnosed <32 ng/ml using secriteria,[10]   50% individuals,[111213] though, country residence local clothing customs, ranges 18-84% studies.']
S22-PMC4770602	PMC4770602	1/2016	S22-PMC4770602	['[14151617] lack of adequate sunlight exposure NEEDED to synthesize Vitamin D3 in the skin, and Oral intakes that are TOO low TO meet the increased demands of Pregnancy are REASONS of epidemic deficiency of Vitamin D during Pregnancy.']	[('IMPORTANT_CONSIDERATION', 46), ('DIFFICULT_TASK', 117), ('PROBABLE_UNDERSTANDING', 172)]	3	[('CHEBI_33279', 'vitamin D5', 67, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 67, 'vitamin D3'), ('UBERON_0000165', 'mouth', 95, 'oral'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('GO_0007565', 'female pregnancy', 223, 'pregnancy')]	0	['[14151617] sunlight exposure synthesize vitamin d3 skin, oral intakes meet   .']
S23-PMC4770602	PMC4770602	1/2016	S23-PMC4770602	['[518]\nbased ON the ROLE of maternal Vitamin D deficiency, AS a POTENTIAL in DEPENDENT RISK FACTOR for Preeclampsia, Vitamin D supplementation in early Pregnancy REMAINS a POSSIBLE intervention and POSSIBLE improved Pregnancy outcomes through PREVENTION or delay of Preeclampsia.']	[('ANOMALY_CURIOUS_FINDING', 12), ('ANOMALY_CURIOUS_FINDING', 12), ('SUPERFICIAL_RELATIONSHIP', 19), ('PROBABLE_UNDERSTANDING', 58), ('INCOMPLETE_EVIDENCE', 63), ('SUPERFICIAL_RELATIONSHIP', 76), ('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 161), ('INCOMPLETE_EVIDENCE', 171), ('INCOMPLETE_EVIDENCE', 197), ('SUPERFICIAL_RELATIONSHIP', 242)]	11	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 102, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 265, 'preeclampsia')]	0	['[518]\nbased maternal  deficiency, preeclampsia,  supplementation   outcomes delay preeclampsia.']
S24-PMC4770602	PMC4770602	1/2016	S24-PMC4770602	['furthermore, because Vitamin D supplementation is simple and cost-effective with a low LIKELIHOOD of toxicity, increased supplementation in Pregnant women is RECOMMEND previously.']	[('PROBABLE_UNDERSTANDING', 87), ('FUTURE_WORK', 158)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 140, 'pregnant')]	0	['furthermore,  supplementation cost-effective toxicity, supplementation  women previously.']
S25-PMC4770602	PMC4770602	1/2016	S25-PMC4770602	['and FURTHER prospective longitudinal STUDIES or randomized controlled trials to assess the POTENTIAL EFFECT of Vitamin D supplementation on adverse Pregnancy outcomes are SUGGESTED.']	[('FUTURE_WORK', 4), ('INCOMPLETE_EVIDENCE', 91), ('SUPERFICIAL_RELATIONSHIP', 101), ('INCOMPLETE_EVIDENCE', 171)]	4	[('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy')]	0	['longitudinal  supplementation  outcomes suggested.']
S58-PMC4770602	PMC4770602	1/2016	S58-PMC4770602	['cases included 68 pregnant women who received supplementation contain Vitamin D (600 iu/d) and control group included 70 pregnant women who received supplementation without Vitamin D. differences between both groups were not statistically significant ( p -value = 0.84)\n\ndiscussion\nEVIDENCE TO EVALUATE the effectiveness of Vitamin D in Pregnancy is no enough and much of what we KNOW comes from observational RATHER than experimental design, THEREFORE, AT PRESENT Vitamin D supplementation is NOT routinely offered to all pregnant women.']	[('INCOMPLETE_EVIDENCE', 282), ('QUESTION_ANSWERED_BY_THIS_WORK', 291), ('INCOMPLETE_EVIDENCE', 380), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 410), ('PROBABLE_UNDERSTANDING', 443), ('INCOMPLETE_EVIDENCE', 454), ('ANOMALY_CURIOUS_FINDING', 494)]	7	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 324, 'vitamin D'), ('GO_0007565', 'female pregnancy', 337, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 465, 'vitamin D')]	0	['cases 68 pregnant women received supplementation contain  (600 iu/d) 70 pregnant women received supplementation . statistically p -value = 0.84)\n\ndiscussion\nevidence   comes design, therefore,  supplementation routinely offered pregnant women.']
S64-PMC4770602	PMC4770602	1/2016	S64-PMC4770602	['[3] in the norwegian mother and child cohort study, the ASSOCIATION between Intake of Vitamin D during Pregnancy and the risk of Preeclampsia in 23,423 Nulliparous Pregnant women was ESTIMATED and authors OBSERVED 27% reduction in risk of Preeclampsia after Vitamin D supplementation in these women.']	[('SUPERFICIAL_RELATIONSHIP', 56), ('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 205)]	3	[('GO_0007631', 'feeding behavior', 76, 'intake'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 129, 'preeclampsia'), ('GO_0046662', 'regulation of oviposition', 152, 'nulliparous'), ('GO_0007565', 'female pregnancy', 164, 'pregnant'), ('GO_0007128', 'meiotic prophase I', 239, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]	0	['[3] norwegian mother child study, intake   preeclampsia 23,423 nulliparous  women authors 27% reduction preeclampsia  supplementation women.']
S65-PMC4770602	PMC4770602	1/2016	S65-PMC4770602	"['[""""[8] investigators in ANOTHER cohort STUDY REPORTED that the risk of Preeclampsia in the female offspring\'s first Pregnancy reduced after regular supplementation with Vitamin D in the first year of Life.""""]']"	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 42)]	2	[('GO_0007128', 'meiotic prophase I', 68, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('UBERON_0000104', 'life cycle', 197, 'life')]	0	"['[""""[8] preeclampsia female offspring*s firncy supplementation win year life.""""]']"
S66-PMC4770602	PMC4770602	1/2016	S66-PMC4770602	['[20] also, ROLE of Vitamin D in the PREVENTION of Preeclampsia is SUPPORTED by two clinical TRIALS, HOWEVER, in one of these STUDIES as an uncontrolled trial, supplementation with a multivitamin/Mineral supplement and halibut Liver oil provided at 20 week Gestation reduced the odds of Preeclampsia.']	[('SUPERFICIAL_RELATIONSHIP', 11), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 66), ('FUTURE_WORK', 92), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 100), ('INCOMPLETE_EVIDENCE', 125)]	6	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 50, 'preeclampsia'), ('CHEBI_46662', 'mineral', 195, 'mineral'), ('UBERON_0002107', 'liver', 226, 'liver'), ('GO_0007565', 'female pregnancy', 256, 'gestation'), ('GO_0007128', 'meiotic prophase I', 286, 'preeclampsia')]	0	['[20] also,  preeclampsia trials, however, trial, supplementation multivitamin/mineral supplement halibut liver oil 20 week  preeclampsia.']
S67-PMC4770602	PMC4770602	1/2016	S67-PMC4770602	['[21] in other study,400 women at 20-24 week Gestation randomized to Vitamin D and Calcium supplements or no treatment, results of this study SHOWS that in the treated group reduction occurred in the incidence of Preeclampsia compared with the untreated group THOUGH this was not statistically significant.']	[('INCOMPLETE_EVIDENCE', 141), ('ANOMALY_CURIOUS_FINDING', 259)]	2	[('GO_0007565', 'female pregnancy', 44, 'gestation'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 82, 'calcium'), ('GO_0007128', 'meiotic prophase I', 212, 'preeclampsia')]	0	['[21] study,400 women 20-24 week   calcium supplements treatment, results treated reduction preeclampsia untreated statistically significant.']
S69-PMC4770602	PMC4770602	1/2016	S69-PMC4770602	['indirectly, during the Gestation Vitamin D consumption MAY AFFECT infant Birth weight.']	[('INCOMPLETE_EVIDENCE', 55), ('SUPERFICIAL_RELATIONSHIP', 59)]	2	[('GO_0007565', 'female pregnancy', 23, 'gestation'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007567', 'parturition', 73, 'birth')]	0	['indirectly,   consumption infant birth weight.']
S71-PMC4770602	PMC4770602	1/2016	S71-PMC4770602	['this result is in SIMILAR with OTHER FINDINGS which REPORTED that Intake of milk, and THEREFORE Vitamin D and Calcium, during Pregnancy is ASSOCIATED with increased infant birth weight.']	[('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 52), ('PROBABLE_UNDERSTANDING', 86), ('SUPERFICIAL_RELATIONSHIP', 139)]	5	[('GO_0007631', 'feeding behavior', 66, 'intake'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 110, 'calcium'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy')]	0	['result intake milk,  calcium,  infant birth weight.']
S74-PMC4770602	PMC4770602	1/2016	S74-PMC4770602	['[25] also, marya et al ., REPORTED the highest Birth weight of infants in mothers who received 600,000 iu of Vitamin D during the seventh and eighth months, of Pregnancy.']	[('INCOMPLETE_EVIDENCE', 26)]	1	[('GO_0007567', 'parturition', 47, 'birth'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy')]	0	['[25] also, marya et al ., birth infants mothers received 600,000 iu  seventh eighth months, .']
S75-PMC4770602	PMC4770602	1/2016	S75-PMC4770602	['[22] IN CONTRAST WITH our results OTHER study SHOWED that low Birth weight is NOTED in infants of mothers supplemented with Vitamin D.\nwe THINKS that some POSSIBLE LIMITATIONS of the present study that SHOULD BE addressed and noted in FUTURE STUDIES are included; unmeasured sun exposure, maternal baseline 25-Oh-D and Preconception, physical activity, local area and early Pregnancy dietary Intake to HELP realize the EFFECT of these FACTORS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 34), ('INCOMPLETE_EVIDENCE', 46), ('ANOMALY_CURIOUS_FINDING', 78), ('INCOMPLETE_EVIDENCE', 138), ('INCOMPLETE_EVIDENCE', 155), ('INCOMPLETE_EVIDENCE', 164), ('FUTURE_WORK', 202), ('FUTURE_WORK', 235), ('FUTURE_WORK', 402), ('SUPERFICIAL_RELATIONSHIP', 419), ('SUPERFICIAL_RELATIONSHIP', 435)]	12	[('GO_0007567', 'parturition', 62, 'birth'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 307, '25-OH-D'), ('PR_000000164', 'BMP2', 309, '-OH'), ('PR_000006444', 'diacylglycerol kinase delta', 313, 'D'), ('GO_0007565', 'female pregnancy', 319, 'preconception'), ('GO_0007565', 'female pregnancy', 374, 'pregnancy'), ('GO_0007631', 'feeding behavior', 392, 'intake')]	0	['[22] results birth infants mothers supplemented .\nwe included; sun exposure, maternal baseline 25-oh-d physical activity, local  dietary intake realize factors.']
S79-PMC4770602	PMC4770602	1/2016	S79-PMC4770602	['in CONCLUSION, results of the PRESENT STUDY DEMONSTRATED that Vitamin D supplementation during the third Trimester of Pregnancy; reduce the RISK of Preeclampsia HOWEVER, this was not statistically significant.']	[('INCOMPLETE_EVIDENCE', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 30), ('INCOMPLETE_EVIDENCE', 44), ('IMPORTANT_CONSIDERATION', 140), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 161)]	5	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 105, 'trimester'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 148, 'preeclampsia')]	0	['conclusion, results  supplementation third trimester preeclampsia however, statistically significant.']
S76-PMC4772030	PMC4772030	1/2016	S76-PMC4772030	['mff as an additional Food ration in the basic Food basket increased estimated daily intakes, in particular for Vitamin A, b-Vitamins (Thiamine, riboflavin and Nicotinamide), Ascorbic Acid, zinc and iron, while the supplementary oil ration for Pregnant women ESPECIALLY improved the intakes of Tocopherols (table 2).']	[('ANOMALY_CURIOUS_FINDING', 258)]	1	[('CHEBI_33290', 'food', 21, 'food'), ('CHEBI_33290', 'food', 46, 'food'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin A'), ('CHEBI_33277', 'gamma-tocotrienol', 124, 'vitamins'), ('CHEBI_26948', 'vitamin B1', 134, 'thiamine'), ('CHEBI_17154', 'nicotinamide', 159, 'nicotinamide'), ('CHEBI_22652', 'ascorbic acid', 174, 'ascorbic acid'), ('GO_0007565', 'female pregnancy', 243, 'pregnant'), ('CHEBI_27013', 'tocopherol', 293, 'tocopherols')]	0	['mff food ration food basket daily intakes, b-vitamins (thiamine, riboflavin nicotinamide), ascorbic acid, zinc iron, supplementary oil ration  women intakes tocopherols (table 2).']
S22-PMC4778858	PMC4778858	3/2016	S22-PMC4778858	['frank maternal Vitamin D deficiency, using levels ranging from less than 12–15.5 ng/ml, HAS BEEN ASSOCIATED with low Birth weight [13], increased rates of small for Gestational age Births [13,14], and gdm [15].']	[('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 97)]	2	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007567', 'parturition', 117, 'birth'), ('GO_0007565', 'female pregnancy', 165, 'gestational'), ('GO_0007567', 'parturition', 181, 'births')]	0	['frank maternal  deficiency, using levels 12–15.5 ng/ml, birth [13], rates  age births [13,14], gdm [15].']
S23-PMC4778858	PMC4778858	3/2016	S23-PMC4778858	['HOWEVER, PREVIOUS STUDIES on Birth weight outcomes and RISK of gdm among Vitamin D deficient mothers DID NOT adequately address rates of maternal obesity, used an inaccurate vitamin d assay, or studied neonates of varying Gestational ages, thus CONFOUNDING interpretation of results.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('IMPORTANT_CONSIDERATION', 55), ('INCOMPLETE_EVIDENCE', 101), ('PROBLEM_COMPLICATION', 245)]	5	[('GO_0007567', 'parturition', 29, 'birth'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 222, 'gestational')]	0	['however, birth outcomes gdm among  mothers rates maternal obesity, vitamin assay, neonates  ages, results.']
S106-PMC4778858	PMC4778858	3/2016	S106-PMC4778858	['THUS, well-designed, interventional studies, with both neonatal and longitudinal follow up outcomes, are NECESSARY in order to provide improved RECOMMENDATIONS for Vitamin D supplementation in Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 105), ('FUTURE_WORK', 144)]	3	[('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy')]	0	['thus, well-designed, interventional studies, neonatal longitudinal outcomes,  supplementation .']
S118-PMC4778858	PMC4778858	3/2016	S118-PMC4778858	['however, Vitamin D levels at the start of Pregnancy among these women are NOT KNOWN.']	[('FULL_UNKNOWN', 74)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy')]	0	['however,  levels  among women known.']
S119-PMC4778858	PMC4778858	3/2016	S119-PMC4778858	['furthermore, supplementation of Vitamin D during Pregnancy CONFOUNDS the outcomes.']	[('PROBLEM_COMPLICATION', 59)]	1	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 49, 'pregnancy')]	0	['furthermore, supplementation   outcomes.']
S120-PMC4778858	PMC4778858	3/2016	S120-PMC4778858	['WHETHER the Vitamin D amount of 400–600 iu of D2Or D3In most Prenatal Vitamin formulations is sufficient to maintain levels > 30 ng/ml, especially among obese women, REMAINS UNKNOWN.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FULL_UNKNOWN', 166)]	2	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('PR_000011011', 'neurobeachin-like protein 1', 46, 'D2or D3in'), ('GO_0007565', 'female pregnancy', 61, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 70, 'vitamin')]	0	['whether  amount 400–600 iu d2or d3in  vitamin formulations maintain levels > 30 ng/ml, among obese women, unknown.']
S130-PMC4778858	PMC4778858	3/2016	S130-PMC4778858	['information on Prenatal Vitamin use or additional Vitamin D supplementation within this cohort WAS NOT COLLECTED.']	[('INCOMPLETE_EVIDENCE', 95), ('INCOMPLETE_EVIDENCE', 99)]	2	[('GO_0007565', 'female pregnancy', 15, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 24, 'vitamin'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]	0	['information  vitamin  supplementation collected.']
S87-PMC4784858	PMC4784858	3/2016	S87-PMC4784858	['EVEN IF national GUIDELINES RECOMMEND the use of dietary supplements to meet REQUIREMENTS for some Nutrients (Folate, Vitamin D, iron or Iodine) during Pregnancy, Nutrient intakes from dietary supplements were not included in the pandiet calculation, like in other studies using diet quality indexes for Pregnancy [11–13].']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('PROBABLE_UNDERSTANDING', 17), ('FUTURE_WORK', 28), ('IMPORTANT_CONSIDERATION', 77)]	5	[('CHEBI_33284', 'nutrient', 99, 'nutrients'), ('CHEBI_30863', '5-azaorotic acid', 110, 'folate'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 137, 'iodine'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('CHEBI_33284', 'nutrient', 163, 'nutrient'), ('GO_0007565', 'female pregnancy', 304, 'pregnancy')]	0	['even national dietary supplements meet nutrients (folate, iron iodine) nutrient intakes dietary supplements pandiet calculation, using diet  [11–13].']
S132-PMC4784858	PMC4784858	3/2016	S132-PMC4784858	['such was the case for 8 out of 34 Nutrients (Thiamin, riboflavin, niacin, Vitamin B6, Folate, Vitamin D, Iodine and zinc) for the french sample and 12 out of 30 (la, ala, Vitamin A, Thiamin, riboflavin, niacin, Vitamin B6, Folate, Vitamin B12, Vitamin C, magnesium and zinc) for the us sample (s4 table).fig 2presents the five Vitamins and Minerals for which the probability of adequacy was lowered the most in the french sample (Thiamin, niacin, Vitamin B6, Folate and Iodine) and in the us sample (Thiamin, Vitamin B6, folate, magnesium and zinc).10.1371/journal.pone.0149858.g002\n\ncaption (fig): fig 2\nprobabilities of adequacy composing pandiet scores for the five Vitamins and Minerals for which the PROBABILITY of adequacy was lowered the most when simulating the changes in the nutritional requirements in the First Trimester of Pregnancy in the french sample (left panel) and in the us sample (right panel).']	[('PROBABLE_UNDERSTANDING', 705)]	1	[('CHEBI_33284', 'nutrient', 34, 'nutrients'), ('CHEBI_26948', 'vitamin B1', 45, 'thiamin'), ('CHEBI_33237', 'vitamin D4', 74, 'vitamin B6'), ('CHEBI_30863', '5-azaorotic acid', 86, 'folate'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 105, 'iodine'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin A'), ('CHEBI_26948', 'vitamin B1', 182, 'thiamin'), ('CHEBI_33237', 'vitamin D4', 211, 'vitamin B6'), ('CHEBI_30863', '5-azaorotic acid', 223, 'folate'), ('CHEBI_33279', 'vitamin D5', 231, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 244, 'vitamin C'), ('CHEBI_33277', 'gamma-tocotrienol', 327, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 340, 'minerals'), ('CHEBI_26948', 'vitamin B1', 430, 'thiamin'), ('CHEBI_33237', 'vitamin D4', 447, 'vitamin B6'), ('CHEBI_30863', '5-azaorotic acid', 459, 'folate'), ('CHEBI_24859', 'iodine atom', 470, 'iodine'), ('CHEBI_26948', 'vitamin B1', 500, 'thiamin'), ('CHEBI_33237', 'vitamin D4', 509, 'vitamin B6'), ('CHEBI_33277', 'gamma-tocotrienol', 669, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 682, 'minerals'), ('GO_0007631', 'feeding behavior', 817, 'first'), ('GO_0009294', 'DNA mediated transformation', 823, 'trimester'), ('GO_0007565', 'female pregnancy', 836, 'pregnancy')]	0	['8 34 nutrients (thiamin, riboflavin, niacin, vitamin b6, folate, iodine zinc) french sample 12 30 (la, ala, thiamin, riboflavin, niacin, vitamin b6, folate, vitamin b12, magnesium zinc) us sample (s4 table).fig 2presents five vitamins minerals lowered french sample (thiamin, niacin, vitamin b6, folate iodine) us sample (thiamin, vitamin b6, folate, magnesium zinc).10.1371/journal.pone.0149858.g002\n\ncaption (fig): fig 2\nprobabilities composing pandiet scores five vitamins minerals lowered simulating changes nutritional trimester  french sample (left panel) us sample (right panel).']
S149-PMC4784858	PMC4784858	3/2016	S149-PMC4784858	['by focusing on Nutrients CONSIDERED as KEY during Pregnancy in french nutritional guidelines: Folate, Vitamin D, Calcium, Iodine and Iron (36) plus Dha, we NOTED that three snack additions (‘cereal bar and yogurt’, ‘toasts and egg’ and ‘pita bread filled with salad and Tuna’) and the proportional increase in Consumed Food weight increased probabilities of adequacy for four key Nutrient Intakes during Pregnancy.']	[('IMPORTANT_CONSIDERATION', 25), ('IMPORTANT_CONSIDERATION', 39), ('ANOMALY_CURIOUS_FINDING', 156)]	3	[('CHEBI_33284', 'nutrient', 15, 'nutrients'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('CHEBI_30863', '5-azaorotic acid', 94, 'folate'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 113, 'calcium'), ('CHEBI_24859', 'iodine atom', 122, 'iodine'), ('CHEBI_24870', 'ion', 133, 'iron'), ('CHEBI_17874', 'dihydrozeatin', 148, 'DHA'), ('NCBITaxon_10088', 'Mus <genus>', 270, 'tuna'), ('GO_0007631', 'feeding behavior', 310, 'consumed'), ('CHEBI_33290', 'food', 319, 'food'), ('CHEBI_33284', 'nutrient', 380, 'nutrient'), ('GO_0007631', 'feeding behavior', 389, 'intakes'), ('GO_0007565', 'female pregnancy', 404, 'pregnancy')]	0	['nutrients  french nutritional guidelines: folate, calcium, iodine iron (36) plus dha, three snack additions (‘cereal bar yogurt’, ‘toasts egg’ ‘pita bread filled salad tuna’) proportional increase consumed food probabilities four nutrient intakes .']
S0-PMC4785305	PMC4785305	3/2016	S0-PMC4785305	['EFFECT of Vitamin D replacement on maternal and neonatal outcomes: a randomised controlled trial in Pregnant women with hypovitaminosis D. a protocol\n\nabstract\n\nintroduction\nthe Vitamin D RECOMMENDED doses during Pregnancy differ between societies.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('FUTURE_WORK', 188)]	2	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 136, 'D'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy')]	0	['effect  replacement maternal neonatal outcomes: randomised  women hypovitaminosis d. protocol\n\nabstract\n\nintroduction\nthe  doses  societies.']
S3-PMC4785305	PMC4785305	3/2016	S3-PMC4785305	['our HYPOTHESIS is that in middle eastern Pregnant women, a Vitamin D dose of 3000\u2005iu/day is REQUIRED to reach a DESIRABLE maternal 25-Hydroxyvitamin D [25(Oh)D] level, and to positively IMPACT infant bone Mineral content (bmc).']	[('INCOMPLETE_EVIDENCE', 4), ('IMPORTANT_CONSIDERATION', 92), ('IMPORTANT_CONSIDERATION', 112), ('SUPERFICIAL_RELATIONSHIP', 186)]	4	[('GO_0007565', 'female pregnancy', 41, 'pregnant'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 131, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 152, '25(OH)D'), ('CHEBI_46662', 'mineral', 205, 'mineral')]	0	['middle eastern  women,  dose 3000\u2005iu/day maternal 25-hydroxyvitamin [25(oh)d] level, positively infant bone mineral content (bmc).']
S19-PMC4785305	PMC4785305	3/2016	S19-PMC4785305	['the findings of this trial will help guide the public health policymaker regarding Vitamin D supplementation in Pregnant women and will allow a step forward in EVIDENCE-BASED RECOMMENDATIONS SPECIFIC to the middle east.']	[('INCOMPLETE_EVIDENCE', 160), ('FUTURE_WORK', 175), ('FUTURE_WORK', 191)]	3	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnant')]	0	['policymaker regarding  supplementation  women step middle east.']
S22-PMC4785305	PMC4785305	3/2016	S22-PMC4785305	['WHILE the total Calcitriol levels double in the first trimester, free Calcitriol levels do not increase until the third trimester and remain so until Lactation.24conversely, Parathyroid hormone (pth) levels decrease early on and increase back to mid-normal range by term.2the total calcium level decreases during Pregnancy, due to haemodilution, WHILE the ionised calcium level remains stable.2vitamin D binding proteins also increase during Pregnancy secondary to high Oestrogen levels,45but the 25-Hydroxyvitamin D (25(Oh)D) level, the single best nutritional INDICATOR of Vitamin D status,6remains stable.7the changes in Calcitriol levels led to the description of Pregnancy as a state of ‘absorptive hypercalciuria’.12the above Adaptive physiology is KEY to SAFETY CONSIDERATIONS when using Vitamin D supplementation during Pregnancy, as well as to determining key biochemical and hormonal parameters to be monitored.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 346), ('SUPERFICIAL_RELATIONSHIP', 562), ('IMPORTANT_CONSIDERATION', 755), ('IMPORTANT_CONSIDERATION', 762), ('IMPORTANT_CONSIDERATION', 769)]	6	[('CHEBI_17823', 'calcitriol', 16, 'calcitriol'), ('CHEBI_17823', 'calcitriol', 70, 'calcitriol'), ('GO_0007595', 'lactation', 150, 'lactation'), ('UBERON_0001132', 'parathyroid gland', 174, 'parathyroid'), ('GO_0007565', 'female pregnancy', 313, 'pregnancy'), ('PR_000006444', 'diacylglycerol kinase delta', 402, 'D'), ('GO_0007565', 'female pregnancy', 442, 'pregnancy'), ('CHEBI_50114', 'estrogen', 470, 'oestrogen'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 497, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 518, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 575, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 624, 'calcitriol'), ('GO_0007565', 'female pregnancy', 668, 'pregnancy'), ('GO_0018888', '3-chloroacrylic acid metabolic process', 732, 'adaptive'), ('CHEBI_27300', 'vitamin D', 795, 'vitamin D'), ('GO_0007565', 'female pregnancy', 828, 'pregnancy')]	0	['calcitriol levels trimester, calcitriol levels increase third trimester lactation.24conversely, parathyroid hormone (pth) levels decrease increase back mid-normal term.2the calcium decreases haemodilution, ionised calcium stable.2vitamin binding proteins increase  secondary oestrogen levels,45but 25-hydroxyvitamin (25(oh)d) level, single nutritional  status,6remains stable.7the changes calcitriol levels  ‘absorptive hypercalciuria’.12the adaptive physiology using  supplementation biochemical hormonal parameters monitored.']
S23-PMC4785305	PMC4785305	3/2016	S23-PMC4785305	['maternal Vitamin D status during Pregnancy\nvitamin D deficiency during Pregnancy is PREVALENT worldwide, ESPECIALLY in developing countries.8in a systematic review of 18 studies conducted in western countries during the first Trimester, white caucasian Pregnant women were found to have a mean 25(Oh)D level between 29 and 73\u2005nmol/l.9mean 25(Oh)D levels were lower in non-caucasian Pregnant women, ranging between 15.2 and 43\u2005nmol/l.9in addition to ethnicity, higher latitude was a significant predisposing FACTOR for hypovitaminosis d.9similarly, in non-western countries, more than half of the Pregnant women who were beyond their first trimester had 25(Oh)D levels below 75\u2005nmol/l; these include countries such as india,10kuwait,11pakistan12and turkey.13even lower levels (<25\u2005nmol/l) HAVE BEEN REPORTED at Delivery in saudi arabia, iran and the united arab emirates.14furthermore, immigrant women were at PARTICULAR RISK.1516an OBSERVATIONAL study from the netherlands SHOWED significantly lower 25(Oh)D levels during the first Trimester in immigrant Pregnant women (turkish, moroccan and others), compared to western participants.17\n\nASSOCIATION between maternal Vitamin D status and maternal adverse outcomes\nVitamin D insufficiency during Pregnancy is ASSOCIATED with adverse maternal outcomes such as increased risk of Gestational diabetes mellitus (gdm), preeclampsia, caesarean-section Delivery and bacterial vaginosis.18in a recent meta-analysis of observational studies, the risk of gdm was FOUND TO BE increased by 40–84% in Pregnant women with low 25(Oh)D levels, defined as <50\u2005nmol/l or <75\u2005nmol/l, DEPENDING ON the studies.19–21while Preeclampsia risk was significantly increased in Vitamin D insufficient women,22c-section rates were INCONSISTENTLY AFFECTED by Vitamin D status.23HOWEVER, THESE FINDINGS REMAIN LIMITED by the inherent BIASES of OBSERVATIONAL studies, INCONSISTENT adjustment for CONFOUNDERS, in addition to the wide HETEROGENEITY in Vitamin D assays and Vitamin D cut-offs definition.']	[('IMPORTANT_CONSIDERATION', 84), ('IMPORTANT_CONSIDERATION', 105), ('SUPERFICIAL_RELATIONSHIP', 507), ('INCOMPLETE_EVIDENCE', 788), ('IMPORTANT_CONSIDERATION', 909), ('INCOMPLETE_EVIDENCE', 932), ('INCOMPLETE_EVIDENCE', 973), ('SUPERFICIAL_RELATIONSHIP', 1139), ('SUPERFICIAL_RELATIONSHIP', 1259), ('ANOMALY_CURIOUS_FINDING', 1503), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1752), ('SUPERFICIAL_RELATIONSHIP', 1767), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1796), ('INCOMPLETE_EVIDENCE', 1807), ('INCOMPLETE_EVIDENCE', 1822), ('INCOMPLETE_EVIDENCE', 1829), ('PROBLEM_COMPLICATION', 1853), ('INCOMPLETE_EVIDENCE', 1863), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1886), ('PROBLEM_COMPLICATION', 1914), ('DIFFICULT_TASK', 1951)]	22	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 51, 'D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 226, 'trimester'), ('GO_0007565', 'female pregnancy', 253, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 294, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 294, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 345, 'D'), ('GO_0007565', 'female pregnancy', 382, 'pregnant'), ('GO_0007565', 'female pregnancy', 596, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 653, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 653, '25(OH)D'), ('GO_0007567', 'parturition', 810, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 1000, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1000, '25(OH)D'), ('GO_0009294', 'DNA mediated transformation', 1032, 'trimester'), ('GO_0007565', 'female pregnancy', 1055, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1168, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 1215, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1246, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1327, 'gestational'), ('GO_0007567', 'parturition', 1396, 'delivery'), ('GO_0007565', 'female pregnancy', 1538, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 1562, '25(OH)D'), ('GO_0007128', 'meiotic prophase I', 1651, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 1700, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1779, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1968, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D')]	0	['maternal  status \nvitamin  worldwide, countries.8in 18 western countries trimester, white caucasian  women 25(oh)d 29 73\u2005nmol/l.9mean 25(oh)d levels non-caucasian  women, 15.2 43\u2005nmol/l.9in addition ethnicity, higher latitude hypovitaminosis d.9similarly, non-western countries, half  women trimester 25(oh)d levels 75\u2005nmol/l; countries india,10kuwait,11pakistan12and turkey.13even levels (<25\u2005nmol/l) delivery saudi arabia, iran united arab emirates.14furthermore, immigrant women netherlands 25(oh)d levels trimester immigrant  women (turkish, moroccan others), western participants.17\n\nassociation maternal  status maternal outcomes\nvitamin  maternal outcomes  diabetes mellitus (gdm), preeclampsia, caesarean-section delivery bacterial vaginosis.18in meta-analysis studies, gdm 40–84%  women 25(oh)d levels, <50\u2005nmol/l <75\u2005nmol/l, studies.19–21while preeclampsia  women,22c-section rates  status.23however, inherent studies, adjustment confounders, addition  assays  cut-offs definition.']
S24-PMC4785305	PMC4785305	3/2016	S24-PMC4785305	"['[""""ASSOCIATION between maternal Vitamin D level and neonatal adverse outcomes\\nlow maternal 25(Oh)D levels were RECENTLY LINKED to fetal programming, and were found TO be ASSOCIATED with adverse events in neonates, resulting in small for Gestational age (sga) at Birth,1923and also later on during childhood, leading to reduced muscle and bone mass in offspring at 4 and 9\\u2005years.2425this MAY BE EXPLAINED by the fact that maternal Vitamin D is ESSENTIAL for fetal Musculoskeletal integrity, as it Regulates neonatal bone accrual, POSSIBLY through specific proteins that are responsible for Placental Calcium Transport.26RECENTLY, data from the southampton women\'s survey (sws) SHOWED that maternal 25(Oh)D level is significantly CORRELATED with Placental Amino Acid transporters Expression, that mediate the Transport Of various Nutrients to the fetus.27furthermore, maternal Vitamin D MAY INFLUENCE the fetal muscle motor Unit size, and CONSEQUENTLY muscle mass and strength after Birth.25it is NOTEWORTHY that fetal bone development is one of the PREDICTORS of peak bone mass, Adult bone Mineral content and Hip geometry, THUS CORRELATING with fracture risk later in Life.2628\\n\\nVitamin d replacement guidelines during Pregnancy\\nthe guidelines regarding Vitamin D replacement or supplementation during Pregnancy VARY substantially.""""]']"	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 108), ('SUPERFICIAL_RELATIONSHIP', 117), ('QUESTION_ANSWERED_BY_THIS_WORK', 161), ('SUPERFICIAL_RELATIONSHIP', 167), ('INCOMPLETE_EVIDENCE', 384), ('ANOMALY_CURIOUS_FINDING', 388), ('PROBABLE_UNDERSTANDING', 391), ('IMPORTANT_CONSIDERATION', 440), ('INCOMPLETE_EVIDENCE', 526), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 614), ('INCOMPLETE_EVIDENCE', 673), ('SUPERFICIAL_RELATIONSHIP', 725), ('INCOMPLETE_EVIDENCE', 882), ('SUPERFICIAL_RELATIONSHIP', 886), ('PROBABLE_UNDERSTANDING', 934), ('ANOMALY_CURIOUS_FINDING', 992), ('SUPERFICIAL_RELATIONSHIP', 1045), ('PROBABLE_UNDERSTANDING', 1120), ('SUPERFICIAL_RELATIONSHIP', 1125), ('DIFFICULT_TASK', 1309)]	21	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('GO_0007565', 'female pregnancy', 234, 'gestational'), ('GO_0007567', 'parturition', 259, 'birth'), ('CHEBI_27300', 'vitamin D', 427, 'vitamin D'), ('UBERON_0002204', 'musculoskeletal system', 460, 'musculoskeletal'), ('GO_0065007', 'biological regulation', 493, 'regulates'), ('UBERON_0001987', 'placenta', 586, 'placental'), ('GO_0006816', 'calcium ion transport', 596, 'calcium transport'), ('CHEBI_71657', 'versiconol acetate', 694, '25(OH)D'), ('UBERON_0001987', 'placenta', 741, 'placental'), ('CHEBI_82880', 'N-acyltetradecaphytosphingosine', 751, 'amino acid'), ('GO_0010467', 'gene expression', 775, 'expression'), ('GO_0006415', 'translational termination', 804, 'transport of ... nutrients'), ('CHEBI_33284', 'nutrient', 825, 'nutrients'), ('CHEBI_27300', 'vitamin D', 872, 'vitamin D'), ('UBERON_0002105', 'vestibulo-auditory system', 919, 'unit'), ('GO_0007567', 'parturition', 978, 'birth'), ('UBERON_0007023', 'adult organism', 1075, 'adult'), ('CHEBI_46662', 'mineral', 1086, 'mineral'), ('UBERON_0001464', 'hip', 1106, 'hip'), ('UBERON_0000104', 'life cycle', 1165, 'life'), ('CHEBI_33229', 'vitamin (role)', 1176, 'Vitamin'), ('GO_0007565', 'female pregnancy', 1216, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1251, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1299, 'pregnancy')]	0	"['[""""association maternn neonatal outcomes\\nlow maternal 25(oh)d levels fetal programming, events neonates, resulting onal age (sga) birth,1923and childhood, muscle bone mass offspring 4 9\\u2005years.2425this vitamin fetal musculoskeletal integrity, neonatal bone accrual, proteins placental calcium transport.26recently, southampton women*s survey (sws) maternal 25(oh)d placental amino acid transporters expression, transport nutrients fetus.27furthermore, vitamin fetal muscle motor unit size, muscle mass birth.25it fetal bone peak bone mass, adult bone mineral content hip geometry, fracture life.2628\\n\\nvitamin replacement guidelig pregnancy\\nthe guidelineng vitamin replacement supplementang pregnancy substantially.""""]']"
S25-PMC4785305	PMC4785305	3/2016	S25-PMC4785305	['the 2010 institute of medicine (iom) report on dietary reference intakes for Calcium and Vitamin D RECOMMENDED 600\u2005iu to Pregnant women as the recommended daily allowance (rda), the rda being the dose that is projected to allow at least 97.5% of the Pregnant women population to reach the DESIRABLE target 25(Oh)D level ≥50\u2005nmol/l.29this RECOMMENDATION was BASED ON OBSERVATIONAL studies, NONE of which were conducted in the middle east.29CONVERSELY, the Endocrine society 2011 GUIDELINES RECOMMENDED that 1500–2000\u2005iu daily of Vitamin D is NEEDED to reach a target 25(Oh)D level ≥75\u2005nmol/l (a RECOMMENDATION that was graded as weak with moderate quality of evidence).30the american college of obstetricians and gynecologists (acog) does not RECOMMEND screening for Vitamin D level in Pregnancy, and abides by the iom RECOMMENDATIONS.31moreover, the who 2012 guidelines on Vitamin D replacement during Pregnancy DID NOT RECOMMEND vitamin D supplementation as part of Prenatal care.32this was based ON a meta-analysis of Vitamin D trials during Pregnancy, which IDENTIFIED a LIMITED NUMBER of high-quality studies DEMONSTRATING a beneficial EFFECT of supplementation on maternal and neonatal outcomes, and CONCLUDED that FURTHER randomised controlled trials (rcts) ARE NEEDED.33in the uk, HOWEVER, Pregnant women are CONSIDERED AT RISK of Vitamin D deficiency, and supplementation with 400\u2005iu daily is REQUIRED.34\nit is NOT CLEAR WHETHER any of the above RECOMMENDED doses are applicable to non-western populations, with lower baseline Vitamin D levels, such as in lebanon and other middle eastern countries.']	[('FUTURE_WORK', 99), ('IMPORTANT_CONSIDERATION', 289), ('FUTURE_WORK', 338), ('INCOMPLETE_EVIDENCE', 357), ('INCOMPLETE_EVIDENCE', 366), ('INCOMPLETE_EVIDENCE', 389), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 437), ('PROBABLE_UNDERSTANDING', 478), ('FUTURE_WORK', 489), ('FUTURE_WORK', 541), ('IMPORTANT_CONSIDERATION', 541), ('FUTURE_WORK', 594), ('FUTURE_WORK', 742), ('FUTURE_WORK', 818), ('INCOMPLETE_EVIDENCE', 912), ('FUTURE_WORK', 920), ('ANOMALY_CURIOUS_FINDING', 998), ('ANOMALY_CURIOUS_FINDING', 998), ('INCOMPLETE_EVIDENCE', 1061), ('INCOMPLETE_EVIDENCE', 1074), ('INCOMPLETE_EVIDENCE', 1113), ('SUPERFICIAL_RELATIONSHIP', 1140), ('INCOMPLETE_EVIDENCE', 1205), ('FUTURE_WORK', 1220), ('FUTURE_WORK', 1264), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1288), ('IMPORTANT_CONSIDERATION', 1316), ('INCOMPLETE_EVIDENCE', 1316), ('IMPORTANT_CONSIDERATION', 1327), ('IMPORTANT_CONSIDERATION', 1401), ('FULL_UNKNOWN', 1419), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1429), ('FUTURE_WORK', 1454)]	33	[('CHEBI_31341', 'calcium dihydroxide', 77, 'Calcium'), ('CHEBI_28384', 'vitamin K', 89, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 89, 'Vitamin'), ('GO_0007565', 'female pregnancy', 121, 'pregnant'), ('GO_0007565', 'female pregnancy', 250, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 309, 'OH)D'), ('PR_000013502', 'parvalbumin alpha', 311, ')D'), ('UBERON_0005063', 'left ventricular compact myocardium', 455, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 528, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 566, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 566, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 766, 'vitamin D'), ('GO_0007565', 'female pregnancy', 785, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('GO_0007565', 'female pregnancy', 902, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 938, 'D'), ('GO_0007565', 'female pregnancy', 967, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1020, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1044, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1297, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1338, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1535, 'vitamin D')]	0	['2010 institute medicine (iom) dietary intakes calcium vitamin 600\u2005iu  women daily allowance (rda), rda dose 97.5%  women population 25(oh)d ≥50\u2005nmol/l.29this studies, middle east.29conversely, endocrine society 2011 1500–2000\u2005iu daily  25(oh)d ≥75\u2005nmol/l (a evidence).30the american college obstetricians gynecologists (acog) screening  abides iom recommendations.31moreover, 2012  replacement  vitamin supplementation  care.32this meta-analysis  high-quality supplementation maternal neonatal outcomes, randomised (rcts) needed.33in uk, however,  women  deficiency, supplementation 400\u2005iu daily required.34\nit doses non-western populations, baseline  levels, lebanon middle eastern countries.']
S26-PMC4785305	PMC4785305	3/2016	S26-PMC4785305	['indeed, the who Pregnancy guidelines clearly STATED that “Vitamin D supplementation will PROBABLY have the most BENEFIT in populations of poor countries, those with darker skin colour and in populations with a high prevalence of Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 45), ('PROBABLE_UNDERSTANDING', 89), ('IMPORTANT_CONSIDERATION', 112)]	3	[('GO_0007565', 'female pregnancy', 16, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 58, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]	0	['indeed,  “vitamin supplementation populations countries, darker skin colour populations  deficiency.']
S28-PMC4785305	PMC4785305	3/2016	S28-PMC4785305	['rcts of Vitamin D supplementation during Pregnancy\ntwo landmark rcts HAVE BEEN conducted in the usa35and the uk.36hollis et al 35SHOWED that in Pregnant women in the usa, with a baseline 25(Oh)D level around 60\u2005nmol/l, a Vitamin dose of 4000\u2005iu daily allowed 82% of participants to reach a 25(Oh)D level of 80\u2005nmol/l, WHILE ONLY 70% and 50% reached this TARGET in the intermediate (2000\u2005iu daily) and low (400\u2005iu daily) doses, respectively.']	[('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 127), ('ANOMALY_CURIOUS_FINDING', 318), ('ANOMALY_CURIOUS_FINDING', 324), ('FUTURE_WORK', 354)]	5	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('GO_0007565', 'female pregnancy', 144, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 187, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 187, '25(OH)D'), ('CHEBI_33229', 'vitamin (role)', 221, 'vitamin'), ('CHEBI_71657', 'versiconol acetate', 290, '25(OH)D')]	0	['rcts  supplementation \ntwo rcts usa35and uk.36hollis et al  women usa, baseline 25(oh)d 60\u2005nmol/l, vitamin dose 4000\u2005iu daily allowed 82% participants 25(oh)d 80\u2005nmol/l, 70% 50% (2000\u2005iu daily) (400\u2005iu daily) doses, respectively.']
S29-PMC4785305	PMC4785305	3/2016	S29-PMC4785305	['cooper et al 36SHOWED that Vitamin D supplementation of 1000\u2005iu daily, COMPARED TO placebo, in Pregnant women in the uk allowed a significant increase in bone Mineral content (bmc) of neonates, HOWEVER, ONLY when they were Born in winter.']	[('INCOMPLETE_EVIDENCE', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 71), ('ANOMALY_CURIOUS_FINDING', 194), ('ANOMALY_CURIOUS_FINDING', 203)]	4	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('CHEBI_46662', 'mineral', 159, 'Mineral'), ('GO_0007567', 'parturition', 223, 'born')]	0	['cooper et al  supplementation 1000\u2005iu daily, placebo,  women uk allowed increase bone mineral content (bmc) neonates, however, born winter.']
S30-PMC4785305	PMC4785305	3/2016	S30-PMC4785305	['ONE STUDY from india, comparing non-intervention to Vitamin D supplementation groups, with the dose being DEPENDENT on 25(Oh)D levels at 20\u2005weeks Gestation, SHOWED that Vitamin D supplementation resulted in a significant difference in the achieved 25(Oh)D level at Delivery (43.1 (81.3) nmol/l in the former group versus 56.8 (47.5) nmol/l in the latter group).37hollis et al 36and sablok et al 37SHOWED that Vitamin D supplementation decreased the RISK of Preterm labour, Gestational diabetes and hypertensive complications (all combined).']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 106), ('INCOMPLETE_EVIDENCE', 157), ('INCOMPLETE_EVIDENCE', 395), ('IMPORTANT_CONSIDERATION', 449)]	5	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 125, 'D'), ('GO_0007565', 'female pregnancy', 146, 'gestation'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 248, '25(OH)D'), ('GO_0007567', 'parturition', 265, 'delivery'), ('CHEBI_27300', 'vitamin D', 409, 'vitamin D'), ('GO_0007565', 'female pregnancy', 457, 'preterm'), ('GO_0007565', 'female pregnancy', 473, 'gestational')]	0	['one india, non-intervention  supplementation groups, dose 25(oh)d levels 20\u2005weeks  supplementation resulted achieved 25(oh)d delivery (43.1 (81.3) nmol/l 56.8 (47.5) nmol/l latter group).37hollis et al sablok et al  supplementation decreased  labour,  diabetes hypertensive (all combined).']
S31-PMC4785305	PMC4785305	3/2016	S31-PMC4785305	['in the middle east and north africa region, there are FEW RECENT rcts that attempted to determine the OPTIMAL regimen of Vitamin D replacement in healthy Pregnant women.38–41WITH the exception of soheilykhah et al 40who ASSESSED the EFFECT of Vitamin D supplementation on Insulin resistance, the primary outcomes in THESE studies were MOSTLY maternal and neonatal 25(Oh)D levels (seeonline supplementary appendix1).']	[('INCOMPLETE_EVIDENCE', 54), ('INCOMPLETE_EVIDENCE', 58), ('IMPORTANT_CONSIDERATION', 102), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 172), ('INCOMPLETE_EVIDENCE', 220), ('SUPERFICIAL_RELATIONSHIP', 233), ('INCOMPLETE_EVIDENCE', 316), ('PROBABLE_UNDERSTANDING', 335)]	8	[('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnant'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('PR_000045358', 'insulin family protein', 272, 'insulin'), ('CHEBI_71657', 'versiconol acetate', 364, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 364, '25 ... OH ... D')]	0	['middle east north africa region, regimen  replacement healthy  women.38–41with soheilykhah et al 40who  supplementation insulin resistance, outcomes maternal neonatal 25(oh)d levels (seeonline supplementary appendix1).']
S32-PMC4785305	PMC4785305	3/2016	S32-PMC4785305	['none of the other clinically IMPORTANT outcomes, such as neonatal size and OTHER anthropometric measurements, neonatal bmc, gdm and c-section rates, were evaluated as primary outcomes in any of these trials (seeonline supplementary appendix1).10.1136/bmjopen-2015-010818.supp1\n\nwe therefore compiled a registry of all ongoing Vitamin D trials in Pregnancy, as captured by their registration on clinicaltrial.gov42(seeonline supplementary appendix2).']	[('IMPORTANT_CONSIDERATION', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 75)]	2	[('CHEBI_27300', 'vitamin D', 326, 'vitamin D'), ('GO_0007565', 'female pregnancy', 346, 'pregnancy')]	0	['none clinically outcomes, neonatal anthropometric measurements, neonatal bmc, gdm c-section rates, outcomes (seeonline supplementary appendix1).10.1136/bmjopen-2015-010818.supp1\n\nwe compiled registry  captured registration clinicaltrial.gov42(seeonline supplementary appendix2).']
S33-PMC4785305	PMC4785305	3/2016	S33-PMC4785305	['in these trials, DIFFERENT doses of Vitamin D, reaching up to 7000\u2005iu daily, are being administered, and the outcomes to be assessed include neonatal weight and length, childhood asthma, maternal bone Mineral density, maternal adverse outcomes, including Preeclampsia and Preterm labour, and neonatal adverse outcomes, such as sga.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 17)]	1	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_46662', 'mineral', 201, 'mineral'), ('GO_0007128', 'meiotic prophase I', 255, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 272, 'preterm')]	0	['trials, doses reaching 7000\u2005iu daily, administered, outcomes neonatal length, childhood asthma, maternal bone mineral density, maternal outcomes, preeclampsia  labour, neonatal outcomes, sga.']
S36-PMC4785305	PMC4785305	3/2016	S36-PMC4785305	['neither addresses the applicability of iom Vitamin D dose RECOMMENDATIONS in Pregnant women in the middle east.']	[('FUTURE_WORK', 58)]	1	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnant')]	0	['neither applicability iom  dose  women middle east.']
S86-PMC4785305	PMC4785305	3/2016	S86-PMC4785305	['Vitamin D supplementation ≤200\u2005iu daily.ii\nexclusion criteria:\n25(Oh)D level <25\u2005nmol/l, AS it would be UNETHICAL to randomise Pregnant women to the low dose of Vitamin D, and 25(Oh)D level >75\u2005nmol/l (30\u2005ng/ml), as Vitamin D supplementation with routine Prenatal multivitamins would be sufficient.']	[('PROBABLE_UNDERSTANDING', 89), ('DIFFICULT_TASK', 104)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 63, '25(OH)D'), ('GO_0007565', 'female pregnancy', 127, 'pregnant'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 176, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 182, 'D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'prenatal')]	0	['vitamin supplementation ≤200\u2005iu daily.ii\nexclusion criteria:\n25(oh)d <25\u2005nmol/l, randomise  women dose 25(oh)d >75\u2005nmol/l (30\u2005ng/ml),  supplementation routine  multivitamins sufficient.']
S125-PMC4785305	PMC4785305	3/2016	S125-PMC4785305	['this meta-analysis SHOWED that, in Pregnant women from the mena region, a Vitamin D dose of 800–2000\u2005iu daily results in an increase in the 25(Oh)D level by 2.5\u2005nmol/l, and a high dose of >2000\u2005iu daily results in an increase in the 25(Oh)D level by 1.67\u2005nmol/l.']	[('INCOMPLETE_EVIDENCE', 19)]	1	[('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 140, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 146, 'D'), ('CHEBI_71657', 'versiconol acetate', 233, '25(OH)D')]	0	['meta-analysis that,  women mena region,  dose 800–2000\u2005iu daily results increase 25(oh)d 2.5\u2005nmol/l, dose >2000\u2005iu daily results increase 25(oh)d 1.67\u2005nmol/l.']
S151-PMC4785305	PMC4785305	3/2016	S151-PMC4785305	['subgroup analysis based on the season will be also performed to check for INTERACTION between the Vitamin D dose and the season of Pregnant women enrolment.']	[('SUPERFICIAL_RELATIONSHIP', 74)]	1	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnant')]	0	['subgroup season  dose season  women enrolment.']
S157-PMC4785305	PMC4785305	3/2016	S157-PMC4785305	['it is NOTEWORTHY that high doses of Vitamin D (up to 4000\u2005iu daily) HAVE BEEN used in PREVIOUS TRIALS conducted during Pregnancy with no reported adverse events (seeonline supplementary appendix1).']	[('ANOMALY_CURIOUS_FINDING', 6), ('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 86)]	3	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy')]	0	['doses  (up 4000\u2005iu daily)  events (seeonline supplementary appendix1).']
S168-PMC4785305	PMC4785305	3/2016	S168-PMC4785305	['furthermore, GIVEN the LACK OF EVIDENCE-BASED guidelines that define the OPTIMAL rda for Vitamin D supplementation during Pregnancy in our population, and the LIMITED NUMBER of randomised clinical trials completed so far in our region, this trial will fill an IMPORTANT KNOWLEDGE GAP.']	[('PROBABLE_UNDERSTANDING', 13), ('INCOMPLETE_EVIDENCE', 23), ('IMPORTANT_CONSIDERATION', 73), ('INCOMPLETE_EVIDENCE', 159), ('IMPORTANT_CONSIDERATION', 260), ('FULL_UNKNOWN', 270)]	6	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy')]	0	['furthermore, rda  supplementation  population, randomised completed region, fill gap.']
S172-PMC4785305	PMC4785305	3/2016	S172-PMC4785305	['the findings of this trial will help guide the public health policymaker regarding Vitamin D supplementation in Pregnant women and will allow a step forward in EVIDENCE-BASED RECOMMENDATIONS SPECIFIC to the middle east.']	[('INCOMPLETE_EVIDENCE', 160), ('FUTURE_WORK', 175), ('FUTURE_WORK', 191)]	3	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnant')]	0	['policymaker regarding  supplementation  women step middle east.']
S25-PMC4800340	PMC4800340	5/2016	S25-PMC4800340	"['[""""THIS STUDY SUGGESTS that low sunlight and PRESUMABLY suboptimal Vitamin D status at Birth is ASSOCIATED with Food Allergy Development in childhood.30a large scale population-based study in australia SHOWED that infants with low Serum 25-Hydroxyvitamin (Oh) D3Levels (≤50 nmol/l) had almost 12 times and 4 times higher risk of developing Peanut and egg allergies, respectively, in the first year of Life THAN infants with adequate Serum Vitamin D level.31HOWEVER, ANOTHER STUDY conducted in germany DEMONSTRATED that 25(Oh)D3Concentration in Pregnant women\'s Serum and in Cord Blood were positively ASSOCIATED with increased risk of Food Allergy Development among children in the first 2 years.32a RECENT randomized double-blind controlled TRIAL SHOWED that maternal Vitamin D3Supplementation for 6 weeks during Lactation increased the risk of Food allergy diagnosis by 3.42 times [95% confidence interval (ci)=1.02–11.77] among children of supplementation group compared to control group by 2 years of age.33due to lack OF robustly designed studies, a causal ASSOCIATION between Vitamin D status during Prenatal and Neonatal Period and Food allergy Development In Children remains INCONCLUSIVE.""""]']"	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 11), ('PROBABLE_UNDERSTANDING', 42), ('SUPERFICIAL_RELATIONSHIP', 93), ('INCOMPLETE_EVIDENCE', 199), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 403), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 452), ('INCOMPLETE_EVIDENCE', 463), ('INCOMPLETE_EVIDENCE', 498), ('SUPERFICIAL_RELATIONSHIP', 598), ('INCOMPLETE_EVIDENCE', 697), ('INCOMPLETE_EVIDENCE', 739), ('INCOMPLETE_EVIDENCE', 745), ('ANOMALY_CURIOUS_FINDING', 1020), ('SUPERFICIAL_RELATIONSHIP', 1059), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1181)]	16	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007567', 'parturition', 84, 'birth'), ('CHEBI_33290', 'food', 109, 'food'), ('GO_0048467', 'gynoecium development', 109, 'food allergy development'), ('UBERON_0001977', 'blood serum', 228, 'serum'), ('CHEBI_60346', 'alpha-Kdo-(2->8)-alpha-Kdo-OAll', 234, '25-hydroxyvitamin (OH) D3levels'), ('NCBITaxon_10088', 'Mus <genus>', 337, 'peanut'), ('UBERON_0000104', 'life cycle', 398, 'life'), ('UBERON_0001977', 'blood serum', 430, 'serum'), ('CHEBI_27300', 'vitamin D', 436, 'vitamin D'), ('CHEBI_74304', '(6Z,9Z,12Z,15Z,18Z,21Z)-3-oxotetracosahexaenoyl-CoA(4-)', 516, '25(OH)D3concentration'), ('GO_0007565', 'female pregnancy', 541, 'pregnant'), ('UBERON_0001977', 'blood serum', 558, 'serum'), ('UBERON_0009472', 'axilla', 571, 'cord blood'), ('CHEBI_33290', 'food', 632, 'food'), ('GO_0048467', 'gynoecium development', 632, 'food allergy development'), ('CHEBI_52915', 'phosphatediyl group', 766, 'vitamin D3supplementation'), ('GO_0007595', 'lactation', 811, 'lactation'), ('CHEBI_33290', 'food', 843, 'food'), ('CHEBI_27300', 'vitamin D', 1079, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1103, 'prenatal'), ('UBERON_0007221', 'neonate stage', 1116, 'neonatal period'), ('CHEBI_33290', 'food', 1136, 'food'), ('GO_0030163', 'protein catabolic process', 1149, 'development in children')]	0	"['[""""this sunlight suboptimn status birth food allergy childhood.30a population-based australia infants serum 25-hydroxyvitamin (oh) d3levels (≤50 nmol/l) 12 times 4 times higher peanut egg allergies, respectively, year life infants sern level.31however, germany 25(oh)d3concentration ant women*s serum cord blood positively food allergy among children 2 years.32a double-blind maternal vitamin d3supplementation 6 weeks lactation food allergy diagnosis 3.42 times [95% confidence interval (ci)=1.02–11.77] among children supplementation group 2 age.33due studies, causal betwen status durital neonatal period food allergy children inconclusive.""""]']"
S51-PMC4800340	PMC4800340	5/2016	S51-PMC4800340	['the results of these studies SUGGEST that differential Dna Methylation in the regions of Genes RELATED to T-Cell Differentiation and balance between th1 and th2 during the critical Period Of early Life MAY BE POTENTIAL mechanisms of allergic disease development.73\n\nepigenetic Regulation by Nutrients\nALTHOUGH POSSIBLE ROLES of Prenatal Folate, N-3 Pufa, and Vitamin D in Immune programming HAVE BEEN SUGGESTED,3474only a LIMITED NUMBER OF STUDIES examined epigenetic Regulation by these Nutrients as a POTENTIAL biological pathway of allergic diseases.']	[('INCOMPLETE_EVIDENCE', 29), ('SUPERFICIAL_RELATIONSHIP', 95), ('INCOMPLETE_EVIDENCE', 202), ('INCOMPLETE_EVIDENCE', 209), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 301), ('ANOMALY_CURIOUS_FINDING', 301), ('INCOMPLETE_EVIDENCE', 310), ('SUPERFICIAL_RELATIONSHIP', 319), ('INCOMPLETE_EVIDENCE', 391), ('INCOMPLETE_EVIDENCE', 401), ('INCOMPLETE_EVIDENCE', 422), ('INCOMPLETE_EVIDENCE', 503)]	12	[('GO_0006306', 'DNA methylation', 55, 'DNA methylation'), ('SO_0000704', 'gene', 89, 'genes'), ('CL_0000084', 'T cell', 106, 'T-cell'), ('GO_0030217', 'T cell differentiation', 106, 'T-cell differentiation'), ('UBERON_0008266', 'periodontal ligament', 181, 'period of ... life'), ('GO_0065007', 'biological regulation', 277, 'regulation'), ('CHEBI_33284', 'nutrient', 291, 'nutrients'), ('GO_0007565', 'female pregnancy', 328, 'prenatal'), ('CHEBI_30863', '5-azaorotic acid', 337, 'folate'), ('CHEBI_80445', '9,10-EOT', 345, 'n-3 PUFA'), ('CHEBI_27300', 'vitamin D', 359, 'vitamin D'), ('GO_0007566', 'embryo implantation', 372, 'immune'), ('UBERON_0002405', 'immune system', 372, 'immune'), ('GO_0065007', 'biological regulation', 468, 'regulation'), ('CHEBI_33284', 'nutrient', 488, 'nutrients')]	0	['results dna methylation regions genes t-cell balance th1 th2 period life mechanisms allergic disease development.73\n\nepigenetic nutrients\nalthough  folate, n-3 pufa,  immune programming suggested,3474only epigenetic nutrients biological allergic diseases.']
S56-PMC4800340	PMC4800340	5/2016	S56-PMC4800340	['THIS STUDY SHOWED that Prenatal Vitamin D-mediated epigenetic Regulation in Tslp increased the RISK of wheezing in children.77more Human STUDIES ARE NEEDED to substantiate the ROLE of epigenetic Regulation by Nutrients in the growing epidemic of Food allergy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 62), ('IMPORTANT_CONSIDERATION', 95), ('FUTURE_WORK', 137), ('SUPERFICIAL_RELATIONSHIP', 176)]	6	[('GO_0007565', 'female pregnancy', 23, 'prenatal'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0065007', 'biological regulation', 62, 'regulation'), ('PR_000016770', 'testis-specific serine/threonine-protein kinase 1', 76, 'TSLP'), ('NCBITaxon_9606', 'Homo sapiens', 131, 'human'), ('GO_0065007', 'biological regulation', 195, 'regulation'), ('CHEBI_33284', 'nutrient', 209, 'nutrients'), ('CHEBI_33290', 'food', 246, 'food')]	0	[' -mediated epigenetic tslp wheezing children.77more human epigenetic nutrients food allergy.']
S20-PMC4811107	PMC4811107	3/2016	S20-PMC4811107	['these analyses COULD identify Pregnant women who NEED a Prenatal Vitamin D intervention tailored to them BASED ON the various characteristics, as well as identifying children who MAY have a lower level of 25(Oh)D at Birth and MAY BE prioritized for Vitamin D screening.']	[('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 49), ('SUPERFICIAL_RELATIONSHIP', 105), ('INCOMPLETE_EVIDENCE', 179), ('INCOMPLETE_EVIDENCE', 226)]	5	[('GO_0007565', 'female pregnancy', 30, 'pregnant'), ('GO_0007565', 'female pregnancy', 56, 'prenatal'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('GO_0007567', 'parturition', 216, 'birth'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D')]	0	[' women   tailored characteristics, children 25(oh)d birth  screening.']
S55-PMC4811107	PMC4811107	3/2016	S55-PMC4811107	['maternal atopic status was included because the primary goal of the cohort was to study allergic outcomes in the children and Prenatal and early Life Vitamin D levels have been investigated for their ROLE in allergic disease development [22,24–27].']	[('SUPERFICIAL_RELATIONSHIP', 200)]	1	[('GO_0007565', 'female pregnancy', 126, 'prenatal'), ('UBERON_0000104', 'life cycle', 145, 'life'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]	0	['maternal atopic status allergic outcomes children  life  levels allergic disease [22,24–27].']
S97-PMC4811107	PMC4811107	3/2016	S97-PMC4811107	['EXAMINED WHETHER Prepregnancy obesity PREDICTED POOR Vitamin D status in neonates in their study of 400 women in pittsburgh, pennsylvania [7].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('SUPERFICIAL_RELATIONSHIP', 38), ('IMPORTANT_CONSIDERATION', 48)]	4	[('GO_0007565', 'female pregnancy', 17, 'prepregnancy'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]	0	['examined  obesity  status neonates 400 women pittsburgh, pennsylvania [7].']
S99-PMC4811107	PMC4811107	3/2016	S99-PMC4811107	['this DIFFERENCE LIKELY LED to the result in which women who were obese before Pregnancy were more LIKELY to have Delivered a child with Vitamin D deficiency COMPARED TO women who had a normal bmi (odds ratio = or = 2.1, 95% confidence interval = ci 1.2, 3.6).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('PROBABLE_UNDERSTANDING', 16), ('SUPERFICIAL_RELATIONSHIP', 23), ('PROBABLE_UNDERSTANDING', 98), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 157)]	5	[('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('GO_0007567', 'parturition', 113, 'delivered'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]	0	['result women obese  delivered child  women normal bmi (odds ratio = = 2.1, 95% confidence interval = ci 1.2, 3.6).']
S109-PMC4811107	PMC4811107	3/2016	S109-PMC4811107	"['[""""NOT ONLY do these studies INDICATE that use of the Prenatal level of 25(Oh)D to represent the child\'s early Life Vitamin D level is not specific, but also the data SUGGEST that a maternal THRESHOLD exists below which the mother LIMITS her CONTRIBUTION of 25(Oh)D to the fetus.""""]']"	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 164), ('PROBABLE_UNDERSTANDING', 188), ('SUPERFICIAL_RELATIONSHIP', 228), ('SUPERFICIAL_RELATIONSHIP', 239)]	6	[('GO_0007565', 'female pregnancy', 51, 'prenatal'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 75, 'D'), ('UBERON_0000104', 'life cycle', 108, 'life'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 255, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 257, '(OH)D')]	0	"['[""""not ttal 25(oh)d child*s lin specific, maternal mother 25(oh)d fetus.""""]']"
S113-PMC4811107	PMC4811107	3/2016	S113-PMC4811107	"['[""""conclusions\\nthe degree to which a newborn\'s Vitamin D [25(Oh)D] level is ASSOCIATED with their mother\'s Prenatal level varies by several INTERRELATED FACTORS including maternal race, Birth order, and the actual maternal level.""""]']"	[('SUPERFICIAL_RELATIONSHIP', 73), ('SUPERFICIAL_RELATIONSHIP', 137), ('SUPERFICIAL_RELATIONSHIP', 150)]	3	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('GO_0007565', 'female pregnancy', 104, 'prenatal'), ('GO_0007567', 'parturition', 183, 'birth')]	0	"['[""""conclusions\\nthe degree newborin [25(oh)d] motheatal maternal race, birth order, actual maternal level.""""]']"
S2-PMC4811441	PMC4811441	3/2016	S2-PMC4811441	['the pathophysiology of the Development Of Hypertension In Pregnancy is UNKNOWN, but studies SUGGEST an ASSOCIATION with Vitamin D status, measured as 25-Hydroxyvitamin D (25(Oh)D).']	[('FULL_UNKNOWN', 71), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 103)]	3	[('GO_0002234', 'detection of endoplasmic reticulum overloading', 27, 'development of hypertension in'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 150, '25-hydroxyvitamin D'), ('CHEBI_33010', 'chromide(1-)', 173, '(OH)D')]	0	['pathophysiology hypertension  unknown,  status, 25-hydroxyvitamin (25(oh)d).']
S12-PMC4811441	PMC4811441	3/2016	S12-PMC4811441	['in conclusion, an increase in 25(Oh)D concentration during Pregnancy of at LEAST 30 nmol/l, REGARDLESS OF Vitamin D status in t1, was ASSOCIATED with a lower odds ratio for Preeclampsia.']	[('PROBABLE_UNDERSTANDING', 75), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 134)]	3	[('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 173, 'preeclampsia')]	0	['conclusion, increase 25(oh)d concentration  30 nmol/l,  status t1, ratio preeclampsia.']
S29-PMC4811441	PMC4811441	3/2016	S29-PMC4811441	['poorer Vitamin D status (measured as 25-Hydroxyvitamin D (25(Oh)D) during Pregnancy HAS BEEN ASSOCIATED with INCREASED RISKS of pe and Gestational hypertension in SOME [11,12] BUT NOT ALL observational studies [13,14].']	[('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 93), ('IMPORTANT_CONSIDERATION', 109), ('INCOMPLETE_EVIDENCE', 163), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 176), ('ANOMALY_CURIOUS_FINDING', 180)]	6	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 37, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 58, '25(OH)D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007565', 'female pregnancy', 135, 'gestational')]	0	['poorer  status (measured 25-hydroxyvitamin (25(oh)d)  pe  hypertension [11,12] [13,14].']
S34-PMC4811441	PMC4811441	3/2016	S34-PMC4811441	['this LIMITS the evaluation of the POTENTIAL ROLE of Vitamin D status during early Pregnancy in the development and progression Of Pe.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 44)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('GO_0001554', 'luteolysis', 127, 'of PE')]	0	[' status  progression pe.']
S39-PMC4811441	PMC4811441	3/2016	S39-PMC4811441	['the primary outcome of the study was TO INVESTIGATE the ASSOCIATION between Vitamin D status and hypertensive disorders in Pregnancy and pe.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 37), ('SUPERFICIAL_RELATIONSHIP', 56)]	2	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy')]	0	['outcome  status hypertensive disorders  pe.']
S87-PMC4811441	PMC4811441	3/2016	S87-PMC4811441	['Vitamin D status was used as time-varying in model 1, where the mean of the 25(Oh)D concentration in t1 and t3 was used as a PROXY for Vitamin D status at Gestational week 25 and the concentration at week 32 (t3) was duplicated for week 37.']	[('SUPERFICIAL_RELATIONSHIP', 125)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'gestational')]	0	['vitamin status time-varying 1, 25(oh)d concentration t1 t3  status  week 25 concentration week 32 (t3) duplicated week 37.']
S136-PMC4811441	PMC4811441	3/2016	S136-PMC4811441	['also, an increase in 25(Oh)D ≥30 nmol/l was not associated with Pregnancy-induced hypertension.10.1371/journal.pone.0152198.t004\n\ncaption (table-wrap): table 4\nbivariable and multivariable logistic regression analysis of the DETERMINANTS of Pregnancy-induced hypertension.bivariablemultivariableabor95% cipbor95% ciplowerupperlowerupper25(Oh)D t10.0081.0081.0011.0140.0240.0021.0020.9931.0100.709obesity t10.3661.4430.8972.3210.131-0.1690.8440.4641.5380.844nulliparity0.3611.4351.0391.9830.0290.2051.2280.8541.7650.269excessive gwg0.4731.6041.1462.2460.0060.3631.4380.9952.0780.054preexisting medical condition t10.6321.8810.8764.0400.1050.0891.0930.4542.6290.842assisted reproduction0.1821.2000.7881.8280.3950.0841.0880.6561.8030.745tobacco use t1-0.6330.5310.2161.3080.169-0.4470.6400.2621.5630.327height0.0541.0551.0291.083<0.0010.0351.0351.0051.0660.021age ≥40 years t1-0.1410.8680.3732.0240.744-0.1920.8250.3122.1840.699dbp t10.0871.0911.0691.114<0.0010.0881.0921.0671.117<0.001\n25(Oh)d = 25-Hydroxyvitamin D, t1 = first trimester, gwg = Gestational weight gain, dbp = diastolic Blood pressure,\ndichotomous: age ≥40 years, obesity, nulliparity, excessive gwg, preexisting medical condition and assisted reproduction\na.adjusted for multifetal Pregnancy, baseline employment status, Gestational age at t1, month of Conception and northern european country of Birth\n\ndiscussion\nthese results are the primary outcome of the gravid study–TO OUR KNOWLEDGE the FIRST STUDY reporting on the RELATIONSHIP between longitudinal Vitamin D status and its RELATION to pe and Gestational bp trajectory.']	[('SUPERFICIAL_RELATIONSHIP', 225), ('PROBABLE_UNDERSTANDING', 1438), ('INCOMPLETE_EVIDENCE', 1459), ('SUPERFICIAL_RELATIONSHIP', 1488), ('SUPERFICIAL_RELATIONSHIP', 1547)]	5	[('CHEBI_71657', 'versiconol acetate', 21, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 21, '25(OH)D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007565', 'female pregnancy', 241, 'pregnancy'), ('CHEBI_33010', 'chromide(1-)', 338, '(OH)D'), ('CHEBI_63056', 'zinc cation', 984, '25(OH'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 994, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 1043, 'gestational'), ('UBERON_0000178', 'blood', 1084, 'blood'), ('GO_0007565', 'female pregnancy', 1247, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1286, 'gestational'), ('GO_0007620', 'copulation', 1318, 'conception'), ('GO_0007567', 'parturition', 1362, 'birth'), ('CHEBI_27300', 'vitamin D', 1522, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1566, 'gestational')]	0	['also, increase 25(oh)d ≥30 nmol/l -induced hypertension.10.1371/journal.pone.0152198.t004\n\ncaption (table-wrap): table 4\nbivariable multivariable logistic regression -induced hypertension.bivariablemultivariableabor95% cipbor95% ciplowerupperlowerupper25(oh)d t10.0081.0081.0011.0140.0240.0021.0020.9931.0100.709obesity t10.3661.4430.8972.3210.131-0.1690.8440.4641.5380.844nulliparity0.3611.4351.0391.9830.0290.2051.2280.8541.7650.269excessive gwg0.4731.6041.1462.2460.0060.3631.4380.9952.0780.054preexisting medical condition t10.6321.8810.8764.0400.1050.0891.0930.4542.6290.842assisted reproduction0.1821.2000.7881.8280.3950.0841.0880.6561.8030.745tobacco t1-0.6330.5310.2161.3080.169-0.4470.6400.2621.5630.327height0.0541.0551.0291.083<0.0010.0351.0351.0051.0660.021age ≥40 t1-0.1410.8680.3732.0240.744-0.1920.8250.3122.1840.699dbp t10.0871.0911.0691.114<0.0010.0881.0921.0671.117<0.001\n25(oh)d = 25-hydroxyvitamin d, t1 = trimester, gwg =  gain, dbp = diastolic blood pressure,\ndichotomous: age ≥40 years, obesity, nulliparity, excessive gwg, preexisting medical condition reproduction\na.adjusted multifetal baseline employment status,  age t1, month northern european country birth\n\ndiscussion\nthese results outcome gravid study–to longitudinal  status pe  bp trajectory.']
S137-PMC4811441	PMC4811441	3/2016	S137-PMC4811441	['our results SUGGEST that an increase of AT LEAST 30 nmol/l in 25(Oh)D concentration during Pregnancy is RELATED to lower odds of pe, REGARDLESS OF Vitamin D status in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 12), ('PROBABLE_UNDERSTANDING', 40), ('SUPERFICIAL_RELATIONSHIP', 104), ('INCOMPLETE_EVIDENCE', 133)]	4	[('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy')]	0	['results increase 30 nmol/l 25(oh)d concentration  pe,  status .']
S141-PMC4811441	PMC4811441	3/2016	S141-PMC4811441	['THEREFORE, IT IS POSSIBLE that Vitamin D status in early Pregnancy MIGHT not play a MAJOR ROLE in Placental Development, but that an increment during Gestation MAY prevent the Development Of Pe.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 67), ('IMPORTANT_CONSIDERATION', 84), ('SUPERFICIAL_RELATIONSHIP', 90), ('INCOMPLETE_EVIDENCE', 160)]	6	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('GO_0001890', 'placenta development', 98, 'placental development'), ('UBERON_0001987', 'placenta', 98, 'placental'), ('GO_0007565', 'female pregnancy', 150, 'gestation'), ('GO_0042494', 'detection of bacterial lipoprotein', 176, 'development of PE')]	0	['therefore,  status  play placental development, increment  pe.']
S167-PMC4811441	PMC4811441	3/2016	S167-PMC4811441	['another STRENGTH is that Blood samples were taken in both early and late Pregnancy, enabling INVESTIGATION of changes in Vitamin D status in RELATION to pe and bp.']	[('IMPORTANT_CONSIDERATION', 8), ('FUTURE_WORK', 93), ('SUPERFICIAL_RELATIONSHIP', 141)]	3	[('UBERON_0000178', 'blood', 25, 'blood'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]	0	['another blood samples late enabling changes  status pe bp.']
S169-PMC4811441	PMC4811441	3/2016	S169-PMC4811441	['our results SHOW that an increment in 25(Oh)D concentration during Pregnancy is ASSOCIATED with lower odds of pe, REGARDLESS OF early Pregnancy Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 80), ('INCOMPLETE_EVIDENCE', 114)]	3	[('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]	0	['results increment 25(oh)d concentration  pe,   status.']
S171-PMC4811441	PMC4811441	3/2016	S171-PMC4811441	['in conclusion, an increase in 25(Oh)D concentration during Pregnancy of at LEAST 30 nmol/l, REGARDLESS OF Vitamin D status at t1, was ASSOCIATED with a lower odds ratio for pe.']	[('PROBABLE_UNDERSTANDING', 75), ('INCOMPLETE_EVIDENCE', 92), ('SUPERFICIAL_RELATIONSHIP', 134)]	3	[('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]	0	['conclusion, increase 25(oh)d concentration  30 nmol/l,  status t1, ratio pe.']
S14-PMC4829940	PMC4829940	5/2016	S14-PMC4829940	['low 25(Oh)D levels HAVE BEEN ASSOCIATED with a range of adverse conditions, from Pregnancy outcomes to childhood illnesses and chronic disease including osteoporosis, cancer and Cardiovascular disease in Adulthood[3], ALTHOUGH randomized controlled trials of Vitamin D supplements do NOT SUPPORT causality for Extra-Skeletal outcomes[4],[5].']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 29), ('ANOMALY_CURIOUS_FINDING', 218), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 284)]	4	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 4, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy'), ('UBERON_0004535', 'cardiovascular system', 178, 'cardiovascular'), ('UBERON_0000113', 'post-juvenile adult stage', 204, 'adulthood'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 310, 'extra-skeletal')]	0	['low 25(oh)d levels conditions,  outcomes childhood illnesses chronic disease osteoporosis, cancer cardiovascular disease adulthood[3],  supplements causality extra-skeletal outcomes[4],[5].']
S20-PMC4829940	PMC4829940	5/2016	S20-PMC4829940	['ALTHOUGH two RECENT randomized controlled trials observed SUGGESTIVE reductions in the incidence of asthma and recurrent wheezing following Vitamin D supplementation during Pregnancy[12],[13], the primary endpoints were not statistically significant.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 58)]	4	[('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy')]	0	['although reductions asthma recurrent wheezing following  supplementation [12],[13], endpoints statistically significant.']
S128-PMC4829940	PMC4829940	5/2016	S128-PMC4829940	['given that Vitamin D status fluctuates throughout Pregnancy, IT IS POSSIBLE that the fetus is more sensitive to Vitamin D levels at certain Gestational periods[6].']	[('INCOMPLETE_EVIDENCE', 61)]	1	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007565', 'female pregnancy', 140, 'gestational')]	0	['given  status fluctuates throughout fetus sensitive  levels  periods[6].']
S136-PMC4832516	PMC4832516	10/2015	S136-PMC4832516	['similarly, NO information was AVAILABLE on maternal residential location, individually-measured sunshine exposure, or Vitamin D supplementation during Pregnancy, HOWEVER EVEN the youngest participant in the uk biobank (aged 38 in our analysis) was Conceived during a time when Gestational Vitamin D supplementation was not RECOMMENDED in the uk.']	[('FULL_UNKNOWN', 11), ('ANOMALY_CURIOUS_FINDING', 162), ('ANOMALY_CURIOUS_FINDING', 170), ('FUTURE_WORK', 323)]	4	[('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy'), ('GO_0070268', 'cornification', 248, 'conceived'), ('GO_0007565', 'female pregnancy', 277, 'gestational'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin D')]	0	['similarly, maternal residential location, individually-measured sunshine exposure,  supplementation youngest participant uk biobank (aged 38 analysis) conceived   supplementation uk.']
S25-PMC4843009	PMC4843009	4/2016	S25-PMC4843009	['Prenatal Vitamin D deficiency INFLUENCES Murine self-grooming behavior36.']	[('SUPERFICIAL_RELATIONSHIP', 30)]	1	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('NCBITaxon_39107', 'Murinae', 41, 'murine')]	0	['  self-grooming behavior36.']
S156-PMC4846845	PMC4846845	4/2016	S156-PMC4846845	['a RECENT meta-analysis did NOT see a positive change in ptb, lbw, pre-eclampsia, and Gestational diabetes rates with Vitamin D supplementation, THOUGH they did CONCLUDE that Vitamin D has “PLAUSIBLE EFFECTS” on many Perinatal outcomes [119].']	[('INCOMPLETE_EVIDENCE', 2), ('ANOMALY_CURIOUS_FINDING', 27), ('ANOMALY_CURIOUS_FINDING', 144), ('INCOMPLETE_EVIDENCE', 160), ('INCOMPLETE_EVIDENCE', 189), ('SUPERFICIAL_RELATIONSHIP', 199)]	6	[('GO_0007565', 'female pregnancy', 85, 'gestational'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('GO_0036268', 'swimming', 216, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 216, 'perinatal')]	0	['meta-analysis positive ptb, lbw, pre-eclampsia,  diabetes rates  supplementation,  “plausible effects” perinatal outcomes [119].']
S157-PMC4846845	PMC4846845	4/2016	S157-PMC4846845	['maternal Vitamin D levels during Pregnancy also PREDICT long-term outcomes for the child including congenital rickets, smaller Arm muscle and higher Insulin resistance, autism spectrum disorders, and asthma in childhood.']	[('SUPERFICIAL_RELATIONSHIP', 48)]	1	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('UBERON_0001460', 'arm', 127, 'arm'), ('PR_000045358', 'insulin family protein', 149, 'insulin')]	0	['maternal  levels  long-term outcomes child congenital rickets, arm muscle higher insulin resistance, autism spectrum disorders, asthma childhood.']
S15-PMC4859539	PMC4859539	5/2016	S15-PMC4859539	['to address this GAP in the literature, the AIM of THIS follow-up STUDY was TO DETERMINE IF maternal Vitamin D status during Pregnancy and/or a child’s current Vitamin D status AFFECT the circulating concentration of Cathelicidin in healthy children years after Delivery.']	[('FULL_UNKNOWN', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 43), ('QUESTION_ANSWERED_BY_THIS_WORK', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 75), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 88), ('SUPERFICIAL_RELATIONSHIP', 176)]	6	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('PR_000006009', 'alpha-catulin', 216, 'cathelicidin'), ('GO_0007567', 'parturition', 261, 'delivery')]	0	['literature, maternal  status  and/or child’s  status circulating concentration cathelicidin healthy children delivery.']
S47-PMC4859539	PMC4859539	5/2016	S47-PMC4859539	['four multivariable regressions were performed TO ASSESS WHETHER any significant ASSOCIATIONS existed between the natural logarithm of each subject’s cathelicidin concentration and each of the following Vitamin D measurements: (1) child’s current 25(Oh)D at time of follow-up, (2) child’s 25(Oh)d at Birth, (3) maternal 25(Oh)D throughout Pregnancy (visits 3 to 7 as area under the curve), and (4) maternal 25(Oh)D one month before Delivery; all analyses controlled for race/ethnicity, age, gender, and percent fat.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 46), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('SUPERFICIAL_RELATIONSHIP', 80)]	3	[('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 246, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 246, '25(OH)D'), ('CHEBI_37972', 'phosphorus-32 atom', 288, '25'), ('CHEBI_17792', 'organohalogen compound', 291, 'OH'), ('GO_0007567', 'parturition', 299, 'birth'), ('CHEBI_71657', 'versiconol acetate', 319, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 319, '25 ... OH ... D'), ('GO_0007565', 'female pregnancy', 338, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 406, '25(OH)D'), ('GO_0007567', 'parturition', 431, 'delivery')]	0	['four multivariable regressions existed natural logarithm subject’s cathelicidin concentration following  measurements: (1) child’s 25(oh)d follow-up, (2) child’s 25(oh)d birth, (3) maternal 25(oh)d throughout  (visits 3 7 curve), (4) maternal 25(oh)d month delivery; race/ethnicity, age, gender, percent fat.']
S97-PMC4859539	PMC4859539	5/2016	S97-PMC4859539	"['[""""in MODELS 1 and 4, there was also a TREND NOTED with the child’s percent fat being positively ASSOCIATED with Cathelicidin (beta = 0.028, p = 0.052 and beta = 0.025, p = 0.087).10.1371/journal.pone.0152711.t003\\n\\ncaption (table-wrap): table 3\\nmultivariable linear regression models assessing factors associated with natural logarithm for Cathelicidin.model 1 \\xa0\\xa0independent variablesbetase1p valuerace/ethnicity\\xa0\\xa0black-0.0390.230.864white---------hispanic-0.1490.2000.459genderfemale---------male0.3180.16 0.047 age0.1450.065 0.028 percent fat0.0280.0140.052child\'s current 25(Oh)D-0.0050.010.598 model 2 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicityblack0.0350.210.868white---------hispanic-0.1490.210.470genderfemale---------male0.2750.170.104age0.2120.07 0.004 percent fat0.0250.020.087child\'s 25(Oh)D at Birth-0.0030.010.748 model 3 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicity\\xa0\\xa0black0.0410.180.821white---------hispanic-0.1220.160.458genderfemale---------male0.0910.140.507age0.1550.07 0.023 percent fat0.0120.010.359maternal 25(Oh)D throughout Pregnancy<-0.000100.999 model 4 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicity\\xa0\\xa0black0.0460.1990.816white---------hispanic-0.0800.1850.669genderfemale---------male0.3180.158 0.047 age0.1510.064 0.021 percent fat0.0260.010.069maternal 25(Oh)D 1-month before Delivery0.0030.010.606\\n1se represents standard error\\n\\ndiscussion\\nin THIS STUDY of healthy children whose mothers had participated in a Vitamin D supplementation trial during Pregnancy, DESPITE DIFFERENCES in both maternal and childhood Vitamin D status, there were no significant differences in Cathelicidin concentration between the three racial/ethnic groups studied.""""]']"	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 36), ('ANOMALY_CURIOUS_FINDING', 42), ('SUPERFICIAL_RELATIONSHIP', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 1391), ('ANOMALY_CURIOUS_FINDING', 1508), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1516)]	7	[('CHEBI_3364', 'Canthiumine', 110, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 110, 'cathelicidin'), ('CHEBI_3461', 'Casuarictin', 337, 'Cathelicidin'), ('CHEBI_71657', 'versiconol acetate', 572, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 572, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 801, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 807, 'D'), ('GO_0007567', 'parturition', 812, 'birth'), ('CHEBI_71657', 'versiconol acetate', 1042, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1048, 'D'), ('GO_0007565', 'female pregnancy', 1061, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 1300, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1300, '25(OH)D'), ('GO_0007567', 'parturition', 1323, 'delivery0'), ('CHEBI_27300', 'vitamin D', 1458, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1497, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1559, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 1618, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 1618, 'cathelicidin')]	0	"['[""""in 4, child’s percent fat positively cathelicidin (beta = 0.028, p = 0.052 beta = 0.025, p = 0.087).10.1371/journal.pone.0152711.t003\\n\\ncaption (table-wrap): table 3\\nmultivariable linear regression natural logarithm cathelicidin.model \\xa0\\xa0independent variablesbetase1p valuerace/ethnicity\\xa0\\xa0black-0.0390.230.864white---------hispanic-0.1490.2000.459genderfemale---------male0.3180.16 0.047 age0.1450.065 0.028 percent fat0.0280.0140.052child*s 25(oh)d-0.0050.010.598 2 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicityblack0.0350.210.868white---------hispanic-0.1490.210.470genderfemale---------male0.2750.170.104age0.2120.07 0.004 percent fat0.0250.020.087child*s 25(oh)d birth-0.0030.010.748 3 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicity\\xa0\\xa0black0.0410.180.821white---------hispanic-0.1220.160.458genderfemale---------male0.0910.140.507age0.1550.07 0.023 percent fat0.359maternal 25(oh)d throughout pregnancy<-0.000100.999 4 \\xa0\\xa0\\xa0independent variablesbetasep valuerace/ethnicity\\xa0\\xa0black0.0460.1990.816white---------hispanic-0.0800.1850.669genderfemale---------male0.3180.158 0.047 age0.1510.064 0.021 percent fat0.0260.010.069maternal 25(oh)d 1-month delivery0.0030.010.606\\n1se error\\n\\ndiscussion\\nin sealthy children whose mothers cipated vitamin supplementation p maternal childhood vitamin status, cathelicidin concentration three racial/ethnic studied.""""]']"
S74-PMC4861121	PMC4861121	5/2016	S74-PMC4861121	['micronutrient analysis REVEALED that, regarding SOME of the KEY Nutrients NECESSARY for a healthy Pregnancy, only 26% of women reached Folate recommendations, 0.9% reached Vitamin D recommendations, 36% met calcium recommendations and 17.6% met iron recommendations, from Food.']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 48), ('IMPORTANT_CONSIDERATION', 60), ('IMPORTANT_CONSIDERATION', 74)]	4	[('CHEBI_33284', 'nutrient', 64, 'nutrients'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('CHEBI_30863', '5-azaorotic acid', 135, 'folate'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D'), ('CHEBI_33290', 'food', 272, 'food')]	0	['micronutrient that, regarding nutrients healthy 26% women folate recommendations, 0.9%  recommendations, 36% met calcium 17.6% met iron recommendations, food.']
S350-PMC4864049	PMC4864049	1/2016	S350-PMC4864049	['this is PARTICULARLY INTERESTING because it LINKS FINDINGS SHOWING decreased levels of Serotonin in asd patients\xa0[160] and reduced levels of Vitamin D. HOWEVER, a previous study FOUND LITTLE EVIDENCE that maternal Gestational Vitamin D levels are RELATED to the asd phenotype among offspring\xa0[161].']	[('ANOMALY_CURIOUS_FINDING', 8), ('ANOMALY_CURIOUS_FINDING', 21), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 44), ('INCOMPLETE_EVIDENCE', 50), ('INCOMPLETE_EVIDENCE', 59), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 152), ('INCOMPLETE_EVIDENCE', 178), ('INCOMPLETE_EVIDENCE', 184), ('SUPERFICIAL_RELATIONSHIP', 247)]	10	[('CHEBI_28790', 'serotonin', 87, 'serotonin'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 214, 'gestational'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]	0	['decreased levels serotonin asd patients\xa0[160] levels . however, maternal   levels asd phenotype among offspring\xa0[161].']
S115-PMC4874157	PMC4874157	5/2016	S115-PMC4874157	['several other STUDIES SUGGEST that, WHENEVER POSSIBLE, Interferon Β treatment SHOULD BE discontinued prior to Conception.21–28HOWEVER, SIMILAR women in OTHER STUDIES continued to receive treatment modalities throughout Pregnancy.1015–19\ninitially, Vitamin D was given as a supplement to address the paucity women MAY SUFFER from during Pregnancy,29and to attend to the Vitamin D deficiency in the general lebanese population.30more RECENT STUDIES have also SHOWN that maintaining adequate levels of Vitamin D during Pregnancy MIGHT have a PROTECTIVE EFFECT and lower the risk of developing Postpartum relapses.31\npsychological support was CRUCIAL in maintaining the mental well-Being of the mother.32some women exhibited signs of anxiety and depression.']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 36), ('INCOMPLETE_EVIDENCE', 45), ('FUTURE_WORK', 78), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 124), ('INCOMPLETE_EVIDENCE', 135), ('INCOMPLETE_EVIDENCE', 152), ('INCOMPLETE_EVIDENCE', 313), ('IMPORTANT_CONSIDERATION', 317), ('INCOMPLETE_EVIDENCE', 432), ('INCOMPLETE_EVIDENCE', 457), ('INCOMPLETE_EVIDENCE', 526), ('SUPERFICIAL_RELATIONSHIP', 539), ('SUPERFICIAL_RELATIONSHIP', 550), ('IMPORTANT_CONSIDERATION', 639)]	16	[('CHEBI_76163', 'isoxicam', 55, 'interferon β'), ('PR_000008918', 'interferon alpha-5', 55, 'interferon β'), ('GO_0007620', 'copulation', 110, 'conception'), ('GO_0007565', 'female pregnancy', 219, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('GO_0007565', 'female pregnancy', 336, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 499, 'vitamin D'), ('GO_0007565', 'female pregnancy', 516, 'pregnancy'), ('GO_0007565', 'female pregnancy', 590, 'postpartum'), ('GO_0016441', 'posttranscriptional gene silencing', 677, '-being')]	0	['several that, possible, interferon β treatment discontinued conception.21–28however, receive treatment modalities throughout .1015–19\ninitially,  supplement women ,29and attend  lebanese population.30more maintaining levels    relapses.31\npsychological maintaining mental well-being mother.32some women anxiety depression.']
S83-PMC4877864	PMC4877864	6/2015	S83-PMC4877864	['furthermore, SEVERE Gestational Vitamin D deficiency in Rats produces pups with increased Brain size and enlarged Ventricles [23], Anatomical abnormalities SIMILAR TO those FOUND in autism [24].']	[('IMPORTANT_CONSIDERATION', 13), ('INCOMPLETE_EVIDENCE', 156), ('INCOMPLETE_EVIDENCE', 173)]	3	[('GO_0007565', 'female pregnancy', 20, 'gestational'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 56, 'rats'), ('UBERON_0000955', 'brain', 90, 'brain'), ('UBERON_0002082', 'cardiac ventricle', 114, 'ventricles'), ('UBERON_0001062', 'anatomical entity', 131, 'anatomical')]	0	['furthermore,   rats pups brain enlarged ventricles [23], anatomical abnormalities autism [24].']
S0-PMC4889866	PMC4889866	5/2016	S0-PMC4889866	['maternal Vitamin D level is ASSOCIATED with Viral toll-like receptor triggered Il-10 response but not the risk of infectious diseases in infancy\n\nabstract\nreports on the EFFECT of Prenatal Vitamin D status on fetal Immune Development and infectious diseases in childhood are LIMITED.']	[('SUPERFICIAL_RELATIONSHIP', 28), ('SUPERFICIAL_RELATIONSHIP', 170), ('INCOMPLETE_EVIDENCE', 275)]	3	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 44, 'Viral'), ('PR_000001470', 'interleukin-28B', 79, 'IL-10'), ('GO_0007565', 'female pregnancy', 180, 'prenatal'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin D'), ('GO_0001822', 'kidney development', 215, 'immune development'), ('UBERON_0002405', 'immune system', 215, 'immune')]	0	['maternal vitamin viral toll-like receptor triggered il-10 response infectious diseases infancy\n\nabstract\nreports   status fetal immune infectious diseases childhood limited.']
S20-PMC4889866	PMC4889866	5/2016	S20-PMC4889866	['furthermore, VERY FEW STUDIES address the IMPACT of Prenatal Vitamin D status on tlr-RELATED Innate Immune Response in neonatal infants.']	[('IMPORTANT_CONSIDERATION', 13), ('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 42), ('SUPERFICIAL_RELATIONSHIP', 85)]	4	[('GO_0007565', 'female pregnancy', 52, 'prenatal'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0045087', 'innate immune response', 93, 'innate immune response'), ('UBERON_0002405', 'immune system', 100, 'immune')]	0	['furthermore,   status tlr-related innate immune response neonatal infants.']
S93-PMC4889866	PMC4889866	5/2016	S93-PMC4889866	['THUS, when addressing the IMPACT of Prenatal Vitamin D status on various outcomes, it MIGHT be IMPORTANT to CONSIDER that Vitamin D levels in the Pregnant mothers and Cord Blood MIGHT not always correspond uniformly.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 86), ('IMPORTANT_CONSIDERATION', 95), ('FUTURE_WORK', 108), ('IMPORTANT_CONSIDERATION', 108), ('INCOMPLETE_EVIDENCE', 178)]	7	[('GO_0007565', 'female pregnancy', 36, 'prenatal'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnant'), ('UBERON_0002240', 'spinal cord', 167, 'cord'), ('UBERON_0000178', 'blood', 172, 'blood')]	0	['thus,   status outcomes,  levels  mothers cord blood uniformly.']
S122-PMC4889866	PMC4889866	5/2016	S122-PMC4889866	['it has also LIMITED the applicability of our result in representing the general population, ALTHOUGH INADEQUATE Vitamin D concentration SEEMS PARTICULARLY common among Pregnant woman [3,19].']	[('INCOMPLETE_EVIDENCE', 12), ('ANOMALY_CURIOUS_FINDING', 92), ('IMPORTANT_CONSIDERATION', 101), ('ANOMALY_CURIOUS_FINDING', 136), ('ANOMALY_CURIOUS_FINDING', 142)]	5	[('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007565', 'female pregnancy', 168, 'pregnant')]	0	['applicability result population,  concentration among  woman [3,19].']
S124-PMC4889866	PMC4889866	5/2016	S124-PMC4889866	['THUS, FUTURE STUDIES RELATED to the EFFECT of Prenatal Vitamin D level on neonatal Innate Immunity and subsequent health outcomes will NEED to focus on populations with more Vitamin d sufficient Pregnant mothers.']	[('PROBABLE_UNDERSTANDING', 0), ('FUTURE_WORK', 6), ('SUPERFICIAL_RELATIONSHIP', 21), ('SUPERFICIAL_RELATIONSHIP', 36), ('FUTURE_WORK', 135)]	5	[('GO_0007565', 'female pregnancy', 46, 'prenatal'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0045087', 'innate immune response', 83, 'innate immunity'), ('CHEBI_33229', 'vitamin (role)', 174, 'vitamin'), ('GO_0007565', 'female pregnancy', 195, 'pregnant')]	0	['thus,   neonatal innate immunity outcomes populations vitamin  mothers.']
S127-PMC4889866	PMC4889866	5/2016	S127-PMC4889866	['finally, ALTHOUGH PRESENT STUDY had OBSERVED an ASSOCIATION between Prenatal Vitamin D status and Viral tlrs-triggered response (Tlr3 and Tlr7/8, both of which recognize Viral rna), the EFFECT of Vitamin D on cpg Double Stranded dna motif (Tlr9) of the Viral Genome also DEMANDS FURTHER EXPLORATION.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 36), ('SUPERFICIAL_RELATIONSHIP', 48), ('SUPERFICIAL_RELATIONSHIP', 186), ('IMPORTANT_CONSIDERATION', 271), ('FUTURE_WORK', 279)]	7	[('GO_0007565', 'female pregnancy', 68, 'prenatal'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('NCBITaxon_1', 'root', 98, 'viral'), ('PR_000001155', 'Toll-like receptor 4', 129, 'TLR3'), ('PR_000001155', 'Toll-like receptor 4', 138, 'TLR7'), ('NCBITaxon_1', 'root', 170, 'viral'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('SO_0000985', 'double', 213, 'double stranded'), ('PR_000001155', 'Toll-like receptor 4', 240, 'TLR9'), ('NCBITaxon_1', 'root', 253, 'viral'), ('SO_0001026', 'genome', 259, 'genome')]	0	['finally,   status viral tlrs-triggered response (tlr3 tlr7/8, viral rna),  cpg stranded dna motif (tlr9) viral genome exploration.']
S132-PMC4889866	PMC4889866	5/2016	S132-PMC4889866	['ALTHOUGH OUR study DID NOT SHOW maternal Vitamin D concentration to have a significant IMPACT on the magnitude or functional capacity of the young infant to defend against infection, we BELIEVE OUR STUDY MAY contribute to a BETTER understanding of the EFFECT of Prenatal Vitamin D status on neonatal Innate Immunity and infectious disease during early Life.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 87), ('INCOMPLETE_EVIDENCE', 186), ('QUESTION_ANSWERED_BY_THIS_WORK', 194), ('INCOMPLETE_EVIDENCE', 204), ('INCOMPLETE_EVIDENCE', 224), ('SUPERFICIAL_RELATIONSHIP', 252)]	9	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 262, 'prenatal'), ('CHEBI_27300', 'vitamin D', 271, 'vitamin D'), ('GO_0045087', 'innate immune response', 300, 'innate immunity'), ('UBERON_0000104', 'life cycle', 352, 'life')]	0	['although maternal  concentration magnitude functional capacity young infant defend infection,   status neonatal innate immunity infectious disease life.']
S3549-PMC4896250	PMC4896250	4/2016	S3549-PMC4896250	['the worldwide EPIDEMIC of Vitamin D deficiency in Pregnancy and the low content of Vitamin D in Breast Milk UNDERLIE the high RISK of deficiency in exclusively Breastfed infants.']	[('IMPORTANT_CONSIDERATION', 14), ('SUPERFICIAL_RELATIONSHIP', 108), ('IMPORTANT_CONSIDERATION', 126)]	3	[('CHEBI_28384', 'vitamin K', 26, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('UBERON_0001348', 'brown adipose tissue', 96, 'breast milk'), ('GO_0007567', 'parturition', 160, 'breastfed')]	0	['vitamin  content  breast milk exclusively breastfed infants.']
S109-PMC4897523	PMC4897523	10/2014	S109-PMC4897523	['ON THE OTHER HAND, the involvement of maternal Vitamin D during Pregnancy in autism REQUIRES PROPER INVESTIGATION.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 84), ('FUTURE_WORK', 93)]	3	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy')]	0	['hand, maternal   autism proper investigation.']
S88-PMC4903143	PMC4903143	5/2016	S88-PMC4903143	['Pregnant women screened in ONE STUDY in western canada, for example, DEMONSTRATED that the majority of women in one city had clearly INADEQUATE Vitamin D levels [75].']	[('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 69), ('IMPORTANT_CONSIDERATION', 133)]	3	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]	0	[' women screened western canada, example, women city  levels [75].']
S92-PMC4903143	PMC4903143	5/2016	S92-PMC4903143	['THE literature has discussed that Vitamin D insufficiency MAY BE ASSOCIATED with first Trimester Pregnancy loss [85,86], Gestational diabetes [103,104], Preeclampsia [89,105], Preterm Birth [92,93], higher rates of primary and emergency caesarean Delivery [94,106], small for Gestational age infants [95], and maternal Postpartum depression [96].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 58), ('SUPERFICIAL_RELATIONSHIP', 65)]	3	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 87, 'trimester'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('GO_0007565', 'female pregnancy', 121, 'gestational'), ('GO_0007128', 'meiotic prophase I', 153, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 176, 'preterm birth'), ('GO_0007567', 'parturition', 247, 'delivery'), ('GO_0007565', 'female pregnancy', 276, 'gestational'), ('GO_0007565', 'female pregnancy', 319, 'postpartum')]	0	[' trimester  loss [85,86],  diabetes [103,104], preeclampsia [89,105],  [92,93], higher rates caesarean delivery [94,106],  age infants [95], maternal  depression [96].']
S97-PMC4903143	PMC4903143	5/2016	S97-PMC4903143	"['[""""an INTERESTING cohort study CORRELATING maternal Vitamin D deficiency at 18 weeks\' Pregnancy and health outcomes of progeny FOUND that Gestational Vitamin D deficiency is ASSOCIATED with impaired Lung development in 6-year-old offspring, Neurocognitive difficulties at age 10, increased risk of Eating disorders in Adolescence, and lower peak bone mass at 20 years [34].""""]']"	[('ANOMALY_CURIOUS_FINDING', 3), ('SUPERFICIAL_RELATIONSHIP', 28), ('INCOMPLETE_EVIDENCE', 124), ('SUPERFICIAL_RELATIONSHIP', 171)]	4	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007565', 'female pregnancy', 135, 'gestational'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('UBERON_0002048', 'lung', 196, 'lung'), ('GO_0050905', 'neuromuscular process', 238, 'neurocognitive'), ('GO_0051318', 'G1 phase', 295, 'eating'), ('GO_0048848', 'neurohypophysis morphogenesis', 315, 'adolescence')]	0	"['[""""an maternn 18 weekncy outcomes progeny thnn lung 6-year-old offspring, neurocognitive age 10, eating disorders adolescence, peak bone mass 20 [34].""""]']"
S98-PMC4903143	PMC4903143	5/2016	S98-PMC4903143	['in addition, Gestational Vitamin D levels MAY EVEN IMPACT Adult health AS there is EARLY EVIDENCE that Vitamin D sufficiency in Pregnancy MAY have a PROTECTIVE ROLE in the Development Of Adult-onset multiple Sclerosis [33].']	[('INCOMPLETE_EVIDENCE', 42), ('ANOMALY_CURIOUS_FINDING', 46), ('SUPERFICIAL_RELATIONSHIP', 51), ('PROBABLE_UNDERSTANDING', 71), ('INCOMPLETE_EVIDENCE', 83), ('INCOMPLETE_EVIDENCE', 138), ('SUPERFICIAL_RELATIONSHIP', 149), ('SUPERFICIAL_RELATIONSHIP', 160)]	8	[('GO_0007565', 'female pregnancy', 13, 'gestational'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('UBERON_0007023', 'adult organism', 58, 'adult'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007565', 'female pregnancy', 128, 'pregnancy'), ('GO_0048513', 'animal organ development', 172, 'development of ... sclerosis'), ('UBERON_0007023', 'adult organism', 187, 'adult')]	0	['addition,   levels adult   adult-onset sclerosis [33].']
S99-PMC4903143	PMC4903143	5/2016	S99-PMC4903143	['with ABUNDANT EVIDENCE of myriad health sequelae ASSOCIATED with Gestational Vitamin D deficiency, there is POTENTIAL for CONSIDERABLE amelioration of maternal and fetal health outcomes by educational and healthcare measures in the Preconception and Prenatal period to secure Vitamin D sufficiency throughout Gestation [76].']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 49), ('INCOMPLETE_EVIDENCE', 108), ('IMPORTANT_CONSIDERATION', 122)]	4	[('GO_0007565', 'female pregnancy', 65, 'gestational'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('GO_0007565', 'female pregnancy', 232, 'preconception'), ('GO_0007565', 'female pregnancy', 250, 'prenatal'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D'), ('GO_0007565', 'female pregnancy', 309, 'gestation')]	0	['abundant sequelae   deficiency, amelioration maternal fetal outcomes educational healthcare   period secure  throughout  [76].']
S113-PMC4903143	PMC4903143	5/2016	S113-PMC4903143	['as discussed, most Pregnant women APPEAR TO BE deficient in Vitamin D.\nmedications in common usage (e.g., some Antibiotics, antacids, and hypertensive Drugs) diminish absorption of magnesium.']	[('ANOMALY_CURIOUS_FINDING', 34)]	1	[('GO_0007565', 'female pregnancy', 19, 'pregnant'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_33282', 'antibacterial agent', 111, 'antibiotics'), ('CHEBI_23888', 'drug', 151, 'drugs')]	0	['discussed,  women .\nmedications usage (e.g., antibiotics, antacids, hypertensive drugs) diminish absorption magnesium.']
S157-PMC4903143	PMC4903143	5/2016	S157-PMC4903143	['AS operative Delivery via caesarean Section MAY result in deficiency or disruption of a healthy biome, steps to diminish the need for operative Delivery by addressing POTENTIALLY modifiable DETERMINANTS such as elevated bmi [159] and Vitamin D deficiency [94] in Pregnancy MAY BE in order.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 167), ('SUPERFICIAL_RELATIONSHIP', 190), ('INCOMPLETE_EVIDENCE', 273)]	5	[('GO_0007567', 'parturition', 13, 'delivery'), ('GO_0007601', 'visual perception', 36, 'section'), ('GO_0007567', 'parturition', 144, 'delivery'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D'), ('GO_0007565', 'female pregnancy', 263, 'pregnancy')]	0	['delivery via caesarean section result healthy biome, diminish delivery elevated bmi [159]  [94]  order.']
S0-PMC4930210	PMC4930210	7/2016	S0-PMC4930210	['the current recommended Vitamin D intake guideline for diet and supplements during Pregnancy is not adequate to achieve Vitamin D sufficiency for most Pregnant women\n\nabstract\n\nbackground\nthe aims of THIS STUDY were TO DETERMINE IF Pregnant women consumed the RECOMMENDED Vitamin D through diet alone or through diet and supplements, and if they achieved the current reference range Vitamin D status when their reported dietary intake met the current RECOMMENDATIONS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 200), ('QUESTION_ANSWERED_BY_THIS_WORK', 216), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 229), ('FUTURE_WORK', 260), ('FUTURE_WORK', 451)]	5	[('CHEBI_28384', 'vitamin K', 24, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'Pregnancy'), ('CHEBI_28384', 'vitamin K', 120, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'Pregnant'), ('GO_0007565', 'female pregnancy', 232, 'pregnant'), ('CHEBI_27300', 'vitamin D', 272, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 383, 'vitamin D')]	0	['vitamin intake diet supplements  achieve vitamin  women\n\nabstract\n\nbackground\nthe  women consumed  diet diet supplements, achieved  status dietary intake met recommendations.']
S8-PMC4930210	PMC4930210	7/2016	S8-PMC4930210	['conclusions\nwe DEMONSTRATED the current rda (600 iu/ day) MAY not be adequate to achieve Vitamin D status >75 nmol/l in SOME Pregnant women who are residing in higher latitudes (calgary, 51°n) in alberta, canada and the current Vitamin D RECOMMENDATIONS for canadian Pregnant women NEED TO be re-evaluated.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 58), ('INCOMPLETE_EVIDENCE', 120), ('FUTURE_WORK', 238), ('IMPORTANT_CONSIDERATION', 282)]	5	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnant'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('GO_0007565', 'female pregnancy', 267, 'pregnant')]	0	['conclusions\nwe rda (600 iu/ day) achieve  status >75 nmol/l  women residing higher latitudes (calgary, 51°n) alberta, canada  canadian  women re-evaluated.']
S10-PMC4930210	PMC4930210	7/2016	S10-PMC4930210	['there is also EVIDENCE that Pregnancy RISKS MAY BE mitigated by Vitamin D supplementation, ALTHOUGH the optimal daily dose is NOT CLEAR [2].']	[('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 38), ('INCOMPLETE_EVIDENCE', 44), ('ANOMALY_CURIOUS_FINDING', 91), ('FULL_UNKNOWN', 126)]	5	[('GO_0007565', 'female pregnancy', 28, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]	0	[' mitigated  supplementation, daily dose [2].']
S11-PMC4930210	PMC4930210	7/2016	S11-PMC4930210	['health canada [3] and the institute of medicine (iom) [4] have RECOMMENDED 600 iu/day intake of Vitamin D during Pregnancy.']	[('FUTURE_WORK', 63)]	1	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy')]	0	['health canada [3] institute medicine (iom) [4] 600 iu/day intake  .']
S19-PMC4930210	PMC4930210	7/2016	S19-PMC4930210	['a combined analysis of two randomized clinical trials of 494 Pregnant women taking 400, 2000, and 4000 iu/day Vitamin D during Pregnancy SHOWED that Vitamin D supplementation of 4000 iu/day was more EFFECTIVE in achieving Serum concentrations ≥ 80 nmol/l than 400 and 2000 iu/day in all women and their neonates REGARDLESS OF race, SUGGESTING that the current dietary RECOMMENDATION in the absence of supplementation in Pregnancy MAY not be OPTIMAL [9].']	[('INCOMPLETE_EVIDENCE', 137), ('SUPERFICIAL_RELATIONSHIP', 199), ('INCOMPLETE_EVIDENCE', 312), ('INCOMPLETE_EVIDENCE', 332), ('FUTURE_WORK', 368), ('INCOMPLETE_EVIDENCE', 430), ('IMPORTANT_CONSIDERATION', 441)]	7	[('GO_0007565', 'female pregnancy', 61, 'pregnant'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('UBERON_0001977', 'blood serum', 222, 'serum'), ('GO_0007565', 'female pregnancy', 420, 'pregnancy')]	0	['combined 494  women 400, 2000, 4000 iu/day    supplementation 4000 iu/day achieving serum concentrations ≥ 80 nmol/l 400 2000 iu/day women neonates race, dietary absence supplementation  [9].']
S21-PMC4930210	PMC4930210	7/2016	S21-PMC4930210	['a RECENT systematic REVIEW of Vitamin D supplementation in Pregnancy CONCLUDED that EVIDENCE is currently INSUFFICIENT TO SUPPORT DEFINITE clinical RECOMMENDATIONS regarding Vitamin D supplementation in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 69), ('INCOMPLETE_EVIDENCE', 84), ('INCOMPLETE_EVIDENCE', 106), ('PROBLEM_COMPLICATION', 106), ('PROBABLE_UNDERSTANDING', 130), ('FUTURE_WORK', 148)]	8	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]	0	[' supplementation  regarding  supplementation .']
S26-PMC4930210	PMC4930210	7/2016	S26-PMC4930210	['we RECENTLY SHOWED that not separating out Plasma 3-epi-25-hydroxycholecalciferol (3-Epi-25(Oh)D3) from Vitamin D status calculation UNDERESTIMATES the classification of Pregnant women and their newborns at risk for Vitamin D insufficiency (>75 nmol/l) [13].']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('PROBLEM_COMPLICATION', 133)]	3	[('UBERON_0001969', 'blood plasma', 43, 'plasma'), ('CHEBI_76629', '2-lysophosphatidic acid', 83, '3-epi-25(OH)D3'), ('PR_000001177', 'D(2) dopamine receptor', 95, 'D3'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'pregnant'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D')]	0	['separating plasma 3-epi-25-hydroxycholecalciferol (3-epi-25(oh)d3)  status calculation classification  women newborns  (>75 nmol/l) [13].']
S27-PMC4930210	PMC4930210	7/2016	S27-PMC4930210	['ALTHOUGH the literature regarding Vitamin D in Pregnancy is growing rapidly, several gaps in our knowledge REMAIN, including the prevalence of Vitamin D deficiency/ insufficiency during Pregnancy and the intake of Vitamin D during Pregnancy NEEDED to ensure optimal status.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 107), ('FUTURE_WORK', 241)]	3	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('GO_0007565', 'female pregnancy', 186, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 214, 'vitamin D'), ('GO_0007565', 'female pregnancy', 231, 'pregnancy')]	0	['although regarding   rapidly, remain,  deficiency/  intake   ensure status.']
S28-PMC4930210	PMC4930210	7/2016	S28-PMC4930210	['our AIMS in the CURRENT STUDY were TO DETERMINE: a) if Pregnant women were Consuming the RECOMMENDED Vitamin D through diet alone or through diet and supplements, and b) IF Pregnant women can achieve the current reference range Vitamin D status when their reported dietary intake of Vitamin D met the current RECOMMENDATIONS.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('QUESTION_ANSWERED_BY_THIS_WORK', 35), ('FUTURE_WORK', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 170), ('FUTURE_WORK', 309)]	6	[('GO_0007565', 'female pregnancy', 55, 'pregnant'), ('GO_0007631', 'feeding behavior', 75, 'consuming'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 173, 'pregnant'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]	0	['determine: a)  women  diet diet supplements, b)  women achieve  status dietary intake  met recommendations.']
S40-PMC4930210	PMC4930210	7/2016	S40-PMC4930210	['HOWEVER, Intake from Food and beverages ONLY accounted for 39% of total Vitamin D intake and the major source (39%) was from milk, which was consumed on a regular basis by participants during the second Trimester of Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 40), ('INCOMPLETE_EVIDENCE', 40)]	3	[('GO_0007631', 'feeding behavior', 9, 'intake'), ('CHEBI_33290', 'food', 21, 'food'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 203, 'trimester'), ('GO_0007565', 'female pregnancy', 216, 'pregnancy')]	0	['however, intake food beverages 39%  intake (39%) milk, consumed participants trimester .']
S42-PMC4930210	PMC4930210	7/2016	S42-PMC4930210	['maternal supplement intake questionnaire (siq)\nfollowing enrollment, the maternal supplement intake questionnaire (siq) was administered by a trained nutrition professional to each participant once during each trimester of Pregnancy and once at 3 months Postpartum to determine current natural health product (nhp) use including Vitamin D. the siq was designed specifically for the apron study and was initially used in a pilot study that included of fifty women in the apron study who completed the questionnaire during their first and second visits TO assess efficacy and the detail of information obtained [15].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 551)]	1	[('GO_0007565', 'female pregnancy', 223, 'pregnancy'), ('GO_0007565', 'female pregnancy', 254, 'postpartum'), ('CHEBI_27300', 'vitamin D', 329, 'vitamin D')]	0	['maternal supplement intake questionnaire (siq)\nfollowing enrollment, maternal supplement intake questionnaire (siq) administered trained nutrition professional participant trimester  3 months  natural product (nhp) . siq fifty women completed questionnaire visits detail [15].']
S83-PMC4930210	PMC4930210	7/2016	S83-PMC4930210	['we measured Vitamin D Metabolites with lc-ms/ms and SHOWED that, except for 25(Oh)D2, there were no significant differences between the two trimesters for any other Metabolite (table 2).10.1371/journal.pone.0157262.t001\n\ncaption (table-wrap): table 1\ncharacteristics of participants in a longitudinal cohort of Pregnant women in alberta, canada.characteristics of participantsoverall (n = 537)age, y31 ± 4 (n = 537)Gestational agea19.6 ± 3.4 (n = 502) race, % (n = 513)black1caucasian87others12 family annual incomeb, % (n = 537)< $70,00019≥ $70,00081 type of education, % (n = 514)< high school2high school8trade school20undergraduate47postgraduate23 prior Births ≥37 weeks Gestation, % (n = 537)058132283140.4 season of sampling, % (n = 546)springc33summerd25falle14winterf28bmig26 ± 5 (n = 537)\naat time of Blood sample.']	[('INCOMPLETE_EVIDENCE', 52)]	1	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_25212', 'metabolite', 22, 'metabolites'), ('CHEBI_77765', '2,4,6-trihydroxybenzophenone(1-)', 76, '25(OH)D2'), ('PR_000029655', '28S rRNA (cytosine-C(5))-methyltransferase', 76, '25(OH)D2'), ('CHEBI_39382', 'flufenoxuron', 165, 'metabolite'), ('GO_0007565', 'female pregnancy', 311, 'Pregnant'), ('GO_0007565', 'female pregnancy', 415, 'Gestational'), ('GO_0007567', 'parturition', 658, 'births'), ('GO_0007565', 'female pregnancy', 675, 'gestation'), ('UBERON_0000178', 'blood', 810, 'blood')]	0	[' metabolites lc-ms/ms that, 25(oh)d2, trimesters metabolite (table 2).10.1371/journal.pone.0157262.t001\n\ncaption (table-wrap): table 1\ncharacteristics participants longitudinal  women alberta, canada.characteristics participantsoverall (n = 537)age, y31 ± 4 (n = 537) agea19.6 ± 3.4 (n = 502) race, % (n = 513)black1caucasian87others12 family annual incomeb, % (n = 537)< $70,00019≥ $70,00081 type education, % (n = 514)< school2high school8trade school20undergraduate47postgraduate23 births ≥37 weeks % (n = 537)058132283140.4 season sampling, % (n = 546)springc33summerd25falle14winterf28bmig26 ± 5 (n = 537)\naat blood sample.']
S86-PMC4930210	PMC4930210	7/2016	S86-PMC4930210	['REPORTED dietary Vitamin D intake (diet and supplements) .table 3shows the reported intake from diet and supplements for all the trimesters of Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]	0	['reported dietary  intake (diet supplements) .table intake diet supplements trimesters .']
S111-PMC4930210	PMC4930210	7/2016	S111-PMC4930210	['there was a significant ASSOCIATION between maternal Plasma 25(Oh)D and total reported Vitamin D intake during the second Trimester of Pregnancy (β: 0.09, 95% ci: 0.06 to 0.13) in an adjusted linear regression model.']	[('SUPERFICIAL_RELATIONSHIP', 24)]	1	[('UBERON_0001969', 'blood plasma', 53, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 60, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 122, 'trimester'), ('GO_0007565', 'female pregnancy', 135, 'pregnancy')]	0	['maternal plasma 25(oh)d  intake trimester  (β: 0.09, 95% ci: 0.06 0.13) adjusted linear regression model.']
S112-PMC4930210	PMC4930210	7/2016	S112-PMC4930210	['season of sampling and race were also significantly ASSOCIATED with 25(Oh)D concentration (table 4).10.1371/journal.pone.0157262.g002\n\ncaption (fig): fig 2\nabsolute concentrations of (a) Plasma 25(Oh)D, and (b) Plasma 3-Epi-25(Oh)D3Versus maternal Vitamin D intake (iu/day) in a longitudinal cohort of Pregnant women and their infants in alberta, canada.']	[('SUPERFICIAL_RELATIONSHIP', 52)]	1	[('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 68, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 187, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 194, '25(OH)D'), ('UBERON_0001969', 'blood plasma', 211, 'plasma'), ('CHEBI_34304', 'fenobucarb', 218, '3-epi-25'), ('CHEBI_51048', '(R,R)-diepoxybutane', 226, '(OH)D3versus'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('GO_0007565', 'female pregnancy', 302, 'pregnant')]	0	['season sampling race 25(oh)d concentration (table 4).10.1371/journal.pone.0157262.g002\n\ncaption (fig): fig 2\nabsolute concentrations (a) plasma 25(oh)d, (b) plasma 3-epi-25(oh)d3versus maternal  intake (iu/day) longitudinal  women infants alberta, canada.']
S126-PMC4930210	PMC4930210	7/2016	S126-PMC4930210	['discussion\nTO OUR KNOWLEDGE, THIS is the largest STUDY TO date to SHOW 44% of Pregnant women with a higher socioeconomic status reported Vitamin D intake (diet and supplements) not meeting the dietary reference intakes (dri) recomendations.']	[('PROBABLE_UNDERSTANDING', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('QUESTION_ANSWERED_BY_THIS_WORK', 49), ('QUESTION_ANSWERED_BY_THIS_WORK', 55), ('INCOMPLETE_EVIDENCE', 66)]	5	[('GO_0007565', 'female pregnancy', 78, 'pregnant'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]	0	['discussion\nto knowledge, 44%  women higher socioeconomic status  intake (diet supplements) meeting dietary intakes (dri) recomendations.']
S127-PMC4930210	PMC4930210	7/2016	S127-PMC4930210	['using lc-ms/ms, we separated epimer from estimation of Vitamin D status and were able to ACCURATELY ESTIMATE the prevalence of Vitamin D insufficiency in our Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 89), ('INCOMPLETE_EVIDENCE', 100)]	2	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('GO_0007565', 'female pregnancy', 158, 'pregnant')]	0	['using lc-ms/ms, separated epimer  status able   women.']
S128-PMC4930210	PMC4930210	7/2016	S128-PMC4930210	['we also FOUND that 20% of Pregnant women had Vitamin D concentraion <75 nmol/l, DESPITE more than half of these women reporting taking more than 600 iu/day of Vitamin D (the current rda) BASED ON their REPORTED intake from diet and supplements.']	[('INCOMPLETE_EVIDENCE', 8), ('ANOMALY_CURIOUS_FINDING', 80), ('INCOMPLETE_EVIDENCE', 187), ('INCOMPLETE_EVIDENCE', 202)]	4	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]	0	['20%  women  concentraion <75 nmol/l, half women 600 iu/day  (the rda) intake diet supplements.']
S132-PMC4930210	PMC4930210	7/2016	S132-PMC4930210	['canadian community nutrition intakes data for non-Pregnant women of Child-Bearing age (19–50 years) REPORTED that 90% of canadian women are not Consuming the current RECOMMENDATIONS for Vitamin D through their diet [25].']	[('INCOMPLETE_EVIDENCE', 100), ('FUTURE_WORK', 166)]	2	[('GO_0007565', 'female pregnancy', 50, 'pregnant'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 68, 'child-bearing'), ('GO_0007631', 'feeding behavior', 144, 'consuming'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D')]	0	['canadian community nutrition intakes non- women child-bearing age (19–50 years) 90% canadian women  diet [25].']
S133-PMC4930210	PMC4930210	7/2016	S133-PMC4930210	['in THE CURRENT STUDY, we SHOWED that Pregnant women are taking small amounts of Vitamin D from Food and beverages in their diet (<200 iu/day), and they are relying on supplemental sources of Vitamin D to meet the current dris.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 25)]	2	[('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_33290', 'food', 95, 'food'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]	0	['study,  women amounts  food beverages diet (<200 iu/day), relying supplemental sources  meet dris.']
S135-PMC4930210	PMC4930210	7/2016	S135-PMC4930210	['OUR FINDINGS are SUPPORTIVE of a GROWING body of LITERATURE SUGGESTING that the RECOMMENDED dose of Vitamin D during Pregnancy is INADEQUATE in preventing Vitamin D deficiency/insufficiency [26].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 49), ('INCOMPLETE_EVIDENCE', 60), ('FUTURE_WORK', 80), ('IMPORTANT_CONSIDERATION', 130), ('PROBLEM_COMPLICATION', 130)]	8	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]	0	['dose    deficiency/insufficiency [26].']
S136-PMC4930210	PMC4930210	7/2016	S136-PMC4930210	['a RECENT STUDY of maternal Vitamin D status at third Trimester of Pregnancy and Postpartum periods of 467 Pregnant women in toronto SHOWED persistent Vitamin D deficiency/ insufficiency in two-thirds of participants DESPITE taking 400 iu/day of Vitamin D through their Prenatal Vitamin D [27].']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 132), ('ANOMALY_CURIOUS_FINDING', 216)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 53, 'trimester'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy'), ('GO_0007565', 'female pregnancy', 80, 'postpartum'), ('GO_0007565', 'female pregnancy', 106, 'pregnant'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D'), ('GO_0007565', 'female pregnancy', 269, 'prenatal'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D')]	0	['maternal  status third trimester   periods 467  women toronto  deficiency/ two-thirds participants 400 iu/day    [27].']
S137-PMC4930210	PMC4930210	7/2016	S137-PMC4930210	['another RECENT american longitudinal STUDY of 193 Pregnant women from mid-Pregnancy to Birth SHOWED Consuming a Prenatal Vitamin D supplement (334 iu/day) did not PREVENT precipitous drops in maternal Plasma 25(Oh)D concentration [28].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 37), ('INCOMPLETE_EVIDENCE', 93), ('SUPERFICIAL_RELATIONSHIP', 163)]	4	[('GO_0007565', 'female pregnancy', 50, 'pregnant'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 87, 'birth'), ('GO_0007631', 'feeding behavior', 100, 'consuming'), ('GO_0007565', 'female pregnancy', 112, 'prenatal'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 201, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 208, '25(OH)D')]	0	['another 193  women mid- birth   supplement (334 iu/day) precipitous drops maternal plasma 25(oh)d concentration [28].']
S138-PMC4930210	PMC4930210	7/2016	S138-PMC4930210	['IN FACT, randomized clinical trials of 2000 and 4000 iu/day Vitamin D during Pregnancy HAVE SHOWN that Vitamin D supplementation of 4000 iu/day was more EFFECTIVE in achieving Serum concentrations ≥80 nmol/l of Vitamin D [9].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 87), ('SUPERFICIAL_RELATIONSHIP', 153)]	3	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('UBERON_0001977', 'blood serum', 176, 'serum'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]	0	['fact, 2000 4000 iu/day    supplementation 4000 iu/day achieving serum concentrations ≥80 nmol/l  [9].']
S140-PMC4930210	PMC4930210	7/2016	S140-PMC4930210	['in addition, we DEMONSTRATED the presence of 3-Epi-25(Oh)D3In all our Pregnant women’s Plasma samples across Pregnancy (second trimester), and that including this epimer in the measurement of Vitamin D status significantly INFLUENCED the classification of prevalence of Vitamin D sufficiency in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 223)]	2	[('CHEBI_15616', '(3S,5S)-3,5-diaminohexanoic acid', 45, '3-epi-25(OH)D3in'), ('PR_000011622', 'S-acyl fatty acid synthase thioesterase, medium chain', 54, 'OH ... D3in'), ('GO_0007565', 'female pregnancy', 70, 'pregnant'), ('UBERON_0001969', 'blood plasma', 87, 'plasma'), ('GO_0007565', 'female pregnancy', 109, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin D'), ('GO_0007565', 'female pregnancy', 295, 'pregnancy')]	0	['addition, presence 3-epi-25(oh)d3in  women’s plasma samples  (second trimester), epimer  status classification  .']
S141-PMC4930210	PMC4930210	7/2016	S141-PMC4930210	['this FINDING is CONSISTENT with our PREVIOUS STUDY SHOWING epimer CAN alter Vitamin D status estimation of Pregnant women at the time of Delivery and in their Cord Blood [13].']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 36), ('INCOMPLETE_EVIDENCE', 51), ('INCOMPLETE_EVIDENCE', 66)]	5	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'pregnant'), ('GO_0007567', 'parturition', 137, 'delivery'), ('UBERON_0002240', 'spinal cord', 159, 'cord'), ('UBERON_0000178', 'blood', 164, 'blood')]	0	['epimer alter  status  women delivery cord blood [13].']
S147-PMC4930210	PMC4930210	7/2016	S147-PMC4930210	['THESE FINDINGS EMPHASIZE THE NEED for FURTHER identification of the functional ROLE and clinical SIGNIFICANCE of 3-Epi-25(Oh)D3In the assessment of Vitamin D status in Pregnant women, given the fact that the cut-off for Vitamin D sufficiency in Pregnancy is UNCLEAR.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 15), ('INCOMPLETE_EVIDENCE', 25), ('FUTURE_WORK', 29), ('FUTURE_WORK', 38), ('SUPERFICIAL_RELATIONSHIP', 79), ('IMPORTANT_CONSIDERATION', 97), ('FULL_UNKNOWN', 258)]	8	[('CHEBI_15616', '(3S,5S)-3,5-diaminohexanoic acid', 113, '3-epi-25(OH)D3in'), ('PR_000002325', 'dynein light chain 1, cytoplasmic', 125, 'D3in'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('GO_0007565', 'female pregnancy', 168, 'pregnant'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('GO_0007565', 'female pregnancy', 245, 'pregnancy')]	0	['functional 3-epi-25(oh)d3in  status  women, cut-off   unclear.']
S154-PMC4930210	PMC4930210	7/2016	S154-PMC4930210	['the lower rate of Vitamin D insufficiency in OUR STUDY COULD BE RELATED to the cohort characteristics involving very educated, high socio-economic status Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 45), ('INCOMPLETE_EVIDENCE', 55), ('SUPERFICIAL_RELATIONSHIP', 64)]	3	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnant')]	0	['rate  characteristics educated, socio-economic status  women.']
S168-PMC4930210	PMC4930210	7/2016	S168-PMC4930210	['WHILE the current canadian cancer society RECOMMENDATIONS [38] are to avoid sun exposure or failing that, use of sunscreen at all times when out in the sun, our participants undoubtedly were getting sunlight exposure AS SEEN by a seasonal variation in 25(Oh)D.\nin CONCLUSION, we FOUND a 20% rate of Vitamin D insufficiency (<75 nmol/l) in a large, well-nourished cohort of Pregnant women.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 42), ('INCOMPLETE_EVIDENCE', 217), ('INCOMPLETE_EVIDENCE', 220), ('INCOMPLETE_EVIDENCE', 264), ('INCOMPLETE_EVIDENCE', 279)]	6	[('CHEBI_71657', 'versiconol acetate', 252, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 252, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin D'), ('GO_0007565', 'female pregnancy', 373, 'pregnant')]	0	['canadian cancer society [38] sun exposure that, sunscreen times sun, participants getting sunlight exposure seasonal 25(oh)d.\nin conclusion, 20% rate  (<75 nmol/l) large, well-nourished  women.']
S170-PMC4930210	PMC4930210	7/2016	S170-PMC4930210	['this FINDING EXTENDS the literature SUGGESTING that 600 iu/day MAY not be enough to achieve Vitamin D status >75 nmol/l in Pregnant women residing in higher latitudes with limited sun exposure.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 36), ('INCOMPLETE_EVIDENCE', 63)]	5	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnant')]	0	['600 iu/day achieve  status >75 nmol/l  women residing higher latitudes sun exposure.']
S172-PMC4930210	PMC4930210	7/2016	S172-PMC4930210	['THESE FINDINGS, together with EXISTING DATA, HIGHLIGHT THE NEED for re-evaluation of our current Vitamin D RECOMMENDATIONS for Pregnant women residing in countries with higher latitude.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 45), ('INCOMPLETE_EVIDENCE', 55), ('FUTURE_WORK', 59), ('FUTURE_WORK', 107)]	6	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'pregnant')]	0	['findings, data, re-evaluation   women residing countries higher latitude.']
S598-PMC4933715	PMC4933715	7/2016	S598-PMC4933715	['(4) ALTHOUGH SOMETIMES SUGGESTED, there SEEMS to be sufficient EVIDENCE that there is no association with asd for many Maternal infections in Pregnancy (i.e., herpes viruses, epstein barr virus, varicella—Zoster Virus, Parvovirus), smoking, exposure to heavy metals or Vitamin D deficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('ANOMALY_CURIOUS_FINDING', 4), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 23), ('ANOMALY_CURIOUS_FINDING', 40), ('INCOMPLETE_EVIDENCE', 63)]	6	[('GO_0007618', 'mating', 119, 'maternal'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy'), ('NCBITaxon_10088', 'Mus <genus>', 205, 'zoster virus'), ('NCBITaxon_10088', 'Mus <genus>', 219, 'parvovirus'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]	0	['(4) suggested, asd maternal infections  (i.e., herpes viruses, epstein barr virus, varicella—zoster virus, parvovirus), smoking, exposure metals  deficiency.']
S6-PMC4934634	PMC4934634	11/2015	S6-PMC4934634	['the EFFECT of Vitamin D supplementation during Pregnancy and early Life on maternal and infant outcomes will be of particular FOCUS in this review.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 126)]	2	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('UBERON_0000104', 'life cycle', 67, 'life')]	0	[' supplementation  life maternal infant outcomes review.']
S18-PMC4934634	PMC4934634	11/2015	S18-PMC4934634	['estimates of Vitamin D deficiency during Pregnancy worldwide range from 8% to 99% of women DEPENDING ON the population and cut-offs used.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 91)]	1	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy')]	0	['estimates   8% 99% women population cut-offs used.']
S19-PMC4934634	PMC4934634	11/2015	S19-PMC4934634	['rickets will not be discussed in this review (readers are referred to a review on this topic by elder and bishop, 2014 [5]) as this paper is FOCUSED on RECENT LITERATURE regarding the IMPORTANCE of maternal Vitamin D status on Pregnancy and infant outcomes, with an EMPHASIS on supplementation trials.healthcare-03-01097-t001_table 1\n\ncaption (table-wrap): table 1\n\ndesignation of Vitamin D status based on circulating Vitamin D levels by the u.s. institute of medicine (iom) and the Endocrine society.Vitamin D statusiomendocrine societydeficiency<12 ng/ml (30 nmol/l)<20 ng/ml (50 nmol/l)insufficiency12–20 ng/ml (30–50 nmol/l)21–29 ng/ml (52.5–72.5 nmol/l)sufficiency>20 ng/ml (50 nmol/l)>30 ng/ml (75 nmol/l)toxicity>50 ng/ml (125 nmol/l)>150 ng/ml (375 nmol/l)\n\n2.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 141), ('INCOMPLETE_EVIDENCE', 152), ('IMPORTANT_CONSIDERATION', 184), ('IMPORTANT_CONSIDERATION', 266)]	4	[('CHEBI_27300', 'vitamin D', 207, 'vitamin D'), ('GO_0007565', 'female pregnancy', 227, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 381, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 419, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 484, 'Endocrine'), ('CHEBI_28384', 'vitamin K', 502, 'Vitamin D')]	0	['rickets (readers elder bishop, 2014 [5]) regarding maternal  status  infant outcomes, supplementation trials.healthcare-03-01097-t001_table 1\n\ncaption (table-wrap): table 1\n\ndesignation  status circulating  levels u.s. institute medicine (iom) endocrine society.vitamin statusiomendocrine societydeficiency<12 ng/ml (30 nmol/l)<20 ng/ml (50 nmol/l)insufficiency12–20 ng/ml (30–50 nmol/l)21–29 ng/ml (52.5–72.5 nmol/l)sufficiency>20 ng/ml (50 nmol/l)>30 ng/ml (75 nmol/l)toxicity>50 ng/ml (125 nmol/l)>150 ng/ml (375 nmol/l)\n\n2.']
S31-PMC4934634	PMC4934634	11/2015	S31-PMC4934634	['CONSISTENT with this, it HAS BEEN REPORTED that obese Pregnant women have lower Vitamin D levels THAN non-obese women, EVEN when they have higher Vitamin D Intakes during the first trimester [9].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 97), ('ANOMALY_CURIOUS_FINDING', 119)]	5	[('GO_0007565', 'female pregnancy', 54, 'pregnant'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('GO_0007631', 'feeding behavior', 156, 'intakes')]	0	['consistent this, obese  women  levels non-obese women, higher  intakes trimester [9].']
S47-PMC4934634	PMC4934634	11/2015	S47-PMC4934634	['THE CURRENT REVIEW is FOCUSED on the EFFECTS of Vitamin D on numerous aspects of Reproduction including Male and Female Fertility, Pregnancy, and infant outcomes as well as childhood and Adult disease (figure 1).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('SUPERFICIAL_RELATIONSHIP', 37)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0000003', 'reproduction', 81, 'reproduction'), ('GO_0007618', 'mating', 104, 'male ...'), ('GO_0007567', 'parturition', 113, 'female fertility'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy'), ('UBERON_0007023', 'adult organism', 187, 'adult')]	0	[' aspects reproduction male female fertility, infant outcomes childhood adult disease (figure 1).']
S55-PMC4934634	PMC4934634	11/2015	S55-PMC4934634	['ONLY 40% of the females inseminated by Vitamin D deficient Rats had normal sized litters compared to 76% from Vitamin D-replete males IN PART due to increased Pregnancy complications.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 134)]	3	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 59, 'rats'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('GO_0007565', 'female pregnancy', 159, 'pregnancy')]	0	['40% females inseminated  rats normal sized litters 76% -replete males  complications.']
S66-PMC4934634	PMC4934634	11/2015	S66-PMC4934634	[', REPORTED that 47.4% of women with recurrent Pregnancy losses (rpl), defined as three or more consecutive spontaneous Abortions before 20 weeks Gestation, had low Serum 25(Oh)D levels e.g., below 30 ng/ml, the Endocrine society cut-off for Vitamin D sufficiency status (table 1) [25].']	[('INCOMPLETE_EVIDENCE', 2)]	1	[('GO_0007565', 'female pregnancy', 46, 'pregnancy'), ('GO_0006915', 'apoptotic process', 119, 'abortions'), ('GO_0007565', 'female pregnancy', 145, 'gestation'), ('UBERON_0001977', 'blood serum', 164, 'serum'), ('CHEBI_71657', 'versiconol acetate', 170, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 170, '25(OH ... D'), ('UBERON_0005063', 'left ventricular compact myocardium', 211, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D')]	0	[', 47.4% women recurrent  losses (rpl), three consecutive spontaneous abortions 20 weeks serum 25(oh)d levels e.g., 30 ng/ml, endocrine society cut-off  status (table 1) [25].']
S72-PMC4934634	PMC4934634	11/2015	S72-PMC4934634	[', DETECTED no difference in Pre-Pregnancy Vitamin D status among healthy danish women who were able to Conceive COMPARED TO those who could not Conceive in a ~6 month time period [28].']	[('INCOMPLETE_EVIDENCE', 2), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112)]	2	[('GO_0007568', 'aging', 28, 'pre'), ('GO_0007565', 'female pregnancy', 32, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007631', 'feeding behavior', 103, 'conceive'), ('GO_0007631', 'feeding behavior', 144, 'conceive')]	0	[', pre-  status among healthy danish women able conceive conceive ~6 month period [28].']
S75-PMC4934634	PMC4934634	11/2015	S75-PMC4934634	['MANY observational STUDIES have LINKED higher maternal Vitamin D status to an increase in rates of both clinical Pregnancy (sonographic presence of a heartbeat following ivf) and live Birth [29,30,31].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 32)]	2	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('GO_0007567', 'parturition', 184, 'birth')]	0	['many higher maternal  status increase rates  (sonographic presence heartbeat following ivf) live birth [29,30,31].']
S80-PMC4934634	PMC4934634	11/2015	S80-PMC4934634	['the positive RELATIONSHIP between maternal Vitamin D status and post-Ivf Pregnancy in non-hispanic white, BUT NOT in asian women, SUGGESTS that genetics play a ROLE in the RELATIONSHIP between Vitamin D and fertility.']	[('SUPERFICIAL_RELATIONSHIP', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 106), ('ANOMALY_CURIOUS_FINDING', 106), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 160), ('SUPERFICIAL_RELATIONSHIP', 172)]	6	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0002006', 'vasoconstriction by vasopressin involved in systemic arterial blood pressure control', 69, 'IVF'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D')]	0	['positive maternal  status post-ivf  non-hispanic white, asian women, genetics play  fertility.']
S82-PMC4934634	PMC4934634	11/2015	S82-PMC4934634	['a supplementation trial involving 128 Vitamin D insufficient (<30 ng/ml, as classified by the authors) iranian women six to eight weeks prior to undergoing freeze-thaw Embryo transfer FOUND no differences in Pregnancy rates between women receiving 50,000 iu Vitamin D/week compared to women receiving Placebo [33].']	[('INCOMPLETE_EVIDENCE', 184)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('UBERON_0000922', 'embryo', 168, 'embryo'), ('GO_0007565', 'female pregnancy', 208, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 301, 'placebo')]	0	['supplementation 128  (<30 ng/ml, authors) iranian women six eight weeks undergoing freeze-thaw embryo transfer  rates women receiving 50,000 iu /week women receiving placebo [33].']
S89-PMC4934634	PMC4934634	11/2015	S89-PMC4934634	['ALTHOUGH the amount of Vitamin D provided through the Supplement is lower than the current rdas set by EITHER the iom or Endocrine society, this study SHOULD provide new INSIGHTS into HOW Periconceptional dietary interventions CAN IMPACT Female and Male Fertility, a RESEARCH area that is presently LACKING.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103), ('FUTURE_WORK', 151), ('INCOMPLETE_EVIDENCE', 170), ('EXPLICIT_QUESTION', 184), ('INCOMPLETE_EVIDENCE', 227), ('SUPERFICIAL_RELATIONSHIP', 231), ('INCOMPLETE_EVIDENCE', 267), ('INCOMPLETE_EVIDENCE', 299)]	9	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 54, 'supplement'), ('UBERON_0005063', 'left ventricular compact myocardium', 121, 'Endocrine'), ('GO_0007565', 'female pregnancy', 188, 'periconceptional'), ('GO_0007601', 'visual perception', 238, 'female ...'), ('GO_0007141', 'male meiosis I', 249, 'male fertility')]	0	['although amount  supplement rdas set endocrine society,  dietary female male fertility, lacking.']
S91-PMC4934634	PMC4934634	11/2015	S91-PMC4934634	['Pregnancy\nthe 2004–2008 national health and nutrition examination survey (nhanes) data SHOWS that the cumulative frequency of Vitamin D deficiency during Pregnancy in all races is 29% according to endocrine society criteria (< 20 ng/ml).']	[('INCOMPLETE_EVIDENCE', 87)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy')]	0	['\nthe 2004–2008 national survey (nhanes) cumulative frequency   races 29% endocrine society criteria (< 20 ng/ml).']
S93-PMC4934634	PMC4934634	11/2015	S93-PMC4934634	['evaluation of nhanes data from 2001 to 2006 using iom GUIDELINES REPORTS that 7% of Pregnant women are Vitamin D deficient (< 12 ng/ml) and 21% are Vitamin D insufficient (12–20 ng/ml) [35].']	[('PROBABLE_UNDERSTANDING', 54), ('INCOMPLETE_EVIDENCE', 65)]	2	[('GO_0007565', 'female pregnancy', 84, 'pregnant'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]	0	['evaluation nhanes 2001 2006 using iom 7%  women  (< 12 ng/ml) 21%  (12–20 ng/ml) [35].']
S97-PMC4934634	PMC4934634	11/2015	S97-PMC4934634	['IN CONTRAST TO iom RECOMMENDATIONS, the endocrine society RECOMMENDS a Vitamin D intake of AT LEAST 600 iu/day, BUT states that 1500–2000 iu/day MAY BE needed for Pregnant or Lactating females to maintain a 25(Oh)D level ≥ 30 ng/ml.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 19), ('FUTURE_WORK', 58), ('PROBABLE_UNDERSTANDING', 91), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('INCOMPLETE_EVIDENCE', 145)]	6	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnant'), ('GO_0007594', 'puparial adhesion', 175, 'lactating'), ('CHEBI_71657', 'versiconol acetate', 207, '25(OH)D')]	0	['iom recommendations, endocrine society  intake 600 iu/day, 1500–2000 iu/day  lactating females maintain 25(oh)d ≥ 30 ng/ml.']
S98-PMC4934634	PMC4934634	11/2015	S98-PMC4934634	['WHILE 25(Oh)D remains constant, the concentrations of total 1,25(Oh)2D and Vitamin D binding protein increase in the first to second Trimester and remain elevated until 3 months Postpartum [36].']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 62, '25(OH)2D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 133, 'trimester'), ('GO_0007565', 'female pregnancy', 178, 'postpartum')]	0	['25(oh)d constant, concentrations 1,25(oh)2d  binding protein increase trimester elevated 3 months  [36].']
S109-PMC4934634	PMC4934634	11/2015	S109-PMC4934634	['Gestational diabetes\nthe IMPACT of Vitamin D on vascular health and Glucose Control CAN LIKEWISE TRANSLATE to adverse EFFECTS of Vitamin D deficiency on Pregnancy outcomes including an INCREASED risk for Gestational diabetes and Preeclampsia.']	[('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 88), ('SUPERFICIAL_RELATIONSHIP', 97), ('SUPERFICIAL_RELATIONSHIP', 118), ('IMPORTANT_CONSIDERATION', 185)]	6	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_28384', 'vitamin K', 35, 'Vitamin D'), ('CHEBI_17234', 'glucose', 68, 'glucose'), ('GO_0046323', 'glucose import', 68, 'glucose control'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('GO_0007565', 'female pregnancy', 204, 'gestational'), ('GO_0007128', 'meiotic prophase I', 229, 'preeclampsia')]	0	[' diabetes\nthe vitamin vascular glucose   outcomes  diabetes preeclampsia.']
S111-PMC4934634	PMC4934634	11/2015	S111-PMC4934634	['the THEORY that Vitamin D supplementation CAN help normalize Blood Glucose levels and reduce the incidence of Gestational diabetes is an active AREA of research.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 42), ('FUTURE_WORK', 144)]	3	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0000178', 'blood', 61, 'blood'), ('CHEBI_17234', 'glucose', 67, 'glucose'), ('GO_0007565', 'female pregnancy', 110, 'gestational')]	0	[' supplementation normalize blood glucose levels  diabetes research.']
S112-PMC4934634	PMC4934634	11/2015	S112-PMC4934634	['first Trimester 25(Oh)D levels were found to be lower in women diagnosed with Gestational diabetes COMPARED TO controls, translating to a 2.6-fold increased risk of developing Gestational diabetes when Serum Vitamin D levels were ≤20 ng/ml, the iom cut-off for Vitamin D sufficiency [42].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 99)]	1	[('GO_0009294', 'DNA mediated transformation', 6, 'trimester'), ('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 22, 'D'), ('GO_0007565', 'female pregnancy', 78, 'gestational'), ('GO_0007565', 'female pregnancy', 176, 'gestational'), ('UBERON_0001977', 'blood serum', 202, 'serum'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D')]	0	['first trimester 25(oh)d levels women diagnosed  diabetes controls, translating 2.6-fold  diabetes serum  levels ≤20 ng/ml, iom cut-off  [42].']
S116-PMC4934634	PMC4934634	11/2015	S116-PMC4934634	['the EFFECTS of Vitamin D supplementation (400 iu /day Vitamin D3) on Insulin and Glucose Metabolism were observed in healthy, Pregnant women in their 25th week of Gestation [45].']	[('SUPERFICIAL_RELATIONSHIP', 4)]	1	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 54, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 54, 'vitamin D3'), ('GO_0007631', 'feeding behavior', 69, 'insulin ...'), ('PR_000045358', 'insulin family protein', 69, 'insulin'), ('CHEBI_17234', 'glucose', 81, 'glucose'), ('GO_0006006', 'glucose metabolic process', 81, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 126, 'pregnant'), ('GO_0007565', 'female pregnancy', 163, 'gestation')]	0	[' supplementation (400 iu /day vitamin d3) insulin glucose metabolism healthy,  women 25th week  [45].']
S123-PMC4934634	PMC4934634	11/2015	S123-PMC4934634	['with regard to Pregnancy outcome, there were no cases of polyhydramnios (the accumulation of excess Amniotic Fluid) in the Vitamin D group compared to 17.4% in the placebo group, and a marked reduction of hyperbilirubinemia in infants from the Vitamin D supplemented group (27.3%) COMPARED TO the placebo group (60.9%) was REPORTED ( p = 0.02) [47].']	[('ANOMALY_CURIOUS_FINDING', 281), ('INCOMPLETE_EVIDENCE', 323)]	2	[('GO_0007565', 'female pregnancy', 15, 'pregnancy'), ('UBERON_0000173', 'amniotic fluid', 100, 'amniotic fluid'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 244, 'vitamin D')]	0	['regard  outcome, cases polyhydramnios (the accumulation excess amniotic fluid)  17.4% placebo group, marked reduction hyperbilirubinemia infants  supplemented (27.3%) placebo (60.9%) p = 0.02) [47].']
S124-PMC4934634	PMC4934634	11/2015	S124-PMC4934634	['these data SUGGEST a positive EFFECT of Vitamin D supplementation on Pregnancy outcomes in women with Gestational diabetes.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 30)]	2	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy'), ('GO_0007565', 'female pregnancy', 102, 'gestational')]	0	['positive  supplementation  outcomes women  diabetes.']
S126-PMC4934634	PMC4934634	11/2015	S126-PMC4934634	[', INVESTIGATED the EFFECTS of Vitamin D co-supplemented with Calcium on Metabolic parameters in women diagnosed with Gestational diabetes starting in their 24th–28th week of Gestation.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 2), ('SUPERFICIAL_RELATIONSHIP', 19)]	2	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 61, 'calcium'), ('GO_0008152', 'metabolic process', 72, 'metabolic'), ('GO_0007565', 'female pregnancy', 117, 'gestational'), ('GO_0007565', 'female pregnancy', 174, 'gestation')]	0	[',  co-supplemented calcium metabolic parameters women diagnosed  diabetes 24th–28th week .']
S129-PMC4934634	PMC4934634	11/2015	S129-PMC4934634	['IN AGREEMENT WITH ANOTHER STUDY by the same group [45], Vitamin D plus calcium supplementation improved fasting Plasma Glucose, serum Insulin, homa-ir, hdl, and ldl in women with Gestational diabetes compared TO placebo.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 209)]	3	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 112, 'plasma'), ('CHEBI_17234', 'glucose', 119, 'glucose'), ('PR_000045358', 'insulin family protein', 134, 'insulin'), ('GO_0007565', 'female pregnancy', 179, 'gestational')]	0	['[45],  plus calcium supplementation fasting plasma glucose, serum insulin, homa-ir, hdl, ldl women  diabetes placebo.']
S131-PMC4934634	PMC4934634	11/2015	S131-PMC4934634	['GIVEN the heightened response with co-supplementation, it SUGGESTS that the EFFECTS of Vitamin D on Gestational diabetes MIGHT be enhanced with the use of Calcium.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 58), ('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 121)]	4	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'gestational'), ('CHEBI_22313', 'alkaline earth metal atom', 155, 'calcium')]	0	['given response co-supplementation,   diabetes calcium.']
S132-PMC4934634	PMC4934634	11/2015	S132-PMC4934634	['WHILE Vitamin D supplementation to women with Gestational diabetes improved Metabolic parameters, what IS NEEDED are clinical trials investigating the extent to WHICH Vitamin D supplementation decreases adverse Perinatal outcomes ASSOCIATED with Gestational diabetes including macrosomia, Respiratory distress, and Postnatal hypoglycemia.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FUTURE_WORK', 103), ('EXPLICIT_QUESTION', 161), ('SUPERFICIAL_RELATIONSHIP', 230)]	4	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'gestational'), ('GO_0008152', 'metabolic process', 76, 'metabolic'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0036268', 'swimming', 211, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 211, 'perinatal'), ('GO_0007565', 'female pregnancy', 246, 'gestational'), ('UBERON_0001004', 'respiratory system', 289, 'respiratory'), ('GO_0007567', 'parturition', 315, 'postnatal')]	0	[' supplementation women  diabetes metabolic parameters,  supplementation decreases perinatal outcomes  diabetes macrosomia, respiratory distress, postnatal hypoglycemia.']
S133-PMC4934634	PMC4934634	11/2015	S133-PMC4934634	['to test the dose response EFFECT of Vitamin D on Glucose Metabolism, doses of 200 iu/day, 50,000 iu/monthly, or 50,000 iu/biweekly Vitamin D3Were chosen to supplement healthy (non-Gestational diabetes), Pregnant women with severe Vitamin D deficiency (7.6 ± 6.3 ng/ml) from the 12th week of Gestation to Delivery [49].']	[('SUPERFICIAL_RELATIONSHIP', 26)]	1	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_17234', 'glucose', 49, 'glucose'), ('GO_0006006', 'glucose metabolic process', 49, 'glucose metabolism'), ('CHEBI_73706', 'bromosuccinate', 131, 'vitamin D3were'), ('PR_000017209', 'utrophin', 131, 'vitamin D3were'), ('GO_0007565', 'female pregnancy', 180, 'gestational'), ('GO_0007565', 'female pregnancy', 203, 'pregnant'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('GO_0007565', 'female pregnancy', 291, 'gestation'), ('GO_0007567', 'parturition', 304, 'delivery')]	0	['dose response  glucose metabolism, doses 200 iu/day, 50,000 iu/monthly, 50,000 iu/biweekly vitamin d3were supplement healthy (non- diabetes),  women  (7.6 ± 6.3 ng/ml) 12th week  delivery [49].']
S149-PMC4934634	PMC4934634	11/2015	S149-PMC4934634	['TO INVESTIGATE the EFFECT of Vitamin D supplementation on Blood pressure and Circulating T Cells, the Rats induced by reduced Uterine perfusion pressure (rupp), a MODEL of preeclampsia, were administered Vitamin D2Or Vitamin D3On Gestation days 14–18 [57].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 19), ('INCOMPLETE_EVIDENCE', 163)]	3	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('UBERON_0000178', 'blood', 58, 'blood'), ('CL_0000080', 'circulating cell', 77, 'circulating'), ('CL_0000084', 'T cell', 89, 'T cells'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 102, 'rats'), ('UBERON_0000995', 'uterus', 126, 'uterine'), ('CHEBI_27329', 'xanthosine phosphate', 204, 'vitamin D2or'), ('PR_000017209', 'utrophin', 204, 'vitamin D2or'), ('CHEBI_63460', 'parkeol', 217, 'vitamin D3on'), ('PR_000017209', 'utrophin', 217, 'vitamin D3on'), ('GO_0007565', 'female pregnancy', 230, 'gestation')]	0	[' supplementation blood pressure circulating cells, rats induced uterine perfusion pressure (rupp), preeclampsia, administered vitamin d2or vitamin d3on  days 14–18 [57].']
S156-PMC4934634	PMC4934634	11/2015	S156-PMC4934634	['the authors CONCLUDED that these LINKS are ONLY SUGGESTIVE since there was no difference in Pregnancy complication risk among the Vitamin D intervention groups.']	[('INCOMPLETE_EVIDENCE', 12), ('SUPERFICIAL_RELATIONSHIP', 33), ('INCOMPLETE_EVIDENCE', 43), ('INCOMPLETE_EVIDENCE', 48)]	4	[('GO_0007565', 'female pregnancy', 92, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]	0	['authors  among  groups.']
S160-PMC4934634	PMC4934634	11/2015	S160-PMC4934634	['combining the main comorbidities, for every 10 ng/ml increase in 25(Oh)D at Delivery, the odds ratio was reduced to 0.84 ( p = 0.006) INDICATING fewer adverse Pregnancy outcomes as maternal Vitamin D levels increased.']	[('INCOMPLETE_EVIDENCE', 134)]	1	[('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 65, '25(OH)D'), ('GO_0007567', 'parturition', 76, 'delivery'), ('GO_0007565', 'female pregnancy', 159, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]	0	['combining main comorbidities, 10 ng/ml increase 25(oh)d delivery, ratio 0.84 p = 0.006)  outcomes maternal  levels increased.']
S164-PMC4934634	PMC4934634	11/2015	S164-PMC4934634	['THUS, it is NOT SURPRISING that this study FOUND no effect of the Vitamin D supplementation on incidences of Preterm Birth, Preeclampsia, or small for Gestation age SINCE 23% of participants had persistent Serum 25(Oh)D below 10 ng/ml which IS CONSIDERED Vitamin D deficiency status by both the iom and endocrine society (table 1).']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 12), ('INCOMPLETE_EVIDENCE', 43), ('PROBABLE_UNDERSTANDING', 165), ('INCOMPLETE_EVIDENCE', 241)]	5	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'preterm birth'), ('GO_0007128', 'meiotic prophase I', 124, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 151, 'gestation'), ('UBERON_0001977', 'blood serum', 206, 'serum'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 212, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]	0	['thus,  supplementation incidences preeclampsia,  age 23% participants serum 25(oh)d 10 ng/ml  status iom endocrine society (table 1).']
S183-PMC4934634	PMC4934634	11/2015	S183-PMC4934634	['higher maternal Vitamin D intake during Pregnancy was FOUND TO BE inversely ASSOCIATED with asthma [68], allergic rhinitis [68], wheezing [69], and eczema in early childhood.']	[('ANOMALY_CURIOUS_FINDING', 54), ('SUPERFICIAL_RELATIONSHIP', 76)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 40, 'pregnancy')]	0	['higher maternal  intake  asthma [68], allergic rhinitis [68], wheezing [69], eczema childhood.']
S192-PMC4934634	PMC4934634	11/2015	S192-PMC4934634	['one randomized controlled trial INVESTIGATED the EFFECTS of Prenatal Vitamin D supplementation on Respiratory outcomes in children at three years of age.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 32), ('SUPERFICIAL_RELATIONSHIP', 49)]	2	[('GO_0007565', 'female pregnancy', 60, 'prenatal'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 98, 'respiratory')]	0	['one   supplementation respiratory outcomes children three age.']
S212-PMC4934634	PMC4934634	11/2015	S212-PMC4934634	['SINCE THE study LOOKED AT the number of visits RATHER than confirmed diagnosis of infection, THIS STUDY SUGGESTS infant Vitamin D supplementation in addition to Prenatal supplementation MIGHT be BENEFICIAL in reducing health care visits for acute Respiratory infections.']	[('PROBLEM_COMPLICATION', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 6), ('INCOMPLETE_EVIDENCE', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 47), ('QUESTION_ANSWERED_BY_THIS_WORK', 93), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 186), ('SUPERFICIAL_RELATIONSHIP', 195)]	8	[('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'prenatal'), ('UBERON_0001004', 'respiratory system', 247, 'respiratory')]	0	['since visits diagnosis infection, infant  supplementation addition  supplementation reducing visits acute respiratory infections.']
S241-PMC4934634	PMC4934634	11/2015	S241-PMC4934634	['POTENTIAL consequences of excess Vitamin D intakes: maternal and infant\nduring Pregnancy, the current RECOMMENDED dietary intake of Vitamin D and upper limit ranges from 200 to 2000 iu/day and 3200 to 10,000 iu/day, respectively (table 2).']	[('INCOMPLETE_EVIDENCE', 0), ('FUTURE_WORK', 102)]	2	[('CHEBI_28384', 'vitamin K', 33, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]	0	['potential excess vitamin intakes: maternal infant\nduring dietary intake  upper ranges 200 2000 iu/day 3200 10,000 iu/day, respectively (table 2).']
S252-PMC4934634	PMC4934634	11/2015	S252-PMC4934634	['similarly, STUDIES ARE NEEDED to address WHETHER women who are Vitamin D sufficient at Conception and receiving high doses of Vitamin D (≥4000 iu/daily) have adverse Pregnancy outcomes.']	[('FUTURE_WORK', 11), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 41), ('EXPLICIT_QUESTION', 41)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007620', 'copulation', 87, 'conception'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy')]	0	['similarly, women  receiving doses  (≥4000 iu/daily)  outcomes.']
S253-PMC4934634	PMC4934634	11/2015	S253-PMC4934634	['also, studies powered TO DETERMINE the EFFECT of separate ethnic groups’ varying baseline Vitamin D levels on 25(Oh)D levels after different Vitamin D supplementation doses will provide more concrete INFORMATION for individualized RECOMMENDATIONS during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('SUPERFICIAL_RELATIONSHIP', 39), ('INCOMPLETE_EVIDENCE', 200), ('FUTURE_WORK', 231)]	4	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 112, '(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy')]	0	['also, powered separate ethnic groups’ baseline  levels 25(oh)d levels  supplementation doses concrete individualized .']
S261-PMC4934634	PMC4934634	11/2015	S261-PMC4934634	['ALTHOUGH both single and daily doses of Vitamin D3Seem to be SAFE, CAUTION SHOULD BE CONSIDERED when supplementing at these high doses in Pregnant women, PARTICULARLY if baseline Vitamin D status is sufficient.']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 61), ('FUTURE_WORK', 67), ('INCOMPLETE_EVIDENCE', 67), ('FUTURE_WORK', 75), ('FUTURE_WORK', 85), ('ANOMALY_CURIOUS_FINDING', 154), ('IMPORTANT_CONSIDERATION', 154)]	8	[('CHEBI_64387', 'thiosultap(1-)', 40, 'vitamin D3seem'), ('GO_0007565', 'female pregnancy', 138, 'pregnant'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D')]	0	['although single daily doses vitamin d3seem safe, supplementing doses  women, baseline  status sufficient.']
S266-PMC4934634	PMC4934634	11/2015	S266-PMC4934634	['as PREVIOUSLY mentioned, short-term studies GENERALLY AGREE with its SAFETY BUT long-term STUDIES ARE NEEDED to address the QUESTION of WHETHER large bolus Vitamin D supplementation during Pregnancy is ASSOCIATED with any adverse health outcomes in the offspring later in Life.']	[('INCOMPLETE_EVIDENCE', 3), ('PROBABLE_UNDERSTANDING', 44), ('INCOMPLETE_EVIDENCE', 54), ('IMPORTANT_CONSIDERATION', 69), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 76), ('FUTURE_WORK', 90), ('EXPLICIT_QUESTION', 124), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 136), ('EXPLICIT_QUESTION', 136), ('SUPERFICIAL_RELATIONSHIP', 202)]	10	[('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('GO_0007565', 'female pregnancy', 189, 'pregnancy'), ('UBERON_0000104', 'life cycle', 272, 'life')]	0	['mentioned, short-term long-term bolus  supplementation  outcomes offspring life.']
S306-PMC4934634	PMC4934634	11/2015	S306-PMC4934634	['WHILE the ESSENTIALITY of adequate Vitamin D during Pregnancy is not DISPUTED, CONTROVERSY exists over the RECOMMENDED dietary intake levels, the mathematical approaches to calculating that level, and the endpoints used to determine REQUIREMENTS; the concentrations of circulating 25(Oh)D that denote deficiency, insufficiency and adequacy status; and WHETHER race, body weight or OTHER factors SHOULD BE TAKEN into account when making dietary RECOMMENDATIONS, similarly, it is NOT CLEAR WHAT Vitamin D supplementation regimens are most EFFECTIVE during Pregnancy; WHETHER mother, child OR both SHOULD BE supplemented; and WHETHER there are long-term CONSEQUENCES of supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('IMPORTANT_CONSIDERATION', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 69), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 79), ('FUTURE_WORK', 107), ('IMPORTANT_CONSIDERATION', 233), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 352), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 381), ('FUTURE_WORK', 395), ('IMPORTANT_CONSIDERATION', 405), ('FUTURE_WORK', 444), ('FULL_UNKNOWN', 478), ('EXPLICIT_QUESTION', 488), ('SUPERFICIAL_RELATIONSHIP', 537), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 565), ('FUTURE_WORK', 595), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 623), ('PROBLEM_COMPLICATION', 651)]	18	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 281, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 281, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 493, 'vitamin D'), ('GO_0007565', 'female pregnancy', 554, 'pregnancy')]	0	['  disputed, dietary intake levels, mathematical calculating level, endpoints requirements; concentrations circulating 25(oh)d denote deficiency, status; race, dietary recommendations, similarly,  supplementation regimens mother, child supplemented; long-term supplementation.']
S102-PMC4934640	PMC4934640	11/2015	S102-PMC4934640	['as mentioned above, smoking in Pregnancy is LINKED to depressive symptoms, more frequent use of Psychotropic Medications and other prescribed Medications, [13] poor maternal nutrition, iron deficiency and low Vitamin D [29].']	[('SUPERFICIAL_RELATIONSHIP', 44)]	1	[('GO_0007565', 'female pregnancy', 31, 'pregnancy'), ('CHEBI_18170', 'selenic acid', 96, 'psychotropic'), ('CHEBI_25441', 'mycothiols', 109, 'medications'), ('CHEBI_25441', 'mycothiols', 142, 'medications'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]	0	['above, smoking  depressive symptoms, psychotropic medications prescribed medications, [13] maternal nutrition, iron  [29].']
S0-PMC4944244	PMC4944244	7/2016	S0-PMC4944244	['risk factors for Antenatal hypovitaminosis d in an urban district in malaysia\n\nabstract\n\nbackground\nPregnant women form one of the HIGH RISK groups facing hypovitaminosis d. low level of Vitamin D will AFFECT directly OR indirectly both mother and fetus.']	[('IMPORTANT_CONSIDERATION', 131), ('SUPERFICIAL_RELATIONSHIP', 202), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 218)]	3	[('GO_0007567', 'parturition', 17, 'antenatal'), ('GO_0007565', 'female pregnancy', 100, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]	0	['risk antenatal hypovitaminosis urban district malaysia\n\nabstract\n\nbackground\n women form hypovitaminosis d.  mother fetus.']
S1-PMC4944244	PMC4944244	7/2016	S1-PMC4944244	['screening Vitamin D in the first Trimester of Pregnancy is IMPORTANT to determine the NECESSARY preventive action.']	[('IMPORTANT_CONSIDERATION', 59), ('IMPORTANT_CONSIDERATION', 86)]	2	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 33, 'trimester'), ('GO_0007565', 'female pregnancy', 46, 'pregnancy')]	0	['screening  trimester  action.']
S9-PMC4944244	PMC4944244	7/2016	S9-PMC4944244	['conclusion\nawareness SHOULD BE raised among malay and indian Pregnant women with secondary and tertiary education who consumed Vitamin D (ESPECIALLY milk) poorly in order to prevent adverse health outcomes.']	[('FUTURE_WORK', 21), ('IMPORTANT_CONSIDERATION', 138)]	2	[('GO_0007565', 'female pregnancy', 61, 'pregnant'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D')]	0	['conclusion\nawareness among malay indian  women secondary tertiary consumed  (especially milk) outcomes.']
S18-PMC4944244	PMC4944244	7/2016	S18-PMC4944244	['[10] reported that Vitamin D status among Pregnant and non-Pregnant women (Reproductive age) living in vietnam SHOWED that the mean Serum 25(Oh)d differed between those living in urban and rural areas (78\xa0nmol/l versus 85\xa0nmol/l) with p \u2009=\u20090.02.']	[('INCOMPLETE_EVIDENCE', 111)]	1	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('GO_0007565', 'female pregnancy', 59, 'pregnant'), ('GO_0000003', 'reproduction', 75, 'reproductive'), ('UBERON_0001977', 'blood serum', 132, 'serum'), ('CHEBI_37972', 'phosphorus-32 atom', 138, '25'), ('CHEBI_17792', 'organohalogen compound', 141, 'OH')]	0	['[10]  status among  non- women (reproductive age) living vietnam serum 25(oh)d living urban rural (78\xa0nmol/l 85\xa0nmol/l) p \u2009=\u20090.02.']
S19-PMC4944244	PMC4944244	7/2016	S19-PMC4944244	['attention also MUST BE given to those who have dark skin, less skin exposed to sunlight and obese because they have a higher RISK of Vitamin D deficiency warranting Vitamin D supplement, mainly during Pregnancy and Lactation [11].']	[('IMPORTANT_CONSIDERATION', 15), ('IMPORTANT_CONSIDERATION', 125)]	2	[('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 201, 'pregnancy'), ('GO_0007595', 'lactation', 215, 'lactation')]	0	['attention dark skin, skin exposed sunlight obese higher   supplement,  lactation [11].']
S21-PMC4944244	PMC4944244	7/2016	S21-PMC4944244	['[12] REVEALED that ethnic minorities (asian) SHOULD BE RECOMMENDED for biochemical screening in early Pregnancy, followed by supplement if low levels of Vitamin D was FOUND.']	[('INCOMPLETE_EVIDENCE', 5), ('FUTURE_WORK', 45), ('FUTURE_WORK', 55), ('INCOMPLETE_EVIDENCE', 167)]	4	[('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]	0	['[12] ethnic minorities (asian) biochemical screening followed supplement levels  found.']
S27-PMC4944244	PMC4944244	7/2016	S27-PMC4944244	['healthcare workers USUALLY ENCOURAGE Pregnant women to increase calcium intake BUT they are LESS AWARE that without sufficient Vitamin D, calcium intake will not have much EFFECT ESPECIALLY during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 19), ('FUTURE_WORK', 27), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 79), ('ANOMALY_CURIOUS_FINDING', 79), ('INCOMPLETE_EVIDENCE', 92), ('IMPORTANT_CONSIDERATION', 97), ('SUPERFICIAL_RELATIONSHIP', 172), ('ANOMALY_CURIOUS_FINDING', 179)]	8	[('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('GO_0007565', 'female pregnancy', 197, 'pregnancy')]	0	['healthcare workers  women increase calcium intake calcium intake .']
S28-PMC4944244	PMC4944244	7/2016	S28-PMC4944244	['THEREFORE, it is NECESSARY to determine the PREVALENCE of hypovitaminosis D among Pregnant women and assess its risk FACTORS to overcome the PROBLEMS caused by lack of Vitamin D.\n\nmethods\n\nsubjects and sampling\na cross-sectional study was conducted in petaling district, selangor.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 44), ('SUPERFICIAL_RELATIONSHIP', 117), ('IMPORTANT_CONSIDERATION', 141), ('PROBLEM_COMPLICATION', 141)]	6	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 74, 'D'), ('GO_0007565', 'female pregnancy', 82, 'pregnant'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D')]	0	['therefore, hypovitaminosis among  women overcome .\n\nmethods\n\nsubjects sampling\na cross-sectional petaling district, selangor.']
S75-PMC4944244	PMC4944244	7/2016	S75-PMC4944244	['caption (table-wrap): table 1\n\nsocio-demographic, Antenatal, skin characteristics and Vitamin D intake of first trimester Pregnant women ( n \u2009=\u2009396)independent variablesnpercentmean\u2009±\u2009sd /\xa0median (iqr 25\xa0%, 75\xa0%)a) socio-demographic factors\u2003age (year)28.06\u2009±\u20094.09 (min\u2009=\u200918, max\u2009=\u200940)\u2003ethnic groups\u2003\u2003malay30777.5\u2003\u2003chinese4411.2\u2003\u2003indian358.8\u2003\u2003others102.5\u2003educational status\u2003\u2003primary school164.0\u2003\u2003secondary school14937.6\u2003\u2003tertiary school23158.4\u2003working status\u2003\u2003working30176.0\u2003\u2003not working9524.0\u2003household members3 (2,4) (min\u2009=\u20092, max\u2009=\u200912)\u2003household income per monthrm3500 (2800,5000) (min\u2009=\u2009rm900, max\u2009=\u2009rm20 000)b) factors related to Antenatal\u2003Week Of Pregnancy10 (8,12) (min\u2009=\u20094, max\u2009=\u200912)\u2003gravidity2 (1,3) (min\u2009=\u20091, max\u2009=\u20099)\u2003parity0 (0,1) (min\u2009=\u20090, max\u2009=\u20096)\u2003smoking status\u2003\u2003yes30.8\u2003\u2003no39399.2\u2003last child Birth\u2003\u2003≤ 2\xa0years12461.1\u2003\u2003>2\xa0years7938.9\u2003\u2003not applicable (first Pregnancy)193\u2003still breastfeeding\u2003\u2003yes4122.9\u2003\u2003no13879.1\u2003\u2003not applicable (no child)217\u2003body mass index (bmi) before Pregnancy(kg/m2)22.69 (19.95, 26.36) (min\u2009=\u200914.29, max\u2009=\u200953.90)\u2003weight at first Antenatal visit (kg)57.70 (49.60,68.00) (min\u2009=\u200933.00, max\u2009=\u2009148.70)c) factors related to skin\u2003fitzpatrick skin classification\u2003\u2003skin type i -ii10326.0\u2003\u2003skin type iii17343.7\u2003\u2003skin type iv-vi12030.3\u2003Melanin indices (using mexameter 18) (0-999.000)302.17 (245.00, 302.17) (min\u2009=\u2009133.33, max\u2009=\u2009949.33)\u2003sun protection score (0-8)5 (4,5) (min\u2009=\u20090, max\u2009=\u20097)\u2003the length of time exposed to sunlight (minutes per week)37.50 (0,150) (min\u2009=\u20090, max\u2009=\u20091680)d) factors related to Vitamin D intake\u2003intake of Vitamin D in Food (iu/day)202.16 (124.94, 334.62) (min\u2009=\u200913.50, max\u2009=\u20091523.12)\u2003the number of respondents taking Antenatal Supplements\u2003\u2003taking Supplements containing Vitamin D4411.1\u2003\u2003taking supplements without Vitamin D intake61.5\u2003\u2003not taking supplement34687.4\u2003Calcium and Vitamin D supplement\u2003\u2003no38697.5\u2003\u2003yes102.5\u2003intake of Vitamin D from Food and supplements (iu/day)220.04 (137.88, 376.45) (min\u2009=\u200915.10, max\u2009=\u20091523.12)\u2003the level of Vitamin D taken from Food and supplements (iu/day)\u2003\u2003<200\xa0iu/day17844.90\u2003\u2003≥200\xa0iu/day21855.10\n\ncaption (table-wrap): table 2\n\nSerum Vitamin D (25(Oh)D) concentrations among first Trimester Pregnant women ( n \u2009=\u2009396)Serum Vitamin dnpercentmedian (iqr 25\xa0%, 75\xa0%)Serum concentration of 25 (Oh)D nmol/l27.11 (19.87,36.99) (min\u2009=\u20097.50, max\u2009=\u2009121.43)Serum concentration of 25 (Oh) D nmol/l (categorized)\u2003<25.00\xa0nmol/l17443.9\u200325-49.99\xa0nmol/l18446.5\u200350-74.99\xa0nmol/l338.3\u2003≥75\xa0nmol/l51.3serum concentration of 25 (Oh) D nmol/l (categorized)\u2003<50\xa0nmol/l35890.4\u2003≥50\xa0nmol/l389.6\ntable\xa03shows the association between each independent variable with hypovitaminosis d. age, ethnicity, education level, fitzpatrick classification, Melanin indices, sun protection score and Intake of Vitamin D from Food have ASSOCIATION with hypovitaminosis D ( p \u2009<\u20090.05).']	[('SUPERFICIAL_RELATIONSHIP', 2779)]	1	[('GO_0007567', 'parturition', 50, 'antenatal'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnant'), ('GO_0003410', 'anterior rotation of the optic cup', 634, 'antenatal Week of pregnancy10'), ('GO_0007567', 'parturition', 806, 'Birth'), ('GO_0007565', 'female pregnancy', 869, 'pregnancy'), ('GO_0007565', 'female pregnancy', 984, 'pregnancy'), ('GO_0007567', 'parturition', 1064, 'antenatal'), ('CHEBI_25179', 'melanins', 1260, 'Melanin'), ('CHEBI_27300', 'vitamin D', 1528, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1555, 'vitamin D'), ('CHEBI_33290', 'food', 1568, 'food'), ('GO_0007567', 'parturition', 1667, 'antenatal'), ('CHEBI_33341', 'titanium atom', 1677, 'supplements'), ('CHEBI_33341', 'titanium atom', 1697, 'supplements'), ('CHEBI_72741', '2-arachidonyl-sn-glycero-3-phosphoethanolamine', 1720, 'vitamin D4411'), ('CHEBI_27300', 'vitamin D', 1764, 'vitamin D'), ('CHEBI_31341', 'calcium dihydroxide', 1815, 'Calcium'), ('CHEBI_27300', 'vitamin D', 1827, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1879, 'vitamin D'), ('CHEBI_33290', 'food', 1894, 'food'), ('CHEBI_27300', 'vitamin D', 1989, 'vitamin D'), ('CHEBI_33290', 'food', 2010, 'food'), ('UBERON_0001977', 'blood serum', 2114, 'Serum'), ('CHEBI_27300', 'vitamin D', 2120, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 2131, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 2131, '25 ... OH ... D'), ('GO_0009294', 'DNA mediated transformation', 2167, 'trimester'), ('GO_0007565', 'female pregnancy', 2177, 'pregnant'), ('UBERON_0001977', 'blood serum', 2203, 'Serum'), ('CHEBI_33229', 'vitamin (role)', 2209, 'vitamin'), ('UBERON_0001977', 'blood serum', 2249, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2272, '25 (OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 2272, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 2279, 'D'), ('UBERON_0001977', 'blood serum', 2333, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2356, '25 (OH) D'), ('CHEBI_71657', 'versiconol acetate', 2489, '25 (OH) D'), ('CHEBI_25179', 'melanins', 2702, 'melanin'), ('GO_0007631', 'feeding behavior', 2744, 'intake'), ('CHEBI_27300', 'vitamin D', 2754, 'vitamin D'), ('CHEBI_33290', 'food', 2769, 'food'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2812, 'D')]	0	['caption (table-wrap): table 1\n\nsocio-demographic, antenatal, skin characteristics  intake trimester  women n \u2009=\u2009396)independent variablesnpercentmean\u2009±\u2009sd /\xa0median (iqr 25\xa0%, 75\xa0%)a) socio-demographic factors\u2003age (year)28.06\u2009±\u20094.09 (min\u2009=\u200918, max\u2009=\u200940)\u2003ethnic groups\u2003\u2003malay30777.5\u2003\u2003chinese4411.2\u2003\u2003indian358.8\u2003\u2003others102.5\u2003educational status\u2003\u2003primary school164.0\u2003\u2003secondary school14937.6\u2003\u2003tertiary school23158.4\u2003working status\u2003\u2003working30176.0\u2003\u2003not working9524.0\u2003household members3 (2,4) (min\u2009=\u20092, max\u2009=\u200912)\u2003household income monthrm3500 (2800,5000) (min\u2009=\u2009rm900, max\u2009=\u2009rm20 000)b) antenatal\u2003week pregnancy10 (8,12) (min\u2009=\u20094, max\u2009=\u200912)\u2003gravidity2 (1,3) (min\u2009=\u20091, max\u2009=\u20099)\u2003parity0 (0,1) (min\u2009=\u20090, max\u2009=\u20096)\u2003smoking status\u2003\u2003yes30.8\u2003\u2003no39399.2\u2003last child birth\u2003\u2003≤ 2\xa0years12461.1\u2003\u2003>2\xa0years7938.9\u2003\u2003not (first )193\u2003still breastfeeding\u2003\u2003yes4122.9\u2003\u2003no13879.1\u2003\u2003not (no child)217\u2003body mass (bmi) (kg/m2)22.69 (19.95, 26.36) (min\u2009=\u200914.29, max\u2009=\u200953.90)\u2003weight antenatal visit (kg)57.70 (49.60,68.00) (min\u2009=\u200933.00, max\u2009=\u2009148.70)c) skin\u2003fitzpatrick skin classification\u2003\u2003skin type -ii10326.0\u2003\u2003skin type iii17343.7\u2003\u2003skin type iv-vi12030.3\u2003melanin indices (using mexameter 18) (0-999.000)302.17 (245.00, 302.17) (min\u2009=\u2009133.33, max\u2009=\u2009949.33)\u2003sun score (0-8)5 (4,5) (min\u2009=\u20090, max\u2009=\u20097)\u2003the length exposed sunlight (minutes week)37.50 (0,150) (min\u2009=\u20090, max\u2009=\u20091680)d)  intake\u2003intake  food (iu/day)202.16 (124.94, 334.62) (min\u2009=\u200913.50, max\u2009=\u20091523.12)\u2003the respondents antenatal supplements\u2003\u2003taking supplements containing vitamin d4411.1\u2003\u2003taking supplements  intake61.5\u2003\u2003not supplement34687.4\u2003calcium  supplement\u2003\u2003no38697.5\u2003\u2003yes102.5\u2003intake  food supplements (iu/day)220.04 (137.88, 376.45) (min\u2009=\u200915.10, max\u2009=\u20091523.12)\u2003the  food supplements (iu/day)\u2003\u2003<200\xa0iu/day17844.90\u2003\u2003≥200\xa0iu/day21855.10\n\ncaption (table-wrap): table 2\n\nserum  (25(oh)d) concentrations among trimester  women n \u2009=\u2009396)serum vitamin dnpercentmedian (iqr 25\xa0%, 75\xa0%)serum concentration 25 (oh)d nmol/l27.11 (19.87,36.99) (min\u2009=\u20097.50, max\u2009=\u2009121.43)serum concentration 25 (oh) nmol/l (categorized)\u2003<25.00\xa0nmol/l17443.9\u200325-49.99\xa0nmol/l18446.5\u200350-74.99\xa0nmol/l338.3\u2003≥75\xa0nmol/l51.3serum concentration 25 (oh) nmol/l (categorized)\u2003<50\xa0nmol/l35890.4\u2003≥50\xa0nmol/l389.6\ntable\xa03shows hypovitaminosis d. age, ethnicity, level, fitzpatrick classification, melanin indices, sun score intake  food hypovitaminosis p \u2009<\u20090.05).']
S96-PMC4944244	PMC4944244	7/2016	S96-PMC4944244	['the Serum Vitamin D level was low PROBABLY BECAUSE our respondents were first Trimester Pregnant women who MAY have morning sickness and limited outdoor physical activity.']	[('PROBABLE_UNDERSTANDING', 34), ('PROBABLE_UNDERSTANDING', 43), ('INCOMPLETE_EVIDENCE', 107)]	3	[('UBERON_0001977', 'blood serum', 4, 'serum'), ('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 78, 'trimester'), ('GO_0007565', 'female pregnancy', 88, 'pregnant')]	0	['serum  respondents trimester  women morning sickness outdoor physical activity.']
S118-PMC4944244	PMC4944244	7/2016	S118-PMC4944244	['LACK of Vitamin D was not found in Pregnant women who consumed Antenatal Vitamin supplements.']	[('PROBLEM_COMPLICATION', 0)]	1	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'pregnant'), ('GO_0007567', 'parturition', 63, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 73, 'vitamin')]	0	['lack   women consumed antenatal vitamin supplements.']
S119-PMC4944244	PMC4944244	7/2016	S119-PMC4944244	['HOWEVER, 20 Pregnant women who consumed Antenatal Vitamins with Vitamin D at least 400\xa0iu/day still had INADEQUATE Vitamin D levels in the third trimester [22].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 104)]	3	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('GO_0007567', 'parturition', 40, 'antenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 50, 'vitamins'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]	0	['however, 20  women consumed antenatal vitamins  400\xa0iu/day  levels third trimester [22].']
S121-PMC4944244	PMC4944244	7/2016	S121-PMC4944244	['[22] SUGGESTED that Vitamin D deficiency is common among Pregnant women in thailand, especially in the first trimester [16].']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnant')]	0	['[22]  among  women thailand, trimester [16].']
S122-PMC4944244	PMC4944244	7/2016	S122-PMC4944244	['their study was SIMILAR TO ours, where intake of Vitamin D supplement or Prenatal Vitamins containing Vitamin D in the first trimester was not associated with adequate Serum 25(Oh)D level.']	[('INCOMPLETE_EVIDENCE', 16)]	1	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 82, 'vitamins'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('UBERON_0001977', 'blood serum', 168, 'serum'), ('CHEBI_33010', 'chromide(1-)', 176, '(OH)D')]	0	['ours, intake  supplement  vitamins containing  trimester serum 25(oh)d level.']
S184-PMC4944244	PMC4944244	7/2016	S184-PMC4944244	['[22] also CLAIMED that there was no significant relationship between pre-Pregnancy bmi parity or gravidity with insufficient Vitamin D level in any trimester.']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]	0	['[22] pre- bmi parity gravidity  trimester.']
S212-PMC4944244	PMC4944244	7/2016	S212-PMC4944244	['certain Dress code and sun block had limited the ability of the skin to synthesize Vitamin D.\nVitamin D Intake from Food is one of the MODIFIABLE FACTORS that CAN reduce the RISK of hypovitaminosis d. a total of 55.1\xa0% of respondents have met the malaysian recommended Nutrient intakes (rni) for Vitamin D in Pregnant women which REQUIRE Intake of 5\xa0μg (200\xa0iu) per day [38,39] (table\xa01).']	[('IMPORTANT_CONSIDERATION', 135), ('SUPERFICIAL_RELATIONSHIP', 146), ('INCOMPLETE_EVIDENCE', 159), ('IMPORTANT_CONSIDERATION', 174), ('IMPORTANT_CONSIDERATION', 330)]	5	[('UBERON_0001348', 'brown adipose tissue', 8, 'dress'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 91, 'D'), ('CHEBI_28384', 'vitamin K', 94, 'Vitamin D'), ('GO_0007631', 'feeding behavior', 104, 'intake'), ('CHEBI_33290', 'food', 116, 'food'), ('CHEBI_33284', 'nutrient', 269, 'Nutrient'), ('CHEBI_27300', 'vitamin D', 296, 'vitamin D'), ('GO_0007565', 'female pregnancy', 309, 'pregnant'), ('GO_0007631', 'feeding behavior', 338, 'intake')]	0	['certain dress code sun block ability skin synthesize .\nvitamin intake food hypovitaminosis d. 55.1\xa0% respondents met malaysian nutrient intakes (rni)   women intake 5\xa0μg (200\xa0iu) day [38,39] (table\xa01).']
S217-PMC4944244	PMC4944244	7/2016	S217-PMC4944244	['[22] also CLAIMED that there was a significant difference in Serum 25(Oh)D between Pregnant women who took 400\xa0iu or more Vitamin D as Supplements during the Antenatal period and Pregnant women who took\u2009<\u2009400\xa0iu/day or none (or 0.19; 95\xa0% ci: 0.06 to 0.56, p <0.01).']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('UBERON_0001977', 'blood serum', 61, 'serum'), ('CHEBI_71657', 'versiconol acetate', 67, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 67, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 83, 'pregnant'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 135, 'supplements'), ('GO_0007567', 'parturition', 158, 'antenatal'), ('UBERON_0001760', 'frontal sinus', 158, 'antenatal'), ('GO_0007565', 'female pregnancy', 179, 'pregnant')]	0	['[22] serum 25(oh)d  women took 400\xa0iu  supplements antenatal period  women took\u2009<\u2009400\xa0iu/day (or 0.19; 95\xa0% ci: 0.06 0.56, p <0.01).']
S225-PMC4944244	PMC4944244	7/2016	S225-PMC4944244	['finally, AWARENESS of high PREVALENCE and DANGERS of hypovitaminosis d during Pregnancy NEEDS TO be highlighted to health care workers so that they are better informed of FACTORS INFLUENCING Vitamin D status.']	[('IMPORTANT_CONSIDERATION', 9), ('IMPORTANT_CONSIDERATION', 27), ('IMPORTANT_CONSIDERATION', 42), ('FUTURE_WORK', 88), ('SUPERFICIAL_RELATIONSHIP', 171), ('SUPERFICIAL_RELATIONSHIP', 179)]	6	[('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]	0	['finally, hypovitaminosis  workers  status.']
S226-PMC4944244	PMC4944244	7/2016	S226-PMC4944244	['health care workers SHOULD also know the functions and the sources of Vitamin D, so that ADVICE COULD BE given to patients especially those with Lactose intolerance or low Milk Consumption during Pregnancy.']	[('FUTURE_WORK', 20), ('FUTURE_WORK', 89), ('INCOMPLETE_EVIDENCE', 96)]	3	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 78, 'D'), ('CHEBI_17716', 'lactose', 145, 'lactose'), ('GO_0001774', 'microglial cell activation', 172, 'milk consumption'), ('GO_0007565', 'female pregnancy', 196, 'pregnancy')]	0	['health workers functions sources patients lactose intolerance milk consumption .']
S227-PMC4944244	PMC4944244	7/2016	S227-PMC4944244	['Calcium supplement with Vitamin D SHOULD BE given earlier to those who do not Consume adequate milk during Pregnancy to prevent adverse health EFFECTS to the mother and fetus.']	[('FUTURE_WORK', 34), ('SUPERFICIAL_RELATIONSHIP', 143)]	2	[('CHEBI_31341', 'calcium dihydroxide', 0, 'Calcium'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007631', 'feeding behavior', 78, 'consume'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy')]	0	['calcium supplement  consume milk  mother fetus.']
S229-PMC4944244	PMC4944244	7/2016	S229-PMC4944244	['dietary Intake of Food containing Vitamin D was found to reduce hypovitaminosis D. nutrition education NEEDS TO BE EMPHASIZED among Pregnant women, ESPECIALLY those of malay and indian ethnicity, who Consume little or no milk, and those who work at desk jobs as INDICATED by high education levels.']	[('FUTURE_WORK', 103), ('IMPORTANT_CONSIDERATION', 109), ('IMPORTANT_CONSIDERATION', 148), ('INCOMPLETE_EVIDENCE', 262)]	4	[('GO_0007631', 'feeding behavior', 8, 'intake'), ('CHEBI_33290', 'food', 18, 'food'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 80, 'D'), ('GO_0007565', 'female pregnancy', 132, 'pregnant'), ('GO_0007631', 'feeding behavior', 200, 'consume')]	0	['dietary intake food containing  hypovitaminosis d. nutrition among  women, malay indian ethnicity, consume milk, desk jobs levels.']
S11-PMC4949006	PMC4949006	7/2016	S11-PMC4949006	['Folic Acid, Iodine, and Calcium in all Pregnant women and Vitamin C in smokers are the ONLY Supplements SO FAR SHOWN to be of value for routine use.']	[('INCOMPLETE_EVIDENCE', 87), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 111)]	3	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('CHEBI_24859', 'iodine atom', 12, 'iodine'), ('CHEBI_22313', 'alkaline earth metal atom', 24, 'calcium'), ('GO_0007565', 'female pregnancy', 39, 'pregnant'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin C'), ('CHEBI_33341', 'titanium atom', 92, 'supplements')]	0	['folic acid, iodine, calcium  women  smokers supplements routine use.']
S132-PMC4949006	PMC4949006	7/2016	S132-PMC4949006	['supplementation does prevent and cure this condition.93–95all studies to date fail to show any significant EFFECTS of Vitamin A supplementation on Pregnancy outcomes for mother or fetus.96more than 10,000 iu of Vitamin A supplementation per day (4 times the recommended daily allowance) increases the risk of cleft lip or palate, Hydrocephalus, and Heart defects.']	[('SUPERFICIAL_RELATIONSHIP', 107)]	1	[('CHEBI_27300', 'vitamin D', 118, 'vitamin A'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin A'), ('UBERON_4100114', 'anterior distal condyle of femur', 330, 'hydrocephalus'), ('UBERON_0000948', 'heart', 349, 'heart')]	0	['supplementation cure condition.93–95all  supplementation  outcomes mother fetus.96more 10,000 iu  supplementation day (4 times daily allowance) cleft lip palate, hydrocephalus, defects.']
S136-PMC4949006	PMC4949006	7/2016	S136-PMC4949006	['Vitamin B6Supplementation HAS BEEN shown in 3 SMALL STUDIES to give a modest gain in Birth weight.99Vitamin C supplementation has not been shown to be of value in improving Pregnancy outcomes,99but HAS SHOWN value for PREVENTION of wheezing and asthma in the children of smokers.100\n\nVitamin E\nONE STUDY CORRELATED risk of wheeze inversely to the level of Vitamin E as well as a linear RELATIONSHIP between the level and the forced Expiratory volume at 1 minute.101NO OTHER STUDIES APPEAR to support OR REFUTE this.']	[('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 46), ('INCOMPLETE_EVIDENCE', 198), ('SUPERFICIAL_RELATIONSHIP', 218), ('INCOMPLETE_EVIDENCE', 294), ('SUPERFICIAL_RELATIONSHIP', 304), ('SUPERFICIAL_RELATIONSHIP', 386), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 462), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 468), ('INCOMPLETE_EVIDENCE', 468), ('ANOMALY_CURIOUS_FINDING', 482), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 500), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 503)]	13	[('CHEBI_10122', 'Zizyphine F', 0, 'Vitamin B6supplementation'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin B6supplementation'), ('GO_0007567', 'parturition', 85, 'birth'), ('CHEBI_65430', 'ardisiphenol A', 98, '99Vitamin C'), ('PR_000004900', 'complement C3', 108, 'C'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 284, 'Vitamin E'), ('CHEBI_27300', 'vitamin D', 356, 'vitamin E'), ('GO_0010467', 'gene expression', 432, 'expiratory')]	0	['vitamin b6supplementation 3 gain birth weight.99vitamin c supplementation  outcomes,99but wheezing asthma children smokers.100\n\nvitamin e\none wheeze  linear forced expiratory volume minute.101no this.']
S138-PMC4949006	PMC4949006	7/2016	S138-PMC4949006	['Vitamin D\nadequate Vitamin D status during Pregnancy is NECESSARY to ensure appropriate maternal responses to the calcium demands of the fetus for bone Mineral accretion.']	[('IMPORTANT_CONSIDERATION', 56)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('CHEBI_46662', 'mineral', 152, 'mineral')]	0	['vitamin d\nadequate  status  ensure maternal responses calcium fetus bone mineral accretion.']
S142-PMC4949006	PMC4949006	7/2016	S142-PMC4949006	['american college of obstetricians and gynecologists103suggests that CURRENT EVIDENCE DOES NOT SUPPORT routine screening of all Pregnant women for Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 68), ('INCOMPLETE_EVIDENCE', 85)]	2	[('GO_0007565', 'female pregnancy', 127, 'pregnant'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D')]	0	['american college obstetricians gynecologists103suggests routine screening  women  deficiency.']
S145-PMC4949006	PMC4949006	7/2016	S145-PMC4949006	['HOWEVER, when Vitamin D deficiency is identified during Pregnancy, supplementation with up to 1000 to 2000 iu/d is CONSIDERED SAFE by MOST EXPERTS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 115), ('IMPORTANT_CONSIDERATION', 126), ('PROBABLE_UNDERSTANDING', 134), ('PROBABLE_UNDERSTANDING', 139)]	5	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnancy')]	0	['however,  supplementation 1000 2000 iu/d experts.']
S147-PMC4949006	PMC4949006	7/2016	S147-PMC4949006	['it HAS BEEN IDENTIFIED as a Nutrient of PUBLIC HEALTH CONCERN by the us department of health and Human services.104\nNUMEROUS STUDIES HAVE SHOWN a prevalence of vitamin d levels of less than 50 nmol/l in 30% to 96% of Pregnant women, increasing with latitude and with nonwhite race.105–111a study done using archived samples of Cord Blood in denmark SHOWED an increased risk of developing schizophrenia with either elevated or low levels of Vitamin D. it was HYPOTHESIZED that IF all the infants COULD have been Born with normal levels there would have been a reduction of 43% in the incidence of schizophrenia among the Adults.112there is also an ASSOCIATION of Vitamin D deficiency and Insulin resistance,113which was reversed with a single injection of the vitamin114(not approved in the united states).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 40), ('INCOMPLETE_EVIDENCE', 116), ('INCOMPLETE_EVIDENCE', 133), ('INCOMPLETE_EVIDENCE', 349), ('INCOMPLETE_EVIDENCE', 458), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 476), ('INCOMPLETE_EVIDENCE', 495), ('SUPERFICIAL_RELATIONSHIP', 647)]	10	[('CHEBI_33284', 'nutrient', 28, 'nutrient'), ('NCBITaxon_10088', 'Mus <genus>', 97, 'Human'), ('GO_0007565', 'female pregnancy', 217, 'pregnant'), ('UBERON_0002240', 'spinal cord', 327, 'cord'), ('UBERON_0000178', 'blood', 332, 'blood'), ('CHEBI_28384', 'vitamin K', 440, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 440, 'Vitamin D'), ('GO_0007567', 'parturition', 511, 'born'), ('UBERON_0007023', 'adult organism', 620, 'adults'), ('CHEBI_27300', 'vitamin D', 662, 'vitamin D'), ('PR_000045358', 'insulin family protein', 687, 'insulin')]	0	['nutrient us department human services.104\nnumerous vitamin levels 50 nmol/l 30% 96%  women, latitude nonwhite race.105–111a done using archived samples cord blood denmark schizophrenia levels vitamin d. infants born normal levels reduction 43% schizophrenia among adults.112there  insulin resistance,113which single injection vitamin114(not approved united states).']
S148-PMC4949006	PMC4949006	7/2016	S148-PMC4949006	['SOME STUDIES REPORT higher long-bone density in fetuses of women with adequate amounts of Vitamin D,115,116but the numbers are SMALL.117the general RECOMMENDATION is 1000 to 2000 mg/d of supplementation, BUT there are no AGREED-UPON levels for sufficiency or insufficiency in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 127), ('FUTURE_WORK', 148), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 204), ('INCOMPLETE_EVIDENCE', 221)]	6	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 276, 'pregnancy')]	0	['higher long-bone density fetuses women amounts ,115,116but small.117the 1000 2000 mg/d supplementation, agreed-upon levels .']
S149-PMC4949006	PMC4949006	7/2016	S149-PMC4949006	['THERE ARE NO STUDIES clearly SHOWING DIFFERENCES in maternal outcomes or fetal survival, Birth weight, or Gestational length relative to Vitamin D,118but studies on bone health (and Lung function and asthma at age 6 years119) SUPPORT a level of AT LEAST 50 nmol/l, which implies a need for some supplementation for all Pregnant women.120–123\n\nCalcium\nwomen lose 3% to 5% of their bone mass while Lactating but rapidly regain it within 6 months after weaning.']	[('FULL_UNKNOWN', 0), ('INCOMPLETE_EVIDENCE', 10), ('INCOMPLETE_EVIDENCE', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 37), ('INCOMPLETE_EVIDENCE', 226), ('PROBABLE_UNDERSTANDING', 245)]	6	[('GO_0007567', 'parturition', 89, 'birth'), ('GO_0007565', 'female pregnancy', 106, 'gestational'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('UBERON_0002048', 'lung', 182, 'lung'), ('GO_0007565', 'female pregnancy', 319, 'pregnant'), ('CHEBI_31341', 'calcium dihydroxide', 343, 'Calcium'), ('GO_0007594', 'puparial adhesion', 396, 'lactating')]	0	['fetal survival, birth weight,  length relative ,118but bone (and lung asthma age 6 years119) 50 nmol/l, supplementation  women.120–123\n\ncalcium\nwomen 3% 5% bone mass lactating rapidly regain 6 months weaning.']
S194-PMC4949006	PMC4949006	7/2016	S194-PMC4949006	['there is GOOD EVIDENCE for supplementation with Vitamin C in Pregnant women who smoke.']	[('PROBABLE_UNDERSTANDING', 9)]	1	[('CHEBI_27300', 'vitamin D', 48, 'vitamin C'), ('GO_0007565', 'female pregnancy', 61, 'pregnant')]	0	['supplementation   women smoke.']
S195-PMC4949006	PMC4949006	7/2016	S195-PMC4949006	['there is NO GOOD current EVIDENCE to SHOW value in supplementation for iron and vitamins A, B6, B12, A, e, or D at this time, ALTHOUGH there are many SUGGESTIVE STUDIES for Vitamin D. all Pregnant women SHOULD BE ENCOURAGED to eat a balanced diet rich in fresh or frozen fruits and vegetables, high-quality Carbohydrates including whole grains, and with a good mix of proteins from beans, lean meats, fish, and seafood.']	[('FULL_UNKNOWN', 9), ('INCOMPLETE_EVIDENCE', 25), ('INCOMPLETE_EVIDENCE', 37), ('ANOMALY_CURIOUS_FINDING', 126), ('INCOMPLETE_EVIDENCE', 150), ('FUTURE_WORK', 203), ('FUTURE_WORK', 213)]	7	[('PR_000004370', 'asialoglycoprotein receptor 2', 89, 'A'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 92, 'B6'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 96, 'B12'), ('PR_000004370', 'asialoglycoprotein receptor 2', 101, 'A'), ('PR_000006444', 'diacylglycerol kinase delta', 110, 'D'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('GO_0007565', 'female pregnancy', 188, 'pregnant'), ('CHEBI_16646', 'carbohydrate', 307, 'carbohydrates')]	0	['supplementation iron vitamins a, b6, b12, a, e, time, .  women eat diet rich fresh frozen fruits vegetables, high-quality carbohydrates whole grains, mix proteins beans, lean meats, fish, seafood.']
S33-PMC4969253	PMC4969253	8/2016	S33-PMC4969253	['[14,15]\n\nPrenatal Vitamin A-ra Signaling INFLUENCES the program of Smooth Muscle differentiation in developing Airways\nthe developing Lung Mesenchyme gives rise to a number of derivatives including Endothelium, cartilage rings, Interstitial Fibroblasts, and vascular and Airway Smooth Muscle.']	[('SUPERFICIAL_RELATIONSHIP', 41)]	1	[('GO_0007565', 'female pregnancy', 9, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 18, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 26, 'A'), ('GO_0023051', 'regulation of signaling', 31, 'signaling'), ('UBERON_0001135', 'smooth muscle tissue', 67, 'smooth muscle'), ('UBERON_0001005', 'respiratory airway', 111, 'airways'), ('UBERON_0004883', 'lung mesenchyme', 134, 'lung mesenchyme'), ('UBERON_0001986', 'endothelium', 198, 'endothelium'), ('UBERON_0005169', 'interstitial tissue', 228, 'interstitial'), ('CL_0000057', 'fibroblast', 241, 'fibroblasts'), ('UBERON_0004230', 'urinary bladder neck smooth muscle', 271, 'airway smooth muscle')]	0	['[14,15]\n\n -ra signaling program smooth muscle airways\nthe lung mesenchyme rise derivatives endothelium, cartilage rings, interstitial fibroblasts, vascular airway smooth muscle.']
S79-PMC4969253	PMC4969253	8/2016	S79-PMC4969253	['these EFFECTS CAN be PREVENTED or alleviated by proper Vitamin A supplementation during Gestation [25].']	[('SUPERFICIAL_RELATIONSHIP', 6), ('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 21)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin A'), ('GO_0007565', 'female pregnancy', 88, 'gestation')]	0	['alleviated proper  supplementation  [25].']
S80-PMC4969253	PMC4969253	8/2016	S80-PMC4969253	['the IMPACT of Prenatal disruption of ra signaling in Adult Airway structure and function HAS BEEN WELL DEMONSTRATED using a MODEL of Vitamin A deficiency in Mice [14].']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 89), ('FUTURE_WORK', 98), ('INCOMPLETE_EVIDENCE', 103), ('INCOMPLETE_EVIDENCE', 124)]	5	[('GO_0007565', 'female pregnancy', 14, 'prenatal'), ('UBERON_0007023', 'adult organism', 53, 'adult'), ('UBERON_0001005', 'respiratory airway', 59, 'airway'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin A'), ('NCBITaxon_10088', 'Mus <genus>', 157, 'mice')]	0	[' ra signaling adult airway structure using  mice [14].']
S82-PMC4969253	PMC4969253	8/2016	S82-PMC4969253	['REMARKABLY, IF returned to normal Vitamin A diet later in Gestation and throughout their Postnatal Life, Adult Mice show a markedly thick Airway Sm layer.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 12)]	2	[('CHEBI_27300', 'vitamin D', 34, 'vitamin A'), ('GO_0007565', 'female pregnancy', 58, 'gestation'), ('GO_0007567', 'parturition', 89, 'postnatal'), ('UBERON_0000104', 'life cycle', 99, 'life'), ('UBERON_0007023', 'adult organism', 105, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 111, 'mice'), ('UBERON_0001005', 'respiratory airway', 138, 'airway'), ('UBERON_0001290', 'proximal straight tubule', 145, 'SM')]	0	['remarkably, returned normal  diet  throughout postnatal life, adult mice thick airway sm layer.']
S84-PMC4969253	PMC4969253	8/2016	S84-PMC4969253	['these OBSERVATIONS STRONGLY SUPPORT the IDEA that Prenatal Vitamin A deficiency predisposes to Airway hyperreactivity.']	[('INCOMPLETE_EVIDENCE', 6), ('PROBABLE_UNDERSTANDING', 19), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 40)]	4	[('GO_0007565', 'female pregnancy', 50, 'prenatal'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin A'), ('UBERON_0001005', 'respiratory airway', 95, 'airway')]	0	['  airway hyperreactivity.']
S1-PMC4971719	PMC4971719	8/2016	S1-PMC4971719	['we performed THIS STUDY TO EVALUATE WHETHER low maternal Vitamin D levels are ASSOCIATED with depressive symptoms in Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 36), ('SUPERFICIAL_RELATIONSHIP', 78)]	4	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy')]	0	['maternal  levels depressive symptoms .']
S8-PMC4971719	PMC4971719	8/2016	S8-PMC4971719	['our primary outcome measure was the ASSOCIATION of maternal Vitamin D levels with bdi scores during early and late Pregnancy and Postpartum.']	[('SUPERFICIAL_RELATIONSHIP', 36)]	1	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('GO_0007565', 'female pregnancy', 129, 'postpartum')]	0	['outcome measure maternal  levels bdi scores late  .']
S9-PMC4971719	PMC4971719	8/2016	S9-PMC4971719	['results\nwe FOUND that Vitamin D levels at 12–20 weeks were inversely ASSOCIATED with bdi scores both at 12—20 and at 34–36 weeks’ Gestation ( p \u2009<\u20090.05, both).']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 69)]	2	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'gestation')]	0	['results\nwe  levels 12–20 weeks bdi scores 12—20 34–36 weeks’  p \u2009<\u20090.05, both).']
S12-PMC4971719	PMC4971719	8/2016	S12-PMC4971719	['conclusions\nin women AT RISK for depression, early Pregnancy low Vitamin D levels are ASSOCIATED with higher depressive symptom scores in early and late Pregnancy.']	[('IMPORTANT_CONSIDERATION', 21), ('SUPERFICIAL_RELATIONSHIP', 86)]	2	[('GO_0007565', 'female pregnancy', 51, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy')]	0	['conclusions\nin women depression,   levels higher depressive symptom scores late .']
S13-PMC4971719	PMC4971719	8/2016	S13-PMC4971719	['FUTURE INVESTIGATIONS SHOULD study WHETHER Vitamin D supplementation in early Pregnancy MAY PREVENT Perinatal depressive symptoms.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 35), ('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 92)]	5	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('GO_0036268', 'swimming', 100, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 100, 'perinatal')]	0	['future  supplementation  perinatal depressive symptoms.']
S19-PMC4971719	PMC4971719	8/2016	S19-PMC4971719	['for instance, a systematic review and meta-analysis of observational studies involving 31,424 non-Pregnant Adults FOUND low Vitamin D levels to be significantly ASSOCIATED with clinical diagnoses of depression [13].']	[('INCOMPLETE_EVIDENCE', 114), ('SUPERFICIAL_RELATIONSHIP', 161)]	2	[('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('UBERON_0007023', 'adult organism', 107, 'adults'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]	0	['instance, meta-analysis 31,424 non- adults  levels diagnoses depression [13].']
S28-PMC4971719	PMC4971719	8/2016	S28-PMC4971719	['in a follow-up study of a subset of this cohort, the authors also DEMONSTRATED an ASSOCIATION of low early Pregnancy Vitamin D levels with Postpartum depressive symptoms [23].']	[('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 82)]	2	[('GO_0007565', 'female pregnancy', 107, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'postpartum')]	0	['follow-up subset cohort, authors   levels  depressive symptoms [23].']
S30-PMC4971719	PMC4971719	8/2016	S30-PMC4971719	['FOUND an ASSOCIATION between low early Pregnancy Vitamin D levels and depressive symptoms measured at 16\xa0weeks Gestation [24].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 9)]	2	[('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'gestation')]	0	['found   levels depressive symptoms 16\xa0weeks  [24].']
S31-PMC4971719	PMC4971719	8/2016	S31-PMC4971719	['the more RECENT huang et al., STUDY EXAMINED the ASSOCIATION 25 Oh Vitamin D levels measured at 15\xa0weeks Gestation with depression and anxiety symptoms measured at that same time point [25].']	[('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 36), ('QUESTION_ANSWERED_BY_THIS_WORK', 36), ('SUPERFICIAL_RELATIONSHIP', 49)]	5	[('CHEBI_63058', '(2R,3S)-EHNA', 61, '25 OH'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'gestation')]	0	['25 oh  levels 15\xa0weeks  depression anxiety symptoms [25].']
S32-PMC4971719	PMC4971719	8/2016	S32-PMC4971719	['SEVERAL STUDIES have evaluated the ASSOCIATION of Vitamin D levels with Postpartum symptoms of depression.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 35)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'postpartum')]	0	['several  levels  symptoms depression.']
S33-PMC4971719	PMC4971719	8/2016	S33-PMC4971719	['robinson, et al., in an unselected australian cohort of caucasian women, FOUND Vitamin D levels at 18\xa0weeks’ Gestation to be ASSOCIATED with Postnatal depressive symptoms measured at 3\xa0days Postpartum [26].']	[('INCOMPLETE_EVIDENCE', 73), ('SUPERFICIAL_RELATIONSHIP', 125)]	2	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'gestation'), ('GO_0007567', 'parturition', 141, 'postnatal'), ('GO_0007565', 'female pregnancy', 190, 'postpartum')]	0	['robinson, et al., unselected australian caucasian women,  levels 18\xa0weeks’  postnatal depressive symptoms 3\xa0days  [26].']
S34-PMC4971719	PMC4971719	8/2016	S34-PMC4971719	['similarly, gur, et al., FOUND a significant ASSOCIATED between mid-Pregnancy Vitamin D levels and depression and depression screen scores measured longitudinally in the Postpartum period among healthy women who were not considered AT RISK for depression [27].']	[('INCOMPLETE_EVIDENCE', 24), ('SUPERFICIAL_RELATIONSHIP', 44), ('IMPORTANT_CONSIDERATION', 231)]	3	[('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'postpartum')]	0	['similarly, gur, et al., mid-  levels depression depression screen scores longitudinally  period among healthy women depression [27].']
S36-PMC4971719	PMC4971719	8/2016	S36-PMC4971719	['FOUND an ASSOCIATION between Vitamin D levels <32\xa0ng/ml measured monthly for 7\xa0months Postpartum and depression symptom scores at these same time points [28].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 9)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'postpartum')]	0	['found  levels <32\xa0ng/ml monthly 7\xa0months  depression symptom scores [28].']
S37-PMC4971719	PMC4971719	8/2016	S37-PMC4971719	['BY CONTRAST, the RECENT nielsen case-control danish national Birth cohort FOUND that high levels of Vitamin D in mid Pregnancy were ASSOCIATED with antidepressant use in the Postpartum Period, an UNEXPECTED FINDING [29].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('INCOMPLETE_EVIDENCE', 74), ('SUPERFICIAL_RELATIONSHIP', 132), ('ANOMALY_CURIOUS_FINDING', 196), ('INCOMPLETE_EVIDENCE', 207)]	6	[('GO_0007567', 'parturition', 61, 'Birth'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy'), ('GO_0007565', 'female pregnancy', 174, 'postpartum'), ('UBERON_2001055', 'pronephric duct opening', 185, 'period')]	0	['contrast, nielsen case-control danish national birth levels  mid  antidepressant  period, [29].']
S38-PMC4971719	PMC4971719	8/2016	S38-PMC4971719	['we CONDUCTED THIS STUDY TO EVALUATE WHETHER Plasma Vitamin D levels, measured in early and late Pregnancy were ASSOCIATED with depression symptom scores at 3 time points during Pregnancy and at 6–8 weeks Postpartum.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 36), ('SUPERFICIAL_RELATIONSHIP', 111)]	5	[('UBERON_0001969', 'blood plasma', 44, 'plasma'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy'), ('GO_0007565', 'female pregnancy', 177, 'pregnancy'), ('GO_0007565', 'female pregnancy', 204, 'postpartum')]	0	['plasma  levels, late  depression symptom scores 3  6–8 weeks .']
S41-PMC4971719	PMC4971719	8/2016	S41-PMC4971719	['we HYPOTHESIZED that lower Vitamin D levels during Pregnancy would be ASSOCIATED with higher depression symptom scores during Pregnancy and at 6–8 weeks Postpartum.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 70)]	2	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('GO_0007565', 'female pregnancy', 153, 'postpartum')]	0	[' levels  higher depression symptom scores  6–8 weeks .']
S44-PMC4971719	PMC4971719	8/2016	S44-PMC4971719	['the primary AIM of this secondary analysis was TO DETERMINE WHETHER low Vitamin D during Pregnancy is ASSOCIATED with depressive symptoms as assessed by the beck depression inventory score at three time points during Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 47), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 60), ('SUPERFICIAL_RELATIONSHIP', 102)]	4	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('GO_0007565', 'female pregnancy', 217, 'pregnancy')]	0	['secondary   depressive symptoms beck depression inventory score three .']
S87-PMC4971719	PMC4971719	8/2016	S87-PMC4971719	['in our primary analysis, we ASSESSED the relationship between Vitamin D as a continuous variable and bdi scores at 12–20 weeks, 34–36 weeks and the 6–8 week Postpartum visits.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 28)]	1	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'postpartum')]	0	['analysis,  continuous bdi scores 12–20 weeks, 34–36 weeks 6–8 week  visits.']
S94-PMC4971719	PMC4971719	8/2016	S94-PMC4971719	['OF NOTE, the endocrine society has SUGGESTED a Vitamin D target for Pregnant women of ≥30\xa0ng/ml [43].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 35)]	2	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnant')]	0	['note, endocrine society   women ≥30\xa0ng/ml [43].']
S127-PMC4971719	PMC4971719	8/2016	S127-PMC4971719	['standard deviation\nfor our primary outcome, we EVALUATED the RELATIONSHIP between Vitamin D levels at two time points and bdi scores at 12–20 weeks, 34–36 weeks and 6–8 weeks Postpartum.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 47), ('SUPERFICIAL_RELATIONSHIP', 61)]	2	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 175, 'postpartum')]	0	['standard deviation\nfor outcome,  levels bdi scores 12–20 weeks, 34–36 weeks 6–8 weeks .']
S128-PMC4971719	PMC4971719	8/2016	S128-PMC4971719	['using analysis of covariance (ancova), and adjusting for season, (winter/non-winter), we FOUND that Vitamin D at 12–20 weeks was a significant PREDICTOR of the Bdi score at 12–20 ( p \u2009<\u20090.05) weeks and at 34–36 weeks Gestation ( p \u2009<\u20090.05).']	[('INCOMPLETE_EVIDENCE', 89), ('SUPERFICIAL_RELATIONSHIP', 143)]	2	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('PR_000004717', 'transcription factor TFIIIB component B**', 160, 'BDI'), ('GO_0007565', 'female pregnancy', 217, 'gestation')]	0	['using covariance (ancova), adjusting season, (winter/non-winter),  12–20 weeks bdi score 12–20 p \u2009<\u20090.05) weeks 34–36 weeks  p \u2009<\u20090.05).']
S129-PMC4971719	PMC4971719	8/2016	S129-PMC4971719	['for every one unit increase in Vitamin D in early Pregnancy there was an APPROXIMATE 0.14 unit decrease in the bdi score at visit 1 (95\xa0% confidence interval −0.26, −0.017) and visit 3 (−0.27, −0.011).']	[('INCOMPLETE_EVIDENCE', 73)]	1	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy')]	0	['unit increase   0.14 unit decrease bdi score visit (95\xa0% confidence interval −0.26, −0.017) visit 3 (−0.27, −0.011).']
S136-PMC4971719	PMC4971719	8/2016	S136-PMC4971719	['HOWEVER, “low Vitamin D” at enrollment was significantly ASSOCIATED with higher bdi score at 34–36 weeks Gestation ( p \u2009=\u20090.05).']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 57)]	2	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'gestation')]	0	['however, “low ” enrollment higher bdi score 34–36 weeks  p \u2009=\u20090.05).']
S138-PMC4971719	PMC4971719	8/2016	S138-PMC4971719	['in this adjusted model, “low Vitamin D”, at visit 1 (again, as a categorical variable) was ASSOCIATED with the bdi at 34–36 weeks’ Gestation ( p \u2009=\u20090.01), WHILE there was a TREND toward ASSOCIATION of low Dha ( p \u2009=\u20090.06) and low epa ( p \u2009=\u20090.09) with higher Bdi scores at that time point as well (r2for the model\u2009=\u20090.12).']	[('SUPERFICIAL_RELATIONSHIP', 91), ('ANOMALY_CURIOUS_FINDING', 155), ('INCOMPLETE_EVIDENCE', 173), ('SUPERFICIAL_RELATIONSHIP', 186)]	4	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'gestation'), ('CHEBI_17874', 'dihydrozeatin', 205, 'DHA'), ('PR_000004717', 'transcription factor TFIIIB component B**', 259, 'BDI')]	0	['adjusted model, “low ”, visit (again, categorical variable) bdi 34–36 weeks’  p \u2009=\u20090.01), toward dha p \u2009=\u20090.06) epa p \u2009=\u20090.09) higher bdi scores (r2for model\u2009=\u20090.12).']
S145-PMC4971719	PMC4971719	8/2016	S145-PMC4971719	['discussion\n\nmain findings\nTHIS STUDY presents EVIDENCE that low Vitamin D levels in early Pregnancy (12–20 weeks) are significantly ASSOCIATED with higher depression symptom scores at in early and late Pregnancy in a group of women AT RISK for depression.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('INCOMPLETE_EVIDENCE', 46), ('SUPERFICIAL_RELATIONSHIP', 132), ('IMPORTANT_CONSIDERATION', 232)]	4	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy')]	0	['discussion\n\nmain findings\nthis presents  levels  (12–20 weeks) higher depression symptom scores late  women depression.']
S146-PMC4971719	PMC4971719	8/2016	S146-PMC4971719	['CONVERSELY, we FOUND that ALTHOUGH there was a TREND toward an ASSOCIATION of most recent Vitamin D levels with the bdi score in later Pregnancy and Postpartum, this trend was not significant and largely disappeared after adjustment for the baseline Bdi score.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 15), ('ANOMALY_CURIOUS_FINDING', 26), ('INCOMPLETE_EVIDENCE', 47), ('SUPERFICIAL_RELATIONSHIP', 63)]	5	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 135, 'pregnancy'), ('GO_0007565', 'female pregnancy', 149, 'postpartum'), ('PR_000004717', 'transcription factor TFIIIB component B**', 250, 'BDI')]	0	['conversely, toward  levels bdi score  disappeared adjustment baseline bdi score.']
S149-PMC4971719	PMC4971719	8/2016	S149-PMC4971719	['another strength of THIS STUDY is that we were able to measure Vitamin D longitudinally as well, both in early and late Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 20)]	1	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy')]	0	['another able measure  longitudinally well, late .']
S152-PMC4971719	PMC4971719	8/2016	S152-PMC4971719	['the LACK OF association OBSERVED between Vitamin D level in early or late Pregnancy and the 6–8 week Postpartum bdi score MAY BE EXPLAINED by the COMPLEXITY of the pathogenesis of Postpartum depression symptoms, OR it MAY represent a TRUE negative FINDING.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 122), ('ANOMALY_CURIOUS_FINDING', 126), ('PROBABLE_UNDERSTANDING', 129), ('DIFFICULT_TASK', 146), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 212), ('INCOMPLETE_EVIDENCE', 218), ('PROBABLE_UNDERSTANDING', 234), ('INCOMPLETE_EVIDENCE', 248)]	10	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007565', 'female pregnancy', 101, 'postpartum'), ('GO_0007565', 'female pregnancy', 180, 'postpartum')]	0	[' late  6–8 week  bdi score pathogenesis  depression symptoms, finding.']
S161-PMC4971719	PMC4971719	8/2016	S161-PMC4971719	['OUR STUDY FOUND an ASSOCIATION between low Vitamin D levels in early Pregnancy and depressive symptoms during Pregnancy BUT NOT Postpartum.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10), ('SUPERFICIAL_RELATIONSHIP', 19), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 120)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007565', 'female pregnancy', 128, 'postpartum')]	0	[' levels  depressive symptoms  .']
S163-PMC4971719	PMC4971719	8/2016	S163-PMC4971719	['the main finding of OUR STUDY is that there exists a RELATIONSHIP between low early-Pregnancy Vitamin D levels and depression symptoms in early and late Pregnancy in women AT risk for depression.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 20), ('SUPERFICIAL_RELATIONSHIP', 53), ('IMPORTANT_CONSIDERATION', 172)]	3	[('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy')]	0	['main early-  levels depression symptoms late  women depression.']
S164-PMC4971719	PMC4971719	8/2016	S164-PMC4971719	['our regression model SUGGESTED that 12\xa0% of the variance in bdi score at 34–36 weeks was PREDICTED by a combination of low Vitamin D, low epa and low Dha levels in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 21), ('SUPERFICIAL_RELATIONSHIP', 89)]	2	[('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_17874', 'dihydrozeatin', 150, 'DHA'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy')]	0	['regression 12\xa0% bdi score 34–36 weeks combination epa dha levels .']
S168-PMC4971719	PMC4971719	8/2016	S168-PMC4971719	['conclusions\nOUR FINDINGS SUGGEST that lower Vitamin D levels in early Pregnancy are ASSOCIATED with depressive symptoms in early and late Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('INCOMPLETE_EVIDENCE', 25), ('SUPERFICIAL_RELATIONSHIP', 84)]	3	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy')]	0	['conclusions\nour  levels  depressive symptoms late .']
S170-PMC4971719	PMC4971719	8/2016	S170-PMC4971719	['IMPORTANT FUTURE AREAS OF RESEARCH would INCLUDE randomized controlled trials of Vitamin D supplementation for women who are screen for depression RISK in early Pregnancy and who are found to have low Vitamin D levels.']	[('FUTURE_WORK', 0), ('IMPORTANT_CONSIDERATION', 0), ('FUTURE_WORK', 10), ('FUTURE_WORK', 41), ('IMPORTANT_CONSIDERATION', 147)]	5	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D')]	0	['important  supplementation women screen depression   levels.']
S0-PMC4973215	PMC4973215	8/2016	S0-PMC4973215	['racial DISPARITIES in Cord Blood Vitamin D levels and its ASSOCIATION with small-for-Gestational-age infants\n\nabstract\n\nobjective:\nTO EXAMINE the RELATIONSHIP of race and maternal characteristics and their ASSOCIATION with Cord Blood Vitamin D levels and small-for-Gestational-age (sga) status.']	[('IMPORTANT_CONSIDERATION', 7), ('SUPERFICIAL_RELATIONSHIP', 58), ('QUESTION_ANSWERED_BY_THIS_WORK', 131), ('SUPERFICIAL_RELATIONSHIP', 146), ('SUPERFICIAL_RELATIONSHIP', 206)]	5	[('UBERON_0002240', 'spinal cord', 22, 'cord'), ('UBERON_0000178', 'blood', 27, 'blood'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'gestational'), ('UBERON_0002240', 'spinal cord', 223, 'cord'), ('UBERON_0000178', 'blood', 228, 'blood'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D'), ('GO_0007565', 'female pregnancy', 265, 'gestational')]	0	['racial cord blood  levels small-for--age infants\n\nabstract\n\nobjective:\nto race maternal characteristics cord blood  levels small-for--age (sga) status.']
S3-PMC4973215	PMC4973215	8/2016	S3-PMC4973215	['results:\nblack race, medicaid status, mean body mass index at Delivery and lack of Prenatal vitamin use were ASSOCIATED with Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 109)]	1	[('GO_0007567', 'parturition', 62, 'delivery'), ('GO_0007565', 'female pregnancy', 83, 'prenatal'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]	0	['results:\nblack race, medicaid status, mass delivery  vitamin  deficiency.']
S7-PMC4973215	PMC4973215	8/2016	S7-PMC4973215	['conclusion:\nidentification of RISK FACTORS (black race, medicaid status, obesity and lack of Prenatal Vitamin use) CAN LEAD TO OPPORTUNITIES for targeted Prenatal Vitamin supplementation to reduce the risk of neonatal Vitamin D deficiency and sga status.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('INCOMPLETE_EVIDENCE', 115), ('PROBABLE_UNDERSTANDING', 119), ('FUTURE_WORK', 127)]	4	[('GO_0007565', 'female pregnancy', 93, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 102, 'vitamin'), ('GO_0007565', 'female pregnancy', 154, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 163, 'vitamin'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D')]	0	['conclusion:\nidentification (black race, medicaid status, obesity  vitamin use)  vitamin supplementation neonatal  sga status.']
S11-PMC4973215	PMC4973215	8/2016	S11-PMC4973215	['several large OBSERVATIONAL studies and meta-analyses have DESCRIBED the ASSOCIATION of maternal Vitamin D deficiency with Pregnancy COMPLICATIONS such as pre-eclampsia, Gestational diabetes and premature Birth.10,11,12,13racial DISPARITIES in maternal and neonatal Vitamin D deficiency HAVE BEEN DESCRIBED.1,14,15vitamin D deficiency is MORE COMMON and more SEVERE in black mothers.10,15,16,17,18,19racial DISPARITIES are also SEEN with Pregnancy COMPLICATIONS such as Preterm birth, pre-eclampsia and Gestational diabetes, as well as adverse neonatal outcomes including low Birth weight and small-for-Gestational-age (sga) status.15,17,20,21HOWEVER, the MAJORITY of studies EXAMINED maternal Vitamin D levels during the first and second Trimesters of Pregnancy7,8,22,23and CORRELATED these levels to neonatal outcomes.']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 73), ('PROBLEM_COMPLICATION', 133), ('IMPORTANT_CONSIDERATION', 229), ('INCOMPLETE_EVIDENCE', 287), ('INCOMPLETE_EVIDENCE', 297), ('PROBABLE_UNDERSTANDING', 338), ('IMPORTANT_CONSIDERATION', 359), ('IMPORTANT_CONSIDERATION', 407), ('INCOMPLETE_EVIDENCE', 428), ('PROBLEM_COMPLICATION', 448), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 643), ('PROBABLE_UNDERSTANDING', 656), ('INCOMPLETE_EVIDENCE', 676), ('SUPERFICIAL_RELATIONSHIP', 775)]	16	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy'), ('GO_0007565', 'female pregnancy', 170, 'gestational'), ('GO_0007567', 'parturition', 205, 'birth'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 322, 'D'), ('GO_0007565', 'female pregnancy', 438, 'pregnancy'), ('GO_0007565', 'female pregnancy', 470, 'preterm'), ('GO_0007565', 'female pregnancy', 503, 'gestational'), ('GO_0007567', 'parturition', 576, 'birth'), ('GO_0007565', 'female pregnancy', 603, 'gestational'), ('CHEBI_27300', 'vitamin D', 694, 'vitamin D'), ('GO_0043033', 'isoamylase complex', 739, 'trimesters'), ('GO_0007565', 'female pregnancy', 753, 'pregnancy7')]	0	['several meta-analyses maternal   pre-eclampsia,  diabetes premature birth.10,11,12,13racial maternal neonatal  described.1,14,15vitamin black mothers.10,15,16,17,18,19racial   birth, pre-eclampsia  diabetes, neonatal outcomes birth small-for--age (sga) status.15,17,20,21however, maternal  levels trimesters ,8,22,23and levels neonatal outcomes.']
S12-PMC4973215	PMC4973215	8/2016	S12-PMC4973215	['far FEWER STUDIES have EXAMINED the RELATIONSHIP between Cord Blood Vitamin D levels, which MAY more ACCURATELY REFLECT fetal levels of Vitamin D, and neonatal outcomes.14,24GIVEN the racial DISPARITIES SEEN in both Vitamin D deficiency and Perinatal outcomes, Vitamin D HAS BEEN PROPOSED as part of the EXPLANATION for this DISPARITY, PARTICULARLY with regard to fetal growth and sga.8\nINCREASED AWARENESS of the GROWING PREVALENCE of maternal Vitamin D deficiency has LED TO an URGENT NEED for CONSIDERATION of supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 36), ('INCOMPLETE_EVIDENCE', 92), ('PROBABLE_UNDERSTANDING', 101), ('SUPERFICIAL_RELATIONSHIP', 112), ('PROBABLE_UNDERSTANDING', 174), ('IMPORTANT_CONSIDERATION', 191), ('INCOMPLETE_EVIDENCE', 203), ('INCOMPLETE_EVIDENCE', 271), ('INCOMPLETE_EVIDENCE', 280), ('PROBABLE_UNDERSTANDING', 304), ('IMPORTANT_CONSIDERATION', 325), ('IMPORTANT_CONSIDERATION', 336), ('IMPORTANT_CONSIDERATION', 387), ('INCOMPLETE_EVIDENCE', 414), ('IMPORTANT_CONSIDERATION', 422), ('SUPERFICIAL_RELATIONSHIP', 470), ('IMPORTANT_CONSIDERATION', 480), ('FUTURE_WORK', 487), ('FUTURE_WORK', 496)]	21	[('UBERON_0002240', 'spinal cord', 57, 'cord'), ('UBERON_0000178', 'blood', 62, 'blood'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0036268', 'swimming', 241, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 241, 'perinatal'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 445, 'vitamin D'), ('GO_0007565', 'female pregnancy', 536, 'pregnancy')]	0	['far cord blood  levels, fetal levels neonatal outcomes.14,24given racial  perinatal outcomes,  disparity, regard fetal sga.8\nincreased maternal  supplementation .']
S14-PMC4973215	PMC4973215	8/2016	S14-PMC4973215	['THUS, sufficient EVIDENCE is LACKING at this time to RECOMMEND routine Vitamin D supplementation during Pregnancy.12HOWEVER, identification of specific RISK FACTORS for Vitamin D deficiency and the additive EFFECTS of these RISK FACTORS MAY LEAD TO OPPORTUNITIES for targeted supplementation with improved outcomes.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('FUTURE_WORK', 53), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116), ('SUPERFICIAL_RELATIONSHIP', 152), ('SUPERFICIAL_RELATIONSHIP', 207), ('SUPERFICIAL_RELATIONSHIP', 224), ('INCOMPLETE_EVIDENCE', 237), ('SUPERFICIAL_RELATIONSHIP', 241), ('FUTURE_WORK', 249)]	10	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]	0	['thus, routine  supplementation .12however,  supplementation outcomes.']
S17-PMC4973215	PMC4973215	8/2016	S17-PMC4973215	['our GOAL was TO IDENTIFY specific high-risk subsets of Pregnant women who MAY BENEFIT from Vitamin D supplementation IN ORDER TO mitigate adverse Perinatal outcomes such as sga.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 13), ('INCOMPLETE_EVIDENCE', 74), ('IMPORTANT_CONSIDERATION', 78), ('QUESTION_ANSWERED_BY_THIS_WORK', 117)]	5	[('GO_0007565', 'female pregnancy', 55, 'pregnant'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0036268', 'swimming', 146, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 146, 'perinatal')]	0	['subsets  women  supplementation mitigate perinatal outcomes sga.']
S29-PMC4973215	PMC4973215	8/2016	S29-PMC4973215	['to explore RELATIONSHIPS between race, Vitamin D levels and sga, we first EVALUATED race as a PREDICTOR of Vitamin D levels (sufficient or deficient) in cord Blood and ASSESSED for POTENTIAL CONFOUNDERS: medicaid status, bmi at Delivery, hypertension, maternal age and Prenatal Vitamin use.']	[('SUPERFICIAL_RELATIONSHIP', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 74), ('SUPERFICIAL_RELATIONSHIP', 94), ('QUESTION_ANSWERED_BY_THIS_WORK', 168), ('INCOMPLETE_EVIDENCE', 181), ('PROBLEM_COMPLICATION', 191)]	6	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0000178', 'blood', 158, 'blood'), ('GO_0007567', 'parturition', 228, 'delivery'), ('GO_0007565', 'female pregnancy', 269, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 278, 'vitamin')]	0	['race,  levels sga, race  levels (sufficient deficient) cord blood confounders: medicaid status, bmi delivery, hypertension, maternal age  vitamin use.']
S43-PMC4973215	PMC4973215	8/2016	S43-PMC4973215	['race, medicaid status, higher bmi at Delivery and lack of Prenatal vitamin use were all ASSOCIATED with Vitamin D deficiency (25(Oh)D <50\u2009nmol\u2009l−1; p<0.01).']	[('SUPERFICIAL_RELATIONSHIP', 88)]	1	[('GO_0007567', 'parturition', 37, 'delivery'), ('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 126, '25(OH)D')]	0	['race, medicaid status, higher bmi delivery  vitamin  (25(oh)d <50\u2009nmol\u2009l−1; p<0.01).']
S45-PMC4973215	PMC4973215	8/2016	S45-PMC4973215	['SIMILARLY, infants on medicaid, a MARKER of socioeconomic status, had higher odds of Vitamin D deficiency (odds ratio (or) 2.3, 95% ci: 1.4, 3.8), WHEREAS Prenatal Vitamin use SHOWED a PROTECTIVE EFFECT (or 0.24, 95% ci: 0.09, 0.62).']	[('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 34), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 147), ('INCOMPLETE_EVIDENCE', 176), ('SUPERFICIAL_RELATIONSHIP', 185), ('SUPERFICIAL_RELATIONSHIP', 196)]	6	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 164, 'vitamin')]	0	['similarly, infants medicaid, socioeconomic status, higher  (odds ratio (or) 2.3, 95% ci: 1.4, 3.8),  vitamin (or 0.24, 95% ci: 0.09, 0.62).']
S48-PMC4973215	PMC4973215	8/2016	S48-PMC4973215	['for instance, at a mean maternal bmi of 32.3\u2009kg\u2009m−2, an infant who is black, on medicaid and no Prenatal vitamin use has an 86% (95% ci: 82, 97) PROBABILITY of Vitamin D deficiency, WHEREAS a black infant who is not on medicaid and with Prenatal vitamin use has a 66% (95% ci: 44, 67) PROBABILITY of Vitamin D deficiency.']	[('PROBABLE_UNDERSTANDING', 145), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 182), ('PROBABLE_UNDERSTANDING', 285)]	3	[('GO_0007565', 'female pregnancy', 96, 'prenatal'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('GO_0007565', 'female pregnancy', 237, 'prenatal'), ('CHEBI_27300', 'vitamin D', 300, 'vitamin D')]	0	['instance, maternal bmi 32.3\u2009kg\u2009m−2, infant black, medicaid  vitamin 86% (95% ci: 82, 97)  deficiency, black infant medicaid  vitamin 66% (95% ci: 44, 67)  deficiency.']
S62-PMC4973215	PMC4973215	8/2016	S62-PMC4973215	['ALTHOUGH the prevalence of Vitamin D deficiency in black mothers and neonates is WELL KNOWN, DEBATE exists as to the RELATIONSHIP between race, Vitamin D deficiency and sga.12,14,15,17,18we EXAMINED this RELATIONSHIP in conjunction with additional maternal characteristics in order TO IDENTIFY groups of Pregnant women who could BENEFIT MOST from Vitamin D supplementation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 81), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 93), ('SUPERFICIAL_RELATIONSHIP', 117), ('QUESTION_ANSWERED_BY_THIS_WORK', 190), ('SUPERFICIAL_RELATIONSHIP', 204), ('QUESTION_ANSWERED_BY_THIS_WORK', 282), ('IMPORTANT_CONSIDERATION', 329), ('PROBABLE_UNDERSTANDING', 337)]	9	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 304, 'pregnant'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin D')]	0	['although  black mothers neonates known, race,  sga.12,14,15,17,18we maternal characteristics  women  supplementation.']
S70-PMC4973215	PMC4973215	8/2016	S70-PMC4973215	"['[""""for white mothers, measurement of maternal Serum 25(Oh)D at <22 weeks\' Gestation SHOWED a u-shaped RELATIONSHIP between Vitamin D status and risk of sga, where the highest risk for sga was SEEN with both low and high Vitamin D levels.""""]']"	[('INCOMPLETE_EVIDENCE', 81), ('SUPERFICIAL_RELATIONSHIP', 99), ('INCOMPLETE_EVIDENCE', 189)]	3	[('UBERON_0001977', 'blood serum', 43, 'serum'), ('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 49, '25(OH)D'), ('GO_0007565', 'female pregnancy', 71, 'gestation'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D')]	0	"['[""""for white mothers, maternal serum 25(oh)d <22 weekion u-shaped betwen status sga, sga hin levels.""""]']"
S78-PMC4973215	PMC4973215	8/2016	S78-PMC4973215	['furthermore, this study was CONDUCTED in hamilton county, ohio, an area with worse Perinatal outcomes THAN national averages, including higher infant mortality, Preterm Birth and low Birth weight rates, as well as CONSIDERABLE racial DISPARITIES in infant mortality and Perinatal outcomes.34all of Cord Blood samples were collected over one winter season, THUS negating seasonal variations in Vitamin D levels that MAY have been SEEN in OTHER STUDIES.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 28), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 102), ('IMPORTANT_CONSIDERATION', 214), ('IMPORTANT_CONSIDERATION', 234), ('PROBABLE_UNDERSTANDING', 356), ('INCOMPLETE_EVIDENCE', 415), ('INCOMPLETE_EVIDENCE', 429), ('INCOMPLETE_EVIDENCE', 437)]	8	[('GO_0036268', 'swimming', 83, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 83, 'perinatal'), ('GO_0007565', 'female pregnancy', 161, 'preterm birth'), ('GO_0007567', 'parturition', 183, 'birth'), ('GO_0036268', 'swimming', 270, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 270, 'perinatal'), ('UBERON_0002240', 'spinal cord', 298, 'cord'), ('UBERON_0000178', 'blood', 303, 'blood'), ('CHEBI_27300', 'vitamin D', 393, 'vitamin D')]	0	['furthermore, hamilton county, ohio, perinatal outcomes national averages, higher infant mortality,  birth rates, racial infant mortality perinatal outcomes.34all cord blood samples winter season, negating seasonal  levels studies.']
S79-PMC4973215	PMC4973215	8/2016	S79-PMC4973215	['finally, we ANALYZED Cord Blood Vitamin D levels at the time of Delivery, RATHER THAN maternal Serum Vitamin D levels during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 81)]	3	[('UBERON_0002240', 'spinal cord', 21, 'cord'), ('UBERON_0000178', 'blood', 26, 'blood'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007567', 'parturition', 64, 'delivery'), ('UBERON_0001977', 'blood serum', 95, 'serum'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy')]	0	['finally, cord blood  levels delivery, maternal serum  levels .']
S80-PMC4973215	PMC4973215	8/2016	S80-PMC4973215	['ALTHOUGH Cord Blood 25(Oh)D levels do CORRELATE to maternal levels, FACTORS that AFFECT fetal growth MAY not be uniform throughout Pregnancy and this DIFFERENCE in timing COULD AFFECT study FINDINGS.1,3,4,5,6in addition, maternal characteristics such as obesity or pre-eclampsia COULD also AFFECT results that MAY NOT HAVE BEEN SEEN IF Vitamin D samples were obtained during early Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 68), ('SUPERFICIAL_RELATIONSHIP', 81), ('INCOMPLETE_EVIDENCE', 101), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 150), ('INCOMPLETE_EVIDENCE', 171), ('SUPERFICIAL_RELATIONSHIP', 177), ('INCOMPLETE_EVIDENCE', 190), ('INCOMPLETE_EVIDENCE', 279), ('SUPERFICIAL_RELATIONSHIP', 290), ('INCOMPLETE_EVIDENCE', 310), ('INCOMPLETE_EVIDENCE', 314), ('INCOMPLETE_EVIDENCE', 318), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 333)]	15	[('UBERON_0002240', 'spinal cord', 9, 'cord'), ('UBERON_0000178', 'blood', 14, 'blood'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 22, '(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D'), ('GO_0007565', 'female pregnancy', 381, 'pregnancy')]	0	['although cord blood 25(oh)d levels maternal levels, fetal throughout  findings.1,3,4,5,6in addition, maternal characteristics obesity pre-eclampsia results  samples .']
S83-PMC4973215	PMC4973215	8/2016	S83-PMC4973215	['obesity is WELL KNOWN to be a RISK FACTOR for Vitamin D deficiency BECAUSE of a Sequestering Of Vitamin D in Adipose Tissue.35maternal obesity during Pregnancy HAS also BEEN ASSOCIATED with lower Vitamin D levels in neonates at Delivery.24,36,37,38our data are CONSISTENT and illustrate the inverse RELATIONSHIP between maternal bmi at Delivery and Vitamin D status after adjusting for confounding variables.']	[('INCOMPLETE_EVIDENCE', 11), ('SUPERFICIAL_RELATIONSHIP', 30), ('PROBABLE_UNDERSTANDING', 67), ('INCOMPLETE_EVIDENCE', 160), ('SUPERFICIAL_RELATIONSHIP', 174), ('INCOMPLETE_EVIDENCE', 261), ('SUPERFICIAL_RELATIONSHIP', 299)]	7	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0051208', 'sequestering of calcium ion', 80, 'sequestering of vitamin D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('UBERON_0001013', 'adipose tissue', 109, 'adipose tissue'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('GO_0007567', 'parturition', 228, 'delivery'), ('GO_0007567', 'parturition', 336, 'delivery'), ('CHEBI_27300', 'vitamin D', 349, 'vitamin D')]	0	['obesity  sequestering  adipose tissue.35maternal obesity   levels neonates delivery.24,36,37,38our maternal bmi delivery  status adjusting variables.']
S84-PMC4973215	PMC4973215	8/2016	S84-PMC4973215	['the increased odds of Vitamin D deficiency in neonates relative to maternal bmi level were SEEN in both blacks and whites in our study population and SUPPORTS SIMILAR FINDINGS SEEN in a study done by bodnar et al.38ALTHOUGH Prenatal Vitamin use was not significantly different between blacks and whites in our study, Prenatal Vitamin use was significant among those with and without Vitamin D deficiency.']	[('INCOMPLETE_EVIDENCE', 91), ('INCOMPLETE_EVIDENCE', 150), ('INCOMPLETE_EVIDENCE', 159), ('INCOMPLETE_EVIDENCE', 176), ('ANOMALY_CURIOUS_FINDING', 215)]	5	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 224, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 233, 'vitamin'), ('GO_0007565', 'female pregnancy', 317, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 326, 'vitamin'), ('CHEBI_27300', 'vitamin D', 383, 'vitamin D')]	0	[' neonates relative maternal bmi blacks whites population done bodnar et al.38although  vitamin blacks whites study,  vitamin among  deficiency.']
S86-PMC4973215	PMC4973215	8/2016	S86-PMC4973215	[',39who FOUND that lack of Prenatal vitamin use was ASSOCIATED with Vitamin D deficiency in white BUT NOT black women.']	[('INCOMPLETE_EVIDENCE', 7), ('SUPERFICIAL_RELATIONSHIP', 51), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 97)]	3	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]	0	[',39who  vitamin  white black women.']
S88-PMC4973215	PMC4973215	8/2016	S88-PMC4973215	['black mothers on medicaid who were obese and did not take Prenatal Vitamins had the highest PROBABILITY of having an infant with Vitamin D deficiency.']	[('PROBABLE_UNDERSTANDING', 92)]	1	[('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 67, 'vitamins'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]	0	['black mothers medicaid obese  vitamins infant  deficiency.']
S94-PMC4973215	PMC4973215	8/2016	S94-PMC4973215	['Vitamin D supplementation during Pregnancy HAS BEEN SHOWN to positively AFFECT Cord Blood Vitamin D levels at Birth.43,44studies of Vitamin D supplementation during Pregnancy THUS FAR HAVE SHOWN CONFLICTING results with respect to Birth weight and reduction of sga.43,45,46,47,48adequately powered and randomized controlled trials of vitamin d supplementation during Pregnancy ARE NEEDED TO ASSESS the IMPACT of supplementation on sga as well as the APPROPRIATE dose and timing of supplementation.']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 72), ('INCOMPLETE_EVIDENCE', 175), ('INCOMPLETE_EVIDENCE', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 195), ('FUTURE_WORK', 377), ('FUTURE_WORK', 388), ('SUPERFICIAL_RELATIONSHIP', 402), ('IMPORTANT_CONSIDERATION', 450)]	9	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 79, 'cord'), ('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007567', 'parturition', 110, 'birth'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('GO_0007565', 'female pregnancy', 165, 'pregnancy'), ('GO_0007567', 'parturition', 231, 'birth'), ('GO_0007565', 'female pregnancy', 367, 'pregnancy')]	0	['vitamin supplementation  positively cord blood  levels birth.43,44studies  supplementation  results respect birth reduction sga.43,45,46,47,48adequately powered vitamin supplementation  supplementation sga dose timing supplementation.']
S96-PMC4973215	PMC4973215	8/2016	S96-PMC4973215	['if Vitamin D supplementation does not occur during Pregnancy, it MAY BE IMPERATIVE to identify and offer additional supplementation beyond the routinely recommended 400\u2009iu per day for all infants.28\nthere were several LIMITATIONS to our study.']	[('FUTURE_WORK', 65), ('IMPORTANT_CONSIDERATION', 72), ('INCOMPLETE_EVIDENCE', 218)]	3	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy')]	0	[' supplementation occur supplementation routinely 400\u2009iu day infants.28\nthere study.']
S99-PMC4973215	PMC4973215	8/2016	S99-PMC4973215	['corresponding maternal Vitamin D status at different Gestations during Pregnancy was UNKNOWN.']	[('FULL_UNKNOWN', 85)]	1	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 53, 'gestations'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy')]	0	['corresponding maternal  status   unknown.']
S102-PMC4973215	PMC4973215	8/2016	S102-PMC4973215	['conclusion\nblack obese mothers on medicaid without Prenatal vitamin use were at the HIGHEST RISK of Delivering neonates with Vitamin D deficiency.']	[('IMPORTANT_CONSIDERATION', 84)]	1	[('GO_0007565', 'female pregnancy', 51, 'prenatal'), ('GO_0006900', 'vesicle budding from membrane', 100, 'delivering'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]	0	['conclusion\nblack obese mothers medicaid  vitamin delivering neonates  deficiency.']
S105-PMC4973215	PMC4973215	8/2016	S105-PMC4973215	['a GREATER UNDERSTANDING of the variables that INFLUENCE Vitamin D status during Pregnancy CAN have an immense PUBLIC HEALTH IMPACT in the reduction of adverse Perinatal outcomes such as sga.']	[('IMPORTANT_CONSIDERATION', 2), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 90), ('IMPORTANT_CONSIDERATION', 110), ('SUPERFICIAL_RELATIONSHIP', 124)]	5	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0036268', 'swimming', 159, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 159, 'perinatal')]	0	[' status  reduction perinatal outcomes sga.']
S77-PMC4976416	PMC4976416	7/2016	S77-PMC4976416	['[58]\n\nvitamin e intake during pregnancy and childhood\nVitamin E supplements in Pregnancy USUALLY contain only small doses of Vitamin E, ALTHOUGH adverse EFFECTS have not been OBSERVED EVEN at higher doses.']	[('INCOMPLETE_EVIDENCE', 89), ('ANOMALY_CURIOUS_FINDING', 136), ('SUPERFICIAL_RELATIONSHIP', 153), ('INCOMPLETE_EVIDENCE', 175), ('ANOMALY_CURIOUS_FINDING', 184)]	5	[('CHEBI_28384', 'vitamin K', 54, 'Vitamin E'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin E')]	0	['[58]\n\nvitamin e intake pregnancy childhood\nvitamin e supplements  contain doses higher doses.']
S0-PMC4979151	PMC4979151	8/2016	S0-PMC4979151	['Prenatal high-dose Vitamin D3Supplementation has balanced EFFECTS on Cord Blood th1 and th2 Responses\n\nabstract\n\nbackground\nantenatal Vitamin D3(vitd3) supplementation significantly increases maternal and neonatal 25-Hydroxyvitamin D3(25(Oh)D3) concentration, YET the EFFECT of an improvement in maternal-fetal Vitamin D status on the neonatal immune response is UNCLEAR.']	[('SUPERFICIAL_RELATIONSHIP', 58), ('ANOMALY_CURIOUS_FINDING', 260), ('SUPERFICIAL_RELATIONSHIP', 268), ('FULL_UNKNOWN', 363)]	4	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_52915', 'phosphatediyl group', 19, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 19, 'vitamin D3supplementation'), ('UBERON_0002240', 'spinal cord', 69, 'cord'), ('UBERON_0000178', 'blood', 74, 'blood'), ('GO_0060033', 'anatomical structure regression', 92, 'responses'), ('CHEBI_33279', 'vitamin D5', 134, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 134, 'vitamin D3'), ('CHEBI_63991', '15-epi-lipoxin B4', 214, '25-hydroxyvitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 232, 'D3'), ('CHEBI_62946', 'ammonium sulfate', 235, '25(OH)D3'), ('PR_000001177', 'D(2) dopamine receptor', 241, 'D3'), ('CHEBI_27300', 'vitamin D', 311, 'vitamin D')]	0	[' high-dose vitamin d3supplementation cord blood th1 th2 responses\n\nabstract\n\nbackground\nantenatal vitamin d3(vitd3) supplementation maternal neonatal 25-hydroxyvitamin d3(25(oh)d3) concentration, maternal-fetal  status neonatal immune response unclear.']
S6-PMC4979151	PMC4979151	8/2016	S6-PMC4979151	['HOWEVER, Pha stimulation significantly induced the Expression of Genes encoding th1 and th2 cytokines and down-regulated a number of Genes INVOLVED in T-Cell Development, Proliferation and Differentiation Of B Cells, signal transduction pathway, transcriptional Regulation and pattern recognition receptors (prrs) in the Vitamin D group (vitd group).']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 139)]	2	[('CHEBI_34926', 'Pitrazepin', 9, 'PHA'), ('GO_0010467', 'gene expression', 51, 'expression'), ('SO_0000704', 'gene', 65, 'genes'), ('SO_0000704', 'gene', 133, 'genes'), ('CL_0000084', 'T cell', 151, 'T-cell'), ('GO_0002296', 'T-helper 1 cell lineage commitment', 151, 'T-cell development'), ('GO_0007565', 'female pregnancy', 171, 'proliferation ...'), ('GO_0030154', 'cell differentiation', 189, 'differentiation of B cells'), ('CL_0000236', 'B cell', 208, 'B cells'), ('GO_0065007', 'biological regulation', 262, 'regulation'), ('CHEBI_27300', 'vitamin D', 321, 'vitamin D')]	0	['however, pha stimulation induced expression genes encoding th1 th2 cytokines down-regulated genes t-cell development,  b cells, signal transduction pathway, transcriptional receptors (prrs)  (vitd group).']
S10-PMC4979151	PMC4979151	8/2016	S10-PMC4979151	['introduction\nthe IMPORTANCE of adequate Vitamin D status during Pregnancy HAS BEEN SUGGESTED by OBSERVATIONAL studies DEMONSTRATING ASSOCIATIONS between low 25(Oh)D3And adverse Birth outcomes, childhood infections, and atopy [1,2].']	[('IMPORTANT_CONSIDERATION', 17), ('INCOMPLETE_EVIDENCE', 74), ('INCOMPLETE_EVIDENCE', 83), ('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 118), ('SUPERFICIAL_RELATIONSHIP', 132)]	6	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('CHEBI_76945', 'manool', 157, '25(OH)D3and'), ('PR_000036846', 'class II olfactory receptor', 157, '25(OH)D3and'), ('GO_0007567', 'parturition', 177, 'birth')]	0	['introduction\nthe  status  25(oh)d3and birth outcomes, childhood infections, atopy [1,2].']
S12-PMC4979151	PMC4979151	8/2016	S12-PMC4979151	['IN CONTRAST, no association [6,7] or negative EFFECTS of high Vitamin D intake in Pregnancy on the RISK of eczema, asthma and wheezing in the offspring HAVE also BEEN SHOWN [8].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 46), ('IMPORTANT_CONSIDERATION', 99), ('INCOMPLETE_EVIDENCE', 152)]	4	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]	0	['contrast, [6,7]  intake  eczema, asthma wheezing offspring [8].']
S13-PMC4979151	PMC4979151	8/2016	S13-PMC4979151	['there is NO CONSENSUS on the cutoff value for Vitamin D deficiency and the optimum dosage for supplementation during Pregnancy REMAINS CONTROVERSIAL.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('INCOMPLETE_EVIDENCE', 127), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135)]	3	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy')]	0	['cutoff  dosage supplementation  controversial.']
S15-PMC4979151	PMC4979151	8/2016	S15-PMC4979151	['maternal Vitamin D status during Pregnancy MAY AFFECT the fetal Immune System and CONTRIBUTE to the risk of development of Immune-mediated diseases and infection in the offspring.']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 47), ('SUPERFICIAL_RELATIONSHIP', 82)]	3	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('UBERON_0002405', 'immune system', 64, 'immune system'), ('UBERON_0002405', 'immune system', 123, 'immune')]	0	['maternal  status  fetal immune system immune-mediated diseases infection offspring.']
S114-PMC4979151	PMC4979151	8/2016	S114-PMC4979151	['discussion\nwe PREVIOUSLY SHOWED that supplementation with vitd3during the 3rd trimester of Pregnancy improved maternal and Cord Blood Vitamin D status [18] and reduction of antibacterial peptide ll-37 in Monocytes [20].']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 25)]	2	[('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 123, 'cord'), ('UBERON_0000178', 'blood', 128, 'blood'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('CL_0000576', 'monocyte', 204, 'monocytes')]	0	['discussion\nwe supplementation vitd3during 3rd trimester  maternal cord blood  status [18] reduction antibacterial peptide ll-37 monocytes [20].']
S117-PMC4979151	PMC4979151	8/2016	S117-PMC4979151	['there is a SCARCITY of in vivo data in Humans during Pregnancy SHOWING EFFECTS of Vitamin D supplementation on neonatal Immune function.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 63), ('SUPERFICIAL_RELATIONSHIP', 71)]	3	[('NCBITaxon_9606', 'Homo sapiens', 39, 'humans'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0002405', 'immune system', 120, 'immune')]	0	['vivo humans   supplementation neonatal immune function.']
S69-PMC4982007	PMC4982007	8/2016	S69-PMC4982007	['n \u2009=\u20095832: age 4\xa0years \u2003n \u2009=\u20095191; age 8\xa0years \u2003n \u2009=\u20097339; age 16\xa0yearsmaternal Gestational weight gain (kg)3 categories of weight gain1: less than recommended2: as recommended3: more than recommendedpre-Pregnancy weight (kg)school entry assessment score-4\xa0yearsiq- wechsler intelligence scale for children -iii-8\xa0yearsadequate final exam results-16\xa0yearschildren of women gained weight\u2009<\u2009expected-↓ school entry assessment score (-0.075 sd) and adequate final-exam results (or\u2009=\u20090.88); ↑weight gain - early and mid Pregnancy -↑school entry assessment score (0.072 and 0.077 sd)↑ weight gain in all three periods of Pregnancy-↑ iq at 8\xa0years (0.070 to 0.078 sd) and ↑pre-Pregnancy weight-↓ school entry assessment score (-0.004 sd/kg), iq (-0.004 sd) and the odds (or\u2009=\u20090.99) of achieving adequate final exam resultsconfounders adjusted for: the child’s sex, current age, ma; me, parity, pre-Pregnancy bmi, smoking and mode of Delivery16 medium\nbmi body mass index, qs quality score, rb risk of bias, ga Gestational age, ma maternal age, bwt Birthweight, ses socio-economic status, me maternal education, pe paternal education, miq maternal intelligence, he home environment, ms maternal smoking, bf breast-feeding, dm maternal diabetes, pih Pregnancy induced hypertension\n\ncaption (table-wrap): table 3\n\nsummary of the studies examining ASSOCIATIONS of maternal Vitamin D status with offspring Cognitive functionauthor, year, sample size, age, country, study designnutrientcognitive functionresults after adjustment for confoundersqs and rb20gale c; 2008 \u2003n \u2009=\u2009178\u2003age 9\xa0years\u2003uk\u2003prospective longitudinalserum Vitamin D concentrations assessed at 28-42 weeks Gestation21.2\xa0% had <27.5\xa0nmol/l28.3\xa0% had 27.5-50\xa0nmol/lwechsler abbreviated scale of intelligencefull-scale, verbal or performance iqno association between Vitamin D concentrations and offspring iq (full-scale, verbal or performance)confounders adjusted for: unadjusted16 medium21whitehouse ajo; 2012\u2003age 5\xa0years ( n \u2009=\u2009534)\u2003age 10\xa0years ( n \u2009=\u2009474)\u2003australia\u2003prospective longitudinalserum Vitamin D concentrations assessed at 18\xa0weeks Gestation25.2\xa0% mothers had insufficiency (≤46\xa0nmol/l)(lowest quartile)peabody picture vocabulary test Receptive Languagechildren of mothers with Vitamin D insufficiency (lowest quartile (≤46\xa0nmol/l) were at INCREASED RISK (or\u2009=\u20091.97) of Language impairment compared to children of mothers without insufficiency (highest quartile (≥72\xa0nmol/l; or\u2009=\u20091.00)confounders adjusted for: ma, ms, parity, family income, season of maternal Blood sampling13 medium22morales\xa0e; 2012 \u2003n \u2009=\u20091820\u2003age 11-23 months\u2003spain\u2003prospective population based\u2003cohort studyplasma Vitamin D concentrations assessed during 12-23 weeks Gestation19.5\xa0% mothers had deficiency (<20\xa0ng/ml)31.5\xa0% had insufficiency (20-30\xa0ng/ml)bayley scales of infant development (mental (mdi) and psychomotor (pdi) developmental score)a positive linear ASSOCIATION between Vitamin D concentrations and mdi and pdiper 10\xa0ng/ml increase in Vitamin D concentrations mdi and pdi score increased by β\u2009=\u20090.79 and β\u2009=\u20090.88 points respectivelycompared to infants of deficient mothers, infants of mothers with normal level scored higher mdi (β\u2009=\u20092.60) and pdi (β\u2009=\u20092.32) points respectivelyconfounders adjusted for: the child’s sex, bwt, area of study, maternal country of origin, ma, parity, Pre-Pregnancy bmi, ses, me, ms, Alcohol and season15 medium\nqs quality score, rb risk of bias, ma maternal age, bwt Birthweight, me Maternal education, ms maternal smoking, bmi body mass index, ses socio-economic status\n\ncaption (table-wrap): table 4\n\nsummary of the studies examining ASSOCIATIONS of maternal Folate status with offspring Cognitive functionauthor, year, sample size, age, country, study designnutrientcognitive functionresults after adjustment for confoundersqs and rb23wu btf; 2012 \u2003n \u2009=\u2009154\u2003age 18 months\u2003canada\u2003prospectiveplasma Folate and thcy concentrations assessed at 16 and 36\xa0weeks Gestationno Folate deficiency (plasma Folate <6.8\xa0nmol/l)high thcy not reportedbayley scales of infant developmentreceptive language, expressive language, Cognitive skills, fine motor and gross motorno ASSOCIATION of Folate and thcy with Cognitive functionconfounders adjusted for: the child’s sex, bf, ethnicity, ma, miq, maternal Fatty Acid level13 medium24tamura t; 2005 \u2003n \u2009=\u2009355\u2003age 5\xa0years\u2003usa\u2003prospective\u2003mothers participated in zinc supplementation trial during Pregnancyred cell and Plasma Folate concentrations – 19, 26 and 37\xa0weeks Gestation and thcy concentrations-26 and 37\xa0weekslow Folate-(Plasma Folate <11\xa0nmol/l)19\xa0weeks- 7.4\xa0%; 26\xa0weeks- 8.2\xa0%; 37\xa0weeks- 14.0\xa0%Red Cell Folate <430\xa0nmol/l)19\xa0weeks- 7.2\xa0%; 26\xa0weeks- 3.8\xa0%; 37\xa0weeks- 3.3\xa0%high thcy (thcy\u2009>\u20097\xa0μmol/l)26\xa0weeks- 8.4\xa0%; 37\xa0weeks- 22.1\xa0%differential ability scale (verbal, nonverbal and general iq), Visual and Auditory sequential Memory (Visual and Auditory Memory span)knox cube (attention span and Short-Term Memory)gross motor scale (gross Motor Development and grooved pegboard (manipulative dexterity)no difference in the mental and psychomotor developmental scores between children of mothers with normal and deficient Folate and thcy groups.']	[('SUPERFICIAL_RELATIONSHIP', 1338), ('IMPORTANT_CONSIDERATION', 2306), ('SUPERFICIAL_RELATIONSHIP', 2901), ('SUPERFICIAL_RELATIONSHIP', 3617), ('SUPERFICIAL_RELATIONSHIP', 4142)]	5	[('GO_0007565', 'female pregnancy', 80, 'gestational'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('GO_0007565', 'female pregnancy', 516, 'pregnancy'), ('GO_0007565', 'female pregnancy', 616, 'pregnancy'), ('GO_0007565', 'female pregnancy', 671, 'pregnancy'), ('GO_0007565', 'female pregnancy', 892, 'pregnancy'), ('GO_0007567', 'parturition', 927, 'delivery16'), ('GO_0007565', 'female pregnancy', 1004, 'gestational'), ('GO_0007596', 'blood coagulation', 1042, 'birthweight'), ('GO_0007565', 'female pregnancy', 1242, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1363, 'vitamin D'), ('GO_0050890', 'cognition', 1395, 'cognitive'), ('CHEBI_27300', 'vitamin D', 1611, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1660, 'gestation21'), ('CHEBI_27300', 'vitamin D', 1818, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2052, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2098, 'gestation25'), ('GO_0000724', 'double-strand break repair via homologous recombination', 2201, 'Receptive languageChildren'), ('CHEBI_27300', 'vitamin D', 2244, 'vitamin D'), ('GO_0006266', 'DNA ligation', 2336, 'language'), ('UBERON_0000178', 'blood', 2527, 'blood'), ('CHEBI_27300', 'vitamin D', 2650, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2703, 'gestation19'), ('CHEBI_27300', 'vitamin D', 2921, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2986, 'vitamin D'), ('GO_0007568', 'aging', 3332, 'pre'), ('GO_0007565', 'female pregnancy', 3336, 'pregnancy'), ('CHEBI_30879', 'alcohol', 3364, 'alcohol'), ('GO_0007596', 'blood coagulation', 3448, 'birthweight'), ('GO_0007618', 'mating', 3464, 'maternal'), ('CHEBI_30863', '5-azaorotic acid', 3642, 'folate'), ('GO_0050890', 'cognition', 3671, 'cognitive'), ('CHEBI_30863', '5-azaorotic acid', 3881, 'folate'), ('GO_0007565', 'female pregnancy', 3940, 'gestationNo'), ('CHEBI_30863', '5-azaorotic acid', 3952, 'folate'), ('CHEBI_30863', '5-azaorotic acid', 3978, 'folate'), ('GO_0050890', 'cognition', 4095, 'cognitive'), ('CHEBI_30863', '5-azaorotic acid', 4157, 'folate'), ('GO_0050890', 'cognition', 4178, 'cognitive'), ('CHEBI_35366', 'fatty acid', 4272, 'fatty acid'), ('GO_0007605', 'sensory perception of sound', 4410, 'pregnancyRed'), ('UBERON_0001969', 'blood plasma', 4432, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 4439, 'folate'), ('GO_0007565', 'female pregnancy', 4483, 'gestation'), ('CHEBI_30863', '5-azaorotic acid', 4536, 'folate'), ('UBERON_0001969', 'blood plasma', 4544, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 4551, 'folate'), ('CL_0000232', 'erythrocyte', 4619, 'Red cell'), ('CHEBI_30863', '5-azaorotic acid', 4628, 'folate'), ('GO_0007601', 'visual perception', 4819, 'Visual'), ('GO_0006754', 'ATP biosynthetic process', 4830, 'Auditory ...'), ('GO_0007613', 'memory', 4850, 'Memory'), ('GO_0007601', 'visual perception', 4858, 'visual'), ('GO_0007605', 'sensory perception of sound', 4869, 'auditory'), ('GO_0007613', 'memory', 4878, 'memory'), ('GO_0007608', 'sensory perception of smell', 4920, 'short-term memory'), ('GO_0009653', 'anatomical structure morphogenesis', 4963, 'motor development'), ('CHEBI_30863', '5-azaorotic acid', 5145, 'folate')]	0	['n \u2009=\u20095832: age 4\xa0years \u2003n \u2009=\u20095191; age 8\xa0years \u2003n \u2009=\u20097339; age 16\xa0yearsmaternal  gain (kg)3 categories gain1: recommended2: recommended3: recommendedpre- (kg)school score-4\xa0yearsiq- wechsler intelligence children -iii-8\xa0yearsadequate final exam results-16\xa0yearschildren women gained weight\u2009<\u2009expected-↓ school score (-0.075 sd) final-exam results (or\u2009=\u20090.88); ↑weight gain mid  -↑school score (0.072 0.077 sd)↑ gain three periods -↑ iq 8\xa0years (0.070 0.078 sd) ↑pre- weight-↓ school score (-0.004 sd/kg), iq (-0.004 sd) (or\u2009=\u20090.99) achieving final exam resultsconfounders adjusted for: child’s sex, age, ma; me, parity, pre- bmi, smoking mode delivery16 medium\nbmi mass index, qs score, rb bias, ga  age, maternal age, bwt birthweight, ses socio-economic status, maternal education, pe paternal education, miq maternal intelligence, home environment, ms maternal smoking, bf breast-feeding, dm maternal diabetes, pih  induced hypertension\n\ncaption (table-wrap): table 3\n\nsummary maternal  status offspring cognitive functionauthor, year, sample size, designnutrientcognitive functionresults adjustment confoundersqs rb20gale c; 2008 \u2003n \u2009=\u2009178\u2003age 9\xa0years\u2003uk\u2003prospective longitudinalserum  concentrations 28-42 weeks .2\xa0% <27.5\xa0nmol/l28.3\xa0% 27.5-50\xa0nmol/lwechsler abbreviated intelligencefull-scale, verbal performance iqno  concentrations offspring iq (full-scale, verbal performance)confounders adjusted for: unadjusted16 medium21whitehouse ajo; 2012\u2003age 5\xa0years n \u2009=\u2009534)\u2003age 10\xa0years n \u2009=\u2009474)\u2003australia\u2003prospective longitudinalserum  concentrations 18\xa0weeks .2\xa0% mothers (≤46\xa0nmol/l)(lowest quartile)peabody picture vocabulary receptive languagechildren mothers  (lowest quartile (≤46\xa0nmol/l) (or\u2009=\u20091.97) language impairment children mothers (highest quartile (≥72\xa0nmol/l; or\u2009=\u20091.00)confounders adjusted for: ma, ms, parity, family income, season maternal blood sampling13 medium22morales\xa0e; 2012 \u2003n \u2009=\u20091820\u2003age 11-23 months\u2003spain\u2003prospective population based\u2003cohort studyplasma  concentrations 12-23 weeks .5\xa0% mothers (<20\xa0ng/ml)31.5\xa0% (20-30\xa0ng/ml)bayley scales infant (mental (mdi) psychomotor (pdi) developmental score)a positive linear  concentrations mdi pdiper 10\xa0ng/ml increase  concentrations mdi pdi score β\u2009=\u20090.79 β\u2009=\u20090.88 respectivelycompared infants mothers, infants mothers normal scored higher mdi (β\u2009=\u20092.60) pdi (β\u2009=\u20092.32) respectivelyconfounders adjusted for: child’s sex, bwt, study, maternal country origin, ma, parity, pre- bmi, ses, me, ms, alcohol season15 medium\nqs score, rb bias, maternal age, bwt birthweight, maternal education, ms maternal smoking, bmi mass index, ses socio-economic status\n\ncaption (table-wrap): table 4\n\nsummary maternal folate status offspring cognitive functionauthor, year, sample size, designnutrientcognitive functionresults adjustment confoundersqs rb23wu btf; 2012 \u2003n \u2009=\u2009154\u2003age 18 months\u2003canada\u2003prospectiveplasma folate thcy concentrations 16 36\xa0weeks  folate (plasma folate <6.8\xa0nmol/l)high thcy reportedbayley scales infant developmentreceptive language, expressive language, cognitive skills, fine motor motorno folate thcy cognitive functionconfounders adjusted for: child’s sex, bf, ethnicity, ma, miq, maternal fatty acid level13 medium24tamura t; 2005 \u2003n \u2009=\u2009355\u2003age 5\xa0years\u2003usa\u2003prospective\u2003mothers participated zinc supplementation pregnancyred cell plasma folate concentrations 19, 26 37\xa0weeks  thcy concentrations-26 37\xa0weekslow folate-(plasma folate <11\xa0nmol/l)19\xa0weeks- 7.4\xa0%; 26\xa0weeks- 8.2\xa0%; 37\xa0weeks- 14.0\xa0%red cell folate <430\xa0nmol/l)19\xa0weeks- 7.2\xa0%; 26\xa0weeks- 3.8\xa0%; 37\xa0weeks- 3.3\xa0%high thcy (thcy\u2009>\u20097\xa0μmol/l)26\xa0weeks- 8.4\xa0%; 37\xa0weeks- 22.1\xa0%differential ability (verbal, nonverbal iq), visual auditory sequential memory (visual auditory memory span)knox cube (attention span short-term memory)gross motor (gross motor grooved pegboard (manipulative dexterity)no mental psychomotor developmental scores children mothers normal folate thcy groups.']
S75-PMC4982007	PMC4982007	8/2016	S75-PMC4982007	['m; 2010 \u2003n \u2009=\u20099983 14\xa0years \u2003n \u2009=\u200910474 16\xa0years\u2003finland\u2003prospective Birth cohort studyhb concentrations at 3rd 7th and 9th Gestational monthsanaemiaschool performance14\xa0years- self report16\xa0years- school report↑maternal hb at 9\xa0months-↑ total school performance score (β\u2009=\u20090.03) and theory score at 14\xa0years and total score at 16\xa0years offspring of mothers with anaemia –low school scores (or\u2009=\u2009-0.05 at 14\xa0years and (or\u2009=\u2009-0.06) at 16\xa0yearsconfounders adjusted for: the child’s sex, bwt, Pregnancy wanted or not, me, social class, parity, marital status, ms, maternal mental health status18 low40davidson pw; 2008 \u2003n \u2009=\u2009229\u2003age 5, 9, 25and 30\xa0months\u2003republic of seychelles\u2003longitudinal cohort studyiron- total body stores at 14-24 weeks of Gestation assessed before the start of iron supplementationbayley scales of infant development: mental development index (mdi) and psychomotor development index (pdi) (9 and 30\xa0months)infant Cognition (fagan infantest-novelty preference) and Visual expectation paradigm –Visual recognition Memory (9 and 25\xa0months)a-not-b and delayed spatial alternation: inhibition, Working Memory, Planning and attention (25\xa0months)no association between maternal iron stores and Cognitive function at any age.confounders adjusted for: the child’s sex, bwt, ma, ses, he, miq and both parents living with the child (yes/no)19 low41lewis sj; 2013 \u2003n \u2009=\u2009~3,500\u2003age 8\xa0years\u2003uk\u2003population based prospective birth cohorthb concentrationsbefore 18\xa0weekshb <11.0\xa0g/dl -8\xa0%after 28\xa0weekshb <11.0\xa0g/dl -30\xa0%wechsler intelligence scale for children-iii- full- scale iqno ASSOCIATION between maternal hb and child’s iqconfounders adjusted for: ga, me, the child’s genotype, Iron supplementation, population stratification15 medium42tran td; 2013 \u2003n \u2009=\u2009378\u2003age 6\xa0months\u2003vietnam\u2003population based prospective cohort studyiron deficiency anaemia (hb <11.0\xa0g/dl and Serum ferritin <15\xa0ng/ml) during 12-28 weeks of Gestation-16\xa0%bayley scales of infant and toddler development-iii edition-Cognitive scoreinfants of anaemic mothers scored 11.6 points (0.77sd) lower in bsid Cognitive scores compared to infants of non-anaemic mothers.confounders adjusted for: parity, ma, me, wealth index, the child’s Birth and current weight, family support, bf.18 low43zhou sj; 2006 \u2003n \u2009=\u2009302\u2003age 4\xa0years; australia\u2003double blind randomized controlled trialiron Supplements (20\xa0mg/day) or placebo from 20\xa0weeks Gestation until deliverycompliance-86\xa0%stanford binet intelligence scale – iq (Verbal Reasoning, Visual Reasoning, Quantitative Reasoning and Short-Term Memory)no difference between the children of supplement group and placebo group in the mean score of composite iq or any subscales iq or in the proportion of children whose iq fell 1 or 2 sd below the mean.confounders adjusted for: sex, Birth order, Gestational age, ma, me, pe, he, bf20 low44li q; 2009 \u2003n \u2009=\u20091305\u2003age 3, 6 and 12\xa0months\u2003double blind cluster randomized controlled trial\u2003china3 intervention groups (all received Folic Acid)Folic Acid alone400\xa0μg ( n \u2009=\u2009471)-controliron 60\xa0mg\u2009+\u2009Folic Acid400\xa0μg ( n \u2009=\u2009438)multiple Micronutrients ((b Vitamins (1,2,3 6 and 12), Vitamin A, d, c, e and minerals (zinc, Iodine, copper, Selenium)\u2009+\u2009iron 30\xa0mg\u2009+\u2009400\xa0μg Folic Acid)) ( n \u2009=\u2009396)daily supplementation from enrolment until Delivery; inadequate information about compliancebayley scales of Infant Development :mental (md) and Psychomotor Development (pd)no significant difference in infants md and pd score at 3 and 6\xa0months and pd score at 12\xa0months between Supplement groupsmean md score among children of multiple Micronutrient group increased by 1 to 1.22 points COMPARED to children of Folic Acid alone, or Folic Acid\u2009+\u2009Iron group at 12\xa0monthsconfounders adjusted for: infants age, sex, Gestational age, apgar score, bwt, infant health, maternal age and bmi, parental education, occupation, ses, number of tablets consumed19 low\nqs quality score , rb risk of bias , hb haemoglobin , ga Gestational age , ma maternal age , bwt birthweight , ses socio-economic status , me maternal education , pe paternal education , miq maternal intelligence , he home environment , ms maternal smoking , bf breast-feeding , bmi body mass index\n\ncaption (table-wrap): table 7\n\nsummary of the studies examining ASSOCIATIONS of maternal Carbohydrate/protein with offspring Cognitive functionauthor, year, sample size, age, country, study designnutrientcognitive functionresults after adjustment for confoundersqs and rb45alderman h; 2014 \u2003n \u2009=\u20096774\u2003age 16-22 years\u2003double blind cluster randomized controlled trial\u2003gambiacarbohydrate/protein supplementsintervention group:2 biscuits daily (1015\xa0kcal Carbohydrate and 22\xa0g protein) from 20\xa0weeks of Gestation to Deliverycontrol group: same Supplements for 20\xa0weeks during Postpartum but not during Pregnancyno information about complianceraven’s progressive matrices- nonverbal reasoning abilitythe mill hill vocabulary testthe backward and forward digit-span testschooling achievement (questionnaire)no difference in any of the Cognitive test scores or schooling achievement between children whose mothers received thesupplements during Pregnancy and children whose mothers received Supplements during Postpartum.confounders adjusted for: the child’s sex, age, ga, me, pe, maternal height, parity, season of Birth, language and village allocation19 low\nqs quality score, rb risk of bias, ga Gestational age, me Maternal education, pe paternal education\n\nmaternal anthropometry (table\xa02)\nall were observational studies and from developed countries [8–19].']	[('SUPERFICIAL_RELATIONSHIP', 1587), ('ANOMALY_CURIOUS_FINDING', 3631), ('SUPERFICIAL_RELATIONSHIP', 4262)]	3	[('GO_0007567', 'parturition', 69, 'Birth'), ('GO_0007565', 'female pregnancy', 124, 'gestational'), ('GO_0007565', 'female pregnancy', 490, 'pregnancy'), ('GO_0007565', 'female pregnancy', 742, 'gestation'), ('GO_0050890', 'cognition', 933, 'cognition'), ('GO_0007601', 'visual perception', 984, 'Visual'), ('GO_0007601', 'visual perception', 1013, 'visual ...'), ('GO_0007613', 'memory', 1032, 'memory'), ('GO_0007631', 'feeding behavior', 1109, 'working memory'), ('GO_0006260', 'DNA replication', 1125, 'planning'), ('GO_0050890', 'cognition', 1207, 'cognitive'), ('CHEBI_24870', 'ion', 1689, 'iron'), ('UBERON_0001977', 'blood serum', 1876, 'serum'), ('GO_0007565', 'female pregnancy', 1924, 'gestation'), ('GO_0050890', 'cognition', 1998, 'cognitive'), ('GO_0050890', 'cognition', 2082, 'cognitive'), ('GO_0007567', 'parturition', 2210, 'birth'), ('CHEBI_33341', 'titanium atom', 2355, 'supplements'), ('GO_0007565', 'female pregnancy', 2404, 'gestation'), ('GO_0016055', 'Wnt signaling pathway', 2483, 'verbal reasoning'), ('GO_0007602', 'phototransduction', 2501, 'visual reasoning'), ('GO_0031028', 'septation initiation signaling', 2519, 'quantitative reasoning'), ('GO_0007608', 'sensory perception of smell', 2546, 'short-term memory'), ('GO_0007567', 'parturition', 2794, 'birth'), ('GO_0007565', 'female pregnancy', 2807, 'gestational'), ('CHEBI_30751', 'formic acid', 2985, 'folic acid'), ('CHEBI_30751', 'formic acid', 2996, 'Folic acid'), ('CHEBI_52727', 'ethyl nile blue A', 3051, 'folic acid400'), ('CHEBI_33839', 'macromolecule', 3088, 'micronutrients'), ('CHEBI_33277', 'gamma-tocotrienol', 3107, 'vitamins'), ('CHEBI_27300', 'vitamin D', 3134, 'vitamin A'), ('CHEBI_24859', 'iodine atom', 3173, 'iodine'), ('CHEBI_27568', 'selenium atom', 3189, 'selenium'), ('CHEBI_30751', 'formic acid', 3221, 'folic acid'), ('GO_0007567', 'parturition', 3288, 'delivery'), ('GO_0060119', 'inner ear receptor cell development', 3354, 'Infant Development'), ('GO_0035210', 'prepupal development', 3390, 'Psychomotor development'), ('CHEBI_16158', 'steroid sulfate', 3523, 'supplement'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 3581, 'micronutrient'), ('CHEBI_30751', 'formic acid', 3655, 'folic acid'), ('CHEBI_30751', 'formic acid', 3676, 'folic acid'), ('CHEBI_24870', 'ion', 3689, 'iron'), ('GO_0007565', 'female pregnancy', 3756, 'gestational'), ('GO_0007565', 'female pregnancy', 3955, 'gestational'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 4287, 'carbohydrate'), ('GO_0050890', 'cognition', 4323, 'cognitive'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 4649, 'carbohydrate'), ('GO_0007565', 'female pregnancy', 4697, 'gestation'), ('GO_0051607', 'defense response to virus', 4710, 'deliveryControl'), ('CHEBI_33341', 'titanium atom', 4738, 'supplements'), ('GO_0007565', 'female pregnancy', 4770, 'postpartum'), ('GO_0007605', 'sensory perception of sound', 4796, 'pregnancyNo'), ('GO_0050890', 'cognition', 5027, 'cognitive'), ('GO_0007565', 'female pregnancy', 5136, 'pregnancy'), ('CHEBI_33341', 'titanium atom', 5182, 'supplements'), ('GO_0007565', 'female pregnancy', 5201, 'postpartum'), ('GO_0007567', 'parturition', 5307, 'birth'), ('GO_0007565', 'female pregnancy', 5390, 'gestational'), ('GO_0007618', 'mating', 5410, 'maternal')]	0	['m; 2010 \u2003n \u2009=\u20099983 14\xa0years \u2003n \u2009=\u200910474 16\xa0years\u2003finland\u2003prospective birth studyhb concentrations 3rd 7th 9th  monthsanaemiaschool performance14\xa0years- report16\xa0years- school report↑maternal hb 9\xa0months-↑ school performance score (β\u2009=\u20090.03) score 14\xa0years score 16\xa0years offspring mothers anaemia –low school scores (or\u2009=\u2009-0.05 14\xa0years (or\u2009=\u2009-0.06) 16\xa0yearsconfounders adjusted for: child’s sex, bwt,  not, me, social class, parity, marital status, ms, maternal mental status18 low40davidson pw; 2008 \u2003n \u2009=\u2009229\u2003age 5, 9, 30\xa0months\u2003republic seychelles\u2003longitudinal studyiron- stores 14-24 weeks  iron supplementationbayley scales infant development: mental (mdi) psychomotor (pdi) (9 30\xa0months)infant cognition (fagan infantest-novelty preference) visual expectation –visual memory (9 25\xa0months)a-not-b delayed spatial alternation: inhibition, working memory, (25\xa0months)no maternal iron stores cognitive age.confounders adjusted for: child’s sex, bwt, ma, ses, he, miq parents living child (yes/no)19 low41lewis sj; 2013 \u2003n \u2009=\u2009~3,500\u2003age 8\xa0years\u2003uk\u2003population birth cohorthb concentrationsbefore 18\xa0weekshb <11.0\xa0g/dl -8\xa0%after 28\xa0weekshb <11.0\xa0g/dl -30\xa0%wechsler intelligence children-iii- full- iqno maternal hb child’s iqconfounders adjusted for: ga, me, child’s genotype, iron supplementation, population stratification15 medium42tran td; 2013 \u2003n \u2009=\u2009378\u2003age 6\xa0months\u2003vietnam\u2003population studyiron anaemia (hb <11.0\xa0g/dl serum ferritin <15\xa0ng/ml) 12-28 weeks -16\xa0%bayley scales infant toddler development-iii edition-cognitive scoreinfants anaemic mothers scored 11.6 (0.77sd) bsid cognitive scores infants non-anaemic mothers.confounders adjusted for: parity, ma, me, wealth index, child’s birth weight, family support, bf.18 low43zhou sj; 2006 \u2003n \u2009=\u2009302\u2003age 4\xa0years; australia\u2003double blind trialiron supplements (20\xa0mg/day) placebo 20\xa0weeks  deliverycompliance-86\xa0%stanford binet intelligence iq (verbal reasoning, visual reasoning, quantitative short-term memory)no children supplement placebo score composite iq subscales iq proportion children whose iq fell 2 sd mean.confounders adjusted for: sex, birth order,  age, ma, me, pe, he, bf20 low44li q; 2009 \u2003n \u2009=\u20091305\u2003age 3, 6 12\xa0months\u2003double blind cluster trial\u2003china3 (all received folic acid)folic acid alone400\xa0μg n \u2009=\u2009471)-controliron 60\xa0mg\u2009+\u2009folic acid400\xa0μg n \u2009=\u2009438)multiple micronutrients ((b vitamins (1,2,3 6 12), d, c, e minerals (zinc, iodine, copper, selenium)\u2009+\u2009iron 30\xa0mg\u2009+\u2009400\xa0μg folic acid)) n \u2009=\u2009396)daily supplementation enrolment delivery; compliancebayley scales infant :mental (md) psychomotor (pd)no infants md pd score 3 6\xa0months pd score 12\xa0months supplement groupsmean md score among children micronutrient 1.22 children folic acid alone, folic acid\u2009+\u2009iron 12\xa0monthsconfounders adjusted for: infants age, sex,  age, apgar score, bwt, infant health, maternal age bmi, parental education, occupation, ses, tablets consumed19 low\nqs score rb hb haemoglobin ga  age maternal age bwt birthweight ses socio-economic status maternal pe paternal miq maternal intelligence home environment ms maternal smoking bf breast-feeding bmi mass index\n\ncaption (table-wrap): table 7\n\nsummary maternal carbohydrate/protein offspring cognitive functionauthor, year, sample size, designnutrientcognitive functionresults adjustment confoundersqs rb45alderman h; 2014 \u2003n \u2009=\u20096774\u2003age 16-22 years\u2003double blind cluster trial\u2003gambiacarbohydrate/protein supplementsintervention group:2 biscuits daily (1015\xa0kcal carbohydrate 22\xa0g protein) 20\xa0weeks  deliverycontrol group: supplements 20\xa0weeks  pregnancyno complianceraven’s progressive matrices- nonverbal abilitythe mill hill vocabulary testthe backward digit-span testschooling achievement (questionnaire)no cognitive scores schooling achievement children whose mothers received thesupplements  children whose mothers received supplements .confounders adjusted for: child’s sex, age, ga, me, pe, maternal height, parity, season birth, language village allocation19 low\nqs score, rb bias, ga  age, maternal education, pe paternal education\n\nmaternal anthropometry (table\xa02)\nall countries [8–19].']
S275-PMC4982007	PMC4982007	8/2016	S275-PMC4982007	['THESE FINDINGS are CONSISTENT with Animal studies which have DEMONSTRATED poor Learning and Memory, and alterations in attention, in response to Vitamin D deficiency before Conception and/or during Gestation [57,58].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 61)]	3	[('NCBITaxon_33208', 'Metazoa', 35, 'animal'), ('GO_0007612', 'learning', 79, 'learning'), ('GO_0007613', 'memory', 92, 'memory'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('GO_0007620', 'copulation', 173, 'conception'), ('GO_0007565', 'female pregnancy', 198, 'gestation')]	0	['animal learning memory, alterations attention, response  and/or  [57,58].']
S359-PMC4982007	PMC4982007	8/2016	S359-PMC4982007	['we FOUND SOME EVIDENCE LINKING maternal obesity and low Micronutrient status, in particular, that of Vitamin D, Folate and B12 during Pregnancy with poorer offspring Cognitive function, SUGGESTING that maternal nutrition is IMPORTANT for optimal offspring Neurodevelopment and Long-Term Cognition.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 186), ('IMPORTANT_CONSIDERATION', 224)]	5	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 56, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 112, 'folate'), ('CHEBI_27778', 'abequose', 123, 'B12'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('GO_0050890', 'cognition', 166, 'cognitive'), ('GO_0007399', 'nervous system development', 256, 'neurodevelopment'), ('GO_0007040', 'lysosome organization', 277, 'long-term cognition')]	0	['maternal obesity micronutrient status, particular, folate b12  offspring cognitive function, maternal nutrition offspring neurodevelopment long-term cognition.']
S93-PMC4988030	PMC4988030	8/2016	S93-PMC4988030	['these Nutrients (total and saturated fat, Cholesterol, sodium, calcium, fiber, Folate, iron, Vitamins C and d, and Choline) were chosen BASED ON their importance to an overall healthy diet and increased Nutrient needs during Pregnancy [33–37].']	[('PROBABLE_UNDERSTANDING', 136), ('SUPERFICIAL_RELATIONSHIP', 136)]	2	[('CHEBI_33284', 'nutrient', 6, 'nutrients'), ('CHEBI_16113', 'cholesterol', 42, 'cholesterol'), ('CHEBI_30863', '5-azaorotic acid', 79, 'folate'), ('CHEBI_27300', 'vitamin D', 93, 'vitamins C'), ('CHEBI_15354', 'choline', 115, 'choline'), ('CHEBI_33284', 'nutrient', 203, 'nutrient'), ('GO_0007565', 'female pregnancy', 225, 'pregnancy')]	0	['nutrients (total saturated fat, cholesterol, sodium, calcium, fiber, folate, iron,  d, choline) healthy diet nutrient  [33–37].']
S164-PMC4988030	PMC4988030	8/2016	S164-PMC4988030	['the three point increase in total hei-2010 score and improvements in Saturated fat, Cholesterol and Vitamin C intake in the pat arm SUGGESTS that simple nutrition messaging, when presented in the context of a more GLOBAL maternal and child health curriculum, MAY promote positive maternal dietary behaviors in the Gestational period.']	[('INCOMPLETE_EVIDENCE', 132), ('IMPORTANT_CONSIDERATION', 214), ('INCOMPLETE_EVIDENCE', 259)]	3	[('CHEBI_51247', 'texas red', 69, 'saturated'), ('CHEBI_16113', 'cholesterol', 84, 'cholesterol'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin C'), ('GO_0007565', 'female pregnancy', 314, 'gestational')]	0	['three increase hei-2010 score saturated fat, cholesterol  intake pat arm nutrition messaging, context maternal child curriculum, positive maternal dietary behaviors  period.']
S337-PMC4989298	PMC4989298	8/2016	S337-PMC4989298	['in RECENT YEARS a POSSIBLE ROLE in PREVENTION HAS BEEN ATTRIBUTED to Vitamin D. indeed, OBSERVATIONAL and cohort studies have DOCUMENTED the existence of a CORRELATION between vitamin d intake (from dietary sources or supplementation) in Pregnant women and children and the risk of wheezing, asthma or Food allergy later in Life.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 27), ('SUPERFICIAL_RELATIONSHIP', 35), ('INCOMPLETE_EVIDENCE', 46), ('SUPERFICIAL_RELATIONSHIP', 55), ('INCOMPLETE_EVIDENCE', 88), ('INCOMPLETE_EVIDENCE', 126), ('SUPERFICIAL_RELATIONSHIP', 156)]	9	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 238, 'pregnant'), ('CHEBI_33290', 'food', 302, 'food'), ('UBERON_0000104', 'life cycle', 324, 'life')]	0	['. indeed, existence vitamin intake (from dietary sources supplementation)  women children wheezing, asthma food allergy life.']
S351-PMC4989298	PMC4989298	8/2016	S351-PMC4989298	['the results of this meta-analysis SUPPORTS a CORRELATION between low Vitamin D status and diseases such as hypertension, rachitism in children, vaginosis in Pregnancy, the level of activity of rheumatoid arthritis, Colorectal cancer and falls in the elderly.']	[('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 45)]	2	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'pregnancy'), ('UBERON_0012652', 'colorectum', 215, 'colorectal')]	0	['results meta-analysis  status diseases hypertension, rachitism children, vaginosis activity rheumatoid arthritis, colorectal cancer falls elderly.']
S355-PMC4989298	PMC4989298	8/2016	S355-PMC4989298	['IS the administration of Vitamin D RECOMMENDED during Pregnancy to prevent allergic diseases in children?']	[('EXPLICIT_QUESTION', 0), ('FUTURE_WORK', 35), ('EXPLICIT_QUESTION', 104)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy')]	0	['administration   allergic diseases children?']
S368-PMC4989298	PMC4989298	8/2016	S368-PMC4989298	['in 2013, a randomised, controlled study by goldring and co-workers studied 113 children receiving Prenatal supplementation of Vitamin D. no effect on atopy, risk of atopic dermatitis, Pulmonary function and exhaled Nitric Oxide was FOUND [125].']	[('INCOMPLETE_EVIDENCE', 232)]	1	[('GO_0007565', 'female pregnancy', 98, 'prenatal'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('UBERON_0002048', 'lung', 184, 'pulmonary'), ('CHEBI_16480', 'nitric oxide', 215, 'nitric oxide')]	0	['2013, randomised, goldring co-workers 113 children receiving  supplementation . atopy, atopic dermatitis, pulmonary exhaled nitric oxide [125].']
S224-PMC4990268	PMC4990268	8/2016	S224-PMC4990268	['multi-Micronutrient supplementation\nvarious Micronutrients HAVE BEEN investigated for their ROLE in Pregnancy outcomes (Iron, Folic Acid, Calcium, magnesium, zinc, Vitamin A/ B-Carotene, Vitamin D3, Iodine, Omega-3 Fatty Acids, and others).']	[('INCOMPLETE_EVIDENCE', 59), ('SUPERFICIAL_RELATIONSHIP', 92)]	2	[('CHEBI_6956', 'Mitragynine', 6, 'Micronutrient'), ('CHEBI_33839', 'macromolecule', 44, 'micronutrients'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('CHEBI_24870', 'ion', 120, 'iron'), ('CHEBI_30751', 'formic acid', 126, 'folic acid'), ('CHEBI_22313', 'alkaline earth metal atom', 138, 'calcium'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin A'), ('CHEBI_27793', 'beta-carotene 5,6-epoxide', 175, 'B-carotene'), ('CHEBI_33279', 'vitamin D5', 187, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 187, 'vitamin D3'), ('CHEBI_24859', 'iodine atom', 199, 'iodine'), ('CHEBI_79370', 'ibho#10', 207, 'omega-3'), ('CHEBI_35366', 'fatty acid', 215, 'fatty acids')]	0	['multi-micronutrient supplementation\nvarious micronutrients  outcomes (iron, folic acid, calcium, magnesium, zinc, / b-carotene, vitamin d3, iodine, omega-3 fatty acids, others).']
S292-PMC4990268	PMC4990268	8/2016	S292-PMC4990268	['antenatal vitamin a\nclose to 20 million Pregnant women annually are ESTIMATED to be Vitamin A deficient (vad) to some degree, most in south and southeast asia[101].']	[('INCOMPLETE_EVIDENCE', 68)]	1	[('GO_0007565', 'female pregnancy', 40, 'pregnant'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin A')]	0	['antenatal vitamin a\nclose 20 million  women annually  (vad) degree, south southeast asia[101].']
S293-PMC4990268	PMC4990268	8/2016	S293-PMC4990268	['YET the Ocular manifestations of Vitamin A deficiency during Pregnancy are RARE except for night blindness which typically occurs late in Pregnancy and is indicative of depleted Liver reserves.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 75)]	2	[('UBERON_0000970', 'eye', 8, 'ocular'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin A'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy'), ('UBERON_0002107', 'liver', 178, 'liver')]	0	['yet ocular manifestations   night blindness occurs late  depleted liver reserves.']
S294-PMC4990268	PMC4990268	8/2016	S294-PMC4990268	['Pregnant women who are Vitamin A deficient and their infants CAN suffer SIGNIFICANT adverse consequences AS a result of this deficiency.']	[('INCOMPLETE_EVIDENCE', 61), ('IMPORTANT_CONSIDERATION', 72), ('PROBABLE_UNDERSTANDING', 105)]	3	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 23, 'vitamin A')]	0	[' women  infants result deficiency.']
S295-PMC4990268	PMC4990268	8/2016	S295-PMC4990268	['as with all supplementation STRATEGIES to prevent the COMPLICATIONS ASSOCIATED with Micronutrient deficiencies, the IMPACT of supplementation in the Antenatal Period will DEPEND ON the overall Vitamin A status of the population and the special demands that Pregnancy makes on Vitamin A reserves.']	[('FUTURE_WORK', 28), ('IMPORTANT_CONSIDERATION', 54), ('PROBLEM_COMPLICATION', 54), ('SUPERFICIAL_RELATIONSHIP', 68), ('SUPERFICIAL_RELATIONSHIP', 116), ('SUPERFICIAL_RELATIONSHIP', 171)]	6	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 84, 'micronutrient'), ('GO_0007567', 'parturition', 149, 'antenatal'), ('UBERON_0006721', 'alisphenoid bone', 149, 'antenatal period'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin A'), ('GO_0007565', 'female pregnancy', 257, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin A')]	0	['supplementation micronutrient deficiencies, supplementation antenatal period  status population   reserves.']
S297-PMC4990268	PMC4990268	8/2016	S297-PMC4990268	['IN FACT, the CURRENT EVIDENCE provides SOME SUPPORT for this RELATED to Vitamin A supplementation during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 39), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 61)]	5	[('CHEBI_27300', 'vitamin D', 72, 'vitamin A'), ('GO_0007565', 'female pregnancy', 105, 'pregnancy')]	0	['fact,  supplementation .']
S298-PMC4990268	PMC4990268	8/2016	S298-PMC4990268	['one additional ISSUE for Vitamin A supplementation in Pregnancy is that high doses of Retinol are a WELL-KNOWN Teratogen IF provided early in Gestation[102].']	[('PROBLEM_COMPLICATION', 15), ('PROBABLE_UNDERSTANDING', 100), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 121)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin A'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('CHEBI_26536', 'retinoic acid', 86, 'retinol'), ('CHEBI_50117', 'phenylglyoxylyl-CoA', 111, 'teratogen'), ('GO_0007565', 'female pregnancy', 142, 'gestation')]	0	['one  supplementation  doses retinol teratogen [102].']
S317-PMC4990268	PMC4990268	8/2016	S317-PMC4990268	['there was NO EVIDENCE that Antenatal Vitamin A supplementation reduced infant mortality, Stillbirth, Preterm Birth or increased Birthweight[19,101,107–110].']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('GO_0007567', 'parturition', 27, 'antenatal'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin A'), ('GO_0001966', 'thigmotaxis', 89, 'stillbirth'), ('GO_0007565', 'female pregnancy', 101, 'preterm birth'), ('GO_0007596', 'blood coagulation', 128, 'birthweight')]	0	['antenatal  supplementation infant mortality, stillbirth,  birthweight[19,101,107–110].']
S323-PMC4990268	PMC4990268	8/2016	S323-PMC4990268	['night blindness in Pregnancy: a stratified analysis of the nepal trial SHOWED significantly higher infant mortality for children Born to women who were night blind during Pregnancy and that Antenatal Vitamin A supplementation attenuated this risk[111].']	[('INCOMPLETE_EVIDENCE', 71)]	1	[('GO_0007565', 'female pregnancy', 19, 'Pregnancy'), ('GO_0007567', 'parturition', 129, 'born'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy'), ('GO_0007567', 'parturition', 190, 'antenatal'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin A')]	0	['night blindness : stratified nepal higher infant mortality children born women night blind  antenatal  supplementation attenuated risk[111].']
S325-PMC4990268	PMC4990268	8/2016	S325-PMC4990268	['these results SUPPORTS the current RECOMMENDATION of treating Pregnant women with Vitamin A who present with night blindness.']	[('INCOMPLETE_EVIDENCE', 14), ('FUTURE_WORK', 35)]	2	[('GO_0007565', 'female pregnancy', 62, 'pregnant'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin A')]	0	['results treating  women  night blindness.']
S1047-PMC4990268	PMC4990268	8/2016	S1047-PMC4990268	['inter-Pregnancy intervals and outcomes of interest: kozuki[330] conducted a review/ meta-analysis based on 5 cohort studies (3 from the brazilian pelotas study [331–333], data from a Vitamin A study in zimbabwe[120], and a filipino study of Intrauterine growth restriction[334]), controlling for CONFOUNDERS.']	[('PROBLEM_COMPLICATION', 296)]	1	[('GO_0007565', 'female pregnancy', 6, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin A'), ('UBERON_0022293', 'reproductive gland secretion', 241, 'intrauterine')]	0	['inter- intervals outcomes interest: kozuki[330] review/ meta-analysis 5 (3 brazilian pelotas [331–333],  zimbabwe[120], filipino intrauterine restriction[334]), controlling confounders.']
S0-PMC4992225	PMC4992225	8/2016	S0-PMC4992225	['a randomized controlled trial of Vitamin D supplementation on Perinatal depression: in iranian Pregnant mothers\n\nabstract\n\nbackground\nMood disorders in Pregnancy and Post-Partum Period are common and CONSIDERED as a PUBLIC HEALTH ISSUE.']	[('IMPORTANT_CONSIDERATION', 200), ('IMPORTANT_CONSIDERATION', 216), ('IMPORTANT_CONSIDERATION', 230)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0036268', 'swimming', 62, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 62, 'perinatal'), ('GO_0007565', 'female pregnancy', 95, 'pregnant'), ('GO_0065007', 'biological regulation', 134, 'Mood'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('GO_0007565', 'female pregnancy', 166, 'post-partum'), ('UBERON_0001699', 'sensory root of facial nerve', 171, 'partum period')]	0	[' supplementation perinatal depression: iranian  mothers\n\nabstract\n\nbackground\nmood disorders   period issue.']
S94-PMC4992225	PMC4992225	8/2016	S94-PMC4992225	['intervention in the Supplement consumer (Vitamin D) group: in 2007 and 2010, the canadian pediatric association RECOMMENDED a daily amount of 2000\xa0iu of Vitamin D for Pregnant and breast-feeding women [47,46].']	[('FUTURE_WORK', 112)]	1	[('CHEBI_16158', 'steroid sulfate', 20, 'supplement'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('GO_0007565', 'female pregnancy', 167, 'pregnant')]	0	['intervention supplement consumer () group: 2007 2010, canadian pediatric daily amount 2000\xa0iu   breast-feeding women [47,46].']
S162-PMC4992225	PMC4992225	8/2016	S162-PMC4992225	['WHILE, the mean depression scores were significantly lower in the Vitamin D group than the control one at 38–40 weeks of Gestation ( p \u2009=\u20090.01) also, at 4 and 8 weeks after Birth ( p \u2009>\u20090.001) (table\xa03).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 121, 'gestation'), ('GO_0007567', 'parturition', 173, 'birth')]	0	['while, depression scores  38–40 weeks  p \u2009=\u20090.01) also, 4 8 weeks birth p \u2009>\u20090.001) (table\xa03).']
S164-PMC4992225	PMC4992225	8/2016	S164-PMC4992225	['results SHOWED that in the Vitamin D group the number of participants with depression scores of <9 were more than the control group at 38–40 weeks of Gestation also, at 4 and 8 weeks after Birth (table\xa03).']	[('INCOMPLETE_EVIDENCE', 8)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'gestation'), ('GO_0007567', 'parturition', 189, 'birth')]	0	['results  participants depression scores <9 38–40 weeks  also, 4 8 weeks birth (table\xa03).']
S175-PMC4992225	PMC4992225	8/2016	S175-PMC4992225	['the results SHOWED that in both subgroups, the Vitamin D group had statistically significant higher 25-Hydroxyvitamin D concentrations at Childbirth and lower depression score at 4 and 8 weeks Postpartum than the control group (table\xa04).']	[('INCOMPLETE_EVIDENCE', 12)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 100, '25-hydroxyvitamin D'), ('GO_0007623', 'circadian rhythm', 138, 'childbirth'), ('GO_0007565', 'female pregnancy', 193, 'postpartum')]	0	['results subgroups,  statistically higher 25-hydroxyvitamin concentrations childbirth depression score 4 8 weeks  (table\xa04).']
S177-PMC4992225	PMC4992225	8/2016	S177-PMC4992225	['caption (table-wrap): table 4\n\n25(Oh)D concentrations and depression scores in nulliparous and multiparous subgroupsvariables mean (sd)nulliparousmultiparousvitamin D groupcontrol groupn p -valuevitamin D groupcontrol groupn p -value*25(Oh)D at baseline (ng/ml)13.13(6.91)13.25 (6.55)41/510.9312.49 (9.08)9.31 (5.34)34/270.1525(Oh)D at Delivery (ng/ml)18.40 (11.38)12.49 (6.29)33/430.0116.58 (8.54)11.36 (5.47)28/250.02depression score at baseline8.41(3.52)8.73 (3.57)41/510.678.47 (4.35)8.48 (4.30)34/270.99depression score at 38-40w Gestation6.47(3.43)7.98 (3.74)38/460.065.80 (3.62)7.44 (4.28)30/270.12depression score at Postpartum (4w)4.59(3.24)7.27 (4.04)34/450.0024.60 (3.40)7.52 (4.70)30/270.01depression score at Postpartum (8w)4.18(3.79)7.24 (3.79)34/450.0014.20 (3.79)7.07 (4.37)30/270.01\n*mann–whitney u test\nwe EXAMINED the CORRELATION between change in Vitamin D concentrations and change in depression scores at 38–40 weeks of Gestation, 4 and 8 weeks Postpartum.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 824), ('SUPERFICIAL_RELATIONSHIP', 837)]	2	[('CHEBI_71657', 'versiconol acetate', 31, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 31, '25(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 165, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 203, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 203, 'D'), ('CHEBI_71657', 'versiconol acetate', 234, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 240, 'D'), ('CHEBI_33010', 'chromide(1-)', 327, '(OH)D'), ('GO_0007567', 'parturition', 336, 'delivery'), ('GO_0007565', 'female pregnancy', 535, 'gestation6'), ('GO_0007565', 'female pregnancy', 625, 'postpartum'), ('GO_0007565', 'female pregnancy', 722, 'postpartum'), ('CHEBI_27300', 'vitamin D', 867, 'vitamin D'), ('GO_0007565', 'female pregnancy', 942, 'gestation'), ('GO_0007565', 'female pregnancy', 967, 'postpartum')]	0	['caption (table-wrap): table 4\n\n25(oh)d concentrations depression scores nulliparous multiparous subgroupsvariables (sd)nulliparousmultiparousvitamin groupcontrol groupn p -valuevitamin groupcontrol groupn p -value*25(oh)d baseline (ng/ml)13.13(6.91)13.25 (6.55)41/510.9312.49 (9.08)9.31 (5.34)34/270.1525(oh)d delivery (ng/ml)18.40 (11.38)12.49 (6.29)33/430.0116.58 (8.54)11.36 (5.47)28/250.02depression score baseline8.41(3.52)8.73 (3.57)41/510.678.47 (4.35)8.48 (4.30)34/270.99depression score 38-40w .47(3.43)7.98 (3.74)38/460.065.80 (3.62)7.44 (4.28)30/270.12depression score  (4w)4.59(3.24)7.27 (4.04)34/450.0024.60 (3.40)7.52 (4.70)30/270.01depression score  (8w)4.18(3.79)7.24 (3.79)34/450.0014.20 (3.79)7.07 (4.37)30/270.01\n*mann–whitney u test\nwe  concentrations depression scores 38–40 weeks 4 8 weeks .']
S230-PMC4992225	PMC4992225	8/2016	S230-PMC4992225	['SURPRISINGLY, the change in Vitamin D concentration (baseline to Childbirth) was not correlated with changes in depression scores from baseline to 38–40 weeks of Gestation or to 4 and 8 weeks Postpartum.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007623', 'circadian rhythm', 65, 'childbirth'), ('GO_0007565', 'female pregnancy', 162, 'gestation'), ('GO_0007565', 'female pregnancy', 192, 'postpartum')]	0	['surprisingly,  concentration (baseline childbirth) changes depression scores baseline 38–40 weeks  4 8 weeks .']
S232-PMC4992225	PMC4992225	8/2016	S232-PMC4992225	['the Vitamin D and control groups were SIMILAR regarding to general characteristics EXCEPT FOR two variables: unplanned Pregnancy and using other Supplements OUT OF THE STUDY’S PROTOCOL.']	[('SUPERFICIAL_RELATIONSHIP', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 83), ('PROBLEM_COMPLICATION', 157)]	3	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('CHEBI_33341', 'titanium atom', 145, 'supplements')]	0	[' regarding characteristics variables:  using supplements study’s protocol.']
S238-PMC4992225	PMC4992225	8/2016	S238-PMC4992225	['PREVIOUS clinical TRIALS, in which Vitamin D supplementations were consumed during Pregnancy [18,58], HAVE NOT EVALUATED the Antenatal and Postnatal depression disorders.']	[('INCOMPLETE_EVIDENCE', 0), ('FULL_UNKNOWN', 102), ('FULL_UNKNOWN', 107)]	3	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007567', 'parturition', 125, 'antenatal'), ('GO_0007567', 'parturition', 139, 'postnatal')]	0	['previous trials,  supplementations consumed  [18,58], antenatal postnatal depression disorders.']
S239-PMC4992225	PMC4992225	8/2016	S239-PMC4992225	['HOWEVER in a cross-sectional study in japan, higher dietary Vitamin D intake was INDEPENDENTLY ASSOCIATED with a lower prevalence of depressive symptoms during Pregnancy [66].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 81), ('SUPERFICIAL_RELATIONSHIP', 95)]	3	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy')]	0	['however cross-sectional japan, higher dietary  intake depressive symptoms  [66].']
S240-PMC4992225	PMC4992225	8/2016	S240-PMC4992225	['ON THE OTHER HAND, the EFFECT of Vitamin D on depression in non-Pregnant People are NOT entirely CLEAR.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 23), ('FULL_UNKNOWN', 84)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 73, 'people')]	0	['hand,  depression non- people clear.']
S241-PMC4992225	PMC4992225	8/2016	S241-PMC4992225	['SOME clinical trials in non-Pregnant People SHOWED that Vitamin D was EFFECTIVE in decreasing depression level.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 70)]	3	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 37, 'people'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D')]	0	['non- people  decreasing depression level.']
S260-PMC4992225	PMC4992225	8/2016	S260-PMC4992225	['it is also POSSIBLE that AS a result of vascular changes in Pregnancy the maternal Cerebral environment is more vulnerable to inflammation PERHAPS, EXPLAINING IN PART the LINK between Vitamin D and depression in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 11), ('PROBABLE_UNDERSTANDING', 25), ('INCOMPLETE_EVIDENCE', 139), ('PROBABLE_UNDERSTANDING', 148), ('INCOMPLETE_EVIDENCE', 159), ('SUPERFICIAL_RELATIONSHIP', 171)]	6	[('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('UBERON_0001893', 'telencephalon', 83, 'cerebral'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 212, 'pregnancy')]	0	['result vascular changes  maternal cerebral environment inflammation perhaps,  depression .']
S261-PMC4992225	PMC4992225	8/2016	S261-PMC4992225	['IN LIGHT OF the inflammatory nature of depression and the strong ROLE of Vitamin D AS an anti-inflammatory and immunomodulator, inflammation MAY MEDIATE the RELATIONSHIP between vitamin d deficiency and depression during Pregnancy [73,74].']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 65), ('PROBABLE_UNDERSTANDING', 83), ('INCOMPLETE_EVIDENCE', 141), ('SUPERFICIAL_RELATIONSHIP', 145), ('SUPERFICIAL_RELATIONSHIP', 157)]	6	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 221, 'pregnancy')]	0	['inflammatory nature depression  anti-inflammatory immunomodulator, inflammation vitamin depression  [73,74].']
S266-PMC4992225	PMC4992225	8/2016	S266-PMC4992225	['staying on Vitamin D consumption until Childbirth resulted in higher Serum 25-Hydroxyvitamin D concentration that induced the EFFECT on Postnatal depression exceeding than Prenatal depression.']	[('SUPERFICIAL_RELATIONSHIP', 126)]	1	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007623', 'circadian rhythm', 39, 'childbirth'), ('UBERON_0001977', 'blood serum', 69, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 75, '25-hydroxyvitamin D'), ('GO_0007567', 'parturition', 136, 'postnatal'), ('GO_0007565', 'female pregnancy', 172, 'prenatal')]	0	['staying  consumption childbirth resulted higher serum 25-hydroxyvitamin concentration induced postnatal depression exceeding  depression.']
S113-PMC4993554	PMC4993554	8/2016	S113-PMC4993554	['Vitamins and other supplements in Pregnancy\nwomen’s awareness about the RECOMMENDATIONS for Supplements in Pregnancy was explored, including vitamins and other RECOMMENDED supplements (Folic Acid and Iodine), as well as those Vitamins for which there were DANGERS ASSOCIATED with excessive doses (Vitamin A, Vitamin D, and Vitamin B6).']	[('FUTURE_WORK', 72), ('FUTURE_WORK', 160), ('IMPORTANT_CONSIDERATION', 256), ('SUPERFICIAL_RELATIONSHIP', 264)]	4	[('CHEBI_28371', 'vitamin K epoxide', 0, 'Vitamins'), ('GO_0007565', 'female pregnancy', 34, 'pregnancy'), ('CHEBI_33341', 'titanium atom', 92, 'supplements'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy'), ('CHEBI_30751', 'formic acid', 185, 'folic acid'), ('CHEBI_24859', 'iodine atom', 200, 'iodine'), ('CHEBI_33277', 'gamma-tocotrienol', 226, 'vitamins'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 305, 'A'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin D'), ('CHEBI_33237', 'vitamin D4', 323, 'vitamin B6'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 331, 'B6')]	0	['vitamins supplements \nwomen’s supplements  explored, vitamins supplements (folic acid iodine), vitamins excessive doses (, vitamin b6).']
S118-PMC4993554	PMC4993554	8/2016	S118-PMC4993554	['less than one-third of the women (30%) correctly identified all the three Nutrients (Vitamin A, Vitamin D, and Vitamin B6) as micro-Nutrients that MAY pose a risk when taken during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 147)]	1	[('CHEBI_33284', 'nutrient', 74, 'nutrients'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('CHEBI_33237', 'vitamin D4', 111, 'vitamin B6'), ('PR_000017255', 'Vang-like protein 1', 111, 'vitamin B6'), ('CHEBI_33284', 'nutrient', 132, 'nutrients'), ('GO_0007565', 'female pregnancy', 181, 'pregnancy')]	0	['less one-third women (30%) three nutrients (, vitamin b6) micro-nutrients .']
S174-PMC4993554	PMC4993554	8/2016	S174-PMC4993554	['the low level of knowledge RELATING to Food that is a rich source of Vitamin A (Liver) is concerning, especially during Pregnancy.']	[('SUPERFICIAL_RELATIONSHIP', 27)]	1	[('CHEBI_33290', 'food', 39, 'food'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin A'), ('UBERON_0002107', 'liver', 80, 'liver'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy')]	0	['food rich  (liver) concerning, .']
S175-PMC4993554	PMC4993554	8/2016	S175-PMC4993554	['although Liver is a rich source of key Nutrients such as Iron and Folate, avoiding it in Pregnancy is RECOMMENDED as it contains a high level of Vitamin A and the upper safer limit is UNCERTAIN.52a high dose of Vitamin A in Pregnancy poses a SERIOUS risk of Birth defects.53ALTHOUGH our study DID NOT provide information on HOW this low awareness of Vitamin A-rich source Food COULD AFFECT Pregnant women’s Food choices, written comments (open text sections of the survey) in the PRESENT STUDY INDICATED that SOME women MAY BE INFLUENCED by some of nonevidence-based information.']	[('FUTURE_WORK', 102), ('FULL_UNKNOWN', 184), ('IMPORTANT_CONSIDERATION', 242), ('ANOMALY_CURIOUS_FINDING', 272), ('INCOMPLETE_EVIDENCE', 293), ('EXPLICIT_QUESTION', 324), ('INCOMPLETE_EVIDENCE', 377), ('SUPERFICIAL_RELATIONSHIP', 383), ('QUESTION_ANSWERED_BY_THIS_WORK', 480), ('INCOMPLETE_EVIDENCE', 494), ('INCOMPLETE_EVIDENCE', 509), ('INCOMPLETE_EVIDENCE', 520), ('SUPERFICIAL_RELATIONSHIP', 527)]	13	[('UBERON_0002107', 'liver', 9, 'liver'), ('CHEBI_33284', 'nutrient', 39, 'nutrients'), ('CHEBI_24870', 'ion', 57, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 66, 'folate'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin A'), ('GO_0007565', 'female pregnancy', 224, 'pregnancy'), ('GO_0007567', 'parturition', 258, 'birth'), ('CHEBI_27300', 'vitamin D', 350, 'vitamin A'), ('CHEBI_33290', 'food', 372, 'food'), ('GO_0007565', 'female pregnancy', 390, 'pregnant'), ('CHEBI_33290', 'food', 407, 'food')]	0	['although liver rich nutrients iron folate, avoiding  contains  upper uncertain.52a dose   birth defects.53although -rich food  women’s food choices, written (open text sections women nonevidence-based information.']
S1-PMC4997421	PMC4997421	8/2016	S1-PMC4997421	['BECAUSE maternal Tissue is progressively depleted of Vitamin A to supply fetal demands, women who become Pregnant while possessing marginal Vitamin A reserves are at INCREASED RISK of vitamin a inadequacy as Pregnancy progresses.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 166)]	2	[('UBERON_0000479', 'tissue', 17, 'tissue'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin A'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin A'), ('GO_0007565', 'female pregnancy', 208, 'pregnancy')]	0	['maternal tissue progressively depleted  supply fetal demands, women  possessing  vitamin inadequacy  progresses.']
S13-PMC4997421	PMC4997421	8/2016	S13-PMC4997421	['introduction\nvitamin a is an ESSENTIAL Nutrient throughout the Lifecycle; HOWEVER, its INFLUENCE is PARTICULARLY CRITICAL during periods when cells Proliferate rapidly and differentiate, such as during Pregnancy.adequate Vitamin A status in the mother is CRITICAL for fetal growth, Morphogenesis, and maturation of multiple Organ Systems, including the Immune System, Lungs, and Eyes [1,2].']	[('IMPORTANT_CONSIDERATION', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 74), ('SUPERFICIAL_RELATIONSHIP', 87), ('IMPORTANT_CONSIDERATION', 100), ('IMPORTANT_CONSIDERATION', 113), ('IMPORTANT_CONSIDERATION', 255)]	6	[('CHEBI_33284', 'nutrient', 39, 'nutrient'), ('UBERON_0000104', 'life cycle', 63, 'lifecycle'), ('GO_0008283', 'cell proliferation', 148, 'proliferate'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin A'), ('GO_0009653', 'anatomical structure morphogenesis', 282, 'morphogenesis'), ('UBERON_0000467', 'anatomical system', 324, 'organ systems'), ('UBERON_0002405', 'immune system', 353, 'immune system'), ('UBERON_0002048', 'lung', 368, 'lungs'), ('UBERON_0000970', 'eye', 379, 'eyes')]	0	['introduction\nvitamin nutrient throughout lifecycle; however, periods cells proliferate rapidly differentiate, .adequate  status mother fetal growth, morphogenesis, maturation organ systems, immune system, lungs, eyes [1,2].']
S14-PMC4997421	PMC4997421	8/2016	S14-PMC4997421	['maternal Vitamin A deficiency increases the RISK of COMPLICATIONS during Pregnancy and in the Postpartum Period and HAS BEEN positively ASSOCIATED with Preterm Delivery [3], maternal infections, night blindness, anemia [4], and Birth defects [5].']	[('IMPORTANT_CONSIDERATION', 44), ('IMPORTANT_CONSIDERATION', 52), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 136)]	4	[('CHEBI_27300', 'vitamin D', 9, 'vitamin A'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('GO_0007565', 'female pregnancy', 94, 'postpartum'), ('UBERON_2001055', 'pronephric duct opening', 105, 'period'), ('GO_0007565', 'female pregnancy', 152, 'preterm'), ('GO_0007567', 'parturition', 160, 'delivery'), ('GO_0007567', 'parturition', 228, 'birth')]	0	['maternal    period positively  delivery [3], maternal infections, night blindness, anemia [4], birth defects [5].']
S32-PMC4997421	PMC4997421	8/2016	S32-PMC4997421	['we chose these categories based on evidence that maternal stores will be rapidly depleted by the developing fetus [14], therefore we deemed it IMPORTANT that a woman begins a Pregnancy with sufficient Vitamin A stores.']	[('IMPORTANT_CONSIDERATION', 143)]	1	[('GO_0007565', 'female pregnancy', 175, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin A')]	0	['maternal stores rapidly depleted fetus [14], woman begins   stores.']
S91-PMC4997421	PMC4997421	8/2016	S91-PMC4997421	['BECAUSE maternal Tissues are progressively depleted of Vitamin A to supply fetal demands [14], women who initially possess marginal or EVEN adequate Vitamin A stores at the beginning of Pregnancy are at an INCREASED RISK of Vitamin A inadequacy as Pregnancy progresses.']	[('PROBABLE_UNDERSTANDING', 0), ('ANOMALY_CURIOUS_FINDING', 135), ('IMPORTANT_CONSIDERATION', 206)]	3	[('UBERON_0000479', 'tissue', 17, 'tissues'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin A'), ('GO_0007565', 'female pregnancy', 186, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin A'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy')]	0	['maternal tissues progressively depleted  supply fetal [14], women possess  stores   inadequacy  progresses.']
S93-PMC4997421	PMC4997421	8/2016	S93-PMC4997421	['FOUND a significantly increased RISK of spontaneous Preterm Delivery, maternal anemia, and Pregnancy-induced hypertension when Retinol levels were below 0.70 µmol/l, and BASED ON those functional EFFECTS RECOMMEND a level of 0.70 µmol/l to define Vitamin A deficiency in Pregnancy [3].']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 32), ('INCOMPLETE_EVIDENCE', 170), ('QUESTION_ANSWERED_BY_THIS_WORK', 170), ('SUPERFICIAL_RELATIONSHIP', 196), ('FUTURE_WORK', 204)]	6	[('GO_0007565', 'female pregnancy', 52, 'preterm'), ('GO_0007567', 'parturition', 60, 'delivery'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('CHEBI_26536', 'retinoic acid', 127, 'retinol'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin A'), ('GO_0007565', 'female pregnancy', 271, 'pregnancy')]	0	['found spontaneous  delivery, maternal anemia, -induced hypertension retinol levels 0.70 µmol/l, functional 0.70 µmol/l   [3].']
S95-PMC4997421	PMC4997421	8/2016	S95-PMC4997421	['THEREFORE, it is IMPERATIVE that women be Vitamin A sufficient prior to Becoming Pregnant in order to avoid depletion of Vitamin A stores DUE TO fetal and Lactation demands and subsequent ramifications to the mother or developing infant.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 17), ('PROBLEM_COMPLICATION', 138)]	3	[('CHEBI_27300', 'vitamin D', 42, 'vitamin A'), ('GO_0007567', 'parturition', 72, 'becoming'), ('GO_0007565', 'female pregnancy', 81, 'pregnant'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin A'), ('GO_0007595', 'lactation', 155, 'lactation')]	0	['therefore, women   depletion  stores fetal lactation mother infant.']
S6-PMC4997567	PMC4997567	8/2016	S6-PMC4997567	['the RISK FACTORS were low socioeconomic status, insufficient family income, poor housing conditions, lack of exposure to sunlight DUE TO cultural practices, sole Breast feeding, and inadequate supplementation of Vitamin D to the children and the Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('PROBLEM_COMPLICATION', 130)]	2	[('UBERON_0000310', 'breast', 162, 'breast'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin D'), ('GO_0007565', 'female pregnancy', 246, 'pregnant')]	0	['socioeconomic status, family income, housing conditions, exposure sunlight cultural practices, breast feeding, supplementation  children  women.']
S54-PMC4997567	PMC4997567	8/2016	S54-PMC4997567	['as regards to the maternal Gestational conditions, the mothers of 175 cases (70%) had more than 3 Pregnancies, compared TO the mothers of 23 controls (9.2%); of 140 cases (56%) has less than 2-year interval between the Pregnancies, compared TO those of 14 controls (5.6%); of 200 cases (80%) exposed to less than half an hour a day, compared to the mothers of 50 controls (20%); of 155 (62%) with no Food rich in Vitamin D, nor calcium, nor Vitamin D supplementation during Pregnancy, compared TO those of 10 controls (4%).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 120), ('QUESTION_ANSWERED_BY_THIS_WORK', 241), ('QUESTION_ANSWERED_BY_THIS_WORK', 494)]	3	[('GO_0007565', 'female pregnancy', 27, 'gestational'), ('GO_0007565', 'female pregnancy', 98, 'pregnancies'), ('GO_0007565', 'female pregnancy', 219, 'pregnancies'), ('CHEBI_33290', 'food', 400, 'food'), ('CHEBI_27300', 'vitamin D', 413, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 441, 'vitamin D'), ('GO_0007565', 'female pregnancy', 474, 'pregnancy')]	0	['regards maternal  conditions, mothers 175 cases (70%) 3 mothers 23 (9.2%); 140 cases (56%) 2-year interval 14 (5.6%); 200 cases (80%) exposed half hour day, mothers 50 (20%); 155 (62%) rich calcium,  supplementation 10 (4%).']
S78-PMC4997567	PMC4997567	8/2016	S78-PMC4997567	['maternally, repeated Pregnancies more than 3 gravida (70%), shortened Pregnancy free intervals to less than 2 years (56%), lack OF adequate sunlight exposure to less than half an hour (80%), and inadequate maternal Gestational supplementation of Calcium and Vitamin D (62%) were contributing RISK FACTORS.']	[('ANOMALY_CURIOUS_FINDING', 128), ('SUPERFICIAL_RELATIONSHIP', 292)]	2	[('GO_0007565', 'female pregnancy', 21, 'pregnancies'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007565', 'female pregnancy', 215, 'gestational'), ('CHEBI_22313', 'alkaline earth metal atom', 246, 'calcium'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D')]	0	['maternally,  3 gravida (70%), shortened  intervals 2 (56%), sunlight exposure half hour (80%), maternal  supplementation calcium  (62%) factors.']
S5-PMC4998950	PMC4998950	4/2016	S5-PMC4998950	['conclusions\nif REFLECTING ASSOCIATIONS for Prenatal hypovitaminosis, THESE FINDINGS IMPLY Gestational Vitamin D substitution AS a means of asd PREVENTION.']	[('PROBABLE_UNDERSTANDING', 15), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 69), ('PROBABLE_UNDERSTANDING', 84), ('SUPERFICIAL_RELATIONSHIP', 84), ('PROBABLE_UNDERSTANDING', 125), ('SUPERFICIAL_RELATIONSHIP', 143)]	7	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('GO_0007565', 'female pregnancy', 90, 'gestational'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]	0	['conclusions\nif  hypovitaminosis,   substitution asd prevention.']
S10-PMC4998950	PMC4998950	4/2016	S10-PMC4998950	['environmental and Genetic FACTORS APPEAR equally IMPORTANT,1ALTHOUGH asd with and without intellectual disability MAY IN PART have DIFFERENT origins.2,3\nin high-latitude countries such as sweden, children of mothers with dark complexion are at PARTICULARLY elevated RISK of asd with intellectual disability.3because such women OFTEN have very low Vitamin d levels due to Melanin absorption of uvb radiation, maternal Vitamin D deficiency HAS BEEN SUGGESTED to CONTRIBUTE to asd risk in offspring.4,5indeed, experimentally induced Vitamin D deficiency in Pregnant dams is REPORTED to AFFECT foetal Neurodevelopment and behaviour in Adult offspring in Rats,4AND a RECENT STUDY DEMONSTRATED lower neonatal Vitamin D levels in children with asd compared with their siblings.6\nearly Life Vitamin D deficiency is THUS a POSSIBLE RISK FACTOR for asd, BUT direct SUPPORT of an ASSOCIATION IS LACKING.4maternal hypovitaminosis d is treatable, THUS INVESTIGATION of the matter IS WARRANTED.']	[('SUPERFICIAL_RELATIONSHIP', 26), ('ANOMALY_CURIOUS_FINDING', 34), ('IMPORTANT_CONSIDERATION', 49), ('ANOMALY_CURIOUS_FINDING', 59), ('INCOMPLETE_EVIDENCE', 114), ('INCOMPLETE_EVIDENCE', 118), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('ANOMALY_CURIOUS_FINDING', 244), ('IMPORTANT_CONSIDERATION', 244), ('IMPORTANT_CONSIDERATION', 266), ('PROBABLE_UNDERSTANDING', 327), ('INCOMPLETE_EVIDENCE', 438), ('SUPERFICIAL_RELATIONSHIP', 460), ('INCOMPLETE_EVIDENCE', 571), ('SUPERFICIAL_RELATIONSHIP', 583), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 655), ('INCOMPLETE_EVIDENCE', 662), ('INCOMPLETE_EVIDENCE', 675), ('PROBABLE_UNDERSTANDING', 807), ('INCOMPLETE_EVIDENCE', 814), ('SUPERFICIAL_RELATIONSHIP', 823), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 844), ('INCOMPLETE_EVIDENCE', 855), ('SUPERFICIAL_RELATIONSHIP', 869), ('INCOMPLETE_EVIDENCE', 881), ('FULL_UNKNOWN', 884), ('PROBABLE_UNDERSTANDING', 934), ('FUTURE_WORK', 939), ('FUTURE_WORK', 967)]	29	[('SO_0000704', 'gene', 18, 'genetic'), ('CHEBI_33229', 'vitamin (role)', 347, 'vitamin'), ('CHEBI_25179', 'melanins', 371, 'melanin'), ('CHEBI_27300', 'vitamin D', 417, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 530, 'vitamin D'), ('GO_0007565', 'female pregnancy', 554, 'pregnant'), ('GO_0007399', 'nervous system development', 597, 'neurodevelopment'), ('UBERON_0007023', 'adult organism', 631, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 650, 'rats'), ('CHEBI_27300', 'vitamin D', 703, 'vitamin D'), ('UBERON_0000104', 'life cycle', 778, 'life'), ('CHEBI_27300', 'vitamin D', 783, 'vitamin D')]	0	['environmental genetic important,1although asd intellectual disability origins.2,3\nin high-latitude countries sweden, children mothers dark complexion asd intellectual disability.3because women vitamin levels melanin absorption uvb radiation, maternal  asd offspring.4,5indeed, experimentally induced   dams foetal neurodevelopment behaviour adult offspring rats,4and neonatal  levels children asd siblings.6\nearly life  asd, lacking.4maternal hypovitaminosis treatable, warranted.']
S14-PMC4998950	PMC4998950	4/2016	S14-PMC4998950	['we considered other parental characteristics described below (also seetable 1) as POTENTIAL CONFOUNDERS or mediators BASED ON their ASSOCIATIONS with asd and Vitamin D deficiency.5,8,9\n\ncaption (table-wrap): table 1\nstudy population characteristics in relation to lifetime maternal history of diagnosed Vitamin D deficiencymaternal history of Vitamin D deficiencycharacteristicnoyes p allindividuals, n (%)509 092 (99.9)547 (0.1)509 639 (100.0)cases of asd with intellectual disability, n (%)2463 (0.5)13 (2.4)<0.00012476 (0.5)cases of asd without intellectual disability, n (%)7396 (1.4)10 (1.8)0.467406 (1.4)male (%)51.352.60.5151.3maternal age, years: mean29.928.5<0.000129.9paternal age, years: mean32.834.0<0.000132.8maternal country of Birth (%)\u2003sweden76.319.2<0.000176.2\u2003europe8.34.60.0028.3\u2003outside europe12.838.9<0.000112.9\u2003sub-saharan africa2.637.3<0.00012.6lowest quintile of disposable family income (%)14.835.6<0.000114.8elementary maternal education (%)15.643.1<0.000115.6elementary paternal education (%)16.832.7<0.000116.8born small for Gestational age (%)2.53.70.092.5premature Birth (<37 weeks, %)5.96.20.075.9maternal history of neuropsychiatric disorder (%)a2.49.3<0.00012.4paternal history of neuropsychiatric disorder (%)a2.02.00.982.0maternal history of affective disorder (%)b15.436.8<0.000115.4paternal history of affective disorder (%)b8.110.80.028.1maternal history of epilepsy (%)1.01.50.251.0paternal history of epilepsy (%)1.00.70.521.0\nparental histories of neuropsychiatric disorder include any in-patient or secondary care out-patient record of diagnosed non-affective psychosis, bipolar disorder, attention-deficit hyperactivity disorder, asd, or intellectual disability.']	[('INCOMPLETE_EVIDENCE', 82), ('PROBLEM_COMPLICATION', 92), ('PROBABLE_UNDERSTANDING', 117), ('SUPERFICIAL_RELATIONSHIP', 117), ('SUPERFICIAL_RELATIONSHIP', 132)]	5	[('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 303, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 343, 'vitamin D'), ('GO_0007567', 'parturition', 742, 'birth'), ('GO_0007565', 'female pregnancy', 1053, 'gestational'), ('GO_0007567', 'parturition', 1095, 'birth')]	0	['parental characteristics (also seetable 1) asd  deficiency.5,8,9\n\ncaption (table-wrap): table 1\nstudy population characteristics lifetime maternal diagnosed  deficiencymaternal  deficiencycharacteristicnoyes p allindividuals, n (%)509 092 (99.9)547 (0.1)509 639 (100.0)cases asd intellectual disability, n (%)2463 (0.5)13 (2.4)<0.00012476 (0.5)cases asd intellectual disability, n (%)7396 (1.4)10 (1.8)0.467406 (1.4)male (%)51.352.60.5151.3maternal age, years: mean29.928.5<0.000129.9paternal age, years: mean32.834.0<0.000132.8maternal country birth (%)\u2003sweden76.319.2<0.000176.2\u2003europe8.34.60.0028.3\u2003outside europe12.838.9<0.000112.9\u2003sub-saharan africa2.637.3<0.00012.6lowest quintile disposable family income (%)14.835.6<0.000114.8elementary maternal (%)15.643.1<0.000115.6elementary paternal (%)16.832.7<0.000116.8born  age (%)2.53.70.092.5premature birth (<37 weeks, %)5.96.20.075.9maternal neuropsychiatric disorder (%)a2.49.3<0.00012.4paternal neuropsychiatric disorder (%)a2.02.00.982.0maternal disorder (%)b15.436.8<0.000115.4paternal disorder (%)b8.110.80.028.1maternal epilepsy (%)1.01.50.251.0paternal epilepsy (%)1.00.70.521.0\nparental histories neuropsychiatric disorder in-patient secondary out-patient diagnosed non-affective psychosis, bipolar disorder, attention-deficit hyperactivity disorder, asd, intellectual disability.']
S39-PMC4998950	PMC4998950	4/2016	S39-PMC4998950	['lastly, we used Vitamin D deficiency recorded at any time as the exposure – and not timed to Pregnancy, AS no cases diagnosed before the Birth of a child were identified.']	[('PROBABLE_UNDERSTANDING', 104)]	1	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('GO_0007567', 'parturition', 137, 'birth')]	0	['lastly,  exposure timed cases diagnosed birth child identified.']
S42-PMC4998950	PMC4998950	4/2016	S42-PMC4998950	['HOWEVER, given that Vitamin D deficiency among Pregnant women in sweden is detected ONLY when outright screened for,12many cases of deficiency are LIKELY to manifest well before any official diagnosis is recorded.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 84), ('PROBABLE_UNDERSTANDING', 147)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnant')]	0	['however,  among  women sweden outright screened for,12many cases manifest official diagnosis recorded.']
S44-PMC4998950	PMC4998950	4/2016	S44-PMC4998950	['this DISCREPANCY MIGHT be DUE TO a limited range of exposure in children of immigrant mothers, AS the majority of children and Pregnant mothers with migrant background have neonatal/Gestational Vitamin D deficiency, ACCORDING TO RECENT swedish REPORTS.6,11\ncausality cannot be inferred from our study.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('INCOMPLETE_EVIDENCE', 17), ('PROBLEM_COMPLICATION', 26), ('PROBABLE_UNDERSTANDING', 95), ('INCOMPLETE_EVIDENCE', 216), ('INCOMPLETE_EVIDENCE', 229), ('INCOMPLETE_EVIDENCE', 244)]	7	[('GO_0007565', 'female pregnancy', 127, 'pregnant'), ('GO_0007565', 'female pregnancy', 182, 'gestational'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D')]	0	['exposure children immigrant mothers, children  mothers migrant background neonatal/  deficiency, swedish reports.6,11\ncausality study.']
S46-PMC4998950	PMC4998950	4/2016	S46-PMC4998950	['AS Vitamin D deficiency in Pregnancy is both PREVALENT and treatable, FURTHER INVESTIGATION of this ASSOCIATION IS NEEDED.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 45), ('FUTURE_WORK', 70), ('FUTURE_WORK', 78), ('SUPERFICIAL_RELATIONSHIP', 100), ('FUTURE_WORK', 112)]	6	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('GO_0007565', 'female pregnancy', 27, 'pregnancy')]	0	['  treatable, needed.']
S232-PMC5000726	PMC5000726	8/2016	S232-PMC5000726	['low maternal Calcium and Vitamin D intake during late Pregnancy HAS BEEN ASSOCIATED with reduced bone Mineral content.']	[('INCOMPLETE_EVIDENCE', 64), ('SUPERFICIAL_RELATIONSHIP', 73)]	2	[('CHEBI_22313', 'alkaline earth metal atom', 13, 'calcium'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('CHEBI_46662', 'mineral', 102, 'mineral')]	0	['low maternal calcium  intake late  bone mineral content.']
S1-PMC5014971	PMC5014971	8/2016	S1-PMC5014971	['RECOMMENDATIONS for adequate levels of circulating 25-Hydroxyvitamin D and appropriate Vitamin D supplementation during Pregnancy DIFFER between the institute of medicine and the Endocrine society.']	[('FUTURE_WORK', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 130)]	2	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 51, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('UBERON_0005063', 'left ventricular compact myocardium', 179, 'Endocrine')]	0	['recommendations levels circulating 25-hydroxyvitamin  supplementation  institute medicine endocrine society.']
S4-PMC5014971	PMC5014971	8/2016	S4-PMC5014971	['a majority INDICATED that Vitamin D insufficiency was a PROBLEM in their patient population (68.4%) and that most of their Pregnant patients would BENEFIT from vitamin D supplementation (66.3%).']	[('INCOMPLETE_EVIDENCE', 11), ('IMPORTANT_CONSIDERATION', 56), ('PROBLEM_COMPLICATION', 56), ('IMPORTANT_CONSIDERATION', 147)]	4	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 168, 'D')]	0	[' patient population (68.4%)  patients vitamin supplementation (66.3%).']
S5-PMC5014971	PMC5014971	8/2016	S5-PMC5014971	['half (52.5%) would RECOMMEND Vitamin D supplementation during Pregnancy to some patients, BUT ONLY 16.8% to all.']	[('FUTURE_WORK', 19), ('ANOMALY_CURIOUS_FINDING', 90)]	2	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy')]	0	['half (52.5%)  supplementation  patients, 16.8% all.']
S6-PMC5014971	PMC5014971	8/2016	S6-PMC5014971	['ONLY one in four (25.8%) routinely screen their Pregnant patients for Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('GO_0007565', 'female pregnancy', 48, 'pregnant'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]	0	['four (25.8%) routinely screen  patients  status.']
S19-PMC5014971	PMC5014971	8/2016	S19-PMC5014971	['as many as 30% of Pregnant women in the us MAY have INADEQUATE Vitamin D status [12].']	[('INCOMPLETE_EVIDENCE', 43), ('IMPORTANT_CONSIDERATION', 52)]	2	[('GO_0007565', 'female pregnancy', 18, 'pregnant'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]	0	['30%  women us  status [12].']
S20-PMC5014971	PMC5014971	8/2016	S20-PMC5014971	['in SOME populations, especially during the winter months in higher latitudes, the proportion of Pregnant women with INADEQUATE Vitamin D status MAY exceed 50% [13], DEPENDING ON whose definition of INADEQUATE is used.']	[('INCOMPLETE_EVIDENCE', 3), ('IMPORTANT_CONSIDERATION', 116), ('INCOMPLETE_EVIDENCE', 144), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 165), ('PROBLEM_COMPLICATION', 198)]	5	[('GO_0007565', 'female pregnancy', 96, 'pregnant'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D')]	0	['populations, winter months higher latitudes, proportion  women  status exceed 50% [13], whose definition used.']
S27-PMC5014971	PMC5014971	8/2016	S27-PMC5014971	['low to moderate quality evidence exists for a PROTECTIVE EFFECT of Vitamin D supplementation during Pregnancy for a number of Pregnancy outcomes, including Preeclampsia, being small for Gestational age, and Preterm labor [20].']	[('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 57)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 156, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 186, 'gestational'), ('GO_0007565', 'female pregnancy', 207, 'preterm')]	0	['low  supplementation   outcomes, preeclampsia,  age,  labor [20].']
S33-PMC5014971	PMC5014971	8/2016	S33-PMC5014971	['Vitamin D supplementation during Pregnancy is GENERALLY CONSIDERED SAFE, THOUGH rigorous studies on high doses of Vitamin D supplementation are LACKING [25].']	[('PROBABLE_UNDERSTANDING', 46), ('INCOMPLETE_EVIDENCE', 56), ('IMPORTANT_CONSIDERATION', 67), ('ANOMALY_CURIOUS_FINDING', 73), ('INCOMPLETE_EVIDENCE', 144)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]	0	['vitamin supplementation  safe, rigorous doses  supplementation [25].']
S34-PMC5014971	PMC5014971	8/2016	S34-PMC5014971	['results from a RECENT STUDY INDICATE that Vitamin D supplementation during Pregnancy with up to 4,000\u2009iu/day is SAFE and EFFECTIVE [26].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 28), ('IMPORTANT_CONSIDERATION', 112), ('SUPERFICIAL_RELATIONSHIP', 121)]	4	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy')]	0	['results  supplementation  4,000\u2009iu/day [26].']
S35-PMC5014971	PMC5014971	8/2016	S35-PMC5014971	['HOWEVER, CONSENSUS on WHAT constitutes adequate Vitamin D status during Pregnancy and the most efficacious means to prevent and treat Vitamin D deficiency/insufficiency in Pregnant women has yet to be reached, leading to DIFFERING assessments of this PUBLIC HEALTH ISSUE [14,19].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 9), ('EXPLICIT_QUESTION', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 221), ('IMPORTANT_CONSIDERATION', 251), ('IMPORTANT_CONSIDERATION', 265)]	6	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 172, 'pregnant')]	0	['however,  status  treat  deficiency/insufficiency  women reached, [14,19].']
S37-PMC5014971	PMC5014971	8/2016	S37-PMC5014971	['the PURPOSE of THIS STUDY was TO ASSESS the practice, knowledge, and opinions of practicing obstetrician-gynecologists regarding screening for Vitamin D status and Vitamin D supplementation of their Pregnant patients.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 30)]	3	[('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007565', 'female pregnancy', 199, 'pregnant')]	0	['practice, knowledge, practicing obstetrician-gynecologists regarding screening  status  supplementation  patients.']
S43-PMC5014971	PMC5014971	8/2016	S43-PMC5014971	['the survey contained questions on physician and patient population demographics, physician opinion regarding health CONCERNS associated with Vitamin D deficiency/insufficiency, and practice patterns regarding screening and supplementing Pregnant women.']	[('IMPORTANT_CONSIDERATION', 116)]	1	[('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 237, 'pregnant')]	0	['survey contained physician patient population demographics, physician regarding  deficiency/insufficiency, regarding screening supplementing  women.']
S63-PMC5014971	PMC5014971	8/2016	S63-PMC5014971	['less than half (45.5%) had read acog committee opinion 495 (co 495) on Vitamin D during Pregnancy, and opinion was split evenly among these physicians on WHETHER this committee opinion had changed their practice regarding Vitamin D screening and supplementation during Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 154)]	1	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D'), ('GO_0007565', 'female pregnancy', 269, 'pregnancy')]	0	['less half (45.5%) read acog committee 495 (co 495)  evenly among physicians committee regarding  screening supplementation .']
S68-PMC5014971	PMC5014971	8/2016	S68-PMC5014971	['a majority of respondents considered Vitamin D supplementation during Pregnancy (82.1%) to be SAFE.']	[('IMPORTANT_CONSIDERATION', 94)]	1	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy')]	0	['respondents  supplementation  (82.1%) safe.']
S69-PMC5014971	PMC5014971	8/2016	S69-PMC5014971	['respondents were CONCERNED about Vitamin D deficiency and osteoporosis (91.1%) and bone fractures (88.1%), but less CONCERNED about other POSSIBLE sequelae of Vitamin D deficiency such as a weakened Immune System (32.7%), Colon cancer (27.7%), Cardiovascular disease (23.8%), impaired glucose Metabolism (22.8%), vulnerability to preeclampsia (22.8%), increased risk of small-for-Gestational-age infant (21.8%), vulnerability to Preterm Labor (19.8%), Breast cancer (14.9%), hypertension (12.9%), and infertility (10.9%).']	[('IMPORTANT_CONSIDERATION', 17), ('IMPORTANT_CONSIDERATION', 116), ('INCOMPLETE_EVIDENCE', 138)]	3	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('UBERON_0002405', 'immune system', 199, 'immune system'), ('UBERON_0001155', 'colon', 222, 'colon'), ('UBERON_0004535', 'cardiovascular system', 244, 'cardiovascular'), ('GO_0008152', 'metabolic process', 293, 'metabolism'), ('GO_0007565', 'female pregnancy', 380, 'gestational'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 429, 'preterm labor'), ('UBERON_0000310', 'breast', 452, 'breast')]	0	['respondents  osteoporosis (91.1%) bone fractures (88.1%), sequelae  immune system (32.7%), colon cancer (27.7%), cardiovascular disease (23.8%), glucose metabolism (22.8%), preeclampsia (22.8%), small-for--age infant (21.8%), preterm labor (19.8%), breast cancer (14.9%), hypertension (12.9%), infertility (10.9%).']
S71-PMC5014971	PMC5014971	8/2016	S71-PMC5014971	['more respondents disagreed (41.6%) than agreed (22.8%) that all Pregnant women SHOULD BE screened for Vitamin D deficiency.']	[('FUTURE_WORK', 79)]	1	[('GO_0007565', 'female pregnancy', 64, 'pregnant'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]	0	['respondents (41.6%) (22.8%)  women screened  deficiency.']
S72-PMC5014971	PMC5014971	8/2016	S72-PMC5014971	['physicians that reported having read co 495 were more LIKELY to screen their Pregnant patients (36.9% always or often versus 17.0% that had not read co 495; p< 0.001) AS were physicians that reported that Vitamin D insufficiency was a PROBLEM in their patient population (32.8% always or often versus 9.7%; p = 0.004).']	[('PROBABLE_UNDERSTANDING', 54), ('PROBABLE_UNDERSTANDING', 167), ('IMPORTANT_CONSIDERATION', 235), ('PROBLEM_COMPLICATION', 235)]	4	[('GO_0007565', 'female pregnancy', 77, 'pregnant'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]	0	['physicians read 495 screen  patients (36.9% 17.0% read 495; p< 0.001) physicians  patient population (32.8% 9.7%; p = 0.004).']
S80-PMC5014971	PMC5014971	8/2016	S80-PMC5014971	['there was a LACK OF consensus of opinion among respondents regarding whether Pregnant women taking Prenatal Vitamins are at low RISK of Vitamin D deficiency, with equal proportions agreeing and disagreeing and the modal response being neutral.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('ANOMALY_CURIOUS_FINDING', 17), ('IMPORTANT_CONSIDERATION', 128)]	3	[('GO_0007565', 'female pregnancy', 77, 'pregnant'), ('GO_0007565', 'female pregnancy', 99, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 108, 'vitamins'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]	0	['among respondents regarding  women  vitamins  deficiency, equal proportions disagreeing modal response neutral.']
S81-PMC5014971	PMC5014971	8/2016	S81-PMC5014971	['most respondents were EITHER neutral (23.8%) OR DISAGREED (41.6%) with the following statement: most of my Pregnant patients will get enough Vitamin D through sun exposure and diet.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 22), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 48)]	2	[('GO_0007565', 'female pregnancy', 107, 'pregnant'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D')]	0	['respondents (41.6%) following statement:  patients get  sun exposure diet.']
S82-PMC5014971	PMC5014971	8/2016	S82-PMC5014971	['about half of respondents RECOMMEND additional Vitamin D supplementation to their Pregnant patients (always = 16.8%, often = 11.9%, and sometimes = 23.8%).']	[('FUTURE_WORK', 26)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnant')]	0	['half respondents  supplementation  patients (always = 16.8%, = 11.9%, = 23.8%).']
S83-PMC5014971	PMC5014971	8/2016	S83-PMC5014971	['physicians who considered Vitamin D insufficiency a PROBLEM among their patients were more LIKELY to think that most of their Pregnant patients would BENEFIT from taking Vitamin D supplements (91.2% versus 16.1%; p< 0.001).']	[('IMPORTANT_CONSIDERATION', 52), ('PROBABLE_UNDERSTANDING', 91), ('IMPORTANT_CONSIDERATION', 150)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'pregnant'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]	0	['physicians  among patients  patients  supplements (91.2% 16.1%; p< 0.001).']
S90-PMC5014971	PMC5014971	8/2016	S90-PMC5014971	['physicians who indicated that Vitamin D insufficiency is a PROBLEM in their patient population were more LIKELY to agree or strongly agree that Vitamin D supplementation during Pregnancy is safe and that all Pregnant women SHOULD BE screened.']	[('IMPORTANT_CONSIDERATION', 59), ('PROBABLE_UNDERSTANDING', 105), ('FUTURE_WORK', 223)]	3	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 177, 'pregnancy'), ('GO_0007565', 'female pregnancy', 208, 'pregnant')]	0	['physicians  patient population  supplementation   women screened.']
S92-PMC5014971	PMC5014971	8/2016	S92-PMC5014971	['these physicians were also more LIKELY to disagree with the following statements: Vitamin D supplementation during Pregnancy is GENERALLY not NECESSARY, they are not CONCERNED about Vitamin D deficiency in their Pregnant patients, Pregnant women taking Prenatal Vitamins are at low RISK for Vitamin D deficiency, and most of my Pregnant patients will get enough vitamin d through sun exposure and diet (table 3).']	[('PROBABLE_UNDERSTANDING', 32), ('PROBABLE_UNDERSTANDING', 128), ('IMPORTANT_CONSIDERATION', 142), ('IMPORTANT_CONSIDERATION', 166), ('IMPORTANT_CONSIDERATION', 282)]	5	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('GO_0007565', 'female pregnancy', 212, 'pregnant'), ('GO_0007565', 'female pregnancy', 231, 'pregnant'), ('GO_0007565', 'female pregnancy', 253, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 262, 'vitamins'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin D'), ('GO_0007565', 'female pregnancy', 328, 'pregnant')]	0	['physicians following statements:  supplementation  necessary,   patients,  women  vitamins  deficiency,  patients get vitamin sun exposure diet (table 3).']
S94-PMC5014971	PMC5014971	8/2016	S94-PMC5014971	['discussion\nthe results of THIS STUDY SUGGEST that practicing obstetrician-gynecologists GENERALLY are SOMEWHAT CONCERNED about the Vitamin D status of their Pregnant patients and consider Vitamin D supplementation during Pregnancy to be SAFE.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('INCOMPLETE_EVIDENCE', 37), ('PROBABLE_UNDERSTANDING', 88), ('INCOMPLETE_EVIDENCE', 102), ('IMPORTANT_CONSIDERATION', 111), ('IMPORTANT_CONSIDERATION', 237)]	6	[('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'pregnant'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('GO_0007565', 'female pregnancy', 221, 'pregnancy')]	0	['discussion\nthe results practicing obstetrician-gynecologists  status  patients  supplementation  safe.']
S97-PMC5014971	PMC5014971	8/2016	S97-PMC5014971	['the responding physicians were GENERALLY not supportive of screening all Pregnant women for Vitamin D status; EVEN among physicians that expressed a CONCERN regarding their patient population, less than half would screen most Pregnant patients.']	[('PROBABLE_UNDERSTANDING', 31), ('ANOMALY_CURIOUS_FINDING', 110), ('IMPORTANT_CONSIDERATION', 149), ('PROBLEM_COMPLICATION', 149)]	4	[('GO_0007565', 'female pregnancy', 73, 'pregnant'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 226, 'pregnant')]	0	['responding physicians screening  women  status; among physicians expressed regarding patient population, half screen  patients.']
S98-PMC5014971	PMC5014971	8/2016	S98-PMC5014971	['there was a LACK OF CONSENSUS regarding the APPROPRIATE level of Vitamin D supplementation during Pregnancy and the value of circulating 25-Hydroxyvitamin D, below which there is CONCERN regarding Vitamin D insufficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 44), ('IMPORTANT_CONSIDERATION', 179), ('PROBLEM_COMPLICATION', 179)]	5	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 137, '25-hydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 197, 'vitamin D')]	0	['regarding  supplementation  circulating 25-hydroxyvitamin d, regarding  insufficiency.']
S101-PMC5014971	PMC5014971	8/2016	S101-PMC5014971	['the result has been CONFLICTING RECOMMENDATIONS from the iom [14,15] and the Endocrine society [19], ESPECIALLY CONCERNING Vitamin D supplementation and APPROPRIATE levels of circulating 25-Oh-D during Pregnancy (table 4).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('FUTURE_WORK', 32), ('IMPORTANT_CONSIDERATION', 101), ('IMPORTANT_CONSIDERATION', 112), ('IMPORTANT_CONSIDERATION', 153)]	5	[('UBERON_0005063', 'left ventricular compact myocardium', 77, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 187, '25-OH-D'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy')]	0	['result iom [14,15] endocrine society [19],  supplementation levels circulating 25-oh-d  (table 4).']
S105-PMC5014971	PMC5014971	8/2016	S105-PMC5014971	['there is also a direct ASSOCIATION between circulating 25-Oh-D and 1,25-Oh2-D, which is not the case outside of Pregnancy, SUGGESTING both higher substrate (25-Oh-D) turnover and a greater EFFECT of 25-Oh-D levels on Vitamin D actions on physiology and Metabolism [2].']	[('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 189)]	3	[('CHEBI_46744', 'DDT-2,3-dihydrodiol', 55, '25-OH-D'), ('CHEBI_78731', '9(R)-HPETE', 69, '25-OH2-D'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 157, '25-OH-D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 199, '25-OH-D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('GO_0008152', 'metabolic process', 253, 'metabolism')]	0	['circulating 25-oh-d 1,25-oh2-d, outside higher substrate (25-oh-d) turnover 25-oh-d levels  physiology metabolism [2].']
S108-PMC5014971	PMC5014971	8/2016	S108-PMC5014971	['EVEN researchers SKEPTICAL of the causality of Vitamin D EFFECTS on Pregnancy outcomes POINT to a knowledge deficit that NEEDS ADDRESSING, ESPECIALLY in areas such as maternal and neonatal infections (e.g., [21]).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 17), ('SUPERFICIAL_RELATIONSHIP', 57), ('INCOMPLETE_EVIDENCE', 87), ('FUTURE_WORK', 121), ('IMPORTANT_CONSIDERATION', 121), ('FUTURE_WORK', 127), ('IMPORTANT_CONSIDERATION', 139)]	8	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy')]	0	['even causality   outcomes addressing, maternal neonatal infections (e.g., [21]).']
S117-PMC5014971	PMC5014971	8/2016	S117-PMC5014971	['the CONFLICT between researchers and experts in Vitamin D Metabolism During Pregnancy APPEARS TO BE reflected in the clinical practice of obstetrician-gynecologists.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('ANOMALY_CURIOUS_FINDING', 86)]	2	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0044694', 'pore-mediated entry of viral genome into host cell', 48, 'vitamin D metabolism during'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy')]	0	[' metabolism  obstetrician-gynecologists.']
S121-PMC5014971	PMC5014971	8/2016	S121-PMC5014971	['the Endocrine society CONSIDERS Pregnant and Lactating women AS HIGH-risk groups for Vitamin D insufficiency and RECOMMENDS universal screening [19].']	[('PROBABLE_UNDERSTANDING', 22), ('PROBABLE_UNDERSTANDING', 61), ('IMPORTANT_CONSIDERATION', 64), ('FUTURE_WORK', 113)]	4	[('UBERON_0005063', 'left ventricular compact myocardium', 4, 'Endocrine'), ('GO_0007565', 'female pregnancy', 32, 'pregnant'), ('GO_0007594', 'puparial adhesion', 45, 'lactating'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]	0	['endocrine society  lactating women  screening [19].']
S130-PMC5014971	PMC5014971	8/2016	S130-PMC5014971	['conclusions\nus obstetricians APPEAR cognizant of the IMPORTANCE of maternal Vitamin D status during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 29), ('IMPORTANT_CONSIDERATION', 53)]	2	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy')]	0	['conclusions\nus obstetricians cognizant maternal  status .']
S131-PMC5014971	PMC5014971	8/2016	S131-PMC5014971	['there is CONCERN regarding Vitamin D insufficiency within their Pregnant patients.']	[('PROBLEM_COMPLICATION', 9)]	1	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnant')]	0	['regarding   patients.']
S132-PMC5014971	PMC5014971	8/2016	S132-PMC5014971	['ALTHOUGH few screen most of their Pregnant patients for Vitamin D status, most would RECOMMEND Vitamin D supplementation EVEN without screening.']	[('ANOMALY_CURIOUS_FINDING', 0), ('FUTURE_WORK', 85), ('ANOMALY_CURIOUS_FINDING', 121)]	3	[('GO_0007565', 'female pregnancy', 34, 'pregnant'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]	0	['although screen  patients  status,  supplementation screening.']
S25-PMC5017622	PMC5017622	9/2016	S25-PMC5017622	['women of Reproductive age, ESPECIALLY Pregnant women, in low and middle income countries are AT RISK of several Micronutrient deficiencies, such as Iron, Folic Acid, Iodine, zinc, Vitamins A and d, riboflavin, b6 and b12, which COULD adversely AFFECT the mother and Pregnancy outcome [13,14,15].']	[('IMPORTANT_CONSIDERATION', 27), ('IMPORTANT_CONSIDERATION', 93), ('INCOMPLETE_EVIDENCE', 228), ('SUPERFICIAL_RELATIONSHIP', 244)]	4	[('GO_0000003', 'reproduction', 9, 'reproductive'), ('GO_0007565', 'female pregnancy', 38, 'pregnant'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 112, 'micronutrient'), ('CHEBI_24870', 'ion', 148, 'iron'), ('CHEBI_30751', 'formic acid', 154, 'folic acid'), ('CHEBI_24859', 'iodine atom', 166, 'iodine'), ('CHEBI_27300', 'vitamin D', 180, 'vitamins A'), ('GO_0007565', 'female pregnancy', 266, 'pregnancy')]	0	['women reproductive age,  women, middle income countries micronutrient deficiencies, iron, folic acid, iodine, zinc,  d, riboflavin, b6 b12, adversely mother  outcome [13,14,15].']
S105-PMC5024431	PMC5024431	9/2016	S105-PMC5024431	['Eating Out less/Eat at home morei want to only dine out for 1 meal a weekeat more at home\u2003evening/night time Eating (e.g., healthier and/or restricting)no Eating after 8:00pmlimit snacks at night\u2003follow\xa0canada’s Food guidefollow canada’s Food guide\u2003follow \ufeffvegetarian/vegan dietseat mostly vegan\u2003follow\xa0fad diets (not gluten free)more alkaline and less Acidic Foods\u2003gluten free (includes wheat free)follow celiac diet\u2003follow\xa0other plans (includes fodmap guidelines, Heart healthy, diabetes, optifast®, weight watchers®, dash, dietitian meal plans, weight lifting, Pregnancy diet, unspecified diet plans)following the dietitian’s plan, eat only my shakes this week, follow diet, follow diabetes diet\u2003glycemic indexkeep a low glycemic index diet\u2003clean Eating (includes unprocessed, whole, fresh, raw, natural foods)Eating cleaner, eat as much raw as possible, to eat fresh Food\u2003supplementstake 600-800 iu Vitamin D daily\u2003planning and preparing Food†cook dinner from scratch a minimum of 3 times per week, plan 4–5 smaller meals per daybetter Planning and Preparing Of Food, plan healthy meals, plan meals\u2003goals describing when Food is Eaten or not Eaten/Eating patternseat breakfast, Lunch, dinner & snack every day, not to eat in between mealseat more regularly, try not to snack so much throughout the day\u2003breakfasteating healthy breakfastincorporate cereal or smoothies more often for breakfast\u2003psychological aspects of Eatingdon’t binge, drink Water or 0 cal drink when hungry, stop emotional eatingto Control Food Intake, respect Food AS a means of nutrition and to satisfy hunger\u2003general Eating improvementseat healthy meals and snacks, eat the RECOMMENDED dv of Minerals and Vitamins, eat a variety of foodseat healthy, eat a balanced diet, eat right to avoid ibs symptoms\noverall, there were n\u2009= \u20091,986, n\u2009= \u2009614, n\u2009= \u2009233, and n\u2009= \u20091,134 daily, weekly, monthly, and one-time write your own goal statements, respectively (excluding irrelevant to health/Nonsense goals); these goals were RARELY tracked.']	[('PROBABLE_UNDERSTANDING', 1538), ('FUTURE_WORK', 1649), ('INCOMPLETE_EVIDENCE', 1993)]	3	[('GO_0006897', 'endocytosis', 0, 'Eating out'), ('GO_0018888', '3-chloroacrylic acid metabolic process', 16, 'Eat'), ('GO_0051318', 'G1 phase', 109, 'eating'), ('GO_0051318', 'G1 phase', 155, 'eating'), ('CHEBI_33290', 'food', 212, 'Food'), ('CHEBI_33290', 'food', 238, 'food'), ('CHEBI_37527', 'acid', 353, 'acidic'), ('CHEBI_33290', 'food', 360, 'foods'), ('UBERON_0000948', 'heart', 466, 'heart'), ('GO_0007565', 'female pregnancy', 564, 'pregnancy'), ('GO_0051318', 'G1 phase', 750, 'eating'), ('GO_0007568', 'aging', 813, 'Eating'), ('CHEBI_33290', 'food', 871, 'food'), ('CHEBI_27300', 'vitamin D', 903, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 911, 'D'), ('CHEBI_33290', 'food', 942, 'food'), ('GO_0006260', 'DNA replication', 1040, 'planning'), ('GO_0007565', 'female pregnancy', 1053, 'preparing of food'), ('CHEBI_33290', 'food', 1066, 'food'), ('CHEBI_33290', 'food', 1125, 'food'), ('GO_0036268', 'swimming', 1133, 'eaten'), ('GO_0036268', 'swimming', 1146, 'eaten'), ('GO_0051318', 'G1 phase', 1152, 'eating'), ('UBERON_0010164', 'collection of hairs', 1182, 'Lunch'), ('GO_0050957', 'equilibrioception', 1421, 'eatingDon'), ('CHEBI_15377', 'water', 1446, 'water'), ('GO_0065007', 'biological regulation', 1504, 'control'), ('CHEBI_33290', 'food', 1512, 'food'), ('GO_0007631', 'feeding behavior', 1512, 'food intake'), ('CHEBI_33290', 'food', 1533, 'food'), ('GO_0051318', 'G1 phase', 1592, 'eating'), ('CHEBI_46751', 'quinolizidine', 1667, 'minerals'), ('CHEBI_33277', 'gamma-tocotrienol', 1680, 'vitamins'), ('GO_0001967', 'suckling behavior', 1959, 'nonsense')]	0	['eating less/eat home morei want dine meal weekeat home\u2003evening/night eating (e.g., healthier and/or restricting)no eating 8:00pmlimit snacks night\u2003follow\xa0canada’s food guidefollow canada’s food guide\u2003follow \ufeffvegetarian/vegan dietseat vegan\u2003follow\xa0fad diets (not gluten free)more alkaline acidic foods\u2003gluten (includes wheat free)follow celiac diet\u2003follow\xa0other (includes fodmap guidelines, healthy, diabetes, optifast®, watchers®, dash, dietitian meal plans, lifting,  diet, diet plans)following dietitian’s plan, eat shakes week, diet, diabetes diet\u2003glycemic indexkeep glycemic diet\u2003clean eating (includes unprocessed, whole, fresh, raw, natural foods)eating cleaner, eat raw possible, eat fresh food\u2003supplementstake 600-800 iu  daily\u2003planning preparing food†cook dinner scratch minimum 3 times week, 4–5 meals daybetter healthy meals, meals\u2003goals food eaten eaten/eating patternseat breakfast, lunch, dinner & snack day, eat mealseat regularly, snack throughout day\u2003breakfasteating healthy breakfastincorporate cereal smoothies breakfast\u2003psychological aspects eatingdon’t binge, drink water 0 cal drink hungry, stop emotional eatingto food intake, respect food nutrition hunger\u2003general eating improvementseat healthy meals snacks, eat dv minerals vitamins, eat foodseat healthy, eat diet, eat ibs symptoms\noverall, n\u2009= \u20091,986, n\u2009= \u2009614, n\u2009= \u2009233, n\u2009= \u20091,134 daily, weekly, monthly, one-time write statements, respectively (excluding health/nonsense goals); tracked.']
S36-PMC5024513	PMC5024513	9/2016	S36-PMC5024513	['HOWEVER the author CONCLUDED that there was SOME consensus in the AVAILABLE LITERATURE that Pregnant adolescents had intakes of energy, iron, Folate, Calcium, Vitamin E and magnesium which were below the dietary RECOMMENDED intakes.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 19), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 66), ('FUTURE_WORK', 212)]	5	[('GO_0007565', 'female pregnancy', 92, 'pregnant'), ('CHEBI_30863', '5-azaorotic acid', 142, 'folate'), ('CHEBI_22313', 'alkaline earth metal atom', 150, 'calcium'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin E')]	0	['however author  adolescents intakes energy, iron, folate, calcium,  magnesium dietary intakes.']
S71-PMC5024513	PMC5024513	9/2016	S71-PMC5024513	['caption (table-wrap): table 2\n\ncharacteristics of included studiesstudy informationparticipantssupplementsmeasurementqualitystudycountrystudy designstudy groupsnumberageinclusion criteriaexclusion criteriasupplement type and dosenumber with available dataestimated compliance: n (%)data collection method (s)time period(s)quality ratingbaker et.al (2009) [23]ukcross-sectional studyna50014–18singleton Pregnancy, age 14–18, Gestational age\u2009<\u2009=20\xa0weeksinability to provide informed consent, preeclampsia, Clotting disorders, hiv/aids, haemoglobinopathies, diabetes, Renal disease, hypertension, multiple Gestations, history of 3=\u2009>\u2009previous Miscarriagespreconception folic acid49834 (6.9)24\xa0h recall (multiple)third Trimester+Folic Acid in early pregnancy498220 (44.2)Iron in early pregnancy49839 (7.8)multivitamins in early pregnancy49819 (3.8)Folic Acid only in 3rd trimester2905 (1.7)Iron and Folic Acid in 3rd trimester29013 (4.5)Iron only in 3rd trimester29042 (14.5)multivitamins in 3rd trimester2907 (2.4)castillo-duran et.al (2001) [43]chilerctzinc supplemented24916.4 (mean)beginning Prenatal visits before 20\xa0weeks Gestation, aged <19 at estimated due dateadolescents whose background included chronic diseases, Drug abuse, mental retardation, illiteracy or Pregnancy due to incest or rape20\xa0mg Zinc Sulphate dailyintervention group - 249at least 50\xa0% compliance24\xa0h Recall (multiple)second and third Trimester+placebo25840\xa0mg Iron Sulphateall participants - 507chan et.al (2006) [24]usarctcontrol group, 2 intervention groups excluded from review*2315–17enrolled before 20\xa0weeks Gestationhypertension, diabetes, Renal or Liver disease, alcohol or tobacco use, using medicines effecting Ca Metabolismno additional supplements reportedfood diary (weighing not mentioned)second and third Trimester−/+chang et.al (2003) [37]usaretrospective chart reviewna91812–17self-reported racial group as african-american; singleton Pregnancybirth results not AVAILABLE DUE TO abortion, Miscarriage or transfer of care90\xa0mg Carbonyl Iron daily plus additional up to 120\xa0mg for those classified as anaemic918not reportednot reportedsecond and third Trimester+dawson et.al (2000) [35]usarctone-a-day without iron2016–20aged 16–20, less than 16\xa0weeks Gestation, no Iron supplementation for previous 30\xa0dayshypertension; diabetes; other medical problems; haemoglobin <11\xa0g/dl; haematocrit <30\xa0%vitamin a 5000\xa0iu, Vitamin D 400\xa0iu, Vitamin E 10\xa0mg, Vitamin C 60\xa0mg, Folic Acid 0.4\xa0mg, Thiamine 1.5\xa0mg, riboflavin 1.7\xa0mg, niacin 20\xa0mg, Pyridoxine 2\xa0mg, Vitamin B- 6\xa0mg, Pantothenic Acid 10\xa0mg20not reportedvenous Blood samplesecond and third Trimester and Delivery−/+one-a-day with iron2018\xa0mg iron, vitamin a 5000\xa0iu, Vitamin D 400\xa0iu, Vitamin E 10\xa0mg, Vitamin C 60\xa0mg, Folic Acid 0.4\xa0mg, Thiamine 1.5\xa0mg, riboflavin 1.7\xa0mg, Niacin 20\xa0mg, Pyridoxine 2\xa0mg, Vitamin B- 6\xa0mg, pantothenic Acid 10\xa0mg20derbyshire (2009) [39]ukcross-sectional studyna2015–19attending Antenatal classes or community clinicsincomplete diarynone reportedfood diary unweighedthird Trimester+gadowsky et.al (1995) [42]canadacross-sectional studyna5814–19not reportednot reportedfolic Acid mean 479\xa0μg/day5882\xa0%Venous Blood samplethird trimester+Elemental Iron mean 31.5\xa0mg/daycyanocobalamin (B12) mean 2.24\xa0μg/dgiddens et.al (2000) [27]usarct (subset from a larger study)na5913–18singleton Pregnancies, between 13 and 19\xa0weeks Gestationnot REPORTEDREPORTED that any contribution from Supplements was not included in analysisfood diary weighedmean over Pregnancy−/+ginde et.al (2010) [32]usasecondary analysis of cross sectional surveyna8413–19not reportednot reportedsome participants taking Vitamin D Supplementsnot reportednot reportedvenous Blood samplemean over Pregnancy+gutierrez et.al (1999) [28]usacross-sectional studyna4613–18self-identified ethnicity as mexican american, primigravida, 13–18 years of agehistory of Miscarriage or health problems, involved in competitive athletic performances or heavy exercise, planned to move away during study periodnone reported24\xa0h recall (single)second and third Trimester+iannotti et.al (2005) [36]usacross-sectional studyna8013–18self-reported racial group as african-american; singleton Pregnancynot reportednone reported10\xa0ml Venous Blood samplesecond and third trimesters+job et.al (1995) [41]australiacross-sectional studyna3513–19not reportednot reportednone REPORTED24\xa0h recallmean over Pregnancy+lee et.al (2013) [25]usacross-sectional studyna15613–18age 18 or under, carrying a single fetus, 12–30 weeks Gestation at recruitmentnot REPORTEDREPORTED that any CONTRIBUTION from Supplements was not included in analysis24\xa0h recall (multiple)<23\xa0weeks Gestation, 23–30 weeks Gestation and mean over Pregnancy+mcguire et.al.']	[('INCOMPLETE_EVIDENCE', 1954), ('PROBLEM_COMPLICATION', 1964), ('INCOMPLETE_EVIDENCE', 3401), ('INCOMPLETE_EVIDENCE', 4377), ('INCOMPLETE_EVIDENCE', 4553), ('SUPERFICIAL_RELATIONSHIP', 4579)]	6	[('GO_0007565', 'female pregnancy', 402, 'pregnancy'), ('GO_0007565', 'female pregnancy', 424, 'gestational'), ('GO_0050817', 'coagulation', 504, 'clotting'), ('UBERON_0002113', 'kidney', 565, 'renal'), ('GO_0007565', 'female pregnancy', 603, 'gestations'), ('GO_0050788', 'sequestering of mercury', 640, 'miscarriagesPreconception'), ('GO_0009294', 'DNA mediated transformation', 715, 'trimester'), ('CHEBI_30751', 'formic acid', 725, 'Folic acid'), ('CHEBI_24870', 'ion', 767, 'Iron'), ('CHEBI_30751', 'formic acid', 844, 'Folic acid'), ('CHEBI_24870', 'ion', 886, 'Iron'), ('CHEBI_30751', 'formic acid', 895, 'folic acid'), ('CHEBI_24870', 'ion', 933, 'Iron'), ('GO_0007565', 'female pregnancy', 1092, 'prenatal'), ('GO_0007565', 'female pregnancy', 1124, 'gestation'), ('CHEBI_23888', 'drug', 1221, 'drug'), ('GO_0007565', 'female pregnancy', 1267, 'pregnancy'), ('CHEBI_10127', 'zonisamide', 1304, 'Zinc sulphate'), ('GO_0060033', 'anatomical structure regression', 1376, 'recall'), ('GO_0009294', 'DNA mediated transformation', 1410, 'trimester'), ('CHEBI_83530', 'atenolol-desisopropyl', 1436, 'iron sulphateAll'), ('GO_0051866', 'general adaptation syndrome', 1589, 'gestationHypertension'), ('UBERON_0002113', 'kidney', 1622, 'renal'), ('UBERON_0002107', 'liver', 1631, 'liver'), ('CHEBI_32588', 'potassium chloride', 1696, 'Ca'), ('GO_0008152', 'metabolic process', 1699, 'metabolismNo'), ('GO_0009294', 'DNA mediated transformation', 1795, 'trimester'), ('GO_0007605', 'sensory perception of sound', 1927, 'pregnancyBirth'), ('GO_0046660', 'female sex differentiation', 1981, 'miscarriage'), ('CHEBI_30255', 'sulfidocarbonate(.1-)', 2018, 'carbonyl iron'), ('GO_0009294', 'DNA mediated transformation', 2142, 'trimester'), ('GO_0007565', 'female pregnancy', 2242, 'gestation'), ('CHEBI_24870', 'ion', 2256, 'iron'), ('CHEBI_27300', 'vitamin D', 2403, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2421, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 2438, 'vitamin C'), ('CHEBI_30751', 'formic acid', 2455, 'folic acid'), ('CHEBI_26948', 'vitamin B1', 2474, 'thiamine'), ('CHEBI_16410', 'pyridoxamine', 2524, 'pyridoxine'), ('CHEBI_27300', 'vitamin D', 2541, 'vitamin B'), ('CHEBI_7916', 'pantothenic acid', 2558, 'pantothenic acid'), ('UBERON_0000178', 'blood', 2601, 'blood'), ('GO_0009294', 'DNA mediated transformation', 2630, 'trimester'), ('GO_0007567', 'parturition', 2644, 'delivery'), ('CHEBI_27300', 'vitamin D', 2707, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 2725, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 2742, 'vitamin C'), ('CHEBI_30751', 'formic acid', 2759, 'folic acid'), ('CHEBI_26948', 'vitamin B1', 2778, 'thiamine'), ('CHEBI_7542', 'neurotensin', 2814, 'niacin'), ('CHEBI_16410', 'pyridoxamine', 2828, 'pyridoxine'), ('CHEBI_27300', 'vitamin D', 2845, 'vitamin B'), ('CHEBI_37527', 'acid', 2874, 'acid'), ('GO_0007567', 'parturition', 2950, 'antenatal'), ('GO_0009294', 'DNA mediated transformation', 3043, 'trimester'), ('CHEBI_37527', 'acid', 3145, 'Acid'), ('UBERON_0001638', 'vein', 3171, 'Venous'), ('UBERON_0000178', 'blood', 3178, 'blood'), ('CHEBI_4779', 'emedastine', 3206, 'Elemental'), ('CHEBI_24870', 'ion', 3216, 'Iron'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 3253, 'B12'), ('GO_0007565', 'female pregnancy', 3351, 'pregnancies'), ('GO_0007565', 'female pregnancy', 3388, 'gestationNot'), ('CHEBI_33341', 'titanium atom', 3445, 'supplements'), ('GO_0007565', 'female pregnancy', 3513, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 3653, 'vitamin D'), ('CHEBI_46978', 'thiazinemonocarboxylic acid', 3663, 'supplementsNot'), ('UBERON_0000178', 'blood', 3705, 'blood'), ('GO_0007565', 'female pregnancy', 3727, 'pregnancy'), ('GO_0046660', 'female sex differentiation', 3887, 'miscarriage'), ('GO_0009294', 'DNA mediated transformation', 4074, 'trimester'), ('GO_0006915', 'apoptotic process', 4201, 'pregnancyNot'), ('UBERON_0001638', 'vein', 4241, 'Venous'), ('UBERON_0000178', 'blood', 4248, 'blood'), ('GO_0007565', 'female pregnancy', 4406, 'pregnancy'), ('GO_0007565', 'female pregnancy', 4525, 'gestation'), ('CHEBI_33341', 'titanium atom', 4597, 'supplements'), ('GO_0007565', 'female pregnancy', 4669, 'gestation'), ('GO_0007565', 'female pregnancy', 4692, 'gestation'), ('GO_0007565', 'female pregnancy', 4716, 'pregnancy')]	0	['caption (table-wrap): table 2\n\ncharacteristics studiesstudy informationparticipantssupplementsmeasurementqualitystudycountrystudy designstudy groupsnumberageinclusion criteriaexclusion criteriasupplement type dosenumber dataestimated compliance: n (%)data collection (s)time period(s)quality ratingbaker et.al (2009) [23]ukcross-sectional studyna50014–18singleton age 14–18,  age\u2009<\u2009=20\xa0weeksinability consent, preeclampsia, clotting disorders, hiv/aids, haemoglobinopathies, diabetes, renal disease, hypertension, 3=\u2009>\u2009previous miscarriagespreconception folic acid49834 (6.9)24\xa0h recall (multiple)third trimester+folic acid pregnancy498220 (44.2)iron pregnancy49839 (7.8)multivitamins pregnancy49819 (3.8)folic acid 3rd trimester2905 (1.7)iron folic acid 3rd trimester29013 (4.5)iron 3rd trimester29042 (14.5)multivitamins 3rd trimester2907 (2.4)castillo-duran et.al (2001) [43]chilerctzinc supplemented24916.4 (mean)beginning  visits 20\xa0weeks aged <19 dateadolescents whose background chronic diseases, drug abuse, mental retardation, illiteracy  incest rape20\xa0mg zinc sulphate dailyintervention 249at 50\xa0% compliance24\xa0h recall (multiple)second third trimester+placebo25840\xa0mg iron sulphateall participants 507chan et.al (2006) [24]usarctcontrol group, 2 review*2315–17enrolled 20\xa0weeks gestationhypertension, diabetes, renal liver disease, alcohol tobacco use, using medicines effecting ca metabolismno supplements reportedfood diary (weighing mentioned)second third trimester−/+chang et.al (2003) [37]usaretrospective chart reviewna91812–17self-reported racial african-american; singleton pregnancybirth results abortion, miscarriage transfer care90\xa0mg carbonyl iron daily plus 120\xa0mg anaemic918not reportednot reportedsecond third trimester+dawson et.al (2000) [35]usarctone-a-day iron2016–20aged 16–20, 16\xa0weeks iron supplementation 30\xa0dayshypertension; diabetes; medical problems; haemoglobin <11\xa0g/dl; haematocrit <30\xa0%vitamin 5000\xa0iu,  400\xa0iu,  10\xa0mg,  60\xa0mg, folic acid 0.4\xa0mg, thiamine 1.5\xa0mg, riboflavin 1.7\xa0mg, niacin 20\xa0mg, pyridoxine 2\xa0mg, 6\xa0mg, pantothenic acid 10\xa0mg20not reportedvenous blood samplesecond third trimester delivery−/+one-a-day iron2018\xa0mg iron, vitamin 5000\xa0iu,  400\xa0iu,  10\xa0mg,  60\xa0mg, folic acid 0.4\xa0mg, thiamine 1.5\xa0mg, riboflavin 1.7\xa0mg, niacin 20\xa0mg, pyridoxine 2\xa0mg, 6\xa0mg, pantothenic acid 10\xa0mg20derbyshire (2009) [39]ukcross-sectional studyna2015–19attending antenatal classes community clinicsincomplete diarynone reportedfood diary unweighedthird trimester+gadowsky et.al (1995) [42]canadacross-sectional studyna5814–19not reportednot reportedfolic acid 479\xa0μg/day5882\xa0%venous blood samplethird trimester+elemental iron 31.5\xa0mg/daycyanocobalamin (b12) 2.24\xa0μg/dgiddens et.al (2000) [27]usarct (subset study)na5913–18singleton 13 19\xa0weeks  supplements analysisfood diary weighedmean −/+ginde et.al (2010) [32]usasecondary surveyna8413–19not reportednot reportedsome participants  supplementsnot reportednot reportedvenous blood samplemean +gutierrez et.al (1999) [28]usacross-sectional studyna4613–18self-identified ethnicity mexican american, primigravida, 13–18 agehistory miscarriage problems, competitive athletic performances exercise, periodnone reported24\xa0h recall (single)second third trimester+iannotti et.al (2005) [36]usacross-sectional studyna8013–18self-reported racial african-american; singleton pregnancynot reportednone reported10\xa0ml venous blood samplesecond third trimesters+job et.al (1995) [41]australiacross-sectional studyna3513–19not reportednot reportednone reported24\xa0h recallmean +lee et.al (2013) [25]usacross-sectional studyna15613–18age 18 under, carrying single fetus, 12–30 weeks  recruitmentnot supplements analysis24\xa0h recall (multiple)<23\xa0weeks 23–30 weeks  +mcguire et.al.']
S104-PMC5024513	PMC5024513	9/2016	S104-PMC5024513	['caption (table-wrap): table 5\n\nintake of Micronutrients in individual studies compared to uk and us dietary reference values - mineralscomparison to uk dietary reference valuecomparison to us dietary reference valuenutrientstudysecond trimesterthird trimestermean over Pregnancysecond trimesterthird trimestermean over Pregnancy n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence intervalcalcium mg/dayabaker (2009)290↔840800, 880290↓840800, 880chan (2006)23↔835711, 95923↔862714, 101023↓835711, 95924↓862714, 1010derbyshire (2009)20↑1007867, 114720↓1007867, 1147giddens (2000)59↑989904, 107459↓989904, 1074gutierrez (1999)46↑15611334, 178946↑16551424, 188646↑15611334, 178946↑16551424, 1886job (1995)70↔923756, 109070↓923756, 1090lee (2013)133↑916838, 995156↑886824, 948133↓916838, 995156↓886824, 948pobocik (2003)434↓743689, 797434↓743689, 797phosphorous mg/daybchan (2006)23↑934811, 105723↑961812, 111023↓934811, 105724↓961812, 1110giddens (2000)59↑13401248, 143259↔13401248, 1432lee (2013)133↑12641182, 1347156↑11961131, 1261133↔12641182, 1347156↔11961131, 1261pobocik (2003)434↑13381279, 1397434↑13381279, 1397iron mg/daycbaker (2009)290↑1715, 19290↓1715, 19castillo-duran (2001) a249↑15.515, 16249↑16.816, 17249↓15.515, 16249↓16.816, 17castillo-duran (2001) b258↑16.616, 17258↑16.816, 17258↓16.616, 17258↓16.816, 17chan (2006)23↑2218, 2623↑2520, 3023↓2218, 2623↔2520, 30derbyshire (2009)20↓12.611, 1420↔12.611, 14giddens (2000)59↔1615, 1759↓1615, 17gutierrez (1999)46↑17.715, 2046↑22.717, 2846↓17.715, 2046↔22.717, 28job (1995)70↓11.210, 1270↓11.210, 12lee (2013)133↑18.817, 20156↑18.617, 20133↓18.817, 20156↓18.617, 20pobocik (2003)434↑2019, 21434↓2019, 21magnesium mg/daydbaker (2009)290↓236227, 245↓236227, 245chan (2006)23↓263230, 29623↓264231, 297↓263230, 296↓264231, 297derbyshire (2009)20↓244218, 270↓244218, 270giddens (2000)59↓252234, 270↓252234, 270lee (2013)133↓237222, 253156↓231218, 244↓237222, 253↓231218, 244pobocik (2003)434↓270258, 282↓270258, 282potassium mg/dayechan (2006)23↓28022512, 309223↓29542635, 327323↓28022512, 309223↓29542635, 3273derbyshire (2009)20↓29482659, 323720↓29482659, 3237zinc mg/dayfbaker (2009)290↑8.17.8, 8.4290↓8.17.8, 8.4castillo-duran (2001) a249↑7.47.1, 7.7249↑7.77.4, 8249↓7.47.1, 7.7249↓7.77.4, 8castillo-duran (2001) b258↑7.47.1, 7.7258↑7.47.2, 7.6258↓7.47.1, 7.7258↓7.47.2, 7.6chan (2006)23↑1611.9, 20.123↑1813.5, 22.523↔1611.9, 20.123↑1813.5, 22.5derbyshire (2009)20↑8.17.4, 8.9207.4, 8.9giddens (2000)59↑11.610.5, 12.759↑11.610.5, 12.7gutierrez (1999)46↑14.512.6, 16.446↑15.313.4, 17.246↑14.512.6, 16.446↑15.313.4, 17.2job (1995)70↑9.58.5, 10.570↑9.58.5, 10.5lee (2013)133↑12.8156↑12.611.4, 13.8133↑12.8156↑12.611.4, 13.8pobocik (2003)434↑1312.2, 13.8434↑1312.2, 13.8sodium mg/daygchan (2006)23↑33162809, 382323↑33232812, 3834↑33162809, 3823↑33232812, 3834derbyshire (2009)20↑30892722, 3456↑30892722, 3456copper μg/dayhgiddens (2000)59↑12001098, 130259↑12001098, 1302lee (2013)133↑11001015, 1185156↑10851021, 1151133↑11001015, 1185156↑10851021, 1151selenium μg/dayigiddens (2000)59↑116109, 12359↑116109, 123\nacomparison to uk Rni 800\xa0mg/day and us rda 1300\xa0mg/day,bcomparison to uk Rni 625\xa0mg/day and us rda 1250\xa0mg/day,ccomparison to uk rni 14.8\xa0mg/day and us rda 27\xa0mg/day,dcomparison to uk rni 300\xa0mg/day and us rda 400\xa0mg/day,ecomparison to uk rni 3500\xa0mg/day and us rda 4700\xa0mg/day,fcomparison to uk rni 7\xa0mg/day and us rda 12\xa0mg/day,gcomparison to uk Rni 1500\xa0mg/day and us rda 1600\xa0mg/day,hcomparison to uk Rni 1000\xa0μg/day and us Rda 1000\xa0μg/day,icomparison to uk rni 60\xa0μg/day and us rda 60\xa0μg/day, ↑ study mean higher than reference value ( p \u2009<\u20090.05), ↔ study mean not different to reference value ( p \u2009<\u20090.05), ↓ study mean lower than reference value ( p \u2009<\u20090.05)\n\ncaption (table-wrap): table 6\n\nintake of Micronutrients in individual studies compared to uk and us dietary reference values - Vitaminscomparison to uk dietary reference valuecomparison to us dietary reference valuenutrientstudysecond trimesterthird trimestermean over Pregnancysecond trimesterthird trimestermean over Pregnancy n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence intervalvitamin d μg/dayabaker (2009)290↓2.12, 2.3290↓2.12, 2.3chan (2006)23↓2.81.9, 3.723↓3.12.2, 423↓2.81.9, 3.723↓3.12.2, 4derbyshire (2009)20↓2.01.5, 2.620↓2.01.5, 2.6giddens (2000)59↓6.45.7, 7.159↓6.45.7, 7.1lee (2013)133↓5.44.7, 6.1156↓5.14.6, 5.6133↓5.44.7, 6.1156↓5.14.6, 5.6vitamin ebbaker (2009)290↓8.98.3, 9.5derbyshire (2009)20↓7.76.5, 8.9gutierrez (1999)46↓10.710.746↓11.28.2, 14.1lee (2013)133↓6.96.2, 7.6156↓6.96.4, 7.4pobocik (2003)434↓87.2, 8.8vitamin ccbaker (2009)290↑160146, 174290↑160146, 174derbyshire (2009)20↑138111, 16520↑138111, 165giddens (2000)59↑128112, 14459↑128112, 144gutierrez (1999)46↑252208, 29646↑231190, 27146↑252208, 29646↑231190, 271job (1995)70↑13592, 17870↑13592, 178lee (2013)133↑9781, 113156↑10694, 118133↑9781, 113156↑10694, 118pobocik (2003)434↑167150, 184434↑167150, 184folatedbaker (2009)290↔285269, 301290↓285269, 301derbyshire (2009)20↓227205, 24920↓227205, 249giddens (2000)59↔312277, 34759↓312277, 347gutierrez (1999)46↑447355, 54046↑393340, 44546↓447355, 54046↓393340, 445lee (2013)133↑829723, 935156↑849645, 1053133↑829723, 935156↑849645, 1053pobocik (2003)434↔292269, 315434↓292269, 315riboflavinechan (2006)23↑2.31.8, 2.823↑2.42, 2.823↑2.31.8, 2.823↑2.42, 2.8giddens (2000)59↑2.359↑2.32.1, 2.5lee (2013)133↑2.52.3, 2.7156↑2.4133↑2.52.3, 2.7156↑2.42.2, 2.6pobocik (2003)434↑2.1434↑2.12, 2.2b12fbaker (2009)290↑5.34.7, 5.9290↑5.34.7, 5.9chan (2006)23↑53.8, 6.223↑5.23.7, 6.723↑53.8, 6.223↑5.23.7, 6.7giddens (2000)59↑5.34.6, 659↑5.34.6, 6lee (2013)133↑5.65, 6.2156↑5.55, 6133↑5.65, 6.2156↑5.55, 6pobocik (2003)434↑5.54.8, 6.2434↑5.54.8, 6.2thiamingbaker (2009)290↑1.61.5, 1.7290↑1.61.5, 1.7giddens (2000)59↑2.11.9, 2.359↑2.11.9, 2.3lee (2013)133↑2.11.9, 2.3156↑2.11.9, 2.3133↑2.11.9, 2.3156↑2.11.9, 2.3pobocik (2003)4342.42.3, 2.54342.42.3, 2.5niacinhbaker (2009)290↑3332, 35290↑3432, 35giddens (2000)59↑2422, 2659↑2422, 26lee (2013)133↑2826, 30156↑2624, 27133↑2826, 30156↑2624, 27pobocik (2003)434↑3029, 31434↑3029, 31b6ibaker (2009)290↑2.32.1, 2.4290↑2.32.1, 2.4giddens (2000)59↑1.91.7, 2.159↑1.91.7, 2.1lee (2013)133↑2.22, 2.4156↑2.11.9, 2.3133↑2.22, 2.4156↑2.11.9, 2.3pobocik (2003)434↑21.9, 2.1434↑21.9, 2.1vitamin ajbaker (2009)290↑759651, 867290↑759651, 867derbyshire (2009)20↑555439, 67120↓555439, 671giddens (2000)↑10559↑1053907, 1199↑105359↑1053907, 1199gutierrez (1999)46↑24921466, 351846↑1971432, 252346↑24921466, 351846↑19781432, 2523job (1995)70↑973802, 114470↑973802, 1144lee (2013)133↑698614, 783156↑666615, 717133↑698614, 783156↓666615, 717pobocik (2003)434↑109944, 1242434↑1093944, 1242vitamin kklee (2013)133↔7057, 83156↔7059, 81\nacomparison to uk Rni 10\xa0μg/day and us rda 15\xa0μg/day,bcomparison to us rda 15\xa0mg/day,ccomparison to uk Rni 40\xa0mg/day and us rda 80\xa0mg/day,dcomparison to uk rni 200\xa0μg/day and us rda 600\xa0μg/day,ecomparison to uk rni 1.1\xa0mg/day and us rda 1.4\xa0mg/day,fcomparison to uk rni 1.5\xa0μg/day and us rda 2.6\xa0μg/day,gcomparison to uk rni 0.8\xa0mg/day and us rda 1.4\xa0mg/day,hcomparison to uk rni 14\xa0mg/day and us rda 18\xa0mg/day,icomparison to uk rni 1.2\xa0mg/day and us rda 1.9\xa0mg/day,jcomparison to uk rni 600\xa0μg/day and us rda 750\xa0μg/day,kcomparison to us ai 75\xa0μg/day, ↑ study mean higher than reference value ( p \u2009<\u20090.05), ↔ study mean not different to reference value ( p \u2009<\u20090.05), ↓ study mean lower than reference value ( p \u2009<\u20090.05)\nthe individual study results SHOW that the MAJORITY of reported Nutrient Intakes were significantly below both the uk rni and us rda for Vitamin D, potassium and magnesium and below the us rda for Calcium, Vitamin E, Folate, Phosphorous and iron.']	[('INCOMPLETE_EVIDENCE', 7670), ('PROBABLE_UNDERSTANDING', 7684)]	2	[('CHEBI_33839', 'macromolecule', 41, 'micronutrients'), ('GO_0007605', 'sensory perception of sound', 269, 'pregnancySecond'), ('GO_0007565', 'female pregnancy', 319, 'pregnancy'), ('CHEBI_52240', 'p-quaterphenyl', 3186, 'RNI'), ('CHEBI_52240', 'p-quaterphenyl', 3242, 'RNI'), ('CHEBI_52240', 'p-quaterphenyl', 3517, 'RNI'), ('CHEBI_52240', 'p-quaterphenyl', 3574, 'RNI'), ('CHEBI_34944', 'RU 5135', 3597, 'RDA'), ('CHEBI_33839', 'macromolecule', 3877, 'micronutrients'), ('CHEBI_60409', 'Ins-1-P-Cer(d18:0/2-OH-26:0)', 3963, 'vitaminsComparison'), ('GO_0007605', 'sensory perception of sound', 4105, 'pregnancySecond'), ('GO_0007565', 'female pregnancy', 4155, 'pregnancy'), ('CHEBI_52240', 'p-quaterphenyl', 6938, 'RNI'), ('CHEBI_52240', 'p-quaterphenyl', 7023, 'RNI'), ('CHEBI_33284', 'nutrient', 7705, 'nutrient'), ('GO_0007631', 'feeding behavior', 7714, 'intakes'), ('CHEBI_27300', 'vitamin D', 7778, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 7838, 'calcium'), ('CHEBI_27300', 'vitamin D', 7847, 'vitamin E'), ('CHEBI_30863', '5-azaorotic acid', 7858, 'folate'), ('CHEBI_30207', 'phosphorus(.)', 7866, 'phosphorous')]	0	['caption (table-wrap): table 5\n\nintake micronutrients individual uk us dietary values mineralscomparison uk dietary valuecomparison us dietary valuenutrientstudysecond trimesterthird trimestermean pregnancysecond trimesterthird trimestermean  n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence intervalcalcium mg/dayabaker (2009)290↔840800, 880290↓840800, 880chan (2006)23↔835711, 95923↔862714, 101023↓835711, 95924↓862714, 1010derbyshire (2009)20↑1007867, 114720↓1007867, 1147giddens (2000)59↑989904, 107459↓989904, 1074gutierrez (1999)46↑15611334, 178946↑16551424, 188646↑15611334, 178946↑16551424, 1886job (1995)70↔923756, 109070↓923756, 1090lee (2013)133↑916838, 995156↑886824, 948133↓916838, 995156↓886824, 948pobocik (2003)434↓743689, 797434↓743689, 797phosphorous mg/daybchan (2006)23↑934811, 105723↑961812, 111023↓934811, 105724↓961812, 1110giddens (2000)59↑13401248, 143259↔13401248, 1432lee (2013)133↑12641182, 1347156↑11961131, 1261133↔12641182, 1347156↔11961131, 1261pobocik (2003)434↑13381279, 1397434↑13381279, 1397iron mg/daycbaker (2009)290↑1715, 19290↓1715, 19castillo-duran (2001) a249↑15.515, 16249↑16.816, 17249↓15.515, 16249↓16.816, 17castillo-duran (2001) b258↑16.616, 17258↑16.816, 17258↓16.616, 17258↓16.816, 17chan (2006)23↑2218, 2623↑2520, 3023↓2218, 2623↔2520, 30derbyshire (2009)20↓12.611, 1420↔12.611, 14giddens (2000)59↔1615, 1759↓1615, 17gutierrez (1999)46↑17.715, 2046↑22.717, 2846↓17.715, 2046↔22.717, 28job (1995)70↓11.210, 1270↓11.210, 12lee (2013)133↑18.817, 20156↑18.617, 20133↓18.817, 20156↓18.617, 20pobocik (2003)434↑2019, 21434↓2019, 21magnesium mg/daydbaker (2009)290↓236227, 245↓236227, 245chan (2006)23↓263230, 29623↓264231, 297↓263230, 296↓264231, 297derbyshire (2009)20↓244218, 270↓244218, 270giddens (2000)59↓252234, 270↓252234, 270lee (2013)133↓237222, 253156↓231218, 244↓237222, 253↓231218, 244pobocik (2003)434↓270258, 282↓270258, 282potassium mg/dayechan (2006)23↓28022512, 309223↓29542635, 327323↓28022512, 309223↓29542635, 3273derbyshire (2009)20↓29482659, 323720↓29482659, 3237zinc mg/dayfbaker (2009)290↑8.17.8, 8.4290↓8.17.8, 8.4castillo-duran (2001) a249↑7.47.1, 7.7249↑7.77.4, 8249↓7.47.1, 7.7249↓7.77.4, 8castillo-duran (2001) b258↑7.47.1, 7.7258↑7.47.2, 7.6258↓7.47.1, 7.7258↓7.47.2, 7.6chan (2006)23↑1611.9, 20.123↑1813.5, 22.523↔1611.9, 20.123↑1813.5, 22.5derbyshire (2009)20↑8.17.4, 8.9207.4, 8.9giddens (2000)59↑11.610.5, 12.759↑11.610.5, 12.7gutierrez (1999)46↑14.512.6, 16.446↑15.313.4, 17.246↑14.512.6, 16.446↑15.313.4, 17.2job (1995)70↑9.58.5, 10.570↑9.58.5, 10.5lee (2013)133↑12.8156↑12.611.4, 13.8133↑12.8156↑12.611.4, 13.8pobocik (2003)434↑1312.2, 13.8434↑1312.2, 13.8sodium mg/daygchan (2006)23↑33162809, 382323↑33232812, 3834↑33162809, 3823↑33232812, 3834derbyshire (2009)20↑30892722, 3456↑30892722, 3456copper μg/dayhgiddens (2000)59↑12001098, 130259↑12001098, 1302lee (2013)133↑11001015, 1185156↑10851021, 1151133↑11001015, 1185156↑10851021, 1151selenium μg/dayigiddens (2000)59↑116109, 12359↑116109, 123\nacomparison uk rni 800\xa0mg/day us rda 1300\xa0mg/day,bcomparison uk rni 625\xa0mg/day us rda 1250\xa0mg/day,ccomparison uk rni 14.8\xa0mg/day us rda 27\xa0mg/day,dcomparison uk rni 300\xa0mg/day us rda 400\xa0mg/day,ecomparison uk rni 3500\xa0mg/day us rda 4700\xa0mg/day,fcomparison uk rni 7\xa0mg/day us rda 12\xa0mg/day,gcomparison uk rni 1500\xa0mg/day us rda 1600\xa0mg/day,hcomparison uk rni 1000\xa0μg/day us rda 1000\xa0μg/day,icomparison uk rni 60\xa0μg/day us rda 60\xa0μg/day, ↑ higher p \u2009<\u20090.05), ↔ p \u2009<\u20090.05), p \u2009<\u20090.05)\n\ncaption (table-wrap): table 6\n\nintake micronutrients individual uk us dietary values vitaminscomparison uk dietary valuecomparison us dietary valuenutrientstudysecond trimesterthird trimestermean pregnancysecond trimesterthird trimestermean  n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence interval n =meanconfidence intervalvitamin μg/dayabaker (2009)290↓2.12, 2.3290↓2.12, 2.3chan (2006)23↓2.81.9, 3.723↓3.12.2, 423↓2.81.9, 3.723↓3.12.2, 4derbyshire (2009)20↓2.01.5, 2.620↓2.01.5, 2.6giddens (2000)59↓6.45.7, 7.159↓6.45.7, 7.1lee (2013)133↓5.44.7, 6.1156↓5.14.6, 5.6133↓5.44.7, 6.1156↓5.14.6, 5.6vitamin ebbaker (2009)290↓8.98.3, 9.5derbyshire (2009)20↓7.76.5, 8.9gutierrez (1999)46↓10.710.746↓11.28.2, 14.1lee (2013)133↓6.96.2, 7.6156↓6.96.4, 7.4pobocik (2003)434↓87.2, 8.8vitamin ccbaker (2009)290↑160146, 174290↑160146, 174derbyshire (2009)20↑138111, 16520↑138111, 165giddens (2000)59↑128112, 14459↑128112, 144gutierrez (1999)46↑252208, 29646↑231190, 27146↑252208, 29646↑231190, 271job (1995)70↑13592, 17870↑13592, 178lee (2013)133↑9781, 113156↑10694, 118133↑9781, 113156↑10694, 118pobocik (2003)434↑167150, 184434↑167150, 184folatedbaker (2009)290↔285269, 301290↓285269, 301derbyshire (2009)20↓227205, 24920↓227205, 249giddens (2000)59↔312277, 34759↓312277, 347gutierrez (1999)46↑447355, 54046↑393340, 44546↓447355, 54046↓393340, 445lee (2013)133↑829723, 935156↑849645, 1053133↑829723, 935156↑849645, 1053pobocik (2003)434↔292269, 315434↓292269, 315riboflavinechan (2006)23↑2.31.8, 2.823↑2.42, 2.823↑2.31.8, 2.823↑2.42, 2.8giddens (2000)59↑2.359↑2.32.1, 2.5lee (2013)133↑2.52.3, 2.7156↑2.4133↑2.52.3, 2.7156↑2.42.2, 2.6pobocik (2003)434↑2.1434↑2.12, 2.2b12fbaker (2009)290↑5.34.7, 5.9290↑5.34.7, 5.9chan (2006)23↑53.8, 6.223↑5.23.7, 6.723↑53.8, 6.223↑5.23.7, 6.7giddens (2000)59↑5.34.6, 659↑5.34.6, 6lee (2013)133↑5.65, 6.2156↑5.55, 6133↑5.65, 6.2156↑5.55, 6pobocik (2003)434↑5.54.8, 6.2434↑5.54.8, 6.2thiamingbaker (2009)290↑1.61.5, 1.7290↑1.61.5, 1.7giddens (2000)59↑2.11.9, 2.359↑2.11.9, 2.3lee (2013)133↑2.11.9, 2.3156↑2.11.9, 2.3133↑2.11.9, 2.3156↑2.11.9, 2.3pobocik (2003)4342.42.3, 2.54342.42.3, 2.5niacinhbaker (2009)290↑3332, 35290↑3432, 35giddens (2000)59↑2422, 2659↑2422, 26lee (2013)133↑2826, 30156↑2624, 27133↑2826, 30156↑2624, 27pobocik (2003)434↑3029, 31434↑3029, 31b6ibaker (2009)290↑2.32.1, 2.4290↑2.32.1, 2.4giddens (2000)59↑1.91.7, 2.159↑1.91.7, 2.1lee (2013)133↑2.22, 2.4156↑2.11.9, 2.3133↑2.22, 2.4156↑2.11.9, 2.3pobocik (2003)434↑21.9, 2.1434↑21.9, 2.1vitamin ajbaker (2009)290↑759651, 867290↑759651, 867derbyshire (2009)20↑555439, 67120↓555439, 671giddens (2000)↑10559↑1053907, 1199↑105359↑1053907, 1199gutierrez (1999)46↑24921466, 351846↑1971432, 252346↑24921466, 351846↑19781432, 2523job (1995)70↑973802, 114470↑973802, 1144lee (2013)133↑698614, 783156↑666615, 717133↑698614, 783156↓666615, 717pobocik (2003)434↑109944, 1242434↑1093944, 1242vitamin kklee (2013)133↔7057, 83156↔7059, 81\nacomparison uk rni 10\xa0μg/day us rda 15\xa0μg/day,bcomparison us rda 15\xa0mg/day,ccomparison uk rni 40\xa0mg/day us rda 80\xa0mg/day,dcomparison uk rni 200\xa0μg/day us rda 600\xa0μg/day,ecomparison uk rni 1.1\xa0mg/day us rda 1.4\xa0mg/day,fcomparison uk rni 1.5\xa0μg/day us rda 2.6\xa0μg/day,gcomparison uk rni 0.8\xa0mg/day us rda 1.4\xa0mg/day,hcomparison uk rni 14\xa0mg/day us rda 18\xa0mg/day,icomparison uk rni 1.2\xa0mg/day us rda 1.9\xa0mg/day,jcomparison uk rni 600\xa0μg/day us rda 750\xa0μg/day,kcomparison us higher p \u2009<\u20090.05), ↔ p \u2009<\u20090.05), p \u2009<\u20090.05)\nthe individual results nutrient intakes uk rni us rda potassium magnesium us rda calcium, folate, phosphorous iron.']
S112-PMC5024513	PMC5024513	9/2016	S112-PMC5024513	['2\n\npooled weighted mean Micronutrient intake compared to uk and us dietary reference values\nmicronutrient analysis by stage of Pregnancy SHOWED that intake of Vitamin D in the second (28\xa0% of the uk rni, ci 26–30\xa0%) and third (31.2\xa0% of the uk rni, ci 0–47\xa0%) trimesters was below recommendations; this was not the case for measures reported as a mean over Pregnancy (54\xa0% of the uk rni, ci 0–114.3\xa0%).']	[('INCOMPLETE_EVIDENCE', 137)]	1	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 24, 'micronutrient'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('GO_0007565', 'female pregnancy', 357, 'pregnancy')]	0	['2\n\npooled weighted micronutrient intake uk us dietary values\nmicronutrient  intake  (28\xa0% uk rni, ci 26–30\xa0%) third (31.2\xa0% uk rni, ci 0–47\xa0%) trimesters recommendations;  (54\xa0% uk rni, ci 0–114.3\xa0%).']
S127-PMC5024513	PMC5024513	9/2016	S127-PMC5024513	['the summary results SHOW that there MAY BE areas of CONCERN in adolescent’s nutritional intake during Pregnancy, PARTICULARLY COMPARED to us RECOMMENDATIONS, with regard to calcium, Vitamin D, Vitamin E, Folate, potassium and magnesium.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 36), ('PROBLEM_COMPLICATION', 52), ('IMPORTANT_CONSIDERATION', 113), ('ANOMALY_CURIOUS_FINDING', 126), ('FUTURE_WORK', 141)]	6	[('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin E'), ('CHEBI_30863', '5-azaorotic acid', 204, 'folate')]	0	['results adolescent’s nutritional intake us recommendations, regard calcium, , folate, potassium magnesium.']
S168-PMC5024513	PMC5024513	9/2016	S168-PMC5024513	['a systematic review of Micronutrient intakes in Pregnancy FOUND that intakes of Folate, Vitamin D and Iron were sub-optimal [63].']	[('INCOMPLETE_EVIDENCE', 58)]	1	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 23, 'micronutrient'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('CHEBI_30863', '5-azaorotic acid', 80, 'folate'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_24870', 'ion', 102, 'iron')]	0	['micronutrient intakes  intakes folate,  iron sub-optimal [63].']
S83-PMC5028238	PMC5028238	10/2016	S83-PMC5028238	['in addition, BENEFITS from Prenatal Vitamin D supplementation are also Modulated by geographic location and OTHER FACTORS.47THEREFORE biological mechanisms that maximize Vitamin D production and absorption would be selected for in the north.']	[('IMPORTANT_CONSIDERATION', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 108), ('SUPERFICIAL_RELATIONSHIP', 114), ('ANOMALY_CURIOUS_FINDING', 122), ('ANOMALY_CURIOUS_FINDING', 122), ('ANOMALY_CURIOUS_FINDING', 122)]	6	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0065007', 'biological regulation', 71, 'modulated'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D')]	0	['addition,   supplementation geographic location factors.47therefore biological mechanisms maximize  production absorption selected north.']
S86-PMC5028238	PMC5028238	10/2016	S86-PMC5028238	['improved hip formation IS THOUGHT TO enable females to produce more offspring and thereby provide another carrier advantage.11,35in addition, Vitamin D HAS BEEN SHOWN to increase chances of Pregnancy for infertile women receiving in Vitro Fertilization.48vitamin d has many pleiotropic ROLES in Reproductive outcomes and CAN AFFECT both male and female Fertility.49THEREFORE, there COULD BE MULTIPLE mechanisms that COULD EXPLAIN WHY evolution favors Vitamin D Production in northern climates through mutations in Dhcr7 (and other Genes).']	[('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 152), ('SUPERFICIAL_RELATIONSHIP', 286), ('INCOMPLETE_EVIDENCE', 321), ('SUPERFICIAL_RELATIONSHIP', 325), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 363), ('INCOMPLETE_EVIDENCE', 382), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 391), ('INCOMPLETE_EVIDENCE', 416), ('PROBABLE_UNDERSTANDING', 422), ('EXPLICIT_QUESTION', 430)]	12	[('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('GO_0007565', 'female pregnancy', 190, 'pregnancy'), ('GO_0007601', 'visual perception', 233, 'vitro'), ('GO_0009566', 'fertilization', 239, 'fertilization'), ('GO_0000003', 'reproduction', 295, 'reproductive'), ('GO_0009566', 'fertilization', 353, 'fertility'), ('CHEBI_27300', 'vitamin D', 451, 'vitamin D'), ('GO_0071611', 'granulocyte colony-stimulating factor production', 451, 'vitamin D production'), ('PR_000006474', 'ATP-dependent RNA helicase A', 514, 'DHCR7'), ('SO_0000704', 'gene', 531, 'genes')]	0	['improved hip formation females produce offspring carrier advantage.11,35in addition,  increase  infertile women receiving fertilization.48vitamin pleiotropic reproductive outcomes male female fertility.49therefore, mechanisms evolution  production northern climates mutations dhcr7 (and genes).']
S201-PMC5028238	PMC5028238	10/2016	S201-PMC5028238	"['[""""COMMENT on Vitamin D3\'s in-direct inhibition of Dhcr7\\nOF NOTE, Vitamin D (Cholecalciferol) decreases the Dhcr7 activity through an indirect mechanism.54there HAS BEEN SOME SPECULATION on the POSSIBILITY of Teratogenic AFFECTS resulting from high doses of Vitamin D when taken as a Prenatal supplement.89HOWEVER, a RECENT REVIEW of Vitamin D supplementation among Pregnant women FOUND that Vitamin D supplementation MAY reduce the RISK of pre-eclampsia, low Birth weight, Preterm Birth90,91and adverse Kidney outcomes in offspring.92BECAUSE the mechanism of Vitamin D3\'s inhibition of Dhcr7 is indirect (UNLIKE our studied Pharmacological Dhcr7 Inhibitors) it is LIKELY to be MEDIATED through a COMPLEX pathway with many INTERACTING feedback loops.""""]']"	[('INCOMPLETE_EVIDENCE', 0), ('ANOMALY_CURIOUS_FINDING', 54), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 167), ('INCOMPLETE_EVIDENCE', 172), ('INCOMPLETE_EVIDENCE', 191), ('SUPERFICIAL_RELATIONSHIP', 218), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 301), ('INCOMPLETE_EVIDENCE', 314), ('INCOMPLETE_EVIDENCE', 378), ('INCOMPLETE_EVIDENCE', 415), ('IMPORTANT_CONSIDERATION', 430), ('PROBABLE_UNDERSTANDING', 530), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 603), ('PROBABLE_UNDERSTANDING', 662), ('SUPERFICIAL_RELATIONSHIP', 675), ('DIFFICULT_TASK', 694), ('SUPERFICIAL_RELATIONSHIP', 720)]	18	[('CHEBI_33279', 'vitamin D5', 11, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 11, 'vitamin D3'), ('PR_000006474', 'ATP-dependent RNA helicase A', 48, 'DHCR7'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 74, 'cholecalciferol'), ('PR_000006474', 'ATP-dependent RNA helicase A', 105, 'DHCR7'), ('CHEBI_50905', 'teratogenic agent', 206, 'teratogenic'), ('GO_0031649', 'heat generation', 206, 'teratogenic'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D'), ('GO_0007565', 'female pregnancy', 281, 'prenatal'), ('CHEBI_27300', 'vitamin D', 331, 'vitamin D'), ('GO_0007565', 'female pregnancy', 363, 'pregnant'), ('CHEBI_27300', 'vitamin D', 389, 'vitamin D'), ('GO_0007567', 'parturition', 457, 'birth'), ('GO_0007565', 'female pregnancy', 471, 'preterm'), ('GO_0042633', 'hair cycle', 479, 'birth90'), ('UBERON_0002113', 'kidney', 501, 'kidney'), ('CHEBI_33279', 'vitamin D5', 557, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 557, 'vitamin D3'), ('PR_000006474', 'ATP-dependent RNA helicase A', 584, 'DHCR7'), ('CHEBI_52217', 'pharmaceutical', 622, 'pharmacological'), ('PR_000006474', 'ATP-dependent RNA helicase A', 638, 'DHCR7'), ('CHEBI_35222', 'inhibitor', 644, 'inhibitors')]	0	"['[""""comment vitamin d3*s in-direct inhibition dhcr7\\nof noin (cholecalciferol) decreases dhcr7 activity mechanism.54there teratogenic resulting dosesin aatal supplement.89however, reviewin supplementation amnant women tin supplementation pre-eclampsia, birth weigterm birth90,91and kidney outcomes offspring.92because vitamin d3*s inhibition dhcr7 (unlike pharmacological dhcr7 inhibitors) feedback loops.""""]']"
S202-PMC5028238	PMC5028238	10/2016	S202-PMC5028238	['studies involving moderate Prenatal Vitamin D supplementation HAVE REPORTED no adverse EFFECTS.89THEREFORE, we would not expect Vitamin D to result in slos-RELATED Teratogenic EFFECTS, ALTHOUGH ADDITIONAL STUDIES would BE NEEDED to ascertain the EFFECTS of large doses of Prenatal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 62), ('SUPERFICIAL_RELATIONSHIP', 87), ('PROBABLE_UNDERSTANDING', 95), ('PROBABLE_UNDERSTANDING', 95), ('SUPERFICIAL_RELATIONSHIP', 156), ('SUPERFICIAL_RELATIONSHIP', 176), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 185), ('FUTURE_WORK', 194), ('FUTURE_WORK', 205), ('FUTURE_WORK', 219), ('SUPERFICIAL_RELATIONSHIP', 246)]	11	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_50905', 'teratogenic agent', 164, 'teratogenic'), ('GO_0007565', 'female pregnancy', 272, 'prenatal'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D')]	0	['studies   supplementation effects.89therefore,  result slos-related teratogenic effects, ascertain doses   supplementation.']
S112-PMC5029041	PMC5029041	9/2016	S112-PMC5029041	['multiple Micronutrient supplements decrease lbw, fgr and stillbirths [69]; HOWEVER, WHETHER deficiencies of Micronutrients such as zinc, Calcium and Vitamin A INTERACT with malaria in Pregnancy REMAINS UNCLEAR [70].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 75), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 84), ('SUPERFICIAL_RELATIONSHIP', 159), ('FULL_UNKNOWN', 194)]	4	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 9, 'micronutrient'), ('CHEBI_33839', 'macromolecule', 108, 'micronutrients'), ('CHEBI_22313', 'alkaline earth metal atom', 137, 'calcium'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin A'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]	0	['multiple micronutrient supplements decrease lbw, fgr stillbirths [69]; however, micronutrients zinc, calcium  malaria  [70].']
S80-PMC5030591	PMC5030591	9/2016	S80-PMC5030591	"['[""""caption (table-wrap): table 4\\n\\nthemes and elements relating to specific Conception and Pregnancy information for women with rheumatoid arthritis and their familiessaying : information that should be discussed by health professionals doing : actions that SHOULD BE undertaken by health professionals review of current Medications in relation to safety during Conception and Pregnancy (100%) prior to Conception and Pregnancy, review current Medication(s) and discuss:\\nmedications vary with respect to their SAFETY during Pregnancy and RISKS related to Fertility, Ovulation, Conception and Miscarriage\\nSOME Medicines used in ra care MAY have EFFECTS on Fertility, Conception and Pregnancy process, for example, regular Nsaids MAY impair fertility and ASSOCIATED RISKS with fetus\\nit is IMPORTANT to time Conceptionprovide GUIDANCE as to WHERE to obtain reliable information about SAFETY of Medicines in Pregnancywhere current Medication(s) is (are) contraindicated for Conception/Pregnancy the following SHOULD BE discussed with the patient:\\nthere are SAFE Medication options pre, during (including Delivery) and Postpregnancy (including Breast feeding)\\ntiming is IMPORTANT in RELATION to ceasing or switching of current Medications and allowing for washout periods prior to Conception\\nthere is a need for close supervision/monitoring by a rheumatologist when discontinuing current Medications prior to Pregnancy, including CONSIDERING POTENTIAL NEED for disease stabilisation on new treatment prior to Conception and Pregnancydiscuss IMPACT of ra pathology on Pregnancy and Pregnancy on ra (100%) there are DIFFERENT SCENARIOS regarding ra disease activity during Pregnancy (eg, POSSIBLE remission/low disease activity)discuss: ra-related pain management options during Pregnancyconception MAY take longer compared with women who do not have rathere is a need to balance disease Control with maternal and fetal health and safetyra MAY AFFECT Pregnancy and Pregnancy MAY AFFECT ra, and there are POSSIBLE adverse outcomes where risks are identified (eg, Prematurity)there are significant risks ASSOCIATED with active or uncontrolled ra for the mother and baby, ESPECIALLY irreversible Joint damage and functional impairmentpregnancy MAY change a patient’s health outlook in the futurethe size of the baby MAY BE smaller than women without ra and MAY also be Delivered pre-term discuss IMPORTANT elements of Preconception care RELEVANT to patient (97.1%) it is IMPORTANT to achieve optimal disease control prior to considering Pregnancy—Planning Conception is preferable after patients achieve and maintain low disease activityencourage and facilitate early discussions with all health practitioners involved in care about family planning to allow for adequate preparationthere is a CRITICAL need for a planned Pregnancy RATHER than an unplanned Pregnancyreview Prenatal nutrition, including need for dietary/vitamin supplements (ie, Folic Acid, calcium, Vitamin D, Iodine, iron)history of previous Attempts To Conceive/Pregnancies or Pregnancy-related complications (eg, Miscarriage) and other relevant patient history (such as smoking/Illicit Drug use history, family history of hereditary issues) MAY AFFECT Pregnancyundertake RELEVANT health checks such as immunisation status (eg, rubella, varicella, pertussis), Sexually Transmitted disease screening, pap test, screening for other Autoimmune disorders that MAY IMPACT on Pregnancyweight management and appropriate exercise are very IMPORTANTCONSIDER the NEED for review of diabetes or impaired Glucose tolerance if RISK factors are present (eg, on Steroid medication or overweight/obese)it is IMPORTANT to manage comorbid conditions, such as diabetes and hypertensionsome women MAY NEED to avoid Conception during a flarera disease activity MAY or MAY not improve with Pregnancy and there is a LIKELIHOOD of Postpartum flares importance of maintaining optimistic outlook and providing positive messages (97.1%) Pregnancy and Breast feeding success rates are near normal in women with mild to moderate ra nowadays (where appropriate for the patient\'s clinical status)ra is not a BARRIER to Pregnancystrategies to address anxiety, stress and depression (if relevant) are IMPORTANT, such as mindfulness meditation need for close monitoring of a patient prior to and during Pregnancy, where indicated (94.1%) it is IMPORTANCE to have a healthcare team with expertise in Autoimmune disorders for SOME women with radetermine THE NEED for high-level obstetric care during a Pregnancy (where indicated), including the need for Anaesthetic inputsome women REQUIRE closer monitoring of their Pregnancy and this is USUALLY proportional to disease activity, comorbidities and maternal historyassess the REQUIREMENTS for any extra treatment or monitoring prior to, or during, Pregnancyit is IMPORTANT to develop a Pregnancy plan, which includes different options for management of ra and support for different scenariosvaginal Delivery MAY NOT always BE POSSIBLE, depending on condition of the patient\'s Hips.""""]']"	[('FUTURE_WORK', 254), ('IMPORTANT_CONSIDERATION', 506), ('IMPORTANT_CONSIDERATION', 534), ('INCOMPLETE_EVIDENCE', 600), ('INCOMPLETE_EVIDENCE', 631), ('SUPERFICIAL_RELATIONSHIP', 640), ('INCOMPLETE_EVIDENCE', 724), ('SUPERFICIAL_RELATIONSHIP', 749), ('IMPORTANT_CONSIDERATION', 760), ('IMPORTANT_CONSIDERATION', 783), ('FUTURE_WORK', 819), ('EXPLICIT_QUESTION', 834), ('IMPORTANT_CONSIDERATION', 877), ('FUTURE_WORK', 1001), ('IMPORTANT_CONSIDERATION', 1049), ('IMPORTANT_CONSIDERATION', 1161), ('SUPERFICIAL_RELATIONSHIP', 1174), ('FUTURE_WORK', 1421), ('IMPORTANT_CONSIDERATION', 1421), ('INCOMPLETE_EVIDENCE', 1433), ('SUPERFICIAL_RELATIONSHIP', 1532), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1605), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1615), ('INCOMPLETE_EVIDENCE', 1677), ('INCOMPLETE_EVIDENCE', 1788), ('INCOMPLETE_EVIDENCE', 1929), ('SUPERFICIAL_RELATIONSHIP', 1933), ('INCOMPLETE_EVIDENCE', 1964), ('SUPERFICIAL_RELATIONSHIP', 1968), ('INCOMPLETE_EVIDENCE', 1993), ('SUPERFICIAL_RELATIONSHIP', 2091), ('IMPORTANT_CONSIDERATION', 2158), ('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2302), ('INCOMPLETE_EVIDENCE', 2343), ('IMPORTANT_CONSIDERATION', 2382), ('SUPERFICIAL_RELATIONSHIP', 2423), ('IMPORTANT_CONSIDERATION', 2457), ('IMPORTANT_CONSIDERATION', 2779), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2817), ('INCOMPLETE_EVIDENCE', 3196), ('SUPERFICIAL_RELATIONSHIP', 3200), ('IMPORTANT_CONSIDERATION', 3226), ('INCOMPLETE_EVIDENCE', 3410), ('SUPERFICIAL_RELATIONSHIP', 3414), ('IMPORTANT_CONSIDERATION', 3485), ('INCOMPLETE_EVIDENCE', 3507), ('SUPERFICIAL_RELATIONSHIP', 3568), ('IMPORTANT_CONSIDERATION', 3646), ('INCOMPLETE_EVIDENCE', 3731), ('FUTURE_WORK', 3735), ('IMPORTANT_CONSIDERATION', 3735), ('INCOMPLETE_EVIDENCE', 3794), ('INCOMPLETE_EVIDENCE', 3801), ('PROBABLE_UNDERSTANDING', 3847), ('DIFFICULT_TASK', 4131), ('IMPORTANT_CONSIDERATION', 4222), ('IMPORTANT_CONSIDERATION', 4364), ('INCOMPLETE_EVIDENCE', 4444), ('INCOMPLETE_EVIDENCE', 4472), ('IMPORTANT_CONSIDERATION', 4600), ('INCOMPLETE_EVIDENCE', 4657), ('IMPORTANT_CONSIDERATION', 4744), ('IMPORTANT_CONSIDERATION', 4831), ('INCOMPLETE_EVIDENCE', 4976), ('DIFFICULT_TASK', 4980)]	66	[('GO_0007631', 'feeding behavior', 72, 'conception ...'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_25441', 'mycothiols', 317, 'medications'), ('GO_0007620', 'copulation', 358, 'conception'), ('GO_0007565', 'female pregnancy', 373, 'pregnancy'), ('GO_0007620', 'copulation', 399, 'conception'), ('GO_0007565', 'female pregnancy', 414, 'pregnancy'), ('CHEBI_60211', 'compound Z', 440, 'medication'), ('GO_0007565', 'female pregnancy', 520, 'pregnancy'), ('GO_0009566', 'fertilization', 551, 'fertility'), ('GO_0030728', 'ovulation', 562, 'ovulation'), ('GO_0007620', 'copulation', 573, 'conception'), ('GO_0046660', 'female sex differentiation', 588, 'miscarriage'), ('CHEBI_25179', 'melanins', 605, 'medicines'), ('GO_0009566', 'fertilization', 651, 'fertility'), ('GO_0007620', 'copulation', 662, 'conception'), ('GO_0007565', 'female pregnancy', 677, 'pregnancy'), ('CHEBI_16039', 'ITP', 717, 'NSAIDs'), ('GO_0070268', 'cornification', 801, 'conceptionProvide'), ('CHEBI_25179', 'melanins', 887, 'medicines'), ('GO_0000712', 'resolution of meiotic recombination intermediates', 900, 'pregnancyWhere'), ('CHEBI_60211', 'compound Z', 923, 'medication'), ('GO_0007620', 'copulation', 966, 'conception'), ('GO_0007565', 'female pregnancy', 977, 'pregnancy'), ('CHEBI_60211', 'compound Z', 1054, 'medication'), ('GO_0007567', 'parturition', 1096, 'delivery'), ('GO_0007565', 'female pregnancy', 1110, 'postpregnancy'), ('UBERON_0000310', 'breast', 1135, 'breast'), ('CHEBI_25441', 'mycothiols', 1218, 'medications'), ('GO_0007620', 'copulation', 1272, 'conception'), ('CHEBI_25441', 'mycothiols', 1379, 'medications'), ('GO_0007565', 'female pregnancy', 1400, 'pregnancy'), ('GO_0007620', 'copulation', 1500, 'conception'), ('GO_0006915', 'apoptotic process', 1515, 'pregnancyDiscuss'), ('GO_0007565', 'female pregnancy', 1558, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1572, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1662, 'pregnancy'), ('GO_0007602', 'phototransduction', 1768, 'pregnancyConception'), ('GO_0065007', 'biological regulation', 1877, 'control'), ('GO_0007565', 'female pregnancy', 1940, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1954, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2051, 'prematurity'), ('UBERON_0004905', 'articulation', 2182, 'joint'), ('GO_0007567', 'parturition', 2355, 'delivered'), ('GO_0007565', 'female pregnancy', 2404, 'preconception'), ('GO_0007565', 'female pregnancy', 2523, 'pregnancy'), ('GO_0006260', 'DNA replication', 2533, 'planning'), ('GO_0007620', 'copulation', 2542, 'conception'), ('GO_0007565', 'female pregnancy', 2807, 'pregnancy'), ('GO_0006412', 'translation', 2842, 'pregnancyReview'), ('GO_0007565', 'female pregnancy', 2858, 'prenatal'), ('CHEBI_30751', 'formic acid', 2930, 'folic acid'), ('CHEBI_27300', 'vitamin D', 2951, 'vitamin D'), ('CHEBI_24859', 'iodine atom', 2962, 'iodine'), ('GO_0000380', 'alternative mRNA splicing, via spliceosome', 2995, 'attempts to conceive'), ('GO_0007565', 'female pregnancy', 3016, 'pregnancies'), ('GO_0007565', 'female pregnancy', 3031, 'pregnancy'), ('GO_0046660', 'female sex differentiation', 3068, 'miscarriage'), ('CHEBI_35704', 'N(2)-acetyl-L-lysine', 3133, 'illicit drug'), ('GO_0051610', 'serotonin uptake', 3207, 'pregnancyUndertake'), ('GO_0019095', 'pole plasm mitochondrial rRNA localization', 3314, 'sexually transmitted'), ('UBERON_0001442', 'skeleton of manus', 3384, 'autoimmune'), ('GO_0006412', 'translation', 3424, 'pregnancyWeight'), ('CHEBI_17234', 'glucose', 3547, 'glucose'), ('CHEBI_35341', 'steroid', 3601, 'steroid'), ('GO_0007620', 'copulation', 3749, 'conception'), ('GO_0007565', 'female pregnancy', 3822, 'pregnancy'), ('GO_0007565', 'female pregnancy', 3861, 'postpartum'), ('GO_0007565', 'female pregnancy', 3964, 'Pregnancy'), ('UBERON_0000310', 'breast', 3978, 'breast'), ('GO_0006915', 'apoptotic process', 4142, 'pregnancyStrategies'), ('GO_0007565', 'female pregnancy', 4323, 'pregnancy'), ('UBERON_0001442', 'skeleton of manus', 4419, 'autoimmune'), ('GO_0007565', 'female pregnancy', 4520, 'pregnancy'), ('CHEBI_38867', 'anaesthetic', 4572, 'anaesthetic'), ('GO_0007565', 'female pregnancy', 4635, 'pregnancy'), ('GO_0007565', 'female pregnancy', 4816, 'pregnancyIt'), ('GO_0007565', 'female pregnancy', 4854, 'pregnancy'), ('GO_0007567', 'parturition', 4967, 'delivery'), ('UBERON_0000988', 'pons', 5044, 'hips')]	0	"['[""""caption (table-wrap): table 4\\n\\nthemes elements conceptionnancy women rheumatoid arthritis familiessaying : professionals : professionals medications conceptionnancy (100%) conceptionnancy, medication(s) discuss:\\nmedications respect dgnancy fertility, ovulation, miscarriage\\nsome medicines ra fertility, conceptiegnancy process, example, nsaids fertility fetus\\nit conceptionprovide obtain medicines pregnancywhere medication(s) (are) conregnancy following patient:\\nthere medication pre, (including delivpregnancy (including breast feeding)\\ntiming ceasing switching medications allowing washout periods conception\\nthere close supervision/monitoring rheumatologist discontinuing medicationo pregnancy, disease stabilisation treatment pregnancydiscuss ra pan pred pregnancy ra (100%) regarding ra disease activg pregnancy (eg, remission/low disease activity)discuss: ra-related pain pregnancyconception longer women rathere balance disease maternal fetal safetyra pred pregnancy ra, outcomes identprematurity)there ra mother baby, irreversible joint functional impairmentpregnancy patient’s outlook futurethe baby women ra delivered pre-term eeconception patient (97.1%) achieve disease cg pregnancy—planning patients achieve maintain disease activityencourage discussions practitioners family preparationthere ford pregnancy pregnew prenatal nutrition, dietary/vitamin supplements (ie, folic acid, vitamin d, iodine, iron)history tpregr pregnancy-related (eg, miscarriage) patient (such smoking/illicit drug history, family hereditary issues) pregnancyundertake checks immunisation status (eg, rubella, varicella, pertussis), sexually transmitted disease screening, pap test, screening autoimmune disorders pregnancyweight exercise diabetes glucose tolerance (eg, steroid medication overweight/obese)it manage comorbid conditions, diabetes hypertensionsome women flarera disease activity imh pregnancy lik postpartum flares maintaining optimistic outlook positive messag) pregnancy breast feeding rates normal women ra nowadays (where patient*s status)ra pregnancystrategies anxiety, depression (if relevant) important, mindfulness meditation close patient g pregnancy, (94.1%) healthcare team expertise autoimmune disorders women radetermine high-level obstetric cara pregnancy (where indicated), anaesthetic inputsome women closer monitorinr pregnancy proportional disease activity, comorbidities maternal historyassess extra treatment to, pregnancyit toa pregnancy plan, includes ra scenariosvaginal delivery possible, condition patient*s hips.""""]']"
S1-PMC5035678	PMC5035678	4/2016	S1-PMC5035678	['objectives\nwe report the FIRST STUDY of the IMPACT of Prenatal Vitamin D supplementation on Postpartum dysglycemia in gdm patients in a randomized clinical trial.']	[('INCOMPLETE_EVIDENCE', 25), ('SUPERFICIAL_RELATIONSHIP', 44)]	2	[('GO_0007565', 'female pregnancy', 54, 'prenatal'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 92, 'postpartum')]	0	['objectives\nwe   supplementation  dysglycemia gdm patients trial.']
S9-PMC5035678	PMC5035678	4/2016	S9-PMC5035678	['conclusions\nALTHOUGH the high Vitamin D supplementation dose in the PRESENT STUDY (compared to the 400 iu/day dose USUALLY recommended for Pregnancy) SAFELY increases the Serum 25Ohd, in gdm cases, the higher dose does not affect the plasma Glucose level or Insulin resistance at short term follow-up after Delivery.']	[('ANOMALY_CURIOUS_FINDING', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 68), ('INCOMPLETE_EVIDENCE', 115), ('IMPORTANT_CONSIDERATION', 150)]	4	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 177, '25OHD'), ('CHEBI_17234', 'glucose', 241, 'glucose'), ('PR_000045358', 'insulin family protein', 258, 'insulin'), ('GO_0007567', 'parturition', 307, 'delivery')]	0	['conclusions\nalthough  supplementation dose (compared 400 iu/day dose serum 25ohd, gdm cases, higher dose plasma glucose insulin resistance term follow-up delivery.']
S109-PMC5035678	PMC5035678	4/2016	S109-PMC5035678	['discussion\nTO OUR KNOWLEDGE, THIS is the FIRST STUDY TO EVALUATE the EFFECTS of Vitamin D supplementation during Pregnancy on Glucose Metabolism shortly after Delivery.']	[('PROBABLE_UNDERSTANDING', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 29), ('INCOMPLETE_EVIDENCE', 41), ('QUESTION_ANSWERED_BY_THIS_WORK', 47), ('QUESTION_ANSWERED_BY_THIS_WORK', 53), ('SUPERFICIAL_RELATIONSHIP', 69)]	6	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('CHEBI_17234', 'glucose', 126, 'glucose'), ('GO_0006006', 'glucose metabolic process', 126, 'glucose metabolism'), ('GO_0007567', 'parturition', 159, 'delivery')]	0	['discussion\nto knowledge,  supplementation  glucose metabolism shortly delivery.']
S110-PMC5035678	PMC5035678	4/2016	S110-PMC5035678	['OUR STUDY DEMONSTRATES that high dose Vitamin D supplementation during Pregnancy in women with gdm and impairment of 25Ohd concentration has no effect on post-Partum Plasma Glucose and Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10)]	2	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 117, '25OHD'), ('GO_0007567', 'parturition', 159, 'partum'), ('UBERON_0001969', 'blood plasma', 166, 'plasma'), ('CHEBI_17234', 'glucose', 173, 'glucose'), ('PR_000045358', 'insulin family protein', 185, 'insulin')]	0	['dose  supplementation  women gdm impairment 25ohd concentration post-partum plasma glucose insulin resistance.']
S112-PMC5035678	PMC5035678	4/2016	S112-PMC5035678	['fifty eight percent of group c remained Vitamin D deficient, which INDICATES that the usual multivitamin that is prescribed for a majority of Pregnant women (containing 400 iu Vitamin D3) is not adequate to correct hypovitaminosis D. THEREFORE, Pregnant women NEED a higher dose of Vitamin D than that typically consumed.']	[('INCOMPLETE_EVIDENCE', 67), ('PROBABLE_UNDERSTANDING', 234), ('IMPORTANT_CONSIDERATION', 260)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 142, 'pregnant'), ('CHEBI_33279', 'vitamin D5', 176, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 176, 'vitamin D3'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 231, 'D'), ('GO_0007565', 'female pregnancy', 245, 'pregnant'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D')]	0	['fifty eight percent c  deficient, usual multivitamin prescribed  women (containing 400 iu vitamin d3) hypovitaminosis d. therefore,  women higher dose  consumed.']
S115-PMC5035678	PMC5035678	4/2016	S115-PMC5035678	['HOWEVER, there is SCARCE INFORMATION about the EFFECT of Vitamin D supplementation on Glucose Metabolism, especially during Pregnancy and after Delivery.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 47)]	3	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_17234', 'glucose', 86, 'glucose'), ('GO_0006006', 'glucose metabolic process', 86, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007567', 'parturition', 144, 'delivery')]	0	['however,  supplementation glucose metabolism,  delivery.']
S117-PMC5035678	PMC5035678	4/2016	S117-PMC5035678	['(26) REVEALED a positive EFFECT of co-supplementation with Vitamin D and Calcium on Insulin resistance during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 25)]	2	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 73, 'calcium'), ('PR_000045358', 'insulin family protein', 84, 'insulin'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy')]	0	['(26) positive co-supplementation  calcium insulin resistance .']
S132-PMC5035678	PMC5035678	4/2016	S132-PMC5035678	['they FOUND that high dose supplementation for a mean of 14 weeks during Pregnancy was not beneficial to the patients’ plasma Glucose level or Insulin resistance during Pregnancy, BUT that their babies BENEFITTED from the supplementation with decreased neonatal hypovitaminosis D. the authors CONCLUDED that the commencement of Vitamin D supplementation MAY HAVE been too late to cause any observable EFFECTS on Β-Cell function, and they SUGGESTED that earlier supplementation, EVEN before Pregnancy, MIGHT be EFFECTIVE.']	[('INCOMPLETE_EVIDENCE', 5), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 179), ('IMPORTANT_CONSIDERATION', 201), ('INCOMPLETE_EVIDENCE', 292), ('INCOMPLETE_EVIDENCE', 353), ('IMPORTANT_CONSIDERATION', 357), ('SUPERFICIAL_RELATIONSHIP', 400), ('INCOMPLETE_EVIDENCE', 437), ('ANOMALY_CURIOUS_FINDING', 477), ('INCOMPLETE_EVIDENCE', 500), ('SUPERFICIAL_RELATIONSHIP', 509)]	11	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('CHEBI_17234', 'glucose', 125, 'glucose'), ('PR_000045358', 'insulin family protein', 142, 'insulin'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 277, 'D'), ('CHEBI_27300', 'vitamin D', 327, 'vitamin D'), ('CL_0000623', 'natural killer cell', 411, 'β-cell'), ('GO_0007565', 'female pregnancy', 489, 'pregnancy')]	0	['dose supplementation 14 weeks  patients’ plasma glucose insulin resistance babies supplementation decreased neonatal hypovitaminosis d. authors commencement  supplementation late β-cell function, supplementation, effective.']
S135-PMC5035678	PMC5035678	4/2016	S135-PMC5035678	['as mentioned by yap, this result MAY INDICATE that it is actually dysglycemia that leads to defects in Liver Hydroxylation of Vitamin D.\nVitamin D supplementation has diverse EFFECTS on the non-Pregnant population.']	[('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 175)]	3	[('UBERON_0002107', 'liver', 103, 'liver'), ('GO_0044444', 'cytoplasmic part', 109, 'hydroxylation'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 137, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 194, 'pregnant')]	0	['yap, result dysglycemia defects liver hydroxylation .\nvitamin supplementation non- population.']
S143-PMC5035678	PMC5035678	4/2016	S143-PMC5035678	['in ANOTHER STUDY of the non-Pregnant population, and CONSISTENT with our results, davidson and colleagues FOUND that a mean supplement dose of 88,865 iu Vitamin D per week, in 56 subjects with hypovitaminosis D and pre-diabetes, had no effect on Insulin resistance and plasma Glucose levels at 3, 6, 9, and 12 months after intervention, compared to 53 subjects in a placebo group (31).']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 106)]	3	[('GO_0007565', 'female pregnancy', 28, 'pregnant'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 209, 'D'), ('PR_000045358', 'insulin family protein', 246, 'insulin'), ('CHEBI_17234', 'glucose', 276, 'glucose')]	0	['non- population, results, davidson colleagues supplement dose 88,865 iu  week, 56 subjects hypovitaminosis pre-diabetes, insulin resistance plasma glucose levels 3, 6, 9, 12 months intervention, 53 subjects placebo (31).']
S147-PMC5035678	PMC5035678	4/2016	S147-PMC5035678	['as PREVIOUSLY discussed, a LIMITED NUMBER OF STUDIES have evaluated the EFFECT of Vitamin D on Glucose Metabolism and Insulin resistance, especially during and after Pregnancy.']	[('INCOMPLETE_EVIDENCE', 3), ('INCOMPLETE_EVIDENCE', 27), ('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 72)]	4	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('CHEBI_17234', 'glucose', 95, 'glucose'), ('GO_0006006', 'glucose metabolic process', 95, 'glucose metabolism'), ('PR_000045358', 'insulin family protein', 118, 'insulin'), ('GO_0007565', 'female pregnancy', 166, 'pregnancy')]	0	['discussed,  glucose metabolism insulin resistance, .']
S160-PMC5035678	PMC5035678	4/2016	S160-PMC5035678	['IN SPITE of these LIMITATIONS, THIS is currently the ONLY study in the literature that evaluates the INFLUENCE of Vitamin D supplementation during Pregnancy on Postpartum dysglycemia.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 31), ('INCOMPLETE_EVIDENCE', 53), ('SUPERFICIAL_RELATIONSHIP', 101)]	5	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy'), ('GO_0007565', 'female pregnancy', 160, 'postpartum')]	0	['limitations,  supplementation   dysglycemia.']
S161-PMC5035678	PMC5035678	4/2016	S161-PMC5035678	['in conclusion, Prenatal Vitamin D supplementation in patients with gdm and hypovitaminosis D SAFELY and significantly increases maternal and neonatal Serum 25Ohd.']	[('IMPORTANT_CONSIDERATION', 93)]	1	[('GO_0007565', 'female pregnancy', 15, 'prenatal'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 91, 'D'), ('UBERON_0001977', 'blood serum', 150, 'serum'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 156, '25OHD')]	0	['conclusion,   supplementation patients gdm hypovitaminosis maternal neonatal serum 25ohd.']
S21-PMC5039809	PMC5039809	10/2016	S21-PMC5039809	['FEW STUDIES to OUR KNOWLEDGE have RELATED maternal Vitamin A nutrition during Pregnancy to Offspring Bone Development.']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 15), ('SUPERFICIAL_RELATIONSHIP', 34)]	3	[('CHEBI_27300', 'vitamin D', 51, 'vitamin A'), ('GO_0007565', 'female pregnancy', 78, 'pregnancy'), ('GO_0007608', 'sensory perception of smell', 91, 'offspring'), ('GO_0048539', 'bone marrow development', 101, 'bone development')]	0	['maternal  nutrition  offspring bone development.']
S89-PMC5039809	PMC5039809	10/2016	S89-PMC5039809	['Serum Vitamin A (Retinol and Β-Carotene) and neonatal bone indexes\nafter adjusting for maternal FACTORS, Gestational age, sex, and age at dxa scan, maternal Serum Retinol in late Pregnancy was significantly negatively ASSOCIATED with offspring total body bmc, ba, and Birth weight BUT NOT bmd or scbmc ( table 3 ).']	[('SUPERFICIAL_RELATIONSHIP', 96), ('SUPERFICIAL_RELATIONSHIP', 218), ('ANOMALY_CURIOUS_FINDING', 281)]	3	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 6, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 17, 'retinol'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 29, 'β-carotene'), ('GO_0007565', 'female pregnancy', 105, 'gestational'), ('UBERON_0001977', 'blood serum', 157, 'serum'), ('CHEBI_26536', 'retinoic acid', 163, 'retinol'), ('GO_0007565', 'female pregnancy', 179, 'pregnancy'), ('GO_0007567', 'parturition', 268, 'birth')]	0	['serum  (retinol β-carotene) neonatal bone indexes\nafter adjusting maternal factors,  age, sex, age dxa scan, maternal serum retinol late  offspring bmc, ba, birth bmd scbmc table 3 ).']
S103-PMC5039809	PMC5039809	10/2016	S103-PMC5039809	['in the final analyses, maternal Vitamin D status in late Pregnancy was included in the MODELS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 87)]	1	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy')]	0	['final analyses, maternal  status late  models.']
S109-PMC5039809	PMC5039809	10/2016	S109-PMC5039809	['PREVIOUS intervention STUDIES have NOT CONSISTENTLY DEMONSTRATED that Prenatal Vitamin A supplementation CAN increase Birth size.']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 35), ('INCOMPLETE_EVIDENCE', 52), ('INCOMPLETE_EVIDENCE', 105)]	4	[('GO_0007565', 'female pregnancy', 70, 'prenatal'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin A'), ('GO_0007567', 'parturition', 118, 'birth')]	0	['previous   supplementation increase birth size.']
S13-PMC5045784	PMC5045784	10/2016	S13-PMC5045784	['introduction\nbronchopulmonary dysplasia (bpd) is the MOST PREVALENT long-term morbidity among surviving EXTREMELY preterm infants and has a MULTIFACTORIAL etiology.1bpd is ASSOCIATED with later risk of reactive Airways disease, such as asthma,2post neonatal mortality and adverse Neurodevelopmental outcomes.1bpd AFFECTS ~20% of preterm infants, and up to 60% of extremely preterm infants who are Born before 26 completed weeks of Gestation.2an ESTIMATED 10\u2009000 to 15\u2009000 infants are affected in the united states each year and this has substantial medical and socioeconomic IMPLICATIONS.2,3\nACCUMULATING epidemiologic EVIDENCE SUGGESTS that Vitamin D deficiency or insufficiency is ASSOCIATED with Respiratory disease in children.']	[('IMPORTANT_CONSIDERATION', 53), ('IMPORTANT_CONSIDERATION', 104), ('DIFFICULT_TASK', 140), ('SUPERFICIAL_RELATIONSHIP', 172), ('SUPERFICIAL_RELATIONSHIP', 313), ('INCOMPLETE_EVIDENCE', 445), ('IMPORTANT_CONSIDERATION', 575), ('INCOMPLETE_EVIDENCE', 592), ('INCOMPLETE_EVIDENCE', 628), ('SUPERFICIAL_RELATIONSHIP', 683)]	10	[('UBERON_0001005', 'respiratory airway', 211, 'airways'), ('GO_0007399', 'nervous system development', 280, 'neurodevelopmental'), ('GO_0007567', 'parturition', 397, 'born'), ('GO_0007565', 'female pregnancy', 431, 'gestation'), ('CHEBI_27300', 'vitamin D', 642, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 699, 'respiratory')]	0	['introduction\nbronchopulmonary dysplasia (bpd) long-term morbidity among surviving preterm infants etiology.1bpd reactive airways disease, asthma,2post neonatal mortality neurodevelopmental outcomes.1bpd ~20% preterm infants, 60% preterm infants born 26 completed weeks .2an 10\u2009000 15\u2009000 infants united year medical socioeconomic implications.2,3\naccumulating epidemiologic  respiratory disease children.']
S14-PMC5045784	PMC5045784	10/2016	S14-PMC5045784	['camargo et al.4DEMONSTRATED that lower maternal Intake of Vitamin D during Pregnancy is ASSOCIATED with recurrent wheezing and asthma in their offspring during early childhood.']	[('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 88)]	2	[('GO_0007631', 'feeding behavior', 48, 'intake'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy')]	0	['camargo et al.4demonstrated maternal intake   recurrent wheezing asthma offspring childhood.']
S58-PMC5045784	PMC5045784	10/2016	S58-PMC5045784	"['[""""our study is IN AGREEMENT with a study by onwuneme et al.16in which, in a cohort of 94 preterm infants (<32 weeks\' Gestation), there was no association with bpd or other morbidities of Prematurity although the authors FOUND an ASSOCIATION between Vitamin D status and acute Respiratory morbidity (AS defined by differences in duration of positive pressure ventilation and highest oxygen concentration required in the delivery room and the odds of requiring assisted ventilation).""""]']"	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 218), ('SUPERFICIAL_RELATIONSHIP', 227), ('PROBABLE_UNDERSTANDING', 297)]	4	[('GO_0007565', 'female pregnancy', 115, 'gestation'), ('GO_0007565', 'female pregnancy', 185, 'prematurity'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 274, 'respiratory')]	0	"['[""""our study onwuneme et al.16in which, 94 preterm infants (<32 weekion), bpd morbidities ity authors betwen status acute respiratory morbidity (as duration positive pressure ventilation oxygen concentration delivery ventilation).""""]']"
S74-PMC5045784	PMC5045784	10/2016	S74-PMC5045784	['fetal and newborn concentrations of 25(Oh)D DEPEND ON and CORRELATE with maternal Serum levels AS the fetus has no endogenous production of 25(Oh)d and DEPENDS on transplacental transfer.28THIS occurs MAINLY in the third trimester and THEREFORE, as we and others PREVIOUSLY REPORTED, preterm infants are at INCREASED RISK of Vitamin D deficiency.10,29our PRIOR STUDY DEMONSTRATED that Birth before 32 completed weeks of Gestation is an INDEPENDENT RISK FACTOR for low 25(Oh)d levels at Birth.']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 58), ('PROBABLE_UNDERSTANDING', 95), ('SUPERFICIAL_RELATIONSHIP', 152), ('PROBABLE_UNDERSTANDING', 187), ('PROBABLE_UNDERSTANDING', 201), ('PROBABLE_UNDERSTANDING', 235), ('INCOMPLETE_EVIDENCE', 263), ('IMPORTANT_CONSIDERATION', 307), ('INCOMPLETE_EVIDENCE', 355), ('INCOMPLETE_EVIDENCE', 367), ('SUPERFICIAL_RELATIONSHIP', 436), ('SUPERFICIAL_RELATIONSHIP', 448)]	13	[('CHEBI_71657', 'versiconol acetate', 36, '25(OH)D'), ('UBERON_0001977', 'blood serum', 82, 'serum'), ('CHEBI_63056', 'zinc cation', 140, '25(OH'), ('CHEBI_27300', 'vitamin D', 325, 'vitamin D'), ('GO_0007567', 'parturition', 385, 'birth'), ('GO_0007565', 'female pregnancy', 420, 'gestation'), ('CHEBI_30778', 'gallic acid', 468, '25(OH)'), ('GO_0007567', 'parturition', 486, 'birth')]	0	['fetal newborn concentrations 25(oh)d maternal serum levels fetus endogenous production 25(oh)d transplacental transfer.28this occurs third trimester therefore, reported, preterm infants birth 32 completed weeks  25(oh)d levels birth.']
S77-PMC5045784	PMC5045784	10/2016	S77-PMC5045784	[', wagner et al.30,31and others have DEMONSTRATED that Vitamin D status at Birth is modifiable through maternal supplementation during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 36)]	1	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007567', 'parturition', 74, 'birth'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy')]	0	[', wagner et al.30,31and  status birth maternal supplementation .']
S78-PMC5045784	PMC5045784	10/2016	S78-PMC5045784	['two RECENTLY published large intervention trials of additional Vitamin D supplementation during Pregnancy in the united states32and europe33showed TRENDS but no significant decreases in the incidence of childhood wheezing and asthma in the first 3 years of Life among the offspring.']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 147)]	2	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy'), ('UBERON_0000104', 'life cycle', 257, 'life')]	0	['two  supplementation  united states32and europe33showed decreases childhood wheezing asthma 3 life among offspring.']
S85-PMC5045784	PMC5045784	10/2016	S85-PMC5045784	['the adequacy of current Postnatal nutritional supplementation of Vitamin D HAS RECENTLY BEEN assessed in Preterm infants in the united states and in europe.']	[('INCOMPLETE_EVIDENCE', 75)]	1	[('GO_0007567', 'parturition', 24, 'postnatal'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 105, 'preterm')]	0	['postnatal nutritional supplementation   infants united europe.']
S87-PMC5045784	PMC5045784	10/2016	S87-PMC5045784	['there are several LIMITATIONS in OUR STUDY, including its SMALL sample size, risk of selection bias and lack of data on Prenatal Vitamin D supplementation and maternal 25(Oh)D levels.']	[('INCOMPLETE_EVIDENCE', 18), ('QUESTION_ANSWERED_BY_THIS_WORK', 33), ('INCOMPLETE_EVIDENCE', 58)]	3	[('GO_0007565', 'female pregnancy', 120, 'prenatal'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 170, '(OH)D')]	0	['study, size, selection   supplementation maternal 25(oh)d levels.']
S2-PMC5051327	PMC5051327	9/2016	S2-PMC5051327	['in THIS PILOT STUDY, we HYPOTHESISED that low maternal Vitamin D levels are over-represented in Pregnancies with fetal distress/Birth asphyxia.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 24), ('QUESTION_ANSWERED_BY_THIS_WORK', 24)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancies'), ('GO_0007567', 'parturition', 128, 'birth')]	0	['study, maternal  levels over-represented  fetal distress/birth asphyxia.']
S9-PMC5051327	PMC5051327	9/2016	S9-PMC5051327	['Birth asphyxia was MORE COMMON in women with Vitamin D deficiency (n=95) in early Pregnancy (or 2.4, 95% ci 1.1 to 5.7).']	[('PROBABLE_UNDERSTANDING', 19)]	1	[('GO_0007567', 'parturition', 0, 'Birth'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]	0	['birth asphyxia women  (n=95)  (or 2.4, 95% ci 1.1 5.7).']
S10-PMC5051327	PMC5051327	9/2016	S10-PMC5051327	['conclusions\nlow Vitamin D levels in early Pregnancy MAY BE ASSOCIATED with emergency caesarean section DUE TO suspected fetal distress and Birth asphyxia.']	[('INCOMPLETE_EVIDENCE', 52), ('SUPERFICIAL_RELATIONSHIP', 59), ('PROBLEM_COMPLICATION', 103)]	3	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('GO_0007567', 'parturition', 139, 'birth')]	0	['conclusions\nlow  levels  caesarean section fetal distress birth asphyxia.']
S11-PMC5051327	PMC5051327	9/2016	S11-PMC5051327	['IF OUR FINDINGS are SUPPORTED by FURTHER STUDIES, PREFERABLY on SEVERE Birth asphyxia, Vitamin D supplementation/sun exposure in Pregnancy MAY lower the risk of subsequent Birth asphyxia.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 20), ('FUTURE_WORK', 33), ('PROBABLE_UNDERSTANDING', 50), ('IMPORTANT_CONSIDERATION', 64), ('INCOMPLETE_EVIDENCE', 139)]	7	[('GO_0007567', 'parturition', 71, 'birth'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy'), ('GO_0007567', 'parturition', 172, 'birth')]	0	['studies, birth asphyxia,  supplementation/sun exposure  birth asphyxia.']
S12-PMC5051327	PMC5051327	9/2016	S12-PMC5051327	['caption (boxed-text)\nstrengths and limitations of THIS STUDY\nTHIS is the FIRST STUDY to SHOW that women who underwent an emergency caesarean section due to suspected fetal distress had lower Vitamin D levels in early Pregnancy as compared to those in a control group.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 50), ('QUESTION_ANSWERED_BY_THIS_WORK', 61), ('INCOMPLETE_EVIDENCE', 73), ('QUESTION_ANSWERED_BY_THIS_WORK', 79), ('INCOMPLETE_EVIDENCE', 88)]	5	[('CHEBI_27300', 'vitamin D', 191, 'vitamin D'), ('GO_0007565', 'female pregnancy', 217, 'pregnancy')]	0	['caption (boxed-text)\nstrengths study\nthis women underwent caesarean section fetal distress  levels  group.']
S15-PMC5051327	PMC5051327	9/2016	S15-PMC5051327	['ONLY one Blood sample drawn from each mother gives us a snapshot of the Vitamin D status in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy')]	0	['blood sample drawn mother us snapshot  status .']
S19-PMC5051327	PMC5051327	9/2016	S19-PMC5051327	['SEVERAL STUDIES HAVE REPORTED increased frequency of emergency caesarean Delivery in RELATION to low Vitamin D,1415but NO PREVIOUS STUDY HAS BEEN particularly designed to study the RELATION between low Vitamin D levels, measured as 25-Hydroxy\xa0(Oh) Vitamin D, in early Pregnancy and the RISK for fetal distress/Birth asphyxia.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 85), ('FULL_UNKNOWN', 119), ('INCOMPLETE_EVIDENCE', 131), ('INCOMPLETE_EVIDENCE', 137), ('SUPERFICIAL_RELATIONSHIP', 181), ('IMPORTANT_CONSIDERATION', 286)]	8	[('GO_0007567', 'parturition', 73, 'delivery'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_29991', 'L-aspartate(1-)', 232, '25-hydroxy (OH)'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('GO_0007565', 'female pregnancy', 268, 'pregnancy'), ('GO_0007567', 'parturition', 310, 'birth')]	0	['several frequency caesarean delivery ,1415but  levels, 25-hydroxy\xa0(oh)  fetal distress/birth asphyxia.']
S37-PMC5051327	PMC5051327	9/2016	S37-PMC5051327	['the mean 25-Oh Vitamin D level was expected to be 50±27.5\u2005nmol/l, BASED ON a scandinavian study.8\n\nresults\nthe background characteristics were not different between cases and controls other than an expected increased PROBABILITY of being Nulliparous and having a Preterm Delivery among women undergoing caesarean Delivery due to suspected fetal distress (table 1).']	[('INCOMPLETE_EVIDENCE', 66), ('PROBABLE_UNDERSTANDING', 217)]	2	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 9, '25-OH'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0046662', 'regulation of oviposition', 238, 'nulliparous'), ('GO_0007565', 'female pregnancy', 263, 'preterm'), ('GO_0007567', 'parturition', 271, 'delivery'), ('GO_0007567', 'parturition', 313, 'delivery')]	0	['25-oh  50±27.5\u2005nmol/l, scandinavian study.8\n\nresults\nthe background characteristics cases nulliparous  delivery among women undergoing caesarean delivery fetal distress (table 1).']
S45-PMC5051327	PMC5051327	9/2016	S45-PMC5051327	['TO STUDY the EFFECT of Vitamin D levels in early Pregnancy and the risk for Birth asphyxia, we divided the study population into two groups: those with vitamin d deficiency (25-Oh Vitamin D <50\u2005nmol/l, n=95) and those who were non-deficient (25-Oh Vitamin d ≥50\u2005nmol/l, n=78) (table 2).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 13)]	2	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 49, 'pregnancy'), ('GO_0007567', 'parturition', 76, 'birth'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 174, '25-OH'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('CHEBI_82341', 'Methylazoxymethanol acetate', 242, '25-OH vitamin')]	0	[' levels  birth asphyxia, population groups: vitamin (25-oh  <50\u2005nmol/l, n=95) non-deficient (25-oh vitamin ≥50\u2005nmol/l, n=78) (table 2).']
S52-PMC5051327	PMC5051327	9/2016	S52-PMC5051327	['discussion\nTHIS PILOT STUDY is the FIRST to SHOW that women who underwent emergency caesarean section due to suspected fetal asphyxia had lower Vitamin D levels in early Pregnancy as COMPARED TO a control group.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 44), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 183)]	5	[('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy')]	0	['discussion\nthis women underwent caesarean section fetal asphyxia  levels  group.']
S55-PMC5051327	PMC5051327	9/2016	S55-PMC5051327	['beside the two STUDIES SHOWING increased caesarean Delivery rate with low Vitamin D levels,1415a large STUDY with Blood drawn in early Pregnancy SHOWED no difference between caesarean and Vaginal Delivery depending on Vitamin D levels after adjustments.22HOWEVER, in the subgroup of women with caesarean Delivery due to fetal distress (n=46), the median 25-Oh Vitamin D level was 32.9\u2005nmol/l, as compared to 46.6\u2005nmol/l among the control group (n=796).']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 103), ('INCOMPLETE_EVIDENCE', 145), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 253)]	5	[('GO_0007567', 'parturition', 51, 'delivery'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('UBERON_0000178', 'blood', 114, 'blood'), ('GO_0007565', 'female pregnancy', 135, 'pregnancy'), ('GO_0007601', 'visual perception', 188, 'vaginal'), ('UBERON_0001987', 'placenta', 188, 'vaginal'), ('GO_0007567', 'parturition', 196, 'delivery'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D'), ('GO_0007567', 'parturition', 304, 'delivery'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 354, '25-OH'), ('CHEBI_27300', 'vitamin D', 360, 'vitamin D')]	0	['beside caesarean delivery rate  levels,1415a blood drawn  caesarean vaginal delivery  levels adjustments.22however, subgroup women caesarean delivery fetal distress (n=46), median 25-oh  32.9\u2005nmol/l, 46.6\u2005nmol/l among (n=796).']
S56-PMC5051327	PMC5051327	9/2016	S56-PMC5051327	['Vitamin D deficiency was ASSOCIATED with a significantly shorter Gestational age at Delivery, which is IN LINE WITH OTHER DATA.23furthermore, there SEEMS TO be an inverse RELATION between low active Vitamin D (1,25-Dihydroxy Vitamin D) and meconium-stained Amniotic Fluid, a sign of fetal distress, in Pregnancies complicated by Intrahepatic cholestasis.24\nthe FINDINGS that more than two-third of mothers were Vitamin D deficient during winter/spring season and one-third at summer are CONSISTENT with PREVIOUS reports.2526in THIS STUDY, we used the LIMITS of 25-Oh Vitamin D SUGGESTED by the iom,17BUT the discussion of WHAT levels SHOULD BE CONSIDERED deficient is ONGOING.']	[('SUPERFICIAL_RELATIONSHIP', 25), ('INCOMPLETE_EVIDENCE', 103), ('INCOMPLETE_EVIDENCE', 116), ('ANOMALY_CURIOUS_FINDING', 148), ('SUPERFICIAL_RELATIONSHIP', 171), ('INCOMPLETE_EVIDENCE', 361), ('INCOMPLETE_EVIDENCE', 487), ('INCOMPLETE_EVIDENCE', 503), ('QUESTION_ANSWERED_BY_THIS_WORK', 527), ('INCOMPLETE_EVIDENCE', 551), ('INCOMPLETE_EVIDENCE', 577), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 598), ('EXPLICIT_QUESTION', 622), ('FUTURE_WORK', 634), ('FUTURE_WORK', 644), ('IMPORTANT_CONSIDERATION', 668)]	16	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'gestational'), ('GO_0007567', 'parturition', 84, 'delivery'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_50341', '1-hydroxyethyl group', 210, '1,25-dihydroxy'), ('CHEBI_27300', 'vitamin D', 225, 'vitamin D'), ('UBERON_0000173', 'amniotic fluid', 257, 'amniotic fluid'), ('GO_0007565', 'female pregnancy', 302, 'pregnancies'), ('UBERON_0001226', 'major calyx', 329, 'intrahepatic'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 561, '25-OH'), ('CHEBI_27300', 'vitamin D', 567, 'vitamin D')]	0	['vitamin shorter  age delivery, data.23furthermore,  (1,25-dihydroxy meconium-stained amniotic fluid, fetal distress,  intrahepatic cholestasis.24\nthe two-third mothers  winter/spring season one-third summer reports.2526in study, 25-oh  iom,17but discussion levels ongoing.']
S57-PMC5051327	PMC5051327	9/2016	S57-PMC5051327	['the daily RECOMMENDED intake of Vitamin D is 600\u2005iu/day in the usa5since the late 1990s in france, there HAVE been official RECOMMENDATIONS of 1000\u2005u vitamin d/day from 32\u2005weeks of Gestation or 100\u2005000 or 200\u2005000\u2005iu as a single dose at 32\u2005weeks in order to lower COMPLICATIONS in newborns.27\nCalcium Homeostasis In the Heart is IMPORTANT for the Contractility and function of the Heart.']	[('FUTURE_WORK', 10), ('IMPORTANT_CONSIDERATION', 105), ('FUTURE_WORK', 124), ('PROBLEM_COMPLICATION', 263), ('IMPORTANT_CONSIDERATION', 328)]	5	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 181, 'gestation'), ('CHEBI_31341', 'calcium dihydroxide', 292, 'Calcium'), ('GO_0007605', 'sensory perception of sound', 292, 'Calcium'), ('GO_0042592', 'homeostatic process', 300, 'homeostasis in'), ('GO_0007605', 'sensory perception of sound', 319, 'heart'), ('UBERON_0000948', 'heart', 319, 'heart'), ('GO_0006936', 'muscle contraction', 346, 'contractility'), ('GO_0007605', 'sensory perception of sound', 380, 'heart'), ('UBERON_0000948', 'heart', 380, 'heart')]	0	['daily intake  600\u2005iu/day usa5since late 1990s france, official 1000\u2005u vitamin d/day 32\u2005weeks  100\u2005000 200\u2005000\u2005iu single dose 32\u2005weeks newborns.27\ncalcium homeostasis contractility heart.']
S72-PMC5051327	PMC5051327	9/2016	S72-PMC5051327	['the fact that there was ONLY one Blood sample drawn from each mother just gives us a snapshot of the Vitamin D status in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 24)]	1	[('UBERON_0000178', 'blood', 33, 'blood'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 127, 'pregnancy')]	0	['blood sample drawn mother us snapshot  status .']
S73-PMC5051327	PMC5051327	9/2016	S73-PMC5051327	['we DID NOT obtain Vitamin D data in late Pregnancy in these women.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy')]	0	['obtain  late  women.']
S82-PMC5051327	PMC5051327	9/2016	S82-PMC5051327	['we FOUND that women Delivered by emergency caesarean section due to suspected fetal distress had lower Vitamin D levels in early Pregnancy and Birth asphyxia was MORE COMMON in Vitamin D deficient women as compared to non-deficient women.']	[('INCOMPLETE_EVIDENCE', 3), ('PROBABLE_UNDERSTANDING', 162)]	2	[('GO_0007567', 'parturition', 20, 'delivered'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy'), ('GO_0007567', 'parturition', 143, 'birth'), ('CHEBI_33229', 'vitamin (role)', 177, 'vitamin'), ('PR_000006444', 'diacylglycerol kinase delta', 185, 'D')]	0	['women delivered caesarean section fetal distress  levels  birth asphyxia vitamin women non-deficient women.']
S83-PMC5051327	PMC5051327	9/2016	S83-PMC5051327	['IF OTHER groups REPRODUCE our FINDINGS and a causal RELATIONSHIP CAN be established, we MIGHT be in a position to lower the risk of fetal distress/Birth asphyxia with Vitamin D supplementation/sun exposure in Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 52), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 88)]	7	[('GO_0007567', 'parturition', 147, 'birth'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]	0	['causal established, position fetal distress/birth asphyxia  supplementation/sun exposure .']
S70-PMC5054480	PMC5054480	9/2016	S70-PMC5054480	['caption (table-wrap): table 2\n\nchanges in Calcium Homeostasis during Pregnancy and Lactationmeasured levelspregnant womanplacentafetuslactating womanserum Catotal Ca ↓Ionized Ca↔Intestinal Absorption twofold ↑active transfer DEPENDENT on Pthrp+ passive transferhigher than maternal levels; Regulated by fetal pthrpionized Ca slightly ↑Bone Resorption ↑Urinary Ca↑unknown↔pth↓↔no transferlowlowpthrpprogressively ↑ secretion by Decidua and Breastsno transfer; Placental and amniotic secretionhigher than in mothersecretion by the Umbilical Cord and Fetal Parathyroid Glands as early as 10 weeks↑↑: secretion by breasts25‐Vitamin D↔transfer; Placental hydroxylationrenal hydroxylation↔1,25‐dihydroxyvitamin dprogressive ↑ by 100%; Calbindin‐D9K ↑no transferlow↔1 α ‐hydroxylase activity↑stimulated by Estradiol, prolactin, Placental Lactogen, pthrppresentpresent in the Kidney↔Calcitonin↑ by 20%secretion by Thyroid and breastsno transfer; Placental secretion↑ in the first 6 weeks\nca, calcium level; Pthrp, Parathyroid Hormone‐Related Protein; Calbindin‐D9K, Vitamin D‐dependent calcium‐binding protein.']	[('SUPERFICIAL_RELATIONSHIP', 225)]	1	[('GO_0055073', 'cadmium ion homeostasis', 42, 'calcium homeostasis'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy'), ('GO_0001764', 'neuron migration', 83, 'lactationMeasured'), ('CHEBI_17793', 'calycosin', 155, 'CaTotal'), ('CHEBI_32588', 'potassium chloride', 163, 'Ca'), ('CHEBI_24870', 'ion', 166, '↓'), ('CHEBI_5893', 'indapamide', 167, 'Ionized'), ('GO_0070481', 'nuclear-transcribed mRNA catabolic process, non-stop decay', 167, 'Ionized'), ('CHEBI_32588', 'potassium chloride', 175, 'Ca'), ('GO_0050892', 'intestinal absorption', 178, 'Intestinal absorption'), ('UBERON_0000160', 'intestine', 178, 'Intestinal'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 238, 'PTHrP'), ('GO_0065007', 'biological regulation', 290, 'regulated'), ('CHEBI_32588', 'potassium chloride', 322, 'Ca'), ('GO_0097578', 'sequestering of copper ion', 335, 'Bone resorption'), ('UBERON_0001088', 'urine', 352, 'Urinary'), ('CHEBI_32588', 'potassium chloride', 360, 'Ca'), ('UBERON_0002450', 'decidua', 427, 'decidua'), ('UBERON_0000310', 'breast', 439, 'breastsNo'), ('UBERON_0001987', 'placenta', 459, 'placental'), ('UBERON_0002331', 'umbilical cord', 529, 'umbilical cord'), ('UBERON_0000922', 'embryo', 548, 'fetal'), ('UBERON_0001132', 'parathyroid gland', 554, 'parathyroid glands'), ('CHEBI_27300', 'vitamin D', 620, 'vitamin D'), ('UBERON_0001987', 'placenta', 640, 'placental'), ('PR_000004968', 'calretinin', 729, 'calbindin'), ('PR_000002325', 'dynein light chain 1, cytoplasmic', 739, 'D9k'), ('CHEBI_23965', 'estradiol', 799, 'estradiol'), ('CHEBI_81588', 'Placental lactogen', 821, 'placental lactogen'), ('PR_000012764', 'piwi-like protein 3', 821, 'placental lactogen'), ('UBERON_0001987', 'placenta', 821, 'placental'), ('UBERON_0002113', 'kidney', 868, 'kidney'), ('CHEBI_17793', 'calycosin', 875, 'Calcitonin'), ('UBERON_0002046', 'thyroid gland', 906, 'thyroid'), ('UBERON_0001987', 'placenta', 938, 'placental'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 999, 'PTHrP'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 1006, 'parathyroid hormone'), ('UBERON_0001132', 'parathyroid gland', 1006, 'parathyroid'), ('PR_000014009', 'regulating synaptic membrane exocytosis protein 1', 1026, 'related protein'), ('PR_000004968', 'calretinin', 1043, 'calbindin'), ('PR_000002325', 'dynein light chain 1, cytoplasmic', 1053, 'D9k'), ('CHEBI_27300', 'vitamin D', 1058, 'vitamin D')]	0	['caption (table-wrap): table 2\n\nchanges calcium homeostasis  lactationmeasured levelspregnant womanplacentafetuslactating womanserum catotal ca ↓ionized ca↔intestinal absorption twofold ↑active transfer pthrp+ passive transferhigher maternal levels; fetal pthrpionized ca ↑bone resorption ↑urinary ca↑unknown↔pth↓↔no transferlowlowpthrpprogressively ↑ secretion decidua breastsno transfer; placental amniotic secretionhigher mothersecretion umbilical cord fetal parathyroid glands 10 weeks↑↑: secretion breasts25‐↔transfer; placental hydroxylationrenal hydroxylation↔1,25‐dihydroxyvitamin dprogressive ↑ 100%; calbindin‐d9k ↑no transferlow↔1 α ‐hydroxylase activity↑stimulated estradiol, prolactin, placental lactogen, pthrppresentpresent kidney↔calcitonin↑ 20%secretion thyroid breastsno transfer; placental secretion↑ 6 weeks\nca, calcium level; pthrp, parathyroid hormone‐related protein; calbindin‐d9k, ‐dependent calcium‐binding protein.']
S48-PMC5062906	PMC5062906	10/2016	S48-PMC5062906	['to address the ROLE of maternal Vitamin D in determining offspring epigenetic state, we used a Mouse MODEL to characterize WHETHER depletion of maternal Vitamin D during Gestation and Lactation AFFECTS epigenetic and developmental outcomes of progeny.']	[('SUPERFICIAL_RELATIONSHIP', 15), ('INCOMPLETE_EVIDENCE', 101), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 123), ('SUPERFICIAL_RELATIONSHIP', 194)]	4	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 95, 'mouse'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'gestation'), ('GO_0007595', 'lactation', 184, 'lactation')]	0	['maternal  offspring epigenetic state, mouse characterize depletion maternal   lactation epigenetic developmental outcomes progeny.']
S232-PMC5062906	PMC5062906	10/2016	S232-PMC5062906	['ONE LIKELY EXPLANATION for the sporadic methylation changes OBSERVED in response to Vitamin D depletion is perturbation of global epigenetic Programming AS an indirect EFFECT of Dysregulation of master epigenetic REGULATORS.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 4), ('PROBABLE_UNDERSTANDING', 11), ('INCOMPLETE_EVIDENCE', 60), ('PROBABLE_UNDERSTANDING', 153), ('SUPERFICIAL_RELATIONSHIP', 168), ('SUPERFICIAL_RELATIONSHIP', 213)]	7	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'programming'), ('GO_0060233', 'oenocyte delamination', 178, 'dysregulation')]	0	['one sporadic methylation changes response  depletion perturbation epigenetic  dysregulation master epigenetic regulators.']
S250-PMC5062906	PMC5062906	10/2016	S250-PMC5062906	['ALTHOUGH Vitamin D deficiency HAS BEEN LINKED to adverse Pregnancy/Birth outcomes [14,46–52], there is currently NO STANDARD practice of screening women for Vitamin D deficiency during Pregnancy nor are there standard RECOMMENDATIONS beyond Prenatal Vitamins for supplementation during this CRITICAL time [53,54].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 39), ('INCOMPLETE_EVIDENCE', 113), ('FUTURE_WORK', 218), ('IMPORTANT_CONSIDERATION', 291)]	6	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 57, 'pregnancy ...'), ('GO_0007567', 'parturition', 67, 'birth'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('GO_0007565', 'female pregnancy', 185, 'pregnancy'), ('GO_0007565', 'female pregnancy', 241, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 250, 'vitamins')]	0	['although  pregnancy/birth outcomes [14,46–52], screening women    vitamins supplementation [53,54].']
S0-PMC5064894	PMC5064894	10/2016	S0-PMC5064894	['maternal Vitamin D supplementation during Pregnancy and Lactation to prevent acute Respiratory infections in infancy in dhaka, bangladesh (mdari trial): protocol for a prospective cohort study nested within a randomized controlled trial\n\nabstract\n\nbackground\nearly Infancy is a HIGH-RISK period for SEVERE acute Respiratory infection (ari), PARTICULARLY in low-income countries with resource-limited Health Systems.']	[('IMPORTANT_CONSIDERATION', 278), ('IMPORTANT_CONSIDERATION', 299), ('IMPORTANT_CONSIDERATION', 341)]	3	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('GO_0007595', 'lactation', 56, 'lactation'), ('UBERON_0001004', 'respiratory system', 83, 'respiratory'), ('UBERON_0000023', 'wing', 265, 'infancy'), ('UBERON_0001004', 'respiratory system', 312, 'respiratory'), ('UBERON_0002423', 'hepatobiliary system', 400, 'health systems')]	0	['maternal  supplementation  lactation acute respiratory infections infancy dhaka, bangladesh (mdari trial): protocol trial\n\nabstract\n\nbackground\nearly infancy period acute respiratory infection (ari), low-income countries resource-limited systems.']
S9-PMC5064894	PMC5064894	10/2016	S9-PMC5064894	['we HYPOTHESIZE that among infants 0–6 months of age, the incidence of microbiologically-confirmed viral ari will be significantly lower in infants whose mothers received high-dose Prenatal/Postpartum Vitamin D supplements versus placebo.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('GO_0007565', 'female pregnancy', 180, 'prenatal'), ('GO_0007565', 'female pregnancy', 189, 'postpartum'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]	0	['among infants 0–6 months age, microbiologically-confirmed viral ari infants whose mothers received high-dose /  supplements placebo.']
S11-PMC5064894	PMC5064894	10/2016	S11-PMC5064894	['discussion\nIF SHOWN to reduce the RISK of viral ari in infancy, integration of maternal Prenatal/Postpartum Vitamin D supplementation into Antenatal Care programs in south asia may be a FEASIBLE primary preventive STRATEGY to reduce THE BURDEN of ari-ASSOCIATED morbidity and mortality in young infants.']	[('INCOMPLETE_EVIDENCE', 11), ('IMPORTANT_CONSIDERATION', 34), ('PROBABLE_UNDERSTANDING', 186), ('FUTURE_WORK', 214), ('IMPORTANT_CONSIDERATION', 233), ('SUPERFICIAL_RELATIONSHIP', 251)]	6	[('GO_0007565', 'female pregnancy', 88, 'prenatal'), ('GO_0007565', 'female pregnancy', 97, 'postpartum'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 139, 'antenatal care')]	0	['discussion\nif viral ari infancy, integration maternal /  supplementation antenatal south asia ari-associated morbidity mortality young infants.']
S32-PMC5064894	PMC5064894	10/2016	S32-PMC5064894	['the FIRST randomized trial of Prenatal Vitamin D supplementation on childhood wheeze was RECENTLY published [25].']	[('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 89)]	2	[('GO_0007565', 'female pregnancy', 30, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]	0	['  supplementation childhood wheeze [25].']
S37-PMC5064894	PMC5064894	10/2016	S37-PMC5064894	['first, THERE HAVE BEEN NO STUDIES examining the EFFECT of Prenatal Vitamin D supplementation on a primary outcome of laboratory-confirmed Viral Respiratory infections in the first 6\xa0months of Life, a high-risk period for both Vitamin D deficiency and Respiratory Tract infections.']	[('FULL_UNKNOWN', 7), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 48)]	4	[('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('NCBITaxon_1', 'root', 138, 'viral'), ('UBERON_0001004', 'respiratory system', 144, 'respiratory'), ('UBERON_0000104', 'life cycle', 192, 'life'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('UBERON_0000065', 'respiratory tract', 251, 'respiratory tract')]	0	['first,   supplementation outcome laboratory-confirmed viral respiratory infections 6\xa0months life, period  respiratory tract infections.']
S38-PMC5064894	PMC5064894	10/2016	S38-PMC5064894	['second, the ROLE of Prenatal Vitamin D as a DETERMINANT of susceptibility to specific Viral infections has NOT BEEN EXAMINED.']	[('SUPERFICIAL_RELATIONSHIP', 12), ('SUPERFICIAL_RELATIONSHIP', 44), ('FULL_UNKNOWN', 107)]	3	[('GO_0007565', 'female pregnancy', 20, 'prenatal'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('NCBITaxon_1', 'root', 86, 'viral')]	0	['second,   viral infections examined.']
S43-PMC5064894	PMC5064894	10/2016	S43-PMC5064894	['we HYPOTHESIZE that among infants 0–6 months, the incidence of microbiologically confirmed ari will be significantly lower in infants of mothers who received a relatively high dose of Vitamin D (28,000\xa0iu/week) during Pregnancy plus continued Postpartum supplementation (to 6\xa0months Postpartum) compared to mothers who received placebo throughout the Prenatal and Postpartum periods.']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 218, 'pregnancy'), ('GO_0007565', 'female pregnancy', 243, 'postpartum'), ('GO_0007565', 'female pregnancy', 283, 'postpartum'), ('GO_0007565', 'female pregnancy', 351, 'prenatal'), ('GO_0007565', 'female pregnancy', 364, 'postpartum')]	0	['among infants 0–6 months, microbiologically ari infants mothers received dose  (28,000\xa0iu/week)  plus  supplementation (to 6\xa0months mothers received placebo throughout   periods.']
S44-PMC5064894	PMC5064894	10/2016	S44-PMC5064894	['if a significantly decreased incidence of microbiologically confirmed ari is FOUND, we will further assess for EFFECT of lower doses of Prenatal maternal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 77), ('SUPERFICIAL_RELATIONSHIP', 111)]	2	[('GO_0007565', 'female pregnancy', 136, 'prenatal'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]	0	['decreased microbiologically ari found, doses  maternal  supplementation.']
S160-PMC5064894	PMC5064894	10/2016	S160-PMC5064894	['we anticipate that the EFFECT of maternal Vitamin D supplementation will be incremental with increasing dose, such that the greatest EFFECT size (vs. placebo) will be observed in the highest dose Vitamin D group with Postpartum continuation (group e in fig.']	[('SUPERFICIAL_RELATIONSHIP', 23), ('SUPERFICIAL_RELATIONSHIP', 133)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('GO_0007565', 'female pregnancy', 217, 'postpartum')]	0	['maternal  supplementation incremental dose, (vs. placebo) dose   continuation (group e fig.']
S185-PMC5064894	PMC5064894	10/2016	S185-PMC5064894	['a specific pairwise comparison between the 28,000\xa0iu/week Prenatal\u2009+\u2009Postpartum group (group e) will be compared to 28,000\xa0iu/week without Postpartum supplementation (group d) TO IDENTIFY the IMPACT of continuing Vitamin D supplementation in the Postpartum period.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 176), ('SUPERFICIAL_RELATIONSHIP', 192)]	2	[('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('GO_0007565', 'female pregnancy', 69, 'postpartum'), ('GO_0007565', 'female pregnancy', 139, 'postpartum'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('GO_0007565', 'female pregnancy', 246, 'postpartum')]	0	['pairwise 28,000\xa0iu/week \u2009+\u2009 (group e) 28,000\xa0iu/week  supplementation (group d)  supplementation  period.']
S193-PMC5064894	PMC5064894	10/2016	S193-PMC5064894	['discussion\nthe mdari study in dhaka, bangladesh leverages the infrastructure of a large randomized placebo controlled, dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation in bangladesh TO TEST the HYPOTHESIS that maternal Vitamin D supplementation CAN decrease infant Respiratory infections during the HIGH RISK first 6\xa0months of infancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 221), ('INCOMPLETE_EVIDENCE', 233), ('INCOMPLETE_EVIDENCE', 284), ('IMPORTANT_CONSIDERATION', 338)]	4	[('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('GO_0007565', 'female pregnancy', 183, 'pregnancy'), ('GO_0007595', 'lactation', 197, 'lactation'), ('CHEBI_27300', 'vitamin D', 258, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 304, 'respiratory')]	0	['discussion\nthe mdari dhaka, bangladesh leverages infrastructure placebo controlled, dose-ranging maternal  supplementation  lactation bangladesh maternal  supplementation decrease infant respiratory infections 6\xa0months infancy.']
S194-PMC5064894	PMC5064894	10/2016	S194-PMC5064894	['IF SHOWN to reduce the RISK of ari in infancy, integration of maternal Prenatal/Postpartum Vitamin D supplementation into Antenatal Care programs in south asia MAY BE a FEASIBLE primary preventive STRATEGY to reduce THE BURDEN of ari-associated morbidity and mortality in young infants.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 23), ('INCOMPLETE_EVIDENCE', 160), ('PROBABLE_UNDERSTANDING', 169), ('FUTURE_WORK', 197), ('IMPORTANT_CONSIDERATION', 216)]	7	[('GO_0007565', 'female pregnancy', 71, 'prenatal'), ('GO_0007565', 'female pregnancy', 80, 'postpartum'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 122, 'antenatal care')]	0	['ari infancy, integration maternal /  supplementation antenatal south asia ari-associated morbidity mortality young infants.']
S126-PMC5084016	PMC5084016	10/2016	S126-PMC5084016	['in the first stage of Pregnancy, Vitamin D (mainly Vitamin D3, the predominant form in the maternal Blood) is INVOLVED in the Regulation Of Cytokine Metabolism and in the Modulation Of the Immune System, thereby contributing to the Embryo Implantation and Regulating the secretion of several hormones.']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('GO_0007565', 'female pregnancy', 22, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33237', 'vitamin D4', 51, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 51, 'Vitamin D3'), ('UBERON_0000178', 'blood', 100, 'blood'), ('GO_0007565', 'female pregnancy', 126, 'regulation of'), ('GO_0009690', 'cytokinin metabolic process', 140, 'cytokine metabolism'), ('GO_0002022', 'detection of dietary excess', 171, 'modulation of ... immune system'), ('UBERON_0002405', 'immune system', 189, 'immune system'), ('GO_0007601', 'visual perception', 232, 'embryo'), ('UBERON_0000922', 'embryo', 232, 'embryo'), ('GO_0007566', 'embryo implantation', 239, 'implantation'), ('GO_0065007', 'biological regulation', 256, 'regulating')]	0	[' (mainly vitamin d3, form maternal blood)  cytokine metabolism immune system, embryo implantation secretion hormones.']
S128-PMC5084016	PMC5084016	10/2016	S128-PMC5084016	['HOWEVER, Vitamin D deficiency is very common during Pregnancy EVEN in countries with sunny climates and is ASSOCIATED with an INCREASED RISK of developing pre-eclampsia and Gestational diabetes mellitus.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 62), ('SUPERFICIAL_RELATIONSHIP', 107), ('IMPORTANT_CONSIDERATION', 126)]	4	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('GO_0007565', 'female pregnancy', 173, 'gestational')]	0	['however,   countries sunny climates pre-eclampsia  diabetes mellitus.']
S129-PMC5084016	PMC5084016	10/2016	S129-PMC5084016	['the season of Birth, ethnicity, and maternal prophylaxis during Pregnancy AFFECT the Vitamin D status of infants.']	[('SUPERFICIAL_RELATIONSHIP', 74)]	1	[('GO_0007567', 'parturition', 14, 'birth'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]	0	['season birth, ethnicity, maternal prophylaxis   status infants.']
S132-PMC5084016	PMC5084016	10/2016	S132-PMC5084016	['DESPITE the LACK OF CONSENSUS on adequate intakes among DIFFERENT countries (table 3), supplementation with Vitamin D is RECOMMENDED for all Pregnant women at a dose of 600 iu/day (15 µg/day) [57].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 12), ('INCOMPLETE_EVIDENCE', 12), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('FUTURE_WORK', 121)]	6	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'pregnant')]	0	['despite intakes among countries (table 3), supplementation   women dose 600 iu/day (15 µg/day) [57].']
S134-PMC5084016	PMC5084016	10/2016	S134-PMC5084016	['prophylaxis with Vitamin D SHOULD BE planned from the beginning and throughout the Pregnancy, as underlined also in the recent consensus document from the italian pediatric societies [61].']	[('FUTURE_WORK', 27), ('IMPORTANT_CONSIDERATION', 27)]	2	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]	0	['prophylaxis  throughout underlined italian pediatric societies [61].']
S0-PMC5084041	PMC5084041	10/2016	S0-PMC5084041	['Vitamin D status during Pregnancy in a multi-ethnic population-representative swedish cohort\n\nabstract\nthere is currently LITTLE INFORMATION on changes in Vitamin D status during Pregnancy and its PREDICTORS.']	[('INCOMPLETE_EVIDENCE', 122), ('SUPERFICIAL_RELATIONSHIP', 197)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 24, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('GO_0007565', 'female pregnancy', 179, 'pregnancy')]	0	['vitamin status  multi-ethnic population-representative swedish cohort\n\nabstract\nthere changes  status  predictors.']
S1-PMC5084041	PMC5084041	10/2016	S1-PMC5084041	['the AIM was TO STUDY the DETERMINANTS of change in Vitamin D status during Pregnancy and of Vitamin D deficiency (<30 nmol/l) in early Pregnancy.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 12), ('SUPERFICIAL_RELATIONSHIP', 25)]	3	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 135, 'pregnancy')]	0	[' status   (<30 nmol/l) .']
S10-PMC5084041	PMC5084041	10/2016	S10-PMC5084041	['the DETERMINANTS of season-corrected change in 25(Oh)D were origin, sun-Seeking behaviour, clothing style, dietary Vitamin D intake, Vitamin D supplementation and recent travel <35° n. in CONCLUSION, season-corrected 25(Oh)D concentration increased during Pregnancy and DEPENDED PARTLY on lifestyle FACTORS.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('INCOMPLETE_EVIDENCE', 188), ('SUPERFICIAL_RELATIONSHIP', 270), ('INCOMPLETE_EVIDENCE', 279), ('SUPERFICIAL_RELATIONSHIP', 299)]	5	[('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 53, 'D'), ('GO_0007601', 'visual perception', 72, 'seeking'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 133, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 141, 'D'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 217, '25(OH)D'), ('GO_0007565', 'female pregnancy', 256, 'pregnancy')]	0	['season-corrected 25(oh)d origin, sun-seeking behaviour, clothing style, dietary  intake, vitamin supplementation travel <35° n. conclusion, season-corrected 25(oh)d concentration  lifestyle factors.']
S17-PMC5084041	PMC5084041	10/2016	S17-PMC5084041	['POOR maternal Vitamin D status during Pregnancy is ASSOCIATED with lower bone Mineral density and muscle strength in the infant [2].']	[('IMPORTANT_CONSIDERATION', 0), ('SUPERFICIAL_RELATIONSHIP', 51)]	2	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('CHEBI_46662', 'mineral', 78, 'mineral')]	0	['poor maternal  status  bone mineral density muscle infant [2].']
S18-PMC5084041	PMC5084041	10/2016	S18-PMC5084041	['POOR maternal Vitamin D status HAS also BEEN ASSOCIATED with Pregnancy COMPLICATIONS such as Preeclampsia [3], premature Birth [4] and infants Born small for Gestational age [5].']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 31), ('SUPERFICIAL_RELATIONSHIP', 45), ('PROBLEM_COMPLICATION', 71)]	4	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 93, 'preeclampsia'), ('GO_0007567', 'parturition', 121, 'birth'), ('GO_0007567', 'parturition', 143, 'born'), ('GO_0007565', 'female pregnancy', 158, 'gestational')]	0	['poor maternal  status  preeclampsia [3], premature birth [4] infants born  age [5].']
S22-PMC5084041	PMC5084041	10/2016	S22-PMC5084041	['SINCE data on Gestational Vitamin D status in populations living at latitudes without seasonality in cutaneous Vitamin D Synthesis are SCARCE, a season-corrected analysis is a way of investigating changes in 25(Oh)D during Pregnancy per se.']	[('PROBLEM_COMPLICATION', 0), ('INCOMPLETE_EVIDENCE', 135)]	2	[('GO_0007565', 'female pregnancy', 14, 'gestational'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 111, 'vitamin D synthesis'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('GO_0007565', 'female pregnancy', 223, 'pregnancy')]	0	['since   status populations living latitudes seasonality cutaneous  synthesis scarce, season-corrected changes 25(oh)d  se.']
S23-PMC5084041	PMC5084041	10/2016	S23-PMC5084041	['such analyses of 25(Oh)D concentrations during Pregnancy SHOW that Vitamin D status between early and late Pregnancy tracks moderately and that change DEPENDS ON supplement use, Gestational weight gain and physical activity [12].']	[('INCOMPLETE_EVIDENCE', 57), ('SUPERFICIAL_RELATIONSHIP', 151)]	2	[('CHEBI_71657', 'versiconol acetate', 17, '25(OH)D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy'), ('GO_0007565', 'female pregnancy', 178, 'gestational')]	0	['25(oh)d concentrations   status late  moderately supplement use,  gain physical activity [12].']
S31-PMC5084041	PMC5084041	10/2016	S31-PMC5084041	['population-representative data on Vitamin D status during Pregnancy IS NEEDED to evaluate the POTENTIAL NEED for new PUBLIC-HEALTH policies and to provide reliable data on potential RISK groups for Vitamin D deficiency.']	[('FUTURE_WORK', 68), ('INCOMPLETE_EVIDENCE', 94), ('FUTURE_WORK', 104), ('IMPORTANT_CONSIDERATION', 117), ('IMPORTANT_CONSIDERATION', 124), ('SUPERFICIAL_RELATIONSHIP', 182)]	6	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D')]	0	['population-representative  status  public-health  deficiency.']
S32-PMC5084041	PMC5084041	10/2016	S32-PMC5084041	['FEW STUDIES have investigated Vitamin D status longitudinally in a large cohort of Pregnant women, and knowledge of change in Vitamin D status during Pregnancy and its DETERMINANTS are LACKING.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 168), ('FULL_UNKNOWN', 185)]	3	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnant'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy')]	0	[' status longitudinally  women,  status  lacking.']
S37-PMC5084041	PMC5084041	10/2016	S37-PMC5084041	['materials and methods\nthe gravid study was DESIGNED TO INVESTIGATE the ASSOCIATION of Vitamin D status during Pregnancy with Preeclampsia and Pregnancy-induced hypertension.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 43), ('QUESTION_ANSWERED_BY_THIS_WORK', 52), ('SUPERFICIAL_RELATIONSHIP', 71)]	3	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 125, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 142, 'pregnancy')]	0	['materials methods\nthe gravid  status  preeclampsia -induced hypertension.']
S106-PMC5084041	PMC5084041	10/2016	S106-PMC5084041	['a season-corrected analysis of change in 25(Oh)D SHOWED that the DETERMINANTS of change in 25(Oh)D during Pregnancy were origin, sun-Seeking behaviour, clothing style, dietary Vitamin D intake at t3, Vitamin D supplementation at t3 and having travelled to <35° n in the past six months (adjusted r2= 0.186) (table 3).']	[('INCOMPLETE_EVIDENCE', 49), ('SUPERFICIAL_RELATIONSHIP', 65)]	2	[('CHEBI_71657', 'versiconol acetate', 41, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 47, 'D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('GO_0007601', 'visual perception', 133, 'seeking'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]	0	['season-corrected 25(oh)d 25(oh)d  origin, sun-seeking behaviour, clothing style, dietary  intake t3,  supplementation t3 travelled <35° n six months (adjusted r2= 0.186) (table 3).']
S107-PMC5084041	PMC5084041	10/2016	S107-PMC5084041	['Gestational weight gain, bmi and age were not significantly associated with change in 25(Oh)D. in the subgroup of women Born in africa and asia, only Vitamin D supplementation at t3 was a DETERMINANT of season-corrected change in Vitamin D status during Pregnancy (adjusted r2= 0.115) (table 3).']	[('SUPERFICIAL_RELATIONSHIP', 188)]	1	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('GO_0007567', 'parturition', 120, 'born'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy')]	0	[' gain, bmi age 25(oh)d. subgroup women born africa asia,  supplementation t3 season-corrected  status  (adjusted r2= 0.115) (table 3).']
S110-PMC5084041	PMC5084041	10/2016	S110-PMC5084041	['discussion\noverall, OUR FINDINGS SHOW that the prevalence of Vitamin D deficiency is low among Pregnant women in sweden.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 20), ('INCOMPLETE_EVIDENCE', 33)]	2	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 95, 'pregnant')]	0	['discussion\noverall,  among  women sweden.']
S116-PMC5084041	PMC5084041	10/2016	S116-PMC5084041	['RISK FACTORS for Vitamin D deficiency (25(Oh)D <30 nmol/l) in early Pregnancy were IN LINE WITH PREVIOUS FINDINGS [13,17,27].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 83), ('INCOMPLETE_EVIDENCE', 96)]	3	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 39, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 45, 'D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy')]	0	['risk  (25(oh)d <30 nmol/l)  [13,17,27].']
S118-PMC5084041	PMC5084041	10/2016	S118-PMC5084041	['FEW STUDIES have PREVIOUSLY investigated changes in Vitamin D status during Pregnancy and results were CONFLICTING.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 17), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103)]	3	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy')]	0	['changes  status  results conflicting.']
S123-PMC5084041	PMC5084041	10/2016	S123-PMC5084041	['this MAY PARTLY be EXPLAINED by less Vitamin D supplement use in late Pregnancy than in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 9), ('PROBABLE_UNDERSTANDING', 19)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy')]	0	[' supplement late  .']
S20-PMC5084734	PMC5084734	5/2016	S20-PMC5084734	['for several Micronutrients, the relative increase in RECOMMENDED intake is ≥50%, such as for Folate and iron during Pregnancy and for Vitamin A, Vitamin C, Vitamin B6, Iodine and zinc during Lactation.']	[('FUTURE_WORK', 53)]	1	[('CHEBI_33839', 'macromolecule', 12, 'micronutrients'), ('CHEBI_30863', '5-azaorotic acid', 93, 'folate'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin C'), ('CHEBI_33237', 'vitamin D4', 156, 'vitamin B6'), ('CHEBI_24859', 'iodine atom', 168, 'iodine'), ('GO_0007595', 'lactation', 191, 'lactation')]	0	['micronutrients, relative increase intake ≥50%, folate iron  , vitamin b6, iodine zinc lactation.']
S24-PMC5085625	PMC5085625	9/2016	S24-PMC5085625	['DEFICIENCY of Vitamin D is commonly diagnosed among Pregnant women worldwide, and WAS SHOWN to be ASSOCIATED with an INCREASED RISK of Pregnancy-related complications [1].']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 82), ('SUPERFICIAL_RELATIONSHIP', 98), ('IMPORTANT_CONSIDERATION', 117)]	4	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'pregnant'), ('GO_0007565', 'female pregnancy', 135, 'pregnancy')]	0	['deficiency  diagnosed among  women worldwide, -related [1].']
S62-PMC5085625	PMC5085625	9/2016	S62-PMC5085625	['DESPITE widespread deficiency of Vitamin D among Pregnant women worldwide, its ROLE in Pregnancy has LARGELY BEEN IGNORED [25,26,27].']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 79), ('INCOMPLETE_EVIDENCE', 101), ('IMPORTANT_CONSIDERATION', 114)]	4	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 49, 'pregnant'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy')]	0	['despite  among  women worldwide,  [25,26,27].']
S64-PMC5085625	PMC5085625	9/2016	S64-PMC5085625	['one POTENTIAL EXPLANATION for such a high prevalence of Vitamin D insufficiency/deficiency among Pregnant polish women is a relatively low number of sunny days in our country.']	[('INCOMPLETE_EVIDENCE', 4), ('PROBABLE_UNDERSTANDING', 14)]	2	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 97, 'pregnant')]	0	['one  insufficiency/deficiency among  polish women sunny days country.']
S68-PMC5085625	PMC5085625	9/2016	S68-PMC5085625	['taking into account INCONCLUSIVE results of cross-sectional and cohort studies analyzing the ASSOCIATION between Vitamin D status and occurrence of Pregnancy pathologies [28,29], the AIM of OUR STUDY was to asses 25(Oh)D status in women with Gestational hypertension (gh).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('SUPERFICIAL_RELATIONSHIP', 93), ('QUESTION_ANSWERED_BY_THIS_WORK', 183), ('QUESTION_ANSWERED_BY_THIS_WORK', 190)]	4	[('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 213, '25(OH)D'), ('GO_0007565', 'female pregnancy', 242, 'gestational')]	0	['taking results cross-sectional analyzing  status occurrence  pathologies [28,29], asses 25(oh)d status women  hypertension (gh).']
S71-PMC5085625	PMC5085625	9/2016	S71-PMC5085625	['[13] who DEMONSTRATED that Vitamin D status CORRELATES significantly with Blood pressure during the first trimester and Gestational systolic Blood pressure trajectory, BUT NOT with the prevalence of gh.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 44), ('ANOMALY_CURIOUS_FINDING', 168)]	3	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('UBERON_0000178', 'blood', 74, 'blood'), ('GO_0007565', 'female pregnancy', 120, 'gestational'), ('UBERON_0000178', 'blood', 141, 'blood')]	0	['[13]  status blood pressure trimester  systolic blood pressure trajectory, gh.']
S74-PMC5085625	PMC5085625	9/2016	S74-PMC5085625	['ANALYZED ASSOCIATIONS between Vitamin D status, Blood pressure at the onset of Pregnancy and occurrence of a mid-Pregnancy decrease in the latter parameters.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 9)]	2	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('UBERON_0000178', 'blood', 48, 'blood'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy')]	0	['analyzed  status, blood pressure onset  occurrence mid- decrease latter parameters.']
S75-PMC5085625	PMC5085625	9/2016	S75-PMC5085625	['moreover, the authors searched for a POTENTIAL mechanism EXPLAINING the ASSOCIATION between Vitamin D status and Pregnancy-related hypertensive disorders.']	[('INCOMPLETE_EVIDENCE', 37), ('PROBABLE_UNDERSTANDING', 57), ('SUPERFICIAL_RELATIONSHIP', 72)]	3	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy')]	0	['moreover, authors  status -related hypertensive disorders.']
S76-PMC5085625	PMC5085625	9/2016	S76-PMC5085625	['SIMILAR TO OUR STUDY, they FOUND no association between Vitamin D status, prevalence of gh, Blood pressure at early Gestation and mid-Pregnancy decrease in this parameter [30].']	[('INCOMPLETE_EVIDENCE', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('INCOMPLETE_EVIDENCE', 27)]	3	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('UBERON_0000178', 'blood', 92, 'blood'), ('GO_0007565', 'female pregnancy', 116, 'gestation'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy')]	0	['similar study,  status, gh, blood pressure  mid- decrease parameter [30].']
S90-PMC5085625	PMC5085625	9/2016	S90-PMC5085625	['ACCORDING to barebring et al., AT LEAST a 30 nmol/l increase in Serum 25(Oh)D concentration is ASSOCIATED with lower odds of pe, REGARDLESS OF Vitamin D status in early Pregnancy [13].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('PROBABLE_UNDERSTANDING', 31), ('SUPERFICIAL_RELATIONSHIP', 95), ('INCOMPLETE_EVIDENCE', 129)]	4	[('UBERON_0001977', 'blood serum', 64, 'serum'), ('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 70, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'pregnancy')]	0	['according barebring et al., 30 nmol/l increase serum 25(oh)d concentration pe,  status  [13].']
S93-PMC5085625	PMC5085625	9/2016	S93-PMC5085625	['it would be INTERESTING to measure Vitamin D levels throughout the whole Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 12)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy')]	0	['measure  levels throughout whole .']
S95-PMC5085625	PMC5085625	9/2016	S95-PMC5085625	['CONSEQUENTLY, Vitamin D level in early Pregnancy is less LIKELY to play a MAJOR ROLE in Placental Development, and it is later increased in this parameter which may PREVENT the development of pe [13].']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 57), ('IMPORTANT_CONSIDERATION', 74), ('SUPERFICIAL_RELATIONSHIP', 80), ('SUPERFICIAL_RELATIONSHIP', 165)]	5	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('GO_0001890', 'placenta development', 88, 'placental development'), ('UBERON_0001987', 'placenta', 88, 'placental')]	0	['consequently,   play placental development, parameter pe [13].']
S109-PMC5085625	PMC5085625	9/2016	S109-PMC5085625	['ALTHOUGH preeclampsia HAS BEEN LINKED to maternal Vitamin D insufficiency/deficiency, STILL LITTLE IS KNOWN on POTENTIAL differences in Placental Metabolism Of this Vitamin in uncomplicated and preeclamptic Pregnancies [32].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 22), ('SUPERFICIAL_RELATIONSHIP', 31), ('ANOMALY_CURIOUS_FINDING', 86), ('IMPORTANT_CONSIDERATION', 86), ('FULL_UNKNOWN', 92), ('INCOMPLETE_EVIDENCE', 111)]	7	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 136, 'placental'), ('UBERON_0001987', 'placenta', 136, 'placental'), ('GO_0006583', 'melanin biosynthetic process from tyrosine', 146, 'metabolism of ... vitamin'), ('CHEBI_33229', 'vitamin (role)', 165, 'vitamin'), ('GO_0007565', 'female pregnancy', 207, 'pregnancies')]	0	['although preeclampsia maternal  insufficiency/deficiency,  metabolism vitamin uncomplicated preeclamptic  [32].']
S119-PMC5085625	PMC5085625	9/2016	S119-PMC5085625	['DID NOT observe significant differences in Vitamin D levels among Pregnant women and healthy controls; NEVERTHELESS, the prevalence of a Vitamin D deficiency in both groups was quite high [23].']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103)]	2	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnant'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]	0	[' levels among  women healthy controls; nevertheless,  [23].']
S126-PMC5085625	PMC5085625	9/2016	S126-PMC5085625	['to summarize, the LINK between Vitamin D and Glucose Metabolism REQUIRES FURTHER STUDIES on larger populations of Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('IMPORTANT_CONSIDERATION', 64), ('FUTURE_WORK', 73)]	3	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_17234', 'glucose', 45, 'glucose'), ('GO_0006006', 'glucose metabolic process', 45, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 114, 'pregnant')]	0	['summarize,  glucose metabolism populations  women.']
S169-PMC5085625	PMC5085625	9/2016	S169-PMC5085625	['conclusions\nin CONCLUSION, both the results of PREVIOUS STUDIES and OUR FINDINGS PRESENTED HERE, documenting the LINK between Maternal deficiency of Vitamin D and the INCREASED RISK of Preeclampsia, POINT TO the IMPORTANT ROLE of an appropriate level and adequate Metabolism Of this Vitamin in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 47), ('QUESTION_ANSWERED_BY_THIS_WORK', 68), ('QUESTION_ANSWERED_BY_THIS_WORK', 81), ('QUESTION_ANSWERED_BY_THIS_WORK', 91), ('SUPERFICIAL_RELATIONSHIP', 113), ('IMPORTANT_CONSIDERATION', 167), ('INCOMPLETE_EVIDENCE', 199), ('IMPORTANT_CONSIDERATION', 212), ('SUPERFICIAL_RELATIONSHIP', 222)]	10	[('GO_0007618', 'mating', 126, 'maternal'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 185, 'preeclampsia'), ('GO_0006583', 'melanin biosynthetic process from tyrosine', 264, 'metabolism of ... vitamin'), ('CHEBI_33229', 'vitamin (role)', 283, 'vitamin'), ('GO_0007565', 'female pregnancy', 294, 'pregnancy')]	0	['conclusions\nin conclusion, results here, maternal  preeclampsia, metabolism vitamin .']
S174-PMC5085625	PMC5085625	9/2016	S174-PMC5085625	['AVAILABLE EVIDENCE is STILL INSUFFICIENT to CONFIRM a causative LINK between Vitamin D and Pregnancy disorders IN LINE WITH hill’s criteria.']	[('INCOMPLETE_EVIDENCE', 0), ('IMPORTANT_CONSIDERATION', 22), ('INCOMPLETE_EVIDENCE', 28), ('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 64), ('INCOMPLETE_EVIDENCE', 111)]	6	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy')]	0	['available causative   disorders hill’s criteria.']
S66-PMC5093678	PMC5093678	10/2016	S66-PMC5093678	['the control group will be provided with the usual Antenatal dietary advice as per nice guidelines on Antenatal care, weight management in Pregnancy and hypertension in Pregnancy.15–17Folic Acid and Vitamin D supplementation will be provided as per national RECOMMENDATIONS for all participants.']	[('FUTURE_WORK', 257)]	1	[('GO_0007567', 'parturition', 50, 'antenatal'), ('GO_0007567', 'parturition', 101, 'antenatal'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('CHEBI_39159', '(S)-trichostatic acid', 181, '17Folic acid'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D')]	0	['usual antenatal dietary nice antenatal care,  hypertension .15–17folic acid  supplementation national participants.']
S14-PMC5115165	PMC5115165	1/2016	S14-PMC5115165	['introduction\npotatoes are the third most commonly Consumed Food crop in the world, after rice and wheat.1in the united states, about 35% of women of Reproductive Age (that is, aged 19-50) Consume potatoes daily, accounting FOR 8% of daily total energy intake.2the health EFFECTS of potatoes are INCONCLUSIVE,13and there HAVE BEEN longstanding DEBATES on the appropriate placement of potatoes in dietary guidance.456nonetheless, the dietary guidelines for americans continue to include potatoes in the vegetable Food group and encourage Consumption.7THOUGH potatoes are rich in Vitamin C, Potassium, dietary fiber, and some Phytochemicals,6unlike other vegetables they CAN have DETRIMENTAL EFFECTS on Glucose Metabolism because they contain large amounts of rapidly absorbable Starch.3indeed, SEVERAL epidemiologic STUDIES have LINKED higher potato Consumption to increased concentrations of fasting Plasma Glucose,8insulin resistance,8and an increased risk of type 2 diabetes mellitus.910\nGestational diabetes mellitus (gdm) is a common COMPLICATION of Pregnancy characterized by Glucose intolerance with onset or first recognition during Pregnancy.11gdm is not only ASSOCIATED with adverse Perinatal outcomes,12it is also RELATED to increased long term Cardiometabolic risk in both mothers and their offspring.1113it is THEREFORE CRUCIAL to identify modifiable RISK FACTORS that COULD CONTRIBUTE to the PREVENTION of gdm.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 223), ('SUPERFICIAL_RELATIONSHIP', 271), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 295), ('INCOMPLETE_EVIDENCE', 320), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 343), ('ANOMALY_CURIOUS_FINDING', 548), ('INCOMPLETE_EVIDENCE', 668), ('IMPORTANT_CONSIDERATION', 677), ('SUPERFICIAL_RELATIONSHIP', 689), ('INCOMPLETE_EVIDENCE', 792), ('SUPERFICIAL_RELATIONSHIP', 827), ('PROBLEM_COMPLICATION', 1037), ('SUPERFICIAL_RELATIONSHIP', 1167), ('SUPERFICIAL_RELATIONSHIP', 1223), ('PROBABLE_UNDERSTANDING', 1321), ('IMPORTANT_CONSIDERATION', 1331), ('SUPERFICIAL_RELATIONSHIP', 1362), ('INCOMPLETE_EVIDENCE', 1380), ('SUPERFICIAL_RELATIONSHIP', 1386), ('SUPERFICIAL_RELATIONSHIP', 1404)]	20	[('GO_0007631', 'feeding behavior', 50, 'consumed'), ('CHEBI_33290', 'food', 59, 'food'), ('GO_0000003', 'reproduction', 149, 'reproductive age'), ('GO_0007631', 'feeding behavior', 188, 'consume'), ('CHEBI_33290', 'food', 511, 'food'), ('GO_0007631', 'feeding behavior', 536, 'consumption'), ('CHEBI_27300', 'vitamin D', 577, 'vitamin C'), ('CHEBI_22314', 'alkali metal atom', 588, 'potassium'), ('CHEBI_26254', 'prenylnaphthoquinone', 623, 'phytochemicals'), ('CHEBI_17234', 'glucose', 700, 'glucose'), ('GO_0006006', 'glucose metabolic process', 700, 'glucose metabolism'), ('CHEBI_28017', 'starch', 776, 'starch'), ('GO_0007631', 'feeding behavior', 848, 'consumption'), ('UBERON_0001969', 'blood plasma', 899, 'plasma'), ('CHEBI_17234', 'glucose', 906, 'glucose'), ('GO_0007565', 'female pregnancy', 989, 'Gestational'), ('GO_0007565', 'female pregnancy', 1053, 'pregnancy'), ('CHEBI_17234', 'glucose', 1080, 'glucose'), ('GO_0007565', 'female pregnancy', 1139, 'pregnancy'), ('GO_0036268', 'swimming', 1191, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1191, 'perinatal'), ('GO_0007599', 'hemostasis', 1254, 'cardiometabolic')]	0	['introduction\npotatoes third consumed food crop world, rice wheat.1in united states, 35% women reproductive age (that is, aged 19-50) consume potatoes daily, 8% daily energy intake.2the potatoes inconclusive,13and placement potatoes dietary guidance.456nonetheless, dietary americans potatoes vegetable food consumption.7though potatoes rich potassium, dietary fiber, phytochemicals,6unlike vegetables glucose metabolism contain amounts rapidly absorbable starch.3indeed, epidemiologic higher potato consumption concentrations fasting plasma glucose,8insulin resistance,8and type 2 diabetes mellitus.910\n diabetes mellitus (gdm)  glucose intolerance onset .11gdm perinatal outcomes,12it term cardiometabolic mothers offspring.1113it gdm.']
S22-PMC5118763	PMC5118763	12/2016	S22-PMC5118763	['ALTHOUGH PREVIOUS reports from this trial SHOWED a high prevalence of anemia, zinc, and Vitamin B-12 deficiencies in early Pregnancy among the women in the trial (14), there was no differential effect of using the mmn regimen on women’s hemoglobin concentration compared with standard Iron–Folic Acid supplementation regimens (11).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 42)]	4	[('CHEBI_27300', 'vitamin D', 88, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 88, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy'), ('CHEBI_24870', 'ion', 285, 'iron'), ('CHEBI_30751', 'formic acid', 290, 'folic acid')]	0	['although anemia, zinc, -12  among women (14), using mmn regimen women’s hemoglobin concentration iron–folic acid supplementation regimens (11).']
S23-PMC5118763	PMC5118763	12/2016	S23-PMC5118763	['in THIS ARTICLE, our AIMS were to compare the effectiveness of different Prenatal Food and Micronutrient regimens as well as the efficacy per Micronutrient capsule in women’s Vitamin B-12, Folate, ferritin, and zinc status.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 21)]	2	[('GO_0007565', 'female pregnancy', 73, 'prenatal'), ('CHEBI_33290', 'food', 82, 'food'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 91, 'micronutrient'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 142, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 175, 'vitamin B-12'), ('CHEBI_30863', '5-azaorotic acid', 189, 'folate')]	0	['article,  food micronutrient regimens micronutrient capsule women’s -12, folate, ferritin, zinc status.']
S151-PMC5118763	PMC5118763	12/2016	S151-PMC5118763	['discussion\nin THIS STUDY, women who were assigned to the mmn regimen had higher concentrations of Plasma Vitamin B-12 at week 30 of Pregnancy, but no other differences between Food and Micronutrient regimens were OBSERVED.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('INCOMPLETE_EVIDENCE', 213)]	2	[('UBERON_0001969', 'blood plasma', 98, 'plasma'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 105, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 132, 'pregnancy'), ('CHEBI_33290', 'food', 176, 'food'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 185, 'micronutrient')]	0	['discussion\nin study, women assigned mmn regimen higher concentrations plasma -12 week 30 food micronutrient regimens observed.']
S160-PMC5118763	PMC5118763	12/2016	S160-PMC5118763	['a positive EFFECT of mmn supplementation on maternal Plasma Vitamin B-12 HAS also BEEN observed among Pregnant women in nepal (17).']	[('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 73)]	2	[('UBERON_0001969', 'blood plasma', 53, 'plasma'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 60, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 102, 'pregnant')]	0	['positive mmn supplementation maternal plasma -12 among  women nepal (17).']
S161-PMC5118763	PMC5118763	12/2016	S161-PMC5118763	['DESPITE supplementation, Plasma Vitamin B-12 decreased from early to late Gestation for all 3 Micronutrient types in OUR STUDY.']	[('ANOMALY_CURIOUS_FINDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 117)]	2	[('UBERON_0001969', 'blood plasma', 25, 'plasma'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 32, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 74, 'gestation'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 94, 'micronutrient')]	0	['despite supplementation, plasma -12 decreased late  3 micronutrient study.']
S162-PMC5118763	PMC5118763	12/2016	S162-PMC5118763	['hemodilution and Placental Transport Of Vitamin B-12 To the Fetus (18) MAY BE POSSIBLE EXPLANATIONS for the OBSERVED decrease in Plasma concentrations of Vitamin B-12.']	[('INCOMPLETE_EVIDENCE', 71), ('INCOMPLETE_EVIDENCE', 78), ('PROBABLE_UNDERSTANDING', 87), ('INCOMPLETE_EVIDENCE', 108)]	4	[('GO_0007565', 'female pregnancy', 17, 'placental'), ('UBERON_0001987', 'placenta', 17, 'placental'), ('GO_0042790', 'nucleolar large rRNA transcription by RNA polymerase I', 27, 'transport of vitamin B-12 to'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 40, 'vitamin B-12'), ('GO_0007631', 'feeding behavior', 60, 'fetus'), ('UBERON_0001969', 'blood plasma', 129, 'plasma'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin B')]	0	['hemodilution  transport -12 fetus (18) decrease plasma concentrations -12.']
S117-PMC5129897	PMC5129897	10/2016	S117-PMC5129897	"['[""""the annual economic BURDEN of crohn\'s disease in canada is $1.7\\xa0billion, WHEREAS that of ulcerative colitis is $1.2\\xa0billion.78several papers HAVE REPORTED inverse CORRELATIONS between Vitamin D status and incidence, prevalence, and/or severity of Inflammatory Bowel disease.79,80\\nEVIDENCE is mounting that higher 25(Oh)D concentrations are ASSOCIATED with BETTER Pregnancy and Birth outcomes.""""]']"	[('IMPORTANT_CONSIDERATION', 20), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 73), ('INCOMPLETE_EVIDENCE', 141), ('SUPERFICIAL_RELATIONSHIP', 163), ('INCOMPLETE_EVIDENCE', 280), ('SUPERFICIAL_RELATIONSHIP', 340), ('IMPORTANT_CONSIDERATION', 356)]	7	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0001782', 'pigmented layer of retina', 247, 'inflammatory bowel'), ('CHEBI_71657', 'versiconol acetate', 313, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 319, 'D'), ('GO_0007565', 'female pregnancy', 363, 'pregnancy'), ('GO_0007567', 'parturition', 377, 'birth')]	0	"['[""""the annual economic crohn*s disease canada $1.7\\xa0billion, ulcerative colitis $1.2\\xa0billion.78several correlationsvitamin status incidence, prevalence, and/or inflammatory bowel disease.79,80\\nevidence higher 25(oh)d concentrations wi pregnancy birth outcomes.""""]']"
S118-PMC5129897	PMC5129897	10/2016	S118-PMC5129897	"['[""""“the CURRENTLY AVAILABLE results INDICATE that Vitamin D supplementation during Pregnancy reduces the RISK of Preterm Birth, low Birth weight, Dental caries of infancy, and neonatal infectious diseases such as Respiratory infections and sepsis.”81furthermore, with UNFOLDING RESEARCH into fetal origins of pediatric and Adult disease, EVIDENCE increasingly INDICATES that Gestational Vitamin D indices MAY determine health in later Life.82for example, an INTERESTING cohort study CORRELATING maternal Vitamin D levels at 18\\xa0weeks\' Pregnancy and health outcomes of progeny FOUND that Gestational Vitamin D deficiency was ASSOCIATED with a higher risk of impaired Lung Development in 6-year-old offspring, Neurocognitive difficulties at age 10\\xa0years, increased risk of Eating disorders in Adolescence, and lower peak bone mass at 20\\xa0y.83\\na RECENT STUDY CONCLUDED that Vitamin D is reduces exacerbations of asthma.84\\n\\nall-cause mortality rate\\ngarland and colleagues85presented a meta-analysis of 32 prospective observational studies that investigated all-cause mortality rate with respect to 25(Oh)D concentration at time of enrollment.""""]']"	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 33), ('IMPORTANT_CONSIDERATION', 102), ('INCOMPLETE_EVIDENCE', 265), ('INCOMPLETE_EVIDENCE', 335), ('INCOMPLETE_EVIDENCE', 357), ('INCOMPLETE_EVIDENCE', 402), ('ANOMALY_CURIOUS_FINDING', 455), ('SUPERFICIAL_RELATIONSHIP', 480), ('INCOMPLETE_EVIDENCE', 572), ('SUPERFICIAL_RELATIONSHIP', 620), ('INCOMPLETE_EVIDENCE', 838), ('INCOMPLETE_EVIDENCE', 851)]	13	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0007565', 'female pregnancy', 110, 'preterm'), ('GO_0007567', 'parturition', 118, 'birth'), ('GO_0007567', 'parturition', 129, 'birth'), ('UBERON_0001091', 'calcareous tooth', 143, 'dental'), ('UBERON_0001004', 'respiratory system', 210, 'respiratory'), ('UBERON_0007023', 'adult organism', 320, 'adult'), ('GO_0007565', 'female pregnancy', 372, 'gestational'), ('CHEBI_27300', 'vitamin D', 384, 'vitamin D'), ('UBERON_0000104', 'life cycle', 432, 'life'), ('CHEBI_27300', 'vitamin D', 501, 'vitamin D'), ('GO_0007565', 'female pregnancy', 531, 'pregnancy'), ('GO_0007565', 'female pregnancy', 583, 'gestational'), ('CHEBI_27300', 'vitamin D', 595, 'vitamin D'), ('GO_0030324', 'lung development', 662, 'lung development'), ('UBERON_0002048', 'lung', 662, 'lung'), ('GO_0050905', 'neuromuscular process', 704, 'neurocognitive'), ('GO_0051318', 'G1 phase', 767, 'eating'), ('GO_0048848', 'neurohypophysis morphogenesis', 787, 'adolescence'), ('CHEBI_27300', 'vitamin D', 866, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1089, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1089, '25(OH ... D')]	0	"['[""""“the results thn supplementation durincy reduces erm birth, birth weight, dental caries infancy, neonatal infectious diseases respiratory infections sepsis.”81furthermore, fetal origins pediatric adult disease, thnn indices life.82for example, maternn levels 18\\xa0wgnancy outcomes progeny foundtamin higher lung 6-year-old offspring, neurocognitive age 10\\xa0years, eating disorders adolescence, peak bone mass 20\\xa0y.83\\na cohat vitamin reduces exacerbations asthma.84\\n\\nall-cause mortality rate\\ngarland colleagues85presented meta-analysis 32 all-cause mortality rate respect 25(oh)d concentration enrollment.""""]']"
S161-PMC5129897	PMC5129897	10/2016	S161-PMC5129897	['those ESTIMATES are SIMILAR TO those in the PREVIOUS PAPER on THIS topic, which ESTIMATED that if the 25(Oh)D concentration of all canadians were raised from a mean value of 67\xa0nmol/l to 105\xa0nmol/l, the death rate could fall by 37,000 (22,300–52,300 deaths), REPRESENTING 16.1% (9.7%–22.7%) of annual deaths, and the economic BURDEN could fall by 6.9% (3.8%–10.0%), or $14.4\xa0billion ($8.0\xa0billion–$20.1\xa0billion).89that paper CONSIDERED HOW Vitamin D AFFECTS cancer, cvd, dm, falls and fractures, Heart disease, influenza and pneumonia, ms, and septicemia as well as Pregnancy and Birth outcomes.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 44), ('INCOMPLETE_EVIDENCE', 53), ('QUESTION_ANSWERED_BY_THIS_WORK', 62), ('INCOMPLETE_EVIDENCE', 80), ('PROBABLE_UNDERSTANDING', 259), ('IMPORTANT_CONSIDERATION', 326), ('INCOMPLETE_EVIDENCE', 425), ('EXPLICIT_QUESTION', 436), ('SUPERFICIAL_RELATIONSHIP', 450)]	11	[('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 440, 'vitamin D'), ('UBERON_0000948', 'heart', 496, 'heart'), ('GO_0007565', 'female pregnancy', 566, 'pregnancy'), ('GO_0007567', 'parturition', 580, 'birth')]	0	['topic, 25(oh)d concentration canadians 67\xa0nmol/l 105\xa0nmol/l, death rate fall 37,000 (22,300–52,300 deaths), 16.1% (9.7%–22.7%) annual deaths, economic fall 6.9% (3.8%–10.0%), $14.4\xa0billion ($8.0\xa0billion–$20.1\xa0billion).89that  cancer, cvd, dm, falls fractures, disease, influenza pneumonia, ms, septicemia  birth outcomes.']
S0-PMC5133057	PMC5133057	10/2016	S0-PMC5133057	['Serum Retinol levels in Pregnant adolescents and their RELATIONSHIP with habitual Food intake, infection and obstetric, nutritional and socioeconomic variables\n\nabstract\nglobally, Vitamin A deficiency (vad) AFFECTS ABOUT 19.1 million Pregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 55), ('SUPERFICIAL_RELATIONSHIP', 207), ('INCOMPLETE_EVIDENCE', 215)]	3	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27810', 'resorcinol', 6, 'Retinol'), ('GO_0007565', 'female pregnancy', 24, 'Pregnant'), ('CHEBI_33290', 'food', 82, 'Food'), ('GO_0007601', 'visual perception', 82, 'Food'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin A'), ('GO_0007565', 'female pregnancy', 234, 'pregnant')]	0	['serum retinol levels  adolescents habitual food intake, infection obstetric, nutritional socioeconomic variables\n\nabstract\nglobally,  (vad) 19.1 million  women.']
S12-PMC5133057	PMC5133057	10/2016	S12-PMC5133057	['during Pregnancy, Vitamin A is IMPORTANT for Cell Division, growth, and maturation of Fetal Organ and Skeletal Systems.']	[('IMPORTANT_CONSIDERATION', 31)]	1	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 18, 'vitamin A'), ('GO_0051301', 'cell division', 45, 'cell division'), ('UBERON_0000922', 'embryo', 86, 'fetal'), ('UBERON_0000062', 'organ', 92, 'organ'), ('UBERON_0004755', 'skeletal tissue', 102, 'skeletal systems')]	0	[' cell division, growth, maturation fetal organ skeletal systems.']
S18-PMC5133057	PMC5133057	10/2016	S18-PMC5133057	['in brazil, vad HAS BEEN DOCUMENTED in the northeast and in SOME parts of the southeast [16]; HOWEVER, there are STILL ONLY a FEW STUDIES that evaluate the Consumption of Vitamin A by Pregnant women [17], and there are EVEN FEWER STUDIES investigating the occurrence of vad among Pregnant teenagers.']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 24), ('INCOMPLETE_EVIDENCE', 59), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 93), ('IMPORTANT_CONSIDERATION', 112), ('INCOMPLETE_EVIDENCE', 118), ('INCOMPLETE_EVIDENCE', 125), ('ANOMALY_CURIOUS_FINDING', 218), ('INCOMPLETE_EVIDENCE', 223)]	9	[('GO_0007631', 'feeding behavior', 155, 'consumption'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin A'), ('GO_0007565', 'female pregnancy', 183, 'pregnant'), ('GO_0007565', 'female pregnancy', 279, 'pregnant')]	0	['brazil, vad northeast parts southeast [16]; however, consumption   women [17], occurrence vad among  teenagers.']
S19-PMC5133057	PMC5133057	10/2016	S19-PMC5133057	['furthermore, TO OUR KNOWLEDGE, no research concomitantly evaluated the ASSOCIATION of diet, C-Reactive Protein levels, and social, nutritional, and Gestational variables with the Vitamin A status of this population.']	[('PROBABLE_UNDERSTANDING', 13), ('SUPERFICIAL_RELATIONSHIP', 71)]	2	[('CHEBI_59147', '3-[(4-methoxyphenylsulfonyloxy)methyl]-5,5-dimethylbutyrolactone', 92, 'C-reactive protein'), ('PR_000005890', 'crooked neck-like protein 1', 92, 'C-reactive protein'), ('GO_0007565', 'female pregnancy', 148, 'gestational'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin A')]	0	['furthermore, knowledge, concomitantly diet, c-reactive protein levels, social, nutritional,   status population.']
S108-PMC5133057	PMC5133057	10/2016	S108-PMC5133057	['it is IMPORTANT TO NOTE that EVEN IF the reduction occurs with more intensity in the second and third quarter due to Plasma volume expansion and increased Vitamin A transfer from the mother to the fetus, special ATTENTION throughout Pregnancy is NECESSARY, PARTICULARLY in the first trimester, when the major changes in the Fetal Development occur.']	[('IMPORTANT_CONSIDERATION', 6), ('ANOMALY_CURIOUS_FINDING', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 34), ('FUTURE_WORK', 212), ('IMPORTANT_CONSIDERATION', 212), ('IMPORTANT_CONSIDERATION', 246), ('IMPORTANT_CONSIDERATION', 257)]	7	[('UBERON_0001969', 'blood plasma', 117, 'plasma'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin A'), ('GO_0007565', 'female pregnancy', 233, 'pregnancy'), ('GO_0002065', 'columnar/cuboidal epithelial cell differentiation', 324, 'fetal development')]	0	['reduction occurs intensity third quarter plasma volume expansion  transfer mother fetus, throughout  necessary, trimester, changes fetal occur.']
S116-PMC5133057	PMC5133057	10/2016	S116-PMC5133057	['[42], where the authors assessed the nutritional status of 75 Pregnant adolescents in venezuela, using the same cutoff points as in OUR STUDY and FOUND low weight in 34.6% of the sample, which also presented insufficient Intake of energy, protein, zinc, Calcium, and Vitamin A.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 132), ('INCOMPLETE_EVIDENCE', 146)]	2	[('GO_0007565', 'female pregnancy', 62, 'pregnant'), ('GO_0007631', 'feeding behavior', 221, 'intake'), ('CHEBI_22313', 'alkaline earth metal atom', 254, 'calcium'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin A')]	0	['[42], authors nutritional status 75  adolescents venezuela, using cutoff 34.6% sample, intake energy, protein, zinc, calcium, .']
S128-PMC5133057	PMC5133057	10/2016	S128-PMC5133057	['moreover, considering the high prevalence of vad OBSERVED in THIS STUDY, as well as its IMPACT on the Pregnancy process, there is a NEED FOR regular assessment of the nutritional status of Prenatal Vitamin A in teens in order to achieve early diagnosis and proper management of this nutritional deficiency.']	[('INCOMPLETE_EVIDENCE', 49), ('QUESTION_ANSWERED_BY_THIS_WORK', 61), ('SUPERFICIAL_RELATIONSHIP', 88), ('FUTURE_WORK', 132)]	4	[('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('GO_0007565', 'female pregnancy', 189, 'prenatal'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin A')]	0	['moreover, vad study,  process, nutritional status   teens achieve diagnosis proper nutritional deficiency.']
S87-PMC5134748	PMC5134748	11/2017	S87-PMC5134748	['(25), they have FOUND that antioxidant elements including Vitamin C decreased in case group in comparison with healthy Pregnant women.']	[('INCOMPLETE_EVIDENCE', 16)]	1	[('CHEBI_27300', 'vitamin D', 58, 'vitamin C'), ('GO_0007565', 'female pregnancy', 119, 'pregnant')]	0	['(25), antioxidant elements  decreased healthy  women.']
S6-PMC5146866	PMC5146866	12/2016	S6-PMC5146866	['deficient cb Vitamin D levels in infants were ASSOCIATED with maternal black, hispanic, or asian race/ethnicity, younger age, and increased number of Pregnancies.']	[('SUPERFICIAL_RELATIONSHIP', 46)]	1	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancies')]	0	['deficient cb  levels infants maternal black, hispanic, asian race/ethnicity, younger age, .']
S7-PMC5146866	PMC5146866	12/2016	S7-PMC5146866	['the LIKELIHOOD for infants to be Born with an insufficient Vitamin D level increases with younger maternal age and the number of Pregnancies as well as asian ethnicity.']	[('PROBABLE_UNDERSTANDING', 4)]	1	[('GO_0007567', 'parturition', 33, 'born'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancies')]	0	['infants born  younger maternal age  asian ethnicity.']
S67-PMC5146866	PMC5146866	12/2016	S67-PMC5146866	['inclusion of maternal race/ethnicity (white vs. non-white), age, and gravidity in the multiple regression models REVEALED INDEPENDENT ASSOCIATION of Vitamin D deficiency and insufficiency in the infant’s cb with non-white maternal race/ethnicity, younger age, and increased number of Pregnancies (table\xa01).']	[('INCOMPLETE_EVIDENCE', 113), ('SUPERFICIAL_RELATIONSHIP', 122), ('SUPERFICIAL_RELATIONSHIP', 134)]	3	[('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('GO_0007565', 'female pregnancy', 284, 'pregnancies')]	0	['inclusion maternal race/ethnicity (white vs. non-white), age, gravidity regression  infant’s cb non-white maternal race/ethnicity, younger age,  (table\xa01).']
S86-PMC5146866	PMC5146866	12/2016	S86-PMC5146866	['we FOUND that INDEPENDENTLY from the race/ethnicity, younger maternal age and increased number of Pregnancies were ASSOCIATED with Vitamin D deficiency and insufficiency in cb of the studied infants.']	[('INCOMPLETE_EVIDENCE', 3), ('SUPERFICIAL_RELATIONSHIP', 14), ('SUPERFICIAL_RELATIONSHIP', 115)]	3	[('GO_0007565', 'female pregnancy', 98, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]	0	['race/ethnicity, younger maternal age   cb infants.']
S89-PMC5146866	PMC5146866	12/2016	S89-PMC5146866	['european data SHOWED both, decreased risk and no effect of parity on Vitamin D insufficiency/deficiency in mothers during Pregnancy [29,30].']	[('INCOMPLETE_EVIDENCE', 14)]	1	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy')]	0	['european both, decreased parity  insufficiency/deficiency mothers  [29,30].']
S101-PMC5146866	PMC5146866	12/2016	S101-PMC5146866	['maternal data that MAY CORRELATE with neonatal Vitamin D levels at Birth, including the pre-Pregnancy weight [35], skin color [13], and sun exposure during Pregnancy [36] were NOT COLLECTED.']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 23), ('INCOMPLETE_EVIDENCE', 176)]	3	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007567', 'parturition', 67, 'birth'), ('GO_0007565', 'female pregnancy', 92, 'pregnancy'), ('GO_0007565', 'female pregnancy', 156, 'pregnancy')]	0	['maternal neonatal  levels birth, pre- [35], skin color [13], sun exposure  [36] collected.']
S106-PMC5146866	PMC5146866	12/2016	S106-PMC5146866	['conclusions\na significant number of infants, especially those Born to mothers of non-white race/ethnicity, younger age, and with a history of multiple Pregnancies, are AT RISK for having insufficient and deficient levels of Vitamin D in cb.']	[('IMPORTANT_CONSIDERATION', 168)]	1	[('GO_0007567', 'parturition', 62, 'born'), ('GO_0007565', 'female pregnancy', 151, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D')]	0	['conclusions\na infants, born mothers non-white race/ethnicity, younger age, levels  cb.']
S0-PMC5155676	PMC5155676	12/2016	S0-PMC5155676	['DETERMINANTS of the maternal 25-Hydroxyvitamin D response to Vitamin D supplementation during Pregnancy\n\nabstract\n\ncontext:\ncurrent approaches to Antenatal Vitamin D supplementation do NOT ACCOUNT for interindividual differences in 25-Hydroxyvitamin D (25(Oh)D) response.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 185)]	2	[('CHEBI_27844', '2*,3*-cyclic AMP', 29, '25-Hydroxyvitamin D'), ('CHEBI_28384', 'vitamin K', 61, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 61, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'Pregnancy'), ('GO_0007567', 'parturition', 146, 'antenatal'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 232, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 253, '25(OH)D')]	0	['determinants maternal 25-hydroxyvitamin response vitamin supplementation \n\nabstract\n\ncontext:\ncurrent antenatal  supplementation interindividual 25-hydroxyvitamin (25(oh)d) response.']
S14-PMC5155676	PMC5155676	12/2016	S14-PMC5155676	['maternal Vitamin D INSUFFICIENCY during Pregnancy is common (1,2), and THERE IS EVIDENCE that this MIGHT have DETRIMENTAL EFFECTS on maternal health, Fetal Development (3,4) and the long-term Skeletal health of children (1,3).']	[('IMPORTANT_CONSIDERATION', 19), ('INCOMPLETE_EVIDENCE', 71), ('INCOMPLETE_EVIDENCE', 99), ('IMPORTANT_CONSIDERATION', 110), ('SUPERFICIAL_RELATIONSHIP', 122)]	5	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 40, 'pregnancy'), ('GO_0002065', 'columnar/cuboidal epithelial cell differentiation', 150, 'fetal development'), ('UBERON_0004288', 'skeleton', 192, 'skeletal')]	0	['maternal   (1,2), maternal health, fetal (3,4) long-term skeletal children (1,3).']
S15-PMC5155676	PMC5155676	12/2016	S15-PMC5155676	['SEVERE maternal Vitamin D deficiency during Pregnancy CAN result in symptomatic hypocalcaemia in the neonate (3).']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 54)]	2	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy')]	0	['severe maternal   result symptomatic hypocalcaemia neonate (3).']
S17-PMC5155676	PMC5155676	12/2016	S17-PMC5155676	['NONETHELESS, the institute of medicine (iom) has SUGGESTED that risk of Vitamin D insufficiency, DEFINED as a 25(Oh)D less than 50 nmol/l, SHOULD BE avoided during Pregnancy (5), and this is SUPPORTED by the RECENT global consensus on the prevention of rickets (6).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 49), ('PROBABLE_UNDERSTANDING', 97), ('FUTURE_WORK', 139), ('INCOMPLETE_EVIDENCE', 191), ('INCOMPLETE_EVIDENCE', 208)]	6	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('GO_0007565', 'female pregnancy', 164, 'pregnancy')]	0	['nonetheless, institute medicine (iom)  insufficiency, 25(oh)d 50 nmol/l, avoided  (5), rickets (6).']
S22-PMC5155676	PMC5155676	12/2016	S22-PMC5155676	['during Pregnancy, maternal hemodilution is ACCOMPANIED by a number OF physiological changes to both Vitamin D Metabolism (15) and maternal body composition (16); such adaptations MIGHT lead to DIFFERENCES in the DETERMINANTS of response to Vitamin D supplementation between Pregnant and nonpregnant women.']	[('SUPERFICIAL_RELATIONSHIP', 43), ('ANOMALY_CURIOUS_FINDING', 67), ('INCOMPLETE_EVIDENCE', 179), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 193), ('SUPERFICIAL_RELATIONSHIP', 212)]	5	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007601', 'visual perception', 100, 'vitamin D'), ('GO_0008152', 'metabolic process', 110, 'metabolism'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D'), ('GO_0007565', 'female pregnancy', 274, 'pregnant')]	0	['maternal hemodilution physiological changes  metabolism (15) maternal composition (16); adaptations response  supplementation  nonpregnant women.']
S69-PMC5155676	PMC5155676	12/2016	S69-PMC5155676	['of the women who were not Vitamin D replete at baseline (n = 509), 78.8% in the Cholecalciferol group were replete at 34 weeks of Gestation, COMPARED WITH ONLY 28.3% of the placebo group ( p< .001).']	[('ANOMALY_CURIOUS_FINDING', 141), ('ANOMALY_CURIOUS_FINDING', 155)]	2	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 80, 'cholecalciferol'), ('GO_0007565', 'female pregnancy', 130, 'gestation')]	0	['women  replete baseline (n = 509), 78.8% cholecalciferol replete 34 weeks 28.3% placebo p< .001).']
S70-PMC5155676	PMC5155676	12/2016	S70-PMC5155676	['similarly, ONLY 48.4% of women who were Vitamin D replete at baseline and received placebo remained Vitamin D replete at 34 weeks of Gestation, compared with 89.8% in the Cholecalciferol group ( p< .001).']	[('ANOMALY_CURIOUS_FINDING', 11)]	1	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'gestation'), ('CHEBI_52550', 'theopalauamide', 171, 'cholecalciferol')]	0	['similarly, 48.4% women  replete baseline received placebo  replete 34 weeks 89.8% cholecalciferol p< .001).']
S75-PMC5155676	PMC5155676	12/2016	S75-PMC5155676	['percentage of women achieving Vitamin D replete status (>50 nmol/l) according to randomization group and season of Deliveryseason of Deliveryplacebo1000 iu/d Cholecalciferol p comparing randomization groupswinter (december–may)13.975.0<.001summer (june–november)54.290.1<.001 p comparing seasons<.001<.001\n\ndeterminants of maternal 25(Oh)D at 34 weeks of Gestation\nin univariate analysis, maternal age, baseline 25(Oh)D, season of Delivery and compliance with study Medication were significantly ASSOCIATED with 34 week 25(Oh)D in both the Placebo and Vitamin D supplementation groups (table 3).']	[('SUPERFICIAL_RELATIONSHIP', 496)]	1	[('CHEBI_28384', 'vitamin K', 30, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 30, 'Vitamin D'), ('GO_0006260', 'DNA replication', 115, 'DeliverySeason'), ('GO_0006260', 'DNA replication', 133, 'DeliveryPlacebo1000'), ('CHEBI_16113', 'cholesterol', 158, 'Cholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 332, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 355, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 412, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 415, 'OH ... D'), ('GO_0007567', 'parturition', 431, 'delivery'), ('CHEBI_60211', 'compound Z', 466, 'medication'), ('CHEBI_71657', 'versiconol acetate', 520, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 520, '25(OH)D'), ('CHEBI_26130', 'biological pigment', 540, 'placebo'), ('CHEBI_27300', 'vitamin D', 552, 'vitamin D')]	0	['percentage women achieving vitamin replete status (>50 nmol/l) randomization season deliveryseason deliveryplacebo1000 iu/d cholecalciferol p randomization groupswinter (december–may)13.975.0<.001summer (june–november)54.290.1<.001 p seasons<.001<.001\n\ndeterminants maternal 25(oh)d 34 weeks \nin univariate analysis, maternal age, baseline 25(oh)d, season delivery medication 34 week 25(oh)d placebo  supplementation (table 3).']
S82-PMC5155676	PMC5155676	12/2016	S82-PMC5155676	['in multiple linear regression analysis, maternal factors significantly ASSOCIATED with greater 25(Oh)D at 34 weeks of Gestation in the Vitamin D supplementation group were lower Pregnancy weight gain (kg) (β = −0.81; 95% confidence interval [ci] −1.39, −0.22; p = .007), higher compliance (%) (β = 0.28; 95%ci 0.072, 0.48; p = .008), higher early Pregnancy 25(Oh)D (nmol/l) (β = 0.28; 95%ci 0.16, 0.40; p< .001), and summer Delivery (summer vs winter) (β = 10.51; 95%ci 6.40, 14.63; p< .001) (figure 2a).']	[('SUPERFICIAL_RELATIONSHIP', 71)]	1	[('CHEBI_71657', 'versiconol acetate', 95, '25(OH)D'), ('GO_0007565', 'female pregnancy', 118, 'gestation'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('GO_0007565', 'female pregnancy', 347, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 357, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 357, '25(OH)D'), ('GO_0007567', 'parturition', 424, 'delivery')]	0	['linear regression analysis, maternal 25(oh)d 34 weeks   supplementation  gain (kg) (β = −0.81; 95% confidence interval [ci] −1.39, −0.22; p = .007), higher (%) (β = 0.28; 95%ci 0.072, 0.48; p = .008), higher  25(oh)d (nmol/l) (β = 0.28; 95%ci 0.16, 0.40; p< .001), summer delivery (summer winter) (β = 10.51; 95%ci 6.40, 14.63; p< .001) (figure 2a).']
S84-PMC5155676	PMC5155676	12/2016	S84-PMC5155676	['when achievement of Vitamin D replete status at 34 weeks of Gestation was considered INSTEAD of absolute 25(Oh)D concentration, in multivariate analyses, Delivery in summer (relative risk [rr] = 1.20; 95%ci 1.09, 1.33; p< .001), white ethnicity (rr = 1.27; 95%ci 1.17, 1.37; p< .001), greater compliance with Medication (%) (rr = 1.01; 95%ci 1.00, 1.02; p = .03), and greater early Pregnancy 25(Oh)D concentration (nmol/l) (rr = 1.003; 95%ci 1.001, 1.006; p = .007) were significantly ASSOCIATED with achieving 25(Oh)D >50 nmol/l in the women randomized to Cholecalciferol.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 85), ('SUPERFICIAL_RELATIONSHIP', 485)]	2	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 105, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 111, 'D'), ('GO_0007567', 'parturition', 154, 'delivery'), ('CHEBI_60211', 'compound Z', 309, 'medication'), ('GO_0007565', 'female pregnancy', 382, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 392, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 511, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 511, '25(OH)D'), ('CHEBI_52550', 'theopalauamide', 557, 'cholecalciferol')]	0	['achievement  replete status 34 weeks  absolute 25(oh)d concentration, multivariate analyses, delivery summer (relative [rr] = 1.20; 95%ci 1.09, 1.33; p< .001), white ethnicity (rr = 1.27; 95%ci 1.17, 1.37; p< .001), medication (%) (rr = 1.01; 95%ci 1.00, 1.02; p = .03),  25(oh)d concentration (nmol/l) (rr = 1.003; 95%ci 1.001, 1.006; p = .007) achieving 25(oh)d >50 nmol/l women cholecalciferol.']
S95-PMC5155676	PMC5155676	12/2016	S95-PMC5155676	['the maternal characteristics ASSOCIATED with 25(Oh)D at 34 weeks of Gestation and achieving Vitamin D replete status were SIMILAR TO those observed in the whole cohort.']	[('SUPERFICIAL_RELATIONSHIP', 29), ('INCOMPLETE_EVIDENCE', 122)]	2	[('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 51, 'D'), ('GO_0007565', 'female pregnancy', 68, 'gestation'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]	0	['maternal characteristics 25(oh)d 34 weeks  achieving  replete status whole cohort.']
S98-PMC5155676	PMC5155676	12/2016	S98-PMC5155676	['however, gaining less weight during Pregnancy, having a higher 25(Oh)D in early Pregnancy, Delivering in summer and having higher compliance with supplementation were INDEPENDENTLY ASSOCIATED with achieving a greater 25(Oh)D concentration in late Pregnancy among women randomized to Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 167), ('SUPERFICIAL_RELATIONSHIP', 181)]	2	[('GO_0007565', 'female pregnancy', 36, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 63, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0006900', 'vesicle budding from membrane', 91, 'delivering'), ('CHEBI_71657', 'versiconol acetate', 217, '25(OH)D'), ('GO_0007565', 'female pregnancy', 247, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]	0	['however, higher 25(oh)d delivering summer higher supplementation achieving 25(oh)d concentration late  among women  supplementation.']
S99-PMC5155676	PMC5155676	12/2016	S99-PMC5155676	['THUS, those women who are AT RISK of Vitamin D insufficiency in early Pregnancy, gain greater weight, and Deliver in winter MIGHT NEED supplementation with a higher dose of Cholecalciferol to achieve SIMILAR 25(Oh)D concentrations.']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 26), ('INCOMPLETE_EVIDENCE', 124), ('IMPORTANT_CONSIDERATION', 130), ('SUPERFICIAL_RELATIONSHIP', 200)]	5	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('GO_0007567', 'parturition', 106, 'deliver'), ('CHEBI_52550', 'theopalauamide', 173, 'cholecalciferol'), ('CHEBI_71657', 'versiconol acetate', 208, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 214, 'D')]	0	['thus, women  gain weight, deliver winter supplementation higher dose cholecalciferol achieve 25(oh)d concentrations.']
S101-PMC5155676	PMC5155676	12/2016	S101-PMC5155676	['TO OUR KNOWLEDGE, the factors which determine the response to Vitamin D supplementation in Pregnancy have not previously been assessed.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy')]	0	['knowledge, response  supplementation  assessed.']
S103-PMC5155676	PMC5155676	12/2016	S103-PMC5155676	['it is WELL RECOGNIZED that Individuals who are overweight or obese are at higher RISK of Vitamin D insufficiency, and this is SIMILARLY OBSERVED in Pregnancy (2,22).']	[('INCOMPLETE_EVIDENCE', 6), ('PROBABLE_UNDERSTANDING', 11), ('IMPORTANT_CONSIDERATION', 81), ('SUPERFICIAL_RELATIONSHIP', 126), ('INCOMPLETE_EVIDENCE', 136)]	5	[('NCBITaxon_1', 'root', 27, 'individuals'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy')]	0	['individuals overweight obese higher  insufficiency,  (2,22).']
S108-PMC5155676	PMC5155676	12/2016	S108-PMC5155676	['weight gain in Pregnancy REPRESENTS NOT ONLY increased fat mass BUT ALSO Feto-Placental Tissues and hemodilution (16); our data, THEREFORE, SUGGEST that overall volume of dilution, and not just adiposity, MAY BE IMPORTANT for response to Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 25), ('ANOMALY_CURIOUS_FINDING', 36), ('ANOMALY_CURIOUS_FINDING', 64), ('PROBABLE_UNDERSTANDING', 129), ('INCOMPLETE_EVIDENCE', 140), ('INCOMPLETE_EVIDENCE', 205), ('IMPORTANT_CONSIDERATION', 212)]	7	[('GO_0007565', 'female pregnancy', 15, 'pregnancy'), ('UBERON_0000981', 'femur', 73, 'feto'), ('UBERON_0002483', 'trabecular bone tissue', 78, 'placental tissues'), ('CHEBI_27300', 'vitamin D', 238, 'vitamin D')]	0	['weight gain  fat mass feto-placental tissues hemodilution (16); data, therefore, volume dilution, adiposity, response  supplementation.']
S109-PMC5155676	PMC5155676	12/2016	S109-PMC5155676	['HOWEVER, IMPORTANTLY, when using a 25(Oh)D more than 50 nmol/l as a cut-point for repletion, Pregnancy weight gain was not an independent predictor of achieving Vitamin D repletion.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 9)]	3	[('CHEBI_71657', 'versiconol acetate', 35, '25(OH)D'), ('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D')]	0	['however, importantly, using 25(oh)d 50 nmol/l cut-point repletion,  gain achieving  repletion.']
S112-PMC5155676	PMC5155676	12/2016	S112-PMC5155676	['HOWEVER, it is NOTABLE that there were marked DIFFERENCES in baseline 25(Oh)D concentrations between these investigations, and we OBSERVED that initial 25(Oh)D status was positively ASSOCIATED with both the LIKELIHOOD of achieving Vitamin D replete status and absolute 25(Oh)D status at 34 weeks of Gestation.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 15), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 46), ('INCOMPLETE_EVIDENCE', 130), ('SUPERFICIAL_RELATIONSHIP', 182), ('PROBABLE_UNDERSTANDING', 207)]	7	[('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 76, 'D'), ('CHEBI_63056', 'zinc cation', 152, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 158, 'D'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 269, '25(OH)D'), ('GO_0007565', 'female pregnancy', 299, 'gestation')]	0	['however, marked baseline 25(oh)d concentrations investigations, 25(oh)d status positively achieving  replete status absolute 25(oh)d status 34 weeks .']
S113-PMC5155676	PMC5155676	12/2016	S113-PMC5155676	['IMPORTANTLY, the difference between the 25(Oh)D achieved at 34 weeks of Gestation in women randomized to Placebo compared with Cholecalciferol decreased with increasing baseline 25(Oh)D. this is CONSISTENT with PREVIOUS STUDIES in Adults, which HAVE SHOWN that the incremental response to Vitamin D supplementation is higher in Vitamin D insufficient than replete subjects (13,14) and that the increase in 25(Oh)D relative to supplementation dose is negatively ASSOCIATED with dose of vitamin D supplement (26).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 195), ('INCOMPLETE_EVIDENCE', 211), ('INCOMPLETE_EVIDENCE', 245), ('SUPERFICIAL_RELATIONSHIP', 461)]	5	[('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('GO_0007565', 'female pregnancy', 72, 'gestation'), ('CHEBI_26130', 'biological pigment', 105, 'placebo'), ('CHEBI_52550', 'theopalauamide', 127, 'cholecalciferol'), ('CHEBI_33010', 'chromide(1-)', 180, '(OH)D'), ('UBERON_0007023', 'adult organism', 231, 'adults'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 328, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 412, 'D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 493, 'D')]	0	['importantly, 25(oh)d achieved 34 weeks  women placebo cholecalciferol decreased baseline 25(oh)d. adults, incremental response  supplementation higher  replete subjects (13,14) increase 25(oh)d relative supplementation dose dose vitamin supplement (26).']
S115-PMC5155676	PMC5155676	12/2016	S115-PMC5155676	['this mechanism MIGHT be IMPORTANT in preventing hypervitaminosis D. HOWEVER, studies comparing the effectiveness of DIFFERING doses of Vitamin D in Pregnancy HAVE SHOWN that 4000 iu/d CAN achieve a higher 25(Oh)D than 400 iu/d (10,28), BUT WHETHER these higher doses are of clinical benefit is YET to be DEMONSTRATED (4,29) and at the general population level, lower doses would be compatible with keeping 25(Oh)D below a concentration which MIGHT be concerning.']	[('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 24), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 116), ('INCOMPLETE_EVIDENCE', 158), ('INCOMPLETE_EVIDENCE', 184), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 236), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 240), ('ANOMALY_CURIOUS_FINDING', 294), ('INCOMPLETE_EVIDENCE', 304), ('INCOMPLETE_EVIDENCE', 442)]	11	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 65, 'D'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 205, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 205, '25(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 211, 'D'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 412, 'D')]	0	['hypervitaminosis d. however, doses   4000 iu/d achieve higher 25(oh)d 400 iu/d (10,28), higher doses (4,29) population level, doses keeping 25(oh)d concentration concerning.']
S118-PMC5155676	PMC5155676	12/2016	S118-PMC5155676	['hollis et al SIMILARLY FOUND that EVEN with 4000 iu/d Vitamin D during Pregnancy, african-american women had lower 25(Oh)D in late Pregnancy than caucasian or hispanic women (10).']	[('SUPERFICIAL_RELATIONSHIP', 13), ('INCOMPLETE_EVIDENCE', 23), ('ANOMALY_CURIOUS_FINDING', 34)]	3	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 115, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 121, 'D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy')]	0	['hollis et al 4000 iu/d  african-american women 25(oh)d late  caucasian hispanic women (10).']
S120-PMC5155676	PMC5155676	12/2016	S120-PMC5155676	['maternal age was also positively ASSOCIATED in univariate analyses with 25(Oh)D achieved at 34 weeks of Gestation in women who received Vitamin D supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 33)]	1	[('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('GO_0007565', 'female pregnancy', 104, 'gestation'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]	0	['maternal age positively univariate 25(oh)d achieved 34 weeks  women received  supplementation.']
S124-PMC5155676	PMC5155676	12/2016	S124-PMC5155676	['AS such, young Pregnant women MIGHT PARTICULARLY REQUIRE ADVICE on the need for, and compliance with, Vitamin D supplementation.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 30), ('ANOMALY_CURIOUS_FINDING', 36), ('IMPORTANT_CONSIDERATION', 36), ('FUTURE_WORK', 49), ('IMPORTANT_CONSIDERATION', 49), ('FUTURE_WORK', 57)]	7	[('GO_0007565', 'female pregnancy', 15, 'pregnant'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]	0	['such, young  women for, with,  supplementation.']
S133-PMC5155676	PMC5155676	12/2016	S133-PMC5155676	['ALTHOUGH this Genetic information CAN enable a more COMPREHENSIVE understanding of the biochemical response to Vitamin D supplementation, the current inability to undertake genotyping on a widespread population basis means this additional information WOULD NOT ALLOW for alterations to current clinical PRACTICE regarding Vitamin D supplementation in Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 34), ('PROBABLE_UNDERSTANDING', 52), ('DIFFICULT_TASK', 251), ('INCOMPLETE_EVIDENCE', 303)]	6	[('SO_0000704', 'gene', 14, 'genetic'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 322, 'vitamin D'), ('GO_0007565', 'female pregnancy', 351, 'pregnancy')]	0	['although genetic biochemical response  supplementation, genotyping population alterations regarding  supplementation .']
S134-PMC5155676	PMC5155676	12/2016	S134-PMC5155676	['finally, during Pregnancy, a number OF physiological changes occur to Vitamin D Metabolism, including an increase in Vitamin D binding protein and 1,25-Dihydroxyvitamin d (15), indices that we were not able to include in our analysis.']	[('ANOMALY_CURIOUS_FINDING', 36)]	1	[('GO_0007565', 'female pregnancy', 16, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 70, 'vitamin D metabolism'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_72671', '(2S,3S)-versiconal hemiacetal acetate', 147, '1,25-dihydroxyvitamin')]	0	['finally, physiological changes occur  metabolism, increase  binding protein 1,25-dihydroxyvitamin (15), indices able analysis.']
S136-PMC5155676	PMC5155676	12/2016	S136-PMC5155676	['FUTURE STUDIES SHOULD AIM to determine appropriate doses to enable consistent repletion of 25(Oh)D during Pregnancy, and OUR FINDINGS SUPPORT the NOTION that clinical approaches to Vitamin D repletion MAY BE informed by individual characteristics.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 15), ('QUESTION_ANSWERED_BY_THIS_WORK', 121), ('INCOMPLETE_EVIDENCE', 134), ('INCOMPLETE_EVIDENCE', 146), ('INCOMPLETE_EVIDENCE', 201)]	6	[('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 93, '(OH ... D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]	0	['future doses repletion 25(oh)d  repletion individual characteristics.']
S41-PMC5167470	PMC5167470	12/2016	S41-PMC5167470	['this was followed by Vitamin 25-Oh-D3 deficiency in 40.5% of patients, B12 deficiency in 22.6%, Vitamin A in 7.7%, Calcium in 6.6%, Vitamin E in 6% and Folic Acid in 5.4%.5in another RECENT prospective STUDY that followed 49 women who got Pregnant after bs, progressively decreasing levels of Vitamins A, D, b12, and iron were OBSERVED over the course of Pregnancy, DESPITE correct compliance with oral supplements, before and during Gestation.']	[('INCOMPLETE_EVIDENCE', 183), ('INCOMPLETE_EVIDENCE', 327), ('ANOMALY_CURIOUS_FINDING', 366)]	3	[('CHEBI_85670', 'N-oleoyl-sn-glycero-3-phosphoethanolamine', 21, 'vitamin 25-OH-D3'), ('CHEBI_27778', 'abequose', 71, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 71, 'B12'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin A'), ('CHEBI_22313', 'alkaline earth metal atom', 115, 'calcium'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin E'), ('CHEBI_30751', 'formic acid', 152, 'folic acid'), ('GO_0007565', 'female pregnancy', 239, 'pregnant'), ('CHEBI_27300', 'vitamin D', 293, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 302, 'A'), ('PR_000006444', 'diacylglycerol kinase delta', 305, 'D'), ('GO_0007565', 'female pregnancy', 355, 'pregnancy'), ('GO_0007565', 'female pregnancy', 434, 'gestation')]	0	['followed vitamin 25-oh-d3 40.5% patients, b12 22.6%,  7.7%, calcium 6.6%,  6% folic acid 5.4%.5in followed 49 women got  bs, progressively decreasing levels d, b12, iron course oral supplements, .']
S43-PMC5167470	PMC5167470	12/2016	S43-PMC5167470	['in this regard, there HAVE BEEN REPORTS of Kidney abnormalities in the offspring of women who took between 40,000 and 50,000 u/d of Vitamin A during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 22), ('INCOMPLETE_EVIDENCE', 32)]	2	[('UBERON_0002113', 'kidney', 43, 'kidney'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 140, 'A'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy')]	0	['regard, kidney abnormalities offspring women took 40,000 50,000 u/d  .']
S100-PMC5167470	PMC5167470	12/2016	S100-PMC5167470	['in this regard, the most FREQUENTLY DESCRIBED maternal Micronutrient deficiency is that of Folic Acid, which entails a high risk of fetal Neural Tube defects.68moreover, there HAVE BEEN case reports of maternal and fetal hypercoagulability due to Vitamin K deficiency following bpd, Ophthalmic and Renal malformations due to SEVERE maternal and fetal Vitamin a deficiency, and megaloblastic anemia due to Vitamin B12 deficiency.69–71\n\nconclusion\nPregnancy after bs is SAFE, both for the mother and for the fetus.']	[('ANOMALY_CURIOUS_FINDING', 25), ('INCOMPLETE_EVIDENCE', 36), ('INCOMPLETE_EVIDENCE', 176), ('IMPORTANT_CONSIDERATION', 325), ('IMPORTANT_CONSIDERATION', 468)]	5	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 55, 'micronutrient'), ('CHEBI_30751', 'formic acid', 91, 'folic acid'), ('UBERON_0001049', 'neural tube', 138, 'neural tube'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin K'), ('UBERON_0000970', 'eye', 283, 'ophthalmic'), ('UBERON_0002113', 'kidney', 298, 'renal'), ('CHEBI_33229', 'vitamin (role)', 351, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 405, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 405, 'vitamin B12'), ('GO_0007565', 'female pregnancy', 446, 'Pregnancy')]	0	['regard, maternal micronutrient folic acid, entails fetal neural tube defects.68moreover, maternal fetal hypercoagulability  following bpd, ophthalmic renal malformations maternal fetal vitamin deficiency, megaloblastic anemia vitamin b12 deficiency.69–71\n\nconclusion\n bs safe, mother fetus.']
S135-PMC5223368	PMC5223368	12/2016	S135-PMC5223368	['Pregnancy health is STRONGLY ASSOCIATED with Serum 25-Hydroxy Vitamin D [26], and the ROLE of Vitamin D in bone mineralization is WELL KNOWN [26,27].']	[('PROBABLE_UNDERSTANDING', 20), ('SUPERFICIAL_RELATIONSHIP', 29), ('SUPERFICIAL_RELATIONSHIP', 86), ('INCOMPLETE_EVIDENCE', 130)]	4	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('UBERON_0001977', 'blood serum', 45, 'serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 51, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]	0	[' serum 25-hydroxy  [26],  bone mineralization [26,27].']
S136-PMC5223368	PMC5223368	12/2016	S136-PMC5223368	['a study in london REPORTED that maternal Vitamin D insufficiency at Pregnancy as early as 19\xa0weeks CAN INFLUENCE Fetal Femoral Development, and SUGGESTED that maternal Vitamin D should be improved in early Pregnancy [14].']	[('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 99), ('SUPERFICIAL_RELATIONSHIP', 103), ('INCOMPLETE_EVIDENCE', 144)]	4	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy'), ('GO_0007631', 'feeding behavior', 113, 'fetal'), ('GO_0009556', 'microsporogenesis', 119, 'femoral development'), ('UBERON_0000981', 'femur', 119, 'femoral'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('GO_0007565', 'female pregnancy', 206, 'pregnancy')]	0	['london maternal   19\xa0weeks fetal femoral development, maternal   [14].']
S185-PMC5223368	PMC5223368	12/2016	S185-PMC5223368	['one of the LIMITATIONS of THIS STUDY was that FACTORS which COULD AFFECT Birth size such as maternal dietary information and maternal Vitamin D status during Pregnancy were NOT available.']	[('INCOMPLETE_EVIDENCE', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 60), ('SUPERFICIAL_RELATIONSHIP', 66), ('ANOMALY_CURIOUS_FINDING', 173)]	6	[('GO_0007567', 'parturition', 73, 'birth'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]	0	['one birth maternal dietary maternal  status  available.']
S116-PMC5240436	PMC5240436	1/2017	S116-PMC5240436	['the LACK OF treatment response DESPITE the provision of adequate doses of Vitamin A and zinc in mmn and sq-lns and reasonable adherence to supplementation [24] COULD HAVE been due to dietary factors inhibiting zinc absorption [48] or haemodilution in the latter half of Pregnancy lowering levels of Retinol binding protein resulting in functional Vitamin A deficiency [49].']	[('INCOMPLETE_EVIDENCE', 4), ('ANOMALY_CURIOUS_FINDING', 31), ('INCOMPLETE_EVIDENCE', 160), ('IMPORTANT_CONSIDERATION', 166)]	4	[('CHEBI_27300', 'vitamin D', 74, 'vitamin A'), ('GO_0007565', 'female pregnancy', 270, 'pregnancy'), ('CHEBI_26536', 'retinoic acid', 299, 'retinol'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin A')]	0	['treatment response provision doses  zinc mmn sq-lns adherence supplementation [24] dietary inhibiting zinc absorption [48] haemodilution latter half  lowering levels retinol binding protein resulting functional  [49].']
S36-PMC5264377	PMC5264377	7/2016	S36-PMC5264377	['EVEN THOUGH tian FOUND a positive ASSOCIATION between maternal Vitamin D levels and infant weight at Birth, Vitamin D supplementation for Pregnant women with low Serum levels of 25(Oh)D3 failed to improve Birth weight outcomes.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 34)]	3	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007567', 'parturition', 101, 'birth'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnant'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_32029', 'potassium acetate', 180, '(OH)D3'), ('PR_000001904', 'platelet endothelial cell adhesion molecule', 183, ')D3'), ('GO_0007567', 'parturition', 205, 'birth')]	0	['even tian positive maternal  levels infant birth,  supplementation  women serum levels 25(oh)d3 birth outcomes.']
S37-PMC5264377	PMC5264377	7/2016	S37-PMC5264377	['IN FACT, the benefits ASSOCIATED with Gestational Vitamin D supplementation are debatable, and MORE RESEARCH IS WARRANTED (dalgard et al ., 2016;dressler et al ., 2016).']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 22), ('FUTURE_WORK', 95)]	3	[('GO_0007565', 'female pregnancy', 38, 'gestational'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]	0	['fact,   supplementation debatable, (dalgard et al ., 2016;dressler et al ., 2016).']
S0-PMC5273824	PMC5273824	1/2017	S0-PMC5273824	['investigation of the Vitamin D nutritional status in women with Gestational diabetes mellitus in beijing\n\nabstract\n\nbackground\nVitamin D deficiency is a common ISSUE, which has RELATION with gdm, during the Pregnant period.']	[('IMPORTANT_CONSIDERATION', 160), ('SUPERFICIAL_RELATIONSHIP', 177)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'gestational'), ('CHEBI_28384', 'vitamin K', 127, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 207, 'pregnant')]	0	['investigation  nutritional status women  diabetes mellitus beijing\n\nabstract\n\nbackground\nvitamin issue, gdm,  period.']
S38-PMC5310660	PMC5310660	1/2017	S38-PMC5310660	['several seasonal factors acting during Pregnancy and the Perinatal Period HAVE BEEN PROPOSED to EXPLAIN these data, including infections, dietary factors (e.g., low intake of antioxidants in winter), and Vitamin D deficiency through lack of sun exposure during Pregnancy.[8].']	[('INCOMPLETE_EVIDENCE', 74), ('INCOMPLETE_EVIDENCE', 84), ('PROBABLE_UNDERSTANDING', 96)]	3	[('GO_0007565', 'female pregnancy', 39, 'pregnancy'), ('GO_0036268', 'swimming', 57, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 57, 'perinatal period'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D'), ('GO_0007565', 'female pregnancy', 261, 'pregnancy')]	0	['several seasonal  perinatal period data, infections, dietary (e.g., intake antioxidants winter),  sun exposure .[8].']
S43-PMC5310660	PMC5310660	1/2017	S43-PMC5310660	['during Pregnancy, when a higher amount of Vitamin D is REQUIRED, many Pregnant women CAN develop a Vitamin D deficiency.']	[('IMPORTANT_CONSIDERATION', 55), ('INCOMPLETE_EVIDENCE', 85)]	2	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnant'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]	0	['higher amount  required,  women  deficiency.']
S44-PMC5310660	PMC5310660	1/2017	S44-PMC5310660	['in ireland, a higher prevalence of Vitamin D deficiency (25(Oh)D <27.5 nmol/l) was OBSERVED in Pregnant than in nonpregnant women, both in spring (44% vs. 18%) and in winter (35% vs 29%) [15].']	[('INCOMPLETE_EVIDENCE', 83)]	1	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('GO_0007565', 'female pregnancy', 95, 'pregnant')]	0	['ireland, higher  (25(oh)d <27.5 nmol/l)  nonpregnant women, spring (44% vs. 18%) winter (35% 29%) [15].']
S48-PMC5310660	PMC5310660	1/2017	S48-PMC5310660	['Gestational Vitamin D concentration IS CONSIDERED IMPORTANT for the Development Of the Immune System.']	[('INCOMPLETE_EVIDENCE', 36), ('IMPORTANT_CONSIDERATION', 50)]	2	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0002020', 'protease binding', 68, 'development of ... immune system'), ('UBERON_0002405', 'immune system', 87, 'immune system')]	0	['  concentration immune system.']
S52-PMC5310660	PMC5310660	1/2017	S52-PMC5310660	['in Animal models, Gestational Vitamin D deficiency AFFECTS Brain Development [23], and the myelination process [24], and it COULD have an EFFECT on Retinal Cells.']	[('SUPERFICIAL_RELATIONSHIP', 51), ('INCOMPLETE_EVIDENCE', 124), ('SUPERFICIAL_RELATIONSHIP', 138)]	3	[('NCBITaxon_33208', 'Metazoa', 3, 'animal'), ('GO_0007565', 'female pregnancy', 18, 'gestational'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007420', 'brain development', 59, 'brain development'), ('UBERON_0000955', 'brain', 59, 'brain'), ('CL_0009004', 'retinal cell', 148, 'retinal cells'), ('UBERON_0000966', 'retina', 148, 'retinal')]	0	['animal models,   brain [23], myelination process [24], retinal cells.']
S5-PMC5318550	PMC5318550	2/2017	S5-PMC5318550	['we EXPLORED how adjusting for socioeconomic status and maternal iq, Childbirth outcomes, Pregnancy Vitamin D status, nutritional intake, exposure to infections, and child age relative to peers in class changed the RELATION between season of Birth and child iq.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 214)]	2	[('GO_0007623', 'circadian rhythm', 68, 'childbirth'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007567', 'parturition', 241, 'birth')]	0	['adjusting socioeconomic status maternal iq, childbirth outcomes,   status, nutritional intake, exposure infections, child age relative peers class season birth child iq.']
S21-PMC5318550	PMC5318550	2/2017	S21-PMC5318550	['the MAJORITY of studies focused on maternal influenza as the primary cause for a higher prevalence of schizophrenia ASSOCIATED with certain Birth months.3poor Prenatal nutrition HAS BEEN PROPOSED to be RELATED to the Birth seasonality of Individuals who develop schizophrenia.4\nadverse Birth outcomes are RISK FACTORS for impaired Cognitive Development.56PREVIOUS STUDIES have repeatedly described RELATIONSHIPS between season of Birth and Birth weight, and duration of Gestation.7\nRECENTLY, a strong INTEREST in the EFFECTS of Vitamin D on development of the Brain emerged.']	[('PROBABLE_UNDERSTANDING', 4), ('SUPERFICIAL_RELATIONSHIP', 116), ('INCOMPLETE_EVIDENCE', 178), ('INCOMPLETE_EVIDENCE', 187), ('SUPERFICIAL_RELATIONSHIP', 202), ('SUPERFICIAL_RELATIONSHIP', 305), ('INCOMPLETE_EVIDENCE', 353), ('SUPERFICIAL_RELATIONSHIP', 398), ('INCOMPLETE_EVIDENCE', 482), ('INCOMPLETE_EVIDENCE', 501), ('SUPERFICIAL_RELATIONSHIP', 517)]	11	[('GO_0007567', 'parturition', 140, 'birth'), ('GO_0007565', 'female pregnancy', 159, 'prenatal'), ('GO_0007567', 'parturition', 217, 'birth'), ('NCBITaxon_1', 'root', 238, 'individuals'), ('GO_0007567', 'parturition', 286, 'birth'), ('GO_0050787', 'detoxification of mercury ion', 331, 'cognitive development'), ('GO_0007567', 'parturition', 430, 'birth'), ('GO_0007567', 'parturition', 440, 'birth'), ('GO_0007565', 'female pregnancy', 470, 'gestation'), ('CHEBI_27300', 'vitamin D', 528, 'vitamin D'), ('UBERON_0000955', 'brain', 560, 'brain')]	0	['maternal influenza higher schizophrenia birth months.3poor  nutrition birth seasonality individuals schizophrenia.4\nadverse birth outcomes cognitive development.56previous season birth birth weight, duration .7\nrecently,  brain emerged.']
S28-PMC5318550	PMC5318550	2/2017	S28-PMC5318550	['next, we determined in additional models WHETHER this ASSOCIATION COULD BE explained by specific variables—thereby testing DIFFERENT HYPOTHESES; (2) sociodemographic factors and maternal iq; (3) child Birth weight and Gestational duration; (4) Pregnancy Vitamin D plasma status; (5) maternal nutritional intake; (6) maternal exposure to fever during Pregnancy; and (7) child age relative to peers at school.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 41), ('SUPERFICIAL_RELATIONSHIP', 54), ('INCOMPLETE_EVIDENCE', 66), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 123), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 133)]	5	[('GO_0007567', 'parturition', 201, 'birth'), ('GO_0007565', 'female pregnancy', 218, 'gestational'), ('GO_0007565', 'female pregnancy', 244, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 254, 'vitamin D'), ('GO_0007565', 'female pregnancy', 350, 'pregnancy')]	0	['next, variables—thereby testing hypotheses; (2) sociodemographic maternal iq; (3) child birth  duration; (4)   plasma status; (5) maternal nutritional intake; (6) maternal exposure fever (7) child age relative peers school.']
S67-PMC5318550	PMC5318550	2/2017	S67-PMC5318550	['portion sizes were estimated using household measures and photographs.21to calculate average daily nutritional values, the dutch Food composition table 2006 was used.22\non the basis of their seasonal variations in PREVIOUS literature, we selected fat, Carbohydrate, Vitamin C, b, Sodium, Potassium, calcium, Phosphorus and zinc intakes and adjusted for energy intake.23\nFolate concentrations were analysed in edta Plasma samples, drawn in early Pregnancy (median 13.1\u2005weeks of Gestation; 90% range 10.5–16.9\u2005weeks).']	[('INCOMPLETE_EVIDENCE', 214)]	1	[('CHEBI_33290', 'food', 129, 'food'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 252, 'carbohydrate'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin C'), ('CHEBI_52632', 'potassium-39 atom', 280, 'sodium'), ('CHEBI_22314', 'alkali metal atom', 288, 'potassium'), ('CHEBI_35885', 'secondary phosphine', 308, 'phosphorus'), ('CHEBI_81245', 'Vulpecholate', 370, 'Folate'), ('UBERON_0001969', 'blood plasma', 414, 'plasma'), ('GO_0007565', 'female pregnancy', 445, 'pregnancy'), ('GO_0007565', 'female pregnancy', 477, 'gestation')]	0	['portion sizes using household photographs.21to calculate average daily nutritional values, dutch food composition table 2006 used.22\non seasonal literature, selected fat, carbohydrate, b, sodium, potassium, calcium, phosphorus zinc intakes adjusted energy intake.23\nfolate concentrations edta plasma samples, drawn  (median 13.1\u2005weeks 90% 10.5–16.9\u2005weeks).']
S95-PMC5318550	PMC5318550	2/2017	S95-PMC5318550	['the percentages of MISSING values within the population for analysis were lower than 20%, except for Maternal Pregnancy nutritional intake (29.9%), presence of maternal fever during Pregnancy (21.5%), maternal Pregnancy crp concentrations (34.9%), and maternal mid-Pregnancy and Cord Blood Vitamin D Plasma concentrations (23.8% and 45.9%).']	[('PROBLEM_COMPLICATION', 19)]	1	[('GO_0007618', 'mating', 101, 'maternal'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('GO_0007565', 'female pregnancy', 210, 'pregnancy'), ('GO_0007565', 'female pregnancy', 265, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 279, 'cord'), ('UBERON_0000178', 'blood', 284, 'blood'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 300, 'plasma')]	0	['percentages values population 20%, maternal  nutritional intake (29.9%), presence maternal fever  (21.5%), maternal  crp concentrations (34.9%), maternal mid- cord blood  plasma concentrations (23.8% 45.9%).']
S103-PMC5318550	PMC5318550	2/2017	S103-PMC5318550	['as shown in the correlation matrix (see onlinesupplementary table s1), child spring Birth negatively CORRELATED with nulliparity (r=−0.03, p=0.008), maternal mid-Pregnancy and Cord Blood Vitamin D Plasma concentrations (r=−0.11, p=0.01 and r=−0.12, p<0.001), child relative age compared with peers in school (r=−0.17, p<0.001) and positively CORRELATED with maternal crp concentrations (r=0.05, p=0.001) and presence of fever in mid-Pregnancy (r=0.06, p=0.001).10.1136/bmjopen-2016-012406.supp3\n\nnext, we tested the change of the association between season of Birth and iq with addition of possible covariates to the basic model, each in a separate model (see onlinesupplementary table s2).']	[('SUPERFICIAL_RELATIONSHIP', 101), ('SUPERFICIAL_RELATIONSHIP', 342)]	2	[('GO_0007567', 'parturition', 84, 'birth'), ('GO_0007565', 'female pregnancy', 162, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 176, 'cord'), ('UBERON_0000178', 'blood', 181, 'blood'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 197, 'plasma'), ('GO_0007565', 'female pregnancy', 433, 'pregnancy'), ('GO_0007567', 'parturition', 560, 'birth')]	0	['matrix (see onlinesupplementary table s1), child spring birth nulliparity (r=−0.03, p=0.008), maternal mid- cord blood  plasma concentrations (r=−0.11, p=0.01 r=−0.12, p<0.001), child relative age peers school (r=−0.17, p<0.001) positively maternal crp concentrations (r=0.05, p=0.001) presence fever mid- (r=0.06, p=0.001).10.1136/bmjopen-2016-012406.supp3\n\nnext, season birth iq addition covariates model, separate (see onlinesupplementary table s2).']
S93-PMC5325195	PMC5325195	2/2017	S93-PMC5325195	['cbhvs also actively promoted facility-based delivery.10.1371/journal.pone.0170739.t001\n\ncaption (table-wrap): table 1\ncbhv messages to Pregnant women transmitted through pictorial counselling cards.1 importance of Antenatal clinic attendance for Pregnant women 2 importance of screening tests, including hiv in Pregnancy 3 importance of intermittent preventive therapy for malaria in Pregnancy using Sulphadoxine-Pyrimethamine tablets 4 importance of skilled attendance in Labor and Postpartum care 5 importance of an Insecticide-treated net and HOW to use it at home 6 types of Food, importance of an adequate and balanced diet in Pregnancy, and Vitamin A supplementation for children 7 the IMPORTANCE of iron and Folic Acid during Pregnancy 8 importance of using Misoprostol tablets after Delivery Of the Baby and HOW to use it 9 the IMPORTANCE of Chlorhexidine gel for Cord care and HOW to apply it on the Cord; avoiding use of POTENTIALLY harmful substances to the Cord 10 the care for low Birth weight babies with kangaroo care 11 HOW to prepare the Oral rehydration Solution (ors) for diarrheal diseases in children under 5 years, and the IMPORTANCE of ors.']	[('EXPLICIT_QUESTION', 546), ('IMPORTANT_CONSIDERATION', 692), ('EXPLICIT_QUESTION', 816), ('IMPORTANT_CONSIDERATION', 836), ('EXPLICIT_QUESTION', 886), ('INCOMPLETE_EVIDENCE', 931), ('EXPLICIT_QUESTION', 1036), ('IMPORTANT_CONSIDERATION', 1145)]	8	[('GO_0007565', 'female pregnancy', 135, 'pregnant'), ('GO_0007567', 'parturition', 214, 'antenatal'), ('GO_0007565', 'female pregnancy', 246, 'pregnant'), ('GO_0007565', 'female pregnancy', 311, 'pregnancy'), ('GO_0007565', 'female pregnancy', 384, 'pregnancy'), ('CHEBI_9329', 'sulfadoxine', 400, 'Sulphadoxine'), ('CHEBI_16610', 'spermidine', 413, 'pyrimethamine'), ('GO_0007612', 'learning', 473, 'labor'), ('GO_0007565', 'female pregnancy', 483, 'postpartum'), ('CHEBI_24852', 'insecticide', 518, 'insecticide'), ('CHEBI_33290', 'food', 579, 'food'), ('GO_0007565', 'female pregnancy', 632, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 647, 'vitamin A'), ('CHEBI_30751', 'formic acid', 715, 'folic acid'), ('GO_0007565', 'female pregnancy', 733, 'pregnancy'), ('CHEBI_63610', 'misoprostol', 765, 'misoprostol'), ('GO_0046697', 'decidualization', 791, 'delivery of ... baby'), ('CHEBI_3647', 'chlorpromazine', 850, 'chlorhexidine'), ('UBERON_0002240', 'spinal cord', 872, 'cord'), ('UBERON_0002240', 'spinal cord', 909, 'cord'), ('UBERON_0002240', 'spinal cord', 969, 'cord'), ('GO_0007567', 'parturition', 994, 'birth'), ('UBERON_0000978', 'leg', 1055, 'Oral'), ('CHEBI_75958', 'solution', 1072, 'Solution')]	0	['cbhvs actively facility-based delivery.10.1371/journal.pone.0170739.t001\n\ncaption (table-wrap): table 1\ncbhv  women transmitted pictorial counselling cards.1 antenatal clinic attendance  women 2 screening tests, hiv  3 intermittent therapy malaria  using sulphadoxine-pyrimethamine tablets 4 skilled attendance labor  5 insecticide-treated net home 6 food, diet  supplementation children 7 iron folic acid  8 using misoprostol tablets delivery baby 9 chlorhexidine gel cord apply cord; avoiding substances cord 10 birth babies kangaroo 11 prepare oral rehydration solution (ors) diarrheal diseases children 5 years, ors.']
S181-PMC5332602	PMC5332602	3/2017	S181-PMC5332602	['THUS, UNLIKE in our MODEL of Prenatal Vitamin A deficiency (single-Micronutrient deficiency) (31), protein deficiency AFFECTED the levels or Homeostatic Control of multiple Macro- and Micronutrients, limiting the ability of neonatal Pigs to adapt/maintain Homeostasis through compensatory mechanisms.']	[('PROBABLE_UNDERSTANDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 6), ('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 118)]	4	[('GO_0007565', 'female pregnancy', 29, 'prenatal'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin A'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 67, 'micronutrient'), ('GO_0042592', 'homeostatic process', 141, 'homeostatic'), ('GO_0065007', 'biological regulation', 153, 'control'), ('CHEBI_34830', 'mefenacet', 173, 'macro'), ('CHEBI_33839', 'macromolecule', 184, 'micronutrients'), ('NCBITaxon_10088', 'Mus <genus>', 233, 'pigs'), ('GO_0042592', 'homeostatic process', 256, 'homeostasis')]	0	['thus,   (single-micronutrient deficiency) (31), protein levels homeostatic macro- micronutrients, ability neonatal pigs adapt/maintain homeostasis compensatory mechanisms.']
S15-PMC5340372	PMC5340372	3/2017	S15-PMC5340372	['REPORTED an inverse CORRELATION between Prenatal Vitamin D intake and recurrent wheezing of offspring [5].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 20)]	2	[('GO_0007565', 'female pregnancy', 40, 'prenatal'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]	0	['reported   intake recurrent wheezing offspring [5].']
S9-PMC5351212	PMC5351212	3/2017	S9-PMC5351212	['HOWEVER, Prenatal administration of Vitamin D had no effect on pro-inflammatory cytokine levels in dams or in fetal Brains SUGGESTING the anti-inflammatory actions of Vitamin d are not the CRITICAL mechanism for its preventive actions in this asd Animal MODEL.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 123), ('IMPORTANT_CONSIDERATION', 189), ('INCOMPLETE_EVIDENCE', 254)]	5	[('GO_0007565', 'female pregnancy', 9, 'prenatal'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('UBERON_0000955', 'brain', 116, 'brains'), ('CHEBI_33229', 'vitamin (role)', 167, 'vitamin'), ('NCBITaxon_33208', 'Metazoa', 247, 'animal')]	0	['however,  administration  pro-inflammatory cytokine levels dams fetal brains anti-inflammatory vitamin asd animal model.']
S10-PMC5351212	PMC5351212	3/2017	S10-PMC5351212	['conclusions\nthis work RAISES the POSSIBILITY that early dietary supplementation with Vitamin D MAY open NEW AVENUES for a successful attenuation or EVEN PREVENTION of Neurodevelopmental disorders following maternal inflammation during Pregnancy.']	[('EXPLICIT_QUESTION', 22), ('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 95), ('FULL_UNKNOWN', 104), ('FUTURE_WORK', 108), ('ANOMALY_CURIOUS_FINDING', 148), ('SUPERFICIAL_RELATIONSHIP', 153)]	7	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007399', 'nervous system development', 167, 'neurodevelopmental'), ('GO_0007565', 'female pregnancy', 235, 'pregnancy')]	0	['conclusions\nthis dietary supplementation  attenuation neurodevelopmental disorders following maternal inflammation .']
S36-PMC5351212	PMC5351212	3/2017	S36-PMC5351212	['INITIAL EVIDENCE for this HYPOTHESIS stems from PREVIOUS OBSERVATIONS SHOWING Prenatal poly(I:c)-induced mia, and developmental Vitamin D deficiency in rodents produce an overlapping spectrum of long-term behavioral abnormalities and early molecular changes in the fetal Brains [33–37].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 48), ('INCOMPLETE_EVIDENCE', 57), ('INCOMPLETE_EVIDENCE', 70)]	5	[('GO_0007565', 'female pregnancy', 78, 'prenatal'), ('CHEBI_16382', 'iodide', 92, 'I:'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('UBERON_0000955', 'brain', 271, 'brains')]	0	['initial stems  poly(i:c)-induced mia, developmental  rodents produce spectrum long-term behavioral abnormalities molecular changes fetal brains [33–37].']
S7-PMC5359891	PMC5359891	3/2017	S7-PMC5359891	['the additional Micronutrients seek to address DEFICIENCIES of SOME b-group Vitamins and Vitamin D that are both common during Pregnancy and that HAVE BEEN ASSOCIATED with maternal dysglycaemia, epigenetic changes and greater offspring adiposity.']	[('IMPORTANT_CONSIDERATION', 46), ('INCOMPLETE_EVIDENCE', 62), ('INCOMPLETE_EVIDENCE', 145), ('SUPERFICIAL_RELATIONSHIP', 155)]	4	[('CHEBI_33839', 'macromolecule', 15, 'micronutrients'), ('CHEBI_33277', 'gamma-tocotrienol', 75, 'vitamins'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'pregnancy')]	0	['micronutrients b-group vitamins   maternal dysglycaemia, epigenetic changes offspring adiposity.']
S42-PMC5359891	PMC5359891	3/2017	S42-PMC5359891	['meta-analysis of observational studies STRONGLY POINTS to a ROLE for maternal Vitamin D deficiency in gdm [37], and additional Vitamin D in Pregnant women with gdm HAS BEEN SHOWN to have beneficial EFFECTS on glycaemia and total and low-density lipoprotein Cholesterol (ldl)-Cholesterol concentrations [38].']	[('PROBABLE_UNDERSTANDING', 39), ('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 60), ('INCOMPLETE_EVIDENCE', 164), ('SUPERFICIAL_RELATIONSHIP', 198)]	5	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('GO_0007565', 'female pregnancy', 140, 'pregnant'), ('CHEBI_16113', 'cholesterol', 257, 'cholesterol'), ('CHEBI_16113', 'cholesterol', 275, 'cholesterol')]	0	['meta-analysis maternal  gdm [37],   women gdm glycaemia low-density lipoprotein cholesterol (ldl)-cholesterol concentrations [38].']
S53-PMC5359891	PMC5359891	3/2017	S53-PMC5359891	['taken TOGETHER, there is strong SUPPORT for NEW intervention studies commencing before Pregnancy to provide myo-inositol and Probiotics, and to improve maternal Vitamin B6, Vitamin B12, Vitamin D and zinc status, AIMED at optimising maternal glycaemia and Glucose supply to the Feto-Placental Unit to promote healthy offspring growth and body composition.']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 44), ('QUESTION_ANSWERED_BY_THIS_WORK', 213)]	4	[('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_26346', 'prostaglandins J', 125, 'probiotics'), ('CHEBI_33237', 'vitamin D4', 161, 'vitamin B6'), ('CHEBI_33229', 'vitamin (role)', 173, 'vitamin'), ('CHEBI_27778', 'abequose', 181, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 181, 'B12'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('CHEBI_17234', 'glucose', 256, 'glucose'), ('UBERON_0000981', 'femur', 278, 'feto'), ('UBERON_0013765', 'digestive system element', 283, 'placental unit')]	0	['taken together, commencing  myo-inositol probiotics, maternal vitamin b6, vitamin b12,  zinc status, optimising maternal glycaemia glucose supply feto-placental unit healthy offspring composition.']
S92-PMC5359891	PMC5359891	3/2017	S92-PMC5359891	['the intervention\nthe nutritional intervention Preconception and during Pregnancy to maintain healthy Glucose Metabolism and offspring health (nipper) intervention comprises: (1) a Micronutrient-enriched nutritional drink containing myo-inositol, Vitamin D, riboflavin, Vitamin B6, Vitamin B12And zinc together with standard Folic Acid, Iodine, calcium, β-Carotene and iron; the quantities PROPOSED are either standard amounts (Myo-Inositol [54]), enhanced amounts that are available in over-the-counter products (Vitamins b6, b12, riboflavin), RECOMMENDED daily allowance amounts in uk for Pregnant women (Vitamin D, zinc, Folic Acid, Iodine) or minimal amounts for Micronutrients LINKED with POTENTIAL DETRIMENTAL EFFECTS at higher doses (Iron, Β-Carotene, Calcium) and (2) Probiotics (containing lactobacillus rhamnosus ncc 4007 (cgmcc 1.3724) also known as lpr and bifidobacterium animalis Sp.']	[('INCOMPLETE_EVIDENCE', 389), ('FUTURE_WORK', 544), ('SUPERFICIAL_RELATIONSHIP', 681), ('INCOMPLETE_EVIDENCE', 693), ('IMPORTANT_CONSIDERATION', 703), ('SUPERFICIAL_RELATIONSHIP', 715)]	6	[('GO_0007565', 'female pregnancy', 46, 'Preconception'), ('GO_0007565', 'female pregnancy', 71, 'Pregnancy'), ('CHEBI_17234', 'glucose', 101, 'Glucose'), ('GO_0006006', 'glucose metabolic process', 101, 'Glucose Metabolism'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 180, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D'), ('CHEBI_33237', 'vitamin D4', 269, 'vitamin B6'), ('CHEBI_10124', 'zolmitriptan', 281, 'vitamin B12and'), ('CHEBI_30751', 'formic acid', 324, 'folic acid'), ('CHEBI_24859', 'iodine atom', 336, 'iodine'), ('CHEBI_23042', 'carotene', 355, 'carotene'), ('CHEBI_25435', 'mutagen', 427, 'myo-inositol'), ('CHEBI_33277', 'gamma-tocotrienol', 513, 'vitamins'), ('GO_0007565', 'female pregnancy', 590, 'pregnant'), ('CHEBI_27300', 'vitamin D', 606, 'vitamin D'), ('CHEBI_30751', 'formic acid', 623, 'folic acid'), ('CHEBI_24859', 'iodine atom', 635, 'iodine'), ('CHEBI_33839', 'macromolecule', 666, 'micronutrients'), ('CHEBI_24870', 'ion', 740, 'iron'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 746, 'β-carotene'), ('CHEBI_22313', 'alkaline earth metal atom', 758, 'calcium'), ('CHEBI_26346', 'prostaglandins J', 775, 'probiotics'), ('NCBITaxon_10088', 'Mus <genus>', 893, 'sp')]	0	['intervention\nthe nutritional   maintain healthy glucose metabolism offspring (nipper) comprises: (1) micronutrient-enriched nutritional drink containing myo-inositol, riboflavin, vitamin b6, vitamin b12and zinc folic acid, iodine, calcium, β-carotene iron; quantities amounts (myo-inositol [54]), amounts over-the-counter products (vitamins b6, b12, riboflavin), daily allowance amounts uk  women (, zinc, folic acid, iodine) amounts micronutrients higher doses (iron, β-carotene, calcium) (2) probiotics (containing lactobacillus rhamnosus ncc 4007 (cgmcc 1.3724) lpr bifidobacterium animalis sp.']
S108-PMC5359891	PMC5359891	3/2017	S108-PMC5359891	['omission from control group SUPPORTED by usual clinical practiceβ-Carotene720\xa0μg (15% of Vitamin A REQUIREMENTS, as Retinol equivalents)required in Pregnancy in some jurisdictionsfolic acid400\xa0μgstandard Preconception RECOMMENDATIONIRON12\xa0mgiron is routinely prescribed and taken before/during Pregnancy, THOUGH WITHOUT CONVINCING EVIDENCE of benefit; low dose included to lessen LIKELIHOOD of additionally receiving a high-dose iron product, which HAS BEEN LINKED with Glucose Metabolism in Pregnancycalcium150\xa0mga low dose of Calcium is commonly taken before/during Pregnancy; provision of this will lessen the LIKELIHOOD of additional products being takeniodine150\xa0μgstandard preconception recommendationprobiotictaking a combination of two Probiotics HAS BEEN LINKED with maintenance of healthy Glucose Metabolism in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 28), ('IMPORTANT_CONSIDERATION', 99), ('FUTURE_WORK', 218), ('ANOMALY_CURIOUS_FINDING', 305), ('INCOMPLETE_EVIDENCE', 312), ('PROBABLE_UNDERSTANDING', 380), ('INCOMPLETE_EVIDENCE', 449), ('SUPERFICIAL_RELATIONSHIP', 458), ('PROBABLE_UNDERSTANDING', 613), ('INCOMPLETE_EVIDENCE', 755), ('SUPERFICIAL_RELATIONSHIP', 764)]	11	[('CHEBI_85000', '1-octadecenoyl-2-icosatetraenoyl-sn-glycero-3-phosphoethanolamine', 65, '-carotene720'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 116, 'retinol'), ('GO_0007565', 'female pregnancy', 148, 'pregnancy'), ('GO_0007565', 'female pregnancy', 204, 'preconception'), ('GO_0007565', 'female pregnancy', 294, 'pregnancy'), ('CHEBI_17234', 'glucose', 470, 'glucose'), ('GO_0006006', 'glucose metabolic process', 470, 'glucose metabolism'), ('GO_0051561', 'positive regulation of mitochondrial calcium ion concentration', 492, 'pregnancyCalcium150'), ('CHEBI_22313', 'alkaline earth metal atom', 528, 'calcium'), ('GO_0007565', 'female pregnancy', 568, 'pregnancy'), ('CHEBI_26346', 'prostaglandins J', 744, 'probiotics'), ('CHEBI_17234', 'glucose', 799, 'glucose'), ('GO_0006006', 'glucose metabolic process', 799, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 821, 'pregnancy')]	0	['omission usual practiceβ-carotene720\xa0μg (15%  requirements, retinol equivalents)required  jurisdictionsfolic acid400\xa0μgstandard  recommendationiron12\xa0mgiron routinely prescribed before/during benefit; dose receiving high-dose iron product, glucose metabolism pregnancycalcium150\xa0mga dose calcium before/during provision products takeniodine150\xa0μgstandard preconception recommendationprobiotictaking combination probiotics maintenance healthy glucose metabolism .']
S110-PMC5359891	PMC5359891	3/2017	S110-PMC5359891	['lactis ncc 2818 (cncm i-3446) also known as bl818control groupfolic Acid400\xa0μgstandard Preconception recommendationiron12\xa0mgiron is routinely prescribed and taken before/during Pregnancy, though WITHOUT CONVINCING EVIDENCE of benefit; low dose included to lessen LIKELIHOOD of additionally receiving a high-dose Iron product, which HAS BEEN LINKED with Glucose Metabolism in Pregnancycalcium150\xa0mga low dose of Calcium is commonly taken before/during Pregnancy; provision of this will lessen the LIKELIHOOD of additional products being takeniodine150\xa0μgstandard Preconception recommendationhttp://www.cdc.gov/Preconception/documents/clinical-content_womensnutritionfactsheet3.pdfβ-Carotene720\xa0μg (15% of Vitamin A REQUIREMENTS, as Retinol equivalents)required in Pregnancy in some jurisdictions\n\noutcome measurements\nthe primary analysis will adjust for site, ethnicity and Preconception glycaemia to account for POTENTIAL imbalance between treatment arms amongst Pregnancies which reach 28\xa0weeks’ Gestation, examining for differences in means between the control and intervention groups for the primary endpoint, specifically the fasting and/or 60-min and/or 2-h Glucose concentrations following a 75-g ogtt at 28\xa0weeks’ Gestation.']	[('INCOMPLETE_EVIDENCE', 195), ('PROBABLE_UNDERSTANDING', 263), ('INCOMPLETE_EVIDENCE', 332), ('SUPERFICIAL_RELATIONSHIP', 341), ('PROBABLE_UNDERSTANDING', 496), ('IMPORTANT_CONSIDERATION', 714), ('INCOMPLETE_EVIDENCE', 913)]	7	[('CHEBI_82451', '3,3*-Dimethoxybenzidine-4,4*-diisocyanate', 68, 'acid400'), ('GO_0007565', 'female pregnancy', 87, 'preconception'), ('GO_0007565', 'female pregnancy', 177, 'pregnancy'), ('CHEBI_24870', 'ion', 312, 'iron'), ('CHEBI_17234', 'glucose', 353, 'glucose'), ('GO_0006006', 'glucose metabolic process', 353, 'glucose metabolism'), ('GO_0051561', 'positive regulation of mitochondrial calcium ion concentration', 375, 'pregnancyCalcium150'), ('CHEBI_22313', 'alkaline earth metal atom', 411, 'calcium'), ('GO_0007565', 'female pregnancy', 451, 'pregnancy'), ('GO_0007565', 'female pregnancy', 562, 'preconception'), ('GO_0007565', 'female pregnancy', 609, 'preconception'), ('CHEBI_52743', 'bromine-79 atom', 681, 'carotene720'), ('CHEBI_27300', 'vitamin D', 704, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 731, 'retinol'), ('GO_0007565', 'female pregnancy', 763, 'pregnancy'), ('GO_0007565', 'female pregnancy', 874, 'preconception'), ('GO_0007565', 'female pregnancy', 964, 'pregnancies'), ('GO_0007565', 'female pregnancy', 998, 'gestation'), ('CHEBI_17234', 'glucose', 1164, 'glucose'), ('GO_0007565', 'female pregnancy', 1222, 'gestation')]	0	['lactis ncc 2818 (cncm i-3446) bl818control groupfolic acid400\xa0μgstandard  recommendationiron12\xa0mgiron routinely prescribed before/during benefit; dose receiving high-dose iron product, glucose metabolism pregnancycalcium150\xa0mga dose calcium before/during provision products takeniodine150\xa0μgstandard  recommendationhttp://www.cdc.gov//documents/clinical-content_womensnutritionfactsheet3.pdfβ-carotene720\xa0μg (15%  requirements, retinol equivalents)required  jurisdictions\n\noutcome measurements\nthe adjust site, ethnicity  glycaemia treatment arms amongst  28\xa0weeks’ endpoint, fasting and/or 60-min and/or 2-h glucose concentrations following 75-g ogtt 28\xa0weeks’ .']
S112-PMC5359891	PMC5359891	3/2017	S112-PMC5359891	['secondary maternal outcomes of the initial phase of the nipper study are:\nmaintenance of a healthy Pregnancy, including normal duration of Gestation (at least 37\xa0weeks’ Gestation), absence of gdm (defined using the international association of the diabetes and Pregnancy study groups criteria: Glucose cut-off values of ≥5.1\xa0mmol/l for fasting Plasma Glucose, and/or ≥10.0\xa0mmol/l for 1-h and/or ≥8.5\xa0mmol/l for 2-h post load), change in fasting Glucose and ogtt Glucose area under the curve from Preconception baseline to 28\xa0weeks’ Gestation, maternal wellbeing/mood, absence of excessive nausea and vomiting, adequate Pregnancy weight gain (institute of medicine criteria) and Vaginal Delivery rates\nreduction in maternal Micronutrient insufficiency, specifically less riboflavin, Vitamin B6, Vitamin B12, zinc and Vitamin D insufficiency, before and during Pregnancy\nalteration in Gut microbiota CONSISTENT with enhanced wellbeing\nalteration in maternal metabolomic and epigenetic biomarkers CONSISTENT with improved maternal and/or offspring wellbeing\nenhancement of Breast Milk Micronutrient content, altered Immunological factors, epigenetic and metabolomic profiles (subsample) and maintenance of healthy Lactogenesis\nsecondary offspring outcomes of the initial phase of the nipper study are:\nneonatal adiposity measured by pea pod\nBirthweight 2500–4000\xa0g, size for Gestational age at Birth and customised birthweight centile\nreduced adiposity gain during Infancy, analysed taking account of infant Feeding\nreduction in Cord Blood c-peptide as a marker of overall glycaemia during Gestation\npromotion of offspring wellbeing and healthy Cardiometabolic RISK FACTORS, including Visceral adiposity and markers of Insulin resistance, during infancy\nalteration in offspring metabolomic and epigenetic biomarkers in Perinatal samples, CONSISTENT with improved infant Metabolic and allergic Wellbeing\nalteration in Gut microbiota to a microbiota ASSOCIATED with infant Metabolic and allergic Wellbeing\n\ndata and biosample collection\nstudy data will be collected by trained research staff using an access-controlled, web-based database (medscinet, stockholm) managed with support from the data management staff of the mrc Lifecourse epidemiology unit and the singapore institute for clinical sciences.']	[('INCOMPLETE_EVIDENCE', 898), ('INCOMPLETE_EVIDENCE', 994), ('SUPERFICIAL_RELATIONSHIP', 1658), ('INCOMPLETE_EVIDENCE', 1835), ('SUPERFICIAL_RELATIONSHIP', 1945)]	5	[('GO_0007565', 'female pregnancy', 99, 'pregnancy'), ('GO_0007565', 'female pregnancy', 139, 'gestation'), ('GO_0007565', 'female pregnancy', 169, 'gestation'), ('GO_0007565', 'female pregnancy', 261, 'Pregnancy'), ('CHEBI_17234', 'glucose', 294, 'glucose'), ('UBERON_0001969', 'blood plasma', 344, 'plasma'), ('CHEBI_17234', 'glucose', 351, 'glucose'), ('CHEBI_17234', 'glucose', 445, 'glucose'), ('CHEBI_17234', 'glucose', 462, 'glucose'), ('GO_0007565', 'female pregnancy', 496, 'preconception'), ('GO_0007565', 'female pregnancy', 532, 'gestation'), ('GO_0007565', 'female pregnancy', 619, 'pregnancy'), ('UBERON_0001987', 'placenta', 678, 'vaginal'), ('GO_0007567', 'parturition', 686, 'delivery'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 723, 'micronutrient'), ('CHEBI_33237', 'vitamin D4', 782, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 794, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 816, 'vitamin D'), ('GO_0007565', 'female pregnancy', 859, 'pregnancy'), ('UBERON_0001555', 'digestive tract', 883, 'gut'), ('UBERON_0001348', 'brown adipose tissue', 1070, 'breast milk'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 1082, 'micronutrient'), ('UBERON_0003222', 'flexor digitorum superficialis', 1113, 'immunological'), ('GO_0001554', 'luteolysis', 1211, 'lactogenesis'), ('GO_0007608', 'sensory perception of smell', 1338, 'Birthweight'), ('GO_0007565', 'female pregnancy', 1372, 'gestational'), ('GO_0007567', 'parturition', 1391, 'birth'), ('UBERON_0000023', 'wing', 1462, 'infancy'), ('GO_0007631', 'feeding behavior', 1505, 'feeding'), ('UBERON_0002240', 'spinal cord', 1526, 'cord'), ('UBERON_0000178', 'blood', 1531, 'blood'), ('GO_0007565', 'female pregnancy', 1587, 'gestation'), ('GO_0007599', 'hemostasis', 1642, 'cardiometabolic'), ('UBERON_0002075', 'viscus', 1682, 'visceral'), ('PR_000045358', 'insulin family protein', 1716, 'insulin'), ('GO_0036268', 'swimming', 1816, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 1816, 'perinatal'), ('GO_0051238', 'sequestering of metal ion', 1867, 'metabolic ... wellbeing'), ('UBERON_0001555', 'digestive tract', 1914, 'gut'), ('GO_0051238', 'sequestering of metal ion', 1968, 'metabolic ... wellbeing'), ('UBERON_0001281', 'hepatic sinusoid', 2220, 'Lifecourse')]	0	['secondary maternal outcomes phase are:\nmaintenance healthy normal duration  (at 37\xa0weeks’ ), absence gdm (defined using international criteria: glucose cut-off values ≥5.1\xa0mmol/l fasting plasma glucose, and/or ≥10.0\xa0mmol/l 1-h and/or ≥8.5\xa0mmol/l 2-h post load), fasting glucose ogtt glucose curve  baseline 28\xa0weeks’ maternal wellbeing/mood, absence excessive nausea vomiting,  gain (institute medicine criteria) vaginal delivery rates\nreduction maternal micronutrient insufficiency, riboflavin, vitamin b6, vitamin b12, zinc  insufficiency, \nalteration gut microbiota wellbeing\nalteration maternal metabolomic epigenetic maternal and/or offspring wellbeing\nenhancement breast milk micronutrient content, altered immunological factors, epigenetic metabolomic (subsample) maintenance healthy lactogenesis\nsecondary offspring outcomes phase are:\nneonatal adiposity pea pod\nbirthweight 2500–4000\xa0g,  age birth customised birthweight centile\nreduced adiposity gain infancy, infant feeding\nreduction cord blood c-peptide glycaemia \npromotion offspring wellbeing healthy cardiometabolic factors, visceral adiposity insulin resistance, infancy\nalteration offspring metabolomic epigenetic perinatal samples, infant metabolic allergic wellbeing\nalteration gut microbiota microbiota infant metabolic allergic wellbeing\n\ndata biosample collection\nstudy trained staff using access-controlled, web-based database (medscinet, stockholm) managed staff mrc lifecourse epidemiology unit singapore institute sciences.']
S121-PMC5371920	PMC5371920	3/2017	S121-PMC5371920	['for the correction of Micronutrient deficiencies, such as Vitamin D deficiency during Pregnancy, traditional randomized controlled trials provide ROBUST, well-controlled FRAMEWORKS for THEORETICAL and pragmatic evaluation of the candidate policy.']	[('INCOMPLETE_EVIDENCE', 146), ('INCOMPLETE_EVIDENCE', 170), ('INCOMPLETE_EVIDENCE', 185)]	3	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 22, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy')]	0	['correction micronutrient deficiencies,  robust, well-controlled policy.']
S137-PMC5371920	PMC5371920	3/2017	S137-PMC5371920	['Vitamin D supplementation APPEARED SAFE; THESE FINDINGS SUPPORT current RECOMMENDATIONS in uk and elsewhere, and MAY SUGGEST the basis for more stratified approaches to Vitamin D supplementation in Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 26), ('IMPORTANT_CONSIDERATION', 35), ('INCOMPLETE_EVIDENCE', 41), ('INCOMPLETE_EVIDENCE', 56), ('FUTURE_WORK', 72), ('INCOMPLETE_EVIDENCE', 113), ('INCOMPLETE_EVIDENCE', 117)]	7	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy')]	0	['vitamin supplementation safe; uk elsewhere, stratified  supplementation .']
S47-PMC5372327	PMC5372327	3/2017	S47-PMC5372327	['BASED ON epidemiological studies, low maternal Intake of Vitamin D at Pregnancy and low Cord Blood 25-Ohd concentration HAVE BEEN ASSOCIATED with a higher risk for asthma, allergic rhinitis and atopic eczema in the offspring, as assessed at 5\xa0years of age [35–38].']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 120), ('SUPERFICIAL_RELATIONSHIP', 130)]	4	[('GO_0007631', 'feeding behavior', 47, 'intake'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 88, 'cord'), ('UBERON_0000178', 'blood', 93, 'blood'), ('CHEBI_72765', 'verruculogen', 99, '25-OHD')]	0	['based epidemiological studies, maternal intake   cord blood 25-ohd concentration higher asthma, allergic rhinitis atopic eczema offspring, 5\xa0years age [35–38].']
S48-PMC5372327	PMC5372327	3/2017	S48-PMC5372327	['HOWEVER, findings have NOT been CONSISTENT [39] and RECENT STUDIES on Prenatal Vitamin D supplementation have not demonstrated an EFFECT on wheezing at 3\xa0years of age [40,41].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 32), ('INCOMPLETE_EVIDENCE', 52), ('SUPERFICIAL_RELATIONSHIP', 130)]	5	[('GO_0007565', 'female pregnancy', 70, 'prenatal'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]	0	['however, [39]   supplementation wheezing 3\xa0years age [40,41].']
S0-PMC5385921	PMC5385921	4/2017	S0-PMC5385921	['Gestational Vitamin D deficiency and autism spectrum disorder\n\nabstract\n\nbackground\nthere is GROWING INTEREST in LINKING Vitamin D deficiency with autism spectrum disorders (asds).']	[('INCOMPLETE_EVIDENCE', 93), ('SUPERFICIAL_RELATIONSHIP', 113)]	2	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]	0	['  autism spectrum disorder\n\nabstract\n\nbackground\nthere  autism spectrum disorders (asds).']
S1-PMC5385921	PMC5385921	4/2017	S1-PMC5385921	['the ASSOCIATION between Vitamin D deficiency during Gestation, a CRITICAL period in Neurodevelopment, and asd is NOT WELL UNDERSTOOD.']	[('SUPERFICIAL_RELATIONSHIP', 4), ('IMPORTANT_CONSIDERATION', 65), ('FULL_UNKNOWN', 113)]	3	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007565', 'female pregnancy', 52, 'gestation'), ('GO_0007399', 'nervous system development', 84, 'neurodevelopment')]	0	[' period neurodevelopment, asd understood.']
S2-PMC5385921	PMC5385921	4/2017	S2-PMC5385921	['AIMS\nTO DETERMINE the ASSOCIATION between Gestational Vitamin D status and asd.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 5), ('SUPERFICIAL_RELATIONSHIP', 22)]	3	[('GO_0007565', 'female pregnancy', 42, 'gestational'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D')]	0	['aims\nto   status asd.']
S6-PMC5385921	PMC5385921	4/2017	S6-PMC5385921	['conclusions\nmid-Gestational Vitamin D deficiency was ASSOCIATED with an INCREASED RISK of asd.']	[('SUPERFICIAL_RELATIONSHIP', 53), ('IMPORTANT_CONSIDERATION', 72)]	2	[('GO_0007565', 'female pregnancy', 16, 'gestational'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]	0	['conclusions\nmid-  asd.']
S7-PMC5385921	PMC5385921	4/2017	S7-PMC5385921	['because Gestational Vitamin D deficiency is readily preventable with SAFE, inexpensive and readily available supplementation, this RISK FACTOR WARRANTS CLOSER SCRUTINY.']	[('IMPORTANT_CONSIDERATION', 69), ('SUPERFICIAL_RELATIONSHIP', 131), ('FUTURE_WORK', 143), ('FUTURE_WORK', 152)]	4	[('GO_0007565', 'female pregnancy', 8, 'gestational'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]	0	['  safe, supplementation, closer scrutiny.']
S13-PMC5385921	PMC5385921	4/2017	S13-PMC5385921	['within the domain of nutritional exposures, there is GROWING INTEREST in the POSSIBLE LINKS between Gestational Vitamin D deficiency and an INCREASED RISK of asd.3–6this research HAS BEEN inspired BY Birth cohort studies, which have provided EVIDENCE that Prenatal Vitamin D deficiency (as assessed in maternal Sera) is ASSOCIATED with a range of later Brain-related outcomes including impaired Language Development7,8and Cognitive Development in offspring.9,10ALTHOUGH SEVERAL STUDIES HAVE REPORTED that Vitamin D deficiency or insufficiency is MORE COMMON in children with asd compared with controls,11few STUDIES addressed the specific HYPOTHESIS that Vitamin D deficiency during Gestation, a CRUCIAL time point in Neurodevelopment, is RELATED to the risk of subsequent asd.']	[('INCOMPLETE_EVIDENCE', 53), ('INCOMPLETE_EVIDENCE', 77), ('SUPERFICIAL_RELATIONSHIP', 86), ('IMPORTANT_CONSIDERATION', 140), ('INCOMPLETE_EVIDENCE', 179), ('ANOMALY_CURIOUS_FINDING', 197), ('INCOMPLETE_EVIDENCE', 242), ('SUPERFICIAL_RELATIONSHIP', 320), ('ANOMALY_CURIOUS_FINDING', 459), ('INCOMPLETE_EVIDENCE', 470), ('INCOMPLETE_EVIDENCE', 486), ('PROBABLE_UNDERSTANDING', 546), ('INCOMPLETE_EVIDENCE', 608), ('INCOMPLETE_EVIDENCE', 639), ('IMPORTANT_CONSIDERATION', 696), ('SUPERFICIAL_RELATIONSHIP', 739)]	16	[('GO_0007565', 'female pregnancy', 100, 'gestational'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007567', 'parturition', 200, 'birth'), ('GO_0007565', 'female pregnancy', 256, 'prenatal'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D'), ('UBERON_0001977', 'blood serum', 311, 'sera'), ('UBERON_0000955', 'brain', 353, 'brain'), ('GO_0001763', 'morphogenesis of a branching structure', 395, 'language development7'), ('GO_0050787', 'detoxification of mercury ion', 422, 'cognitive development'), ('CHEBI_27300', 'vitamin D', 505, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 655, 'vitamin D'), ('GO_0007565', 'female pregnancy', 683, 'gestation'), ('GO_0007399', 'nervous system development', 718, 'neurodevelopment')]	0	['within domain nutritional exposures,   asd.3–6this birth studies,   (as maternal sera) brain-related outcomes language development7,8and cognitive offspring.9,10although  children asd controls,11few  neurodevelopment, asd.']
S15-PMC5385921	PMC5385921	4/2017	S15-PMC5385921	['THIS STUDY REPORTED lower 25-Hydroxyvitamin D (25Ohd) concentrations in neonatal samples from the asd cases compared with their unaffected siblings.6RECENTLY, a chinese asd case–control study ( n =68 cases) compared first trimester (11–13 weeks) maternal 25Ohd concentrations and REPORTED significantly lower concentrations of 25Ohd in the asd cases compared with their gender- and age-matched controls.12\nwe RECENTLY REPORTED an ASSOCIATION between developmental Vitamin D deficiency and a measure of social impairment within the autism spectrum, based on a large dutch Birth cohort.13in this study, Vitamin D was measured at two occasions: at mid-Gestation and at Birth.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 148), ('INCOMPLETE_EVIDENCE', 280), ('INCOMPLETE_EVIDENCE', 409), ('INCOMPLETE_EVIDENCE', 418), ('SUPERFICIAL_RELATIONSHIP', 430)]	7	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 26, '25-hydroxyvitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 47, '25OHD'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 255, '25OHD'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 327, '25OHD'), ('CHEBI_27300', 'vitamin D', 464, 'vitamin D'), ('GO_0007567', 'parturition', 571, 'birth'), ('CHEBI_27300', 'vitamin D', 601, 'vitamin D'), ('GO_0007565', 'female pregnancy', 649, 'gestation'), ('GO_0007567', 'parturition', 666, 'birth')]	0	['25-hydroxyvitamin (25ohd) concentrations neonatal samples asd cases unaffected siblings.6recently, chinese n =68 cases) trimester (11–13 weeks) maternal 25ohd concentrations concentrations 25ohd asd cases gender- age-matched controls.12\nwe developmental  measure social impairment autism spectrum, dutch birth cohort.13in study,  occasions: mid- birth.']
S18-PMC5385921	PMC5385921	4/2017	S18-PMC5385921	['we had the opportunity to explore the ASSOCIATION between developmental Vitamin D status and risk of asd, based on the same dutch Birth cohort in which we previously reported an ASSOCIATION between low mid-Gestational and neonatal Vitamin D concentrations and autistic traits.13within the cohort, we had access to an extensive set of POTENTIAL CONFOUNDING variables as well as the children’s individual-level Genome-wide genotype data.']	[('SUPERFICIAL_RELATIONSHIP', 38), ('SUPERFICIAL_RELATIONSHIP', 178), ('INCOMPLETE_EVIDENCE', 334), ('PROBLEM_COMPLICATION', 344)]	4	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007567', 'parturition', 130, 'birth'), ('GO_0007565', 'female pregnancy', 206, 'gestational'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('SO_0001026', 'genome', 409, 'genome')]	0	['developmental  status asd, dutch birth mid- neonatal  concentrations autistic traits.13within cohort, access set children’s individual-level genome-wide genotype data.']
S121-PMC5385921	PMC5385921	4/2017	S121-PMC5385921	['the FINDING from THIS STUDY LENDS weight to the GROWING BODY of epidemiological and Animal MODEL-based research LINKING Gestational Vitamin D deficiency and altered Brain Development.']	[('INCOMPLETE_EVIDENCE', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 17), ('PROBABLE_UNDERSTANDING', 28), ('INCOMPLETE_EVIDENCE', 48), ('INCOMPLETE_EVIDENCE', 91), ('SUPERFICIAL_RELATIONSHIP', 112)]	6	[('NCBITaxon_33208', 'Metazoa', 84, 'animal'), ('GO_0007565', 'female pregnancy', 120, 'gestational'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('GO_0007420', 'brain development', 165, 'brain development'), ('UBERON_0000955', 'brain', 165, 'brain')]	0	['epidemiological animal model-based   altered brain development.']
S123-PMC5385921	PMC5385921	4/2017	S123-PMC5385921	['Rodent MODELS BASED ON transient Prenatal exposure to Vitamin D deficiency have FOUND a range of persistent molecular, neurochemical and behavioural changes of interest to neuropsychiatry.32a number OF STUDIES have LINKED asd with Neuronal Migration.33migration-ASSOCIATED phenotypes such as changes in Neuronal density and volume, aberrant Minicolumns and heterotopias HAVE BEEN detected in patients with asd.34,35as Neuronal Migration starts at 6 weeks Gestation and USUALLY ends around 24 weeks Gestation, the OBSERVED ASSOCIATION between our mid-Gestation samples, which were drawn at ~20 weeks Gestation, and risk of asd CORROBORATES our PREVIOUS FINDINGS LINKING Vitamin D deficiency with abnormal Brain Development.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 7), ('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 14), ('PROBABLE_UNDERSTANDING', 14), ('INCOMPLETE_EVIDENCE', 80), ('INCOMPLETE_EVIDENCE', 199), ('SUPERFICIAL_RELATIONSHIP', 215), ('SUPERFICIAL_RELATIONSHIP', 262), ('INCOMPLETE_EVIDENCE', 370), ('INCOMPLETE_EVIDENCE', 469), ('INCOMPLETE_EVIDENCE', 513), ('SUPERFICIAL_RELATIONSHIP', 522), ('INCOMPLETE_EVIDENCE', 626), ('INCOMPLETE_EVIDENCE', 643), ('SUPERFICIAL_RELATIONSHIP', 661)]	15	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Rodent'), ('GO_0007565', 'female pregnancy', 33, 'prenatal'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CL_0000540', 'neuron', 231, 'neuronal'), ('GO_0001764', 'neuron migration', 231, 'neuronal migration'), ('CL_0000540', 'neuron', 303, 'neuronal'), ('UBERON_0016512', 'lumen of duodenum', 341, 'minicolumns'), ('CL_0000540', 'neuron', 418, 'neuronal'), ('GO_0001764', 'neuron migration', 418, 'neuronal migration'), ('GO_0007565', 'female pregnancy', 455, 'gestation'), ('GO_0007565', 'female pregnancy', 498, 'gestation'), ('GO_0007565', 'female pregnancy', 550, 'gestation'), ('GO_0007565', 'female pregnancy', 599, 'gestation'), ('CHEBI_27300', 'vitamin D', 669, 'vitamin D'), ('GO_0007420', 'brain development', 704, 'brain development'), ('UBERON_0000955', 'brain', 704, 'brain')]	0	['rodent transient  exposure  molecular, neurochemical behavioural changes neuropsychiatry.32a asd neuronal migration.33migration-associated phenotypes changes neuronal density volume, aberrant minicolumns heterotopias patients asd.34,35as neuronal migration starts 6 weeks  ends 24 weeks mid- samples, drawn ~20 weeks asd  abnormal brain development.']
S140-PMC5385921	PMC5385921	4/2017	S140-PMC5385921	['developmental Vitamin D deficiency at mid-Gestation was ASSOCIATED with a twofold increased risk of asd.']	[('SUPERFICIAL_RELATIONSHIP', 56)]	1	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'gestation')]	0	['developmental  mid- twofold asd.']
S143-PMC5385921	PMC5385921	4/2017	S143-PMC5385921	['just as Prenatal Folate supplementation has reduced the incidence of spina bifida, we SPECULATE that Prenatal Vitamin D supplementation MAY reduce the incidence of asd.']	[('INCOMPLETE_EVIDENCE', 86), ('INCOMPLETE_EVIDENCE', 136)]	2	[('GO_0007565', 'female pregnancy', 8, 'prenatal'), ('CHEBI_30863', '5-azaorotic acid', 17, 'folate'), ('GO_0007565', 'female pregnancy', 101, 'prenatal'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]	0	[' folate supplementation spina bifida,   supplementation asd.']
S2-PMC5405075	PMC5405075	4/2017	S2-PMC5405075	['SINCE asthma is presented with high incidence in childhood and neonatal Vitamin D stores DEPEND on maternal Vitamin levels, a POSSIBLE programming EFFECT of maternal Vitamin D status during Gestation was SUGGESTED.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBLEM_COMPLICATION', 0), ('SUPERFICIAL_RELATIONSHIP', 89), ('INCOMPLETE_EVIDENCE', 126), ('SUPERFICIAL_RELATIONSHIP', 147), ('INCOMPLETE_EVIDENCE', 204)]	6	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 108, 'vitamin'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('GO_0007565', 'female pregnancy', 190, 'gestation')]	0	['since asthma childhood neonatal  stores maternal vitamin levels, programming maternal  status  suggested.']
S4-PMC5405075	PMC5405075	4/2017	S4-PMC5405075	['in the randomized controlled clinical trials (rcts) that followed, increased doses of Vitamin D were tested in Pregnant women being at high RISK of having an asthmatic child.']	[('IMPORTANT_CONSIDERATION', 140)]	1	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'pregnant')]	0	['(rcts) followed, doses   women asthmatic child.']
S5-PMC5405075	PMC5405075	4/2017	S5-PMC5405075	['ALTHOUGH, the results of rcts SHOWED a POTENTIAL ASSOCIATION with asthma-RELATED phenotypes RATHER than asthma per se , the low toxicity of Vitamin D supplements make it TEMPTING to SPECULATE that Pregnant women at a high RISK of obtaining a child with asthma MAY BE benefited, ESPECIALLY if they are Vitamin D deficient.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 49), ('SUPERFICIAL_RELATIONSHIP', 73), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 92), ('INCOMPLETE_EVIDENCE', 170), ('INCOMPLETE_EVIDENCE', 182), ('IMPORTANT_CONSIDERATION', 222), ('INCOMPLETE_EVIDENCE', 260), ('ANOMALY_CURIOUS_FINDING', 278)]	12	[('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007565', 'female pregnancy', 197, 'pregnant'), ('CHEBI_27300', 'vitamin D', 301, 'vitamin D')]	0	['although, results rcts asthma-related phenotypes asthma se toxicity  supplements  women obtaining child asthma benefited,  deficient.']
S9-PMC5405075	PMC5405075	4/2017	S9-PMC5405075	['SINCE asthma is presented with high incidence in childhood, a POSSIBLE programming EFFECT of maternal Vitamin D status during Gestation HAS BEEN PROPOSED.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBLEM_COMPLICATION', 0), ('INCOMPLETE_EVIDENCE', 62), ('SUPERFICIAL_RELATIONSHIP', 83), ('INCOMPLETE_EVIDENCE', 136), ('INCOMPLETE_EVIDENCE', 145)]	6	[('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'gestation')]	0	['since asthma childhood, programming maternal  status  proposed.']
S10-PMC5405075	PMC5405075	4/2017	S10-PMC5405075	['besides, Pregnant women and infants are in high RISK of Vitamin D insufficiency (7–11).']	[('IMPORTANT_CONSIDERATION', 48)]	1	[('GO_0007565', 'female pregnancy', 9, 'pregnant'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D')]	0	['besides,  women infants  (7–11).']
S11-PMC5405075	PMC5405075	4/2017	S11-PMC5405075	['several OBSERVATIONAL STUDIES explored THIS issue and SUGGESTED a PUTATIVE PROTECTIVE ROLE of Prenatal Vitamin D sufficiency in the development Of Wheezing and Asthma in the offspring [reviewed in ref.']	[('INCOMPLETE_EVIDENCE', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 39), ('INCOMPLETE_EVIDENCE', 54), ('PROBABLE_UNDERSTANDING', 66), ('SUPERFICIAL_RELATIONSHIP', 75), ('SUPERFICIAL_RELATIONSHIP', 86)]	6	[('GO_0007565', 'female pregnancy', 94, 'prenatal'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0001503', 'ossification', 144, 'of wheezing'), ('GO_0006953', 'acute-phase response', 160, 'asthma')]	0	['several   wheezing asthma offspring [reviewed ref.']
S15-PMC5405075	PMC5405075	4/2017	S15-PMC5405075	['Vitamin D levels during Pregnancy\nthe main ROLE of Vitamin D during Pregnancy is to maintain Serum calcium levels by promoting calcium absorption in the Intestine and allowing proper function of Parathyroid hormone.']	[('SUPERFICIAL_RELATIONSHIP', 43)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 24, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy'), ('UBERON_0001977', 'blood serum', 93, 'serum'), ('UBERON_0000160', 'intestine', 153, 'intestine'), ('UBERON_0001132', 'parathyroid gland', 195, 'parathyroid')]	0	['vitamin levels \nthe main   maintain serum calcium levels promoting calcium absorption intestine allowing proper parathyroid hormone.']
S17-PMC5405075	PMC5405075	4/2017	S17-PMC5405075	['ALTHOUGH 25(Oh)D circulating levels do not substantially differentiate or MAY BE reduced compared to non-Pregnant women, Serum concentrations of Vitamin D active Metabolite, 1,25(Oh)2D, are significantly elevated from early Pregnancy (13,14).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 74)]	2	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('UBERON_0001977', 'blood serum', 121, 'serum'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 162, 'metabolite'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 176, '25(OH)2D'), ('GO_0007565', 'female pregnancy', 224, 'pregnancy')]	0	['although 25(oh)d circulating levels non- women, serum concentrations  metabolite, 1,25(oh)2d, elevated  (13,14).']
S19-PMC5405075	PMC5405075	4/2017	S19-PMC5405075	['it SHOULD BE NOTICED that high Maternal Intake of 25(Oh)D or exceeding Vitamin D Serum levels during Pregnancy is not COMPLICATED from either hypercalcemia or hypercalciuria (16).']	[('IMPORTANT_CONSIDERATION', 3), ('ANOMALY_CURIOUS_FINDING', 13), ('DIFFICULT_TASK', 118)]	3	[('GO_0007618', 'mating', 31, 'maternal'), ('GO_0007631', 'feeding behavior', 40, 'intake'), ('CHEBI_71657', 'versiconol acetate', 50, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0001977', 'blood serum', 81, 'serum'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy')]	0	['maternal intake 25(oh)d exceeding  serum levels  hypercalciuria (16).']
S28-PMC5405075	PMC5405075	4/2017	S28-PMC5405075	['AS a result, Vitamin D deficiency during Pregnancy exerts SIGNIFICANT IMPACT on Vitamin D status of newborns and subsequently on early Childhood (9,28).']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 58), ('SUPERFICIAL_RELATIONSHIP', 70)]	3	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('UBERON_0013628', 'pollical pad', 135, 'childhood')]	0	['result,   exerts  status newborns childhood (9,28).']
S29-PMC5405075	PMC5405075	4/2017	S29-PMC5405075	['the IMPACT of Vitamin D exposure in utero\nthe DEPENDENCE of the developing fetus on maternal Vitamin D status TOGETHER with the REPORTED extra Skeletal function of the hormone and Vitamin D deficiency EPIDEMIC during the last years led to FURTHER INVESTIGATION of the CONSEQUENCES of maternal Vitamin D insufficiency on Pregnancy outcomes (6,29,30).']	[('SUPERFICIAL_RELATIONSHIP', 4), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 110), ('INCOMPLETE_EVIDENCE', 128), ('IMPORTANT_CONSIDERATION', 201), ('FUTURE_WORK', 239), ('PROBLEM_COMPLICATION', 268)]	7	[('CHEBI_28384', 'vitamin K', 14, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('UBERON_0004288', 'skeleton', 143, 'skeletal'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D'), ('GO_0007565', 'female pregnancy', 320, 'pregnancy')]	0	['vitamin exposure utero\nthe fetus maternal  status extra skeletal hormone  last maternal   outcomes (6,29,30).']
S30-PMC5405075	PMC5405075	4/2017	S30-PMC5405075	['Gestational Vitamin D has now been LINKED to a variety of diseases such as osteoporosis, Autoimmune disorders, altered Brain Development and Adult mental health, Food allergies, and asthma (17,29,31–33).']	[('SUPERFICIAL_RELATIONSHIP', 35)]	1	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('UBERON_0001442', 'skeleton of manus', 89, 'autoimmune'), ('GO_0007420', 'brain development', 119, 'brain development'), ('UBERON_0000955', 'brain', 119, 'brain'), ('UBERON_0007023', 'adult organism', 141, 'adult'), ('CHEBI_33290', 'food', 162, 'food')]	0	['  diseases osteoporosis, autoimmune disorders, altered brain adult mental health, food allergies, asthma (17,29,31–33).']
S34-PMC5405075	PMC5405075	4/2017	S34-PMC5405075	['maternal Vitamin D status and ASSOCIATIONS with asthma in early Life\nthe PUTATIVE EFFECT of Prenatal exposure to Vitamin D on asthmatic phenotypes in early Life has been initially investigated via observational studies based on either maternal dietary Intake of Vitamin D or 25(Oh)D levels in Venous maternal and/or Cord Blood [reviewed in ref.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('PROBABLE_UNDERSTANDING', 73), ('SUPERFICIAL_RELATIONSHIP', 82)]	3	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('UBERON_0000104', 'life cycle', 64, 'Life'), ('GO_0007565', 'female pregnancy', 92, 'prenatal'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('UBERON_0000104', 'life cycle', 156, 'life'), ('GO_0007631', 'feeding behavior', 252, 'intake'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 275, '25(OH)D'), ('UBERON_0001638', 'vein', 293, 'venous'), ('UBERON_0002240', 'spinal cord', 316, 'cord'), ('UBERON_0000178', 'blood', 321, 'blood')]	0	['maternal vitamin status asthma life\nthe  exposure  asthmatic phenotypes life via maternal dietary intake  25(oh)d levels venous maternal and/or cord blood [reviewed ref.']
S42-PMC5405075	PMC5405075	4/2017	S42-PMC5405075	['INCONSISTENCIES across studies HAVE BEEN ATTRIBUTED to a plethora of FACTORS such as diverse study designs, MISSING significant follow-up, lack OF a clear definition of vitamin d sufficiency in Pregnancy, REMARKABLE fluctuations in populations in different latitudes, Genetic heterogeneity, the diversity of assays employed (69), low repeatability of Serum 25(Oh)D values (37), variety of Vitamin D status DETERMINANTS, multifactorial nature and phenotypical diversity of asthma, as well as imprecision in diagnosing asthma in early Life.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 31), ('SUPERFICIAL_RELATIONSHIP', 41), ('SUPERFICIAL_RELATIONSHIP', 69), ('PROBLEM_COMPLICATION', 108), ('ANOMALY_CURIOUS_FINDING', 144), ('ANOMALY_CURIOUS_FINDING', 205), ('SUPERFICIAL_RELATIONSHIP', 406)]	8	[('GO_0007565', 'female pregnancy', 194, 'pregnancy'), ('SO_0000704', 'gene', 268, 'genetic'), ('UBERON_0001977', 'blood serum', 351, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 360, 'OH)D'), ('CHEBI_27300', 'vitamin D', 389, 'vitamin D'), ('UBERON_0000104', 'life cycle', 533, 'life')]	0	['inconsistencies designs, follow-up, definition vitamin fluctuations populations latitudes, genetic heterogeneity, diversity assays employed (69), repeatability serum 25(oh)d values (37),  status determinants, nature phenotypical diversity asthma, diagnosing asthma life.']
S44-PMC5405075	PMC5405075	4/2017	S44-PMC5405075	['OF NOTE, Food base approaches MAY BE ASSUMED AS a better representative of long-term Vitamin D Intake, which MIGHT INFLUENCE the fetus during all stages of Gestation and EVEN ex utero .']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 37), ('PROBABLE_UNDERSTANDING', 37), ('PROBABLE_UNDERSTANDING', 45), ('INCOMPLETE_EVIDENCE', 109), ('SUPERFICIAL_RELATIONSHIP', 115), ('ANOMALY_CURIOUS_FINDING', 170)]	8	[('CHEBI_33290', 'food', 9, 'food'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007631', 'feeding behavior', 95, 'intake'), ('GO_0007565', 'female pregnancy', 156, 'gestation')]	0	['note, food representative long-term  intake, fetus stages  ex utero .']
S46-PMC5405075	PMC5405075	4/2017	S46-PMC5405075	['moreover, both Animal and in vitro experiments have DEMONSTRATED a positive IMPACT of Prenatal Vitamin D exposure on aspects of Lung function and the process of inflammation, which are CONSIDERED to CONTRIBUTE to asthma pathogenesis (70–72).']	[('INCOMPLETE_EVIDENCE', 52), ('SUPERFICIAL_RELATIONSHIP', 76), ('INCOMPLETE_EVIDENCE', 185), ('SUPERFICIAL_RELATIONSHIP', 199)]	4	[('NCBITaxon_33208', 'Metazoa', 15, 'animal'), ('GO_0007565', 'female pregnancy', 86, 'prenatal'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('UBERON_0002048', 'lung', 128, 'lung')]	0	['moreover, animal experiments positive   exposure aspects lung process inflammation, asthma pathogenesis (70–72).']
S51-PMC5405075	PMC5405075	4/2017	S51-PMC5405075	['in a RECENT randomized placebo-controlled double-blind trial in new zealand, Vitamin D was administrated in unselected Pregnant women from the 27\u2009weeks of Gestation and subsequently in their infants during the first 6\u2009months of Life (placebo/placebo, 1,000/400\u2009iu, and 2,000/800\u2009iu).']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnant'), ('GO_0007565', 'female pregnancy', 155, 'gestation'), ('UBERON_0000104', 'life cycle', 228, 'life')]	0	['placebo-controlled double-blind zealand,  administrated unselected  women 27\u2009weeks  infants 6\u2009months life (placebo/placebo, 1,000/400\u2009iu, 2,000/800\u2009iu).']
S54-PMC5405075	PMC5405075	4/2017	S54-PMC5405075	['HOWEVER, these clinical trials were BIASED by many LIMITATIONS, such as SMALL SIZE, Vitamin D administration ONLY in the last Trimester of Pregnancy, POSSIBLY INADEQUATE maternal dose administration, WHILE authors also acknowledged that they were NOT PRIMARY designed to assess the specific outcome.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 36), ('PROBLEM_COMPLICATION', 36), ('INCOMPLETE_EVIDENCE', 51), ('INCOMPLETE_EVIDENCE', 72), ('INCOMPLETE_EVIDENCE', 109), ('INCOMPLETE_EVIDENCE', 150), ('IMPORTANT_CONSIDERATION', 159), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 200), ('INCOMPLETE_EVIDENCE', 247)]	10	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 126, 'trimester'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy')]	0	['however, limitations, size,  administration last trimester maternal dose administration, authors outcome.']
S58-PMC5405075	PMC5405075	4/2017	S58-PMC5405075	['caption (table-wrap): table 1\n\nrandomized control trials on Vitamin D supplementation during Pregnancy and asthma/wheezing .referencecountry and enrollment periodstudy populationintervention armsnumber/age of children at outcome assessmentintake of intervention from/untileffect on median Vitamin D levels (ng/ml)outcomes of interestmain FINDINGSGOLDRING et al.']	[('INCOMPLETE_EVIDENCE', 338)]	1	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin D')]	0	['caption (table-wrap): table 1\n\nrandomized  supplementation  asthma/wheezing .referencecountry enrollment periodstudy populationintervention armsnumber/age children outcome assessmentintake from/untileffect median  levels (ng/ml)outcomes interestmain et al.']
S73-PMC5405075	PMC5405075	4/2017	S73-PMC5405075	['Pregnant women on HIGH RISK to obtain children with asthma were randomized to either an interventional arm receiving 4,400\u2009iu of Vitamin D or to a control arm receiving 400\u2009iu, as usual care, from 10 to 18\u2009weeks of Gestation until Delivery.']	[('IMPORTANT_CONSIDERATION', 18)]	1	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007565', 'female pregnancy', 215, 'gestation'), ('GO_0007567', 'parturition', 231, 'delivery')]	0	[' women obtain children asthma interventional arm receiving 4,400\u2009iu  arm receiving 400\u2009iu, usual care, 10 18\u2009weeks  delivery.']
S78-PMC5405075	PMC5405075	4/2017	S78-PMC5405075	['OF NOTE, DESPITE the intervention significantly increased circulating Vitamin D levels in women, 1-year Postpartum no difference was preserved (76).']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 9)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 104, 'postpartum')]	0	['note, circulating  levels women, 1-year  (76).']
S89-PMC5405075	PMC5405075	4/2017	S89-PMC5405075	['moreover, it HAS BEEN PROPOSED that studies SHOULD focus on Vitamin D status in early Pregnancy and supplementary administration SHOULD BE initiated from the first Trimester of Gestation in order to observe the OPTIMAL EFFECT on RISK of childhood asthma, THOUGH EVIDENCE from chawes et al.’s clinical trial DID NOT CONFIRM this NOTION (75).']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 22), ('FUTURE_WORK', 44), ('FUTURE_WORK', 129), ('IMPORTANT_CONSIDERATION', 211), ('SUPERFICIAL_RELATIONSHIP', 219), ('IMPORTANT_CONSIDERATION', 229), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 255), ('ANOMALY_CURIOUS_FINDING', 255), ('INCOMPLETE_EVIDENCE', 262), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 307), ('INCOMPLETE_EVIDENCE', 328)]	12	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 164, 'trimester'), ('GO_0007565', 'female pregnancy', 177, 'gestation')]	0	['moreover,  status  supplementary administration trimester  childhood asthma, chawes et al.’s (75).']
S93-PMC5405075	PMC5405075	4/2017	S93-PMC5405075	['a plethora of environmental and Genetic/epigenetic FACTORS CONTRIBUTE in a COMPLEX manner to a PARTLY understood pathogenesis, WHILE the shifted Vitamin D Metabolism during Pregnancy is also NOT FULLY ELUCIDATED.']	[('SUPERFICIAL_RELATIONSHIP', 51), ('SUPERFICIAL_RELATIONSHIP', 59), ('DIFFICULT_TASK', 75), ('INCOMPLETE_EVIDENCE', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('INCOMPLETE_EVIDENCE', 191)]	6	[('SO_0000704', 'gene', 32, 'genetic'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 145, 'vitamin D metabolism'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy')]	0	['environmental genetic/epigenetic manner pathogenesis,  metabolism  elucidated.']
S96-PMC5405075	PMC5405075	4/2017	S96-PMC5405075	['SHIFTING the discussion to a clinical platform, Vitamin D administration during Pregnancy has NOT YET been justified.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('FULL_UNKNOWN', 94)]	2	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy')]	0	['shifting discussion platform,  administration  justified.']
S102-PMC5405075	PMC5405075	4/2017	S102-PMC5405075	['HOWEVER, given the RATHER low toxicity of such a Supplement, Pregnant women at a high risk of obtaining a child with asthma MAY BE benefited, especially IF they are Vitamin D deficient.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 19), ('INCOMPLETE_EVIDENCE', 124), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 153)]	4	[('CHEBI_16158', 'steroid sulfate', 49, 'supplement'), ('GO_0007565', 'female pregnancy', 61, 'pregnant'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]	0	['however, toxicity supplement,  women obtaining child asthma benefited,  deficient.']
S57-PMC5410409	PMC5410409	4/2017	S57-PMC5410409	['three large Birth cohort studies SHOWED CONSISTENT positive ASSOCIATIONS between maternal Intake of Vitamin E in Pregnancy and PREVENTION of childhood asthma or wheeze at 2 years of age [5].']	[('INCOMPLETE_EVIDENCE', 33), ('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 40), ('SUPERFICIAL_RELATIONSHIP', 60), ('SUPERFICIAL_RELATIONSHIP', 127)]	5	[('GO_0007567', 'parturition', 12, 'birth'), ('GO_0007631', 'feeding behavior', 90, 'intake'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin E'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy')]	0	['three birth positive maternal intake   childhood asthma wheeze 2 age [5].']
S62-PMC5410409	PMC5410409	4/2017	S62-PMC5410409	['SOME REPORTED that high maternal Vitamin D intake during Pregnancy was ASSOCIATED with reduced RISK of wheezing in the child, WHILE SOME SHOWED no effect.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 5), ('SUPERFICIAL_RELATIONSHIP', 71), ('IMPORTANT_CONSIDERATION', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 126), ('INCOMPLETE_EVIDENCE', 132), ('INCOMPLETE_EVIDENCE', 137)]	7	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy')]	0	['maternal  intake  wheezing child, effect.']
S15-PMC5418719	PMC5418719	5/2017	S15-PMC5418719	['CONSIDERING the high incidence of Vitamin D deficiency/insufficiency in preterm infants that miss the late Gestation period, which builds Vitamin D stores from mother to fetus, a Vitamin D supply MIGHT be NECESSARY and URGENT to compensate the sufficient Vitamin D level.']	[('IMPORTANT_CONSIDERATION', 0), ('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 196), ('IMPORTANT_CONSIDERATION', 205), ('IMPORTANT_CONSIDERATION', 219)]	5	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'gestation'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]	0	['considering  deficiency/insufficiency preterm infants late  period,  stores mother fetus,  supply compensate  level.']
S98-PMC5418719	PMC5418719	5/2017	S98-PMC5418719	['CONSIDERING the high prevalence of Vitamin D deficiency in Pregnant mothers, sufficient Vitamin D supply in preterm infants COULD BE IMPORTANT to quickly correct the fetal low Plasma levels of Vitamin D. a Vitamin D intake of 800\xa0iu to 1000\xa0iu per day during first Months Of Life is RECOMMENDED BASED ON european GUIDELINES [21].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 124), ('IMPORTANT_CONSIDERATION', 133), ('FUTURE_WORK', 283), ('PROBABLE_UNDERSTANDING', 295), ('ANOMALY_CURIOUS_FINDING', 301), ('PROBABLE_UNDERSTANDING', 313)]	8	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 59, 'pregnant'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 176, 'plasma'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('UBERON_0005445', 'segment of pes', 265, 'months of life')]	0	['considering   mothers,  supply preterm infants quickly fetal plasma levels .  intake 800\xa0iu 1000\xa0iu day months life european [21].']
S109-PMC5418719	PMC5418719	5/2017	S109-PMC5418719	['[23] reported that daily supplementation of Vitamin D in doses of 800\xa0iu compared with 400\xa0iu APPEARS to reduce the prevalence of Vitamin D deficiency at 40\xa0weeks pma in preterm infants of 28 to 34\xa0weeks Gestation.']	[('ANOMALY_CURIOUS_FINDING', 94)]	1	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 204, 'gestation')]	0	['[23] daily supplementation  doses 800\xa0iu 400\xa0iu  40\xa0weeks pma preterm infants 28 34\xa0weeks .']
S110-PMC5418719	PMC5418719	5/2017	S110-PMC5418719	['a randomized controlled trial in 100 infants with Gestational age between 23 and 27\xa0weeks DEMONSTRATED that the 800\xa0iu/d dose of Vitamin D supplementation PREVENTED Vitamin D deficiency, without toxicity, with concentrations above the desired 25(Oh)D range of 20–60\xa0ng/ml in the majority of infants on day 28 [2].']	[('INCOMPLETE_EVIDENCE', 90), ('SUPERFICIAL_RELATIONSHIP', 155)]	2	[('GO_0007565', 'female pregnancy', 50, 'gestational'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 243, '25(OH)D')]	0	['100 infants  age 23 27\xa0weeks 800\xa0iu/d dose  supplementation  deficiency, toxicity, concentrations 25(oh)d 20–60\xa0ng/ml infants day 28 [2].']
S117-PMC5418719	PMC5418719	5/2017	S117-PMC5418719	['in addition, circulating 25(Oh)D levels are INFLUENCED by ethnicity, Genetic factors and maternal FACTORS such as Prenatal Vitamin D intake and Gestational diabetes mellitus [27,28].']	[('SUPERFICIAL_RELATIONSHIP', 44), ('SUPERFICIAL_RELATIONSHIP', 98)]	2	[('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 31, 'D'), ('SO_0000704', 'gene', 69, 'genetic'), ('GO_0007565', 'female pregnancy', 114, 'prenatal'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007565', 'female pregnancy', 144, 'gestational')]	0	['addition, circulating 25(oh)d levels ethnicity, genetic maternal   intake  diabetes mellitus [27,28].']
S118-PMC5418719	PMC5418719	5/2017	S118-PMC5418719	['MANY STUDIES have REVEALED a substantial proportion of Vitamin D deficiency in the middle east, hispanic women, african americans and asian countries during Pregnancy, compared to western countries [7,23,29,30].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 18)]	2	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 157, 'pregnancy')]	0	['many proportion  middle east, hispanic women, african americans asian countries western countries [7,23,29,30].']
S121-PMC5418719	PMC5418719	5/2017	S121-PMC5418719	['[31] IDENTIFIED that the overall prevalence of Vitamin D deficiency (<20\xa0ng/ml) was 77.3% and the prevalence of Vitamin D deficiency (<10\xa0ng/ml) was 28.6% among Pregnant women in korea.']	[('INCOMPLETE_EVIDENCE', 5)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnant')]	0	['[31]  (<20\xa0ng/ml) 77.3%  (<10\xa0ng/ml) 28.6% among  women korea.']
S128-PMC5418719	PMC5418719	5/2017	S128-PMC5418719	['[36] RECENTLY CONFIRMED that women who had Vitamin D insufficiency during Pregnancy were AT RISK of developing Gestational diabetes and Delivering small for Gestational age infants in a systematic review.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 89)]	3	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007565', 'female pregnancy', 111, 'gestational'), ('GO_0006900', 'vesicle budding from membrane', 136, 'delivering'), ('GO_0007565', 'female pregnancy', 157, 'gestational')]	0	['[36] women    diabetes delivering  age infants review.']
S0-PMC5421133	PMC5421133	5/2017	S0-PMC5421133	['marginal vitamin a deficiency EXACERBATES Memory deficits following aβ1-42injection in Rats\n\nabstract\n\nbackground:\nALTHOUGH clinical Vitamin A deficiency (vad), which is a PUBLIC HEALTH PROBLEM developing throughout the world, has been well controlled, marginal Vitamin A deficiency (mvad) is far more PREVALENT, especially among Pregnant women and preschool children in china.']	[('SUPERFICIAL_RELATIONSHIP', 30), ('ANOMALY_CURIOUS_FINDING', 115), ('IMPORTANT_CONSIDERATION', 172), ('IMPORTANT_CONSIDERATION', 302)]	4	[('GO_0007613', 'memory', 42, 'Memory'), ('NCBITaxon_10088', 'Mus <genus>', 87, 'Rats'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin A'), ('GO_0007565', 'female pregnancy', 330, 'pregnant')]	0	['marginal vitamin memory following aβ1-42injection rats\n\nabstract\n\nbackground:\nalthough  (vad), throughout world, controlled,  (mvad) prevalent, among  women preschool children china.']
S0-PMC5426325	PMC5426325	4/2017	S0-PMC5426325	['Prenatal exposure to Vitamin D from fortified Margarine and risk of fractures in late childhood: period and cohort results from 222 000 subjects in the d-tect observational study\n\nabstract:normal\nPrenatal low Vitamin D MAY have CONSEQUENCES for bone health.']	[('INCOMPLETE_EVIDENCE', 219), ('IMPORTANT_CONSIDERATION', 228)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_6784', 'mestranol', 46, 'margarine'), ('GO_0007565', 'female pregnancy', 196, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]	0	[' exposure  fortified margarine fractures late childhood: period results 222 000 subjects d-tect study\n\nabstract:normal\n  bone health.']
S11-PMC5426325	PMC5426325	4/2017	S11-PMC5426325	['the study DID NOT PROVIDE EVIDENCE that Prenatal exposure to extra Vitamin D from a mandatory fortification programme of 1·25 µg Vitamin D/100 g Margarine was sufficient to INFLUENCE the risk of fractures in late childhood, REGARDLESS OF season of Birth.']	[('INCOMPLETE_EVIDENCE', 10), ('SUPERFICIAL_RELATIONSHIP', 173), ('INCOMPLETE_EVIDENCE', 224)]	3	[('GO_0007565', 'female pregnancy', 40, 'prenatal'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('CHEBI_6784', 'mestranol', 145, 'margarine'), ('GO_0007567', 'parturition', 248, 'birth')]	0	[' exposure extra  fortification programme 1·25 µg /100 g margarine fractures late childhood, season birth.']
S17-PMC5426325	PMC5426325	4/2017	S17-PMC5426325	['we used this historical change in fortification legislation TO EXAMINE the INFLUENCE of extra Prenatal Vitamin D exposure from fortified Margarine on the risk of fractures during Pubertal-related Growth Spurts, which has the highest fracture incidence(4).']	[('QUESTION_ANSWERED_BY_THIS_WORK', 60), ('SUPERFICIAL_RELATIONSHIP', 75)]	2	[('GO_0007565', 'female pregnancy', 94, 'prenatal'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('CHEBI_6784', 'mestranol', 137, 'margarine'), ('GO_0007567', 'parturition', 179, 'pubertal'), ('UBERON_0002445', 'ulnare', 196, 'growth spurts')]	0	['fortification legislation extra   exposure fortified margarine fractures pubertal-related spurts, fracture incidence(4).']
S24-PMC5426325	PMC5426325	4/2017	S24-PMC5426325	['in addition, it was HYPOTHESISED that the Vitamin D fortification during sun-deprived months of Gestation would be ASSOCIATED with the greatest risk reduction of offspring childhood fractures.']	[('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 115)]	2	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'gestation')]	0	['addition,  fortification sun-deprived months  reduction offspring childhood fractures.']
S27-PMC5426325	PMC5426325	4/2017	S27-PMC5426325	['we DID NOT identify OTHER abrupt societal changes during 1983–1988 that POTENTIALLY COULD INFLUENCE our results, neither in relation to fortification practices in other Food products for Consumption(31,32), nor in relation to Margarine intake in the danish population(33)or in relation to national RECOMMENDATIONS for Vitamin D supplementation to Pregnant women or infants.']	[('INCOMPLETE_EVIDENCE', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 20), ('INCOMPLETE_EVIDENCE', 72), ('INCOMPLETE_EVIDENCE', 84), ('SUPERFICIAL_RELATIONSHIP', 90), ('FUTURE_WORK', 298)]	6	[('CHEBI_33290', 'food', 169, 'food'), ('GO_0007631', 'feeding behavior', 187, 'consumption'), ('CHEBI_6784', 'mestranol', 226, 'margarine'), ('CHEBI_27300', 'vitamin D', 318, 'vitamin D'), ('GO_0007565', 'female pregnancy', 347, 'pregnant')]	0	['abrupt societal changes 1983–1988 results, fortification practices food products consumption(31,32), margarine intake danish population(33)or national  supplementation  women infants.']
S29-PMC5426325	PMC5426325	4/2017	S29-PMC5426325	['HENCE, Prenatal exposure to extra Vitamin D from fortification is assumed to be the only parameter that separates the Individuals in the two exposure groups.']	[('PROBABLE_UNDERSTANDING', 0)]	1	[('GO_0007565', 'female pregnancy', 7, 'prenatal'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('NCBITaxon_1', 'root', 118, 'individuals')]	0	['hence,  exposure extra  fortification parameter separates individuals exposure groups.']
S117-PMC5426325	PMC5426325	4/2017	S117-PMC5426325	['the study DID NOT PROVIDE EVIDENCE that Prenatal exposure to extra Vitamin D from fortification was sufficient to INFLUENCE the risk of fractures in late childhood, REGARDLESS OF season of Birth.']	[('INCOMPLETE_EVIDENCE', 10), ('SUPERFICIAL_RELATIONSHIP', 114), ('INCOMPLETE_EVIDENCE', 165)]	3	[('GO_0007565', 'female pregnancy', 40, 'prenatal'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007567', 'parturition', 189, 'birth')]	0	[' exposure extra  fortification fractures late childhood, season birth.']
S119-PMC5426325	PMC5426325	4/2017	S119-PMC5426325	['THUS, we CANNOT RULE OUT WHETHER the Birth cohort results REFLECT a TRUE adverse EFFECT of Vitamin D on bone; one PREVIOUS STUDY did indeed report borderline significant inverse ASSOCIATIONS between maternal late Pregnancy 25(Oh)D concentrations and offspring Forearm fractures(12).']	[('PROBABLE_UNDERSTANDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 25), ('SUPERFICIAL_RELATIONSHIP', 58), ('PROBABLE_UNDERSTANDING', 68), ('SUPERFICIAL_RELATIONSHIP', 81), ('INCOMPLETE_EVIDENCE', 114), ('SUPERFICIAL_RELATIONSHIP', 178)]	8	[('GO_0007567', 'parturition', 37, 'birth'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 223, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 223, '25(OH)D'), ('UBERON_0002386', 'forelimb zeugopod', 260, 'forearm')]	0	['thus, birth results  bone; borderline maternal late  25(oh)d concentrations offspring forearm fractures(12).']
S120-PMC5426325	PMC5426325	4/2017	S120-PMC5426325	['also, in the danish national Birth cohort, mid-Pregnancy maternal supplementation with >10 µg Vitamin D/d was ASSOCIATED with a 30 % higher risk of offspring Forearm fractures(37).']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('GO_0007567', 'parturition', 29, 'Birth'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0002386', 'forelimb zeugopod', 158, 'forearm')]	0	['also, danish national birth cohort, mid- maternal supplementation >10 µg /d 30 % higher offspring forearm fractures(37).']
S136-PMC5426325	PMC5426325	4/2017	S136-PMC5426325	['in the avon longitudinal study of parents and children (alspac) study, uv-b-exposure during the third Trimester of Pregnancy was used as a PROXY for Vitamin D status, and the exposure was directly ASSOCIATED with bone Mineral content (bmc), bone area and bmd among 6955 children at age 9·9 years(8).']	[('SUPERFICIAL_RELATIONSHIP', 139), ('SUPERFICIAL_RELATIONSHIP', 197)]	2	[('GO_0009294', 'DNA mediated transformation', 102, 'trimester'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('CHEBI_46662', 'mineral', 218, 'mineral')]	0	['parents children (alspac) study, uv-b-exposure third trimester   status, exposure bone mineral content (bmc), bone bmd among 6955 children age 9·9 years(8).']
S143-PMC5426325	PMC5426325	4/2017	S143-PMC5426325	['intervention studies with supplementation of Vitamin D in Pregnancy are currently ONGOING(9,55).']	[('IMPORTANT_CONSIDERATION', 82)]	1	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy')]	0	['intervention supplementation   ongoing(9,55).']
S151-PMC5426325	PMC5426325	4/2017	S151-PMC5426325	['IT IS POSSIBLE that this amount was too small to INFLUENCE fracture risk at the population level, EVEN when we CONFINED the analysis to those Pregnancies with habitually low Vitamin D during late trimesters, that is, those Giving Birth during winter months.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 49), ('ANOMALY_CURIOUS_FINDING', 98), ('INCOMPLETE_EVIDENCE', 111)]	4	[('GO_0007565', 'female pregnancy', 142, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('GO_0040007', 'growth', 223, 'giving'), ('GO_0007567', 'parturition', 230, 'birth')]	0	['amount fracture population level,  habitually  late trimesters, is, birth winter months.']
S152-PMC5426325	PMC5426325	4/2017	S152-PMC5426325	['UNFORTUNATELY, we LACK INFORMATION on Vitamin D status among danish women in the Reproductive age during the fortification period, BUT for comparision, a study SHOWED that among 850 Pregnant women recruited from the second-largest city in denmark in 1988–1989 (the period without fortification), only 6·3 of the Pregnant women had a Serum 25(Oh)D concentration ≤25 nmol/l(12); the median concentrations of 76·2 (95 % ci 23·0, 152·1) nmol/l were also above the ‘OPTIMAL level’ as STATED by the us Endocrine society(62,63).']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 18), ('INCOMPLETE_EVIDENCE', 23), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('INCOMPLETE_EVIDENCE', 160), ('IMPORTANT_CONSIDERATION', 461), ('INCOMPLETE_EVIDENCE', 479)]	7	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0000003', 'reproduction', 81, 'reproductive'), ('GO_0007565', 'female pregnancy', 182, 'pregnant'), ('GO_0007565', 'female pregnancy', 312, 'pregnant'), ('UBERON_0001977', 'blood serum', 333, 'serum'), ('CHEBI_71657', 'versiconol acetate', 339, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 339, '25(OH)D'), ('UBERON_0005063', 'left ventricular compact myocardium', 496, 'Endocrine')]	0	['unfortunately,  status among danish women reproductive age fortification period, comparision, among 850  women recruited second-largest city denmark 1988–1989 (the period fortification), 6·3  women serum 25(oh)d concentration ≤25 nmol/l(12); median concentrations 76·2 (95 % ci 23·0, 152·1) nmol/l ‘optimal level’ us endocrine society(62,63).']
S162-PMC5426325	PMC5426325	4/2017	S162-PMC5426325	['conclusion\nthe study DID NOT PROVIDE EVIDENCE that Prenatal exposure to extra Vitamin D from a mandatory fortification programme, adding1·25 µg Vitamin D/100 g Margarine, was sufficient to INFLUENCE the risk of fractures in late childhood, REGARDLESS OF season of Birth.']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 189), ('INCOMPLETE_EVIDENCE', 240)]	4	[('GO_0007565', 'female pregnancy', 51, 'prenatal'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('CHEBI_6784', 'mestranol', 160, 'margarine'), ('GO_0007567', 'parturition', 264, 'birth')]	0	['conclusion\nthe  exposure extra  fortification programme, adding1·25 µg /100 g margarine, fractures late childhood, season birth.']
S30-PMC5436890	PMC5436890	5/2017	S30-PMC5436890	['the KEY STRATEGIES of the nns includes growth monitoring and promotion, ENCOURAGING behaviour change to improve good nutritional practices, Vitamin A supplementation, zinc supplementation during treatment of diarrhoea and Iron/Folic Acid supplementation for Pregnant women.']	[('IMPORTANT_CONSIDERATION', 4), ('FUTURE_WORK', 8), ('FUTURE_WORK', 72)]	3	[('CHEBI_27300', 'vitamin D', 140, 'vitamin A'), ('CHEBI_24870', 'ion', 222, 'iron'), ('CHEBI_30751', 'formic acid', 227, 'folic acid'), ('GO_0007565', 'female pregnancy', 258, 'pregnant')]	0	['nns includes promotion, behaviour nutritional practices,  supplementation, zinc supplementation treatment diarrhoea iron/folic acid supplementation  women.']
S148-PMC5452160	PMC5452160	4/2017	S148-PMC5452160	['3.4 predictors of multiple Micronutrient deficiencies\nwhen exploring predictors of mmn deficiencies (≥3 of the following: iron, zinc, Vitamin A, vitamin B12And/or Folate), women in the second Trimester of Pregnancy were less LIKELY to have mmn deficiencies (or: 0.31, 95% ci: 0.21, 0.45) than women in the third trimester.']	[('PROBABLE_UNDERSTANDING', 225)]	1	[('CHEBI_6956', 'Mitragynine', 27, 'Micronutrient'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin A'), ('CHEBI_82295', 'Bitumens', 153, 'B12and'), ('CHEBI_30863', '5-azaorotic acid', 163, 'folate'), ('GO_0009294', 'DNA mediated transformation', 192, 'trimester'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy')]	0	['3.4 micronutrient deficiencies\nwhen mmn (≥3 following: iron, zinc, vitamin b12and/or folate), women trimester  mmn (or: 0.31, 95% ci: 0.21, 0.45) women third trimester.']
S20-PMC5473979	PMC5473979	6/2017	S20-PMC5473979	['several Micronutrients such as iron, zinc, Folate, Vitamin B-6, B-12, Calcium, Selenium, and N-3 Fatty Acids have BEEN LINKED to maternal mental health and wellbeing [9,10] HOWEVER, much of the work to date has focused on the Postpartum period.']	[('ANOMALY_CURIOUS_FINDING', 114), ('SUPERFICIAL_RELATIONSHIP', 119), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 173)]	3	[('CHEBI_33839', 'macromolecule', 8, 'micronutrients'), ('CHEBI_30863', '5-azaorotic acid', 43, 'folate'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 51, 'vitamin B-6'), ('PR_000004770', 'Polycomb complex protein BMI-1', 64, 'B-12'), ('CHEBI_22313', 'alkaline earth metal atom', 70, 'calcium'), ('CHEBI_27568', 'selenium atom', 79, 'selenium'), ('CHEBI_30256', 'thiocarbonyl group', 93, 'n-3'), ('CHEBI_35366', 'fatty acid', 97, 'fatty acids'), ('GO_0007565', 'female pregnancy', 226, 'postpartum')]	0	['several micronutrients iron, zinc, folate, -6, b-12, calcium, selenium, n-3 fatty acids maternal mental wellbeing [9,10] however,  period.']
S16-PMC5474873	PMC5474873	6/2017	S16-PMC5474873	['Animal studies HAVE SHOWN that deficiency of Prenatal Vitamin D is ASSOCIATED with persistent changes in Adult Brain structure, neurochemistry, and behavior (5,7).']	[('INCOMPLETE_EVIDENCE', 15), ('SUPERFICIAL_RELATIONSHIP', 67)]	2	[('NCBITaxon_33208', 'Metazoa', 0, 'Animal'), ('GO_0007565', 'female pregnancy', 45, 'prenatal'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('UBERON_0007023', 'adult organism', 105, 'adult'), ('UBERON_0000955', 'brain', 111, 'brain')]	0	['animal   changes adult brain structure, neurochemistry, behavior (5,7).']
S131-PMC5487839	PMC5487839	3/2016	S131-PMC5487839	['an increased risk of malformations events has NOT been OBSERVED in Humans (LIMITED DATA) [360]cvitamin dthe ROLE for Vitamin D supplementation in Pregnancy is CONTROVERSIAL, BUT there is NO EVIDENCE of a reduction in adverse Pregnancy outcomes (e.g., Preeclampsia, Stillbirth, neonatal death) [361] or improvement in bone Mineral content in children in studies in which supplementation was given INDEPENDENTLY from Blood levels [362].']	[('FULL_UNKNOWN', 46), ('INCOMPLETE_EVIDENCE', 75), ('SUPERFICIAL_RELATIONSHIP', 108), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 159), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 174), ('INCOMPLETE_EVIDENCE', 187), ('SUPERFICIAL_RELATIONSHIP', 396)]	7	[('NCBITaxon_9606', 'Homo sapiens', 67, 'humans'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy'), ('GO_0007565', 'female pregnancy', 225, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 251, 'preeclampsia'), ('GO_0001966', 'thigmotaxis', 265, 'stillbirth'), ('CHEBI_46662', 'mineral', 322, 'mineral'), ('UBERON_0000178', 'blood', 415, 'blood')]	0	['malformations events humans (limited data) [360]cvitamin dthe  supplementation  controversial, reduction  outcomes (e.g., preeclampsia, stillbirth, neonatal death) [361] bone mineral content children supplementation blood levels [362].']
S201-PMC5487839	PMC5487839	3/2016	S201-PMC5487839	['the data obtained in a relatively SMALL group of patients are IN LINE WITH REPORTS on the advantages of vegetal proteins in reducing Kidney disease progression in non-Pregnant Humans, with a systematic review on vegan-vegetarian diets in Pregnancy, and with the position of the american dietary association, provided that b12, iron and Vitamin D are Controlled and supplied upon NEED [170–178].']	[('INCOMPLETE_EVIDENCE', 34), ('INCOMPLETE_EVIDENCE', 62), ('INCOMPLETE_EVIDENCE', 75), ('IMPORTANT_CONSIDERATION', 379)]	4	[('UBERON_0002113', 'kidney', 133, 'kidney'), ('GO_0007565', 'female pregnancy', 167, 'pregnant'), ('NCBITaxon_9606', 'Homo sapiens', 176, 'humans'), ('GO_0007565', 'female pregnancy', 238, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D'), ('GO_0065007', 'biological regulation', 350, 'controlled')]	0	['patients vegetal proteins reducing kidney disease progression non- humans, vegan-vegetarian diets position american dietary association, b12, iron  supplied [170–178].']
S103-PMC5489519	PMC5489519	6/2017	S103-PMC5489519	['PREVIOUSLY, it HAS BEEN SHOWN that Vitamin D deficiency during Pregnancy increases genotoxic RISKS in newborns40.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 93)]	3	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy')]	0	['previously,   genotoxic newborns40.']
S78-PMC5510234	PMC5510234	7/2017	S78-PMC5510234	['the authors REPORTED that EVEN in regions where Vitamin A deficiency is a PUBLIC HEALTH CONCERN, Vitamin A supplementation for PREVENTION of Prenatal mtct is not RECOMMENDED.58finally a RECENT REVIEW done on the vitamin a supplementation for the reduction of the RISK of mother-to-child transmission of hiv, REPORTED that early observational studies FOUND an ASSOCIATION between Vitamin A deficiency and increased rates of mtct of hiv.']	[('INCOMPLETE_EVIDENCE', 12), ('ANOMALY_CURIOUS_FINDING', 26), ('IMPORTANT_CONSIDERATION', 74), ('SUPERFICIAL_RELATIONSHIP', 127), ('FUTURE_WORK', 162), ('INCOMPLETE_EVIDENCE', 186), ('IMPORTANT_CONSIDERATION', 263), ('INCOMPLETE_EVIDENCE', 308), ('INCOMPLETE_EVIDENCE', 350), ('SUPERFICIAL_RELATIONSHIP', 359)]	10	[('CHEBI_27300', 'vitamin D', 48, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin A'), ('GO_0007565', 'female pregnancy', 141, 'prenatal'), ('CHEBI_27300', 'vitamin D', 379, 'vitamin A')]	0	['authors regions  concern,  supplementation  mtct recommended.58finally done vitamin supplementation reduction mother-to-child transmission hiv,  rates mtct hiv.']
S4-PMC5513133	PMC5513133	7/2017	S4-PMC5513133	['these sources were retrieved, collected, indexed, and ASSESSED for availability of Pregnancy-related data on pe and Vitamin D.\n\nresults\nseveral case-control studies and cross-sectional studies HAVE SHOWN an ASSOCIATION between Vitamin D status and pe, ALTHOUGH EVIDENCE HAS BEEN INCONSISTENT.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 54), ('INCOMPLETE_EVIDENCE', 193), ('SUPERFICIAL_RELATIONSHIP', 207), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 252), ('INCOMPLETE_EVIDENCE', 261), ('INCOMPLETE_EVIDENCE', 270), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 279)]	7	[('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D')]	0	['sources retrieved, collected, indexed, availability -related pe .\n\nresults\nseveral case-control cross-sectional  status pe, inconsistent.']
S30-PMC5513133	PMC5513133	7/2017	S30-PMC5513133	['WHILE the pathogenesis of pe INVOLVES a number of biological Processes, there are several HYPOTHESES to SUGGEST HOW Vitamin D levels MAY AFFECT these processes (table1).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 90), ('INCOMPLETE_EVIDENCE', 104), ('EXPLICIT_QUESTION', 112), ('INCOMPLETE_EVIDENCE', 133), ('SUPERFICIAL_RELATIONSHIP', 137)]	7	[('GO_0007565', 'female pregnancy', 61, 'processes'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]	0	['pathogenesis pe biological  levels processes (table1).']
S46-PMC5513133	PMC5513133	7/2017	S46-PMC5513133	['during the course of Pregnancy, EVIDENCE from observational studies SHOWS DIVERGENT data on the concentration of Serum 25(Oh)D levels in different Trimesters of Pregnancy, with EITHER decline [41], increase [42], or absence of change in Vitamin D levels with progression [43,44].']	[('INCOMPLETE_EVIDENCE', 32), ('INCOMPLETE_EVIDENCE', 68), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 74), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 177)]	4	[('GO_0007565', 'female pregnancy', 21, 'pregnancy'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 119, '25(OH)D'), ('GO_0043033', 'isoamylase complex', 147, 'trimesters'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]	0	['concentration serum 25(oh)d levels trimesters decline [41], increase [42], absence  levels progression [43,44].']
S82-PMC5513133	PMC5513133	7/2017	S82-PMC5513133	['role of Vitamin D and Vitamin D Receptor (vdr) in Calcium Homeostasis\nthe EFFECTS of Calcium supplementation on Pregnancy-induced hypertensive disorders are well characterized.']	[('SUPERFICIAL_RELATIONSHIP', 74)]	1	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 22, 'vitamin D receptor'), ('GO_0050817', 'coagulation', 50, 'calcium'), ('GO_0042592', 'homeostatic process', 58, 'homeostasis'), ('CHEBI_22313', 'alkaline earth metal atom', 85, 'calcium'), ('GO_0007565', 'female pregnancy', 112, 'pregnancy')]	0	['role   receptor (vdr) calcium homeostasis\nthe calcium supplementation -induced hypertensive disorders characterized.']
S91-PMC5513133	PMC5513133	7/2017	S91-PMC5513133	['given the ROLE of Vitamin D in Modulation of inflammation and Immune function, Placental Implantation, Angiogenesis and adverse Birth outcomes such as low Birth weight and sga, we EXAMINED the EVIDENCE that Vitamin D MAY play a ROLE in the etiology and PREVENTION of pe in this manuscript.']	[('SUPERFICIAL_RELATIONSHIP', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 180), ('INCOMPLETE_EVIDENCE', 193), ('INCOMPLETE_EVIDENCE', 217), ('SUPERFICIAL_RELATIONSHIP', 228), ('SUPERFICIAL_RELATIONSHIP', 253)]	6	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0065007', 'biological regulation', 31, 'modulation'), ('UBERON_0002405', 'immune system', 62, 'immune'), ('GO_0007565', 'female pregnancy', 79, 'placental'), ('UBERON_0001987', 'placenta', 79, 'placental'), ('GO_0007566', 'embryo implantation', 89, 'implantation'), ('GO_0001525', 'angiogenesis', 103, 'angiogenesis'), ('GO_0007567', 'parturition', 128, 'birth'), ('GO_0007567', 'parturition', 155, 'birth'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]	0	['given  inflammation immune function,  implantation, angiogenesis birth outcomes birth sga,  play etiology pe manuscript.']
S92-PMC5513133	PMC5513133	7/2017	S92-PMC5513133	['methods\n\nsearch strategy\nthe review protocol was designed a priori to answer the QUESTION, “WHAT are the EFFECTS of Vitamin D concentrations and supplementation during Pregnancy on pre-eclampsia in women?” we conducted a literature search using medline electronic databases (via pubmed) to identify published studies until february 2015.']	[('EXPLICIT_QUESTION', 81), ('EXPLICIT_QUESTION', 92), ('SUPERFICIAL_RELATIONSHIP', 105)]	3	[('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy')]	0	['methods\n\nsearch strategy\nthe protocol question, “what  concentrations supplementation  pre-eclampsia women?” using medline electronic databases (via pubmed) february 2015.']
S100-PMC5513133	PMC5513133	7/2017	S100-PMC5513133	['selected journal articles were then retrieved, collected, indexed, and ASSESSED for availability of Pregnancy-related data on pe and Vitamin D by jp and pg.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 71)]	1	[('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]	0	['selected journal articles retrieved, collected, indexed, availability -related pe  jp pg.']
S101-PMC5513133	PMC5513133	7/2017	S101-PMC5513133	['the inclusion criteria for this review were availability of an abstract, clinical data on Vitamin D concentrations and/or supplementation in ASSOCIATION with pih outcomes in any global setting, and subjects that included Pregnant participants aged 18\xa0years and above without other medical co-morbidities.']	[('SUPERFICIAL_RELATIONSHIP', 141)]	1	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('GO_0007565', 'female pregnancy', 221, 'pregnant')]	0	['inclusion criteria availability abstract,  concentrations and/or supplementation pih outcomes setting, subjects  participants aged 18\xa0years medical co-morbidities.']
S102-PMC5513133	PMC5513133	7/2017	S102-PMC5513133	['studies were excluded IF they were reviews, commentaries, editorials, letters, non-Human studies, didn’t include maternal Vitamin D measured during Gestation as a primary or secondary variable, or did not include pe as a primary or secondary outcome.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 22)]	1	[('NCBITaxon_9606', 'Homo sapiens', 83, 'human'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'gestation')]	0	['studies reviews, commentaries, editorials, letters, non-human studies, didn’t maternal   secondary variable, pe secondary outcome.']
S121-PMC5513133	PMC5513133	7/2017	S121-PMC5513133	['another prospective cohort study of nulliparous women with singleton Pregnancies FOUND no significant association between Vitamin D deficiency in the 1st Trimester and risk for pe; HOWEVER, at 24–26\xa0weeks of Gestation mean maternal 25(Oh)D was significantly lower in women who developed pe COMPARED WITH those who did not ( p \xa0=\xa00.03) [60].']	[('INCOMPLETE_EVIDENCE', 81), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 181), ('ANOMALY_CURIOUS_FINDING', 181), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 290)]	4	[('GO_0007565', 'female pregnancy', 69, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 154, 'trimester'), ('GO_0007565', 'female pregnancy', 208, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 232, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 232, '25(OH ... D')]	0	['another nulliparous women singleton   1st trimester pe; however, 24–26\xa0weeks  maternal 25(oh)d women pe p \xa0=\xa00.03) [60].']
S129-PMC5513133	PMC5513133	7/2017	S129-PMC5513133	['germany, 2–14 [85]case control20 – women with peat Delivery43 – healthy Pregnant controls\u2003mohaghegh et al., iran, 2015 [89]case control41 -- women with pe 50 – healthy Pregnant controlstime of labor\u2003powe, usa, 2010 [86]nested case control39 -- developed pe 131 – healthy Pregnant controls1st Trimester\u2003robinson et al., usa, 2010 [25]case control50 -- women with eospe29\xa0weeks Gestation100 – healthy Pregnant controls\u2003schneuer et al., australia, 2014 [114]nested case control5109 Pregnant women (223 with pe and 29/223 with eospe)10–14\xa0weeks Gestation\u2003singla et al., india, 2015 [87]case control74 -- nulliparous women with pe>30\xa0weeks Gestation100 -- healthy nulliparous controls\u2003ullah et al., bangladesh, 2013 [82]case control33 -- women with pe>20\xa0weeks Gestation79 – normal Pregnancy controls\u2003wetta et al., uk, 2013 [96]case control100 -women with pe15–21\xa0weeks Gestation200 – healthy Pregnant controls\u2003woodham et al., usa, 2011 [15]nested case control41 – women with severe pe2nd trimester121 – uncomplicated birth controls\u2003xu et al., usa, 2014 [53]case control100 – women with pe≤ 24\xa0weeks Gestation100 – uncomplicated Birth controls\u2003yu et al., uk, 2012 [115]case control60 –late pe11–13\xa0weeks Gestation30 –early pe1000 – healthy controlsretrospective cohort study\u2003alvarez-fernandez et al., spain, 2014 [90]retrospective cohort257 -- women attending obstetric triage with suspicion of pe1st trimester and 20\xa0weeks of Gestation\u2003scholl et al., usa, 2013 [78]retrospective cohort1141 -- low income and minority Pregnant womenentry to care (mean 13.7\xa0±\xa05.7\xa0weeks)prospective cohort studies\u2003burris et al., usa, 2014 [94]prospective cohort1591 -- Pregnant women16.4–36.9\xa0weeks Gestation\u2003haugen et al., norway, 2000 [77]prospective cohort23,423 -- Pregnant womenvitamin D intake at weeks 15, 22, and 30 Gestation\u2003shand et al., canada, 2010 [37]prospective cohort221 -- women at risk for pe10–20\xa0weeks Gestation\u2003wei et al., canda 2012 [60]prospective cohort697 -- Pregnant women receiving Vitamin C and e supplementation for the PREVENTION of pe12–18\xa0weeks Gestation, 24-26 weeks Gestation\u2003wei, canada, 2013 [14]prospective cohort697 -- Pregnant women receiving Vitamin C and e supplementation for the PREVENTION of pe24–26\xa0weeks Gestation\u2003zhou, china, 2014 [116]prospective cohort74 – women with pe16–20 weeks\xa0Gestation\n\ncaption (table-wrap): table 3\n\nASSOCIATION between Vitamin D and pre-eclampsia (pe) in observational studiesauthor, location, yearkey findingsresultsaugust et al., usa, 1992 [88]↓ 1,25Oh2D in women with pe vs chronic htn and normal women1,25 Oh2D levels:pe: 37.8 +/− 15\xa0pg/ml chronic htn: 75 +/− 15\xa0pg/ml ( p \xa0<\xa00.05); normal women: 65 +/− 10\xa0pg/ml ( p \xa0<\xa00.05)fernandez- alonzo et al., spain, 2012 [97]↔ Pe and 25(Oh)D levels25(Oh)D: <49.9\xa0nmol/l: 28.6% (2/7 women); 49.9–74.9\xa0nmol/l: 42.9% (3/7 women); ≥ 74.9\xa0nmol/l: 28.6% (2/7 women) ( p \xa0=\xa00.91)pena hr, et al.']	[('SUPERFICIAL_RELATIONSHIP', 2026), ('SUPERFICIAL_RELATIONSHIP', 2199), ('SUPERFICIAL_RELATIONSHIP', 2350)]	3	[('GO_0007567', 'parturition', 51, 'delivery43'), ('GO_0007565', 'female pregnancy', 72, 'pregnant'), ('GO_0007565', 'female pregnancy', 168, 'pregnant'), ('GO_0007565', 'female pregnancy', 271, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 292, 'trimester'), ('GO_0007565', 'female pregnancy', 376, 'gestation100'), ('GO_0007565', 'female pregnancy', 399, 'pregnant'), ('GO_0007565', 'female pregnancy', 479, 'pregnant'), ('GO_0007565', 'female pregnancy', 541, 'gestation'), ('GO_0007565', 'female pregnancy', 635, 'gestation100'), ('GO_0007565', 'female pregnancy', 756, 'gestation79'), ('GO_0007565', 'female pregnancy', 777, 'pregnancy'), ('GO_0007565', 'female pregnancy', 865, 'gestation200'), ('GO_0007565', 'female pregnancy', 888, 'pregnant'), ('GO_0007565', 'female pregnancy', 1095, 'gestation100'), ('GO_0007567', 'parturition', 1124, 'birth'), ('GO_0007565', 'female pregnancy', 1199, 'gestation30'), ('GO_0007565', 'female pregnancy', 1422, 'gestation'), ('GO_0007565', 'female pregnancy', 1513, 'pregnant'), ('GO_0007565', 'female pregnancy', 1646, 'pregnant'), ('GO_0007565', 'female pregnancy', 1676, 'gestation'), ('GO_0007565', 'female pregnancy', 1746, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1768, 'D'), ('GO_0007565', 'female pregnancy', 1801, 'gestation'), ('GO_0007565', 'female pregnancy', 1899, 'gestation'), ('GO_0007565', 'female pregnancy', 1961, 'pregnant'), ('CHEBI_27300', 'vitamin D', 1986, 'vitamin C'), ('GO_0007565', 'female pregnancy', 2054, 'gestation'), ('GO_0007565', 'female pregnancy', 2077, 'gestation'), ('GO_0007565', 'female pregnancy', 2134, 'pregnant'), ('CHEBI_27300', 'vitamin D', 2159, 'vitamin C'), ('GO_0007565', 'female pregnancy', 2227, 'gestation'), ('GO_0007565', 'female pregnancy', 2308, 'gestation'), ('CHEBI_27300', 'vitamin D', 2370, 'vitamin D'), ('CHEBI_72639', '13-HODE', 2501, '25OH2D'), ('CHEBI_72639', '13-HODE', 2558, '25 OH2D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2724, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2731, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2747, '(OH)D')]	0	['germany, 2–14 [85]case control20 women peat delivery43 healthy  controls\u2003mohaghegh et al., iran, 2015 [89]case control41 -- women pe 50 healthy  controlstime labor\u2003powe, usa, 2010 [86]nested control39 -- pe 131 healthy  controls1st trimester\u2003robinson et al., usa, 2010 [25]case control50 -- women eospe29\xa0weeks  healthy  controls\u2003schneuer et al., australia, 2014 [114]nested control5109  women (223 pe 29/223 eospe)10–14\xa0weeks \u2003singla et al., india, 2015 [87]case control74 -- nulliparous women pe>30\xa0weeks  -- healthy nulliparous controls\u2003ullah et al., bangladesh, 2013 [82]case control33 -- women pe>20\xa0weeks  normal  controls\u2003wetta et al., uk, 2013 [96]case control100 -women pe15–21\xa0weeks  healthy  controls\u2003woodham et al., usa, 2011 [15]nested control41 women pe2nd trimester121 uncomplicated birth controls\u2003xu et al., usa, 2014 [53]case control100 women pe≤ 24\xa0weeks  uncomplicated birth controls\u2003yu et al., uk, 2012 [115]case control60 –late pe11–13\xa0weeks  –early pe1000 healthy controlsretrospective study\u2003alvarez-fernandez et al., spain, 2014 [90]retrospective cohort257 -- women attending obstetric triage pe1st trimester 20\xa0weeks \u2003scholl et al., usa, 2013 [78]retrospective cohort1141 -- income  womenentry (mean 13.7\xa0±\xa05.7\xa0weeks)prospective studies\u2003burris et al., usa, 2014 [94]prospective cohort1591 --  women16.4–36.9\xa0weeks \u2003haugen et al., norway, 2000 [77]prospective cohort23,423 --  womenvitamin intake weeks 15, 22, 30 \u2003shand et al., canada, 2010 [37]prospective cohort221 pe10–20\xa0weeks \u2003wei et al., canda 2012 [60]prospective cohort697 --  women receiving  e supplementation pe12–18\xa0weeks 24-26 weeks \u2003wei, canada, 2013 [14]prospective cohort697 --  women receiving  e supplementation pe24–26\xa0weeks \u2003zhou, china, 2014 [116]prospective cohort74 women pe16–20 weeks\xa0\n\ncaption (table-wrap): table 3\n\nassociation  pre-eclampsia (pe) studiesauthor, location, yearkey findingsresultsaugust et al., usa, 1992 [88]↓ 1,25oh2d women pe chronic htn normal women1,25 oh2d levels:pe: 37.8 +/− 15\xa0pg/ml chronic htn: 75 +/− 15\xa0pg/ml p \xa0<\xa00.05); normal women: 65 +/− 10\xa0pg/ml p \xa0<\xa00.05)fernandez- alonzo et al., spain, 2012 [97]↔ pe 25(oh)d levels25(oh)d: <49.9\xa0nmol/l: 28.6% (2/7 women); 49.9–74.9\xa0nmol/l: 42.9% (3/7 women); ≥ 74.9\xa0nmol/l: 28.6% (2/7 women) p \xa0=\xa00.91)pena hr, et al.']
S132-PMC5513133	PMC5513133	7/2017	S132-PMC5513133	['germany, 2–14 [85]↓ 25(Oh)D levels in pe in summer compared to controls, 1,25(Oh)2D ↓ only in winter25(Oh)D: pe:18.2\xa0±\xa017.1; control: 49.2\xa0±\xa029.2\xa0ng/ml, ( p \xa0<\xa00.001); 1,25(Oh)2D: 291\xa0±\xa0217 vs 612.3\xa0±\xa0455\xa0pmol/ml ( p \xa0<\xa00.05)mohaghegh et al., iran, 2015 [89]↓ mean 25(Oh)D in pe compared to Pregnant controls without pe25(Oh)D:Pe: 37.9\xa0±\xa033.9\xa0nmol/lcontrols: 58.2\xa0±\xa038.2\xa0nmol/l( p \xa0=\xa00.001)powe, usa, 2010 [86]↔ women with pe and controls with 25(Oh)D\xa0<\xa015.0\xa0nmol/ladjusted or: 1.3595% ci: 0.40 to 4.50robinson et al., usa, 2010 [25]↑ eospe in women with maternal 25(Oh)D levels <=19.6\xa0nmol/l compared to levels >19.6\xa0nmol/lor: 3.6095% ci: 1.71–7.58( p \xa0<\xa00.001)schneuer et al., australia, 2014 [114]↔ pe or eospe and low 25(Oh)D (< 25\xa0nmol/l)adjusted or- all pe: 0.4695% ci: 0.19–1.10adjusted or- eospe: 1.4095% ci: 0.20 to 9.89singla et al., india, 2015 [87]↓ mean Serum Vitamin D in women with pe vs controlspe: 24.2\xa0±\xa012.4\xa0nmol/l controls: 36.9\xa0±\xa016.7\xa0nmol/l;( p \xa0=\xa00.0001)ullah et al., bangladesh, 2013 [82]↑ pe per 25\xa0nmol/l decrease in 25(Oh)D leveladjusted or: 1.6695% ci: 1.05–3.02wetta et al., uk, 2013 [96]↔ between pe and 25-Oh D\xa0<\xa030\xa0ng/ml and <37.4\xa0nmol/l<30\xa0ng/ml adjusted or: 1.195% ci: 0.6–2.0adjusted or: 1.4 (<37.4\xa0nmol/l)95% ci: 0.7–3.0woodham et al., usa, 2011 [15]↓ severe pe in women with 10\xa0nmol/l increase in maternal 25(Oh)D leveladjusted or: 0.6295% ci: 0.51–0.76xu et al., usa, 2014 [53]↑ pe in women with Vitamin D deficiency (<37.5\xa0nmol/l)or: 4.495% ci: 1.8–10.8yu et al., uk, 2012 [115]↔ Serum Vitamin D raw values in pe and controls25(Oh)D levels: controls: 46.8\xa0nmol/l (27.8–70.0;)early pe: 32.2\xa0nmol/l (22.7–50.4); late pe: 39.2\xa0nmol/l (22.1–63.0) ( p \xa0=\xa00.231)alvarez-fernandez et al., spain, 2014 [90]↑ pe in women with 25(Oh)D levels <50\xa0nmol/l compared TO levels >50\xa0nmol/l after 20\xa0weeks of Gestationor: 4.695% ci:1.4–15( p \xa0=\xa00.010)scholl et al., usa, 2013 [78]↑ pe in women with 25(Oh)D\xa0<\xa049.9\xa0nmol/l and hyperparathyroidismadjusted or: 2.8695% ci: 1.28–6.41burris et al., usa, 2014 [94]↔ Pe and 25(Oh)D levels compared at each 25\xa0nmol/l increase in 25 (Oh)Dadjusted or: 1.1495% ci: 0.77–1.67haugen et al., norway, 2000 [77]↓ pe in women taking 10–15 mcg/d as compared with no supplementsadjusted or: 0.7395% ci: 0.58–0.92shand et al., canada, 2010 [37]↔ pe and 25(Oh)D levels <37.5\xa0nmol/ladjusted or: 0.9195% ci: 0.31–2.62wei et al., canda 2012 [60]↔ Pe and 25(Oh)D\xa0<\xa050\xa0nmol/ladjusted or: 1.2495% ci: 0.58–2.67( p \xa0=\xa00.58)wei, canada, 2013 [14]↑ pe and women with ↓ pigf levels and maternal 25(Oh)d\xa0<\xa050\xa0nmol/ladjusted or: 2.9795% ci: 1.23–7.20zhou, china, 2014 [116]↔ pe and 25(Oh)D levels25(Oh)D levelsgroup a ( n \xa0=\xa013): 41.4\xa0±\xa06.5\xa0nmol/l; group b ( n \xa0=\xa036): 62.1\xa0±\xa07.0\xa0nmol/l; group c ( n \xa0=\xa025): 89.6\xa0±\xa013.0\xa0nmol/l; ( p \xa0=\xa00.900)\na case-cohort study of women from 12 different united states (us) sites whose vitamin D levels were measured at ≤26\xa0weeks of Gestation SHOWED that 25(Oh)D levels greater than 50\xa0nmol/l were ASSOCIATED with a 40% reduction in risk for severe pe (0.65 [95% ci 0.43 to 0.98]), although there was no reduction in absolute and relative risk for the milder clinical subtypes of pe when 25(Oh)D levels were greater than 50\xa0nmol/l [79].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 1791), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2293), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2609), ('INCOMPLETE_EVIDENCE', 2914), ('SUPERFICIAL_RELATIONSHIP', 2969)]	5	[('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 26, 'D'), ('CHEBI_73285', '3-iodo-4-aminobenzyl-5*-N-methylcarboxamidoadenosine', 75, '25(OH)2D ↓'), ('CHEBI_33010', 'chromide(1-)', 102, '(OH)D'), ('CHEBI_82784', 'PVP38-Ag NP', 168, '1,25(OH)2D'), ('CHEBI_71657', 'versiconol acetate', 265, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 265, '25'), ('PR_000011614', 'opioid growth factor receptor', 268, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 271, 'D'), ('GO_0007565', 'female pregnancy', 291, 'pregnant'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 322, 'OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 327, 'PE'), ('CHEBI_71657', 'versiconol acetate', 444, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 444, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 725, 'OH)D'), ('UBERON_0001977', 'blood serum', 867, 'serum'), ('CHEBI_27300', 'vitamin D', 873, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 1043, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1043, '25(OH ... D'), ('CHEBI_72765', 'verruculogen', 1134, '25-OH D'), ('CHEBI_71657', 'versiconol acetate', 1343, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1434, 'vitamin D'), ('UBERON_0001977', 'blood serum', 1519, 'serum'), ('CHEBI_27300', 'vitamin D', 1525, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 1566, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1759, 'OH)D'), ('GO_0007565', 'female pregnancy', 1830, 'gestationOR'), ('CHEBI_71657', 'versiconol acetate', 1920, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2030, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2037, '25(OH)D'), ('CHEBI_982', '2-Aceto-2-hydroxybutanoate', 2091, '25 (OH)DAdjusted'), ('CHEBI_71657', 'versiconol acetate', 2303, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2303, '25(OH)D'), ('CHEBI_51383', 'hydridocarbon(3.)', 2393, 'PE'), ('CHEBI_71657', 'versiconol acetate', 2400, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 2534, '25(OH'), ('CHEBI_71657', 'versiconol acetate', 2619, '25(OH)D'), ('CHEBI_33010', 'chromide(1-)', 2635, '(OH)D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 2865, 'D'), ('GO_0007565', 'female pregnancy', 2904, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 2926, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 3159, '25(OH)D')]	0	['germany, 2–14 [85]↓ 25(oh)d levels pe summer controls, 1,25(oh)2d winter25(oh)d: pe:18.2\xa0±\xa017.1; control: 49.2\xa0±\xa029.2\xa0ng/ml, p \xa0<\xa00.001); 1,25(oh)2d: 291\xa0±\xa0217 612.3\xa0±\xa0455\xa0pmol/ml p \xa0<\xa00.05)mohaghegh et al., iran, 2015 [89]↓ 25(oh)d pe  pe25(oh)d:pe: 37.9\xa0±\xa033.9\xa0nmol/lcontrols: 58.2\xa0±\xa038.2\xa0nmol/l( p \xa0=\xa00.001)powe, usa, 2010 [86]↔ women pe 25(oh)d\xa0<\xa015.0\xa0nmol/ladjusted or: 1.3595% ci: 0.40 4.50robinson et al., usa, 2010 [25]↑ eospe women maternal 25(oh)d levels <=19.6\xa0nmol/l levels >19.6\xa0nmol/lor: 3.6095% ci: 1.71–7.58( p \xa0<\xa00.001)schneuer et al., australia, 2014 [114]↔ pe eospe 25(oh)d (< 25\xa0nmol/l)adjusted or- pe: 0.4695% ci: 0.19–1.10adjusted or- eospe: 1.4095% ci: 0.20 9.89singla et al., india, 2015 [87]↓ serum  women pe controlspe: 24.2\xa0±\xa012.4\xa0nmol/l controls: 36.9\xa0±\xa016.7\xa0nmol/l;( p \xa0=\xa00.0001)ullah et al., bangladesh, 2013 [82]↑ pe 25\xa0nmol/l decrease 25(oh)d leveladjusted or: 1.6695% ci: 1.05–3.02wetta et al., uk, 2013 [96]↔ pe 25-oh d\xa0<\xa030\xa0ng/ml <37.4\xa0nmol/l<30\xa0ng/ml adjusted or: 1.195% ci: 0.6–2.0adjusted or: 1.4 (<37.4\xa0nmol/l)95% ci: 0.7–3.0woodham et al., usa, 2011 [15]↓ pe women 10\xa0nmol/l increase maternal 25(oh)d leveladjusted or: 0.6295% ci: 0.51–0.76xu et al., usa, 2014 [53]↑ pe women  (<37.5\xa0nmol/l)or: 4.495% ci: 1.8–10.8yu et al., uk, 2012 [115]↔ serum  raw values pe controls25(oh)d levels: controls: 46.8\xa0nmol/l (27.8–70.0;)early pe: 32.2\xa0nmol/l (22.7–50.4); late pe: 39.2\xa0nmol/l (22.1–63.0) p \xa0=\xa00.231)alvarez-fernandez et al., spain, 2014 [90]↑ pe women 25(oh)d levels <50\xa0nmol/l levels >50\xa0nmol/l 20\xa0weeks : 4.695% ci:1.4–15( p \xa0=\xa00.010)scholl et al., usa, 2013 [78]↑ pe women 25(oh)d\xa0<\xa049.9\xa0nmol/l hyperparathyroidismadjusted or: 2.8695% ci: 1.28–6.41burris et al., usa, 2014 [94]↔ pe 25(oh)d levels 25\xa0nmol/l increase 25 (oh)dadjusted or: 1.1495% ci: 0.77–1.67haugen et al., norway, 2000 [77]↓ pe women 10–15 mcg/d supplementsadjusted or: 0.7395% ci: 0.58–0.92shand et al., canada, 2010 [37]↔ pe 25(oh)d levels <37.5\xa0nmol/ladjusted or: 0.9195% ci: 0.31–2.62wei et al., canda 2012 [60]↔ pe 25(oh)d\xa0<\xa050\xa0nmol/ladjusted or: 1.2495% ci: 0.58–2.67( p \xa0=\xa00.58)wei, canada, 2013 [14]↑ pe women pigf levels maternal 25(oh)d\xa0<\xa050\xa0nmol/ladjusted or: 2.9795% ci: 1.23–7.20zhou, china, 2014 [116]↔ pe 25(oh)d levels25(oh)d levelsgroup n \xa0=\xa013): 41.4\xa0±\xa06.5\xa0nmol/l; b n \xa0=\xa036): 62.1\xa0±\xa07.0\xa0nmol/l; c n \xa0=\xa025): 89.6\xa0±\xa013.0\xa0nmol/l; p \xa0=\xa00.900)\na case-cohort women 12 united (us) sites whose vitamin levels ≤26\xa0weeks  25(oh)d levels 50\xa0nmol/l 40% reduction pe (0.65 [95% ci 0.43 0.98]), reduction absolute relative milder subtypes pe 25(oh)d levels 50\xa0nmol/l [79].']
S135-PMC5513133	PMC5513133	7/2017	S135-PMC5513133	['another nested case control study of 225 women with singleton Pregnancies REPORTED an or of 5.41 for severe pe among women with mid-Gestation Vitamin D deficiency after controlling for multi-parity (95% ci: 2.02–14.52) compared to women with Vitamin D levels of at least 75\xa0nmol/l [80].']	[('INCOMPLETE_EVIDENCE', 74)]	1	[('GO_0007565', 'female pregnancy', 62, 'pregnancies'), ('GO_0007565', 'female pregnancy', 132, 'gestation'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D')]	0	['another 225 women singleton  5.41 pe among women mid-  controlling multi-parity (95% ci: 2.02–14.52) women  levels 75\xa0nmol/l [80].']
S142-PMC5513133	PMC5513133	7/2017	S142-PMC5513133	['a RECENT north indian case control STUDY of nulliparous women with pe and singleton Pregnancies REPORTED Serum Vitamin D to be significantly lower among pe cases vs. controls at the time of delivery (24.2 +/− 12.4\xa0nmol/l, 36.9 +/− 16.7\xa0nmol/l, respectively; p \xa0=\xa00.0001).']	[('INCOMPLETE_EVIDENCE', 2), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 96)]	3	[('GO_0007565', 'female pregnancy', 84, 'pregnancies'), ('UBERON_0001977', 'blood serum', 105, 'serum'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 119, 'D')]	0	['north indian nulliparous women pe singleton  serum  among pe cases vs. delivery (24.2 +/− 12.4\xa0nmol/l, 36.9 +/− 16.7\xa0nmol/l, respectively; p \xa0=\xa00.0001).']
S145-PMC5513133	PMC5513133	7/2017	S145-PMC5513133	['ALTHOUGH these STUDIES FIND an inverse ASSOCIATION between Vitamin D levels and pe, this ASSOCIATION MAY BE CONFOUNDED by the Gestational age at Serum collection.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 39), ('SUPERFICIAL_RELATIONSHIP', 89), ('INCOMPLETE_EVIDENCE', 101), ('DIFFICULT_TASK', 108)]	8	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 126, 'gestational'), ('UBERON_0001977', 'blood serum', 145, 'serum')]	0	['although  levels pe,  age serum collection.']
S165-PMC5513133	PMC5513133	7/2017	S165-PMC5513133	['there HAVE BEEN a SMALL NUMBER OF clinical trials studying ASSOCIATIONS between maternal Vitamin D and hypertensive disorders in Pregnancy (table4).']	[('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 18), ('SUPERFICIAL_RELATIONSHIP', 59)]	3	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]	0	['maternal  hypertensive disorders  (table4).']
S170-PMC5513133	PMC5513133	7/2017	S170-PMC5513133	['caption (table-wrap): table 4\n\nASSOCIATION of Vitamin D supplementation and Pregnancy-induced hypertension (pih) outcomes in clinical trialsauthor, location, yearstudy designsubjectsinterventionkey findingsresultsolsen and secher, denmark, 1990 [91]randomized controlled clinical trial5644 Pregnant women2500\xa0iu Vitamin D supplement versus no Supplement at week 20 of Pregnancy↓ pe31.5% reduction in the odds ( p \xa0<\xa00.005)olsen et al., europe, 2000 [98]randomized placebo controlled clinical trial386 women who previously experienced pih2.7\xa0g N-3 Fatty Acids/day given from 33\xa0weeks until Delivery vs Olive Oil placebo↔ pih recurrence riskor\xa0=\xa00.9895% ci: 0.63–1.53\n\nevidence that SUGGESTS no association between maternal Vitamin D deficiency and pe\nWHILE the PRECEDING STUDIES SUPPORT a LINK between Vitamin D deficiency during Pregnancy and risk of pe, SOME STUDIES present CONFLICTING EVIDENCE (tables2and3).']	[('SUPERFICIAL_RELATIONSHIP', 31), ('INCOMPLETE_EVIDENCE', 681), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 750), ('INCOMPLETE_EVIDENCE', 760), ('INCOMPLETE_EVIDENCE', 778), ('SUPERFICIAL_RELATIONSHIP', 788), ('INCOMPLETE_EVIDENCE', 855), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 876), ('INCOMPLETE_EVIDENCE', 888)]	9	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy'), ('GO_0007565', 'female pregnancy', 290, 'pregnant'), ('CHEBI_27300', 'vitamin D', 312, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 343, 'supplement'), ('GO_0007565', 'female pregnancy', 368, 'pregnancy'), ('GO_0007567', 'parturition', 377, '↓'), ('CHEBI_30256', 'thiocarbonyl group', 543, 'n-3'), ('CHEBI_35366', 'fatty acid', 547, 'fatty acids'), ('GO_0007567', 'parturition', 589, 'delivery'), ('CHEBI_50695', 'monobactam', 601, 'olive oil'), ('CHEBI_27300', 'vitamin D', 722, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 801, 'vitamin D'), ('GO_0007565', 'female pregnancy', 829, 'pregnancy')]	0	['caption (table-wrap): table 4\n\nassociation  supplementation -induced hypertension (pih) outcomes trialsauthor, location, yearstudy designsubjectsinterventionkey findingsresultsolsen secher, denmark, 1990 [91]randomized trial5644  women2500\xa0iu  supplement supplement week 20 pe31.5% reduction p \xa0<\xa00.005)olsen et al., europe, 2000 [98]randomized placebo trial386 women experienced pih2.7\xa0g n-3 fatty acids/day 33\xa0weeks delivery olive oil placebo↔ pih recurrence riskor\xa0=\xa00.9895% ci: 0.63–1.53\n\nevidence maternal  pe\nwhile preceding   pe, (tables2and3).']
S177-PMC5513133	PMC5513133	7/2017	S177-PMC5513133	['RETROSPECTIVELY ANALYZED Vitamin D status and the risk of pe in 697 nulliparous women with singleton Pregnancies in a randomized, placebo-controlled trial of vitamin c and e supplementation for the PREVENTION of pe.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 16), ('SUPERFICIAL_RELATIONSHIP', 198)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnancies')]	0	['retrospectively  status pe 697 nulliparous women singleton  randomized, placebo-controlled vitamin c e supplementation pe.']
S229-PMC5513133	PMC5513133	7/2017	S229-PMC5513133	['in a cochrane review of Vitamin D supplementation for women during Pregnancy, women who received Vitamin D and Calcium supplementation had a lower RISK of pre-eclampsia than those not receiving any intervention (rr 0.51; 95% ci 0.32 to 0.80; three trials, 1114 women, moderate quality), YET an increased risk for Preterm Birth (rr\xa0=\xa01.57; 95% ci: 1.02–2.43; three studies, 798 women, moderate quality).']	[('IMPORTANT_CONSIDERATION', 147), ('ANOMALY_CURIOUS_FINDING', 287)]	2	[('CHEBI_28384', 'vitamin K', 24, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 111, 'calcium'), ('GO_0007565', 'female pregnancy', 313, 'preterm birth')]	0	['cochrane vitamin supplementation women women received  calcium supplementation pre-eclampsia receiving (rr 0.51; 95% ci 0.32 0.80; three trials, 1114 women, quality),  (rr\xa0=\xa01.57; 95% ci: 1.02–2.43; three studies, 798 women, quality).']
S237-PMC5513133	PMC5513133	7/2017	S237-PMC5513133	['additionally, investigators SHOULD ATTEMPT to assess Preconception and early Pregnancy dietary intake, sun exposure or baseline Vitamin D status.']	[('FUTURE_WORK', 28), ('DIFFICULT_TASK', 35)]	2	[('GO_0007565', 'female pregnancy', 53, 'preconception'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]	0	['additionally,   dietary intake, sun exposure baseline  status.']
S238-PMC5513133	PMC5513133	7/2017	S238-PMC5513133	['studies that find a ROLE early in Pregnancy, before the clinical onset of pe, SUGGEST that Vitamin D MAY play a ROLE in the Modulation of a pro-inflammatory response or Regulation of Angiogenic factors.']	[('SUPERFICIAL_RELATIONSHIP', 20), ('INCOMPLETE_EVIDENCE', 78), ('INCOMPLETE_EVIDENCE', 101), ('SUPERFICIAL_RELATIONSHIP', 112)]	4	[('GO_0007565', 'female pregnancy', 34, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0065007', 'biological regulation', 124, 'modulation'), ('GO_0065007', 'biological regulation', 169, 'regulation'), ('GO_0001525', 'angiogenesis', 183, 'angiogenic')]	0	['studies onset pe,  play pro-inflammatory response angiogenic factors.']
S240-PMC5513133	PMC5513133	7/2017	S240-PMC5513133	['DESPITE EVIDENCE that low Vitamin D levels increase RISK for pe early in Pregnancy, VERY FEW STUDIES have tried TO RELATE this EFFECT with the Regulation Of Angiogenic or anti-Angiogenic factors.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 8), ('IMPORTANT_CONSIDERATION', 52), ('INCOMPLETE_EVIDENCE', 84), ('QUESTION_ANSWERED_BY_THIS_WORK', 112), ('SUPERFICIAL_RELATIONSHIP', 115), ('SUPERFICIAL_RELATIONSHIP', 127), ('SUPERFICIAL_RELATIONSHIP', 143)]	9	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('GO_0006110', 'regulation of glycolytic process', 143, 'regulation of angiogenic'), ('GO_0001525', 'angiogenesis', 176, 'angiogenic')]	0	['despite  levels increase pe angiogenic anti-angiogenic factors.']
S247-PMC5513133	PMC5513133	7/2017	S247-PMC5513133	['RECENTLY, participants in the Vitamin D for antenatal asthma (vdaart) randomized double-blind placebo controlled trial took a daily dose of 4000\xa0iu Vitamin D supplementation plus a multivitamin with 400\xa0iu Vitamin D or placebo (placebo pill plus a multi-Vitamin with 400\xa0iu Vitamin D daily) TO ASSESS the EFFECT of Vitamin D supplementation on the frequency of pe among Pregnant women with a high risk for atopic disease [110].']	[('INCOMPLETE_EVIDENCE', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 291), ('SUPERFICIAL_RELATIONSHIP', 305)]	3	[('CHEBI_28384', 'vitamin K', 30, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 206, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 254, 'vitamin'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 315, 'vitamin D'), ('GO_0007565', 'female pregnancy', 370, 'pregnant')]	0	['recently, participants vitamin antenatal asthma (vdaart) double-blind placebo took daily dose 4000\xa0iu  supplementation plus multivitamin 400\xa0iu  placebo (placebo pill plus multi-vitamin 400\xa0iu  daily)  supplementation frequency pe among  women atopic disease [110].']
S253-PMC5513133	PMC5513133	7/2017	S253-PMC5513133	['HOWEVER, women with a Serum Vitamin D status of ≥75\xa0nmol/l that was maintained from enrollment through late Pregnancy had a significantly lower RISK of pe versus women who had <75\xa0nmol/l ( p \xa0=\xa00.04).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 144)]	3	[('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'pregnancy')]	0	['however, women serum  status ≥75\xa0nmol/l enrollment late  pe women <75\xa0nmol/l p \xa0=\xa00.04).']
S254-PMC5513133	PMC5513133	7/2017	S254-PMC5513133	['BUT this Vitamin D level was maintained in ONLY 74% of Pregnancies in the supplementation group by weeks 32 to 38 of Gestation, SUGGESTING that supplementation at EVEN earlier time-points or before Pregnancy MAY BE NECESSARY to maintain sufficient Vitamin D levels that are PROTECTIVE against pe.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 43), ('INCOMPLETE_EVIDENCE', 128), ('ANOMALY_CURIOUS_FINDING', 163), ('INCOMPLETE_EVIDENCE', 208), ('IMPORTANT_CONSIDERATION', 215), ('SUPERFICIAL_RELATIONSHIP', 274)]	8	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 55, 'pregnancies'), ('GO_0007565', 'female pregnancy', 117, 'gestation'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D')]	0	[' 74%  supplementation weeks 32 38 supplementation time-points  maintain  levels pe.']
S263-PMC5513133	PMC5513133	7/2017	S263-PMC5513133	['[25] SUGGEST that Vitamin D deficiency MAY BE a FACTOR in the DISPROPORTIONATE incidence of adverse Pregnancy outcomes in african american women since this group had the lowest Vitamin D levels among the populations they studied.']	[('INCOMPLETE_EVIDENCE', 5), ('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 48), ('ANOMALY_CURIOUS_FINDING', 62)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin D')]	0	['[25]   outcomes african american women lowest  levels among populations studied.']
S267-PMC5513133	PMC5513133	7/2017	S267-PMC5513133	['results from Vitamin D supplementation during Pregnancy did not show a statistically significant independent EFFECT of Vitamin D on the RISK of pe and pih.']	[('SUPERFICIAL_RELATIONSHIP', 109), ('IMPORTANT_CONSIDERATION', 136)]	2	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]	0	['results  supplementation  statistically  pe pih.']
S267-PMC5521778	PMC5521778	7/2017	S267-PMC5521778	['discussion\nlocal Synthesis Of Vitamin A Isomers From Β-Carotene MAY BE required for certain physiological Processes, especially when Vitamin A is insufficient.']	[('INCOMPLETE_EVIDENCE', 64)]	1	[('GO_0019539', 'hydroxymate-containing siderophore biosynthetic process', 17, 'synthesis of vitamin A ... from ... -carotene'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin A'), ('SO_0001060', 'sequence_variant', 40, 'isomers'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 53, 'β-carotene'), ('GO_0007565', 'female pregnancy', 106, 'processes'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin A')]	0	['discussion\nlocal synthesis  isomers β-carotene physiological  insufficient.']
S97-PMC5523023	PMC5523023	7/2017	S97-PMC5523023	['Prenatal supplementation of Vitamin C and E improved Pulmonary functions of newborns of smoking mothers (59), BUT in a large placebo-controlled study, this EFFECT was not confirmed (60).']	[('ANOMALY_CURIOUS_FINDING', 110), ('SUPERFICIAL_RELATIONSHIP', 156)]	2	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 42, 'E'), ('UBERON_0002048', 'lung', 53, 'pulmonary')]	0	[' supplementation  e pulmonary functions newborns smoking mothers (59), placebo-controlled study, (60).']
S0-PMC5524288	PMC5524288	7/2017	S0-PMC5524288	['maternal 25(Oh)D concentrations ≥40 ng/ml ASSOCIATED with 60% lower Preterm Birth RISK among general obstetrical patients at an urban medical center\n\nabstract\n\nbackground\nGIVEN the HIGH RATE of Preterm Birth (ptb) nationwide and data from rcts DEMONSTRATING risk reduction with Vitamin D supplementation, the medical university of south carolina (musc) implemented a NEW standard of care for Pregnant women to receive Vitamin D testing and supplementation.']	[('SUPERFICIAL_RELATIONSHIP', 42), ('IMPORTANT_CONSIDERATION', 82), ('INCOMPLETE_EVIDENCE', 171), ('IMPORTANT_CONSIDERATION', 181), ('INCOMPLETE_EVIDENCE', 244), ('FULL_UNKNOWN', 367)]	6	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 68, 'preterm birth'), ('GO_0007565', 'female pregnancy', 194, 'preterm birth'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('GO_0007565', 'female pregnancy', 392, 'pregnant'), ('CHEBI_27300', 'vitamin D', 418, 'vitamin D')]	0	['maternal 25(oh)d concentrations ≥40 ng/ml 60%  among obstetrical patients urban medical center\n\nabstract\n\nbackground\ngiven rate  (ptb) nationwide rcts reduction  supplementation, medical university south carolina (musc) implemented  women receive  testing supplementation.']
S21-PMC5524288	PMC5524288	7/2017	S21-PMC5524288	['in those clinical trials, 4000 iu/day of Vitamin D was FOUND to SAFELY achieve a concentration of at least 32 ng/ml by early in the second Trimester in a diverse group of Pregnant women [13–15].']	[('INCOMPLETE_EVIDENCE', 55), ('IMPORTANT_CONSIDERATION', 64)]	2	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 139, 'trimester'), ('GO_0007565', 'female pregnancy', 171, 'pregnant')]	0	['trials, 4000 iu/day  achieve concentration 32 ng/ml trimester  women [13–15].']
S24-PMC5524288	PMC5524288	7/2017	S24-PMC5524288	['trials, the medical university of south carolina (musc) INITIATED a NEW standard of care for Pregnant women that included routine Vitamin D testing and supplementation in september 2015.']	[('INCOMPLETE_EVIDENCE', 56), ('FULL_UNKNOWN', 68)]	2	[('GO_0007565', 'female pregnancy', 93, 'pregnant'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]	0	['trials, medical university south carolina (musc)  women routine  testing supplementation september 2015.']
S39-PMC5524288	PMC5524288	7/2017	S39-PMC5524288	['for this analysis, women Pregnant with multiples and those participating in Vitamin D clinical trials at musc were EXCLUDED.']	[('INCOMPLETE_EVIDENCE', 115)]	1	[('GO_0007565', 'female pregnancy', 25, 'pregnant'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]	0	['analysis, women  multiples participating  musc excluded.']
S112-PMC5524288	PMC5524288	7/2017	S112-PMC5524288	['IMPROVING the Vitamin D status of women with underlying conditions MAY AVERT the need for a medically indicated Preterm Delivery.']	[('FUTURE_WORK', 0), ('FUTURE_PREDICTION', 67), ('SUPERFICIAL_RELATIONSHIP', 71)]	3	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'preterm'), ('GO_0007567', 'parturition', 120, 'delivery')]	0	['improving  status women conditions medically  delivery.']
S118-PMC5524288	PMC5524288	7/2017	S118-PMC5524288	['among women with initial 25(Oh)D concentrations <40 ng/ml, the significantly lower ptb rate (60%) for those who achieved ≥40 ng/ml COMPARED TO those who did not reach the target concentration on a follow-up test SUGGESTS that maternal Vitamin D status is a MODIFIABLE RISK FACTOR that CAN be addressed during the Prenatal period.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 131), ('INCOMPLETE_EVIDENCE', 212), ('IMPORTANT_CONSIDERATION', 257), ('SUPERFICIAL_RELATIONSHIP', 268), ('INCOMPLETE_EVIDENCE', 285)]	5	[('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 25, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D'), ('GO_0007565', 'female pregnancy', 313, 'prenatal')]	0	['among women 25(oh)d concentrations <40 ng/ml, ptb rate (60%) achieved ≥40 ng/ml concentration follow-up maternal  status  period.']
S127-PMC5524288	PMC5524288	7/2017	S127-PMC5524288	['a LIMITATION of THIS STUDY was that nearly two-thirds of the women (63%) had ONLY one 25(Oh)D test during Pregnancy, which PROHIBITED assessment by Trimester and a more thorough analysis of Vitamin D BENEFIT among those with low initial levels.']	[('INCOMPLETE_EVIDENCE', 2), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('INCOMPLETE_EVIDENCE', 77), ('DIFFICULT_TASK', 123), ('IMPORTANT_CONSIDERATION', 200)]	5	[('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 86, '25(OH)D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 148, 'trimester'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]	0	['two-thirds women (63%) 25(oh)d trimester thorough  among levels.']
S1-PMC5537904	PMC5537904	7/2017	S1-PMC5537904	['we EXAMINED ASSOCIATIONS between Prenatal Vitamin D intake, 25-Hydroxyvitamin D (25(Oh)D) in Cord Blood, and offspring size and body composition at Birth and 5 months.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('SUPERFICIAL_RELATIONSHIP', 12)]	2	[('GO_0007565', 'female pregnancy', 33, 'prenatal'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 60, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 93, 'cord'), ('UBERON_0000178', 'blood', 98, 'blood'), ('GO_0007567', 'parturition', 148, 'birth')]	0	['  intake, 25-hydroxyvitamin (25(oh)d) cord blood, offspring composition birth 5 months.']
S5-PMC5537904	PMC5537904	7/2017	S5-PMC5537904	['non-hispanic white race, lower Pre-Pregnancy bmi, higher Prenatal Vitamin D intake, and summer Births were ASSOCIATED with higher Cord Blood 25(Oh)D. higher 25(Oh)D was ASSOCIATED with lower Birthweight ( β = –6.22, p = 0.02), but as maternal bmi increased, this ASSOCIATION became increasingly positive in direction and magnitude ( β = 1.05, p = 0.04).']	[('SUPERFICIAL_RELATIONSHIP', 107), ('SUPERFICIAL_RELATIONSHIP', 169), ('SUPERFICIAL_RELATIONSHIP', 263)]	3	[('GO_0007568', 'aging', 31, 'pre'), ('GO_0007565', 'female pregnancy', 35, 'pregnancy'), ('GO_0007565', 'female pregnancy', 57, 'prenatal'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007567', 'parturition', 95, 'births'), ('UBERON_0002240', 'spinal cord', 130, 'cord'), ('UBERON_0000178', 'blood', 135, 'blood'), ('CHEBI_63056', 'zinc cation', 141, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 147, 'D'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 157, '25(OH ... D'), ('GO_0007596', 'blood coagulation', 191, 'birthweight')]	0	['non-hispanic white race, pre- bmi, higher   intake, summer births higher cord blood 25(oh)d. higher 25(oh)d birthweight β = –6.22, p = 0.02), maternal bmi increased, became positive magnitude β = 1.05, p = 0.04).']
S12-PMC5537904	PMC5537904	7/2017	S12-PMC5537904	['APPROXIMATELY 33% of Pregnant women in the united states have Vitamin D deficiency, defined as 25-Hydroxyvitamin D (25Ohd) < 50 nmol/l, EVEN THOUGH 73% report using Vitamin D-containing Prenatal supplements [2].']	[('INCOMPLETE_EVIDENCE', 0), ('ANOMALY_CURIOUS_FINDING', 136)]	2	[('GO_0007565', 'female pregnancy', 21, 'pregnant'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 95, '25-hydroxyvitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 116, '25OHD'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 186, 'prenatal')]	0	['approximately 33%  women united  deficiency, 25-hydroxyvitamin (25ohd) 50 nmol/l, 73% using -containing  supplements [2].']
S14-PMC5537904	PMC5537904	7/2017	S14-PMC5537904	['Prenatal Vitamin D deficiency HAS BEEN ASSOCIATED with pre-term Birth [4,5], low birthweight [5,6], and small for Gestational age offspring [5,6,7], WHILE Prenatal Vitamin D supplementation HAS BEEN SHOWN to increase offspring Birth weight and length [8].']	[('INCOMPLETE_EVIDENCE', 30), ('SUPERFICIAL_RELATIONSHIP', 39), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 149), ('INCOMPLETE_EVIDENCE', 190)]	4	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 64, 'birth'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('GO_0007565', 'female pregnancy', 155, 'prenatal'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('GO_0007567', 'parturition', 227, 'birth')]	0	['  pre-term birth [4,5], birthweight [5,6],  age offspring [5,6,7],   supplementation increase offspring birth length [8].']
S15-PMC5537904	PMC5537904	7/2017	S15-PMC5537904	['Prenatal Vitamin D exposure MAY also INFLUENCE offspring adiposity through reduced availability of the biologically active vitamin d metabolite, 1Α, 25-Dihydroxyvitamin D, which inhibits Parathyroid hormone and Intracellular calcium, thereby AFFECTING Lipogenesis and Lipolysis [9,10,11,12,13].']	[('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 37), ('SUPERFICIAL_RELATIONSHIP', 242)]	3	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_67472', '15-epi-lupulin B', 145, '1α, 25-dihydroxyvitamin D'), ('UBERON_0001132', 'parathyroid gland', 187, 'parathyroid'), ('GO_0005622', 'intracellular anatomical structure', 211, 'intracellular'), ('GO_0008610', 'lipid biosynthetic process', 252, 'lipogenesis'), ('GO_0016042', 'lipid catabolic process', 268, 'lipolysis')]	0	['  exposure offspring adiposity availability biologically vitamin metabolite, 1α, 25-dihydroxyvitamin d, inhibits parathyroid hormone intracellular calcium, lipogenesis lipolysis [9,10,11,12,13].']
S16-PMC5537904	PMC5537904	7/2017	S16-PMC5537904	['current Human EVIDENCE SUPPORTING the ASSOCIATION between Prenatal Vitamin D intake, neonatal Vitamin D status, and offspring adiposity is MIXED.']	[('INCOMPLETE_EVIDENCE', 14), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 38), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 139)]	4	[('NCBITaxon_9606', 'Homo sapiens', 8, 'human'), ('GO_0007565', 'female pregnancy', 58, 'prenatal'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]	0	['current human   intake, neonatal  status, offspring adiposity mixed.']
S17-PMC5537904	PMC5537904	7/2017	S17-PMC5537904	['WHILE NUMEROUS STUDIES HAVE REPORTED that higher maternal Vitamin D intake (from Food and/or dietary supplements) is ASSOCIATED with increased Prenatal and/or cord Blood 25(Oh)D levels [14,15,16,17], it is NOT CLEAR WHETHER this TRANSLATES TO an EFFECT on neonatal adiposity.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 6), ('INCOMPLETE_EVIDENCE', 23), ('SUPERFICIAL_RELATIONSHIP', 117), ('FULL_UNKNOWN', 206), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 216), ('SUPERFICIAL_RELATIONSHIP', 229), ('SUPERFICIAL_RELATIONSHIP', 246)]	8	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_33290', 'food', 81, 'food'), ('GO_0007565', 'female pregnancy', 143, 'prenatal'), ('UBERON_0000178', 'blood', 164, 'blood'), ('CHEBI_71657', 'versiconol acetate', 170, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 176, 'D')]	0	['higher maternal  intake (from food and/or dietary supplements)  and/or cord blood 25(oh)d levels [14,15,16,17], neonatal adiposity.']
S21-PMC5537904	PMC5537904	7/2017	S21-PMC5537904	['PRIOR STUDIES VARY strongly in methodology, PARTICULARLY in regard to assessment of Prenatal Vitamin D intake, timing and source of 25(Oh)D measurements, a method for assessing neonatal adiposity, and CONSIDERATION of OTHER contributing factors such as maternal obesity.']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 14), ('IMPORTANT_CONSIDERATION', 44), ('FUTURE_WORK', 201), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 218)]	5	[('GO_0007565', 'female pregnancy', 84, 'prenatal'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 138, 'D')]	0	['prior methodology, regard   intake, timing 25(oh)d measurements, neonatal adiposity, maternal obesity.']
S23-PMC5537904	PMC5537904	7/2017	S23-PMC5537904	['in addition, FEW STUDIES EXAMINED WHETHER Gestational weight gain OR body mass index (bmi) modify the ASSOCIATIONS between Prenatal Vitamin D intake, neonatal Vitamin D status, and offspring adiposity.']	[('INCOMPLETE_EVIDENCE', 13), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 34), ('SUPERFICIAL_RELATIONSHIP', 102)]	4	[('GO_0007565', 'female pregnancy', 42, 'gestational'), ('GO_0007565', 'female pregnancy', 123, 'prenatal'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]	0	['addition,  gain mass (bmi)   intake, neonatal  status, offspring adiposity.']
S25-PMC5537904	PMC5537904	7/2017	S25-PMC5537904	['THUS, the PURPOSE of THIS analysis was TO EXAMINE the ASSOCIATIONS between Prenatal Vitamin D intake, neonatal Vitamin D status, and early Life body composition.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 21), ('QUESTION_ANSWERED_BY_THIS_WORK', 39), ('SUPERFICIAL_RELATIONSHIP', 54)]	5	[('GO_0007565', 'female pregnancy', 75, 'prenatal'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('UBERON_0000104', 'life cycle', 139, 'life')]	0	['thus,   intake, neonatal  status, life composition.']
S51-PMC5537904	PMC5537904	7/2017	S51-PMC5537904	['using this MODEL, we ESTIMATED usual daily Intake of Vitamin D from Food sources during Pregnancy (iu/day).']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 21)]	2	[('GO_0007631', 'feeding behavior', 43, 'intake'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_33290', 'food', 68, 'food'), ('GO_0007565', 'female pregnancy', 88, 'pregnancy')]	0	['using model, usual daily intake  food sources  (iu/day).']
S55-PMC5537904	PMC5537904	7/2017	S55-PMC5537904	['dose) for each Supplement, and used manufacturer data on Nutrient composition to ESTIMATE average daily dose of Vitamin D from dietary supplements (iu/day) during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 81)]	1	[('CHEBI_16158', 'steroid sulfate', 15, 'supplement'), ('CHEBI_33284', 'nutrient', 57, 'nutrient'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy')]	0	['dose) supplement, manufacturer nutrient composition average daily dose  dietary supplements (iu/day) .']
S102-PMC5537904	PMC5537904	7/2017	S102-PMC5537904	['the FIRST analysis evaluated the ASSOCIATION of maternal oral Intake of Vitamin D during Pregnancy with Cord Blood 25(Oh)D. this model was adjusted for season of Birth, maternal age, pre-Pregnancy bmi, race/ethnicity, household income, gwg, and Gestational age at Birth and considered the following interaction terms: Vitamin D intake × bmi, Vitamin D intake × gwg, Vitamin D intake × race/ethnicity, season × bmi, season × gwg, and season × race/ethnicity.']	[('INCOMPLETE_EVIDENCE', 4), ('SUPERFICIAL_RELATIONSHIP', 33)]	2	[('GO_0007631', 'feeding behavior', 62, 'intake'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 104, 'cord'), ('UBERON_0000178', 'blood', 109, 'blood'), ('CHEBI_71657', 'versiconol acetate', 115, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 115, '25(OH ... D'), ('GO_0007567', 'parturition', 162, 'birth'), ('GO_0007565', 'female pregnancy', 187, 'pregnancy'), ('GO_0007565', 'female pregnancy', 245, 'gestational'), ('GO_0007567', 'parturition', 264, 'birth'), ('CHEBI_27300', 'vitamin D', 318, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 342, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 366, 'vitamin D')]	0	['maternal oral intake   cord blood 25(oh)d. adjusted season birth, maternal age, pre- bmi, race/ethnicity, household income, gwg,  age birth following terms:  intake × bmi,  intake × gwg,  intake × race/ethnicity, season × bmi, season × gwg, season × race/ethnicity.']
S143-PMC5537904	PMC5537904	7/2017	S143-PMC5537904	['AS EXPECTED, 25(Oh)D at Birth was PREDICTED by both modifiable (maternal bmi, Prenatal Vitamin D intake) and non-modifiable (race/ethnicity, season of Birth) FACTORS.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 34), ('SUPERFICIAL_RELATIONSHIP', 158)]	3	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 19, 'D'), ('GO_0007567', 'parturition', 24, 'birth'), ('GO_0007565', 'female pregnancy', 78, 'prenatal'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007567', 'parturition', 151, 'birth')]	0	['expected, 25(oh)d birth (maternal bmi,   intake) non-modifiable (race/ethnicity, season birth) factors.']
S144-PMC5537904	PMC5537904	7/2017	S144-PMC5537904	['randomized clinical trials HAVE SHOWN that Prenatal Vitamin D supplementation increases both maternal 25(Oh)D and offspring birthweight [8].']	[('INCOMPLETE_EVIDENCE', 27)]	1	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 105, 'OH ... D')]	0	['randomized   supplementation maternal 25(oh)d offspring birthweight [8].']
S166-PMC5537904	PMC5537904	7/2017	S166-PMC5537904	['these data are IN AGREEMENT with results of Prenatal Vitamin D supplementation trials, which REPORTED that EVEN with supplementation, women with non-white race/ethnicity, higher pre-Pregnancy bmis, and winter Deliveries had lower 25(Oh)D levels in Pregnancy [15,61].']	[('INCOMPLETE_EVIDENCE', 15), ('INCOMPLETE_EVIDENCE', 93), ('ANOMALY_CURIOUS_FINDING', 107)]	3	[('GO_0007565', 'female pregnancy', 44, 'prenatal'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('GO_0007567', 'parturition', 209, 'deliveries'), ('CHEBI_71657', 'versiconol acetate', 230, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 230, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy')]	0	['results   supplementation trials, supplementation, women non-white race/ethnicity, higher pre- bmis, winter deliveries 25(oh)d levels  [15,61].']
S173-PMC5537904	PMC5537904	7/2017	S173-PMC5537904	['continued RESEARCH into the IMPLICATIONS of Cord Blood 25(Oh)D status IS NEEDED to guide RECOMMENDATIONS for Prenatal Vitamin D intake.']	[('FUTURE_WORK', 10), ('IMPORTANT_CONSIDERATION', 28), ('FUTURE_WORK', 70), ('FUTURE_WORK', 89)]	4	[('UBERON_0002240', 'spinal cord', 44, 'cord'), ('UBERON_0000178', 'blood', 49, 'blood'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('GO_0007565', 'female pregnancy', 109, 'prenatal'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]	0	['continued cord blood 25(oh)d status   intake.']
S179-PMC5537904	PMC5537904	7/2017	S179-PMC5537904	['we were ONLY able to use crude ESTIMATES of offspring Intake of Vitamin D Postnatally from formula or infant supplements, which MAY have prevented us from detecting ASSOCIATIONS between 25(Oh)D at Birth and 5-month body composition that varied by Postnatal Vitamin D intake.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 31), ('INCOMPLETE_EVIDENCE', 128), ('SUPERFICIAL_RELATIONSHIP', 165)]	4	[('GO_0007631', 'feeding behavior', 54, 'intake'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'postnatally'), ('CHEBI_71657', 'versiconol acetate', 186, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 192, 'D'), ('GO_0007567', 'parturition', 197, 'birth'), ('GO_0007567', 'parturition', 247, 'postnatal'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin D')]	0	['able offspring intake   formula infant supplements, us 25(oh)d birth 5-month composition postnatal  intake.']
S181-PMC5537904	PMC5537904	7/2017	S181-PMC5537904	['the ethnically-diverse cohort, validated measures of 25(Oh)D and body composition, and detailed data on maternal Vitamin D intake during Pregnancy are all STRENGTHS of our study.']	[('IMPORTANT_CONSIDERATION', 155)]	1	[('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 53, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy')]	0	['ethnically-diverse cohort, 25(oh)d composition, maternal  intake  study.']
S0-PMC5539754	PMC5539754	8/2017	S0-PMC5539754	['season and Vitamin D status are INDEPENDENTLY ASSOCIATED with Glucose Homeostasis in Pregnancy\n\nabstract\n\nbackground\nVitamin D status and season are intrinsically LINKED, and both have been PROPOSED to be ASSOCIATED with Glucose Homeostasis in Pregnancy, with CONFLICTING results.']	[('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 46), ('SUPERFICIAL_RELATIONSHIP', 163), ('INCOMPLETE_EVIDENCE', 190), ('SUPERFICIAL_RELATIONSHIP', 205), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 260)]	6	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_17234', 'glucose', 62, 'glucose'), ('GO_0042593', 'glucose homeostasis', 62, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 117, 'Vitamin D'), ('CHEBI_17234', 'glucose', 221, 'glucose'), ('GO_0042593', 'glucose homeostasis', 221, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 244, 'pregnancy')]	0	['season  status glucose homeostasis \n\nabstract\n\nbackground\nvitamin status season intrinsically linked, glucose homeostasis results.']
S17-PMC5539754	PMC5539754	8/2017	S17-PMC5539754	['in Pregnancy, the ASSOCIATION between low Vitamin D levels and abnormalities in Glucose tolerance is the subject of scientific DEBATE, with SOME STUDIES reporting that maternal Insulin sensitivity, fasting Glucose and Gestational diabetes are not associated with 25ohd [7], WHILE others have FOUND inverse ASSOCIATIONS between 25ohd, fasting Glucose [8] and risk of Gestational diabetes [9].']	[('SUPERFICIAL_RELATIONSHIP', 18), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 127), ('INCOMPLETE_EVIDENCE', 140), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 274), ('INCOMPLETE_EVIDENCE', 292), ('SUPERFICIAL_RELATIONSHIP', 306)]	6	[('GO_0007565', 'female pregnancy', 3, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_17234', 'glucose', 80, 'glucose'), ('PR_000045358', 'insulin family protein', 177, 'insulin'), ('CHEBI_17234', 'glucose', 206, 'glucose'), ('GO_0007565', 'female pregnancy', 218, 'gestational'), ('CHEBI_17234', 'glucose', 342, 'glucose'), ('GO_0007565', 'female pregnancy', 366, 'gestational')]	0	[' levels abnormalities glucose tolerance subject scientific debate, maternal insulin sensitivity, fasting glucose  diabetes 25ohd [7], 25ohd, fasting glucose [8]  diabetes [9].']
S18-PMC5539754	PMC5539754	8/2017	S18-PMC5539754	['HOWEVER, the MAJORITY of Vitamin D supplementation intervention trials in Pregnancy have not had a SIGNIFICANT IMPACT on maternal and offspring health [10].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 13), ('IMPORTANT_CONSIDERATION', 99)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy')]	0	['however,  supplementation  maternal offspring [10].']
S104-PMC5539754	PMC5539754	8/2017	S104-PMC5539754	['additionally, those at risk of Vitamin D deficiency in early Pregnancy are more LIKELY to have increased fasting Glucose in late Pregnancy, INDEPENDENT of season.']	[('PROBABLE_UNDERSTANDING', 80), ('SUPERFICIAL_RELATIONSHIP', 140)]	2	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('CHEBI_17234', 'glucose', 113, 'glucose'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]	0	['additionally,   fasting glucose late season.']
S105-PMC5539754	PMC5539754	8/2017	S105-PMC5539754	['GIVEN that the ASSOCIATION between early Gestation through extended winter and Insulin resistance is INDEPENDENT of Serum 25Ohd <30\xa0nmol/l, our NOVEL FINDINGS IMPLY that seasonal variation in Insulin resistance MAY NOT be fully EXPLAINED by differences in Vitamin D status.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 15), ('SUPERFICIAL_RELATIONSHIP', 101), ('INCOMPLETE_EVIDENCE', 144), ('PROBABLE_UNDERSTANDING', 159), ('INCOMPLETE_EVIDENCE', 211), ('PROBABLE_UNDERSTANDING', 228)]	7	[('GO_0007565', 'female pregnancy', 41, 'gestation'), ('PR_000045358', 'insulin family protein', 79, 'insulin'), ('UBERON_0001977', 'blood serum', 116, 'serum'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 122, '25OHD'), ('PR_000045358', 'insulin family protein', 192, 'insulin'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D')]	0	['given  winter insulin resistance serum 25ohd <30\xa0nmol/l, seasonal insulin resistance  status.']
S152-PMC5539754	PMC5539754	8/2017	S152-PMC5539754	['HOWEVER, UNLIKE the Hapo trial, we FOUND increased fasting Plasma Glucose in late Pregnancy among those at risk of Vitamin D deficiency.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('INCOMPLETE_EVIDENCE', 35)]	3	[('CHEBI_17883', 'hydrogen chloride', 20, 'HAPO'), ('UBERON_0001969', 'blood plasma', 59, 'plasma'), ('CHEBI_17234', 'glucose', 66, 'glucose'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]	0	['however, hapo trial, fasting plasma glucose late  among  deficiency.']
S153-PMC5539754	PMC5539754	8/2017	S153-PMC5539754	['a recent meta-analysis of OBSERVATIONAL studies REPORTED that Vitamin D\xa0<\xa050\xa0nmol/l was ASSOCIATED with an INCREASED RISK (or\xa0=\xa01.53) of developing Gestational diabetes [9].']	[('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 88), ('IMPORTANT_CONSIDERATION', 107)]	4	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'gestational')]	0	['meta-analysis \xa0<\xa050\xa0nmol/l (or\xa0=\xa01.53)  diabetes [9].']
S154-PMC5539754	PMC5539754	8/2017	S154-PMC5539754	['many women who Gestate through a typical winter in the northern hemisphere are AT RISK of Vitamin D deficiency [4,5].']	[('IMPORTANT_CONSIDERATION', 79)]	1	[('GO_0007565', 'female pregnancy', 15, 'gestate'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]	0	['many women  typical winter northern hemisphere  [4,5].']
S155-PMC5539754	PMC5539754	8/2017	S155-PMC5539754	['POOR Vitamin D intakes HAVE BEEN REPORTED among Pregnant women living in ireland [5].']	[('IMPORTANT_CONSIDERATION', 0), ('INCOMPLETE_EVIDENCE', 23)]	2	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'pregnant')]	0	['poor  intakes among  women living ireland [5].']
S156-PMC5539754	PMC5539754	8/2017	S156-PMC5539754	['in the clinical setting, Pregnant women SHOULD receive advice about Vitamin D, especially during winter.']	[('FUTURE_WORK', 40)]	1	[('GO_0007565', 'female pregnancy', 25, 'pregnant'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]	0	['setting,  women receive winter.']
S157-PMC5539754	PMC5539754	8/2017	S157-PMC5539754	['winter-time supplementation of 1000\xa0iu/day Vitamin D is an EFFECTIVE STRATEGY to improve 25Ohd in Pregnancy [45].']	[('PROBABLE_UNDERSTANDING', 59)]	1	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 89, '25OHD'), ('GO_0007565', 'female pregnancy', 98, 'pregnancy')]	0	['winter-time supplementation 1000\xa0iu/day  25ohd  [45].']
S158-PMC5539754	PMC5539754	8/2017	S158-PMC5539754	['at present, there REMAINS a LACK OF CONSENSUS regarding RECOMMENDATIONS for uvb exposure for the Production Of Vitamin D for Pregnant Women [46].']	[('INCOMPLETE_EVIDENCE', 18), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 28), ('FUTURE_WORK', 56)]	3	[('GO_0018240', 'protein S-linked glycosylation via cysteine', 97, 'production of vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnant women')]	0	['present, regarding uvb exposure production   [46].']
S159-PMC5539754	PMC5539754	8/2017	S159-PMC5539754	['OUR FINDINGS SUGGEST that women at risk of Vitamin D deficiency in early Pregnancy have altered Glucose Metabolism in later Gestation, BUT the evidence is NOT CONSISTENT for Insulin resistance.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 13), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 135), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 155)]	4	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy'), ('CHEBI_17234', 'glucose', 96, 'glucose'), ('GO_0006006', 'glucose metabolic process', 96, 'glucose metabolism'), ('GO_0007565', 'female pregnancy', 124, 'gestation'), ('PR_000045358', 'insulin family protein', 174, 'insulin')]	0	['women   altered glucose metabolism insulin resistance.']
S160-PMC5539754	PMC5539754	8/2017	S160-PMC5539754	['thus, RECOMMENDATIONS for Vitamin D supplementation to improve Glucose Homeostasis in Pregnancy CANNOT BE made BASED ON our results.']	[('FUTURE_WORK', 6), ('INCOMPLETE_EVIDENCE', 96), ('PROBABLE_UNDERSTANDING', 111)]	3	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_17234', 'glucose', 63, 'glucose'), ('GO_0042593', 'glucose homeostasis', 63, 'glucose homeostasis'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy')]	0	['thus,  supplementation glucose homeostasis  results.']
S175-PMC5539754	PMC5539754	8/2017	S175-PMC5539754	['participants at risk of Vitamin D deficiency at their first Antenatal visit were LIKELY to have increased fasting Glucose at 28\xa0weeks’ Gestation, REGARDLESS OF season.']	[('PROBABLE_UNDERSTANDING', 81), ('INCOMPLETE_EVIDENCE', 146)]	2	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007567', 'parturition', 60, 'antenatal'), ('CHEBI_17234', 'glucose', 114, 'glucose'), ('GO_0007565', 'female pregnancy', 135, 'gestation')]	0	['participants  antenatal visit fasting glucose 28\xa0weeks’ season.']
S49-PMC5540678	PMC5540678	7/2017	S49-PMC5540678	['IN ORDER TO ASSESS CONFOUNDING arising from OTHER dimensions of diet, we additionally adjusted separately for maternal Intake of Vitamin E, zinc, Selenium, n -3 Polyunsaturated Fatty Acids (Pufas), N -6 Pufas, and total fruits and vegetables in Pregnancy [1,29–31].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 9), ('PROBLEM_COMPLICATION', 19), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 44)]	4	[('GO_0007631', 'feeding behavior', 119, 'intake'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 146, 'selenium'), ('CHEBI_26203', 'polyprenol triphosphate', 161, 'polyunsaturated'), ('CHEBI_35366', 'fatty acid', 177, 'fatty acids'), ('CHEBI_86926', 'S a S b S', 190, 'PUFAs'), ('CHEBI_73643', 'Phe-Phe-Asp', 198, 'n -6 PUFAs'), ('GO_0007565', 'female pregnancy', 245, 'pregnancy')]	0	['arising dimensions diet, adjusted separately maternal intake zinc, selenium, n -3 polyunsaturated fatty acids (pufas), n -6 pufas, fruits vegetables  [1,29–31].']
S73-PMC5540678	PMC5540678	7/2017	S73-PMC5540678	"['[""""additional separate adjustment for maternal Intake of Vitamin E, zinc, selenium, n-3 Pufas, n-6 Pufas, and total fruits and vegetables in Pregnancy DID NOT substantially alter the main findings (data not shown), nor did additional separate adjustment for child\'s free Sugar intake at age 3\\u2005years (supplementary table e3).""""]']"	[('INCOMPLETE_EVIDENCE', 148)]	1	[('GO_0007631', 'feeding behavior', 44, 'intake'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin E'), ('CHEBI_86926', 'S a S b S', 85, 'PUFAs'), ('CHEBI_86926', 'S a S b S', 96, 'PUFAs'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy'), ('CHEBI_24870', 'ion', 268, 'sugar')]	0	"['[""""additional separate adjustment maternal intake n e, zinc, selenium, n-3 pufas, n-6 pufas, fruits vegetables ncy alter main (data shown), separate adjustment child*s sugar intake age 3\\u2005years (supplementary table e3).""""]']"
S14-PMC5546866	PMC5546866	8/2017	S14-PMC5546866	['antenatal Vitamin D supplementation is now RECOMMENDED for all Pregnant women in many national GUIDELINES (1–3) AS SEVERE maternal Vitamin D deficiency CAN result in symptomatic neonatal hypocalcemia (4).']	[('FUTURE_WORK', 43), ('PROBABLE_UNDERSTANDING', 95), ('PROBABLE_UNDERSTANDING', 112), ('IMPORTANT_CONSIDERATION', 115), ('INCOMPLETE_EVIDENCE', 152)]	5	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnant'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]	0	['antenatal  supplementation  women national (1–3) maternal  result symptomatic neonatal hypocalcemia (4).']
S26-PMC5546866	PMC5546866	8/2017	S26-PMC5546866	['CONSIDERING this and the physiological changes to the Vitamin D pathway in Pregnancy, it is THEREFORE POSSIBLE that the Genetic variants ASSOCIATED with baseline Serum 25(Oh)d status and the response to supplementation also differ between the Pregnant and nonpregnant state.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 92), ('INCOMPLETE_EVIDENCE', 102), ('SUPERFICIAL_RELATIONSHIP', 137)]	4	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('SO_0000704', 'gene', 120, 'genetic'), ('UBERON_0001977', 'blood serum', 162, 'serum'), ('CHEBI_30778', 'gallic acid', 168, '25(OH)'), ('GO_0007565', 'female pregnancy', 243, 'pregnant')]	0	['considering physiological changes  genetic variants baseline serum 25(oh)d status response supplementation  nonpregnant state.']
S118-PMC5546866	PMC5546866	8/2017	S118-PMC5546866	['discussion\nTHIS STUDY ASSESSED the RELATIONSHIPS between common Genetic variants and the response to Vitamin D supplementation in Pregnancy; rs12785878 in dhcr7 was ASSOCIATED with 25(Oh)D status in early Pregnancy prior to Vitamin D supplementation, WHEREAS rs10741657 in Cyp2R1 and rs2282679 in gc were ASSOCIATED with both the achieved and change in 25(Oh)D concentration following supplementation with 1000 iu/d Cholecalciferol.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 22), ('SUPERFICIAL_RELATIONSHIP', 35), ('SUPERFICIAL_RELATIONSHIP', 165), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 251), ('SUPERFICIAL_RELATIONSHIP', 305)]	6	[('SO_0000704', 'gene', 64, 'genetic'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('CHEBI_30778', 'gallic acid', 181, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 187, 'D'), ('GO_0007565', 'female pregnancy', 205, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 273, 'CYP2R1'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 356, 'OH)D'), ('CHEBI_52550', 'theopalauamide', 416, 'cholecalciferol')]	0	['discussion\nthis genetic variants response  supplementation rs12785878 dhcr7 25(oh)d status   supplementation, rs10741657 cyp2r1 rs2282679 gc achieved 25(oh)d concentration following supplementation 1000 iu/d cholecalciferol.']
S125-PMC5546866	PMC5546866	8/2017	S125-PMC5546866	['(11) (15 to 18 nmol/l) than our cohort (9 to 10 nmol/l), BUT this COULD REFLECT the higher Cholecalciferol doses used in those studies and/or alterations in Vitamin D Metabolism and volume of distribution in Pregnancy.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 57), ('INCOMPLETE_EVIDENCE', 66), ('SUPERFICIAL_RELATIONSHIP', 72)]	3	[('CHEBI_52550', 'theopalauamide', 91, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 157, 'vitamin D metabolism'), ('GO_0007565', 'female pregnancy', 208, 'pregnancy')]	0	['(11) (15 18 nmol/l) (9 10 nmol/l), higher cholecalciferol doses and/or alterations  metabolism volume distribution .']
S132-PMC5546866	PMC5546866	8/2017	S132-PMC5546866	['we FOUND that the rs10741657 Snp was not associated with baseline 25(Oh)D BUT was ASSOCIATED with the response to Gestational Vitamin D supplementation, THEREFORE SUGGESTING that this Snp ONLY modifies 25(Oh)D status when the substrate is more readily available and that at the baseline measurement, saturation of the enzyme had not been reached.']	[('INCOMPLETE_EVIDENCE', 3), ('ANOMALY_CURIOUS_FINDING', 74), ('SUPERFICIAL_RELATIONSHIP', 82), ('PROBABLE_UNDERSTANDING', 153), ('INCOMPLETE_EVIDENCE', 163), ('ANOMALY_CURIOUS_FINDING', 188)]	6	[('SO_0000694', 'SNP', 29, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 66, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('SO_0000694', 'SNP', 184, 'SNP'), ('CHEBI_71657', 'versiconol acetate', 202, '25(OH)D')]	0	['rs10741657 snp baseline 25(oh)d response   supplementation, snp modifies 25(oh)d status substrate baseline measurement, saturation enzyme reached.']
S68-PMC5576167	PMC5576167	8/2017	S68-PMC5576167	['Folic Acid was FOUND TO BE the most common dietary supplements used among Pregnant women (95.9%; n \xa0=\xa094) followed by iron, calcium and Vitamin D (88.8, 81.6 and 41%, respectively).']	[('ANOMALY_CURIOUS_FINDING', 15)]	1	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('GO_0007565', 'female pregnancy', 74, 'pregnant'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]	0	['folic acid dietary supplements among  women (95.9%; n \xa0=\xa094) followed iron, calcium  (88.8, 81.6 41%, respectively).']
S88-PMC5576167	PMC5576167	8/2017	S88-PMC5576167	['the prevalence of Vitamin D deficiency and insufficiency (50.0 and 43.8%, respectively) HAS BEEN reported among Pregnant saudi women with adequate Vitamin D Intake (≥600\xa0iu/day) among ONLY 8.1% of Pregnant women [14,31,32].']	[('INCOMPLETE_EVIDENCE', 88), ('ANOMALY_CURIOUS_FINDING', 184)]	2	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'pregnant'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('GO_0007631', 'feeding behavior', 157, 'intake'), ('GO_0007565', 'female pregnancy', 197, 'pregnant')]	0	[' (50.0 43.8%, respectively) among  saudi women  intake (≥600\xa0iu/day) among 8.1%  women [14,31,32].']
S61-PMC5623264	PMC5623264	9/2017	S61-PMC5623264	['caption (table-wrap): table 2\n\ncharacteristics of interventionsreviewinterventionpopulationdose (mean range)frequencystart of interventionmccauley\xa0 et\xa0al 24vitamin alow-risk and high-risk (women with no, moderate, or severe Vitamin A deficiency)great variation between trials: 3000–600\u2009000 iudaily or weeklymost studies in second Trimesterrumbold\xa0 et\xa0al 45vitamin clow-risk and high-risk (nine studies recruited women with high or increased risk of pre-eclampsia)common dosage 1000\u2009mg (100–2000\u2009mg)dailymost studies in second Trimesterrumbold\xa0 et\xa0al 46vitamin elow-risk and high-risk (nine studies recruited women with high or increased risk of pre-eclampsia)common dosage 400 iu (100\u2009mg, 200–800 iu)dailymost studies in second Trimesterde-regil\xa0 et\xa0al 25Folic Acidwomen with and without history of Neural Tube defects0.4–4.0\u2009mgdailypericonceptional period (before Pregnancy until 12\u2009weeks of Pregnancy)lassi\xa0 et\xa0al 26Folic Acidlow riskcommon dosage 5\u2009mg (range 0.01–400\u2009mg)dailyinitiation varied from 8\u2009weeks of Pregnancy until 3\u2009days Postpartuman\xa0 et\xa0al 27calciumlow-risk1.0–2.0\u2009gdaily11–24\u2009weeks of Pregnancybuppasiri\xa0 et\xa0al 28calciumlow-risk and high-risk (three trials recruited only adolescents)1.0\u2009g (range 0.3–2.0\u2009mg)dailymost trials at or after 20\u2009weeks’ Gestational agehofmeyr\xa0 et\xa0al 29calciumlow-risk and high-risk (high-risk of pre-eclampsia; adolescents)high dose:\xa0≥1\u2009g/day (1.5–2.0\u2009g), low-dose:\xa0<1\u2009g/daydailysecond Trimesterpeña-rosas\xa0 et\xa0al 30ironlow-risk and high-risk (anaemic and non-anaemic women)9–900\u2009mgdailymost trials before 20\u2009weeks’ Gestationharding\xa0 et\xa0al 31iodinelow-risk75–300\u2009µgdailyduring Pregnancy, Postpartum, or Pregnancy and Postpartummakrides\xa0 et\xa0al 32magnesiumlow-risk and high-risk (Pregnancy-induced hypertension, risk of ptb365\u2009mg (64–1000\u2009mg)dailymost trials in first Trimesterota\xa0 et\xa0al 33zinclow-risk and high-risk (one trial recruited women with high risk of sga)5–44\u2009mg (90\u2009mg in one trial)Dailybefore Conception (two trials from 26\u2009weeks’ Gestation)soltani\xa0 et\xa0al 34zincna20\u2009mgdaily6–20\u2009weeks until Deliveryfall\xa0 et\xa0al 35mmnmainly low-riskmmn formulation that Delivered approximately 1 rdadailyin Pregnancyhaider\xa0 et\xa0al 36mmnlow-risk and high-riskdifferent Mmn composition in all trials (14 trials included Iron and Folic Acid in Mmn)dailyvaried (first, second or third Trimester)ramakrishnan\xa0 et\xa0al 37mmnlow-risk and high-riskmost trials used unimmap (1–2\u2009rad) formulation with 30\u2009mg or 60\u2009mg irondailyfirst or second Trimesterota\xa0 et\xa0al 38proteinlow-risk and high-risk (well-nourished and undernourished women)nutritional educationbalanced energy/protein: 118–1017 kcal/6–44\u2009ghigh protein: 40\u2009gmonthlydailydailysecond trimestersecond to third trimesterbefore 30\u2009weeks’ Gestationmakrides et al 39prostaglandinlow-risk and high-risk Pregnanciescommon dosage: 2.7\u2009g of Epa and dhadailycommonly after 16\u2009weeks’ Gestationsalvig\xa0 et\xa0al 40n-3 Fatty Acidslow-risk and high-risk (previous ptb or iugr)2.7\u2009gdailylow-risk: week 30, high-risk: week 18–21duley\xa0 et\xa0al 41reduced Saltlow-risklow dietary Salt: 20 or 50\xa0mmol/daydaily12–20\u2009weeks’ Gestationsalam et\xa0al 42antihelminthicslow-risk and high-risk (infected with Intestinal Helminth)400\u2009mg Albendazole with or without iron/Folate or 500\u2009mg Mebendazole with ironsingle-dose (iron daily)second trimesterradeva-petrova et al 43antimalarialslow-risk and high-risk(1)\xa0Chloroquine: 300\u2009mg(2)\xa0Pyrimethamine: 100\u2009mg/25\u2009mg(3)\xa0Proguanil: 100\u2009mg(4)\xa0Pyrimethamine-Dapsone: 25\u2009mg/100\u2009mg or 12.5\u2009mg/100\u2009mg(5)\xa0Sulfadoxine-Pyrimethamine: 1500\u2009mg/75\u2009mg(6)\xa0Meﬂoquine: 500\u2009mg loading dose, 250\u2009mg weekly for 4\u2009weeks, 125\u2009mg weekly until Delivery(1)\xa0weekly(2)\xa0monthly/weekly(3)\xa0daily(4)\xa0every 2\u2009weeks or weekly(5)\xa0up to four doses(6)\xa0weeklyfrom first Prenatal visitmuanda\xa0 et\xa0al 44antimalarialslow-risk and high-riskany type of Antimalarial Drug (Chloroquine, Sulfadoxine-Pyrimethamine, Mefloquine, Dapsone-Pyrimethamine)two to three doses or more, weekly or dailyduring Pregnancy (no specification)\nDha, Docosahexaenoic Acid; Epa, Eicosapentaenoic Acid; iu, international units; iugr, Intrauterine growth restriction; lbw, low Birth weight; mmn, multiple Micronutrients; na, not available; ptb, Preterm Birth; rad, RECOMMENDED dietary allowance; sga, small-for-Gestational age; unimmap, united nations multiple Micronutrient antenatal preparation.']	[('FUTURE_WORK', 4187)]	1	[('CHEBI_27300', 'vitamin D', 224, 'vitamin A'), ('GO_0035146', 'tube fusion', 330, 'trimesterRumbold'), ('GO_0035146', 'tube fusion', 526, 'trimesterRumbold'), ('GO_0043033', 'isoamylase complex', 728, 'trimesterDe'), ('CHEBI_51593', '3,5-dibromopyridine', 753, '25Folic acidWomen'), ('UBERON_0001049', 'neural tube', 799, 'neural tube'), ('GO_0007565', 'female pregnancy', 865, 'pregnancy'), ('GO_0007565', 'female pregnancy', 893, 'pregnancy'), ('CHEBI_75626', 'oleyl oleate', 916, '26Folic acidLow'), ('GO_0007565', 'female pregnancy', 1013, 'pregnancy'), ('GO_0007596', 'blood coagulation', 1036, 'postpartumAn'), ('GO_0007605', 'sensory perception of sound', 1102, 'pregnancyBuppasiri'), ('GO_0007565', 'female pregnancy', 1264, 'gestational'), ('GO_0043143', 'regulation of translation by machinery localization', 1430, 'trimesterPeña'), ('GO_0007530', 'sex determination', 1559, 'gestationHarding'), ('GO_0007565', 'female pregnancy', 1620, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1631, 'postpartum'), ('GO_0007565', 'female pregnancy', 1646, 'pregnancy'), ('GO_0007598', 'blood coagulation, extrinsic pathway', 1660, 'postpartumMakrides'), ('GO_0007565', 'female pregnancy', 1721, 'pregnancy'), ('GO_0042790', 'nucleolar large rRNA transcription by RNA polymerase I', 1809, 'trimesterOta'), ('CHEBI_34674', 'dextran sulfate', 1935, 'DailyBefore'), ('GO_0007620', 'copulation', 1947, 'conception'), ('GO_0007565', 'female pregnancy', 1985, 'gestation'), ('GO_0007567', 'parturition', 2045, 'deliveryFall'), ('GO_0007567', 'parturition', 2106, 'delivered'), ('GO_0001523', 'retinoid metabolic process', 2143, 'pregnancyHaider'), ('UBERON_0003109', 'parapophysis', 2203, 'MMN'), ('CHEBI_24870', 'ion', 2253, 'iron'), ('CHEBI_30751', 'formic acid', 2262, 'folic acid'), ('UBERON_0003109', 'parapophysis', 2276, 'MMN'), ('GO_0009294', 'DNA mediated transformation', 2316, 'trimester'), ('GO_0042790', 'nucleolar large rRNA transcription by RNA polymerase I', 2465, 'trimesterOta'), ('GO_0007565', 'female pregnancy', 2717, 'gestationMakrides'), ('GO_0007602', 'phototransduction', 2779, 'pregnanciesCommon'), ('CHEBI_34733', 'EPN', 2814, 'EPA'), ('GO_0007565', 'female pregnancy', 2855, 'gestationSalvig'), ('CHEBI_50484', 'hepta-2,4,6-trienoic acid', 2884, 'fatty acidsLow'), ('CHEBI_33462', 'phosphonate(1-)', 3013, 'saltLow'), ('CHEBI_24866', 'salt', 3037, 'salt'), ('GO_0007565', 'female pregnancy', 3078, 'gestationSalam'), ('UBERON_0000160', 'intestine', 3154, 'intestinal'), ('NCBITaxon_10036', 'Mesocricetus auratus', 3165, 'helminth'), ('CHEBI_16664', 'albendazole', 3181, 'albendazole'), ('CHEBI_30863', '5-azaorotic acid', 3214, 'folate'), ('CHEBI_6751', 'mepanipyrim', 3231, 'mebendazole'), ('CHEBI_3637', 'chloroprocaine hydrochloride', 3354, 'Chloroquine'), ('CHEBI_8665', 'Pyridostigmine', 3377, 'Pyrimethamine'), ('CHEBI_8494', 'Propiverine hydrochloride', 3408, 'Proguanil'), ('CHEBI_8665', 'Pyridostigmine', 3429, 'Pyrimethamine'), ('CHEBI_4325', 'dapsone', 3443, 'dapsone'), ('CHEBI_9328', 'sulfadiazine', 3486, 'Sulfadoxine'), ('CHEBI_16610', 'spermidine', 3498, 'pyrimethamine'), ('CHEBI_6723', 'megestrol acetate', 3530, 'Meﬂoquine'), ('GO_0007567', 'parturition', 3609, 'delivery'), ('GO_0007565', 'female pregnancy', 3722, 'prenatal'), ('CHEBI_35443', 'anthelminthic drug', 3799, 'antimalarial drug'), ('CHEBI_3638', 'chloroquine', 3818, 'chloroquine'), ('CHEBI_9322', 'sulbenicillin', 3831, 'sulfadoxine'), ('CHEBI_16610', 'spermidine', 3843, 'pyrimethamine'), ('CHEBI_63609', 'mefloquine', 3858, 'mefloquine'), ('CHEBI_4325', 'dapsone', 3870, 'dapsone'), ('CHEBI_16610', 'spermidine', 3878, 'pyrimethamine'), ('GO_0007565', 'female pregnancy', 3942, 'pregnancy'), ('CHEBI_17874', 'dihydrozeatin', 3971, 'DHA'), ('CHEBI_36003', 'decenoic acid', 3976, 'docosahexaenoic acid'), ('CHEBI_34733', 'EPN', 3998, 'EPA'), ('CHEBI_36003', 'decenoic acid', 4003, 'eicosapentaenoic acid'), ('UBERON_0022293', 'reproductive gland secretion', 4057, 'intrauterine'), ('GO_0007567', 'parturition', 4099, 'birth'), ('CHEBI_33839', 'macromolecule', 4127, 'micronutrients'), ('GO_0007565', 'female pregnancy', 4167, 'preterm'), ('GO_0007567', 'parturition', 4175, 'birth'), ('GO_0007565', 'female pregnancy', 4233, 'gestational'), ('CHEBI_6956', 'Mitragynine', 4283, 'Micronutrient')]	0	['caption (table-wrap): table 2\n\ncharacteristics interventionsreviewinterventionpopulationdose (mean range)frequencystart interventionmccauley\xa0 et\xa0al 24vitamin alow-risk (women no, moderate,  deficiency)great trials: 3000–600\u2009000 iudaily weeklymost trimesterrumbold\xa0 et\xa0al 45vitamin clow-risk (nine recruited women pre-eclampsia)common dosage 1000\u2009mg (100–2000\u2009mg)dailymost trimesterrumbold\xa0 et\xa0al 46vitamin elow-risk (nine recruited women pre-eclampsia)common dosage 400 iu (100\u2009mg, 200–800 iu)dailymost trimesterde-regil\xa0 et\xa0al 25folic acidwomen neural tube defects0.4–4.0\u2009mgdailypericonceptional period (before  12\u2009weeks )lassi\xa0 et\xa0al 26folic acidlow riskcommon dosage 5\u2009mg (range 0.01–400\u2009mg)dailyinitiation 8\u2009weeks  3\u2009days postpartuman\xa0 et\xa0al 27calciumlow-risk1.0–2.0\u2009gdaily11–24\u2009weeks pregnancybuppasiri\xa0 et\xa0al 28calciumlow-risk (three recruited adolescents)1.0\u2009g (range 0.3–2.0\u2009mg)dailymost 20\u2009weeks’  agehofmeyr\xa0 et\xa0al 29calciumlow-risk (high-risk pre-eclampsia; adolescents)high dose:\xa0≥1\u2009g/day (1.5–2.0\u2009g), low-dose:\xa0<1\u2009g/daydailysecond trimesterpeña-rosas\xa0 et\xa0al 30ironlow-risk (anaemic non-anaemic women)9–900\u2009mgdailymost 20\u2009weeks’ gestationharding\xa0 et\xa0al 31iodinelow-risk75–300\u2009µgdailyduring  postpartummakrides\xa0 et\xa0al 32magnesiumlow-risk (-induced hypertension, ptb365\u2009mg (64–1000\u2009mg)dailymost trimesterota\xa0 et\xa0al 33zinclow-risk (one recruited women sga)5–44\u2009mg (90\u2009mg trial)dailybefore (two 26\u2009weeks’ )soltani\xa0 et\xa0al 34zincna20\u2009mgdaily6–20\u2009weeks deliveryfall\xa0 et\xa0al 35mmnmainly low-riskmmn formulation delivered rdadailyin pregnancyhaider\xa0 et\xa0al 36mmnlow-risk high-riskdifferent mmn composition (14 iron folic acid mmn)dailyvaried (first, third trimester)ramakrishnan\xa0 et\xa0al 37mmnlow-risk high-riskmost unimmap (1–2\u2009rad) formulation 30\u2009mg 60\u2009mg irondailyfirst trimesterota\xa0 et\xa0al 38proteinlow-risk (well-nourished undernourished women)nutritional educationbalanced energy/protein: 118–1017 kcal/6–44\u2009ghigh protein: 40\u2009gmonthlydailydailysecond trimestersecond third trimesterbefore 30\u2009weeks’  et al 39prostaglandinlow-risk pregnanciescommon dosage: 2.7\u2009g epa dhadailycommonly 16\u2009weeks’ \xa0 et\xa0al 40n-3 fatty acidslow-risk (previous ptb iugr)2.7\u2009gdailylow-risk: week 30, high-risk: week 18–21duley\xa0 et\xa0al 41reduced saltlow-risklow dietary salt: 20 50\xa0mmol/daydaily12–20\u2009weeks’  et\xa0al 42antihelminthicslow-risk (infected intestinal helminth)400\u2009mg albendazole iron/folate 500\u2009mg mebendazole ironsingle-dose (iron daily)second trimesterradeva-petrova et al 43antimalarialslow-risk high-risk(1)\xa0chloroquine: 300\u2009mg(2)\xa0pyrimethamine: 100\u2009mg/25\u2009mg(3)\xa0proguanil: 100\u2009mg(4)\xa0pyrimethamine-dapsone: 25\u2009mg/100\u2009mg 12.5\u2009mg/100\u2009mg(5)\xa0sulfadoxine-pyrimethamine: 1500\u2009mg/75\u2009mg(6)\xa0meﬂoquine: 500\u2009mg loading dose, 250\u2009mg weekly 4\u2009weeks, 125\u2009mg weekly delivery(1)\xa0weekly(2)\xa0monthly/weekly(3)\xa0daily(4)\xa0every 2\u2009weeks weekly(5)\xa0up four doses(6)\xa0weeklyfrom  visitmuanda\xa0 et\xa0al 44antimalarialslow-risk high-riskany type antimalarial drug (chloroquine, sulfadoxine-pyrimethamine, mefloquine, dapsone-pyrimethamine)two three doses more, weekly dailyduring  (no specification)\ndha, docosahexaenoic acid; epa, eicosapentaenoic acid; iu, international units; iugr, intrauterine restriction; lbw, birth weight; mmn, micronutrients; na, available; ptb,  birth; rad, dietary allowance; sga, small-for- age; unimmap, united nations micronutrient antenatal preparation.']
S73-PMC5623264	PMC5623264	9/2017	S73-PMC5623264	['twenty-two studies ASSESSED the EFFECT of the INTERVENTIONS on ptb.24–43 45 46all systematic reviews included individually\xa0rcts,24–469 cluster-rcts24 30–32 35 36 38 42 45and 10\xa0both rcts and quasi-rcts.24 26 29–32 43–46the number of included trials per review ranged from 241to 61 trials.30the number of included participants in the reviews ranged from 603 participants41to over 310\u2009000 participants.24supplementation with Vitamins was reported in five reviews,24–26 45 46supplementation with Minerals in eight reviews27–34and mmn supplementation was assessed in three reviews.35–37there was one review on protein supplementation and nutritional education38and two reviews REPORTED on marine oil and Fatty Acid supplementation.39 40one review evaluated reduced Salt intake,41one deworming42and two reviews preventive Antimalarial drugs.43 44\n\nmethodological quality of the included reviews\nsixteen reviews were of high quality.24–26 28–33 36 38 39 42 43 45 46six reviews were assessed to be of moderate quality.27 34 37 40 41 44only one included review had a score of three and, therefore, was judged to be of low methodological quality (table 1).35\n\neffects of interventions\n\noral supplementation with Vitamins alone or in combination\nfive systematic reviews INVESTIGATED the EFFECT of oral supplementation with Vitamin A,24vitamin C45Or Vitamin E during Pregnancy46And oral Folic Acid supplementation25 26during the Periconceptional period and Pregnancy (see\xa0onlinesupplementary table 6).']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 32), ('SUPERFICIAL_RELATIONSHIP', 46), ('INCOMPLETE_EVIDENCE', 673), ('QUESTION_ANSWERED_BY_THIS_WORK', 1260), ('SUPERFICIAL_RELATIONSHIP', 1277)]	6	[('CHEBI_33277', 'gamma-tocotrienol', 423, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 493, 'minerals'), ('CHEBI_35366', 'fatty acid', 700, 'fatty acid'), ('CHEBI_24866', 'salt', 761, 'salt'), ('CHEBI_67261', '(Z)-2,3-dehydroadipyl-CoA(5-)', 817, 'antimalarial'), ('CHEBI_33277', 'gamma-tocotrienol', 1203, 'vitamins'), ('CHEBI_27300', 'vitamin D', 1313, 'vitamin A'), ('CHEBI_528968', '1-O-(alpha-D-galactopyranosyl)-N-(8-phenyloctanoyl)phytosphingosine', 1333, 'C45or'), ('PR_000001309', 'CD70 molecule', 1333, 'C45or'), ('CHEBI_27300', 'vitamin D', 1339, 'vitamin E'), ('GO_0006412', 'translation', 1356, 'pregnancy46and'), ('CHEBI_30751', 'formic acid', 1376, 'folic acid'), ('UBERON_0001844', 'cochlea', 1418, 'periconceptional'), ('GO_0007565', 'female pregnancy', 1446, 'pregnancy')]	0	['twenty-two ptb.24–43 45 46all individually\xa0rcts,24–469 cluster-rcts24 30–32 35 36 38 42 45and 10\xa0both rcts quasi-rcts.24 26 29–32 43–46the ranged 241to 61 trials.30the participants ranged 603 participants41to 310\u2009000 participants.24supplementation vitamins five reviews,24–26 45 46supplementation minerals eight reviews27–34and mmn supplementation three reviews.35–37there protein supplementation nutritional education38and marine oil fatty acid supplementation.39 40one salt intake,41one deworming42and antimalarial drugs.43 44\n\nmethodological reviews\nsixteen quality.24–26 28–33 36 38 39 42 43 45 46six quality.27 34 37 40 41 44only score three and, therefore, methodological (table 1).35\n\neffects interventions\n\noral supplementation vitamins combination\nfive oral supplementation ,24vitamin c45or  pregnancy46and oral folic acid supplementation25 26during periconceptional period  (see\xa0onlinesupplementary table 6).']
S74-PMC5623264	PMC5623264	9/2017	S74-PMC5623264	['Vitamin A\na review including 19 rcts, quasi-rcts and cluster-rcts randomising over 310\u2009000 Pregnant women living in areas with endemic Vitamin A deficiency or in areas with adequate Intake assessed the EFFECT of Vitamin A supplementation or one of its derivatives alone or in combination with other supplements on lbw and ptb.24vitamin a alone compared with placebo or no treatment did not reduce lbw or ptb.']	[('SUPERFICIAL_RELATIONSHIP', 202)]	1	[('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin A'), ('GO_0007565', 'female pregnancy', 91, 'pregnant'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin A'), ('GO_0007631', 'feeding behavior', 182, 'intake'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin A')]	0	['vitamin a\na 19 rcts, quasi-rcts cluster-rcts randomising 310\u2009000  women living endemic  intake  supplementation derivatives combination supplements lbw ptb.24vitamin placebo treatment lbw ptb.']
S78-PMC5623264	PMC5623264	9/2017	S78-PMC5623264	['Vitamin E\ntwenty-one rcts and quasi-rcts randomising 22\u2009129 Pregnant women living in areas with inadequate Vitamin E intake or areas with PRESUMED adequate intake were included in this review.46any Vitamin E supplementation did not reduce ptb, sga or iugr.']	[('PROBABLE_UNDERSTANDING', 138)]	1	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin E'), ('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin E')]	0	['vitamin e\ntwenty-one rcts quasi-rcts randomising 22\u2009129  women living  intake intake review.46any  supplementation ptb, sga iugr.']
S93-PMC5623264	PMC5623264	9/2017	S93-PMC5623264	['multiple Micronutrient supplementation\nthe EFFECT of mmn supplementation on lbw, ptb and sga was assessed in three reviews (see\xa0onlinesupplementary table 8).35–37mmn supplementation provided one RECOMMENDED daily nutrient intake of Vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, Vitamin B12, Folic Acid, Vitamin C, vitamin d, Vitamin E, copper, Selenium and Iodine with iron and zinc to Pregnant women.47a significant reduction of lbw in the range of 11%–14%\u2009and a significant reduction of sga in the range of 10%–17%\u2009could BE observed following mmn supplementation in all three reviews.']	[('SUPERFICIAL_RELATIONSHIP', 43), ('FUTURE_WORK', 195), ('ANOMALY_CURIOUS_FINDING', 532)]	3	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 9, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin A'), ('CHEBI_27718', 'alpha-Fuc-(1->2)-[alpha-Fuc-(1->2)-beta-Gal-(1->3)-alpha-GalNAc-(1->3)]-beta-Gal-(1->4)-beta-GlcNAc-(1->3)-beta-Gal-(1->4)-beta-Glc-(1<->1*)-Cer', 251, 'B1'), ('CHEBI_18245', 'carboxylato group', 263, 'B2'), ('CHEBI_51231', 'DAPI', 283, 'B6'), ('CHEBI_33279', 'vitamin D5', 287, 'vitamin B12'), ('CHEBI_30751', 'formic acid', 300, 'folic acid'), ('CHEBI_27300', 'vitamin D', 312, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 334, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 353, 'selenium'), ('CHEBI_24859', 'iodine atom', 366, 'iodine'), ('GO_0007565', 'female pregnancy', 395, 'pregnant')]	0	['multiple micronutrient supplementation\nthe mmn supplementation lbw, ptb sga three (see\xa0onlinesupplementary table 8).35–37mmn supplementation daily nutrient intake vitamin b1, vitamin b2, niacin, vitamin b6, vitamin b12, folic acid, vitamin d, copper, selenium iodine iron zinc  women.47a reduction lbw 11%–14%\u2009and reduction sga 10%–17%\u2009could following mmn supplementation three reviews.']
S121-PMC5623264	PMC5623264	9/2017	S121-PMC5623264	['piso et al FOUND that Vitamin C supplementation during Pregnancy increased the RISK of ptb and magnesium supplementation decreased the RISK of ptb, lbw and sga.15HOWEVER, the cochrane reviews from which data were extracted had previously been updated and new studies had been added resulting in changed conclusions.']	[('INCOMPLETE_EVIDENCE', 11), ('IMPORTANT_CONSIDERATION', 79), ('IMPORTANT_CONSIDERATION', 135), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 160)]	4	[('CHEBI_27300', 'vitamin D', 22, 'vitamin C'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy')]	0	['piso et al  supplementation  ptb magnesium supplementation decreased ptb, lbw sga.15however, cochrane extracted added resulting conclusions.']
S122-PMC5623264	PMC5623264	9/2017	S122-PMC5623264	['currently, there is NO EVIDENCE that magnesium or Vitamin C supplementation during Pregnancy positively or negatively AFFECT the RISK of ptb, lbw or sga.']	[('INCOMPLETE_EVIDENCE', 20), ('SUPERFICIAL_RELATIONSHIP', 118), ('IMPORTANT_CONSIDERATION', 129)]	3	[('CHEBI_27300', 'vitamin D', 50, 'vitamin C'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]	0	['currently, magnesium  supplementation  positively ptb, lbw sga.']
S36-PMC5634602	PMC5634602	10/2017	S36-PMC5634602	['IMPORTANTLY, SEVERAL STUDIES have DOCUMENTED an ASSOCIATION with decreasing 25(Oh)D levels and lower Gestational age at Delivery allowing for a situation where preterm infants are a highly vulnerable population at Birth with regards to their Vitamin D status [15,28,30].']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 48)]	4	[('CHEBI_71657', 'versiconol acetate', 76, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 82, 'D'), ('GO_0007565', 'female pregnancy', 101, 'gestational'), ('GO_0007567', 'parturition', 120, 'delivery'), ('GO_0007567', 'parturition', 214, 'birth'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D')]	0	['importantly, decreasing 25(oh)d levels  age delivery allowing situation preterm infants population birth regards  status [15,28,30].']
S66-PMC5634602	PMC5634602	10/2017	S66-PMC5634602	['Gestational age, Birth anthropometrics and in hospital growth are presented intable 2.10.1371/journal.pone.0185950.t002\n\ncaption (table-wrap): table 2\nGestational age, Birth anthropometrics and in hospital growth by Vitamin D3Supplementation group.variable400 iu800 iup-valuenmedianiqrnmedianiqr Birth weight, grams 161405.5270161392.56321.00 Birth weight %ile 1633301639.5390.33 Gestational age at delivery 163121630.355.350.75 Birth length, cm 16395.51639.510.10.94 Birth length %ile 1615241624.536.50.36 Birth Head circumference, cm 1627.521627.54.150.66 Birth hc %ile 162051163940.50.71 weight at 36 weeks, grams 142378.5393122542472.50.23 weight %ile 36 weeks 1418201227.5310.14 length at 36 weeks, cm 14432.21245.753.650.09 length %ile 36 weeks 1411151228450.06 hc at 36 weeks, cm 1432.13.51233.252.050.75 hc %ile 36 weeks 1430.562124429.50.52\n\n25Ohd changes by Vitamin D dose\nCord Blood 25(Oh)D3Levels were significantly CORRELATED with Gestational age (r = 0.40, p = 0.04), but had no CORRELATION with sex or race.']	[('SUPERFICIAL_RELATIONSHIP', 928), ('SUPERFICIAL_RELATIONSHIP', 993)]	2	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('GO_0007567', 'parturition', 17, 'birth'), ('GO_0007565', 'female pregnancy', 151, 'Gestational'), ('GO_0007567', 'parturition', 168, 'birth'), ('CHEBI_52915', 'phosphatediyl group', 216, 'vitamin D3supplementation'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 216, 'vitamin D3supplementation'), ('GO_0007567', 'parturition', 296, 'Birth'), ('GO_0007567', 'parturition', 343, 'Birth'), ('GO_0007565', 'female pregnancy', 380, 'Gestational'), ('GO_0007567', 'parturition', 429, 'Birth'), ('GO_0007567', 'parturition', 468, 'Birth'), ('GO_0007567', 'parturition', 507, 'Birth'), ('UBERON_0000033', 'head', 513, 'head'), ('GO_0007567', 'parturition', 558, 'Birth'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 851, '25OHD'), ('CHEBI_27300', 'vitamin D', 868, 'vitamin D'), ('UBERON_0000948', 'heart', 883, 'Cord'), ('UBERON_0000178', 'blood', 888, 'blood'), ('CHEBI_51924', 'ethyl 2-cyanoacetoacetate', 894, '25(OH)D3levels'), ('PR_000006775', 'cytoplasmic dynein 2 heavy chain 1', 900, 'D3levels'), ('GO_0007565', 'female pregnancy', 944, 'gestational')]	0	[' age, birth anthropometrics hospital intable 2.10.1371/journal.pone.0185950.t002\n\ncaption (table-wrap): table 2\n age, birth anthropometrics hospital vitamin d3supplementation group.variable400 iu800 iup-valuenmedianiqrnmedianiqr birth weight, grams 161405.5270161392.56321.00 birth %ile 1633301639.5390.33  age delivery 163121630.355.350.75 birth length, cm 16395.51639.510.10.94 birth length %ile 1615241624.536.50.36 birth head circumference, cm 1627.521627.54.150.66 birth hc %ile 162051163940.50.71 36 weeks, grams 142378.5393122542472.50.23 %ile 36 weeks 1418201227.5310.14 length 36 weeks, cm 14432.21245.753.650.09 length %ile 36 weeks 1411151228450.06 hc 36 weeks, cm 1432.13.51233.252.050.75 hc %ile 36 weeks 1430.562124429.50.52\n\n25ohd changes  dose\ncord blood 25(oh)d3levels  age (r = 0.40, p = 0.04), sex race.']
S136-PMC5634602	PMC5634602	10/2017	S136-PMC5634602	['we were unable to adequately assess maternal Vitamin D intake during Pregnancy in the cohort studied, AS maternal records OFTEN DID NOT report the amount of Vitamin D in the prescribed Prenatal vitamin.']	[('PROBABLE_UNDERSTANDING', 102), ('PROBABLE_UNDERSTANDING', 122), ('INCOMPLETE_EVIDENCE', 128)]	3	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('GO_0007565', 'female pregnancy', 185, 'prenatal')]	0	['maternal  intake  studied, maternal records amount  prescribed  vitamin.']
S137-PMC5634602	PMC5634602	10/2017	S137-PMC5634602	['HOWEVER, given that the MAJORITY of Prenatal Vitamins have 400 iu of Vitamin D and this has not been shown to increase levels in Pregnancy this LIKELY does not have any IMPACT on our DESCRIBED results.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 24), ('PROBABLE_UNDERSTANDING', 144), ('SUPERFICIAL_RELATIONSHIP', 169), ('INCOMPLETE_EVIDENCE', 183)]	5	[('GO_0007565', 'female pregnancy', 36, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 45, 'vitamins'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]	0	['however,  vitamins 400 iu  increase levels  results.']
S149-PMC5634602	PMC5634602	10/2017	S149-PMC5634602	['our results AGREE with PREVIOUS EVIDENCE that SUPPORTS an ASSOCIATION between Vitamin D status, Gestational age, and growth in premature infants.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 46), ('SUPERFICIAL_RELATIONSHIP', 58)]	4	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'gestational')]	0	['results  status,  age, premature infants.']
S104-PMC5638722	PMC5638722	8/2017	S104-PMC5638722	['EVEN if the ratios of eos and los were greater in the group with Vitamin D levels <5 ng/ml, after performing logistic regression analysis for Gestational age and Birth weight, we determined that the Vitamin D level was not an independent risk factor.']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('GO_0007565', 'female pregnancy', 142, 'gestational'), ('GO_0007567', 'parturition', 162, 'birth'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D')]	0	['even ratios eos los  levels <5 ng/ml, performing logistic regression  age birth weight,  factor.']
S107-PMC5638722	PMC5638722	8/2017	S107-PMC5638722	['SEVERE preeclampsia is FOUND TO BE 5.4 fold more in the 15- to 20-week Pregnant who have Vitamin D levels <20 ng/ml19).']	[('IMPORTANT_CONSIDERATION', 0), ('ANOMALY_CURIOUS_FINDING', 23)]	2	[('GO_0007565', 'female pregnancy', 71, 'pregnant'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]	0	['severe preeclampsia 5.4 fold 15- 20-week   levels <20 ng/ml19).']
S111-PMC5638722	PMC5638722	8/2017	S111-PMC5638722	['BUT with the results of OUR STUDY, no relation between the Cord-Blood Vitamin D levels and Gestational diabetes incidence is FOUND.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 24), ('INCOMPLETE_EVIDENCE', 125)]	3	[('UBERON_0002240', 'spinal cord', 59, 'cord'), ('UBERON_0000178', 'blood', 64, 'blood'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'gestational')]	0	['results study, cord-blood  levels  diabetes found.']
S114-PMC5638722	PMC5638722	8/2017	S114-PMC5638722	['DUE TO the absence of Serum Vitamin D levels of the mothers who have premature Deliveries, the results obtained give ONLY INDIRECT DATA about maternal morbidities and Vitamin D. epidemiologic STUDIES ARE NEEDED for investigating the POSSIBLE maternal EFFECTS of low Vitamin D levels during Pregnancy.']	[('PROBLEM_COMPLICATION', 0), ('INCOMPLETE_EVIDENCE', 117), ('INCOMPLETE_EVIDENCE', 122), ('FUTURE_WORK', 192), ('INCOMPLETE_EVIDENCE', 233), ('SUPERFICIAL_RELATIONSHIP', 251)]	6	[('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007567', 'parturition', 79, 'deliveries'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('GO_0007565', 'female pregnancy', 290, 'pregnancy')]	0	['due absence serum  levels mothers premature deliveries, results maternal morbidities . epidemiologic maternal  levels .']
S119-PMC5638722	PMC5638722	8/2017	S119-PMC5638722	['one of the factors ACCEPTED as a REGULATOR is Vitamin D. in A STUDY, small for Gestational age probability was FOUND TO BE 7.5 fold higher in the babies of the mothers with <15 ng/ml Vitamin D levels23).']	[('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 33), ('INCOMPLETE_EVIDENCE', 60), ('ANOMALY_CURIOUS_FINDING', 111)]	4	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'gestational'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D')]	0	['one . study,  age 7.5 fold higher babies mothers <15 ng/ml  levels23).']
S120-PMC5638722	PMC5638722	8/2017	S120-PMC5638722	['BUT, ON THE OTHER HAND, there are also studies which DID NOT FIND a RELATIONSHIP between the Pregnancy Vitamin D levels and Birth weight and length.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 5), ('INCOMPLETE_EVIDENCE', 53), ('SUPERFICIAL_RELATIONSHIP', 68)]	4	[('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007567', 'parturition', 124, 'birth')]	0	['but, hand,   levels birth length.']
S44-PMC5640793	PMC5640793	9/2017	S44-PMC5640793	"['[""""the lancet \'s 2013 maternal and child nutrition series RECOMMENDS ten nutrition-specific INTERVENTIONS, including sufficient and diverse Foods for adolescent girls and women; iron, Folic Acid, and Calcium supplementation in Pregnancy; good infant and young child Feeding practices; Vitamin A, iron, and preventive zinc supplementation for children; and treatment for moderate and severe acute malnutrition.5strikingly HOWEVER, expanding the coverage of these nutrition-specific INTERVENTIONS to 90% of mothers and children would only reduce stunting by an ESTIMATED 20%.5larger reductions than these REQUIRE increasing access to family Planning, health services for Pregnant women and children, investments in Water and sanitation, social safety nets, girls\' education, and women\'s empowerment.6a pragmatic approach to design community STRATEGIES for stunting reduction MIGHT THEREFORE be to prioritise action on immediate determinants (infection control, nutrition, and care in the first 1000 days) while providing an enabling social environment for changes in more distal determinants, for example by sharing information about health, nutrition, and sanitation entitlements, and bolstering women\'s agency.""""]']"	[('FUTURE_WORK', 55), ('SUPERFICIAL_RELATIONSHIP', 89), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 418), ('ANOMALY_CURIOUS_FINDING', 418), ('SUPERFICIAL_RELATIONSHIP', 478), ('INCOMPLETE_EVIDENCE', 556), ('FUTURE_WORK', 600), ('IMPORTANT_CONSIDERATION', 600), ('FUTURE_WORK', 836), ('INCOMPLETE_EVIDENCE', 870), ('PROBABLE_UNDERSTANDING', 876)]	11	[('CHEBI_33290', 'food', 137, 'foods'), ('CHEBI_30751', 'formic acid', 181, 'folic acid'), ('CHEBI_22313', 'alkaline earth metal atom', 197, 'calcium'), ('GO_0007565', 'female pregnancy', 224, 'pregnancy'), ('GO_0007631', 'feeding behavior', 263, 'feeding'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin A'), ('GO_0006260', 'DNA replication', 636, 'planning'), ('GO_0007565', 'female pregnancy', 666, 'pregnant'), ('CHEBI_15377', 'water', 710, 'water')]	0	"['[""""the lancet *s 2013 maternal child nutrition ten nutrition-specific interventions, foods adolescent girls women; iron, folic acid, calcium supplementation ncy; infant young child feeding practicen a, iron, zinc supplementation children; treatment acute malnutrition.5strikingly however, coverage nutrition-specific 90% mothers children stunting 20%.5larger reductions access family planning, services fant women children, water sanitation, social nets, girls* education, women*s empowerment.6a community stunting reduction (infection control, nutrition, 1000 days) enabling social environment changes distal determinants, example sharing health, nutrition, sanitation entitlements, women*s agency.""""]']"
S0-PMC5659607	PMC5659607	10/2017	S0-PMC5659607	['Prenatal Vitamin D supplementation reduces RISK of asthma/recurrent wheeze in early childhood: a combined analysis of two randomized controlled trials\n\nabstract\n\nbackground\nwe RECENTLY published two independent randomized controlled trials of Vitamin D supplementation during Pregnancy, both INDICATING a >20% reduced risk of asthma/recurrent wheeze in the offspring by 3 years of age.']	[('IMPORTANT_CONSIDERATION', 43), ('INCOMPLETE_EVIDENCE', 176), ('INCOMPLETE_EVIDENCE', 292)]	3	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('GO_0007565', 'female pregnancy', 276, 'pregnancy')]	0	['  supplementation reduces asthma/recurrent wheeze childhood: combined trials\n\nabstract\n\nbackground\nwe  supplementation >20% asthma/recurrent wheeze offspring 3 age.']
S13-PMC5659607	PMC5659607	10/2017	S13-PMC5659607	['conclusions\nthis combined analysis SHOWS that Vitamin D supplementation during Pregnancy results in a significant reduced risk of asthma/recurrent wheeze in the offspring, ESPECIALLY among women with 25(Oh)D level ≥ 30 ng/ml at randomization, where the risk was almost halved.']	[('INCOMPLETE_EVIDENCE', 35), ('ANOMALY_CURIOUS_FINDING', 172)]	2	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 200, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 200, '25(OH)D')]	0	['conclusions\nthis combined  supplementation  results asthma/recurrent wheeze offspring, among women 25(oh)d ≥ 30 ng/ml randomization, halved.']
S17-PMC5659607	PMC5659607	10/2017	S17-PMC5659607	['(3) epidemiological studies HAVE SHOWN that high dietary Vitamin D intake during Pregnancy reduces the risk of asthma/recurrent wheeze in the offspring[4,5].']	[('INCOMPLETE_EVIDENCE', 28)]	1	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnancy')]	0	['(3) epidemiological dietary  intake  reduces asthma/recurrent wheeze offspring[4,5].']
S19-PMC5659607	PMC5659607	10/2017	S19-PMC5659607	['THEREFORE, we RECENTLY conducted two independent randomized controlled trials (rcts) of increased Vitamin D supplementation during Pregnancy to prevent childhood asthma/recurrent wheeze in the offspring by age 3 years: the Vitamin D antenatal asthma reduction trial (vdaart[7]) and the copenhagen prospective studies on asthma in childhood 2010 (copsac2010[8]).']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 14)]	2	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 223, 'Vitamin D')]	0	['therefore, (rcts)  supplementation  childhood asthma/recurrent wheeze offspring age 3 years: vitamin antenatal asthma reduction (vdaart[7]) copenhagen asthma childhood 2010 (copsac2010[8]).']
S67-PMC5659607	PMC5659607	10/2017	S67-PMC5659607	['the main PURPOSE of the study was to conduct a combined analysis of the effect estimates and individual patient data from our own two large rcts (copsac2010and vdaart), which are very aligned with respect to Vitamin D dosage, time of intervention during Pregnancy, number of enrolled women, and offspring outcome definition[9,10].']	[('QUESTION_ANSWERED_BY_THIS_WORK', 9)]	1	[('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('GO_0007565', 'female pregnancy', 254, 'pregnancy')]	0	['main conduct combined individual patient rcts (copsac2010and vdaart), respect  dosage, enrolled women, offspring outcome definition[9,10].']
S68-PMC5659607	PMC5659607	10/2017	S68-PMC5659607	['HOWEVER, a literature search REVEALED one additional trial of Vitamin D supplementation in Pregnancy and subsequent asthma/recurrent wheeze performed by goldring et al., which DIFFERED markedly from our trials by enrolling 180 women at Pregnancy week 27 and randomizing them to either no Vitamin D, 800 iu Ergocalciferol daily until Delivery or a single oral bolus of 200,000 iu Cholecalciferol[22].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 176)]	3	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin D'), ('CHEBI_4910', 'etomidate', 306, 'ergocalciferol'), ('GO_0007567', 'parturition', 333, 'delivery'), ('CHEBI_52550', 'theopalauamide', 379, 'cholecalciferol')]	0	['however,  supplementation  asthma/recurrent wheeze goldring et al., enrolling 180 women  week 27 randomizing 800 iu ergocalciferol daily delivery single oral bolus 200,000 iu cholecalciferol[22].']
S72-PMC5659607	PMC5659607	10/2017	S72-PMC5659607	['the Vitamin D intervention resulted in a significant increase in the mothers post-interventional 25(Oh)D levels in both trials (table 1): in vdaart an increase from 23ng/ml to 39ng/ml and in copsac2010an increase from 31ng/ml to 43ng/ml, respectively.10.1371/journal.pone.0186657.t001\n\ncaption (table-wrap): table 1\ncharacteristics of the two trials.trialno.interventionduration of interventionfollow-upinclusion/ exclusion criteria25(Oh)D levels:control group (pre- to post-intervention)25(Oh)D levels: treatment group (pre- to post-intervention)asthma/ wheeze ESTIMATES (95% ci) vdaart, double blinded, multicenter rct, usa (2009) 806active: 4,000 + 400 iu/dplacebo:400 iu/dfrom 10–18 weeks of Gestation until Birth3 years of follow-up by quarterly phone calls andannual visits to the clinicinclusion: parental asthma, allergy or eczemaexclusion: maternal chronic disease23 ng/ml to 27 ng/ml23 ng/ml to 39 ng/mlhr: 0.8 (0.6–1.00)or: 0.72 (0.52–1.00) copsac2010, double blinded, single center rct, denmark (2008) 581active: 2,400 + 400 iu/dplacebo: 400 iu/dfrom 22–26 weeks of Gestation until 1 week Postpartum3 years of follow-up with visits to the clinic at age 1\xa0week, 1, 3, 6, 12, 18, 24, 30, 36 months and at acute Airway symptoms, plus a daily diaryinclusion: no criteriaexclusion: maternal chronic disease31 ng/ml to 29 ng/ml31 ng/ml to 43 ng/mlhr: 0.76 (0.52–1.12)or: 0.77 (0.5–1.18)\nin vdaart, 625 women (78%) had an initial 25(Oh)D level <30 ng/ml (307 received Vitamin d and 318 placebo) and 176 women (22%) had a level ≥30 ng/ml at trial entry (95 received Vitamin D and 81 placebo).']	[('INCOMPLETE_EVIDENCE', 562)]	1	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 97, '25(OH ... D'), ('CHEBI_33010', 'chromide(1-)', 434, '(OH)D'), ('CHEBI_71657', 'versiconol acetate', 488, '25(OH)D'), ('GO_0007565', 'female pregnancy', 696, 'gestation'), ('GO_0007567', 'parturition', 712, 'birth3'), ('GO_0007565', 'female pregnancy', 1078, 'gestation'), ('GO_0007565', 'female pregnancy', 1101, 'postpartum3'), ('UBERON_0001005', 'respiratory airway', 1221, 'airway'), ('CHEBI_71657', 'versiconol acetate', 1435, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 1435, '25(OH ... D'), ('CHEBI_33229', 'vitamin (role)', 1473, 'vitamin'), ('CHEBI_27300', 'vitamin D', 1570, 'vitamin D')]	0	[' resulted increase mothers post-interventional 25(oh)d levels (table 1): vdaart increase 23ng/ml 39ng/ml copsac2010an increase 31ng/ml 43ng/ml, respectively.10.1371/journal.pone.0186657.t001\n\ncaption (table-wrap): table 1\ncharacteristics trials.trialno.interventionduration interventionfollow-upinclusion/ exclusion criteria25(oh)d levels:control (pre- post-intervention)25(oh)d levels: treatment (pre- post-intervention)asthma/ wheeze (95% ci) vdaart, blinded, multicenter rct, usa (2009) 806active: 4,000 + 400 iu/dplacebo:400 iu/dfrom 10–18 weeks  birth3 follow-up quarterly phone andannual visits clinicinclusion: parental asthma, allergy eczemaexclusion: maternal chronic disease23 ng/ml 27 ng/ml23 ng/ml 39 ng/mlhr: 0.8 (0.6–1.00)or: 0.72 (0.52–1.00) copsac2010, blinded, single rct, denmark (2008) 581active: 2,400 + 400 iu/dplacebo: 400 iu/dfrom 22–26 weeks  week  follow-up visits clinic age 1\xa0week, 1, 3, 6, 12, 18, 24, 30, 36 months acute airway symptoms, plus daily diaryinclusion: criteriaexclusion: maternal chronic disease31 ng/ml 29 ng/ml31 ng/ml 43 ng/mlhr: 0.76 (0.52–1.12)or: 0.77 (0.5–1.18)\nin vdaart, 625 women (78%) 25(oh)d <30 ng/ml (307 received vitamin 318 placebo) 176 women (22%) ≥30 ng/ml (95 received  81 placebo).']
S97-PMC5659607	PMC5659607	10/2017	S97-PMC5659607	['SHOWED similar results with a significantly reduced risk of asthma/wheeze at 3 years of age in the Vitamin D intervention group, compared to controls: or = 0.76 (95% ci, 0.59–0.96), p = 0.02 ( fig 3 ), with little variation among the included studies: i2= 0%, p = 0.97.10.1371/journal.pone.0186657.g003\n\ncaption (fig): fig 3\nforest plots of the meta-analysis of asthma/recurrent wheeze in all three published randomized trials of Vitamin D intervention in Pregnancy and subsequent asthma/recurrent wheeze at age 3 years.']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 430, 'vitamin D'), ('GO_0007565', 'female pregnancy', 456, 'pregnancy')]	0	['showed results asthma/wheeze 3 age  group, controls: = 0.76 (95% ci, 0.59–0.96), p = 0.02 fig 3 ), among studies: i2= 0%, p = 0.97.10.1371/journal.pone.0186657.g003\n\ncaption (fig): fig 3\nforest plots meta-analysis asthma/recurrent wheeze three   asthma/recurrent wheeze age 3 years.']
S113-PMC5659607	PMC5659607	10/2017	S113-PMC5659607	['Lower Respiratory Tract infections (lrti) are analyzed by poisson regression model.Vitamin D vs.placeboipdor (95% ci)asthma/ recurrent wheeze0.75 (0.57–0.97)p = 0.03total Ige > median0.93 (0.73–1.18)p = 0.43specific Ige > 0.35ku/l1.05 (0.77–1.43)p = 0.78eczema0.91 (0.71–1.18)p = 0.47lrti0.92 (0.75–1.14)p = 0.44\n\ndiscussion\nin THIS combined analysis of the two largest rcts to date of Vitamin D supplementation during Pregnancy, we SHOWED that the supplementation resulted in a significant and clinically IMPORTANT 26% reduced risk of asthma/recurrent wheeze in the offspring until age 3, with a more pronounced 46% reduced risk if the women had 25(Oh)d level ≥30ng/ml at trial entry.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 328), ('INCOMPLETE_EVIDENCE', 433), ('IMPORTANT_CONSIDERATION', 506)]	3	[('UBERON_0004905', 'articulation', 0, 'Lower respiratory tract'), ('CHEBI_28384', 'vitamin K', 83, 'Vitamin D'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 171, 'IgE'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 216, 'IgE'), ('CHEBI_27300', 'vitamin D', 386, 'vitamin D'), ('GO_0007565', 'female pregnancy', 419, 'pregnancy'), ('CHEBI_63056', 'zinc cation', 647, '25(OH')]	0	['lower respiratory tract infections (lrti) poisson regression model.vitamin vs.placeboipdor (95% ci)asthma/ recurrent wheeze0.75 (0.57–0.97)p = 0.03total ige > median0.93 (0.73–1.18)p = 0.43specific ige > 0.35ku/l1.05 (0.77–1.43)p = 0.78eczema0.91 (0.71–1.18)p = 0.47lrti0.92 (0.75–1.14)p = 0.44\n\ndiscussion\nin combined largest rcts  supplementation supplementation resulted clinically 26% asthma/recurrent wheeze offspring age 3, 46% women 25(oh)d ≥30ng/ml entry.']
S114-PMC5659607	PMC5659607	10/2017	S114-PMC5659607	['these results UNDERLINE that Vitamin D supplementation during Pregnancy MAY BE an IMPORTANT FACTOR in the PREVENTION of childhood asthma.']	[('PROBABLE_UNDERSTANDING', 14), ('INCOMPLETE_EVIDENCE', 72), ('IMPORTANT_CONSIDERATION', 82), ('SUPERFICIAL_RELATIONSHIP', 92), ('SUPERFICIAL_RELATIONSHIP', 106)]	5	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy')]	0	['results  supplementation  childhood asthma.']
S130-PMC5659607	PMC5659607	10/2017	S130-PMC5659607	['furthermore, including a third trial of Vitamin D supplementation in the meta-analysis, which intervened at a later Pregnancy stage (week 27) and with a much lower dose (800 iu/day) [22] also SHOWED an overall PROTECTIVE EFFECT of Vitamin D on Development Of Asthma/recurrent Wheeze.']	[('INCOMPLETE_EVIDENCE', 192), ('SUPERFICIAL_RELATIONSHIP', 210), ('SUPERFICIAL_RELATIONSHIP', 221)]	3	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('GO_0009602', 'detection of symbiont', 244, 'development of asthma'), ('GO_0006386', 'termination of RNA polymerase III transcription', 276, 'wheeze')]	0	['furthermore, third  supplementation meta-analysis, intervened  (week 27) dose (800 iu/day) [22]  asthma/recurrent wheeze.']
S132-PMC5659607	PMC5659607	10/2017	S132-PMC5659607	['a recent meta-analysis SUPPORTS our finding of a significant reduction in asthma/wheeze from Prenatal Vitamin D supplementation[11].']	[('INCOMPLETE_EVIDENCE', 23)]	1	[('GO_0007565', 'female pregnancy', 93, 'prenatal'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]	0	['meta-analysis reduction asthma/wheeze   supplementation[11].']
S138-PMC5659607	PMC5659607	10/2017	S138-PMC5659607	['when the two trials were initiated, IT WAS THOUGHT that the EFFECTS of Vitamin D were confined to the Alveolar stage of Lung Development, occurring in the third Trimester of Pregnancy[28].']	[('ANOMALY_CURIOUS_FINDING', 36), ('INCOMPLETE_EVIDENCE', 39), ('SUPERFICIAL_RELATIONSHIP', 60)]	3	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('UBERON_0003215', 'alveolus', 102, 'alveolar'), ('GO_0030324', 'lung development', 120, 'lung development'), ('UBERON_0002048', 'lung', 120, 'lung'), ('GO_0009294', 'DNA mediated transformation', 161, 'trimester'), ('GO_0007565', 'female pregnancy', 174, 'pregnancy')]	0	['initiated,  alveolar lung development, occurring third trimester [28].']
S139-PMC5659607	PMC5659607	10/2017	S139-PMC5659607	['HOWEVER, EMERGING EVIDENCE arising from Lung Gene Expression data from our own lab have SUBSEQUENTLY SHOWN that Vitamin D already has EFFECTS at the stage of Branching Morphogenesis of the fetal Lung occurring in the first Trimester of Pregnancy prior to randomization in both these trials[2].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 134)]	4	[('UBERON_0002048', 'lung', 40, 'lung'), ('GO_0010467', 'gene expression', 45, 'gene expression'), ('SO_0000704', 'gene', 45, 'gene'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0001763', 'morphogenesis of a branching structure', 158, 'branching morphogenesis'), ('UBERON_0002048', 'lung', 195, 'lung'), ('GO_0009294', 'DNA mediated transformation', 223, 'trimester'), ('GO_0007565', 'female pregnancy', 236, 'pregnancy')]	0	['however, arising lung gene expression lab  branching morphogenesis fetal lung occurring trimester  randomization trials[2].']
S140-PMC5659607	PMC5659607	10/2017	S140-PMC5659607	['THEREFORE, initiating the supplementation at 10–18 weeks’ Gestation in vdaart and in particular at 22–26 weeks’ Gestation in copsac2010was PRESUMABLY too late to achieve a maximal EFFECT of Vitamin D on fetal Lung Development.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 139), ('SUPERFICIAL_RELATIONSHIP', 180)]	3	[('GO_0007565', 'female pregnancy', 58, 'gestation'), ('GO_0007565', 'female pregnancy', 112, 'gestation'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('GO_0030324', 'lung development', 209, 'lung development'), ('UBERON_0002048', 'lung', 209, 'lung')]	0	['therefore, supplementation 10–18 weeks’  vdaart 22–26 weeks’  copsac2010was late achieve maximal  fetal lung development.']
S148-PMC5659607	PMC5659607	10/2017	S148-PMC5659607	['this is CONSISTENT with a RECENT rct SHOWING no effect on Cat specific Ige levels, WHEREAS decreased house-Dust Mite specific Ige was SHOWN in the offspring of mothers supplemented with Vitamin D during Pregnancy[31].']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 37), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 83), ('INCOMPLETE_EVIDENCE', 134)]	5	[('NCBITaxon_33208', 'Metazoa', 58, 'cat'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 71, 'IgE'), ('NCBITaxon_10088', 'Mus <genus>', 107, 'dust'), ('NCBITaxon_10088', 'Mus <genus>', 112, 'mite'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 126, 'IgE'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]	0	['cat ige levels, decreased house-dust mite ige offspring mothers supplemented  [31].']
S152-PMC5659607	PMC5659607	10/2017	S152-PMC5659607	['FUTURE STUDIES SHOULD explore the OPTIMAL timing and level of Vitamin D supplementation during Pregnancy.']	[('FUTURE_WORK', 0), ('FUTURE_WORK', 15), ('IMPORTANT_CONSIDERATION', 34)]	3	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('GO_0007565', 'female pregnancy', 95, 'pregnancy')]	0	['future timing  supplementation .']
S153-PMC5659607	PMC5659607	10/2017	S153-PMC5659607	['conclusion\nthis combined analysis SHOWS a significant and clinically IMPORTANT 26% PROTECTIVE EFFECT of Vitamin D supplementation during Pregnancy on the RISK of asthma/recurrent wheeze in the offspring, with a more pronounced risk reduction of 46% in women with 25(Oh)D level ≥ 30 ng/ml at trial entry.']	[('INCOMPLETE_EVIDENCE', 34), ('IMPORTANT_CONSIDERATION', 69), ('SUPERFICIAL_RELATIONSHIP', 83), ('SUPERFICIAL_RELATIONSHIP', 94), ('IMPORTANT_CONSIDERATION', 154)]	5	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 263, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 263, '25(OH)D')]	0	['conclusion\nthis combined clinically 26%  supplementation  asthma/recurrent wheeze offspring, reduction 46% women 25(oh)d ≥ 30 ng/ml entry.']
S154-PMC5659607	PMC5659607	10/2017	S154-PMC5659607	['Prenatal care STRATEGIES targeted at raising Vitamin D levels in Pregnant women SHOULD THEREFORE BE CONSIDERED.']	[('FUTURE_WORK', 14), ('FUTURE_WORK', 80), ('PROBABLE_UNDERSTANDING', 87), ('ANOMALY_CURIOUS_FINDING', 97), ('FUTURE_WORK', 100)]	5	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnant')]	0	['  levels  women considered.']
S5-PMC5664622	PMC5664622	9/2017	S5-PMC5664622	['HOWEVER, ONLY 16% of the Pregnant women reached the optimal Vitamin D concentration during summer.']	[('ANOMALY_CURIOUS_FINDING', 0), ('ANOMALY_CURIOUS_FINDING', 9)]	2	[('GO_0007565', 'female pregnancy', 25, 'pregnant'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]	0	['however, 16%  women  concentration summer.']
S13-PMC5664622	PMC5664622	9/2017	S13-PMC5664622	['IN LIGHT OF the ONGOING DEBATE on the OPTIMAL Vitamin D concentration in Pregnant women, MOST EXPERTS are of the OPINION that the 25(Oh)D concentration in maternal Blood SHOULD exceed 30 ng/ml [2,8,9].']	[('PROBABLE_UNDERSTANDING', 0), ('IMPORTANT_CONSIDERATION', 16), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 24), ('IMPORTANT_CONSIDERATION', 38), ('PROBABLE_UNDERSTANDING', 89), ('PROBABLE_UNDERSTANDING', 94), ('INCOMPLETE_EVIDENCE', 113), ('FUTURE_WORK', 170), ('IMPORTANT_CONSIDERATION', 170)]	9	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 130, '25(OH)D'), ('UBERON_0000178', 'blood', 164, 'blood')]	0	[' concentration  women, 25(oh)d concentration maternal blood exceed 30 ng/ml [2,8,9].']
S35-PMC5664622	PMC5664622	9/2017	S35-PMC5664622	['the content of Vitamin D in Vitamin/Mineral supplements for Pregnant women, as well as single-component Vitamin D preparations, was ESTIMATED on the BASIS of our earlier analysis [14].']	[('INCOMPLETE_EVIDENCE', 132), ('INCOMPLETE_EVIDENCE', 149)]	2	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 28, 'vitamin'), ('CHEBI_46662', 'mineral', 36, 'mineral'), ('GO_0007565', 'female pregnancy', 60, 'pregnant'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]	0	['content  vitamin/mineral supplements  women, single-component  preparations, [14].']
S65-PMC5664622	PMC5664622	9/2017	S65-PMC5664622	['other factors RELATED to Serum Vitamin D concentration\nmultivariate regression analysis REVEALED that, apart from the season of the year, Vitamin D concentration was AFFECTED by the following FACTORS: maternal use of Vitamin D supplements, weight gain in Pregnancy, Gestational diabetes mellitus (gdm), and—in case of Cord Blood—also with Maternal age.']	[('SUPERFICIAL_RELATIONSHIP', 14), ('INCOMPLETE_EVIDENCE', 88), ('SUPERFICIAL_RELATIONSHIP', 166), ('SUPERFICIAL_RELATIONSHIP', 192)]	4	[('UBERON_0001977', 'blood serum', 25, 'Serum'), ('CHEBI_28384', 'vitamin K', 31, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 31, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 217, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy'), ('GO_0007565', 'female pregnancy', 266, 'gestational'), ('UBERON_0002240', 'spinal cord', 318, 'cord'), ('UBERON_0000178', 'blood', 323, 'blood'), ('GO_0007618', 'mating', 339, 'maternal')]	0	['serum vitamin concentration\nmultivariate regression that, season year,  concentration following factors: maternal  supplements, gain  diabetes mellitus (gdm), and—in cord blood—also maternal age.']
S77-PMC5664622	PMC5664622	9/2017	S77-PMC5664622	['our results are CONSISTENT with the FINDINGS of OTHER authors, who have also CONFIRMED Vitamin D deficiency among Pregnant women in poland [3,5,17,18,19], ALTHOUGH REPORTS in the polish literature on better Vitamin D saturation in the summer are LESS UNAMBIGUOUS.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 36), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 48), ('INCOMPLETE_EVIDENCE', 77), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 155), ('ANOMALY_CURIOUS_FINDING', 155), ('INCOMPLETE_EVIDENCE', 164), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 246), ('INCOMPLETE_EVIDENCE', 246), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 251)]	10	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnant'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]	0	['results authors,  among  women poland [3,5,17,18,19], polish  saturation summer unambiguous.']
S83-PMC5664622	PMC5664622	9/2017	S83-PMC5664622	['reports from OTHER european countries also FOUND a TENDENCY for higher Vitamin D levels among Pregnant women during summer, e.g., in germany which is located at a similar latitude as poland [20], as well as countries with very DIFFERENT geographic location and sun exposure, such as greece [12], or norway [21].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 13), ('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 51), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 227)]	4	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnant')]	0	['reports european countries higher  levels among  women summer, e.g., germany located latitude poland [20], countries geographic location sun exposure, greece [12], norway [21].']
S87-PMC5664622	PMC5664622	9/2017	S87-PMC5664622	['the RECOMMENDED levels of Vitamin D were FOUND in ONLY 5% of the Pregnant women in germany [20], and 16.5% in ukraine [22].']	[('FUTURE_WORK', 4), ('INCOMPLETE_EVIDENCE', 41), ('ANOMALY_CURIOUS_FINDING', 50), ('INCOMPLETE_EVIDENCE', 50)]	4	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnant')]	0	['levels  5%  women germany [20], 16.5% ukraine [22].']
S92-PMC5664622	PMC5664622	9/2017	S92-PMC5664622	['a study conducted in belgium FOUND that Pregnant women who avoid sun exposure are at a 2-fold higher RISK for severe Vitamin D deficiency [25].']	[('INCOMPLETE_EVIDENCE', 29), ('IMPORTANT_CONSIDERATION', 101)]	2	[('GO_0007565', 'female pregnancy', 40, 'pregnant'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]	0	['belgium  women sun exposure 2-fold higher  [25].']
S94-PMC5664622	PMC5664622	9/2017	S94-PMC5664622	['REGARDLESS, DESPITE Vitamin/Mineral supplementation in Pregnancy, maternal intake of Vitamin D REMAINS below the RECOMMENDED levels, MOSTLY BECAUSE 75% of the multi-component Supplements for Pregnant women which are available in poland contain small amount of Vitamin D (5–10 µg) [14], as compared to the recommended dose of 37.5–50 µg [8].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 12), ('INCOMPLETE_EVIDENCE', 95), ('FUTURE_WORK', 113), ('PROBABLE_UNDERSTANDING', 133), ('PROBABLE_UNDERSTANDING', 140)]	6	[('CHEBI_33229', 'vitamin (role)', 20, 'vitamin'), ('CHEBI_46662', 'mineral', 28, 'mineral'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 175, 'supplements'), ('GO_0007565', 'female pregnancy', 191, 'pregnant'), ('CHEBI_27300', 'vitamin D', 260, 'vitamin D')]	0	['regardless, vitamin/mineral supplementation maternal intake  levels, 75% multi-component supplements  women poland contain  (5–10 µg) [14], dose 37.5–50 µg [8].']
S98-PMC5664622	PMC5664622	9/2017	S98-PMC5664622	['the PROBLEM of low doses of Vitamin D in preparations for Pregnant women APPEARS TO BE GLOBAL.']	[('IMPORTANT_CONSIDERATION', 4), ('PROBLEM_COMPLICATION', 4), ('ANOMALY_CURIOUS_FINDING', 73), ('IMPORTANT_CONSIDERATION', 87)]	4	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnant')]	0	['doses  preparations  women global.']
S110-PMC5664622	PMC5664622	9/2017	S110-PMC5664622	['in OUR STUDY, we CONFIRMED DETRIMENTAL EFFECTS of excessive weight gain in Pregnancy which results in diminished Vitamin D concentration.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('INCOMPLETE_EVIDENCE', 17), ('IMPORTANT_CONSIDERATION', 27), ('SUPERFICIAL_RELATIONSHIP', 39)]	4	[('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]	0	['study, excessive gain  results diminished  concentration.']
S114-PMC5664622	PMC5664622	9/2017	S114-PMC5664622	['AS Vitamin D concentration was measured immediately before the Delivery, we LACK DATA on pre-Pregnancy, as well as the first Trimester of Pregnancy, values.']	[('PROBABLE_UNDERSTANDING', 0), ('FULL_UNKNOWN', 76)]	2	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('GO_0007567', 'parturition', 63, 'delivery'), ('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('GO_0009294', 'DNA mediated transformation', 125, 'trimester'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy')]	0	[' concentration immediately delivery, pre-, trimester values.']
S118-PMC5664622	PMC5664622	9/2017	S118-PMC5664622	['it SEEMS that the ESTIMATED Vitamin D consumption is a RELIABLE result AS it is CONSISTENT with OTHER REPORTS, which for years have INDICATED a consistently low amount of Vitamin D in the diet of polish Pregnant women (2.6–2.8 µg/day) [13,35].']	[('ANOMALY_CURIOUS_FINDING', 3), ('INCOMPLETE_EVIDENCE', 18), ('IMPORTANT_CONSIDERATION', 55), ('PROBABLE_UNDERSTANDING', 71), ('INCOMPLETE_EVIDENCE', 80), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 96), ('INCOMPLETE_EVIDENCE', 102), ('INCOMPLETE_EVIDENCE', 132)]	8	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('GO_0007565', 'female pregnancy', 203, 'pregnant')]	0	[' consumption result reports, amount  diet polish  women (2.6–2.8 µg/day) [13,35].']
S119-PMC5664622	PMC5664622	9/2017	S119-PMC5664622	['the same HAS BEEN FOUND for young non-Pregnant women, who Consume on average 2.4 µg/day of Vitamin D [36].']	[('INCOMPLETE_EVIDENCE', 9)]	1	[('GO_0007565', 'female pregnancy', 38, 'pregnant'), ('GO_0007631', 'feeding behavior', 58, 'consume'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]	0	['young non- women, consume average 2.4 µg/day  [36].']
S128-PMC5664622	PMC5664622	9/2017	S128-PMC5664622	['we also DID NOT investigate pre-Pregnancy Vitamin D intake, which MAY have had SOME IMPACT on its concentration in the first trimester.']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 66), ('INCOMPLETE_EVIDENCE', 79), ('SUPERFICIAL_RELATIONSHIP', 84)]	4	[('GO_0007565', 'female pregnancy', 32, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]	0	['pre-  intake, concentration trimester.']
S129-PMC5664622	PMC5664622	9/2017	S129-PMC5664622	['also, it is VITAL TO BEAR IN MIND that in OUR STUDY the analysis of Vitamin D level was conducted on the day of the Delivery, which does not signify that the concentration was typical for the entire course of Pregnancy or at least its significant part.']	[('IMPORTANT_CONSIDERATION', 12), ('QUESTION_ANSWERED_BY_THIS_WORK', 42)]	2	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007567', 'parturition', 116, 'delivery'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]	0	['also, bear  day delivery, concentration typical entire course  part.']
S132-PMC5664622	PMC5664622	9/2017	S132-PMC5664622	['conclusions\nON THE BASIS OF the FINDINGS of OUR STUDY, conducted among polish Pregnant women, it SEEMS SAFE to conclude that significantly low levels of Vitamin D concentration among Pregnant women in poland MAY in FACT be a common occurrence.']	[('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 32), ('QUESTION_ANSWERED_BY_THIS_WORK', 44), ('ANOMALY_CURIOUS_FINDING', 97), ('IMPORTANT_CONSIDERATION', 103), ('INCOMPLETE_EVIDENCE', 208), ('ANOMALY_CURIOUS_FINDING', 215)]	7	[('GO_0007565', 'female pregnancy', 78, 'pregnant'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D'), ('GO_0007565', 'female pregnancy', 183, 'pregnant')]	0	['conclusions\non study, among polish  women, levels  concentration among  women poland occurrence.']
S136-PMC5664622	PMC5664622	9/2017	S136-PMC5664622	['HOWEVER, that level does not apply to the overall EFFECT of Vitamin D on the course of Pregnancy and maternal health.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 50)]	2	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy')]	0	['however, apply  course  maternal health.']
S36-PMC5679631	PMC5679631	11/2017	S36-PMC5679631	['data regarding POSSIBLE CONFOUNDERS and Vitamin D exposure through Supplement use was assessed from questionnaires sent to all parents at 34 weeks of Gestation, the time of Fecal sampling and 3 months Postpartum, respectively.']	[('INCOMPLETE_EVIDENCE', 15), ('PROBLEM_COMPLICATION', 24)]	2	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 67, 'supplement'), ('GO_0007565', 'female pregnancy', 150, 'gestation'), ('UBERON_0000922', 'embryo', 173, 'fecal'), ('GO_0007565', 'female pregnancy', 201, 'postpartum')]	0	['data regarding  exposure supplement questionnaires sent parents 34 weeks fecal sampling 3 months respectively.']
S105-PMC5679631	PMC5679631	11/2017	S105-PMC5679631	['600 (reference)0 (reference)quintile 2680.01 (-0.21, 0.24)0.01 (-0.21, 0.22)quintile 349-0.11 (-0.35, 0.14)-0.18 (-0.41, 0.06)quintile 4510.02 (-0.22, 0.26)0.04 (-0.20, 0.28)quintile 558-0.06 (-0.30, 0.17)0.08 (-0.17, 0.33)p for linear trendp = 0.459\n&number of children colonized;\n#adjusted for: place and mode of Delivery, number of siblings, recruitment group, total bacterial counts, sex, vaginitis during the last month of Pregnancy, mode of infant nutrition and season of Blood sampling; quintile 5 is the highest quintile;\n* remained statistically significant after correction with fdr (q < 0.05)\n\nVitamin D supplementation of the infant\nthere was no influence of Vitamin D supplementation of the infant during the first month of Life on the prevalence of any of the bacterial species or groups (data not shown).table 5shows the ASSOCIATION between Vitamin D supplementation of the infant in the first month of Life and the log10cfus of the different bacteria in children colonized with the respective bacterial group or species (for a visualisation of the data in univariable boxplots see alsos3 fig).10.1371/journal.pone.0188011.t005\n\ncaption (table-wrap): table 5\nassociation between Vitamin D supplementation of the infant and log10colony forming units/g Feces of bacterial species or groups in Breast Fed infants (n = 616) colonized with the respective bacteria.Vitamin D supplement use of Breast feeding infantsvitamin D supplementationbacteria&nunadjusted b (95% ci)#adjusted b (95% ci)no use bifidobacterium spp.']	[('SUPERFICIAL_RELATIONSHIP', 836)]	1	[('GO_0007567', 'parturition', 315, 'delivery'), ('GO_0007565', 'female pregnancy', 428, 'pregnancy'), ('UBERON_0000178', 'blood', 478, 'blood'), ('CHEBI_28384', 'vitamin K', 605, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 671, 'vitamin D'), ('UBERON_0000104', 'life cycle', 737, 'life'), ('CHEBI_27300', 'vitamin D', 856, 'vitamin D'), ('UBERON_0000104', 'life cycle', 918, 'life'), ('CHEBI_27300', 'vitamin D', 1194, 'vitamin D'), ('UBERON_0001988', 'feces', 1266, 'feces'), ('GO_0007567', 'parturition', 1306, 'breast'), ('UBERON_0000310', 'breast', 1306, 'breast'), ('GO_0007631', 'feeding behavior', 1313, 'fed'), ('CHEBI_28384', 'vitamin K', 1374, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 1374, 'Vitamin'), ('UBERON_0000310', 'breast', 1402, 'Breast'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1432, 'D')]	0	['600 (reference)0 (reference)quintile 2680.01 (-0.21, 0.24)0.01 (-0.21, 0.22)quintile 349-0.11 (-0.35, 0.14)-0.18 (-0.41, 0.06)quintile 4510.02 (-0.22, 0.26)0.04 (-0.20, 0.28)quintile 558-0.06 (-0.30, 0.17)0.08 (-0.17, 0.33)p linear trendp = 0.459\n&number children colonized;\n#adjusted for: place mode delivery, siblings, recruitment group, bacterial counts, sex, vaginitis last month mode infant nutrition season blood sampling; quintile 5 quintile;\n* statistically correction fdr (q 0.05)\n\nvitamin supplementation infant\nthere  supplementation infant month life bacterial species (data shown).table 5shows  supplementation infant month life log10cfus bacteria children colonized respective bacterial species (for visualisation univariable boxplots alsos3 fig).10.1371/journal.pone.0188011.t005\n\ncaption (table-wrap): table 5\nassociation  supplementation infant log10colony forming units/g feces bacterial species breast fed infants (n = 616) colonized respective bacteria.vitamin supplement breast feeding infantsvitamin supplementationbacteria&nunadjusted b (95% ci)#adjusted b (95% ci)no bifidobacterium spp.']
S137-PMC5679631	PMC5679631	11/2017	S137-PMC5679631	['HERE we report on an ASSOCIATION between Prenatal Vitamin D exposure and the abundance of several key bacterial taxa in the infant Intestinal microbiota.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('SUPERFICIAL_RELATIONSHIP', 21)]	2	[('GO_0007565', 'female pregnancy', 41, 'prenatal'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0000160', 'intestine', 131, 'intestinal')]	0	['  exposure abundance bacterial taxa infant intestinal microbiota.']
S159-PMC5679631	PMC5679631	11/2017	S159-PMC5679631	['TO OUR KNOWLEDGE, THIS is the FIRST report of a large scale observational study INDICATING that Prenatal Vitamin D exposure, AS measured either by maternal use of multivitamin supplements containing Vitamin D, or 25(Oh)D quintiles, INFLUENCES several IMPORTANT bacterial taxa within the infant Gut.']	[('PROBABLE_UNDERSTANDING', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 18), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 80), ('PROBABLE_UNDERSTANDING', 125), ('SUPERFICIAL_RELATIONSHIP', 232), ('IMPORTANT_CONSIDERATION', 251)]	7	[('GO_0007565', 'female pregnancy', 96, 'prenatal'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 213, '25(OH)D'), ('UBERON_0001555', 'digestive tract', 294, 'gut')]	0	['knowledge,   exposure, maternal multivitamin supplements containing 25(oh)d quintiles, bacterial taxa infant gut.']
S46-PMC5682869	PMC5682869	11/2017	S46-PMC5682869	['HOWEVER, still a well-balanced ovo-lacto vegetarian diet USUALLY enables good Nutrient status in Pregnancy, when supplemented with Vitamin D, Folic Acid, Iodine, iron, Vitamin B12 and zinc, and, in cases of a fish-free diet, with Dha [19].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 57)]	2	[('CHEBI_33284', 'nutrient', 78, 'nutrient'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_30751', 'formic acid', 142, 'folic acid'), ('CHEBI_24859', 'iodine atom', 154, 'iodine'), ('CHEBI_33279', 'vitamin D5', 168, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 176, 'B12'), ('CHEBI_17874', 'dihydrozeatin', 230, 'DHA')]	0	['however, well-balanced ovo-lacto vegetarian diet nutrient status supplemented folic acid, iodine, iron, vitamin b12 zinc, and, cases fish-free diet, dha [19].']
S76-PMC5682869	PMC5682869	11/2017	S76-PMC5682869	['EARLY STUDIES concerning Vitamin D in Pregnancy SHOWED an ASSOCIATION with Preeclampsia and caesarean section but also Glucose tolerance, abnormal foetal Grown pattern, Preterm Birth and Reproductive failure.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 48), ('SUPERFICIAL_RELATIONSHIP', 58)]	3	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 75, 'preeclampsia'), ('CHEBI_17234', 'glucose', 119, 'glucose'), ('GO_0040007', 'growth', 154, 'grown'), ('GO_0007565', 'female pregnancy', 169, 'preterm'), ('GO_0007567', 'parturition', 177, 'birth'), ('GO_0000003', 'reproduction', 187, 'reproductive')]	0	['early   preeclampsia caesarean section glucose tolerance, abnormal foetal grown pattern,  birth reproductive failure.']
S0-PMC5706533	PMC5706533	11/2017	S0-PMC5706533	['Vitamin D supplementation during Pregnancy: state of the evidence from a systematic review of randomised trials\n\nabstract\nobjectives \xa0TO ESTIMATE the EFFECTS of Vitamin D supplementation during Pregnancy on 11 maternal and 27 neonatal/infant outcomes; TO DETERMINE frequencies at which trial outcome data were missing, unreported, or inconsistently reported; and to project the POTENTIAL contributions of registered ongoing or planned trials.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 134), ('INCOMPLETE_EVIDENCE', 137), ('SUPERFICIAL_RELATIONSHIP', 150), ('QUESTION_ANSWERED_BY_THIS_WORK', 252), ('INCOMPLETE_EVIDENCE', 378)]	5	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('GO_0007565', 'female pregnancy', 194, 'pregnancy')]	0	['vitamin supplementation : randomised trials\n\nabstract\nobjectives \xa0to  supplementation  11 maternal 27 neonatal/infant outcomes; frequencies outcome missing, unreported, reported; registered trials.']
S10-PMC5706533	PMC5706533	11/2017	S10-PMC5706533	['there was STRONG EVIDENCE that Prenatal Vitamin D reduced the risk of offspring wheeze by age 3 years (0.81, 0.67 to 0.98; two comparisons).']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('GO_0007565', 'female pregnancy', 31, 'prenatal'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]	0	['  offspring wheeze age 3 (0.81, 0.67 0.98; comparisons).']
S14-PMC5706533	PMC5706533	11/2017	S14-PMC5706533	['conclusions \xa0most trials on Prenatal Vitamin D published by september 2017 were SMALL and of low quality.']	[('INCOMPLETE_EVIDENCE', 80)]	1	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D')]	0	['conclusions \xa0most   september 2017 quality.']
S18-PMC5706533	PMC5706533	11/2017	S18-PMC5706533	['beyond its established INFLUENCE on bone growth and Calcium Homeostasis,1vitamin D and its RELATED Metabolites have HYPOTHESISED EFFECTS on the risk of Cardiovascular diseases,2cancer,3respiratory infections,4asthma,5conditions RELATED to Pregnancy (such as pre-eclampsia, Gestational diabetes), and Birth outcomes.6concern that Vitamin D deficiency is a global PUBLIC HEALTH PROBLEM HAS BEEN sparked by numerous REPORTS of the high proportion of Individuals in studies throughout the world who have relatively low Serum/Plasma concentrations of 25-hydroxyvitamin d (25(Oh)D),7the conventional circulating BIOMARKER of Vitamin D status.8there HAS BEEN particular ATTENTION to the high prevalence of vitamin d deficiency in Pregnant women and newborns.7\nin 2010, dietary reference intakes for Vitamin D for canada and the us from the institute of medicine were based solely on bone health—particularly in young children (for instance, rickets) and older Adults (for instance, osteoporosis).1considerable SKEPTICISM was cast onto the LINK between Vitamin D and Extraskeletal health conditions or the POTENTIAL benefits (versus risks) of intakes larger than the recommended dietary allowance (600 iu/day for MOST children and Adults).1THE institute’s report DID NOT RECOMMEND higher intakes during Pregnancy and Lactation.1a 2016 update of the cochrane collaboration systematic review and meta-analysis of trials of Vitamin D in Pregnancy (versus placebo or no Supplement), HOWEVER, TENTATIVELY CONCLUDED that Prenatal Vitamin D supplementation “MAY reduce the risk of pre-eclampsia, low birthweight and Preterm Birth.”6other RECENT systematic reviews that included trials with active control arms (in which participants received Vitamin D) ACKNOWLEDGED the POTENTIAL EFFECT of Vitamin D on fetal growth910but DID NOT FIND evidence of EFFECTS on OTHER maternal, fetal, or infant outcomes.91011citing the 2016 cochrane review,6the world health organization guidelines for Antenatal care ADVISE against routine Vitamin D supplementation in Pregnancy.12dietary and supplementation RECOMMENDATIONS, HOWEVER, vary widely across other professional organisations (appendix 1), and there REMAINS a LACK OF CONSENSUS on target health outcomes, indications for Prenatal supplementation, or EVIDENCE BASED regimens for supplement dose (or fortification STRATEGIES).']	[('SUPERFICIAL_RELATIONSHIP', 23), ('SUPERFICIAL_RELATIONSHIP', 91), ('INCOMPLETE_EVIDENCE', 116), ('SUPERFICIAL_RELATIONSHIP', 129), ('SUPERFICIAL_RELATIONSHIP', 228), ('IMPORTANT_CONSIDERATION', 362), ('IMPORTANT_CONSIDERATION', 376), ('PROBLEM_COMPLICATION', 376), ('INCOMPLETE_EVIDENCE', 384), ('INCOMPLETE_EVIDENCE', 413), ('SUPERFICIAL_RELATIONSHIP', 606), ('INCOMPLETE_EVIDENCE', 643), ('IMPORTANT_CONSIDERATION', 663), ('INCOMPLETE_EVIDENCE', 663), ('IMPORTANT_CONSIDERATION', 1003), ('SUPERFICIAL_RELATIONSHIP', 1032), ('INCOMPLETE_EVIDENCE', 1098), ('PROBABLE_UNDERSTANDING', 1205), ('INCOMPLETE_EVIDENCE', 1231), ('INCOMPLETE_EVIDENCE', 1255), ('FUTURE_WORK', 1263), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1471), ('INCOMPLETE_EVIDENCE', 1480), ('INCOMPLETE_EVIDENCE', 1492), ('INCOMPLETE_EVIDENCE', 1543), ('INCOMPLETE_EVIDENCE', 1623), ('INCOMPLETE_EVIDENCE', 1738), ('PROBABLE_UNDERSTANDING', 1738), ('INCOMPLETE_EVIDENCE', 1755), ('SUPERFICIAL_RELATIONSHIP', 1765), ('INCOMPLETE_EVIDENCE', 1807), ('SUPERFICIAL_RELATIONSHIP', 1832), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 1843), ('FUTURE_WORK', 1983), ('FUTURE_WORK', 2075), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2092), ('ANOMALY_CURIOUS_FINDING', 2092), ('INCOMPLETE_EVIDENCE', 2177), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2187), ('INCOMPLETE_EVIDENCE', 2187), ('INCOMPLETE_EVIDENCE', 2277), ('FUTURE_WORK', 2339)]	42	[('GO_0055073', 'cadmium ion homeostasis', 52, 'calcium homeostasis'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 81, 'D'), ('CHEBI_25212', 'metabolite', 99, 'metabolites'), ('UBERON_0004535', 'cardiovascular system', 152, 'cardiovascular'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy'), ('GO_0007565', 'female pregnancy', 273, 'gestational'), ('GO_0007567', 'parturition', 300, 'birth'), ('CHEBI_27300', 'vitamin D', 329, 'vitamin D'), ('NCBITaxon_1', 'root', 447, 'individuals'), ('UBERON_0001977', 'blood serum', 515, 'serum'), ('UBERON_0001969', 'blood plasma', 521, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 567, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin D'), ('GO_0007565', 'female pregnancy', 723, 'pregnant'), ('CHEBI_27300', 'vitamin D', 792, 'vitamin D'), ('UBERON_0007023', 'adult organism', 953, 'adults'), ('CHEBI_27300', 'vitamin D', 1045, 'vitamin D'), ('UBERON_0001431', 'distal carpal bone 2', 1059, 'extraskeletal'), ('UBERON_0007023', 'adult organism', 1223, 'adults'), ('GO_0007565', 'female pregnancy', 1295, 'pregnancy'), ('GO_0007595', 'lactation', 1309, 'lactation'), ('CHEBI_27300', 'vitamin D', 1413, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1426, 'pregnancy'), ('CHEBI_16158', 'steroid sulfate', 1458, 'supplement'), ('GO_0007565', 'female pregnancy', 1507, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1516, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1601, 'preterm birth'), ('CHEBI_27300', 'vitamin D', 1727, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1775, 'vitamin D'), ('GO_0007567', 'parturition', 1968, 'antenatal'), ('CHEBI_27300', 'vitamin D', 2006, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2035, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2248, 'prenatal')]	0	['beyond bone calcium homeostasis,1vitamin metabolites cardiovascular diseases,2cancer,3respiratory infections,4asthma,5conditions  (such pre-eclampsia,  diabetes), birth outcomes.6concern  sparked proportion individuals throughout world serum/plasma concentrations 25-hydroxyvitamin (25(oh)d),7the circulating  status.8there vitamin  women newborns.7\nin 2010, dietary intakes  canada us institute medicine bone health—particularly young children (for instance, rickets) older adults (for instance, osteoporosis).1considerable onto  extraskeletal conditions (versus risks) intakes dietary allowance (600 iu/day children adults).1the institute’s higher intakes  lactation.1a 2016 update cochrane collaboration meta-analysis   (versus placebo supplement), however,   supplementation “may pre-eclampsia, birthweight .”6other arms (in participants received  fetal growth910but maternal, fetal, infant outcomes.91011citing 2016 cochrane review,6the world organization antenatal routine  supplementation .12dietary supplementation recommendations, however, professional organisations (appendix 1), outcomes,  supplementation, regimens supplement dose (or fortification strategies).']
S19-PMC5706533	PMC5706533	11/2017	S19-PMC5706533	['given the numerous trials on Prenatal Vitamin D published since 2015 and the RESTRICTED scope of the 2016 cochrane review, we UNDERTOOK an updated systematic review of Vitamin D in Pregnancy TO ASSESS the current and future state of the evidence from randomised controlled trials.']	[('INCOMPLETE_EVIDENCE', 77), ('QUESTION_ANSWERED_BY_THIS_WORK', 126), ('QUESTION_ANSWERED_BY_THIS_WORK', 191), ('QUESTION_ANSWERED_BY_THIS_WORK', 191), ('QUESTION_ANSWERED_BY_THIS_WORK', 194)]	5	[('GO_0007565', 'female pregnancy', 29, 'prenatal'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('GO_0007565', 'female pregnancy', 181, 'pregnancy')]	0	['given   2015 2016 cochrane review,   randomised trials.']
S20-PMC5706533	PMC5706533	11/2017	S20-PMC5706533	['we SPECIFICALLY AIMED to estimate the EFFECTS of Vitamin D supplementation during Pregnancy on maternal, neonatal, and infant outcomes, taking into consideration the quality of AVAILABLE evidence and heterogeneity across studies; determine frequencies at which relevant outcome variable data were missing, unreported, or inconsistently reported among trials that were otherwise eligible for inclusion; and IDENTIFY ONGOING or PLANNED STUDIES of Vitamin D supplementation during Pregnancy to project the state of EVIDENCE that COULD accrue in the next decade.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 16), ('SUPERFICIAL_RELATIONSHIP', 38), ('INCOMPLETE_EVIDENCE', 177), ('FUTURE_WORK', 406), ('IMPORTANT_CONSIDERATION', 415), ('FUTURE_WORK', 426), ('INCOMPLETE_EVIDENCE', 434), ('INCOMPLETE_EVIDENCE', 512), ('INCOMPLETE_EVIDENCE', 526)]	10	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 445, 'vitamin D'), ('GO_0007565', 'female pregnancy', 478, 'pregnancy')]	0	[' supplementation  maternal, neonatal, infant outcomes, studies; frequencies outcome missing, unreported, among eligible inclusion;  supplementation  accrue decade.']
S63-PMC5706533	PMC5706533	11/2017	S63-PMC5706533	['we ASSESSED the potential contribution of eligible planned/ongoing Prenatal Vitamin D trials by identifying the number of participants and trials for the same prespecified list of maternal or child outcomes as in the systematic review of completed trials.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3)]	1	[('GO_0007565', 'female pregnancy', 67, 'prenatal'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]	0	['eligible planned/ongoing   participants prespecified list maternal child outcomes completed trials.']
S80-PMC5706533	PMC5706533	11/2017	S80-PMC5706533	['figures are number (percentage) unless stated otherwisecharacteristicall trialsregular dose trials*Bolus dose trials*trials4337†8†intervention arms55469participants enrolled:\u2003total840676871031\u2003median within individual trials (min-max)133 (16-1134)133 (16-1134)118 (50-235)meta-analyses to which each trial contributed:\u2003median maternal outcomes (min-max)2 (0-6)2 (0-6)2 (0-4)\u2003median newborn/infant outcomes (min-max)3 (0-17)3 (0-17)4 (0-7)\u2003trials that DID not contribute data to any meta-analyses2 (4.7)2 (5.4)0 (0.0)geographical region:\u2003europe7 (16.3)7 (18.9)2 (25.0)\u2003south east asia6 (14.0)2 (5.4)4 (50.0)\u2003americas5 (11.6)5 (13.5)0 (0.0)\u2003eastern mediterranean21 (48.8)19 (51.4)2 (25.0)\u2003western pacific4 (9.3)4 (10.8)0 (0.0)health status at enrolment:\u2003generally healthy37 (86.0)33 (89.2)6 (75.0)\u2003Gestational diabetes4 (9.3)2 (5.4)2 (25.0)\u2003hypocalcaemia1 (2.3)1 (2.7)\u2003multiple sclerosis1 (2.3)1 (2.7)0 (0.0)baseline Vitamin D status‡:\u2003mean 25(Oh)D <30 nmol/l10 (23.3)9 (24.3)2 (25.0)\u2003mean 25(Oh)D ≥30 nmol/l23 (53.5)20 (54.1)3 (37.5)\u2003not reported10 (23.3)8 (21.6)3 (37.5)type of Vitamin D§:\u2003d24 (7.3)3 (6.5)1 (11.1)\u2003d348 (87.3)40 (87.0)8 (88.9)\u2003not reported3 (5.5)3 (6.5)0 (0.0)supplementation frequency§:\u2003daily31 (56.4)31 (67.4)—\u2003weekly5 (9.1)5 (10.9)—\u2003every 2 weeks6 (10.9)6 (13.0)—\u2003monthly3 (5.5)3 (6.5)—\u2003 every 2 months1 (1.8)1 (2.2)—\u2003single dose3 (5.5)—3 (33.3)\u2003two doses4 (7.3)—4 (44.4)\u2003other2 (3.6)—2 (22.2)intervention dose§¶:\u2003median (min-max)2000 (200-7543)2000 (200-7543)—\u2003regular dose <2000 iu/day24 (52.2)24 (52.2)—\u2003regular dose ≥2000 iu/day22 (47.8)22 (47.8)—control intervention type:\u2003placebo29 (67.4)23 (62.2)8 (100.0)\u2003active14 (32.6)14 (37.8)0 (0.0)median Vitamin D dose in active control arms (min-max)400 (200-600)400 (200-600)—timing of initiation of supplementation§:\u20031st trimester19 (34.5)18 (39.1)1 (11.1)\u20032nd trimester30 (54.5)24 (52.2)6 (66.7)\u20033rd trimester5 (9.1)3 (6.5)2 (22.2)\u2003not reported1 (1.8)1 (2.2)0 (0.0)\n*regular dosing refers to regimens in which Supplement was administered at least three times at regular frequency throughout Pregnancy (daily, weekly, every 2 weeks, monthly, or every 2 months ); bolus dosing refers to interventions administered either once or twice during intervention period.']	[('ANOMALY_CURIOUS_FINDING', 451)]	1	[('NCBITaxon_10088', 'Mus <genus>', 99, 'Bolus'), ('GO_0007565', 'female pregnancy', 796, 'Gestational'), ('CHEBI_27300', 'vitamin D', 915, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 939, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 988, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 1078, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1671, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 1981, 'supplement'), ('GO_0007565', 'female pregnancy', 2062, 'pregnancy')]	0	['figures (percentage) otherwisecharacteristicall trialsregular dose trials*bolus dose trials*trials4337†8†intervention arms55469participants enrolled:\u2003total840676871031\u2003median individual (min-max)133 (16-1134)133 (16-1134)118 (50-235)meta-analyses contributed:\u2003median maternal outcomes (min-max)2 (0-6)2 (0-6)2 (0-4)\u2003median newborn/infant outcomes (min-max)3 (0-17)3 (0-17)4 (0-7)\u2003trials meta-analyses2 (4.7)2 (5.4)0 (0.0)geographical region:\u2003europe7 (16.3)7 (18.9)2 (25.0)\u2003south east asia6 (14.0)2 (5.4)4 (50.0)\u2003americas5 (11.6)5 (13.5)0 (0.0)\u2003eastern mediterranean21 (48.8)19 (51.4)2 (25.0)\u2003western pacific4 (9.3)4 (10.8)0 (0.0)health status enrolment:\u2003generally healthy37 (86.0)33 (89.2)6 (75.0)\u2003 diabetes4 (9.3)2 (5.4)2 (25.0)\u2003hypocalcaemia1 (2.3)1 (2.7)\u2003multiple sclerosis1 (2.3)1 (2.7)0 (0.0)baseline  status‡:\u2003mean 25(oh)d <30 nmol/l10 (23.3)9 (24.3)2 (25.0)\u2003mean 25(oh)d ≥30 nmol/l23 (53.5)20 (54.1)3 (37.5)\u2003not reported10 (23.3)8 (21.6)3 (37.5)type §:\u2003d24 (7.3)3 (6.5)1 (11.1)\u2003d348 (87.3)40 (87.0)8 (88.9)\u2003not reported3 (5.5)3 (6.5)0 (0.0)supplementation frequency§:\u2003daily31 (56.4)31 (67.4)—\u2003weekly5 (9.1)5 (10.9)—\u2003every 2 weeks6 (10.9)6 (13.0)—\u2003monthly3 (5.5)3 (6.5)—\u2003 2 months1 (1.8)1 (2.2)—\u2003single dose3 (5.5)—3 (33.3)\u2003two doses4 (7.3)—4 (44.4)\u2003other2 (3.6)—2 (22.2)intervention dose§¶:\u2003median (min-max)2000 (200-7543)2000 (200-7543)—\u2003regular dose <2000 iu/day24 (52.2)24 (52.2)—\u2003regular dose ≥2000 iu/day22 (47.8)22 (47.8)—control type:\u2003placebo29 (67.4)23 (62.2)8 (100.0)\u2003active14 (32.6)14 (37.8)0 (0.0)median  dose arms (min-max)400 (200-600)400 (200-600)—timing initiation supplementation§:\u20031st trimester19 (34.5)18 (39.1)1 (11.1)\u20032nd trimester30 (54.5)24 (52.2)6 (66.7)\u20033rd trimester5 (9.1)3 (6.5)2 (22.2)\u2003not reported1 (1.8)1 (2.2)0 (0.0)\n*regular dosing refers regimens supplement administered three times frequency throughout  (daily, weekly, 2 weeks, monthly, 2 months ); bolus dosing refers administered twice period.']
S89-PMC5706533	PMC5706533	11/2017	S89-PMC5706533	['no published trials were conducted in africa, THOUGH one large trial in tanzania (n=2300) is ongoing and projected to be completed and published before 2024\n\ncaption (fig)\n\nfig 3 \xa0effective equivalent daily Vitamin D dose (iu/day) versus maternal baseline mean 25-Hydroxyvitamin D (25(Oh)D) concentration (nmol/l) in published Prenatal Vitamin D supplementation trials with regular dosing regimens (29 trials; 36 comparisons).']	[('ANOMALY_CURIOUS_FINDING', 46)]	1	[('CHEBI_27300', 'vitamin D', 207, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 261, '25-hydroxyvitamin D'), ('CHEBI_30778', 'gallic acid', 282, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 288, 'D'), ('GO_0007565', 'female pregnancy', 327, 'prenatal'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]	0	['africa, tanzania (n=2300) completed 2024\n\ncaption (fig)\n\nfig 3 \xa0effective daily  dose (iu/day) maternal baseline 25-hydroxyvitamin (25(oh)d) concentration (nmol/l)   supplementation dosing regimens (29 trials; 36 comparisons).']
S98-PMC5706533	PMC5706533	11/2017	S98-PMC5706533	['caption (table-wrap): table 2\n\npooled risk ratios from primary meta-analyses of EFFECTS of Vitamin D supplementation during Pregnancy on maternal and neonatal/infant outcomesoutcomestrials reporting eligible outcometrials included*intervention-control comparisons included*participants included*risk ratio (95% ci)i2(%) maternal pre-eclampsia3337061.09 (0.43 to 2.76)67†Gestational hypertension2225641.69 (0.73 to 3.92)0gestational diabetes55510300.65 (0.39 to 1.08)45stillbirth16161946060.75 (0.51 to 1.13)0caesarean section17161832401.02 (0.93 to 1.12)0preterm labor4447760.52 (0.26 to 1.05)51hypercalcaemia4111753.11 (0.87 to 11.08)—hypercalciuria2111603.00 (0.12 to 72.56)—hypocalcaemia2112000.05†(0.01 to 0.18)—admission to hospital55517760.97 (0.69 to 1.35)0 neonatal/infant Preterm Birth14131537571.00 (0.77 to 1.30)0low Birth weight87711560.74 (0.47 to 1.16)47small for Gestational age5577410.60†(0.40 to 0.90)0congenital malformations54425090.93 (0.61 to 1.42)0neonatal death53412020.48 (0.16 to 1.49)0.0hypercalcaemia111730.97 (0.31 to 3.08)—hypocalcaemia2111260.10 (0.01 to 1.83)—admission to Neonatal Intensive Care unit55619970.92 (0.66 to 1.28)21respiratory infections (general)1122230.97 (0.77 to 1.23)0upper Respiratory Tract infections2243890.91 (0.77 to 1.06)0lower Respiratory Tract infections44617690.97 (0.84 to 1.12)0asthma or recurrent/persistent wheeze by age 3 years22213870.81†(0.67 to 0.98)0\n*intervention-control group comparisons with zero events in both groups excluded from primary meta-analyses.']	[('SUPERFICIAL_RELATIONSHIP', 80)]	1	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007565', 'female pregnancy', 370, 'Gestational'), ('GO_0007128', 'meiotic prophase I', 781, 'Preterm'), ('GO_0043174', 'nucleoside salvage', 789, 'birth14131537571'), ('GO_0007567', 'parturition', 828, 'birth'), ('GO_0007565', 'female pregnancy', 878, 'gestational'), ('UBERON_0001759', 'vagus nerve', 1104, 'neonatal'), ('UBERON_0001007', 'digestive system', 1113, 'intensive care'), ('UBERON_0000065', 'respiratory tract', 1224, 'respiratory tract'), ('UBERON_0000065', 'respiratory tract', 1284, 'respiratory tract')]	0	['caption (table-wrap): table 2\n\npooled ratios meta-analyses  supplementation  maternal neonatal/infant outcomesoutcomestrials eligible outcometrials included*intervention-control comparisons included*participants included*risk ratio (95% ci)i2(%) maternal pre-eclampsia3337061.09 (0.43 2.76)67† hypertension2225641.69 (0.73 3.92)0gestational diabetes55510300.65 (0.39 1.08)45stillbirth16161946060.75 (0.51 1.13)0caesarean section17161832401.02 (0.93 1.12)0preterm labor4447760.52 (0.26 1.05)51hypercalcaemia4111753.11 (0.87 11.08)—hypercalciuria2111603.00 (0.12 72.56)—hypocalcaemia2112000.05†(0.01 0.18)—admission hospital55517760.97 (0.69 1.35)0 neonatal/infant preterm birth14131537571.00 (0.77 1.30)0low birth weight87711560.74 (0.47 1.16)47small  age5577410.60†(0.40 0.90)0congenital malformations54425090.93 (0.61 1.42)0neonatal death53412020.48 (0.16 1.49)0.0hypercalcaemia111730.97 (0.31 3.08)—hypocalcaemia2111260.10 (0.01 1.83)—admission neonatal intensive unit55619970.92 (0.66 1.28)21respiratory infections (general)1122230.97 (0.77 1.23)0upper respiratory tract infections2243890.91 (0.77 1.06)0lower respiratory tract infections44617690.97 (0.84 1.12)0asthma recurrent/persistent wheeze age 3 years22213870.81†(0.67 0.98)0\n*intervention-control comparisons zero events meta-analyses.']
S105-PMC5706533	PMC5706533	11/2017	S105-PMC5706533	['inclusion of all trials irrespective of these criteria, HOWEVER, SUGGESTED that Vitamin D COULD reduce the risk of Gestational diabetes (risk ratio 0.61, 95% confidence interval 0.45 to 0.83; 14 comparisons; 2643 participants) (table s5 and fig s10 in appendix 10).']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 56), ('INCOMPLETE_EVIDENCE', 65), ('INCOMPLETE_EVIDENCE', 90)]	3	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'gestational')]	0	['inclusion irrespective criteria, however,   diabetes (risk ratio 0.61, 95% confidence interval 0.45 0.83; 14 comparisons; 2643 participants) (table s5 fig s10 appendix 10).']
S109-PMC5706533	PMC5706533	11/2017	S109-PMC5706533	['pooling of 37 comparisons INDICATED that Prenatal Vitamin D supplementation (versus low dose, no Vitamin D, or placebo) increased mean Birth weight by an average of 58 g (fig 4).']	[('INCOMPLETE_EVIDENCE', 26)]	1	[('GO_0007565', 'female pregnancy', 41, 'prenatal'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007567', 'parturition', 135, 'birth')]	0	['pooling 37 comparisons   supplementation (versus dose, placebo) birth average 58 g (fig 4).']
S115-PMC5706533	PMC5706533	11/2017	S115-PMC5706533	['caption (fig)\n\nfig 4 \xa0a: weighted mean differences (wmds) and b: cumulative wmds for effect of Prenatal Vitamin D supplementation on mean Birth weight (g), ESTIMATED with random effects meta-analysis, based on 37 intervention-control comparisons in 30 randomised controlled trials of regular or bolus regimen Vitamin D at any dose in studies published by september 2017\nCONSISTENT with the pooled EFFECT on mean Birth weight—but in a smaller subset of only seven comparisons—vitamin d reduced the risk of small for Gestational age (sga) (table 2; table s14 and fig s30 in appendix 10).']	[('INCOMPLETE_EVIDENCE', 156), ('INCOMPLETE_EVIDENCE', 370), ('SUPERFICIAL_RELATIONSHIP', 397)]	3	[('GO_0007565', 'female pregnancy', 95, 'prenatal'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007567', 'parturition', 138, 'birth'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D'), ('GO_0007567', 'parturition', 412, 'birth'), ('GO_0007565', 'female pregnancy', 515, 'gestational')]	0	['caption (fig)\n\nfig 4 \xa0a: weighted (wmds) b: cumulative wmds   supplementation birth (g), random meta-analysis, 37 intervention-control comparisons 30 randomised bolus regimen  dose september 2017\nconsistent pooled birth weight—but subset seven comparisons—vitamin  age (sga) (table 2; table s14 fig s30 appendix 10).']
S118-PMC5706533	PMC5706533	11/2017	S118-PMC5706533	['there was NO APPARENT effect of Vitamin D on Gestational age at Birth (table 3; table s18 and figs s37-s38 in appendix 10) or the risk of Preterm Birth (table 2; table s19 and figs s39-s41 in appendix 10).']	[('ANOMALY_CURIOUS_FINDING', 10)]	1	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 45, 'gestational'), ('GO_0007567', 'parturition', 64, 'birth'), ('GO_0007565', 'female pregnancy', 138, 'preterm birth')]	0	['  age birth (table 3; table s18 figs s37-s38 appendix 10)  (table 2; table s19 figs s39-s41 appendix 10).']
S121-PMC5706533	PMC5706533	11/2017	S121-PMC5706533	['the pooled estimate from two high quality regular dose trials in high income countries (total 1387 participants) INDICATED that Prenatal Vitamin D supplementation significantly decreased the RISK of persistent/recurrent wheeze in offspring by age 3 years (table 2; fig s51 in appendix 10).']	[('INCOMPLETE_EVIDENCE', 113), ('IMPORTANT_CONSIDERATION', 191)]	2	[('GO_0007565', 'female pregnancy', 128, 'prenatal'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]	0	['pooled dose income countries (total 1387 participants)   supplementation decreased persistent/recurrent wheeze offspring age 3 (table 2; fig s51 appendix 10).']
S132-PMC5706533	PMC5706533	11/2017	S132-PMC5706533	['caption (fig)\n\nfig 5 \xa0proportion of all participants (n=8406) enrolled in eligible trials for which maternal and neonatal/infant outcomes were reported and met criteria for case definition and method of ascertainment; reported but did not meet minimum criteria; reported, but in manner that prevented inclusion of data in meta-analysis; missing because of loss of follow-up in trials for which outcome was reported for some participants or BECAUSE of apparent incomplete reporting of planned outcomes; or MISSING BECAUSE outcome was not assessed or not mentioned in published reports\n\nfuture projections of evidence based on registered ongoing/planned trials\nwe identified 35 registered trials of Prenatal Vitamin D with a total target enrolment of 12\u2009530 participants, of which 19 (54%) were completed but unpublished, 11 (31%) were ongoing or planned, and five (14%) had indeterminate status (fig 2; table a and fig a in appendix 11).']	[('PROBLEM_COMPLICATION', 440), ('PROBLEM_COMPLICATION', 505), ('PROBLEM_COMPLICATION', 513)]	3	[('GO_0007565', 'female pregnancy', 697, 'prenatal'), ('CHEBI_27300', 'vitamin D', 706, 'vitamin D')]	0	['caption (fig)\n\nfig 5 \xa0proportion participants (n=8406) enrolled eligible maternal neonatal/infant outcomes met criteria definition ascertainment; meet minimum criteria; reported, manner inclusion meta-analysis; loss follow-up outcome participants outcomes; outcome reports\n\nfuture registered ongoing/planned trials\nwe 35 registered   enrolment 12\u2009530 participants, 19 (54%) completed unpublished, 11 (31%) planned, five (14%) indeterminate status (fig 2; table fig appendix 11).']
S145-PMC5706533	PMC5706533	11/2017	S145-PMC5706533	['discussion\nthough trials of Prenatal Vitamin D supplementation are being published at an ACCELERATING pace, randomised controlled trials published up to 2017 were GENERALLY SMALL, low quality, and RARELY designed to examine clinical outcomes.']	[('IMPORTANT_CONSIDERATION', 89), ('PROBABLE_UNDERSTANDING', 163), ('INCOMPLETE_EVIDENCE', 173), ('INCOMPLETE_EVIDENCE', 197)]	4	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D')]	0	['discussion\nthough   supplementation pace, randomised 2017 small, quality, outcomes.']
S148-PMC5706533	PMC5706533	11/2017	S148-PMC5706533	['THOUGH SOME OBSERVATIONAL STUDIES HAVE SHOWN ASSOCIATIONS between maternal Vitamin D deficiency and Gestational diabetes and pre-eclampsia,22we DID NOT FIND ROBUST corroborating evidence from randomised controlled trials.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 7), ('INCOMPLETE_EVIDENCE', 12), ('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 45), ('INCOMPLETE_EVIDENCE', 144), ('INCOMPLETE_EVIDENCE', 157)]	8	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'gestational')]	0	['though maternal   diabetes pre-eclampsia,22we randomised trials.']
S155-PMC5706533	PMC5706533	11/2017	S155-PMC5706533	['for example, Prenatal Vitamin D supplementation in deficient women modifies neonatal Calcium Homeostasis,31BUT clinical CORRELATES (such as symptomatic infant hypocalcaemia) were RARE and infrequently ascertained across trials.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 105), ('SUPERFICIAL_RELATIONSHIP', 120), ('INCOMPLETE_EVIDENCE', 179)]	3	[('GO_0007565', 'female pregnancy', 13, 'prenatal'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0055073', 'cadmium ion homeostasis', 85, 'calcium homeostasis')]	0	['example,   supplementation women modifies neonatal calcium homeostasis,31but (such symptomatic infant hypocalcaemia) trials.']
S157-PMC5706533	PMC5706533	11/2017	S157-PMC5706533	['one of the most ROBUST FINDINGS in our systematic review—which has been PREVIOUSLY REPORTED32—was the beneficial EFFECT of Prenatal Vitamin D on RISK of persistent/recurrent wheeze (or asthma) in offspring, BASED ON data from two large well conducted trials in which wheeze/asthma was the primary outcome.3334this is broadly CONSISTENT with the POSSIBLY positive EFFECT of Vitamin D on severity of illness in Adults with asthma.5before Prenatal Vitamin D CAN be RECOMMENDED as a routine preventive measure against childhood asthma, HOWEVER, FURTHER WORK IS REQUIRED to CLARIFY the minimum effective dose and longer term follow-up to determine IF OBSERVED early EFFECTS on symptoms TRANSLATE into reductions in the incidence of asthma and improvements in Pulmonary function.']	[('INCOMPLETE_EVIDENCE', 16), ('INCOMPLETE_EVIDENCE', 23), ('INCOMPLETE_EVIDENCE', 72), ('INCOMPLETE_EVIDENCE', 83), ('SUPERFICIAL_RELATIONSHIP', 113), ('IMPORTANT_CONSIDERATION', 145), ('INCOMPLETE_EVIDENCE', 207), ('ANOMALY_CURIOUS_FINDING', 213), ('INCOMPLETE_EVIDENCE', 325), ('INCOMPLETE_EVIDENCE', 345), ('SUPERFICIAL_RELATIONSHIP', 363), ('INCOMPLETE_EVIDENCE', 455), ('FUTURE_WORK', 462), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 532), ('FUTURE_WORK', 541), ('IMPORTANT_CONSIDERATION', 557), ('FUTURE_WORK', 569), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 643), ('INCOMPLETE_EVIDENCE', 646), ('SUPERFICIAL_RELATIONSHIP', 661), ('SUPERFICIAL_RELATIONSHIP', 681)]	21	[('GO_0007565', 'female pregnancy', 123, 'prenatal'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 373, 'vitamin D'), ('UBERON_0007023', 'adult organism', 409, 'adults'), ('GO_0007565', 'female pregnancy', 436, 'prenatal'), ('CHEBI_27300', 'vitamin D', 445, 'vitamin D'), ('UBERON_0002048', 'lung', 754, 'pulmonary')]	0	['one review—which reported32—was   persistent/recurrent wheeze (or asthma) offspring, wheeze/asthma outcome.3334this positive  illness adults asthma.5before   routine measure childhood asthma, however, minimum dose longer term follow-up symptoms reductions asthma pulmonary function.']
S167-PMC5706533	PMC5706533	11/2017	S167-PMC5706533	['for example, for the EFFECT of Vitamin D on pre-eclampsia, de-regil and colleagues REPORTED a pooled risk ratio of 0.52 (95% confidence interval 0.25 to 1.05) based on two trials that we included in our review, but neither of which met our minimum criteria for case definitions and methods of ascertainment: one trial ONLY mentioned the exclusion of a participant for “severe pre-eclampsia,”38AND the other REPORTED frequencies of pre-eclampsia but DID NOT mention any screening or diagnostic procedures.39de-regil and colleagues also REPORTED that Vitamin D reduced the RISK of Preterm Birth based on thee trials,6but the current meta-analysis based on 15 comparisons produced REASONABLY strong evidence of a null effect.']	[('SUPERFICIAL_RELATIONSHIP', 21), ('INCOMPLETE_EVIDENCE', 83), ('INCOMPLETE_EVIDENCE', 318), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 391), ('INCOMPLETE_EVIDENCE', 407), ('INCOMPLETE_EVIDENCE', 449), ('INCOMPLETE_EVIDENCE', 535), ('IMPORTANT_CONSIDERATION', 571), ('PROBABLE_UNDERSTANDING', 678)]	9	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 549, 'vitamin D'), ('GO_0007565', 'female pregnancy', 579, 'preterm birth')]	0	['example,  pre-eclampsia, de-regil colleagues pooled ratio 0.52 (95% confidence interval 0.25 1.05) review, met minimum criteria definitions ascertainment: exclusion participant “severe pre-eclampsia,”38and frequencies pre-eclampsia mention screening diagnostic procedures.39de-regil colleagues   thee trials,6but meta-analysis 15 comparisons effect.']
S173-PMC5706533	PMC5706533	11/2017	S173-PMC5706533	['although we intend to update this review regularly (the platform for FUTURE real time dissemination is STILL TO BE DETERMINED), we project LIMITED aggregate gains from the 35 MOSTLY SMALL TRIALS of Prenatal Vitamin D supplementation trials that are registered as completed, ongoing, or planned.']	[('FUTURE_WORK', 69), ('FULL_UNKNOWN', 103), ('INCOMPLETE_EVIDENCE', 139), ('INCOMPLETE_EVIDENCE', 175), ('INCOMPLETE_EVIDENCE', 182)]	5	[('GO_0007565', 'female pregnancy', 198, 'prenatal'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]	0	['although update regularly (the platform dissemination determined), aggregate 35   supplementation registered completed, ongoing, planned.']
S176-PMC5706533	PMC5706533	11/2017	S176-PMC5706533	['in the meantime, we ENDORSE the NOTION that WHENEVER feasible, investigators SHOULD report all clinically IMPORTANT outcomes, EVEN in SMALL trials that are individually UNDERPOWERED to detect EFFECTS on such outcomes.45\njohn ioannidis RECENTLY REMARKED that “systematic reviews MAY SOMETIMES be most helpful IF, INSTEAD of focusing on the summary of the evidence, HIGHLIGHT the BIASES that are INVOLVED and what NEEDS to be done to remedy the state-of-the-EVIDENCE in the given field.”46we conclude that there is currently INSUFFICIENT EVIDENCE to guide RECOMMENDATIONS for Prenatal Vitamin D supplementation.']	[('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 32), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 44), ('FUTURE_WORK', 77), ('IMPORTANT_CONSIDERATION', 106), ('ANOMALY_CURIOUS_FINDING', 126), ('INCOMPLETE_EVIDENCE', 134), ('PROBLEM_COMPLICATION', 169), ('SUPERFICIAL_RELATIONSHIP', 192), ('INCOMPLETE_EVIDENCE', 235), ('ANOMALY_CURIOUS_FINDING', 244), ('ANOMALY_CURIOUS_FINDING', 244), ('INCOMPLETE_EVIDENCE', 278), ('INCOMPLETE_EVIDENCE', 282), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 308), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 312), ('INCOMPLETE_EVIDENCE', 364), ('PROBLEM_COMPLICATION', 378), ('SUPERFICIAL_RELATIONSHIP', 394), ('FUTURE_WORK', 412), ('INCOMPLETE_EVIDENCE', 456), ('INCOMPLETE_EVIDENCE', 523), ('FUTURE_WORK', 554)]	23	[('GO_0007565', 'female pregnancy', 574, 'prenatal'), ('CHEBI_27300', 'vitamin D', 583, 'vitamin D')]	0	['meantime, feasible, clinically outcomes, individually outcomes.45\njohn ioannidis “systematic helpful if, evidence, remedy field.”46we   supplementation.']
S177-PMC5706533	PMC5706533	11/2017	S177-PMC5706533	['cautious PROJECTIONS for the next decade SUGGEST that we will eventually know more about Vitamin D in Pregnancy THAN we do now, BUT in the absence of a coordinated effort and funding to conduct large new trials, SOME of the most CRITICAL QUESTIONS about the effectiveness of Prenatal Vitamin D supplementation will PROBABLY REMAIN unanswered in the foreseeable FUTURE.']	[('FUTURE_WORK', 9), ('FUTURE_WORK', 9), ('INCOMPLETE_EVIDENCE', 41), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 112), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 128), ('INCOMPLETE_EVIDENCE', 212), ('IMPORTANT_CONSIDERATION', 229), ('EXPLICIT_QUESTION', 238), ('PROBABLE_UNDERSTANDING', 315), ('INCOMPLETE_EVIDENCE', 324), ('FUTURE_WORK', 361)]	11	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('GO_0007565', 'female pregnancy', 275, 'prenatal'), ('CHEBI_27300', 'vitamin D', 284, 'vitamin D')]	0	['cautious decade eventually   now, absence coordinated funding conduct trials,   supplementation foreseeable future.']
S178-PMC5706533	PMC5706533	11/2017	S178-PMC5706533	['what is already known on THIS topic\nnumerous randomised trials and systematic reviews of Vitamin D supplementation during Pregnancy HAVE BEEN published, with CONFLICTING results and conclusions\nrecommendations regarding Vitamin D supplementation vary widely among medical and professional organisations, and who currently RECOMMENDS against routine Prenatal Vitamin D supplementation\n\nwhat THIS STUDY adds\nsystematic review and meta-analyses of 43 trials including 8406 participants SHOWED that Prenatal Vitamin D supplementation was ASSOCIATED with increased maternal and cord Serum 25-Hydroxyvitamin D concentrations, increased mean birth weight, reduced the risk of small for Gestational age, reduced the risk of wheeze in offspring, and increased infant length at one year of age\nthere was a LACK OF EVIDENCE OF benefits of Prenatal Vitamin D supplementation for maternal health conditions RELATED to Pregnancy, no effect on other Birth outcomes of PUBLIC HEALTH IMPORTANCE such as Preterm Birth, and SCANT EVIDENCE on safety outcomes\nFEW of the trials were designed to test the EFFECT of Vitamin D on clinical or functional outcomes, and most trials were SMALL and at overall high or UNCERTAIN risk of bias\nthirty five planned or ongoing Prenatal Vitamin D trials COULD contribute an additional 12\u2009530 participants to FUTURE systematic reviews\n\npubmed central:']	[('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('INCOMPLETE_EVIDENCE', 132), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 158), ('FUTURE_WORK', 322), ('QUESTION_ANSWERED_BY_THIS_WORK', 390), ('INCOMPLETE_EVIDENCE', 483), ('SUPERFICIAL_RELATIONSHIP', 534), ('INCOMPLETE_EVIDENCE', 796), ('SUPERFICIAL_RELATIONSHIP', 894), ('IMPORTANT_CONSIDERATION', 953), ('IMPORTANT_CONSIDERATION', 967), ('INCOMPLETE_EVIDENCE', 1005), ('INCOMPLETE_EVIDENCE', 1039), ('SUPERFICIAL_RELATIONSHIP', 1083), ('INCOMPLETE_EVIDENCE', 1160), ('FULL_UNKNOWN', 1189), ('INCOMPLETE_EVIDENCE', 1269), ('FUTURE_WORK', 1323)]	18	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 228, 'D'), ('GO_0007565', 'female pregnancy', 349, 'prenatal'), ('CHEBI_27300', 'vitamin D', 358, 'vitamin D'), ('GO_0007565', 'female pregnancy', 495, 'prenatal'), ('CHEBI_27300', 'vitamin D', 504, 'vitamin D'), ('UBERON_0001977', 'blood serum', 578, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 584, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 679, 'gestational'), ('GO_0007565', 'female pregnancy', 828, 'prenatal'), ('CHEBI_27300', 'vitamin D', 837, 'vitamin D'), ('GO_0007565', 'female pregnancy', 905, 'pregnancy'), ('GO_0007567', 'parturition', 935, 'birth'), ('GO_0007565', 'female pregnancy', 986, 'preterm'), ('GO_0007567', 'parturition', 994, 'birth'), ('CHEBI_27300', 'vitamin D', 1093, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1243, 'prenatal'), ('CHEBI_27300', 'vitamin D', 1252, 'vitamin D')]	0	['topic\nnumerous randomised  supplementation  published, results conclusions\nrecommendations regarding  supplementation among medical professional organisations, routine   supplementation\n\nwhat adds\nsystematic meta-analyses 43 8406 participants   supplementation maternal cord serum 25-hydroxyvitamin concentrations, birth weight,  age, wheeze offspring, infant length year age\nthere   supplementation maternal conditions birth outcomes  birth, outcomes\nfew  functional outcomes, bias\nthirty five   12\u2009530 participants reviews\n\npubmed central:']
S43-PMC5716389	PMC5716389	9/2017	S43-PMC5716389	['there is NO INFORMATION on the ASSOCIATION between maternal Vitamin A status during Pregnancy and infant Immune Response.']	[('FULL_UNKNOWN', 9), ('SUPERFICIAL_RELATIONSHIP', 31)]	2	[('CHEBI_27300', 'vitamin D', 60, 'vitamin A'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('GO_0006955', 'immune response', 105, 'immune response'), ('UBERON_0002405', 'immune system', 105, 'immune')]	0	['maternal  status  infant immune response.']
S22-PMC5732382	PMC5732382	12/2017	S22-PMC5732382	['Pregnant women are among the MOST VULNERABLE, with a high risk of iron deficiency (60% among Pregnant woman) and Vitamin A deficiency (39%) [7].']	[('IMPORTANT_CONSIDERATION', 29), ('IMPORTANT_CONSIDERATION', 34)]	2	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 93, 'pregnant'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin A')]	0	[' women among vulnerable, iron (60% among  woman)  (39%) [7].']
S0-PMC5732505	PMC5732505	12/2017	S0-PMC5732505	['maternal Vitamin D status, Gestational diabetes and infant Birth size\n\nabstract\n\nbackground\nmaternal Vitamin D status HAS BEEN ASSOCIATED with both Gestational diabetes mellitus (gdm) and fetal growth restriction, HOWEVER, the EVIDENCE is INCONSISTENT.']	[('INCOMPLETE_EVIDENCE', 118), ('SUPERFICIAL_RELATIONSHIP', 127), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 214), ('INCOMPLETE_EVIDENCE', 227), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 239)]	5	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 27, 'gestational'), ('GO_0007567', 'parturition', 59, 'birth'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 148, 'gestational')]	0	['maternal  status,  diabetes infant birth size\n\nabstract\n\nbackground\nmaternal  status  diabetes mellitus (gdm) fetal restriction, however, inconsistent.']
S15-PMC5732505	PMC5732505	12/2017	S15-PMC5732505	['a sufficient maternal Vitamin D status, specified AS 25(Oh)D above 50\xa0nmol/l, MAY BE a threshold above which the physiological REQUIREMENTS of Pregnancy are achieved.']	[('PROBABLE_UNDERSTANDING', 50), ('INCOMPLETE_EVIDENCE', 78), ('IMPORTANT_CONSIDERATION', 127)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 59, 'D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]	0	['maternal  status, specified 25(oh)d 50\xa0nmol/l, physiological  achieved.']
S48-PMC5732505	PMC5732505	12/2017	S48-PMC5732505	['we employed ucb 25(Oh)D to REFLECT both the maternal Vitamin D status at the end of Pregnancy and the newborn’s Vitamin D status at Birth [1].']	[('PROBABLE_UNDERSTANDING', 27)]	1	[('CHEBI_71657', 'versiconol acetate', 16, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('GO_0007567', 'parturition', 132, 'birth')]	0	['employed ucb 25(oh)d maternal  status  newborn’s  status birth [1].']
S99-PMC5732505	PMC5732505	12/2017	S99-PMC5732505	['MAJORITY (95%) of the mothers took Vitamin D supplements during Pregnancy, MOST of them were highly educated (75% had at least a bachelor level education), and 73% had normal weight before Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('PROBABLE_UNDERSTANDING', 75)]	2	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007565', 'female pregnancy', 189, 'pregnancy')]	0	['majority (95%) mothers took  supplements educated (75% bachelor education), 73% normal .']
S104-PMC5732505	PMC5732505	12/2017	S104-PMC5732505	['NO DIFFERENCES between the groups were OBSERVED in SEVERAL other characteristics, including gwg, duration of Gestation, and supplemental Vitamin D intake.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 39), ('INCOMPLETE_EVIDENCE', 51)]	3	[('GO_0007565', 'female pregnancy', 109, 'gestation'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]	0	['characteristics, gwg, duration supplemental  intake.']
S117-PMC5732505	PMC5732505	12/2017	S117-PMC5732505	['the PREVALENCE of Vitamin D deficiency [25(Oh)D\u2009<\u200950\xa0nmol/l] during Pregnancy was SIMILAR between mothers with or without gdm [4.9% (4/81) vs 3.3% (21/642), p \u2009=\u20090.51].']	[('IMPORTANT_CONSIDERATION', 4), ('SUPERFICIAL_RELATIONSHIP', 82)]	2	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 46, 'D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy')]	0	[' [25(oh)d\u2009<\u200950\xa0nmol/l]  mothers gdm [4.9% (4/81) 3.3% (21/642), p \u2009=\u20090.51].']
S132-PMC5732505	PMC5732505	12/2017	S132-PMC5732505	['abbreviations: gwg, Gestational weight gain; gdm, Gestational diabetes mellitus; 25(Oh)D, 25-Hydroxy Vitamin D; suboptimal, ucb, Umbilical Cord Blood; 25(Oh)D\u2009<\u200980\xa0nmol/l; optimal 25(Oh)D\u2009≥\u200980\xa0nmol/l\n\ndiscussion\nthe primary FOCUS of this work was TO DETERMINE WHETHER 25(Oh)D concentration differs between mothers with AND without gdm, and WHETHER Vitamin D status AFFECTS Birth size in normal-Birth-weight infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 224), ('QUESTION_ANSWERED_BY_THIS_WORK', 247), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 260), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 340), ('SUPERFICIAL_RELATIONSHIP', 365)]	5	[('GO_0007565', 'female pregnancy', 20, 'gestational'), ('GO_0007565', 'female pregnancy', 50, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 81, '25(OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 90, '25-hydroxy vitamin D'), ('UBERON_0002331', 'umbilical cord', 129, 'umbilical cord'), ('UBERON_0000178', 'blood', 144, 'blood'), ('CHEBI_71657', 'versiconol acetate', 151, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 268, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 348, 'vitamin D'), ('GO_0007567', 'parturition', 373, 'birth'), ('GO_0007567', 'parturition', 394, 'birth')]	0	['abbreviations: gwg,  gain; gdm,  diabetes mellitus; 25(oh)d, 25-hydroxy vitamin d; suboptimal, ucb, umbilical cord blood; 25(oh)d\u2009<\u200980\xa0nmol/l; 25(oh)d\u2009≥\u200980\xa0nmol/l\n\ndiscussion\nthe 25(oh)d concentration mothers gdm,  status birth normal-birth-weight infants.']
S136-PMC5732505	PMC5732505	12/2017	S136-PMC5732505	['INTERESTINGLY, Pregnancy Vitamin D status ASSOCIATED positively with Birth weight, BUT an inverse ASSOCIATION was OBSERVED between newborn Vitamin D status and Head circumference at Birth.']	[('ANOMALY_CURIOUS_FINDING', 0), ('SUPERFICIAL_RELATIONSHIP', 42), ('ANOMALY_CURIOUS_FINDING', 83), ('SUPERFICIAL_RELATIONSHIP', 98), ('INCOMPLETE_EVIDENCE', 114)]	5	[('GO_0007565', 'female pregnancy', 15, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007567', 'parturition', 69, 'birth'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('UBERON_0000033', 'head', 160, 'head'), ('GO_0007567', 'parturition', 182, 'birth')]	0	['interestingly,   status positively birth weight, newborn  status head circumference birth.']
S141-PMC5732505	PMC5732505	12/2017	S141-PMC5732505	['HOWEVER, we OBSERVED that Vitamin D deficiency at Delivery was more PREVALENT in mothers with gdm compared with non-gdm mothers, BUT this was not marked during Pregnancy.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 12), ('IMPORTANT_CONSIDERATION', 68), ('ANOMALY_CURIOUS_FINDING', 129)]	4	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007567', 'parturition', 50, 'delivery'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy')]	0	['however,  delivery mothers gdm non-gdm mothers, marked .']
S152-PMC5732505	PMC5732505	12/2017	S152-PMC5732505	['maternal Vitamin D status ASSOCIATED with Birth size: Pregnancy 25(Oh)D SHOWED a positive ASSOCIATION towards Birth weight, BUT ucb 25(Oh)D an inverse ASSOCIATION with Head circumference, WHILE ONLY the inverse ASSOCIATION with Head circumference was VERIFIED with linear model.']	[('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 72), ('SUPERFICIAL_RELATIONSHIP', 90), ('ANOMALY_CURIOUS_FINDING', 124), ('SUPERFICIAL_RELATIONSHIP', 151), ('ANOMALY_CURIOUS_FINDING', 188), ('ANOMALY_CURIOUS_FINDING', 194), ('SUPERFICIAL_RELATIONSHIP', 211), ('INCOMPLETE_EVIDENCE', 251)]	9	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 42, 'birth'), ('GO_0007565', 'female pregnancy', 54, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 64, '25(OH)D'), ('GO_0007567', 'parturition', 110, 'birth'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('UBERON_0000033', 'head', 168, 'head'), ('UBERON_0000033', 'head', 228, 'head')]	0	['maternal  status birth size:  25(oh)d positive birth weight, ucb 25(oh)d head circumference, head circumference linear model.']
S176-PMC5732505	PMC5732505	12/2017	S176-PMC5732505	['sufficient maternal Vitamin D status, specified AS 25(Oh)D above 50\xa0nmol/l, SEEMS a threshold value, above which the physiological REQUIREMENTS of Pregnancy are achieved.']	[('PROBABLE_UNDERSTANDING', 48), ('PROBABLE_UNDERSTANDING', 76), ('IMPORTANT_CONSIDERATION', 131)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 51, '25(OH)D'), ('GO_0007565', 'female pregnancy', 147, 'pregnancy')]	0	['sufficient maternal  status, specified 25(oh)d 50\xa0nmol/l, value, physiological  achieved.']
S100-PMC5738092	PMC5738092	12/2017	S100-PMC5738092	['except the Prenatal supplementation of Vitamin A and Β-Carotene, all the variables had significant (p <0.001) ASSOCIATION with infant’s size at Birth.']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('GO_0007565', 'female pregnancy', 11, 'prenatal'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 53, 'β-carotene'), ('GO_0007567', 'parturition', 144, 'birth')]	0	['except  supplementation  β-carotene, (p <0.001) infant’s birth.']
S123-PMC5738092	PMC5738092	12/2017	S123-PMC5738092	['OUR STUDY REVEALED that all the maternal variables EXAMINED, except Vitamin A and Β- Carotene supplement receipt during Pregnancy, were significantly ASSOCIATED with Birth size.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('INCOMPLETE_EVIDENCE', 10), ('QUESTION_ANSWERED_BY_THIS_WORK', 51), ('SUPERFICIAL_RELATIONSHIP', 150)]	4	[('CHEBI_27300', 'vitamin D', 68, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 82, 'β- carotene'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('GO_0007567', 'parturition', 166, 'birth')]	0	['maternal examined,  β- carotene supplement receipt birth size.']
S40-PMC5741981	PMC5741981	12/2018	S40-PMC5741981	['when Prenatal Vitamins were REPORTED, we considered them as multivitamins designed for Pregnant women containing more and/or other Vitamins than Folic Acid and Vitamin D.\nwomen were asked if they obtained information about medication before and during Pregnancy.']	[('INCOMPLETE_EVIDENCE', 28)]	1	[('GO_0007565', 'female pregnancy', 5, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 14, 'vitamins'), ('GO_0007565', 'female pregnancy', 87, 'pregnant'), ('CHEBI_33277', 'gamma-tocotrienol', 131, 'vitamins'), ('CHEBI_30751', 'formic acid', 145, 'folic acid'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('GO_0007565', 'female pregnancy', 252, 'pregnancy')]	0	[' vitamins reported, multivitamins  women containing and/or vitamins folic acid .\nwomen medication .']
S140-PMC5758521	PMC5758521	1/2018	S140-PMC5758521	['MOST STUDIES on Vitamins A and E in Pregnancy HAVE BEEN focused on the ASSOCIATION with fetal growth, and the FINDINGS HAVE BEEN INCONSISTENT33–35.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 46), ('SUPERFICIAL_RELATIONSHIP', 71), ('INCOMPLETE_EVIDENCE', 110), ('INCOMPLETE_EVIDENCE', 119), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 129)]	6	[('CHEBI_27300', 'vitamin D', 16, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 25, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 31, 'E'), ('GO_0007565', 'female pregnancy', 36, 'pregnancy')]	0	[' e  fetal growth, inconsistent33–35.']
S144-PMC5758521	PMC5758521	1/2018	S144-PMC5758521	['REPORTED that maternal Α-Tocopherol concentrations were positively ASSOCIATED with Birth weight, BUT poston and colleagues FOUND that Prenatal supplementation with Α-Tocopherol and Vitamin C was ASSOCIATED with elevated risk of low Birth weight8.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 67), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 97), ('ANOMALY_CURIOUS_FINDING', 97), ('INCOMPLETE_EVIDENCE', 123), ('SUPERFICIAL_RELATIONSHIP', 195)]	6	[('CHEBI_27725', 'butin', 23, 'α-tocopherol'), ('GO_0007567', 'parturition', 83, 'birth'), ('GO_0007565', 'female pregnancy', 134, 'prenatal'), ('CHEBI_27725', 'butin', 164, 'α-tocopherol'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin C'), ('GO_0007567', 'parturition', 232, 'birth')]	0	['reported maternal α-tocopherol concentrations positively birth weight, poston colleagues  supplementation α-tocopherol  birth weight8.']
S159-PMC5784894	PMC5784894	1/2018	S159-PMC5784894	['the mavidos study, a randomised controlled trial of Vitamin D supplementation to Pregnant women RECENTLY REPORTED changes in bmc in babies Born during the winter months.']	[('INCOMPLETE_EVIDENCE', 96), ('INCOMPLETE_EVIDENCE', 105)]	2	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnant'), ('GO_0007567', 'parturition', 139, 'born')]	0	['mavidos study, randomised  supplementation  women changes bmc babies born winter months.']
S187-PMC5784894	PMC5784894	1/2018	S187-PMC5784894	['xue et al IDENTIFIED Dna Methylation changes in 2 generations of offspring from dams exposed to dietary Vitamin D deficiency throughout Gestation and weaning[38].']	[('INCOMPLETE_EVIDENCE', 10)]	1	[('GO_0006306', 'DNA methylation', 21, 'DNA methylation'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 136, 'gestation')]	0	['xue et al dna methylation changes 2 generations offspring dams exposed dietary  throughout  weaning[38].']
S191-PMC5784894	PMC5784894	1/2018	S191-PMC5784894	['THIS work THUS establishes Early Life Vitamin D deficiency as a FACTOR that CAN CONTRIBUTE to Adult osteoporosis; offers a POTENTIAL Solution–supplementation of Vitamin D during Pregnancy and infancy; and presents a MODEL system TO IDENTIFY pathways that COULD BE TARGETED in Adult Life to prevent or treat osteoporosis, a GLOBAL health PROBLEM.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 0), ('PROBABLE_UNDERSTANDING', 10), ('SUPERFICIAL_RELATIONSHIP', 64), ('INCOMPLETE_EVIDENCE', 76), ('SUPERFICIAL_RELATIONSHIP', 80), ('INCOMPLETE_EVIDENCE', 123), ('INCOMPLETE_EVIDENCE', 216), ('QUESTION_ANSWERED_BY_THIS_WORK', 229), ('INCOMPLETE_EVIDENCE', 255), ('FUTURE_WORK', 264), ('IMPORTANT_CONSIDERATION', 323), ('IMPORTANT_CONSIDERATION', 337)]	12	[('UBERON_0001847', 'lobule of pinna', 27, 'early life'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('UBERON_0007023', 'adult organism', 94, 'adult'), ('CHEBI_75958', 'solution', 133, 'solution'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('UBERON_0000113', 'post-juvenile adult stage', 276, 'adult life')]	0	['establishes life  adult osteoporosis; offers solution–supplementation   infancy; presents system adult life treat osteoporosis, problem.']
S0-PMC5812027	PMC5812027	2/2018	S0-PMC5812027	['trajectory of Vitamin D status during Pregnancy in RELATION to neonatal Birth size and fetal survival: a prospective cohort study\n\nabstract\n\nbackground\nwe INVESTIGATED the ASSOCIATIONS between Vitamin D status in early and late Pregnancy with neonatal small for Gestational age (sga), low Birth weight (lbw) and Preterm Delivery.']	[('SUPERFICIAL_RELATIONSHIP', 51), ('QUESTION_ANSWERED_BY_THIS_WORK', 155), ('SUPERFICIAL_RELATIONSHIP', 172)]	3	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 38, 'pregnancy'), ('GO_0007567', 'parturition', 72, 'birth'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('GO_0007565', 'female pregnancy', 228, 'pregnancy'), ('GO_0007565', 'female pregnancy', 262, 'gestational'), ('GO_0007567', 'parturition', 289, 'birth'), ('GO_0007565', 'female pregnancy', 312, 'preterm'), ('GO_0007567', 'parturition', 320, 'delivery')]	0	['trajectory  status  neonatal birth fetal survival: study\n\nabstract\n\nbackground\nwe  status late  neonatal  age (sga), birth (lbw)  delivery.']
S1-PMC5812027	PMC5812027	2/2018	S1-PMC5812027	['furthermore, ASSOCIATIONS between Vitamin D status and Pregnancy loss were studied.']	[('SUPERFICIAL_RELATIONSHIP', 13)]	1	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 55, 'pregnancy')]	0	['furthermore,  status  loss studied.']
S14-PMC5812027	PMC5812027	2/2018	S14-PMC5812027	['THUS, both higher Vitamin D status in late Pregnancy and Gestational Vitamin D status trajectory CAN be SUSPECTED to play a ROLE in healthy Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 97), ('PROBABLE_UNDERSTANDING', 104), ('SUPERFICIAL_RELATIONSHIP', 124)]	4	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 43, 'pregnancy'), ('GO_0007565', 'female pregnancy', 57, 'gestational'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 140, 'pregnancy')]	0	['thus, higher  status late    status trajectory play healthy .']
S19-PMC5812027	PMC5812027	2/2018	S19-PMC5812027	['we have PREVIOUSLY SHOWN that higher Vitamin D status in late Pregnancy and larger increase in Vitamin D status during Pregnancy is ASSOCIATED with lower risk of Preeclampsia [3].']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 132)]	2	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 162, 'preeclampsia')]	0	['higher  status late  increase  status  preeclampsia [3].']
S20-PMC5812027	PMC5812027	2/2018	S20-PMC5812027	['ASSOCIATIONS HAVE also BEEN SHOWN between Vitamin D insufficiency (<\u200950\xa0nmol/l) and increased risk of infant small for Gestational age (sga) and low birth weight (lbw) [4].']	[('SUPERFICIAL_RELATIONSHIP', 0), ('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 28)]	3	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 119, 'gestational')]	0	['associations  (<\u200950\xa0nmol/l) infant  age (sga) birth (lbw) [4].']
S33-PMC5812027	PMC5812027	2/2018	S33-PMC5812027	['our OBJECTIVES were to study the ASSOCIATIONS between Vitamin D status in both early and late Pregnancy, as well as change in Vitamin D status during Pregnancy with neonatal sga, lbw and Preterm Delivery.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('SUPERFICIAL_RELATIONSHIP', 33)]	2	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('GO_0007565', 'female pregnancy', 187, 'preterm'), ('GO_0007567', 'parturition', 195, 'delivery')]	0	[' status late  status  neonatal sga, lbw  delivery.']
S34-PMC5812027	PMC5812027	2/2018	S34-PMC5812027	['ASSOCIATIONS between Vitamin D status in early Pregnancy and Pregnancy loss WERE also STUDIED.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('QUESTION_ANSWERED_BY_THIS_WORK', 76)]	2	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy')]	0	['associations  status   loss studied.']
S62-PMC5812027	PMC5812027	2/2018	S62-PMC5812027	['season was coded as a binary variable, since this EXPLAINED 30% of Vitamin D status in a PREVIOUS STUDY in Pregnant women at the same latitude [16].']	[('PROBABLE_UNDERSTANDING', 50), ('INCOMPLETE_EVIDENCE', 89)]	2	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'pregnant')]	0	['season coded binary variable,  women latitude [16].']
S108-PMC5812027	PMC5812027	2/2018	S108-PMC5812027	['discussion\nwe FOUND that higher Vitamin D status among women in late, BUT NOT early, Pregnancy was ASSOCIATED with lower probability of sga and lbw.']	[('INCOMPLETE_EVIDENCE', 14), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 70), ('SUPERFICIAL_RELATIONSHIP', 99)]	3	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy')]	0	['discussion\nwe higher  status among women late, early,  sga lbw.']
S111-PMC5812027	PMC5812027	2/2018	S111-PMC5812027	['we also FOUND that lower Vitamin D status in early Pregnancy was RELATED to Pregnancy loss.']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 65)]	2	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnancy'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy')]	0	[' status   loss.']
S115-PMC5812027	PMC5812027	2/2018	S115-PMC5812027	['THUS, preeclampsia does not SEEM to MEDIATE the ASSOCIATIONS between Vitamin D status trajectory and neonatal Birth size or Preterm Birth.']	[('PROBABLE_UNDERSTANDING', 0), ('ANOMALY_CURIOUS_FINDING', 28), ('SUPERFICIAL_RELATIONSHIP', 36), ('SUPERFICIAL_RELATIONSHIP', 48)]	4	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007567', 'parturition', 110, 'birth'), ('GO_0007565', 'female pregnancy', 124, 'preterm birth')]	0	['thus, preeclampsia  status trajectory neonatal birth .']
S116-PMC5812027	PMC5812027	2/2018	S116-PMC5812027	['we have PREVIOUSLY SHOWN that the DETERMINANTS of season-corrected change in 25Ohd during Pregnancy include origin, sun-exposure and dietary as well as supplementary Vitamin D Intake [18].']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 34)]	2	[('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 77, '25OHD'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D'), ('GO_0007631', 'feeding behavior', 176, 'intake')]	0	['season-corrected 25ohd  origin, sun-exposure dietary supplementary  intake [18].']
S118-PMC5812027	PMC5812027	2/2018	S118-PMC5812027	['AS the results between change in 25Ohd and neonatal Birth size and Preterm Delivery REMAINED after adjustment for season of Conception, origin and Vitamin D supplementation, Vitamin D status trajectory CAN be SUSPECTED to play a ROLE in healthy Pregnancy.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 84), ('INCOMPLETE_EVIDENCE', 202), ('PROBABLE_UNDERSTANDING', 209), ('SUPERFICIAL_RELATIONSHIP', 229)]	5	[('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 33, '25OHD'), ('GO_0007567', 'parturition', 52, 'birth'), ('GO_0007565', 'female pregnancy', 67, 'preterm'), ('GO_0007567', 'parturition', 75, 'delivery'), ('GO_0007620', 'copulation', 124, 'conception'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('GO_0007565', 'female pregnancy', 245, 'pregnancy')]	0	['results 25ohd neonatal birth  delivery adjustment season conception, origin  supplementation,  status trajectory play healthy .']
S127-PMC5812027	PMC5812027	2/2018	S127-PMC5812027	['this COULD BE INTERPRETED AS SUPPORT of our finding that late RATHER than early Pregnancy Vitamin D status is the stronger PREDICTOR of fetal growth restriction.']	[('INCOMPLETE_EVIDENCE', 5), ('PROBABLE_UNDERSTANDING', 14), ('INCOMPLETE_EVIDENCE', 29), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 62), ('SUPERFICIAL_RELATIONSHIP', 123)]	5	[('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]	0	['late   status fetal restriction.']
S131-PMC5812027	PMC5812027	2/2018	S131-PMC5812027	['we DID NOT SEE a u-shaped ASSOCIATION between early Pregnancy Vitamin D status and sga, as PREVIOUSLY INDICATED [9].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 3), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 91), ('INCOMPLETE_EVIDENCE', 102)]	4	[('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D')]	0	['u-shaped   status sga, [9].']
S136-PMC5812027	PMC5812027	2/2018	S136-PMC5812027	['supplementation CAN THEREFORE ONLY PARTLY EXPLAIN the large proportion with high Vitamin D status, and OTHER LIKELY CONTRIBUTORS are Pregnancy associated Endocrine changes and POSSIBLY lifestyle FACTORS.']	[('INCOMPLETE_EVIDENCE', 16), ('PROBABLE_UNDERSTANDING', 20), ('INCOMPLETE_EVIDENCE', 30), ('INCOMPLETE_EVIDENCE', 35), ('PROBABLE_UNDERSTANDING', 42), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103), ('PROBABLE_UNDERSTANDING', 109), ('SUPERFICIAL_RELATIONSHIP', 116), ('INCOMPLETE_EVIDENCE', 176), ('SUPERFICIAL_RELATIONSHIP', 195)]	10	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('GO_0006397', 'mRNA processing', 154, 'endocrine')]	0	['supplementation proportion  status,  endocrine changes lifestyle factors.']
S137-PMC5812027	PMC5812027	2/2018	S137-PMC5812027	['TO OUR KNOWLEDGE, ours is one of the FIRST studies to find ASSOCIATIONS between Vitamin D status and Pregnancy loss.']	[('PROBABLE_UNDERSTANDING', 0), ('INCOMPLETE_EVIDENCE', 37), ('SUPERFICIAL_RELATIONSHIP', 59)]	3	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy')]	0	['knowledge,  status  loss.']
S141-PMC5812027	PMC5812027	2/2018	S141-PMC5812027	['one earlier study, from denmark, FOUND that lower Vitamin D status in early Pregnancy was ASSOCIATED with Pregnancy loss in the first trimester [24].']	[('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 90)]	2	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy')]	0	['one study, denmark,  status   loss trimester [24].']
S145-PMC5812027	PMC5812027	2/2018	S145-PMC5812027	['DESPITE FEW cases of iufd in the gravid cohort, our results SUGGEST that Vitamin D deficiency in early Pregnancy MAY BE LINKED to iufd.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 60), ('INCOMPLETE_EVIDENCE', 113), ('SUPERFICIAL_RELATIONSHIP', 120)]	5	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]	0	['despite cases iufd gravid cohort, results   iufd.']
S152-PMC5812027	PMC5812027	2/2018	S152-PMC5812027	['in addition, Vitamin D status among women who Terminated the Pregnancy WAS NOT ASSESSED.']	[('INCOMPLETE_EVIDENCE', 71), ('QUESTION_ANSWERED_BY_THIS_WORK', 79)]	2	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0042778', 'tRNA end turnover', 46, 'terminated'), ('GO_0007565', 'female pregnancy', 61, 'pregnancy')]	0	['addition,  status among women terminated  assessed.']
S160-PMC5812027	PMC5812027	2/2018	S160-PMC5812027	['INTERESTINGLY, Vitamin D status at t1- around the time the maternal Blood flow of the Placenta is fully developed- is ONLY RELATED to Pregnancy loss.']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 118), ('SUPERFICIAL_RELATIONSHIP', 123)]	3	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('UBERON_0000178', 'blood', 68, 'blood'), ('UBERON_0001987', 'placenta', 86, 'placenta'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy')]	0	['interestingly,  status t1- maternal blood flow placenta developed-  loss.']
S162-PMC5812027	PMC5812027	2/2018	S162-PMC5812027	['high Vitamin D status in late, BUT NOT early, Pregnancy was ASSOCIATED with lower odds of sga and lbw.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 31), ('SUPERFICIAL_RELATIONSHIP', 60)]	2	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'pregnancy')]	0	['high  status late, early,  sga lbw.']
S164-PMC5812027	PMC5812027	2/2018	S164-PMC5812027	['both higher late Pregnancy Vitamin D status and Gestational Vitamin D status trajectory CAN be SUSPECTED to play a ROLE in healthy Pregnancy.']	[('INCOMPLETE_EVIDENCE', 88), ('PROBABLE_UNDERSTANDING', 95), ('SUPERFICIAL_RELATIONSHIP', 115)]	3	[('GO_0007565', 'female pregnancy', 17, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'gestational'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy')]	0	['higher late   status   status trajectory play healthy .']
S0-PMC5827025	PMC5827025	2/2018	S0-PMC5827025	['INFLUENT FACTORS of Gestational Vitamin D deficiency and its RELATION to an INCREASED RISK of Preterm Delivery in chinese population\n\nabstract\nGestational Vitamin D deficiency (vdd) HAS BEEN LINKED with adverse Pregnant outcomes.']	[('SUPERFICIAL_RELATIONSHIP', 0), ('SUPERFICIAL_RELATIONSHIP', 9), ('SUPERFICIAL_RELATIONSHIP', 61), ('IMPORTANT_CONSIDERATION', 76), ('INCOMPLETE_EVIDENCE', 182), ('SUPERFICIAL_RELATIONSHIP', 191)]	6	[('GO_0007565', 'female pregnancy', 20, 'gestational'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'preterm'), ('GO_0007567', 'parturition', 102, 'delivery'), ('GO_0007565', 'female pregnancy', 143, 'Gestational'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('GO_0007565', 'female pregnancy', 211, 'pregnant')]	0	['influent    delivery chinese population\n\nabstract\n  (vdd)  outcomes.']
S6-PMC5827025	PMC5827025	2/2018	S6-PMC5827025	['INTERESTINGLY, 8.23% Delivered Preterm infants among subjects with vdd (adjusted rr: 4.02; 95% ci: 2.33, 6.92) and 3.81% among subjects with Gestational Vitamin D insufficiency (vdi) (adjusted rr: 2.07; 95% ci: 1.16, 3.71).']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('GO_0007567', 'parturition', 21, 'delivered'), ('GO_0007565', 'female pregnancy', 31, 'preterm'), ('GO_0007565', 'female pregnancy', 141, 'gestational'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]	0	['interestingly, 8.23% delivered  infants among subjects vdd (adjusted rr: 4.02; 95% ci: 2.33, 6.92) 3.81% among subjects   (vdi) (adjusted rr: 2.07; 95% ci: 1.16, 3.71).']
S9-PMC5827025	PMC5827025	2/2018	S9-PMC5827025	['in conclusion, pre-Pregnancy bmi, seasonality and multivitamin use are INFLUENT FACTORS of Gestational Vitamin D status.']	[('SUPERFICIAL_RELATIONSHIP', 71), ('SUPERFICIAL_RELATIONSHIP', 80)]	2	[('GO_0007565', 'female pregnancy', 19, 'pregnancy'), ('GO_0007565', 'female pregnancy', 91, 'gestational'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]	0	['conclusion, pre- bmi, seasonality multivitamin   status.']
S15-PMC5827025	PMC5827025	2/2018	S15-PMC5827025	['ALTHOUGH SOME POTENTIAL INFLUENT FACTORS for Vitamin D status, such as seasonality, age, smoking, race and ethnicity HAVE BEEN IDENTIFIED in SEVERAL case-control STUDIES6–8, research REPORTS on the INFLUENT FACTORS for Gestational Vitamin D status in a population-based cohort are LACKING.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 9), ('INCOMPLETE_EVIDENCE', 14), ('SUPERFICIAL_RELATIONSHIP', 24), ('SUPERFICIAL_RELATIONSHIP', 33), ('INCOMPLETE_EVIDENCE', 117), ('INCOMPLETE_EVIDENCE', 127), ('INCOMPLETE_EVIDENCE', 141), ('INCOMPLETE_EVIDENCE', 162), ('INCOMPLETE_EVIDENCE', 183), ('SUPERFICIAL_RELATIONSHIP', 198), ('SUPERFICIAL_RELATIONSHIP', 207), ('FULL_UNKNOWN', 281), ('INCOMPLETE_EVIDENCE', 281)]	15	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0007565', 'female pregnancy', 219, 'gestational'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D')]	0	['although  status, seasonality, age, smoking, race ethnicity case-control studies6–8,   status population-based lacking.']
S17-PMC5827025	PMC5827025	2/2018	S17-PMC5827025	['IN CONTRAST, the reports from randomized controlled trials INDICATE that Gestational Vitamin D supplementation CAN markedly decrease Pregnancy COMPLICATIONS including Preeclampsia and Pregnancy induced hypertension11.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 59), ('INCOMPLETE_EVIDENCE', 111), ('PROBLEM_COMPLICATION', 143)]	4	[('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 167, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 184, 'pregnancy')]	0	['contrast,   supplementation decrease  preeclampsia  induced hypertension11.']
S35-PMC5827025	PMC5827025	2/2018	S35-PMC5827025	['influence of demographic characteristics on Gestational Serum 25(Oh)D concentration\nthe demographic characteristics for INFLUENCING Gestational Vitamin D status were analyzed.']	[('SUPERFICIAL_RELATIONSHIP', 120)]	1	[('GO_0007565', 'female pregnancy', 44, 'gestational'), ('UBERON_0001977', 'blood serum', 56, 'serum'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 62, '25(OH)D'), ('GO_0007565', 'female pregnancy', 132, 'gestational'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]	0	['influence demographic characteristics  serum 25(oh)d concentration\nthe demographic characteristics   status analyzed.']
S74-PMC5827025	PMC5827025	2/2018	S74-PMC5827025	['discussion\nthe PRESENT STUDY analyzed Vitamin D status among 3598 Pregnant women.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 15)]	1	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnant')]	0	['discussion\nthe  status among 3598  women.']
S78-PMC5827025	PMC5827025	2/2018	S78-PMC5827025	['a report DEMONSTRATED that socio-economic status INFLUENCES Gestational Vitamin D status26.']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 49)]	2	[('GO_0007565', 'female pregnancy', 60, 'gestational'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]	0	['socio-economic status   status26.']
S81-PMC5827025	PMC5827025	2/2018	S81-PMC5827025	['results SHOW that these factors did not affect Gestational Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 8)]	1	[('GO_0007565', 'female pregnancy', 47, 'gestational'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]	0	['results   status.']
S101-PMC5827025	PMC5827025	2/2018	S101-PMC5827025	['follow-up, SEVERAL randomized TRIAL of Vitamin D supplementation FOUND that the rate of Preterm Delivery is significant more lower in Pregnant women with Serum 25(Oh)D ≥40\u2009ng/ml COMPARED TO those with Serum 25(Oh)D ≤20\u2009ng/ml, SUGGESTING higher 25(Oh)D concentration was ASSOCIATED with an decreased risk of Preterm Delivery35–38.']	[('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 65), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 178), ('INCOMPLETE_EVIDENCE', 226), ('SUPERFICIAL_RELATIONSHIP', 270)]	5	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'preterm'), ('GO_0007567', 'parturition', 96, 'delivery'), ('GO_0007565', 'female pregnancy', 134, 'pregnant'), ('UBERON_0001977', 'blood serum', 154, 'serum'), ('CHEBI_63056', 'zinc cation', 160, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 166, 'D'), ('UBERON_0001977', 'blood serum', 201, 'serum'), ('CHEBI_71657', 'versiconol acetate', 207, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 210, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 213, 'D'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('GO_0007565', 'female pregnancy', 307, 'preterm'), ('GO_0008219', 'cell death', 315, 'delivery35')]	0	['follow-up,  supplementation rate  delivery  women serum 25(oh)d ≥40\u2009ng/ml serum 25(oh)d ≤20\u2009ng/ml, higher 25(oh)d concentration decreased  delivery35–38.']
S102-PMC5827025	PMC5827025	2/2018	S102-PMC5827025	['the INCONSISTENCY of PAST FINDINGS MAY BE RELATED to following REASONS: first, cohort among Pregnant women with relatively Vitamin D replete, with a history of Preterm Delivery or at high risk for Preeclampsia; second, Gestational Vitamin D status is a LINK to ethnic DISPARITIES in adverse Birth outcomes24.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 4), ('INCOMPLETE_EVIDENCE', 4), ('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 35), ('SUPERFICIAL_RELATIONSHIP', 42), ('PROBABLE_UNDERSTANDING', 63), ('SUPERFICIAL_RELATIONSHIP', 253), ('IMPORTANT_CONSIDERATION', 268)]	9	[('GO_0007565', 'female pregnancy', 92, 'pregnant'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'preterm'), ('GO_0007567', 'parturition', 168, 'delivery'), ('GO_0007128', 'meiotic prophase I', 197, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 219, 'gestational'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('GO_0007567', 'parturition', 291, 'birth')]	0	['following reasons: first, among  women  replete,  delivery preeclampsia; second,   status ethnic birth outcomes24.']
S103-PMC5827025	PMC5827025	2/2018	S103-PMC5827025	['ALTHOUGH a RECENT STUDY in northeast china DEMONSTRATED that vdd was more PREVALENT in the SEVERE preterm group than in the mildly preterm group and the in-term group, they DID NOT analyze the ASSOCIATION between vdd and an INCREASED RISK of Preterm Delivery BECAUSE Vitamin D status at prior to labor cannot be used to assess risk of Preterm Delivery39.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 11), ('INCOMPLETE_EVIDENCE', 43), ('IMPORTANT_CONSIDERATION', 74), ('IMPORTANT_CONSIDERATION', 91), ('INCOMPLETE_EVIDENCE', 173), ('SUPERFICIAL_RELATIONSHIP', 193), ('IMPORTANT_CONSIDERATION', 224), ('PROBLEM_COMPLICATION', 259)]	10	[('GO_0007565', 'female pregnancy', 242, 'preterm'), ('GO_0007567', 'parturition', 250, 'delivery'), ('CHEBI_27300', 'vitamin D', 267, 'vitamin D'), ('GO_0007565', 'female pregnancy', 335, 'preterm'), ('GO_0007567', 'parturition', 343, 'delivery39')]	0	['although northeast china vdd preterm mildly preterm in-term group, vdd  delivery  status labor  delivery39.']
S104-PMC5827025	PMC5827025	2/2018	S104-PMC5827025	['the PRESENT STUDY analyzed the ASSOCIATION between Vitamin D status during first- and second-Trimester and Preterm Delivery in chinese population.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('SUPERFICIAL_RELATIONSHIP', 31)]	2	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 93, 'trimester'), ('GO_0007565', 'female pregnancy', 107, 'preterm'), ('GO_0007567', 'parturition', 115, 'delivery')]	0	[' status first- second-trimester  delivery chinese population.']
S40-PMC5831579	PMC5831579	3/2018	S40-PMC5831579	['daily intake of energy, Carbohydrate, protein, fat, Alcohol, Caffeine, Sodium, iron, calcium, Vitamin D, Docosahexaenoic Acid (Dha), dietary Folate equivalents (dfe), natural Folate, synthetic Folate (from fortified foods), methionine, Choline, betaine, and Vitamins b6 and b12 were analyzed, since those Nutrients are part of the nutritional RECOMMENDATION for a healthy Pregnancy [9,17–20].']	[('FUTURE_WORK', 343)]	1	[('CHEBI_16730', 'chloramphenicol 3-acetate', 24, 'carbohydrate'), ('CHEBI_30879', 'alcohol', 52, 'alcohol'), ('CHEBI_27732', 'caffeine', 61, 'caffeine'), ('CHEBI_52632', 'potassium-39 atom', 71, 'sodium'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('CHEBI_36003', 'decenoic acid', 105, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 127, 'DHA'), ('CHEBI_30863', '5-azaorotic acid', 141, 'folate'), ('CHEBI_30863', '5-azaorotic acid', 175, 'folate'), ('CHEBI_30863', '5-azaorotic acid', 193, 'folate'), ('CHEBI_15354', 'choline', 236, 'choline'), ('CHEBI_33277', 'gamma-tocotrienol', 258, 'vitamins'), ('CHEBI_33284', 'nutrient', 305, 'nutrients'), ('GO_0007565', 'female pregnancy', 372, 'pregnancy')]	0	['daily intake energy, carbohydrate, protein, fat, alcohol, caffeine, sodium, iron, calcium, docosahexaenoic acid (dha), dietary folate equivalents (dfe), natural folate, synthetic folate (from fortified foods), methionine, choline, betaine, vitamins b6 b12 analyzed, nutrients nutritional healthy  [9,17–20].']
S104-PMC5831579	PMC5831579	3/2018	S104-PMC5831579	['fruits and vegetables, foods that require preparation, protein, Carbohydrate, Nutrients related to One-Carbon Metabolism pathway, Dha, Vitamin D, iron, sodium, Calcium and Caffeine were more strongly CORRELATED to the ‘seasoned vegetables and lean meats,’ which was the dietary pattern that COULD CONTRIBUTE MOST to a healthy pre-Pregnancy nutrition [9,17–20], followed by ‘lentils, whole grains and soups’ pattern.']	[('SUPERFICIAL_RELATIONSHIP', 200), ('INCOMPLETE_EVIDENCE', 291), ('SUPERFICIAL_RELATIONSHIP', 297), ('PROBABLE_UNDERSTANDING', 308)]	4	[('CHEBI_16730', 'chloramphenicol 3-acetate', 64, 'carbohydrate'), ('CHEBI_33284', 'nutrient', 78, 'nutrients'), ('GO_0006730', 'one-carbon metabolic process', 99, 'one-carbon metabolism'), ('CHEBI_17874', 'dihydrozeatin', 130, 'DHA'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 160, 'calcium'), ('CHEBI_27732', 'caffeine', 172, 'caffeine'), ('GO_0007565', 'female pregnancy', 330, 'pregnancy')]	0	['fruits vegetables, foods preparation, protein, carbohydrate, nutrients one-carbon metabolism pathway, dha, iron, sodium, calcium caffeine ‘seasoned vegetables lean meats,’ dietary healthy pre- nutrition [9,17–20], followed ‘lentils, whole grains soups’ pattern.']
S1-PMC5838372	PMC5838372	3/2018	S1-PMC5838372	['the AIM of THIS STUDY was TO EVALUATE maternal Vitamin D status and its EFFECT on neonatal Vitamin D concentrations after a support programme for Pregnant women was introduced.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 4), ('QUESTION_ANSWERED_BY_THIS_WORK', 11), ('QUESTION_ANSWERED_BY_THIS_WORK', 26), ('SUPERFICIAL_RELATIONSHIP', 72)]	4	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnant')]	0	['maternal  status neonatal  concentrations programme  women introduced.']
S10-PMC5838372	PMC5838372	3/2018	S10-PMC5838372	['ONLY 14.4% of Pregnant women took 1000-1200 iu/day of Vitamin D. when the mother groups were evaluated in terms of risk factors, there were significant differences in daily vitamin intake and clothing style (p<0.001 and p<0.001 respectively).']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('GO_0007565', 'female pregnancy', 14, 'pregnant'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D')]	0	['14.4%  women took 1000-1200 iu/day . mother terms factors, daily vitamin intake clothing style (p<0.001 p<0.001 respectively).']
S11-PMC5838372	PMC5838372	3/2018	S11-PMC5838372	['conclusion:\nVitamin D deficiency in Pregnant women and their infants is STILL a SERIOUS health PROBLEM in turkey, although a Vitamin D support programme during Pregnancy has been launched by the department of health.']	[('IMPORTANT_CONSIDERATION', 72), ('IMPORTANT_CONSIDERATION', 80), ('IMPORTANT_CONSIDERATION', 95)]	3	[('CHEBI_28384', 'vitamin K', 12, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 36, 'pregnant'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy')]	0	['conclusion:\nvitamin  women infants turkey,  programme  launched department health.']
S16-PMC5838372	PMC5838372	3/2018	S16-PMC5838372	['DESPITE the launch of a Vitamin D support programme for Pregnant women by the ministry of health, Vitamin D deficiency in Pregnant women and their infants continues to be a SERIOUS health PROBLEM in turkey.']	[('ANOMALY_CURIOUS_FINDING', 0), ('IMPORTANT_CONSIDERATION', 173), ('IMPORTANT_CONSIDERATION', 188)]	3	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnant'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'pregnant')]	0	['despite launch  programme  women ministry health,   women infants turkey.']
S20-PMC5838372	PMC5838372	3/2018	S20-PMC5838372	['the lack of Vitamin D during Pregnancy is the MOST IMPORTANT RISK FACTOR for infantile rickets and MAY also result in POOR fetal growth and Neonatal Development (8,9,10,11).']	[('PROBABLE_UNDERSTANDING', 46), ('IMPORTANT_CONSIDERATION', 51), ('SUPERFICIAL_RELATIONSHIP', 61), ('INCOMPLETE_EVIDENCE', 99), ('IMPORTANT_CONSIDERATION', 118)]	5	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007565', 'female pregnancy', 29, 'pregnancy'), ('GO_0021985', 'neurohypophysis development', 140, 'neonatal development')]	0	['  infantile rickets result fetal neonatal (8,9,10,11).']
S79-PMC5838372	PMC5838372	3/2018	S79-PMC5838372	['the Vitamin D dose that the world health organization RECOMMENDS for Pregnant women is 200 iu/day (17).']	[('FUTURE_WORK', 54)]	1	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant')]	0	[' dose world organization  women 200 iu/day (17).']
S82-PMC5838372	PMC5838372	3/2018	S82-PMC5838372	['the SAFETY dose during Pregnancy is NOT CLEAR, but hollis et al (20) SHOWED that Vitamin D supplementation of 4000 iu/day for achieving adequate levels was SAFE and EFFECTIVE in Pregnant women.']	[('IMPORTANT_CONSIDERATION', 4), ('FULL_UNKNOWN', 36), ('INCOMPLETE_EVIDENCE', 69), ('IMPORTANT_CONSIDERATION', 156), ('SUPERFICIAL_RELATIONSHIP', 165)]	5	[('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnant')]	0	['dose  clear, hollis et al (20)  supplementation 4000 iu/day achieving levels  women.']
S88-PMC5838372	PMC5838372	3/2018	S88-PMC5838372	['studies REPORTED from different countries HAVE SHOWN a prevalence of Vitamin D deficiency in Pregnant women and in infants ranging from 4% to 60% and from 3% to 86%, respectively (24,25).']	[('INCOMPLETE_EVIDENCE', 8), ('INCOMPLETE_EVIDENCE', 42)]	2	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007565', 'female pregnancy', 93, 'pregnant')]	0	['studies countries   women infants 4% 60% 3% 86%, respectively (24,25).']
S90-PMC5838372	PMC5838372	3/2018	S90-PMC5838372	['in a study from india, it HAS BEEN REPORTED that 84% of Pregnant women had Vitamin D concentrations <22.5 ng/ml (27).']	[('INCOMPLETE_EVIDENCE', 26), ('INCOMPLETE_EVIDENCE', 35)]	2	[('GO_0007565', 'female pregnancy', 56, 'pregnant'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]	0	['india, 84%  women  concentrations <22.5 ng/ml (27).']
S92-PMC5838372	PMC5838372	3/2018	S92-PMC5838372	['PREVIOUS STUDIES HAVE SHOWN that Vitamin D deficiency is common in Pregnant women in turkey.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 17)]	2	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnant')]	0	['previous   women turkey.']
S96-PMC5838372	PMC5838372	3/2018	S96-PMC5838372	['in 2008, halicioglu et al (32) FOUND that 50.4% of Pregnant women in i̇zmir, a city in a sunny region of turkey, had Blood Vitamin d levels ≤10 ng/ml.']	[('INCOMPLETE_EVIDENCE', 31)]	1	[('GO_0007565', 'female pregnancy', 51, 'pregnant'), ('UBERON_0000178', 'blood', 116, 'blood'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D')]	0	['2008, halicioglu et al (32) 50.4%  women i̇zmir, city sunny region turkey, bloodd levels ≤10 ng/ml.']
S97-PMC5838372	PMC5838372	3/2018	S97-PMC5838372	['in a study conducted in ankara in 2010, Vitamin D deficiency (≤20 ng/ml) in Pregnant women and their infants were FOUND TO BE 62.6% and 58.6%, respectively (33).']	[('ANOMALY_CURIOUS_FINDING', 114)]	1	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnant')]	0	['ankara 2010,  (≤20 ng/ml)  women infants 62.6% 58.6%, respectively (33).']
S98-PMC5838372	PMC5838372	3/2018	S98-PMC5838372	['it should BE NOTED that all of these studies were conducted prior to the introduction of the national Pregnancy Vitamin D supplementation programme.']	[('ANOMALY_CURIOUS_FINDING', 10), ('ANOMALY_CURIOUS_FINDING', 13)]	2	[('GO_0007565', 'female pregnancy', 102, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 120, 'D')]	0	['introduction national   supplementation programme.']
S99-PMC5838372	PMC5838372	3/2018	S99-PMC5838372	['in THIS PRESENT STUDY, mean Vitamin D level was FOUND TO be 14.82±11.45 ng/ml in Pregnant women and 13.16±7.16 ng/ml in their infants.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('ANOMALY_CURIOUS_FINDING', 48)]	3	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnant')]	0	['study,  14.82±11.45 ng/ml  women 13.16±7.16 ng/ml infants.']
S101-PMC5838372	PMC5838372	3/2018	S101-PMC5838372	['all these data CONFIRM that Vitamin D deficiency continues to be a PROBLEM in Pregnant women and their infants in turkey, DESPITE the introduction of the supplementation programme.']	[('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 67), ('PROBLEM_COMPLICATION', 67), ('ANOMALY_CURIOUS_FINDING', 122)]	4	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'pregnant')]	0	['  women infants turkey, introduction supplementation programme.']
S105-PMC5838372	PMC5838372	3/2018	S105-PMC5838372	['these results SHOW that high dose Vitamin D support is NECESSARY during Pregnancy and that the support program SHOULD BE continued.']	[('INCOMPLETE_EVIDENCE', 14), ('IMPORTANT_CONSIDERATION', 55), ('FUTURE_WORK', 111)]	3	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 72, 'pregnancy')]	0	['results dose   program continued.']
S112-PMC5838372	PMC5838372	3/2018	S112-PMC5838372	['THESE FINDINGS SHOW that covered clothing style is an IMPORTANT factor for Vitamin D deficiency in Pregnant women in turkey.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('IMPORTANT_CONSIDERATION', 54)]	3	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007565', 'female pregnancy', 99, 'pregnant')]	0	['covered clothing style   women turkey.']
S113-PMC5838372	PMC5838372	3/2018	S113-PMC5838372	['when we evaluated the infants ACCORDING to the Vitamin D levels of their mothers, we found no difference between groups in terms of gender, Gestational age, birth weight, Delivery route and the levels of ca, p and alp.']	[('SUPERFICIAL_RELATIONSHIP', 30)]	1	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 140, 'gestational'), ('GO_0007567', 'parturition', 171, 'delivery')]	0	['infants  levels mothers, terms gender,  age, birth weight, delivery route levels ca, p alp.']
S125-PMC5838372	PMC5838372	3/2018	S125-PMC5838372	['conclusion\nalthough a Vitamin D support programme was launched for Pregnant women by the ministry of health in 2011, Vitamin D deficiency in Pregnant women and their infants is STILL a SERIOUS health PROBLEM in turkey in 2016.']	[('IMPORTANT_CONSIDERATION', 177), ('IMPORTANT_CONSIDERATION', 185), ('IMPORTANT_CONSIDERATION', 200)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'pregnant'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('GO_0007565', 'female pregnancy', 141, 'pregnant')]	0	['conclusion\nalthough  programme launched  women ministry 2011,   women infants turkey 2016.']
S17-PMC5841533	PMC5841533	2/2018	S17-PMC5841533	['introduction\nan ESTIMATED 250\u2009million children GLOBALLY are denied the opportunity to reach their full developmental potential DUE TO the combined EFFECTS of poverty and undernutrition.1poor nutrition during Pregnancy CONTRIBUTES to maternal morbidity and mortality, increases the risks of low Birth weight and poor development, and exacerbates the risk of chronic disease in Adulthood.2 3many Pregnant women face Micronutrient deficiencies: an ESTIMATED 15.3% globally lack Vitamin A, 28.5% lack Iodine and 38% have iron-deficiency anaemia.1 4nutritional deprivation in Pregnancy CAN alter neural growth in the fetus and AFFECT Cognitive functioning, hindering children’s chances in school and CONTRIBUTING to the intergenerational transmission of poverty.5–9\nthe world health organisation (who) currently RECOMMENDS Iron and Folic Acid (ifa) supplementation in Pregnancy to improve maternal and Perinatal outcomes, BUT NOT multiple Micronutrient (mmn)supplementation.10–12could Antenatal Micronutrient supplementation improve children’s long-term Cognitive functioning?']	[('INCOMPLETE_EVIDENCE', 16), ('IMPORTANT_CONSIDERATION', 47), ('PROBLEM_COMPLICATION', 127), ('SUPERFICIAL_RELATIONSHIP', 147), ('SUPERFICIAL_RELATIONSHIP', 218), ('INCOMPLETE_EVIDENCE', 445), ('INCOMPLETE_EVIDENCE', 581), ('SUPERFICIAL_RELATIONSHIP', 622), ('SUPERFICIAL_RELATIONSHIP', 695), ('FUTURE_WORK', 807), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 917), ('ANOMALY_CURIOUS_FINDING', 917), ('EXPLICIT_QUESTION', 1070)]	13	[('GO_0007565', 'female pregnancy', 208, 'pregnancy'), ('GO_0007567', 'parturition', 294, 'birth'), ('UBERON_0000113', 'post-juvenile adult stage', 376, 'adulthood'), ('GO_0007565', 'female pregnancy', 394, 'pregnant'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 414, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 475, 'vitamin A'), ('CHEBI_24859', 'iodine atom', 497, 'iodine'), ('GO_0007565', 'female pregnancy', 571, 'pregnancy'), ('GO_0050890', 'cognition', 629, 'cognitive'), ('CHEBI_24870', 'ion', 818, 'Iron'), ('CHEBI_30751', 'formic acid', 827, 'Folic Acid'), ('GO_0007565', 'female pregnancy', 863, 'pregnancy'), ('GO_0036268', 'swimming', 897, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 897, 'perinatal'), ('CHEBI_6956', 'Mitragynine', 934, 'Micronutrient'), ('GO_0007567', 'parturition', 980, 'antenatal'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 990, 'micronutrient'), ('GO_0050890', 'cognition', 1049, 'cognitive')]	0	['introduction\nan 250\u2009million children denied developmental combined poverty undernutrition.1poor nutrition  maternal morbidity mortality, birth development, chronic disease adulthood.2 3many  women micronutrient deficiencies: 15.3% 28.5% iodine 38% iron-deficiency anaemia.1 4nutritional deprivation  alter neural fetus cognitive functioning, hindering children’s school intergenerational transmission poverty.5–9\nthe world organisation (who) iron folic acid (ifa) supplementation  maternal perinatal outcomes, micronutrient (mmn)supplementation.10–12could antenatal micronutrient supplementation children’s long-term cognitive functioning?']
S19-PMC5841533	PMC5841533	2/2018	S19-PMC5841533	['supplementation with single Micronutrients during Pregnancy APPEARS TO have little influence on children’s Cognitive outcomes: 10 trials conducted in high-income, middle-income and low-income settings FOUND no effects of Antenatal iron, zinc, Vitamin A or Choline supplementation on Cognitive functions.13–20supplementation with mmn, on the OTHER HAND, COULD AFFECT children’s Cognitive functions via three RELATED pathways.']	[('ANOMALY_CURIOUS_FINDING', 60), ('INCOMPLETE_EVIDENCE', 201), ('ANOMALY_CURIOUS_FINDING', 341), ('INCOMPLETE_EVIDENCE', 353), ('SUPERFICIAL_RELATIONSHIP', 359), ('SUPERFICIAL_RELATIONSHIP', 407)]	6	[('CHEBI_33839', 'macromolecule', 28, 'micronutrients'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy'), ('GO_0050890', 'cognition', 107, 'cognitive'), ('GO_0007567', 'parturition', 221, 'antenatal'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin A'), ('CHEBI_15354', 'choline', 256, 'choline'), ('GO_0050890', 'cognition', 283, 'cognitive'), ('GO_0050890', 'cognition', 377, 'cognitive')]	0	['supplementation single micronutrients  children’s cognitive outcomes: 10 high-income, middle-income low-income settings antenatal iron, zinc,  choline supplementation cognitive functions.13–20supplementation mmn, hand, children’s cognitive functions via three pathways.']
S113-PMC5941617	PMC5941617	5/2018	S113-PMC5941617	['moreover, newborns from deficient mothers are at INCREASED RISK for Vitamin D deficiency AS Cord Blood and neonatal 25(Oh)D levels highly CORRELATE with maternal Vitamin d status during Gestation [92,93].']	[('IMPORTANT_CONSIDERATION', 49), ('PROBABLE_UNDERSTANDING', 89), ('SUPERFICIAL_RELATIONSHIP', 138)]	3	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 92, 'cord'), ('UBERON_0000178', 'blood', 97, 'blood'), ('CHEBI_71657', 'versiconol acetate', 116, '25(OH)D'), ('CHEBI_33229', 'vitamin (role)', 162, 'vitamin'), ('GO_0007565', 'female pregnancy', 186, 'gestation')]	0	['moreover, newborns mothers  cord blood neonatal 25(oh)d levels maternal vitamin status  [92,93].']
S134-PMC5941617	PMC5941617	5/2018	S134-PMC5941617	['Ketoconazole)• infants Born from mothers with multiple RISK FACTORS for Vitamin D deficiency, particularly in absence of Vitamin D supplementation during Pregnancy\n\npreterm\npreterm infants are AT RISK for Calcium-Phosphorus Metabolism alterations, with POSSIBLE development of osteopenia of prematurity [120].']	[('SUPERFICIAL_RELATIONSHIP', 55), ('IMPORTANT_CONSIDERATION', 193), ('INCOMPLETE_EVIDENCE', 253)]	3	[('CHEBI_47519', 'ketoconazole', 0, 'ketoconazole'), ('GO_0007567', 'parturition', 23, 'born'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy'), ('CHEBI_30272', 'arsonium', 205, 'calcium-phosphorus'), ('GO_0050655', 'dermatan sulfate proteoglycan metabolic process', 205, 'calcium-phosphorus metabolism')]	0	['ketoconazole)• infants born mothers  deficiency, absence  supplementation \n\npreterm\npreterm infants calcium-phosphorus metabolism alterations, osteopenia prematurity [120].']
S139-PMC5941617	PMC5941617	5/2018	S139-PMC5941617	['in addition to optimize bone mineralization during fetal Life, Vitamin D status HAS BEEN ASSOCIATED with acute Respiratory morbidity in preterm infants Born <\u200932\xa0weeks Gestation [124].']	[('INCOMPLETE_EVIDENCE', 80), ('SUPERFICIAL_RELATIONSHIP', 89)]	2	[('UBERON_0000104', 'life cycle', 57, 'life'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 111, 'respiratory'), ('GO_0007567', 'parturition', 152, 'born'), ('GO_0007565', 'female pregnancy', 168, 'gestation')]	0	['addition optimize bone mineralization fetal life,  status acute respiratory morbidity preterm infants born <\u200932\xa0weeks  [124].']
S143-PMC5941617	PMC5941617	5/2018	S143-PMC5941617	['DIFFERENTLY, CONSIDERING the high prevalence of Vitamin D deficiency during Pregnancy, the espghan RECOMMENDED for preterm infants a Vitamin D intake of 800–1000\xa0iu/day during the first months of Life to rapidly correct fetal low Serum 25(Oh)D levels [125].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('PROBABLE_UNDERSTANDING', 13), ('FUTURE_WORK', 99)]	3	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('UBERON_0000104', 'life cycle', 196, 'life'), ('UBERON_0001977', 'blood serum', 230, 'serum'), ('CHEBI_71657', 'versiconol acetate', 236, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 236, '25(OH ... D')]	0	['differently,  espghan preterm infants  intake 800–1000\xa0iu/day months life rapidly fetal serum 25(oh)d levels [125].']
S147-PMC5941617	PMC5941617	5/2018	S147-PMC5941617	['SOME STUDIES evaluated the EFFECT of Vitamin D supplementation at DIFFERENT doses in preterm infants of various Gestational age and Birth weight [124,128–146].']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 27), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 66)]	3	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'gestational'), ('GO_0007567', 'parturition', 132, 'birth')]	0	[' supplementation doses preterm infants  age birth [124,128–146].']
S157-PMC5941617	PMC5941617	5/2018	S157-PMC5941617	['SUGGESTED for extremely low Gestational age newborns an initial Vitamin D supplementation at 800\xa0iu/day for 1–2\xa0weeks to restore Serum 25(Oh)D levels followed by a lower dosage (200\xa0iu/day) [143].']	[('INCOMPLETE_EVIDENCE', 0)]	1	[('GO_0007565', 'female pregnancy', 28, 'gestational'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0001977', 'blood serum', 129, 'serum'), ('CHEBI_71657', 'versiconol acetate', 135, '25(OH)D')]	0	['suggested  age newborns  supplementation 800\xa0iu/day 1–2\xa0weeks restore serum 25(oh)d levels followed dosage (200\xa0iu/day) [143].']
S272-PMC5941617	PMC5941617	5/2018	S272-PMC5941617	['maternal Vitamin D status during Pregnancy MAY significantly INFLUENCE fetal and neonatal bone mass, as RECENTLY CONFIRMED by the sacn [25].']	[('INCOMPLETE_EVIDENCE', 43), ('SUPERFICIAL_RELATIONSHIP', 61), ('INCOMPLETE_EVIDENCE', 104), ('INCOMPLETE_EVIDENCE', 113)]	4	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'pregnancy')]	0	['maternal  status  fetal neonatal bone mass, sacn [25].']
S277-PMC5941617	PMC5941617	5/2018	S277-PMC5941617	['RECENTLY an english rct (mavidos) failed to demonstrate an EFFECT of maternal Vitamin D supplementation (1000\xa0iu/day from 14\xa0week of Gestation until Delivery) on offspring bone mass assessed within 2\xa0weeks of Birth by dxa.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 59)]	2	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'gestation'), ('GO_0007567', 'parturition', 149, 'delivery'), ('GO_0007567', 'parturition', 209, 'birth')]	0	['recently english (mavidos) maternal  supplementation (1000\xa0iu/day 14\xa0week  delivery) offspring bone mass 2\xa0weeks birth dxa.']
S280-PMC5941617	PMC5941617	5/2018	S280-PMC5941617	['another smaller rct on 50 newborns FAILED TO demonstrate an EFFECT of Vitamin D supplementation during Pregnancy (2000\xa0iu/day from 26 to 28\xa0weeks until Childbirth) on infant bone mass measured at 23\u2009±\u200910\xa0days by dxa [234].']	[('ANOMALY_CURIOUS_FINDING', 35), ('SUPERFICIAL_RELATIONSHIP', 60)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy'), ('GO_0007623', 'circadian rhythm', 152, 'childbirth')]	0	['another 50 newborns  supplementation  (2000\xa0iu/day 26 28\xa0weeks childbirth) infant bone mass 23\u2009±\u200910\xa0days dxa [234].']
S297-PMC5941617	PMC5941617	5/2018	S297-PMC5941617	['OTHER STUDIES have FOUND an inverse ASSOCIATION between Vitamin D concentrations in Pregnancy and the RISK of Respiratory infections in newborns or children during the first 3\xa0years of life [253,254].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 19), ('SUPERFICIAL_RELATIONSHIP', 36), ('IMPORTANT_CONSIDERATION', 102)]	4	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('UBERON_0001004', 'respiratory system', 110, 'respiratory')]	0	[' concentrations  respiratory infections newborns children 3\xa0years life [253,254].']
S313-PMC5941617	PMC5941617	5/2018	S313-PMC5941617	['finally, LIMITED DATA are available on Vitamin D supplementation in Pregnancy and the RISK of Respiratory infections in the offspring [272,273].']	[('INCOMPLETE_EVIDENCE', 9), ('IMPORTANT_CONSIDERATION', 86)]	2	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnancy'), ('UBERON_0001004', 'respiratory system', 94, 'respiratory')]	0	['finally,  supplementation  respiratory infections offspring [272,273].']
S359-PMC5941617	PMC5941617	5/2018	S359-PMC5941617	['furthermore, PREVIOUS STUDIES focused on the ASSOCIATION between Serum 25(Oh)D levels and the Expression of Genes INVOLVED in the Proliferation and Cells Differentiation, showing an anti-proliferative activity of Vitamin D with CONSEQUENTLY remodeling inhibition [309–312].']	[('INCOMPLETE_EVIDENCE', 13), ('SUPERFICIAL_RELATIONSHIP', 45), ('SUPERFICIAL_RELATIONSHIP', 114), ('PROBABLE_UNDERSTANDING', 228)]	4	[('UBERON_0001977', 'blood serum', 65, 'serum'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 77, 'D'), ('GO_0010467', 'gene expression', 94, 'expression'), ('SO_0000704', 'gene', 108, 'genes'), ('GO_0007565', 'female pregnancy', 130, 'proliferation ...'), ('GO_0030154', 'cell differentiation', 148, 'cells differentiation'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D')]	0	['furthermore, serum 25(oh)d levels expression genes  cells differentiation, anti-proliferative activity  remodeling inhibition [309–312].']
S361-PMC5941617	PMC5941617	5/2018	S361-PMC5941617	['about the ROLE of Vitamin D in the immunopathogenesis of allergic skin diseases, Vitamin D induces the production of Antimicrobial Peptides, as Beta-Defensin and Cathelicidin, causing a reduction of the bacterial infections that MAY exacerbate asthma and atopic dermatitis (ad) [316,317].']	[('SUPERFICIAL_RELATIONSHIP', 10), ('INCOMPLETE_EVIDENCE', 229)]	2	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_65381', 'albizoside C', 117, 'antimicrobial'), ('GO_0007565', 'female pregnancy', 131, 'peptides'), ('PR_000006033', 'cathepsin S', 144, 'beta-defensin'), ('PR_000006009', 'alpha-catulin', 162, 'cathelicidin')]	0	[' immunopathogenesis allergic skin diseases,  production antimicrobial beta-defensin cathelicidin, reduction bacterial infections asthma atopic dermatitis (ad) [316,317].']
S366-PMC5941617	PMC5941617	5/2018	S366-PMC5941617	['OBSERVATIONAL studies on the RELATIONSHIP between Vitamin D in Pregnancy and wheezing, asthma, and allergies Development in early Life SHOWED UNCLEAR results.']	[('INCOMPLETE_EVIDENCE', 0), ('SUPERFICIAL_RELATIONSHIP', 29), ('INCOMPLETE_EVIDENCE', 135), ('FULL_UNKNOWN', 142)]	4	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy'), ('GO_0048513', 'animal organ development', 109, '... development'), ('UBERON_0000104', 'life cycle', 130, 'life')]	0	['observational   wheezing, asthma, allergies life results.']
S521-PMC5941617	PMC5941617	5/2018	S521-PMC5941617	['several OBSERVATIONAL STUDIES have LINKED autism spectrum disorders and low Serum 25(Oh)D levels during Pregnancy because of Vitamin D pleiotropic activity [469–476].']	[('INCOMPLETE_EVIDENCE', 8), ('SUPERFICIAL_RELATIONSHIP', 35)]	2	[('UBERON_0001977', 'blood serum', 76, 'serum'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 88, 'D'), ('GO_0007565', 'female pregnancy', 104, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]	0	['several autism spectrum disorders serum 25(oh)d levels   pleiotropic activity [469–476].']
S538-PMC5941617	PMC5941617	5/2018	S538-PMC5941617	['Pregnancy and breastfeeding\nthe high prevalence of Vitamin D deficiency in Pregnant women is a worldwide health PROBLEM REGARDLESS OF latitude, Food Intake or socio-economic status [93].']	[('IMPORTANT_CONSIDERATION', 112), ('INCOMPLETE_EVIDENCE', 120)]	2	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnant'), ('CHEBI_33290', 'food', 144, 'food'), ('GO_0007631', 'feeding behavior', 144, 'food intake')]	0	[' breastfeeding\nthe   women latitude, food intake socio-economic status [93].']
S539-PMC5941617	PMC5941617	5/2018	S539-PMC5941617	['data about Vitamin D intake and status in Pregnant women are relatively SCARCE but CONFIRM THIS scenario.']	[('INCOMPLETE_EVIDENCE', 72), ('INCOMPLETE_EVIDENCE', 83), ('QUESTION_ANSWERED_BY_THIS_WORK', 91)]	3	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnant')]	0	['data  intake status  women scenario.']
S545-PMC5941617	PMC5941617	5/2018	S545-PMC5941617	['during Pregnancy Vitamin D Metabolism changes so that maternal Serum 1,25(Oh)2D levels significantly rise to meet increased calcium REQUIREMENTS for Fetal Skeleton mineralization, WHEREAS fetal Vitamin D stores are exclusively DEPENDENT on maternal Vitamin D status.']	[('IMPORTANT_CONSIDERATION', 132), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 180), ('SUPERFICIAL_RELATIONSHIP', 227)]	3	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 17, 'vitamin D metabolism'), ('UBERON_0001977', 'blood serum', 63, 'serum'), ('CHEBI_37958', 'dye', 69, '1,'), ('CHEBI_66212', '5,7,3*,4*-tetrahydroxy-2*-(3,3-dimethylallyl)isoflavone', 71, '25(OH)2D'), ('UBERON_0000922', 'embryo', 149, 'fetal'), ('UBERON_0004288', 'skeleton', 155, 'skeleton'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 249, 'vitamin D')]	0	['  metabolism changes maternal serum 1,25(oh)2d levels rise meet calcium fetal skeleton mineralization, fetal  stores exclusively maternal  status.']
S548-PMC5941617	PMC5941617	5/2018	S548-PMC5941617	['in addition, Vitamin D plays a KEY ROLE in the Immunological Adaptation NEEDED for the onset and maintenance of a normal Pregnancy [500].']	[('IMPORTANT_CONSIDERATION', 31), ('SUPERFICIAL_RELATIONSHIP', 35), ('IMPORTANT_CONSIDERATION', 72)]	3	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0002455', 'humoral immune response mediated by circulating immunoglobulin', 47, 'immunological adaptation'), ('GO_0007565', 'female pregnancy', 121, 'pregnancy')]	0	['addition,  plays immunological adaptation onset maintenance normal  [500].']
S551-PMC5941617	PMC5941617	5/2018	S551-PMC5941617	['moreover, maternal Vitamin D deficiency HAS BEEN ASSOCIATED with INCREASED risk of several obstetrics diseases (spontaneous Pregnancy Loss, Preterm and/or small-for-Gestational age Birth, Gestational diabetes pre-eclampsia) [502–506].']	[('INCOMPLETE_EVIDENCE', 40), ('SUPERFICIAL_RELATIONSHIP', 49), ('IMPORTANT_CONSIDERATION', 65)]	3	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0006508', 'proteolysis', 124, 'pregnancy loss'), ('GO_0007565', 'female pregnancy', 140, 'preterm'), ('GO_0007565', 'female pregnancy', 165, 'gestational'), ('GO_0007567', 'parturition', 181, 'birth'), ('GO_0007565', 'female pregnancy', 188, 'gestational')]	0	['moreover, maternal  obstetrics diseases (spontaneous pregnancy loss,  and/or small-for- age birth,  diabetes pre-eclampsia) [502–506].']
S552-PMC5941617	PMC5941617	5/2018	S552-PMC5941617	['in addition, Vitamin D deficiency during Pregnancy MAY negatively AFFECT long-term offspring Extraskeletal health outcomes, with INCREASED risk of infant Respiratory Tract infections, asthma, wheeze, and eczema [273,380,507,508].']	[('INCOMPLETE_EVIDENCE', 51), ('SUPERFICIAL_RELATIONSHIP', 66), ('IMPORTANT_CONSIDERATION', 129)]	3	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('UBERON_0001431', 'distal carpal bone 2', 93, 'extraskeletal'), ('UBERON_0000065', 'respiratory tract', 154, 'respiratory tract')]	0	['addition,   long-term offspring extraskeletal outcomes, infant respiratory tract infections, asthma, wheeze, eczema [273,380,507,508].']
S554-PMC5941617	PMC5941617	5/2018	S554-PMC5941617	['supplementing Pregnant women with Vitamin D in a single or continued dose increases Serum 25(Oh)D at term and MAY reduce the RISK of Preeclampsia, low Birth weight and Preterm Birth.']	[('INCOMPLETE_EVIDENCE', 110), ('IMPORTANT_CONSIDERATION', 125)]	2	[('GO_0007565', 'female pregnancy', 14, 'pregnant'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('UBERON_0001977', 'blood serum', 84, 'serum'), ('CHEBI_71657', 'versiconol acetate', 90, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 93, 'OH ... D'), ('GO_0007128', 'meiotic prophase I', 133, 'preeclampsia'), ('GO_0007567', 'parturition', 151, 'birth'), ('GO_0007565', 'female pregnancy', 168, 'preterm'), ('GO_0007567', 'parturition', 176, 'birth')]	0	['supplementing  women  single dose serum 25(oh)d term preeclampsia, birth  birth.']
S556-PMC5941617	PMC5941617	5/2018	S556-PMC5941617	['the royal college of obstetricians & gynaecoloists RECOMMENDED Vitamin D supplementation with 400\xa0iu/day for all Pregnant women.']	[('FUTURE_WORK', 51)]	1	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]	0	['royal college obstetricians & gynaecoloists  supplementation 400\xa0iu/day  women.']
S558-PMC5941617	PMC5941617	5/2018	S558-PMC5941617	['indeed, Vitamin D supplementation with 400\xa0iu/day HAS BEEN REPORTED insufficient in Pregnancy, PARTICULARLY for women at higher RISK of Vitamin D deficiency [512,513].']	[('INCOMPLETE_EVIDENCE', 50), ('ANOMALY_CURIOUS_FINDING', 95), ('IMPORTANT_CONSIDERATION', 128)]	3	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]	0	['indeed,  supplementation 400\xa0iu/day women higher  [512,513].']
S560-PMC5941617	PMC5941617	5/2018	S560-PMC5941617	['SUGGESTED that a Vitamin D intake of AT LEAST 4000\xa0iu/day SHOULD BE CONSIDERED in all Pregnant women to maintain Serum 25(Oh)D levels ≥40\xa0ng/ml [513,514].']	[('INCOMPLETE_EVIDENCE', 0), ('PROBABLE_UNDERSTANDING', 37), ('FUTURE_WORK', 58), ('FUTURE_WORK', 68)]	4	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnant'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 119, '25(OH)D')]	0	['suggested  intake 4000\xa0iu/day  women maintain serum 25(oh)d levels ≥40\xa0ng/ml [513,514].']
S561-PMC5941617	PMC5941617	5/2018	S561-PMC5941617	['screening for Vitamin D deficiency during Pregnancy is STILL DEBATED.']	[('IMPORTANT_CONSIDERATION', 55), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 61)]	2	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy')]	0	['screening   debated.']
S566-PMC5941617	PMC5941617	5/2018	S566-PMC5941617	['veiled women) and/or constant use of sunscreens• Malabsorption syndromes• chronic therapies AFFECTING Vitamin D Metabolism• obesity• risk of pre-eclampsia• Alcohol abuse• bone pain• hypocalcemia• a previous child with rickets• Pregnant adolescents\nin the present consensus we RECOMMEND Vitamin D supplementation in all Pregnant and breastfeeding women since the beginning of Pregnancy at a dose of 600\xa0iu/day.']	[('SUPERFICIAL_RELATIONSHIP', 92), ('FUTURE_WORK', 276)]	2	[('GO_0046661', 'male sex differentiation', 49, 'Malabsorption'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 102, 'vitamin D metabolism'), ('CHEBI_30879', 'alcohol', 156, 'Alcohol'), ('GO_0007565', 'female pregnancy', 227, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D'), ('GO_0007565', 'female pregnancy', 319, 'pregnant'), ('GO_0007565', 'female pregnancy', 375, 'pregnancy')]	0	['veiled women) and/or sunscreens• malabsorption syndromes• chronic therapies  metabolism• obesity• pre-eclampsia• alcohol abuse• bone pain• hypocalcemia• child rickets•  adolescents\nin  supplementation  breastfeeding women  dose 600\xa0iu/day.']
S568-PMC5941617	PMC5941617	5/2018	S568-PMC5941617	['we do not RECOMMEND routine screening of Serum 25(Oh)D levels in all Pregnant and breastfeeding women, BUT we SUGGEST to CONSIDER Vitamin D testing in women with multiple RISK FACTORS for Vitamin D deficiency, PARTICULARLY if not receiving Vitamin D supplementation.']	[('FUTURE_WORK', 10), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 103), ('INCOMPLETE_EVIDENCE', 110), ('FUTURE_WORK', 121), ('SUPERFICIAL_RELATIONSHIP', 171), ('ANOMALY_CURIOUS_FINDING', 210), ('IMPORTANT_CONSIDERATION', 210)]	7	[('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 47, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D')]	0	['routine screening serum 25(oh)d levels  breastfeeding women,  testing women  deficiency, receiving  supplementation.']
S619-PMC5941617	PMC5941617	5/2018	S619-PMC5941617	['adolescents are PARTICULARLY AT RISK of hypovitaminosis d.\nVitamin D status of newborns is INFLUENCED by ethnicity, season of Birth, and maternal Vitamin D status during Pregnancy.']	[('IMPORTANT_CONSIDERATION', 16), ('IMPORTANT_CONSIDERATION', 29), ('SUPERFICIAL_RELATIONSHIP', 91)]	3	[('CHEBI_28384', 'vitamin K', 59, 'Vitamin D'), ('GO_0007567', 'parturition', 126, 'birth'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy')]	0	['adolescents hypovitaminosis d.\nvitamin status newborns ethnicity, season birth, maternal  status .']
S661-PMC5941617	PMC5941617	5/2018	S661-PMC5941617	['RECENT STUDIES SUGGEST a RELATIONSHIP between maternal Vitamin D status during Pregnancy and bone mass of the fetus and the newborn.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 15), ('SUPERFICIAL_RELATIONSHIP', 25)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy')]	0	['recent maternal  status  bone mass fetus newborn.']
S720-PMC5941617	PMC5941617	5/2018	S720-PMC5941617	['we SUGGEST to CONSIDER serum 25(Oh)D testing in women with multiple RISK FACTORS for Vitamin D deficiency, PARTICULARLY if not receiving Vitamin D supplementation, and/or with specific conditions POSSIBLY AFFECTING Pregnancy course (table\xa09).']	[('INCOMPLETE_EVIDENCE', 3), ('FUTURE_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 68), ('ANOMALY_CURIOUS_FINDING', 107), ('IMPORTANT_CONSIDERATION', 107), ('INCOMPLETE_EVIDENCE', 196), ('SUPERFICIAL_RELATIONSHIP', 205)]	7	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 35, 'D'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy')]	0	['serum 25(oh)d testing women  deficiency, receiving  supplementation, and/or conditions  course (table\xa09).']
S721-PMC5941617	PMC5941617	5/2018	S721-PMC5941617	['we RECOMMEND Vitamin D supplementation in all Pregnant and breastfeeding women at a dose of 600\xa0iu/day.']	[('FUTURE_WORK', 3)]	1	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0007565', 'female pregnancy', 46, 'pregnant')]	0	[' supplementation  breastfeeding women dose 600\xa0iu/day.']
S24-PMC5952272	PMC5952272	5/2018	S24-PMC5952272	['for this purpose, 10 Micronutrients are added to the flour, including b1, b2, b6, b12, Folic Acid, niacin, iron, zinc, Vitamin A, and Vitamin D.4\nDESPITE all the above-mentioned actions, anaemia PREVALENCE is STILL high among Pregnant women, Lactating mothers, and children less than 5\u2009years of age.']	[('ANOMALY_CURIOUS_FINDING', 146), ('IMPORTANT_CONSIDERATION', 195), ('IMPORTANT_CONSIDERATION', 209)]	3	[('CHEBI_33839', 'macromolecule', 21, 'micronutrients'), ('CHEBI_30751', 'formic acid', 87, 'folic acid'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 226, 'pregnant'), ('GO_0007594', 'puparial adhesion', 242, 'lactating')]	0	['purpose, 10 micronutrients added flour, b1, b2, b6, b12, folic acid, niacin, iron, zinc, .4\ndespite above-mentioned actions, anaemia among  women, lactating mothers, children 5\u2009years age.']
S147-PMC5952272	PMC5952272	5/2018	S147-PMC5952272	['experiment on Animal models SHOWED that 1,25 Dihydroxyvitamin D3 Prenatal supplementations were PROTECTIVE for offsprings against induced Maternal Immune Activation (mia).42maternal Immune Activation in experimental Animals Reproduces asd-like symptoms via significant increase of proinflammatory cytokines; however, administration of Vitamin D has blocked the emergence of asd-relevant deficits in social INTERACTION, stereotyped behaviour, and emotional Learning and Memory.42RECENTLY, sotodehasl et al43have reviewed 80 articles LINKING autism and Vitamin D. the authors found no significant DIFFERENCES between children with asd and neurotypical developed children.43this was also SUPPORTED by a canadian prospective cohort study that included 3852 children.44forty-one children were diagnosed with asd, who have no difference in the level of Vitamin D in their Serum compared with non-asd children.']	[('INCOMPLETE_EVIDENCE', 28), ('SUPERFICIAL_RELATIONSHIP', 96), ('SUPERFICIAL_RELATIONSHIP', 406), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 476), ('SUPERFICIAL_RELATIONSHIP', 532), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 595), ('INCOMPLETE_EVIDENCE', 685)]	7	[('NCBITaxon_33208', 'Metazoa', 14, 'animal'), ('CHEBI_63912', '19-hydroxyprostaglandin H2', 40, '1,25 dihydroxyvitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 62, 'D3'), ('GO_0007565', 'female pregnancy', 65, 'prenatal'), ('GO_0007618', 'mating', 138, 'maternal'), ('GO_0060819', 'inactivation of X chromosome by genetic imprinting', 147, 'immune activation'), ('UBERON_0002405', 'immune system', 147, 'immune'), ('GO_0060819', 'inactivation of X chromosome by genetic imprinting', 182, 'immune activation'), ('UBERON_0002405', 'immune system', 182, 'immune'), ('NCBITaxon_33208', 'Metazoa', 216, 'animals'), ('GO_0000003', 'reproduction', 224, 'reproduces'), ('CHEBI_27300', 'vitamin D', 335, 'vitamin D'), ('GO_0007612', 'learning', 456, 'learning'), ('GO_0007613', 'memory', 469, 'memory'), ('CHEBI_27300', 'vitamin D', 551, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 847, 'vitamin D'), ('UBERON_0001977', 'blood serum', 866, 'serum')]	0	['experiment animal 1,25 dihydroxyvitamin d3  supplementations offsprings induced maternal immune activation (mia).42maternal immune activation animals asd-like symptoms via increase proinflammatory cytokines; however, administration  blocked asd-relevant social interaction, behaviour, emotional learning memory.42recently, sotodehasl et al43have 80 articles autism . authors children asd neurotypical children.43this 3852 children.44forty-one children diagnosed asd,  serum non-asd children.']
S239-PMC5956785	PMC5956785	5/2018	S239-PMC5956785	['exploring elements of Vitamin D status that MAY have a ROLE in disease development such as early Life and Gestational Vitamin D status as well as Genes in the Vitamin D pathway will help TO CLARIFY the ROLE of Vitamin D.\nseason of Birth HAS BEEN SUGGESTED to have an IMPACT on the risk of developing a number of Autoimmune diseases such as multiple sclerosis, type 1 diabetes and celiac disease [78].']	[('INCOMPLETE_EVIDENCE', 44), ('SUPERFICIAL_RELATIONSHIP', 55), ('FUTURE_WORK', 187), ('SUPERFICIAL_RELATIONSHIP', 202), ('INCOMPLETE_EVIDENCE', 237), ('SUPERFICIAL_RELATIONSHIP', 267)]	6	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('UBERON_0000104', 'life cycle', 97, 'life'), ('GO_0007565', 'female pregnancy', 106, 'gestational'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('SO_0000704', 'gene', 146, 'genes'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('GO_0007567', 'parturition', 231, 'birth'), ('UBERON_0001442', 'skeleton of manus', 312, 'autoimmune')]	0	['exploring elements  status disease life   status genes  .\nseason birth autoimmune diseases sclerosis, type diabetes celiac disease [78].']
S29-PMC5995352	PMC5995352	6/2018	S29-PMC5995352	['inborn rickets due to Vitamin D deficiency, however, is very RARE, but MAY BE seen in children of mothers with SEVERE Vitamin D deficiency, osteomalacia and low s-calcium during Pregnancy [11].']	[('INCOMPLETE_EVIDENCE', 61), ('INCOMPLETE_EVIDENCE', 71), ('IMPORTANT_CONSIDERATION', 111)]	3	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy')]	0	['inborn rickets  deficiency, however, rare, children mothers  deficiency, osteomalacia s-calcium  [11].']
S34-PMC5995352	PMC5995352	6/2018	S34-PMC5995352	['ALTHOUGH maternal Vitamin D status during Pregnancy has no impact on foetal Bone mineralisation IF Calcium supply is adequate, observational studies have LINKED low maternal Vitamin D levels with smaller child bone mass and impaired linear growth in the first 12 months of Life [18–20].']	[('ANOMALY_CURIOUS_FINDING', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 96), ('SUPERFICIAL_RELATIONSHIP', 154)]	3	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('GO_0007567', 'parturition', 76, 'bone'), ('CHEBI_22313', 'alkaline earth metal atom', 99, 'calcium'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('UBERON_0000104', 'life cycle', 273, 'life')]	0	['although maternal  status  foetal bone mineralisation calcium supply adequate, maternal  levels child bone mass linear 12 months life [18–20].']
S92-PMC5995352	PMC5995352	6/2018	S92-PMC5995352	['compared to children in the highest Cord 25Ohd quartile, children in the lowest quartile were more often Born during winter and spring and more LIKELY had mothers of non-western ethnicity, mothers with pre-Gestational bmi above 25 kg/m2, mothers with parity above three children, mothers who took less than the recommended Vitamin D supplement of 10 μg/day, or mothers who Smoked during Pregnancy,table 1.10.1371/journal.pone.0198724.t001\n\ncaption (table-wrap): table 1\nbasic characteristics of the 2010 participants.nquartiles of Cord 25Ohd, nmol/lp-value*< 30.730.8–45.145.2–60.6> 60.7 maternal characteristics maternal height, cm2010168.3 ± 6.51168.0 ± 6.6168.2 ± 6.1168.5 ± 6.10.7maternal pre-Gestational weight, kg201069 [60–80]266 [60–74]66 [59–75]65 [59–73]<0.001 Pregestational bmi, kg/m2201024.3 [21.8–28.1]23.3 [21.4–26.0]23.5 [21.1–26.2]22.8 [21.0–25.6]<0.001 Gestational weight gain, kg87315.1 ± 6.315.0 ± 5.615.5 ± 5.614.5 ± 5.20.4maternal age, y201029.8 ± 4.630.4 ± 4.330.3 ± 4.330.0 ± 4.60.1smoking in Pregnancy, n (%) <0.001 \u2003smoker9843 (8.6)18 (3.6)19 (3.8)18 (3.6)\u2003non-smoker1912460 (91.4)484 (96.4)484 (96.2)484 (96.4)maternal educational level, n (%)0.2\u2003lower25274 (19.5)64 (16.3)54 (13.7)60 (17.7)\u2003intermediate908218 (57.5)230 (58.7)245 (62.2)215 (63.2)\u2003higher34587 (23.0)98 (25.0)95 (24.1)65 (19.1)ethnicity, n (%) <0.001 \u2003western1918459 (93.2)482 (95.8)486 (98.6)491 (97.1)\u2003non-western9244 (6.8)20 (4.2)17 (1.4)11 (2.9)skin-type**, n (%)0.2\u2003i/ii white29986 (22.6)84 (21.3)66 (16.7)63 (18.4)\u2003iii darker white889207 (54.3)239 (60.5)249 (62.8)194 (56.7)\u2003iv brown30982 (21.5)67 (16.9)78 (19.7)82 (23.9)\u2003v/vi dark brown176 (1.6)5 (1.3)3 (0.6)3 (1.0)parity, n (%) <0.001 \u2003first child1109230 (45.7)282 (56.2)295 (58.7)302 (60.2)\u2003second child679204 (40.6)164 (32.7)156 (31.0)155 (30.9)\u2003third child or more22269 (13.7)56 (11.1)52 (10.3)45 (8.9)time spent outdoors, mother, n (%) 0.002 \u2003never/rarely3111 (2.9)7 (1.8)7 (1.8)6 (1.8)\u2003sometimes29595 (24.9)84 (21.2)62 (15.7)54 (15.8)\u2003often920204 (54.4)252 (63.6)256 (64.7)208 (60.8)\u2003most of the time27072 (18.8)53 (13.4)71 (17.8)74 (21.6)Vitamin D supplementation in Pregnancy, mother, n (%) <0.001 \u2003≤10 μg/day15764 (23.4)33 (10.7)36 (11.4)24 (8.5)\u2003>10 μg/day1023210 (76.6)275 (89.3)281 (88.6)257 (91.5) paternal characteristics paternal height, cm1223182.6 ± 6.7182.5 ± 7.0183.2± 6.6182.3± 6.70.3 child characteristics Gestational age (ga) at Birth, w201040 [39–41]40 [39–41]40 [39–41]40 [39–41]0.6season of Birth n (%) <0.001 \u2003winter (dec-feb)489190 (37.7)143 (28.5)107 (21.3)49 (9.8)\u2003spring (mar-may)496158 (31.4)144 (28.7)106 (21.1)88 (17.5)\u2003summer (jun-aug)47729 (5.8)78 (15.5)135 (26.8)235 (46.8)\u2003autumn (sep-nov)548126 (25.1)137 (27.3)155 (30.8)130 (25.9)child sex, n (%)0.6\u2003girls948241 (47.9)228 (45.4)247 (49.1)232 (46.2)\u2003boys1062262 (52.1)274 (54.6)256 (50.9)270 (53.8)child age at 18 months examination, m135018.7 [18.3–19.4]18.8 [18.2–19.4]18.0 [18.4–19.6]19.0 [18.4–19.5]0.03 duration of exclusive breastfeeding, w123018 [6–34]19 [11–24]20 [10–24]20 [12–24]0.06intake of infant formula after 8 weeks of age0.06\u2003yes9219 (6.5)21 (6.2)34 (10.3)18 (5.2)\u2003no1219275 (93.5)319 (93.8)297 (89.7)328 (94.8)dietary intake of Calcium, mg/day1243489 [213–756]495 [230–751]495 [224–757]489 [211–747]0.06dietary intake of Vitamin D, μg/day11851.14 ± 1.011.18 ± 1.661.04 ± 0.900.98 ± 1.00.2vitamin D supplementation, μg/day9433.47 ± 2.213.98 ± 1.363.88 ± 1.454.03 ± 1.59 0.002\nanova was used for comparing means of numerical, normally distributed variables.']	[('PROBABLE_UNDERSTANDING', 144)]	1	[('UBERON_0002240', 'spinal cord', 36, 'cord'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 41, '25OHD'), ('GO_0007567', 'parturition', 105, 'born'), ('GO_0007565', 'female pregnancy', 206, 'gestational'), ('CHEBI_27300', 'vitamin D', 323, 'vitamin D'), ('GO_0007601', 'visual perception', 373, 'smoked'), ('GO_0007565', 'female pregnancy', 387, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 531, 'cord'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 536, '25OHD'), ('GO_0007565', 'female pregnancy', 697, 'gestational'), ('GO_0007565', 'female pregnancy', 771, 'Pregestational'), ('GO_0007565', 'female pregnancy', 871, 'Gestational'), ('GO_0007565', 'female pregnancy', 1017, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 2097, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 2126, 'pregnancy'), ('GO_0007565', 'female pregnancy', 2379, 'Gestational'), ('GO_0007567', 'parturition', 2403, 'birth'), ('GO_0007567', 'parturition', 2468, 'birth'), ('CHEBI_22313', 'alkaline earth metal atom', 3186, 'calcium'), ('CHEBI_27300', 'vitamin D', 3279, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 3354, 'D')]	0	['compared children cord 25ohd quartile, children lowest quartile born winter spring mothers non-western ethnicity, mothers pre- bmi 25 kg/m2, mothers parity three children, mothers took  supplement 10 μg/day, mothers smoked ,table 1.10.1371/journal.pone.0198724.t001\n\ncaption (table-wrap): table 1\nbasic characteristics 2010 participants.nquartiles cord 25ohd, nmol/lp-value*< 30.730.8–45.145.2–60.6> 60.7 maternal characteristics maternal height, cm2010168.3 ± 6.51168.0 ± 6.6168.2 ± 6.1168.5 ± 6.10.7maternal pre- weight, kg201069 [60–80]266 [60–74]66 [59–75]65 [59–73]<0.001  bmi, kg/m2201024.3 [21.8–28.1]23.3 [21.4–26.0]23.5 [21.1–26.2]22.8 [21.0–25.6]<0.001  gain, kg87315.1 ± 6.315.0 ± 5.615.5 ± 5.614.5 ± 5.20.4maternal age, y201029.8 ± 4.630.4 ± 4.330.3 ± 4.330.0 ± 4.60.1smoking n (%) <0.001 \u2003smoker9843 (8.6)18 (3.6)19 (3.8)18 (3.6)\u2003non-smoker1912460 (91.4)484 (96.4)484 (96.2)484 (96.4)maternal educational level, n (%)0.2\u2003lower25274 (19.5)64 (16.3)54 (13.7)60 (17.7)\u2003intermediate908218 (57.5)230 (58.7)245 (62.2)215 (63.2)\u2003higher34587 (23.0)98 (25.0)95 (24.1)65 (19.1)ethnicity, n (%) <0.001 \u2003western1918459 (93.2)482 (95.8)486 (98.6)491 (97.1)\u2003non-western9244 (6.8)20 (4.2)17 (1.4)11 (2.9)skin-type**, n (%)0.2\u2003i/ii white29986 (22.6)84 (21.3)66 (16.7)63 (18.4)\u2003iii darker white889207 (54.3)239 (60.5)249 (62.8)194 (56.7)\u2003iv brown30982 (21.5)67 (16.9)78 (19.7)82 (23.9)\u2003v/vi dark brown176 (1.6)5 (1.3)3 (0.6)3 (1.0)parity, n (%) <0.001 \u2003first child1109230 (45.7)282 (56.2)295 (58.7)302 (60.2)\u2003second child679204 (40.6)164 (32.7)156 (31.0)155 (30.9)\u2003third child more22269 (13.7)56 (11.1)52 (10.3)45 (8.9)time spent outdoors, mother, n (%) 0.002 \u2003never/rarely3111 (2.9)7 (1.8)7 (1.8)6 (1.8)\u2003sometimes29595 (24.9)84 (21.2)62 (15.7)54 (15.8)\u2003often920204 (54.4)252 (63.6)256 (64.7)208 (60.8)\u2003most time27072 (18.8)53 (13.4)71 (17.8)74 (21.6)vitamin supplementation mother, n (%) <0.001 \u2003≤10 μg/day15764 (23.4)33 (10.7)36 (11.4)24 (8.5)\u2003>10 μg/day1023210 (76.6)275 (89.3)281 (88.6)257 (91.5) paternal characteristics paternal height, cm1223182.6 ± 6.7182.5 ± 7.0183.2± 6.6182.3± 6.70.3 child characteristics  age (ga) birth, w201040 [39–41]40 [39–41]40 [39–41]40 [39–41]0.6season birth n (%) <0.001 \u2003winter (dec-feb)489190 (37.7)143 (28.5)107 (21.3)49 (9.8)\u2003spring (mar-may)496158 (31.4)144 (28.7)106 (21.1)88 (17.5)\u2003summer (jun-aug)47729 (5.8)78 (15.5)135 (26.8)235 (46.8)\u2003autumn (sep-nov)548126 (25.1)137 (27.3)155 (30.8)130 (25.9)child sex, n (%)0.6\u2003girls948241 (47.9)228 (45.4)247 (49.1)232 (46.2)\u2003boys1062262 (52.1)274 (54.6)256 (50.9)270 (53.8)child age 18 months examination, m135018.7 [18.3–19.4]18.8 [18.2–19.4]18.0 [18.4–19.6]19.0 [18.4–19.5]0.03 duration breastfeeding, w123018 [6–34]19 [11–24]20 [10–24]20 [12–24]0.06intake infant formula 8 weeks age0.06\u2003yes9219 (6.5)21 (6.2)34 (10.3)18 (5.2)\u2003no1219275 (93.5)319 (93.8)297 (89.7)328 (94.8)dietary intake calcium, mg/day1243489 [213–756]495 [230–751]495 [224–757]489 [211–747]0.06dietary intake μg/day11851.14 ± 1.011.18 ± 1.661.04 ± 0.900.98 ± 1.00.2vitamin supplementation, μg/day9433.47 ± 2.213.98 ± 1.363.88 ± 1.454.03 ± 1.59 0.002\nanova numerical, distributed variables.']
S145-PMC5995352	PMC5995352	6/2018	S145-PMC5995352	['covariates\nCord 25Ohd was RELATED with season of Birth, maternal ethnicity, pre-Gestational bmi, parity, maternal Vitamin D supplementation and smoking in Pregnancy, which is CONSISTENT with the literature [33–35].']	[('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 175)]	2	[('UBERON_0000948', 'heart', 11, 'Cord'), ('CHEBI_72652', '7,2*-dihydroxy-4*-methoxyisoflavan-4-ylium cation', 16, '25OHD'), ('GO_0007567', 'parturition', 49, 'birth'), ('GO_0007565', 'female pregnancy', 80, 'gestational'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 155, 'pregnancy')]	0	['covariates\ncord 25ohd season birth, maternal ethnicity, pre- bmi, parity, maternal  supplementation smoking [33–35].']
S152-PMC5995352	PMC5995352	6/2018	S152-PMC5995352	['this was IN KEEPING WITH OUR FINDINGS, SUPPORTING that early Pregnancy Vitamin D status does not affect offspring linear growth.']	[('INCOMPLETE_EVIDENCE', 9), ('QUESTION_ANSWERED_BY_THIS_WORK', 25), ('INCOMPLETE_EVIDENCE', 39)]	3	[('GO_0007565', 'female pregnancy', 61, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]	0	['keeping findings,   status offspring linear growth.']
S0-PMC6011374	PMC6011374	6/2018	S0-PMC6011374	['Vitamin D levels in an australian and new zealand cohort and the ASSOCIATION with Pregnancy outcome\n\nabstract\n\nbackground\nPregnant women are at INCREASED SUSCEPTIBILITY to Vitamin D deficiency.']	[('SUPERFICIAL_RELATIONSHIP', 65), ('IMPORTANT_CONSIDERATION', 144)]	2	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy'), ('GO_0007565', 'female pregnancy', 122, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D')]	0	['vitamin levels australian zealand  outcome\n\nabstract\n\nbackground\n women  deficiency.']
S1-PMC6011374	PMC6011374	6/2018	S1-PMC6011374	['hence, there is CONTINUING INTEREST in determining HOW Vitamin D INFLUENCES Pregnancy health.']	[('INCOMPLETE_EVIDENCE', 16), ('EXPLICIT_QUESTION', 51), ('SUPERFICIAL_RELATIONSHIP', 65)]	3	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy')]	0	['hence,   health.']
S2-PMC6011374	PMC6011374	6/2018	S2-PMC6011374	['we AIMED to compare Vitamin D status in two distinct populations of Pregnant women in australia and new zealand and TO INVESTIGATE the RELATIONSHIP between Vitamin D status and Pregnancy outcome.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('QUESTION_ANSWERED_BY_THIS_WORK', 116), ('SUPERFICIAL_RELATIONSHIP', 135)]	3	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 68, 'pregnant'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('GO_0007565', 'female pregnancy', 177, 'pregnancy')]	0	[' status populations  women australia zealand  status  outcome.']
S10-PMC6011374	PMC6011374	6/2018	S10-PMC6011374	['a POSSIBLE ASSOCIATION between fetal sex, Vitamin D status and gdm provides FURTHER QUESTIONS and ENCOURAGES continual RESEARCH and discussion into the ROLE of Vitamin D in Pregnancy, particularly in Vitamin D replete populations.']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 76), ('EXPLICIT_QUESTION', 84), ('FUTURE_WORK', 98), ('SUPERFICIAL_RELATIONSHIP', 152)]	6	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('GO_0007565', 'female pregnancy', 173, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]	0	['fetal sex,  status gdm discussion   replete populations.']
S12-PMC6011374	PMC6011374	6/2018	S12-PMC6011374	['background\nwith an increasing prevalence of Vitamin D deficiency and insufficiency reported both in australia and new zealand, as well as worldwide [1], there is CONTINUING INTEREST in determining HOW Vitamin D deficiency MAY INFLUENCE health in Pregnancy.']	[('INCOMPLETE_EVIDENCE', 162), ('EXPLICIT_QUESTION', 197), ('INCOMPLETE_EVIDENCE', 222), ('SUPERFICIAL_RELATIONSHIP', 226)]	4	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D'), ('GO_0007565', 'female pregnancy', 246, 'pregnancy')]	0	['background\nwith  australia zealand, [1],  .']
S13-PMC6011374	PMC6011374	6/2018	S13-PMC6011374	['evidence SUGGESTS that Vitamin D deficiency is ASSOCIATED with a number of Pregnancy COMPLICATIONS including Preeclampsia (pe), Gestational diabetes mellitus (gdm) and spontaneous Preterm Birth (Sptb) [2–4].']	[('INCOMPLETE_EVIDENCE', 9), ('SUPERFICIAL_RELATIONSHIP', 47), ('PROBLEM_COMPLICATION', 85)]	3	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 109, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 128, 'gestational'), ('GO_0007565', 'female pregnancy', 180, 'preterm birth'), ('PR_000015390', 'sterol O-acyltransferase 2', 195, 'sPTB')]	0	['evidence   preeclampsia (pe),  diabetes mellitus (gdm) spontaneous  (sptb) [2–4].']
S14-PMC6011374	PMC6011374	6/2018	S14-PMC6011374	['HOWEVER, INCONSISTENCIES between studies reflect UNCERTAINTY about the true EFFECT of Vitamin D deficiency on Pregnancy outcome [5,6].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('FULL_UNKNOWN', 49), ('SUPERFICIAL_RELATIONSHIP', 76)]	4	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy')]	0	['however,   outcome [5,6].']
S19-PMC6011374	PMC6011374	6/2018	S19-PMC6011374	['the incidence of Vitamin D deficiency (˂50\xa0nmol/l) is frequent among Pregnant women EVEN in areas such as australia and the north island of new zealand where sunlight exposure is high.']	[('ANOMALY_CURIOUS_FINDING', 84)]	1	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant')]	0	[' (˂50\xa0nmol/l) among  women australia north island zealand sunlight exposure high.']
S21-PMC6011374	PMC6011374	6/2018	S21-PMC6011374	['reports from lower-risk groups have INDICATED that Vitamin D deficiency occurs in 25–55% of Pregnant women [11–13].']	[('INCOMPLETE_EVIDENCE', 36)]	1	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 92, 'pregnant')]	0	['reports lower-risk  occurs 25–55%  women [11–13].']
S22-PMC6011374	PMC6011374	6/2018	S22-PMC6011374	['there are numerous studies which HAVE SHOWN that Vitamin D deficiency is ASSOCIATED with adverse Pregnancy outcomes (most recent: [14–17]), particularly in populations that reside at higher latitudes.']	[('INCOMPLETE_EVIDENCE', 33), ('SUPERFICIAL_RELATIONSHIP', 73)]	2	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy')]	0	['  outcomes (most recent: [14–17]), populations reside higher latitudes.']
S24-PMC6011374	PMC6011374	6/2018	S24-PMC6011374	['PREVIOUS STUDIES on Pregnant australian and new zealand women have reported that WHILE circulating 25(Oh)D was significantly lower in women with pe, Sptb, gdm and those who Delivered a small-for Gestational age (sga) infant, no association between Vitamin D deficiency and these Pregnancy complications was found after adjusting for covariates [18–20].']	[('INCOMPLETE_EVIDENCE', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 81)]	2	[('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 99, '25(OH)D'), ('PR_000015390', 'sterol O-acyltransferase 2', 149, 'sPTB'), ('GO_0007567', 'parturition', 173, 'delivered'), ('GO_0007565', 'female pregnancy', 195, 'gestational'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('GO_0007565', 'female pregnancy', 279, 'pregnancy')]	0	['previous  australian zealand women circulating 25(oh)d women pe, sptb, gdm delivered small-for  age (sga) infant,   adjusting covariates [18–20].']
S26-PMC6011374	PMC6011374	6/2018	S26-PMC6011374	['furthermore, the Gestation at which Vitamin D was measured is also IMPORTANT.']	[('IMPORTANT_CONSIDERATION', 67)]	1	[('GO_0007565', 'female pregnancy', 17, 'gestation'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]	0	['furthermore,   important.']
S27-PMC6011374	PMC6011374	6/2018	S27-PMC6011374	['in the case of Preterm Delivery, Vitamin D status measured closer to the Delivery date was more significantly ASSOCIATED with Preterm Delivery than earlier measures [26].']	[('SUPERFICIAL_RELATIONSHIP', 110)]	1	[('GO_0007565', 'female pregnancy', 15, 'preterm'), ('GO_0007567', 'parturition', 23, 'delivery'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007567', 'parturition', 73, 'delivery'), ('GO_0007565', 'female pregnancy', 126, 'preterm'), ('GO_0007567', 'parturition', 134, 'delivery')]	0	[' delivery,  status closer delivery  delivery [26].']
S29-PMC6011374	PMC6011374	6/2018	S29-PMC6011374	['using a robust, validated chemiluminescent-based assay to measure Serum 25(Oh)D [27], we AIMED TO INVESTIGATE the DIFFERENCES between Vitamin D status in early Pregnancy in two distinct populations of Nulliparous women from australia and new zealand.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 89), ('QUESTION_ANSWERED_BY_THIS_WORK', 95), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 114)]	3	[('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 72, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 160, 'pregnancy'), ('GO_0046662', 'regulation of oviposition', 201, 'nulliparous')]	0	['using robust, chemiluminescent-based assay measure serum 25(oh)d [27],  status  populations nulliparous women australia zealand.']
S30-PMC6011374	PMC6011374	6/2018	S30-PMC6011374	['we also AIMED TO EXAMINE the RELATIONSHIP between Serum 25(Oh)D at 15\u2009±\u20091\xa0weeks’ Gestation and the risk of an adverse Pregnancy outcome and included determining the EFFECT modification of fetal sex on the ASSOCIATION between maternal Vitamin D status and Pregnancy outcome.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 8), ('QUESTION_ANSWERED_BY_THIS_WORK', 14), ('SUPERFICIAL_RELATIONSHIP', 29), ('SUPERFICIAL_RELATIONSHIP', 165), ('SUPERFICIAL_RELATIONSHIP', 205)]	5	[('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 56, '25(OH)D'), ('GO_0007565', 'female pregnancy', 81, 'gestation'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D'), ('GO_0007565', 'female pregnancy', 255, 'pregnancy')]	0	['serum 25(oh)d 15\u2009±\u20091\xa0weeks’   outcome fetal sex maternal  status  outcome.']
S63-PMC6011374	PMC6011374	6/2018	S63-PMC6011374	['HOWEVER, after adjusting for maternal age, bmi, sei, smoking status and Alcohol consumption at 15\u2009±\u20091\xa0weeks’ Gestation, ethnicity, recreational walking and season, the women recruited in adelaide STILL had significantly lower Serum 25(Oh)D when compared with those in auckland (adelaide: 58.4\u2009±\u200950.3 vs. auckland: 70.2\u2009±\u200954.5\xa0nmol/l, p\u2009<\u20090.001) INDICATING the INFLUENCE of OTHER CONFOUNDERS not measured as part of the study on Vitamin D status.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 196), ('INCOMPLETE_EVIDENCE', 345), ('SUPERFICIAL_RELATIONSHIP', 360), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 373), ('PROBLEM_COMPLICATION', 379)]	6	[('CHEBI_30879', 'alcohol', 72, 'alcohol'), ('GO_0007565', 'female pregnancy', 109, 'gestation'), ('UBERON_0001977', 'blood serum', 226, 'serum'), ('CHEBI_71657', 'versiconol acetate', 232, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 232, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 428, 'vitamin D')]	0	['however, adjusting maternal age, bmi, sei, smoking status alcohol consumption 15\u2009±\u20091\xa0weeks’ ethnicity, recreational walking season, women recruited adelaide serum 25(oh)d auckland (adelaide: 58.4\u2009±\u200950.3 vs. auckland: 70.2\u2009±\u200954.5\xa0nmol/l, p\u2009<\u20090.001)  status.']
S77-PMC6011374	PMC6011374	6/2018	S77-PMC6011374	['HOWEVER, when each Pregnancy complication was analysed separately, a 53% decreased risk for gdm was observed with high Vitamin D status when compared to moderate-high status (arr: 0.47; 95% ci: 0.23, 0.96).']	[('ANOMALY_CURIOUS_FINDING', 0)]	1	[('GO_0007565', 'female pregnancy', 19, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]	0	['however,  separately, 53% decreased gdm  status moderate-high status (arr: 0.47; 95% ci: 0.23, 0.96).']
S79-PMC6011374	PMC6011374	6/2018	S79-PMC6011374	['ALTHOUGH, the point estimates INDICATED a marginal increased risk for developing any Pregnancy complication with severe (<\u200925\xa0nmol/l) Vitamin D deficiency compared to those who had levels between 50 and 75\xa0nmol/l (arr: 1.10; 95% ci: 0.89, 1.36).']	[('ANOMALY_CURIOUS_FINDING', 0), ('INCOMPLETE_EVIDENCE', 30)]	2	[('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]	0	['although,  (<\u200925\xa0nmol/l)  levels 50 75\xa0nmol/l (arr: 1.10; 95% ci: 0.89, 1.36).']
S80-PMC6011374	PMC6011374	6/2018	S80-PMC6011374	['caption (table-wrap): table 2\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaneous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status categorised based on standardised quartiles and clinical definitions of Vitamin D statuspregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci)standardised quartiles**\u2003low711 (25)328 (46)0.95 (0.85, 1.07)46 (6)1.02 (0.66, 1.57))57 (8)0.97 (0.67, 1.42)28 (4)0.79 (0.47, 1.30)36 (5)0.83 (0.54, 1.29)84 (12)1.02 (0.75, 1.39)\u2003low-moderate755 (27)318 (42)1.00 (0.90, 1.12)42 (6)1.07 (0.69, 1.64)65 (9)1.06 (0.74, 1.52)25 (3)0.67 (0.39, 1.16)33 (4)0.87 (0.56, 1.3572 (10)0.98 (0.73, 1.32)\u2003moderate-high702 (25)309 (44)1.0†37 (5)1.0†50 (7)1.0†28 (4)1.0†39 (6)1.0†81 (12)1.0†\u2003high630 (23)258 (41)0.93 (0.82, 1.06)†35 (6)1.24 (0.78, 1.96)40 (6)0.87 (0.58, 1.30)10 (2) 0.47(0.23, 0.96) 30 (5)0.77 (0.48, 1.25)60 (10)0.80 (0.57, 1.11)Vitamin d status\u2003<25 nmol/l99 (4)51 (52)1.10 (0.89, 1.36)8 (8)1.44 (0.68, 3.03))6 (6)0.70 (0.32, 1.52)5 (5)0.98 (0.38, 2.52)7 (7)1.44 (0.68, 3.04)13 (13)1.15 (0.66, 2.01)\u200325-50 nmol/l673 (24)301 (45)0.93 (0.83, 1.03)45 (7)1.18 (0.80, 1.75)59 (9)0.97 (0.71, 1.34)26 (4)0.89 (0.54, 1.47)29 (4)0.75 (0.48, 1.16)74 (11)0.93 (0.69, 1.24)\u2003>50-75 nmol/l928 (33)428 (46)1.0†48 (5)1.0†80 (9)1.0†35 (4)1.0†52 (6)1.0†107 (12)1.0†\u2003>75 nmol/l1098 (39)435 (40)0.95 (0.86, 1.04)60 (5)1.28 (0.87, 1.87)67 (6)0.82 (0.59, 1.12)†26 (2)0.78 (0.48, 1.28)51 (5)0.86 (0.59, 1.26)104 (9)0.86 (0.67, 1.12)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that Serum was sampled based as previously described [34]\n†reference category\n\nSerum 25(Oh)D, Pregnancy outcome and fetal sex\nas THERE IS EVIDENCE to SUGGEST that Vitamin D Metabolism within the Placenta MAY DIFFER with respect to fetal sex [35] THUS, we ASSESSED the EFFECT of “standardised” Vitamin D status on Pregnancy outcome stratified by fetal sex (table\xa03).']	[('INCOMPLETE_EVIDENCE', 2230), ('INCOMPLETE_EVIDENCE', 2251), ('INCOMPLETE_EVIDENCE', 2305), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 2309), ('PROBABLE_UNDERSTANDING', 2347), ('QUESTION_ANSWERED_BY_THIS_WORK', 2356), ('SUPERFICIAL_RELATIONSHIP', 2369)]	7	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 210, 'preterm birth'), ('GO_0007565', 'female pregnancy', 245, 'gestational'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 369, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 1141, 'Vitamin'), ('GO_0007565', 'female pregnancy', 1882, 'gestation'), ('CHEBI_30879', 'alcohol', 1906, 'alcohol'), ('UBERON_0001977', 'blood serum', 2060, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 2066, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 2066, '25(OH)D'), ('UBERON_0001977', 'blood serum', 2106, 'serum'), ('UBERON_0001977', 'blood serum', 2180, 'Serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 2189, 'OH)D'), ('GO_0007565', 'female pregnancy', 2195, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 2264, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 2264, 'vitamin D metabolism'), ('UBERON_0001987', 'placenta', 2296, 'placenta'), ('CHEBI_27300', 'vitamin D', 2394, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2414, 'pregnancy')]	0	['caption (table-wrap): table 2\n\nadjusted relative (arr)  complication, preeclampsia (pe),  hypertension (gh),  diabetes mellitus (gdm), spontaneous  (sptb) small-for- age (sga)  status categorised standardised quartiles definitions  statuspregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci) n (%)arr*(95% ci)standardised quartiles**\u2003low711 (25)328 (46)0.95 (0.85, 1.07)46 (6)1.02 (0.66, 1.57))57 (8)0.97 (0.67, 1.42)28 (4)0.79 (0.47, 1.30)36 (5)0.83 (0.54, 1.29)84 (12)1.02 (0.75, 1.39)\u2003low-moderate755 (27)318 (42)1.00 (0.90, 1.12)42 (6)1.07 (0.69, 1.64)65 (9)1.06 (0.74, 1.52)25 (3)0.67 (0.39, 1.16)33 (4)0.87 (0.56, 1.3572 (10)0.98 (0.73, 1.32)\u2003moderate-high702 (25)309 (44)1.0†37 (5)1.0†50 (7)1.0†28 (4)1.0†39 (6)1.0†81 (12)1.0†\u2003high630 (23)258 (41)0.93 (0.82, 1.06)†35 (6)1.24 (0.78, 1.96)40 (6)0.87 (0.58, 1.30)10 (2) 0.47(0.23, 0.96) 30 (5)0.77 (0.48, 1.25)60 (10)0.80 (0.57, 1.11)vitamin status\u2003<25 nmol/l99 (4)51 (52)1.10 (0.89, 1.36)8 (8)1.44 (0.68, 3.03))6 (6)0.70 (0.32, 1.52)5 (5)0.98 (0.38, 2.52)7 (7)1.44 (0.68, 3.04)13 (13)1.15 (0.66, 2.01)\u200325-50 nmol/l673 (24)301 (45)0.93 (0.83, 1.03)45 (7)1.18 (0.80, 1.75)59 (9)0.97 (0.71, 1.34)26 (4)0.89 (0.54, 1.47)29 (4)0.75 (0.48, 1.16)74 (11)0.93 (0.69, 1.24)\u2003>50-75 nmol/l928 (33)428 (46)1.0†48 (5)1.0†80 (9)1.0†35 (4)1.0†52 (6)1.0†107 (12)1.0†\u2003>75 nmol/l1098 (39)435 (40)0.95 (0.86, 1.04)60 (5)1.28 (0.87, 1.87)67 (6)0.82 (0.59, 1.12)†26 (2)0.78 (0.48, 1.28)51 (5)0.86 (0.59, 1.26)104 (9)0.86 (0.67, 1.12)\n*relative women adjusted age, maternal mass index, ethnicity (non caucasian vs. caucasian), smoking status 15\u2009±\u20091\xa0weeks’  (no vs. yes), alcohol consumption 15\u2009±\u20091\xa0weeks’ (no yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) recruitment site (auckland vs. adelaide)\n**serum 25(oh)d standardised month serum sampled [34]\n†reference category\n\nserum 25(oh)d,  outcome fetal sex\nas  metabolism placenta respect fetal sex [35] thus, “standardised”  status  outcome stratified fetal sex (table\xa03).']
S86-PMC6011374	PMC6011374	6/2018	S86-PMC6011374	['caption (table-wrap): table 3\n\nadjusted relative risks (arr) of Pregnancy complications from any complication, Preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaeous Preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status and stratified by fetal sexpregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci)standardised quartiles**males\u2003low367 (26)173 (47)1.00 (0.85, 1.18)24 (7)1.24 (0.65, 2.34)31 (8)1.11 (0.64, 1.94)18 (5)1.25 (0.58, 2.68)22 (6)1.09 (0.60, 1.98)43 (12)1.14 (0.73, 1.79)\u2003low-moderate364 (26)163 (45)1.01 (0.86, 1.19))20 (5)1.11 (0.58, 2.12)32 (9)1.25 (0.73, 2.13)13 (4)1.06 (0.48, 2.38)18 (5)0.93 (0.49, 1.76)45 (12)1.23 (0.80, 1.88)\u2003moderate-high359 (25)152 (42)1.0†16 (4)1.0†23 (6)1.0†11 (3)1.0†18 (5)1.0†35 (10)1.0†\u2003high325 (23)111 (34)0.86 (0.71, 1.04)15 (5)1.18 (0.59, 2.36)17 (5)0.90 (0.50, 1.62)4 (1)0.45 (0.15, 1.38)15 (5)0.97 (0.50, 1.88)26 (8)0.77 (0.47, 1.26)females\u2003low380 (28)169 (44)0.91 (0.77, 1.06)23 (6)0.85 (0.47, 1.55)30 (8)0.87 (0.52, 1.45)13 (3)0.51 (0.25, 1.04)14 (4)0.61 (0.31, 1.18)45 (12)0.88 (0.58, 1.35)\u2003low-moderate353 (26)168 (48)0.99 (0.85, 1.15)24 (7)1.03 (0.57, 1.85)31 (9)0.92 (0.57, 1.50)9 (3) 0.44(0.20, 0.97) 18 (5)0.79 (0.43, 1.45)33 (9)0.74 (0.48, 1.13)\u2003moderate-high334 (24)149 (45)1.0†19 (6)1.0†28 (8)1.0†17 (5)1.0†21 (6)1.0†31 (9)1.0†\u2003high314 (23)128 (41)1.00 (0.84, 1.19)19 (6)1.29 (0.70, 2.35)20 (6)0.85 (0.49, 1.46)6 (2)0.48 (0.19, 1.23)12 (4)0.60 (0.30, 1.21)29 (9)0.82 (0.53, 1.28)\n*relative risks compared to all women were adjusted for age, maternal body mass index, ethnicity (non caucasian vs. caucasian), smoking status at 15\u2009±\u20091\xa0weeks’ Gestation (no vs. yes), Alcohol consumption at 15\u2009±\u20091\xa0weeks’ (no vs yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) and recruitment site (auckland vs. adelaide)\n**Serum 25(Oh)D was standardised for month that serum was sampled based as previously described [34]\n†reference category\n\ndiscussion\nthis study ADDS TO THE current body of LITERATURE on Vitamin D status in a population of Pregnant australian and new zealand women and provides INSIGHT into normal circulating levels of 25(Oh)D in early Pregnancy.']	[('INCOMPLETE_EVIDENCE', 2125), ('INCOMPLETE_EVIDENCE', 2258)]	2	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 111, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007565', 'female pregnancy', 161, 'gestational'), ('GO_0007565', 'female pregnancy', 209, 'preterm birth'), ('GO_0007565', 'female pregnancy', 244, 'gestational'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D'), ('GO_0007565', 'female pregnancy', 1805, 'gestation'), ('CHEBI_30879', 'alcohol', 1829, 'alcohol'), ('UBERON_0001977', 'blood serum', 1983, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 1989, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1989, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 2167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 2203, 'pregnant'), ('CHEBI_71657', 'versiconol acetate', 2300, '25(OH)D'), ('GO_0007565', 'female pregnancy', 2317, 'pregnancy')]	0	['caption (table-wrap): table 3\n\nadjusted relative (arr)  complication, preeclampsia (pe),  hypertension (gh),  diabetes mellitus (gdm), spontaeous  (sptb) small-for- age (sga)  status stratified fetal sexpregnancy complicationsall womenany complicationpeghgdmsptbsga n (%) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci) n (%)arr* (95% ci)standardised quartiles**males\u2003low367 (26)173 (47)1.00 (0.85, 1.18)24 (7)1.24 (0.65, 2.34)31 (8)1.11 (0.64, 1.94)18 (5)1.25 (0.58, 2.68)22 (6)1.09 (0.60, 1.98)43 (12)1.14 (0.73, 1.79)\u2003low-moderate364 (26)163 (45)1.01 (0.86, 1.19))20 (5)1.11 (0.58, 2.12)32 (9)1.25 (0.73, 2.13)13 (4)1.06 (0.48, 2.38)18 (5)0.93 (0.49, 1.76)45 (12)1.23 (0.80, 1.88)\u2003moderate-high359 (25)152 (42)1.0†16 (4)1.0†23 (6)1.0†11 (3)1.0†18 (5)1.0†35 (10)1.0†\u2003high325 (23)111 (34)0.86 (0.71, 1.04)15 (5)1.18 (0.59, 2.36)17 (5)0.90 (0.50, 1.62)4 (1)0.45 (0.15, 1.38)15 (5)0.97 (0.50, 1.88)26 (8)0.77 (0.47, 1.26)females\u2003low380 (28)169 (44)0.91 (0.77, 1.06)23 (6)0.85 (0.47, 1.55)30 (8)0.87 (0.52, 1.45)13 (3)0.51 (0.25, 1.04)14 (4)0.61 (0.31, 1.18)45 (12)0.88 (0.58, 1.35)\u2003low-moderate353 (26)168 (48)0.99 (0.85, 1.15)24 (7)1.03 (0.57, 1.85)31 (9)0.92 (0.57, 1.50)9 (3) 0.44(0.20, 0.97) 18 (5)0.79 (0.43, 1.45)33 (9)0.74 (0.48, 1.13)\u2003moderate-high334 (24)149 (45)1.0†19 (6)1.0†28 (8)1.0†17 (5)1.0†21 (6)1.0†31 (9)1.0†\u2003high314 (23)128 (41)1.00 (0.84, 1.19)19 (6)1.29 (0.70, 2.35)20 (6)0.85 (0.49, 1.46)6 (2)0.48 (0.19, 1.23)12 (4)0.60 (0.30, 1.21)29 (9)0.82 (0.53, 1.28)\n*relative women adjusted age, maternal mass index, ethnicity (non caucasian vs. caucasian), smoking status 15\u2009±\u20091\xa0weeks’  (no vs. yes), alcohol consumption 15\u2009±\u20091\xa0weeks’ (no yes), recreational walking (1-3×/week and\u2009≥\u20094×/week vs. never) recruitment site (auckland vs. adelaide)\n**serum 25(oh)d standardised month serum sampled [34]\n†reference category\n\ndiscussion\nthis  status population  australian zealand women normal circulating levels 25(oh)d .']
S87-PMC6011374	PMC6011374	6/2018	S87-PMC6011374	['it is the largest prospective cohort study TO ASSESS Vitamin D status within the international scope cohort, comparing and combining two distinct populations of Pregnant women living at similar latitude and provides a GREATER UNDERSTANDING of Vitamin D deficiency and the risk of adverse Pregnancy outcomes.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 43), ('INCOMPLETE_EVIDENCE', 218)]	2	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnant'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('GO_0007565', 'female pregnancy', 288, 'pregnancy')]	0	['largest  status international cohort, combining populations  women living latitude   outcomes.']
S89-PMC6011374	PMC6011374	6/2018	S89-PMC6011374	['this was independent of diet and lifestyles factors including bmi and sei and highlights the DIFFICULTY in understanding the ROLE of Vitamin D in Pregnancy in Human cohort studies.']	[('DIFFICULT_TASK', 93), ('SUPERFICIAL_RELATIONSHIP', 125)]	2	[('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy'), ('NCBITaxon_9606', 'Homo sapiens', 159, 'human')]	0	['diet lifestyles bmi sei   human studies.']
S90-PMC6011374	PMC6011374	6/2018	S90-PMC6011374	['HOWEVER, there was a protective ASSOCIATION of having high Vitamin D at 15\u2009±\u20091\xa0weeks’ Gestation and gdm once standardised based on month Serum was sampled.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('SUPERFICIAL_RELATIONSHIP', 32)]	2	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'gestation'), ('UBERON_0001977', 'blood serum', 137, 'serum')]	0	['however,  15\u2009±\u20091\xa0weeks’  gdm standardised month serum sampled.']
S94-PMC6011374	PMC6011374	6/2018	S94-PMC6011374	['PREVIOUS STUDIES HAVE SHOWN a positive ASSOCIATION between socioeconomic status and Vitamin D in both Pregnant and non-Pregnant women [36,37].']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 17), ('SUPERFICIAL_RELATIONSHIP', 39)]	3	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'pregnant'), ('GO_0007565', 'female pregnancy', 119, 'pregnant')]	0	['previous positive socioeconomic status   non- women [36,37].']
S101-PMC6011374	PMC6011374	6/2018	S101-PMC6011374	['THEREFORE, the protective ROLE of high 25(Oh)D 15\u2009±\u20091\xa0weeks’ Gestation against gdm, as seen with a decreased risk of gdm in women within the ‘high’ quartile of standardised Vitamin D compared to moderate-high, is CONSISTENT with knowledge about Vitamin D and diabetes.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 26), ('INCOMPLETE_EVIDENCE', 213)]	3	[('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('GO_0007565', 'female pregnancy', 61, 'gestation'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D')]	0	['therefore, 25(oh)d 15\u2009±\u20091\xa0weeks’  gdm, decreased gdm women ‘high’ quartile standardised  moderate-high,  diabetes.']
S102-PMC6011374	PMC6011374	6/2018	S102-PMC6011374	['this is also CONSISTENT with another study that observed an increased risk of gdm with Vitamin D deficiency in early Pregnancy (aor: 3.40; 95% ci: 2.03–4.98 [17]) and offers POTENTIAL physiological CONNECTIONS between Vitamin D status and the progression of Insulin resistance in Pregnant women.']	[('INCOMPLETE_EVIDENCE', 13), ('INCOMPLETE_EVIDENCE', 174), ('SUPERFICIAL_RELATIONSHIP', 198)]	3	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D'), ('PR_000045358', 'insulin family protein', 258, 'insulin'), ('GO_0007565', 'female pregnancy', 280, 'pregnant')]	0	['gdm   (aor: 3.40; 95% ci: 2.03–4.98 [17]) offers physiological  status progression insulin resistance  women.']
S103-PMC6011374	PMC6011374	6/2018	S103-PMC6011374	['furthermore, studies HAVE SHOWN that Vitamin D supports early Placental Development [44,45] in which, abnormal Placentation CAN be a characteristic of a number of Pregnancy complications including gdm, pe, Sptb and sga [46].']	[('INCOMPLETE_EVIDENCE', 21), ('INCOMPLETE_EVIDENCE', 124)]	2	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0001890', 'placenta development', 62, 'placental development'), ('UBERON_0001987', 'placenta', 62, 'placental'), ('GO_0001890', 'placenta development', 111, 'placentation'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy'), ('PR_000015390', 'sterol O-acyltransferase 2', 206, 'sPTB')]	0	['furthermore,  placental [44,45] which, abnormal placentation  gdm, pe, sptb sga [46].']
S107-PMC6011374	PMC6011374	6/2018	S107-PMC6011374	['in THIS STUDY, we observed marginal sex-specific DIFFERENCES between early Pregnancy Vitamin D status and Pregnancy outcome where by high Vitamin D status and carrying a male fetus was moderately ASSOCIATED with decreasing the risk of having any Pregnancy complication.']	[('QUESTION_ANSWERED_BY_THIS_WORK', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 49), ('SUPERFICIAL_RELATIONSHIP', 196)]	3	[('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 246, 'pregnancy')]	0	['study, sex-specific   status  outcome  status carrying male fetus moderately decreasing  complication.']
S108-PMC6011374	PMC6011374	6/2018	S108-PMC6011374	['CONVERSELY, high Vitamin D status and carrying a female fetus was not associated with changing the risk of having any Pregnancy complication.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0)]	1	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 118, 'pregnancy')]	0	['conversely,  status carrying female fetus changing  complication.']
S109-PMC6011374	PMC6011374	6/2018	S109-PMC6011374	['indeed, for the risk of gdm an OPPOSITE EFFECT of Vitamin D status in early Pregnancy was observed DEPENDING ON fetal sex.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 31), ('SUPERFICIAL_RELATIONSHIP', 40), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 99)]	3	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy')]	0	['indeed, gdm  status  fetal sex.']
S110-PMC6011374	PMC6011374	6/2018	S110-PMC6011374	['this is similar to that which has PREVIOUSLY been shown in the RELATIONSHIP between Vitamin D status at ≤26\xa0weeks’ Gestation and Placental pathology in Pregnancy [51] SUGGESTING that male and female fetuses respond differently to maternal Vitamin D status.']	[('INCOMPLETE_EVIDENCE', 34), ('SUPERFICIAL_RELATIONSHIP', 63), ('INCOMPLETE_EVIDENCE', 167)]	3	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'gestation'), ('UBERON_0001987', 'placenta', 129, 'placental'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 239, 'vitamin D')]	0	[' status ≤26\xa0weeks’  placental pathology  [51] male female fetuses respond maternal  status.']
S111-PMC6011374	PMC6011374	6/2018	S111-PMC6011374	['lack of statistically significant associations with other Pregnancy complications MAY reflect the fact that this was a largely Vitamin D-replete population (>\u200972% with Serum 25(Oh)D\u2009>\u200950\xa0nmol/l) LIKELY DUE TO their residence latitude as low Serum 25(Oh)D was found in the scope ireland cohort [52].']	[('INCOMPLETE_EVIDENCE', 82), ('PROBABLE_UNDERSTANDING', 195), ('PROBLEM_COMPLICATION', 202)]	3	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D'), ('UBERON_0001977', 'blood serum', 168, 'serum'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 177, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 180, 'D'), ('UBERON_0001977', 'blood serum', 241, 'serum'), ('CHEBI_71657', 'versiconol acetate', 247, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 247, '25(OH)D')]	0	['lack statistically  -replete population (>\u200972% serum 25(oh)d\u2009>\u200950\xa0nmol/l) residence latitude serum 25(oh)d ireland [52].']
S112-PMC6011374	PMC6011374	6/2018	S112-PMC6011374	['indeed many of the studies that have assessed the ASSOCIATION between Vitamin D status and adverse Pregnancy outcome that have reported statistically significant differences HAVE BEEN in populations with higher rates of Vitamin D deficiency [2,4].']	[('SUPERFICIAL_RELATIONSHIP', 50), ('INCOMPLETE_EVIDENCE', 174)]	2	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 99, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D')]	0	['indeed  status  outcome statistically populations higher rates  [2,4].']
S113-PMC6011374	PMC6011374	6/2018	S113-PMC6011374	['high dose (>\u20092000\xa0iu) Vitamin D supplementation is ASSOCIATED with decreasing risk of Pregnancy complications [23–25].']	[('SUPERFICIAL_RELATIONSHIP', 51)]	1	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('GO_0007565', 'female pregnancy', 86, 'pregnancy')]	0	['high dose (>\u20092000\xa0iu)  supplementation decreasing  [23–25].']
S118-PMC6011374	PMC6011374	6/2018	S118-PMC6011374	['during Gestation, fetal demand for Calcium increases and it is IMPERATIVE that maternal Vitamin D status remain adequate to support increased Calcium absorption from the Gut [54].']	[('IMPORTANT_CONSIDERATION', 63)]	1	[('GO_0007565', 'female pregnancy', 7, 'gestation'), ('CHEBI_22313', 'alkaline earth metal atom', 35, 'calcium'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 142, 'calcium'), ('UBERON_0001555', 'digestive tract', 170, 'gut')]	0	['fetal calcium maternal  status calcium absorption gut [54].']
S121-PMC6011374	PMC6011374	6/2018	S121-PMC6011374	['HOWEVER, DIFFERENCES in Vitamin D status between the women recruited in adelaide and those recruited in auckland reflect obvious DIFFICULTIES in studying HOW Vitamin D MAY support healthy Pregnancies.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 9), ('DIFFICULT_TASK', 129), ('EXPLICIT_QUESTION', 154), ('INCOMPLETE_EVIDENCE', 168)]	5	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('GO_0007565', 'female pregnancy', 188, 'pregnancies')]	0	['however,  status women recruited adelaide recruited auckland  healthy .']
S122-PMC6011374	PMC6011374	6/2018	S122-PMC6011374	['a POSSIBLE CONNECTION between fetal sex, Vitamin D status and Pregnancy complications REVEALS FURTHER QUESTIONS and ENCOURAGES continual RESEARCH and discussion into the ROLE of Vitamin D in Pregnancy, particularly in Vitamin D replete populations.']	[('INCOMPLETE_EVIDENCE', 2), ('SUPERFICIAL_RELATIONSHIP', 11), ('INCOMPLETE_EVIDENCE', 86), ('FUTURE_WORK', 94), ('FUTURE_WORK', 116), ('SUPERFICIAL_RELATIONSHIP', 170)]	6	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('GO_0007565', 'female pregnancy', 191, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D')]	0	['fetal sex,  status  discussion   replete populations.']
S56-PMC6043562	PMC6043562	7/2018	S56-PMC6043562	['Prenatal Vitamin D intake from Foods showed a TREND toward decreased feno measures in Adolescence (table\xa03).']	[('INCOMPLETE_EVIDENCE', 46)]	1	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_33290', 'food', 31, 'foods'), ('GO_0048848', 'neurohypophysis morphogenesis', 86, 'adolescence')]	0	['  intake foods toward decreased feno adolescence (table\xa03).']
S106-PMC6043562	PMC6043562	7/2018	S106-PMC6043562	['IN KEEPING WITH our HYPOTHESIS, we OBSERVED that higher Prenatal intakes of N-3 polyunsaturated Fatty Acids (a POTENTIAL immunomodulatory agent), Vitamin D (an antioxidant and Immunomodulatory Agent) and Folate were ASSOCIATED with lower levels of allergic disease BIOMARKERS.']	[('INCOMPLETE_EVIDENCE', 0), ('INCOMPLETE_EVIDENCE', 20), ('INCOMPLETE_EVIDENCE', 35), ('INCOMPLETE_EVIDENCE', 111), ('SUPERFICIAL_RELATIONSHIP', 216), ('SUPERFICIAL_RELATIONSHIP', 265)]	6	[('GO_0007565', 'female pregnancy', 56, 'prenatal'), ('CHEBI_30256', 'thiocarbonyl group', 76, 'n-3'), ('CHEBI_35366', 'fatty acid', 96, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('CHEBI_35476', 'antipsychotic agent', 176, 'immunomodulatory agent'), ('CHEBI_30863', '5-azaorotic acid', 204, 'folate')]	0	['keeping hypothesis, higher  intakes n-3 polyunsaturated fatty acids (a immunomodulatory agent),  (an antioxidant immunomodulatory agent) folate levels allergic disease biomarkers.']
S107-PMC6043562	PMC6043562	7/2018	S107-PMC6043562	['IN CONTRAST with OTHER Nutrients, total Vitamin E intake in Pregnancy APPEARED TO amplify the adverse EFFECT of Prenatal exposure to Pm2.5on Feno measured in adolescence, SUGGESTING a synergy between these two exposures.']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('ANOMALY_CURIOUS_FINDING', 3), ('ALTERNATIVE_OPTIONS_CONTROVERSY', 17), ('ANOMALY_CURIOUS_FINDING', 70), ('SUPERFICIAL_RELATIONSHIP', 102), ('INCOMPLETE_EVIDENCE', 171)]	6	[('CHEBI_33284', 'nutrient', 23, 'nutrients'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin E'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('GO_0007565', 'female pregnancy', 112, 'prenatal'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 133, 'PM2'), ('CHEBI_32035', 'potassium hydroxide', 141, 'FeNO')]	0	['nutrients,  intake  amplify  exposure pm2.5on feno adolescence, synergy exposures.']
S117-PMC6043562	PMC6043562	7/2018	S117-PMC6043562	['two other Prenatal Nutrients with immunomodulatory potential, N-3 polyunsaturated Fatty Acids and Vitamin D, were also ASSOCIATED with lower Feno levels in OUR STUDY.']	[('SUPERFICIAL_RELATIONSHIP', 119), ('QUESTION_ANSWERED_BY_THIS_WORK', 156)]	2	[('GO_0007565', 'female pregnancy', 10, 'prenatal'), ('CHEBI_33284', 'nutrient', 19, 'nutrients'), ('CHEBI_30256', 'thiocarbonyl group', 62, 'n-3'), ('CHEBI_35366', 'fatty acid', 82, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_32035', 'potassium hydroxide', 141, 'FeNO')]	0	['two  nutrients immunomodulatory potential, n-3 polyunsaturated fatty acids feno levels study.']
S161-PMC6043562	PMC6043562	7/2018	S161-PMC6043562	['Prenatal exposure INTERACTIONS MAY play an IMPORTANT ROLE, AS EVIDENCED by the POTENTIAL synergy between Vitamin E and Pm2.5.']	[('SUPERFICIAL_RELATIONSHIP', 18), ('INCOMPLETE_EVIDENCE', 31), ('IMPORTANT_CONSIDERATION', 43), ('SUPERFICIAL_RELATIONSHIP', 53), ('PROBABLE_UNDERSTANDING', 59), ('INCOMPLETE_EVIDENCE', 62), ('INCOMPLETE_EVIDENCE', 79)]	7	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin E'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 119, 'PM2')]	0	[' exposure play role, synergy  pm2.5.']
S21-PMC6056931	PMC6056931	7/2018	S21-PMC6056931	['the Nutrients MOST STUDIED during Pregnancy include b-vitamins (particularly Folic Acid), Vitamin D, iron, Long-Chain polyunsaturated Fatty Acids (particularly N-3 Fatty Acids) and Iodine [8,10].']	[('INCOMPLETE_EVIDENCE', 14)]	1	[('CHEBI_33284', 'nutrient', 4, 'nutrients'), ('GO_0007565', 'female pregnancy', 34, 'pregnancy'), ('CHEBI_30751', 'formic acid', 77, 'folic acid'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_28911', 'cob(III)alamin', 107, 'long-chain'), ('CHEBI_35366', 'fatty acid', 134, 'fatty acids'), ('31', 'ACACA (human)', 160, 'n'), ('CHEBI_35366', 'fatty acid', 164, 'fatty acids'), ('CHEBI_24859', 'iodine atom', 181, 'iodine')]	0	['nutrients  b-vitamins (particularly folic acid), iron, long-chain polyunsaturated fatty acids (particularly n-3 fatty acids) iodine [8,10].']
S22-PMC6056931	PMC6056931	7/2018	S22-PMC6056931	['HOWEVER, adequate maternal intakes of zinc and Vitamin A MAY also be IMPORTANT for optimal Pregnancy outcomes, as well as for maternal and offspring health [11–13].']	[('ALTERNATIVE_OPTIONS_CONTROVERSY', 0), ('INCOMPLETE_EVIDENCE', 57), ('IMPORTANT_CONSIDERATION', 69)]	3	[('CHEBI_27300', 'vitamin D', 47, 'vitamin A'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy')]	0	['however, maternal intakes zinc   outcomes, maternal offspring [11–13].']
S106-PMC5273824	PMC5273824	1/2017	S106-PMC5273824	['THEREFORE, Consumption of Vitamin D2-containing supplements is ASSOCIATED with higher Vitamin D2 DETECTION rate among Pregnant women.']	[('PROBABLE_UNDERSTANDING', 0), ('SUPERFICIAL_RELATIONSHIP', 63), ('INCOMPLETE_EVIDENCE', 97)]	3	[('GO_0007631', 'feeding behavior', 11, 'consumption'), ('CHEBI_28934', 'vitamin D2', 26, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 26, 'Vitamin D2'), ('CHEBI_28934', 'vitamin D2', 86, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 86, 'Vitamin D2'), ('GO_0007565', 'female pregnancy', 118, 'pregnant')]	0	['therefore, consumption -containing supplements higher  rate among  women.']
S78-PMC5513133	PMC5513133	7/2017	S78-PMC5513133	['in ONE STUDY, oral Vitamin D2 (vd2, 270\xa0iu/day) and Vitamin D3 (vd3, 15\xa0iu/day) lowered mean Arterial blood pressure (mm\xa0hg) in Pregnant Rats infused with Autoantibodies to Angiotensin Ii Type I Receptor (vd2: 105 +/−2, vd3: 109 +/− 2) versus Rats that were infused with Autoantibodies to Angiotensin Ii Type I Receptor but did not receive oral vd2 or vd3 (121 +/− 4) [64].']	[('INCOMPLETE_EVIDENCE', 3)]	1	[('CHEBI_28934', 'vitamin D2', 19, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 19, 'vitamin D2'), ('CHEBI_33279', 'vitamin D5', 52, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 52, 'vitamin D3'), ('UBERON_0001637', 'artery', 93, 'arterial'), ('GO_0007565', 'female pregnancy', 128, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 137, 'rats'), ('GO_0044308', 'axonal spine', 155, 'autoantibodies'), ('PR_000001683', 'vasopressin V2 receptor', 173, 'Angiotensin II type I receptor'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 243, 'rats'), ('GO_0044308', 'axonal spine', 271, 'autoantibodies'), ('PR_000001683', 'vasopressin V2 receptor', 289, 'Angiotensin II type I receptor')]	0	['study, oral  (vd2, 270\xa0iu/day) vitamin d3 (vd3, 15\xa0iu/day) lowered arterial blood pressure (mm\xa0hg)  rats infused autoantibodies angiotensin ii type receptor (vd2: 105 +/−2, vd3: 109 +/− 2) rats infused autoantibodies angiotensin ii type receptor receive oral vd2 vd3 (121 +/− 4) [64].']
